PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, J; Zou, AR; Splawski, I; Keating, MT; Sanguinetti, MC				Chen, J; Zou, AR; Splawski, I; Keating, MT; Sanguinetti, MC			Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INWARD RECTIFIER; CARDIAC-ARRHYTHMIA; PORE REGION; VOLTAGE-DEPENDENCE; MISSENSE MUTATION; XENOPUS OOCYTES; K+ CHANNELS; INACTIVATION; RECTIFICATION; SPECIFICITY	Mutations in the human ether-a-go-go-related gene (HERG) cause long QT syndrome, an inherited disorder of cardiac repolarization that predisposes affected individuals to life-threatening arrhythmias, HERG encodes the cardiac rapid delayed rectifier potassium channel that mediates repolarization of ventricular action potentials. In this study, we used the oocyte expression system and voltage clamp techniques to determine the functional consequences of eight long QT syndrome-associated mutations located in the amino-terminal region of HERG (F29L, N33T, G53R, R56Q, C66G, H70R, A78P, and L86R), Mutant subunits formed functional channels with altered gating properties when expressed alone in oocytes, Deactivation was accelerated by all mutations. Some mutants shifted the voltage dependence of channel availability to more positive potentials. Voltage ramps indicated that fast deactivation of mutant channels would reduce outward current during the repolarization phase of the cardiac action potential and cause prolongation of the corrected QT interval, QT(c), The amino-terminal region of HERG was recently crystallized and shown to possess a Per-Amt-Sim (PAS) domain. The location of these mutations suggests they may disrupt the PAS domain and interfere with its interaction with the S4-S5 linker of the HERG channel.	Univ Utah, Eccles Inst Human Genet, Dept Med, Div Cardiol, Salt Lake City, UT 84112 USA; Univ Utah, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Sanguinetti, MC (corresponding author), Univ Utah, Eccles Inst Human Genet, Dept Med, Div Cardiol, 15 N 2030 East,Rm 4220, Salt Lake City, UT 84112 USA.	mike.sanguinetti@hci.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338, R01HL055236] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55236, HL52338] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto K, 1998, HUM MUTAT, pS184; Benson DW, 1996, CIRCULATION, V93, P1791, DOI 10.1161/01.CIR.93.10.1791; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dausse E, 1996, J MOL CELL CARDIOL, V28, P1609, DOI 10.1006/jmcc.1996.0151; Dunlap JC, 1998, CURR OPIN GENET DEV, V8, P400, DOI 10.1016/S0959-437X(98)80109-3; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; LeesMiller JP, 1997, CIRC RES, V81, P719; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; London B, 1997, CIRC RES, V81, P870; Nakajima T, 1998, CIRC RES, V83, P415, DOI 10.1161/01.RES.83.4.415; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Satler CA, 1998, HUM GENET, V102, P265, DOI 10.1007/s004390050690; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; SchulzeBahr E, 1995, NEW ENGL J MED, V333, P1783; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Tanaka T, 1997, CIRCULATION, V95, P565, DOI 10.1161/01.CIR.95.3.565; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang JL, 1998, J GEN PHYSIOL, V112, P637, DOI 10.1085/jgp.112.5.637; Wang SM, 1997, FEBS LETT, V417, P43, DOI 10.1016/S0014-5793(97)01245-3; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	38	184	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10113	10118		10.1074/jbc.274.15.10113	http://dx.doi.org/10.1074/jbc.274.15.10113			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187793	hybrid			2022-12-25	WOS:000079663500032
J	Li, WM; Nagineni, CN; Ge, H; Efiok, B; Chepelinsky, AB; Egwuagu, CE				Li, WM; Nagineni, CN; Ge, H; Efiok, B; Chepelinsky, AB; Egwuagu, CE			Interferon consensus sequence-binding protein is constitutively expressed and differentially regulated in the ocular lens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; TRANSCRIPTION FACTORS; GAMMA-INTERFERON; ALPHA-CRYSTALLIN; GENE-EXPRESSION; TRANSGENIC MICE; HISTONE GENE; ICSBP GENE; IFN; RESPONSES	Interferon signaling is mediated by STATs and interferon regulatory factor (IRF) families of transcription factors. Ten distinct IRFs have been described and most are expressed in a variety of cells except for interferon consensus sequence-binding protein (ICSBP) and lymphoid-specific IRF/Pip that are thought to be exclusively expressed in lymphoid cells. We show here for the first time that ICSBP is constitutively and inducibly expressed in the mouse lens, In contrast to lymphoid cells with exclusive expression of ICSBP in the nucleus, ICSBP is present in both the cytoplasm and nucleus of the lens cell. However, ICSBP in the nucleus is of lower apparent molecular weight. We further show that the ICSBP promoter is constitutively bound by lens nuclear factors and that its activation requires binding of additional factors including STAT1. Furthermore, transcriptional activation of ICSBP gene by interferon gamma is accompanied by selective nuclear localization of ICSBP in proliferating epithelial cells but not in the nuclei of nondividing cells in the lens fiber compartment. Constitutive and inducible expression of ICSBP in the ocular lens and differential regulation of its subcellular localization in the developing lens suggest that ICSBP may have nonimmunity related functions and that the commonly held view that it is lymphoid-specific be modified.	NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA; NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Mol Hematol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Egwuagu, CE (corresponding author), NEI, Immunol Lab, NIH, Bldg 10,10-10N116,10 Ctr Dr,1858, Bethesda, MD 20892 USA.				NATIONAL EYE INSTITUTE [Z01EY000253, Z01EY000315, ZIAEY000315] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; Dosch E, 1998, GENE, V210, P265, DOI 10.1016/S0378-1119(98)00063-8; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EGWUAGU CE, 1994, DEV BIOL, V166, P557, DOI 10.1006/dbio.1994.1337; EGWUAGU CE, 1994, INVEST OPHTH VIS SCI, V35, P332; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; GAO CY, 1995, DEV BIOL, V169, P185, DOI 10.1006/dbio.1995.1136; Gao CY, 1997, DEV GENET, V20, P267; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; JUNWIRTH C, 1995, P NATL ACAD SCI USA, V92, P3105; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; MATSUYAMA T, 1995, NUCLEIC ACIDS RES, V23, P2127, DOI 10.1093/nar/23.12.2127; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Moore DD, 1995, GLOB MOB SURV; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Nelson N, 1996, J IMMUNOL, V156, P3711; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; POLITIS AD, 1994, J IMMUNOL, V152, P2270; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SAX CM, 1995, EXP EYE RES, V61, P125, DOI 10.1016/S0014-4835(95)80066-2; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHARF R, 1995, J BIOL CHEM, V270, P13063, DOI 10.1074/jbc.270.22.13063; Sharf R, 1997, J BIOL CHEM, V272, P9785; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VALENTE G, 1992, EUR J IMMUNOL, V22, P2403, DOI 10.1002/eji.1830220933; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1997, J MOL MED-JMM, V75, P348, DOI 10.1007/s001090050120; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; Yamagata T, 1996, MOL CELL BIOL, V16, P1283	36	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9686	9691		10.1074/jbc.274.14.9686	http://dx.doi.org/10.1074/jbc.274.14.9686			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092656	hybrid			2022-12-25	WOS:000079451800075
J	Moldes, M; Feve, B; Pairault, J				Moldes, M; Feve, B; Pairault, J			Molecular cloning of a major mRNA species in murine 3T3 adipocyte lineage - Differentiation-dependent expression, regulation, and identification as semicarbazide-sensitive amine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADHESION PROTEIN-1 REVEALS; VASCULAR SMOOTH-MUSCLE; HUMAN UMBILICAL ARTERY; BROWN ADIPOSE-TISSUE; INSULIN-RESISTANCE; RAT AORTA; MESSENGER-RNA; GLUCOSE-TRANSPORT; HYDROGEN-PEROXIDE	In an effort to identify novel mRNAs modulated during the course of adipose conversion, we have used a simplified differential display technique and have isolated a cDNA encoding an amine oxidase tremendously expressed in the adipocyte, the semicarbazide-sensitive amine oxidase (SSAO), The predicted amino acid sequence (765 amino acids) is likely to be the homologue of the human placental amine oxidase and of the partially known sequence of the rat adipocyte membrane amine oxidase, SSAO mRNAs are present in several tissues, but strikingly, the highest levels of gene expression are found in adipose tissue and aorta. Enzyme transcript levels are barely detectable in preadipocytes but are induced several hundred-fold during the adipocyte differentiation of 3T3-L1 or 3T3-F442A cells and of rat precursor primary cultures. These changes in transcript levels parallel a sharp increase in SSAO enzyme activity. The biochemical properties of the SSAO present in 3T3-L1 or 3T3-F442A adipocytes closely resemble the features of the SSAO activity previously described in white and brown adipose tissues. Interestingly, SSAO mRNA levels and enzyme activity drop in response to effecters of the cAMP pathway and to the cytokine tumor necrosis factor-alpha, indicating that two major signaling molecules of adipose tissue development and metabolism can control SSAO function, Moreover, the expression of SSAO transcripts and activity are clearly down-regulated in white adipose tissue from obese Zucker rats. Because of its known stimulatory effect on glucose transport, its biochemical properties and its pattern of expression and regulation, SSAO could play an important role in the regulation of adipocyte homeostasis.	Univ Paris 06, Ctr Rech Biomed Cordeliers, UPRES A 7079 CNRS, F-75270 Paris 06, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Pairault, J (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, UPRES A 7079 CNRS, 15 Rue Ecole Med, F-75270 Paris 06, France.	pairault@infobiogen.fr	Moldes-Garnaud, Marthe/E-4817-2017	Moldes-Garnaud, Marthe/0000-0002-9950-2267; Feve, Bruno/0000-0001-6577-9009				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ANTRAS J, 1991, MOL CELL ENDOCRINOL, V82, P183, DOI 10.1016/0303-7207(91)90030-V; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BARRAND MA, 1982, BIOCHEM PHARMACOL, V31, P2177, DOI 10.1016/0006-2952(82)90511-1; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Bono P, 1998, J IMMUNOL, V161, P2953; Bono P, 1998, J IMMUNOL, V160, P5563; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONFORTI L, 1993, BIOCHEM PHARMACOL, V46, P603, DOI 10.1016/0006-2952(93)90544-7; CORNELIUS P, 1991, J CELL PHYSIOL, V146, P298, DOI 10.1002/jcp.1041460215; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CZECH MP, 1974, J BIOL CHEM, V249, P1001; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; DOBSON DE, 1987, J BIOL CHEM, V262, P1804; ELLIOTT J, 1989, BIOCHEM PHARMACOL, V38, P1507, DOI 10.1016/0006-2952(89)90191-3; Enrique-Tarancon G, 1998, J BIOL CHEM, V273, P8025, DOI 10.1074/jbc.273.14.8025; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Frohman Michael A., 1995, P381; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GRUNFELD C, 1991, TRENDS ENDOCRIN MET, V2, P213, DOI 10.1016/1043-2760(91)90027-K; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HYSMITH RM, 1987, J CARDIOVASC PHARM, V9, P668, DOI 10.1097/00005344-198706000-00005; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LEWINSOHN R, 1978, BIOCHEM PHARMACOL, V27, P1857, DOI 10.1016/0006-2952(78)90033-3; LEWINSOHN R, 1981, J PHARM PHARMACOL, V33, P569, DOI 10.1111/j.2042-7158.1981.tb13868.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLE SA, 1980, J BIOL CHEM, V255, P888; LIVINGSTON JN, 1977, J BIOL CHEM, V252, P560; Lizcano JM, 1998, BIOCHEM J, V331, P69, DOI 10.1042/bj3310069; Lizcano JM, 1996, BIOCHEM PHARMACOL, V52, P187, DOI 10.1016/0006-2952(96)00132-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYLES GA, 1992, BIOCHEM PHARMACOL, V43, P1409, DOI 10.1016/0006-2952(92)90196-P; LYLES GA, 1995, BIOCHEM PHARMACOL, V49, P416, DOI 10.1016/0006-2952(94)00421-H; LYLES GA, 1985, J PHARM PHARMACOL, V37, P637, DOI 10.1111/j.2042-7158.1985.tb05100.x; MATSUMOTO T, 1982, BIOCHEM PHARMACOL, V31, P2207, DOI 10.1016/0006-2952(82)90520-2; MAY JM, 1979, J BIOL CHEM, V254, P9017; Morris NJ, 1997, J BIOL CHEM, V272, P9388; MU D, 1994, J BIOL CHEM, V269, P9926; MUCHMORE DB, 1982, BIOCHEMISTRY-US, V21, P3886, DOI 10.1021/bi00259a025; NEGREL R, 1978, P NATL ACAD SCI USA, V75, P6054, DOI 10.1073/pnas.75.12.6054; OKUYAMA T, 1961, ARCH BIOCHEM BIOPHYS, V95, P242, DOI 10.1016/0003-9861(61)90141-2; PAPE ME, 1988, MOL ENDOCRINOL, V2, P395, DOI 10.1210/mend-2-5-395; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PEKALA P, 1983, J EXP MED, V157, P1360, DOI 10.1084/jem.157.4.1360; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; PRECIOUS E, 1988, BIOCHEM PHARMACOL, V37, P707, DOI 10.1016/0006-2952(88)90145-1; RAIMONDI L, 1992, COMP BIOCHEM PHYS B, V102, P953, DOI 10.1016/0305-0491(92)90108-4; RAIMONDI L, 1991, BIOCHEM PHARMACOL, V41, P469, DOI 10.1016/0006-2952(91)90549-K; RODBELL M, 1964, J BIOL CHEM, V239, P375; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; RYDER TA, 1979, HISTOCHEMISTRY, V62, P93, DOI 10.1007/BF00537010; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; Smith DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/jem.188.1.17; SOKOLOV BP, 1994, NUCLEIC ACIDS RES, V22, P4009, DOI 10.1093/nar/22.19.4009; SPIEGELMAN BM, 1981, CELL, V24, P503, DOI 10.1016/0092-8674(81)90341-X; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WIBO M, 1980, EUR J BIOCHEM, V112, P87, DOI 10.1111/j.1432-1033.1980.tb04990.x; Zhang XP, 1996, GENE, V179, P279, DOI 10.1016/S0378-1119(96)00387-3	78	77	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9515	9523		10.1074/jbc.274.14.9515	http://dx.doi.org/10.1074/jbc.274.14.9515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092636	hybrid			2022-12-25	WOS:000079451800055
J	Suhy, DA; Simon, KD; Linzer, DIH; O'Halloran, TV				Suhy, DA; Simon, KD; Linzer, DIH; O'Halloran, TV			Metallothionein is part of a zinc-scavenging mechanism for cell survival under conditions of extreme zinc deprivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; TRANSCRIPTION FACTOR; DIETARY ZINC; CADMIUM-RESISTANT; CONFERS RESISTANCE; RESPONSE ELEMENT; HEPATOMA-CELLS; MOUSE CELLS; RAT-LIVER; EXPRESSION	Metallothionein (MT) is a small cysteine-rich protein thought to play a critical role in cellular detoxification of inorganic species by sequestering metal ions that are present in elevated concentrations. We demonstrate here that metallothionein can play an important role at the other end of the homeostatic spectrum by scavenging an essential metal in a mouse fibroblast cell line that has been cultured under conditions of extreme zinc deprivation (LZA-LTK-). These cells unexpectedly produce constitutively high levels of metallothionein mRNA; however, the MT protein accumulates only when high concentrations of zinc are provided in the media. Until this MT pool is saturated, no measurable zinc remains in the external media. In this case, zinc deprivation leads to amplification of the MT gene locus in the LZA-LTK- cell line. Furthermore, the intracellular zinc levels in the fully adapted cells remain at the normal level of 0.4 fmol zinc/cell, even when extracellular zinc concentration is decreased by 2 orders of magnitude relative to normal media.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2145 Sheridan Rd, Evanston, IL 60208 USA.	t-ohalloran@nwu.edu	O'Halloran, Thomas/ABE-6125-2021; Das, Simon Kumar/AAC-4266-2019	O'Halloran, Thomas/0000-0001-8732-5059; 	NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052627] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA60553] Funding Source: Medline; NIDDK NIH HHS [R01 DK52627] Funding Source: Medline; NIGMS NIH HHS [R01 GM38784, R01 GM038784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI YB, 1991, METHOD ENZYMOL, V205, P108; BEACH LR, 1981, P NATL ACAD SCI-BIOL, V78, P2110, DOI 10.1073/pnas.78.4.2110; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BLALOCK TL, 1988, J NUTR, V118, P222, DOI 10.1093/jn/118.2.222; BREMNER I, 1993, METALLOTHIONEIN, V3, P111; Brouwer M, 1996, ADV INORG BIOCHEM, P235; CHOPRA A, 1990, J CELL PHYSIOL, V142, P316, DOI 10.1002/jcp.1041420214; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; COUSINS RJ, 1992, J NUTR, V122, P56, DOI 10.1093/jn/122.1.56; Cui L, 1998, J NUTR, V128, P1092, DOI 10.1093/jn/128.7.1092; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; CZAJA MJ, 1991, J CELL PHYSIOL, V147, P434, DOI 10.1002/jcp.1041470308; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; FREEDMAN JH, 1986, J BIOL CHEM, V261, P1840; FREEDMAN JH, 1989, BIOCHIM BIOPHYS ACTA, V992, P145, DOI 10.1016/0304-4165(89)90003-2; GALLANT KR, 1986, BIOCHEM CELL BIOL, V64, P8, DOI 10.1139/o86-002; GALLANT KR, 1987, J NUTR, V117, P709, DOI 10.1093/jn/117.4.709; GICK GG, 1982, J BIOL CHEM, V257, P9049; GRAHAM JM, 1992, CELL BIOL LABFAX, P7; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; ISZARD MB, 1995, TOXICOL APPL PHARM, V133, P305, DOI 10.1006/taap.1995.1155; JIN NZ, 1993, BIOL TRACE ELEM RES, V36, P183, DOI 10.1007/BF02783177; Kelly EJ, 1996, J NUTR, V126, P1782; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLAASSEN CD, 1993, METALLOTHIONEIN, V3, P207; KRAKER AJ, 1988, CANCER RES, V48, P3381; LANE LC, 1978, ANAL BIOCHEM, V86, P655, DOI 10.1016/0003-2697(78)90792-3; Lee DK, 1996, MOL REPROD DEV, V43, P158, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;158::AID-MRD4&gt;3.0.CO;2-Q; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MAYO KE, 1982, J BIOL CHEM, V257, P3061; MENARD MP, 1981, J NUTR, V111, P1353, DOI 10.1093/jn/111.8.1353; MESSER HH, 1982, J NUTR, V112, P652, DOI 10.1093/jn/112.4.652; MINKEL DT, 1980, BIOCHEM J, V191, P475, DOI 10.1042/bj1910475; MINKEL DT, 1979, CANCER RES, V39, P2451; MORRISON JN, 1987, J NUTR, V117, P1588, DOI 10.1093/jn/117.9.1588; PALMITER RD, 1995, TOXICOL APPL PHARM, V135, P139, DOI 10.1006/taap.1995.1216; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; PATTANAIK A, 1994, J INORG BIOCHEM, V54, P91, DOI 10.1016/0162-0134(94)80023-5; PRASAD AS, 1991, AM J CLIN NUTR, V53, P403, DOI 10.1093/ajcn/53.2.403; PRASAD AS, 1976, TRACE ELEMENTS HUMAN, P1; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; RICHARDS MP, 1976, J NUTR, V106, P1591, DOI 10.1093/jn/106.11.1591; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIMKE RT, 1984, CELL, V37, P705, DOI 10.1016/0092-8674(84)90406-9; SCHROEDER JJ, 1991, J NUTR, V121, P844, DOI 10.1093/jn/121.6.844; SCHROEDER JJ, 1991, METHOD ENZYMOL, V205, P575; SELDEN RF, 1987, CURRENT PROTOCOLS MO; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUHY DA, 1996, MET IONS BIOL SYST, V32, P558; TOHOYAMA H, 1992, FEMS MICROBIOL LETT, V95, P81, DOI 10.1111/j.1574-6968.1992.tb05346.x; UDOM AO, 1980, BIOCHEM J, V187, P329, DOI 10.1042/bj1870329; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WAALKES MP, 1993, METALLOTHIONEIN, V3, P243; WAN M, 1995, EXPERIENTIA, V51, P606, DOI 10.1007/BF02128753; YAMAMOTO T, 1980, CELL, V22, P787, DOI 10.1016/0092-8674(80)90555-3; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	67	116	123	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9183	9192		10.1074/jbc.274.14.9183	http://dx.doi.org/10.1074/jbc.274.14.9183			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092590	hybrid			2022-12-25	WOS:000079451800009
J	Ujita, M; McAuliffe, J; Suzuki, M; Hindsgaul, O; Clausen, H; Fukuda, MN; Fukuda, M				Ujita, M; McAuliffe, J; Suzuki, M; Hindsgaul, O; Clausen, H; Fukuda, MN; Fukuda, M			Regulation of I-branched poly-N-acetyllactosamine synthesis - Concerted actions by i-extension enzyme, I-branching enzyme, and beta 1,4-galactosyltransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP-I; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; HUMAN-ERYTHROCYTE-MEMBRANE; EMBRYONAL CARCINOMA-CELLS; LINKED SUGAR CHAINS; L-SELECTIN; LYMPHOCYTE ADHESION; EXPRESSION CLONING; POLYSIALIC ACID; UDP-GALACTOSE	I-branched poly-N-acetyllactosamine is a unique carbohydrate composed of N-acetyllactosamine branches attached to linear poly-N-acetyllactosamine, which is synthesized by I-branching beta 1,6-N-acetylglucosaminyl-transferase. I-branched poly-N-acetyllactosamine can carry bivalent functional oligosaccharides such as sialyl Lewis(x), which provide much better carbohydrate ligands than monovalent functional oligosaccharides. In the present study, we first demonstrate that I-branching beta 1,6-N-acetylglucosaminyltransferase cloned from human PA-1 embryonic carcinoma cells transfers beta 1,6-linked GlcNAc preferentially to galactosyl residues of N-acetyllactosamine close to nonreducing terminals, We then demonstrate that among various beta 1,4-galactosyltransferases (beta 4Gal-Ts), beta 4Gal-TI is most efficient in adding a galactose to linear and branched poly-N-acetyllactosamines. When a beta 1,6-GlcNAc branched poly-N-acetyllactosamine was incubated with a mixture of beta 4Gal-TI and i-extension beta 1,3-N-acetylglucosaminyltransferase, the major product was the oligosaccharide with one N-acetyllactosamine extension on the linear Gal beta 1-->4GlcNAc beta 1-->3 side chain, Only a minor product contained galactosylated I-branch without N-acetyllactosamine extension. This finding was explained by the fact that beta 4Gal-TI adds a galactose poorly to beta 1,6-GlcNAc attached to linear poly-N-acetyllactosamines, while beta 1,3-N-acetylglucosaminyltransferase and beta 4Gal-TI efficiently add N-acetyllactosamine to linear poly-N-acetyllactosamines. Together, these results strongly suggest that galactosylation of I-branch is a rate-limiting step in I-branched poly-N-acetyllactosamine synthesis, allowing poly-N-acetyllactosamine extension mostly along the linear poly-N-acetyllactosamine side chain. These findings are entirely consistent with previous findings that poly-N-acetyllactosamines in human erythrocytes, PA-1 embryonic carcinoma cells, and rabbit erythrocytes contain multiple, short I-branches.	Burnham Inst, Glycobiol Program, Canc Res Ctr, La Jolla, CA 92037 USA; Univ Copenhagen, Sch Dent, DK-2200 Copenhagen, Denmark	Sanford Burnham Prebys Medical Discovery Institute; University of Copenhagen	Fukuda, M (corresponding author), Burnham Inst, Glycobiol Program, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		clausen, henrik/AAD-8016-2021	Clausen, Henrik/0000-0002-0915-5055	NATIONAL CANCER INSTITUTE [R01CA048737, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; DABROWSKI U, 1984, J BIOL CHEM, V259, P7648; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; FUKUDA M, 1984, J BIOL CHEM, V259, P925; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUKUDA MN, 1982, J BIOL CHEM, V257, P446; FUKUDA MN, 1992, CRC HDB ENDOGLYCOSID, P55; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GU J, 1992, J BIOL CHEM, V267, P2994; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; IMAI Y, 1993, NATURE, V361, P555; JARNEFELT J, 1978, J BIOL CHEM, V253, P8006; Kido M, 1998, BIOCHEM BIOPH RES CO, V245, P860, DOI 10.1006/bbrc.1998.8537; KRUSIUS T, 1978, EUR J BIOCHEM, V92, P289, DOI 10.1111/j.1432-1033.1978.tb12747.x; LEE N, 1990, J BIOL CHEM, V265, P20476; LOWE BJ, 1994, MOL GLYCOBIOLOGY, P163; Mattila P, 1998, J BIOL CHEM, V273, P27633, DOI 10.1074/jbc.273.42.27633; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; MURAMATSU T, 1979, CELL, V18, P183, DOI 10.1016/0092-8674(79)90367-2; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; PILLER F, 1984, J BIOL CHEM, V259, P3385; Renkonen O, 1997, GLYCOBIOLOGY, V7, P453, DOI 10.1093/glycob/7.4.453-c; ROMANS DG, 1980, J IMMUNOL, V124, P2807; ROPP PA, 1991, J BIOL CHEM, V266, P23863; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Sakamoto Y, 1998, J BIOL CHEM, V273, P27625, DOI 10.1074/jbc.273.42.27625; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; SRIVASTAVA G, 1992, CARBOHYD RES, V224, P83, DOI 10.1016/0008-6215(92)84095-A; Toppila S, 1997, EUR J IMMUNOL, V27, P1360, DOI 10.1002/eji.1830270610; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; TURUNEN JP, 1995, J EXP MED, V182, P1133, DOI 10.1084/jem.182.4.1133; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WANG WC, 1991, J BIOL CHEM, V266, P23185; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; YOSHIMA H, 1980, J BIOL CHEM, V255, P793; ZDEBSKA E, 1983, CARBOHYD RES, V120, P113, DOI 10.1016/0008-6215(83)88011-2	52	40	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9296	9304		10.1074/jbc.274.14.9296	http://dx.doi.org/10.1074/jbc.274.14.9296			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092606	hybrid			2022-12-25	WOS:000079451800025
J	Carman, CV; Lisanti, MP; Benovic, JL				Carman, CV; Lisanti, MP; Benovic, JL			Regulation of G protein-coupled receptor kinases by caveolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; SCAFFOLDING DOMAIN; ADENYLYL-CYCLASE; TYROSINE KINASE; BINDING; AGONIST; EXPRESSION; SUBUNITS	G protein-coupled receptor kinases (GRKs) have been principally characterized by their ability to phosphorylate and desensitize G protein-coupled receptors, However, recent studies suggest that GRKs may have more diverse protein/protein interactions in cells. Based on the identification of a consensus caveolin binding motif within the pleckstrin homology domain of GRK2, we tested the direct binding of purified full-length GRK2 to various glutathione S-transferase-caveolin-1 fusion proteins, and we discovered a specific interaction of GRK2 with the caveolin scaffolding domain. Interestingly, analysis of GRK1 and GRK5, which lack a pleckstrin homology domain, revealed in vitro binding properties similar to those of GRK2, Maltose-binding protein caveolin and glutathione S-transferase-GRK fusion proteins were used to map overlapping regions in the N termini of both GRK2 and GRK5 that appear to mediate conserved GRK/caveolin interactions. In vivo association of GRK2 and caveolin was suggested by co-fractionation of GRK2 with caveolin in A431 and NIH-3T3 cells and was further supported by co-immunoprecipitation of GRK2 and caveolin in COS-l cells. Functional significance for the GRK/caveolin interaction was demonstrated by the potent inhibition of GRK-mediated phosphorylation of both receptor and peptide substrates by caveolin-1 and -3 scaffolding domain peptides, These data reveal a novel mode for the regulation of GRKs that is likely to play an important role in their cellular function.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Jefferson University; Jefferson University; Jefferson University; Yeshiva University; Albert Einstein College of Medicine	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu	Carman, Christopher/L-8108-2016; Lisanti, Michael P/C-6866-2013; Carman, Christopher V./AAX-8995-2020; Lisanti, Michael/B-6131-2018	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548; Lisanti, Michael/0000-0003-2034-1382	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944, R29GM050443] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM44944, GM50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; KEEN JH, 1990, ADV CELL BIOL, V3, P153; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; KIM CM, 1993, RECEPTOR, V3, P39; Kudej RK, 1997, J MOL CELL CARDIOL, V29, P2735, DOI 10.1006/jmcc.1997.0508; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; Oka N, 1997, AM J PHYSIOL-CELL PH, V273, pC1957, DOI 10.1152/ajpcell.1997.273.6.C1957; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Ping PP, 1997, AM J PHYSIOL-HEART C, V273, pH707, DOI 10.1152/ajpheart.1997.273.2.H707; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; ROETTGER BF, 1995, J CELL BIOL, V128, P1029, DOI 10.1083/jcb.128.6.1029; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	50	149	150	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8858	8864		10.1074/jbc.274.13.8858	http://dx.doi.org/10.1074/jbc.274.13.8858			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085129	hybrid			2022-12-25	WOS:000079451600071
J	Eckhardt, M; Gotza, B; Gerardy-Schahn, R				Eckhardt, M; Gotza, B; Gerardy-Schahn, R			Membrane topology of the mammalian CMP-sialic acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE 3'-PHOSPHATE 5'-PHOSPHOSULFATE; N-ACETYLGLUCOSAMINE TRANSPORTER; UDP-GALACTOSE TRANSPORTER; ALPHA-MANNOSIDASE-II; MOLECULAR-CLONING; GOLGI-APPARATUS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; P-GLYCOPROTEIN	Nucleotide sugar transporters form a family of distantly related membrane proteins of the Golgis apparatus and the endoplasmic reticulum. The first transporter sequences have been identified within the last 2 years. However, information about the secondary and tertiary structure for these molecules has been limited to theoretical considerations. In the present study, an epitope-insertion approach was used to investigate the membrane topology of the CMP-sialic acid transporter. Immunofluorescence studies were carried out to analyze the orientation of the introduced epitopes in semipermeabilized cells. Both an amino-terminally introduced FLAG sequence and a carboxyl-terminal hemagglutinin tag were found to be oriented toward the cytosol. Results obtained with CMP sialic acid transporter variants that contained the hemagglutinin epitope in potential intermembrane loop structures were in good correlation with the presence of 10 transmembrane regions. This building concept seems to be preserved also in other mammalian and nonmammalian nucleotide sugar transporters. Moreover, the functional analysis of the generated mutants demonstrated that insertions in or very close to membrane-spanning regions inactivate the transport process, whereas those in hydrophilic loop structures have no detectable effect on the activity. This study points the way toward understanding structure-function relationships of nucleotide sugar transporters.	Hannover Med Sch, Inst Med Mikrobiol, D-30625 Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	rgs@mikrobio.h.shuttle.de						Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BARON MD, 1990, J BIOL CHEM, V265, P19928; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; CAPASSO JM, 1984, P NATL ACAD SCI-BIOL, V81, P7051, DOI 10.1073/pnas.81.22.7051; CAPASSO JM, 1984, BIOCHIM BIOPHYS ACTA, V777, P133, DOI 10.1016/0005-2736(84)90505-4; CECCHELLI R, 1985, EUR J BIOCHEM, V153, P111, DOI 10.1111/j.1432-1033.1985.tb09275.x; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HARVEY BE, 1993, BIOCHEM BIOPH RES CO, V190, P571, DOI 10.1006/bbrc.1993.1086; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; HIRSCHBERG CB, 1997, GOLGI APPARATUS, P163; Ishida N, 1996, J BIOCHEM, V120, P1074; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KUHN NJ, 1976, BIOCHEM J, V154, P243, DOI 10.1042/bj1540243; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGE Y, 1991, J LIPID RES, V32, P329; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PESSINO A, 1991, J BIOL CHEM, V266, P20213; Reuter G, 1996, BIOL CHEM H-S, V377, P325; ROST B, 1995, PROTEIN SCI, V4, P521; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Slotboom DJ, 1996, J BIOL CHEM, V271, P31317, DOI 10.1074/jbc.271.49.31317; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WHITE SH, 1990, J MEMBRANE BIOL, V115, P145, DOI 10.1007/BF01869453; YAMAGUCHI A, 1992, FEBS LETT, V307, P229, DOI 10.1016/0014-5793(92)80773-A; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	52	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8779	8787		10.1074/jbc.274.13.8779	http://dx.doi.org/10.1074/jbc.274.13.8779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085119	hybrid			2022-12-25	WOS:000079451600061
J	Hanachi, P; Hershey, JWB; Vornlocher, HP				Hanachi, P; Hershey, JWB; Vornlocher, HP			Characterization of the p33 subunit of eukaryotic translation initiation factor-3 from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; RABBIT RETICULOCYTES; PRT1 PROTEIN; FACTOR EIF3; YEAST; COMPLEX; IDENTIFICATION; DIVERSITY; COMPONENT; DOMAIN	Eukaryotic translation initiation factor-3 (eIF3) is a large multisubunit complex that binds to the 40 S ribosomal subunit and promotes the binding of methionyl-tRNA(i) and mRNA. The molecular mechanism by which eIF3 exerts these functions is incompletely understood. We report here the cloning and characterization of TIF35, the Saccharomyces cerevisiae gene encoding the p33 subunit of eIF3. p33 is an essential protein of 30,501 Da that is required in vivo for initiation of protein synthesis. Glucose repression of TIF35 expressed from a GAL1 promoter results in depletion of both the p33 and p89 subunits. Expression of histidine-tagged p33 in yeast in combination with Ni2+ affinity chromatography allows the isolation of a complex containing the p135, p110, p90, p39, and p38 subunits of eIF3. The p33 subunit binds both mRNA and rRNA fragments due to an RNA recognition motif near its C terminus. Deletion of the C-terminal 71 amino acid residues causes loss of RNA binding, but expression of the truncated form as the sole source of p33 nevertheless supports the slow growth of yeast. These results indicate that the p33 subunit of eIF3 plays an important role in the initiation phase of protein synthesis and that its RNA-binding domain is required for optimal activity.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Hershey, JWB (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; Block KL, 1998, J BIOL CHEM, V273, P31901, DOI 10.1074/jbc.273.48.31901; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CIGAN AM, 1987, GENE, V59, P1; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; EVANS DRH, 1995, MOL CELL BIOL, V15, P4525; FEINBERG B, 1982, J BIOL CHEM, V257, P846; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; Greenberg JR, 1998, J BIOL CHEM, V273, P23485, DOI 10.1074/jbc.273.36.23485; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; Guthrie C, 1991, GUIDE YEAST GENETICS; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Staehelin T, 1979, Methods Enzymol, V60, P136; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	34	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8546	8553		10.1074/jbc.274.13.8546	http://dx.doi.org/10.1074/jbc.274.13.8546			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085088	hybrid			2022-12-25	WOS:000079451600030
J	Pei, DQ				Pei, DQ			Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; GELATINASE-A; CELL-SURFACE; MT-MMPS; DIFFERENTIAL EXPRESSION; HUMAN STROMELYSIN-3; BREAST-CARCINOMA; MESSENGER-RNA; STROMAL CELLS; CANCER CELLS	A new member of the membrane-type matrix metalloproteinase (MT-MMP) subfamily tentatively named MT5-MMP was isolated from mouse brain cDNA library. It is predicted to contain (i) a candidate signal sequence, (ii) a propeptide region with the highly conserved PRCGVPD sequence, (iii) a potential furin recognition motif RRRRNKR, (iv) a zinc-binding catalytic domain, (v) a hemopexin-like domain, (vi) a 24 residue hydrophobic domain as a potential transmembrane domain, and (vii) a short cytosolic domain. Reverse transcriptase-polymerase chain reaction analysis of its transcripts indicates that MT5-MMP is expressed in a brain-specific manner consistent with the origin of its EST clone from cerebellum. It is also highly expressed during embryonic development at stages day 11 and 15. Like other MT-MMPs, MT5-MMP specifically activates progelatinase A when co-expressed in Madin-Darby canine kidney cells. Its ability to activate progelatinase A is dependent on its proteolytic activity since a mutation converting Glu to Ala in the zinc binding motif HE(255)LGH renders MT5-MMP inactive against progelatinase A. In contrast to other MT-MMPs, MT5-MMP tends to shed from cell surface as soluble proteinases, thus offering flexibility as both a cell bound and soluble proteinase for extracellular matrix remodeling processes. Taken together, these properties serve to distinguish MT5-MMP as a versatile MT-MMP playing an important role in extracellular matrix remodeling events in the brain and during embryonic development.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Gilles C, 1996, INT J CANCER, V65, P209; Imai K, 1996, CANCER RES, V56, P2707; Imamura T, 1998, J CANCER RES CLIN, V124, P65, DOI 10.1007/s004320050137; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Li H, 1998, MOL CARCINOGEN, V22, P84; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Matsumoto SI, 1997, BBA-GENE STRUCT EXPR, V1354, P159, DOI 10.1016/S0167-4781(97)00120-6; Nagase H, 1998, Cell Res, V8, P179; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohtani H, 1996, INT J CANCER, V68, P565, DOI 10.1002/(SICI)1097-0215(19961127)68:5<565::AID-IJC2>3.0.CO;2-X; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shofuda K, 1997, J BIOL CHEM, V272, P9749; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Theret N, 1998, AM J PATHOL, V153, P945, DOI 10.1016/S0002-9440(10)65636-2; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Ueno H, 1997, CANCER RES, V57, P2055; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1996, KIDNEY INT, V49, pS68; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yamamoto M, 1996, CANCER RES, V56, P384	38	215	224	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8925	8932		10.1074/jbc.274.13.8925	http://dx.doi.org/10.1074/jbc.274.13.8925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085137	hybrid			2022-12-25	WOS:000079451600079
J	Soskic, V; Nyakatura, E; Roos, M; Muller-Esterl, W; Godovac-Zimmermann, J				Soskic, V; Nyakatura, E; Roos, M; Muller-Esterl, W; Godovac-Zimmermann, J			Correlations in palmitoylation and multiple phosphorylation of rat bradykinin B-2 receptor in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; MASS-SPECTROMETRY; B2 RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BOVINE RHODOPSIN; KINASE; IDENTIFICATION	Rat bradykinin B-2 receptor from unstimulated Chinese hamster ovary cells transfected with the corresponding cDNA has been isolated, and subsequent mass spectrometric analysis of multiple phosphorylated species and of the palmitoylation attachment site is described. Bradykinin B-2 receptor was isolated on oligo(dT)-cellulose using N-(epsilon-maleimidocaproyloxy) succinimide-Met-lys-bradykinin coupled to a protected (dA)(30)-mer. This allowed a one-step isolation of the receptor on an oligo(dT)-cellulose column via variation solely of salt concentration. After enzymatic in-gel digestion, matrix-assisted laser desorption ionization and electrospray ion trap mass spectrometric analysis of the isolated rat bradykinin B-2 receptor showed phosphorylation at Ser(365), Ser(371), Ser(378), Ser(380), and Thr(374). Further phosphorylation at Tyr(362) and Tyr(161) was observed. Rat bradykinin receptor B-2 receptor is also palmitoylated at Cys(356). All of the phosphorylation sites except for Tyr(161) cluster at the carboxyl-terminal domain of the receptor located on the cytoplasmic face of the cell membrane. Surprisingly, many of the post-translational modifications were shown by MSn mass spectroscopic analysis to be correlated pairwise, e.g. diphosphorylation at Ser(365) and Ser(371), at Ser(378) and Ser(380), and at Thr(374) and Ser(380) as well as mutually exclusive phosphorylation at Tyr(352) and palmitoylation at Cys(356). The last correlation may be involved in a receptor internalization motif. Pairwise correlations and mutual exclusion of phosphorylation and palmitoylation suggest critical roles of multiple post-translational modifications for the regulation of activity, coupling to intracellular signaling pathways, and/or sequestration of the bradykinin receptor.	Inst Mol Biotechnol eV, D-07745 Jena, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Godovac-Zimmermann, J (corresponding author), UCL, Ctr Mol Med, 5 Univ St, London WC1E 6JJ, England.	j.godovac-zimmermann@ucl.ac.uk	Zimmermann, Jasminka Godovac/E-6863-2010					AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; GODOVACZIMMERMA.J, 1999, IN PRESS ELECTROPHOR; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; KHOUJA A, 1992, J DEV PHYSIOL, V18, P263; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; Minshall RD, 1997, CIRC RES, V81, P848; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Ohguro H, 1996, J BIOL CHEM, V271, P5215; Ottleben H, 1997, EUR J BIOCHEM, V244, P471, DOI 10.1111/j.1432-1033.1997.00471.x; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PARK J, 1994, BRAZ J MED BIOL RES, V27, P1707; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; REGOLI D, 1980, PHARMACOL REV, V32, P1; Roos M, 1998, J BIOL CHEM, V273, P924, DOI 10.1074/jbc.273.2.924; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; Taketo M, 1997, BBA-MOL CELL RES, V1355, P89, DOI 10.1016/S0167-4889(96)00126-7; Taylor JA, 1996, RAPID COMMUN MASS SP, V10, P679, DOI 10.1002/(SICI)1097-0231(199604)10:6<679::AID-RCM528>3.0.CO;2-Q; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61	44	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8539	8545		10.1074/jbc.274.13.8539	http://dx.doi.org/10.1074/jbc.274.13.8539			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085087	hybrid			2022-12-25	WOS:000079451600029
J	Stefaner, I; Praetor, A; Hunziker, W				Stefaner, I; Praetor, A; Hunziker, W			Nonvectorial surface transport, endocytosis via a di-leucine-based motif, and bidirectional transcytosis of chimera encoding the cytosolic tail of rat FcRn expressed in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; GOLGI NETWORK LOCALIZATION; CYTOPLASMIC DOMAIN DETERMINANT; MANNOSE 6-PHOSPHATE RECEPTOR; BASOLATERAL SORTING SIGNAL; KINASE-II PHOSPHORYLATION; COATED PIT LOCALIZATION; MDCK CELLS; HUMAN PLACENTA; CALMODULIN ANTAGONIST	Transfer of passive immunity from the mother to the fetus or newborn involves the transport of IgG across several epithelia, Depending on the species, IgG is transported prenatally across the placenta and yolk sac or is absorbed from colostrum and milk by the small intestine of the suckling newborn. In both cases apical to basolateral transepithelial transport of IgG is thought to be mediated by FcRn, an IgG Fc receptor with homology to major histocompatibility class I antigens, Here, we analyzed the intracellular routing of chimera encoding the rat FcRn tail fused to the ecto- and transmembrane domain of the macrophage Fc gamma RIIb, Newly synthesized chimera were delivered in a nonvectorial manner to the apical and basolateral cell surface, from where the chimera were able to internalize and transcytose, Apical to basolateral and basolateral to apical transcytosis were differently regulated. This intracellular routing of the chimera is similar to that of the native FcRn, indicating that the cytosolic tail of the receptor is necessary and sufficient to endow an unrelated FcR with the intracellular transport behavior of FcRn, Furthermore, the di-leucine motif in the cytosolic domain of FcRn was required for rapid and efficient endocytosis but not for basolateral sorting of the chimera.	Univ Lausanne, BIL Biomed Res Ctr, Inst Biochem, CH-1066 Epalinges, Switzerland	University of Lausanne	Hunziker, W (corresponding author), Univ Lausanne, BIL Biomed Res Ctr, Inst Biochem, 155 Ch des Boveresses, CH-1066 Epalinges, Switzerland.	Walter.Hunziker@ib.unil.ch	Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; Ellinger, Isabella/0000-0001-6335-076X				APODACA G, 1994, J BIOL CHEM, V269, P19005; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BRAMBELL FWR, 1956, PROC R SOC SER B-BIO, V145, P170, DOI 10.1098/rspb.1956.0024; BRAMBELL FWR, 1954, LANCET, V1, P964; Brambell FWR., 1970, N HOLL RES MONOGR FR, V18; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Cardone MH, 1996, J CELL BIOL, V133, P997, DOI 10.1083/jcb.133.5.997; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; Chapin SJ, 1996, J BIOL CHEM, V271, P1336, DOI 10.1074/jbc.271.3.1336; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1998, J MAMMARY GLAND BIOL, V3, P287, DOI 10.1023/A:1018715511178; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; Leach JL, 1996, J IMMUNOL, V157, P3317; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MELLMAN IS, 1983, J CELL BIOL, V96, P887, DOI 10.1083/jcb.96.3.887; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; MORRIS B, 1974, J PHYSIOL-LONDON, V241, P761, DOI 10.1113/jphysiol.1974.sp010683; Mostov KE, 1995, COLD SPRING HARB SYM, V60, P775, DOI 10.1101/SQB.1995.060.01.083; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Reich V, 1996, J CELL SCI, V109, P2133; RODEWALD R, 1980, J CELL BIOL, V85, P18, DOI 10.1083/jcb.85.1.18; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WHITNEY JA, 1995, CELL, V83, P703	60	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8998	9005		10.1074/jbc.274.13.8998	http://dx.doi.org/10.1074/jbc.274.13.8998			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085147	hybrid			2022-12-25	WOS:000079451600089
J	Tamatani, M; Che, YH; Matsuzaki, H; Ogawa, S; Okado, H; Miyake, S; Mizuno, T; Tohyama, M				Tamatani, M; Che, YH; Matsuzaki, H; Ogawa, S; Okado, H; Miyake, S; Mizuno, T; Tohyama, M			Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NF kappa B activation in primary hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INDUCED APOPTOSIS; RECOMBINANT ADENOVIRUS; PREVENTS APOPTOSIS; GLOBAL-ISCHEMIA; TRANSGENIC MICE; GROWTH-FACTORS; FACTOR-ALPHA; INDUCTION; INHIBITION	Emerging data indicate that tumor necrosis factor (TNF) exerts a neuroprotective effect in response to brain injury. Here we examined the mechanism of TNF in preventing neuronal death in primary hippocampal neurons. TNF protected neurons against hypoxia- or nitric oxide-induced injury, with an increase in the antiapoptotic proteins Bcl-2 and Bcl-x as determined by Western blot and reverse transcriptase-polymerase chain reaction analysis. Treatment of neurons with an antisense oligonucleotide to bcl-2 mRNA or that to bcl-x mRNA blocked the up-regulation of Bcl-2 or Bcl-x expression, respectively, and partially inhibited the neuroprotective effect induced by TNF. Moreover, adenovirus-mediated overexpression of Bcl-2 significantly inhibited hypoxia- or nitric oxide-induced neuronal death. To examine the possible involvement of a transcription factor, NF kappa B, in the regulation of Bcl-2 and Bcl-x expression in TNF-treated neurons, an adenoviral vector capable of expressing a mutated form of I kappa B was used to infect neurons prior to TNF treatment. Expression of the mutant NF kappa B completely inhibited NF kappa B DNA binding activity and inhibited both TNF-induced up-regulation of Bcl-2 and Bcl-x expression and neuroprotective effect. These findings indicate that induction of Bcl-2 and Bcl-x expression through NF kappa B activation is involved in the neuroprotective action of TNF against hypoxia- or nitric oxide-induced injury.	Osaka Univ, Sch Med, Dept Anat & Neurosci, Osaka 5650872, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurobiol, Tokyo 1838526, Japan	Osaka University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Tamatani, M (corresponding author), Osaka Univ, Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Osaka 5650872, Japan.	tama@anat2.med.osaka-u.ac.jp	MATSUZAKI, HIDEO/AAE-5246-2020	MATSUZAKI, HIDEO/0000-0002-6869-1261				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARBARA JAJ, 1994, EMBO J, V13, P843, DOI 10.1002/j.1460-2075.1994.tb06327.x; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BESSHO R, 1994, BIOCHEM PHARMACOL, V48, P1883, DOI 10.1016/0006-2952(94)90586-X; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; FRANKOWSKI H, 1995, NEUROREPORT, V6, P1919; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Isenmann S, 1998, BRAIN PATHOL, V8, P49; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Okuyama T, 1998, GENE THER, V5, P1047, DOI 10.1038/sj.gt.3300704; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SATO T, 1994, P NATL ACAD SCI USA, V94, P5113; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Tamatani M, 1998, CELL DEATH DIFFER, V5, P911, DOI 10.1038/sj.cdd.4400439; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG ZH, 1995, J IMMUNOL, V155, P3722; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	48	509	542	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8531	8538		10.1074/jbc.274.13.8531	http://dx.doi.org/10.1074/jbc.274.13.8531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085086	hybrid			2022-12-25	WOS:000079451600028
J	Sun, H; Molday, RS; Nathans, J				Sun, H; Molday, RS; Nathans, J			Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; HAMSTER P-GLYCOPROTEIN; DRUG TRANSPORT; FUNCTIONAL RECONSTITUTION; FUNDUS FLAVIMACULATUS; RIM PROTEIN; MACULAR DEGENERATION; PIGMENT EPITHELIUM; CYSTIC-FIBROSIS; VISUAL PIGMENTS	Many substrates for P-glycoprotein, an ABC transporter that mediates multidrug resistance in mammalian cells, have been shown to stimulate its ATPase activity in vitro. In the present study, we used this property as a criterion to search for natural and artificial substrates and/or allosteric regulators of ABCR, the rod photoreceptor-specific ABC transporter responsible for Stargardt disease, an early onset macular degeneration. ABCR was immunoaffinity purified to apparent homogeneity from bovine rod outer segments and reconstituted into liposomes, All-trans-retinal, a candidate ligand, stimulates the ATPase activity of ABCR 3-4-fold, with a half-maximal effect at 10-15 mu M. 11-cis- and 13-cis-retinal show similar activity. All-trans-retinal stimulates the ATPase activity of ABCR with Michaelis-Menten behavior indicative of simple noncooperative binding that is associated with a rate-limiting enzyme-substrate intermediate in the pathway of ATP hydrolysis. Among 37 structurally diverse non-retinoid compounds, including nine previously characterized substrates or sensitizers of P-glycoprotein, only four show significant ATPase stimulation when tested at 20 mu M. The dose-response curves of these four compounds are indicative of multiple binding sites and/or modes of interaction with ABCR, Two of these compounds, amiodarone and digitonin, can act synergistically with all-trans retinal, implying that they interact with a site or sites on ABCR different from the one with which all-trans-retinal interacts, Unlike retinal, amiodarone appears to interact with both free and ATP-bound ABCR, Together with clinical observations on Stargardt disease and the localization of ABCR to rod outer segment disc membranes, these data suggest that retinoids, and most likely retinal, are the natural substrates for transport by ABCR in rod outer segments. These observations have significant implications for understanding the visual cycle and the pathogenesis of Stargardt disease and for the identification of compounds that could modify the natural history of Stargardt disease or other retinopathies associated with impaired ABCR function.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Neurosci, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Ophthalmol, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Sch Med, Baltimore, MD 21205 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of British Columbia	Nathans, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 805 PCTB,725 N Wolfe St, Baltimore, MD 21205 USA.	jnathans@jhmi.edu		Nathans, Jeremy/0000-0001-8106-5460				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COOK NJ, 1988, J BIOL CHEM, V263, P11382; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; Corson DW, 1996, PHOTOCHEM PHOTOBIOL, V63, P595, DOI 10.1111/j.1751-1097.1996.tb05661.x; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327; DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; DOWLING JE, 1958, P NATL ACAD SCI USA, V44, P648, DOI 10.1073/pnas.44.7.648; Dryja T. P., 1998, SCIENCE, V279; DUNN S, 1994, BIOCHEMISTRY-US, V33, P757; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; ELDRED GE, 1998, RETINAL PIGMENT EPIT, P651; FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; GLENN AM, 1994, RETINA-J RET VIT DIS, V14, P27, DOI 10.1097/00006982-199401000-00006; Guymer R, 1998, RETINAL PIGMENT EPIT, P693; HARLOW E, 1988, ANTIBODIES LAB MANUA, P300; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; KLEIN BA, 1967, AM J OPHTHALMOL, V64, P3; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P183; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649; OKANO T, 1989, BIOCHEMISTRY-US, V28, P8848, DOI 10.1021/bi00448a025; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; POO MM, 1974, NATURE, V247, P438, DOI 10.1038/247438a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; RANDO RR, 1990, ANGEW CHEM INT EDIT, V29, P461, DOI 10.1002/anie.199004611; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Rebbeor JF, 1998, BBA-BIOMEMBRANES, V1369, P85, DOI 10.1016/S0005-2736(97)00185-5; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; RODEN DM, 1996, PHARMACOL BASIS THER, P858; RODIECK RW, 1998, 1 STEPS SEEING, P155; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SEGEL IH, 1976, BIOCH CALCULATIONS, P246; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Sharom FJ, 1996, BIOCHEM J, V320, P421, DOI 10.1042/bj3200421; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; Thomson JL, 1997, CURR EYE RES, V16, P741, DOI 10.1076/ceyr.16.7.741.5060; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812	68	286	294	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8269	8281		10.1074/jbc.274.12.8269	http://dx.doi.org/10.1074/jbc.274.12.8269			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075733	hybrid			2022-12-25	WOS:000079268100092
J	Englaro, W; Bahadoran, P; Bertolotto, C; Busca, R; Derijard, B; Livolsi, A; Peyron, JF; Ortonne, JP; Ballotti, R				Englaro, W; Bahadoran, P; Bertolotto, C; Busca, R; Derijard, B; Livolsi, A; Peyron, JF; Ortonne, JP; Ballotti, R			Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation	ONCOGENE			English	Article						TNF alpha; inhibition of melanogenesis; tyrosinase; NF kappa B; melanoma cells	MELANOCYTE-STIMULATING HORMONE; TYROSINASE ACTIVITY; ULTRAVIOLET-LIGHT; PROTEIN-KINASES; CELL-DEATH; PHOSPHORYLATION; DEGRADATION; KERATINOCYTES; TRANSCRIPTION; CYTOKINES	Melanogenesis is a physiological process resulting in the synthesis of melanin pigments which play a crucial protective role against skin photocarcinogenesis. lit vivo, solar ultraviolet light triggers the secretion of numerous keratinocyte-derived factors that are implicated in the regulation of melanogenesis. Among these, tumor necrosis factor alpha. (TNF alpha), a cytokine implicated in the pro-inflammatory response, down-regulates pigment synthesis in vitro. In this report, we aimed to determine the molecular mechanisms by which this cytokine inhibits melanogenesis in B16 melanoma cells. First, we show that TNF alpha inhibits the activity and protein expression of tyrosinase which is the key enzyme of melanogenesis, Further, we demonstrate that this effect is subsequent to a down-regulation of the tyrosinase promoter activity in both basal and cAMP-induced melanogenesis, Finally, we present evidence indicating that the inhibitory effect of TNF alpha on melanogenesis is dependent on nuclear factor kappa B (NF kappa B) activation. Indeed, overexpression of this transcription factor in B16 cells is sufficient to inhibit tyrosinase promoter activity, Furthermore, a mutant of inhibitory kappa B (I kappa B), that prevents NF kappa B activation, is able to revert the effect of TNF alpha on the tyrosinase promoter activity. Taken together, our results clarify the mechanisms by which TNF alpha inhibits pigmentation and point out the key role of NF kappa B in the regulation of melanogenesis.	Fac Med, INSERM, U385, F-06107 Nice 2, France; Fac Med, CJF 9605, F-06107 Nice, France; Fac Sci, Ctr Biochim, CNRS, UMR 134, F-06018 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013; Bertolotto-Ballotti, Corine/O-2155-2016	Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X; Bertolotto, Corine/0000-0001-6971-7753; Bahadoran, Philippe/0000-0002-2481-0556; BALLOTTI, Robert/0000-0002-7322-4908				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bennicelli J L, 1993, Exp Dermatol, V2, P186, DOI 10.1111/j.1600-0625.1993.tb00031.x; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HUNT G, 1994, J CELL SCI, V107, P205; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OKEEFE E, 1974, P NATL ACAD SCI USA, V71, P2500, DOI 10.1073/pnas.71.6.2500; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1989, J IMMUNOL, V142, P1943; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	33	56	59	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1553	1559		10.1038/sj.onc.1202446	http://dx.doi.org/10.1038/sj.onc.1202446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102625				2022-12-25	WOS:000078770700005
J	Bonini, MG; Radi, R; Ferrer-Sueta, G; Ferreira, AMD; Augusto, O				Bonini, MG; Radi, R; Ferrer-Sueta, G; Ferreira, AMD; Augusto, O			Direct EPR detection of the carbonate radical anion produced from peroxynitrite and carbon dioxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; FLASH-PHOTOLYSIS; AQUEOUS-SOLUTION; SUPEROXIDE; DECOMPOSITION; OXIDATIONS; RESONANCE; CHEMISTRY; TYROSINE; KINETICS	The biological effects of peroxynitrite have been recently considered to be largely dependent on its reaction with carbon dioxide, which is present in high concentrations in intra- and extracellular compartments, Peroxynitrite anion (ONOO-) reacts rapidly with carbon dioxide, forming an adduct, nitrosoperoxocarboxylate (ONOOCO2-), whose decomposition has been proposed to produce reactive intermediates such as the carbonate radical (CO3radical anion). Here, by the use of rapid mixing continuous flow electron paramagnetic resonance (EPR), we directly detected the carbonate radical in flow mixtures of peroxynitrite with bicarbonate-carbon dioxide over the pH range of 6-9. The radical was unambiguously identified by its EPR parameters (g = 2.0113; line width = 5.5 G) and by experiments with bicarbonate labeled with C-13. In this case, the singlet EPR signal obtained with C-12 bicarbonate splits into the expected doublet because of C-13 (a(C-13)= 11.7 G). The singlet spectrum of the unlabeled radical was invariant between pH 6 and 9, confirming that in this pH range the detected radical is the carbonate radical anion (CO3radical anion). Importantly, in addition to contributing to the understanding of nitrosoperoxocarboxylate decomposition pathways, this is the first report unambiguously demonstrating the formation of the carbonate radical anion at physiological pHs by direct EPR spectroscopy.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Quim, BR-05599970 Sao Paulo, Brazil; Univ Republ, Fac Ciencias, Unidad Asociada Enzimol, Montevideo 11800, Uruguay; Univ Republ, Fac Med, Dept Bioquim, Montevideo 11800, Uruguay	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidad de la Republica, Uruguay; Universidad de la Republica, Uruguay	Augusto, O (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, Caixa Postal 26077, BR-05599970 Sao Paulo, Brazil.		Ferrer-Sueta, Gerardo/C-3316-2011; Da Costa Ferreira, Ana Maria/C-2244-2012; Augusto, Ohara/D-3839-2012	Ferrer-Sueta, Gerardo/0000-0002-8663-8480; Da Costa Ferreira, Ana Maria/0000-0001-9898-1692; Augusto, Ohara/0000-0002-7220-4286				[Anonymous], [No title captured]; Augusto O, 1996, BRAZ J MED BIOL RES, V29, P853; AUGUSTO O, 1994, ARCH BIOCHEM BIOPHYS, V310, P118, DOI 10.1006/abbi.1994.1147; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BEHAR D, 1972, J PHYS CHEM-US, V76, P1710, DOI 10.1021/j100656a007; Bisby RH, 1998, J CHEM SOC FARADAY T, V94, P2069, DOI 10.1039/a801239c; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; CHANTRY GW, 1962, MOL PHYS, V5, P589, DOI 10.1080/00268976200100671; CHEN S, 1973, J PHYS CHEM-US, V77, P1111, DOI 10.1021/j100628a006; Dean J.A., 1979, LANGES HDB CHEM, Vtwelth, P5; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; ERIKSEN TE, 1985, RADIAT PHYS CHEM, V26, P197, DOI 10.1016/0146-5724(85)90185-2; Gatti RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P36, DOI 10.1006/abbi.1997.0451; Goldstein S, 1998, J AM CHEM SOC, V120, P3458, DOI 10.1021/ja9733043; GOMES LF, 1996, THESIS U SAO PAULO; HISATSUN.IC, 1970, J PHYS CHEM-US, V74, P3225, DOI 10.1021/j100711a013; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEVINSKY NG, 1994, HARRISONS PRINCIPLES, P253; LILIE J, 1978, RADIAT PHYS CHEM, V11, P225, DOI 10.1016/0146-5724(78)90101-2; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Lymar SV, 1998, INORG CHEM, V37, P294, DOI 10.1021/ic970946i; MEHLHORN RJ, 1972, MEMBRANE MOL BIOL, P192; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Merenyi G, 1997, CHEM RES TOXICOL, V10, P1216, DOI 10.1021/tx970101j; Merenyi G, 1998, CHEM RES TOXICOL, V11, P712, DOI 10.1021/tx980043h; MICHELSON AM, 1983, BIOCHIMIE, V65, P95, DOI 10.1016/S0300-9084(83)80179-5; PRYOR WA, 1988, FREE RADICAL BIO MED, V4, P219, DOI 10.1016/0891-5849(88)90043-3; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; Saha A, 1998, FREE RADICAL BIO MED, V24, P653, DOI 10.1016/S0891-5849(97)00365-1; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; SYMONS M, 1987, CHEM BIOCH ASPECTS E, P16; TREININ A, 1970, J AM CHEM SOC, V92, P5821, DOI 10.1021/ja00723a001; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; Wertz J.E., 1972, ELECTRON SPIN RESON, P450; WOLCOTT RG, 1994, J BIOL CHEM, V269, P9721	43	269	276	3	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10802	10806		10.1074/jbc.274.16.10802	http://dx.doi.org/10.1074/jbc.274.16.10802			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196155	hybrid			2022-12-25	WOS:000079751900023
J	Stoss, O; Schwaiger, FW; Cooper, TA; Stamm, S				Stoss, O; Schwaiger, FW; Cooper, TA; Stamm, S			Alternative splicing determines the intracellular localization of the novel nuclear protein Nop30 and its interaction with the splicing factor SRp30c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; C-TERMINAL DOMAIN; MESSENGER-RNA; FIBRILLAR CENTERS; SERINE-RICH; SR PROTEINS; IN-VIVO; EXPRESSION; GENE; TRANSCRIPTION	We report on the molecular cloning of a novel human cDNA by its interaction with the splicing factor SRp30c in a yeast two-hybrid screen. This cDNA is predominantly expressed in muscle and encodes a protein that is present in the nucleoplasm and concentrated in nucleoli. It was therefore termed Nop30 (nucleolar protein of 30 kDa). We have also identified a related cDNA with a different carboxyl terminus. Sequencing of the NOP gene demonstrated that both cDNAs are generated by alternative 5' splice site usage from a single gene that consists of four exons, spans at least 1800 nucleotides, and is located on chromosome 16q21-q23. The alternative 5' splice site usage introduces a frameshift creating two different carboxyl termini. The carboxyl terminus of Nop30 is rich in serines and arginines and has been found to target the protein into the nucleus, whereas its isoform is characterized by proline/glutamic acid dipeptides in its carboxyl terminus and is predominantly found in the cytosol. Interaction studies in yeast, in vitro protein interaction assays, and co-immunoprecipitations demonstrated that Nop30 multimerizes and binds to the RS domain of SRp30c but not to other splicing factors tested. Overexpression of Nop30 changes alternative exon usage in preprotachykinin and SRp20 reporter genes, suggesting that Nop30 influences alternative splice site selection in vivo.	Max Planck Inst Neurobiol, D-82152 Martinsried, Germany; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Max Planck Society; Baylor College of Medicine; Baylor College of Medicine	Stamm, S (corresponding author), Max Planck Inst Neurobiol, Am Klopferspitz 18A, D-82152 Martinsried, Germany.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045565, R29HL045565] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BORGESE N, 1993, FEBS LETT, V325, P70, DOI 10.1016/0014-5793(93)81416-W; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; delaLuna S, 1996, J CELL SCI, V109, P2443; DERENZINI M, 1993, J HISTOCHEM CYTOCHEM, V41, P829, DOI 10.1177/41.6.8315275; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1995, RNA, V1, P663; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Geertman R, 1996, BBA-GENE STRUCT EXPR, V1306, P147, DOI 10.1016/0167-4781(96)00036-X; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; Hanamura A, 1998, RNA, V4, P430; HANAUER A, 1983, NUCLEIC ACIDS RES, V11, P3503, DOI 10.1093/nar/11.11.3503; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; IWATA H, 1995, UROL RES, V23, P27, DOI 10.1007/BF00298847; JORDAN EG, 1981, J CELL SCI, V52, P373; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Korb J, 1996, ACTA VIROL, V40, P81; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATTOX W, 1991, GENE DEV, V5, P786, DOI 10.1101/gad.5.5.786; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MCLONE DG, 1975, AM J ANAT, V142, P273, DOI 10.1002/aja.1001420302; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MIKHAYLOVA VT, 1994, EXP CELL RES, V212, P10, DOI 10.1006/excr.1994.1112; Monaghan KG, 1997, AM J MED GENET, V73, P180, DOI 10.1002/(SICI)1096-8628(1997)73:2<180::AID-AJMG13>3.0.CO;2-Q; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; OCHS R, 1983, EXP CELL RES, V146, P139, DOI 10.1016/0014-4827(83)90332-4; OCHS RL, 1989, EXP CELL RES, V184, P552, DOI 10.1016/0014-4827(89)90354-6; Ochs RL, 1996, MOL BIOL CELL, V7, P1015, DOI 10.1091/mbc.7.7.1015; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; PFEFFER U, 1995, CANCER RES, V55, P2158; Sambrook J., 2002, MOL CLONING LAB MANU; Sarkissian M, 1996, J BIOL CHEM, V271, P31106, DOI 10.1074/jbc.271.49.31106; SCHMAUSS C, 1989, NUCLEIC ACIDS RES, V17, P1733, DOI 10.1093/nar/17.4.1733; SCHMITT AB, 1999, IN PRESS J NEUROBIOL; Schul W, 1998, J CELL BIOCHEM, V70, P159, DOI 10.1002/(SICI)1097-4644(19980801)70:2<159::AID-JCB2>3.0.CO;2-N; SHAW PJ, 1995, EMBO J, V14, P2896, DOI 10.1002/j.1460-2075.1995.tb07289.x; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Snow BE, 1997, GENOMICS, V43, P165, DOI 10.1006/geno.1997.4794; SOMMERVILLE J, 1986, TRENDS BIOCHEM SCI, V11, P438, DOI 10.1016/0968-0004(86)90242-2; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; SUN Q, 1993, GENE DEV, V7, P3519; Vilardell J, 1997, MOL CELL BIOL, V17, P1959, DOI 10.1128/MCB.17.4.1959; Vissers CJ, 1996, ACTA HISTOCHEM, V98, P113, DOI 10.1016/S0065-1281(96)80028-6; WANG J, 1995, RNA, V1, P335; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	63	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10951	10962		10.1074/jbc.274.16.10951	http://dx.doi.org/10.1074/jbc.274.16.10951			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196175	hybrid			2022-12-25	WOS:000079751900043
J	Zhang, J; Barak, LS; Anborgh, PH; Laporte, SA; Caron, MG; Ferguson, SSG				Zhang, J; Barak, LS; Anborgh, PH; Laporte, SA; Caron, MG; Ferguson, SSG			Cellular trafficking of G protein-coupled receptor/beta-arrestin endocytic complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; INTERNALIZATION SIGNAL; PLASMA-MEMBRANE; DESENSITIZATION; SEQUESTRATION; RESENSITIZATION; PHOSPHORYLATION; KINASE; DEPHOSPHORYLATION	beta-Arrestins are multifunctional proteins identified on the basis of their ability to bind and uncouple G protein-coupled receptors (GPCR) from heterotrimeric G proteins, In addition, beta-arrestins play a central role in mediating GPCR endocytosis, a key regulatory step in receptor resensitization. In this study, we visualize the intracellular trafficking of beta-arrestin2 in response to activation of several distinct GPCRs including the beta(2)-adrenergic receptor (beta(2)AR), angiotensin II type 1A receptor (AT(1A)R), dopamine D1A receptor (D1AR), endothelin type A receptor (ETAR), and neurotensin receptor (NTR). Our results reveal that in response to beta(2)AR activation, beta-arrestin2 translocation to the plasma membrane shares the same pharmacological profile as described for receptor activation and sequestration, consistent with a role for beta-arrestin as the agonist-driven switch initiating receptor endocytosis. Whereas redistributed beta-arrestins are confined to the periphery of cells and do not traffic along with activated beta(2)AR, D1AR, and ETAR in endocytic vesicles, activation of AT(1A)R and NTR triggers a clear time-dependent redistribution of beta-arrestins to intracellular vesicular compartments where they colocalize with internalized receptors. Activation of a chimeric AT(1A)R with the beta(2)AR carboxyl-terminal tail results in a beta-arrestin membrane localization pattern similar to that observed in response to beta(2)AR activation. In contrast, the corresponding chimeric beta(2)AR with the AT(1A)R carboxyl-terminal tail gains the ability to translocate beta-arrestin to intracellular vesicles. These results demonstrate that the cellular trafficking of beta-arrestin proteins is differentially regulated by the activation of distinct GPCRs. Furthermore, they suggest that the carboxyl-tail of the receptors might be involved in determining the stability of receptor/beta-arrestin complexes and cellular distribution of beta-arrestins.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA; Univ Western Ontario, Dept Physiol, John P Robarts Res Inst, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, John P Robarts Res Inst, London, ON N6A 5K8, Canada	Duke University; Duke University; Western University (University of Western Ontario); Western University (University of Western Ontario)	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane/ABC-4228-2021; Laporte, Stephane A/F-3282-2012	Laporte, Stephane/0000-0002-0633-543X; 	NINDS NIH HHS [NS 19576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Bohm SK, 1997, BIOCHEM J, V322, P1; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FERGUSON S, 1996, J PHYSIOL PHARMACOL, V74, P1095; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Krueger KM, 1997, J BIOL CHEM, V272, P5; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	40	185	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10999	11006		10.1074/jbc.274.16.10999	http://dx.doi.org/10.1074/jbc.274.16.10999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196181	hybrid			2022-12-25	WOS:000079751900049
J	Adduci, AJ; Schlegel, R				Adduci, AJ; Schlegel, R			The transmembrane domain of the E5 oncoprotein contains functionally discrete helical faces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PAPILLOMAVIRUS-E5 TRANSFORMING PROTEIN; VACUOLAR H+-ATPASE; BOVINE PAPILLOMAVIRUS; MEMBRANE-PROTEIN; KIN RECOGNITION; ALPHA-HELICES; GOLGI ENZYMES; AMINO-ACIDS; ION-CHANNEL	The E5 protein of bovine papillomavirus is a 44-amino acid, Golgi-resident, type II transmembrane protein that efficiently transforms immortalized mouse fibroblasts. The transmembrane (TM) domain of E5 is not only critical for biological activity, it also regulates interactions with cellular targets including the platelet derived growth factor receptor (PDGF-R) and the 16-kDa subunit of the vacuolar proton ATPase (V-ATPase), In order to define the specific TM amino acids essential for E5 biological and biochemical activity, we performed scanning alanine mutagenesis on 25 of the 30 potential TRI residues and genetically mapped discrete Lu-helical domains which separately regulated the ability of E5 to bind PDGF-R, activate PDGF-R, and to form oligomers. Alanine substitutions at positions 17, 21, and 24 (which lie on the same helical face) greatly inhibited E5 association with the PDGF-R, suggesting that this region comprises the receptor binding site. PDGF-R activation also mapped to a specific but broader domain in E5; mutant proteins with alanines on one helical face (positions 8, 9, 11, 16, 19, 22, and 23) continued to induce PDGF-R tyrosine phosphorylation, whereas mutant proteins with alanines on the opposite helical face (positions 7, 10, 13, 17, 18, 21, 24, and 25) did not, indicating that the latter helical face was critical for mediating receptor transphosphorylation. Interestingly, these "activation-defective" mutants segregated into two classes: 1) those that were unable to form dimers but that could still form higher order oligomers and transform cells, and 2) those that were defective for PDGF-R binding and were transformation-incompetent. These findings suggest that the ability of E5 to dimerize and to bind PDGF-R is important for receptor activation, However, since several transformation-competent E5 mutants were defective for binding and/or activating PDGF-R, it is apparent that E5 must have additional activities to mediate cell transformation. Finally, alanine substitutions also defined two separate helical faces critical for E5/E5 interactions (homodimer formation). Thus, our data identify distinct E5 helical faces that regulate homologous and heterologous intramembrane interactions and define two new classes of biologically active TM mutants.	Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20007 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Sch Med, Dept Pathol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	schleger@medlib.georgetown.edu			NCI NIH HHS [R01 CA-53371] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SCHLEGEL R, 1987, CANCER CELL, V5, P87; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117	41	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10249	10258		10.1074/jbc.274.15.10249	http://dx.doi.org/10.1074/jbc.274.15.10249			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187811	hybrid			2022-12-25	WOS:000079663500050
J	Delphin, C; Ronjat, M; Deloulme, JC; Garin, G; Debussche, L; Higashimoto, Y; Sakaguchi, K; Baudier, J				Delphin, C; Ronjat, M; Deloulme, JC; Garin, G; Debussche, L; Higashimoto, Y; Sakaguchi, K; Baudier, J			Calcium-dependent interaction of S100B with the C-terminal domain of the tumor suppressor p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; WILD-TYPE P53; DNA-BINDING; S-100 PROTEINS; IMMUNOHISTOCHEMICAL LOCALIZATION; OLIGOMERIZATION DOMAIN; CA2+-DEPENDENT MANNER; TRANSCRIPTION FACTORS; IONS BINDING; CELL-CYCLE	Irt vitro, the S100B protein interacts with baculovirus recombinant p53 protein and protects p53 from thermal denaturation, This effect is isoform-specific and is not observed with S100A1, S100A6, or calmodulin, Using truncated p53 proteins in the N-terminal (p53(1-320)) and C-terminal (p53(73-393)) domains, we localized the S100B-binding region to the C-terminal region of p53, We have confirmed a calcium-dependent interaction of the S100B with a synthetic peptide corresponding to the C-terminal region of p53 (residues 319-393 in human p53) using plasmon resonance experiments on a BIAcore system. In the presence of calcium, the equilibrium affinity of the S100B for the C-terminal region of p53 immobilized on the sensor chip was 24 +/- 10 nM. To narrow down the region within p53 involved in S100B binding, two synthetic peptides, O1(357-381) (residues 357-381 in mouse p53) and YF-O2(320-346) (residues 320-346 in mouse p53), covering the C-terminal region of p53 were compared for their interaction with purified S100B, Only YF-O2 peptide interacts with S100B with high affinity. The YF-O2 motif is a critical determinant for the thermostability of p53 and also corresponds to a domain responsible for cytoplasmic sequestration of p53, Our results may explain the rescue of nuclear wild type p53 activities by S100B in fibroblast cell lines expressing the temperature-sensitive p53val135 mutant at the nonpermissive temperature.	CEA Grenoble, INSERM, U244,DBMS,BRCE, Ctr Etud Nucl Grenoble, F-38054 Grenoble 9, France; Ctr Etud Nucl Grenoble, Lab Chim Prot, F-38054 Grenoble, France; Ctr Etud Nucl Grenoble, Lab Canaux Ion & Signalizat, F-38054 Grenoble, France; Rhone Poulenc Rorer SA, Ctr Rech Vitry Alfortville, Inst Biotechnol, F-94403 Vitry Sur Seine, France; NIH, Cell Biol Lab, Bethesda, MD 20892 USA	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; CEA; Sanofi-Aventis; Sanofi France; National Institutes of Health (NIH) - USA	Baudier, J (corresponding author), CEA Grenoble, INSERM, U244,DBMS,BRCE, Ctr Etud Nucl Grenoble, 17 Rue Martyrs, F-38054 Grenoble 9, France.	jbaudier@cea.fr	Baudier, Jacques/O-2183-2016; jacques, baudier/T-3300-2019; Deloulme, Jean Christophe/P-6858-2017; Christian, Delphin/P-9284-2017	Deloulme, Jean Christophe/0000-0002-2234-5865; Christian, Delphin/0000-0003-3240-8695; jacques, baudier/0000-0001-8427-4444; Ronjat, Michel/0000-0002-9728-6425; Higashimoto, Yuichiro/0000-0003-1382-8598				BAUDIER J, 1986, J BIOL CHEM, V261, P8204; BAUDIER J, 1982, FEBS LETT, V147, P165, DOI 10.1016/0014-5793(82)81033-8; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BIANCHI R, 1993, J BIOL CHEM, V268, P12669; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Drohat AC, 1997, PROTEIN SCI, V6, P1577, DOI 10.1002/pro.5560060721; FAN K, 1982, BRAIN RES, V237, P498, DOI 10.1016/0006-8993(82)90462-0; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hermann S, 1998, CELL CALCIUM, V23, P135, DOI 10.1016/S0143-4160(98)90112-9; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; IVANENKOV VV, 1995, J BIOL CHEM, V270, P14651, DOI 10.1074/jbc.270.24.14651; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; MARKS A, 1990, EXP CELL RES, V187, P59, DOI 10.1016/0014-4827(90)90116-R; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; NAKAJIMA T, 1982, AM J SURG PATHOL, V6, P715, DOI 10.1097/00000478-198212000-00003; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Rustandi RR, 1998, BIOCHEMISTRY-US, V37, P1951, DOI 10.1021/bi972701n; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1998, MOL CELL BIOL, V18, P4272, DOI 10.1128/MCB.18.7.4272; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHASHI K, 1984, AM J PATHOL, V116, P497; Tsoporis JN, 1997, J BIOL CHEM, V272, P31915, DOI 10.1074/jbc.272.50.31915; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; VANELDIK LJ, 1986, J HISTOCHEM CYTOCHEM, V34, P977, DOI 10.1177/34.8.3734419; Wilder PT, 1998, PROTEIN SCI, V7, P794, DOI 10.1002/pro.5560070330; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249	47	62	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10539	10544		10.1074/jbc.274.15.10539	http://dx.doi.org/10.1074/jbc.274.15.10539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187847	hybrid			2022-12-25	WOS:000079663500086
J	Nakashima, S; Wang, SL; Hisamoto, N; Sakai, H; Andoh, M; Matsumoto, K; Nozawa, Y				Nakashima, S; Wang, SL; Hisamoto, N; Sakai, H; Andoh, M; Matsumoto, K; Nozawa, Y			Molecular cloning and expression of a stress-responsive mitogen-activated protein kinase-related kinase from Tetrahymena cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; POLYMERASE CHAIN-REACTION; MAP-KINASE; MAMMALIAN-CELLS; DIFFERENTIAL DISPLAY; ARABIDOPSIS-THALIANA; MESSENGER-RNA; SAP KINASES; YEAST; GENE	To identify genes responsive to cold stress, we employed the differential display mRNA analysis technique to isolate a novel gene from Tetrahymena thermophila which encodes a protein kinase of 430 amino acids, A homolog of this kinase with 90% amino acid sequence identity was also found in T, pyriformis. Both kinases contain 11 subdomains typical of protein kinases, Sequence analysis revealed that the predicted amino acid sequences resemble those of mitogen-activated protein kinase (MAPK), especially p38 and stress-activated protein kinase which are known to be involved in various stress responses. However, it should be noted that the tyrosine residue in the normally conserved MAPK phosphorylation site (Thr-X-Tyr) is replaced by histidine (Thr(226)-Gly-His(228)) in this MAPK-related kinase (MRK). The recombinant MRK expressed in Escherichia coli phosphorylated myelin basic protein (MBP) and became autophosphorylated, However, the mutated recombinant protein in which Thr(226) was replaced by Ala lost the ability to phosphorylate MBP, suggesting that Thr(226) residue is essential for kinase activity. The MRK mRNA transcript in T, thermophila increased markedly upon temperature downshift from 35 to 15 degrees C (0.8 degrees C/min), Interestingly, osmotic shock either by sorbitol (100-200 mM) or NaCl (25-100 mM) also induced mRNA expression of the MRK in T, pyriformis. In addition, the activity of the kinase as determined by an immune complex kinase assay using MBP as a substrate was also induced by osmotic stress. This is the first demonstration of a MAPK-related kinase in the unicellular eukaryotic protozoan Tetrahymena that is induced by physical stresses such as cold temperature and osmolarity, The present results suggest that this MRK may function in the stress-signaling pathway in Tetrahymena cells.	Gifu Univ, Sch Med, Dept Biochem, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5008705, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Gifu University; Gifu University; Nagoya University	Nakashima, S (corresponding author), Gifu Univ, Sch Med, Dept Biochem, Tsukasamachi 40, Gifu 5008705, Japan.	bio@cc.gifu-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CUPPLES CG, 1986, P NATL ACAD SCI USA, V83, P5160, DOI 10.1073/pnas.83.14.5160; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Doerig CM, 1996, GENE, V177, P1, DOI 10.1016/0378-1119(96)00281-8; EDAMATSU M, 1991, BIOCHEM BIOPH RES CO, V175, P543, DOI 10.1016/0006-291X(91)91599-8; Elliott A., 1973, BIOL TETRAHYMENA; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALL JG, 1974, P NATL ACAD SCI USA, V71, P3078, DOI 10.1073/pnas.71.8.3078; GASKINS C, 1994, MOL CELL BIOL, V14, P6996, DOI 10.1128/MCB.14.10.6996; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HILL D. L., 1972, BIOCH PHYSL TETRAHYM; HOROWITZ S, 1985, P NATL ACAD SCI USA, V82, P2452, DOI 10.1073/pnas.82.8.2452; ITO T, 1994, FEBS LETT, V351, P231, DOI 10.1016/0014-5793(94)00867-1; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MIZOGUCHI T, 1993, FEBS LETT, V336, P440, DOI 10.1016/0014-5793(93)80852-L; Mizoguchi T, 1997, TRENDS BIOTECHNOL, V15, P15, DOI 10.1016/S0167-7799(96)10074-3; Mizoguchi T, 1996, P NATL ACAD SCI USA, V93, P765, DOI 10.1073/pnas.93.2.765; Nakashima S, 1996, BIOCHEM J, V317, P29, DOI 10.1042/bj3170029; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOZAWA Y, 1988, PHYSL REGULATION MEM, P239; NOZAWA Y, 1979, BIOCH PHYSL PROTOZOA, V2, P275; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Rose MD., 1990, METHODS YEAST GENETI; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; TAKEMASA T, 1990, J BIOL CHEM, V265, P2514; Thompson G.A. Jr, 1984, Biomembranes, V12, P397; UMEKI S, 1982, BIOCHEM INT, V4, P101; UMEKI S, 1993, ADV CELL MOL BIOL M, V2, P447; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; WILSON C, 1993, PLANT MOL BIOL, V23, P543, DOI 10.1007/BF00019302; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289	56	25	29	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9976	9983		10.1074/jbc.274.15.9976	http://dx.doi.org/10.1074/jbc.274.15.9976			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187773	hybrid			2022-12-25	WOS:000079663500012
J	Pilcher, BK; Dumin, J; Schwartz, MJ; Mast, BA; Schultz, GS; Parks, WC; Welgus, HG				Pilcher, BK; Dumin, J; Schwartz, MJ; Mast, BA; Schultz, GS; Parks, WC; Welgus, HG			Keratinocyte collagenase-1 expression requires an epidermal growth factor receptor autocrine mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTITIAL COLLAGENASE; FACTOR-ALPHA; GENE-EXPRESSION; TYROSINE KINASE; 92-KDA GELATINASE; TISSUE INHIBITOR; MICE LACKING; EGF RECEPTOR; HUMAN-SKIN; ACTIVATION	In response to cutaneous injury, expression of collagenase-1 is induced in keratinocytes via alpha(2)beta(1) contact with native type I collagen, and enzyme activity is essential for cell migration over this substratum. However, the cellular mechanism(s) mediating integrin signaling remain poorly understood. We demonstrate here that treatment of keratinocytes cultured on type I collagen with epidermal growth factor receptor (EGFR) blocking antibodies or a specific receptor antagonist inhibited cell migration across type I collagen and the matrix-directed stimulation of collagenase-1 production. Additionally, stimulation of collagenase-1 expression by hepatocyte growth factor, transforming growth factor-beta 1, and interferon-gamma was blocked by EGFR inhibitors, suggesting a required EGFR autocrine signaling step for enzyme expression. Collagenase-1 mRNA was not detectable in keratinocytes isolated immediately from normal skin, but increased progressively following 2 h of contact with collagen, In contrast, EGFR mRNA was expressed at high steady-state levels in keratinocytes isolated immediately from intact skin but was absent following 2 h cell contact with collagen, suggesting down-regulation following receptor activation. Indeed, tyrosine phosphorylation of the EGFR was evident as early as 10 min following cell contact with collagen, Treatment of keratinocytes cultured on collagen with EGFR antagonist or heparin-binding (HB)-EGF neutralizing antibodies dramatically inhibited the sustained expression (6-24 h) of collagenase-1 mRNA, whereas initial induction by collagen alone (2 h) was unaffected. Finally, expression of collagenase-1 in ex vivo wounded skin and re-epithelialization of partial thickness porcine burn wounds was blocked following treatment with EGFR inhibitors. These results demonstrate that keratinocyte contact with type I collagen is sufficient to induce collagenase-1 expression, whereas sustained enzyme production requires autocrine EGFR activation by HB-EGF as an obligatory intermediate step, thereby maintaining collagenase-l-dependent migration during the re-epithelialization of epidermal wounds.	Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Florida, Hlth Sci Ctr, Dept Obstet & Gynecol, Gainesville, FL 32610 USA; Univ Florida, Hlth Sci Ctr, Dept Surg, Gainesville, FL 32610 USA	Washington University (WUSTL); Washington University (WUSTL); State University System of Florida; University of Florida; State University System of Florida; University of Florida	Pilcher, BK (corresponding author), Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA.	bpilcher@im.wustl.edu	Parks, William C./AAH-6786-2021		PHS HHS [K-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BROWN G, 1987, NEW ENGL J MED, V321, P76; BROWN GL, 1986, J EXP MED, V163, P1319; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CHEN YQ, 1992, J INVEST DERMATOL, V98, P615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TW, 1982, COLLAGEN REL RES, V3, P205; CYBULSKY AV, 1994, J CLIN INVEST, V94, P68, DOI 10.1172/JCI117350; Doyle GAR, 1997, J BIOL CHEM, V272, P11840, DOI 10.1074/jbc.272.18.11840; Dunsmore SE, 1996, J BIOL CHEM, V271, P24576, DOI 10.1074/jbc.271.40.24576; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FINI ME, 1994, J BIOL CHEM, V269, P11291; Forsyth IA, 1997, MOL CELL ENDOCRINOL, V126, P41, DOI 10.1016/S0303-7207(96)03967-6; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GULLICK WJ, 1985, PROC R SOC SER B-BIO, V226, P127, DOI 10.1098/rspb.1985.0087; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; IMAI T, 1995, BIOL REPROD, V52, P928, DOI 10.1095/biolreprod52.4.928; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; JIANG CK, 1993, P NATL ACAD SCI USA, V90, P6786, DOI 10.1073/pnas.90.14.6786; JU WD, 1993, J INVEST DERMATOL, V100, P628; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; McCawley LJ, 1997, ENDOCRINOLOGY, V138, P121, DOI 10.1210/en.138.1.121; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Mignatti P., 1996, MOL CELLULAR BIOL WO, P427; Nanney LB, 1996, MOL CELLULAR BIOL WO, P171; PALADINI R, 1995, J CELL BIOL, V132, P381; PARKS WC, 1998, MATRIX METALLOPROTEI; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Pilcher BK, 1997, J BIOL CHEM, V272, P18147, DOI 10.1074/jbc.272.29.18147; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; PROSSER IW, 1989, AM J PATHOL, V135, P1073; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; SAARIALHOKERE UK, 1995, J INVEST DERMATOL, V104, P982, DOI 10.1111/1523-1747.ep12606231; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SAARIALHOKERE UK, 1993, J INVEST DERMATOL, V100, P335, DOI 10.1111/1523-1747.ep12470032; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; STOSCHECK CM, 1992, J INVEST DERMATOL, V99, P645, DOI 10.1111/1523-1747.ep12668143; STRICKLIN GP, 1994, J INVEST DERMATOL, V103, P488, DOI 10.1111/1523-1747.ep12395601; STRICKLIN GP, 1978, BIOCHEMISTRY-US, V17, P2331, DOI 10.1021/bi00605a012; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Sudbeck BD, 1997, J BIOL CHEM, V272, P22103, DOI 10.1074/jbc.272.35.22103; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; THEADGILL DW, 1995, SCIENCE, V269, P230; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689	54	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10372	10381		10.1074/jbc.274.15.10372	http://dx.doi.org/10.1074/jbc.274.15.10372			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187826	hybrid			2022-12-25	WOS:000079663500065
J	Papi, A; Johnston, SL				Papi, A; Johnston, SL			Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappa B-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; COMMON COLD VIRUS; ASTHMATIC SUBJECTS; ALLERGIC SUBJECTS; OLD CHILDREN; IN-VIVO; EXACERBATIONS; INFLAMMATION; STIMULATION; INDUCTION	Virus infections, the majority of which are rhinovirus infections, are the major cause of asthma exacerbations. Treatment is unsatisfactory, and the pathogenesis unclear. Lower airway lymphocyte and eosinophil recruitment and activation are strongly implicated, but the mechanisms regulating these processes are unknown. Intercellular adhesion molecule-1 (ICAM-1) has a central role in inflammatory cell recruitment to the airways in asthma and is the cellular receptor for 90% of rhinoviruses. We hypothesized that rhinovirus infection of lower airway epithelium might induce ICARI-1 expression, promoting both inflammatory cell infiltration and rhinovirus infection. We therefore investigated the effect of rhinovirus infection on respiratory epithelial cell ICAM-1 expression and regulation to identify new targets for treatment of virus-induced asthma exacerbations. We observed that rhinovirus infection of primary bronchial epithelial cells and the A549 respiratory epithelial cell line increased ICAM-1 cell surface expression over 12- and 3-fold, respectively. We then investigated the mechanisms of this induction in A549 cells and observed rhinovirus-induction of ICAM-1 promoter activity and ICAM-1 mRNA transcription. Rhinovirus induction of ICAM-1 promoter activity was critically dependent upon up-regulation of NP-kappa B proteins binding to the -187/-178 NF-kappa B binding site on the ICAM-1 promoter. The principal components of the rhinovirus-induced binding proteins were NF-kappa B p65 homo- or heterodimers. These studies identify ICAM-1 and NF-kappa B as new targets for the development of therapeutic interventions for virus-induced asthma exacerbations.	Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Johnston, SL (corresponding author), Univ Southampton, Southampton Gen Hosp, Tramona Rd, Southampton SO16 6YD, Hants, England.	slj1@soton.ac.il	Johnston, Sebastian Lennox/I-2423-2012; Papi, alberto/AAC-1888-2019	Johnston, Sebastian Lennox/0000-0003-3009-9200; PAPI, ALBERTO/0000-0002-6924-4500				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; Broide DH, 1998, AM J RESP CELL MOL, V18, P218, DOI 10.1165/ajrcmb.18.2.2829; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490, DOI 10.1164/ajrccm.152.5.7582282; Chin JE, 1998, AM J RESP CELL MOL, V18, P158, DOI 10.1165/ajrcmb.18.2.2565m; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653, DOI 10.1164/ajrccm.150.6.7524984; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; Dumitrascu D., 1997, Journal of Allergy and Clinical Immunology, V99, pS403; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GELEZIUNAS R, 1994, FASEB J, V8, P593, DOI 10.1096/fasebj.8.9.8005387; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Johnston SL, 1998, J IMMUNOL, V160, P6172; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Johnston SL, 1995, DIAGNOSTIC PROCEDURE, P553; Kaur B, 1998, BRIT MED J, V316, P118; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Maniatis T., 1989, MOL CLONING LAB MANU; MANOLITSAS ND, 1994, EUR RESPIR J, V7, P1438; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; SCHNEIDERSCHAULIES J, 1995, P NATL ACAD SCI USA, V92, P3943, DOI 10.1073/pnas.92.9.3943; SEMNANI RT, 1994, J EXP MED, V180, P2125, DOI 10.1084/jem.180.6.2125; SHARON RF, 1998, AM J RESP CRIT CARE, V157, P22; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749, DOI 10.1152/ajplung.1997.273.4.L749; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VAN SG, 1990, J IMMUNOL, V144, P4579; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689, DOI 10.1164/ajrccm/148.3.689; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; WITEK TJ, 1995, J ALLERGY CLIN IMMUN, V95, P258; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431	50	265	274	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9707	9720		10.1074/jbc.274.14.9707	http://dx.doi.org/10.1074/jbc.274.14.9707			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092659	hybrid			2022-12-25	WOS:000079451800078
J	Wu, G; Wei, CH; Kulmacz, RJ; Osawa, Y; Tsai, AL				Wu, G; Wei, CH; Kulmacz, RJ; Osawa, Y; Tsai, AL			A mechanistic study of self-inactivation of the peroxidase activity in prostaglandin H synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; MANGANO PROTOPORPHYRIN-IX; ARACHIDONIC-ACID; VESICULAR GLAND; FATTY-ACIDS; CYCLOOXYGENASE; BIOSYNTHESIS; REDUCTION; KINETICS; HYDROPEROXIDES	Prostaglandin H synthase (PGHS) is a self-activating and self-inactivating enzyme. Both the peroxidase and cyclooxygenase activities have a limited number of catalytic turnovers. Sequential stopped-flow measurements were used to analyze the kinetics of PGHS-1 peroxidase self-inactivation during reaction with several different hydroperoxides. The inactivation followed single exponential kinetics, with a first-order rate constant of 0.2-0.5 s(-1) at 24 degrees C. This rate was independent of the peroxide species and concentration used, strongly suggesting that the self-inactivation process originates after formation of Compound I and probably with Intermediate II, which contains an oxyferryl heme and a tyrosyl radical. Kinetic scan and rapid scan experiments were used to monitor the heme changes during the inactivation process. The results from both experiments converged to a simple, linear, two-step mechanism in which Intermediate II is first converted in a faster step (0.5-2 s(-1)) to a new compound, Intermediate III, which undergoes a subsequent slower (0.01-0.05 s(-1)) transition to a terminal species. Rapid-quench and high pressure liquid chromatography analysis indicated that Intermediate III likely retains an intact heme group that is not covalently linked with the PGHS-1 protein.	Univ Texas, Hlth Sci Ctr, Div Hematol, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Div Hematol, Dept Internal Med, Houston, TX 77030 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Div Hematol, POB 20708, Houston, TX 77225 USA.	atsai@heart.med.uth.tmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030509, R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52170, GM30509, GM44911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bakovic M, 1996, J BIOL CHEM, V271, P2048, DOI 10.1074/jbc.271.4.2048; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EGAN RW, 1979, J BIOL CHEM, V254, P3295; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HSUANYU YC, 1990, BIOCHEM CELL BIOL, V68, P965, DOI 10.1139/o90-142; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MACDONALD ID, 1989, ARCH BIOCHEM BIOPHYS, V272, P194, DOI 10.1016/0003-9861(89)90210-5; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; Marnett L. J., 1991, PEROXIDASES CHEM BIO, V1, P293; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; OHKI S, 1979, J BIOL CHEM, V254, P829; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; Tsai AL, 1997, BIOCHEMISTRY-US, V36, P13085, DOI 10.1021/bi970397s; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034	31	62	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9231	9237		10.1074/jbc.274.14.9231	http://dx.doi.org/10.1074/jbc.274.14.9231			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092596	hybrid			2022-12-25	WOS:000079451800015
J	Kasahara, J; Fukunaga, K; Miyamoto, E				Kasahara, J; Fukunaga, K; Miyamoto, E			Differential effects of a calcineurin inhibitor on glutamate-induced phosphorylation of Ca2+/calmodulin-dependent protein kinases in cultured rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CEREBELLAR GRANULE CELLS; II MUTANT MICE; CA-2+-INDEPENDENT FORM; DEPENDENT MECHANISM; GENE-EXPRESSION; PHOSPHATASE 2A; CALMODULIN; ACTIVATION; BRAIN	Calcium/calmodulin-dependent protein kinases (CaM kinases) are major multifunctional enzymes that play important roles in calcium-mediated signal transduction. To characterize their regulatory mechanisms in neurons, we compared glutamate-induced phosphorylation of CaM kinase IV and CaM kinase II in cultured rat hippocampal neurons. We observed that dephosphorylation of these kinases followed different time courses, suggesting different regulatory mechanisms for each kinase. Okadaic acid, an inhibitor of protein phosphatase (PP) 1 and PP2A, increased the phosphorylation of both kinases, In contrast, cyclosporin A, an inhibitor of calcineurin, showed different effects: the phosphorylation and activity of CaM kinase IV were significantly increased with this inhibitor, but those of CaM kinase II were not significantly increased. Cyclosporin A treatment of neurons increased phosphorylation of Thr(196) Of CaM kinase TV, the activated form with CaM kinase kinase, which was recognized with an anti-phospho-Thr(196) antibody. Moreover, recombinant CaM kinase TV was dephosphorylated and inactivated with calcineurin as well as with PP1, PP2A, and PP2C in vitro. These results suggest that CaM kinase IV, but not CaM kinase II, is directly regulated with calcineurin.	Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Kumamoto University	Miyamoto, E (corresponding author), Kumamoto Univ, Sch Med, Dept Pharmacol, 2-2-1 Honjo, Kumamoto 8600811, Japan.							BARNES GN, 1995, J NEUROCHEM, V64, P340; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; MATSUMOTO K, 1995, ENDOCRINOLOGY, V136, P3784, DOI 10.1210/en.136.9.3784; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MIYANO O, 1992, J BIOL CHEM, V267, P1198; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OHTA Y, 1988, J BIOL CHEM, V263, P11540; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; SAITOH Y, 1987, J NEUROCHEM, V49, P1286, DOI 10.1111/j.1471-4159.1987.tb10022.x; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; YAMAKAWA T, 1992, BRAIN RES, V597, P220, DOI 10.1016/0006-8993(92)91477-V; YANAGIHARA N, 1994, MOL PHARMACOL, V46, P423; YANO S, 1994, J BIOL CHEM, V269, P5428	40	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9061	9067		10.1074/jbc.274.13.9061	http://dx.doi.org/10.1074/jbc.274.13.9061			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085155	hybrid			2022-12-25	WOS:000079451600097
J	Stecher, H; Gelb, MH; Saari, JC; Palczewski, K				Stecher, H; Gelb, MH; Saari, JC; Palczewski, K			Preferential release of 11-cis-retinol from retinal pigment epithelial cells in the presence of cellular retinaldehyde-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALL-TRANS-RETINOIDS; VITAMIN-A; VISUAL CYCLE; MEMBRANES; ISOMERIZATION; BIOSYNTHESIS	In photoreceptor cells of the retina, photoisomerization of 11-cis-retinal to all-trans-retinal triggers phototransduction. Regeneration of 11-cis-retinal proceeds via a complex set of reactions in photoreceptors and in adjacent retinal pigment epithelial cells where all-trans-retinol is isomerized to 11-cis-retinol. Our results show that isomerization in vitro only occurs in the presence of ape-cellular retinaldehyde-binding protein. This retinoid-binding protein may drive the reaction by mass action, overcoming the thermodynamically unfavorable isomerization, Furthermore, this 11-cis-retinol/11-cis retinal-specific binding protein potently stimulates hydrolysis of endogenous 11-cis-retinyl esters but has no effect on hydrolysis of all-trans-retinyl esters, Ape-cellular retinaldehyde-binding protein probably exerts its effect by trapping the 11-cis-retinol product. When retinoid-depleted retinal pigment epithelial microsomes were preincubated with different amounts of all-trans-retinol to form all-trans-retinyl esters and then [H-3]all-trans-retinol was added, as predicted, the specific radioactivity of [H-3]all-trans-retinyl esters increased during subsequent reaction. However, the specific radioactivity of newly formed 11-cis-retinol stayed constant during the course of the reaction, and it was largely unaffected by expansion of the all-trans-retinyl ester pool during the preincubation. The absence of dilution establishes that most of the ester pool does not participate in isomerization, which in turn suggests that a retinoid intermediate other than all-trans-retinyl ester is on the isomerization reaction pathway.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.			gelb, michael/0000-0001-7000-5219	NATIONAL EYE INSTITUTE [P30EY001730] Funding Source: NIH RePORTER; NEI NIH HHS [EY01730, EY080611, EY02317] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALPERN M, 1971, VISION RES, V11, P539, DOI 10.1016/0042-6989(71)90075-7; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BERNSTEIN PS, 1986, BIOCHEMISTRY-US, V25, P6473, DOI 10.1021/bi00369a020; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGES CDB, 1982, METHOD ENZYMOL, V81, P463; BRIDGES CDB, 1980, VISION RES, V20, P355, DOI 10.1016/0042-6989(80)90022-X; BROWN PK, 1956, J BIOL CHEM, V222, P865; Crabb JW, 1998, METH MOL B, V89, P91; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FULTON BS, 1987, BIOCHEMISTRY-US, V26, P7938, DOI 10.1021/bi00398a059; GOLDSTEI.EB, 1970, VISION RES, V10, P1065, DOI 10.1016/0042-6989(70)90082-9; GOLDSTEIN EB, 1967, VISION RES, V7, P837, DOI 10.1016/0042-6989(67)90004-1; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; KNOWLES A, 1977, EYE, V28, P118; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS GM, 1988, J CHROMATOGR, V438, P383, DOI 10.1016/S0021-9673(00)90269-3; McDowell J. H., 1993, PHOTORECEPTOR CELLS, V15, P123; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; RANDO RR, 1983, J AM CHEM SOC, V105, P2879, DOI 10.1021/ja00347a058; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; SAARI JC, 1990, METHOD ENZYMOL, V190, P156; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; Saari John C., 1994, P351; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; TREHAN A, 1990, BIOCHEMISTRY-US, V29, P309, DOI 10.1021/bi00454a001; Wald G, 1935, J GEN PHYSIOL, V19, P351, DOI 10.1085/jgp.19.2.351; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; ZIMMERMAN WF, 1974, VISION RES, V14, P795, DOI 10.1016/0042-6989(74)90143-6; ZIMMERMAN WF, 1975, EXP EYE RES, V21, P325, DOI 10.1016/0014-4835(75)90043-3	34	105	114	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8577	8585		10.1074/jbc.274.13.8577	http://dx.doi.org/10.1074/jbc.274.13.8577			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085092	hybrid			2022-12-25	WOS:000079451600034
J	Jayadev, S; Petranka, JG; Cheran, SK; Biermann, JA; Barrett, JC; Murphy, E				Jayadev, S; Petranka, JG; Cheran, SK; Biermann, JA; Barrett, JC; Murphy, E			Reduced capacitative calcium entry correlates with vesicle accumulation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE-C; INTRACELLULAR CALCIUM; CA2+ INFLUX; NEOPLASTIC PROGRESSION; CELL-LINE; DNA FRAGMENTATION; STORE DEPLETION; XENOPUS OOCYTES; LEUKEMIA-CELLS	A preneoplastic variant of Syrian hamster embryo cells, sup(+), exhibits decreased endoplasmic reticulum calcium levels and subsequently undergoes apoptosis in low serum conditions (Preston, G, A, Barrett, J, C,, Biermann, J, A, and Murphy, E, (1997) Cancer Res. 57, 537-542). This decrease in endoplasmic reticulum calcium appears to be due, at least in part, to reduced capacitative calcium entry at the plasma membrane. Thus we investigated whether inhibition of capacitative calcium entry per se could reduce endoplasmic reticulum calcium and induce apoptosis of cells. We find that treatment with either SKF96365 (30-100 mu M) Or cell-impermeant 1,2-bis(o-amino-5-bromophenoxy)ethane-N,N,N',N'-tetra-acetic acid (5-10 mM) is able to induce apoptosis of cells in conditions where apoptosis does not normally occur. Because previous work has implicated vesicular trafficking as a mechanism of regulating capacitative calcium entry, we investigated whether disruption of vesicular trafficking could lead to decreased capacitative calcium entry and subsequent apoptosis of cells. Coincident with low serum-induced apoptosis, we observed an accumulation of vesicles within the cell, suggesting deregulated vesicle trafficking, Treatment of cells with bafilomycin (30-100 nM), an inhibitor of the endosomal proton ATPase, produced an accumulation of vesicles, decreased capacitative entry, and induced apoptosis, These data suggest that deregulation of vesicular transport results in reduced capacitative calcium entry which in turn results in apoptosis.	NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Jayadev, S (corresponding author), NIEHS, Mol Carcinogenesis Lab, POB 12233,MD D2-03, Res Triangle Pk, NC 27709 USA.	jayadev@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES023020, Z01ES050142] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; Baldwin SA, 1995, BIOSCIENCE REP, V15, P419, DOI 10.1007/BF01204346; BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; BELLOMO G, 1992, CANCER RES, V52, P1342; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; Chen W, 1996, J BIOL CHEM, V271, P7398, DOI 10.1074/jbc.271.13.7398; DAVIES EV, 1995, BIOCHEM BIOPH RES CO, V206, P348, DOI 10.1006/bbrc.1995.1048; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; HEMING TA, 1995, J EXP BIOL, V198, P1711; HENOMATSU N, 1993, EUR J CELL BIOL, V62, P127; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOLMAN GD, 1994, J BIOL CHEM, V269, P17516; ISEKI R, 1993, J IMMUNOL, V151, P5198; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; MAGNELLI L, 1993, BIOCHEM BIOPH RES CO, V194, P1394, DOI 10.1006/bbrc.1993.1979; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MONTERO M, 1993, J BIOL CHEM, V268, P13055; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUNKER R, 1992, ANN HEMATOL, V65, P50, DOI 10.1007/BF01715127; MURPHY CT, 1995, CELL CALCIUM, V18, P245, DOI 10.1016/0143-4160(95)90069-1; MURPHY E, 1989, P NATL ACAD SCI USA, V86, P2981, DOI 10.1073/pnas.86.8.2981; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; PEREZSALA D, 1995, J BIOL CHEM, V270, P6235, DOI 10.1074/jbc.270.11.6235; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PRESTON GA, 1994, CANCER RES, V54, P4214; Preston GA, 1997, CANCER RES, V57, P537; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; Shrode LD, 1997, AM J PHYSIOL-CELL PH, V272, pC1968, DOI 10.1152/ajpcell.1997.272.6.C1968; Somasundaram B, 1996, J BIOL CHEM, V271, P26096, DOI 10.1074/jbc.271.42.26096; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TRUMP BF, 1995, GROWTH FACTORS TUMOR, P121; VOLLENWEIDER I, 1991, ELECTRON MICROSC REV, V4, P249, DOI 10.1016/0892-0354(91)90005-W; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, INT REV CYTOL, P755; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T	76	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8261	8268		10.1074/jbc.274.12.8261	http://dx.doi.org/10.1074/jbc.274.12.8261			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075732	hybrid			2022-12-25	WOS:000079268100091
J	Swanton, E; Savory, P; Cosulich, S; Clarke, P; Woodman, P				Swanton, E; Savory, P; Cosulich, S; Clarke, P; Woodman, P			Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts	ONCOGENE			English	Article						ICH-1; caspase cleavage; cytochrome c; dATP	CELL-FREE SYSTEM; CYTOCHROME-C; INITIATES APOPTOSIS; DEATH DOMAIN; GRANZYME-B; PROTEIN; ACTIVATION; PROTEASES; CASPASES; INTERACTS	Apoptosis is accompanied by the activation of a number of apoptotic proteases (caspases) which selectively cleave specific cellular substrates. Caspases themselves are zymogens which are activated by proteolysis. It is widely believed that 'initiator' caspases are recruited to and activated within apoptotic signalling complexes, and then cleave and activate downstream 'effector' caspases, While activation of the effector caspase, caspase-3, has indeed been observed as distal to activation of several different initiator caspases, evidence for a further downstream proteolytic cascade is limited. In particular, there is little evidence that cellular levels of caspase-3 that are activated via one pathway are sufficient to cleave and activate other initiator caspases, To address this issue, the ability of caspase-3, activated upon addition to cytosolic extracts of cytochrome c, to cause cleavage of caspase-2 was investigated. It was demonstrated that cleavage of caspase-2 follows, and is dependent upon, activation of caspase-3, Moreover, the activation of both caspases was inhibited by Bcl-2, Together, these data indicate that Bcl-2 can protect cells from apoptosis by acting at a point downstream from release of mitochondrial cytochrome c, thereby preventing a caspase-3 dependent proteolytic cascade.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Woodman, P (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.		Clarke, Paul R./AAA-6803-2020; Clarke, Paul R/B-1684-2009	Swanton, Eileithyia/0000-0002-3299-4228; Clarke, Paul R/0000-0003-3525-2622				BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Butt AJ, 1998, J BIOL CHEM, V273, P6763, DOI 10.1074/jbc.273.12.6763; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Polverino AJ, 1997, J BIOL CHEM, V272, P7013, DOI 10.1074/jbc.272.11.7013; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	97	128	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1781	1787		10.1038/sj.onc.1202490	http://dx.doi.org/10.1038/sj.onc.1202490			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086332				2022-12-25	WOS:000079090000001
J	Choundhury, GG; Kim, YS; Simon, M; Wozney, J; Harris, S; Ghosh-Choundhury, N; Abboud, HE				Choundhury, GG; Kim, YS; Simon, M; Wozney, J; Harris, S; Ghosh-Choundhury, N; Abboud, HE			Bone morphogenetic protein 2 inhibits platelet-derived growth factor-induced c-fos gene transcription and DNA synthesis in mesangial cells - Involvement of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; FAMILY MEDIATOR SMAD1; TGF-BETA; SIGNALING PATHWAYS; EYE DEVELOPMENT; MAP KINASE; BMP; DIFFERENTIATION; KIDNEY; NUCLEUS	Bone morphogenetic proteins (BMPs) play an important role in nephrogenesis. The biologic effect and mechanism of action of these proteins in the adult kidney has not yet been studied. We investigated the effect of BMP2, a member of these growth and differentiation factors, on mitogenic signal transduction pathways induced by platelet-derived growth factor (PDGF) in glomerular mesangial cells. PDGF is a growth and survival factor for these cells in vitro and in vivo. Incubation of mesangial cells with increasing concentrations of BMP2 inhibited PDGF-induced DNA synthesis in a dose-dependent manner with maximum inhibition at 250 ng/ml. Immune complex tyrosine kinase assay of PDGF receptor beta immunoprecipitates from lysates of mesangial cells treated with PDGF showed no inhibitory effect of BMP2 on PDGF receptor tyrosine phosphorylation, This indicates that the inhibition of DNA synthesis is likely due to postreceptor events. However, BMP2 significantly inhibited PDGF-stimulated mitogen-activated protein kinase (MAPK) activity that phosphorylates the Elk-1 transcription factor, a component of the ternary complex factor. Using a fusion protein-based reporter assay, we also show that BMP2 blocks PDGF-induced Elk-1-mediated transcription. Furthermore, we demonstrate that BMP2 inhibits PDGF-induced transcription of c-fos gene, a natural target of Elk-1 that normally forms a ternary complex that activates the serum response element of the c-fos gene. These data provide the first evidence that in mesangial cells, BMP2 signaling cross-talks with MAPK-based transcriptional events to inhibit PDGF-induced DNA synthesis. One target for this inhibition is the early response gene c-fos.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA; Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA; Inst Genet, Cambridge, MA 01810 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Choundhury, GG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044728] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050190, R01DK043988, R29DK050190] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44728] Funding Source: Medline; NIDDK NIH HHS [DK 50190, DK43988] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud Hanna E., 1995, P573; ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; BERNIER SM, 1992, J CELL PHYSIOL, V152, P317, DOI 10.1002/jcp.1041520213; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; BRUIJN JA, 1994, J LAB CLIN MED, V123, P34; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHOUDHURY GG, 1991, J BIOL CHEM, V266, P8068; CHOUDHURY GG, 1994, KIDNEY INT, V46, P37, DOI 10.1038/ki.1994.242; CHOUDHURY GG, 1993, AM J PHYSIOL, V265, pF634, DOI 10.1152/ajprenal.1993.265.5.F634; Choudhury GG, 1997, AM J PHYSIOL-RENAL, V273, pF931, DOI 10.1152/ajprenal.1997.273.6.F931; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; GLASS WF, 1991, AM J PHYSIOL, V261, pF336, DOI 10.1152/ajprenal.1991.261.2.F336; GRANDALIANO G, 1994, AM J PHYSIOL-RENAL, V267, pF528, DOI 10.1152/ajprenal.1994.267.4.F528; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hsuan J J, 1989, Prog Growth Factor Res, V1, P23, DOI 10.1016/0955-2235(89)90039-2; Ide H, 1997, CANCER RES, V57, P5022; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; JAFFER F, 1989, AM J PATHOL, V135, P261; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOHNSON RJ, 1993, J LAB CLIN MED, V121, P190; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MACKAY NG, 1992, ABSTR KIDN INT, V41, P703; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MCKAY K, 1989, J CLIN INVEST, V83, P1160; Nakaoka T, 1997, J CLIN INVEST, V100, P2824, DOI 10.1172/JCI119830; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Niehrs C, 1996, NATURE, V381, P561, DOI 10.1038/381561a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Treisman R, 1990, Semin Cancer Biol, V1, P47; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOZNEY JM, 1992, MOL REPROD DEV, V32, P160, DOI 10.1002/mrd.1080320212	52	54	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10897	10902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196167				2022-12-25	WOS:000079751900035
J	Fan, LZ; Wiederkehr, MR; Collazo, R; Wang, HM; Crowder, LA; Moe, OW				Fan, LZ; Wiederkehr, MR; Collazo, R; Wang, HM; Crowder, LA; Moe, OW			Dual mechanisms of regulation of Na/H exchanger NHE-3 by parathyroid hormone in rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; NA+-H+ EXCHANGER; DEPENDENT PROTEIN-KINASE; CAMP-MEDIATED INHIBITION; ACID-BASE HOMEOSTASIS; METABOLIC-ACIDOSIS; PROXIMAL TUBULES; BICARBONATE ABSORPTION; CALCIUM-TRANSPORT; ANGIOTENSIN-II	Parathyroid hormone (PTH) is a potent inhibitor of mammalian renal proximal tubule sodium absorption via suppression of the apical membrane Na/H exchanger (NHE-3). We examined the mechanisms by which PTH inhibits NHE-3 activity by giving an acute intravenous PTD bolus to parathyroidectomized rats. Parathyroidectomy per se increased apical membrane NHE-3 activity and antigen. Acute infusion of PTH caused a time-dependent decrease in NHE-3 activity as early as 30 min. Decrease in NHE-3 activity at 30 and 60 min was accompanied by increased NHE-3 phosphorylation. In contrast to the rapid changes in NHE-3 activity and phosphorylation, decrease in apical membrane NHE-3 antigen was not detectable until 4-12 h after the PTH bolus, The decrease in apical membrane NHE-3 occurred in the absence of changes in total renal cortical NHE-3 antigen. Pretreatment of the animals with the microtubule-disrupting agent colchicine blocked the PTH-induced decrease in apical NHE-3 antigen. We propose that PTH acutely cause a decrease in NHE-3 intrinsic transport activity possibly via a phosphorylation-dependent mechanism followed by a decrease in apical membrane NHE-3 antigen via changes in protein trafficking.	Dept Vet Affairs Med Ctr, Med Serv, Dallas, TX 75225 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75225 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Moe, OW (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIDDK NIH HHS [T32 DK07257-17, DK48482] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK048482, T32DK007257, R01DK048482] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUS ZS, 1973, AM J PHYSIOL, V224, P1143, DOI 10.1152/ajplegacy.1973.224.5.1143; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BANK N, 1976, J CLIN INVEST, V58, P336, DOI 10.1172/JCI108477; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BIEMESDERFER D, 1997, J AM SOC NEPHROL, V8, P3; CHABARDES D, 1975, PFLUG ARCH EUR J PHY, V354, P229, DOI 10.1007/BF00584646; COHN DE, 1983, AM J PHYSIOL, V245, pF217, DOI 10.1152/ajprenal.1983.245.2.F217; COLLAZO R, 1998, J AM SOC NEPHROL, V9, P4; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; GESEK FA, 1990, AM J PHYSIOL, V258, pF514, DOI 10.1152/ajprenal.1990.258.3.F514; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V416, P615, DOI 10.1007/BF00370605; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HOLTROP ME, 1979, CALCIFIED TISSUE INT, V27, P129, DOI 10.1007/BF02441175; HULTER H, 1985, AM J PHYSIOL, V248, pF739, DOI 10.1152/ajprenal.1985.248.6.F739; HULTER HN, 1983, AM J PHYSIOL, V245, pF450, DOI 10.1152/ajprenal.1983.245.4.F450; HULTER HN, 1985, KIDNEY INT, V28, P187, DOI 10.1038/ki.1985.139; IINO Y, 1979, AM J PHYSIOL, V236, pF387, DOI 10.1152/ajprenal.1979.236.4.F387; JADHAV AL, 1992, CLIN EXP HYPERTENS A, V14, P653, DOI 10.3109/10641969209036213; JOU YS, 1993, MOL CARCINOGEN, V8, P234, DOI 10.1002/mc.2940080406; KAHN AM, 1985, AM J PHYSIOL, V248, pF212, DOI 10.1152/ajprenal.1985.248.2.F212; KAWASHIMA H, 1982, MINER ELECTROLYTE ME, V9, P227; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; Keusch I, 1998, KIDNEY INT, V54, P1224, DOI 10.1046/j.1523-1755.1998.00115.x; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; KUROKAWA K, 1992, KIDNEY PHYSL PATHOPH; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; LIU FY, 1989, J CLIN INVEST, V84, P83, DOI 10.1172/JCI114174; MARONE CC, 1983, J LAB CLIN MED, V101, P264; MCKINNEY TD, 1980, AM J PHYSIOL, V239, pF127, DOI 10.1152/ajprenal.1980.239.2.F127; MCKINNEY TD, 1980, AM J PHYSIOL, V238, pF166, DOI 10.1152/ajprenal.1980.238.3.F166; MILLER RT, 1987, J BIOL CHEM, V262, P9115; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MORAN A, 1988, BIOCHIM BIOPHYS ACTA, V969, P48, DOI 10.1016/0167-4889(88)90087-0; MORI Y, 1992, PHARMACOL TOXICOL, V70, P201, DOI 10.1111/j.1600-0773.1992.tb00457.x; PASTORIZAMUNOZ E, 1992, J CLIN INVEST, V89, P1485, DOI 10.1172/JCI115739; PENG Y, 1998, J AM SOC NEPHROL, V9, P10; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; PREISIG PA, 1987, J CLIN INVEST, V80, P970, DOI 10.1172/JCI113190; PUSCHETT JB, 1976, KIDNEY INT, V9, P501, DOI 10.1038/ki.1976.64; RESHKIN SJ, 1991, J MEMBRANE BIOL, V124, P227, DOI 10.1007/BF01994356; SASAKI S, 1991, AM J PHYSIOL, V260, pF833, DOI 10.1152/ajprenal.1991.260.6.F833; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SHEIKHHAMAD D, 1993, AM J PHYSIOL, V264, pF737, DOI 10.1152/ajprenal.1993.264.4.F737; SOLEIMANI M, 1992, J CLIN INVEST, V90, P211, DOI 10.1172/JCI115838; SUKI WN, 1979, AM J PHYSIOL, V237, pF1, DOI 10.1152/ajprenal.1979.237.1.F1; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; WEINMAN EJ, 1989, J MEMBRANE BIOL, V109, P233, DOI 10.1007/BF01870280; WEINMAN EJ, 1988, J MEMBRANE BIOL, V101, P11, DOI 10.1007/BF01872815; Wu MS, 1996, J BIOL CHEM, V271, P32749, DOI 10.1074/jbc.271.51.32749; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004; Zhao H, 1999, J BIOL CHEM, V274, P3978, DOI 10.1074/jbc.274.7.3978	61	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11289	11295		10.1074/jbc.274.16.11289	http://dx.doi.org/10.1074/jbc.274.16.11289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196218	hybrid			2022-12-25	WOS:000079751900086
J	Aparicio, JF; Colina, AJ; Ceballos, E; Martin, JF				Aparicio, JF; Colina, AJ; Ceballos, E; Martin, JF			The biosynthetic gene cluster for the 26-membered ring polyene macrolide pimaricin - A New polyketide synthase organization encoded by two subclusters separated by functionalization genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; MULTIFUNCTIONAL ENZYME; ACID SYNTHASE; ACTIVE-SITE; SEQUENCE; CLONING; SPECIFICITY; RAPAMYCIN; DOMAINS; MOTIFS	The biosynthetic gene cluster for the 26-membered ring of the polyene macrolide pimaricin extends for about 110 kilobase pairs of contiguous DNA in the genome of Streptomyces natalensis, Two sets of polyketide synthase (PKS) genes are separated by a group of small polyketide-functionalizing genes. Two of the polyketide synthase genes, pimS0 and pimS1, have been fully sequenced and disrupted proving the involvement of each of these genes in pimaricin biosynthesis, The pimS0 gene encodes a relatively small acetate-activating PKS (similar to 193 kDa) that appears to work as a loading protein which "presents" the starter unit to the second PKS subunit. The pimS1 gene encodes a giant multienzyme (similar to 710 kDa) harboring 15 activities responsible for the first four cycles of chain elongation in pimaricin biosynthesis, resulting in formation of the polyene chromophore.	Inst Biotechnol, Leon 24006, Spain		Martin, JF (corresponding author), Inst Biotechnol, Sci Pk Leon,Avda Real N1, Leon 24006, Spain.	degjmm@unileon.es	Aparicio, Jesús F./K-8686-2014	Aparicio, Jesús F./0000-0003-4242-4701				ALBERTINI AM, 1995, MICROBIOL-SGM, V141, P299, DOI 10.1099/13500872-141-2-299; Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; APARICIO JF, 1994, J BIOL CHEM, V269, P8524; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V719, P11; Brown DW, 1996, P NATL ACAD SCI USA, V93, P14873, DOI 10.1073/pnas.93.25.14873; CHATER KF, 1981, GENE, V14, P183, DOI 10.1016/0378-1119(81)90114-1; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CRIADO LM, 1993, GENE, V126, P135, DOI 10.1016/0378-1119(93)90602-Y; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONADIO S, 1992, GENE, V111, P51, DOI 10.1016/0378-1119(92)90602-L; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gil J.A., 1997, BIOTECHNOLOGY ANTIBI, V2nd ed., P551; Hanahan D, 1985, DNA CLONING PRACTICA; HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014-5793(95)01119-Y; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MANWARING DG, 1969, J ANTIBIOT, V22, P545, DOI 10.7164/antibiotics.22.545; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; MARTIN JF, 1977, ANNU REV MICROBIOL, V31, P12; MARTIN JF, 1975, BIOCHEM BIOPH RES CO, V71, P1103; MEURER G, 1995, J BACTERIOL, V177, P477, DOI 10.1128/jb.177.2.477-481.1995; OHagan D., 1991, POLYKETIDE METABOLIT; OMURA S, 1984, MACROLIDE ANTIBIOTIC, P351; RODICIO MR, 1985, GENE, V34, P283, DOI 10.1016/0378-1119(85)90137-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPP T, 1995, J BACTERIOL, V177, P3673, DOI 10.1128/jb.177.13.3673-3679.1995; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; STAUNTON J, 1991, ANGEW CHEM INT EDIT, V30, P1302, DOI 10.1002/anie.199113021; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001	37	97	114	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10133	10139		10.1074/jbc.274.15.10133	http://dx.doi.org/10.1074/jbc.274.15.10133			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187796	hybrid			2022-12-25	WOS:000079663500035
J	Chuang, JL; Wynn, RM; Song, JL; Chuang, DT				Chuang, JL; Wynn, RM; Song, JL; Chuang, DT			GroEL/GroES-dependent reconstitution of alpha(2)beta(2), tetramers of human mitochondrial branched chain alpha-ketoacid decarboxylase - Obligatory interaction of chaperonins with an alpha beta dimeric intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID DEHYDROGENASE COMPLEX; SYRUP-URINE-DISEASE; DODECAMERIC GLUTAMINE-SYNTHETASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; PYRUVATE-DEHYDROGENASE; QUATERNARY STRUCTURE; CRYSTAL-STRUCTURE; REACTION CYCLE; IN-VITRO	The decarboxylase component (E1) of the human mitochondrial branched chain alpha-ketoacid dehydrogenase multienzyme complex (similar to 4-5 x 10(3) kDa) is a thiamine pyrophosphate-dependent enzyme, comprising two 45.5-kDa alpha subunits and two 37.8-kDa beta subunits, In the present study, His(6)-tagged E1 alpha(2)beta(2) tetramers (171 kDa) denatured in 8 M urea were competently reconstituted in vitro at 23 degrees C with an absolute requirement for chaperonins GroEL/GroES and Mg-ATP, Unexpectedly, the kinetics for the recovery of El activity was very slow with a rate constant of 290 M-1 s(-1). Renaturation of El with a similarly slow kinetics was also achieved using individual GroEL-alpha and GroEL-beta complexes as combined substrates, However, the beta subunit was markedly more prone to misfolding than the alpha in the absence of GroEL. The alpha subunit was released as soluble monomers from the GroEL-alpha complex alone in the presence of GroES and Mg-ATP, In contrast, the beta subunit discharged from the GroEL-beta complex readily rebound to GroEL when the alpha subunit was absent. Analysis of the assembly state showed that the His(6)-alpha and beta subunits released from corresponding GroEL-polypeptide complexes assembled into a highly structured but inactive 85.5-kDa alpha beta dimeric intermediate, which subsequently dimerized to produce the active alpha(2)beta(2) tetrameter, The purified alpha beta dimer isolated from Escherichia coli lysates was capable of binding to GroEL to produce a stable GroEL-alpha beta ternary complex. Incubation of this novel ternary complex with GroES and Mg-ATP resulted in recovery of E1 activity, which also followed slow kinetics with a rate constant of 138 M-1 s(-1). Dimers were regenerated from the GroEL-alpha beta complex, but they needed to interact with GroEL/GroES again, thereby perpetuating the cycle until the conversion from dimers to tetramers was complete. Our study describes an obligatory role of chaperonins in priming the dimeric intermediate for subsequent tetrameric assembly, which is a slow step in the reconstitution of E1 alpha(2)beta(2) tetramers.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuang01@utsw.swmed.edu		Wynn, Richard/0000-0002-1879-2136	NIDDK NIH HHS [DK-26758] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHUANG DT, 1988, METHOD ENZYMOL, V166, P146; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; Fedorov AN, 1997, J MOL BIOL, V268, P712, DOI 10.1006/jmbi.1997.1007; FISHER CR, 1991, J CLIN INVEST, V88, P1034, DOI 10.1172/JCI115363; FISHER MT, 1993, J BIOL CHEM, V268, P13777; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; FLYNN GC, 1993, P NATL ACAD SCI USA, V90, P10826, DOI 10.1073/pnas.90.22.10826; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GUZMANVERDUZCO LM, 1987, J BACTERIOL, V169, P5201, DOI 10.1128/jb.169.11.5201-5208.1987; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; HU CWC, 1983, J BIOL CHEM, V258, P2315; Huang YS, 1999, J BIOL CHEM, V274, P10405, DOI 10.1074/jbc.274.15.10405; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LESSARD IAD, 1994, J BIOL CHEM, V269, P10378; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; LILIE H, 1995, J MOL BIOL, V248, P190, DOI 10.1006/jmbi.1995.0211; Llorca O, 1997, FEBS LETT, V405, P195, DOI 10.1016/S0014-5793(97)00186-5; Mande SC, 1996, SCIENCE, V271, P1655; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13587; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; Sambrook J., 1989, MOL CLONING LABORATO, V3, pA3; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WYNN RM, 1992, J BIOL CHEM, V267, P1881; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; WYNN RM, 1994, BIOCHEMISTRY-US, V33, P8962, DOI 10.1021/bi00196a014; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	52	27	27	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10395	10404		10.1074/jbc.274.15.10395	http://dx.doi.org/10.1074/jbc.274.15.10395			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187829	hybrid			2022-12-25	WOS:000079663500068
J	Hiki, K; D'Andrea, RJ; Furze, J; Crawford, J; Woollatt, E; Sutherland, GR; Vadas, MA; Gamble, JR				Hiki, K; D'Andrea, RJ; Furze, J; Crawford, J; Woollatt, E; Sutherland, GR; Vadas, MA; Gamble, JR			Cloning, characterization, and chromosomal location of a novel human K+-Cl- cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; POTASSIUM CHANNEL GENE; CHLORIDE COTRANSPORTER; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; EPILEPSY; FAMILY; TRANSPORT; MUTATION; RAT	Differential display polymerase chain reaction has been used to isolate genes regulated in vascular endothelial cells by the angiogenic factor vascular endothelial cell growth factor (VEGF). Analysis of one of the bands consistently up-regulated by VEGF led us to the identification of a cDNA from a human umbilical vein endothelial cell library that is 77% identical to the human K+-Cl- cotransporter1 (KCC1), We have referred to the predicted protein as K+-Cl- cotransporter 3 (KCC3), Hydrophobicity analysis of the KCC3 amino acid sequence showed an almost identical pattern to KCC1, suggesting 12 membrane-spanning segments, a large extracellular loop with potential N-glycosylation sites, and cytoplasmic N- and C-terminal regions, The KCC3 mRNA was highly expressed in brain, heart, skeletal muscle, and kidney, showing a distinct pattern and size from KCC1 and KCC2. The KCC3 mRNA level in endothelial cells increased on treatment with VEGF and decreased with the proinflammatory cytokine tumor necrosis factor alpha, whereas KCC1 mRNA levels remained unchanged. Stable overexpression of KCC3 cDNA in HEK293 cells produced a glycoprotein of approximately 150 kDa, which was reduced to 120 kDa by glycosidase digestion. An increased initial uptake rate of Rb-86 was seen in clones with high KCC3 expression, which was dependent on extracellular Cl- but not Na+ and was inhibitable by the loop diuretic agent furosemide, The KCC3 genomic localization was shown to be 15q13 by fluorescence in situ hybridization, Radiation hybrid analysis placed KCC3 within an area associated with juvenile myoclonic epilepsy. These results suggest KCC3 is a new member of the KCC family that is under distinct regulation from KCC1.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Dept Human Immunol, Adelaide, SA 5000, Australia; Univ Adelaide, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Dept Cytogenet & Mol Genet, Ctr Med Genet, N Adelaide, SA 5006, Australia	Institute Medical & Veterinary Science Australia; University of Adelaide	Gamble, JR (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Dept Human Immunol, Frome Rd, Adelaide, SA 5000, Australia.		Sutherland, Grant Robert/D-2606-2012; Crawford, Joanna/F-9135-2013; Vadas, Mathew/R-1378-2019	Crawford, Joanna/0000-0003-0786-6889; Gamble, Jennifer/0000-0002-0179-9964				Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388; ELSLIE FV, 1997, HUM MOL GENET, V6, P1329; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gibson JS, 1998, J PHYSIOL-LONDON, V511, P225, DOI 10.1111/j.1469-7793.1998.225bi.x; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; HAAS M, 1994, AM J PHYSIOL, V267, P869; Harling H, 1997, EMBO J, V16, P5855, DOI 10.1093/emboj/16.19.5855; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; KRAMHOFT B, 1986, AM J PHYSIOL, V251, pC369, DOI 10.1152/ajpcell.1986.251.3.C369; Krarup T, 1998, AM J PHYSIOL-CELL PH, V275, pC239, DOI 10.1152/ajpcell.1998.275.1.C239; LAUF PK, 1983, AM J PHYSIOL, V245, pC445, DOI 10.1152/ajpcell.1983.245.5.C445; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; Moore-Hoon ML, 1998, BIOCHEM BIOPH RES CO, V244, P15, DOI 10.1006/bbrc.1998.8206; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1998, CLIN GENET, V54, P169; TOMIYAMA S, 1987, MANUAL MONOCLONAL AN, P178; Topper JN, 1997, J CLIN INVEST, V99, P2941, DOI 10.1172/JCI119489; WALL RT, 1978, J CELL PHYSIOL, V96, P203, DOI 10.1002/jcp.1040960209; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201; ZADEOPPEN AMM, 1990, J MEMBRANE BIOL, V118, P143, DOI 10.1007/BF01868471	32	147	152	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10661	10667		10.1074/jbc.274.15.10661	http://dx.doi.org/10.1074/jbc.274.15.10661			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187864	hybrid			2022-12-25	WOS:000079663500103
J	Ng, PWP; Porter, AG; Janicke, RU				Ng, PWP; Porter, AG; Janicke, RU			Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; ETOPOSIDE-INDUCED APOPTOSIS; DOMAIN-CONTAINING PROTEIN; DEATH GENE CED-3; CELL-DEATH; FAS; PROTEASES; ACTIVATION; HOMOLOG; SPECIFICITIES	Caspase-10/a (Mch4) and caspase-10/b (FLICE2) are related death effector domain-containing cysteine aspartases presumed to be at or near the apex of apoptotic signaling pathways. We report the cloning and characterization of two novel proteins that are splice isoforms of the caspase-10 family. Caspase-10/c is a truncated protein that is essentially a prodomain-only form of the caspase that lacks proteolytic activity in vitro but efficiently induces the formation of perinuclear filamentous structures and cell death in vivo, Caspase-10/c mRNA is specifically up-regulated upon TNF stimulation, suggesting a potential role of this isoform in amplifying the apoptotic response to extracellular stimuli such as cytokines, Caspase-10/d is a hybrid of the known caspases Mch4 and FLICE2, as it is identical to FLICE2 except for the small (p12) catalytic subunit, which is identical to Mch4, Caspase-10/d is proteolytically active in vitro and also induces cell death in vivo, although it is less active than Mch4. The mRNAs for all known isoforms of caspase-10 are abundantly expressed in fetal lung, kidney, and skeletal muscle but are very poorly expressed or absent in these tissues in the adult, implying a possible role for the caspase-10 family in fetal development.	Natl Univ Singapore, Inst Mol & Cell Biol, TNF & Cell Death Grp, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Porter, AG (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, TNF & Cell Death Grp, 30 Med Dr, Singapore 117609, Singapore.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Droin N, 1998, ONCOGENE, V16, P2885, DOI 10.1038/sj.onc.1201821; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hu SM, 1998, J BIOL CHEM, V273, P29648, DOI 10.1074/jbc.273.45.29648; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	37	75	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10301	10308		10.1074/jbc.274.15.10301	http://dx.doi.org/10.1074/jbc.274.15.10301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187817	hybrid			2022-12-25	WOS:000079663500056
J	Takeda, Y; Tashima, M; Takahashi, A; Uchiyama, T; Okazaki, T				Takeda, Y; Tashima, M; Takahashi, A; Uchiyama, T; Okazaki, T			Ceramide generation in nitric oxide-induced apoptosis - Activation of magnesium-dependent neutral sphingomyelinase via caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-INDUCED APOPTOSIS; LEUKEMIA HL-60 CELLS; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; ACID SPHINGOMYELINASE; PHORBOL ESTER; DEATH; DIFFERENTIATION; MACROPHAGES; REQUIREMENT	Sodium nitroprusside (SNP), a NO donor, has been recognized as an inducer of apoptosis in various cell. lines. Here, we demonstrated the intracellular formation of ceramide, a lipid signal mediator, in SNP-induced apoptosis in human leukemia HL-60 cells and investigated the mechanisms of ceramide generation. The levels of intracellular ceramide increased to, at most, 160% of the control level in a time- and dose-dependent manner when the cells were treated with 1 mM SNP, SNP also decreased the sphingomyelin level to similar to 70% of the control level and increased magnesium-dependent neutral sphingomyelinase (N-SMase) activity to 160% of the control activity 2 h after treatment. Neither acid SMase nor magnesium-independent N-SMase was affected by SNP, Caspases are thought to be key enzymes in apoptotic cell death. Acetyl-Asp-Glu-Val-Asp-aldehyde, a synthetic tetrapeptide inhibitor of caspases, inhibited magnesium-dependent N-SMase, ceramide generation, and apoptosis, Moreover, recombinant purified caspase-3 increased magnesium-dependent N-SMase in a cell-free system. These results suggest that the findings that SNP increased ceramide generation and magnesium-dependent N-SMase activity via caspase-3 are interesting to future study to determine the relation between caspases and sphingolipid metabolites in NO-mediated signaling.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068397, Japan	Kyoto University	Okazaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaharamachi, Kyoto 6068397, Japan.	toshiroo@kuhp.kyoto-u.ac.jp						ADAMS LB, 1990, J IMMUNOL, V144, P2725; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dobashi K, 1997, J NEUROCHEM, V68, P1896; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FEHSEL K, 1995, J IMMUNOL, V155, P2858; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAWKINS DJ, 1988, BIOCHIM BIOPHYS ACTA, V969, P289, DOI 10.1016/0167-4889(88)90064-X; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Jun CD, 1997, CELL IMMUNOL, V176, P41, DOI 10.1006/cimm.1996.1064; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; Kuo ML, 1996, BIOCHEM BIOPH RES CO, V219, P502, DOI 10.1006/bbrc.1996.0263; KWON G, 1996, BIOCHIM BIOPHYS ACTA, V1210, P308; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; LIU J, 1994, J BIOL CHEM, V269, P3047; Loweth AC, 1997, FEBS LETT, V400, P285, DOI 10.1016/S0014-5793(96)01392-0; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishio E, 1996, BIOCHEM BIOPH RES CO, V221, P163, DOI 10.1006/bbrc.1996.0563; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Sawai H, 1997, J BIOL CHEM, V272, P2452; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; STADLER J, 1991, ARCH SURG-CHICAGO, V126, P186; STRUM JC, 1994, J BIOL CHEM, V269, P15493; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YONEDA T, 1994, JPN J MED TECH, V43, P1045	54	111	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10654	10660		10.1074/jbc.274.15.10654	http://dx.doi.org/10.1074/jbc.274.15.10654			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187863	hybrid			2022-12-25	WOS:000079663500102
J	Kim, KH; Carman, GM				Kim, KH; Carman, GM			Phosphorylation and regulation of choline kinase from Saccharomyces cerevisiae by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; ESCHERICHIA-COLI; CYCLIC-AMP; CKI GENE; YEAST; PURIFICATION; CELLS; EXPRESSION; CLONING; METABOLISM	The CK11-encoded choline kinase (ATP:choline phosphotransferase, EC 2.7.1.32) from Saccharomyces cerevisiae was phosphorylated in vivo on multiple serine residues. Activation of protein kinase A activity in vivo resulted in a transient increase in the phosphorylation of choline kinase. This phosphorylation was accompanied by a stimulation in choline kinase activity. In vitro, protein kinase A phosphorylated choline kinase on a serine residue with a stoichiometry (0.44 mol of phosphate/mol of choline kinase) consistent with one phosphorylation site/choline kinase subunit. The major phosphopeptide derived from the enzyme phosphorylated in vitro by protein kinase A was common to one of the major phosphopeptides derived from the enzyme phosphorylated in vivo. Protein kinase A activity was dose- and time-dependent and dependent on the concentrations of ATP (K-m 2.1 mu M) and choline kinase (K-m 0.12 mu M). Phosphorylation of choline kinase with protein kinase A resulted in a stimulation (1.9-fold) in choline kinase activity whereas alkaline phosphatase treatment of choline kinase resulted in a 60% decrease in choline kinase activity. The mechanism of the protein kinase A-mediated stimulation in choline kinase activity involved an increase in the apparent V-max values with respect to ATP (2.6-fold) and choline (2.7-fold). Overall, the results reported here were consistent with the conclusion that choline kinase was regulated by protein kinase A phosphorylation.	Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, Dept Food Sci, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Greenberg ML, 1996, MICROBIOL REV, V60, P1; Harlow E., 1988, ANTIBODIES LAB MANUA; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; ISHIDATE K, 1984, J BIOL CHEM, V259, P4706; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; Kim KH, 1998, J BIOL CHEM, V273, P6844, DOI 10.1074/jbc.273.12.6844; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PORTER TJ, 1990, J BIOL CHEM, V265, P414; PORTER TJ, 1992, METHOD ENZYMOL, V209, P134; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; Segel IH, 1975, ENZYME KINETICS BEHA; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; THEVELEIN JM, 1985, J GEN MICROBIOL, V131, P3199; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; UCHIDA T, 1990, BIOCHIM BIOPHYS ACTA, V1043, P281, DOI 10.1016/0005-2760(90)90028-V; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Yamashita S, 1997, BBA-LIPID LIPID MET, V1348, P63, DOI 10.1016/S0005-2760(97)00104-5	49	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9531	9538		10.1074/jbc.274.14.9531	http://dx.doi.org/10.1074/jbc.274.14.9531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092638	hybrid			2022-12-25	WOS:000079451800057
J	Meakin, SO; MacDonald, JIS; Gryz, EA; Kubu, CJ; Verdi, JM				Meakin, SO; MacDonald, JIS; Gryz, EA; Kubu, CJ; Verdi, JM			The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA - A model for discriminating proliferation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-DEPENDENT INTERACTION; AFFINITY NEUROTROPHIN RECEPTOR; PC12 CELL-DIFFERENTIATION; NEURONAL DIFFERENTIATION; TYROSINE PHOSPHATASE; INSULIN-RECEPTOR; INTRACELLULAR DOMAIN; KINASE ACTIVATION; NPEY MOTIF; PROTEIN	We have isolated a human cDNA for the signaling adapter molecule FRS-2/suc1-associated neurotrophic factor target and shown that it is tyrosine-phosphorylated in response to nerve growth factor (NGF) stimulation. Importantly, we demonstrate that the phosphotyrosine binding domain of FRS-2 directly binds the Trk receptors at the same phosphotyrosine residue that binds the signaling adapter Shc, suggesting a model in which competitive binding between FRS-2 and Shc regulates differentiation versus proliferation. Consistent with this model, FRS-S binds Grb-2, Crk, the SH2 domain containing tyrosine phosphatase SH-PTP-S, the cyclin-dependent kinase substrate p13(suc1), and the Src homology 3 (SH3) domain of Src, providing a functional link between TrkA, cell cycle, and multiple NGF signaling effectors. Importantly, overexpression of FRS-2 in cells expressing an NGF nonresponsive TrkA receptor mutant reconstitutes the ability of NGF to stop cell cycle progression and to stimulate neuronal differentiation.	John P Robarts Res Inst, Neurodegenerat Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Neurodegenerat Res Grp, 100 Perth Dr, London, ON N6A 5K8, Canada.	smeakin@rri.on.ca	Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frade JM, 1996, NATURE, V383, P166; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; Goldsmith BA, 1997, J NEUROCHEM, V69, P1014; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; James P, 1996, GENETICS, V144, P1425; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; Majdan M, 1997, J NEUROSCI, V17, P6988; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meakin SO, 1997, J NEUROCHEM, V69, P954; Meakin SO, 1998, J NEUROCHEM, V71, P1875; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	187	195	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9861	9870		10.1074/jbc.274.14.9861	http://dx.doi.org/10.1074/jbc.274.14.9861			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092678	hybrid			2022-12-25	WOS:000079451800097
J	Narhi, L; Wood, SJ; Steavenson, S; Jiang, YJ; Wu, GM; Anafi, D; Kaufman, SA; Martin, F; Sitney, K; Denis, P; Louis, JC; Wypych, J; Biere, AL; Citron, M				Narhi, L; Wood, SJ; Steavenson, S; Jiang, YJ; Wu, GM; Anafi, D; Kaufman, SA; Martin, F; Sitney, K; Denis, P; Louis, JC; Wypych, J; Biere, AL; Citron, M			Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; LEWY BODIES; DEMENTIA; PROTEIN	Parkinson's disease (PD) is a neurodegenerative disorder that is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major component of which are filaments consisting of alpha-synuclein. Two recently identified point mutations in alpha-synuclein are the only known genetic causes of PD, but their pathogenic mechanism is not understood. Here we show that both wild type and mutant alpha-synuclein form insoluble fibrillar aggregates with antiparallel beta-sheet structure upon incubation at physiological temperature in vitro. Importantly, aggregate formation is accelerated by both PD-linked mutations. Under the experimental conditions, the lag time for the formation of precipitable aggregates is about 280 h for the wild type protein, 180 h for the A30P mutant, and only 100 h for the A53T mutant protein. These data suggest that the formation of alpha-synuclein aggregates could be a critical step in PD pathogenesis, which is accelerated by the PD-linked mutations.	Amgen Inc, Thousand Oaks, CA 91320 USA	Amgen	Citron, M (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	mcitron@amgen.com						Baba M, 1998, AM J PATHOL, V152, P879; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DONG A, 1992, BIOCHEMISTRY-US, V31, P9364, DOI 10.1021/bi00154a006; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	16	610	631	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9843	9846		10.1074/jbc.274.14.9843	http://dx.doi.org/10.1074/jbc.274.14.9843			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092675	hybrid			2022-12-25	WOS:000079451800094
J	Onate, L; Vicente-Carbajosa, J; Lara, P; Diaz, I; Carbonero, P				Onate, L; Vicente-Carbajosa, J; Lara, P; Diaz, I; Carbonero, P			Barley BLZ2, a seed-specific bZIP protein that interacts with BLZ1 in vivo and activates transcription from the GCN4-like motif of B-hordein promoters in barley endosperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; DNA-BINDING; MICROPROJECTILE BOMBARDMENT; OPAQUE-2 ENCODES; PROLAMIN GENES; WHEAT; DIMERIZATION; RECOGNIZES; SEQUENCES; TOBACCO	A barley endosperm cDNA, encoding a DNA-binding protein of the bZIP class of transcription factors, BLZ2, has been characterized. The Blz2 mRNA expression is restricted to the endosperm, where it precedes that of the hordein genes. BLZ2, expressed in bacteria, binds specifically to the GCN4-like motif (GLM; 5'-GTGAGT-CAT-3') in a 43-base pair oligonucleotide derived from the promoter region of a Hor-2 gene (B1-hordein), This oligonucleotide also includes the prolamin box (PB; 5'-TGTAAAG-3'). Binding by BLZ2 is prevented when the GLM is mutated to 5'-GTGctTCtc-3' but not when mutations affect the PB, The BLZ2 protein is a potent transcriptional activator in a yeast two-hybrid system where it dimerizes with BLZ1, a barley bZIP protein encoded by the ubiquitously expressed Blz1 gene. Transient expression experiments in co-bombarded developing barley endosperms demonstrate that BLZ2 transactivates transcription from the GLM of the Hor-2 gene promoter and that this activation is also partially dependent on the presence of an intact PB. A drastic decrease in GUS activity is observed in co-bombarded barley endosperms when using as effecters equimolar mixtures of Blz2 and Blz1 in antisense constructs. These results strongly implicate the endosperm-specific BLZ2 protein from barley, either as a homodimer or as a heterodimer with BLZ1, as an important transcriptional activator of seed storage protein genes containing the GLM in their promoters.	Univ Politecn Madrid, Lab Bioquim & Biol Mol, Dept Biotecnol, ETS Ingn Agron, E-28040 Madrid, Spain	Universidad Politecnica de Madrid	Carbonero, P (corresponding author), Univ Politecn Madrid, Lab Bioquim & Biol Mol, Dept Biotecnol, ETS Ingn Agron, E-28040 Madrid, Spain.	pcarbonero@bit.etsia.upm.es	Oñate-Sánchez, Luis J/C-6274-2017; Vicente-Carbajosa, Jesus/A-9368-2008; Diaz, Isabel/I-8840-2014	Oñate-Sánchez, Luis J/0000-0001-7047-5739; Vicente-Carbajosa, Jesus/0000-0002-6332-1712; Diaz, Isabel/0000-0001-9865-902X				ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; Ausubel FA, 1990, CURRENT PROTOCOLS MO; AZAD AA, 1980, NUCLEIC ACIDS RES, V8, P4365, DOI 10.1093/nar/8.19.4365; BEVAN M, 1993, PHILOS T R SOC B, V342, P209, DOI 10.1098/rstb.1993.0149; BRANDT A, 1985, CARLSBERG RES COMMUN, V50, P333, DOI 10.1007/BF02907156; COLOT V, 1987, EMBO J, V6, P3559, DOI 10.1002/j.1460-2075.1987.tb02685.x; DEPATER S, 1994, PLANT J, V6, P133, DOI 10.1046/j.1365-313X.1994.6020133.x; DIAZ I, 1995, MOL GEN GENET, V248, P592, DOI 10.1007/BF02423455; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENTWISTLE J, 1991, PLANT MOL BIOL, V17, P1217, DOI 10.1007/BF00028737; FORDE BG, 1985, NUCLEIC ACIDS RES, V7, P1869; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; Guerin J, 1997, PLANT PHYSIOL, V114, P55, DOI 10.1104/pp.114.1.55; GUILTINAN MJ, 1994, PLANT MOL BIOL, V26, P1041, DOI 10.1007/BF00040687; HAMMONDKOSACK MCU, 1993, EMBO J, V12, P545, DOI 10.1002/j.1460-2075.1993.tb05686.x; HARTINGS H, 1989, EMBO J, V8, P2795, DOI 10.1002/j.1460-2075.1989.tb08425.x; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HULL GA, 1991, PLANT MOL BIOL, V17, P1111, DOI 10.1007/BF00037153; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; IZAWA T, 1993, J MOL BIOL, V230, P1131, DOI 10.1006/jmbi.1993.1230; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIKKERT JR, 1993, PLANT CELL TISS ORG, V33, P221, DOI 10.1007/BF02319005; Kreis M., 1992, BARLEY GENETICS MOL; LAGRIMINI LM, 1987, P NATL ACAD SCI USA, V84, P7542, DOI 10.1073/pnas.84.21.7542; LEISY DJ, 1990, PLANT MOL BIOL, V14, P41, DOI 10.1007/BF00015653; LOHMER S, 1991, EMBO J, V10, P617, DOI 10.1002/j.1460-2075.1991.tb07989.x; LOHMER S, 1993, PLANT CELL, V5, P65, DOI 10.1105/tpc.5.1.65; Mena M, 1998, PLANT J, V16, P53, DOI 10.1046/j.1365-313x.1998.00275.x; MULLER M, 1995, J PLANT PHYSIOL, V145, P606, DOI 10.1016/S0176-1617(11)81271-X; MULLER M, 1993, PLANT J, V4, P343, DOI 10.1046/j.1365-313X.1993.04020343.x; Nakase M, 1997, PLANT MOL BIOL, V33, P513, DOI 10.1023/A:1005784717782; PIROVANO L, 1994, PLANT MOL BIOL, V24, P515, DOI 10.1007/BF00024119; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; RANDOLPH E, 1992, BIOTECHNIQUES, V13, P18; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V87, P46, DOI 10.1073/pnas.87.1.46; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SORENSEN MB, 1989, MOL GEN GENET, V217, P195, DOI 10.1007/BF02464881; SUMNERSMITH M, 1985, NUCLEIC ACIDS RES, V13, P3905, DOI 10.1093/nar/13.11.3905; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAYLOR MG, 1991, PLANT CELL REP, V10, P120, DOI 10.1007/BF00232041; UENG P, 1988, PLANT PHYSIOL, V86, P1281, DOI 10.1104/pp.86.4.1281; VARAGONA MJ, 1992, PLANT CELL, V4, P1213, DOI 10.1105/tpc.4.10.1213; VASIL V, 1991, BIO-TECHNOL, V9, P743, DOI 10.1038/nbt0891-743; Vicente-Carbajosa J, 1998, PLANT J, V13, P629, DOI 10.1111/j.1365-313X.1998.00068.x; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; YUNES JA, 1994, PLANT CELL, V6, P237, DOI 10.1105/tpc.6.2.237	53	96	107	1	23	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9175	9182		10.1074/jbc.274.14.9175	http://dx.doi.org/10.1074/jbc.274.14.9175			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092589	Green Accepted, hybrid			2022-12-25	WOS:000079451800008
J	Saitoh, O; Kubo, Y; Odagiri, M; Ichikawa, M; Yamagata, K; Sekine, T				Saitoh, O; Kubo, Y; Odagiri, M; Ichikawa, M; Yamagata, K; Sekine, T			RGS7 and RGS8 differentially accelerate G protein-mediated modulation of K+ currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; MUSCARINIC POTASSIUM CHANNEL; GTPASE-ACTIVATING PROTEINS; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; ALPHA-SUBUNITS; AXIS FORMATION; RAT-BRAIN; EXPRESSION; FAMILY	The recently discovered family of RGS (regulators of G protein signaling) proteins acts as GTPase activating proteins which bind to alpha subunits of heterotrimeric G; proteins. We previously showed that a brain-specific RGS, RGS8 speeds up the activation and deactivation kinetics of the G protein-coupled inward rectifier K+ channel (GIRK) upon receptor stimulation (Saitoh, O., Kubo, Y., Miyatani, Y., Asano, T., and Nakata, H. (1997) Nature 390, 525-529). Here we report the isolation of a full-length rat cDNA of another brain-specific RGS, RGS7. In situ hybridization study revealed that RGS7 mRNA is predominantly expressed in Golgi cells within granule cell layer of cerebellar cortex. We observed that RGS7 recombinant protein binds preferentially to G alpha(o), G alpha(i3), and G alpha(z). When co-expressed with GIRK1/2 in Xenopus oocytes, RGS7 and RGS8 differentially accelerate G protein-mediated modulation of GIRK. RGS7 clearly accelerated activation of GIRK current similarly with RGS8 but the acceleration effect of deactivation was significantly weaker than that of RGS8. These acceleration properties of RGS proteins may play important roles in the rapid regulation of neuronal excitability and the cellular responses to short-lived stimulations.	Tokyo Metropolitan Inst Neurosci, Dept Mol & Cellular Neurobiol, Fuchu, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Fuchu, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Dept Anat & Embryol, Fuchu, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Dept Mol Neurobiol, Fuchu, Tokyo 1838526, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Saitoh, O (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Mol & Cellular Neurobiol, 2-6 Musashidai, Fuchu, Tokyo 1838526, Japan.			Kubo, Yoshihiro/0000-0001-6707-0837				Abe M, 1996, EXP CELL RES, V229, P48, DOI 10.1006/excr.1996.0342; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; FAUBOBERT E, 1997, P NATL ACAD SCI USA, V94, P2945; Gold SJ, 1997, J NEUROSCI, V17, P8024; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Karschin C, 1996, J NEUROSCI, V16, P3559; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; Kubo Y, 1996, J BIOL CHEM, V271, P15729, DOI 10.1074/jbc.271.26.15729; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; VRIES LD, 1995, P NATL ACAD SCI USA, V92, P11916; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	36	73	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9899	9904		10.1074/jbc.274.14.9899	http://dx.doi.org/10.1074/jbc.274.14.9899			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092682	hybrid			2022-12-25	WOS:000079451800101
J	Luo, J; Jankowski, J; Knobloch, M; Van der Giet, M; Gardanis, K; Russ, T; Vahlensieck, U; Neumann, J; Schmitz, W; Tepel, M; Deng, MC; Zidek, W; Schluter, H				Luo, J; Jankowski, J; Knobloch, M; Van der Giet, M; Gardanis, K; Russ, T; Vahlensieck, U; Neumann, J; Schmitz, W; Tepel, M; Deng, MC; Zidek, W; Schluter, H			Identification and characterization of diadenosine 5 ',5 '''-P-1,P-2-diphosphate and diadenosine 5 ',5 '''-P-1,P-3-triphosphate in human myocardial tissue	FASEB JOURNAL			English	Article						diadenosine polyphosphates; cardiac-specific granules; vasoactivity; force contraction; L-type calcium current	INDUCED INHIBITION; HUMAN-PLATELETS; INDUCED RELEASE; NITRIC-OXIDE; RAT; POLYPHOSPHATES; 5',5'''-P1,P4-TETRAPHOSPHATE; TETRAPHOSPHATE; RECEPTOR; HEXAPHOSPHATE	We examined whether human cardiac tissue contains diadenosine polyphosphates and investigated their physiological role. Extracts from human cardiac tissue from transplant recipients were fractionated by size exclusion-, affinity-, anion exchange- and reversed-phase chromatography. MALDI-MS analysis of two absorbing fractions revealed molecular masses of 676.2 Da and 756.0 Da. The UV spectra of both fractions were identical to that of adenosine. Postsource decay MALDI mass spectrometry indicated that the molecules with a mass of 676.2 Da and 757.0 Da contained AMP and ATP, respectively. As shown by enzymatic cleavage, both molecules consist of two adenosines interconnected by either two or three phosphates in 5'-positions of the riboses. Two substances can be identified as 5',5'''-P-1,P-2-diphosphate (Ap(2)A) and 5',5'''-P-1,P-3-triphosphate (Ap(3)A). Ap(2)A and Ap(3)A, together with ATP and ADP, are stored in myocardial-specific granules in biologically active concentrations. In the isolated perfused rat heart, Ap(2)A and Ap(3)A caused dose-dependent coronary vasodilations. In myocardial preparations, Ap(2)A and Ap(3)A attenuated the effect of isoproterenol, exerting a negative inotropic effect. The calcium current of guinea pig ventricular myocytes, stimulated by isoproterenol, was also attenuated by Ap(2)A and Ap(3)A. The presence of Ap(2)A and Ap(3)A in cardiac-specific granules and the actions of these substances on the myocardium and coronary vessels indicate a role for these substances as endogenous modulators of myocardial functions and coronary perfusion.	Ruhr Univ Bochum, Marien Hosp, Med Klin 1, Univ Klin, D-44625 Herne, Germany; Goethe Univ Frankfurt, Inst Analyt Chem, Frankfurt, Germany; Univ Munster, Inst Pharmakol & Toxikol, Munster, Germany; Univ Munster, Klin & Poliklin Thorax Herz Gefasschirurg, D-4400 Munster, Germany; Univ Munster, Inst Pharmaceut Chem, D-4400 Munster, Germany	Ruhr University Bochum; St. Marien Hospital; University of Munster; University of Munster; University of Munster	Schluter, H (corresponding author), Ruhr Univ Bochum, Marien Hosp, Med Klin 1, Univ Klin, Holkeskampring 40, D-44625 Herne, Germany.	Hartmut.Schlueter@ruhr-uni-bochum.de	Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; Tepel, Martin/0000-0002-0086-0997				BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBOLD AJ, 1973, CARDIOVASC RES, V7, P351; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; FLODGAARD H, 1982, BIOCHEM J, V208, P737, DOI 10.1042/bj2080737; Garrison PN, 1992, AP4A OTHER DINUCLEOS, P29; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; HILDERMAN RH, 1991, J BIOL CHEM, V266, P6915; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; Hoyle CHV, 1996, BRIT J PHARMACOL, V118, P1294, DOI 10.1111/j.1476-5381.1996.tb15536.x; Jovanovic A, 1997, BIOCHEM PHARMACOL, V54, P219, DOI 10.1016/S0006-2952(97)00262-1; Jovanovic A, 1996, PFLUG ARCH EUR J PHY, V431, P800, DOI 10.1007/BF02253848; Jovanovic A, 1998, FEBS LETT, V423, P314, DOI 10.1016/S0014-5793(98)00114-8; Jovanovic A, 1996, BRIT J PHARMACOL, V117, P233, DOI 10.1111/j.1476-5381.1996.tb15180.x; KAUFMANN R, 1994, INT J MASS SPECTROM, V131, P355, DOI 10.1016/0168-1176(93)03876-N; MAN RYK, 1990, J LIPID MEDIATOR, V2, P75; NORDHOFF E, 1992, RAPID COMMUN MASS SP, V6, P771, DOI 10.1002/rcm.1290061212; OGILVIE A, 1992, AP4A OTHER DINUCLEOS, P229; PINTOR J, 1992, NEUROSCI LETT, V136, P141, DOI 10.1016/0304-3940(92)90034-5; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1995, J NEUROCHEM, V64, P670; PLATEAU P, 1992, AP4A OTHER DINUCLEOS, P63; Ralevic V, 1996, BRIT J PHARMACOL, V118, P428, DOI 10.1111/j.1476-5381.1996.tb15420.x; RALEVIC V, 1995, J PHYSIOL-LONDON, V483, P703, DOI 10.1113/jphysiol.1995.sp020615; ROTILAN P, 1991, FEBS LETT, V280, P371, DOI 10.1016/0014-5793(91)80334-Y; Rubino A, 1996, J PHYSIOL-LONDON, V495, P515, DOI 10.1113/jphysiol.1996.sp021611; Schluter H, 1996, J AUTON PHARMACOL, V16, P357, DOI 10.1111/j.1474-8673.1996.tb00053.x; Schluter H, 1998, J CLIN INVEST, V101, P682, DOI 10.1172/JCI119882; SCHLUTER H, 1993, J CHROMATOGR, V639, P17, DOI 10.1016/0021-9673(93)83083-5; STELLA L, 1995, J CARDIOVASC PHARM, V25, P1001, DOI 10.1097/00005344-199506000-00021; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; Vahlensieck U, 1996, BRIT J PHARMACOL, V119, P835, DOI 10.1111/j.1476-5381.1996.tb15748.x; vanderGiet M, 1997, BRIT J PHARMACOL, V120, P1453, DOI 10.1038/sj.bjp.0701074; VARSHAVSKY A, 1983, CELL, V34, P711, DOI 10.1016/0092-8674(83)90526-3; VIALS A, 1993, BRIT J PHARMACOL, V109, P424, DOI 10.1111/j.1476-5381.1993.tb13586.x; Zamecnik P. C., 1968, REGULATORY MECHANISM, P3; ZIMMERMANN H, 1993, J PHYSIOLOGY-PARIS, V87, P159, DOI 10.1016/0928-4257(93)90027-Q	37	46	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					695	705		10.1096/fasebj.13.6.695	http://dx.doi.org/10.1096/fasebj.13.6.695			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094930				2022-12-25	WOS:000079527200011
J	Perrella, MA; Pellacani, A; Wiesel, P; Chin, MT; Foster, LC; Ibanez, M; Hsieh, CM; Reeves, R; Yet, SF; Lee, ME				Perrella, MA; Pellacani, A; Wiesel, P; Chin, MT; Foster, LC; Ibanez, M; Hsieh, CM; Reeves, R; Yet, SF; Lee, ME			High mobility group-I(Y) protein facilitates nuclear factor-kappa B binding and transactivation of the inducible nitric-oxide synthase promoter/enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; IFN-BETA GENE; INTERFERON-GAMMA; VIRUS INDUCTION; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL-PROTEINS; NO SYNTHASE; DNA-BINDING; EXPRESSION	Nitric oxide (NO), a free radical gas whose production is catalyzed by the enzyme NO synthase, participates in the regulation of multiple organ systems. The inducible isoform of NO synthase (iNOS) is transcriptionally upregulated by inflammatory stimuli; a critical mediator of this process is nuclear factor (NF)-kappa B, Our objective was to determine which regulatory elements other than NF-kappa B binding sites are important for activation of the MOS promoter/enhancer. We also wanted to identify transcription factors that may be functioning in conjunction with NF-kappa B (subunits p50 and p65) to drive iNOS transcription. Deletion analysis of the iNOS promoter/enhancer revealed that an AT-rich sequence (-61 to -54) downstream of the NF-kappa B site (-85 to -76) in the 5'-flanking sequence was important for iNOS induction by interleukin-1 beta and endotoxin in vascular smooth muscle cells. This AT-rich sequence, corresponding to an octamer (Oct) binding site, bound the architectural transcription factor high mobility group (HMG)-I(Y) protein. Electrophoretic mobility shift assays showed that HMG-I(Y) and NF-kappa B subunit p50 bound to the iNOS promoter/enhancer to form a ternary complex. The formation of this complex required HMG-I(Y) binding at the Oct site. The location of an HMG-I(Y) binding site typically overlaps that of a recruited transcription factor. In the iNOS promoter/enhancer, however, HMG-I(Y) formed a complex with p50 while binding downstream of the NF-kappa B site. Furthermore, overexpression of HMG-I(Y) potentiated iNOS promoter/enhancer activity by p50 and p65 in transfection experiments, suggesting that HMG-I(Y) contributes to the transactivation of MOS by NF-kappa B.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Brigham & Womens Hosp, Crit Care Div, Boston, MA 02115 USA; Washington State Univ, Dept Biochem & Biophys, Pullman, WA 99164 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Washington State University	Perrella, MA (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 667 Huntington Ave, Boston, MA 02115 USA.	perrella@cvlab.harvard.edu	Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [HL03194, HL60788, HL03745] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ECKNER R, 1989, NUCLEIC ACIDS RES, V17, P5947, DOI 10.1093/nar/17.15.5947; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HELMKE RJ, 1987, IN VITRO CELL DEV B, V23, P567; IGNARRO JJ, 1990, ANN REV PHARM TOXICO, V30, P35; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEGER H, 1995, MOL CELL BIOL, V15, P3738; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; REEVES R, 1990, J BIOL CHEM, V265, P8573; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sambrook J., 2002, MOL CLONING LAB MANU; Sawada T, 1997, J IMMUNOL, V158, P5267; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xie QW, 1997, J BIOL CHEM, V272, P14867, DOI 10.1074/jbc.272.23.14867; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	55	58	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9045	9052		10.1074/jbc.274.13.9045	http://dx.doi.org/10.1074/jbc.274.13.9045			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085153	hybrid			2022-12-25	WOS:000079451600095
J	Zhang, LL; Song, LX; Parker, EM				Zhang, LL; Song, LX; Parker, EM			Calpain inhibitor I increases beta-amyloid peptide production by inhibiting the degradation of the substrate of gamma-secretase - Evidence that substrate availability limits beta-amyloid peptide production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LINKED PRESENILIN-1; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CELLS; GENE; RATIO; VIVO	The calpain inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN) has been reported to have complex effects on the production of the beta-amyloid peptide (A beta), In this study, the effects of ALLN on the processing of the amyloid precursor protein (APP) to A beta were examined in 293 cells expressing APP or the C-terminal 100 amino acids of APP (C100), In cells expressing APP or low levels of C100, ALLN increased A beta 40 and A beta 42 secretion at low concentrations, decreased A beta 40 and A beta 42 secretion at high concentrations, and increased cellular levels of C100 in a concentration-dependent manner by inhibiting C100 degradation. Low concentrations of ALLN increased A beta 42 secretion more dramatically than A beta 40 secretion. ALLN treatment of cells expressing high levels of C100 did not alter cellular C100 levels and inhibited A beta 40 and A beta 42 secretion with similar IC50 values. These results suggest that C100 can be processed both by gamma-secretase and by a degradation pathway that is inhibited by low concentrations of ALLN, The data are consistent with inhibition of gamma-secretase by high concentrations of ALLN but do not support previous assertions that ALLN is a selective inhibitor of the gamma-secretase producing A beta 40. Rather, A beta 42 secretion may be more dependent on C100 substrate concentration than A beta 40 secretion.	Schering Plough Corp, Res Inst, Dept Cent Nervous Syst & Cardiovasc Res, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Zhang, LL (corresponding author), Schering Plough Corp, Res Inst, Dept Cent Nervous Syst & Cardiovasc Res, K15-3-3600,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	lili.zhang@spcorp.com						Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; CLARK RF, 1995, NAT GENET, V11, P219, DOI 10.1038/ng1095-219; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; DYKES T, 1993, FEBS LETT, V335, P89; DYKES T, 1992, FEBS LETT, V309, P20; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Savage MJ, 1998, J NEUROSCI, V18, P1743; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y	23	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8966	8972		10.1074/jbc.274.13.8966	http://dx.doi.org/10.1074/jbc.274.13.8966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085142	hybrid			2022-12-25	WOS:000079451600084
J	Fujimoto, N; Yeh, SY; Kang, HY; Inui, S; Chang, HC; Mizokami, A; Chang, CS				Fujimoto, N; Yeh, SY; Kang, HY; Inui, S; Chang, HC; Mizokami, A; Chang, CS			Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN; STEROID-RECEPTORS; HORMONE RECEPTOR; PROTEIN; CANCER; GENE; ACTIVATION; MUTATION; TRANSCRIPTION; CYTOSKELETON	Androgen receptor (AR) is a hormone-activated transcriptional factor that can bind to androgen response elements and that regulates the transcription of target genes via a mechanism that presumably involves cofactors. We report here the cloning of a novel AR coactivator ARA55 using a yeast two-hybrid system. ARA55 consists of 444 amino acids with the predicted molecular mass of 55 kDa and its sequence shows very high homology to mouse hic5, a TGF-beta 1-inducible gene. Yeast and mammalian two-hybrid systems and co immunoprecipitation assays all prove ARA55 can bind to AR in a ligand-dependent manner. Transient transfection assay in prostate cancer DU145 cells further demonstrates that ARA55 can enhance AR transcriptional activity in the presence of 1 nM dihydrotestosterone or its antagonists such as 100 nM 17 beta-estradiol or 1 mu M hydroxyflutamide, Our data also suggest the C-terminal half of ARA55, which includes three LIM motifs, is sufficient to interact with AR. Northern blot and polymerase chain reaction quantitation showed ARA55 can be expressed differently in normal prostate and prostate tumor cells. Together, our data suggests that ARA55 may play very important roles in the progression of prostate cancer by the modulation of AR transactivation.	Univ Rochester, Ctr Med, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Med Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, Ctr Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Ctr Med, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@pathology.rochester.edu	Kang, Hong-Yo/W-9031-2019	Kang, Hong-Yo/0000-0003-0626-5037; CHANG, HONG-CHIANG/0000-0001-5411-6680	NCI NIH HHS [CA55639, CA68568] Funding Source: Medline; NIDDK NIH HHS [DK51346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; ONATE SA, 1995, SCIENCE, V270, P1354; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG C, 1997, THESIS U WISCONSIN M; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	28	226	233	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8316	8321		10.1074/jbc.274.12.8316	http://dx.doi.org/10.1074/jbc.274.12.8316			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075738	hybrid			2022-12-25	WOS:000079268100097
J	Ahmad, N; Gupta, S; Mukhtar, H				Ahmad, N; Gupta, S; Mukhtar, H			Involvement of retinoblastoma (Rb) and E2F transcription factors during photodynamic therapy of human epidermoid carcinoma cells A431	ONCOGENE			English	Article						photodynamic therapy; cell cycle; retinoblastoma (pRb); E2F	MOUSE LYMPHOMA-CELLS; CYCLE PROGRESSION; INDUCED ABLATION; CANCER-CELLS; NITRIC-OXIDE; APOPTOSIS; INDUCTION; PROTEINS; KINASE; PHOTOSENSITIZERS	Photodynamic therapy (PDT), a promising new therapeutic modality for the management of a variety of solid malignancies and many non-malignant diseases, is a bimodal therapy using a porphyrin based photosensitizing chemical and visible light. The proper understanding of the mechanism of PDT-mediated cancer cell-kill may result in improving the efficacy of this treatment modality. Earlier we have shown (PI oc. Natl, Acad. Sci, USA; 95: 6977-6982, 1998) that silicon phthalocyanine (Pc4)-PDT results in an induction of the cyclin kinase inhibitor WAF1/CIP1/p21 which, by inhibiting cyclins (E and DI) and cyclin dependent kinases (cdk2 and cdk6), results in a G0/G1-phase arrest followed by apoptosis in human epidermoid carcinoma cells A431. We have also demonstrated the generation of nitric oxide during PDT-mediated apoptosis (Cancer Res.; 58: 1785-1788, 1998), Retinoblastoma (pRb) and E2F family transcription factors are important proteins, which regulate the G1-->S transition in the cell cycle. Here, we pro, ide evidence for the involvement of pRb-E2F/DP machinery as an important contributor of PDT-mediated cell cycle arrest and apoptosis, Western blot analysis demonstrated a decrease in the hyper-phosphorylated form of pRb at 3, 6 and 12 h post-PDT with a relative increase in hypo-phosphorylated pRb, Western blot analysis also revealed that PDT-caused decrease in phosphorylation of pRb occurs at serine-780, The ELISA data demonstrated a time dependent accumulation of hypo-phosphorylated pRb by PDT, This response was accompanied with down-regulation in the protein expression of all five E2F (1-5) family transcription factors, and their heterodimeric partners DP1 and DP2, These results suggest that Pc4-PDT of A431 cells results in a down regulation of hyper-phosphorylated pRb protein with a relative increase in hypo-phosphorylated pRb that, in turn, compromises with the availability of free E2F, We suggest that these events result in a stoppage of the cell cycle progression at G1-->S transition thereby leading to a G0/G1 phase arrest and a subsequent apoptotic cell death, These data provide an evidence for the involvement of pRb-E2F/DP machinery in PDT-mediated cell cycle arrest leading to apoptosis.	Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University	Mukhtar, H (corresponding author), Case Western Reserve Univ, Dept Dermatol, 11100 Euclid Ave, Cleveland, OH 44106 USA.			Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [P30 CA 43703, R01 CA51802, P01 CA 48735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703, P01CA048735, R01CA051802] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; Agarwal R, 1996, PHOTOCHEM PHOTOBIOL, V63, P547, DOI 10.1111/j.1751-1097.1996.tb03082.x; Ahmad N, 1998, P NATL ACAD SCI USA, V95, P6977, DOI 10.1073/pnas.95.12.6977; BenHur E, 1997, PHOTOCHEM PHOTOBIOL, V65, P456, DOI 10.1111/j.1751-1097.1997.tb08589.x; Bowen C, 1998, CANCER RES, V58, P3275; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Goldberg Y, 1996, ONCOGENE, V12, P893; Gomer CJ, 1996, CANCER RES, V56, P2355; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V54, P1093, DOI 10.1111/j.1751-1097.1991.tb02133.x; Granville DJ, 1997, CELL DEATH DIFFER, V4, P623, DOI 10.1038/sj.cdd.4400286; Gupta S, 1998, CANCER RES, V58, P1785; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Ishida A, 1997, J BIOL CHEM, V272, P10050; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Linke SP, 1997, ONCOGENE, V15, P337, DOI 10.1038/sj.onc.1201200; LUNA MC, 1994, CANCER RES, V54, P1374; Luo Y, 1996, PHOTOCHEM PHOTOBIOL, V63, P528, DOI 10.1111/j.1751-1097.1996.tb03079.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; PASS HI, 1993, JNCI-J NATL CANCER I, V85, P443, DOI 10.1093/jnci/85.6.443; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; Separovic D, 1997, CANCER RES, V57, P1717; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TOM R, 1997, J NATL CANCER I, V89, P112; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZAIDI SIA, 1993, PHOTOCHEM PHOTOBIOL, V58, P771, DOI 10.1111/j.1751-1097.1993.tb04969.x	41	28	33	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1891	1896		10.1038/sj.onc.1202493	http://dx.doi.org/10.1038/sj.onc.1202493			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086343				2022-12-25	WOS:000079090000012
J	Tahara, H; Yasui, W; Tahara, E; Fujimoto, J; Ito, K; Tamai, K; Nakayama, J; Ishikawa, F; Tahara, E; Ide, T				Tahara, H; Yasui, W; Tahara, E; Fujimoto, J; Ito, K; Tamai, K; Nakayama, J; Ishikawa, F; Tahara, E; Ide, T			Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections	ONCOGENE			English	Article						telomerase; in situ detection; hTERT; immuno-histochemistry; colorectal carcinoma	MAMMALIAN TELOMERASE; SUBUNIT GENE; CELLS; PROTEIN; CANCER; RNA; EXPRESSION; STOMACH	Human telomerase is expressed in germ tissues and in the majority of primary tumors. Cell renewal tissues and some pre-cancerous tissues also have weak telomerase activity, Yet, neither the exact location and frequency of telomerase-positive cells nor the changes in telomerase expression during differentiation or carcinogenesis of individual cells are known. This paper reports on the expression of hTERT (telomerase reverse transcriptase) protein in tumor and non-tumor colorectal tissues by Western blotting and tissue sections by immunohistochemistry using antibodies raised against partial peptides of hTERT, Though telomerase activity and hTERT expression at both mRNA and protein levels were generally higher in tumor part than in non-tumor part, these two were not always correlated: expression of hTERT did not always give rise to high telomerase activity. Colonic carcinoma cell nuclei were stained with anti-hTERT antibodies but not with antigen-preabsorbed antibodies. In normal mucosa, hTERT protein was expressed, though weaker than in carcinoma, in all colonic crypt epithelial cells except those at the tip; the expressing-cell distribution was much wider than that of Ki-67 positive cells which were located at the bottom of the crypt, Isolated crypt contained a significant level of hTERT protein revealed by Western blotting, while having very weak telomerase activity. Telomerase activity was detected in epithelial cells only at the bottom half of the crypt, Specific hTERT-staining was positive in tissue lymphocytes but negative in almost all other stromal cells. It is of interest to see whether a significant level of hTERT expression with low telomerase activity is characteristic of physiologically regenerating tissues containing stem cells, In situ detection of the hTERT protein mill permit further analysis of cancer diagnosis and stem cell differentiation.	Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Hiroshima 734, Japan; Hiroshima Univ, Sch Med, Dept Pathol 1, Hiroshima 734, Japan; Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 226, Japan; Med & Biol Labs Co Ltd, Nagano, Japan	Hiroshima University; Hiroshima University; Tokyo Institute of Technology	Ide, T (corresponding author), Hiroshima Univ, Sch Med, Dept Cellular & Mol Biol, Kasumi 1-2-3, Hiroshima 734, Japan.		Nakayama, Jun-ichi/C-6003-2011; Tamai, Katsuyuki/F-4743-2013; Ishikawa, Fuyuki/AAU-4056-2021	Nakayama, Jun-ichi/0000-0002-5597-8239; Tamai, Katsuyuki/0000-0003-4094-3911; Ishikawa, Fuyuki/0000-0002-5580-2305				Avilion AA, 1996, CANCER RES, V56, P645; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Ohyashiki K, 1997, CANCER RES, V57, P2100; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Tahara H, 1995, CLIN CANCER RES, V1, P1245; Yasui W, 1996, J PATHOL, V180, P122, DOI 10.1002/(SICI)1096-9896(199610)180:2<122::AID-PATH647>3.0.CO;2-C	20	151	170	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1561	1567		10.1038/sj.onc.1202458	http://dx.doi.org/10.1038/sj.onc.1202458			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102626				2022-12-25	WOS:000078770700006
J	Im, H; Seo, EJ; Yu, MH				Im, H; Seo, EJ; Yu, MH			Metastability in the inhibitory mechanism of human alpha(1)-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN ALPHA-1-PROTEINASE INHIBITOR; SERPIN CONFORMATIONAL CHANGE; SERINE-PROTEASE INHIBITOR; INFLUENZA HEMAGGLUTININ; CRYSTAL-STRUCTURE; ENVELOPE GLYCOPROTEIN; HYDROPHOBIC CORE; REACTIVE LOOP; HINGE REGION	Metastability of the native form of proteins has been recognized as a mechanism of biological regulation. The energy-loaded structure of the fusion protein of influenza virus and the strained native structure of serpins (serine protease inhibitors) are typical examples. To understand the structural basis and functional role of the native metastability of inhibitory serpins, we characterized stabilizing mutations of alpha(1)-antitrypsin in a region presumably involved in complex formation with a target protease, We found various unfavorable interactions such as overpacking of side chains, polar-nonpolar interactions, and cavities as the structural basis of the native metastability, For several stabilizing mutations, there was a concomitant decrease in the inhibitory activity. Remarkably, some substitutions at Lys-335 increased the stability over 6 kcal mol(-1) with simultaneous loss of activity over 30% toward porcine pancreatic elastase, Considering the location and energetic cost of Lys-335, we propose that this lysine plays a pivotal role in conformational switch during complex formation. Our current results are quite contradictory to those of previously reported hydrophobic core mutations, which increased the stability up to 9 kcal mol(-1) without any significant loss of activity. It appears that the local strain of inhibitory serpins is critical for the inhibitory activity.	Korea Res Inst Biosci & Biotechnol, Natl Creat Res Initiat Ctr, Taejon 305600, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Yu, MH (corresponding author), Korea Res Inst Biosci & Biotechnol, Natl Creat Res Initiat Ctr, POB 115, Taejon 305600, South Korea.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Hillier BJ, 1998, FOLD DES, V3, P87, DOI 10.1016/S1359-0278(98)00014-5; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Kocher JP, 1996, STRUCTURE, V4, P1517, DOI 10.1016/S0969-2126(96)00157-8; KWON KS, 1994, J BIOL CHEM, V269, P9627; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SCHREIBER C, 1994, STRUCTURE, V2, P945, DOI 10.1016/S0969-2126(94)00096-4; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; TRAVIS J, 1981, METHOD ENZYMOL, V80, P754; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; WEI AZ, 1994, NAT STRUCT BIOL, V1, P251, DOI 10.1038/nsb0494-251; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	45	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11072	11077		10.1074/jbc.274.16.11072	http://dx.doi.org/10.1074/jbc.274.16.11072			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196190	hybrid			2022-12-25	WOS:000079751900058
J	Muller, ML; Jensen, M; Taiz, L				Muller, ML; Jensen, M; Taiz, L			The vacuolar H+-ATPase of lemon fruits is regulated by variable H+/ATP coupling and slip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L STORAGE TISSUE; BETA-VULGARIS; PROTON SLIP; ENERGY TRANSDUCTION; TONOPLAST VESICLES; GAMMA-SUBUNIT; SYNTHASE; MECHANISM; PH; INHIBITION	Lemon fruit tonoplasts, unlike those of seedling epicotyls, contain nitrate-insensitive H+-ATPase activity (Muller, M. L,, Irkens-Kiesecker, U,, Rubinstein, B., and Taiz, L. (1996) J, Biol. Chem. 271, 1916-1924). However, the degree of nitrate-insensitivity fluctuates during the course of the year with a seasonal frequency. Nitrate uncouples H+ pumping from ATP hydrolysis both in epicotyls and in nitrate-sensitive fruit V-ATPases. Neither bafilomycin nor oxidation cause uncoupling. The initial rate H+/ATP coupling ratios of epicotyl and the nitrate-sensitive fruit proton pumping activities are the same. However, the H+/ATP coupling ratio of the nitrate-insensitive fruit H+ pumping activity is lower than that of nitrate-sensitive and epicotyl V-ATPases, Several properties of the nitrate-insensitive H+-ATPase of the fruit indicate that it is a modified V-ATPase rather than a P-ATPase: 1) insensitivity to low concentrations of vanadate; 2) it is initially strongly uncoupled by nitrate, but regains coupling as catalysis proceeds; 3) both the nitrate-sensitive and nitrate-insensitive fruit H+-pumps have identical K-m values for MgATP, and show similar pH-dependent slip and proton leakage rates. We conclude that the ability of the juice sac V-ATPase to build up steep pH gradients involves three factors: variable coupling, i.e. the ability to regain coupling under conditions that initially induce uncoupling; a low pH dependent slip rate; the low proton permeability of the membrane.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Taiz, L (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.							BENNETT AB, 1984, PLANT PHYSIOL, V74, P545, DOI 10.1104/pp.74.3.545; BOWMAN J, 1996, MYCOTA, V3, P57; BRISKIN DP, 1991, PLANT PHYSIOL, V95, P242, DOI 10.1104/pp.95.1.242; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; DSCHIDA WJA, 1995, J BIOL CHEM, V270, P1557, DOI 10.1074/jbc.270.4.1557; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Evron Y, 1997, PLANT PHYSIOL, V115, P1549, DOI 10.1104/pp.115.4.1549; EVRON Y, 1990, BIOCHIM BIOPHYS ACTA, V1019, P115, DOI 10.1016/0005-2728(90)90131-M; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; GUERN J, 1989, PLANT PHYSIOL, V89, P27, DOI 10.1104/pp.89.1.27; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KIBAK H, 1993, J BIOL CHEM, V268, P23325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mattsson JP, 1996, BBA-BIOMEMBRANES, V1280, P98, DOI 10.1016/0005-2736(95)00285-5; Merzendorfer H, 1997, J EXP BIOL, V200, P225; MORIYAMA Y, 1988, ION PUMPS STRUCTURE, P387; Muller ML, 1997, J BIOL CHEM, V272, P12762, DOI 10.1074/jbc.272.19.12762; Muller ML, 1996, J BIOL CHEM, V271, P1916; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OSTER G, 1999, IN PRESS ENCY MOL BI; PALMGREN MG, 1990, PLANT PHYSIOL, V94, P882, DOI 10.1104/pp.94.3.882; POPE AJ, 1988, PLANT PHYSIOL, V86, P1315, DOI 10.1104/pp.86.4.1315; POPOV N, 1975, ACTA BIOL MED GER, V34, P1441; RAUTIALA TJ, 1993, BIOCHEM BIOPH RES CO, V194, P50, DOI 10.1006/bbrc.1993.1783; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; REA PA, 1987, BIOCHIM BIOPHYS ACTA, V904, P1, DOI 10.1016/0005-2736(87)90080-0; SCHMIDT AL, 1993, ARCH BIOCHEM BIOPHYS, V301, P165, DOI 10.1006/abbi.1993.1129; Taiz Lincoln, 1996, P291; TU SI, 1987, ARCH BIOCHEM BIOPHYS, V256, P625, DOI 10.1016/0003-9861(87)90620-5; XIE XS, 1993, J BIOL CHEM, V268, P25063; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHANG K, 1992, J BIOL CHEM, V267, P14539	38	37	38	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10706	10716		10.1074/jbc.274.16.10706	http://dx.doi.org/10.1074/jbc.274.16.10706			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196141	hybrid			2022-12-25	WOS:000079751900009
J	Camarero, S; Sarkar, S; Ruiz-Duenas, FJ; Martinez, MJ; Martinez, AT				Camarero, S; Sarkar, S; Ruiz-Duenas, FJ; Martinez, MJ; Martinez, AT			Description of a versatile peroxidase involved in the natural degradation of lignin that has both manganese peroxidase and lignin peroxidase substrate interaction sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASIDIOMYCETE PHANEROCHAETE-CHRYSOSPORIUM; PLEUROTUS-ERYNGII; WHEAT-STRAW; HORSERADISH-PEROXIDASE; ANGSTROM RESOLUTION; BJERKANDERA-ADUSTA; CRYSTAL-STRUCTURE; BINDING-SITE; OXIDATIVE-DEGRADATION; CATALYTIC PROPERTIES	Two major peroxidases are secreted by the fungus Pleurotus eryngii in lignocellulose cultures. One is similar to Phanerochaete chrysosporium manganese-dependent peroxidase, The second protein (PS1), although catalyzing the oxidation of Mn2+ to Mn3+ by H2O2, differs from the above enzymes by its manganese-independent activity enabling it to oxidize substituted phenols and synthetic dyes, as well as the lignin peroxidase (LiP) substrate veratryl alcohol. This is by a mechanism similar to that reported for LiP, as evidenced by p-dimethoxybenzene oxidation yielding benzoquinone. The apparent kinetic constants showed high activity on Mn2+, but methoxyhydroquinone was the natural substrate with the highest enzyme affinity (this and other phenolic substrates are not efficiently oxidized by the P, chrysosporium peroxidases). A three-dimensional model was built using crystal models from four fungal peroxidase as templates. The model suggests high structural affinity of this versatile peroxidase with LiP but shows a putative Mn2+ binding site near the internal heme propionate, involving G1u(36), Glu(40), and Asp(181). A specific substrate interaction site for Mn2+ is supported by kinetic data showing noncompetitive inhibition with other peroxidase substrates, Moreover, residues reported as involved in LiP interaction with veratryl alcohol and other aromatic substrates are present in peroxidase PS1 such as His(82) at the heme-channel opening, which is remarkably similar to that of P, chrysosporium LiP, and Trp(170) at the protein surface, These residues could be involved in two different hypothetical long range electron transfer pathways from substrate (His(82)-Ala(83)-Asn(84)-His(47)-heme and Trp(170)-Leu(171)-heme) similar to those postulated for LiP.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Martinez, AT (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	cibm149@fresno.csic.es	Ruiz-Dueñas, Francisco J/L-9837-2015; Camarero, Susana/K-3172-2014; Martínez, Angel T/G-7284-2017; Martinez, Maria Jesus/F-9147-2015	Ruiz-Dueñas, Francisco J/0000-0002-9837-5665; Camarero, Susana/0000-0002-2812-895X; Martínez, Angel T/0000-0002-1584-2863; Martinez, Maria Jesus/0000-0003-2166-1097				ASADA Y, 1995, BBA-PROTEIN STRUCT M, V1251, P205, DOI 10.1016/0167-4838(95)00102-Z; Banci L, 1997, J BIOTECHNOL, V53, P253, DOI 10.1016/S0168-1656(97)01677-5; BAO WL, 1994, FEBS LETT, V354, P297, DOI 10.1016/0014-5793(94)01146-X; Blodig W, 1998, BIOCHEMISTRY-US, V37, P8832, DOI 10.1021/bi9727186; Camarero S, 1996, APPL ENVIRON MICROB, V62, P1070, DOI 10.1128/AEM.62.3.1070-1072.1996; Camarero S, 1998, J PULP PAP SCI, V24, P197; Caramelo L, 1999, APPL ENVIRON MICROB, V65, P916; DATTA A, 1991, APPL ENVIRON MICROB, V57, P1453, DOI 10.1128/AEM.57.5.1453-1460.1991; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; Eriksson K.-E., 1990, MICROBIAL ENZYMATIC; FAISON BD, 1983, APPL ENVIRON MICROB, V46, P1140, DOI 10.1128/AEM.46.5.1140-1145.1983; FARRELL RL, 1989, ENZYME MICROB TECH, V11, P322, DOI 10.1016/0141-0229(89)90014-8; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; GLENN JK, 1986, ARCH BIOCHEM BIOPHYS, V251, P688, DOI 10.1016/0003-9861(86)90378-4; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; GLUMOFF T, 1990, EUR J BIOCHEM, V187, P515, DOI 10.1111/j.1432-1033.1990.tb15333.x; GOLD MH, 1993, MICROBIOL REV, V57, P605, DOI 10.1128/MMBR.57.3.605-622.1993; Guillen F, 1997, ARCH BIOCHEM BIOPHYS, V339, P190, DOI 10.1006/abbi.1996.9834; HARVEY PJ, 1990, J BIOTECHNOL, V13, P169, DOI 10.1016/0168-1656(90)90102-H; HATAKKA A, 1994, FEMS MICROBIOL REV, V13, P125, DOI 10.1016/0168-6445(94)90076-0; Heinfling A, 1998, FEMS MICROBIOL LETT, V165, P43, DOI 10.1016/S0378-1097(98)00255-9; Heinfling A, 1998, FEBS LETT, V428, P141, DOI 10.1016/S0014-5793(98)00512-2; Heinfling A, 1998, APPL ENVIRON MICROB, V64, P2788; Higuchi T., 1997, BIOCH MOL BIOL WOOD, P1, DOI [10.1007/978-3-642-60469-0_1, DOI 10.1007/978-3-642-60469-0_1, 10.1007/978-3-642-60469-0]; JOHNSON F, 1994, PROTEINS, V20, P312, DOI 10.1002/prot.340200404; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Kishi K, 1996, BIOCHEMISTRY-US, V35, P8986, DOI 10.1021/bi960679c; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; KUWAHARA M, 1984, FEBS LETT, V169, P247, DOI 10.1016/0014-5793(84)80327-0; Lobos S, 1998, GENE, V206, P185, DOI 10.1016/S0378-1119(97)00583-0; MARTINEZ AT, 1994, FEMS MICROBIOL REV, V13, P265, DOI 10.1016/0168-6445(94)90084-1; MARTINEZ AT, 1997, 16 C SOC ESP MICR UL, P89; Martinez MJ, 1996, EUR J BIOCHEM, V237, P424, DOI 10.1111/j.1432-1033.1996.0424k.x; Martinez-Inigo MJ, 1997, HOLZFORSCHUNG, V51, P543, DOI 10.1515/hfsg.1997.51.6.543; Mester T, 1998, J BIOL CHEM, V273, P15412, DOI 10.1074/jbc.273.25.15412; Munoz C, 1997, APPL ENVIRON MICROB, V63, P2166; Palmieri G, 1998, 7TH INTERNATIONAL CONFERENCE ON BIOTECHNOLOGY IN THE PULP AND PAPER INDUSTRY, VOL B, pB253; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Ruiz-Duenas FJ, 1999, MOL MICROBIOL, V31, P223, DOI 10.1046/j.1365-2958.1999.01164.x; Sarkar S, 1997, BBA-PROTEIN STRUCT M, V1339, P23, DOI 10.1016/S0167-4838(96)00201-4; Schoemaker H E, 1994, Bioorg Med Chem, V2, P509, DOI 10.1016/0968-0896(94)80021-9; SCHOEMAKER HE, 1994, FEMS MICROBIOL REV, V13, P321, DOI 10.1111/j.1574-6976.1994.tb00052.x; Shimada M., 1991, WOOD CELLULOSIC CHEM, P557; STEINLIN H, 1979, HOLS ALS ROHSTOFF WE, P14; Sundaramoorthy M, 1997, J BIOL CHEM, V272, P17574, DOI 10.1074/jbc.272.28.17574; SUNDERAMOORTHY M, 1984, J BIOL CHEM, V269, P32769; *TAPPI, 1993, TEST METH 1992 1993; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; VARES T, 1995, APPL ENVIRON MICROB, V61, P3515, DOI 10.1128/AEM.61.10.3515-3520.1995; VEITCH NC, 1995, EUR J BIOCHEM, V233, P650, DOI 10.1111/j.1432-1033.1995.650_2.x	55	271	288	2	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10324	10330		10.1074/jbc.274.15.10324	http://dx.doi.org/10.1074/jbc.274.15.10324			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187820	Green Published, hybrid			2022-12-25	WOS:000079663500059
J	Dombrowski, S; Hoffmann, M; Guha, C; Binder, S				Dombrowski, S; Hoffmann, M; Guha, C; Binder, S			Continuous primary sequence requirements in the 18-nucleotide promoter of dicot plant mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION SITES; RNA-POLYMERASES; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; IDENTIFICATION; ARABIDOPSIS; DNA; PEA; PLASTIDS	The nucleotide requirements of mitochondrial promoters of dicot plants were studied in detail in a pea in vitro transcription system. Deletions in the 5' regions of three different transcription initiation sites from pea, soybean, and Oenothera identified a crucial AT-rich sequence element (AT-Box) comprising nucleotide positions -14 to -9 relative to the first transcribed nucleotide. Transversion of the AT-Box sequence to complementary nucleotide identities results in an almost complete loss of promoter activity, suggesting that primary structure rather than a simple accumulation of adenines and thymidines in this region is essential for promoter activity. This promoter segment thus appears to be involved in sequence specific binding of a respective protein factor(s) rather than merely loosening and melting the DNA helix during or for an initiation event. Manipulation of nucleotide identities in the 3' portion of the pea atp9 promoter and the respective S'-flanking region revealed that essential sequences extend to positions +3/+4 beyond this transcription start site. Efficient transcription initiation at an 18-base pair promoter sequence ranging from nucleotide positions -14 to +4 integrated into different sequence contexts shows this element to be sufficient for autonomous promoter function independent of surrounding sequences.	Univ Ulm, Allgemeine Bot, D-89069 Ulm, Germany	Ulm University	Binder, S (corresponding author), Univ Ulm, Allgemeine Bot, Albert-Einstein-Allee 11, D-89069 Ulm, Germany.	stefan.binder@biologie.uni-ulm.de						ANTOSHECHKIN I, 1995, MOL CELL BIOL, V15, P7032; BINDER S, 1993, J BIOL CHEM, V268, P7849; Binder S, 1996, PLANT MOL BIOL, V32, P303, DOI 10.1007/BF00039387; BINDER S, 1993, NUCLEIC ACIDS RES, V21, P5012, DOI 10.1093/nar/21.22.5012; BINDER S, 1995, J BIOL CHEM, V270, P22182, DOI 10.1074/jbc.270.38.22182; BROWN GG, 1991, MOL GEN GENET, V228, P345, DOI 10.1007/BF00260626; Caoile AGFS, 1997, NUCLEIC ACIDS RES, V25, P4055, DOI 10.1093/nar/25.20.4055; COVELLO PS, 1991, CURR GENET, V20, P245, DOI 10.1007/BF00326239; Dombrowski S, 1998, PLANT MITOCHONDRIA: FROM GENE TO FUNCTION, P165; Giese A, 1996, MOL GEN GENET, V252, P429, DOI 10.1007/BF02173008; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; Hajdukiewicz PTJ, 1997, EMBO J, V16, P4041, DOI 10.1093/emboj/16.13.4041; Hatzack F, 1998, PLANT PHYSIOL, V116, P519, DOI 10.1104/pp.116.2.519; Hedtke B, 1997, SCIENCE, V277, P809, DOI 10.1126/science.277.5327.809; Hubschmann T, 1998, PLANT MOL BIOL, V36, P493, DOI 10.1023/A:1005924502336; Kapoor S, 1997, PLANT J, V11, P327, DOI 10.1046/j.1365-313X.1997.11020327.x; Larsson NG, 1996, NAT GENET, V13, P296, DOI 10.1038/ng0796-296; Maliga P, 1998, TRENDS PLANT SCI, V3, P4, DOI 10.1016/S1360-1385(97)87981-2; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MULLIGAN RM, 1991, MOL CELL BIOL, V11, P533, DOI 10.1128/MCB.11.1.533; NAKAZONO M, 1995, PLANT SCI, V105, P227, DOI 10.1016/0168-9452(94)04046-X; RAPP WD, 1993, MOL CELL BIOL, V13, P7232, DOI 10.1128/MCB.13.12.7232; RAPP WD, 1992, EMBO J, V11, P1065, DOI 10.1002/j.1460-2075.1992.tb05145.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; Tiranti V, 1997, HUM MOL GENET, V6, P615, DOI 10.1093/hmg/6.4.615; TRACY RL, 1995, CURR GENET, V28, P205, DOI 10.1007/BF00309779; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; Weihe A, 1997, NUCLEIC ACIDS RES, V25, P2319, DOI 10.1093/nar/25.12.2319; Yan B, 1997, CURR GENET, V32, P287, DOI 10.1007/s002940050279	31	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10094	10099		10.1074/jbc.274.15.10094	http://dx.doi.org/10.1074/jbc.274.15.10094			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187790	hybrid			2022-12-25	WOS:000079663500029
J	Haskell, CA; Cleary, MD; Charo, IF				Haskell, CA; Cleary, MD; Charo, IF			Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction - Rapid flow arrest of CX(3)CR1-expressing cells is independent of G-protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTORS; DIRECTED MIGRATION; CHEMOTAXIS; CX(3)CR1; LINE; INTERNALIZATION; LYMPHOCYTES; MICROGLIA; ROLES; BRAIN	Fractalkine is a novel multidomain protein expressed on the surface of activated endothelial cells. Cells expressing the chemokine receptor CX(3)CR1 adhere to fractalkine with high affinity, but it is not known if adherence requires G-protein activation and signal transduction. To investigate the cell adhesion properties of fractalkine, we created mutated forms of CX(3)CR1 that have little or no ability to transduce intracellular signals. Cells expressing signaling-incompetent forms of CX(3)CR1 bound rapidly and with high affinity to immobilized fractalkine in both static and flow assays. Video microscopy revealed that CX(3)CR1-expressing cells bound more rapidly to fractalkine than to VCAM-1 (60 versus 190 ms). Unlike VCAM-1, fractalkine did not mediate cell rolling, and after capture on fractalkine, cells did not dislodge. Finally, soluble fractalkine induced intracellular calcium fluxes and chemotaxis, but it did not activate integrins. Taken together these data provide strong evidence that CX(3)CR1, a seven-transmembrane domain receptor, mediates robust cell adhesion to fractalkine in the absence of G-protein activation and suggest a novel role for this receptor as an adhesion molecule.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai H, 1997, J BIOL CHEM, V272, P25037, DOI 10.1074/jbc.272.40.25037; Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Franci C, 1996, J IMMUNOL, V157, P5606; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Pachynski RK, 1998, J IMMUNOL, V161, P952; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	25	186	198	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10053	10058		10.1074/jbc.274.15.10053	http://dx.doi.org/10.1074/jbc.274.15.10053			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187784	hybrid			2022-12-25	WOS:000079663500023
J	Meng, Q; Malinovskii, V; Huang, W; Hu, YJ; Chung, L; Nagase, H; Bode, W; Maskos, K; Brew, K				Meng, Q; Malinovskii, V; Huang, W; Hu, YJ; Chung, L; Nagase, H; Bode, W; Maskos, K; Brew, K			Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1 ' residue of substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-TISSUE INHIBITOR; GROWTH-PROMOTING ACTIVITY; AMINO-TERMINAL DOMAIN; PROGELATINASE-A; BINDING; FAMILY; STROMELYSIN-1; RECEPTOR; CLONING; REGION	The unregulated activities of matrix metalloproteinases (MMPs) are implicated in disease processes including arthritis and tumor cell invasion and metastasis, NMP activities are controlled by four homologous endogenous protein inhibitors, tissue inhibitors of metalloproteinases (TIMPs), yet different TIMPs show little specificity for individual MMPs. The large interaction interface in the TIMP-1.MMP-3 complex includes a contiguous region of TIMP-1 around the disulfide bond between Cys(1) and Cys(70) that inserts into the active site of MMP-3. The effects of fifteen different substitutions for threonine 2 of this region reveal that this residue makes a large contribution to the stability of complexes with MMPs and has a dominant influence on the specificity for different MMPs. The size, charge, and hydrophobicity of residue 2 are key factors in the specificity of TIMP. Threonine 2 of TIMP-1 interacts with the S1' specificity pocket of MMP-3, which is a key to substrate specificity, but the structural requirements in TIMP-1 residue 2 for MMP binding differ greatly from those for the corresponding residue of a peptide substrate. These results demonstrate that TIMP variants with substitutions for Thr(2) represent suitable starting points for generating more targeted TIMPs for investigation and for intervention in MMP-related diseases.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS USA; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	University of Miami; University of Kansas; University of Kansas Medical Center; Max Planck Society	Brew, K (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.		Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019; Malinovskii, Vladimir A./AAF-9048-2019	Brew, Keith/0000-0003-1306-1032; Malinovskii, Vladimir A./0000-0001-6261-0398	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nagase H, 1996, ZINC METALLOPROTEASE, P153; OSHEA M, 1992, BIOCHEMISTRY-US, V31, P10146, DOI 10.1021/bi00157a002; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267; WOESSNER JF, 1994, ANN NY ACAD SCI, V732, P11	36	69	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10184	10189		10.1074/jbc.274.15.10184	http://dx.doi.org/10.1074/jbc.274.15.10184			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187802	hybrid			2022-12-25	WOS:000079663500041
J	Okamoto, PM; Tripet, B; Litowski, J; Hodges, RS; Vallee, RB				Okamoto, PM; Tripet, B; Litowski, J; Hodges, RS; Vallee, RB			Multiple distinct coiled-coils are involved in dynamin self-assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CONFORMATIONAL CHANGE; PLECKSTRIN HOMOLOGY DOMAINS; GTPASE ACTIVITY; MECHANOCHEMICAL ENZYME; ACIDIC PHOSPHOLIPIDS; MAMMALIAN-CELLS; BINDING-SITE; SH3 DOMAINS; PROTEIN; ENDOCYTOSIS	Dynamin, a 100-kDa GTPase, has been implicated to be involved in synaptic vesicle recycling, receptor-mediated endocytosis, and other membrane sorting processes. Dynamin self-assembles into helical collars around the necks of coated pits and other membrane invaginations and mediates membrane scission. In vitro, dynamin has been reported to exist as dimers, tetramers, ring-shaped oligomers, and helical polymers. In this study we sought to define self-assembly regions in dynamin, Deletion of two closely spaced sequences near the dynamin-1 C terminus abolished self-association as assayed by co-immunoprecipitation and the yeast interaction trap, and reduced the sedimentation coefficient from 7.5 to 4.5 S, Circular dichroism spectroscopy and equilibrium ultracentrifugation of synthetic peptides revealed coiled-coil formation within the C-terminal assembly domain and at a third, centrally located site. Two of the peptides formed tetramers, supporting a role for each in the monomer-tetramer transition and providing novel insight into the organization of the tetramer, Partial deletions of the C-terminal assembly domain reversed the dominant inhibition of endocytosis by dynamin-1 GTPase mutants. Self association was also observed between different dynamin isoforms, Taken altogether, our results reveal two distinct coiled-coil-containing assembly domains that can recognize other dynamin isoforms and mediate endocytic inhibition. In addition, our data strongly suggests a parallel model for dynamin subunit self-association.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, MRC, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada	University of Massachusetts System; University of Massachusetts Worcester; University of Alberta; University of Alberta	Vallee, RB (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01605 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26701] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Carr JF, 1997, J BIOL CHEM, V272, P28030, DOI 10.1074/jbc.272.44.28030; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GANS PJ, 1991, BIOPOLYMERS, V31, P1605, DOI 10.1002/bip.360311315; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Liu JP, 1996, J NEUROCHEM, V66, P2074; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MELEN K, 1992, J BIOL CHEM, V267, P25898; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SEREDA TJ, 1993, J CHROMATOGR, V646, P17, DOI 10.1016/S0021-9673(99)87003-4; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Tripet B, 1997, J BIOL CHEM, V272, P8946; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	43	68	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10277	10286		10.1074/jbc.274.15.10277	http://dx.doi.org/10.1074/jbc.274.15.10277			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187814	hybrid			2022-12-25	WOS:000079663500053
J	Pingoud, V; Thole, H; Christ, F; Grindl, W; Wende, W; Pingoud, A				Pingoud, V; Thole, H; Christ, F; Grindl, W; Wende, W; Pingoud, A			Photocross-linking of the homing endonuclease PI-SceI to its recognition sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC ENDONUCLEASE; DNA-BINDING SITES; CROSS-LINKING; I-CREI; CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; SUBSTITUTED RNA; PROTEIN; CLEAVAGE; SUBSTRATE	PI-SceI is an intein-encoded protein that belongs to the LAGLIDADG family of homing endonucleases, According to the crystal structure and mutational studies, this endonuclease consists of two domains, one responsible for protein splicing, the other for DNA cleavage, and both presumably for DNA binding, To define the DNA binding site of PI-SceI, photocross-linking was used to identify amino acid residues in contact with DNA, Sixty-three double-stranded oligodeoxynucleotides comprising the minimal recognition sequence and containing single 5-iodopyrimidine substitutions in almost all positions of the recognition sequence were synthesized and irradiated in the presence of PI-SceI with a helium/cadmium laser (325 nm), The best cross-linking yield (approximately 30%) was obtained with an oligodeoxynucleotide with a B-iododeoxyuridine at position +9 in the bottom strand, The subsequent analysis showed that cross-linking had occurred with amino acid His-333, 6 amino acids after the second LAGLIDADG motif, With the H333A variant of PI-SceI or in the presence of excess unmodified oligodeoxynucleotide, no cross-linking was observed, indicating the specificity of the crosslinking reaction. Chemical modification of His residues in PI-SceI by diethylpyrocarbonate leads to a substantial reduction in the binding and cleavage activity of PI-SceI, This inactivation can be suppressed by substrate binding. This result further supports the finding that at least one His residue is in close contact to the DNA, Based on these and published results, conclusions are drawn regarding the DNA binding site of PI-SceI.	Univ Giessen, Inst Biochem, Fachbereich Biol, D-35392 Giessen, Germany; Hannover Med Sch, Zentrum Kinderheilkunde, D-30623 Hannover, Germany	Justus Liebig University Giessen; Hannover Medical School	Pingoud, V (corresponding author), Univ Giessen, Inst Biochem, Fachbereich Biol, FB 15,Heinrich-Buff-Ring 58, D-35392 Giessen, Germany.	vera.pingoud@chemie.bio.uni-giessen.de	Wende, Wolfgang/F-6127-2014; Christ, Frauke/H-7513-2018	Christ, Frauke/0000-0001-9580-3874; Wende, Wolfgang/0000-0001-6577-9535				Aagaard C, 1997, NUCLEIC ACIDS RES, V25, P1523, DOI 10.1093/nar/25.8.1523; Argast GM, 1998, J MOL BIOL, V280, P345, DOI 10.1006/jmbi.1998.1886; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; Curcio MJ, 1996, CELL, V84, P9, DOI 10.1016/S0092-8674(00)80987-3; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; Derbyshire V, 1997, J MOL BIOL, V265, P494, DOI 10.1006/jmbi.1996.0754; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; Gimble FS, 1996, J MOL BIOL, V263, P163, DOI 10.1006/jmbi.1996.0567; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1993, J BIOL CHEM, V268, P21844; Grindl W, 1998, NUCLEIC ACIDS RES, V26, P1857, DOI 10.1093/nar/26.8.1857; He ZN, 1998, J BIOL CHEM, V273, P4607, DOI 10.1074/jbc.273.8.4607; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; HENKE RM, 1995, EMBO J, V14, P5094, DOI 10.1002/j.1460-2075.1995.tb00191.x; HODGES RA, 1992, NUCLEIC ACIDS RES, V20, P6153, DOI 10.1093/nar/20.23.6153; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Jin YJ, 1997, J BIOL CHEM, V272, P7352, DOI 10.1074/jbc.272.11.7352; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; Loizos N, 1996, J MOL BIOL, V255, P412, DOI 10.1006/jmbi.1996.0034; LYKKEANDERSEN J, 1994, NUCLEIC ACIDS RES, V22, P4583, DOI 10.1093/nar/22.22.4583; LykkeAndersen J, 1996, NUCLEIC ACIDS RES, V24, P3982, DOI 10.1093/nar/24.20.3982; LykkeAndersen J, 1997, EMBO J, V16, P3272, DOI 10.1093/emboj/16.11.3272; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Meisenheimer KM, 1996, NUCLEIC ACIDS RES, V24, P981, DOI 10.1093/nar/24.5.981; MUELLER JE, 1995, EMBO J, V14, P5724, DOI 10.1002/j.1460-2075.1995.tb00259.x; Mueller JE, 1996, GENE DEV, V10, P2158, DOI 10.1101/gad.10.17.2158; Norris CL, 1996, J AM CHEM SOC, V118, P5796, DOI 10.1021/ja9607852; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; Pingoud V, 1998, BIOCHEMISTRY-US, V37, P8233, DOI 10.1021/bi980013d; Seligman LM, 1997, GENETICS, V147, P1653; STUMP WT, 1995, RNA, V1, P55; THOLE HH, 1995, EUR J BIOCHEM, V231, P510, DOI 10.1111/j.1432-1033.1995.tb20726.x; Turmel M, 1997, NUCLEIC ACIDS RES, V25, P2610, DOI 10.1093/nar/25.13.2610; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; Wende W, 1996, NUCLEIC ACIDS RES, V24, P4123, DOI 10.1093/nar/24.21.4123; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; Wong DL, 1998, NUCLEIC ACIDS RES, V26, P645, DOI 10.1093/nar/26.2.645	41	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10235	10243		10.1074/jbc.274.15.10235	http://dx.doi.org/10.1074/jbc.274.15.10235			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187809	hybrid			2022-12-25	WOS:000079663500048
J	Van Patten, SM; Hanson, E; Bernasconi, R; Zhang, K; Manavalan, P; Cole, ES; McPherson, JM; Edmunds, T				Van Patten, SM; Hanson, E; Bernasconi, R; Zhang, K; Manavalan, P; Cole, ES; McPherson, JM; Edmunds, T			Oxidation of methionine residues in antithrombin - Effects on biological activity and heparin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-ANTIPLASMIN; EMPHYSEMA; ALPHA-1-ANTITRYPSIN; INACTIVATION; INHIBITOR; AFFINITY; ASN-135	Commercially available human plasma-derived preparations of the serine protease inhibitor antithrombin (AT) were shown to contain low levels of oxidation, and we sought to determine whether oxidation might be a means of regulating the protein's inhibitory activity. A recombinant form of AT, with similarly low levels of oxidation as purified, was treated with hydrogen peroxide in order to study the effect of oxidation, specifically methionine oxidation, on the biochemical properties of this protein. AT contains two adjacent methionine residues near the reactive site loop cleaved by thrombin (Met(314) and Met(315)) and two exposed methionines that border on the heparin binding region of AT (Met(17) and Met(20)), In forced oxidations with hydrogen peroxide, the methionines at 314 and 315 were found to be the most susceptible to oxidation, but their oxidation did not affect either thrombin-inhibitory activity or heparin binding, Methionines at positions 17 and 20 were significantly oxidized only at higher concentrations of peroxide, at which point heparin affinity was decreased. However at saturating heparin concentrations, activity was only marginally decreased for these highly oxidized samples of AT. Structural studies indicate that highly oxidized AT is less able to undergo the complete conformational change induced by heparin, most probably due to oxidation of Met(17), Since this does not occur in less oxidized, and presumably more physiologically relevant, forms of AT such as those found in plasma preparations, oxidation does not appear to be a means of controlling AT activity.	Genzyme Corp, Struct Prot Chem Grp, Framingham, MA 01701 USA	Sanofi-Aventis; Genzyme Corporation	Van Patten, SM (corresponding author), Genzyme Corp, Struct Prot Chem Grp, 1Mt Rd, Framingham, MA 01701 USA.							BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Edmunds T, 1998, BLOOD, V91, P4561, DOI 10.1182/blood.V91.12.4561; FAN BQ, 1993, J BIOL CHEM, V268, P17588; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GETTINS PGW, 1996, SERPINS STRUCTURES F; GROSS E, 1968, ANN NY ACAD SCI, V151, P556, DOI 10.1111/j.1749-6632.1968.tb11915.x; JANOFF A, 1983, AM REV RESPIR DIS, V127, pS31; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; JOPPICHKUHN R, 1982, ANAL BIOCHEM, V119, P73, DOI 10.1016/0003-2697(82)90666-2; Keck RG, 1996, ANAL BIOCHEM, V236, P56, DOI 10.1006/abio.1996.0131; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; OGUSHI F, 1991, J CLIN INVEST, V87, P1060, DOI 10.1172/JCI115066; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Perlmutter DH, 1996, ANN MED, V28, P385, DOI 10.3109/07853899608999097; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SHIEH BH, 1987, J BIOL CHEM, V262, P6055; STIEF TW, 1988, THROMB RES, V49, P581, DOI 10.1016/0049-3848(88)90255-1; SWAIM MW, 1988, J LEUKOCYTE BIOL, V43, P365, DOI 10.1002/jlb.43.4.365; TEH LC, 1987, J BIOL CHEM, V262, P6472; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; VOGT W, 1992, IMMUNOBIOLOGY, V184, P384, DOI 10.1016/S0171-2985(11)80595-4; WEINER H, 1966, J BIOL CHEM, V241, P2687	25	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10268	10276		10.1074/jbc.274.15.10268	http://dx.doi.org/10.1074/jbc.274.15.10268			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187813	hybrid			2022-12-25	WOS:000079663500052
J	Wang, Q; Hasan, G; Pikielny, CW				Wang, Q; Hasan, G; Pikielny, CW			Preferential expression of biotransformation enzymes in the olfactory organs of Drosophila melanogaster, the antennae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONOSYLTRANSFERASE ISOZYMES; ANTHERAEA-POLYPHEMUS; SIGNAL SEQUENCES; ODORANT-BINDING; DRUG-METABOLISM; RAT-LIVER; GENE; PROTEIN; SYSTEM; TRANSFERASE	Biotransformation enzymes have been found in the olfactory epithelium of vertebrates, We now show that in Drosophila melanogaster, a UDP-glycosyltransferase (UGT), as well as a short chain dehydrogenase/reductase and a cytochrome P450 are expressed specifically or preferentially in the olfactory organs, the antennae. The evolutionarily conserved expression of biotransformation enzymes in olfactory organs suggests that they play an important role in olfaction, In addition, we describe five Drosophila UGTs belonging to two families. All five UGTs contain a putative transmembrane domain at their C terminus as is the case for vertebrate UGTs where it is required for enzymatic activity, The primary sequence of the C terminus, including part of the transmembrane domain, differs between the two families but is highly conserved not only within each Drosophila family, but also between the members of one of the Drosophila families and vertebrate UGTs, The partial overlap of the conserved primary sequence with the transmembrane domain suggests that this part of the protein is involved in specific interactions occurring at the membrane surface. The presence of different C termini in the two Drosophila families suggests that they interact with different targets, one of which is conserved between Drosophila and vertebrates.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA; Natl Ctr Biol Sci, TIFR Ctr, Bangalore 560012, Karnataka, India	Rutgers State University New Brunswick; Rutgers State University Medical Center; Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Pikielny, CW (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Hasan, Gaiti/I-5851-2015; Hasan, Gaiti/P-4107-2019	Hasan, Gaiti/0000-0001-7194-383X; Hasan, Gaiti/0000-0001-7194-383X				AHMAD SA, 1992, ARCH INSECT BIOCHEM, V21, P207, DOI 10.1002/arch.940210305; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAKER TC, 1988, J EXP BIOL, V137, P29; BENARIE N, 1993, BIOCHEM J, V292, P379, DOI 10.1042/bj2920379; Bossuyt X, 1997, BIOCHEM J, V323, P645, DOI 10.1042/bj3230645; BRIERLEY CH, 1993, BIOESSAYS, V15, P749, DOI 10.1002/bies.950151108; COHEN MB, 1994, GENE, V146, P267, DOI 10.1016/0378-1119(94)90304-2; Cols N, 1997, FEBS LETT, V413, P191, DOI 10.1016/S0014-5793(97)00894-6; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; DUTTON DJ, 1962, COMP BIOCH PHYSL, V7, P39; Feyereisen R, 1995, TOXICOL LETT, V82-3, P83, DOI 10.1016/0378-4274(95)03470-6; GUENGERICH FP, 1993, AM SCI, V81, P440; HekmatScafe DS, 1997, J NEUROSCI, V17, P1616; Hovemann BT, 1997, GENE, V189, P213, DOI 10.1016/S0378-1119(96)00851-7; Hu ZH, 1997, VIRUS RES, V47, P91, DOI 10.1016/S0168-1702(96)01406-2; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; LAZARD D, 1990, BIOCHEMISTRY-US, V29, P7433, DOI 10.1021/bi00484a012; LAZARD D, 1991, NATURE, V349, P790, DOI 10.1038/349790a0; LEE BU, 1995, GENE DEV, V9, P2964, DOI 10.1101/gad.9.23.2964; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Maser E, 1997, EUR J BIOCHEM, V249, P365, DOI 10.1111/j.1432-1033.1997.00365.x; MCKENNA MP, 1994, J BIOL CHEM, V269, P16340; Meech R, 1996, DNA CELL BIOL, V15, P489, DOI 10.1089/dna.1996.15.489; Meech R, 1997, J BIOL CHEM, V272, P26913, DOI 10.1074/jbc.272.43.26913; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; Nebert DW, 1996, DNA CELL BIOL, V15, P273, DOI 10.1089/dna.1996.15.273; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; Oliver D., 1970, DROS INFORM SERV, V45, P58; OREILLY DR, 1989, SCIENCE, V245, P1110, DOI 10.1126/science.2505387; Owens IS, 1996, J PHARMACOKINET BIOP, V24, P491, DOI 10.1007/BF02353476; PIKIELNY CW, 1994, NEURON, V12, P39; Rausell C, 1997, ARCH INSECT BIOCHEM, V34, P347, DOI 10.1002/(SICI)1520-6327(1997)34:3<347::AID-ARCH8>3.0.CO;2-R; RYBCZYNSKI R, 1990, J BIOL CHEM, V265, P19712; Shen HX, 1997, ONCOL RES, V9, P295; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; TEPHLY TR, 1990, TRENDS PHARMACOL SCI, V11, P276, DOI 10.1016/0165-6147(90)90008-V; VOGT RG, 1985, P NATL ACAD SCI USA, V82, P8827, DOI 10.1073/pnas.82.24.8827; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1982, J MOL BIOL, V159, P537, DOI 10.1016/0022-2836(82)90300-X	42	97	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10309	10315		10.1074/jbc.274.15.10309	http://dx.doi.org/10.1074/jbc.274.15.10309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187818	hybrid			2022-12-25	WOS:000079663500057
J	Dafforn, TR; Mahadeva, R; Elliott, PR; Sivasothy, P; Lomas, DA				Dafforn, TR; Mahadeva, R; Elliott, PR; Sivasothy, P; Lomas, DA			A kinetic mechanism for the polymerization of alpha(1)-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CRYSTAL-STRUCTURE; PROTEINASE-INHIBITORS; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL-CHANGES; ANTITHROMBIN-III; REACTIVE LOOP; HINGE REGION; SERPINS; DISEASE	The mutation in the Z deficiency variant of alpha(1)-antitrypsin perturbs the structure of the protein to allow a unique intermolecular linkage. These loop-sheet polymers are retained within the endoplasmic reticulum of hepatocytes to form inclusions that are associated with neonatal hepatitis, juvenile cirrhosis, and hepatocellular carcinoma. The process of polymer formation has been investigated here by intrinsic: tryptophan fluorescence, fluorescence polarization, circular dichroic spectra and extrinsic fluorescence with 8-anilino-1-naphthalenesulfonic acid and tetramethylrhodamine-5-iodoacetamide. These biophysical techniques have demonstrated that alpha(1)-antitrypsin polymerization is a two-stage process and have allowed the calculation of rates for both of these steps. The initial fast phase is unimolecular and likely to represent temperature-induced protein unfolding, while the slow phase is bimolecular and associated with loop-sheet interaction and polymer formation. The naturally occurring Z, S, and I variants and recombinant site-directed reactive loop and shutter domain mutants of alpha(1)-antitrypsin were used to demonstrate the close association between protein stability and rate of alpha(1)-antitrypsin polymerization, Taken together, these data allow us to propose a kinetic mechanism for alpha(1)-antitrypsin polymer formation that involves the generation of an unstable intermediate, which can form polymers or generate latent protein.	Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Med, Resp Med Unit, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Dafforn, TR (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.		Dafforn, Tim/A-9072-2015	Dafforn, Tim/0000-0003-2257-6679				AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; AULAK KS, 1993, J BIOL CHEM, V268, P18088; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; BAUMANN U, 1992, J MOL BIOL, V226, P1207, DOI 10.1016/0022-2836(92)91062-T; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BRUCE D, 1994, J CLIN INVEST, V94, P2265, DOI 10.1172/JCI117589; BRUCH M, 1988, J BIOL CHEM, V263, P16626; BUSBY TF, 1981, J BIOL CHEM, V256, P2140; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; Chang WSW, 1998, J BIOL CHEM, V273, P3695, DOI 10.1074/jbc.273.6.3695; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Kim DY, 1996, BIOCHEM BIOPH RES CO, V226, P378, DOI 10.1006/bbrc.1996.1364; Koloczek H, 1996, PROTEIN SCI, V5, P2226, DOI 10.1002/pro.5560051109; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LINDO VS, 1995, BRIT J HAEMATOL, V89, P589, DOI 10.1111/j.1365-2141.1995.tb08368.x; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; Lomas D, 1997, EUR RESPIR J, V10, P672; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WEI AZ, 1992, J MOL BIOL, V226, P273, DOI 10.1016/0022-2836(92)90140-F; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	47	197	206	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9548	9555		10.1074/jbc.274.14.9548	http://dx.doi.org/10.1074/jbc.274.14.9548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092640	hybrid			2022-12-25	WOS:000079451800059
J	Hwang, Y; Burgin, A; Bushman, F				Hwang, Y; Burgin, A; Bushman, F			DNA contacts stimulate catalysis by a poxvirus topoisomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLLUSCUM CONTAGIOSUM; NUCLEOTIDE-SEQUENCE; VIRUS TOPOISOMERASE; CRYSTAL-STRUCTURE; SV40 DNA; CLEAVAGE; BINDING; IDENTIFICATION; PREFERENCE; GENOME	Eukaryotic type 1B topoisomerases act by forming covalent enzyme-DNA intermediates that transiently nick DNA and thereby release DNA supercoils. Here we present a study of the topoisomerase encoded by the pathogenic poxvirus molluscum contagiosum, Our studies of DNA sites favored for catalysis reveal a larger recognition site than the 5'-(T/C)CCTT-3' sequence previously identified for poxvirus topoisomerases. Separate assays of initial DNA binding and covalent complex formation revealed that different DNA sequences were important for each reaction step. The location of the protein-DNA contacts was mapped by analyzing mutant sites and inosine-substituted DNAs, Some of the bases flanking the 5'-(T/C)CCTT-3' sequence were selectively important for covalent complex formation but not initial DNA binding. Interactions important for catalysis were probed with 5'-bridging phosphorothiolates at the site of strand cleavage, which permitted covalent complex formation but prevented subsequent religation. Kinetic studies revealed that the flanking sequences that promoted recovery of covalent complexes increased initial cleavage instead of inhibiting resealing of the nicked intermediate. These data 1) indicate that previously unidentified DNA contacts can accelerate a step between initial binding and covalent complex formation and 2) help specify models for conformational changes promoting catalysis.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	Salk Institute; California State University System; San Diego State University	Bushman, F (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.							ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BURGIN AB, 1995, NUCLEIC ACIDS RES, V23, P2973, DOI 10.1093/nar/23.15.2973; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hwang Y, 1998, J VIROL, V72, P3401, DOI 10.1128/JVI.72.4.3401-3406.1998; KLEMPERER N, 1995, VIROLOGY, V206, P203, DOI 10.1016/S0042-6822(95)80035-2; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; PETERSEN CS, 1992, DERMATOLOGY, V184, P19, DOI 10.1159/000247492; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SCHWARTZ JJ, 1992, J AM ACAD DERMATOL, V27, P583, DOI 10.1016/0190-9622(92)70226-6; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1989, VIROLOGY, V170, P302, DOI 10.1016/0042-6822(89)90384-X; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	31	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9160	9168		10.1074/jbc.274.14.9160	http://dx.doi.org/10.1074/jbc.274.14.9160			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092587	Green Submitted, hybrid			2022-12-25	WOS:000079451800006
J	Li, JP; DeFea, K; Roth, RA				Li, JP; DeFea, K; Roth, RA			Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; 3T3-L1 ADIPOCYTES; MAMMALIAN TARGET; GROWTH-FACTOR; SERINE/THREONINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; DIABETES-MELLITUS; IRS-1; ACTIVATION	Serine/threonine phosphorylation of insulin receptor substrate 1 (IRS-1) has been implicated as a negative regulator of insulin signaling. Prior studies have indicated that this negative regulation by protein kinase C involves the mitogen-activated protein kinase and phosphorylation of serine 612 in IRS-1, In the present studies, the negative regulation by platelet-derived growth factor (PDGF) was compared with that induced by endothelin-1, an activator of protein kinase C. In contrast to endothelin-1, the inhibitory effects of PDGF did not require mitogen-activated protein kinase or the phosphorylation of serine 612. Instead, three other serines in the phosphorylation domain of IRS-1 (serines 632, 662, and 731) were required for the negative regulation by PDGF. In addition, the PDGF-activated serine/threonine kinase called Akt was found to inhibit insulin signaling. Moreover, this inhibition required the same IRS-1 serine residues as the inhibition by PDGF, Finally, the negative regulatory effects of PDGF and Akt were inhibited by rapamycin, an inhibitor of the mammalian target of rapamycin (mTOR), one of the downstream targets of Akt, These studies implicate the phosphatidylinositol 3-kinase/Akt kinase cascade as an additional negative regulatory pathway for the insulin signaling cascade.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Roth, RA (corresponding author), Stanford Med Ctr, Dept Mol Pharmacol, Stanford, CA 94305 USA.	roth@cmgm.stanford.edu		DeFea, Kathryn/0000-0001-6056-907X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, R01DK034926] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 34926] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHOU YC, 1994, BIOCHEM BIOPH RES CO, V202, P688, DOI 10.1006/bbrc.1994.1985; CLERK A, 1994, J BIOL CHEM, V269, P32848; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Ferri C, 1997, EXP CLIN ENDOCR DIAB, V105, P38, DOI 10.1055/s-0029-1211794; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; Haddad TC, 1997, J BIOL CHEM, V272, P19525, DOI 10.1074/jbc.272.31.19525; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Juan CC, 1996, BIOCHEM BIOPH RES CO, V227, P694, DOI 10.1006/bbrc.1996.1571; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LAM K, 1994, J BIOL CHEM, V269, P20648; Li PM, 1996, BIOCHEM BIOPH RES CO, V223, P80, DOI 10.1006/bbrc.1996.0849; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Sarman B, 1998, DIABETES METAB REV, V14, P171, DOI 10.1002/(SICI)1099-0895(199806)14:2<171::AID-DMR207>3.0.CO;2-G; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; White MF, 1998, CURR TOP MICROBIOL, V228, P179	36	187	199	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9351	9356		10.1074/jbc.274.14.9351	http://dx.doi.org/10.1074/jbc.274.14.9351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092613	hybrid			2022-12-25	WOS:000079451800032
J	Desgranges, P; Barbaud, C; Caruelle, JP; Barritault, D; Gautron, J				Desgranges, P; Barbaud, C; Caruelle, JP; Barritault, D; Gautron, J			A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle	FASEB JOURNAL			English	Article						skeletal muscle; RGTA; ischemia	FIBROBLAST GROWTH-FACTOR; SKELETAL-MUSCLE; FACTOR-I; DERIVATIVES; INJURY; REPERFUSION; EXPRESSION; INHIBITION; SULFATE; REPAIR	Ischemia and denervation of EDL muscle of adult rat induce a large central zone of degeneration surrounded by a thin zone of peripheral surviving muscle fibers. Muscle regeneration is a complex phenomenon in which many agents interact, such as growth factors and heparan sulfate components of the extracellular matrix. We have shown that synthetic polymers, called RGTA las regenerating agents), which imitate the heparan sulfates, are able to stimulate tissue repair when applied at the site of injury. In crushed muscles, RGTA were found to accelerate both regeneration and reinnervation. In vitro, RGTA act as protectors and potentiators of various heparin binding growth factors (HBGF). It was postulated that in vivo their tissue repair properties were due in part to an increase of bioavailability of endogenously released HBGF. In the present work, we show that ischemic and denervated EDL muscle treated by a unique injection of RGTA differs from the control after 1 wk in several aspects: 1) the epimysial postinflammatory reaction is inhibited and the area of fibrotic tissue among fibers is reduced; 2) the peripheral zone, as measured by the number of intact muscle fibers, was increased by more than twofold; and 3) In the central zone, RGTA enhances the regeneration of the muscle fibers as well as muscle revascularization. These results suggest that RGTA both protects muscle fibers from degeneration and preserves the differentiated state of the surviving fibers. For the first time it is demonstrated that a functionalized polymeric compound can prevent some of the damage resulting from muscle ischemia. RGTA may therefore open a new therapeutic approach for muscle fibrosis and other postischemic muscle pathologies.	Univ Paris 12, Lab Rech Croissance Cellulaire Regenerat & Repara, CNRS, UPRESA 7053, F-94010 Creteil, France	Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Barritault, D (corresponding author), Univ Paris 12, Lab Rech Croissance Cellulaire Regenerat & Repara, CNRS, UPRESA 7053, F-94010 Creteil, France.	barritault@univ-paris12.fr						AAMIRI A, 1995, CR ACAD SCI III-VIE, V318, P1037; Aamiri A, 1995, NEUROSCI LETT, V201, P243, DOI 10.1016/0304-3940(95)12182-X; ANDERSON JE, 1991, MUSCLE NERVE, V14, P268, DOI 10.1002/mus.880140311; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; CARLSON BM, 1975, PFLUG ARCH EUR J PHY, V353, P215, DOI 10.1007/BF00584285; CARLSON BM, 1975, ANAT RECORD, V183, P47, DOI 10.1002/ar.1091830106; CARLSON BM, 1983, MED SCI SPORT EXER, V15, P187; Desgranges F, 1997, INT J ARTIF ORGANS, V20, P589, DOI 10.1177/039139889702001009; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLORINI JA, 1989, AM J PHYSIOL, V125, P701; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; GAUTRON J, 1995, CR ACAD SCI III-VIE, V318, P671; GULATI AK, 1983, J CELL BIOL, V97, P957, DOI 10.1083/jcb.97.4.957; HANSENSMITH FM, 1980, AM J ANAT, V158, P65, DOI 10.1002/aja.1001580107; Husmann Irene, 1996, Cytokine and Growth Factor Reviews, V7, P249, DOI 10.1016/S1359-6101(96)00029-9; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; LEFAUCHEUR JP, 1995, J NEUROIMMUNOL, V57, P85, DOI 10.1016/0165-5728(94)00166-L; LETOURNEUR D, 1993, IN VITRO CELL DEV-AN, V29A, P67; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MAUZAC M, 1984, BIOMATERIALS, V5, P301, DOI 10.1016/0142-9612(84)90078-4; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 1996, INT J BIOL MACROMOL, V18, P141, DOI 10.1016/0141-8130(95)01074-2; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; Meddahi A, 1995, BIOCHIMIE, V77, P703, DOI 10.1016/0300-9084(96)88185-5; Mitchell CA, 1996, GROWTH FACTORS, V13, P37, DOI 10.3109/08977199609034565; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; PADUA RR, 1995, MOL CELL BIOCHEM, V143, P129, DOI 10.1007/BF01816946; SCHOLLMEYER JE, 1986, EXP CELL RES, V163, P413, DOI 10.1016/0014-4827(86)90072-8; TARDIEU M, 1992, J CELL PHYSL, V150, P94; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; YAMADA S, 1989, MED SCI SPORT EXER, V21, pS173	33	65	71	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					761	766		10.1096/fasebj.13.6.761	http://dx.doi.org/10.1096/fasebj.13.6.761			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094936				2022-12-25	WOS:000079527200017
J	Harrison, CA; Raftery, MJ; Walsh, J; Alewood, P; Iismaa, SE; Thliveris, S; Geczy, CL				Harrison, CA; Raftery, MJ; Walsh, J; Alewood, P; Iismaa, SE; Thliveris, S; Geczy, CL			Oxidation regulates the inflammatory properties of the murine S100 protein S100A8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEINS; IONIZATION MASS-SPECTROMETRY; LOW-DENSITY-LIPOPROTEIN; HUMAN-NEUTROPHILS; CHEMOTACTIC PROTEIN; HYDROGEN-PEROXIDE; COMPLEX-FORMATION; HL-60 CELLS; IN-VIVO; CP-10	The myeloid cell-derived calcium-binding murine protein, S100A8, is secreted to act as a chemotactic factor at picomolar concentrations, stimulating recruitment of myeloid cells to inflammatory sites, S100A8 may be exposed to oxygen metabolites, particularly hypochlorite, the major oxidant generated by activated neutrophils at inflammatory sites. Here we show that hypochlorite oxidizes the single Cys residue (Cys(41)) of S100A8. Electrospray mass spectrometry and SDS-polyacrylamide gel electrophoresis analysis indicated that low concentrations of hypochlorite (40 mu M) converted 70-80% of S100A8 to the disulfide-linked homodimer, The mass was 20,707 Da, 92 Da more than expected, indicating additional oxidation of susceptible amino acids (possibly methionine). Phorbol 12-myristate 13-acetate activation of differentiated HL-60 granulocytic cells generated an oxidative burst that was sufficient to efficiently oxidize exogenous S100A8 within 10 min, and results implicate involvement of the myeloperoxidase system. Moreover, disulfide-linked dimer was identified in lung lavage fluid of mice with endotoxin-induced pulmonary injury. S100A8 dimer was inactive in chemotaxis and failed to recruit leukocytes in vivo. Positive chemotactic activity of recombinant Ala(41)S100A8 indicated that Cys41 was not essential for function and suggested that covalent dimerization may structurally modify accessibility of the chemotactic hinge domain. Disulfide-dependent dimerization may be a physiologically significant regulatory mechanism controlling S100A8-provoked leukocyte recruitment.	Univ New S Wales, Sch Pathol, Cytokine Res Unit, Kensington, NSW 2052, Australia; Univ Queensland, Ctr Drug Design & Dev, St Lucia, Qld 4072, Australia	University of New South Wales Sydney; University of Queensland	Geczy, CL (corresponding author), Univ New S Wales, Sch Pathol, Cytokine Res Unit, Kensington, NSW 2052, Australia.		Iismaa, Siiri/A-9924-2008; Iismaa, Siiri/C-9300-2013	Iismaa, Siiri/0000-0003-2409-7356; Harrison, Craig/0000-0003-1059-3682				BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BAUDIER J, 1988, J BIOL CHEM, V263, P5876; BERNTZEN HB, 1991, SCAND J RHEUMATOL, V20, P74, DOI 10.3109/03009749109165280; BRUN JG, 1994, J RHEUMATOL, V21, P733; CLARK RA, 1982, J IMMUNOL, V129, P2725; Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6; Dean RT, 1997, BIOCHEM J, V324, P1; DEVERY JM, 1994, J IMMUNOL, V152, P1888; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Drohat AC, 1997, PROTEIN SCI, V6, P1577, DOI 10.1002/pro.5560060721; GOEBELER M, 1993, J LEUKOCYTE BIOL, V53, P11, DOI 10.1002/jlb.53.1.11; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; Golden BE, 1996, ARCH DIS CHILD, V74, P136, DOI 10.1136/adc.74.2.136; Hansson M, 1996, J IMMUNOL, V156, P42; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Hu SP, 1996, BLOOD, V87, P3919, DOI 10.1182/blood.V87.9.3919.bloodjournal8793919; Hunter MJ, 1998, J BIOL CHEM, V273, P12427, DOI 10.1074/jbc.273.20.12427; IISMAA SE, 1994, DNA CELL BIOL, V13, P183, DOI 10.1089/dna.1994.13.183; Johne B, 1997, J CLIN PATHOL-MOL PA, V50, P113; JOHNSSON N, 1990, J BIOL CHEM, V265, P14464; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kocher M, 1996, INFECT IMMUN, V64, P1342, DOI 10.1128/IAI.64.4.1342-1350.1996; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; Kumar RK, 1998, PATHOLOGY, V30, P51, DOI 10.1080/00313029800169665; LACKMANN M, 1992, J BIOL CHEM, V267, P7499; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; NASKALSKI JW, 1994, ANN BIOL CLIN-PARIS, V52, P451; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Raftery MJ, 1997, RAPID COMMUN MASS SP, V11, P405, DOI 10.1002/(SICI)1097-0231(19970228)11:4<405::AID-RCM823>3.0.CO;2-A; Raftery MJ, 1998, J AM SOC MASS SPECTR, V9, P533, DOI 10.1016/S1044-0305(98)00020-8; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROTH J, 1993, BIOCHEM BIOPH RES CO, V191, P565, DOI 10.1006/bbrc.1993.1255; RYAN J, 1988, J IMMUNOL, V141, P2110; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Scotto C, 1998, J BIOL CHEM, V273, P3901, DOI 10.1074/jbc.273.7.3901; SOHNLE PG, 1991, J INFECT DIS, V163, P187, DOI 10.1093/infdis/163.1.187; Szarka RJ, 1997, J IMMUNOL METHODS, V202, P49, DOI 10.1016/S0022-1759(96)00236-0; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; TEIGELKAMP S, 1991, J BIOL CHEM, V266, P13462; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WILCKENS T, 1995, TRENDS PHARMACOL SCI, V16, P193, DOI 10.1016/S0165-6147(00)89021-5; Wu SM, 1997, J BIOL CHEM, V272, P20627, DOI 10.1074/jbc.272.33.20627; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yen T, 1997, BLOOD, V90, P4812, DOI 10.1182/blood.V90.12.4812.4812_4812_4821; YU H, 1995, J BIOL CHEM, V270, P15719, DOI 10.1074/jbc.270.26.15719; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	54	109	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8561	8569		10.1074/jbc.274.13.8561	http://dx.doi.org/10.1074/jbc.274.13.8561			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085090	hybrid			2022-12-25	WOS:000079451600032
J	Hilton, JC; Temple, CA; Rajagopalan, KV				Hilton, JC; Temple, CA; Rajagopalan, KV			Re-design of Rhodobacter sphaeroides dimethyl sulfoxide reductase - Enhancement of adenosine N-1-oxide reductase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-SP DENITRIFICANS; N-OXIDE REDUCTASE; MOLYBDOPTERIN GUANINE DINUCLEOTIDE; RAY-ABSORPTION SPECTROSCOPY; SITE-DIRECTED MUTAGENESIS; FORMATE DEHYDROGENASE-H; LIVER SULFITE OXIDASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MOLYBDENUM-COFACTOR	The periplasmic DMSO reductase from Rhodobacter sphaeroides f. sp. denitrificans has been expressed in Escherichia coli BL21(DE3) cells in its mature form and with the R. sphaeroides or E. coli N-terminal signal sequence. Whereas the R. sphaeroides signal sequence prevents formation of active enzyme, addition of a 6x Histag at the N terminus of the mature peptide maximizes production of active enzyme and allows for affinity purification. The recombinant protein contains 1.7-1.9 guanines and greater than 0.7 molybdenum atoms per molecule and has a DMSO reductase activity of 3.4-3.7 units/nmol molybdenum, compared with 3.7 units/nmol molybdenum for enzyme purified from R. sphaeroides. The recombinant enzyme differs from the native enzyme in its color and spectrum but is indistinguishable from the native protein after redox cycling with reduced methyl viologen and Me,SO. Substitution of Cys for the molybdenum-ligating Ser-147 produced a protein with DMSO reductase activity of 1.4-1.5 units/nmol molybdenum. The mutant protein differs from wild type in its color and absorption spectrum in both the oxidized and reduced states. This substitution leads to losses of 61-99% of activity toward five substrates, but the adenosine N-1-oxide reductase activity increases by over 400%.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu						AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BAKER KP, 1991, MOL MICROBIOL, V5, P901, DOI 10.1111/j.1365-2958.1991.tb00764.x; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BILOUS PT, 1988, J BACTERIOL, V170, P1511, DOI 10.1128/jb.170.4.1511-1518.1988; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; FINNEGAN MG, 1993, INORG CHEM, V32, P2616, DOI 10.1021/ic00064a005; GARDE J, 1995, J BIOL CHEM, V270, P6644, DOI 10.1074/jbc.270.12.6644; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P12906, DOI 10.1021/ja972109l; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1999, IN PRESS J AM CHEM S; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; Hilton JC, 1996, BBA-PROTEIN STRUCT M, V1294, P111, DOI 10.1016/0167-4838(96)00015-5; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; HILTON JC, 1996, THESIS DUKE U; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUCKLESB.DP, 1973, ANAL BIOCHEM, V56, P591, DOI 10.1016/0003-2697(73)90226-1; JOHNSON JL, 1988, METHOD ENZYMOL, V158, P371, DOI 10.1016/0076-6879(88)58069-2; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Knablein J, 1996, J MOL BIOL, V263, P40, DOI 10.1006/jmbi.1996.0554; Knablein J, 1997, BIOL CHEM, V378, P303; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; McAlpine AS, 1998, J MOL BIOL, V275, P613, DOI 10.1006/jmbi.1997.1513; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; Pollock VV, 1997, J BIOL CHEM, V272, P3355, DOI 10.1074/jbc.272.6.3355; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; Rajagopalan KV, 1996, ESCHERICHIA COLI SAL, P674; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Shaw AL, 1996, BBA-BIOENERGETICS, V1276, P176, DOI 10.1016/0005-2728(96)00092-8; SHIMOKAWA O, 1979, J BIOCHEM, V86, P1709, DOI 10.1093/oxfordjournals.jbchem.a132691; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; Trieber CA, 1996, J BIOL CHEM, V271, P27339, DOI 10.1074/jbc.271.44.27339; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; YAMAMOTO I, 1995, BIOSCI BIOTECH BIOCH, V59, P1850, DOI 10.1271/bbb.59.1850; YOSHIDA Y, 1991, J BACTERIOL, V173, P3277, DOI 10.1128/jb.173.11.3277-3281.1991	49	54	54	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8428	8436		10.1074/jbc.274.13.8428	http://dx.doi.org/10.1074/jbc.274.13.8428			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085074	hybrid			2022-12-25	WOS:000079451600016
J	Rettenberger, PM; Oka, K; Ellgaard, L; Petersen, HH; Christensen, A; Martensen, PM; Monard, D; Etzerodt, M; Chan, L; Andreasen, PA				Rettenberger, PM; Oka, K; Ellgaard, L; Petersen, HH; Christensen, A; Martensen, PM; Monard, D; Etzerodt, M; Chan, L; Andreasen, PA			Ligand binding properties of the very low density lipoprotein receptor - Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of M-r 40,000 receptor-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR-INHIBITOR; LDL-RECEPTOR; 39-KDA PROTEIN; UROKINASE RECEPTOR; APOLIPOPROTEIN-E; VLDL RECEPTOR; MEDIATED ENDOCYTOSIS; MOLECULAR CHAPERONE; TERMINAL DOMAIN; COMPLEXES	The very low density lipoprotein receptor (VLDLR) binds, among other ligands, the M-r 40,000 receptor-associated protein (RAP) and a variety of serine proteinase-serpin complexes, including complexes of the proteinase urokinase-type plasminogen activator (uPA) with the serpins plasminogen activator inhibitor-1 (PAI-1) and protease nexin-1 (PN-1). We have analyzed the binding of RAP, uPA.PAI-1, and uPA.PN-1 to two naturally occurring VLDLR variants, VLDLR-I, containing all eight complement-type repeats, and VLDLR-III, lacking the third complement-type repeat, encoded by exon 4. VLDLR-III displayed similar to 4-fold lower binding of RAP than VLDLR-I and similar to 10-fold lower binding of the most C-terminal one of the three domains of RAP. In contrast, the binding of uPA PAI-1 and uPA PN-1 to the two VLDLR variants was indistinguishable. Surprisingly, uPA PN-1, but not uPA PAI-1, competed RAP binding to both VLDLR variants. These observations show that the third complement-type repeat plays a crucial role in maintaining the contact sites needed for optimal recognition of RAP, but does not affect the proteinase-serpin complex contact sites, and that two ligands can show full cross-competition without sharing the same contacts with the receptor. These results elucidate the mechanisms of molecular recognition of ligands by receptors of the low density lipoprotein receptor family.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Aarhus University; Baylor College of Medicine; Baylor College of Medicine; Friedrich Miescher Institute for Biomedical Research	Andreasen, PA (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, 10C Gustav Wieda Vej, DK-8000 Aarhus C, Denmark.		Ellgaard, Lars/I-9034-2014; Martensen, Pia/I-3996-2012	Ellgaard, Lars/0000-0002-7018-0137; Martensen, Pia Moller/0000-0002-1259-0226	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Bu GJ, 1996, J BIOL CHEM, V271, P22218, DOI 10.1074/jbc.271.36.22218; Christie RH, 1996, J NEUROPATH EXP NEUR, V55, P491, DOI 10.1097/00005072-199604000-00012; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; ESSER V, 1988, J BIOL CHEM, V263, P13282; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; Kasza A, 1997, EUR J BIOCHEM, V248, P270, DOI 10.1111/j.1432-1033.1997.00270.x; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; MADSEN B, 1999, IN PRESS FIBRINOLYSI; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; Mikhailenko I, 1997, J BIOL CHEM, V272, P6784, DOI 10.1074/jbc.272.10.6784; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; MUNCH M, 1993, BIOCHIM BIOPHYS ACTA, V1202, P29, DOI 10.1016/0167-4838(93)90059-Z; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; NYKJAER A, 1994, J IMMUNOL, V152, P505; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; OKA K, 1994, GENOMICS, V20, P298, DOI 10.1006/geno.1994.1171; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Orlando RA, 1997, P NATL ACAD SCI USA, V94, P2368, DOI 10.1073/pnas.94.6.2368; Rodenburg KW, 1998, BIOCHEM J, V329, P55; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; SOMMER J, 1989, GENE, V85, P453, DOI 10.1016/0378-1119(89)90439-3; STRICKLAND DK, 1994, FIBRINOLYSIS, V8, P204, DOI 10.1016/0268-9499(94)90718-8; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	55	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8973	8980		10.1074/jbc.274.13.8973	http://dx.doi.org/10.1074/jbc.274.13.8973			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085143	hybrid			2022-12-25	WOS:000079451600085
J	Yuan, T; Ouyang, H; Vogel, HJ				Yuan, T; Ouyang, H; Vogel, HJ			Surface exposure of the methionine side chains of calmodulin in solution - A nitroxide spin label and two-dimensional NMR study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SEQUENCE-INDEPENDENT RECOGNITION; PROBING PROTEIN-STRUCTURE; CALCIUM-FREE CALMODULIN; NITRIC-OXIDE SYNTHASE; CARDIAC TROPONIN-C; TERMINAL DOMAIN; APO-CALMODULIN; CENTRAL HELIX; PROTEOLYTIC FRAGMENTS	Binding of calcium to calmodulin (CaM) causes a conformational change in this ubiquitous calcium regulatory protein that allows the activation of many target proteins. Met residues make up a large portion of its hydrophobic target binding surfaces. In this work, we have studied the surface exposure of the Met residues in the apo- and calcium-bound states of CaM in solution, Complexes of calcium-CaM with synthetic peptides derived from the CaM-binding domains of myosin light chain kinase, constitutive nitric-oxide synthase, and CaM-dependent protein kinase I were also studied. The surface exposure was measured by NMR by studying the effects of the soluble nitroxide spin label, 4-hydroxyl-2,2,6,6-tetramethylpiperidinyl-1-oxy, on the line widths and relaxation rates of the Met methyl resonances in samples of biosynthetically C-13-methyl-Met-labeled CaM. The Met residues move from an almost completely buried state in apo-CaM to an essentially fully exposed state in Ca2+, CaM. Binding of two Ca2+ to the C-terminal lobe of CaM causes full exposure of the C-terminal Met residues and a partial exposure of the N-terminal Met side chains. Binding of the three target peptides blocks the access of the nitroxide surface probe to nearly all Met residues, although the mode of binding is distinct for the three peptides studied. These data show that calcium binding to CaM controls the surface exposure of the Met residues, thereby providing the switch for target protein binding.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Vogel, HJ (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	vogel@ucalgary.ca						BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Beatty EJ, 1996, BIOCHEMISTRY-US, V35, P7635, DOI 10.1021/bi960684g; Brown SE, 1997, J BIOL CHEM, V272, P3389, DOI 10.1074/jbc.272.6.3389; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; COCCO MJ, 1994, PROTEIN SCI, V3, P267; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Edwards RA, 1998, BIOCHEM J, V331, P149, DOI 10.1042/bj3310149; ESPOSITO G, 1992, J MOL BIOL, V224, P659, DOI 10.1016/0022-2836(92)90551-T; Fabian H, 1996, EUR BIOPHYS J BIOPHY, V24, P195; FESIK SW, 1991, J AM CHEM SOC, V113, P7080, DOI 10.1021/ja00018a080; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GELLMAN SH, 1991, BIOCHEMISTRY-US, V30, P6633, DOI 10.1021/bi00241a001; George SE, 1996, BIOCHEMISTRY-US, V35, P8307, DOI 10.1021/bi960495y; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1984, BIOCHEMISTRY-US, V23, P3124, DOI 10.1021/bi00309a003; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; MACKALL J, 1991, BIOCHEMISTRY-US, V30, P7242, DOI 10.1021/bi00243a028; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Molinari H, 1997, BIOPHYS J, V73, P382, DOI 10.1016/S0006-3495(97)78078-0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Paakkonen K, 1998, J BIOL CHEM, V273, P15633, DOI 10.1074/jbc.273.25.15633; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P1179, DOI 10.1021/bi00004a011; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Peters JA, 1996, PROG NUCL MAG RES SP, V28, P283, DOI 10.1016/0079-6565(95)01026-2; PETROS AM, 1990, BIOCHEMISTRY-US, V29, P10041, DOI 10.1021/bi00495a005; PETROS AM, 1994, METHOD ENZYMOL, V239, P717; PETROS AM, 1992, J BIOMOL NMR, V2, P11, DOI 10.1007/BF02192797; Sia SK, 1997, J BIOL CHEM, V272, P18216, DOI 10.1074/jbc.272.29.18216; SIIVARI K, 1995, FEBS LETT, V366, P104, DOI 10.1016/0014-5793(95)00504-3; SMITH LJ, 1991, BIOCHEMISTRY-US, V30, P986, DOI 10.1021/bi00218a015; Sorensen BR, 1998, BIOCHEMISTRY-US, V37, P4244, DOI 10.1021/bi9718200; STAROVASNIK MA, 1992, PROTEIN SCI, V1, P245; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; URBAUER JL, 1995, BIOCHEMISTRY-US, V34, P8099, DOI 10.1021/bi00025a016; VanderSpoel D, 1996, PROTEIN SCI, V5, P2044; VOGEL HJ, 1995, MOL CELL BIOCHEM, V149, P3, DOI 10.1007/BF01076558; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WALTERSSON Y, 1993, BIOCHEMISTRY-US, V32, P7866, DOI 10.1021/bi00082a005; WILLIAMSON MP, 1992, CHEM SOC REV, V21, P227, DOI 10.1039/cs9922100227; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WOLFF J, 1986, BIOCHEMISTRY-US, V25, P7950, DOI 10.1021/bi00372a025; YUAN SX, 1988, EUR J BIOCHEM, V175, P119, DOI 10.1111/j.1432-1033.1988.tb14173.x; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328; YUAN T, 1995, BIOCHEMISTRY-US, V34, P10690, DOI 10.1021/bi00033a045; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313; ZHANG MJ, 1993, J BIOL CHEM, V268, P22420; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P1163, DOI 10.1021/bi00171a016; ZHANG MJ, 1994, J BIOL CHEM, V269, P15546; ZHANG MJ, 1995, J BIOL CHEM, V270, P20901, DOI 10.1074/jbc.270.36.20901; Zhou N, 1997, BIOCHEMISTRY-US, V36, P2817, DOI 10.1021/bi9625713	64	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8411	8420		10.1074/jbc.274.13.8411	http://dx.doi.org/10.1074/jbc.274.13.8411			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085072	hybrid			2022-12-25	WOS:000079451600014
J	Basu, SS; York, JD; Raetz, CRH				Basu, SS; York, JD; Raetz, CRH			A phosphotransferase that generates phosphatidylinositol 4-phosphate (PtdIns-4-P) from phosphatidylinositol and lipid A in Rhizobium leguminosarum - A membrane-bound enzyme linking lipid A and PtdIns-4-P biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; PERIBACTEROID MEMBRANE; SALMONELLA-TYPHIMURIUM; LIPOPOLYSACCHARIDE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; A BIOSYNTHESIS; PURIFICATION; ENDOTOXIN	Membranes of Rhizobium leguminosarum contain a 3-deoxy-D-manno-octulosonic acid (Kdo)-activated lipid A 4'-phosphatase required for generating the unusual phosphate-deficient lipid A found in this organism. The enzyme has been solubilized with Triton X-100 and purified 80-fold. As shown by co-purification and thermal inactivation studies, the 4'-phosphatase catalyzes not only the hydrolysis of (Kdo)(2)-[4'-P-32]lipid IVA but also the transfer the 4'-phosphate of Kdo(2)-[4'-P-32]lipid IVA to the inositol headgroup of phosphatidylinositol (PtdIns) to generate PtdIns-4-P. Like the 4'-phosphatase, the phosphotransferase activity is not present in Escherichia coli, Rhizobium meliloti, or the nodulation-defective mutant 24AR of R. leguminosarum. The specific activity for the phosphotransferase reaction is about 2 times higher than that of the 4'-phosphatase, The phosphotransferase assay conditions are similar to those used for PtdIns kinases, except that ATP and Mg2+ are omitted. The apparent K-m for PtdIns is similar to 500 mu M versus 20-100 mu M for most PtdIns kinases, but the phosphotransferase specific activity in crude cell extracts is higher than that of most PtdIns kinases, The phosphotransferase is absolutely specific for the 4-position of PtdIns and is highly selective for PtdIns as the acceptor. The 4'-phosphatase/phosphotransferase can be eluted from heparin- or Cibacron blue-agarose with PtdIns. A phosphoenzyme intermediate may account for the dual function of this enzyme, since a single P-32-labeled protein species (M-r similar to 68,000) can be trapped and visualized by SDS gel electrophoresis of enzyme preparations incubated with Kdo(2)-[4'-P-32]lipid IVA. Although PtdIns is not detected in cultures ofR, leguminosarum/etli (CE3), PtdIns may be synthesized during nodulation or supplied by plant membranes, given that soybean PtdIns is an excellent phosphate acceptor. A bacterial enzyme for generating PtdIns-4-P and a direct link between lipid A and PtdIns-4-P biosynthesis have not been reported previously.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NHLBI NIH HHS [HL-55672] Funding Source: Medline; NIGMS NIH HHS [R37 GM051796, GM-51796, R01 GM051796-01A1, R01 GM051796] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051796, R37GM051796] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAL AK, 1980, CAN J MICROBIOL, V26, P1096, DOI 10.1139/m80-182; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADLEY DJ, 1986, J CELL SCI, V85, P47; Brewin N. J., 1995, Nitrogen fixation: fundamentals and applications. Proceedings of the 10th International Congress on Nitrogen Fixation, St. Petersburg, Russia, May 28-June 3, 1995., P455; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Carlson R. W., 1992, Plant biotechnology and development., P33; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; DEMAAGD RA, 1989, J BACTERIOL, V171, P1143, DOI 10.1128/jb.171.2.1143-1150.1989; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GERSON T, 1975, APPL MICROBIOL, V30, P193, DOI 10.1128/AEM.30.2.193-198.1975; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; HONG ZG, 1994, P NATL ACAD SCI USA, V91, P9617, DOI 10.1073/pnas.91.20.9617; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; JENKINS GH, 1991, BIOCHIM BIOPHYS ACTA, V1080, P11, DOI 10.1016/0167-4838(91)90105-9; JONES NC, 1977, J BIOL CHEM, V252, P7405; JONES NC, 1977, J BIOL CHEM, V252, P7398; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; Kearns MA, 1998, EMBO J, V17, P4004, DOI 10.1093/emboj/17.14.4004; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; LIN S, 1998, FASEB J, V12; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; MILLER JH, 1972, EXP MOL GENETICS; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NOEL KD, 1986, J BACTERIOL, V168, P1392, DOI 10.1128/jb.168.3.1392-1401.1986; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; ORGAMBIDE GG, 1993, LIPIDS, V28, P975, DOI 10.1007/BF02537117; PEROTTO S, 1994, MOL PLANT MICROBE IN, V7, P99, DOI 10.1094/MPMI-7-0099; PEROTTO S, 1995, MOL PLANT MICROBE IN, V8, P560, DOI 10.1094/MPMI-8-0560; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PORTER FD, 1988, J BIOL CHEM, V263, P8989; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; PRIEFER UB, 1989, J BACTERIOL, V171, P6161, DOI 10.1128/jb.171.11.6161-6168.1989; Que NLS, 1998, FASEB J, V12, pA1284; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROANTREE RJ, 1967, ANNU REV MICROBIOL, V21, P443, DOI 10.1146/annurev.mi.21.100167.002303; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Stukey J, 1997, PROTEIN SCI, V6, P469; Tang Y, 1998, APPL ENVIRON MICROB, V64, P1963; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; Whitehead LF, 1997, PHYSIOL PLANTARUM, V100, P30, DOI 10.1034/j.1399-3054.1997.1000103.x; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; XIA WM, 1995, J BACTERIOL, V177, P2926, DOI 10.1128/jb.177.10.2926-2928.1995; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220	71	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11139	11149		10.1074/jbc.274.16.11139	http://dx.doi.org/10.1074/jbc.274.16.11139			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196199	hybrid, Green Accepted			2022-12-25	WOS:000079751900067
J	Basu, SS; White, KA; Que, NLS; Raetz, CRH				Basu, SS; White, KA; Que, NLS; Raetz, CRH			A deacylase in Rhizobium leguminosarum membranes that cleaves the 3-O-linked beta-hydroxymyristoyl moiety of lipid A precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE ENDOTOXIN; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; LIPOPOLYSACCHARIDE BIOSYNTHESIS; STRUCTURAL CHARACTERIZATION; SIGNAL-TRANSDUCTION; DEFICIENT MUTANT; A BIOSYNTHESIS; HOST-DEFENSE; GENE	Lipid A from the nitrogen-fixing bacterium Rhizobium leguminosarum displays many structural differences compared with lipid A of Escherichia coli, R, Leguminosarum lipid A lacks the usual 1- and 4'-phosphate groups but is derivatized with a galacturonic acid substituent at position 4', R, leguminosarum lipid A often contains an aminogluconic acid moiety in place of the proximal glucosamine l-phosphate unit. Striking differences also exist in the secondary acyl chains attached to E, coli versus R, leguminosarum lipid A, specifically the presence of 27-hydroxyoctacosanoate and the absence of laurate and myristate in R. leguminosarum, Recently, we have found that lipid A isolated by pH 4.5 hydrolysis of R, leguminosaram cells is more heterogeneous than previously reported (Que, N, L, S,, Basu, S, S., White, K, A., and Raetz, C. R. H. (1998) FASEB J. 12, A1284 (abstr.)), Lipid A species lacking the 3-O-linked beta-hydroxymyristoyl residue on the proximal unit contribute to this heterogeneity. We now describe a membrane-bound deacylase from R, leguminosarum that removes a single ester-linked beta-hydroxymyristoyl moiety from some lipid A precursors, including lipid X, lipid IVA, and (3-deoxy-D-manno-octulosonic acid)(2)-lipid IVA. The enzyme does not cleave E. coli lipid A or lipid A precursors containing an acyloxyacyl moiety on the distal glucosamine unit. The enzyme is not present in extracts of E, coli or Rhizobium meliloti, but it is readily demonstrable in membranes of Pseudomonas aeruginosa, which also contains a significant proportion of 3-O-deacylated lipid A species. Optimal reaction rates are seen between pH 5.5 and 6.5. The enzyme requires a nonionic detergent and divalent metal ions for activity. It cleaves the monosaccharide lipid X at about 5% the rate of lipid IVA and (3-deoxy-D-manno-octulosonic acid)(2)-lipid IVA. H-1 MMR spectroscopy of the deacylase reaction product, generated with lipid IVA as the substrate, confirms unequivocally that the enzyme cleaves only the ester-linked beta-hydroxymyristoyl residue at the 3-position of the glucosamine disaccharide.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051796, R37GM051796] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51796, R01 GM051796, R37 GM051796, R01 GM051796-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DROZANSKI W, 1986, EUR J BIOCHEM, V155, P433, DOI 10.1111/j.1432-1033.1986.tb09509.x; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; HAGEN FS, 1991, BIOCHEMISTRY-US, V30, P8415, DOI 10.1021/bi00098a020; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; KARIBIAN D, 1991, INT J MASS SPECTROM, V111, P273, DOI 10.1016/0168-1176(91)85060-Y; KARUNARATNE DN, 1992, ARCH BIOCHEM BIOPHYS, V299, P368, DOI 10.1016/0003-9861(92)90289-9; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEVIN J, 1993, BACTERIAL ENDOTOXIN; LIN S, 1998, FASEB J, V12; LONG SR, 1993, CELL, V73, P921, DOI 10.1016/0092-8674(93)90271-Q; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 1998, FASEB J, V12, pA1284; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAY BL, 1984, J BIOL CHEM, V259, P4852; RAY BL, 1987, J BIOL CHEM, V262, P1122; REEVES PR, 1994, BACTERIAL CELL WALL, V27, P281; REYNOLDS LJ, 1991, METHOD ENZYMOL, V197, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROSNER MR, 1979, J BIOL CHEM, V254, P5926; RUSSA R, 1985, ARCH MICROBIOL, V141, P284, DOI 10.1007/BF00428838; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VERRET CR, 1982, J BIOL CHEM, V257, P222; VERRET CR, 1982, J BIOL CHEM, V257, P228; Whitehead LF, 1997, PHYSIOL PLANTARUM, V100, P30, DOI 10.1034/j.1399-3054.1997.1000103.x; Zarrouk H, 1997, J BACTERIOL, V179, P3756, DOI 10.1128/jb.179.11.3756-3760.1997	56	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11150	11158		10.1074/jbc.274.16.11150	http://dx.doi.org/10.1074/jbc.274.16.11150			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196200	hybrid, Green Accepted			2022-12-25	WOS:000079751900068
J	Carpentier, M; Allain, F; Haendler, B; Denys, A; Mariller, C; Benaissa, M; Spik, G				Carpentier, M; Allain, F; Haendler, B; Denys, A; Mariller, C; Benaissa, M; Spik, G			Two distinct regions of cyclophilin B are involved in the recognition of a functional receptor and of glycosaminoglycans on T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; CYCLOSPORINE-A; BINDING-SITES; HUMAN BLOOD; CRYSTAL-STRUCTURE; CELL-ADHESION; IV COLLAGEN; PROTEIN; SEQUENCE	Cyclophilin B is a cyclosporin A-binding protein exhibiting peptidyl-prolyl cis/trans isomerase activity. We have previously shown that it interacts with two types of binding sites on T lymphocytes. The type I sites correspond to specific functional receptors and the type II sites to sulfated glycosaminoglycans. The interactions of cyclophilin B with type I and type II sites are reduced in the presence of cyclosporin A and of a synthetic peptide mimicking the N-terminal part of cyclophilin B, respectively, suggesting that the protein possesses two distinct binding regions. In this study, we intended to characterize the areas of cyclophilin B involved in the interactions with binding sites present on Jurkat cells. The use of cyclophilin B mutants modified in the N-terminal region demonstrated that the (3)Lys-Lys-Lys(5) and (14)Tyr-Phe-Asp(16) clusters are probably solely required for the interactions with the type II sites. We further engineered mutants of the conserved central core of cyclophilin B, which bears the catalytic and the cyclosporin A binding sites as an approach to localize the binding regions for the type I sites. The enzymatic activity of cyclophilin B was dramatically reduced after substitution of the Arg(62) and Phe(67) residues, whereas the cyclosporin A binding activity was destroyed by mutation of the Trp(128) residue and strongly decreased after modification of the Phe(67) residue. Only the substitution of the Trp(128) residue reduced the binding of the resulting cyclophilin B mutant to type I binding sites. The catalytic site of cyclophilin B therefore did not seem to be essential for cellular binding and the cyclosporin A binding site appeared to be partially involved in the binding to type I sites.	Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; Schering AG, Res Labs, D-13342 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Schering AG	Spik, G (corresponding author), Univ Sci & Tech Lille Flandres Artois, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France.			Allain, Fabrice/0000-0002-4484-6302				ALLAIN F, 1995, J IMMUNOL METHODS, V178, P113, DOI 10.1016/0022-1759(94)00249-V; Allain F, 1996, BIOCHEM J, V317, P565, DOI 10.1042/bj3170565; ALLAIN F, 1994, J BIOL CHEM, V269, P16537; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; Denys A, 1997, IMMUNOLOGY, V91, P609, DOI 10.1046/j.1365-2567.1997.00296.x; Denys A, 1998, TRANSPLANTATION, V65, P1076, DOI 10.1097/00007890-199804270-00012; Denys A, 1998, BIOCHEM J, V336, P689, DOI 10.1042/bj3360689; Endrich MM, 1998, EUR J BIOCHEM, V252, P441, DOI 10.1046/j.1432-1327.1998.2520441.x; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FRIEDMAN J, 1993, P NATL ACAD SCI USA, V90, P6815, DOI 10.1073/pnas.90.14.6815; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILAT D, 1994, J IMMUNOL, V153, P4899; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1986, J BIOL CHEM, V261, P8547; KE HM, 1991, P NATL ACAD SCI USA, V88, P9483, DOI 10.1073/pnas.88.21.9483; KE HM, 1993, P NATL ACAD SCI USA, V90, P11850, DOI 10.1073/pnas.90.24.11850; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; LIU J, 1990, P NATL ACAD SCI USA, V87, P2304, DOI 10.1073/pnas.87.6.2304; Mariller C, 1996, BIOCHEM J, V317, P571, DOI 10.1042/bj3170571; Mariller C, 1996, BBA-PROTEIN STRUCT M, V1293, P31, DOI 10.1016/0167-4838(95)00230-8; MIKOL V, 1994, P NATL ACAD SCI USA, V91, P5183, DOI 10.1073/pnas.91.11.5183; MITCHELL WM, 1968, J BIOL CHEM, V243, P4683; PRICE ER, 1994, P NATL ACAD SCI USA, V91, P3931, DOI 10.1073/pnas.91.9.3931; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RAHMAN M, 1994, J MOL GRAPHICS, V12, P212, DOI 10.1016/0263-7855(94)80090-1; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHNEIDER H, 1994, BIOCHEMISTRY-US, V33, P8218, DOI 10.1021/bi00193a007; Sherry B, 1998, P NATL ACAD SCI USA, V95, P1758, DOI 10.1073/pnas.95.4.1758; SPIK G, 1991, J BIOL CHEM, V266, P10735; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Tegeder I, 1997, J CLIN IMMUNOL, V17, P380, DOI 10.1023/A:1027364207544; WILKE MS, 1990, J INVEST DERMATOL, V95, P264, DOI 10.1111/1523-1747.ep12484883; XU Q, 1992, J BIOL CHEM, V267, P11968; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	45	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10990	10998		10.1074/jbc.274.16.10990	http://dx.doi.org/10.1074/jbc.274.16.10990			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196180	hybrid			2022-12-25	WOS:000079751900048
J	Heath, RJ; Rubin, JR; Holland, DR; Zhang, EL; Snow, ME; Rock, CO				Heath, RJ; Rubin, JR; Holland, DR; Zhang, EL; Snow, ME; Rock, CO			Mechanism of triclosan inhibition of bacterial fatty acid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; REDUCTASE FABI; MYCOBACTERIUM-TUBERCULOSIS; SALMONELLA-TYPHIMURIUM; BIOSYNTHESIS; TARGET; GENE; NADH; ENVM	Triclosan is a broad-spectrum antibacterial agent that inhibits bacterial fatty acid synthesis at the enoyl-acyl carrier protein reductase (FabI) step. Resistance to triclosan in Escherichia coli is acquired through a missense mutation in the fabI gene that leads to the expression of FabI[G93V], The specific activity and substrate affinities of FabI[G93V] are similar to FabI. Two different binding assays establish that triclosan dramatically increases the affinity of FabI for NAD(+). In contrast, triclosan does not increase the binding of NAD(+) to FabI[G93V]. The x-ray crystal structure of the FabI-NAD(+)-triclosan complex confirms that hydrogen bonds and hydrophobic interactions between triclosan and both the protein and the NAD(+) cofactor contribute to the formation of a stable ternary complex, with the drug binding at the enoyl substrate site. These data show that the formation of a noncovalent "bi-substrate" complex accounts for the effectiveness of triclosan as a FabI inhibitor and illustrates that mutations in the FabI active site that interfere with the formation of a stable FabI-NAD(+)-triclosan ternary complex acquire resistance to the drug.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Parke Davis Pharmaceut Res, Dept Biomol Struct & Drug Design, Ann Arbor, MI 48105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; Pfizer; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		ID, IMCACAT/D-5867-2014	Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARTZOKAS CA, 1984, NEW ENGL J MED, V311, P1422, DOI 10.1056/NEJM198411293112207; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; EGAN AF, 1973, GENET RES, V21, P3603; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; JACKOWSKI S, 1991, EMERGING TARGETS ANT, P151; McMurry LM, 1998, NATURE, V394, P531, DOI 10.1038/28970; REGOS J, 1979, DERMATOLOGICA, V158, P72, DOI 10.1159/000250746; REGOS J, 1974, ZBL BAKT-INT J MED M, V226, P390; Rock C. O., 1996, NEW COMPREHENSIVE BI, V31, P35; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; VISCHER WA, 1974, ZBL BAKT-INT J MED M, V226, P376; WEBSTER J, 1992, J HOSP INFECT, V21, P137, DOI 10.1016/0195-6701(92)90033-I; WEEKS G, 1968, J BIOL CHEM, V243, P1180; Zhang Y, 1998, J BACTERIOL, V180, P3295, DOI 10.1128/JB.180.13.3295-3303.1998	27	392	409	7	121	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11110	11114		10.1074/jbc.274.16.11110	http://dx.doi.org/10.1074/jbc.274.16.11110			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196195	hybrid			2022-12-25	WOS:000079751900063
J	Koizumi, J; Okamoto, Y; Onogi, H; Mayeda, A; Krainer, AR; Hagiwara, M				Koizumi, J; Okamoto, Y; Onogi, H; Mayeda, A; Krainer, AR; Hagiwara, M			The subcellular localization of SF2/ASF is regulated by direct interaction with SR protein kinases (SRPKs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICE-SITE SELECTION; ALTERNATIVE 5'; SERINE-RICH; CELL-CYCLE; RNA; PHOSPHORYLATION; DOMAINS; PURIFICATION; FACTOR-SF2; INVITRO	Serine/arginine-rich (SR) proteins play an important role in constitutive and alternative pre-mRNA splicing. The C-terminal arginine serine domain of these proteins, such as SF2/ASF, mediates protein-protein interactions and is phosphorylated in vivo. Using glutathione S-transferase (GST)-SF2/ASF-affinity chromatography, the SF2/ASF kinase activity was co-purified from HeLa cells with a 95-kDa protein, which was recognized by an anti SR protein kinase (SRPK) 1 monoclonal antibody. Recombinant SRPK1 and SRPK2 bound to and phosphorylated GST-SF2/ASF in vitro. Phosphopeptide mapping showed that identical sites were phosphorylated in the pull-down kinase reaction with HeLa extracts and by recombinant SRPKs, Epitope-tagged SF2/ASF transiently expressed in COS7 cells co-immunoprecipitated with SRPKs, Deletion analysis mapped the phosphorylation sites to a region containing an (Arg-Ser)(8) repeat beginning at residue 204, and far-Western analysis showed that the region is required for binding of SRPKs to SF2/ASF, Further binding studies showed that SRPKs bound unphosphorylated SF2/ASF but did not bind phosphorylated SF2/ASF, Expression of an SRPK2 kinase-inactive mutant caused accumulation of SF2/ASF in the cytoplasm. These results suggest that the formation of complexes between SF2/ASF and SRPKs, which is influenced by the phosphorylation state of SF2/ASF, may have regulatory roles in the assembly and localization of this splicing factor.	Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, Tokyo 113, Japan; Nagoya Univ, Sch Med, Dept Surg, Showa Ku, Nagoya, Aichi 466, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Tokyo Medical & Dental University (TMDU); Nagoya University; Cold Spring Harbor Laboratory	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.		Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Krainer, Adrian/0000-0001-9024-9501	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CACERESJF, 1998, GENES DEV, V12, P55; Cao WH, 1997, RNA, V3, P1456; CARDINALI B, 1994, FEBS LETT, V352, P276, DOI 10.1016/0014-5793(94)00973-2; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Nikolakaki E, 1997, J BIOL CHEM, V272, P6208, DOI 10.1074/jbc.272.10.6208; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	32	108	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11125	11131		10.1074/jbc.274.16.11125	http://dx.doi.org/10.1074/jbc.274.16.11125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196197	hybrid			2022-12-25	WOS:000079751900065
J	Masuda, S; Yoshida, M; Nagashima, KVP; Shimada, K; Matsuura, K				Masuda, S; Yoshida, M; Nagashima, KVP; Shimada, K; Matsuura, K			A new cytochrome subunit bound to the photosynthetic reaction center in the purple bacterium, Rhodovulum sulfidophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULATUS-PUF OPERON; LIGHT-HARVESTING PROTEINS; MESSENGER-RNA STABILITY; AMINO-ACID SEQUENCE; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-CAPSULATUS; RUBRIVIVAX-GELATINOSUS; ELECTRON-TRANSFER; B870 ANTENNA; GENES	The nucleotide sequence of the puf operon, which contains the genes encoding the B870 light-harvesting protein and the reaction center complex of the purple photosynthetic bacterium, Rhodovulum sulfidophilum, was determined. The operon, which consisted of six genes, pufQ, pufB, pufA, pufL, pufM, and pufC, is a new variety in photosynthetic bacteria in the sense that pufQ and pufC coexist. The amino acid sequence of the cytochrome subunit of the reaction center deduced from the pufC sequence revealed that this cytochrome contains only three possible heme binding motifs; the heme-1-binding motif of the corresponding tetraheme cytochrome subunits was not present. This is the first exception of the '"tetraheme" cytochrome family in purple bacteria and green filamentous bacteria. The pufC sequence also revealed that the sixth axial ligands to heme-1 and heme-2 irons were not present in the cytochrome either. This cytochrome was actually detected in membrane preparation as a 43-kDa protein and shown to associate functionally with the photosynthetic reaction center as the immediate electron donor to the photo-oxidized special pair of bacteriochlorophyll, This new cytochrome should be useful for studies on the role of each heme in the cytochrome subunit of the bacterial reaction center and the evolution of proteins in photosynthetic electron transfer systems.	Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan	Tokyo Metropolitan University	Masuda, S (corresponding author), Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan.		Masuda, Shinji/A-2703-2014; Nagashima, Kenji V. P./M-2208-2017	Masuda, Shinji/0000-0002-5349-4927; Nagashima, Kenji V. P./0000-0002-4526-6625				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; BAUER CE, 1988, J BIOL CHEM, V263, P4820; BAUER CE, 1988, P NATL ACAD SCI USA, V85, P7074, DOI 10.1073/pnas.85.19.7074; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; Cogdell R. J., 1995, ANOXYGENIC PHOTOSYNT, P315; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DRACHEVA S, 1991, BIOCHEMISTRY-US, V30, P11451, DOI 10.1021/bi00112a012; DRACHEVA SM, 1988, EUR J BIOCHEM, V171, P253, DOI 10.1111/j.1432-1033.1988.tb13784.x; Dutton P.L, 1978, PHOTOSYNTHETIC BACTE, P525; GONG L, 1994, J BACTERIOL, V173, P2946; Heck C, 1996, MOL MICROBIOL, V20, P1165, DOI 10.1111/j.1365-2958.1996.tb02637.x; HIRAISHI A, 1994, INT J SYST BACTERIOL, V44, P15, DOI 10.1099/00207713-44-1-15; KLUG G, 1987, EMBO J, V6, P3515, DOI 10.1002/j.1460-2075.1987.tb02677.x; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; Kortluke C, 1997, J BACTERIOL, V179, P5247, DOI 10.1128/jb.179.17.5247-5258.1997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBETANZ R, 1991, MOL MICROBIOL, V5, P1459, DOI 10.1111/j.1365-2958.1991.tb00792.x; LILBURN TG, 1992, BIOCHIM BIOPHYS ACTA, V1100, P160; Maniatis T., 1989, MOL CLONING LAB MANU; MASUDA S, 1998, P 11 INT C PHOT; MATSUURA K, 1988, FEBS LETT, V237, P21, DOI 10.1016/0014-5793(88)80163-7; MATSUURA K, 1994, J PLANT RES, V107, P191, DOI 10.1007/BF02346017; Matsuura K., 1990, CURRENT RES PHOTOSYN, V1, P193; MICHEL H, 1986, EMBO J, V5, P1149, DOI 10.1002/j.1460-2075.1986.tb04340.x; Nagashima KVP, 1997, J MOL EVOL, V45, P131, DOI 10.1007/PL00006212; Nagashima KVP, 1996, FEBS LETT, V385, P209, DOI 10.1016/0014-5793(96)00382-1; NAGASHIMA KVP, 1994, J BIOL CHEM, V269, P2477; Nagashima KVP, 1996, PHOTOSYNTH RES, V50, P61, DOI 10.1007/BF00018221; Nagashima KVP, 1997, PLANT CELL PHYSIOL, V38, P1249, DOI 10.1093/oxfordjournals.pcp.a029112; Nagashima KVP, 1998, PHOTOSYNTH RES, V55, P349, DOI 10.1023/A:1005912810674; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; Osyczka A, 1998, BIOCHEMISTRY-US, V37, P11732, DOI 10.1021/bi980910h; SHIOI Y, 1986, PLANT CELL PHYSIOL, V27, P567; TAYLOR DP, 1983, J BACTERIOL, V154, P580, DOI 10.1128/JB.154.2.580-590.1983; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; WEYER KA, 1987, EMBO J, V6, P2197, DOI 10.1002/j.1460-2075.1987.tb02490.x; WIESSNER C, 1990, J BACTERIOL, V172, P2877, DOI 10.1128/jb.172.6.2877-2887.1990; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YOUVAN DC, 1984, CELL, V37, P949, DOI 10.1016/0092-8674(84)90429-X; ZHU YS, 1986, J BIOL CHEM, V261, P366	42	36	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10795	10801		10.1074/jbc.274.16.10795	http://dx.doi.org/10.1074/jbc.274.16.10795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196154	hybrid			2022-12-25	WOS:000079751900022
J	Naver, H; Haldrup, A; Scheller, HV				Naver, H; Haldrup, A; Scheller, HV			Cosuppression of photosystem I subunit PSI-H in Arabidopsis thaliana - Efficient electron transfer and stability of photosystem I is dependent upon the PSI-H subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; SYNECHOCOCCUS-SP; F-B; CORE; FERREDOXIN; COMPLEXES; PROTEIN; IDENTIFICATION; RECONSTITUTION; PLASTOCYANIN	PSI-H is an intrinsic membrane protein of 10 kDa that is a subunit of photosystem I (PSI). PSI-II is one of the three PSI subunits found only in eukaryotes. The function of PSI-H was characterized in Arabidopsis plants transformed with a psaH cDNA in sense orientation. Cosuppressed plants containing less than 3% PSI-H are smaller than wild type when grown on sterile media but are similar to wild type under optimal conditions. PSI complexes lacking PSI-H contain 50% PSI-L, whereas other PSI subunits accumulate in wild type amounts. PSI devoid of PSI-H has only 61% NADP(+) photoreduction activity compared with wild type and is highly unstable in the presence of urea as determined from flash-induced absorbance changes at 834 nm. Our data show that PSI-H is required for stable accumulation of PSI and efficient electron transfer in the complex. The plants lacking PSI-H compensate for the less efficient PSI with a 15% increase in the P700/chlorophyll ratio, and this compensation is sufficient to prevent overreduction of the plastoquinone pool as evidenced by normal photochemical quenching of fluorescence. Nonphotochemical quenching is approximately 60% of the wild type value, suggesting that the proton gradient across the thylakoid membrane is decreased in the absence of PSI-H.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark	University of Copenhagen	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.	scheller@biobase.dk	Scheller, Henrik V/A-8106-2008; Scheller, Henrik/AAH-4770-2020	Scheller, Henrik V/0000-0002-6702-3560; Scheller, Henrik/0000-0002-6702-3560; Haldrup, Anna/0000-0002-2348-7072; Naver, Helle/0000-0002-7364-3862				ANDERSEN B, 1992, PHYSIOL PLANTARUM, V84, P154, DOI 10.1111/j.1399-3054.1992.tb08778.x; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FLACHMANN R, 1995, PLANT CELL, V7, P149, DOI 10.1105/tpc.7.2.149; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; HALDRUP A, 1999, IN PRESS PLANT J, V17; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; HOJ PB, 1987, J BIOL CHEM, V262, P12676; Jansson S, 1996, PLANT PHYSIOL, V112, P409, DOI 10.1104/pp.112.1.409; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kjaer B, 1996, PHOTOSYNTH RES, V47, P33, DOI 10.1007/BF00017751; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; Naver H, 1998, J BIOL CHEM, V273, P18778, DOI 10.1074/jbc.273.30.18778; Naver H, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P631; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; Scheller HV, 1997, PHYSIOL PLANTARUM, V100, P842, DOI 10.1034/j.1399-3054.1997.1000410.x; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SETIF PQY, 1995, BIOCHEMISTRY-US, V34, P9059, DOI 10.1021/bi00028a015; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; ZAMBRYSKI P, 1983, EMBO J, V2, P2143, DOI 10.1002/j.1460-2075.1983.tb01715.x; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	31	42	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10784	10789		10.1074/jbc.274.16.10784	http://dx.doi.org/10.1074/jbc.274.16.10784			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196152	hybrid			2022-12-25	WOS:000079751900020
J	Sargent, TG; DuBois, CC; Buller, AM; Lloyd, JA				Sargent, TG; DuBois, CC; Buller, AM; Lloyd, JA			The roles of 5 '-HS2, 5 '-HS3, and the gamma-globin TATA, CACCC, and stage selector elements in suppression of beta-globin expression in early development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; DOMINANT CONTROL REGION; TRANSCRIPTION FACTOR NF-E2; HIGH-LEVEL EXPRESSION; KRUPPEL-LIKE FACTOR; TRANSGENIC MICE; CHROMATIN STRUCTURE; REGULATED TRANSCRIPTION; HYPERSENSITIVE SITE-2; GENE-TRANSCRIPTION	The roles of HS2 and HS3 from the human beta-globin locus control region and of the TATA, CACCC, and stage selector elements of the gamma-globin promoter, in competitive inhibition of beta-globin gene expression in early development, were tested using stable transfections of HEL and K562 cells. Cells with an HS3 gamma beta construct demonstrate that HS3 exhibits enhancing activity, but compared with HS2, this site participates less consistently in the inhibition of embryonic/fetal beta-globin expression. In cells with HS3HS2 gamma beta constructs, the two HS sites act in concert to more effectively enhance gamma-globin gene expression and to drive stage-specific expression of the gamma- and beta-globin genes. A gamma-globin gene with a -161 promoter can competitively inhibit beta-globin gene expression. HS3HS2 gamma beta constructs were used to determine the effects of gamma-globin promoter mutations within this region on competition. The CACCC and TATA elements, but not the stage selector element, inhibit inappropriate embryonic/fetal stage expression of the beta-globin gene. The mutation in the gamma-globin TATA element results in the use of two major alternative transcription start sites, The data suggest that proteins binding to the gamma-globin CACCC and TATA elements interact with those binding to HS2 and/or HS3 to preclude beta-globin transcription in early development.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA	Virginia Commonwealth University	Lloyd, JA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, POB 980033, Richmond, VA 23298 USA.				NHLBI NIH HHS [R01 HL060080] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060080] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1993, MOL BIOL CELL, V4, P1077, DOI 10.1091/mbc.4.10.1077; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1995, NUCLEIC ACIDS RES, V23, P3473, DOI 10.1093/nar/23.17.3473; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Elnitski L, 1997, J BIOL CHEM, V272, P369; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; Gallagher PG, 1999, J BIOL CHEM, V274, P6062, DOI 10.1074/jbc.274.10.6062; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; Hug BA, 1996, MOL CELL BIOL, V16, P2906; Jackson JD, 1996, J BIOL CHEM, V271, P11871, DOI 10.1074/jbc.271.20.11871; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; Lam LT, 1998, J BIOL CHEM, V273, P24223, DOI 10.1074/jbc.273.37.24223; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; Ley TJ, 1998, ANN NY ACAD SCI, V850, P45, DOI 10.1111/j.1749-6632.1998.tb10461.x; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MARTIN DI, 1996, CURR OPIN GENE DEV, V4, P488; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MICHELSON AM, 1983, J BIOL CHEM, V258, P5245; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; Navas PA, 1998, MOL CELL BIOL, V18, P4188, DOI 10.1128/MCB.18.7.4188; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ronchi A, 1996, EMBO J, V15, P143, DOI 10.1002/j.1460-2075.1996.tb00342.x; Sabatino DE, 1998, MOL CELL BIOL, V18, P6634, DOI 10.1128/MCB.18.11.6634; Sargent TG, 1999, DNA CELL BIOL, V18, P293, DOI 10.1089/104454999315358; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WHITELAW E, 1990, MOL CELL BIOL, V10, P6596, DOI 10.1128/MCB.10.12.6596; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	58	11	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11229	11236		10.1074/jbc.274.16.11229	http://dx.doi.org/10.1074/jbc.274.16.11229			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196210	hybrid			2022-12-25	WOS:000079751900078
J	Takai, D; Isobe, K; Hayashi, JI				Takai, D; Isobe, K; Hayashi, JI			Transcomplementation between different types of respiration-deficient mitochondria with different pathogenic mutant mitochondrial DNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATIVE DISEASES; HUMAN BRAIN; MUTATION; CELLS; RECOMBINATION; DELETIONS	Two cell lines were used for determination of whether interaction occurred between different types of respiration-deficient mitochondria, One was a respiration-deficient rho(-) cell line having mutant mitochondrial DNA (mtDNA) with a 5,196-base pair deletion including five tRNA genes (tRNA(Gly,) (Arg,) (Ser(AGY),) (Leu(CUN),) (His)), Delta mtDNA(5196), causing Kearns-Sayre syndrome. The other was a respiration-deficient syn(-) cell line having mutant mtDNA with an A to G substitution at 4,269 in the tRNA(Ile) gene, mtDNA4269, causing fatal cardiomyopathy, The occurrence of mitochondrial interaction was examined by determining whether cybrids constructed by fusion of enucleated rho(-) Cells with syn(-) cells became respiration competent by exchanging their tRNAs. No cybrids were isolated in selection medium, where only respiration-competent cells could survive, suggesting that no interaction occurred, or that it occurred so slowly that sufficient recovery of mitochondrial respiratory function was not attained by the time of selection. The latter possibility was confirmed by the observations that heteroplasmic cybrids with both mutant mtDNA4269 and Delta mtDNA(5196) isolated without selection showed restored mitochondrial respiration activity. This demonstration of transcomplementation between different respiration-deficient mitochondria will help in understanding the relationship between somatic mutant mtDNAs and the roles of such mutations in aging processes.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; University of Tsukuba	Hayashi, JI (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan.	jih45@sakura.cc.tsukuba.ac.jp						BELLIARD G, 1979, NATURE, V281, P401, DOI 10.1038/281401a0; CLAYTON D, 1984, ANNU REV BIOCHEM, V53, P537; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; DUJON B, 1974, GENETICS, V78, P415; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1985, EXP CELL RES, V160, P387, DOI 10.1016/0014-4827(85)90185-5; HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43; Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; MONNAT RJ, 1986, GENE, V43, P205, DOI 10.1016/0378-1119(86)90208-8; OLIVER NA, 1982, MOL CELL BIOL, V2, P30, DOI 10.1128/MCB.2.1.30; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Shitara H, 1998, GENETICS, V148, P851; SOONG NW, 1992, NAT GENET, V2, P318; Takai D, 1997, J BIOL CHEM, V272, P6028, DOI 10.1074/jbc.272.9.6028; TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	22	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11199	11202		10.1074/jbc.274.16.11199	http://dx.doi.org/10.1074/jbc.274.16.11199			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196206	hybrid			2022-12-25	WOS:000079751900074
J	Zhang, HF; Yu, JH; Chen, SH; Morgan, BP; Abagyan, R; Tomlinson, S				Zhang, HF; Yu, JH; Chen, SH; Morgan, BP; Abagyan, R; Tomlinson, S			Identification of the individual residues that determine human CD59 species selective activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT REGULATORY PROTEIN; MOLECULAR-CLONING; C9; C5B-9; SITE; C8; XENOTRANSPLANTATION; INHIBITION; ALGORITHM; PEPTIDES	Formation of the cytolytic membrane attack complex of complement on host cells is inhibited by the membrane-bound glycoprotein, CD59, The inhibitory activity of CD59 is species restricted, and human CD59 is not effective against rat complement. Previous functional analysis of chimeric human/rat CD59 proteins indicated that the residues responsible for the species selective function of human CD59 map to a region contained between positions 40 and 66 in the primary structure. By comparative analysis of rat and human CD59 models and by mutational analysis of candidate residues, we now identify the individual residues within the 40-66 region that confer species selective function on human CD59, All nonconserved residues within the 40-66 sequence were substituted from human to rat residues in a series of chimeric human/rat CD59 mutant proteins. Functional analysis revealed that the individual human to rat residue substitutions F47A, T51L, R55E, and R65Q each produced a mutant human CD59 protein with enhanced rat complement inhibitory activity with the single F47A substitution having the most significant effect. Interestingly, the side chains of the residues at positions 47, 51, and 55 are all located on the short single helix (residues 47-55) of CD59 and form an exposed continuous strip parallel to the helix axis. A single human CD59 mutant protein containing rat residue substitutions at all three helix residues produced a protein with species selective activity comparable to that of rat CD59, We further found that synthetic peptides spanning the human CD59 helix sequence were able to inhibit the binding of human CD59 to human C8, but had little effect on the binding of rat CD59 to rat C8.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Skirball Inst, Dept Biochem, New York, NY 10016 USA; Univ Wales Coll Med, Dept Biochem Med, Cardiff C4F 4XN, S Glam, Wales	New York University; Cardiff University	Tomlinson, S (corresponding author), NYU, Med Ctr, Dept Pathol, MSB 126,550 1st Ave, New York, NY 10016 USA.	tomlis01@popmail.med.nyu.edu		Morgan, Paul/0000-0003-4075-7676	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034451, R01AI034451] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 34451] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Bodian DL, 1997, J EXP MED, V185, P507, DOI 10.1084/jem.185.3.507; Byrne G, 1997, TRANSPLANTATION, V63, P149, DOI 10.1097/00007890-199701150-00027; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; DIAZ R, 1988, J BIOL CHEM, V263, P6093; FLETCHER CM, 1994, STRUCTURE, V2, P185, DOI 10.1016/S0969-2126(00)00020-4; Harlow E., 1988, ANTIBODIES LAB MANUA; Hinchliffe SJ, 1998, J IMMUNOL, V160, P3924; JONES J, 1990, COMPLEMENT INFLAMMAT, V7, P42, DOI 10.1159/000463125; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; Lehto T, 1997, IMMUNOLOGY, V90, P121, DOI 10.1046/j.1365-2567.1997.00120.x; Maher SE, 1998, TRANSPLANTATION, V66, P1094, DOI 10.1097/00007890-199810270-00021; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MERI S, 1990, IMMUNOLOGY, V71, P1; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; NINOMIYA H, 1992, J BIOL CHEM, V267, P13675; Petranka J, 1996, BLOOD CELL MOL DIS, V22, P281, DOI 10.1006/bcmd.1996.0111; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; ROLLINS SA, 1991, J IMMUNOL, V146, P2345; RUSHMERE NK, 1994, BIOCHEM J, V304, P595, DOI 10.1042/bj3040595; RYAN US, 1995, NAT MED, V1, P967, DOI 10.1038/nm0995-967; Squinto SP, 1996, CURR OPIN BIOTECH, V7, P641, DOI 10.1016/S0958-1669(96)80076-0; TOMLINSON S, 1994, J IMMUNOL, V152, P1927; Totrov M, 1996, J STRUCT BIOL, V116, P138, DOI 10.1006/jsbi.1996.0022; Yu J, 1999, CLIN EXP IMMUNOL, V115, P13; Yu JH, 1997, BIOCHEMISTRY-US, V36, P9423, DOI 10.1021/bi970832i; Yu JH, 1997, J EXP MED, V185, P745, DOI 10.1084/jem.185.4.745; Zhao XJ, 1998, J BIOL CHEM, V273, P10665, DOI 10.1074/jbc.273.17.10665	29	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10969	10974		10.1074/jbc.274.16.10969	http://dx.doi.org/10.1074/jbc.274.16.10969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196177	hybrid			2022-12-25	WOS:000079751900045
J	Fayadat, L; Niccoli-Sire, P; Lanet, J; Franc, JL				Fayadat, L; Niccoli-Sire, P; Lanet, J; Franc, JL			Role of heme in intracellular trafficking of thyroperoxidase and involvement of H2O2 generated at the apical surface of thyroid cells in autocatalytic covalent heme binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-METABOLISM; PEROXIDASE; MYELOPEROXIDASE; LACTOPEROXIDASE; PURIFICATION; RECEPTOR; ENZYMES; PATHWAY; FAMILY	Thyroperoxidase (TPO) is a glycosylated hemoprotein that plays a key role in thyroid hormone synthesis, We previously showed that in CHO cells expressing human TPO (hTPO) only 2% of synthesized hTPO reaches the cell surface. Herein, we investigated the role of heme moiety insertion in the exit of hTPO from the endoplasmic reticulum, Peroxidase activity at the cell surface and cell surface expression of hTPO were decreased by similar to 30 and similar to 80%, respectively, with succinyl acetone, an inhibitor of heme biosynthesis, and were increased by 20% with holotransferrin and aminolevulinic acid, precursors of heme biosynthesis, Results were similar with holotransferrin plus aminolevulinic acid or hemin, but hemin increased cell surface activity more efficiently (+120%) relative to the control, It had been suggested (DePillis, G,, Ozaki, S,, Kuo, J, M,, Maltby, D, A., and Ortiz de Montellano, P, R, (1997) J, Biol, Chem, 272, 8857-8960) that covalent attachment of heme to mammalian peroxidases could be an H2O2-dependent autocatalytic processing. In our study, heme associated intracellularly with hTPO, and we hypothesized that there was insufficient exposure to H2O2 in Chinese hamster ovary cells before hTPO reached the cell surface. After a 10-min incubation, 10 mu M H2O2 led to a 65% increase in cell surface activity. In contrast, in thyroid cells, H2O2 was synthesized at the apical cell surface and allowed covalent attachment of heme, Two-day incubation of primocultures of thyroid cells with catalase led to a 30% decrease in TPO activity at the cell surface. In conclusion, we provide compelling evidence for an essential role of 1) heme incorporation in the intracellular trafficking of hTPO and of 2) H2O2 generated at the apical pole of thyroid cells in the autocatalytic covalent heme binding to the TPO molecule.	Univ Mediterranee, Fac Med, INSERM, U38, F-13385 Marseille 5, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Franc, JL (corresponding author), Univ Mediterranee, Fac Med, INSERM, U38, 27 Bd J Moulin, F-13385 Marseille 5, France.		Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				Andersson LA, 1996, J BIOL CHEM, V271, P3406, DOI 10.1074/jbc.271.7.3406; ARNLJOTS K, 1987, J BIOL CHEM, V262, P10430; BANGA JP, 1990, FEBS LETT, V266, P133, DOI 10.1016/0014-5793(90)81524-R; CALS MM, 1991, EUR J BIOCHEM, V198, P733, DOI 10.1111/j.1432-1033.1991.tb16073.x; CHAMBARD M, 1983, J CELL BIOL, V96, P1172, DOI 10.1083/jcb.96.4.1172; DePillis GD, 1997, J BIOL CHEM, V272, P8857; Fan JL, 1996, J AUTOIMMUN, V9, P529, DOI 10.1006/jaut.1996.0071; Fayadat L, 1998, ENDOCRINOLOGY, V139, P4277, DOI 10.1210/en.139.10.4277; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; Gorin Y, 1996, EUR J BIOCHEM, V240, P807, DOI 10.1111/j.1432-1033.1996.0807h.x; Guo J, 1998, ENDOCRINOLOGY, V139, P999, DOI 10.1210/en.139.3.999; Halliwell B., 1991, FREE RADICAL BIO MED, P86; HOSSAYA T, 1967, J BIOL CHEM, V242, P2828; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; Kooter IM, 1997, J AM CHEM SOC, V119, P11542, DOI 10.1021/ja9725460; KRINSKY MM, 1971, J BIOL CHEM, V246, P4755; Kuras R, 1997, J BIOL CHEM, V272, P32427, DOI 10.1074/jbc.272.51.32427; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAUSEEF WM, 1992, BLOOD, V80, P2622; NEARY JT, 1984, METHOD ENZYMOL, V107, P445; NUNEZ J, 1982, VITAM HORM, V39, P175, DOI 10.1016/S0083-6729(08)61137-1; OHTAKI S, 1985, J BIOL CHEM, V260, P441; Ponka P, 1997, BLOOD, V89, P1; RAWITCH AB, 1979, ARCH BIOCHEM BIOPHYS, V194, P244, DOI 10.1016/0003-9861(79)90615-5; Richardson DR, 1996, BLOOD, V87, P3477, DOI 10.1182/blood.V87.8.3477.bloodjournal8783477; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; Taurog A, 1998, THYROID, V8, P185, DOI 10.1089/thy.1998.8.185; TAUROG A, 1991, THYROID, P51; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288	30	73	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10533	10538		10.1074/jbc.274.15.10533	http://dx.doi.org/10.1074/jbc.274.15.10533			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187846	hybrid			2022-12-25	WOS:000079663500085
J	Hanisch, FG; Muller, S; Hassan, H; Clausen, H; Zachara, N; Gooley, AA; Paulsen, H; Alving, K; Peter-Katalinic, J				Hanisch, FG; Muller, S; Hassan, H; Clausen, H; Zachara, N; Gooley, AA; Paulsen, H; Alving, K; Peter-Katalinic, J			Dynamic epigenetic regulation of initial O-glycosylation by UDP-N-acetylgalactosamine : peptide N-acetylgalactosaminyltransferases - Site-specific glycosylation of MUC1 repeat peptide influences the substrate qualities at adjacent or distant Ser/Thr positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; TANDEM REPEAT; SUBMAXILLARY-GLAND; IN-VIVO; LINKED GLYCOSYLATION; GALNAC-TRANSFERASES; LOCALIZATION; SEQUENCES; GLYCOPEPTIDES; CLONING	In search of possible epigenetic regulatory mechanisms ruling the initiation of O-glycosylation by polypeptide:N-acetylgalactosaminyltransferases, we studied the influences of mono- and disaccharide substituents of glycopeptide substrates on the site-specific in vitro addition of N-acetylgalactosamine (GalNAc) residues by recombinant GalNAc-Ts (rGalNAc-T1, -T2, and -T3), The substrates were 20-mers (HGV20) or 21-mers (AHG21) of the MUC1 tandem repeat peptide carrying GalNAc alpha or Gal beta 1-3GalNAc alpha at different positions. The enzymatic products were analyzed by MALDI mass spectrometry and Edman degradation for the number and sites of incorporated GalNAc. Disaccharide placed on the first position of the diad Ser-16-Thr-17 prevents glycosylation of the second, whereas disaccharide on the second position of Ser-16-Thr-17 and Thr-5-Ser-6 does not prevent GalNAc addition to the first. Multiple disaccharide substituents suppress any further glycosylation at the remaining sites. Glycosylation of Ser-16 is negatively affected by glycosylation at position -6 (Thr-10) or -10 (Ser-6) and is inhibited by disaccharide at position -11 (Thr-5), suggesting the occurrence of glycosylation-induced effects on distant acceptor sites. Kinetic studies revealed the accelerated addition of GalNAc to Ser-16 adjacent Do GalNAc-substituted Thr-17, demonstrating positive regulatory effects induced by glycosylation on the monosaccharide level. These antagonistic effects of mono- and disaccharides could underlie a postulated regulatory mechanism.	Univ Cologne, Inst Biochem, D-50931 Cologne, Germany; Univ Copenhagen, Sch Dent, Dept Oral Diagnost, DK-2200 Copenhagen, Denmark; Macquarie Univ, Macquarie Ctr Analyt Biotechnol, Sydney, NSW 2109, Australia; Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany	University of Cologne; University of Copenhagen; Macquarie University; University of Hamburg; University of Munster	Hanisch, FG (corresponding author), Univ Cologne, Inst Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	franz.hanisch@uni-koeln.de	clausen, henrik/AAD-8016-2021					Antonyraj KJ, 1998, ARCH BIOCHEM BIOPHYS, V356, P197, DOI 10.1006/abbi.1998.0779; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Brockhausen I, 1996, GLYCOCONJUGATE J, V13, P849, DOI 10.1007/BF00702349; BUTENHOF KJ, 1993, BIOCHEMISTRY-US, V32, P2650, DOI 10.1021/bi00061a025; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; FONTENOT JD, 1993, CANCER RES, V53, P5386; Gerken TA, 1998, J BIOL CHEM, V273, P26580, DOI 10.1074/jbc.273.41.26580; Goletz S, 1997, GLYCOBIOLOGY, V7, P881, DOI 10.1093/glycob/7.7.881; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Karsten U, 1998, CANCER RES, V58, P2541; Kirnarsky L, 1998, BIOCHEMISTRY-US, V37, P12811, DOI 10.1021/bi981034a; Mathieux N, 1997, J CHEM SOC PERK T 1, P2359, DOI 10.1039/a701742a; MIMURA Y, 1992, INT J BIOL MACROMOL, V14, P242, DOI 10.1016/S0141-8130(05)80036-4; Muller S, 1997, J BIOL CHEM, V272, P24780, DOI 10.1074/jbc.272.40.24780; Nehrke K, 1996, J BIOL CHEM, V271, P7061, DOI 10.1074/jbc.271.12.7061; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rottger S, 1998, J CELL SCI, V111, P45; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; STADIE TRE, 1995, EUR J BIOCHEM, V229, P140, DOI 10.1111/j.1432-1033.1995.tb20448.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; ZACHARA NE, 1998, IN PRESS MUCIN METHO	28	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9946	9954		10.1074/jbc.274.15.9946	http://dx.doi.org/10.1074/jbc.274.15.9946			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187769	hybrid			2022-12-25	WOS:000079663500008
J	Humbert-Lan, G; Pieler, T				Humbert-Lan, G; Pieler, T			Regulation of DNA binding activity and nuclear transport of B-Myb in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; C-MYB; GENE-PRODUCT; FUNCTIONAL DOMAINS; S-PHASE; A-MYB; EXPRESSION; ACTIVATION; TRANSCRIPTION; PROTEINS	DNA binding activity and nuclear transport of B-Myb in Xenopus oocytes are negatively regulated. Two distinct sequence elements in the C-terminal portion of the protein are responsible for these different inhibitory activities. A C-terminal Xenopus B-Myb protein fragment inhibits the DNA binding activity of the N-terminal repeats in trans, indicating that intramolecular folding may result in masking of the DNA binding function. Xenopus B-Myb contains two separate nuclear localization signals (NLSs), which, in Xenopus oocytes, function only outside the context of the full-length protein. Fusion of an additional NLS to the full-length protein overcomes the inhibition of nuclear import, suggesting that masking of the NLS function rather than cytoplasmic anchoring is responsible for the negative regulation of Xenopus B-Myb nuclear transfer. During Xenopus embryogenesis, when inhibition of nuclear import is relieved, Xenopus B-myb is preferentially expressed in the developing nervous system and neural crest cells. Within the developing neural tube, Xenopus B-myb gene transcription occurs preferentially in proliferating, non-differentiated cells.	Univ Gottingen, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany	University of Gottingen	Pieler, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	tpieler@gwdg.de						ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FAVIER D, 1994, ONCOGENE, V9, P305; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; KALKBRENNER F, 1990, ONCOGENE, V5, P6657; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIROV N, 1994, MOL CELL BIOL, V14, P713, DOI 10.1128/MCB.14.1.713; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Latham KE, 1996, ONCOGENE, V13, P1161; Li HS, 1997, DEVELOPMENT, V124, P603; Lipsick JS, 1996, ONCOGENE, V13, P223; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; Robinson C, 1996, ONCOGENE, V12, P1855; Rudt F, 1996, EMBO J, V15, P1383, DOI 10.1002/j.1460-2075.1996.tb00480.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sambrook J., 2002, MOL CLONING LAB MANU; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10293	10300		10.1074/jbc.274.15.10293	http://dx.doi.org/10.1074/jbc.274.15.10293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187816	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000079663500055
J	Schutze, S; Machleidt, T; Adam, D; Schwandner, R; Wiegmann, K; Kruse, ML; Heinrich, M; Wickel, M; Kronke, M				Schutze, S; Machleidt, T; Adam, D; Schwandner, R; Wiegmann, K; Kruse, ML; Heinrich, M; Wickel, M; Kronke, M			Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; INDUCED CELL-DEATH; MEDIATED ENDOCYTOSIS; TNF-RECEPTOR; HUMAN-NEUTROPHILS; GROWTH-FACTOR; NEUTRAL SPHINGOMYELINASE; ACID SPHINGOMYELINASE; PHOSPHOLIPASE-C	The 55-kDa receptor for tumor necrosis factor (TR55) triggers multiple signaling cascades initiated by adapter proteins like TRADD and FAN. By use of the primary amine monodansylcadaverine (MDC), we addressed the functional role of tumor necrosis factor (TNF) receptor internalization for intracellular signal distribution, We show that MDC does not prevent the interaction of the p55 TNF receptor (TR55) with FAN and TRADD, Furthermore, the activation of plasmamembrane-associated neutral sphingomyelinase activation as well as the stimulation of proline-directed protein kinases were not affected in MDC-treated cells. In contrast, activation of signaling enzymes that are linked to the "death domain" of TR55, like acid sphingomyelinase and c-Jun-N-terminal protein kinase as well as TNF signaling of apoptosis in U937 and L929 cells, are blocked in the presence of MDC. The results of our study suggest a role of TR55 internalization for the activation of select TR55 death domain signaling pathways including those leading to apoptosis.	Univ Kiel, Inst Immunol, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, D-24105 Kiel, Germany	University of Kiel; University of Kiel	Schutze, S (corresponding author), Univ Kiel, Inst Immunol, D-24105 Kiel, Germany.	schuetze@immunologie.uni-kiel.de	Adam, Dieter/E-9763-2010; Schütze, Stefan/C-8596-2011	Adam, Dieter/0000-0002-5668-5032; 				Adam D, 1998, BIOCHEM J, V333, P343, DOI 10.1042/bj3330343; Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ANDRIEU N, 1995, J BIOL CHEM, V270, P24518, DOI 10.1074/jbc.270.41.24518; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADLEY JR, 1993, J IMMUNOL, V150, P5544; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FOLK JE, 1973, ADV ENZYMOL RAMB, V38, P109; GEHR G, 1992, J IMMUNOL, V149, P911; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GRELL M, 1994, J IMMUNOL, V153, P1963; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGUCHI M, 1994, J IMMUNOL, V152, P3550; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KULL FC, 1981, CANCER RES, V41, P4885; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lazdins JK, 1997, J EXP MED, V185, P81, DOI 10.1084/jem.185.1.81; LIU J, 1994, J BIOL CHEM, V269, P3047; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MAXFIELD FR, 1979, NATURE, V277, P661, DOI 10.1038/277661a0; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; MOSSELMANS R, 1988, J IMMUNOL, V141, P3096; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PEAVY DE, 1984, ENDOCRINOLOGY, V114, P753, DOI 10.1210/endo-114-3-753; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PORTEU F, 1994, J BIOL CHEM, V269, P2834; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Ray E, 1996, FEBS LETT, V378, P235, DOI 10.1016/0014-5793(95)01462-4; Ray E, 1997, CYTOKINE, V9, P587, DOI 10.1006/cyto.1997.0206; RESINK TJ, 1990, MOL PHARMACOL, V38, P244; RIKIHISA Y, 1994, INFECT IMMUN, V62, P5126, DOI 10.1128/IAI.62.11.5126-5132.1994; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; SCHLEGEL R, 1982, P NATL ACAD SCI-BIOL, V79, P2291, DOI 10.1073/pnas.79.7.2291; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SCHUTZE S, 1991, J EXP MED, V174, P975, DOI 10.1084/jem.174.5.975; SCHUTZE S, 1995, CYTOKINES PRACTICAL, P93; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WATANABE N, 1988, J BIOL CHEM, V263, P10262; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	66	178	179	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10203	10212		10.1074/jbc.274.15.10203	http://dx.doi.org/10.1074/jbc.274.15.10203			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187805	hybrid			2022-12-25	WOS:000079663500044
J	Vassiliev, IR; Yu, JP; Jung, YS; Schulz, R; Ganago, AO; McIntosh, L; Golbeck, JH				Vassiliev, IR; Yu, JP; Jung, YS; Schulz, R; Ganago, AO; McIntosh, L; Golbeck, JH			The cysteine-proximal aspartates in the F-X-binding niche of photosystem I - Effect of alanine and lysine replacements on photoautotrophic growth, electron transfer rates, single-turnover flash efficiency, and EPR spectral properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; IRON-SULFUR CENTERS; CHLAMYDOMONAS-REINHARDTII; 4FE-4S CLUSTERS; ACCEPTOR A(1); PSAC SUBUNIT; FERREDOXIN; CORE; SPECTROSCOPY; CHLOROPLASTS	The F-X electron acceptor in Photosystem I (PS I) is a highly electronegative (E-m = -705 mV) interpolypeptide [4Fe-4S] cluster ligated by cysteines 556 and 565 on PsaB and cysteines 574 and 583 on PsaA in Synechocystis sp, PCC 6803. An aspartic acid is adjacent to each of these cysteines on PsaB and adjacent to the proline-proximal cysteine on PsaA We investigated the effect of D566(saB) and D557(PsaB) on electron transfer through F-X by changing each aspartate to the neutral alanine or to the positively charged lysine either singly (D566A(PsaB), D557A(Psab), D566K(PsaB), and D557K(PsaB)) or in pairs (D557A(PsaB)/D566A(PsaB) and D557K(PsaB)/D566A(PsaB)). All mutants except for D557K(PsaB)/D566A(PsaB) grew photoautotrophically, but the growth of D557K(PsaB) and D557A(PsaB)/D566A(PsaB) was impaired under low light. The doubling time was increased, and the chlorophyll content per cell was lower in D557K(PsaB) and D557A(PsaB)/D566A(PsaB) relative to the wild type and the other mutants. Nevertheless, the rates of NADP(+) photoreduction in PS I complexes from all mutants were no less than 75% of that of the wild type. The kinetics of back-reaction of the electron accepters on a single-turnover flash showed efficient electron transfer to the terminal accepters F-A and F-B in PS I complexes from all mutants. The EPR spectrum of F-X was identical to that in the wild type in all but the single and double D566A(PsaB) mutants, where the high-field resonance was shifted downfield. We conclude that the impaired growth of some of the mutants is related to a reduced accumulation of PS I rather than to photosynthetic efficiency. The chemical nature and the charge of the amino acids adjacent to the cysteine ligands on PsaB do not appear to be significant factors in the efficiency of electron transfer through F-X.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Nebraska System; University of Nebraska Lincoln; Michigan State University	Golbeck, JH (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	jhg5@psu.edu		Yu, Jianping/0000-0003-0466-3197				ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; Berg J.M., 1982, IRON SULFUR PROTEINS, P1; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; CHAMOROVSKY SK, 1982, PHOTOBIOCH PHOTOBIOP, V4, P195; Diaz-Quintana A, 1998, BIOCHEMISTRY-US, V37, P3429, DOI 10.1021/bi972469l; EVANS MCW, 1976, BIOCHEM J, V158, P71, DOI 10.1042/bj1580071; FontecillaCamps JC, 1996, J BIOL INORG CHEM, V1, P91, DOI 10.1007/s007750050027; Golbeck J. H., 1995, CRC HDB ORGANIC PHOT, P1407; GOLBECK JH, 1986, BIOCHIM BIOPHYS ACTA, V849, P16, DOI 10.1016/0005-2728(86)90091-5; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Hallahan BJ, 1995, PHOTOSYNTH RES, V46, P257, DOI 10.1007/BF00020438; HOJ PB, 1986, J BIOL CHEM, V261, P14292; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; Lojero CG, 1996, PHOTOSYNTH RES, V47, P293, DOI 10.1007/BF02184290; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; Moulis JM, 1996, J BIOL INORG CHEM, V1, P2, DOI 10.1007/s007750050017; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; NITSCHKE W, 1993, BIOCHEMISTRY-US, V32, P8871, DOI 10.1021/bi00085a019; RODDAY SM, 1993, PHOTOSYNTH RES, V36, P1, DOI 10.1007/BF00018069; RODDAY SM, 1995, BIOCHEMISTRY-US, V34, P6328, DOI 10.1021/bi00019a010; Schubert WD, 1997, J MOL BIOL, V272, P741, DOI 10.1006/jmbi.1997.1269; SCHULZ R, 1995, PHOTOSYNTHESIS LIGHT, V2, P119; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; Vassiliev IR, 1998, BIOPHYS J, V74, P2029, DOI 10.1016/S0006-3495(98)77909-3; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; VASSILIEV IR, 1995, BIOPHYS J, V69, P1544, DOI 10.1016/S0006-3495(95)80026-3; VASSILIEV IR, 1995, PHOTOSYNTHESIS LIGHT, V2, P131; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WEBBER AN, 1993, J BIOL CHEM, V268, P12990; Yu JP, 1997, J BIOL CHEM, V272, P8032, DOI 10.1074/jbc.272.12.8032; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656	32	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9993	10001		10.1074/jbc.274.15.9993	http://dx.doi.org/10.1074/jbc.274.15.9993			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187775	hybrid			2022-12-25	WOS:000079663500014
J	Dikalov, SI; Vitek, MP; Maples, KR; Mason, RP				Dikalov, SI; Vitek, MP; Maples, KR; Mason, RP			Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; SPIN-TRAP; HYDROGEN-PEROXIDE; PROTEIN; NEUROTOXICITY; INHIBITION; TOXICITY; ADDUCT; IRON; DECOMPOSITION	Amyloid beta (A beta) peptides play an important, role in the pathogenesis of Alzheimer's disease. Free radical generation by A beta peptides was suggested to be a key mechanism of their neurotoxicity. Reports that neurotoxic free radicals derived from A beta-(1-40) and A beta-(25-35) peptides react with the spin trap N-tert-butyl-alpha-phenylnitrone (PBN) to form a PBN/*A beta peptide radical adduct with a specific triplet ESR. signal assert that the peptide itself was the source of free radicals. We now report that three A beta peptides, A beta-(1-40), A beta-(25-35), and A beta-(40-1), do not yield radical adducts with PEN from the Oklahoma Medical Research Foundation (OMRF). Incontrast to OMRF PEN, incubation of Sigma PEN in phosphate buffer without A beta peptides produced a three-line ESR spectrum, It was shown that this nitroxide is di-tert-butylnitroxide and is formed in the Sigma PEN solution as a result of transition metal-catalyzed auto-oxidation of the respective hydroxylamine present as an impurity in the Sigma PEN. Under some conditions, incubation of PEN from Sigma with A beta-(1-40) or A beta-(25-35) can stimulate the formation of di-tert-butylnitroxide. It was shown that A beta peptides enhanced oxidation of cyclic hydroxylamine 1-hydroxy-4-oxo-2,2,6,6-tetramethylpiperidine (TEMPONE-H), which was strongly inhibited by the treatment of phosphate buffer with Chelex-100. It was shown that ferric and cupric ions are effective oxidants of TEMPONE-H. The data obtained allow us to conclude that under some conditions toxic A beta peptides A beta-(1-40) and A beta-(25-35) enhance metal-catalyzed oxidation of hydroxylamine derivatives, but do not spontaneously form peptide-derived free radicals.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC 27710 USA; Centaur Pharmaceut Inc, Sunnyvale, CA 94086 USA; Novosibirsk Chem Kinet & Combust Inst, Novosibirsk 630090, Russia	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS	Dikalov, SI (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109; Dikalov, Sergey/0000-0003-2976-6184; Vitek, Michael/0000-0001-8140-8048				Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Balakrishnan R, 1998, J PEPT RES, V51, P91; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bondy SC, 1998, BRAIN RES, V799, P91, DOI 10.1016/S0006-8993(98)00461-2; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P7889; CHAMULITRAT W, 1993, J BIOL CHEM, V268, P11520; Cohen G., 1985, CRC HDB METHODS OXYG, P55; DAVIES MJ, 1997, RADICAL MED PROTEIN, P235; Dikalov S, 1997, BIOCHEM BIOPH RES CO, V230, P54, DOI 10.1006/bbrc.1996.5880; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V295, P205, DOI 10.1016/0003-9861(92)90507-S; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HENSLEY K, 1995, NEUROREPORT, V6, P489, DOI 10.1097/00001756-199502000-00021; HENSLEY K, 1995, NEUROREPORT, V6, P493, DOI 10.1097/00001756-199502000-00022; HINTON RD, 1992, J ORG CHEM, V57, P2646, DOI 10.1021/jo00035a020; KALYANARAMAN B, 1979, TETRAHEDRON LETT, V50, P4809; Kato M, 1997, J NEUROCHEM, V68, P1889; Klegeris A, 1997, J NEUROSCI RES, V49, P229, DOI 10.1002/(SICI)1097-4547(19970715)49:2<229::AID-JNR11>3.0.CO;2-W; LAGERCRANTZ C, 1991, FREE RADICAL RES COM, V14, P395, DOI 10.3109/10715769109093428; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; MACKOR A, 1967, TETRAHEDRON LETT, V5, P385; MAKINO K, 1981, RADIAT RES, V86, P294, DOI 10.2307/3575507; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Montine KS, 1998, J NEUROPATH EXP NEUR, V57, P415, DOI 10.1097/00005072-199805000-00005; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sayre LM, 1997, CHEM RES TOXICOL, V10, P518, DOI 10.1021/tx970009n; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHUBERT D, 1995, BIOCHEM BIOPH RES CO, V216, P702, DOI 10.1006/bbrc.1995.2678; SENTJURC M, 1992, FREE RADICAL BIO MED, V13, P151, DOI 10.1016/0891-5849(92)90077-T; Smith MA, 1995, J NEUROL SCI, V134, P92, DOI 10.1016/0022-510X(95)00213-L; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; SUBBARAO KV, 1990, J NEUROCHEM, V55, P342, DOI 10.1111/j.1471-4159.1990.tb08858.x; WERTZ JE, 1986, ELECTRON SPIN RESON, P450; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	39	103	104	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9392	9399		10.1074/jbc.274.14.9392	http://dx.doi.org/10.1074/jbc.274.14.9392			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092619	hybrid			2022-12-25	WOS:000079451800038
J	Garvish, JF; Lloyd, RS				Garvish, JF; Lloyd, RS			The catalytic mechanism of a pyrimidine dimer-specific glycosylase (pdg) abasic lyase, chlorella virus-pdg	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T4 ENDONUCLEASE-V; FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE; EXCISION-REPAIR ENZYME; BETA-ELIMINATION; AMINO-TERMINUS; FPG PROTEIN; CIS-SYN; SITE; BACTERIOPHAGE-T4; INTERMEDIATE	The repair of UV light-induced cyclobutane pyrimidine dimers can proceed via the base excision repair pathway, in which the initial step is catalyzed by DNA glycosylase/abasic (AP) lyases, The prototypical enzyme studied for this pathway is endonuclease V from the bacteriophage T4 (T4 bacteriophage pyrimidine dimer glycosylase (T4-pdg)), The first homologue for T4-pdg has been found in a strain of Chlorella virus (strain Paramecium bursaria Chlorella virus-1), which contains a gene that predicts an amino acid sequence homology of 41% with T4-pdg. Because both the structure and critical catalytic residues are known for T4-pdg, homology modeling of the Chlorella virus pyrimidine dimer glycosylase (cv-pdg) predicted that a conserved glutamic acid residue (Glu-23) would be important for catalysis at pyrimidine dimers and abasic sites. Site-directed mutations were constructed at Glu-23 to assess the necessity of a negatively charged residue at that position (Gln-23) and the importance of the length of the negatively charged side chain (Asp-23). E23Q lost glycosylase activity completely but retained low levels of AP lyase activity. In contrast, E23D retained near wild type glycosylase and AP lyase activities on cis-syn dimers but completely lost its activity on the trans-syn II dimer, which is very efficiently cleaved by the wild type cv-pdg. As has been shown for other glyscosylases, the wild type cv-pdg catalyzes the cleavage at dimers or AP sites via formation of an imino intermediate, as evidenced by the ability of the enzyme to be covalently trapped on substrate DNA when the reactions are carried out in the presence of a strong reducing agent; in contrast, E23D was very poorly trapped on cis-syn dimers but was readily trapped on DNA containing AP sites. It is proposed that Glu-23 protonates the sugar ring, so that the imino intermediate can be formed.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	rslloyd@utmb.edu		Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES04091, ES06676] Funding Source: Medline; PHS HHS [T327254] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V259, P751, DOI 10.1042/bj2590751; Bogenhagen DF, 1998, J BIOL CHEM, V273, P7888, DOI 10.1074/jbc.273.14.7888; CASTAING B, 1992, NUCLEIC ACIDS RES, V20, P389, DOI 10.1093/nar/20.3.389; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOI T, 1992, P NATL ACAD SCI USA, V89, P9420, DOI 10.1073/pnas.89.20.9420; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1990, J BIOL CHEM, V265, P3424; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; Furuta M, 1997, APPL ENVIRON MICROB, V63, P1551, DOI 10.1128/AEM.63.4.1551-1556.1997; HORI N, 1992, NUCLEIC ACIDS RES, V20, P4761, DOI 10.1093/nar/20.18.4761; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Jiang DY, 1997, J BIOL CHEM, V272, P32230, DOI 10.1074/jbc.272.51.32230; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; Lloyd RS, 1999, PROG NUCLEIC ACID RE, V62, P155; Lloyd RS, 1998, MUTAT RES-DNA REPAIR, V408, P159, DOI 10.1016/S0921-8777(98)00032-9; MANAHARAN M, 1988, J AM CHEM SOC, V110, P2690; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; McCullough AK, 1998, J BIOL CHEM, V273, P13136, DOI 10.1074/jbc.273.21.13136; McCullough AK, 1997, J BIOL CHEM, V272, P27210, DOI 10.1074/jbc.272.43.27210; McCullough AK, 1996, J BIOL CHEM, V271, P32147, DOI 10.1074/jbc.271.50.32147; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Scharer OD, 1997, CURR OPIN CHEM BIOL, V1, P526, DOI 10.1016/S1367-5931(97)80048-8; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SMITH CA, 1993, J BIOL CHEM, V268, P11143; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; WANG SY, 1976, PHOTOCHEM PHOTOBIOL, V1, P169; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335	32	19	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9786	9794		10.1074/jbc.274.14.9786	http://dx.doi.org/10.1074/jbc.274.14.9786			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092668	hybrid			2022-12-25	WOS:000079451800087
J	Ye, D; Willhite, DC; Blanke, SR				Ye, D; Willhite, DC; Blanke, SR			Identification of the minimal intracellular vacuolating domain of the Helicobacter pylori vacuolating toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PROTEIN TOXINS; VIRULENCE FACTORS; PROTECTIVE ANTIGEN; DIPHTHERIA-TOXIN; MAMMALIAN-CELLS; LETHAL FACTOR; HELA-CELLS; CYTOTOXIN; INFECTION; VACA	Helicobacter pylori secretes a cytotoxin (VacA) that induces the formation of large vacuoles originating from late endocytic vesicles in sensitive mammalian cells. Although evidence is accumulating that VacA is an A-B toxin, distinct A and B fragments have not been identified. To localize the putative catalytic A-fragment, we transfected HeLa cells with plasmids encoding truncated forms of VacA fused to green fluorescence protein. By analyzing truncated VacA fragments for intracellular vacuolating activity, we reduced the minimal functional domain to the amino-terminal 422 residues of VacA, which is less than one-half of the full-length protein (953 amino acids). VacA is frequently isolated as a proteolytically nicked protein of two fragments that remain noncovalently associated and retain vacuolating activity. Neither the amino-terminal 311 residue fragment (p33) nor the carboxyl-terminal 642 residue fragment (p70) of proteolytically nicked VacA are able to induce cellular vacuolation by themselves. However, cotransfection of HeLa cells with separate plasmids expressing both p33 and p70 resulted in vacuolated cells. Further analysis revealed that a minimal fragment comprising just residues 312-478 functionally complemented p33. Collectively, our results suggest a novel molecular architecture for VacA, with cytosolic localization of both fragments of nicked toxin required to mediate intracellular vacuolating activity.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston	Blanke, SR (corresponding author), Univ Houston, Dept Biol & Biochem, 430 Houston Sci Ctr,3201 Cullen Blvd, Houston, TX 77204 USA.	sblanke@uh.edu						ARORA N, 1992, J BIOL CHEM, V267, P15542; Atherton JC, 1998, BRIT MED BULL, V54, P105; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Blanke SR, 1996, P NATL ACAD SCI USA, V93, P8437, DOI 10.1073/pnas.93.16.8437; Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; Burroni D, 1998, INFECT IMMUN, V66, P5547, DOI 10.1128/IAI.66.11.5547-5550.1998; CATRENICH CE, 1992, J MED MICROBIOL, V37, P389, DOI 10.1099/00222615-37-6-389; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CORRADIN G, 1971, P NATL ACAD SCI USA, V68, P3036, DOI 10.1073/pnas.68.12.3036; COVER TL, 1993, INFECT IMMUN, V61, P1427, DOI 10.1128/IAI.61.4.1427-1431.1993; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; Cover TL, 1998, TRENDS MICROBIOL, V6, P127, DOI 10.1016/S0966-842X(98)01231-1; COVER TL, 1991, INFECT IMMUN, V59, P1264, DOI 10.1128/IAI.59.4.1264-1270.1991; Cover TL, 1996, MOL MICROBIOL, V20, P241, DOI 10.1111/j.1365-2958.1996.tb02612.x; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1996, ADV INTERNAL MED, V41, P85; deBernard M, 1997, MOL MICROBIOL, V26, P665, DOI 10.1046/j.1365-2958.1997.5881952.x; DRAZIN R, 1971, J BIOL CHEM, V246, P1504; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; KATO I, 1969, J BIOL CHEM, V244, P1004; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MILNE JC, 1995, MOL MICROBIOL, V15, P661, DOI 10.1111/j.1365-2958.1995.tb02375.x; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Moll G, 1995, EUR J BIOCHEM, V234, P947, DOI 10.1111/j.1432-1033.1995.947_a.x; MONTECUCCO C, 1994, FEBS LETT, V346, P92, DOI 10.1016/0014-5793(94)00449-8; Montecucco C, 1996, EXPERIENTIA, V52, P1026, DOI 10.1007/BF01952098; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; Pagliaccia C, 1998, P NATL ACAD SCI USA, V95, P10212, DOI 10.1073/pnas.95.17.10212; Papini E, 1996, J MED MICROBIOL, V45, P84, DOI 10.1099/00222615-45-2-84; PAPINI E, 1993, FEMS MICROBIOL LETT, V113, P155, DOI 10.1016/0378-1097(93)90262-Z; PAPINI E, 1994, P NATL ACAD SCI USA, V91, P9720, DOI 10.1073/pnas.91.21.9720; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Seto K, 1998, FEBS LETT, V431, P347, DOI 10.1016/S0014-5793(98)00788-1; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; van Doorn LJ, 1998, J CLIN MICROBIOL, V36, P2597, DOI 10.1128/JCM.36.9.2597-2603.1998; Wang HJ, 1998, J INFECT DIS, V178, P207, DOI 10.1086/515600; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	49	100	110	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9277	9282		10.1074/jbc.274.14.9277	http://dx.doi.org/10.1074/jbc.274.14.9277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092603	hybrid			2022-12-25	WOS:000079451800022
J	George, CH; Kendall, JM; Evans, WH				George, CH; Kendall, JM; Evans, WH			Intracellular trafficking pathways in the assembly of connexins into gap junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; CALCIUM ENVIRONMENTS; DEPENDENT TRANSPORT; HELA-CELLS; PROTEIN; COMMUNICATION; GOLGI; CHANNEL; RAT	Trafficking pathways underlying the assembly of connexins into gap junctions were examined using living COS-7 cells expressing a range of connexin-aequorin (Cx-Aeq) chimeras. By measuring the chemiluminescence of the aequorin fusion partner, the translocation of oligomerized connexins from intracellular stores to the plasma membrane was shown to occur at different rates that depended on the connexin isoform. Treatment of COS-7 cells expressing Cx32-Aeq and Cx43-Aeq with brefeldin A inhibited the movement of these chimera to the plasma membrane by 84 +/- 4 and 88 +/- 4%, respectively. Nocodazole treatment of the cells expressing Cx32-Aeq and Cx43-Aeq produced 29 +/- 16 and 4 +/- 7% inhibition, respectively. in contrast, the transport of Cx26 to the plasma membrane, studied using a construct (Cx26/43T-Aeq) in which the short cytoplasmic carboxyl-terminal tail of Cx26 was replaced with the extended carboxyl terminus of Cx43, was inhibited 89 +/- 5% by nocodazole and was minimally affected by exposure of cells to brefeldin A (17 +/- 11%). The transfer of Lucifer yellow across gap junctions between cells expressing wild-type Cx32, Cx43, and the corresponding Cx32-Aeq and Cx43-Aeq chimeras was reduced by nocodazole treatment and abolished by brefeldin A treatment. However, the extent of dye coupling between cells expressing wild-type Cx26 or the Cx26/43T-Aeq chimeras was not significantly affected by brefeldin A treatment, but after nocodazole treatment, transfer of dye to neighboring cells was greatly reduced. These contrasting effects of brefeldin A and nocodazole on the trafficking properties and intercellular dye transfer are interpreted to suggest that two pathways contribute to the routing of connexins to the gap junction.	Univ Wales, Coll Med, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	George, CH (corresponding author), Wales Heart Res Inst, Dept Cardiol, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.			George, Christopher/0000-0001-9852-1135				BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BLENNERHASSETT MG, 1991, AM J PHYSIOL, V261, pC1001, DOI 10.1152/ajpcell.1991.261.6.C1001; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; CHEN L, 1995, J THEOR BIOL, V176, P39, DOI 10.1006/jtbi.1995.0174; CIDARREGUI A, 1995, J NEUROSCI, V15, P4259; Cleves AE, 1997, CURR BIOL, V7, pR318, DOI 10.1016/S0960-9822(06)00148-5; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Diez JA, 1998, GAP JUNCTIONS, P130; Draguhn A, 1998, NATURE, V394, P189, DOI 10.1038/28184; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; ENKVIST MOK, 1992, J NEUROCHEM, V59, P519, DOI 10.1111/j.1471-4159.1992.tb09401.x; FALK MM, 1997, EMBO J, V16, P2704; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FISHMAN GI, 1991, P NATL ACAD SCI USA, V88, P3525, DOI 10.1073/pnas.88.9.3525; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; George CH, 1998, BIOCHEM BIOPH RES CO, V247, P785, DOI 10.1006/bbrc.1998.8835; George CH, 1998, J BIOL CHEM, V273, P29822, DOI 10.1074/jbc.273.45.29822; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Grindstaff KK, 1998, MOL BIOL CELL, V9, P685, DOI 10.1091/mbc.9.3.685; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HAMMOND C, 1994, J CELL BIOL, V126, P231; Hirschberg K, 1998, J CELL BIOL, V143, P1485, DOI 10.1083/jcb.143.6.1485; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIDDER GM, 1987, P NATL ACAD SCI USA, V84, P3718, DOI 10.1073/pnas.84.11.3718; KOJIMA T, 1994, J CELL SCI, V107, P3579; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Martin PEM, 1998, J BIOL CHEM, V273, P1719, DOI 10.1074/jbc.273.3.1719; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; Nadarajah B, 1998, J NEUROSCI, V18, P7881; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Nicholson BJ, 1998, GAP JUNCTIONS, P3; NILSSON T, 1997, MOL B INT U, P189; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POUS C, 1992, EUR J BIOCHEM, V203, P277, DOI 10.1111/j.1432-1033.1992.tb19857.x; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; Reimann J, 1997, CURR OPIN IMMUNOL, V9, P462, DOI 10.1016/S0952-7915(97)80096-9; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; SAKAI T, 1991, J BIOCHEM-TOKYO, V109, P528, DOI 10.1093/oxfordjournals.jbchem.a123415; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Torok K, 1997, BIOCHEM J, V326, P479; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; vanDeurs B, 1996, J CELL SCI, V109, P1655; Wacker I, 1997, J CELL SCI, V110, P1453; Wang XG, 1996, PFLUG ARCH EUR J PHY, V431, P844	54	99	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8678	8685		10.1074/jbc.274.13.8678	http://dx.doi.org/10.1074/jbc.274.13.8678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085106	hybrid			2022-12-25	WOS:000079451600048
J	Ito, M; Yu, RN; Jameson, JL; Ito, M				Ito, M; Yu, RN; Jameson, JL; Ito, M			Mutant vasopressin precursors that cause autosomal dominant neurohypophyseal diabetes insipidus retain dimerization and impair the secretion of wild-type proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPHYSIN-II GENE; SINGLE-BASE SUBSTITUTION; CODING REGION; ARGININE-VASOPRESSIN; BIOSYNTHETIC PRECURSOR; MUTATION; OXYTOCIN; IDENTIFICATION; KINDREDS; SIGNAL	Autosomal dominant familial neurohypophyseal diabetes insipidus is caused by mutations in the arginine vasopressin (AVP) gene. We demonstrated recently that mutant AVP precursors accumulate within the endoplasmic reticulum of neuronal cells, leading to cellular toxicity. In this study, the possibility that mutant AVP precursors interact with wild-type (WT) proteins to alter their processing and function was explored. WT and mutant precursors were epitope-tagged to allow them to be distinguished in transfected cells. An in vivo cross-linking reaction revealed homo- and heterodimer formation between WT and mutant precursors. Mutant precursors were also shown to impair intracellular trafficking of WT precursors from the endoplasmic reticulum to the Golgi apparatus. In addition to the cytotoxicity caused by mutant AVP precursors, the interaction between the WT and mutant precursors suggests that a dominant-negative mechanism may also contribute to the pathogenesis of familial neurohypophyseal diabetes insipidus.	Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University	Jameson, JL (corresponding author), Northwestern Univ, Sch Med, Div Endocrinol Metab & Mol Med, Tarry 15-709,303 E Chicago Ave, Chicago, IL 60611 USA.	ljameson@nwu.edu		Jameson, James/0000-0001-9538-4059				ANDO S, 1987, J BIOL CHEM, V262, P12962; ANGAL S, 1982, BIOCHEMISTRY-US, V21, P1574, DOI 10.1021/bi00536a017; BAHNSEN U, 1992, EMBO J, V11, P19, DOI 10.1002/j.1460-2075.1992.tb05022.x; BAYLIS PH, 1995, ENDOCRINOLOGY, P406; BERGERON C, 1991, ACTA NEUROPATHOL, V81, P345, DOI 10.1007/BF00305879; BRAVERMAN LE, 1965, ANN INTERN MED, V63, P503, DOI 10.7326/0003-4819-63-3-503; BRESLOW E, 1971, J BIOL CHEM, V246, P5179; BRESLOW E, 1990, ADV ENZYMOL RAMB, V63, P1; BRESLOW E, 1973, BIOCHEMISTRY-US, V12, P4644, DOI 10.1021/bi00747a016; BRESLOW E, 1972, MOL PHARMACOL, V8, P75; BROWNSTEIN MJ, 1980, SCIENCE, V207, P373, DOI 10.1126/science.6153132; Calvo B, 1998, J CLIN ENDOCR METAB, V83, P995, DOI 10.1210/jc.83.3.995; CHEN LQ, 1991, P NATL ACAD SCI USA, V88, P4240, DOI 10.1073/pnas.88.10.4240; de Bree FM, 1998, CELL MOL NEUROBIOL, V18, P173, DOI 10.1023/A:1022564803093; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN JR, 1967, BRAIN, V90, P707, DOI 10.1093/brain/90.3.707; Hansen LK, 1997, TRENDS ENDOCRIN MET, V8, P363, DOI 10.1016/S1043-2760(97)00157-4; Heppner C, 1998, J CLIN ENDOCR METAB, V83, P693, DOI 10.1210/jc.83.2.693; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; ITO M, 1991, J CLIN INVEST, V87, P725, DOI 10.1172/JCI115052; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Ito M, 1997, J CLIN INVEST, V99, P1897, DOI 10.1172/JCI119357; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; KANMERA T, 1985, J BIOL CHEM, V260, P8474; KRISHNAMANI MRS, 1993, J CLIN ENDOCR METAB, V77, P596, DOI 10.1210/jc.77.3.596; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCLEOD JF, 1993, J CLIN ENDOCR METAB, V77, pA599, DOI 10.1210/jcem.77.3.8370682; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NAGAI I, 1984, ACTA ENDOCRINOL-COP, V105, P318, DOI 10.1530/acta.0.1050318; NAGASAKI H, 1995, J CLIN ENDOCR METAB, V80, P1352, DOI 10.1210/jc.80.4.1352; NICOLAS P, 1978, J BIOL CHEM, V253, P2633; Rauch F, 1996, CLIN ENDOCRINOL, V44, P45, DOI 10.1046/j.1365-2265.1996.628449.x; REPASKE DR, 1994, J CLIN ENDOCR METAB, V79, P421, DOI 10.1210/jc.79.2.421; Rittig S, 1996, AM J HUM GENET, V58, P107; Rutishauser J, 1996, J CLIN ENDOCR METAB, V81, P192, DOI 10.1210/jc.81.1.192; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUSVILLE E, 1985, J BIOL CHEM, V260, P236; Ueta Y, 1996, J CLIN ENDOCR METAB, V81, P1787, DOI 10.1210/jc.81.5.1787; YUASA H, 1993, J CLIN ENDOCR METAB, V77, P600, DOI 10.1210/jc.77.3.600	39	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9029	9037		10.1074/jbc.274.13.9029	http://dx.doi.org/10.1074/jbc.274.13.9029			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085151	hybrid			2022-12-25	WOS:000079451600093
J	Mallender, WD; Szegletes, T; Rosenberry, TL				Mallender, WD; Szegletes, T; Rosenberry, TL			Organophosphorylation of acetylcholinesterase in the presence of peripheral site ligands - Distinct effects of propidium and fasciculin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO-CALIFORNICA; CRYSTAL-STRUCTURE; ACTIVE-SITE; INHIBITION; BINDING; DISSOCIATION; SPECIFICITY; HYDROLYSIS; ACYLATION; SUBSTRATE	Structural analysis of acetylcholinesterase (AChE) has revealed two sites of ligand interaction in the active site gorge: an acylation site at the base of the gorge and a peripheral site at its mouth. A goal of our studies is to understand how ligand binding to the peripheral site alters the reactivity of substrates and organophosphates at the acylation site. Kinetic rate constants were determined for the phosphorylation of AChE by two fluorogenic organophosphates, 7-[(diethoxyphosphoryl) oxy]-1-methylquinolinium iodide (DEPQ) and 7-[(methylethoxyphosphonyl)oxy] -4-methylcoumarin (EMPC), by monitoring release of the fluorescent leaving group, Rate constants obtained with human erythrocyte AChE were in good agreement with those obtained for recombinant human AChE produced from a high level Drosophila S2 cell expression system. First-order rate constants k(OP) were 1,600 +/- 300 min(-1) for DEPQ and 150 +/- 11 min(-1) for EMPC, and second-order rate constants k(OP)/K-OP were 193 +/- 13 mu M-1 min(-1) for DEPQ and 0.7-1.0 +/- 0.1 mu M-1 min(-1) for EMPC; Binding of the small ligand propidium to the AChE peripheral site decreased K-OP/K-OP by factors of 2-20 for these organophosphates, Such modest inhibitory effects are consistent with our recently proposed steric blockade model (Szegletes, T,, Mallender, W. D., and Rosenberry, T. L. (1998) Biochemistry 37, 4206-4216), Moreover, the binding of propidium resulted in a clear increase in ho, for EMPC, suggesting that molecular or electronic strain caused by the proximity of propidium to EMPC in the ternary complex may promote phosphorylation, In contrast, the binding of the polypeptide neurotoxin fasciculin to the peripheral site of AChE dramatically decreased phosphorylation rate constants. Values of k(OP)/K-OP were decreased by factors of 10(3) to 10(5), and k(OP) was decreased by factors of 300-4,000, Such pronounced inhibition suggested a conformational change in the acylation site induced by fasciculin binding, As a note of caution to other investigators, measurements of phosphorylation of the fasciculin-AChE complex by AChE inactivation gave misleading rate constants because a small fraction of the AChE was resistant to inhibition by fasciculin.	Mayo Fdn Med Educ & Res, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Dept Res, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Rosenberry, TL (corresponding author), Mayo Fdn Med Educ & Res, Dept Pharmacol, Jacksonville, FL 32224 USA.	rosenberry@mayo.edu			NINDS NIH HHS [NS-16577] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016577] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albaret C, 1997, PROTEINS, V28, P543, DOI 10.1002/(SICI)1097-0134(199708)28:4<543::AID-PROT8>3.0.CO;2-A; Aldridge W.N., 1972, FRONT BIOL, p[xvi, 328]; [Anonymous], ENZYMES 3E; BARAK D, 1994, J BIOL CHEM, V269, P6296; BARLOW PN, 1987, J AM CHEM SOC, V109, P253, DOI 10.1021/ja00235a038; BERMAN HA, 1989, J BIOL CHEM, V264, P3942; BERMAN HA, 1990, BIOCHEMISTRY-US, V29, P10640, DOI 10.1021/bi00499a010; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BURGEN ASV, 1949, BRIT J PHARM CHEMOTH, V4, P219, DOI 10.1111/j.1476-5381.1949.tb00540.x; Costagli C, 1998, BIOCHEM PHARMACOL, V55, P1733, DOI 10.1016/S0006-2952(97)00676-X; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GINSBURG S, 1966, J MED CHEM, V9, P632, DOI 10.1021/jm00322a051; GORDON MA, 1978, ANAL BIOCHEM, V85, P519, DOI 10.1016/0003-2697(78)90249-X; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HART GJ, 1973, BIOCHEMISTRY-US, V12, P2940, DOI 10.1021/bi00739a026; Hosea NA, 1996, BIOCHEMISTRY-US, V35, P10995, DOI 10.1021/bi9611220; Incardona JP, 1996, MOL BIOL CELL, V7, P595, DOI 10.1091/mbc.7.4.595; KITZ RJ, 1967, MOL PHARMACOL, V3, P225; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1986, BIOCHEM PHARMACOL, V35, P1079, DOI 10.1016/0006-2952(86)90142-5; MAGLOTHIN JA, 1975, BIOCHIM BIOPHYS ACTA, V403, P370, DOI 10.1016/0005-2744(75)90066-2; RADIC Z, 1995, J BIOL CHEM, V270, P20391, DOI 10.1074/jbc.270.35.20391; Radic Z, 1998, STRUCTURE AND FUNCTION OF CHOLINESTERASES AND RELATED PROTEINS, P211; RADIC Z, 1999, IN PRESS CHEM BIOL I; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROSENBERRY TL, 1971, BIOCHEMISTRY-US, V10, P4114, DOI 10.1021/bi00798a016; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; Rosenberry TL, 1996, BIOCHEMISTRY-US, V35, P685, DOI 10.1021/bi952431d; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; WILSON IB, 1951, J BIOL CHEM, V190, P111	37	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8491	8499		10.1074/jbc.274.13.8491	http://dx.doi.org/10.1074/jbc.274.13.8491			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085081	hybrid			2022-12-25	WOS:000079451600023
J	Nancy, V; Wolthuis, RMF; de Tand, MF; Janoueix-Lerosey, I; Bos, JL; de Gunzburg, J				Nancy, V; Wolthuis, RMF; de Tand, MF; Janoueix-Lerosey, I; Bos, JL; de Gunzburg, J			Identification and characterization of potential effector molecules of the Ras-related GTPase Rap2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP DISSOCIATION STIMULATOR; NUCLEOTIDE EXCHANGE FACTOR; MAP KINASE ACTIVATION; C-FOS PROMOTER; PROTEIN-KINASE; PLASMA-MEMBRANE; BINDING DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; FACTOR RLF	In search for effecters of the Ras-related GTPase Rapa, we used the yeast two-hybrid method and identified the C-terminal Ras/Rap interaction domain of the Ral exchange factors (RalGEFs) Ral GDP dissociation stimulator (RalGDS), RalGDS-like (RGL), and RalGDS-like factor (Rlf), These proteins, which also interact with activated Ras and Rap1, are effecters of Ras and mediate the activation of Ral in response to the activation of Ras. Here we show that the full-length RalGEFs interact with the GTP-bound form of Rap2 in the two-hybrid system as well as in vitro. When co-transfected in HeLa cells, an activated Rapa mutant (Rap2Val-12) but not an inactive protein (Rap2Ala-35) co-immunoprecipitates with RalGDS and Rlf; moreover, Rap2-RalGEF complexes can be isolated from the particulate fraction of transfected cells and were localized by confocal microscopy to the resident compartment of Rap2, i.e. the endoplasmic reticulum. However, the overexpression of activated Rap2 neither leads to the activation of the Ral GTPase via RalGEFs nor inhibits Ras-dependent Ral activation in vivo. Several hypotheses that could explain these results, including compartmentalization of proteins involved in signal transduction, are discussed. Our results suggest that in cells, the interaction of Rap2 with RalGEFs might trigger other cellular responses than activation of the Ral GTPase.	Inst Curie, INSERM, U248, Sect Rech, Paris 05, France; Univ Utrecht, Physiol Chem Lab, NL-3508 TA Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Utrecht University	de Gunzburg, J (corresponding author), Inst Curie, INSERM, U248, Sect Rech, 26 Rue Ulm, Paris 05, France.	gunzburg@curie.fr	Janoueix-Lerosey, Isabelle/G-1758-2018	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Wolthuis, Rob/0000-0002-3109-1588				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BERANGER F, 1991, ONCOGENE, V6, P1835; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Esser D, 1998, BIOCHEMISTRY-US, V37, P13453, DOI 10.1021/bi9811664; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Geyer M, 1997, NAT STRUCT BIOL, V4, P694, DOI 10.1038/nsb0997-694; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEROSEY I, 1991, J BIOL CHEM, V266, P4315; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; Murai H, 1997, J BIOL CHEM, V272, P10483; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Papin C, 1996, ONCOGENE, V12, P2213; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tamada M, 1997, ONCOGENE, V15, P2959, DOI 10.1038/sj.onc.1201582; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	72	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8737	8745		10.1074/jbc.274.13.8737	http://dx.doi.org/10.1074/jbc.274.13.8737			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085114	hybrid			2022-12-25	WOS:000079451600056
J	Parent, JL; Labrecque, P; Orsini, MJ; Benovic, JL				Parent, JL; Labrecque, P; Orsini, MJ; Benovic, JL			Internalization of the TXA(2) receptor alpha and beta isoforms - Role of the differentially spliced COOH terminus in agonist-promoted receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; THROMBOXANE A(2) RECEPTOR; PLATELET-ACTIVATING-FACTOR; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC TAIL; ALPHA(2)-ADRENERGIC RECEPTORS; HOMOLOGOUS DESENSITIZATION; INTRACELLULAR TRAFFICKING; CHOLINERGIC RECEPTORS	Thromboxane A(2) (TXA(2)) potently stimulates platelet aggregation and smooth muscle constriction and is thought to play a role in myocardial infarction, atherosclerosis, and bronchial asthma, The TXA(2) receptor (TXA(2)R) is a member of the G protein-coupled receptor family and is found as two alternatively spliced isoforms, alpha (343 residues) and beta (407 residues), which share the first 328 residues. In the present report, we demonstrate by enzyme-linked immunosorbent assay and immunofluorescence microscopy that the TXA(2)R beta, but not the TXA(2)R alpha, undergoes agonist-induced internalization when expressed in HEK293 cells as well as several other cell types. Various dominant negative mutants were used to demonstrate that the internalization of the TXA(2)R beta is dynamin-, GRK-, and arrestin-dependent in HEK293 cells, suggesting the involvement of receptor phosphorylation and clathrin-coated pits in this process. Interestingly, the agonist-stimulated internalization of both the alpha and beta isoforms, but not of a mutant truncated after residue 328, can be promoted by overexpression of arrestin-3, identifying the C-tails of both receptors as necessary in arrestin-3 interaction, Simultaneous mutation of two dileucine motifs in the C-tail of TXA(2)R beta did not affect agonist-promoted internalization. Analysis of various C-tail deletion mutants revealed that a region between residues 355 and 366 of the TXA(2)R beta is essential for agonist-promoted internalization. These data demonstrate that alternative splicing of the TXA(2)R plays a critical role in regulating arrestin binding and subsequent receptor internalization.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu						BARAK LS, 1994, J BIOL CHEM, V269, P2790; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DORN GW, 1991, J PHARMACOL EXP THER, V259, P228; DORN GW, 1992, AM J PHYSIOL, V31, pC991; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; HALUSHKA PV, 1995, J LIPID MEDIAT CELL, V12, P361, DOI 10.1016/0929-7855(95)00023-J; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Hermans E, 1996, MOL PHARMACOL, V49, P365; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; KONG GH, 1994, J BIOL CHEM, V269, P13084; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KUNZ D, 1992, J BIOL CHEM, V267, P9101; LAMEH J, 1992, J BIOL CHEM, V267, P13406; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Menard L, 1996, BIOCHEMISTRY-US, V35, P4155, DOI 10.1021/bi952961+; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; MORO O, 1993, J BIOL CHEM, V268, P6862; MURRAY R, 1989, P NATL ACAD SCI USA, V86, P124, DOI 10.1073/pnas.86.1.124; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P379, DOI 10.1016/0929-7855(95)00024-K; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OKWU AK, 1992, J PHARMACOL EXP THER, V262, P238; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P23682, DOI 10.1074/jbc.272.38.23682; Petrou C, 1997, J BIOL CHEM, V272, P2326; Pierce KL, 1997, J BIOL CHEM, V272, P883, DOI 10.1074/jbc.272.2.883; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Roettger BF, 1997, MOL PHARMACOL, V51, P357; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; Sakai K, 1996, J PHARMACOL EXP THER, V276, P829; Sandvig Kirsten, 1994, Trends in Cell Biology, V4, P275, DOI 10.1016/0962-8924(94)90211-9; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; SPURNEY RF, 1994, AM J PHYSIOL, V267, pF467, DOI 10.1152/ajprenal.1994.267.3.F467; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TSUGA H, 1994, J BIOL CHEM, V269, P32522; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; VANKOPPEN CJ, 1995, EUR J BIOCHEM, V234, P536; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6; Yukawa M, 1997, CIRC RES, V80, P551, DOI 10.1161/01.RES.80.4.551; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	80	170	176	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8941	8948		10.1074/jbc.274.13.8941	http://dx.doi.org/10.1074/jbc.274.13.8941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085139	hybrid			2022-12-25	WOS:000079451600081
J	Pourquier, P; Ueng, LM; Fertala, J; Wang, D; Park, HJ; Essigmann, JM; Bjornsti, MA; Pommier, Y				Pourquier, P; Ueng, LM; Fertala, J; Wang, D; Park, HJ; Essigmann, JM; Bjornsti, MA; Pommier, Y			Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages - 7,8-dihydro-8-oxoguanine and 5-hydroxycytosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE TYROSINE; SACCHAROMYCES-CEREVISIAE; IONIZING-RADIATION; ESCHERICHIA-COLI; ENDONUCLEASE-III; ABASIC SITES; CAMPTOTHECIN; CLEAVAGE; REPAIR; 8-HYDROXYGUANINE	We recently showed that abasic sites, uracil mismatches, nicks, and gaps can trap DNA topoisomerase I (top1) when these lesions are introduced in the vicinity of a top1 cleavage site (Pourquier, P., Ueng, L.-M., Kohlhagen, G., Mazumder, A, Gupta, Ri., Kohn, K. W., and Pommier, Y, (1997) J. Biol. Chem. 272, 7792-7796; Pourquier, P., Pilon, A. A, Kohlhagen, G., Mazumder, A., Sharma, A, and Pommier, Y. (1997) J. Biol. Chem. 26441-26447). In this study, we investigated the effects on top1 of an abundant base damage generated by various oxidative stresses: 7,8-dihydro-8-oxoguanine (8-oxoG). Using purified eukaryotic top1 and oligonucleotides containing the 8-oxoG modification, we found a 3-7-fold increase in top1-mediated DNA cleavage when 8-oxoG was present at the +1 or +2 position relative to the cleavage site. Another oxidative lesion, 8-hydroxycytosine, also enhanced top1 cleavage by a-fold when incorporated at the +1 position of the scissile strand. 8-oxoG at the +1 position enhanced noncovalent top1 DNA binding and had no detectable effect on DNA religation or on the incision step. top1 trapping by 8-oxoG was markedly enhanced when asparagine adjacent to the catalytic tyrosine was mutated to histidine, suggesting a direct interaction between this residue and the DNA major groove immediately downstream from the top1 cleavage site. Altogether, these results demonstrate that oxidative base lesions can increase top1 binding to DNA and induce top1 cleavage complexes.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University; Massachusetts Institute of Technology (MIT)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bldg 37,Rm 5D02, Bethesda, MD 20892 USA.	pommier@nih.gov	Pourquier, Philippe/O-8030-2018	Pourquier, Philippe/0000-0001-5326-3005	NATIONAL CANCER INSTITUTE [R01CA058755, R35CA052127] Funding Source: NIH RePORTER; NCI NIH HHS [CA52127, CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; ENG WK, 1989, J BIOL CHEM, V264, P13373; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; FUJIMORI A, 1995, CANCER RES, V55, P1339; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hsieh T, 1994, Adv Pharmacol, V29A, P191; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Kreutzer DA, 1998, P NATL ACAD SCI USA, V95, P3578, DOI 10.1073/pnas.95.7.3578; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Morham SG, 1996, MOL CELL BIOL, V16, P6804; Morningstar ML, 1997, CHEM RES TOXICOL, V10, P1345, DOI 10.1021/tx970052a; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; Pommier Y, 1996, SEMIN ONCOL, V23, P3; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; PURMAL AA, 1994, NUCLEIC ACIDS RES, V22, P72, DOI 10.1093/nar/22.1.72; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; Wang D, 1997, BIOCHEMISTRY-US, V36, P8628, DOI 10.1021/bi970341y; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LK, 1997, BIOCHEMISTRY-US, V36, P3909, DOI 10.1021/bi962754p; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; YEH YC, 1994, J BIOL CHEM, V269, P15498; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053	57	158	162	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8516	8523		10.1074/jbc.274.13.8516	http://dx.doi.org/10.1074/jbc.274.13.8516			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085084	hybrid			2022-12-25	WOS:000079451600026
J	Yanaga, F; Morimoto, S; Ohtsuki, I				Yanaga, F; Morimoto, S; Ohtsuki, I			Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; PROTEIN-C GENE; MISSENSE MUTATION; ALPHA-TROPOMYOSIN; SUDDEN-DEATH; MYOSIN; EXPRESSION; REPLACEMENT; COMPONENTS	Human wild-type cardiac troponin T, I, C and five troponin T mutants (I79N, R92Q, F110I, E244D, and R278C) causing familial hypertrophic cardiomyopathy were expressed in Escherichia coli, and then were purified and incorporated into rabbit cardiac myofibrils using a troponin exchange technique. The Ca2+-sensitive ATPase activity of these myofibrillar preparations was measured in order to examine the functional consequences of these troponin mutations. An I79N troponin T mutation was found to cause a definite increase in Ca2+ sensitivity of the myofibrillar ATPase activity without inducing any significant change in the maximum level of ATPase activity. A detailed analysis indicated the inhibitory action of troponin I to be impaired by the I79N troponin T mutation. Two more troponin T mutations (R92Q and R278C) were also found to have a Ca2+-sensitizing effect without inducing any change in maximum ATPase activity. Two other troponin T mutations (F110I and E244D) had no Ca2+-sensitizing effects on the ATPase activity, but remarkably potentiated the maximum level of ATPase activity. These findings indicate that hypertrophic cardiomyopathy-linked troponin T mutations have at least two different effects on the Ca2+-sensitive ATPase activity, Ca2+-sensitization and potentiation of the maximum level of the ATPase activity.	Kyushu Univ, Fac Med, Dept Clin Pharmacol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Yanaga, F (corresponding author), Kyushu Univ, Fac Med, Dept Clin Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yanaga@clipharm.med.kyushu-u.ac.jp		Morimoto, Sachio/0000-0001-9171-3636				BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Bottinelli R, 1998, CIRC RES, V82, P106; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HATAKENAKA M, 1991, BIOCHEM BIOPH RES CO, V181, P1022, DOI 10.1016/0006-291X(91)92039-M; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; Marian AJ, 1997, CIRC RES, V81, P76, DOI 10.1161/01.RES.81.1.76; MARIAN AJ, 1995, CIRCULATION, V92, P1336, DOI 10.1161/01.CIR.92.5.1336; MCKENNA WJ, 1989, CIRCULATION, V80, P1489, DOI 10.1161/01.CIR.80.5.1489; Moolman JC, 1997, J AM COLL CARDIOL, V29, P549, DOI 10.1016/S0735-1097(96)00530-X; MORIMOTO S, 1987, J BIOCHEM-TOKYO, V101, P291, DOI 10.1093/oxfordjournals.jbchem.a121913; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; NakajimaTaniguchi C, 1997, J MOL CELL CARDIOL, V29, P839, DOI 10.1006/jmcc.1996.0322; OHTSUKI I, 1986, ADV PROTEIN CHEM, V38, P1, DOI 10.1016/S0065-3233(08)60525-2; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; PAN BS, 1987, J BIOL CHEM, V262, P7839; POTTER K, 1996, NAT GENET, V13, P63; RUEGG JC, 1986, CALCIUM MUSCLE ACTIV, P183; SHIRAISHI F, 1992, J BIOCHEM-TOKYO, V111, P61, DOI 10.1093/oxfordjournals.jbchem.a123719; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; YAMAMOTO K, 1982, J BIOCHEM-TOKYO, V93, P1061	32	101	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8806	8812		10.1074/jbc.274.13.8806	http://dx.doi.org/10.1074/jbc.274.13.8806			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085122	hybrid			2022-12-25	WOS:000079451600064
J	Moskaluk, CA; Tian, Q; Marshall, CR; Rumpel, CA; Franquemont, DW; Frierson, HF				Moskaluk, CA; Tian, Q; Marshall, CR; Rumpel, CA; Franquemont, DW; Frierson, HF			Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors	ONCOGENE			English	Article						c-kit; oncogene; gene mutation; sarcoma; gastrointestinal tract	RECEPTOR TYROSINE KINASE; CELL GROWTH-FACTOR; INTERSTITIAL-CELLS; ELECTRICAL RHYTHMICITY; TISSUES; CAJAL; EXPRESSION; PROTEIN; LIGAND; INTESTINE	The c-kit gene encodes a transmembrane receptor kinase (KIT) which is expressed in the majority of human gastrointestinal stromal tumors (GISTs), a subtype of gastrointestinal mesenchymal neoplasms. A previous study identified mutations in the juxtamembrane (JR I) domain of c-X-it in five of six GISTs (Science 279: 577, 1998), To better define the frequency and spectrum of c-kit gene mutations in mesenchymal neoplasms of the GI tract that had been characterized for KIT protein expression, we examined archived tissue samples for mutations in the JM domain by PCR amplification and DNA sequencing. c-kit JM domain mutations were found in nine of 56 mesenchymal tumors (46 GISTs, eight leiomyomas, two leiomyosarcomas) and occurred exclusively in GISTs (21%), Seven of the nine mutations consisted of intragenic deletions of one to 19 codons, There was one insertion mutation that added 12 codons and one missense mutation (Val560Asp), None of the mutations disrupted the downstream reading frame of the gene, The single missense mutation (Val560Asp) is very similar to the only other missense mutation reported in GISTs (Val599Asp). Of the 46 GISTs, 43,were strongly positive for KIT protein expression and negative for diffuse expression of desmin, Neither KIT expression nor gene mutations,were found in gastrointestinal leiomyomas or leiomyosarcomas. We conclude that mutation of the c-kit JM domain does not occur in gastrointestinal mesenchymal neoplasms,vith well developed-smooth muscle differentiation, and is restricted to GISTs, However, since these mutations are only found in a minority of GISTs, further investigation into the mechanisms of c-kit gene activation in this group of neoplasms is warranted.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Penrose Hosp, Dept Pathol, Colorado Springs, CO 80907 USA	University of Virginia; University of Virginia	Moskaluk, CA (corresponding author), Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [K08CA074431] Funding Source: NIH RePORTER; NCI NIH HHS [5K08CA74431-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; FRANQUEMONT DW, 1992, AM J SURG PATHOL, V16, P947, DOI 10.1097/00000478-199210000-00004; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; HJERMSTAD BM, 1987, AM J SURG PATHOL, V11, P383, DOI 10.1097/00000478-198705000-00007; HORIE K, 1993, HUM REPROD, V8, P1955, DOI 10.1093/oxfordjournals.humrep.a137967; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Isozaki K, 1997, AM J GASTROENTEROL, V92, P332; Kenny SE, 1998, J PEDIATR SURG, V33, P130, DOI 10.1016/S0022-3468(98)90379-7; Kindblom LG, 1998, AM J PATHOL, V152, P1259; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kluppel M, 1998, DEV DYNAM, V211, P60; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MATSUDA R, 1993, AM J PATHOL, V142, P339; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216; SARLOMORIKALA M, 1998, IN PRESS MOD PATHOL; SAUL SH, 1987, AM J SURG PATHOL, V11, P464, DOI 10.1097/00000478-198706000-00007; Torihashi S, 1997, GASTROENTEROLOGY, V112, P144, DOI 10.1016/S0016-5085(97)70229-4; Tsujimura T, 1996, BLOOD, V87, P273; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P279, DOI 10.1053/gast.1996.v111.pm8690192; Vliagoftis H, 1997, J ALLERGY CLIN IMMUN, V100, P435, DOI 10.1016/S0091-6749(97)70131-3; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	30	147	160	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1897	1902		10.1038/sj.onc.1202496	http://dx.doi.org/10.1038/sj.onc.1202496			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086344				2022-12-25	WOS:000079090000013
J	Philips, A; Huet, X; Plet, A; Rech, J; Vie, A; Blanchard, JM				Philips, A; Huet, X; Plet, A; Rech, J; Vie, A; Blanchard, JM			Anchorage-dependent expression of cyclin A in primary cells requires a negative DNA regulatory element and a functional Rb	ONCOGENE			English	Article						cyclin A; Rb; adhesion; primary cells	CCAAT-BINDING PROTEIN; A GENE-EXPRESSION; RETINOBLASTOMA PROTEIN; TRANSCRIPTIONAL REPRESSION; INDEPENDENT GROWTH; DOWN-REGULATION; NUDE MICE; RAS; PROGRESSION; TUMORIGENICITY	Many cells, when cultured in suspension, fail to express cyclin A, a regulatory component of cell cycle kinases cdc2 and cdk2 and as a consequence, do not enter S phase, However, many cell type-specific differences are disclosed between not only normal and transformed cells, but also between cell lines whose proliferation is strictly anchorage-dependent, These apparent discrepancies are seen in established cell lines most probably because of adaptative events that have occurred during cell culture, We have therefore used primary cells to understand how cyclin A transcription is controlled by cell anchorage properties, To this aim, we have used embryonic fibroblasts from either wild type, Rb(-/-) or p107(-/-)/p130(-/-) mice and tested the effect of an ectopic expression of Rb mutants. In the experiments reported here, we show that anchorage-dependent expression of cyclin A (i) is reflected by the irt vivo occupancy of a negative DNA regulatory element previously shown to be instrumental in the down regulation of cyclin A transcription in quiescent cells (Cell Cycle Responsive Element: CCRE) (ii) requires a functional Rb but neither p107 nor p130 (iii) mutation of the CCRE abolishes both adhesion-dependent regulation and response to Rb.	Inst Mol Genet, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Mol Genet, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020					Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BOS JL, 1989, CANCER RES, V49, P4682; Carstens CP, 1996, EXP CELL RES, V229, P86, DOI 10.1006/excr.1996.0346; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; COLBURN NH, 1978, CANCER RES, V38, P624; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Downward J, 1997, CURR BIOL, V7, P258; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GIRARD F, 1991, CELL, V67, P1; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kramer A, 1996, J BIOL CHEM, V271, P6579; Kramer A, 1997, CANCER RES, V57, P5117; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PAGANO M, 1992, EMBO J, V88, P1039; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	50	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1819	1825		10.1038/sj.onc.1202530	http://dx.doi.org/10.1038/sj.onc.1202530			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086336				2022-12-25	WOS:000079090000005
J	Valentinis, B; Morrione, A; Peruzzi, F; Prisco, M; Reiss, K; Baserga, R				Valentinis, B; Morrione, A; Peruzzi, F; Prisco, M; Reiss, K; Baserga, R			Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion	ONCOGENE			English	Article						anchorage-independence; apoptosis; IGI-I receptor; ras; Akt	GROWTH-FACTOR-I; BREAST-CANCER CELLS; ANCHORAGE-INDEPENDENT GROWTH; ACTIVATED PROTEIN-KINASE; RAS-TRANSFORMED CELLS; MYC-INDUCED APOPTOSIS; ANTISENSE RNA; TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; HEMATOPOIETIC-CELLS	The type 1 insulin-like growth factor receptor (IGF-IR) is known to protect cells from a variety of apoptotic injuries. In several instances, the anti-apoptotic effect of the wild type IGF-IR is more evident under conditions of anchorage-independence than in cells in monolayer cultures. We have investigated IGF-IR signaling in cells in anoikis, a form of apoptosis that occurs when cells are denied attachment to the extra-cellular matrix. IGF-I protects mouse embryo fibroblasts (MEF) from anoikis caused by withdrawal of growth factors. Survival is dependent on the concentration of TGF-I and a sufficient number of functional IGF-I receptors. In this model, IGF-I protection correlates best,vith ras activation and cell-to-cell aggregation, while PI3-kinase, Akt and MAP kinases seem to play a lesser, alternative role.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Baserga, R (corresponding author), 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.		Peruzzi, Francesca/M-9804-2014		NATIONAL CANCER INSTITUTE [R01CA053484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53484] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON SA, 1968, SCIENCE, V162, P1024, DOI 10.1126/science.162.3857.1024; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CLARK S, 1991, BIOCHEM J, V276, P27, DOI 10.1042/bj2760027; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 1997, CANCER RES, V57, P2687; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GunnMoore FJ, 1997, BIOCHEM J, V324, P365, DOI 10.1042/bj3240365; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hsing AY, 1996, CANCER RES, V56, P5146; Jung YK, 1996, J BIOL CHEM, V271, P5112; KATO H, 1993, J BIOL CHEM, V268, P2655; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawada M, 1997, BIOCHEM BIOPH RES CO, V231, P735, DOI 10.1006/bbrc.1997.6179; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kuzumaki T, 1996, BBA-MOL CELL RES, V1310, P185, DOI 10.1016/0167-4889(95)00166-2; Lebowitz PF, 1997, CANCER RES, V57, P708; Lee CT, 1996, CANCER RES, V56, P3038; Lin TH, 1997, J BIOL CHEM, V272, P8849; LONG L, 1995, CANCER RES, V55, P1006; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1355, DOI 10.1210/en.138.3.1355; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pass HI, 1996, CANCER RES, V56, P4044; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; PRISCO M, IN PRESS HORMONES ME; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Turner BC, 1997, CANCER RES, V57, P3079; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1996, BIOCHEM BIOPH RES CO, V224, P362, DOI 10.1006/bbrc.1996.1034; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wu YL, 1996, J CELL PHYSIOL, V168, P499, DOI 10.1002/(SICI)1097-4652(199609)168:3<499::AID-JCP2>3.0.CO;2-K; Zamorano J, 1996, J IMMUNOL, V157, P4926; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	71	79	79	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1827	1836		10.1038/sj.onc.1202471	http://dx.doi.org/10.1038/sj.onc.1202471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086337				2022-12-25	WOS:000079090000006
J	Ho, CL; Noji, M; Saito, K				Ho, CL; Noji, M; Saito, K			Plastidic pathway of serine biosynthesis - Molecular cloning and expression of 3-phosphoserine phosphatase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE DECARBOXYLASE COMPLEX; PHOSPHOSERINE AMINOTRANSFERASE; SEQUENCE; GENES; INHIBITION	In plants, Ser is biosynthesized by two different pathways: a photorespiratory pathway via Gly and a plastidic pathway via the phosphorylated metabolites from 5-phosphoglycerate. In contrast to the better characterization of the photorespiratory pathway at a molecular level, the molecular regulation and significance of the plastidic pathway are not yet well. understood. An Arabidopsis thaliana cDNA encoding 3-phosphoserine phosphatase, the enzyme that is responsible for the conversion of 3-phosphoserine to Ser in the final step of the plastidic pathway of Ser biosynthesis, was cloned by functional complementation of an Escherichia coli serB(-) mutant. The 1.1-kilobase pair full-length cDNA, encoding 295 amino acids in its open reading frame, contains a putative organelle targeting presequence. Chloroplastic targeting has been demonstrated by particle gun bombardment using an N-terminal 60-amino acid green fluorescence protein fusion protein. Southern hybridization suggested the existence of a single-copy gene that mapped to chromosome 1. 3-Phosphoserine phosphatase enzyme activity was detected in vitro in the overexpressed protein in E. coli. Northern analysis revealed preferential gene expression in leaf and root tissues of light-grown plants with an similar to 1.5-fold abundance in the root compared with the leaf tissues. This indicates the possible role of the plastidic pathway in supplying Ser to non-photosynthetic tissues, in contrast to the function of the photorespiratory pathway in photosynthetic tissues. This work completes the molecular cloning and characterization of the three genes involved in the plastidic pathway of Ser biosynthesis in higher plants.	Chiba Univ, Fac Pharmaceut Sci, Res Ctr Med Resources, Lab Mol Biol & Biotechnol,Inage Ku, Chiba 2638522, Japan	Chiba University	Saito, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Res Ctr Med Resources, Lab Mol Biol & Biotechnol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.		Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				BRYAN JK, 1988, BIOCH PLANTS COMPREH, V16, P175; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Collet JF, 1998, J BIOL CHEM, V273, P14107, DOI 10.1074/jbc.273.23.14107; Collet JF, 1997, FEBS LETT, V408, P281, DOI 10.1016/S0014-5793(97)00438-9; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FELL DA, 1988, BIOCHEM J, V256, P97, DOI 10.1042/bj2560097; FELSENSTEIN J, 1995, PHYLIP 3 57C; Fiske CH, 1925, J BIOL CHEM, V66, P375; GREENLER JM, 1990, PLANT PHYSIOL, V94, P1484, DOI 10.1104/pp.94.3.1484; Ho CL, 1999, J BIOL CHEM, V274, P397, DOI 10.1074/jbc.274.1.397; Ho CL, 1998, PLANT J, V16, P443, DOI 10.1046/j.1365-313x.1998.00313.x; ICHIHARA A, 1957, J BIOL CHEM, V224, P331; KEYS AJ, 1980, BIOCH PLANTS, V5, P359; KREBBERS E, 1988, PLANT MOL BIOL, V11, P745, DOI 10.1007/BF00019515; LARSSON C, 1979, PHYSIOL PLANTARUM, V45, P7, DOI 10.1111/j.1399-3054.1979.tb01654.x; LISTER C, 1993, PLANT J, V4, P745, DOI 10.1046/j.1365-313X.1993.04040745.x; Noji M, 1998, J BIOL CHEM, V273, P32739, DOI 10.1074/jbc.273.49.32739; PIZER LI, 1964, J BIOL CHEM, V239, P4219; REYNOLDS PH, 1986, PLANT  PHYSL, V81, P283; Saito K, 1997, PLANT MOL BIOL, V33, P359, DOI 10.1023/A:1005730725764; Sambrook J., 2002, MOL CLONING LAB MANU; SERVAITES JC, 1977, PLANT PHYSIOL, V60, P461, DOI 10.1104/pp.60.4.461; SNELL K, 1986, TRENDS BIOCHEM SCI, V11, P241, DOI 10.1016/0968-0004(86)90184-2; SRINIVASAN R, 1995, PLANT PHYSIOL, V109, P161, DOI 10.1104/pp.109.1.161; STOLZ M, 1994, Z NATURFORSCH C, V49, P63; TAKAIWA F, 1985, PLANT MOL BIOL, V4, P355, DOI 10.1007/BF02418257; TOLBERT NE, 1980, BIOCH PLANTS, V2, P488; TURNER SR, 1993, MOL GEN GENET, V236, P402, DOI 10.1007/BF00277140; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WALKER JL, 1986, ARCH BIOCHEM BIOPHYS, V248, P626, DOI 10.1016/0003-9861(86)90517-5	31	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11007	11012		10.1074/jbc.274.16.11007	http://dx.doi.org/10.1074/jbc.274.16.11007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196182	hybrid			2022-12-25	WOS:000079751900050
J	Chen, JH; Turner, PC; Rees, HH				Chen, JH; Turner, PC; Rees, HH			Molecular cloning and characterization of hemolymph 3-dehydroecdysone 3 beta-reductase from the cotton leafworm, Spodoptera littoralis - A new member of the third superfamily of oxidoreductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECDYSTEROID BIOSYNTHESIS; ALCOHOL-DEHYDROGENASE; PROTHORACIC GLANDS; MANDUCA-SEXTA; BOMBYX-MORI; PROTEINS; PURIFICATION; EXPRESSION; SEQUENCE; ENZYME	The primary product of the prothoracic glands of last instar larvae of Spodoptera littoralis is 3-dehydroecdysone (3DE). After secretion, 3DE is reduced to ecdysone by 3DE 3 beta-reductase in the hemolymph, We have previously purified and characterized 3DE 3 beta-reductase from the hemolymph of S, littoralis, In this study, cDNA clones encoding the enzyme were obtained by reverse transcription-polymerase chain reaction, employing primers based on the amino acid sequences, in conjunction with 5'- and 3'-rapid amplification of cDNA ends. Multiple polyadenylation signals and AT-rich elements were found in the 3'-untranslated region, suggesting that this region may have a role in regulation of expression of the gene. Conceptual translation and amino acid sequence analysis suggest that 3DE 3 beta-reductase from S, littoralis is a new member of the third superfamily of oxidoreductases, Northern analysis shows that 3DE 3 beta-reductase mRNA transcripts are widely distributed, but are differentially expressed, in some tissues. The developmental profile of the mRNA revealed that the gene encoding 3DE 3 beta-reductase is only transcribed in the second half of the last larval instar and that this fluctuation in expression accounts for the change in the enzyme activity during the instar, Southern analysis indicates that the 3DE 3 beta-reductase is encoded by a single gene, which probably contains at least one intron.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	Rees, HH (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,Crown St, Liverpool L69 7ZB, Merseyside, England.							ARONSON BD, 1989, J BIOL CHEM, V264, P5226; BLAIS C, 1991, CR ACAD SCI III-VIE, V313, P359; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BRUCE NC, 1994, BIOCHEM J, V299, P805, DOI 10.1042/bj2990805; Chen JH, 1996, EUR J BIOCHEM, V242, P394, DOI 10.1111/j.1432-1033.1996.0394r.x; CHEN JH, 1994, BIOCHEM J, V299, P711, DOI 10.1042/bj2990711; EKLUND H, 1985, BIOCHEMISTRY-US, V24, P8005, DOI 10.1021/bi00348a025; EKLUND H, 1989, BIOCHEM SOC T, V17, P293, DOI 10.1042/bst0170293; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; GELMAN DB, 1991, ARCH INSECT BIOCHEM, V17, P93, DOI 10.1002/arch.940170204; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; HORJALES E, 1985, J BIOL CHEM, V260, P5445; JEFFERY J, 1988, ADV ENZYMOL RAMB, V61, P47; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; Kiriishi S, 1990, EXPERIENTIA, V46, P57; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; Koolman J, 1989, ECDYSONE; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont R., 1984, P196; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOUNIER N, 1991, INSECT BIOCHEM, V21, P523, DOI 10.1016/0020-1790(91)90106-O; Nomura Y, 1996, INSECT BIOCHEM MOLEC, V26, P249, DOI 10.1016/0965-1748(95)00083-6; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; REES HH, 1995, EUR J ENTOMOL, V92, P9; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAKURAI S, 1989, ARCH INSECT BIOCHEM, V10, P179, DOI 10.1002/arch.940100303; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; WANG XP, 1995, INSECT BIOCHEM MOLEC, V25, P1001, DOI 10.1016/0965-1748(95)00033-R; WARREN JT, 1988, P NATL ACAD SCI USA, V85, P958, DOI 10.1073/pnas.85.3.958; Watson R.D., 1989, P188	33	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10551	10556		10.1074/jbc.274.15.10551	http://dx.doi.org/10.1074/jbc.274.15.10551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187849	hybrid			2022-12-25	WOS:000079663500088
J	Muller, T; Choidas, A; Reichmann, E; Ullrich, A				Muller, T; Choidas, A; Reichmann, E; Ullrich, A			Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; E-CADHERIN; CARCINOMA-CELLS; ALPHA-CATENIN; FUNCTIONAL INTERACTION; SIGNALING PATHWAY; COMPLEX-FORMATION	Cell migration requires precise control, which is altered or lost when tumor cells become invasive and metastatic, Although the integrity of cell-cell contacts, such as adherens junctions, is essential for the maintenance of functional epithelia, they need to be rapidly disassembled during migration. The transmembrane cell adhesion protein E-cadherin and the cytoplasmic catenins are molecular elements of these structures. Here we demonstrate that epithelial cell migration is accompanied by tyrosine phosphorylation of beta-catenin and an increase of its free cytoplasmic pool. We show further that the protein-tyrosine phosphatase LAR (leukocyte common antigen related) colocalizes with the cadherin-catenin complex in epithelial cells and associates with beta-catenin and plakoglobin, Interestingly, ectopic expression of protein-tyrosine phosphatase (PTP) LAR inhibits epithelial cell migration by preventing phosphorylation and the increase in the free pool of beta-catenin; moreover, it inhibits tumor formation in nude mice. These data support a function for PTP LAR in the regulation of epithelial cell-cell contacts at adherens junctions as well as in the control of beta-catenin signaling functions. Thus PTP-LAR appears to play an important role in the maintenance of epithelial integrity, and a loss of its regulatory function may contribute to malignant progression and metastasis.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany; Swiss Inst Expt Canc Res, ISREC, CH-1066 Epalinges, Switzerland	Max Planck Society; Swiss Institute Experimental Cancer Research	Muller, T (corresponding author), ARIAD Pharmaceut Inc, 26 Landsdowne St, Cambridge, MA 02139 USA.	Thomas.Mueller@ariad.com						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BECKER KF, 1994, CANCER RES, V54, P3845; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; BOYER B, 1992, EXP CELL RES, V201, P347, DOI 10.1016/0014-4827(92)90283-E; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BUCKLEY A, 1985, P NATL ACAD SCI USA, V82, P7340, DOI 10.1073/pnas.82.21.7340; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng J, 1997, J BIOL CHEM, V272, P7264, DOI 10.1074/jbc.272.11.7264; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kratochwil K, 1996, GENE DEV, V10, P1382, DOI 10.1101/gad.10.11.1382; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MANSBRIDGE JN, 1992, J CELL PHYSIOL, V151, P433, DOI 10.1002/jcp.1041510302; MANSKE M, 1994, INT REV CYTOL, V155, P49, DOI 10.1016/S0074-7696(08)62096-3; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOMMERS CL, 1994, CANCER RES, V54, P3544; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TCHAO R, 1982, CELL MOTILITY, V4, P333; THIERY JP, 1985, ANNU REV CELL BIOL, V1, P91, DOI 10.1146/annurev.cellbio.1.1.91; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; TUCKER GC, 1990, CANCER RES, V50, P129; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Weng LP, 1998, CURR BIOL, V8, P247, DOI 10.1016/S0960-9822(98)70106-X; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; ZHOU P, 1995, GENE DEV, V9, P570	78	267	275	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10173	10183		10.1074/jbc.274.15.10173	http://dx.doi.org/10.1074/jbc.274.15.10173			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187801	hybrid			2022-12-25	WOS:000079663500040
J	Ruban, AV; Lee, PJ; Wentworth, M; Young, AJ; Horton, P				Ruban, AV; Lee, PJ; Wentworth, M; Young, AJ; Horton, P			Determination of the stoichiometry and strength of binding of xanthophylls to the photosystem II light harvesting complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL FLUORESCENCE; HIGHER-PLANTS; GREEN PLANTS; IN-VITRO; PHOTOSYNTHETIC MEMBRANES; CYCLE; PROTEINS; ENERGY; ZEAXANTHIN; PHOTOPROTECTION	Xanthophylls have a crucial role in the structure and function of the light harvesting complexes of photosystem II (LHCII) in plants. The binding of xanthophylls to LHCII has been investigated, particularly with respect to the xanthophyll cycle carotenoids violaxanthin and zeaxanthin, It was found that most of the violaxanthin pool was loosely bound to the major complex and could be removed by mild detergent treatment. Gentle solubilization of photosystem II particles and thylakoids allowed the isolation of complexes, including a newly described oligomeric preparation, enriched in trimers, that retained all of the in vivo violaxanthin pool, It was estimated that each LHCII monomer can bind at least one violaxanthin, The extent to which different pigments can be removed from LHCII indicated that the relative strength of binding was chlorophyll b > neoxanthin > chlorophyll a > lutein > zeaxanthin > violaxanthin. The xanthophyll binding sites are of two types: internal sites binding lutein and peripheral sites binding neoxanthin and violaxanthin, In CP29, a minor LHCII, both a lutein site and the neoxanthin site can be occupied by violaxanthin. Upon activation of the violaxanthin de-epoxidase, the highest de-epoxidation state was found for the main LHCII component and the lowest for CP29, suggesting that only violaxanthin loosely bound to LHCII is available for de-epoxidation.	Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Sheffield S10 2TN, S Yorkshire, England; Liverpool John Moores Univ, Sch Biol & Earth Sci, Liverpool L3 3AF, Merseyside, England	University of Sheffield; Liverpool John Moores University	Horton, P (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Robert Hill Inst, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	p.horton@sheffield.ac.uk	Horton, Peter/A-3958-2012	Horton, Peter/0000-0002-6095-1460; Young, Andrew/0000-0001-6251-0944				ALFONSO M, 1994, BIOCHEMISTRY-US, V33, P10494, DOI 10.1021/bi00200a034; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Boekema EJ, 1998, FEBS LETT, V424, P95, DOI 10.1016/S0014-5793(98)00147-1; Bugos RC, 1998, J BIOL CHEM, V273, P15321, DOI 10.1074/jbc.273.25.15321; CAMERATA KV, 1992, PHOTOSYNTH RES, V33, P235; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DIANESE P, 1991, J BIOL CHEM, V266, P8136; Eskling M, 1997, PHYSIOL PLANTARUM, V100, P806, DOI 10.1034/j.1399-3054.1997.1000407.x; Farber A, 1997, PLANT PHYSIOL, V115, P1609, DOI 10.1104/pp.115.4.1609; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Gilmore AM, 1997, PHYSIOL PLANTARUM, V99, P197, DOI 10.1034/j.1399-3054.1997.990127.x; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; Hurry V, 1997, PLANT PHYSIOL, V113, P639, DOI 10.1104/pp.113.2.639; JOHNSON GN, 1993, PLANT CELL ENVIRON, V16, P681, DOI 10.1111/j.1365-3040.1993.tb00486.x; KUHLBRANDT W, 1994, NATURE, V367, P130; LEE AL, 1995, PLANT PHYSIOL, V85, P495; OWENS TG, 1992, RES PHOTOSYNTHESIS, V4, P179; Pagano A, 1998, J BIOL CHEM, V273, P17154, DOI 10.1074/jbc.273.27.17154; PETER GF, 1991, J BIOL CHEM, V266, P16745; PFUNDEL E, 1994, PHOTOSYNTH RES, V42, P89, DOI 10.1007/BF02187121; PHILLIP D, 1995, PHOTOSYNTH RES, V43, P273, DOI 10.1007/BF00029940; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; Ros F, 1998, EUR J BIOCHEM, V253, P653, DOI 10.1046/j.1432-1327.1998.2530653.x; Ruban AV, 1998, PHOTOCHEM PHOTOBIOL, V68, P829, DOI 10.1562/0031-8655(1998)068<0829:ESELDN>2.3.CO;2; Ruban AV, 1998, BIOCHEMISTRY-US, V37, P11586, DOI 10.1021/bi9809369; RUBAN AV, 1995, PHOTOCHEM PHOTOBIOL, V61, P216, DOI 10.1111/j.1751-1097.1995.tb03964.x; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P30, DOI 10.1016/0005-2728(92)90061-6; Ruban AV, 1997, BIOCHEMISTRY-US, V36, P7855, DOI 10.1021/bi9630725; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; THAYER SS, 1990, PHOTOSYNTH RES, V23, P331, DOI 10.1007/BF00034864; YAMAMOTO HY, 1962, ARCH BIOCHEM BIOPHYS, V97, P168, DOI 10.1016/0003-9861(62)90060-7; YAMAMOTO HY, 1996, OXYGENIC PHOTOSYNTHE, P539, DOI DOI 10.1007/0-306-48127-8_30	37	227	234	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10458	10465		10.1074/jbc.274.15.10458	http://dx.doi.org/10.1074/jbc.274.15.10458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187836	hybrid			2022-12-25	WOS:000079663500075
J	Slack, A; Cervoni, N; Pinard, M; Szyf, M				Slack, A; Cervoni, N; Pinard, M; Szyf, M			DNA methyltransferase is a downstream effector of cellular transformation triggered by simian virus 40 large T antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG ISLAND; EMBRYO FIBROBLASTS; SIGNALING PATHWAY; GENE-EXPRESSION; CYTOSINE-DNA; METHYLATION; TARGET; (CYTOSINE-5)-METHYLTRANSFERASE; TUMORIGENESIS; ANTISENSE	This paper tests the hypothesis that DNA methyltransferase plays a causal role in cellular transformation induced by SV40 T antigen. We show that T antigen expression results in elevation of DNA methyltransferase (MeTase) mRNA, DNA MeTase protein levels, and global genomic DNA methylation. A T antigen mutant that has lost the ability to bind pRb does not induce DNA MeTase. This up-regulation of DNA MeTase by T antigen occurs mainly at the posttranscriptional level by altering mRNA stability. Inhibition of DNA MeTase by antisense oligonucleotide inhibitors results in inhibition of induction of cellular transformation by T antigen as determined by a transient transfection and soft agar assay. These results suggest that elevation of DNA MeTase is an essential component of the oncogenic program induced by T antigen.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							AARONSON SA, 1968, VIROLOGY, V36, P254, DOI 10.1016/0042-6822(68)90142-6; ADAMS RLP, 1979, BIOCHIM BIOPHYS ACTA, V561, P345, DOI 10.1016/0005-2787(79)90143-6; ALMAZAN G, 1992, BRAIN RES, V579, P234, DOI 10.1016/0006-8993(92)90056-F; Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHRISTMAN JK, 1993, CARCINOGENESIS, V14, P551, DOI 10.1093/carcin/14.4.551; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEVINE AJ, 1977, VIROLOGY, V77, P419; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NELKIN BD, 1991, BLOOD, V77, P2431; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; ROY N, 1992, NUCLEIC ACIDS RES, V20, P5753, DOI 10.1093/nar/20.21.5753; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SZYF M, 1991, J BIOL CHEM, V266, P10027; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P238; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; Vertino PM, 1996, MOL CELL BIOL, V16, P4555, DOI 10.1128/mcb.16.8.4555; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092	34	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10105	10112		10.1074/jbc.274.15.10105	http://dx.doi.org/10.1074/jbc.274.15.10105			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187792	hybrid			2022-12-25	WOS:000079663500031
J	Bittova, L; Sumandea, M; Cho, W				Bittova, L; Sumandea, M; Cho, W			A structure-function study of the C2 domain of cytosolic phospholipase A(2) - Identification of essential calcium ligands and hydrophobic membrane binding residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INTERFACIAL CATALYSIS; NUCLEAR-ENVELOPE; HIGH-AFFINITY; TRANSLOCATION; SPECIFICITY; SURFACE; PENETRATION; DIVERSITY	The C2 domain of cytosolic phospholipase A(2) (cPLA(2)) is involved in the Ca2+-dependent membrane binding of this protein. To identify protein residues in the C2 domain of cPLA(2) essential for its Ca2+ and membrane binding, we selectively mutated Ca2+ ligands and putative membrane-binding residues of cPLA(2) and measured the effects of mutations on its enzyme activity, membrane binding affinity, and monolayer penetration. The mutations of five Ca2+ ligands (D40N, D43N, N65A, D93N, N95A) show differential effects on the membrane binding and activation of cPLA(2) indicating that two calcium ions bound to the C2 domain have differential roles. The mutations of hydrophobic residues (F35A, M38A, L39A, Y96A, Y97A, M98A) in the calcium binding loops show that the membrane binding of cPLA(2) is largely driven by hydrophobic interactions resulting from the penetration of these residues into the hydrophobic core of the membrane. Leu(39) and Val(97) are fully inserted into the membrane, whereas Phe(35) and Tyr(96) are partially inserted. Finally, the mutations of four cationic residues in a beta-strand (R57E/K58E/R59E/R61E) have modest and negligible effects on the binding of cPLA(2) to zwitterionic and anionic membranes, respectively, indicating that they are not directly involved in membrane binding. In conjunction with our previous study on the C2 domain of protein kinase C-alpha (Medkova, M,. and Cho, W. (1998) J, Biol Chem, 273, 17544-17552), these results demonstrate that C2 domains are not only a membrane docking unit but also a module that triggers membrane penetration of protein and that individual Ca2+ lions bound to the calcium binding loops play differential roles in the membrane binding and activation of their parent proteins.	Univ Illinois, Dept Chem MC 111, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, W (corresponding author), Univ Illinois, Dept Chem MC 111, 845 W Taylor St, Chicago, IL 60607 USA.		Bittova, Lenka/K-4375-2015	Bittova, Lenka/0000-0002-3556-5234	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52598, GM53987] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; Davletov B, 1998, J BIOL CHEM, V273, P19093, DOI 10.1074/jbc.273.30.19093; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kates M., 1986, TECHNIQUES LIPIDOLOG, P114; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; LANDS WEM, 1960, J BIOL CHEM, V235, P2233; Lee BI, 1996, BIOCHEMISTRY-US, V35, P4231, DOI 10.1021/bi9524777; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VERGER R, 1982, CHEM PHYS LIPIDS, V30, P189, DOI 10.1016/0009-3084(82)90052-4; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c	35	118	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9665	9672		10.1074/jbc.274.14.9665	http://dx.doi.org/10.1074/jbc.274.14.9665			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092653	hybrid			2022-12-25	WOS:000079451800072
J	Kim, HS; Garcia, J; Exley, M; Johnson, KW; Balk, SP; Blumberg, RS				Kim, HS; Garcia, J; Exley, M; Johnson, KW; Balk, SP; Blumberg, RS			Biochemical characterization of CD1d expression in the absence of beta(2)-microglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE MOLECULE; IMMUNOGLOBULIN-E PRODUCTION; V(ALPHA)14 NKT CELLS; NK1.1(+) T-CELLS; MOUSE CD1; ANTIGEN; GENE; RECOGNITION; MICE; BETA-2-MICROGLOBULIN	CD1d is a major histocompatibility complex class I-like molecule that exhibits a distinct antigen processing pathway that functions in the presentation of hydrophobic antigens to T cells. CD1d has been previously shown to be expressed on the cell surface of human intestinal epithelial cell lines in vivo and a transfected cell line in vitro independently of beta(2)-microglobulin (beta(2)m). To define the relationship between CD1d and beta(2)m and characterize the biochemical structure of CD1d in the absence of beta(2)m, we have used a newly generated series of CD1d transfectants and CD1d-specific antibodies. These studies show that in the absence of beta(2)m, CD1d is expressed on the cell surface as a 45-kDa glycoprotein that is sensitive to endoglycosidase-H and is reduced to 37-kDa after N-glycanase digestion. In contrast, in the presence of beta(2)m, CD1d is expressed on the cell surface as a 48-kDa endoglycosidase-H-resistant glycoprotein. Pulse-chase metabolic labeling studies demonstrate that acquisition of endoglycosidase-H resistance of CD1d is observed in the presence of beta(2)m but not in the absence of beta(2)m even after a 24-h chase period. Thus, CD1d is able to be transported to the cell surface independently of beta(2)m; however, in the absence of beta(2)m, the glycosylation pattern of CD1d is altered and consistent with an immature glycoprotein.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol,Dept Med, Boston, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Blumberg, RS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol,Dept Med, 75 Francis St, Boston, MA 02115 USA.	rblumberg@rics.bwh.harvard.edu		Exley, Mark/0000-0002-5088-1032	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002549, R01DK044319, R37DK044319] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 09682-02] Funding Source: Medline; NIDDK NIH HHS [K08 DK02549-01, DK-44319] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano M, 1998, J IMMUNOL, V161, P1710; BALK SP, 1989, P NATL ACAD SCI USA, V86, P252, DOI 10.1073/pnas.86.1.252; BALK SP, 1994, SCIENCE, V265, P259, DOI 10.1126/science.7517575; BALK SP, 1991, J IMMUNOL, V146, P768; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; Beckman EM, 1996, J IMMUNOL, V157, P2795; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BILSLAND CAG, 1991, EUR J IMMUNOL, V21, P71, DOI 10.1002/eji.1830210112; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; BLUMBERG RS, 1995, IMMUNOL REV, V147, P5, DOI 10.1111/j.1600-065X.1995.tb00085.x; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CANCHIS PW, 1993, IMMUNOLOGY, V80, P561; CARDELL S, 1995, J EXP MED, V182, P993, DOI 10.1084/jem.182.4.993; Colgan SP, 1996, AM J PHYSIOL-CELL PH, V271, pC276, DOI 10.1152/ajpcell.1996.271.1.C276; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GUSSOW D, 1987, J IMMUNOL, V139, P3132; ICHIMIYA S, 1994, J IMMUNOL, V153, P1112; Joyce S, 1998, SCIENCE, V279, P1541, DOI 10.1126/science.279.5356.1541; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kasai K, 1997, CLIN EXP IMMUNOL, V109, P317, DOI 10.1046/j.1365-2249.1997.3661267.x; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; Murakami M, 1998, J IMMUNOL, V160, P2649; PARHAM P, 1983, J BIOL CHEM, V258, P6179; SOMNAYWADGAONKA.K, 1999, IN PRESS INT IMMUNOL; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Sydora BC, 1996, J IMMUNOL, V156, P4209; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teitell M, 1997, J IMMUNOL, V158, P2143; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339; ZHENG XX, 1995, J IMMUNOL, V154, P5590	44	77	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9289	9295		10.1074/jbc.274.14.9289	http://dx.doi.org/10.1074/jbc.274.14.9289			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092605	hybrid			2022-12-25	WOS:000079451800024
J	Sui, XM; Bramlett, KS; Jorge, MC; Swanson, DA; von Eschenbach, AC; Jenster, G				Sui, XM; Bramlett, KS; Jorge, MC; Swanson, DA; von Eschenbach, AC; Jenster, G			Specific androgen receptor activation by an artificial coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CARBOXYL-TERMINAL REGIONS; NUCLEAR RECEPTOR; HISTONE ACETYLTRANSFERASE; TRANSCRIPTIONAL COACTIVATORS; TRANSACTIVATION DOMAIN; HORMONE RECEPTOR; FACTOR-TFIIB; BINDING; VP16	Transcription activation of steroid receptors, such as the androgen receptor (AR), is mediated by coactivators, which bridge the receptor to the preinitiation complex. To develop a tool for studying the role of the AR in normal development and disease, we constructed artificial coactivators consisting of the transcription activation domains of VP16 or p65/RelA and the AR hinge and ligand-binding domain (AR(LBD)), which has been shown to interact with the AR N-terminal domain. The artificial VP16-AR(LBD), and AR(LBD)-p65 coactivators interacted with the AR N terminus and wild-type AR in an androgen-dependent and androgen-specific manner. VP16-AR(LBD) and AR(LBD)-p65 enhanced the AR transactivity up to 4- and 13-fold, respectively, without affecting the expression of the AR protein. The coactivators did not enhance the transcription activity of the progesterone receptor (PR) or the glucocorticoid receptor (GR), showing their specificity for the AR. In addition, to construct PR- and GR-specific coactivators, the VP16 activation domain was fused to the PR and GR hinge/ligand-binding domain. Although VP16-PRLBD, and VP16-GR(LBD), interacted with the C-terminal portion of steroid receptor coactivator-l, they did not enhance the transcription activity of their receptor. The presented strategy of directing activation domains or other protein activities into the RNA-hound AR complex provides a novel means of manipulating AR function in vitro and in vivo.	Univ Texas, MD Anderson Cancer Ctr, Dept Urol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Jenster, G (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Urol, 1515 Holcombe Blvd,Box 026, Houston, TX 77030 USA.							BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Gupta R, 1996, NUCLEIC ACIDS RES, V24, P2324, DOI 10.1093/nar/24.12.2324; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Tetel MJ, 1997, MOL ENDOCRINOL, V11, P1114, DOI 10.1210/me.11.8.1114; WAGNER LA, 1995, BLOOD, V86, P3265; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J	43	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9449	9454		10.1074/jbc.274.14.9449	http://dx.doi.org/10.1074/jbc.274.14.9449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092626	hybrid			2022-12-25	WOS:000079451800045
J	Bonaventura, C; Bonaventura, J; Shih, DTB; Iben, ET; Friedman, J				Bonaventura, C; Bonaventura, J; Shih, DTB; Iben, ET; Friedman, J			Altered ligand rebinding kinetics due to distal-side effects in hemoglobin Chico (Lys(beta 66)(E10)-> Thr)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLVED RESONANCE RAMAN; GEMINATE RECOMBINATION; HEME-PROTEINS; TERTIARY-STRUCTURE; PROXIMAL CONTROL; POCKET POLARITY; DOCKING SITE; MYOGLOBIN; BINDING; CO	Hb Chico is an unusual human hemoglobin variant that has lowered oxygen affinity, but unaltered cooperativity and anion sensitivity. Previous studies showed these features to be associated with distal-side heme pocket alterations that confer increased structural rigidity on the molecule and that increase water content in the beta-chain heme pocket. We report here that the extent of nanosecond geminate rebinding of oxygen to the variant and its isolated beta-chains is appreciably decreased. Structural alterations in this variant decrease its oxygen recombination rates without significantly altering rates of migration out of the heme pocket. Data analysis indicates that one or more barriers that impede rebinding of oxygen from docking sites in the heme pocket are increased, with less consequence for CO rebinding. Resonance Raman spectra show no significant alterations in spectral regions sensitive to interactions between the heme iron and the proximal histidine residue, confirming that the functional differences in the variant are due to distal-side heme pocket alterations. These effects are discussed in the context of a schematic representation of heme pocket wells and barriers that could aid the design of novel hemoglobins with altered ligand affinity without loss of the normal allosteric responses that facilitate unloading of oxygen to respiring tissues.	Duke Univ, Marine Freshwater Biomed Ctr, Sch Environm, Marine Lab, Beaufort, NC 28516 USA; TMC, Inst Cell & Mol Biol, Taipei 110, Taiwan; IBM Corp, San Jose, CA 95193 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Duke University; International Business Machines (IBM); Yeshiva University; Albert Einstein College of Medicine	Bonaventura, C (corresponding author), Duke Univ, Marine Freshwater Biomed Ctr, Sch Environm, Marine Lab, Beaufort, NC 28516 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004287, P30ES001908, P50ES001908] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL5108] Funding Source: Medline; NIEHS NIH HHS [ESO4287, ESO1908] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ALPERT B, 1979, CHEM PHYS LETT, V64, P11, DOI 10.1016/0009-2614(79)87265-6; ANTONIMI E, 1971, HEMOGLOBIN MYOGLOBIN; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Baldwin J.M., 1975, Progress Biophys Molec Biol, V29, P225; BANGCHAROENPAURPONG O, 1984, J AM CHEM SOC, V106, P5688, DOI 10.1021/ja00331a045; BONAVENTURA C, 1991, J BIOL CHEM, V266, P23033; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; Carlson ML, 1996, BIOCHEMISTRY-US, V35, P1125, DOI 10.1021/bi951767k; CARLSON ML, 1994, BIOCHEMISTRY-US, V33, P10597, DOI 10.1021/bi00201a005; CHANCE MR, 1990, BIOCHEMISTRY-US, V29, P5537, DOI 10.1021/bi00475a018; CHERNOFF DA, 1980, P NATL ACAD SCI USA, V77, P5606, DOI 10.1073/pnas.77.10.5606; DUDDELL DA, 1979, J CHEM SOC CHEM COMM, P75, DOI 10.1039/c39790000075; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; FRIEDMAN JM, 1980, NATURE, V284, P570, DOI 10.1038/284570a0; FRIEDMAN JM, 1985, SCIENCE, V228, P1273, DOI 10.1126/science.4001941; GERACI G, 1969, J BIOL CHEM, V244, P4664; GIBSON QH, 1992, J BIOL CHEM, V267, P22022; HO C, 1987, BIOCHEMISTRY-US, V26, P6299, DOI 10.1021/bi00394a001; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; JONGEWARD KA, 1988, J AM CHEM SOC, V110, P380, DOI 10.1021/ja00210a011; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; Kwiatkowski LD, 1998, BIOCHEMISTRY-US, V37, P4325, DOI 10.1021/bi970866q; LI T, 1994, BIOCHEMISTRY-US, V33, P1438; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; MORRIS RJ, 1980, J BIOL CHEM, V255, P8050; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PERUTZ MF, 1983, MOL BIOL EVOL, V1, P1; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; PETRICH JW, 1988, BIOCHEMISTRY-US, V27, P4049, DOI 10.1021/bi00411a022; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; SCOTT TW, 1985, J AM CHEM SOC, V107, P3702, DOI 10.1021/ja00298a047; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SHIH DTB, 1987, J MOL BIOL, V195, P453, DOI 10.1016/0022-2836(87)90666-8; SMERDON SJ, 1991, BIOCHEMISTRY-US, V30, P6252, DOI 10.1021/bi00239a025; Spiro T.G., 1983, IRON PORPHYRINS P2, P89; Spiro TG, 1997, J BIOL INORG CHEM, V2, P516, DOI 10.1007/s007750050164; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SZABO A, 1972, BIOCHEM BIOPH RES CO, V46, P855, DOI 10.1016/S0006-291X(72)80219-5; Tian WD, 1996, BIOCHEMISTRY-US, V35, P3487, DOI 10.1021/bi952474u; TRAYLOR TG, 1980, ADV CHEM SER, V191, P219	56	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8686	8693		10.1074/jbc.274.13.8686	http://dx.doi.org/10.1074/jbc.274.13.8686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085107	hybrid			2022-12-25	WOS:000079451600049
J	Ichikawa, H; Halberg, R; Kroos, L				Ichikawa, H; Halberg, R; Kroos, L			Negative regulation by the Bacillus subtilis GerE protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL GENE-EXPRESSION; SIGMA-FACTOR; RNA-POLYMERASE; SPORE COAT; REPRESSES TRANSCRIPTION; SPATIAL CONTROL; SWITCH PROTEIN; SPORULATION; PROMOTER; BINDING	GerE is a transcription factor produced in the mother cell compartment of sporulating Bacillus subtilis. It is a critical regulator of cot genes encoding proteins that form the spore coat late in development. Most cot genes, and the gerE gene, are transcribed by sigma(K) RNA polymerase, Previously, it was shown that the GerE protein inhibits transcription in vitro of the sigK gene encoding sigma(K). Here, we show that GerE binds near the sigK transcriptional start site, to act as a repressor. A sigK-lacZ fusion containing the GerE-binding site in the promoter region was expressed at a a-fold lower level during sporulation of wild-type cells than gerE mutant cells, Likewise, the level of SigK protein (i,e, pro-sigma(K) and sigma(K)) was lower in sporulating wild-type cells than in a gerE mutant. These results demonstrate that sigma(K)-dependent transcription of gerE initiates a negative feedback loop in which GerE acts as a repressor to limit production of di, In addition, GerE directly represses transcription of particular cot genes. We show that GerE binds to two sites that span the -35 region of the cotD promoter. A low level of GerE activated transcription of cotD by sigma(K) RNA polymerase in vitro, but a higher level of GerE repressed cotD transcription. The upstream GerE-binding site was required for activation but not for repression. These results suggest that a rising level of GerE in sporulating cells may first activate cotD transcription from the upstream site then repress transcription as the downstream site becomes occupied. Negative regulation by GerE, in addition to its positive effects on transcription, presumably ensures that dl and spore coat proteins are synthesized at optimal levels to produce a germination-competent spore.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Kroos, L (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.				NIGMS NIH HHS [GM43585] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043585, R01GM043585] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER HL, 1986, P NATL ACAD SCI USA, V83, P9438, DOI 10.1073/pnas.83.24.9438; CUTTING S, 1989, J MOL BIOL, V207, P393, DOI 10.1016/0022-2836(89)90262-3; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DANIEL RA, 1993, J MOL BIOL, V232, P468, DOI 10.1006/jmbi.1993.1403; ERRINGTON J, 1986, J GEN MICROBIOL, V132, P2967; HALBERG R, 1994, J MOL BIOL, V243, P425, DOI 10.1006/jmbi.1994.1670; HALBERG R, 1992, J MOL BIOL, V228, P840, DOI 10.1016/0022-2836(92)90868-K; Harwood C.R., 1990, MOL BIOL METHODS BAC; Henriques AO, 1997, J BACTERIOL, V179, P1887, DOI 10.1128/jb.179.6.1887-1897.1997; Henriques AO, 1997, J BACTERIOL, V179, P389, DOI 10.1128/jb.179.2.389-398.1997; HOLLAND SK, 1987, J GEN MICROBIOL, V133, P2381; KAHN D, 1991, MOL MICROBIOL, V5, P987, DOI 10.1111/j.1365-2958.1991.tb00774.x; KENNEY TJ, 1991, J BACTERIOL, V173, P3282, DOI 10.1128/jb.173.11.3282-3290.1991; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KROOS L, 1999, IN PRESS MOL MICROBI, V31; KUNKEL B, 1988, J BACTERIOL, V170, P3513, DOI 10.1128/jb.170.8.3513-3522.1988; KUNKEL B, 1989, GENE DEV, V3, P1735, DOI 10.1101/gad.3.11.1735; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Miller JH., 1972, EXPT MOL GENETICS; MOIR A, 1981, J BACTERIOL, V146, P1106, DOI 10.1128/JB.146.3.1106-1116.1981; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; ROELS S, 1995, J BACTERIOL, V177, P6263, DOI 10.1128/jb.177.21.6263-6275.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SANDMAN K, 1988, J MOL BIOL, V200, P461, DOI 10.1016/0022-2836(88)90536-0; STEVENS CM, 1990, MOL MICROBIOL, V4, P543, DOI 10.1111/j.1365-2958.1990.tb00622.x; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; TATTI KM, 1991, J BACTERIOL, V173, P7828, DOI 10.1128/jb.173.24.7828-7833.1991; Zhang B, 1997, J BACTERIOL, V179, P972, DOI 10.1128/jb.179.3.972-975.1997; Zhang B, 1997, J BACTERIOL, V179, P6138, DOI 10.1128/jb.179.19.6138-6144.1997; ZHANG JK, 1994, J MOL BIOL, V240, P405, DOI 10.1006/jmbi.1994.1456; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D; ZHENG LB, 1992, J MOL BIOL, V226, P1037, DOI 10.1016/0022-2836(92)91051-P; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	34	29	29	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8322	8327		10.1074/jbc.274.12.8322	http://dx.doi.org/10.1074/jbc.274.12.8322			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075739	hybrid			2022-12-25	WOS:000079268100098
J	Ackermann, EJ; Taylor, JK; Narayana, R; Bennett, CF				Ackermann, EJ; Taylor, JK; Narayana, R; Bennett, CF			The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; TNF-INDUCED APOPTOSIS; INDUCED CELL-DEATH; CYTOCHROME-C; GENE-EXPRESSION; INHIBITION; MITOCHONDRIA; PROTEASES	In this study, we utilized potent antisense oligonucleotides to examine the role of two Bcl-2 family members found in human umbilical vein endothelial cells (HUVEC). The first, A1, is thought to be a TNF-alpha-inducible cytoprotective gene, and the second, Bcl-XL, is constitutively expressed. Inhibition of the constitutive levels of Bcl-XL caused 10-25% of the cell population to undergo apoptosis and increased the susceptibility of cells to treatment with low concentrations of staurosporin or ceramide. The caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp(OMe)CH, prevented DNA fragmentation and Delta Ym loss caused by Bcl-XL inhibition or Bcl-XL inhibition combined with staurosporin. However, disruption of Delta Ym caused by Bcl-XL inhibition combined with ceramide treatment was not inhibited by benzyloxycarbonyl-Val-Ala-Asp(OMe)-CH2, although DNA fragmentation was completely prevented. Taken together, these results demonstrate a direct protective role for Bcl-XL under normal resting conditions and under low level apoptotic challenges to HUVEC. Furthermore, Bcl-XL protects cells from caspase-dependent and -independent mechanisms of Delta Ym disruption. In contrast to Bcl-XL, Al inhibition did not show a marked effect on the susceptibility of HUVEC to undergo apoptosis in response to TNF-alpha, ceramide, or staurosporin. These results demonstrate that although Al may be a cytoprotective gene induced by TNF-alpha, it is not primarily responsible for HUVEC resistance to this cytokine.	ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Ackermann, EJ (corresponding author), ISIS Pharmaceut, Dept Mol Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; BEDNARCZUK TA, 1991, BIOTECHNIQUES, V10, P478; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DEMARIA R, 1997, SCIENCE, V277, P1625; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MONIA BP, 1993, J BIOL CHEM, V268, P14514; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Shimizu S, 1996, ONCOGENE, V13, P21; Slowik MR, 1997, LAB INVEST, V77, P257; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	40	94	102	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11245	11252		10.1074/jbc.274.16.11245	http://dx.doi.org/10.1074/jbc.274.16.11245			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196212	hybrid			2022-12-25	WOS:000079751900080
J	Doering, T; Holleran, WM; Potratz, A; Vielhaber, G; Elias, PM; Suzuki, K; Sandhoff, K				Doering, T; Holleran, WM; Potratz, A; Vielhaber, G; Elias, PM; Suzuki, K; Sandhoff, K			Sphingolipid activator proteins are required for epidermal permeability barrier formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STRATUM-CORNEUM; GAUCHER-DISEASE; LYSOSOMAL DEGRADATION; ENZYMATIC-HYDROLYSIS; BETA-GLUCOSIDASE; SAPOSIN-C; DEFICIENCY; GLUCOCEREBROSIDASE; CERAMIDES; PATIENT	The epidermal permeability barrier is maintained by extracellular lipid membranes within the interstices of the stratum corneum, Ceramides, the major components of these multilayered membranes, derive in large part from hydrolysis of glucosylceramides mediated by stratum corneum beta-glucocerebrosidase (beta-GlcCerase), Prosaposin (pSAP) is a large precursor protein that is proteolytically cleaved to form four distinct sphingolipid activator proteins, which stimulate enzymatic hydrolysis of sphingolipids, including glucosylceramide, Recently, pSAP has been eliminated in a mouse model using targeted deletion and homologous recombination. In addition to the extracutaneous findings noted previously, our present data indicate that pSAP deficiency in the epidermis has significant consequences including: 1) an accumulation of epidermal glucosylceramides together with below normal levels of ceramides; 2) alterations in lipids that are bound by ester linkages to proteins of the cornified cell envelope; 3) a thickened stratum lucidum with evidence of scaling; and 4) a striking abnormality in lamellar membrane maturation within the interstices of the stratum corneum. Together, these results demonstrate that the production of pSAP, and presumably mature sphingolipid activator protein generation, is required for normal epidermal barrier formation and function. Moreover, detection of significant amounts of covalently bound omega-OH-GlcCer in pSAP-deficient epidermis suggests that deglucosylation to omega-OH-Cer is not a requisite step prior to covalent attachment of lipid to cornified envelope proteins.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Vet Affairs Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Res Unit 190, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94121 USA; Univ N Carolina, Sch Med, Dept Neurol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA	University of Bonn; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sandhoff, K (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard-Domagh-Str 1, D-53121 Bonn, Germany.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019098, P01AR039448] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39448, AR19098] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; Chang-Yi Cui, 1997, Journal of Investigative Dermatology, V109, P319, DOI 10.1111/1523-1747.ep12335839; DOWNING DT, 1992, J LIPID RES, V33, P301; ELIAS PM, 1991, ADV LIPID RES, V33, P301; FISCHER G, 1978, BIOCHIM BIOPHYS ACTA, V528, P69, DOI 10.1016/0005-2760(78)90053-X; FU Q, 1994, J MOL NEUROSCI, V5, P59, DOI 10.1007/BF02736694; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; GRAY GM, 1975, J LIPID RES, V16, P441; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HO MW, 1975, FEBS LETT, V53, P243, DOI 10.1016/0014-5793(75)80029-9; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; HOLLERAN WM, 1993, J CLIN INVEST, V91, P1656, DOI 10.1172/JCI116374; HOLLERAN WM, 1990, J LIPID RES, V31, P1655; HOLLERAN WM, 1994, J CLIN INVEST, V93, P1756, DOI 10.1172/JCI117160; HOU SYE, 1991, J INVEST DERMATOL, V96, P215, DOI 10.1111/1523-1747.ep12461361; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; Liu YJ, 1998, P NATL ACAD SCI USA, V95, P2503, DOI 10.1073/pnas.95.5.2503; MADISON KC, 1990, J INVEST DERMATOL, V95, P657, DOI 10.1111/1523-1747.ep12514333; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; MOTTA S, 1993, BIOCHIM BIOPHYS ACTA, V1182, P147, DOI 10.1016/0925-4439(93)90135-N; Oya Y, 1998, ACTA NEUROPATHOL, V96, P29, DOI 10.1007/s004010050857; POULOS A, 1984, BIOCHIM BIOPHYS ACTA, V793, P141, DOI 10.1016/0005-2760(84)90315-1; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; ROBSON KJ, 1994, J LIPID RES, V35, P2060; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; Sidransky E, 1996, PEDIATR RES, V39, P134, DOI 10.1203/00006450-199601000-00020; SUZUKI K, 1995, ESSAYS BIOCHEM, V29, P25; TAYAMA M, 1993, BIOCHEM J, V290, P401, DOI 10.1042/bj2900401; Vaccaro AM, 1997, J BIOL CHEM, V272, P16862, DOI 10.1074/jbc.272.27.16862; WEILER S, 1995, PROTEIN SCI, V4, P756; WERTZ PW, 1983, J LIPID RES, V24, P753; WERTZ PW, 1985, J INVEST DERMATOL, V84, P410, DOI 10.1111/1523-1747.ep12265510; WERTZ PW, 1989, J INVEST DERMATOL, V92, P109, DOI 10.1111/1523-1747.ep13071317; WERTZ PW, 1987, BIOCHIM BIOPHYS ACTA, V917, P108, DOI 10.1016/0005-2760(87)90290-6; WERTZ PW, 1983, J LIPID RES, V24, P759; Wilkening G, 1998, J BIOL CHEM, V273, P30271, DOI 10.1074/jbc.273.46.30271	38	109	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11038	11045		10.1074/jbc.274.16.11038	http://dx.doi.org/10.1074/jbc.274.16.11038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196186	Green Published, hybrid			2022-12-25	WOS:000079751900054
J	Sugimoto, Y; Sanuki, S; Ohsako, S; Higashimoto, Y; Kondo, M; Kurawaki, J; Ibrahim, HR; Aoki, T; Kusakabe, T; Koga, K				Sugimoto, Y; Sanuki, S; Ohsako, S; Higashimoto, Y; Kondo, M; Kurawaki, J; Ibrahim, HR; Aoki, T; Kusakabe, T; Koga, K			Ovalbumin in developing chicken eggs migrates from egg white to embryonic organs while changing its conformation and thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINASE-INHIBITOR; TRYPSIN-INHIBITOR; YOLK; SEQUENCES; HEN	Ovalbumin was detected in developing chicken eggs. The large majority of these ovalbumin molecules was found to be in a heat-stable form reminiscent of S-ovalbumin, About 83 and 90% of the ovalbumin population was in a heat-stable form in day 14 or stage 40 amniotic fluid and day 18 or stage 44 egg yolk, respectively, whereas ovalbumin in newly deposited eggs was in the heat-unstable, native form. Purified preparations of stable ovalbumin from egg white and amniotic fluid showed a les's ordered configuration than native ovalbumin, as analyzed by circular dichroism and differential scanning calorimetry. In addition, mass spectrometric analysis exhibited distinct size microheterogeneity between the stable and native forms of ovalbumin, Immunohisotochemical study revealed that ovalbumin was present in the central nervous system and other embryonic organs. These results indicated that egg white ovalbumin migrates into the developing embryo while changing its higher order structure.	Kagoshima Univ, Fac Agr, Dept Biochem Sci & Technol, Kagoshima 8900065, Japan; Natl Inst Environm Studies, Tsukuba, Ibaraki 3050053, Japan; Saga Univ, Fac Sci & Engn, Dept Chem, Saga 8408502, Japan; Kagoshima Univ, Fac Sci, Dept Chem, Kagoshima 8900065, Japan; Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Lab Sericulture, Higashi Ku, Fukuoka 8128581, Japan	Kagoshima University; National Institute for Environmental Studies - Japan; Saga University; Kagoshima University; Kyushu University	Sugimoto, Y (corresponding author), Kagoshima Univ, Fac Agr, Dept Biochem Sci & Technol, 1-21-24 Korimoto, Kagoshima 8900065, Japan.		Ibrahim, Hisham/AAB-3945-2021	Ibrahim, Hisham/0000-0002-7809-900X; Higashimoto, Yuichiro/0000-0003-1382-8598				BAINTNER K, 1974, DEV BIOL, V36, P272, DOI 10.1016/0012-1606(74)90050-5; BURLEY RW, 1989, AVIAN EGG CHEM BIOL, P129; CLARKE EP, 1992, BIOCHIM BIOPHYS ACTA, V1129, P246, DOI 10.1016/0167-4781(92)90498-O; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; EGELANDSDAL B, 1980, J FOOD SCI, V45, P570, DOI 10.1111/j.1365-2621.1980.tb04103.x; GANNON F, 1979, NATURE, V278, P428, DOI 10.1038/278428a0; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HASSEL J, 1971, DEV BIOL, V26, P3880; HUNTINGTON JA, 1995, PROTEIN SCI, V4, P613; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; Koketsu M., 1997, HEN EGGS THEIR BASIC, P99; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marshall ME, 1951, J BIOL CHEM, V185, P155; MCINDOE WM, 1960, J EMBRYOL EXP MORPH, V8, P47; Mellet P, 1996, J BIOL CHEM, V271, P30311, DOI 10.1074/jbc.271.48.30311; Nguyen L. T. H., 1984, CSIRO Food Research Quarterly, V44, P44; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; OSUGA DT, 1977, FOOD PROTEINS, P209; OUCHTERLONY O, 1949, ACTA PATHOL MIC SC, V26, P507; ROMANOFF AL, 1960, AVIAN EMVRYO STRUCTU, P209; SAITO Z, 1966, CAN J BIOCHEM CELL B, V44, P293, DOI 10.1139/o66-035; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH MB, 1964, AUST J BIOL SCI, V17, P261, DOI 10.1071/BI9640261; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SUGIMOTO Y, 1989, BIOCHIM BIOPHYS ACTA, V992, P400, DOI 10.1016/0304-4165(89)90104-9; SUGIMOTO Y, 1984, BIOCHIM BIOPHYS ACTA, V788, P117, DOI 10.1016/0167-4838(84)90303-0; Sugimoto Y, 1996, BBA-PROTEIN STRUCT M, V1295, P96; Tatsumi E, 1997, J BIOCHEM, V122, P300; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	32	77	78	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11030	11037		10.1074/jbc.274.16.11030	http://dx.doi.org/10.1074/jbc.274.16.11030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196185	hybrid			2022-12-25	WOS:000079751900053
J	Han, GM; Hampson, DR				Han, GM; Hampson, DR			Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVELY SPLICED FORMS; EXTRACELLULAR DOMAIN; AGONIST SELECTIVITY; HIGH-AFFINITY; LOCALIZATION; EXPRESSION; RAT; CHORIOGONADOTROPIN; HIPPOCAMPUS; MODULATION	The metabotropic glutamate receptor (mGluR) 4 subtype of metabotropic glutamate receptor is a presynaptic receptor that modulates neurotransmitter release. We have characterized the properties of a truncated, epitope-tagged construct containing part of the extracellular amino-terminal domain of mGluR4, The truncated receptor was secreted into the cell culture medium of transfected human embryonic kidney cells. The oligomeric structure of the soluble truncated receptor was assessed by gel electrophoresis. In the presence of high concentrations of a reducing agent, the truncated receptor migrated as a monomer; at lower concentrations of the reducing agent, only higher molecular weight oligomers were observed. Competition binding experiments using the radiolabeled agonist [H-3]L-2-amino-4-phosphonobutyric acid revealed that the rank order of potency of metabotropic ligands at the truncated receptor was similar to that of the full-length membrane-bound receptor. However, the truncated receptor displayed higher affinities for agonists and lower affinities for antagonists compared with the full-length receptor. Deglycosylation produced a shift in the relative molecular weight of the soluble protein from M-r = 71,000 to M-r = 63,000; deglycosylation had no effect on the binding of [H-3]L-2-amino-4-phosphonobutyric acid, indicating that the asparagine-linked carbohydrates are not necessary for agonist binding. These results demonstrate that although the primary determinants of ligand binding to mGluR4 are contained within the first 548 amino acids of the receptor, additional amino acids located downstream of this region may influence the affinity of ligands for the binding site.	Univ Toronto, Fac Pharm, Toronto, ON M5S 252, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 252, Canada	University of Toronto; University of Toronto	Hampson, DR (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.							Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bradley SR, 1996, J NEUROSCI, V16, P2044; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Eriksen L, 1995, BRIT J PHARMACOL, V116, P3279, DOI 10.1111/j.1476-5381.1995.tb15136.x; Everts I, 1997, MOL PHARMACOL, V52, P861, DOI 10.1124/mol.52.5.861; FLOR PJ, 1995, NEUROPHARMACOLOGY, V34, P149, DOI 10.1016/0028-3908(94)00149-M; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; HAMPSON DR, 1994, NEUROSCIENCE, V60, P325, DOI 10.1016/0306-4522(94)90246-1; Hudtloff C, 1998, BRIT J PHARMACOL, V124, P971, DOI 10.1038/sj.bjp.0701910; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pekhletski R, 1996, J NEUROSCI, V16, P6364; PERTERSON GL, 1984, P NATL ACAD SCI USA, V81, P4993; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Thomsen C, 1999, J NEUROCHEM, V72, P835, DOI 10.1046/j.1471-4159.1999.0720835.x; Thomsen C, 1997, NEUROPHARMACOLOGY, V36, P21, DOI 10.1016/S0028-3908(96)00153-0; Tones MA, 1995, NEUROREPORT, V7, P117, DOI 10.1097/00001756-199512290-00028; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; XIE YB, 1990, J BIOL CHEM, V265, P21411	28	70	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10008	10013		10.1074/jbc.274.15.10008	http://dx.doi.org/10.1074/jbc.274.15.10008			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187777	hybrid			2022-12-25	WOS:000079663500016
J	Matsushita, M; Nairn, AC				Matsushita, M; Nairn, AC			Inhibition of the Ca2+/calmodulin-dependent protein kinase I cascade by cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; INTRASTERIC REGULATION; BRAIN CALMODULIN; CDNA CLONING; RAT-BRAIN; PHOSPHORYLATION; ACTIVATION	Several recent studies have shown that Ca2+/calmodulin-dependent protein kinase I (CaMKI) is phosphorylated and activated by a protein kinase (CaMKK) that is itself subject to regulation by Ca2+/calmodulin. In the present study, we demonstrate that this enzyme cascade is regulated by cAMP-mediated activation of cAMP-dependent protein kinase (PKA), In vitro, CaMKK is phosphorylated by PKA and this is associated with inhibition of enzyme activity. The major site of phosphorylation is threonine 108, although additional sites are phosphorylated with lower efficiency. In vitro, CaMKK is also phosphorylated by CaMKI at the same sites as PKA, suggesting that this regulatory phosphorylation might play a role as a negative-feedback mechanism, In intact PC12 cells, activation of PKA with forskolin resulted in a rapid inhibition of both CaMKK and CaMKI activity. In hippocampal slices CaMKK was phosphorylated under basal conditions, and activation of PKA led to an increase in phosphorylation. Two-dimensional phosphopeptide mapping indicated that activation of PKA led to increased phosphorylation of multiple sites including threonine 108. These results indicate that in vitro and in intact cells the CaMKK/CaMKI cascade is subject to inhibition by PKA-mediated phosphorylation of CaMKK. The phosphorylation and inhibition of CaMKK by PKA is likely to be involved in modulating the balance between cAMP- and Ca2+-dependent signal transduction pathways.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Rockefeller University	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, 1230 York Ave, New York, NY 10021 USA.	nairn@rockvax.rockefeller.edu		Nairn, Angus/0000-0002-7075-0195				Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BURNS F, 1996, INTRACELLULAR SIGNAL, P29; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; Greengard P, 1998, BRAIN RES REV, V26, P274, DOI 10.1016/S0165-0173(97)00057-X; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Herberg FW, 1997, PROTEIN SCI, V6, P569; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; MITSUI K, 1993, J BIOL CHEM, V268, P13422; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P407; NAIRN AC, 1996, TRANSLATIONAL CONTRO, P295; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PICCIOTTO MR, 1996, INTRACELLULAR SIGNAL, P251; Pickett-Gies CA., 1986, ENZYMES, V17, P395; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4360; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	68	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10086	10093		10.1074/jbc.274.15.10086	http://dx.doi.org/10.1074/jbc.274.15.10086			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187789	hybrid			2022-12-25	WOS:000079663500028
J	Banbula, A; Mak, P; Bugno, M; Silberring, J; Dubin, A; Nelson, D; Travis, J; Potempa, J				Banbula, A; Mak, P; Bugno, M; Silberring, J; Dubin, A; Nelson, D; Travis, J; Potempa, J			Prolyl tripeptidyl peptidase from Porphyromonas gingivalis - A novel enzyme with possible pathological implications for the development of periodontitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTEROIDES-GINGIVALIS; CYSTEINE PROTEINASES; GLYCYLPROLYL PROTEASE; ESCHERICHIA-COLI; GENE; PURIFICATION; GENERATION; EXPRESSION; ACTIVATION; GINGIPAIN	Porphyromonas gingivalis possesses a complex proteolytic system, which is essential for both its growth and evasion of host defense mechanisms, In this report we characterized, both at a protein and genomic level, a novel peptidase of this system with prolyl tripeptidyl peptidase activity. The enzyme was purified to homogeneity, and its enzymatic activity and biochemical properties were investigated The amino acid sequence at the amino terminus and of internal peptide fragments enabled identification of the gene encoding this enzyme, which we refer to as PtpA for prolyl tripeptidyl peptidase A. The gene encodes an 82-kDa protein, which contains a GWSYGG motif, characteristic for members of the S9 prolyl oligopeptidase family of serine proteases. However, it does not share any structural similarity to Other tripeptidyl peptidases, which, belong to the subtilisin family. The production of prolyl tripeptidyl peptidase may contribute to the pathogenesis of periodontal tissue destruction through the mutual interaction of this enzyme, host and bacterial collagenases, and, dipeptidyl peptidases in the degradation of collagen during the course of infection.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Jagiellonian Univ, Fac Chem, PL-31120 Krakow, Poland; Jagiellonian Univ, Reg Lab, PL-31120 Krakow, Poland	University System of Georgia; University of Georgia; Jagiellonian University; Jagiellonian University; Jagiellonian University	Potempa, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	potempa@arches.uga.edu	Silberring, Jerzy/AGA-5631-2022; Nelson, Daniel C./I-2198-2012	Silberring, Jerzy/0000-0002-4362-8362; Nelson, Daniel C./0000-0003-3248-4831; Mak, Pawel/0000-0002-5222-3922				ABIKO Y, 1985, J DENT RES, V64, P106, DOI 10.1177/00220345850640020201; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BARUA PK, 1989, INFECT IMMUN, V57, P2522, DOI 10.1128/IAI.57.8.2522-2528.1989; BOURGEAU G, 1992, INFECT IMMUN, V60, P3186, DOI 10.1128/IAI.60.8.3186-3192.1992; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; Cicala C, 1998, LIFE SCI, V62, P1817, DOI 10.1016/S0024-3205(97)01167-3; Cunningham DF, 1997, BBA-PROTEIN STRUCT M, V1343, P160, DOI 10.1016/S0167-4838(97)00134-9; CURTIS MA, 1993, J GEN MICROBIOL, V139, P949, DOI 10.1099/00221287-139-5-949; Dashper SG, 1998, J DENT RES, V77, P1133; Gazi MI, 1997, ORAL MICROBIOL IMMUN, V12, P240, DOI 10.1111/j.1399-302X.1997.tb00386.x; GRENIER D, 1989, INFECT IMMUN, V57, P3265, DOI 10.1128/IAI.57.11.3265-3269.1989; GRENIER D, 1987, INFECT IMMUN, V55, P3131, DOI 10.1128/IAI.55.12.3131-3136.1987; HINODE D, 1992, ARCH ORAL BIOL, V37, P859, DOI 10.1016/0003-9969(92)90120-W; HONG WJ, 1990, J CELL BIOL, V111, P323, DOI 10.1083/jcb.111.2.323; IMAMURA T, 1995, INFECT IMMUN, V63, P4877, DOI 10.1128/IAI.63.12.4877-4882.1995; Imamura T, 1997, J BIOL CHEM, V272, P16062, DOI 10.1074/jbc.272.25.16062; IMAMURA T, 1995, INFECT IMMUN, V63, P1999, DOI 10.1128/IAI.63.5.1999-2003.1995; JIN KC, 1989, J ENDODONT, V15, P463, DOI 10.1016/S0099-2399(89)80025-1; KABASHIMA T, 1995, ARCH BIOCHEM BIOPHYS, V320, P123, DOI 10.1006/abbi.1995.1349; KIYAMA M, 1998, BIOCHIM BIOPHYS ACTA, V1369, P39; MADDEN TE, 1995, INFECT IMMUN, V63, P238, DOI 10.1128/IAI.63.1.238-247.1995; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; PIKE R, 1994, J BIOL CHEM, V269, P406; Potempa Jan, 1995, Perspectives in Drug Discovery and Design, V2, P445, DOI 10.1007/BF02172037; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLOTS J, 1986, J CLIN PERIODONTOL, V13, P570, DOI 10.1111/j.1600-051X.1986.tb00849.x; SOCRANSKY SS, 1992, J PERIODONTOL, V63, P322, DOI 10.1902/jop.1992.63.4s.322; Stenfors C, 1997, J BIOL CHEM, V272, P5747, DOI 10.1074/jbc.272.9.5747; Travis J, 1997, J PERIODONTAL RES, V32, P120, DOI 10.1111/j.1600-0765.1997.tb01392.x; WALTER R, 1980, MOL CELL BIOCHEM, V30, P111; WINGROVE JA, 1992, J BIOL CHEM, V267, P18902; YARON A, 1993, CRIT REV BIOCHEM MOL, V28, P31, DOI 10.3109/10409239309082572	34	78	81	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9246	9252		10.1074/jbc.274.14.9246	http://dx.doi.org/10.1074/jbc.274.14.9246			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092598	hybrid			2022-12-25	WOS:000079451800017
J	Gheber, L; Kuo, SC; Hoyt, MA				Gheber, L; Kuo, SC; Hoyt, MA			Motile properties of the kinesin-related Cin8p spindle motor extracted from Saccharomyces cerevisiae cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST PYRUVATE-CARBOXYLASE; MICROTUBULE-BASED MOTILITY; MITOTIC SPINDLE; CHROMOSOME SEGREGATION; PROTEIN KLP61F; FISSION YEAST; DROSOPHILA; GENE; MOVEMENT; DYNEIN	We have developed microtubule binding and motility assays for Cin8p, a kinesin-related mit-otic spindle motor protein from Saccharomyces cerevisiae. The methods examine Cin8p rapidly purified from crude yeast cell extracts. We created a recombinant form of CIN8 that fused the biotin carrying polypeptide from yeast pyruvate carboxylase to the carboxyl terminus of Cin8p, This form was biotinated in yeast cells and provided Cin8p activity in vivo, Avidin-coated glass surfaces were used to specifically bind biotinated Cin8p from crude extracts, Microtubules bound to the Cin8p-coated surfaces and moved at 3.4 +/- 0.5 mu m/min in the presence of ATP. Force production by Cin8p was directed toward the plus ends of microtubules. A mutation affecting the microtubule-binding site within the motor domain (cin8-F467A) decreased Cin8p's ability to bind microtubules to the glass surface by > 10-fold, but reduced gliding velocity by only 35%. The cin8-3 mutant form, affecting the alpha 2 helix of the motor domain, caused a moderate defect in microtubule binding, but motility was severely affected, cin8-F467A cells, but not cin8-3 cells, were greatly impaired in bipolar spindle forming ability, We conclude that microtubule binding by Cin8p is more important than motility for proper spindle formation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Hoyt, MA (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,3400 N Charles St, Baltimore, MD 21218 USA.	hoyt@jhu.edu			NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON NR, 1995, MOL BIOL CELL, V6, P1563, DOI 10.1091/mbc.6.11.1563; Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; BELL CW, 1982, METHOD CELL BIOL, V24, P373; BERLINER E, 1994, J BIOL CHEM, V269, P8610; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; COHN SA, 1989, J BIOL CHEM, V264, P4290; COLE DG, 1994, J BIOL CHEM, V269, P22913; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HIBBERD MG, 1984, CURR TOP CELL REGUL, V24, P357; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUO SC, 1991, J CELL SCI, P135; LEGUELLEC R, 1991, MOL CELL BIOL, V11, P3395, DOI 10.1128/MCB.11.6.3395; LIM F, 1988, J BIOL CHEM, V263, P11493; LIM F, 1987, ARCH BIOCHEM BIOPHYS, V258, P259, DOI 10.1016/0003-9861(87)90343-2; Nicolas G, 1997, BIOTECHNIQUES, V22, P430, DOI 10.2144/97223bm11; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SAMBROOKI J, 1989, MOL CLONING LAB MANU; Saunders W, 1997, MOL BIOL CELL, V8, P1025, DOI 10.1091/mbc.8.6.1025; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SAWIN KE, 1995, P NATL ACAD SCI USA, V92, P4289, DOI 10.1073/pnas.92.10.4289; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SHERMAN F, 1983, METHODS YEAST GENETI, P61; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P1575, DOI 10.1021/bi00005a013; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; WALKER ME, 1991, BIOCHEM BIOPH RES CO, V176, P1210, DOI 10.1016/0006-291X(91)90414-3; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	47	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9564	9572		10.1074/jbc.274.14.9564	http://dx.doi.org/10.1074/jbc.274.14.9564			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092642	hybrid			2022-12-25	WOS:000079451800061
J	Zou, YZ; Komuro, I; Yamazaki, T; Kudoh, S; Uozumi, H; Kadowaki, T; Yazaki, Y				Zou, YZ; Komuro, I; Yamazaki, T; Kudoh, S; Uozumi, H; Kadowaki, T; Yazaki, Y			Both G(s) and G(i) proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; INDUCED CARDIAC-HYPERTROPHY; BETA-ADRENERGIC-RECEPTOR; ACTIVATES MAP KINASE; TYROSINE KINASE; PERTUSSIS-TOXIN; GROWTH-FACTOR; SRC FAMILY; CYCLIC-AMP; DEPENDENT ACTIVATION	Activation of beta-adrenoreceptors induces cardiomyocyte hypertrophy. In the present study, we examined isoproterenol-evoked intracellular signal transduction pathways leading to activation of extracellular signal-regulated kinases (ERKs) and cardiomyocyte hypertrophy. Inhibitors for cAMP and protein kinase A (PKA) abolished isoproterenol-evoked ERK activation, suggesting that G(s) protein is involved in the activation. Inhibition of G(i) protein by pertussis toxin, however, also suppressed isoproterenol-induced ERK activation. Overexpression of the G(beta gamma) subunit binding domain of the beta-adrenoreceptor kinase 1 and of COOH-terminal Src kinase, which inhibit functions of G(beta gamma) and the Src family tyrosine kinases, respectively, also inhibited isoproterenol-induced ERR activation. Overexpression of dominant-negative mutants of Ras and Raf-1 kinase and of the beta-adrenoreceptor mutant that lacks phosphorylation sites by PICA abolished isoproterenol-stimulated ERK activation. The isoproterenol-induced increase in protein synthesis was also suppressed by inhibitors for PRA, G(i), tyrosine kinases, or Ras. These results suggest that isoproterenol induces ERR activation and cardiomyocyte hypertrophy through two different G proteins, G(s) and G(i). cAMP-dependent PKA activation through G(s), may phosphorylate the beta-adrenoreceptor, leading to coupling of the receptor from G(s) to G(i). Activation of G(i) activates ERKs through G(beta gamma), Src family tyrosine kinases, Ras, and Raf-1 kinase.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Hlth Serv Ctr, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Komuro, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.							ABRAMSON SN, 1988, BIOCHEM PHARMACOL, V37, P4289, DOI 10.1016/0006-2952(88)90609-0; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BRAND T, 1993, J MOL CELL CARDIOL, V25, P1325, DOI 10.1006/jmcc.1993.1145; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; ECKEL J, 1985, AM J PHYSIOL, V249, pH212, DOI 10.1152/ajpheart.1985.249.2.H212; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; GRAHAM RM, 1990, CLEV CLIN J MED, V57, P481; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HAUSDORFF WP, 1989, CELL SIGNAL, V1, P377, DOI 10.1016/0898-6568(89)90056-9; HEIDEMANN SR, 1985, J CELL BIOL, V100, P916, DOI 10.1083/jcb.100.3.916; HORDIJIK PL, 1994, J BIOL CHEM, V269, P35334; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Jones LG, 1996, LIFE SCI, V58, P617, DOI 10.1016/0024-3205(95)02323-2; KARLINER JS, 1990, EXPERIENTIA, V46, P81, DOI 10.1007/BF01955423; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KINUGAWA KI, 1995, CARDIOVASC RES, V30, P419, DOI 10.1016/S0008-6363(95)00063-1; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAKS MM, 1973, CHEST, V64, P75, DOI 10.1378/chest.64.1.75; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; LONNQVIST F, 1989, BIOCHEM BIOPH RES CO, V161, P654, DOI 10.1016/0006-291X(89)92649-1; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCKEE EE, 1978, J BIOL CHEM, V253, P1030; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OKADA M, 1991, J BIOL CHEM, V266, P24249; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHORB W, 1994, J BIOL CHEM, V269, P19626; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIRI FM, 1988, AM J PHYSIOL, V255, pH452, DOI 10.1152/ajpheart.1988.255.3.H452; SLOTKIN TA, 1995, TOXICOL APPL PHARM, V133, P188, DOI 10.1006/taap.1995.1141; STRULOVICI B, 1984, SCIENCE, V225, P837, DOI 10.1126/science.6089331; TERZIC A, 1993, PHARMACOL REV, V45, P147; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; VAN BT, 1995, NATURE, V376, P781; VAN CE, 1989, CELL, V59, P45; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WIESNER RJ, 1991, AM J PHYSIOL, V260, pL179, DOI 10.1152/ajplung.1991.260.4.L179; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamazaki T, 1997, CIRCULATION, V95, P1260; YAO H, 1995, J BIOL CHEM, V270, P20748, DOI 10.1074/jbc.270.35.20748; ZIERHUT W, 1989, CIRC RES, V65, P1417, DOI 10.1161/01.RES.65.5.1417; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	63	131	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9760	9770		10.1074/jbc.274.14.9760	http://dx.doi.org/10.1074/jbc.274.14.9760			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092665	hybrid			2022-12-25	WOS:000079451800084
J	Assefa, Z; Vantieghem, A; Declercq, W; Vandenabeele, P; Vandenheede, JR; Merlevede, W; de Witte, P; Agostinis, P				Assefa, Z; Vantieghem, A; Declercq, W; Vandenabeele, P; Vandenheede, JR; Merlevede, W; de Witte, P; Agostinis, P			The activation of the c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; TRANSDUCTION PATHWAY; CYTOCHROME-C; MAP KINASE; NH2-TERMINAL KINASE; EPITHELIAL-CELLS; JNK ACTIVATION; GROWTH-FACTOR; STRESS; DEATH	In this study, we elucidate signaling pathways induced by photodynamic therapy (PDT) with hypericin. We show that PDT rapidly activates JNK1 while irreversibly inhibiting ERK2 in several cancer cell lines. In HeLa cells, sustained PDT-induced JNK1 and p38 mitogen-activated protein kinase (MAPK) activations overlap the activation of a DEVD-directed caspase activity, poly(ADP-ribose) polymerase (PARP) cleavage, and the onset of apoptosis, The caspase inhibitors benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) and benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone (zDEVD-fmk) protect cells against apoptosis and inhibit DEVD-specific caspase activity and PARP cleavage without affecting JNK1 and p38 MAPK activations, Conversely, stable overexpression of CrmA, the serpin-like inhibitor of caspase-1 and caspase-8, has no effect on PDT-induced PARP cleavage, apoptosis, or JNK1/p38 activations. Cell transfection with the dominant negative inhibitors of the c-Jun N-terminal kinase (JNK) pathway, SEK-AL and TAM-67, or pretreatment with the p38 MAPK inhibitor PD169316 enhances PDT-induced apoptosis, A similar increase in PDT-induced apoptosis was observed by expression of the dual specificity phosphatase MKP-1, The simultaneous inhibition of both stress kinases by pretreating cells with PD169316 after transfection with either TAM-67 or SEK-AL produces a more pronounced sensitizing effect. Cell pretreatment with the p38 inhibitor PD169316 causes faster kinetics of DEVD-caspase activation and PARP cleavage and strongly oversensitizes the cells to apoptosis following PDT, These observations indicate that the JNK1 and p38 MAPK pathways play an important role in cellular resistance against PDT-induced apoptosis with hypericin.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Pharm, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; State Univ Ghent VIB, Dept Mol Biol, B-9000 Ghent, Belgium	KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University	Agostinis, P (corresponding author), Katholieke Univ Leuven, Fac Med, Div Biochem, Herestr 49, B-3000 Louvain, Belgium.	Patricia.Agostinis@med.huleuven.ac.be	Assefa, Zerihun/V-5641-2017; Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Assefa, Zerihun/0000-0001-7803-5228; Agostinis, Patrizia/0000-0003-1314-2115; Vandenabeele, Peter/0000-0002-6669-8822; de Witte, Peter/0000-0002-9989-9567				AGOSTINIS P, 1995, BIOCHEM PHARMACOL, V49, P1615, DOI 10.1016/0006-2952(95)00097-J; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Alecu M, 1998, ANTICANCER RES, V18, P4651; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DBAIDO GS, 1997, J EXP MED, V3, P481; DOUGHERTY TJ, 1992, EUR J CANCER, V28A, P1734, DOI 10.1016/0959-8049(92)90080-L; Fox FE, 1998, J INVEST DERMATOL, V111, P327, DOI 10.1046/j.1523-1747.1998.00278.x; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harris MS, 1996, CURR EYE RES, V15, P255, DOI 10.3109/02713689609007619; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; JOU P, 1997, MOL CELL BIOL, V17, P24; KAFMANN SH, 1993, CANCER RES, V53, P3976; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kick G, 1996, BRIT J CANCER, V74, P30, DOI 10.1038/bjc.1996.311; Klotz LO, 1998, CANCER RES, V58, P4297; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARIAS R, 1993, CELL, V73, P381; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; VANDENBOGAERDE AL, 1996, ANTICANCER RES, V16, P1611; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Weller M, 1997, NEUROL RES, V19, P459; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; ZHANG W, 1995, CANCER LETT, V96, P31, DOI 10.1016/0304-3835(95)03914-I; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	58	187	200	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8788	8796		10.1074/jbc.274.13.8788	http://dx.doi.org/10.1074/jbc.274.13.8788			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085120	hybrid			2022-12-25	WOS:000079451600062
J	Nosek, J; Tomaska, L; Pagacova, B; Fukuhara, H				Nosek, J; Tomaska, L; Pagacova, B; Fukuhara, H			Mitochondrial telomere-binding protein from Candida parapsilosis suggests an evolutionary adaptation of a nonspecific single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SSB; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; YEAST; REPLICATION; PHOSPHORYLATION; RESOLUTION; KINASE; GENES	The mitochondrial genome in a number of organisms is represented by linear DNA molecules with defined terminal structures. The telomeres of linear mitochondrial DNA (mtDNA) of yeast Candida parapsilosis consist of tandem arrays of large repetitive units possessing single-stranded 5' extension of about 110 nucleotides. Recently we identified the first mitochondrial telomere-binding protein (mtTBP) that specifically binds a sequence derived from the extreme end of C, parapsilosis linear mtDNA and protects it from attack, by various DNA-modifying enzymes (Tomaska, L',, Nosek, J,, and Fukuhara, H, (1997) J, Biol, Chem, 272, 3049-3059). Here we report the isolation of MTP1, the gene encoding mtTBP of C. parapsilosis, Sequence analysis revealed that mtTBP shares homology with several bacterial and mitochondrial single-stranded DNA-binding proteins that nonspecifically bind to single-stranded DNA with high affinity, Recombinant mtTBP displays a preference for the telomeric 5' overhang of C, parapsilosis mtDNA. The heterologous expression of a mtTBP-GFP fusion protein resulted in its localization to the mitochondria but was unable to functionally substitute for the loss of the S. cerevisiae homologue Rimlp, Analysis of the MTP1 gene and its translation product mtTBP may provide an insight into the evolutionary origin of linear mitochondrial genomes and the role it plays in their replication and maintenance.	Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; Comenius Univ, Fac Nat Sci, Dept Genet, Bratislava 84215, Slovakia; Ctr Univ Paris 11, Inst Curie, Sect Rech, F-91405 Orsay, France	Comenius University Bratislava; Comenius University Bratislava; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Nosek, J (corresponding author), Comenius Univ, Fac Nat Sci, Dept Biochem, Mlynska Dolina CH-1, Bratislava 84215, Slovakia.	nosek@fns.uniba.sk	Nosek, Jozef/A-7581-2008; Tomaska, Lubomir/I-3071-2014	Nosek, Jozef/0000-0002-1020-5451; Tomaska, Lubomir/0000-0003-4886-1910; Kucejova, Blanka/0000-0002-5058-330X				APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CURTH U, 1991, EUR J BIOCHEM, V196, P87, DOI 10.1111/j.1432-1033.1991.tb15789.x; CURTH U, 1994, EUR J BIOCHEM, V221, P435, DOI 10.1111/j.1432-1033.1994.tb18756.x; DINOUEL N, 1993, MOL CELL BIOL, V13, P2315, DOI 10.1128/MCB.13.4.2315; Edgell DR, 1997, CELL, V89, P995, DOI 10.1016/S0092-8674(00)80285-8; FANG G, 1995, TELOMERES, P69; FUKUHARA H, 1993, MOL CELL BIOL, V13, P2309, DOI 10.1128/MCB.13.4.2309; GARRITY PA, 1995, PCR 2 PRACTICAL APPR, P309; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; NOSEK J, 1995, MOL GEN GENET, V247, P61, DOI 10.1007/BF00425822; Nosek J, 1998, TRENDS GENET, V14, P184, DOI 10.1016/S0168-9525(98)01443-7; NOSEK J, 1994, J BACTERIOL, V176, P5622, DOI 10.1128/JB.176.18.5622-5630.1994; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Suck D, 1997, NAT STRUCT BIOL, V4, P161, DOI 10.1038/nsb0397-161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIRANTI V, 1993, GENE, V126, P219, DOI 10.1016/0378-1119(93)90370-I; Tomaska L, 1997, J BIOL CHEM, V272, P3049, DOI 10.1074/jbc.272.5.3049; Tomaska L, 1998, BIOCHEM BIOPH RES CO, V242, P457, DOI 10.1006/bbrc.1997.7968; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; Webster G, 1997, FEBS LETT, V411, P313, DOI 10.1016/S0014-5793(97)00747-3; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153	35	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8850	8857		10.1074/jbc.274.13.8850	http://dx.doi.org/10.1074/jbc.274.13.8850			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085128	hybrid			2022-12-25	WOS:000079451600070
J	Pan, QT; Simpson, RU				Pan, QT; Simpson, RU			c-myc intron element-binding proteins are required for 1,25-dihydroxyvitamin D-3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMYELOCYTIC LEUKEMIA-CELLS; KINASE-C; TELOMERASE ACTIVITY; HOMEOBOX GENE; HOMEODOMAIN PROTEINS; TRANSCRIPTIONAL REGULATION; TERMINAL DIFFERENTIATION; TRANSGENIC MICE; IMMORTAL CELLS; MESSENGER-RNA	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) suppresses c-myc expression during differentiation of HL-60 cells along the monocytic pathway by blocking transcriptional elongation at the first exon/intron border of the c-myc gene. In the present study, the physiological relevance of three putative regulatory protein binding sites found within a 280-base pair region in intron 1 of the c-myc gene was explored. HL-60 promyelocytic leukemia cells were transiently transfected with three different c-mye promoter constructs cloned upstream of a chloramphenicol acetyltransferase (CAT) reporter gene. With the wild-type c-myc promoter construct (pMPCAT), which contains MIE1, MIE2, and MIE3 binding sites, 1,25-(OH)(2)D-3 was able to decrease CAT activity by 45.4 +/- 7.9% (mean +/- S.E,, n = 8). The ability of 1,25-(OH)(2)D-3 to inhibit CAT activity was significantly decreased to 18.5 +/- 4.3% (59.3% reversal, p < 0.02) when examined with a MIE1 deletion construct (pMPCAT-MIE1). Moreover, 1,25-(OH)(2)D-3 was completely ineffective at suppressing CAT activity in cells transfected with pMPCAT-287, a construct without MIE1, MIE2, and MIE3 binding sites (-6.5 +/- 10.9%, p < 0.002), MIE1- and MIE2-binding proteins induced by 1,25-(OH)(2)D-3 had similar gel shift mobilities, while MIE3-binding proteins migrated differently. Furthermore, chelerythrine chloride, a selective protein kinase C (PKC) inhibitor, and a PKC beta antisense oligonucleotide completely blocked the binding of nuclear proteins induced by 1,25-(OH)(2)D-3 to MIE1, MIE2, and MIE3, A 1,25-(OH)(2)D-3-inducible MIE1-binding protein was identified to be HOXB4. HOXB4 levels were significantly increased in response to 1,25-(OH)(2)D-3. Taken together, these results indicate that HOXB4 is one of the nuclear phosphoproteins involved in c-mye transcription elongation block during HL-60 cell differentiation by 1,25-(OH)(2)D-3.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Simpson, RU (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.	robsim@umich.edu	Pan, Quintin/E-3808-2011		NCI NIH HHS [CA69568] Funding Source: Medline; NIDCR NIH HHS [DE10337] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010337] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCIONI L, 1992, EMBO J, V11, P265, DOI 10.1002/j.1460-2075.1992.tb05049.x; BENDAVID L, 1991, VIROLOGY, V182, P382, DOI 10.1016/0042-6822(91)90686-6; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLATT C, 1992, CELL GROWTH DIFFER, V3, P671; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CELETTI A, 1993, INT J CANCER, V53, P237, DOI 10.1002/ijc.2910530211; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORSETTI MT, 1992, NUCLEIC ACIDS RES, V20, P4465, DOI 10.1093/nar/20.17.4465; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; Fujimoto K, 1997, BIOCHEM BIOPH RES CO, V241, P775, DOI 10.1006/bbrc.1997.7806; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONGSUWAN K, 1988, EMBO J, V7, P2131, DOI 10.1002/j.1460-2075.1988.tb03052.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LILL MC, 1995, BLOOD, V85, P692, DOI 10.1182/blood.V85.3.692.bloodjournal853692; MACFARLANE DE, 1994, J BIOL CHEM, V269, P4327; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTELL RE, 1988, BIOCHEM PHARMACOL, V37, P635, DOI 10.1016/0006-2952(88)90136-0; OBEID LM, 1990, J BIOL CHEM, V265, P2370; Pan Q, 1997, BIOCHEM PHARMACOL, V54, P909, DOI 10.1016/S0006-2952(97)00286-4; Pan Q, 1996, ENDOCRINOLOGY, V137, P4154, DOI 10.1210/en.137.10.4154; PATTENGALE P, 1986, CURR TOP MICROBIOL, V132, P9; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SATO Y, 1987, BLOOD, V70, P1654; Savoysky E, 1996, BIOCHEM BIOPH RES CO, V226, P329, DOI 10.1006/bbrc.1996.1356; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Sharma HW, 1995, P NATL ACAD SCI USA, V92, P12343, DOI 10.1073/pnas.92.26.12343; SHEN WF, 1989, P NATL ACAD SCI USA, V86, P8536, DOI 10.1073/pnas.86.21.8536; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Simpson RU, 1998, J BIOL CHEM, V273, P19587, DOI 10.1074/jbc.273.31.19587; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SIMPSON RU, 1986, BIOESSAYS, V4, P65, DOI 10.1002/bies.950040206; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; VALLERGA A, 1991, P AM SOC HEMATOL, V78, pA254; YOKOYAMA K, 1987, P NATL ACAD SCI USA, V84, P7363, DOI 10.1073/pnas.84.21.7363; YU BW, 1993, J BIOL CHEM, V268, P19586; ZAJAC-KAYE M, 1990, J BIOL CHEM, V265, P4547; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZAPPAVIGNA V, 1991, EMBO J, V10, P4177, DOI 10.1002/j.1460-2075.1991.tb04996.x	48	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8437	8444		10.1074/jbc.274.13.8437	http://dx.doi.org/10.1074/jbc.274.13.8437			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085075	hybrid			2022-12-25	WOS:000079451600017
J	Rodriguez, MS; Thompson, J; Hay, RT; Dargemont, C				Rodriguez, MS; Thompson, J; Hay, RT; Dargemont, C			Nuclear retention of I kappa B alpha protects it from signal-induced degradation and inhibits nuclear factor kappa B transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; EXPORT PATHWAY; P50 PRECURSOR; REV PROTEIN; CELL-CYCLE; PHOSPHORYLATION; UBIQUITINATION; KINASE; FAMILY; CRM1	Transcriptional activation of nuclear factor kappa B (NF-kappa B) is mediated by signal-induced phosphorylation and degradation of its inhibitor, I kappa B alpha. However, NF-kappa B activation induces rapid resynthesis of I kappa B alpha, which is responsible for post-induction repression of transcription. Newly synthesized I kappa B alpha translocates to the nucleus, where it dissociates NF-kappa B from DNA and transports NF-kappa B from the nucleus to the cytoplasm in a nuclear export sequence-dependent process that is sensitive to leptomycin B (LMB), In the present study, LMB was used as a tool to inhibit nuclear export sequence-mediated nuclear protein export and evaluate the consequences for regulation of NF-kappa B-dependent transcriptional activity. Pretreatment of cells with LMB inhibits NF-kappa B-dependent transcriptional activation mediated by interleukin 1 beta or tumor necrosis factor alpha. This is a consequence of the inhibition of signal-induced degradation of I kappa B alpha. Although LMB treatment does not affect the signal transduction pathway leading to I kappa B alpha degradation, it blocks I kappa B alpha nuclear export. I kappa B alpha is thus accumulated in the nucleus, and in this compartment it is resistant to signal-induced degradation. These results indicate that the signal-induced degradation of I kappa B alpha is mainly, if not exclusively, a cytoplasmic process. An efficient nuclear export of I kappa B alpha is therefore essential for maintaining a low level of I kappa B alpha in the nucleus and allowing NF-kappa B to be transcriptionally active upon cell stimulation.	Univ St Andrews, Sch Biomed Sci, Inst Biomol Sci, St Andrews KY16 9TS, Fife, Scotland; Inst Curie, CNRS, Unite Mixte Rech 144, F-75248 Paris 05, France	University of St Andrews; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Sorbonne Universite	Hay, RT (corresponding author), Univ St Andrews, Sch Biomed Sci, Inst Biomol Sci, N Haugh, St Andrews KY16 9TS, Fife, Scotland.	rth@st-and.ac.uk	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hodges M, 1998, CURR BIOL, V8, pR749, DOI 10.1016/S0960-9822(07)00477-0; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WOJCIK C, 1995, EUR J CELL BIOL, V68, P191; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	61	206	210	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9108	9115		10.1074/jbc.274.13.9108	http://dx.doi.org/10.1074/jbc.274.13.9108			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085161	hybrid			2022-12-25	WOS:000079451600103
J	Wood, DE; Newcomb, EW				Wood, DE; Newcomb, EW			Caspase-dependent activation of calpain during drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ICE/CED-3 PROTEASE; INHIBITORS; CLEAVAGE; BAX; PROTEOLYSIS; DEGRADATION; CYTOSOL; ROLES; P53	We have previously demonstrated that calpain is responsible for the cleavage of Bax, a proapoptotic protein, during drug-induced apoptosis of HL-60 cells (Wood, D, E,, Thomas, A., Devi, L, A, Berman, Y,, Beavis, R. C., Reed, J, C,, and Newcomb, E, W, (1998) Oncogene 17, 1069-1078). Here we show the sequential activation of caspases and calpain during drug-induced apoptosis of HL-60 cells. Time course experiments using the topoisomerase I inhibitor 9-amino-20(S)-camptothecin revealed that cleavage of caspase-3 substrates poly(ADP-ribose) polymerase (PARP) and the retinoblastoma protein as well as DNA fragmentation occurred several hours before calpain activation and Bax cleavage. Pretreatment with the calpain inhibitor calpeptin blocked calpain activation and Bax cleavage but did not inhibit PARP cleavage, DNA fragmentation, or 9-amino-20(S)camptothecin-induced morphological changes and cell death. Pretreatment with the pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk) inhibited PARP cleavage, DNA fragmentation, calpain activation, and Bax cleavage and increased cell survival by 40%. Interestingly, Z-VAD-fmk-treated cells died in a caspase- and calpain-independent manner that appeared morphologically distinct from apoptosis. Our results suggest that excessive or uncontrolled calpain activity may play a role downstream of and distinct from caspases in the degradation phase of apoptosis.	NYU, Dept Pathol, Ctr Med, New York, NY 10016 USA	New York University	Newcomb, EW (corresponding author), NYU, Dept Pathol, Ctr Med, 550 1St Ave,MSB 531, New York, NY 10016 USA.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chen SJ, 1998, MOL CELL BIOCHEM, V178, P141, DOI 10.1023/A:1006893528428; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Grynspan F, 1997, BRAIN RES, V763, P145, DOI 10.1016/S0006-8993(97)00384-3; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kimura Y, 1998, NAT MED, V4, P915, DOI 10.1038/nm0898-915; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; MCGAHON AJ, 1995, METHODS CELL BIOL CE, V46, P174; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Meredith J, 1998, J BIOL CHEM, V273, P19525, DOI 10.1074/jbc.273.31.19525; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Musleh W, 1997, P NATL ACAD SCI USA, V94, P9451, DOI 10.1073/pnas.94.17.9451; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1997, J IMMUNOL, V158, P3690; Thomas A, 1996, ONCOGENE, V12, P1055; Tsuji T, 1998, NEUROSCI LETT, V248, P109, DOI 10.1016/S0304-3940(98)00348-6; Ueyama H, 1998, J NEUROL SCI, V155, P163, DOI 10.1016/S0022-510X(97)00309-2; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847	49	167	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8309	8315		10.1074/jbc.274.12.8309	http://dx.doi.org/10.1074/jbc.274.12.8309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075737	hybrid			2022-12-25	WOS:000079268100096
J	Bahassi, EM; O'Dea, MH; Allali, N; Messens, J; Gellert, M; Couturier, M				Bahassi, EM; O'Dea, MH; Allali, N; Messens, J; Gellert, M; Couturier, M			Interactions of CcdB with DNA gyrase - Inactivation of GyrA, poisoning of the gyrase-DNA complex, and the antidote action of CcdA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNA; SEX FACTOR-F; BREAKAGE-REUNION DOMAIN; LETD CCDB; KILLER PROTEIN; PLASMID PROTEINS; SUBUNIT-A; CLEAVAGE; TRANSCRIPTION; REPLICATION	The F plasmid-carried bacterial toxin, the CcdB protein, is known to act on DNA gyrase in two different ways. CcdB poisons the gyrase-DNA complex, blocking the passage of polymerases and leading to double-strand breakage of the DNA. Alternatively, in cells that overexpress CcdB, the A subunit of DNA gyrase (GyrA) has been found as an inactive complex with CcdB, We have reconstituted the inactive GyrA-CcdB complex by denaturation and renaturation of the purified GyrA dimer in the presence of CcdB, This inactivating interaction involves the N-terminal domain of GyrA, because similar inactive complexes were formed by denaturing and renaturing N-terminal fragments of the GyrA protein in the presence of CcdB, Single amino acid mutations, both in GyrA and in CcdB, that prevent CcdB-induced DNA cleavage also prevent formation of the inactive complexes, indicating that some essential interaction sites of GyrA and of CcdB are common to both the poisoning and the inactivation processes. Whereas the lethal effect of CcdB is most probably due to poisoning of the gyrase-DNA complex, the inactivation pathway may prevent cell death through formation of a toxin antitoxin-like complex between CcdB and newly translated GyrA subunits, Both poisoning and inactivation can be prevented and reversed in the presence of the F plasmid-encoded antidote, the CcdA protein. The products of treating the inactive GyrA-CcdB complex with CcdA are free GyrA and a CcdB-CcdA complex of approximately 44 kDa, which may correspond to a (CcdB),(CcdA), heterotetramer.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Free Univ Brussels, Dept Biol Mol, Lab Genet Procaryotes, B-1640 Rhode St Genese, Belgium; Free Univ Brussels VIB, B-1640 Rhode St Genese, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Gellert, M (corresponding author), NIDDK, Mol Biol Lab, NIH, Bldg 5,Rm 241,5 Ctr Dr, Bethesda, MD 20892 USA.		Messens, Joris/AAH-3008-2020	Messens, Joris/0000-0002-2128-8264				BAHASSI EM, 1995, MOL MICROBIOL, V15, P1031, DOI 10.1111/j.1365-2958.1995.tb02278.x; BAILONE A, 1985, P NATL ACAD SCI USA, V82, P5973, DOI 10.1073/pnas.82.17.5973; BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; BERNARD P, 1991, MOL GEN GENET, V226, P297, DOI 10.1007/BF00273616; BEX F, 1983, EMBO J, V2, P1853, DOI 10.1002/j.1460-2075.1983.tb01671.x; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; CLERGET M, 1991, NEW BIOL, V3, P780; Critchlow SE, 1997, J MOL BIOL, V273, P826, DOI 10.1006/jmbi.1997.1357; DRLICA K, 1978, J MOL BIOL, V120, P145, DOI 10.1016/0022-2836(78)90061-X; Drlica K, 1994, Adv Pharmacol, V29A, P263; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; HANE MW, 1969, J BACTERIOL, V99, P238, DOI 10.1128/JB.99.1.238-241.1969; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; HOROWITZ DS, 1987, J BIOL CHEM, V262, P5339; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; Kaneko T, 1996, MOL GEN GENET, V250, P593; KAROUI H, 1983, EMBO J, V2, P1863, DOI 10.1002/j.1460-2075.1983.tb01672.x; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Maki S, 1996, J MOL BIOL, V256, P473, DOI 10.1006/jmbi.1996.0102; MAKI S, 1992, J BIOL CHEM, V267, P12244; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MENZEL R, 1983, CELL, V34, P105, DOI 10.1016/0092-8674(83)90140-X; Menzel R, 1994, Adv Pharmacol, V29A, P39; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIKI T, 1984, J MOL BIOL, V174, P605, DOI 10.1016/0022-2836(84)90086-X; MIZUUCHI K, 1984, J BIOL CHEM, V259, P9199; Murayama N, 1996, J MOL BIOL, V256, P483, DOI 10.1006/jmbi.1996.0103; PATO ML, 1990, P NATL ACAD SCI USA, V87, P8716, DOI 10.1073/pnas.87.22.8716; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; SALMON MA, 1994, MOL GEN GENET, V244, P530, DOI 10.1007/BF00583904; Scheirer KE, 1997, J BIOL CHEM, V272, P27202, DOI 10.1074/jbc.272.43.27202; STEYAERT J, 1993, J MOL BIOL, V231, P513, DOI 10.1006/jmbi.1993.1301; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; TRAVERS AA, 1982, HEAT SHOCK BACTERIA, P127; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; Wigley D.B., 1995, NUCL ACIDS MOL BIOL, P165; WILLMOTT CJR, 1994, J MOL BIOL, V242, P351, DOI 10.1006/jmbi.1994.1586; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	49	80	83	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10936	10944		10.1074/jbc.274.16.10936	http://dx.doi.org/10.1074/jbc.274.16.10936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196173	hybrid			2022-12-25	WOS:000079751900041
J	Chang, TM; Chang, CH; Wagner, DR; Chey, WY				Chang, TM; Chang, CH; Wagner, DR; Chey, WY			Porcine pancreatic phospholipase A(2) stimulates secretin release from secretin-producing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEEDBACK-REGULATION; BINDING-SITE; CHOLECYSTOKININ; EXPRESSION; PEPTIDE; JUICE; PURIFICATION; MECHANISM; RECEPTOR; RATS	We have isolated, from canine pancreatic juice, two 14-kDa proteins with secretin-releasing activity that had N-terminal sequence homology with canine pancreatic phospholipase A(2) (PLA(2)). In this study we have obtained evidence that secretin-releasing activity is an intrinsic property of pancreatic PLA(2). Porcine pancreatic PLA(2) from Sigma or Boehringer Mannheim was fractionated into several peaks by reverse phase high performance liquid chromatography, They were tested for stimulation of secretin release from murine neuroendocrine intestinal tumor cell line STC-1 and secretin cells enriched mucosal cell preparations isolated from rat upper small intestine. Each enzyme preparation was found to contain several components of secretin-releasing activity, Each bioactive fraction was purified to homogeneity by rechromatography and then subjected to mass spectral analysis and assays of PLA(2) and secretin-releasing activities. It was found that the fraction with highest enzymatic activity also had the highest secretin-releasing activity and the same M-r as porcine pancreatic PLA(2). Moreover, it also had the same N-terminal amino acid sequence (up to 30 residues determined) as that of porcine pancreatic PLA(2), suggesting that it was identical to the enzyme. Purified porcine pancreatic PLA(2) also stimulated secretin release concentration-dependently from both STC-1 cells and a mucosal cell preparation enriched in secretin-containing endocrine cells isolated from rat duodenum. Abolishment of the enzymatic activity by pretreatment with bromophenacyl bromide did not affect its secretin-releasing activity. The stimulatory effect of purified pancreatic PLA(2) on secretin secretion from STC-1 cells was inhibited by an L-type Ca2+ channel blocker, by down-regulation of protein kinase C or by pretreatment of the cell with pertussis toxin, It is concluded that porcine pancreatic PLA(2) possesses an intrinsic secretin-releasing activity that was independent of its enzymatic activity. This action is pertussis toxin-sensitive and is in part dependent on Ca2+ influx through the L-type channel and activation of protein kinase C.	Univ Rochester, Sch Med & Dent, Konar Ctr Digest & Liver Dis, Dept Med, Rochester, NY 14642 USA	University of Rochester	Chang, TM (corresponding author), Univ Rochester, Med Ctr, Konar Ctr Digest & Liver Dis, POB 646,601 Elmwood Ave, Rochester, NY 14642 USA.				NIDDK NIH HHS [DDK25962] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025962] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Chang CH, 1996, AM J PHYSIOL-GASTR L, V271, pG516, DOI 10.1152/ajpgi.1996.271.3.G516; CHANG CH, 1994, BBA-MOL CELL RES, V1221, P339, DOI 10.1016/0167-4889(94)90259-3; CHANG CH, 1998, AM J PHYSIOL, V275, pG190; CHANG TM, 1980, DIGEST DIS SCI, V25, P529, DOI 10.1007/BF01315215; CHANG TM, 1996, REGUL PEP, V64, P22; DEGEUS P, 1987, NUCLEIC ACIDS RES, V15, P3743, DOI 10.1093/nar/15.9.3743; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; HANADA K, 1995, FEBS LETT, V373, P85, DOI 10.1016/0014-5793(95)01005-Y; Herzig KH, 1996, P NATL ACAD SCI USA, V93, P7927, DOI 10.1073/pnas.93.15.7927; ISHIZAKI J, 1993, FEBS LETT, V324, P349, DOI 10.1016/0014-5793(93)80149-O; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; IWAI K, 1987, J BIOL CHEM, V262, P8956; KANEMASA T, 1992, FEBS LETT, V303, P217, DOI 10.1016/0014-5793(92)80523-J; KISHINO J, 1994, J BIOL CHEM, V269, P5092; KISHINO J, 1992, BIOCHEM BIOPH RES CO, V186, P1025, DOI 10.1016/0006-291X(92)90849-G; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LI P, 1990, J CLIN INVEST, V86, P1474, DOI 10.1172/JCI114864; LI P, 1994, DIGEST DIS SCI, V39, P1806; LI P, 1998, PANCREAS, V17, P445; LU L, 1989, AM J PHYSIOL, V256, pG430, DOI 10.1152/ajpgi.1989.256.2.G430; MATSUDA Y, 1987, RES COMMUN CHEM PATH, V58, P281; MIYASAKA K, 1989, AM J PHYSIOL, V257, pG175, DOI 10.1152/ajpgi.1989.257.2.G175; MURAKAMI M, 1994, ANN NY ACAD SCI, V744, P84, DOI 10.1111/j.1749-6632.1994.tb52726.x; NOMURA K, 1994, ENDOCRINOLOGY, V135, P603, DOI 10.1210/en.135.2.603; REYNOLDS LJ, 1994, ANAL BIOCHEM, V217, P25, DOI 10.1006/abio.1994.1079; RINDI G, 1990, AM J PATHOL, V136, P1349; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SHIRATORI K, 1986, GASTROENTEROLOGY, V91, P1171, DOI 10.1016/S0016-5085(86)80013-0; Song Y, 1997, GASTROENTEROLOGY, V112, pA483; Soubeyrand S, 1997, J BIOL CHEM, V272, P222, DOI 10.1074/jbc.272.1.222; Spannagel AW, 1996, P NATL ACAD SCI USA, V93, P4415, DOI 10.1073/pnas.93.9.4415; SUN G, 1989, GASTROENTEROLOGY, V96, P1173, DOI 10.1016/0016-5085(89)91638-7; TOHKIN M, 1993, J BIOL CHEM, V268, P2865	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10758	10764		10.1074/jbc.274.16.10758	http://dx.doi.org/10.1074/jbc.274.16.10758			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196148	hybrid			2022-12-25	WOS:000079751900016
J	Olshevskaya, EV; Boikov, S; Ermilov, A; Krylov, D; Hurley, JB; Dizhoor, AM				Olshevskaya, EV; Boikov, S; Ermilov, A; Krylov, D; Hurley, JB; Dizhoor, AM			Mapping functional domains of the guanylate cyclase regulator protein, GCAP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONE DYSTROPHY; ACTIVATING PROTEIN; CALCIUM-BINDING; PHOTORECEPTOR; EXPRESSION; CLONING; MUTANT; RECOVERIN; VISION; RETGC	Guanylate cyclase regulator protein (GCAP)-2 is a Ca2+-binding protein that regulates photoreceptor outer segment membrane guanylate cyclase (RetGC) in a Ca2+-sensitive manner. GCAP-2 activates RetGC at free Ca2+ concentrations below 100 nM, characteristic of light-adapted photoreceptors, and inhibits RetGC when free Ca2+ concentrations are above the 500 nM level, characteristic of dark-adapted photoreceptors. We have mapped functional domains in GCAP-2 by using deletion mutants and chimeric proteins in which parts of GCAP-2 were substituted with corresponding fragments of other closely related recoverin-like proteins that do not regulate RetGC, We find that in addition to the EF-hand Ca2+-binding centers there are three regions that contain GCAP-2-specific sequences essential for regulation of RetGC. 1) The region between Phe(78) and Asp(113) determines whether GCAP-2 activates outer segment RetGC in low or high Ca2+ concentrations. Substitution of this domain with the corresponding region from neurocalcin causes a paradoxical behavior of the chimeric proteins, They activate RetGC only at high and not at low Ca2+ concentrations, 2) The amino acid sequence of GCAP-2 between Lys(29) and Phe(48) that includes the EF-hand-related motif EF-1 is essential both for activation of RetGC at low Ca2+ and inhibition at high Ca2+ concentrations. Most of the remaining N-terminal region can be substituted with recoverin or neurocalcin sequences without loss of GCAP-2 function. 3) Region Val(171)-Asn(189), adjacent to the C-terminal EF-4 contributes to activation of RetGC, but it is not essential for the ability of Ca2+-loaded GCAP-2 to inhibit RetGC, Other regions of the molecule can be substituted with the corresponding fragments from neurocalcin or recoverin, or even partially deleted without preventing GCAP-2 from regulating RetGC, Substitution of these three domains in GCAP-2 with corresponding neurocalcin sequences also affects activation of individual recombinant RetGC-1 and RetGC-2 expressed in HEK293 cells.	Wayne State Univ, Sch Med, Dept Ophthalmol, Kresge Eye Inst, Detroit, MI 48201 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, HHMI, Seattle, WA 98195 USA	Wayne State University; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Dizhoor, AM (corresponding author), Wayne State Univ, Sch Med, Dept Ophthalmol, Kresge Eye Inst, 4717 St Antoine, Detroit, MI 48201 USA.	adizhoor@med.wayne.edu		Dizhoor, Alexander/0000-0001-6770-9186	NATIONAL EYE INSTITUTE [R01EY011522] Funding Source: NIH RePORTER; NEI NIH HHS [EY06641, EY11522] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; Celio MR, 1996, GUIDEBOOK CALCIUM BI; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V36, P11995; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; Howes K, 1998, INVEST OPHTH VIS SCI, V39, P867; Kachi S, 1999, EXP EYE RES, V68, P465, DOI 10.1006/exer.1998.0629; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOCH KW, 1991, J BIOL CHEM, V266, P8634; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Krishnan A, 1998, MOL CELL BIOCHEM, V178, P251, DOI 10.1023/A:1006860018300; Krylov DM, 1999, J BIOL CHEM, V274, P10833, DOI 10.1074/jbc.274.16.10833; LADANT D, 1995, J BIOL CHEM, V270, P3179; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; Olshevskaya EV, 1997, J BIOL CHEM, V272, P14327, DOI 10.1074/jbc.272.22.14327; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; Pugh EN, 1997, BIOSCIENCE REP, V17, P429; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sampath AP, 1998, J GEN PHYSIOL, V111, P53, DOI 10.1085/jgp.111.1.53; SITARAMAYYA A, 1995, MOL CELL BIOCHEM, V148, P139, DOI 10.1007/BF00928151; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Surguchov A, 1997, GENOMICS, V39, P312, DOI 10.1006/geno.1996.4513; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	36	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10823	10832		10.1074/jbc.274.16.10823	http://dx.doi.org/10.1074/jbc.274.16.10823			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196158	hybrid			2022-12-25	WOS:000079751900026
J	Syed, V; Gomez, E; Hecht, NB				Syed, V; Gomez, E; Hecht, NB			mRNAs encoding a von Ebner's-like protein and the Huntington disease protein are induced in rat male germ cells by Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN MESSENGER-RNA; RETINOL-BINDING-PROTEIN; GENE-EXPRESSION; APOLIPOPROTEIN-D; GLAND PROTEIN; SULFATED GLYCOPROTEIN-1; SEMINIFEROUS EPITHELIUM; WIDESPREAD EXPRESSION; PARACRINE REGULATION; SPERMATOGENIC CELLS	The success of spermatogenesis is dependent upon closely coordinated interactions between Sertoli cells and germ cells. To identify specific molecules that mediate interactions between somatic cells and germ cells in the rat testis, Sertoli cell-germ cell co-cultures and mRNA differential display were used. Two cDNAs, clone 1 (660 nucleotides) and clone 2 (390 nucleotides) were up-regulated when Sertoli cells were co-cultured with pachytene spermatocytes or round spermatids, Northern blot analyses confirmed the differential display expression patterns. Sequence analyses indicated that clone 1 was similar to a von Ebner's gland protein (87% at the nucleotide level and 80% at the amino acid level) and clone 2 was identical to a region of the Huntington disease protein. The von Ebner's-like protein mRNA was induced after 4 h of co-culture, while the Huntington disease protein required 18 h of co-culture for expression. The von Ebner's-like protein was induced in germ cells by a secreted Sertoli cell factor(s) smaller than 10 kDa that is sensitive to freezing and thawing or boiling, The Huntington disease protein was induced in germ cells by a Sertoli cell secreted factor(s) larger than 10 kDa which survives freezing and thawing, but is inactivated by boiling.	Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA; Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Hecht, NB (corresponding author), Univ Penn, Ctr Res Reprod & Womens Hlth, 415 Curie Blvd,752B CRB 6142, Philadelphia, PA 19104 USA.				NICHD NIH HHS [T32HD07305, HD-11878] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011878, T32HD007305] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALCIVAR AA, 1989, DEV BIOL, V135, P263, DOI 10.1016/0012-1606(89)90178-4; Avallet O, 1997, BIOCHEM BIOPH RES CO, V238, P905, DOI 10.1006/bbrc.1997.7275; AYERLELIEVRE C, 1988, P NATL ACAD SCI USA, V85, P2628, DOI 10.1073/pnas.85.8.2628; BARDIN CW, 1988, PHYSL REPRODUCTION, V1, P933; BOYLES JK, 1990, J LIPID RES, V31, P2243; Braghiroli L, 1998, BIOL REPROD, V59, P111, DOI 10.1095/biolreprod59.1.111; CHENG CY, 1989, J BIOL CHEM, V264, P21386; Chung SSW, 1998, ENDOCRINOLOGY, V139, P1853, DOI 10.1210/en.139.4.1853; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; DRAYNA DT, 1987, DNA-J MOLEC CELL BIO, V6, P199, DOI 10.1089/dna.1987.6.199; Eddy EM, 1998, SEMIN CELL DEV BIOL, V9, P451, DOI 10.1006/scdb.1998.0201; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Flower DR, 1996, BIOCHEM J, V318, P1; FRIEDEN E, 1976, ADV ENZYMOL RAMB, V44, P187; FUJISAWA M, 1992, MOL CELL ENDOCRINOL, V84, P79, DOI 10.1016/0303-7207(92)90074-G; GALDIERI M, 1983, EXP CELL RES, V145, P191, DOI 10.1016/S0014-4827(83)80020-2; GALDIERI M, 1984, J ANDROL, V5, P409; GILMONT RR, 1990, BIOL REPROD, V43, P139, DOI 10.1095/biolreprod43.1.139; GODOVAC-ZIMMERMANN J, 1988, TRENDS BIOCHEM SCI, V13, P64, DOI 10.1016/0968-0004(88)90031-X; GRISMA J, 1998, J BIOL CHEM, V273, P21040; GRISMA J, 1997, J BIOL CHEM, V272, P6499; GRISWOLF MD, 1995, BIOL REPROD, V25, P211; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HALL K, 1986, INSULIN LIKE GROWTH, P611; Hoeben E, 1996, MOL CELL ENDOCRINOL, V118, P37, DOI 10.1016/0303-7207(96)03764-1; HOFFMAN A, 1996, DEV DYNAM, V27, P332; Holzfeind P, 1996, FEBS LETT, V395, P95, DOI 10.1016/0014-5793(96)01008-3; HOOGEVEEN AT, 1993, HUM MOL GENET, V2, P2069, DOI 10.1093/hmg/2.12.2069; HUGGENVIK J, 1981, J REPROD FERTIL, V61, P403, DOI 10.1530/jrf.0.0610403; HUGGENVIK JI, 1987, ENDOCRINOLOGY, V120, P332, DOI 10.1210/endo-120-1-332; IRELAND ME, 1987, ENDOCRINOLOGY, V120, P1317, DOI 10.1210/endo-120-4-1317; JEGOU B, 1993, ENDOCRINOLOGY, V132, P2557, DOI 10.1210/en.132.6.2557; JEGOU B, 1993, INT REV CYTOL, V147, P25, DOI 10.1016/S0074-7696(08)60766-4; JEGOU B, 1984, INT J ANDROL, V7, P244, DOI 10.1111/j.1365-2605.1984.tb00781.x; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; LANDEGENT JE, 1986, HUM GENET, V73, P354, DOI 10.1007/BF00279100; Lee JW, 1997, ENDOCRINOLOGY, V138, P2081, DOI 10.1210/en.138.5.2081; LEMAGUERESSE B, 1988, J ENDOCRINOL, V118, pR13, DOI 10.1677/joe.0.118R013; LEMAGUERESSE B, 1988, MOL CELL ENDOCRINOL, V58, P65; LEMAGUERESSEBATTISTONI B, 1994, ENDOCRINOLOGY, V135, P2404, DOI 10.1210/en.135.6.2404; LI LY, 1989, BIOL REPROD, V40, P317, DOI 10.1095/biolreprod40.2.317; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MAGUIRE SM, 1993, MOL CELL ENDOCRINOL, V94, P79, DOI 10.1016/0303-7207(93)90054-N; Maguire SM, 1997, J MOL ENDOCRINOL, V19, P67, DOI 10.1677/jme.0.0190067; MARESCHAL JC, 1980, FEBS LETT, V110, P268, DOI 10.1016/0014-5793(80)80089-5; Monsees TK, 1997, ADV EXP MED BIOL, V424, P111; MORALES CR, 1989, MOL ENDOCRINOL, V3, P725, DOI 10.1210/mend-3-4-725; MORRIS ID, 1987, INT J ANDROL, V10, P691, DOI 10.1111/j.1365-2605.1987.tb00371.x; OBryan MK, 1997, J ANDROL, V18, P637; OLSON L, 1987, CELL TISSUE RES, V248, P275; ONODA M, 1993, BIOCHEM BIOPH RES CO, V197, P688, DOI 10.1006/bbrc.1993.2534; ONODA M, 1991, IN VITRO CELL DEV B, V27, P215; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; PERSICHETTI F, 1995, MOL MED, V1, P374, DOI 10.1007/BF03401575; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; PINEAU C, 1989, ENDOCRINOLOGY, V124, P2720, DOI 10.1210/endo-124-6-2720; PINEAU C, 1990, MOL CELL ENDOCRINOL, V72, P13, DOI 10.1016/0303-7207(90)90235-Z; PINONLATAILLADE G, 1988, MOL CELL ENDOCRINOL, V58, P51, DOI 10.1016/0303-7207(88)90053-6; PORTER SB, 1985, J ANDROL, V6, P197; PROVOST PR, 1990, J LIPID RES, V31, P2057; REDL B, 1992, J BIOL CHEM, V267, P20282; RITZEN EM, 1983, J STEROID BIOCHEM, V19, P499, DOI 10.1016/0022-4731(83)90209-1; RIVAROLA MA, 1986, INT J ANDROL, V9, P424, DOI 10.1111/j.1365-2605.1986.tb00905.x; RIVAROLA MA, 1985, ENDOCRINOLOGY, V117, P1796, DOI 10.1210/endo-117-5-1796; SANG QX, 1990, BIOL REPROD, V43, P946, DOI 10.1095/biolreprod43.6.946; Schlatt S, 1997, EUR J ENDOCRINOL, V137, P107, DOI 10.1530/eje.0.1370107; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SCHMITT I, 1995, HUM MOL GENET, V4, P1173, DOI 10.1093/hmg/4.7.1173; SCHTEINGART HF, 1989, MOL CELL ENDOCRINOL, V67, P73, DOI 10.1016/0303-7207(89)90232-3; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P845, DOI 10.1210/endo-124-2-845; SKINNER MK, 1989, MOL ENDOCRINOL, V3, P625, DOI 10.1210/mend-3-4-625; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SMITH EP, 1987, ENDOCRINOLOGY, V120, P186, DOI 10.1210/endo-120-1-186; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; Syed V, 1997, J ANDROL, V18, P264; Syed V, 1998, ENDOCRINOLOGY, V139, P3503, DOI 10.1210/en.139.8.3503; SYED V, 1997, MOL REPROD DEV, V47, P1; SYLVESTER SR, 1984, BIOL REPROD, V31, P1087, DOI 10.1095/biolreprod31.5.1087; TINDALL DJ, 1985, INT REV CYTOL, V94, P127, DOI 10.1016/S0074-7696(08)60395-2; Tokugawa Y, 1998, BIOL REPROD, V58, P600, DOI 10.1095/biolreprod58.2.600; TRES LL, 1986, EXP CELL RES, V162, P33, DOI 10.1016/0014-4827(86)90424-6; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VANDERDONK JA, 1986, EXP CELL RES, V164, P191, DOI 10.1016/0014-4827(86)90466-0; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; vantHof W, 1997, J BIOL CHEM, V272, P1837; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561; Walensky LD, 1998, J BIOL CHEM, V273, P9378, DOI 10.1074/jbc.273.16.9378; WRIGHT WW, 1995, DEV GENET, V16, P104, DOI 10.1002/dvg.1020160203; ZHU LJ, 1994, J ANDROL, V15, P575	91	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10737	10742		10.1074/jbc.274.16.10737	http://dx.doi.org/10.1074/jbc.274.16.10737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196145	hybrid			2022-12-25	WOS:000079751900013
J	Edelstein, C; Shapiro, SD; Klezovitch, O; Scanu, AM				Edelstein, C; Shapiro, SD; Klezovitch, O; Scanu, AM			Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between Kringles IV-4 and IV-5 - Potential relevance to lipoprotein(a) biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROSCLEROTIC PLAQUES; MATRIX METALLOPROTEINASES; INCREASED EXPRESSION; FRAGMENTS; ELASTASE; PROTEIN; LESIONS; ENZYME; URINE; LOCALIZATION	In this study we found that macrophage metalloelastase, MMP-12 cleaves, in vitro, apolipoprotein(a) (apo(a)) in the Asn(3518)-Val(3519) bond located in the linker region between kringles IV-4 and IV-5, a bond immediately upstream of the Ile(3520)-Leu(3521) bond, shown previously to be the site of action by neutrophil elastase (NE), We have also shown that human apo(a) injected into the tail vein of control mice undergoes degradation as reflected by the appearance of immunoreactive fragments in the plasma and in the urine of these animals. To define whether either or both of these enzymes may be responsible for the in vivo apo(a) cleavage, we injected intravenously MMP-12(-/-), NE-/- mice and litter mates, all of the same strain, with either lipoprotein(a) (Lp(a)), full-length free apo(a), or its N-terminal fragment, F1, obtained by the in vitro cleavage of apo(a) by NE. In the plasma of Lp(a)/apo(a)-injected mice, F1 was detected in control and NE-/- mice but was virtually absent in the MMP-12(-/-) mice. Moreover, fragments of the F1 type were present in the urine of the animals except for the MMP-12(-/-) mice. These fragments were significantly smaller in size than those observed in the plasma. All of the animals injected with F1 exhibited small sized fragments in their urine. These observations provide evidence that, in the mouse strain used, MMP-12 plays an important role in the generation of F1 from injected human Lp(a)/apo(a) and that this fragment undergoes further cleavage during renal transit via a mechanism that is neither NE- nor MMP-12-dependent. Thus, factors influencing the expression of MMP-12 may have a modulating action on the biology of Lp(a).	Univ Chicago, Dept Med MC5041, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	University of Chicago; University of Chicago; Washington University (WUSTL)	Edelstein, C (corresponding author), Univ Chicago, Dept Med MC5041, 5841 S Maryland Ave, Chicago, IL 60637 USA.	celina@medicine.bsd.uchicago.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029594, P01HL018577] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594, HL-18577] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Argraves KM, 1997, J CLIN INVEST, V100, P2170, DOI 10.1172/JCI119753; Banda MJ, 1981, BIOCHEM J, V193, P569; Chandler S, 1996, BIOCHEM BIOPH RES CO, V228, P421, DOI 10.1006/bbrc.1996.1677; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1995, BIOCHEMISTRY-US, V34, P16483, DOI 10.1021/bi00050a032; Edelstein C, 1997, J BIOL CHEM, V272, P11079; FLESS GM, 1989, J LIPID RES, V30, P651; FLESS GM, 1994, BIOCHEMISTRY-US, V33, P13492, DOI 10.1021/bi00249a038; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Li ZH, 1996, AM J PATHOL, V148, P121; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Mooser V, 1996, J CLIN INVEST, V98, P2414, DOI 10.1172/JCI119055; Mooser V, 1996, J CLIN INVEST, V97, P858, DOI 10.1172/JCI118487; Nikkari ST, 1996, AM J PATHOL, V149, P1427; OIDA K, 1992, CLIN CHEM, V38, P2244; Piedagnel R, 1999, J BIOL CHEM, V274, P1614, DOI 10.1074/jbc.274.3.1614; Scanu AM, 1997, J LIPID RES, V38, P2193; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SHAH PK, 1995, CIRCULATION, V92, P1565; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; THOMPSON RW, 1995, J CLIN INVEST, V93, P9748	29	21	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10019	10023		10.1074/jbc.274.15.10019	http://dx.doi.org/10.1074/jbc.274.15.10019			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187779	hybrid			2022-12-25	WOS:000079663500018
J	Lotti, LV; Mottola, G; Torrisi, MR; Bonatti, S				Lotti, LV; Mottola, G; Torrisi, MR; Bonatti, S			A different intracellular distribution of a single reporter protein is determined at steady state by KKXX or KDEL retrieval signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CD8 GLYCOPROTEIN; LUMINAL ER PROTEINS; ENDOPLASMIC-RETICULUM; INTERMEDIATE COMPARTMENT; GOLGI-COMPLEX; CIS-GOLGI; TRANSMEMBRANE PROTEINS; DISULFIDE-ISOMERASE; TRANSPORT VESICLES; MEMBRANE-PROTEINS	To establish the specific contribution to protein topology of KKXX and KDEL retrieval motifs, we have determined by immunogold electron microscopy and cell fractionation the intracellular distribution at steady state of the transmembrane and anchorless versions of human CD8 protein, tagged with KKXX (CD8-E19) and KDEL (CD8-K), respectively, and stably expressed in epithelial rat cells (Martire, G,, Mottola, G., Pascale, M. C., Malagolini, N., Turrini, I., Serafini-Cessi, F,, Jackson, M, R., and Bonatti, S, (1996) J. Biol. Chem. 271, 3541-3547). The CD8-E19 protein is represented by a single form, initially O-glycosylated: only about half of it is located in the endoplasmic reticulum, whereas more than 30% of the total is present in the intermediate compartment and cis-Golgi complex. In the latter compartments, CD8-E19 colocalizes with beta-coat protein (COP) (COPI component) and shows the higher density of labeling. Conversely, about 90% of the total CD8-KDEL protein is localized in clusters on the endoplasmic reticulum, where significant co-localization with Sec-23p (COPII component) is observed, and unglycosylated and initially O-glycosylated forms apparently constitute a single pool. Altogether, these results suggest that KKXX and KDEL retrieval motifs have different topological effects on theirs own at steady state: the first results in a specific enrichment in the intermediate compartment and cis-Golgi complex, and the latter dictates residency in the endoplasmic reticulum.	Ist Nazl Ric Canc, Sez Biotechnol, I-00161 Rome, Italy; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; Ist Dermatol S Maria & S Gallicano, I-00100 Rome, Italy; Univ Naples Federico 2, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Genoa; IRCCS AOU San Martino IST; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); University of Naples Federico II	Bonatti, S (corresponding author), Ist Nazl Ric Canc, Sez Biotechnol, Viale Regina Elena 324, I-00161 Rome, Italy.	bonatti@unina.it	Mottola, Giovanna/Y-7540-2019	Mottola, Giovanna/0000-0002-7541-0472				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BONATTI S, 1989, J BIOL CHEM, V264, P12590; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; LEHAY DJ, 1992, CELL, V68, P1145; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; Lotti LV, 1996, EXP CELL RES, V227, P323, DOI 10.1006/excr.1996.0281; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; Martire G, 1996, J BIOL CHEM, V271, P3541; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rottger S, 1998, J CELL SCI, V111, P45; SARASTE J, 1987, J CELL BIOL, V105, P2021, DOI 10.1083/jcb.105.5.2021; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCECKMAN R, 1996, SCIENCE, V271, P1526; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SERAFINICESSI F, 1995, ADV EXP MED BIOL, V376, P135; SINGH I, 1990, EMBO J, V9, P631, DOI 10.1002/j.1460-2075.1990.tb08155.x; SLOT JW, 1981, J CELL BIOL, V90, P533, DOI 10.1083/jcb.90.2.533; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; TANG BL, 1994, EUR J CELL BIOL, V65, P298; TATU U, 1997, J CELL BIOL, V136, P556; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; VERDE C, 1995, EUR J CELL BIOL, V67, P267; WILSON DW, 1993, J BIOL CHEM, V268, P7465	53	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10413	10420		10.1074/jbc.274.15.10413	http://dx.doi.org/10.1074/jbc.274.15.10413			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187831	hybrid			2022-12-25	WOS:000079663500070
J	Lu, YM; Brush, J; Stewart, TA				Lu, YM; Brush, J; Stewart, TA			NSP1 defines a novel family of adaptor proteins linking integrin and tyrosine kinase receptors to the c-Jun N-terminal kinase stress-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MEDIATED CELL-ADHESION; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVITY; NH2-TERMINAL KINASE; SUBSTRATE P130(CAS); V-SRC; PHOSPHORYLATION; CRK; CASCADE	As part of a program to further understand the mechanism by which extracellular signals are coordinated and cell-specific outcomes are generated, we have cloned a novel class of related adaptor molecules (NSP1, NSP2, and NSP3) and have characterized in more detail one of the members, NSP1, NSP1 has an She-related SH2 domain and a putative proline/serine-rich SH3 interaction domain. Treatment of cells with epidermal growth factor or insulin leads to NSP1 phosphorylation and increased association with a hypophosphorylated adaptor protein, p130(Cas). In contrast, cell contact with fibronectin results in Cas phosphorylation and a transient dissociation of NSP1 from p130(Cas). Increased expression of NSP1 in 293 cells induces activation of JNK1, but not of ERK2, Consistent with this observation, NSP1 increases the activity of an AP-1-containing promoter. Thus, we have described a novel family of adaptor proteins, one of which may be involved in the process by which receptor tyrosine kinase and integrin receptors control the c-Jun N-terminal kinase/stress-activated protein kinase pathway.	Genentech Inc, Dept Endocrine Res, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Stewart, TA (corresponding author), Genentech Inc, Dept Endocrine Res, M-S 37,1 DNA Way, S San Francisco, CA 94080 USA.							Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mo YY, 1996, CANCER RES, V56, P2633; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamura T, 1996, ONCOGENE, V13, P1111; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	48	52	59	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10047	10052		10.1074/jbc.274.15.10047	http://dx.doi.org/10.1074/jbc.274.15.10047			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187783	hybrid			2022-12-25	WOS:000079663500022
J	Yan, MH; Lee, J; Schilbach, S; Goddard, A; Dixit, V				Yan, MH; Lee, J; Schilbach, S; Goddard, A; Dixit, V			mE10, a novel caspase recruitment domain-containing proapoptotic molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMR STRUCTURE; CELL-DEATH; OLIGOMERIZATION; MUTAGENESIS; APOPTOSIS; CARD	Apoptotic signaling is mediated by homophilic interactions between conserved domains present in components of the death pathway. The death domain, death effector domain, and caspase recruitment domain (CARD) are examples of such interaction motifs, We have identified a novel mammalian CARD-containing adaptor molecule termed mE10 (mammalian E10), The N-terminal CARD of mE10 exhibits significant homology (47% identity and 64% similarity) to the CARD of a gene from Equine Herpesvirus type 2, The C-terminal region is unique. Overexpression of mE10 in MCF-7 human breast carcinoma cells induces apoptosis, Mutational analysis indicates that CARD-mediated mE10 oligomerization is essential for killing activity. The C terminus of mE10 bound to the zymogen form of caspase-9 and promoted its processing to the active dimeric species. Taken together, these data suggest a model where autoproteolytic activation of pro-caspase-9 is mediated by mE10-induced oligomerization.	Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Dixit, V (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, S San Francisco, CA 94080 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; MENGARTNER M, 1998, SCIENCE, V281, P1298; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355	16	103	118	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10287	10292		10.1074/jbc.274.15.10287	http://dx.doi.org/10.1074/jbc.274.15.10287			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187815	hybrid			2022-12-25	WOS:000079663500054
J	Zhang, AM; Potvin, B; Zaiman, A; Chen, W; Kumar, R; Phillips, L; Stanley, P				Zhang, AM; Potvin, B; Zaiman, A; Chen, W; Kumar, R; Phillips, L; Stanley, P			The gain-of-function Chinese hamster ovary mutant LEC11B expresses one of two Chinese hamster FUT6 genes due to the loss of a negative regulatory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUCOSYL-TRANSFERASE GENES; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MOUSE MAMMARY-GLAND; GDP-FUCOSE; CHO CELLS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; P-SELECTIN; LEUKOCYTE TRAFFICKING; ACCEPTOR SPECIFICITY; HORMONAL-REGULATION	The LEC11 Chinese hamster ovary (CHO) gain-of-function mutant expresses an alpha(1,3)fucosyltransferase (alpha(1,3)Fuc-T) activity that generates the Le(X), sialyl-Le(X), and VIM-2 glycan determinants and has been extensively used for studies of E-selectin ligand specificity, In order to identify regulatory mechanisms that control alpha(1,3)Fuc-T expression in mammals, mechanisms of FUT gene expression were investigated in LEC11 cells and two new, independent mutants, LEC11A and LEC11B. Northern and ribonuclease protection analyses, using probes that span the coding region of a cloned CHO FUT gene, detected transcripts in each LEC11 mutant but not in CHO cells or other gain-of-function CHO mutants that express a different alpha(1,3)Fuc-T activity. Coding region sequence analysis and alpha(1,3)Fuc-T acceptor specificity comparisons with recombinant human Fuc-TV and Fuc0TVI showed that the cloned FUT gene is orthologous to the human FUT6 gene. Southern analyses identified two closely related FUT6 genes in the Chinese hamster, whose evolutionary relationships are discussed. The blots showed that rearrangements had occurred in LEC11A and LEC11 genomic DNA, consistent with a cis mechanism of FUT6 gene activation in these mutants. By contrast, somatic cell hybrid analyses revealed that LEC11B cells express FUT6 gene transcripts due to the loss of a trans-acting, negative regulatory factor. Sequencing of reverse transcriptase-polymerase chain reaction products identified unique 5'- and 3'-untranslated region sequences in FUT6 gene transcripts from each LEC11 mutant. Northern and Southern analyses with gene-specific probes showed that LEC11A cells express only the cgFUT6A gene (where cg is Cricetulus griseus), whereas LEC11 and LEC11B cells express only the cgFUT6 gene. In LEC11A x LEC11B hybrid cells, the cgFUT6A gene was predominantly expressed, as predicted if a trans-acting negative regulatory factor functions to suppress cgFUT6B gene expression in CHO cells. This factor is predicted to be a cell type-specific regulator of FUT6 gene expression in mammals.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Cytel Corp, San Diego, CA 92121 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, P (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM T32 07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON GJ, 1993, COMPUT APPL BIOSCI, V9, P729; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BrinkmanVanderLinden ECM, 1996, J BIOL CHEM, V271, P14492, DOI 10.1074/jbc.271.24.14492; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; Costache M, 1997, J BIOL CHEM, V272, P29721, DOI 10.1074/jbc.272.47.29721; Costache M, 1997, TRANSFUS CLIN BIOL, V4, P367, DOI 10.1016/S1246-7820(97)80042-0; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DeVries T, 1997, GLYCOBIOLOGY, V7, P921, DOI 10.1093/glycob/7.7.921; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; FARRELL SA, 1977, SOMAT CELL GENET, V3, P539, DOI 10.1007/BF01539124; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Fitch W.M., 1970, EVOL BIOL, V4, P67; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; Kannagi R, 1997, GLYCOCONJUGATE J, V14, P577, DOI 10.1023/A:1018532409041; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Ma J, 1996, J BIOL CHEM, V271, P11197, DOI 10.1074/jbc.271.19.11197; Ma J, 1997, INDIAN J BIOCHEM BIO, V34, P110; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mas E, 1998, GLYCOBIOLOGY, V8, P605, DOI 10.1093/glycob/8.6.605; MCCURLEY RS, 1995, GENOMICS, V26, P142, DOI 10.1016/0888-7543(95)80094-3; Miller M J, 1994, J Comput Biol, V1, P257, DOI 10.1089/cmb.1994.1.257; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; POTVIN B, 1990, J BIOL CHEM, V265, P1615; Raju TS, 1998, J BIOL CHEM, V273, P14090, DOI 10.1074/jbc.273.23.14090; REGUIGNE I, 1994, CYTOGENET CELL GENET, V66, P104, DOI 10.1159/000133677; ReguigneArnould I, 1996, CR ACAD SCI III-VIE, V319, P783; RUDNICKI MA, 1988, MOL CELL BIOL, V8, P406, DOI 10.1128/MCB.8.1.406; SALLUSTIO S, 1989, SOMAT CELL MOLEC GEN, V15, P387, DOI 10.1007/BF01534890; STANLEY P, 1975, SOMAT CELL GENET, V1, P3, DOI 10.1007/BF01538729; Stanley P, 1996, GLYCOBIOLOGY, V6, P695, DOI 10.1093/glycob/6.7.695; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	58	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10439	10450		10.1074/jbc.274.15.10439	http://dx.doi.org/10.1074/jbc.274.15.10439			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187834	hybrid			2022-12-25	WOS:000079663500073
J	Chao, TH; Ember, JA; Ember, JA; Wang, MY; Bayon, Y; Hugli, TE; Ye, RD				Chao, TH; Ember, JA; Ember, JA; Wang, MY; Bayon, Y; Hugli, TE; Ye, RD			Role of the second extracellular loop of human C3a receptor in agonist binding and receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C5A RECEPTOR; PROTEIN-COUPLED RECEPTORS; HUMAN MAST-CELLS; ANAPHYLATOXIN RECEPTOR; MOLECULAR-CLONING; EXPRESSION CLONING; ACTIVATION; ANTIBODIES; ANALOGS; SITE	The C3a anaphylatoxin receptor (C3aR) is a G protein-coupled receptor with an unusually large second extracellular loop (e2 loop, similar to 172 amino acids). To determine the function of this unique structure, chimeric and deletion mutants were prepared and analyzed in transfected RBL-2H3 cells. Whereas replacement of the C3aR N-terminal segment with that from the human C5a receptor had minimal effect on C3a binding, substitution of the e2 loop with a smaller e2 loop from the C5a receptor (C5aR) abolished binding of I-125-C3a and C3a-stimulated calcium mobilization. However, as much as 65% of the e2 loop sequence (amino acids 198-308) may be removed without affecting C3a binding or calcium responses. The e2 loop sequences adjacent to the transmembrane domains contain multiple aspartate residues and are found to play an important role in C3a binding based on deletion mutagenesis. Replacement of five aspartate residues in the e2 loop with lysyl residues significantly compromised both the binding and functional capabilities of the C3a receptor mediated by intact C3a or by two C3a analog peptides. These data suggest a two-site C3a-C3aR interaction model similar to that established for C5a/C5aR. The anionic residues near the N and C termini of the C3aR e2 loop constitute a non-effector secondary interaction site with cationic residues in the C-terminal helical region of C3a, whereas the C3a C-terminal sequence LGLAR engages the primary effector site in C3aR.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Ye, RD (corresponding author), Univ Illinois, Dept Pharmacol MC868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020; BAyón, Yolanda/L-7635-2014	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; BAyón, Yolanda/0000-0003-3089-5485	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI040176, R01AI033503, R01AI041670, R56AI033503, R01AI040176] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40176, AI33503, AI41670] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Ames RS, 1996, FEBS LETT, V395, P157, DOI 10.1016/0014-5793(96)01018-6; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; CHENOWETH DE, 1980, MOL IMMUNOL, V17, P151, DOI 10.1016/0161-5890(80)90067-X; CHENOWETH DE, 1979, BIOCHEM BIOPH RES CO, V68, P227; COCHRANE CG, 1968, J EXP MED, V127, P368; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; Fischer WH, 1997, J IMMUNOL, V159, P4279; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; Fukuoka Y, 1998, J IMMUNOL, V161, P2977; Fukuoka Y, 1998, BIOCHEM BIOPH RES CO, V242, P663, DOI 10.1006/bbrc.1997.8034; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GOLDSTEIN IM, 1988, INFLAMMATION BASIC P, P55; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hartmann K, 1997, BLOOD, V89, P2863, DOI 10.1182/blood.V89.8.2863; Hawlisch H, 1998, J IMMUNOL, V160, P2947; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hsu MH, 1997, IMMUNOGENETICS, V47, P64, DOI 10.1007/s002510050327; HUGLI TE, 1981, MOL CELL BIOCHEM, V41, P59; HUGLI TE, 1989, CURR TOP MICROBIOL I, V153, P181; MERY L, 1993, EUR J HAEMATOL, V51, P282; MONK PN, 1995, J BIOL CHEM, V270, P16625, DOI 10.1074/jbc.270.28.16625; MORGAN EL, 1993, J IMMUNOL, V151, P377; Nilsson G, 1996, J IMMUNOL, V157, P1693; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; PERRET JJ, 1992, BIOCHEM J, V288, P911, DOI 10.1042/bj2880911; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Tornetta MA, 1997, J IMMUNOL, V158, P5277	40	44	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9721	9728		10.1074/jbc.274.14.9721	http://dx.doi.org/10.1074/jbc.274.14.9721			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092660	hybrid, Green Published			2022-12-25	WOS:000079451800079
J	Chinni, C; de Niese, MR; Tew, DJ; Jenkins, AL; Bottomley, SP; Mackie, EJ				Chinni, C; de Niese, MR; Tew, DJ; Jenkins, AL; Bottomley, SP; Mackie, EJ			Thrombin, a survival factor for cultured myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-DEFICIENT MUSCLE; PROTEIN-COUPLED RECEPTORS; MOUSE MUSCLE; PLATELET ACTIVATION; ENDOTHELIAL-CELLS; ALPHA-THROMBIN; EXPRESSION; APOPTOSIS; DIFFERENTIATION; INHIBITION	Three members of the family of protease-activated receptors (PARs), PARs-1, -3 and -4, have been identified as thrombin receptors, PAR-1 is expressed by primary myoblast cultures, and expression is repressed once myoblasts fuse to form myotubes, The current study was undertaken to investigate the hypothesis that thrombin inhibits myoblast fusion, Primary rodent myoblast cultures were deprived of serum to promote myoblast fusion and then cultured in the presence or absence of thrombin, Thrombin inhibited myoblast fusion, but another notable effect was observed; 50% of control cells were apoptotic within 24 h of serum deprivation, whereas less than 15% of thrombin-treated cells showed signs of apoptosis. Proteolysis was required for the effect of thrombin, but no other serine protease tested mimicked the action of thrombin. Neither a PAR-1- nor a PAR-4-activating peptide inhibited apoptosis or fusion, and myoblast cultures were negative for PAR-3 expression. Myoblasts exposed to thrombin for 1 h and then changed to medium without thrombin accumulated apoptosis inhibitory activity in their medium over the subsequent 20 h, Thus the protective action of thrombin appears to be effected through cleavage of an unidentified thrombin receptor, leading to secretion of a downstream apoptosis inhibitory factor. These results demonstrate that thrombin functions as a survival factor for myoblasts and is likely to play an important role in muscle development and repair.	Univ Melbourne, Sch Vet Sci, Parkville, Vic 3052, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	University of Melbourne; Monash University	Mackie, EJ (corresponding author), Univ Melbourne, Sch Vet Sci, Parkville, Vic 3052, Australia.		Mackie, Eleanor J/B-2045-2008; Jenkins, Alicia/N-2482-2015	Mackie, Eleanor J/0000-0002-8057-5407; 				Abraham LA, 1998, J BONE MINER RES, V13, P818, DOI 10.1359/jbmr.1998.13.5.818; Allen DL, 1997, AM J PHYSIOL-CELL PH, V273, pC579, DOI 10.1152/ajpcell.1997.273.2.C579; AUSTIN L, 1992, J NEUROL SCI, V112, P185, DOI 10.1016/0022-510X(92)90149-F; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P234; BRASS LF, 1993, THROMB HAEMOSTASIS, V70, P217; Citron BA, 1997, THROMB RES, V87, P303, DOI 10.1016/S0049-3848(97)00132-1; COLLER BS, 1993, J BIOL CHEM, V268, P20741; CRAGO AM, 1995, EXP CELL RES, V219, P650, DOI 10.1006/excr.1995.1275; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Glazner GW, 1997, DEV BRAIN RES, V99, P148, DOI 10.1016/S0165-3806(96)00213-1; Guttridge DC, 1997, J BIOL CHEM, V272, P24117, DOI 10.1074/jbc.272.39.24117; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Jenkins Alison L., 1993, Journal of Biological Chemistry, V268, P21432; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; LIM RW, 1984, DEV BIOL, V105, P48, DOI 10.1016/0012-1606(84)90260-4; LINKHART TA, 1981, DEV BIOL, V86, P19, DOI 10.1016/0012-1606(81)90311-0; LIU LB, 1994, BRIT J HAEMATOL, V88, P592, DOI 10.1111/j.1365-2141.1994.tb05078.x; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; Piccardoni P, 1996, THROMB HAEMOSTASIS, V76, P780; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; SANDRI M, 1995, FEBS LETT, V373, P291, DOI 10.1016/0014-5793(95)00908-R; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; Suidan HS, 1996, J BIOL CHEM, V271, P29162, DOI 10.1074/jbc.271.46.29162; Tews DS, 1997, NEUROPATH APPL NEURO, V23, P141; TIDBALL JG, 1995, J CELL SCI, V108, P2197; Ueno A, 1996, IMMUNOLOGY, V88, P76, DOI 10.1046/j.1365-2567.1996.d01-635.x; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	34	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9169	9174		10.1074/jbc.274.14.9169	http://dx.doi.org/10.1074/jbc.274.14.9169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092588	hybrid			2022-12-25	WOS:000079451800007
J	Lee, B; Sharron, M; Blanpain, C; Doranz, BJ; Vakili, J; Setoh, P; Berg, E; Liu, G; Guy, HR; Durell, SR; Parmentier, M; Chang, CN; Price, K; Tsang, M; Doms, RW				Lee, B; Sharron, M; Blanpain, C; Doranz, BJ; Vakili, J; Setoh, P; Berg, E; Liu, G; Guy, HR; Durell, SR; Parmentier, M; Chang, CN; Price, K; Tsang, M; Doms, RW			Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AMINO-TERMINAL DOMAIN; HIV-1 INFECTION; ENVELOPE GLYCOPROTEINS; DISEASE PROGRESSION; EXTRACELLULAR LOOP; CELL-LINES; V3 LOOP; TYPE-1; RECEPTOR	The chemokine receptor CCR5 is the major coreceptor for R5 human immunodeficiency virus type-1 strains. We mapped the epitope specificities of 18 CCR5 monoclonal antibodies (mAbs) to identify domains of CCR5 required for chemokine binding, gp120 binding, and for inducing conformational changes in Env that lead to membrane fusion, We identified mAbs that bound to N-terminal epitopes, extracellular loop 2 (ECL2) epitopes, and multidomain (MD) epitopes composed of more than one single extracellular domain. N-terminal mAbs recognized specific residues that span the first 13 amino acids of CCR5, while nearly all ECL2 mAbs recognized residues Tyr-184 to Phe-189. In addition, all MD epitopes involved ECL2, including at least residues Lys-171. and Glu-172, We found that ECL2-specific mAbs were more efficient than NH2- or MD-antibodies in blocking RANTES or MIP-1 beta binding. By contrast, N-terminal mAbs blocked gp120-CCR5 binding more effectively than ECL2 mAbs. Surprisingly, ECL2 mAbs were more potent inhibitors of viral infection than N-terminal mAbs, Thus, the ability to block virus infection did not correlate with the ability to block gp120 binding. Together, these results imply that chemokines and Env bind to distinct but overlapping sites in CCR5, and suggest that the N-terminal domain of CCR5 is more important for gp120 binding while the extracellular loops are more important for inducing conformational changes in Env that lead to membrane fusion and virus infection. Measurements of individual antibody affinities coupled with kinetic analysis of equilibrium binding states also suggested that there are multiple conformational states of CCR5. A previously described mAb, 2D7, was unique in its ability to effectively block both chemokine and Env binding as well as coreceptor activity. 2D7 bound to a unique antigenic determinant in the first half of ECL2 and recognized a far greater proportion of cell surface CCR5 molecules than the other mAbs examined. Thus, the epitope recognized by 2D7 may represent a particularly attractive target for CCR5 antagonists.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Free Univ Brussels, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; PDL Inc, Fremont, CA USA; NCI, Math Biol Lab, NIH, Bethesda, MD 20892 USA; R&D Syst, Minneapolis, MN 55413 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Wistar Institute	Doms, RW (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, 806 Abramson,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	doms@mail.med.upenn.edu	Lee, Benhur/A-8554-2016	Lee, Benhur/0000-0003-0760-1709; Parmentier, Marc/0000-0001-8081-4685	NHLBI NIH HHS [K08 HL03923-01] Funding Source: Medline; PHS HHS [R01-40880, R44 A141299-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003923] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; ASJO B, 1986, LANCET, V2, P660; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BARDEAU B, 1998, J BIOL CHEM, V72, P7125; Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571; Berger EA, 1997, AIDS, V11, pS3; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Bieniasz P. D., 1998, FRONT BIOSCI, V3, P44; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Broder CC, 1997, J LEUKOCYTE BIOL, V62, P20, DOI 10.1002/jlb.62.1.20; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; DOMS RW, 1998, HUMAN RETROVIRUSES A, V3, P1; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; DRAIC T, 1998, J VIROL, V72, P279; EugenOlsen J, 1997, AIDS, V11, P305, DOI 10.1097/00002030-199703110-00007; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 1998, J VIROL, V72, P2105, DOI 10.1128/JVI.72.3.2105-2112.1998; Frade JMR, 1997, J CLIN INVEST, V100, P497, DOI 10.1172/JCI119558; Frade JMR, 1997, J IMMUNOL, V159, P5576; Guy H R, 1996, Ion Channels, V4, P1; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Hill CM, 1997, J VIROL, V71, P6296, DOI 10.1128/JVI.71.9.6296-6304.1997; Hoffman TL, 1998, P NATL ACAD SCI USA, V95, P11360, DOI 10.1073/pnas.95.19.11360; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LIMBIRD LE, 1996, CELL SURFACE RECEPTO; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Paxton WA, 1998, VIROLOGY, V244, P66, DOI 10.1006/viro.1998.9082; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Rizzuto CD, 1997, J VIROL, V71, P4847, DOI 10.1128/JVI.71.6.4847-4851.1997; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Ross TM, 1998, P NATL ACAD SCI USA, V95, P7682, DOI 10.1073/pnas.95.13.7682; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; Stables J, 1997, ANAL BIOCHEM, V252, P115, DOI 10.1006/abio.1997.2308; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	58	307	340	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9617	9626		10.1074/jbc.274.14.9617	http://dx.doi.org/10.1074/jbc.274.14.9617			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092648	hybrid			2022-12-25	WOS:000079451800067
J	Agrawal, RK; Penczek, P; Grassucci, RA; Burkhardt, N; Nierhaus, KH; Frank, J				Agrawal, RK; Penczek, P; Grassucci, RA; Burkhardt, N; Nierhaus, KH; Frank, J			Effect of buffer conditions on the position of tRNA on the 70 S ribosome as visualized by cryoelectron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; ANGSTROM RESOLUTION; ELONGATION CYCLE; MODEL; SITE; REFINEMENT; MOVEMENT	The effect of buffer conditions on the binding position of tRNA on the Escherichia coli 70 S ribosome have been studied by means of three-dimensional (3D) cryoelectron microscopy. Either deacylated tRNA(f)(met) or fMet-tRNA(f)(Met) were bound to the 70 S ribosomes, which were programmed with a 46-nucleotide mRNA having AUG codon in the middle, under two different buffer conditions (conventional buffer: containing Tris and higher Mg2+ concentration [10-15 mM]; and polyamine buffer: containing Hepes, lower Mg2+ concentration [6 mM], and polyamines). Difference maps, obtained by subtracting 3D maps of naked control ribosome in the corresponding buffer from the 3D maps of tRNA ribosome complexes, reveal the distinct locations of tRNA on the ribosome. The position of deacylated tRNA(f)(Met) depends on the buffer condition used, whereas that of fMet-tRNA(f)(Met) remains the same in both buffer conditions. The acylated tRNA binds in the classical P site, whereas deacylated tRNA binds mostly in an intermediate P/E position under the conventional buffer condition and mostly in the position corresponding to the classical P site, i.e. in the P/P state, under the polyamine buffer conditions.	SUNY Albany, Wadsworth Ctr, Dept Biomed Sci, Albany, NY 12201 USA; Howard Hughes Med Inst, Albany, NY 12201 USA; Max Planck Inst Mol Genet, D-14195 Berlin, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Wadsworth Center; Howard Hughes Medical Institute; Max Planck Society	Agrawal, RK (corresponding author), SUNY Albany, Wadsworth Ctr, Dept Biomed Sci, POB 509, Albany, NY 12201 USA.	agrawal@wadsworth.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM055440] Funding Source: NIH RePORTER; NIGMS NIH HHS [1RO1 GM 55440, 1R37 GM 29169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1996, J BIOL CHEM, V271, P21285, DOI 10.1074/jbc.271.35.21285; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; AGRAWAL RK, 1998, J BIOCH CELL BIOL, V31, P2413; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; Bommer U, 1997, SUBCELLULAR FRACTION, P271; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Frank J, 1998, BIOPHYS J, V74, P589, DOI 10.1016/S0006-3495(98)77817-8; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; KUTAY UR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P193, DOI 10.1016/0167-4781(90)90165-X; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; LILL R, 1987, J MOL BIOL, V196, P137, DOI 10.1016/0022-2836(87)90516-X; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Nierhaus KH, 1997, P NATL ACAD SCI USA, V94, P10499, DOI 10.1073/pnas.94.20.10499; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PODKOWINSKI J, 1991, NUCLEIC ACIDS RES, V19, P801, DOI 10.1093/nar/19.4.801; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; WESTHOF E, 1988, ACTA CRYSTALLOGR A, V44, P112, DOI 10.1107/S010876738700446X; Zhu J, 1997, J STRUCT BIOL, V118, P197, DOI 10.1006/jsbi.1997.3845; ZIMMERMANN RA, 1990, RIBOSOME, P331	33	85	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8723	8729		10.1074/jbc.274.13.8723	http://dx.doi.org/10.1074/jbc.274.13.8723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085112	hybrid			2022-12-25	WOS:000079451600054
J	Jenkins, BJ; Le, F; Gonda, TJ				Jenkins, BJ; Le, F; Gonda, TJ			A cell type-specific constitutive point mutant of the common beta-subunit of the human granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5 receptors requires the GM-CSF receptor alpha-subunit for activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH SIGNAL TRANSDUCTION; HIGH-AFFINITY BINDING; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; NEU ONCOGENE; CHAIN; LIGAND; MUTATIONS; RECONSTITUTION; RESIDUES	The high affinity receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) consists of a cytokine-specific alpha-subunit (hGMR alpha) and a common signal-transducing beta-subunit (hpc) that is shared with the interleukin-3 and -5 receptors, We have previously identified a constitutively active extracellular point mutant of hpc, I374N, that can confer factor independence on murine FDC-P1 cells but not BAF-B03 or CTLL-2 cells (Jenkins, B. J., D'Andrea, R. J., and Gonda, T. J. (1995) EMBO J. 14, 4276-4287), This restricted activity suggested the involvement of cell type-specific signaling molecules in the activation of this mutant. We report here that one such molecule is the mouse GMR alpha (mGMR alpha) subunit, since introduction of mGMR alpha, but not hGMR alpha, into BAF-B03 or CTLL-2 cells expressing the I374N mutant conferred factor independence, Experiments utilizing mouse/human chimeric GMR alpha subunits indicated that the species specificity lies in the extracellular domain of GMRa. Importantly, the requirement for mGMR alpha correlated with the ability of I374N (but not wild-type hpc) to constitutively associate with mGMRa. Expression of I374N in human factor-dependent UT7 cells also led to factor-independent proliferation, with concomitant up-regulation of hGMR alpha surface expression. Taken together, these findings suggest a critical role for association with GMR alpha in the constitutive activity of I374N.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia	Gonda, TJ (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Frome Rd, Adelaide, SA 5000, Australia.		jenkins, brendan/A-2401-2009; jenkins, brendan/J-7854-2012	Jenkins, Brendan/0000-0002-7552-4656				ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Barry SC, 1997, BLOOD, V89, P842, DOI 10.1182/blood.V89.3.842; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EDER M, 1994, J BIOL CHEM, V269, P30173; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HUGHES SH, 1979, CELL, V18, P347, DOI 10.1016/0092-8674(79)90054-0; Jenkins BJ, 1996, J BIOL CHEM, V271, P29707, DOI 10.1074/jbc.271.47.29707; Jenkins BJ, 1998, BLOOD, V92, P1989, DOI 10.1182/blood.V92.6.1989; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOMATSU N, 1991, CANCER RES, V51, P341; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; Mui Alice L.-F., 1994, Progress in Growth Factor Research, V5, P15, DOI 10.1016/0955-2235(94)90015-9; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; Rapoport AP, 1996, BLOOD, V87, P112; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1997, BLOOD, V90, P3005, DOI 10.1182/blood.V90.8.3005	41	17	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8669	8677		10.1074/jbc.274.13.8669	http://dx.doi.org/10.1074/jbc.274.13.8669			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085105	hybrid			2022-12-25	WOS:000079451600047
J	Pandey, P; Avraham, S; Place, A; Kumar, V; Majumder, PK; Cheng, KD; Nakazawa, A; Saxena, S; Kharbanda, S				Pandey, P; Avraham, S; Place, A; Kumar, V; Majumder, PK; Cheng, KD; Nakazawa, A; Saxena, S; Kharbanda, S			Bcl-x(L) blocks activation of related adhesion focal tyrosine kinase proline-rich tyrosine kinase 2 and stress-activated protein kinase c-Jun N-terminal protein kinase in the cellular response to methylmethane sulfonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; INDUCED APOPTOSIS; DEATH PATHWAY; POLY(ADP-RIBOSE) POLYMERASE; PROTEOLYTIC ACTIVATION; JNK ACTIVATION; BCL-2; CELLS; INDUCTION	The stress-activated protein kinase/c-Jun N-terminal protein kinase (JNK) is induced in response to ionizing radiation and other DNA-damaging agents. Recent studies indicate that activation of JNK is necessary for induction of apoptosis in response to diverse agents. Here we demonstrate that methylnethane sulfonate (MMS)-induced activation of JNK is inhibited by overexpression of the anti-apoptotic protein Bcl-x(L), but not by caspase inhibitors CrmA and p35, By contrast, UV-induced JNK activity is insensitive to Bcl-x(L). The results demonstrate that treatment with MMS is associated with an increase in tyrosine phosphorylation of related adhesion focal tyrosine kinase (RAFTK)/proline-rich tyrosine kinase 2 (PYK2), an upstream effector of JNK and that this phosphorylation is inhibited by overexpression of Bcl-x(L). Furthermore, overexpression of a dominant-negative mutant of RAFTK (RAFTK K-M) inhibits MMS-induced JNK activation, The results indicate that inhibition of RAFTK phosphorylation by MMS in Bcl-x(L) cells is attributed to an increase in tyrosine phosphatase activity in these cells. Hence, treatment of Bcl-x(L) cells with sodium vanadate, a tyrosine phosphatase inhibitor, restores MMS-induced activation of RAFTK and JNK. These findings indicate that RAFTK-dependent induction of JNK in response to MMS is sensitive to Bcl-x(L), but not to CrmA. and p35, by a mechanism that inhibits tyrosine phosphorylation and thereby activation of RAFTK. Taken together, these findings support a novel role for Bcl-x(L) that is independent of the caspase cascade.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Manitoba	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	surender_kharbanda@dfci.harvard.edu		Kumar, Vijay/0000-0001-6477-8274	NATIONAL CANCER INSTITUTE [R01CA075216] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA75216] Funding Source: Medline; NHLBI NIH HHS [HL55445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BERANEK DT, 1980, CARCINOGENESIS, V1, P595, DOI 10.1093/carcin/1.7.595; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Knowlton K, 1998, J SURG RES, V76, P22, DOI 10.1006/jsre.1998.5277; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; NATRAJAN AT, 1984, MUTAT RES, V128, P31; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SALEEM A, 1995, J IMMUNOL, V154, P4150; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SMITH GJ, 1986, AM J PATHOL, V122, P488; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; YAN MH, 1994, NATURE, V372, P798; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	60	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8618	8623		10.1074/jbc.274.13.8618	http://dx.doi.org/10.1074/jbc.274.13.8618			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085098	hybrid			2022-12-25	WOS:000079451600040
J	Ugolini, F; Adelaide, J; Charafe-Jauffret, E; Nguyen, C; Jacquemier, J; Jordan, B; Birnbaum, D; Pebusque, MJ				Ugolini, F; Adelaide, J; Charafe-Jauffret, E; Nguyen, C; Jacquemier, J; Jordan, B; Birnbaum, D; Pebusque, MJ			Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes	ONCOGENE			English	Article						amplification; breast cancer; tumor suppressor gene; oncogene; FGFR1; FRP1/FRZB; cDNA array; gene expression; chromosome 8	HUMAN GENOME; SUSCEPTIBILITY GENE; DNA AMPLIFICATION; FACTOR HEREGULIN; LINKAGE ANALYSIS; SEQUENCE TAGS; MAP; FAMILY; CELLS; HETEROZYGOSITY	Deletions and amplifications are frequent alterations of the short arm of chromosome 8 associated with various types of cancers, including breast cancers. This indicates the likely presence of tumor suppressor genes and oncogenes, In the present study, we have used the expressed sequence tag (EST) map of 8p11-21 to assemble a set of available cDNAs representing genes from this region. DNA arrays were prepared for expression analysis and search for genes potentially involved in breast cancer, Underexpresion in tumoral breast cells (versus normal breast) was observed for 15 transcripts, Among these, the Frizzled-related gene FRP1/FRZB, was turned off in 78% of breast carcinomas, suggesting that the lack of its product may be associated with malignant transformation, Overexpression in tumoral breast cells was observed for 13 genes. The FGFR1 gene, that encodes a tyrosine kinase receptor for members of the fibroblast growth factor family, was identified as a good candidate for one amplification unit, Taken together, our results demonstrate that such a strategy can rapidly identify genes with an altered pattern of expression and provide candidate genes for malignancies.	INSERM U119, Oncol Mol Lab, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Anatomopathol, F-13009 Marseille, France; Ctr Immunol Marseille Luminy, TAGC, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Pebusque, MJ (corresponding author), INSERM U119, Oncol Mol Lab, 27 Bd Lei Roure, F-13009 Marseille, France.		ADELAIDE, José JA/O-4390-2017; Nguyen, Catherine/M-4119-2016; Charafe-Jauffret, emmanuelle/P-6009-2017	ADELAIDE, José JA/0000-0003-4364-9857; Nguyen, Catherine/0000-0001-9376-6360; Birnbaum, Daniel/0000-0001-7920-9883; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Anbazhagan R, 1998, AM J PATHOL, V152, P815; Bacus SS, 1996, ONCOGENE, V12, P2535; Barlund M, 1997, GENE CHROMOSOME CANC, V20, P372, DOI 10.1002/(SICI)1098-2264(199712)20:4<372::AID-GCC8>3.0.CO;2-Z; Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Chaffanet M, 1998, ONCOGENE, V16, P945, DOI 10.1038/sj.onc.1201601; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courjal F, 1997, CANCER RES, V57, P4360; Dale TC, 1996, CANCER RES, V56, P4320; DIB A, 1995, ONCOGENE, V10, P995; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Granjeaud S, 1996, GENET ANAL-BIOMOL E, V12, P151, DOI 10.1016/1050-3862(95)00128-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jordan BR, 1998, J BIOCHEM-TOKYO, V124, P251, DOI 10.1093/oxfordjournals.jbchem.a022104; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Leach RJ, 1996, CYTOGENET CELL GENET, V75, P71, DOI 10.1159/000134460; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lyne JC, 1997, CANCER J SCI AM, V3, P21; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miller G, 1997, GENOME RES, V7, P1027, DOI 10.1101/gr.7.10.1027; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438; Pennisi E, 1998, SCIENCE, V279, P1445; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; POPOVICI C, 1999, IN PRESS BLOOD; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Rocha D, 1997, IMMUNOGENETICS, V46, P142, DOI 10.1007/s002510050253; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Seitz S, 1997, ONCOGENE, V14, P741, DOI 10.1038/sj.onc.1200881; Tanner MM, 1996, CANCER RES, V56, P3441; Theillet C, 1998, NAT MED, V4, P767, DOI 10.1038/nm0798-767; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WILLIAMSON AR, 1995, J NIH RES, V7, P61; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zorn AM, 1997, CURR BIOL, V7, pR501, DOI 10.1016/S0960-9822(06)00248-X; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	54	112	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1903	1910		10.1038/sj.onc.1202739	http://dx.doi.org/10.1038/sj.onc.1202739			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086345				2022-12-25	WOS:000079090000014
J	Bousquet, C; Melmed, S				Bousquet, C; Melmed, S			Critical role for STAT3 in murine pituitary adrenocorticotropin hormone leukemia inhibitory factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PROOPIOMELANOCORTIN GENE-EXPRESSION; CORTICOTROPIN-RELEASING-FACTOR; ONCOSTATIN-M; FACTOR-RECEPTOR; TRANSCRIPTIONAL SYNERGY; INTERFERON-GAMMA; GROWTH-HORMONE; ADRENAL AXIS; LIF RECEPTOR	Leukemia inhibitory factor (LIF) is a pleiotropic neuroimmune cytokine that promotes corticotroph cell differentiation and induces proopiomelanocortin (POMC) mRNA expression and adrenocorticotropin hormone (ACTH) secretion. However, molecular mechanisms for this induction remain elusive. We therefore developed ACTH-secreting AtT20 transformants for wild-type or mutated STAT3, a cytokine signaling molecule, to address whether STAT3 is a determinant of LIF-mediated ACTH regulation. We show that these mutants act in a dominant negative manner by blocking endogenous STAT3 tyrosine phosphorylation or STAT3 DNA binding. Attenuation of STAT3 activity in the dominant negative AtT20 clones prevented LIF from promoting transcriptional activation of the POMC promoter (2.1-fold), whereas this LIF action was enhanced (7.7-fold; p < 0.05) in wild-type STAT3-overexpressing clones in comparison to mock-transfected cells (4.5-fold). However, wildtype or dominant negative STAT3-overexpressing clones showed comparable (4-fold) POMC induction after treatment with cyclic adenosine monophosphate (cAMP), an alternate inducer of POMC transcription, indicating the STAT3 specificity for LIF signaling. Moreover, dominant negative inactivation of STAT3 activity resulted in abrogation of LIF-induced POMC mRNA levels and ACTH secretion, confirming the in vivo role of STAT3 in LIF-mediated corticotroph action. Chemical or molecular blockade of the mitogen-activated protein kinase pathway did not affect LIF-mediated corticotroph function. These results indicate that STAT3 is a critical intrapituitary component of the LIF-mediated neuroimmunoendocrine interface in corticotroph cells.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,2015, Los Angeles, CA 90048 USA.		Bousquet, Corinne/P-2917-2014	Bousquet, Corinne/0000-0002-2501-0593	NIDDK NIH HHS [DK33802] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033802] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKITA S, 1995, J CLIN INVEST, V95, P1288, DOI 10.1172/JCI117779; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; BESEDOVSKY HO, 1992, FRONT NEUROENDOCRIN, V13, P61; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Bousquet C, 1997, J BIOL CHEM, V272, P10551; Boutillier A L, 1998, Pituitary, V1, P33, DOI 10.1023/A:1009966808106; BOUTILLIER AL, 1995, MOL ENDOCRINOL, V9, P745, DOI 10.1210/me.9.6.745; BOUTILLIER AL, 1991, MOL ENDOCRINOL, V5, P1301, DOI 10.1210/mend-5-9-1301; Chesnokova V, 1998, ENDOCRINOLOGY, V139, P2209, DOI 10.1210/en.139.5.2209; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kojima H, 1996, ONCOGENE, V12, P547; Liu B, 1995, BIOCHEM J, V312, P827, DOI 10.1042/bj3120827; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; NAKAJIMA K, 1996, EMBO J, V15, P3951; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Ray D, 1997, ENDOCR REV, V18, P206, DOI 10.1210/er.18.2.206; Ray DW, 1996, J CLIN INVEST, V97, P1852, DOI 10.1172/JCI118615; Sacerdote Paola, 1994, Neuroimmunomodulation, V1, P357, DOI 10.1159/000097188; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575, DOI 10.1210/endo-125-1-575; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SUDA T, 1989, ENDOCRINOLOGY, V124, P1444, DOI 10.1210/endo-124-3-1444; THOMA B, 1994, J BIOL CHEM, V269, P6215; VALE W, 1983, RECENT PROG HORM RES, V39, P245; Wang ZY, 1996, ENDOCRINOLOGY, V137, P2947, DOI 10.1210/en.137.7.2947; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837	45	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10723	10730		10.1074/jbc.274.16.10723	http://dx.doi.org/10.1074/jbc.274.16.10723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196143	hybrid			2022-12-25	WOS:000079751900011
J	Chen, Y; Morrow, JD; Roberts, LJ				Chen, Y; Morrow, JD; Roberts, LJ			Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PROSTAGLANDIN-D SYNTHASE; INTRACELLULAR GLUTATHIONE; GROWTH-INHIBITION; METABOLITE; MECHANISM; J(2); 9-DEOXY-DELTA-9,DELTA-12-13,14-DIHYDROPROSTAGLANDIN-D2; 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2; DELTA-12-PROSTAGLANDIN-J2	Cyclopentenone prostaglandins A(2) and J(2) are reactive compounds that possess unique biological activities. However, the extent to which they are formed in vivo remains unclear. In this study, we explored whether D-2/E-2-isoprostanes undergo dehydration in vivo to form A(2)/J(2)-isoprostanes. Oxidation of arachidonic acid in vitro generated a series of compounds that were confirmed to be A(2)/J(2)-isoprostanes by mass spectrometric analyses. A(2)/J(2)-isoprostanes were detected in vivo esterified to lipids in livers from normal rats at a level of 5.1 +/- 2.3 ng/g, and levels increased dramatically by a mean of 24-fold following administration of CCl4. An A(2)-isoprostane, 15-A(2t)-isoprostane, was obtained and found to readily undergo Michael addition with glutathione and to adduct covalently to protein. A(2)/J(2)-isoprostanes could not be detected in the circulation, even following CCl4 administration, which we hypothesized might be explained by rapid formation of adducts. This was supported by finding that essentially all the radioactivity excreted into the urine following infusion of radiolabaled 15-A(2t)-isoprostane into a human volunteer was in the form of a polar conjugate(s). These data identify a new class of reactive compounds that are produced in vivo as products of the isoprostane pathway that can exert biological effects relevant to the pathobiology of oxidant injury.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Roberts, LJ (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	jack.roberts@mcmail.vanderbilt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM42057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; ATTALLAH A, 1974, PROSTAG OTH LIPID M, V5, P69, DOI 10.1016/S0090-6980(74)80133-4; BOYLAND E, 1968, BIOCHEM J, V109, P651, DOI 10.1042/bj1090651; Bui T, 1998, BBA-GENE STRUCT EXPR, V1397, P31, DOI 10.1016/S0167-4781(97)00214-5; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1989, ADV PROSTAG THROMB L, V19, P415; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; FUKUSHIMA M, 1982, BIOCHEM BIOPH RES CO, V109, P626, DOI 10.1016/0006-291X(82)91986-6; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HIRATA Y, 1988, J BIOL CHEM, V263, P16619; HONN KV, 1985, BIOCHEM BIOPH RES CO, V129, P34, DOI 10.1016/0006-291X(85)91398-1; JONSSON HT, 1976, J LIPID RES, V17, P1; KIKAWA Y, 1984, P NATL ACAD SCI-BIOL, V81, P1317, DOI 10.1073/pnas.81.5.1317; Kim HS, 1996, PROSTAGLANDINS, V51, P413, DOI 10.1016/0090-6980(96)00047-0; KIM IK, 1993, FEBS LETT, V321, P209, DOI 10.1016/0014-5793(93)80110-G; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; MARINEZCAYUELA M, 1995, BIOCHIMIE PARIS, V77, P147; Melegos DN, 1996, CLIN CHEM, V42, P1984; MIDDLEDITCH BS, 1975, PROSTAGLANDINS, V9, P409, DOI 10.1016/0090-6980(75)90147-1; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1991, ANAL BIOCHEM, V193, P142, DOI 10.1016/0003-2697(91)90054-W; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P506; PACEASCIAK CR, 1989, ADV PROSTAG THROMB L, V18, P1; Parker J, 1995, PROSTAGLANDINS, V50, P359, DOI 10.1016/0090-6980(95)00136-0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSELLO J, 1978, J CHROMATOGR SCI, V16, P177, DOI 10.1093/chromsci/16.5.177; Santoro MG, 1997, TRENDS MICROBIOL, V5, P276, DOI 10.1016/S0966-842X(97)01066-4; SHAHABI NA, 1987, EXP CELL BIOL, V55, P18; STEHLE RG, 1977, J PHARM SCI-US, V66, P1590, DOI 10.1002/jps.2600661123; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; Tokugawa Y, 1998, BIOL REPROD, V58, P600, DOI 10.1095/biolreprod58.2.600	39	137	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10863	10868		10.1074/jbc.274.16.10863	http://dx.doi.org/10.1074/jbc.274.16.10863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196163	hybrid			2022-12-25	WOS:000079751900031
J	Biberstine-Kinkade, KJ; Yu, LX; Dinauer, MC				Biberstine-Kinkade, KJ; Yu, LX; Dinauer, MC			Mutagenesis of an arginine- and lysine-rich domain in the gp91(phox) subunit of the phagocyte NADPH-oxidase flavocytochrome b(558)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; GTP-BINDING PROTEIN; RESPIRATORY BURST ACTIVITY; SITE-DIRECTED MUTAGENESIS; SRC HOMOLOGY-3 DOMAINS; MEDIATED GENE-TRANSFER; BONE-MARROW CELLS; HUMAN-NEUTROPHILS; CYTOCHROME B(558); SUPEROXIDE PRODUCTION	Site-directed mutagenesis was used to generate a series of mutants harboring point or multiple substitutions within the hydrophilic, polybasic domain of gp91(phox) encompassed by residues 86-102, which was previously identified as a site of interaction with p47(phox) during phagocyte NADPH oxidase assembly. Recombinant wild-type or mutant gp91(phox) was expressed in a human myeloid leukemia cell line in which the endogenous gp91(phox) gene was disrupted by gene targeting. NADPH oxidase activity was measured in a cytochrome c reduction assay following granulocytic differentiation of cells that expressed recombinant gp91(phox), Expression of a gp91(phox) mutant in which amino acids 89-97 were replaced with nine alternate amino acids abolished NADPH oxidase activity. Expression of gp91(phox) mutants R89T, D95A, D95R, R96A, R96E, or K102T did not significantly affect NADPH oxidase activity. However, mutations of individual or paired arginine residues at positions 91 and 92 had substantial effects on superoxide generation. The R91E/R92E mutation completely abolished both NADPH oxidase activity and membrane-translocation of the cytosolic oxidase proteins p47(phox), P67(phox), Rac1, and Rac2, The phorbol 12-myristate 13-acetate-induced rate of superoxide production was reduced by similar to 75% in cells expressing R91T/R92A, R91E, or R92E gp91(phox) along with an increased lag time to the maximal rates of superoxide production relative to cells expressing wild-type gp91(phox), Taken together, these results demonstrate that Arg(91) and Arg(92) of gp91(phox) are essential for flavocytochrome b(558) function in granulocytes and suggest that these residues participate in the interaction of gp91(phox) with the cytosolic oxidase proteins.	Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med,Dept Pediat Hematol Oncol, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Dinauer, MC (corresponding author), Indiana Univ, Sch Med, Canc Res Inst, Herman B Wells Ctr Pediat Res, 1044 W Walnut, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu						ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Bjorgvinsdottir H, 1997, BLOOD, V89, P41, DOI 10.1182/blood.V89.1.41.41_41_48; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; DeLeo FR, 1996, J IMMUNOL METHODS, V198, P35, DOI 10.1016/0022-1759(96)00144-5; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DINAUER M, 1998, HEMATOLOGY INFANCY C, P889; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; Ding CJ, 1996, BLOOD, V88, P1834; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Downey G P, 1995, Curr Opin Hematol, V2, P76; Downey GP, 1998, J IMMUNOL, V160, P434; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; DUSI S, 1995, BIOCHEM J, V308, P991, DOI 10.1042/bj3080991; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; FUJITA I, 1987, BIOCHIM BIOPHYS ACTA, V931, P41, DOI 10.1016/0167-4889(87)90048-6; GREEN SP, 1994, J LEUKOCYTE BIOL, V55, P530, DOI 10.1002/jlb.55.4.530; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P299, DOI 10.1016/0167-4889(90)90225-3; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; KLEINBERG ME, 1994, BIOCHEMISTRY-US, V33, P2490, DOI 10.1021/bi00175a018; KLEINBERG ME, 1992, BIOCHEMISTRY-US, V31, P2686, DOI 10.1021/bi00125a008; KLEINBERG ME, 1990, J BIOL CHEM, V265, P15577; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; KUME A, 1994, BLOOD, V84, P3311; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J CLIN INVEST, V93, P2120, DOI 10.1172/JCI117207; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LEVY R, 1994, BBA-MOL CELL RES, V1220, P253, DOI 10.1016/0167-4889(94)90146-5; Maniatis T., 1982, MOL CLONING LAB MANU; NAUSEEF WM, 1993, EUR J HAEMATOL, V51, P301; NAUSEEF WM, 1993, J BIOL CHEM, V268, P23646; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Park MY, 1997, BIOCHEM BIOPH RES CO, V234, P531, DOI 10.1006/bbrc.1997.6672; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1992, BLOOD, V79, P1563; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Roos D, 1996, IMMUNOL TODAY, V17, P517; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TOSI MF, 1992, AM J CLIN PATHOL, V97, P566, DOI 10.1093/ajcp/97.4.566; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Zhen L, 1998, J BIOL CHEM, V273, P6575, DOI 10.1074/jbc.273.11.6575; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	57	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10451	10457		10.1074/jbc.274.15.10451	http://dx.doi.org/10.1074/jbc.274.15.10451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187835	hybrid			2022-12-25	WOS:000079663500074
J	Di Fiore, B; Guarguaglini, G; Palena, A; Kerkhoven, RM; Bernards, R; Lavia, P				Di Fiore, B; Guarguaglini, G; Palena, A; Kerkhoven, RM; Bernards, R; Lavia, P			Two E2F sites control growth-regulated and cell cycle-regulated transcription of the Htf9-a/RanBP1 gene through functionally distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-MYB TRANSCRIPTION; PROTEIN FAMILY MEMBERS; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; SUBCELLULAR-LOCALIZATION; HOUSEKEEPING PROMOTER; SUBUNIT COMPOSITION; BINDING-SITE; HTF9-C GENES; IN-VIVO	The gene encoding Ran-binding protein 1 (RanBP1) is transcribed in a cell cycle-dependent manner. The RanBP1 promoter contains two binding sites for E2F factors, named E2F-c, located proximal to the transcription start, and E2F-b, falling in a more distal promoter region, We have now induced site-directed mutagenesis in both sites. We have found that the distal E2F-b site, together with a neighboring Spl element, actively controls up-regulation of transcription in S phase. The proximal E2F-c site plays no apparent role in cycling cells yet is required for transcriptional repression upon growth arrest. Protein binding studies suggest that each E2F site mediates specific interactions with individual E2F family members. In addition, transient expression assays with mutagenized promoter constructs indicate that the functional role of each site is also dependent on its position relative to other regulatory elements in the promoter context. Thus, the two E2F sites play opposite genetic functions and control RanBP1 transcription through distinct molecular mechanisms.	Univ Rome La Sapienza, CNR, Ctr Evolutionary Genet, I-00185 Rome, Italy; Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Netherlands Cancer Institute	Lavia, P (corresponding author), Univ Rome La Sapienza, CNR, Ctr Evolutionary Genet, Via Apuli 4, I-00185 Rome, Italy.	lavia@axrma.uniroma1.it	Lavia, Patrizia/J-5793-2019; Lavia, Patrizia/AAL-3982-2021	Lavia, Patrizia/0000-0003-3310-6701; Bernards, Rene/0000-0001-8677-3423				Allen KE, 1997, J CELL SCI, V110, P2819; Battistoni A, 1997, J CELL SCI, V110, P2345; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Bennett JD, 1996, ONCOGENE, V13, P1073; Bernards R, 1997, BBA-REV CANCER, V1333, pM33, DOI 10.1016/S0304-419X(97)00027-9; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P157; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; COUTAVAS EE, 1994, MAMM GENOME, V5, P623, DOI 10.1007/BF00411457; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; delaLuna S, 1996, J CELL SCI, V109, P2443; Di Matteo G, 1998, J BIOL CHEM, V273, P495, DOI 10.1074/jbc.273.1.495; DIMATTEO G, 1995, CELL GROWTH DIFFER, V6, P1213; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Geng Y, 1996, ONCOGENE, V12, P1173; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Guarguaglini G, 1997, BIOCHEM J, V325, P277, DOI 10.1042/bj3250277; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Magae J, 1996, J CELL SCI, V109, P1717; MAYOL X, 1998, FRONT BIOSCI, V3, P11; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 1997, MOL CELL BIOL, V17, P5508; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Pu RT, 1997, MOL BIOL CELL, V8, P1955, DOI 10.1091/mbc.8.10.1955; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; SOMMA MP, 1991, NUCLEIC ACIDS RES, V19, P2817, DOI 10.1093/nar/19.11.2817; STAPLETON G, 1993, NUCLEIC ACIDS RES, V21, P2465, DOI 10.1093/nar/21.10.2465; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Tommasi S, 1997, J BIOL CHEM, V272, P30483, DOI 10.1074/jbc.272.48.30483; Tsuneoka M, 1997, ONCOGENE, V14, P2301, DOI 10.1038/sj.onc.1201067; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZHU LG, 1995, MOL CELL BIOL, V15, P3552	54	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10339	10348		10.1074/jbc.274.15.10339	http://dx.doi.org/10.1074/jbc.274.15.10339			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187822	Green Published, hybrid			2022-12-25	WOS:000079663500061
J	Firestein, BL; Bredt, DS				Firestein, BL; Bredt, DS			Interaction of neuronal nitric-oxide synthase and phosphofructokinase-M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY PROTEIN PSD-95; CENTRAL-NERVOUS-SYSTEM; NEONATAL RAT-BRAIN; 6-PHOSPHOFRUCTO-1-KINASE ISOENZYMES; CORTICAL CULTURES; SKELETAL-MUSCLE; PDZ DOMAINS; FRUCTOSE-1,6-BISPHOSPHATE; ENZYME; NEUROTOXICITY	Neurons that express neuronal nitric-oxide synthase (nNOS) are resistant to NO-induced neurotoxicity; however, the mechanism by which these neurons are protected is not clear. To identify proteins possibly involved in this process, we performed affinity chromatography with the nNOS PDZ domain, a N-terminal motif that mediates protein interactions. Using this method to fractionate soluble tissue extracts, we identified the muscle isoform of phosphofructokinase (PFK-M) as a protein that binds to nNOS both in brain and skeletal muscle. PFK-RI interacts with the PDZ domain of nNOS, and nNOS-PFK-M binding can be competed by peptides that bind to the PDZ domain of nNOS, We found that nNOS is significantly associated with PFK-M in skeletal muscle because nNOS can be immunodepleted from cytosolic skeletal muscle extracts using an antibody directed against PFK-M, In brain, nNOS and PFK-M are both enriched in synaptosomes, and specifically, in the synaptic vesicle fraction, where they can interact. At the cellular level, PFK-M is enriched in neurons that express nNOS protein. As fructose-1,6-bisphosphate, the product of PFK activity, is neuroprotective, the interaction of nNOS and PFK may contribute to neuroprotection of nNOS positive cells.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Firestein, BL (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444,513 Parnassus Ave, San Francisco, CA 94143 USA.	bonfire@itsa.ucsf.edu	Bredt, David/J-4872-2012	Firestein, Bonnie/0000-0002-1679-3565	NINDS NIH HHS [R01-NS36017] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036017] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aoki C, 1997, BRAIN RES, V750, P25, DOI 10.1016/S0006-8993(96)01147-X; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; BERNASCONI C, 1983, RES COMMUN CHEM PATH, V42, P281; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1997, CURR OPIN NEUROBIOL, V7, P374, DOI 10.1016/S0959-4388(97)80065-7; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dawson VL, 1996, J NEUROSCI, V16, P2479; de la Torre JC, 1998, BRAIN RES, V779, P285, DOI 10.1016/S0006-8993(97)01169-4; DUNAWAY GA, 1985, J BIOL CHEM, V260, P4180; DUNAWAY GA, 1987, BIOCHEM J, V242, P667, DOI 10.1042/bj2420667; ERECINSKA M, 1995, J NEUROCHEM, V65, P2765; Espanol MT, 1998, ANESTHESIOLOGY, V88, P461, DOI 10.1097/00000542-199802000-00025; FOE LG, 1985, J BIOL CHEM, V260, P726; Garner JA, 1996, J NEUROCHEM, V67, P845; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Gracy KN, 1997, BRAIN RES, V747, P259, DOI 10.1016/S0006-8993(96)01249-8; HASSINEN IE, 1991, CIRCULATION, V83, P584, DOI 10.1161/01.CIR.83.2.584; Hawkins RD, 1996, NEURON, V16, P465, DOI 10.1016/S0896-6273(00)80064-1; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIRTLEY ME, 1977, MOL CELL BIOCHEM, V18, P141, DOI 10.1007/BF00280279; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; PARDUCZ A, 1994, NEUROSCIENCE, V62, P93, DOI 10.1016/0306-4522(94)90317-4; RIGOBELLO MP, 1982, FARMACO-ED SCI, V37, P459; Roberts CK, 1997, AM J PHYSIOL-ENDOC M, V273, pE220, DOI 10.1152/ajpendo.1997.273.1.E220; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Sola A, 1996, BRAIN RES, V741, P294, DOI 10.1016/S0006-8993(96)00984-5; Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092-8674(00)81796-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; Zeitschel U, 1996, J NEUROCHEM, V67, P2573; Zhao SM, 1997, BIOCHEMISTRY-US, V36, P8318, DOI 10.1021/bi962814r	51	61	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10545	10550		10.1074/jbc.274.15.10545	http://dx.doi.org/10.1074/jbc.274.15.10545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187848	hybrid			2022-12-25	WOS:000079663500087
J	Hong, SP; Piper, MD; Sinclair, DA; Dawes, IW				Hong, SP; Piper, MD; Sinclair, DA; Dawes, IW			Control of expression of one-carbon metabolism genes of Saccharomyces cerevisiae is mediated by a tetrahydrofolate-responsive protein binding to a glycine regulatory region including a core 5 '-CTTCTT-3 ' motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; LIPOAMIDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; CLEAVAGE SYSTEM; CARRIER PROTEIN; LPD1 GENE; SITES; DECARBOXYLASE; SYNTHETASE; REPRESSION	Expression of yeast genes involved in one-carbon metabolism is controlled by glycine, by L-methionine, and by nitrogen sources. Here we report a novel control element containing a core CTTCTT moth mediating the glycine response, demonstrating that a protein binds this element, that binding is modulated by tetrahydrofolate, and that folate is required for the in vivo glycine response. In an heterologous CYC1 promoter the region needed for the glycine response of GCV2 (encoding the P-subunit of glycine decarboxylase) mediated repression that was relieved by glycine. It was also responsible for L-methionine control but not nitrogen repression. GCV1 and GCV3 have an homologous region in their promoters. The GCV1 region conferred a glycine response on an heterologous promoter acting as a repressor or activator depending on promoter context. A protein was identified that bound to the glycine regulatory regions of GCV1 and GCV2 only if the CTTCTT motif was intact. This protein protected a 17-base pair CATCN(7)CTTCTT region of GCV2 that is conserved between GCV1 and GCV2. Protein binding was increased by tetrahydrofolate, and use of a foil deletion mutant indicated the involvement of a folate in the in vivo glycine response. Tetrahydrofolate or a derivative may act as a Ligand for the transcription factor controlling expression of one-carbon metabolism genes.	Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Dawes, IW (corresponding author), Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia.	i.dawes@unsw.edu.au	Piper, Matthew/C-1714-2008	Piper, Matthew/0000-0003-3245-7219; Sinclair, David/0000-0002-9936-436X				Blakley R.L., 1969, N HOLLAND RES MONOGR, P1; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; COSSINS EA, 1966, BIOCHEM J, V101, P542, DOI 10.1042/bj1010542; CUNNINGHAM TS, 1993, J BACTERIOL, V175, P5851, DOI 10.1128/JB.175.18.5851-5861.1993; DAUGHERTY JR, 1993, J BACTERIOL, V175, P64, DOI 10.1128/JB.175.1.64-73.1993; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; GHRIST AC, 1995, J BACTERIOL, V177, P4980, DOI 10.1128/jb.177.17.4980-4984.1995; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; HIRAGA K, 1980, J BIOL CHEM, V255, P1671; Kaiser C., 1994, METHODS YEAST GENETI; KOICHI H, 1974, J BIOCHEM-TOKYO, V75, P1113; LIN BF, 1994, J BIOL CHEM, V269, P9705; LOR KL, 1972, BIOCHEM J, V130, P773, DOI 10.1042/bj1300773; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKENZIE KQ, 1977, GENETICS, V86, P85; McNeil JB, 1997, GENE, V186, P13, DOI 10.1016/S0378-1119(96)00670-1; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nagarajan L, 1997, J BIOL CHEM, V272, P4444, DOI 10.1074/jbc.272.7.4444; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; ROSS J, 1988, J GEN MICROBIOL, V134, P1131; RUET A, 1984, EMBO J, V3, P343, DOI 10.1002/j.1460-2075.1984.tb01809.x; SAGERS RD, 1961, J BACTERIOL, V81, P541, DOI 10.1128/JB.81.4.541-549.1961; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SHANE B, 1989, VITAM HORM, V45, P263; Sinclair DA, 1996, MOL MICROBIOL, V19, P611, DOI 10.1046/j.1365-2958.1996.419947.x; SINCLAIR DA, 1994, MOL CELL BIOL, V14, P214, DOI 10.1128/MCB.14.1.214; SINCLAIR DA, 1995, GENETICS, V140, P1213; STABEN C, 1986, J BIOL CHEM, V261, P4629; STANWAY C, 1987, NUCLEIC ACIDS RES, V15, P6855, DOI 10.1093/nar/15.17.6855; ULANE R, 1972, J BACTERIOL, V109, P34, DOI 10.1128/JB.109.1.34-43.1972; YOSHIDA T, 1972, J BIOCHEM, V72, P1503, DOI 10.1093/oxfordjournals.jbchem.a130042	37	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10523	10532		10.1074/jbc.274.15.10523	http://dx.doi.org/10.1074/jbc.274.15.10523			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187845	hybrid			2022-12-25	WOS:000079663500084
J	Juge-Aubry, CE; Hammar, E; Siegrist-Kaiser, C; Pernin, A; Takeshita, A; Chin, WW; Burger, AG; Meier, CA				Juge-Aubry, CE; Hammar, E; Siegrist-Kaiser, C; Pernin, A; Takeshita, A; Chin, WW; Burger, AG; Meier, CA			Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a dependent trans-activating domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOID-X RECEPTOR; KINASE-MEDIATED PHOSPHORYLATION; NUCLEAR RECEPTOR; PROTEIN-KINASE; ESTROGEN-RECEPTOR; SIGNALING PATHWAYS; CO-REPRESSOR; GAMMA; BINDING	The peroxisome proliferator-activated receptors (PPARs) are a subgroup of nuclear receptors activated by fatty acids and eicosanoids, In addition, they are subject to phosphorylation by insulin, resulting in the activation of PPAR alpha, while inhibiting PPAR gamma under certain conditions. However, it was hitherto unclear whether the stimulatory effect of insulin on PPAR alpha was direct and by which mechanism it occurs. We now demonstrate that amino acids 1-92 of hPPAR alpha contain an activation function (AF)-1-like domain, which is further activated by insulin through a pathway involving the mitogen-activated protein kinases p42 and p44, Further analysis of the amino-terminal region of PPAR alpha revealed that the insulin-induced trans-activation occurs through the phosphorylation of two mitogen-activated protein kinase sites at positions 12 and 21, both of which are conserved across evolution. The characterization of a strong AF-1 region in PPAR alpha, stimulating transcription one-fourth as strongly as the viral protein VP16, is compatible with the marked basal transcriptional activity of this isoform in transfection experiments. However, it is intriguing that the activity of this AF-1 region is modulated by the phosphorylation of two serine residues, both of which must be phosphorylated in order to activate transcription. This is in contrast to PPAR gamma 2, which was previously shown to be phosphorylated at a single site in a motif that is not homologous to the sites now described in PPAR alpha. Although the molecular details involved in the phosphorylation-dependent enhancement of the transcriptional activity of PPAR alpha remain to be elucidated, we demonstrate that the effect of insulin on the AF-1 region of PPAR alpha can be mimicked by the addition of triiodothyronine receptor beta 1, a strong binder of corepressor proteins. In addition, a triiodothyronine receptor beta 1 mutant deficient in interacting with corepressors is unable to activate PPAR alpha, These observations suggest that the AF-1 region of PPAR alpha is partially silenced by corepressor proteins, which might interact in a phosphorylation-dependent manner.	Univ Hosp Geneva, Div Endocrinol & Diabet, CH-1211 Geneva 14, Switzerland; Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; Univ Hosp Geneva, Dept Med, Med Clin 2, CH-1211 Geneva, Switzerland	University of Geneva; Harvard University; Brigham & Women's Hospital; University of Geneva	Meier, CA (corresponding author), Univ Hosp Geneva, Div Endocrinol & Diabet, CH-1211 Geneva 14, Switzerland.	cameier@genet.ch		Hammar, Eva/0000-0002-3267-2202				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Camp HS, 1997, J BIOL CHEM, V272, P10811; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lemberger T, 1996, ANN NY ACAD SCI, V804, P231, DOI 10.1111/j.1749-6632.1996.tb18619.x; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	32	149	154	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10505	10510		10.1074/jbc.274.15.10505	http://dx.doi.org/10.1074/jbc.274.15.10505			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187842	hybrid			2022-12-25	WOS:000079663500081
J	Merritt, SE; Mata, M; Nihalani, D; Zhu, CX; Hu, XP; Holzman, LB				Merritt, SE; Mata, M; Nihalani, D; Zhu, CX; Hu, XP; Holzman, LB			The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ZIPPER-BEARING KINASE; SIGNAL-TRANSDUCTION PATHWAY; GLUTATHIONE-S-TRANSFERASE; N-TERMINAL KINASE; C-JUN; MOLECULAR-CLONING; INDUCED APOPTOSIS; FUSION PROTEINS; STRESS	Mixed lineage kinases DLK (dual leucine zipper-bearing kinase) and MLK3 have been proposed to function as mitogen-activated protein kinase kinase kinases in pathways leading to stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Differences in primary protein structure place these MLK (mixed Lineage kinase) enzymes in separate subfamilies and suggest that they perform distinct functional roles. Both DLK and MLK3 associated with, phosphorylated, and activated MKK7 in vitro. Unlike MLK3, however, DLK did not phosphorylate or activate recombinant MKK4 in vitro, In confirmatory experiments performed in vivo, DLK both associated with and activated MKK7, The relative localization of endogenous DLK, MLK3, MKK4, and MKK7 was determined in cells of the nervous system. Distinct from MLK3, which was identified in non-neuronal cells, DLK and MKK7 were detected predominantly in neurons in sections of adult rat cortex by immunocytochemistry. Subcellular fractionation experiments of cerebral cortex identified DLK and MKK7 in similar nuclear and extranuclear subcellular compartments. Concordant with biochemical experiments, however, MKK4 occupied compartments distinct from that of DLK and MKK7, That DLK and MKK7 occupied subcellular compartments distinct from MKK4 was confirmed by immunocytochemistry in primary neuronal culture. The dissimilar cellular specificity of DLK and MLK3 and the specific substrate utilization and subcellular compartmentation of DLK suggest that specific mixed Lineage kinases participate in unique signal transduction events.	Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; Dept Vet Affairs, Ann Arbor, MI 48105 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; Dept Vet Affairs, Pittsburgh, PA 15213 USA	University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, 1560 Med Sci Res Bldg 2, Ann Arbor, MI 48109 USA.	lholzman@umich.edu	nihalani, deepak/AAK-9453-2020	Holzman, Lawrence/0000-0002-8961-234X				BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GAO B, 1995, NEUROSCIENCE, V65, P101, DOI 10.1016/0306-4522(94)00480-S; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Kenney AM, 1998, J NEUROSCI, V18, P1318; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	36	84	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10195	10202		10.1074/jbc.274.15.10195	http://dx.doi.org/10.1074/jbc.274.15.10195			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187804	hybrid			2022-12-25	WOS:000079663500043
J	Shimada, H; Nagano, S; Ariga, Y; Unno, M; Egawa, T; Hishiki, T; Ishimura, Y				Shimada, H; Nagano, S; Ariga, Y; Unno, M; Egawa, T; Hishiki, T; Ishimura, Y			Putidaredoxin-cytochrome P450(cam) interaction - Spin state of the heme iron modulates putidaredoxin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN ACTIVATION; P-450CAM; CAMPHOR; MODEL; FERREDOXIN; RESOLUTION; MECHANISM	During the monooxygenase reaction catalyzed by cytochrome P450(cam) (P450(cam)), a ternary complex of P450(cam), reduced putidaredoxin, and d-camphor is formed as an obligatory reaction intermediate. When ligands such as CO, NO, and O-2 bind to the heme iron of P450(cam) in the intermediate complex, the EPR spectrum of reduced putidaredoxin with a characteristic signal at 346 millitesla at 77 K changed into a spectrum having a new signal at 348 millitesla. The experiment with O-2 was carried out by employing a mutant P450(cam) with Asp(251) --> Asn or Gly where the rate of electron transfer from putidaredoxin to oxyferrous P450(cam) is considerably reduced. Such a ligand-induced EPR spectral change of putidaredoxin was also shown in situ in Pseudomonas putida, Mutations introduced into the neighborhood of the iron-sulfur cluster of putidaredoxin revealed that a Ser(44) --> Gly mutation mimicked the ligand-induced spectral change of putidaredoxin. Arg(109) and Arg(112), which are in the putative putidaredoxin binding site of P450(cam), were essential for the spectral changes of putidaredoxin in the complex. These results indicate that a change in the P450(cam) active site that is the consequence of an altered spin state is transmitted to putidaredoxin within the ternary complex and produces a conformational change of the 2Fe-2S active center.	Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, Tokyo 1608582, Japan; Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Toyonaka, Osaka 5608531, Japan	Keio University; Osaka University	Shimada, H (corresponding author), Keio Univ, Sch Med, Dept Biochem, Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	shimada@med.keio.ac.jp		Unno, Masashi/0000-0002-5016-6274				BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; DUGAD LB, 1990, BIOCHEMISTRY-US, V29, P2263, DOI 10.1021/bi00461a009; GERBER NC, 1994, J BIOL CHEM, V269, P4260; Gunsalus I C, 1978, Methods Enzymol, V52, P166; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; HINTZ MJ, 1982, J BIOL CHEM, V257, P4324; Holden M, 1997, J BIOL CHEM, V272, P21720, DOI 10.1074/jbc.272.35.21720; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; Ishimura Y., 1987, CYTOCHROME P 450 NEW, P151; KATAGIRI M, 1968, J BIOL CHEM, V243, P3543; LIPSCOMB JD, 1980, BIOCHEMISTRY-US, V19, P3590, DOI 10.1021/bi00556a027; LIPSCOMB JD, 1976, J BIOL CHEM, V251, P1116; PETERSON JA, 1970, J BACTERIOL, V103, P714, DOI 10.1128/JB.103.3.714-721.1970; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; Pochapsky TC, 1996, BIOCHIMIE, V78, P723, DOI 10.1016/S0300-9084(97)82530-8; POCHAPSKY TC, 1994, BIOCHEMISTRY-US, V33, P6424, DOI 10.1021/bi00187a006; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; ROOME PW, 1983, J BIOL CHEM, V258, P2593; SANDS RH, 1974, Q REV BIOPHYS, V7, P443, DOI 10.1017/S0033583500001517; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; SHIMADA H, 1993, CYTOCHROME P450 BIOC, P299; SHIMADA H, 1997, CATAL MET C, V19, P195; SHIMADA H, 1990, INT S OXYGENASES OXY, P133; SHIRO Y, 1989, J AM CHEM SOC, V111, P7707, DOI 10.1021/ja00202a007; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1975, THESIS U ILLINOIS UR; TSIBRIS JCM, 1968, P NATL ACAD SCI USA, V59, P959, DOI 10.1073/pnas.59.3.959; Unno M, 1997, J AM CHEM SOC, V119, P6614, DOI 10.1021/ja963785a; Unno M, 1996, J BIOL CHEM, V271, P17869, DOI 10.1074/jbc.271.30.17869	30	34	34	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9363	9369		10.1074/jbc.274.14.9363	http://dx.doi.org/10.1074/jbc.274.14.9363			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092615	hybrid			2022-12-25	WOS:000079451800034
J	Meynell, HM; Thomas, NW; James, PS; Holland, J; Taussig, MJ; Nicoletti, C				Meynell, HM; Thomas, NW; James, PS; Holland, J; Taussig, MJ; Nicoletti, C			Up-regulation of microsphere transport across the follicle-associated epithelium of Peyer's patch by exposure to Streptococcus pneumoniae R36a	FASEB JOURNAL			English	Article						M cell; enterocyte; mucosal immunity; FAE; antigen delivery	M-CELLS; IMMUNE-RESPONSES; INFECTION; ANTIGEN; BACTERIUM; MICE	Transport of antigens through the follicle-associated epithelium (FAE) of Peyer's patch (PP) is the critical first step in the induction of mucosal immune responses. We have previously described that short-term exposure to Streptococcus pneumoniae R36a induced dramatic morphological alterations of the FAE in rabbit PP. These results prompted us to investigate whether the pneumococci-induced modifications were accompanied by enhanced ability of the FAE to transport antigens. We addressed this problem by evaluating the ability of the FAE to bind, internalize, and transport fluorescent polystyrene microparticles, highly specific to rabbit M cells, after exposure to S. pneumoniae. Quantitative study revealed a marked increase in the number of microspheres in PP tissues exposed to S. pneumoniae compared to tissues exposed to either phosphate-buffered saline or Escherichia coli DH5 alpha as controls. No sign of bacterially induced damage to the epithelial barrier was observed. Further confocal microscopy analysis of the FAE surface showed that a significant increase in the number of cells that showed both morphological and functional features of M cells took place within pneumococci-treated PP tissues. These data provide the first direct evidence that the FAE-specific antigen sampling function may be manipulated to improve antigen and drug delivery to the intestinal immune system.	Babraham Inst, Lab Mol Recognit, Cambridge CB2 4AT, England; Babraham Inst, Lab Cell Signaling, Cambridge, England; Univ Nottingham, Sch Pharmaceut Sci, Nottingham NG7 2RD, England; Queens Med Ctr, Dept Human Anat & Cell Biol, Nottingham NG7 2UH, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Nottingham; University of Nottingham	Nicoletti, C (corresponding author), Babraham Inst, Lab Mol Recognit, Cambridge CB2 4AT, England.	claudio.nicoletti@bbsrc.ac.uk						Borghesi C, 1996, J PATHOL, V180, P326, DOI 10.1002/(SICI)1096-9896(199611)180:3<326::AID-PATH656>3.0.CO;2-6; Gebert A, 1996, INT REV CYTOL, V167, P91, DOI 10.1016/S0074-7696(08)61346-7; JEPSON MA, 1993, CELL TISSUE RES, V271, P399, DOI 10.1007/BF02913722; JEPSON MA, 1992, HISTOCHEM J, V24, P33, DOI 10.1007/BF01043285; Jepson MA, 1998, TRENDS MICROBIOL, V6, P359, DOI 10.1016/S0966-842X(98)01337-7; Jepson MA, 1993, J DRUG TARGET, V1, P245, DOI 10.3109/10611869308996082; JONES BD, 1994, J EXP MED, V180, P15, DOI 10.1084/jem.180.1.15; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; LAGRANDERIE M, 1993, VACCINE, V11, P1283, DOI 10.1016/0264-410X(93)90096-G; Madara JL, 1997, SCIENCE, V277, P910, DOI 10.1126/science.277.5328.910; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NEUTRA MR, 1993, J CELL SCI, P209; REGOLI M, 1995, ANN ANAT, V177, P119, DOI 10.1016/S0940-9602(11)80057-9; REGOLI M, 1994, ANAT REC, V239, P47, DOI 10.1002/ar.1092390106; Robinson K, 1997, NAT BIOTECHNOL, V15, P653, DOI 10.1038/nbt0797-653; Sansonetti PJ, 1996, INFECT IMMUN, V64, P2752, DOI 10.1128/IAI.64.7.2752-2764.1996; SAVIDGE TC, 1991, AM J PATHOL, V139, P177; SMITH MW, 1987, AM J PATHOL, V128, P385; SMITH MW, 1988, HISTOCHEM J, V20, P443, DOI 10.1007/BF01002430	20	67	68	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					611	619		10.1096/fasebj.13.6.611	http://dx.doi.org/10.1096/fasebj.13.6.611			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094922				2022-12-25	WOS:000079527200003
J	Karasawa, K; Qiu, XY; Lee, TC				Karasawa, K; Qiu, XY; Lee, TC			Purification and characterization from rat kidney membranes of a novel platelet-activating factor (PAF)-dependent transacetylase that catalyzes the hydrolysis of PAF, formation of PAF analogs, and C(2)-ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; COA-INDEPENDENT TRANSACETYLASE; FACTOR-ACETYLHYDROLASE-II; HL-60 CELLS; SPHINGOSINE; CERAMIDE; STRESS; KINASE; 1-ACYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; SPHINGOMYELINASE	We have previously identified two enzyme activities that transfer the acetyl group from platelet-activating factor (PAF) in a CoA-independent manner to lysoplasmalogen or sphingosine in HL-60 cells, endothelial cells, and a variety of rat tissues. These were termed as PAF: lysoplasmalogen (lysophospholipid) transacetylase and PAF:sphingosine transacetylase, respectively. In the present study, we have solubilized and purified this PAF-dependent transacetylase 13,700-fold from rat kidney membranes (mitochondrial plus microsomal membranes) based on the PAF:lysoplasmalogen transacetylase activity. The mitochondria and microsomes were prepared and washed three times, then solubilized with 0.04% Tween 20 at a detergent/protein (w/w) ratio of 0.1. The solubilized fractions from mitochondria and microsomes were combined and subjected to sequential column chromatographies on DEAE-Sepharose, hydroxyapatite, phenyl Sepharose, and chromatofocusing. The enzyme was further purified by native-polyacrylamide gel electrophoresis (PAGE) and affinity gel matrix in which the competitive inhibitor of the enzyme, 1-O-hexadecyl-2-N-methylcarbamyl-sn-glycero-3-phosphoethanolamine was covalently attached to the CH-Sepharose. On SDS-PAGE, the purified enzyme showed a single homogeneous band with an apparent molecular mass of 40 kDa. The purified enzyme catalyzed transacetylation of the acetyl group not only from PAF to lysoplasmalogen forming plasmalogen analogs of PAF, but also to sphingosine producing N-acetylsphingosine (C(2)-ceramide). In addition, this enzyme acted as a PAF-acetylhydrolase in the absence of lipid acceptor molecules. These results suggest that PAF dependent transacetylase is an enzyme that modifies the cellular functions of PAF through generation of other diverse lipid mediators.	Oak Ridge Associated Univ, Biochem Basic & Appl Res Unit, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Lee, TC (corresponding author), Oak Ridge Associated Univ, Biochem Basic & Appl Res Unit, Oak Ridge, TN 37831 USA.	leetc@orau.gov		Carter, Michelle Qiu/0000-0002-0710-7420	NHLBI NIH HHS [HL-52492] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052492] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balestrieri ML, 1997, J BIOL CHEM, V272, P17431, DOI 10.1074/jbc.272.28.17431; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; Goyal J, 1997, J BIOL CHEM, V272, P16231, DOI 10.1074/jbc.272.26.16231; HANNUM YA, 1987, SCIENCE, V243, P670; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; Lee TC, 1996, ADV EXP MED BIOL, V416, P113; LEE TC, 1992, J BIOL CHEM, V267, P19992; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; NIETO ML, 1991, J BIOL CHEM, V266, P18699; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 1997, BBA-LIPID LIPID MET, V1348, P311, DOI 10.1016/S0005-2760(97)00067-2; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; RodriguezLafrasse C, 1997, BIOCHEM J, V325, P787, DOI 10.1042/bj3250787; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; TESSNER TG, 1990, J BIOL CHEM, V265, P21032; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; TRIGGIANI M, 1991, J IMMUNOL, V147, P660; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	32	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8655	8661		10.1074/jbc.274.13.8655	http://dx.doi.org/10.1074/jbc.274.13.8655			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085103	hybrid			2022-12-25	WOS:000079451600045
J	Kim, E; Ambroziak, P; Otto, JC; Taylor, B; Ashby, M; Shannon, K; Casey, PJ; Young, SG				Kim, E; Ambroziak, P; Otto, JC; Taylor, B; Ashby, M; Shannon, K; Casey, PJ; Young, SG			Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-FACTOR; SACCHAROMYCES-CEREVISIAE; PROTEIN PRENYLATION; K-RAS; ISOPRENYLATED PEPTIDES; ENDOPLASMIC-RETICULUM; N-RAS; CARBOXYL; PROTEOLYSIS; METHYLATION	Little is known about the enzyme(s) required for the endoproteolytic processing of mammalian Ras proteins. We identified a mouse gene (designated Rce1) that shares sequence homology with a yeast gene (RCE1) implicated in the proteolytic processing of Ras2p. To define the role of Rce1 in mammalian Ras processing, we generated and analyzed Rce1-deficient mice. Reel deficiency was lethal late in embryonic development (after embryonic day 15.5). Multiple lines of evidence revealed that Rce1-deficient embryos and cells lacked the ability to endoproteolytically process Ras proteins. First, Ras proteins from Rce1-deficient cells migrated more slowly on SDS-polyacrylamide gels than Ras proteins from wild-type embryos and fibroblasts. Second, metabolic labeling of Rce1-deficient cells revealed that the Ras proteins were not carboxymethylated. Finally, membranes from Rce1 deficient fibroblasts lacked the capacity to proteolytically process farnesylated Ha-Ras, N-Ras, and Ki-Ras or geranylgeranylated Ki-Ras. The processing of two other prenylated proteins, the farnesylated G(gamma 1) subunit of transducin and geranylgeranylated Rap1B, was also blocked. The absence of endoproteolytic processing and carboxymethylation caused Ras proteins to be mislocalized within cells. These studies indicate that Reel is responsible for the endoproteolytic processing of the Ras proteins in mammals and suggest a broad role for this gene in processing other prenylated CAAX proteins.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94141 USA; Acacia Biosci Inc, Richmond, CA 94806 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University	Kim, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, P01HL047660] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41633, HL-47660] Funding Source: Medline; NIA NIH HHS [AG-15451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Boyartchuk VL, 1998, GENETICS, V150, P95; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; COX AD, 1995, METHOD ENZYMOL, V255, P195; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; Farese RV, 1996, J LIPID RES, V37, P347; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gibbs JB, 1997, CURR OPIN CHEM BIOL, V1, P197, DOI 10.1016/S1367-5931(97)80010-5; GILBERT BA, 1995, METHOD ENZYMOL, V250, P206; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1993, PHARMACOL THERAPEUT, V59, P281, DOI 10.1016/0163-7258(93)90071-K; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	41	146	150	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8383	8390		10.1074/jbc.274.13.8383	http://dx.doi.org/10.1074/jbc.274.13.8383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085069	hybrid			2022-12-25	WOS:000079451600011
J	Li, X; Dy, RC; Cance, WG; Graves, LM; Earp, HS				Li, X; Dy, RC; Cance, WG; Graves, LM; Earp, HS			Interactions between two cytoskeleton-associated tyrosine kinases: Calcium-dependent tyrosine kinase and focal adhesion tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; N-TERMINAL KINASE; PROTEIN-COUPLED RECEPTORS; ANGIOTENSIN-II; GROWTH-FACTOR; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; FAMILY MEMBERS; T-LYMPHOCYTES; ACTIVATION	The calcium-dependent tyrosine kinase (CADTK), also known as Pyk2/RAFTK/CAK beta/FAX2, is a cytoskeleton-associated tyrosine kinase. We compared CADTK regulation with that of the highly homologous focal adhesion tyrosine kinase (FAK). First, we generated site-specific CADTK mutants. Mutation of Tyr(402) eliminated autophosphorylation and significantly decreased kinase activity. Mutation of Tyr(881), a putative Src kinase phosphorylation site predicted to bind Grb2, had little effect on CADTK regulation. Src family tyrosine kinases resulted in CADTK tyrosine phosphorylation even when co-expressed with the Tyr(402)/Tyr(881) double mutant, suggesting that Src/Fyn etc. phosphorylate additional tyrosine residues. Interestingly, CADTK tyrosine-phosphorylated FAK when both were transiently expressed, but FAK did not phosphorylate CADTK. Biochemical experiments confirmed direct CADTK phosphorylation of FAK. This phosphorylation utilized tyrosine residues other than Tyr(397), Tyr(925), Or Tyr(576)/Tyr(577), suggesting that new SH2-binding sites might be created by CADTK-dependent FAK phosphorylation. Last, expression of the CADTK carboxyl terminus (CRNK) abolished CADTK but not FAK autophosphorylation. In contrast, FAK carboxyl terminus overexpression inhibited both FAK and CADTK autophosphorylation, suggesting that a FAK-dependent cytoskeletal function may be necessary for CADTK activation. Thus, CADTK and FAK, which both bind to some, but not necessarily the same, cytoskeletal elements, may be involved in coordinate regulation of cytoskeletal structure and signaling.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Earp, HS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	hse@med.unc.edu	Graves, Lee/AAG-5470-2021		NCI NIH HHS [CA65910] Funding Source: Medline; NIGMS NIH HHS [GM54010] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cazaubon S, 1997, J NEUROSCI, V17, P6203; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; COBB BS, 1994, MOL CELL BIOL, V15, P2819; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EARP HS, 1995, J BIOL CHEM, V270, P28440; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Guo XYD, 1998, BLOOD, V92, p253A; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MCCUNE BK, 1989, J BIOL CHEM, V264, P15501; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SEGER R, 1994, J BIOL CHEM, V269, P25699; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang JF, 1997, BLOOD, V90, P3507, DOI 10.1182/blood.V90.9.3507; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	62	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8917	8924		10.1074/jbc.274.13.8917	http://dx.doi.org/10.1074/jbc.274.13.8917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085136	hybrid, Green Published			2022-12-25	WOS:000079451600078
J	Ranganathan, G; Kaakaji, R; Kern, PA				Ranganathan, G; Kaakaji, R; Kern, PA			Role of protein kinase C in the translational regulation of lipoprotein lipase in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DOWN-REGULATION; HUMAN ADIPOSE-TISSUE; RAT ADIPOCYTES; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; PHORBOL ESTERS; CHRONIC ACTIVATION; THYROID-HORMONE; INSULIN; GLUCOSE	The hypertriglyceridemia of diabetes is accompanied by decreased lipoprotein lipase (LPL) activity in adipocytes, Although the mechanism for decreased LPL is not known, elevated glucose is known to increase diacylglycerol, which activates protein kinase C (PKC), To determine whether PKC is involved in the regulation of LPL, we studied the effect of 12-O-tetradecanoyl phorbol 13-acetate (TPA) on adipocytes, LPL activity was inhibited when TPA was added to cultures of 3T3-F442A and rat primary adipocytes, The inhibitory effect of TPA on LPL activity was observed after 6 h of treatment, and was observed at a concentration of 6 nM. 100 nM TPA yielded maximal (80%) inhibition of LPL. No stimulation of LPL occurred after short term addition of TPA to cultures. To determine whether TPA treatment of adipocytes decreased LPL synthesis, cells were labeled with [S-35]methionine and LPL protein was immunoprecipitated, LPL synthetic rate decreased after 6 h of TPA treatment. Western blot analysis of cell lysates indicated a decrease in LPL mass after TPA treatment. Despite this decrease in LPL synthesis, there was no change in LPL mRNA in the TPA-treated cells. Long term treatment of cells with TPA is known to down-regulate PKC, To assess the involvement of the different PRC isoforms, Western blotting was performed. TPA treatment of 3T3-F442A adipocytes decreased PKC alpha, beta, delta, and epsilon, isoforms, whereas PKC lambda, theta, zeta, mu, iota, and gamma remained unchanged or decreased minimally. To directly assess the effect of PRC inhibition, PKC inhibitors (calphostin C and staurosporine) were added to cultures. The PI(C inhibitors inhibited LPL activity rapidly (within 60 min). Thus, activation of PKC did not increase LPL, but inhibition of PKC resulted in decreased LPL synthesis by inhibition of translation, indicating a constitutive role of PKC in LPL gene expression.	John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Ranganathan, G (corresponding author), John L McClellan Mem Vet Adm Med Ctr, 151LR,4300 W 7th St, Little Rock, AR 72205 USA.	Ranganathangouri@exchange.UAMS.edu			NIDDK NIH HHS [DK 39176] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039176, R01DK039176, R29DK039176] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; Avignon A, 1996, DIABETES, V45, P1396, DOI 10.2337/diabetes.45.10.1396; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; Deloulme JC, 1997, J BIOL CHEM, V272, P27369, DOI 10.1074/jbc.272.43.27369; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Haneda M, 1995, J DIABETES COMPLICAT, V9, P246, DOI 10.1016/1056-8727(95)80013-5; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; Iverius P H, 1986, Methods Enzymol, V129, P691; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Kern PA, 1996, J LIPID RES, V37, P2332; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; KWON YK, 1993, MOL CELL BIOL, V13, P6547, DOI 10.1128/MCB.13.10.6547; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; ONG JM, 1988, J BIOL CHEM, V263, P12933; ONG JM, 1989, J BIOL CHEM, V264, P3177; ONG JM, 1992, MOL ENDOCRINOL, V6, P61, DOI 10.1210/me.6.1.61; PFEIFER MA, 1983, DIABETES, V32, P525, DOI 10.2337/diabetes.32.6.525; PYKALISTO OJ, 1975, J CLIN INVEST, V56, P1108, DOI 10.1172/JCI108185; RAISONNIER A, 1994, COMP BIOCH PHYSL, P385; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, METH MOL B, V109, P329; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; RANGANATHAN G, 1994, CIRCULATION; Rouis M, 1997, ARTERIOSCL THROM VAS, V17, P1400, DOI 10.1161/01.ATV.17.7.1400; SAFFARI B, 1992, J LIPID RES, V33, P241; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; SHEA TB, 1994, FEBS LETT, V350, P223, DOI 10.1016/0014-5793(94)00769-1; SIMSOLO RB, 1992, J LIPID RES, V33, P89; TASKINEN MR, 1979, DIABETOLOGIA, V17, P351, DOI 10.1007/BF01236268; TAVANGAR K, 1992, J CLIN INVEST, V90, P1672, DOI 10.1172/JCI116039; Wijsman EM, 1998, ARTERIOSCL THROM VAS, V18, P215, DOI 10.1161/01.ATV.18.2.215; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	48	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9122	9127		10.1074/jbc.274.13.9122	http://dx.doi.org/10.1074/jbc.274.13.9122			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085163	hybrid			2022-12-25	WOS:000079451600105
J	Heller, R; Munscher-Paulig, F; Grabner, R; Till, U				Heller, R; Munscher-Paulig, F; Grabner, R; Till, U			L-ascorbic acid potentiates nitric oxide synthesis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; VITAMIN-C STATUS; RELAXING FACTOR; CYCLIC-GMP; ANTIOXIDANT; DYSFUNCTION; SYNTHASE; VASODILATION; DISEASE; ADULTS	Ascorbic acid has been shown to enhance impaired endothelium-dependent vasodilation in patients with atherosclerosis by a mechanism that is thought to involve protection of nitric oxide (NO) from inactivation by free oxygen radicals. The present study in human endothelial cells from umbilical veins and coronary arteries investigates whether L-ascorbic acid additionally affects cellular NO synthesis. Endothelial cells were incubated for 24 h with 0.1-100 mu M ascorbic acid and were subsequently stimulated for 15 min with ionomycin (2 mu M) Or thrombin (1 unit/ml) in the absence of extracellular ascorbate. Ascorbate pretreatment led to a 3-fold increase of the cellular production of NO measured as the formation of its co-product citrulline and as the accumulation of its effector molecule cGMP. The effect was saturated at 100 mu M and followed a similar kinetics as seen for the uptake of ascorbate into the cells. The investigation of the precursor molecule L-gulonolactone and of different ascorbic acid derivatives suggests that the enediol structure of ascorbate is essential for its effect on NO synthesis. Ascorbic acid did not induce the expression of the NO synthase (NOS) protein nor enhance the uptake of the NOS substrate L-arginine into endothelial cells. The ascorbic acid effect was minimal when the citrulline formation was measured in cell lysates from ascorbate-pretreated cells in the presence of known cofactors for NOS activity. However, when the cofactor tetrahydrobiopterin was omitted from the assay, a similar potentiating effect of ascorbate pretreatment as seen in intact cells was demonstrated, suggesting that ascorbic acid may either enhance the availability of tetrahydrobiopterin or increase its affinity for the endothelial NOS. Our data suggest that intracellular ascorbic acid enhances NO synthesis in endothelial cells and that this may explain, in part, the beneficial vascular effects of ascorbic acid.	Univ Jena, Ctr Vasc Biol & Med, D-99089 Erfurt, Germany	Friedrich Schiller University of Jena	Heller, R (corresponding author), Univ Jena, Ctr Vasc Biol & Med, Norhauser Str 78, D-99089 Erfurt, Germany.	heller@zmkh.ef.uni-jena.de	Heller, Regine/AAC-9353-2019					ALHEID U, 1987, THROMB RES, V47, P561, DOI 10.1016/0049-3848(87)90361-6; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Bult H, 1996, MOL MED TODAY, V2, P510; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Cooke JP, 1997, ANNU REV MED, V48, P489, DOI 10.1146/annurev.med.48.1.489; CUNNINGHAM JJ, 1991, METABOLISM, V40, P146, DOI 10.1016/0026-0495(91)90165-S; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; FLUHARTY AL, 1976, BIOCHIM BIOPHYS ACTA, V429, P508, DOI 10.1016/0005-2744(76)90298-9; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARRY PJ, 1982, AM J CLIN NUTR, V36, P332, DOI 10.1093/ajcn/36.2.332; Heitzer T, 1996, CIRCULATION, V94, P6, DOI 10.1161/01.CIR.94.1.6; HELLER R, 1994, AGENTS ACTIONS, V45, P177; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Hornig B, 1998, CIRCULATION, V97, P363; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACHLIN LJ, 1979, AM J CLIN NUTR, V32, P325, DOI 10.1093/ajcn/32.2.325; MAY JM, 1995, BIOCHEMISTRY-US, V34, P12721, DOI 10.1021/bi00039a031; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P351; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; Ness AR, 1996, J HYPERTENS, V14, P503; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; SCHECTMAN G, 1989, AM J PUBLIC HEALTH, V79, P158, DOI 10.2105/AJPH.79.2.158; SCHMIDT K, 1992, BIOCHEM J, V281, P297, DOI 10.1042/bj2810297; Solzbach U, 1997, CIRCULATION, V96, P1513, DOI 10.1161/01.CIR.96.5.1513; Som S, 1983, Acta Vitaminol Enzymol, V5, P243; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617; TSUJIMURA M, 1982, J NUTR SCI VITAMINOL, V28, P467, DOI 10.3177/jnsv.28.467; Weber P, 1996, INT J VITAM NUTR RES, V66, P19; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; WESTENDORP RGJ, 1994, J VASC RES, V31, P42, DOI 10.1159/000159030; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1	39	174	179	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8254	8260		10.1074/jbc.274.12.8254	http://dx.doi.org/10.1074/jbc.274.12.8254			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075731	hybrid			2022-12-25	WOS:000079268100090
J	Ettenberg, SA; Keane, MM; Nau, MM; Frankel, M; Wang, LM; Pierce, JH; Lipkowitz, S				Ettenberg, SA; Keane, MM; Nau, MM; Frankel, M; Wang, LM; Pierce, JH; Lipkowitz, S			cbl-b inhibits epidermal growth factor receptor signaling	ONCOGENE			English	Article						cbl proteins; EGF receptor; signal transduction	PROTEIN-COUPLED RECEPTORS; PROTOONCOGENE C-CBL; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; V-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; T-CELLS; KINASE; ACTIVATION	The role of cbl-b in signaling by the epidermal growth factor receptor (EGFR),vas studied and compared with c-cbl, We demonstrate in vivo, that chl-b, like c-cbl, is phosphorylated and recruited to the EGFR upon EGF stimulation and both cbl proteins can bind to the Grb2 adaptor protein, To investigate the functional role of chi proteins in EGFR signaling, we transfected cbl-b or c-cbl into 32D cells overexpressing the EGFR (32D/EGFR), This cell line is absolutely dependent on exogenous IL-3 or EGF for sustained growth. 32D/EGFR cells overexpressing cbl-b showed markedly inhibited growth in EGF compared to c-cbl transfectants and vector controls, This growth inhibition by cbl-b was the result of a dramatic increase in the number of cells undergoing apoptosis, Consistent with this finding, chl-b overexpression markedly decreased the amplitude and duration of AKT activation upon EGF stimulation compared to either vector controls or c-cbl overexpressing cells. In addition, the duration of EGF mediated MAP kinase and Jun kinase activation in cells overespressing cbl-b is shortened. These data demonstrate that cbl-b inhibits EGF-induced cell growth and that cbl-b and c-cbl have distinct roles in EGF mediated signaling.	USN Hosp, NCI, Med Branch, Dept Genet, Bethesda, MD 20889 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; NCI, Mol & Cellular Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Navy; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lipkowitz, S (corresponding author), USN Hosp, NCI, Med Branch, Dept Genet, Bethesda, MD 20889 USA.				NATIONAL CANCER INSTITUTE [ZIASC007263, Z01SC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Andoniou CE, 1996, ONCOGENE, V12, P1981; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, J BIOL CHEM, V269, P21103; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; IHLE JN, 1981, J IMMUNOL, V126, P2184; IHLE JN, 1982, J IMMUNOL, V129, P2431; JONGEWARD GD, 1995, GENETICS, V139, P1553; KEANE MM, 1995, ONCOGENE, V10, P2367; Khwaja A, 1996, ONCOGENE, V12, P2491; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1996, ONCOGENE, V12, P1117; Liu YC, 1997, J BIOL CHEM, V272, P168; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Meisner H, 1997, MOL CELL BIOL, V17, P2217, DOI 10.1128/MCB.17.4.2217; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Odai H, 1995, JPN J CANCER RES, V86, P1119, DOI 10.1111/j.1349-7006.1995.tb03303.x; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PRYSTOWSKY MB, 1982, J IMMUNOL, V129, P2337; Smit L, 1997, CRIT REV ONCOGENESIS, V8, P359, DOI 10.1615/CritRevOncog.v8.i4.50; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Ueno H, 1998, BLOOD, V91, P46, DOI 10.1182/blood.V91.1.46.46_46_53; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	46	101	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1855	1866		10.1038/sj.onc.1202499	http://dx.doi.org/10.1038/sj.onc.1202499			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086340				2022-12-25	WOS:000079090000009
J	de Lera, TL; Folgueira, L; Martin, AG; Dargemont, C; Pedraza, MA; Bermejo, M; Bonay, P; Fresno, M; Alcami, J				de Lera, TL; Folgueira, L; Martin, AG; Dargemont, C; Pedraza, MA; Bermejo, M; Bonay, P; Fresno, M; Alcami, J			Expression of I kappa B alpha in the nucleus of human peripheral blood T lymphocytes	ONCOGENE			English	Article						IKB alpha; NF-kappa B; nuclear; T lymphocytes	TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; REL ONCOGENE; C-REL; P50; PROTEIN; SUBUNIT; SIGNAL; PHOSPHORYLATION	According to current models the inhibitory capacity of I kappa B alpha would be mediated through the retention of Rel/NF-kappa B proteins in the cytosol. However, I kappa B alpha has also been detected in the nucleus of cell lines and when overexpressed by transient transfection. To gain better insight into the potential role of nuclear I kappa B alpha in a physiological context we have analysed its presence in the nucleus of human peripheral blood T lymphocytes (PBL). We demonstrate the nuclear localization of I kappa B alpha in PBL by different techniques: Western blot, indirect immunofluorescence and electron microscopy. Low levels of nuclear I kappa B alpha were detected in resting cells whereas a superinduction was obtained after PMA activation. The nuclear pool of I kappa B alpha showed a higher stability than cytosolic I kappa B alpha and was partially independent of the resynthesis of the protein. Unexpectedly, the presence of nuclear I kappa B alpha did not inhibit NF-kappa B binding to DNA and this phenomenon was not due to the presence of I kappa B beta at the nuclear level. Immunoprecipitation experiments failed to demonstrate an association between nuclear I kappa B alpha and NF-kappa B proteins. Our results demonstrate that in resting and PMA-activated human PBL, I kappa B alpha is present in the nucleus in an apparently inactive form unable to disrupt NF-kappa B binding from DNA.	Hosp 12 Octubre, Ctr Invest, Microbiol Serv, E-28041 Madrid, Spain; Inst Curie, CNRS, UMR 144, Lab Transport Nucleocytoplasm, F-75231 Paris, France; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	Hospital Universitario 12 de Octubre; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Autonomous University of Madrid	Alcami, J (corresponding author), Hosp 12 Octubre, Ctr Invest, Microbiol Serv, E-28041 Madrid, Spain.		Folgueira, Lola/C-7958-2016; Alcami, Pepe/T-2242-2018	Folgueira, Lola/0000-0002-3730-015X; Alcami, Pepe/0000-0003-0023-7377; Fresno Escudero, Manuel/0000-0002-9223-5477; Bermejo, Mercedes/0000-0001-9909-8578				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BACHELERIE F, 1991, NATURE, V350, P709, DOI 10.1038/350709a0; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; LAI JH, 1994, J BIOL CHEM, V269, P30077; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MOORE NC, 1995, J IMMUNOL, V155, P4653; MORIN PJ, 1992, NUCLEIC ACIDS RES, V20, P2453, DOI 10.1093/nar/20.10.2453; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PIMENTELMUINOS FX, 1995, EUR J IMMUNOL, V25, P179, DOI 10.1002/eji.1830250130; PIMENTELMUINOS FX, 1994, J BIOL CHEM, V269, P24424; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413	49	23	23	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1581	1588		10.1038/sj.onc.1202455	http://dx.doi.org/10.1038/sj.onc.1202455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102628				2022-12-25	WOS:000078770700008
J	Beall, A; Bagwell, D; Woodrum, D; Stoming, TA; Kato, K; Suzuki, A; Rasmussen, H; Brophy, CM				Beall, A; Bagwell, D; Woodrum, D; Stoming, TA; Kato, K; Suzuki, A; Rasmussen, H; Brophy, CM			The small heat shock-related protein, HSP20, is phosphorylated on serine 16 during cyclic nucleotide-dependent relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; 20-KDA PROTEIN; ELECTROPHORESIS; VASORELAXATION; RESOLUTION; PEPTIDE; KINASE	The small heat shock-related protein 20 (HSP20) is present in four isoforms in bovine carotid artery smooth muscles. Three of the isoforms are phosphorylated and one is not. Increases in the phosphorylation of two isoforms of HSP20 (isoform 3, pI 5.9; and 8, pI 5.7) are associated with cyclic nucleotide-dependent relaxation of bovine carotid artery smooth muscles. Increases in the phosphorylation of another isoform (isoform 4, pI 6.0) are associated with phorbol ester-induced contraction of bovine carotid artery smooth muscles. In this investigation we determined that isoforms 3 and 8 are phosphorylated on Ser(16) of the HSP20 molecule during activation of cAMP-dependent signaling pathways. Phosphorylation state-specific antibodies produced against a peptide containing phosphorylated Ser(16) recognized isoforms 3 and 8 but not isoform 4. In human vascular tissue, only isoform 3 is present. Incubation of transiently permeabilized strips of bovine carotid artery smooth muscle with synthetic peptides in which Ser(16) is phosphorylated, inhibits contractile responses to high extracellular KCl and to serotonin, These data suggest that phosphorylation of HSP20 on Ser(16) modulates cAMP-dependent vasorelaxation.	Med Coll Georgia, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Dept Med, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Augusta Vet Adm Med Ctr, Augusta, GA 30912 USA; Inst Dev Res, Human Serv Ctr, Dept Biochem, Kasugai, Aichi 48003, Japan; Yokohama City Univ, Sch Med, Dept Mol Biol, Yokohama, Kanagawa 236, Japan	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Yokohama City University	Brophy, CM (corresponding author), Med Coll Georgia, Dept Surg, 1120 15th St, Augusta, GA 30912 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058027] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL58027-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beall A, 1999, BBA-MOL CELL RES, V1449, P41, DOI 10.1016/S0167-4889(98)00169-4; Beall AC, 1997, J BIOL CHEM, V272, P11283; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; Brophy CM, 1997, J VASC SURG, V25, P390, DOI 10.1016/S0741-5214(97)70361-6; Brophy CM, 1997, BIOL REPROD, V57, P1354, DOI 10.1095/biolreprod57.6.1354; Brophy CM, 1999, J VASC SURG, V29, P326, DOI 10.1016/S0741-5214(99)70385-X; Brophy CM, 1998, J VASC SURG, V27, P963, DOI 10.1016/S0741-5214(98)70279-4; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Inaguma Y, 1996, GENE, V178, P145, DOI 10.1016/0378-1119(96)00356-3; Jerius H, 1999, J VASC SURG, V29, P678, DOI 10.1016/S0741-5214(99)70314-9; KATO K, 1994, J BIOL CHEM, V269, P15302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN JK, 1997, AM J PHYSIOL, V273, P930; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; MORGAN JP, 1982, PFLUG ARCH EUR J PHY, V395, P75, DOI 10.1007/BF00584972; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Rosales OR, 1997, BIOCHEM J, V326, P385, DOI 10.1042/bj3260385; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; TAKUWA Y, 1988, MOL CELL ENDOCRINOL, V60, P71, DOI 10.1016/0303-7207(88)90121-9; TAKUWA Y, 1987, J CLIN INVEST, V80, P248, DOI 10.1172/JCI113055	24	120	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11344	11351		10.1074/jbc.274.16.11344	http://dx.doi.org/10.1074/jbc.274.16.11344			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196226	hybrid			2022-12-25	WOS:000079751900094
J	Ben Mamoun, C; Beckerich, JM; Gaillardin, C; Kepes, F				Ben Mamoun, C; Beckerich, JM; Gaillardin, C; Kepes, F			Disruption of YHC8, a member of the TSR1 gene family, reveals its direct involvement in yeast protein translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PREPRO-ALPHA-FACTOR; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; DIPEPTIDYL AMINOPEPTIDASE; SIGNAL SEQUENCE; RECOGNITION; TRANSPORT; COMPLEX; POLYPEPTIDE	Genetic studies of Saccharomyces cerevisiae have identified many components acting to deliver specific proteins to their cellular locations. Genome analysis, however, has indicated that additional genes may also participate in such protein trafficking. The product of the yeast Yarrowia lipolytica TSR1 gene promotes the signal recognition particle-dependent translocation of secretory proteins through the endoplasmic reticulum. Here we describe the identification of a new gene family of proteins that is well conserved among different yeast species. The TSR1 genes encode polypeptides that share the same protein domain distribution and, like Tsr1p, may play an important role in the early steps of the signal recognition particle-dependent translocation pathway. We have identified five homologues of the TSR1 gene, four of them from the yeast Saccharomyces cerevisiae and the other from Hansenula polymorpha. We generated a null mutation in the S. cerevisiae YHC8 gene, the closest homologue to Y. lipolytica TSR1, and used different soluble (carboxypeptidase Y, LY-factor, invertase) and membrane (dipeptidyl-aminopeptidase) secretory proteins to study its phenotype. A large accumulation of soluble protein precursors was detected in the mutant strain. Immunofluorescence experiments show that Yhc8p is localized in the endoplasmic reticulum. We propose that the YHC8 gene is a new and important component of the S. cerevisiae endoplasmic reticulum membrane and that it functions in protein translocation/insertion of secretory proteins through or into this compartment.	Inst Natl Agron Paris Grignon, Ctr Biotechnol Agroind, CNRS, INRA,Lab Genet Mol & Cellulaire, F-78850 Thiverval Grignon, France; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; CEA Saclay, DSV, DBCM, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Washington University (WUSTL); Washington University (WUSTL); CEA; UDICE-French Research Universities; Universite Paris Saclay	Ben Mamoun, C (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.	choukri@borcim.wustl.edu						AGAPHONOV MO, 1994, YEAST, V10, P509, DOI 10.1002/yea.320100410; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BenMamoun C, 1997, J BIOL CHEM, V272, P24594, DOI 10.1074/jbc.272.39.24594; BENMAMOUN C, 1996, J BIOL CHEM, V271, P23895; BRAKE AJ, 1983, MOL CELL BIOL, V3, P1440, DOI 10.1128/MCB.3.8.1440; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DUNTZE W, 1970, SCIENCE, V168, P1472, DOI 10.1126/science.168.3938.1472; ESMON PC, 1987, J BIOL CHEM, V262, P4387; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FANG H, 1994, MOL BIOL CELL, V5, P933, DOI 10.1091/mbc.5.9.933; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GREEN R, 1986, J BIOL CHEM, V261, P7558; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HE F, 1992, J BIOL CHEM, V267, P1932; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; Maftahi M, 1996, YEAST, V12, P859, DOI 10.1002/(SICI)1097-0061(199607)12:9<859::AID-YEA978>3.0.CO;2-Q; Maniatis T., 1982, MOL CLONING LAB MANU; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PERLMAN D, 1982, P NATL ACAD SCI-BIOL, V79, P781, DOI 10.1073/pnas.79.3.781; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SINGH A, 1983, NUCLEIC ACIDS RES, V11, P4049, DOI 10.1093/nar/11.12.4049; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; TOYN J, 1988, EMBO J, V7, P4347, DOI 10.1002/j.1460-2075.1988.tb03333.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	43	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11296	11302		10.1074/jbc.274.16.11296	http://dx.doi.org/10.1074/jbc.274.16.11296			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196219	Green Published, hybrid			2022-12-25	WOS:000079751900087
J	Yamamoto, H; Kishida, S; Kishida, M; Ikeda, S; Takada, S; Kikuchi, A				Yamamoto, H; Kishida, S; Kishida, M; Ikeda, S; Takada, S; Kikuchi, A			Phosphorylation of Axin, a Wnt signal negative regulator, by glycogen synthase kinase-3 beta regulates its stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; MAMMARY EPITHELIAL-CELLS; APC TUMOR-SUPPRESSOR; MOUSE FUSED LOCUS; BETA-CATENIN; XENOPUS EMBRYOS; POLARITY GENE; PROTEIN; PATHWAY; DROSOPHILA	Axin forms a complex with glycogen synthase kinase-3 beta (GSK-3 beta) and beta-catenin and promotes GSK-3 beta-dependent phosphorylation of beta-catenin, thereby stimulating the degradation of beta-catenin. Because GSH-3 beta also phosphorylates Axin in the complex, the physiological significance of the phosphorylation of Axin was examined. Treatment of COS cells with LiCl, a GSK-3 beta inhibitor, and okadaic acid, a protein phosphatase inhibitor, decreased and increased, respectively, the cellular protein level of Axin. Pulse-chase analyses showed that the phosphorylated form of Axin was more stable than the unphosphorylated form and that an Axin mutant, in which the possible phosphorylation sites for GSK-3 beta were mutated, exhibited a shorter half-life than wild type Axin, Dvl-1, which was genetically shown to function upstream of GSK-3 beta, inhibited the phosphorylation of Axin by GSK-3 beta in vitro. Furthermore, Wnt-3a-containing conditioned medium down-regulated Axin and accumulated beta-catenin in L cells and expression of DV1-1(Delta PDZ), in which the PDZ domain was deleted, suppressed this action of Wnt-3a, These results suggest that the phosphorylation of Axin is important for the regulation of its stability and that Wnt down-regulates Axin through Dv1.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Japan Sci & Technol Corp, Hiroshima 7348551, Japan; Kyoto Univ, Fac Sci, Ctr Mol & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Hiroshima University; Japan Science & Technology Agency (JST); Kyoto University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@mcai.med.hiroshima-u.ac.jp		Takada, Shinji/0000-0003-4125-6056; kishida, shosei/0000-0003-0405-851X				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dale TC, 1998, BIOCHEM J, V329, P209; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; GLUECKSOHNSCHOENHEIMER S, 1949, J EXP ZOOL, V110, P47, DOI 10.1002/jez.1401100105; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Klingensmith J, 1996, MECH DEVELOP, V58, P15, DOI 10.1016/S0925-4773(96)00549-7; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PERRY WL, 1995, GENETICS, V141, P321; Pizzuti A, 1996, HUM MOL GENET, V5, P953, DOI 10.1093/hmg/5.7.953; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Shibamoto S, 1998, GENES CELLS, V3, P659; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; SUSSMAN DJ, 1994, DEV BIOL, V166, P73, DOI 10.1006/dbio.1994.1297; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wagner U, 1997, FEBS LETT, V411, P369, DOI 10.1016/S0014-5793(97)00733-3; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	41	297	308	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10681	10684		10.1074/jbc.274.16.10681	http://dx.doi.org/10.1074/jbc.274.16.10681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196136	hybrid			2022-12-25	WOS:000079751900004
J	Liu, HG; Maurice, DH				Liu, HG; Maurice, DH			Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases - A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; VASCULAR SMOOTH-MUSCLE; NUCLEOTIDE PHOSPHODIESTERASES; SELECTIVE-INHIBITION; MESSENGER-RNA; C INHIBITOR; CELLS; FAMILY; GENE; STIMULATION	In this study, we describe a novel mechanism by which a protein kinase C (PKC)-mediated activation of the Raf-extracellular signal-regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade regulates the activity and membrane targeting of members of the cyclic AMP-specific phosphodiesterase D family (PDE4D), Using a combination of pharmacological and biochemical approaches, we show that increases in intracellular cAMP cause a protein kinase A-mediated phosphorylation and activation of the two PDE4D variants expressed in vascular smooth muscle cells, namely PDE4D3 and PDE4D5. In addition, we show that stimulation of PKC via the associated activation of the Raf-MEK-ERK cascade results in the phosphorylation and activation of PDE4D3 in these cells. Furthermore, our studies demonstrate that simultaneous activation of both the protein kinase A and PKC-Raf-MEK-ERK pathways allows for a coordinated activation of PDE4D3 and for the translocation of the particulate PDE4D3 to the cytosolic fraction of these cells. These data are presented and discussed in the context of the activation of the Raf-MEK-ERK cascade acting to modulate the activation and subcellular targeting of PDE4D gene products mediated by cAMP.	Queens Univ, Pharmaceut Mfg Assoc Canada, Hlth Res Fdn,Med Res Council Canada, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Maurice, DH (corresponding author), Queens Univ, Pharmaceut Mfg Assoc Canada, Hlth Res Fdn,Med Res Council Canada, Dept Pathol, Botterell Hall,A221, Kingston, ON K7L 3N6, Canada.	Mauriced@post.queensu.ca	Maurice, Donald/AAE-9332-2019					ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; DAVIS CW, 1979, J CYCLIC NUCL PROT, V5, P65; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Erdogan S, 1997, BIOCHEM J, V321, P165, DOI 10.1042/bj3210165; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; Ho PD, 1998, J BIOL CHEM, V273, P21730, DOI 10.1074/jbc.273.34.21730; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; KOMAS N, 1991, BRIT J PHARMACOL, V104, P495, DOI 10.1111/j.1476-5381.1991.tb12457.x; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; LOUGHNEY K, 1996, HANDB IMMUNOPHARM, P1; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; Manning CD, 1996, J PHARMACOL EXP THER, V276, P810; Maurice D. H., 1998, Cell Biochemistry and Biophysics, V29, P35, DOI 10.1007/BF02737827; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Palmer D, 1998, CIRC RES, V82, P852; Polson JB, 1996, ANNU REV PHARMACOL, V36, P403, DOI 10.1146/annurev.pa.36.040196.002155; Rose RJ, 1997, BRIT J PHARMACOL, V122, P233, DOI 10.1038/sj.bjp.0701376; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Scott JD, 1997, SOC GEN PHY, V52, P227; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; TETSUKA T, 1995, AM J PHYSIOL-RENAL, V268, pF808, DOI 10.1152/ajprenal.1995.268.5.F808; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164	32	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10557	10565		10.1074/jbc.274.15.10557	http://dx.doi.org/10.1074/jbc.274.15.10557			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187850	hybrid			2022-12-25	WOS:000079663500089
J	Read, JA; Wilkinson, KW; Tranter, R; Sessions, RB; Brady, RL				Read, JA; Wilkinson, KW; Tranter, R; Sessions, RB; Brady, RL			Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMALARIAL DRUG; IDENTIFICATION; ERYTHROCYTES; PROTEINS; TARGET; DESIGN	Although the molecular mechanism by which chloroquine exerts its effects on the malarial parasite Plasmodium falciparum remains unclear, the drug has previously been found to interact specifically with the glycolytic enzyme lactate dehydrogenase from the parasite. In this study we have determined the crystal structure of the complex between chloroquine and P. falciparum lactate dehydrogenase. The bound chloroquine is clearly seen within the NADH binding pocket of the enzyme, occupying a position similar to that of the adenyl ring of the cofactor. Chloroquine hence competes with NADH for binding to the enzyme, acting as a competitive inhibitor for this critical glycolytic enzyme. Specific interactions between the drug and amino acids unique to the malarial form of the enzyme suggest this binding is selective. Inhibition studies confirm that chloroquine acts as a weak inhibitor of lactate dehydrogenase, with mild selectivity for the parasite enzyme. As chloroquine has been shown to accumulate to millimolar concentrations within the food vacuole in the gut of the parasite, even low levels of inhibition may contribute to the biological efficacy of the drug, The structure of this enzyme-inhibitor complex provides a template from which the quinoline moiety might be modified to develop more efficient inhibitors of the enzyme.	Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Ctr Mol Recognit, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Brady, RL (corresponding author), Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England.		Conners, Rebecca/C-2608-2013	Conners, Rebecca/0000-0002-8653-1771; Sessions, Richard/0000-0003-0320-0895				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; Dunn CR, 1996, NAT STRUCT BIOL, V3, P912, DOI 10.1038/nsb1196-912; FITCH CD, 1972, P HELM SOC WASH, V39, P265; FOLEY M, 1994, J BIOL CHEM, V269, P6955; GINSBURG H, 1987, BIOCHEM PHARMACOL, V36, P1567, DOI 10.1016/0006-2952(87)90038-4; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Menting JG, 1997, MOL BIOCHEM PARASIT, V88, P215, DOI 10.1016/S0166-6851(97)00095-9; MUSICK WDL, 1979, J BIOL CHEM, V254, P7611; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERS W, 1970, CHEMOTHERAPY DRUG RE, P540; PIONTEK K, 1990, PROTEINS, V7, P74, DOI 10.1002/prot.340070108; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; VANDERJAGT DL, 1990, MOL BIOCHEM PARASIT, V42, P277, DOI 10.1016/0166-6851(90)90171-H; WHITE JL, 1976, J MOL BIOL, V102, P759, DOI 10.1016/0022-2836(76)90290-4; WILKS HM, 1992, BIOCHEMISTRY-US, V31, P7802, DOI 10.1021/bi00149a009; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	20	73	77	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10213	10218		10.1074/jbc.274.15.10213	http://dx.doi.org/10.1074/jbc.274.15.10213			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187806	hybrid			2022-12-25	WOS:000079663500045
J	Varvas, K; Jarving, I; Koljak, R; Valmsen, K; Brash, AR; Samel, N				Varvas, K; Jarving, I; Koljak, R; Valmsen, K; Brash, AR; Samel, N			Evidence of a cyclooxygenase-related prostaglandin synthesis in coral - The allene oxide pathway is not involved in prostaglandin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; PLEXAURA-HOMOMALLA; 15-HYDROXYEICOSATETRAENOIC ACID; ENDOPEROXIDE SYNTHASE; MARINE PROSTANOIDS; GERSEMIA-FRUTICOSA; LIPOXYGENASE; IDENTIFICATION; EICOSANOIDS; CONVERSION	Certain corals are rich natural sources of prostaglandins, the metabolic origin of which has remained undefined. By analogy with the lipoxygenase/allene oxide synthase pathway to jasmonic acid in plants, the presence of (8R)-lipoxygenase and allene oxide synthase in the coral Plexaura homomalla suggested a potential metabolic route to prostaglandins (Brash, A. R., Baertshi, S. W., Ingram, C.D., and Harris, T. M. (1987) J. Biol. Chem. 262, 15829-15839). Other evidence, from the Arctic coral Gersemia fruticosa, has indicated a cyclooxygenase intermediate in the biosynthesis (Varvas, K., Koljak, R., Jarving, I., Pehk, T., and Samel, N. (1994) Tetrahedron Lett. 35, 8267-8270). In the present study, active preparations of G. fruticosa have been used to identify both types of arachidonic acid metabolism and specific inhibitors were used to establish the enzyme type involved in the prostaglandin biosynthesis. The synthesis of prostaglandins and (11R)-hydroxyeicosatetraenoic acid was inhibited by mammalian cyclooxygenase inhibitors (indomethacin, aspirin, and tolfenamic acid), while the formation of the products of the 8-lipoxygenase/allene oxide pathway was not affected or was increased. The specific cyclooxygenase-a inhibitor, nimesulide, did not inhibit the synthesis of prostaglandins in coral. We conclude that coral uses two parallel routes for the initial oxidation of polyenoic acids: the cyclooxygenase route, which leads to optically active prostaglandins, and the lipoxygenase/allene oxide synthase metabolism, the role of which remains to be established. An enzyme related to mammalian cyclooxygenases is the key to prostaglandin synthesis in coral. Based on our inhibitor data, the catalytic site of this evolutionary early cyclooxygenase appears to differ significantly from both known mammalian cyclooxygenases.	Tallinn Univ Technol, Inst Chem, Dept Bioorgan Chem, EE-12618 Tallinn, Estonia; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Tallinn University of Technology; Vanderbilt University	Varvas, K (corresponding author), Tallinn Univ Technol, Inst Chem, Dept Bioorgan Chem, Akad Tee 15, EE-12618 Tallinn, Estonia.	kylli@boc.ic.ee	Samel, Nigulas/A-1420-2019	Valmsen, Karin/0000-0001-5303-6654	FOGARTY INTERNATIONAL CENTER [R03TW000404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053638] Funding Source: NIH RePORTER; FIC NIH HHS [11 RO3 TW00404-01] Funding Source: Medline; NIGMS NIH HHS [GM 53638] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILD GS, 1978, J BIOL CHEM, V253, P21; BRASH AR, 1989, ADV PROSTAG THROMB L, V19, P70; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; BRASH AR, 1989, J AM CHEM SOC, V111, P1891, DOI 10.1021/ja00187a060; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BRYANT RW, 1982, J BIOL CHEM, V257, P6050; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; BUNDY GL, 1986, J BIOL CHEM, V261, P747; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1975, J CHEM SOC CHEM COMM, P277, DOI 10.1039/c39750000277; COREY EJ, 1987, TETRAHEDRON LETT, V28, P4247, DOI 10.1016/S0040-4039(00)96476-1; COREY EJ, 1988, TETRAHEDRON LETT, V29, P2555, DOI 10.1016/S0040-4039(00)86110-9; DIMARZO V, 1993, BIOCHEM J, V295, P23, DOI 10.1042/bj2950023; GERWICK WH, 1993, TOP CURR CHEM, V167, P117; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; GROWEISS A, 1990, J NAT PROD, V53, P222, DOI 10.1021/np50067a039; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1980, BIOCHEM BIOPH RES CO, V95, P1090, DOI 10.1016/0006-291X(80)91584-3; HAMBERG M, 1992, BIOCHIM BIOPHYS ACTA, V1165, P1, DOI 10.1016/0005-2760(92)90069-8; HAWKINS DJ, 1987, J BIOL CHEM, V262, P7629; HEMLER ME, 1978, BIOCHEMISTRY-US, V17, P1772, DOI 10.1021/bi00602a031; HUBBARD WC, 1980, PROSTAGLANDINS, V20, P431; KIEFER HC, 1975, ANAL BIOCHEM, V68, P336, DOI 10.1016/0003-2697(75)90714-9; LATYSHEV NA, 1988, CHEM NAT PROD, V3, P447; LIGHT RJ, 1972, EUR J BIOCHEM, V28, P232, DOI 10.1111/j.1432-1033.1972.tb01906.x; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MEADE EA, 1993, J BIOL CHEM, V268, P6610; PANOSSIAN AG, 1987, PROSTAG OTH LIPID M, V33, P363, DOI 10.1016/0090-6980(87)90019-0; PEERS KE, 1983, CHEM PHYS LIPIDS, V32, P49, DOI 10.1016/0009-3084(83)90069-5; POWELL WS, 1982, J BIOL CHEM, V257, P9457; SETTY BNY, 1985, BIOCHIM BIOPHYS ACTA, V833, P484, DOI 10.1016/0005-2760(85)90106-7; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SONG WC, 1991, ARCH BIOCHEM BIOPHYS, V290, P427, DOI 10.1016/0003-9861(91)90562-W; VANOS CPA, 1981, BIOCHIM BIOPHYS ACTA, V663, P177, DOI 10.1016/0005-2760(81)90204-6; VARVAS K, 1994, TETRAHEDRON LETT, V35, P8267, DOI 10.1016/0040-4039(94)88299-1; VARVAS K, 1993, TETRAHEDRON LETT, V34, P3643, DOI 10.1016/S0040-4039(00)73658-6; WEINHEIMER AJ, 1969, TETRAHEDRON LETT, P5185	39	39	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9923	9929		10.1074/jbc.274.15.9923	http://dx.doi.org/10.1074/jbc.274.15.9923			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187766	hybrid			2022-12-25	WOS:000079663500005
J	Carty, SM; Sreekumar, KR; Raetz, CRH				Carty, SM; Sreekumar, KR; Raetz, CRH			Effect of cold shock on lipid A biosynthesis in Escherichia coli - Induction at 12 degrees C of an acyltransferase specific for palmitoleoyl-acyl carrier protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE REQUIREMENT GENE; ACID-DEFICIENT MUTANT; SALMONELLA-TYPHIMURIUM; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; FATTY-ACID; 3-DEOXY-D-MANNOOCTULOSONATE-8-PHOSPHATE SYNTHETASE; ENDOTOXIN BIOSYNTHESIS; MULTICOPY SUPPRESSOR; MEMBRANE LIPIDS; A PRECURSORS	Palmitoleate is not present in lipid A isolated from Escherichia coli grown at 30 degrees C or higher, but it comprises similar to 11% of the fatty acyl chains of lipid A in cells grown at 12 degrees C. The appearance of palmitoleate at 12 degrees C is accompanied by a decline in laurate from -18% to similar to 5.5%. We now report that wild-type E. coli shifted from 30 degrees C to 12 degrees C acquire a novel palmitoleoyl-acyl carrier protein (ACP)-dependent acyltransferase that acts on the key lipid A precursor Kdo(2)-lipid IVA. The palmitoleoyl transferase is induced more than 30-fold upon cold shock, as judged by assaying extracts of cells shifted to 12 degrees C. The induced activity is maximal after 2 h of cold shock, and then gradually declines but does not disappear. Strains harboring an insertion mutation in the lpxL(htrB) gene, which encodes the enzyme that normally transfers laurate from lauroyl-ACP to Kdo(2)-lipid IVA (Clementz, T., Bednarski, J. J., and Raetz, C. R. H. (1996) J. Biol. Chem. 271, 12095-12102) are not defective in the cold-induced palmitoleoyl transferase. Recently, a gene displaying 54% identity and 73% similarity at the protein level to lpxL was found in the genome off. coli. This lpxL homologue, designated lpxP, encodes the cold shock-induced palmitoleoyl transferase. Extracts of cells containing lpxP on the multicopy plasmid pSK57 exhibit a 10-fold increase in the specific activity of the cold-induced palmitoleoyl transferase compared with cells lacking the plasmid. The elevated specific activity of the palmitoleoyl transferase under conditions of cold shock is attributed to greatly increased levels of lpxP mRNA. The replacement of laurate with palmitoleate in lipid A may reflect the desirability of maintaining the optimal outer membrane fluidity at 12 degrees C.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	Duke University; Tufts University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, T32GM008558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, GM-34123, GM08558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Carty SM, 1997, FASEB J, V11, pA1423; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; CLEMENTZ T, 1995, FASEB J, V9, pA1311; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; DIN ZZ, 1993, BIOCHEMISTRY-US, V32, P4579, DOI 10.1021/bi00068a014; DIRIENZO JM, 1983, EUR J BIOCHEM, V135, P351, DOI 10.1111/j.1432-1033.1983.tb07661.x; Fang L, 1997, MOL MICROBIOL, V23, P355, DOI 10.1046/j.1365-2958.1997.2351592.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; Goldenberg D, 1997, MOL GEN GENET, V256, P282, DOI 10.1007/s004380050571; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; GREEN PR, 1981, J BIOL CHEM, V256, P1151; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HAMPTON RY, 1988, J BIOL CHEM, V263, P14802; HOFER M, 1991, CHEM PHYS LIPIDS, V59, P167, DOI 10.1016/0009-3084(91)90005-V; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; KELLY TM, 1993, J BIOL CHEM, V268, P19866; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Lands W E, 1988, Prog Clin Biol Res, V282, P11; LIPKA G, 1988, CHEM PHYS LIPIDS, V48, P267, DOI 10.1016/0009-3084(88)90097-7; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; MORRISON DC, 1992, BACTERIAL ENDOTOXIC, V1; Murphy NR, 1996, BIOTECHNIQUES, V21, P934; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; QUINN PJ, 1980, CRC CR REV BIOCH MOL, V8, P1, DOI 10.3109/10409238009105466; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; Raetz CRH, 1998, PROG CLIN BIOL RES, V397, P1; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1977, J BIOL CHEM, V252, P4895; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SILBERT DF, 1975, ANNU REV BIOCHEM, V44, P315, DOI 10.1146/annurev.bi.44.070175.001531; SINENSKY M, 1974, P NATL ACAD SCI USA, V71, P522, DOI 10.1073/pnas.71.2.522; SMALL DM, 1986, PHYSICAL CHEM LIPIDS, V4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Thieringer HA, 1998, BIOESSAYS, V20, P49; Tiku PE, 1996, SCIENCE, V271, P815, DOI 10.1126/science.271.5250.815; VANALPHEN L, 1979, EUR J BIOCHEM, V101, P571; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; WOLLENWEBER HW, 1983, EUR J BIOCHEM, V130, P167; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	75	123	133	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9677	9685		10.1074/jbc.274.14.9677	http://dx.doi.org/10.1074/jbc.274.14.9677			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092655	hybrid			2022-12-25	WOS:000079451800074
J	Maatta, A; Jaakkola, P; Jalkanen, M				Maatta, A; Jaakkola, P; Jalkanen, M			Extracellular matrix-dependent activation of syndecan-1 expression in keratinocyte growth factor-treated keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CELL-SURFACE; FIBROBLAST GROWTH; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; GENE-EXPRESSION; FIBRONECTIN; PROTEIN; RECEPTOR; BINDING	Syndecan-1 is a major heparan sulfate proteoglycan of the epidermis. Its expression is strongly induced in migrating and proliferating keratinocytes during wound healing and, on the other hand, diminished or lost in invasive squamous cell carcinoma. We have recently found in the syndecan-1 gene an enhancer (fibroblast growth factor-inducible response element (FIRE)) that activates gene expression in wound edge keratinocytes (Jaakkola, P., Kontusaari, S., Kauppi, T., Maatta, A., and Jalkanen, M. (1998) FASEB J. 12, 959-969). Now, we demonstrate that the activation of this enhancer by keratinocyte growth factor (KGF) is modulated by the components of the extracellular matrix (ECM), MCA-3D mouse immortal keratinocytes growing on fibrillar collagen failed to activate FiRE and subsequently to induce syndecan-1 in response to KGF, The same cells growing on fibronectin or laminin, however, increased FiRE-dependent reporter gene expression upon KGF treatment. The inhibition of the KGF induction by collagen appears to be specific for signaling to FiRE, as the increase in cell proliferation by KGF was not affected. The effect was selective to KGF, as EGF-induction was independent on ECM composition. Changes in the transcription factor binding were not involved in the differential activation of FiRE, as the levels and composition of the AP-1 complexes were unchanged. However, application of anisomycin, an activator of Jun amino-terminal kinase, resulted in a lower response in cells growing on collagen compared with fibronectin, These results indicate that the composition of ECM and availability of growth factors can play a role in the epidermal regulation of syndecan-1 expression and that FiRE is a novel target for gene regulation by the extracellular matrix.	Univ Turku, Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, FIN-20521 Turku, Finland	University of Turku; Abo Akademi University	Maatta, A (corresponding author), Imperial Canc Res Fund, Keratinocyte Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	a.maatta@icrf.icnet.uk	Jaakkola, Panu M/B-4355-2012	Jaakkola, Panu/0000-0002-2365-4985; Maatta, Arto/0000-0003-3759-1310				AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CLARK RAF, 1985, J INVEST DERMATOL, V84, P378, DOI 10.1111/1523-1747.ep12265466; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; INKI P, 1991, AM J PATHOL, V139, P1333; INKI P, 1992, LAB INVEST, V66, P314; INKI P, 1994, EUR J CELL BIOL, V63, P43; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Jaakkola P, 1998, ONCOGENE, V17, P1279, DOI 10.1038/sj.onc.1202002; Jaakkola P, 1998, FASEB J, V12, P959, DOI 10.1096/fasebj.12.11.959; JALKANEN M, 1985, J CELL BIOL, V101, P976, DOI 10.1083/jcb.101.3.976; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KATO M, 1995, MOL BIOL CELL, V6, P559, DOI 10.1091/mbc.6.5.559; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KURKINEN M, 1980, LAB INVEST, V43, P47; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; Lin TH, 1997, J BIOL CHEM, V272, P8849; MALI M, 1993, J BIOL CHEM, V268, P24215; MALI M, 1994, J BIOL CHEM, V269, P27795; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; NAKATO H, 1995, DEVELOPMENT, V121, P3687; OKEEFE EJ, 1985, J INVEST DERMATOL, V85, P125, DOI 10.1111/1523-1747.ep12276531; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SAUNDERS S, 1989, J CELL BIOL, V107, P1199; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; STAIANNOCOICO L, 1994, J EXP MED, V178, P865; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; VIHINEN T, 1993, J BIOL CHEM, V268, P17261; Vihinen T, 1996, J BIOL CHEM, V271, P12532, DOI 10.1074/jbc.271.21.12532; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	49	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9891	9898		10.1074/jbc.274.14.9891	http://dx.doi.org/10.1074/jbc.274.14.9891			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092681	hybrid			2022-12-25	WOS:000079451800100
J	Komori, H; Ichikawa, S; Hirabayashi, Y; Ito, M				Komori, H; Ichikawa, S; Hirabayashi, Y; Ito, M			Regulation of intracellular ceramide content in B16 melanoma cells - Biological implications of ceramide glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE GLYCOSPHINGOLIPIDS; CANCER-CELLS; ENDOGLYCOCERAMIDASE; SPHINGOMYELIN; DIFFERENTIATION; HYDROLYSIS; METABOLISM; DEATH; GLUCOSYLTRANSFERASE; PHOSPHATIDYLCHOLINE	We previously reported that ceramide released from glycosphingolipids (GSLs) by endoglycoceramidase was directly metabolized to GSLs, and thus the content of GSLs was constantly maintained in B16 melanoma cells (Ito, M., and Komori, H. (1996) J. Biol. Chem. 271, 12655-12660). In this study, the metabolism of ceramide released from sphingomyelin (SM) by bacterial sphingomyelinase (SMase) was examined using B16 cells and their GSL-deficient mutant counterpart GM95 cells. Treatment of B16 melanoma cells with bacterial SMase effectively hydrolyzed SM on the plasma membrane, Under these conditions, NeuAc alpha 2,3Gal beta 1,4Glc beta 1,1ceramide was significantly increased. Interestingly, UDP-glucose: ceramide glucosyltransferase-1 (GlcT-1) activity and GSL synthesis, but not SM synthesis or sphingosine generation, were found to be up-regulated by SMase treatment. The up-regulation of GSL synthesis seemed to occur at both the transcriptional and post-translational steps of GlcT-1 synthesis. Accumulation of ceramide by bacterial SMase was much higher in GM95 cells than in the parental cells. When the enzyme was removed from the culture medium, the intracellular ceramide level in B16 cells, but not that in the mutant cells, normalized, No rapid restoration of SM in either of the cell lines was observed after removal of the enzyme. SMase treatment strongly inhibited DNA synthesis in GM95 cells but not that in B16 cells. In the presence of D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of GlcT-1, SMase treatment markedly increased the ceramide content and thus inhibited DNA synthesis in B16 cells. Our study provides the first evidence that GlcT-1 functions to regulate the level of intracellular ceramide by glycosylation of the ceramide when it is present in excess.	Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, Fukuoka 8128581, Japan; RIKEN, Inst Phys & Chem Res, Frontier Res Program, Lab Cellular Glycobiol, Wako, Saitama 3510198, Japan	Kyushu University; RIKEN	Ito, M (corresponding author), Kyushu Univ, Fac Agr, Marine Biochem Lab, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.			ito, Makoto/0000-0003-3159-7818; Hirabayashi, Yoshio/0000-0002-5774-7354				BASU S, 1973, J BIOL CHEM, V248, P1388; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Gillard BK, 1998, EXP CELL RES, V242, P561, DOI 10.1006/excr.1998.4126; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hidari KIPJ, 1996, J BIOL CHEM, V271, P14636, DOI 10.1074/jbc.271.24.14636; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; ITO M, 1991, J BIOL CHEM, V266, P7919; ITO M, 1986, J BIOL CHEM, V261, P14278; ITO M, 1989, J BIOL CHEM, V264, P9510; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; ITO M, 1993, EUR J BIOCHEM, V218, P637, DOI 10.1111/j.1432-1033.1993.tb18417.x; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JI L, 1995, GLYCOBIOLOGY, V5, P343, DOI 10.1093/glycob/5.3.343; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kok JW, 1997, J BIOL CHEM, V272, P21128, DOI 10.1074/jbc.272.34.21128; Kok JW, 1998, BIOCHEM J, V333, P779, DOI 10.1042/bj3330779; KOMORI H, 1995, FEBS LETT, V374, P299, DOI 10.1016/0014-5793(95)01137-4; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MERRILL AH, 1993, ADV LIPID RES, V26, P215; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PLATT FM, 1994, J BIOL CHEM, V269, P8362; RADIN NS, 1993, ADV LIPID RES, V26, P183; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; TITBALL RW, 1993, MICROBIOL REV, V57, P347, DOI 10.1128/MMBR.57.2.347-366.1993; YOKOYAMA K, 1995, FEBS LETT, V368, P477, DOI 10.1016/0014-5793(95)00714-K; Zhang P, 1997, J BIOL CHEM, V272, P9609	37	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8981	8987		10.1074/jbc.274.13.8981	http://dx.doi.org/10.1074/jbc.274.13.8981			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085144	hybrid			2022-12-25	WOS:000079451600086
J	Lukiw, WJ; Martinez, J; Pelaez, RP; Bazan, NG				Lukiw, WJ; Martinez, J; Pelaez, RP; Bazan, NG			The interleukin-1 type 2 receptor gene displays immediate early gene responsiveness in glucocorticoid-stimulated human epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA DEGRADATION; II RECEPTOR; MOLECULAR MECHANISMS; IL-1 RECEPTORS; DECOY RECEPTOR; AP-1 ACTIVITY; EXPRESSION; DEXAMETHASONE; INHIBITION	Human epidermal keratinocytes (HEKs) in primary culture (P2-P4) were used to study glucocorticoid (GC)mediated transcription of the genes encoding the constitutively expressed interleukin-1 type 1 receptor (IL-1R1) and the inducible interleukin-1 type 2 receptor (IL-1R2). Utilizing Northern dot blot analysis and a quantitative reverse transcription-polymerase chain reaction protocol for IL-1R1 and IL-1R2, dexamethasone and, in particular, the budesonide epimer R were shown to effectively and rapidly induce transcription from the IL-IR2 gene when compared with IL-1R1 or beta-actin RNA message levels in the same sample. Southern blot analysis of newly generated IL-1R2 reverse transcription-polymerase chain reaction products using end-labeled IL-1R2 intron probes suggested that GC enhancement of IL-1R2 expression was regulated primarily at the level of de novo transcription. GC-induced IL-1R2 gene transcription displayed features characteristic of a classical immediate early gene response, including a signal transduction function, a relatively low basal abundance, a rapid, transient induction, cycloheximide superinduction, actinomycin D suppression, and a rapid decay of IL-1R2 RNA message. Parallel time course kinetic analysis of IL-1R2 RNA message levels with Western immunoblotting revealed tight coupling of de novo IL-IR2 gene transcription with translation of the IL-1R2 RNA message; a newly synthesized (similar to 46-kDa) IL-1RS protein was detected in the HEK growth medium as early as 1 h after budesonide epimer R treatment. These data indicate that different GC compounds can variably up-regulate the IL-1R2 response in HEKs through transcription-mediated mechanisms and, for the first time, suggest that a gene encoding a soluble cytokine receptor can respond like an immediate early gene.	Louisiana State Univ, Med Ctr, Ctr Neurosci, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Ind Farmaceut & Especialidades SA, ARISTEGUI, Dept Res & Dev, Madrid 28006, Spain	Louisiana State University System; Louisiana State University System	Bazan, NG (corresponding author), Louisiana State Univ, Med Ctr, Ctr Neurosci, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.	nbazan@lsumc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	PHS HHS [RY02377] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Brown EA, 1996, CYTOKINE, V8, P828; BURGER D, 1995, J CLIN INVEST, V96, P38, DOI 10.1172/JCI118045; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DAHLBERG E, 1984, MOL PHARMACOL, V25, P70; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Fink GW, 1997, CYTOKINE, V9, P1023, DOI 10.1006/cyto.1997.0260; Gabellec MM, 1996, J NEUROIMMUNOL, V66, P65, DOI 10.1016/0165-5728(96)00021-5; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GoppeltStruebe M, 1997, BIOCHEM PHARMACOL, V53, P1389, DOI 10.1016/S0006-2952(97)00018-X; GRANT AJ, 1992, P NATL ACAD SCI USA, V89, P2165, DOI 10.1073/pnas.89.6.2165; GROVES RW, 1994, AM J PATHOL, V145, P1048; GROVES RW, 1995, J IMMUNOL, V154, P4065; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; LUKIW WJ, 1996, ALZHEIMERS RES, V2, P221; MAK JCW, 1995, AM J PHYSIOL-LUNG C, V268, pL41, DOI 10.1152/ajplung.1995.268.1.L41; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORGAN JI, 1995, TRENDS NEUROSCI, V18, P66; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nishiyori A, 1997, MOL BRAIN RES, V50, P237, DOI 10.1016/S0169-328X(97)00195-2; Orlando S, 1997, J IMMUNOL, V158, P3861; Rauschmayr T, 1997, P NATL ACAD SCI USA, V94, P5814, DOI 10.1073/pnas.94.11.5814; RE F, 1994, J EXP MED, V179, P739, DOI 10.1084/jem.179.2.739; Re F, 1996, J EXP MED, V183, P1841, DOI 10.1084/jem.183.4.1841; REDDY ST, 1994, J LEUKOCYTE BIOL, V55, P192, DOI 10.1002/jlb.55.2.192; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; Smith CL, 1998, ARZNEIMITTEL-FORSCH, V48, P957; Smith M, 1996, MOL CELL ENDOCRINOL, V122, P151, DOI 10.1016/0303-7207(96)03878-6; Struhl Kevin, 1997, Genes and Function, V1, P5; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; William R, 1998, J IMMUNOL, V161, P957; Ye K, 1996, CYTOKINE, V8, P421, DOI 10.1006/cyto.1996.0058	47	14	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8630	8638		10.1074/jbc.274.13.8630	http://dx.doi.org/10.1074/jbc.274.13.8630			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085100	hybrid			2022-12-25	WOS:000079451600042
J	Funatsu, N; Miyata, S; Kumanogoh, H; Shigeta, M; Hamada, K; Endo, Y; Sokawa, Y; Maekawa, S				Funatsu, N; Miyata, S; Kumanogoh, H; Shigeta, M; Hamada, K; Endo, Y; Sokawa, Y; Maekawa, S			Characterization of a novel rat brain glycosylphosphatidylinositol-anchored protein (Kilon), a member of the IgLON cell adhesion molecule family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED MEMBRANE SUBDOMAINS; IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; OPIOID-BINDING; NERVOUS-SYSTEM; IG SUPERFAMILY; DOMAINS; EXPRESSION; CADHERIN; SURFACE	In the central nervous system, many cell adhesion molecules are known to participate in the establishment and remodeling of the neural circuit. Some of the cell adhesion molecules are known to be anchored to the membrane by the glycosylphosphatidylinositol (GPI) inserted to their C termini, and many GPI-anchored proteins are known to be localized in a Triton-insoluble membrane fraction of low density or so-called "raft," In this study, we surveyed the GPI-anchored proteins in the Triton-insoluble low density fraction from 2-week-old rat brain by solubilization with phosphatidylinositol-specific phospholipase C, By Western blotting and partial peptide sequencing after the deglycosylation with peptide N-glycosidase F, the presence of Thy-1, F3/contactin, and T-cadherin was shown. In addition, one of the major proteins, having an apparent molecular mass of 36 kDa after the peptide N-glycosidase F digestion, was found to be a novel protein, The result of cDNA cloning showed that the protein is an immunoglobulin superfamily member with three C2 domains and has six putative glycosylation sites. Since this protein shows high sequence similarity to IgLON family members including LAMP, OBCAM, neurotrimin, CEPU-1, AvGP50, and GP55, we termed this protein Kilon (a kindred of IgLON). Kilon-specific monoclonal antibodies were produced, and Western blotting analysis showed that expression of Kilon is restricted to brain, and Kilon has an apparent molecular mass of 46 kDa in SDS-polyacrylamide gel electrophoresis in its expressed form, In brain, the expression of Kilon is already detected in E16 stage, and its level gradually increases during development. Kilon immunostaining was observed in the cerebral cortex and hippocampus, in which the strongly stained puncta were observed on dendrites and soma of pyramidal neurons.	Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan; Kyoto Inst Technol, Venture Lab, Kyoto 6068585, Japan	Kyoto Institute of Technology; Kyoto Institute of Technology	Maekawa, S (corresponding author), Kyoto Inst Technol, Dept Biotechnol, Kyoto 6068585, Japan.							Asou H, 1996, J NEUROSCI RES, V45, P571, DOI 10.1002/(SICI)1097-4547(19960901)45:5<571::AID-JNR7>3.0.CO;2-9; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; CLARKE GA, 1994, J CELL SCI, V107, P3393; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Hachisuka A, 1996, NEUROCHEM INT, V28, P373, DOI 10.1016/0197-0186(95)00108-5; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; Hancox KA, 1997, MOL BRAIN RES, V44, P273, DOI 10.1016/S0169-328X(96)00228-8; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; Henke RC, 1997, J NEUROSCI RES, V49, P655, DOI 10.1002/(SICI)1097-4547(19970915)49:6<655::AID-JNR1>3.3.CO;2-0; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; HOSOYA H, 1995, NEUROSCI LETT, V186, P83, DOI 10.1016/0304-3940(95)11287-7; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P106; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; LIPPMAN DA, 1992, GENE, V117, P249, DOI 10.1016/0378-1119(92)90734-7; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; Maekawa S, 1997, BBA-BIOMEMBRANES, V1323, P1, DOI 10.1016/S0005-2736(96)00222-2; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PIMENTA AF, 1995, NEURON, V15, P287, DOI 10.1016/0896-6273(95)90034-9; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; ROSEN CL, 1992, J CELL BIOL, V117, P617, DOI 10.1083/jcb.117.3.617; SCHOFIELD PR, 1989, EMBO J, V8, P489, DOI 10.1002/j.1460-2075.1989.tb03402.x; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Spaltmann F, 1996, J NEUROSCI, V16, P1770; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STRUYK AF, 1995, J NEUROSCI, V15, P2141, DOI 10.1523/JNEUROSCI.15-03-02141.1995; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; Wick MJ, 1996, MOL BRAIN RES, V36, P322, DOI 10.1016/0169-328X(95)00258-T; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Wilson DJA, 1996, J CELL SCI, V109, P3129; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; ZACCO A, 1990, J NEUROSCI, V10, P73; ZHUKAREVA V, 1995, DEVELOPMENT, V121, P1161	55	102	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8224	8230		10.1074/jbc.274.12.8224	http://dx.doi.org/10.1074/jbc.274.12.8224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075727	hybrid			2022-12-25	WOS:000079268100086
J	Basar, T; Havlicek, V; Bezouskova, S; Halada, P; Hackett, M; Sebo, P				Basar, T; Havlicek, V; Bezouskova, S; Halada, P; Hackett, M; Sebo, P			The conserved lysine 860 in the additional fatty-acylation site of Bordetella pertussis adenylate cyclase is crucial for toxin function independently of its acylation status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HEMOLYSIN; CELL-INVASIVE ACTIVITY; MASS-SPECTROMETRY; ACTIVATION; PROTEIN; HLYA; PENETRATION; EXPRESSION; RESOLUTION; INFECTION	The Bordetella pertussis RTX (repeat in toxin family protein) adenylate cyclase toxin-hemolysin (ACT) acquires biological activity upon a single amide-linked palmitoylation of the E-amino group of lysine 983 (Lys(983)) by the accessory fatty-acyltransferase CyaC. However, an additional conserved RTX acylation site can be identified in ACT at lysine 860 (Lys(860)), and this residue becomes palmitoylated when recombinant ACT (r-Ec-ACT) is produced together with CyaC in Escherichia coli K12. We have eliminated this additional acylation site by replacing Lys(860) Of ACT with arginine, leucine, and cysteine residues. Two-dimensional gel electrophoresis and microcapillary high performance liquid chromatography/tandem mass spectrometric analyses of mutant proteins confirmed that the two sites are acylated independently in vivo and that mutations of Lys860 did not affect the quantitative acylation of Lys983 by palmitoyl (C16:0) and palmitoleil (cis Delta 9 C16:1) fatty-acyl groups. Nevertheless, even the most conservative substitution of lysine 860 by an arginine residue caused a 10-fold decrease of toxin activity. This resulted from a B-fold reduction of cell association capacity and a further 2-fold reduction in cell penetration efficiency of the membrane-bound K860R toxin, These results suggest that lysine 860 plays by itself a crucial structural role in membrane insertion and translocation of the toxin, independently of its acylation status.	Acad Sci Czech Republ, Inst Microbiol, CZ-14220 Prague 4, Czech Republic; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of Washington; University of Washington Seattle	Sebo, P (corresponding author), Acad Sci Czech Republ, Inst Microbiol, Videnska 1083, CZ-14220 Prague 4, Czech Republic.		Basar, Tamer/V-6613-2019; Halada, Petr/H-3330-2014; SEBO, Peter/N-2043-2019; SEBO, Peter/F-7423-2011; Havlicek, Vladimir/H-2626-2014	Halada, Petr/0000-0002-7229-3450; SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Havlicek, Vladimir/0000-0002-8614-7059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046440] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46440-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Beaver W.L., 1991, CLIN J SPORT MED, V1, P27; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BENZ R, 1994, J BIOL CHEM, V269, P27231; BETSOU F, 1995, INFECT IMMUN, V63, P3309, DOI 10.1128/IAI.63.9.3309-3315.1995; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; GORDON VM, 1989, J BIOL CHEM, V264, P14792; Gray M, 1998, J BIOL CHEM, V273, P18260, DOI 10.1074/jbc.273.29.18260; GuzmanVerri C, 1997, J BACTERIOL, V179, P5959, DOI 10.1128/jb.179.18.5959-5962.1997; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; HACKETT M, 1995, J BIOL CHEM, V270, P20250, DOI 10.1074/jbc.270.35.20250; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HANSKI E, 1985, J BIOL CHEM, V260, P5526; Hanski E, 1991, SOURCEBOOK BACTERIAL, P349; HEWLETT EL, 1983, CLIN RES, V31, pA365; HEWLETT EL, 1991, J BIOL CHEM, V266, P17503; ISSARTEL JP, 1991, NATURE, V351, P759, DOI 10.1038/351759a0; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; LEPAGE G, 1986, J LIPID RES, V27, P114; Ludwig A, 1996, J BACTERIOL, V178, P5422, DOI 10.1128/jb.178.18.5422-5430.1996; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pellett S, 1996, INFECT IMMUN, V64, P3081, DOI 10.1128/IAI.64.8.3081-3087.1996; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; SAKAMOTO H, 1992, J BIOL CHEM, V267, P13598; Sambrook J., 2002, MOL CLONING LAB MANU; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; STANLEY P, 1994, SCIENCE, V266, P1992, DOI 10.1126/science.7801126; SZABO G, 1994, J BIOL CHEM, V269, P22496; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Wang HL, 1998, ANAL CHEM, V70, P205, DOI 10.1021/ac971036l; Wang HL, 1997, ANAL BIOCHEM, V250, P162, DOI 10.1006/abio.1997.2214; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	43	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10777	10783		10.1074/jbc.274.16.10777	http://dx.doi.org/10.1074/jbc.274.16.10777			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196151	hybrid			2022-12-25	WOS:000079751900019
J	DeGraff, JL; Gagnon, AW; Benovic, JL; Orsini, MJ				DeGraff, JL; Gagnon, AW; Benovic, JL; Orsini, MJ			Role of arrestins in endocytosis and signaling of alpha(2)-adrenergic receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EPIDERMAL GROWTH-FACTOR; BETA-ARRESTIN; ALPHA-2-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; OPIOID RECEPTOR; KINASE PATHWAY; ACTIVATION; DESENSITIZATION	We investigated the role of arrestins in the trafficking of human alpha(2)-adrenergic receptors (alpha(2)-ARs) and the effect of receptor trafficking on p42/p44 RAP kinase activation. alpha(2)-ARs expressed in COS-1 cells demonstrated a modest level of agonist-mediated internalization, with alpha(2c) > alpha(2b) > alpha(2a). However, upon coexpression of arrestin-2 (beta-arrestin-1) or arrestin-3 (beta-arrestin-2), internalization of the alpha(2b) AR was dramatically enhanced and redistribution of receptors to clathrin coated vesicles and endosomes was observed. Internalization of the alpha 2c AR was selectively promoted by coexpression of arrestin-3, while alpha 2a AR internalization was only slightly stimulated by coexpression of either arrestin. Coexpression of GRK2 had no effect on the internalization of any alpha 2-AR subtype, either in the presence or absence of arrestins. Internalization of the alpha 2b and alpha 2c ARs was inhibited by coexpression of dominant negative dynamin-K44A However, alpha 2-AR-mediated activation of either endogenous or cotransfected p42/p44 mitogen-activated protein (IMAP) kinase was not affected by either dynamin-K44A or arrestin-3. Moreover, activation of p42/ p44 MAP kinase by endogenous epidermal growth factor, lysophosphatidic acid, and beta(2)-adrenergic receptors was also unaltered by dynamin-K44A. In summary, our data suggest that internalization of the alpha(2b), alpha(2c), and to a lesser extent alpha(2a) ARs, is both arrestin- and dynamin de pendent. However, endocytosis does not appear to be required for alpha(2)-adrenergic, epidermal growth factor, lysophosphatidic acid, or beta(2)-adrenergic receptor-mediated p42/p44 MAP kinase activation in COS-1 cells.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NIAID NIH HHS [5-T32-AI07523] Funding Source: Medline; NIDDK NIH HHS [5-T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM47419] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; EASON MG, 1992, J BIOL CHEM, V267, P25473; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; JEWELLMOTZ EA, 1995, BIOCHEMISTRY-US, V34, P11946, DOI 10.1021/bi00037a036; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LI JG, 1999, IN PRESS J BIOL CHEM, V274; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	39	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11253	11259		10.1074/jbc.274.16.11253	http://dx.doi.org/10.1074/jbc.274.16.11253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196213	hybrid			2022-12-25	WOS:000079751900081
J	Iida, SI; Yamamoto, K; Irimura, T				Iida, SI; Yamamoto, K; Irimura, T			Interaction of human macrophage C-type lectin with O-linked N-acetylgalactosamine residues on mucin glycopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; SURFACE-PLASMON RESONANCE; HELICAL COILED-COIL; ASIALOGLYCOPROTEIN RECEPTOR; MOLECULAR-CLONING; ANIMAL LECTINS; BINDING; EXPRESSION; AFFINITY; CDNA	A fluorescein-labeled synthetic peptide, PTTTPITTTT-TK, was converted into O-glycosylated glycopeptides with various numbers of attached N-acetyl-D-galactosamines (GalNAcs) by in vitro glycosylation with UDP-Gal-NAc and a microsomal fraction of LS174T human colon carcinoma cells, Glycopeptides with 1, 3, 5, and 6 GalNAc residues (G1, G3, G5, and G6) were obtained, and their sizes were confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, Their sequences were determined by a peptide sequencer to be PTTTGalNAcPITTTTK for G1, PTGalNAcTTPITGalNAc TGalNAcTTK for G3, PTTGalNAcTGalNAcPITGalNAcTGalNAc- TGalNAcTK for G5, and PTGalNAcTGalNAcTGalNAcPITGalNAc. TGalNAcTGalNAcTK for G6, A calcium-type human macrophage lectin (HML) was prepared in a recombinant form, and its interaction with these glycopeptides was investigated by surface plasmon resonance (SPR) spectroscopy and fluorescence polarization. The affinity of recombinant HML (rHML) for immobilized glycopeptides increased, as revealed by SPR, in parallel with the number of GalNAc. The highest affinity was obtained when the G6-peptide was immobilized at high density, Fluorescence polarization equilibrium-binding assays also revealed that the affinity of rHML for soluble glycopeptides increased, depending on the number of attached GalNAcs. Carbohydrate recognition domain (CRD) fragments of HML were prepared, and their affinity for these four glycopeptides was also determined, this affinity was apparently lower than that of rHML, Affinity constants of rHML for the G3- and G5-peptides were 11- and 38-fold higher, respectively, than for the G1-peptide, whereas those of CRD fragments were only 2- and 6-fold higher, respectively. A chemical cross-linking study revealed that rHML but not recombinant CRD forms trimers in an aqueous solution. Thus, preferential binding of densely glycosylated O-linked glycopeptides should be due to the trimer formation of rHML.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Irimura, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							ADLER P, 1995, J BIOL CHEM, V270, P5164, DOI 10.1074/jbc.270.10.5164; BEAVIL AJ, 1992, P NATL ACAD SCI USA, V89, P753, DOI 10.1073/pnas.89.2.753; BOVIN NV, 1993, GLYCOCONJUGATE J, V10, P142, DOI 10.1007/BF00737711; BYRD JC, 1988, CANCER RES, V48, P6678; CHECOVICH WJ, 1995, NATURE, V375, P254, DOI 10.1038/375254a0; DIERKS SE, 1993, J IMMUNOL, V150, P2372; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hosoi T, 1998, GLYCOBIOLOGY, V8, P791, DOI 10.1093/glycob/8.8.791; IMAI Y, 1994, J IMMUNOL METHODS, V171, P23, DOI 10.1016/0022-1759(94)90224-0; Imai Y, 1995, IMMUNOLOGY, V86, P591; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; KAWAKAMI K, 1994, JPN J CANCER RES, V85, P744, DOI 10.1111/j.1349-7006.1994.tb02423.x; Kim YS, 1996, GLYCOCONJUGATE J, V13, P693, DOI 10.1007/BF00702333; LEE RT, 1987, GLYCOCONJUGATE J, V4, P317, DOI 10.1007/BF01048365; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; MacKenzie CR, 1996, J BIOL CHEM, V271, P1527, DOI 10.1074/jbc.271.3.1527; Mizuochi S, 1997, GLYCOBIOLOGY, V7, P137, DOI 10.1093/glycob/7.1.137; OZAKI K, 1992, J BIOL CHEM, V267, P9229; Reddish MA, 1997, GLYCOCONJUGATE J, V14, P549, DOI 10.1023/A:1018576224062; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; SAKAMAKI T, 1995, J LEUKOCYTE BIOL, V57, P407, DOI 10.1002/jlb.57.3.407; Schuck P, 1996, ANAL BIOCHEM, V240, P262, DOI 10.1006/abio.1996.0356; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Suzuki N, 1996, J IMMUNOL, V156, P128; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	32	75	79	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10697	10705		10.1074/jbc.274.16.10697	http://dx.doi.org/10.1074/jbc.274.16.10697			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196140	hybrid			2022-12-25	WOS:000079751900008
J	Kitayama, S; Ikeda, T; Mitsuhata, C; Sato, T; Morita, K; Dohi, T				Kitayama, S; Ikeda, T; Mitsuhata, C; Sato, T; Morita, K; Dohi, T			Dominant negative isoform of rat norepinephrine transporter produced by alternative RNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; DOPAMINE TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; NORADRENALINE TRANSPORTER; H-3 NISOXETINE; MESSENGER-RNA; UPTAKE SITES; GENE; EXPRESSION; RECEPTOR	We have cloned from rat brain a family of alternatively spliced cDNAs from a single gene, which encodes a norepinephrine transporter (NET) having variations at the 3'-region including both coding and noncoding regions. This produces two transporter isoforms, rNETa and rNETb, which differ at their COOH termini, The rNETa isoform reveals a COOH terminus homologous to human NET and transports norepinephrine. In contrast, rNETb revealed no detectable transport function but reduced functional expression of rNETa when both isoforms were expressed in the same cell. Thus, rNETb potentially functions as a dominant negative inhibitor of rNETa activity. Go-expression of rNETb with a gamma-aminobutyric acid transporter (rGAT1), a serotonin transporter (rSERT), and a dopamine transporter (rDAT) reduced their transport activity. No reduction was found with the glutamate/aspartate transporter (rGLAST), Alternative RNA splicing of NET suggests a novel mechanism for the regulation of synaptic transmission.	Hiroshima Univ, Sch Dent, Dept Pharmacol, Minami Ku, Hiroshima 734, Japan	Hiroshima University	Kitayama, S (corresponding author), Hiroshima Univ, Sch Dent, Dept Pharmacol, Minami Ku, Kasumi 1-2-3, Hiroshima 734, Japan.							Amara S G, 1991, Curr Opin Neurobiol, V1, P84, DOI 10.1016/0959-4388(91)90014-X; BAUER ME, 1992, BRAIN RES, V582, P208, DOI 10.1016/0006-8993(92)90134-U; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; CEBELLS JF, 1995, J NEUROCHEM, V65, P502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fritz JD, 1998, J NEUROCHEM, V70, P2241; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; JURSKY F, 1994, J EXP BIOL, V196, P283; Kitayama S, 1996, JPN J PHARMACOL, V72, P195, DOI 10.1254/jjp.72.195; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACROIX D, 1991, J PHARMACOL EXP THER, V257, P1081; LANGER SZ, 1988, PROG NEURO-PSYCHOPH, V12, P193, DOI 10.1016/0278-5846(88)90037-1; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; LINGEN B, 1994, FEBS LETT, V342, P235, DOI 10.1016/0014-5793(94)80508-3; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; Nagai M, 1998, NEUROSCI LETT, V244, P165, DOI 10.1016/S0304-3940(98)00158-X; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; PORZGEN P, 1995, BIOCHEM BIOPH RES CO, V215, P1145, DOI 10.1006/bbrc.1995.2582; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sairam MR, 1996, BIOCHEM BIOPH RES CO, V226, P717, DOI 10.1006/bbrc.1996.1419; SCHAEFFER JC, 1991, MOL BRAIN RES, V9, P271; SZOT P, 1993, BRAIN RES, V618, P308, DOI 10.1016/0006-8993(93)91281-V; TEJANIBUTT SM, 1990, EUR J PHARMACOL, V191, P239, DOI 10.1016/0014-2999(90)94155-Q; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WANG YL, 1991, MOL ENDOCRINOL, V5, P1707, DOI 10.1210/mend-5-11-1707; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733	33	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10731	10736		10.1074/jbc.274.16.10731	http://dx.doi.org/10.1074/jbc.274.16.10731			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196144	hybrid			2022-12-25	WOS:000079751900012
J	Maziarz, KM; Monaco, HL; Shen, F; Ratnam, M				Maziarz, KM; Monaco, HL; Shen, F; Ratnam, M			Complete mapping of divergent amino acids responsible for differential ligand binding of folate receptors alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED KB CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; MEMBRANE-TRANSPORT; LEUKEMIA-CELLS; MEDIATED ENDOCYTOSIS; INCREASED EXPRESSION; MURINE L1210; TUMOR-CELLS; MA104 CELLS; PROTEIN	The folate receptor (FR) type alpha may be distinguished from FR-beta by its higher affinity for the circulating folate coenzyme, (GS)-5-methyltetrahydrofolate (B-CH(3)H(4)folate), and its opposite stereospecificity for reduced folate coenzymes, Previous studies showed that a single leucine to alanine substitution at position 49 of the mature protein sequence is responsible for the functional divergence of FR-beta (Shen, F,, Zheng, X, Wang, H,, and Ratnam, M. (1997) Biochemistry 36, 6157-6163); however, the results also indicated that the minimum requirement for conversion of FR-beta to the functional equivalent of FR-alpha should include amino acid substitution(s) downstream of residue 92 in addition to mutation of L49A. To pinpoint those residues, chimeric FR-beta(L49A)/FR-alpha constructs including progressively shorter segments of FR-alpha downstream of position 92 as well as selected point mutants were studied, Simultaneous substitution of Leu-49, Phe-104, and Gly-166 in FR-beta with the corresponding FR-alpha residues Ala, Val, and Glu, respectively, reconstituted the ligand binding characteristics of FR-alpha. The results also exclude a role for other residues in FR-alpha in determining its functional divergence, A homology model of FR-alpha based on the three-dimensional structure of the chicken riboflavin-binding protein is used to show the position of residues 49, 104, and 166 in relation to the hydrophobic cleft corresponding to the riboflavin-binding pocket.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA; Univ Pavia, Dept Genet, I-27100 Pavia, Italy	University of Pavia	Ratnam, M (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43614 USA.			Monaco, Hugo L./0000-0002-2067-0365	NCI NIH HHS [R29 CA57598] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA057598] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; BIRN H, 1993, AM J PHYSIOL, V264, pC302, DOI 10.1152/ajpcell.1993.264.2.C302; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRUGER AT, 1992, X PLOR VERSION 3 1 S; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CONEY LR, 1991, CANCER RES, V51, P6125; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; HAMAZUME Y, 1987, J BIOCHEM-TOKYO, V101, P217, DOI 10.1093/oxfordjournals.jbchem.a121894; HENDERSON GB, 1990, BIOCHEM PHARMACOL, V39, P2019, DOI 10.1016/0006-2952(90)90624-T; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1991, CANCER CHEMOTH PHARM, V28, P115, DOI 10.1007/BF00689699; JANSEN G, 1989, CANCER RES, V49, P2455; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; Ladino CA, 1997, INT J CANCER, V73, P859; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEAMON CP, 1994, J DRUG TARGET, V2, P101, DOI 10.3109/10611869409015898; LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572; LEAMON CP, 1993, BIOCHEM J, V291, P855, DOI 10.1042/bj2910855; LEAMON CP, 1992, J BIOL CHEM, V267, P24966; LEAMON CP, 1993, J BIOL CHEM, V268, P24847; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE RJ, 1994, J BIOL CHEM, V269, P3198; LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; Mathias CJ, 1998, J NUCL MED, V39, P1579; Mathias CJ, 1996, J NUCL MED, V37, P1003; Mathias CJ, 1998, NUCL MED BIOL, V25, P585, DOI 10.1016/S0969-8051(98)00030-4; Monaco HL, 1997, EMBO J, V16, P1475, DOI 10.1093/emboj/16.7.1475; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NORIOKA N, 1985, J BIOCHEM-TOKYO, V97, P19, DOI 10.1093/oxfordjournals.jbchem.a135044; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; Ross JF, 1999, CANCER-AM CANCER SOC, V85, P348, DOI 10.1002/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEN F, 1995, BIOCHEMISTRY-US, V34, P5660, DOI 10.1021/bi00016a042; SHEN F, 1994, BIOCHEMISTRY-US, V33, P1209, DOI 10.1021/bi00171a021; Shen F, 1997, BIOCHEM J, V327, P759, DOI 10.1042/bj3270759; Shen F, 1997, BIOCHEMISTRY-US, V36, P6157, DOI 10.1021/bi9626564; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; TUREK JJ, 1993, J CELL SCI, V106, P423; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WANG S, 1995, P NATL ACAD SCI USA, V92, P3318, DOI 10.1073/pnas.92.8.3318; Wang S, 1997, BIOCONJUGATE CHEM, V8, P673, DOI 10.1021/bc9701297; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; WEITMAN SD, 1992, CANCER RES, V52, P3396; WESTERHOF GR, 1991, CANCER RES, V51, P5507; WESTERHOF GR, 1995, MOL PHARMACOL, V48, P459; Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277; YAN W, 1995, BIOCHEMISTRY-US, V34, P14594, DOI 10.1021/bi00044a039	54	53	56	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11086	11091		10.1074/jbc.274.16.11086	http://dx.doi.org/10.1074/jbc.274.16.11086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196192	hybrid			2022-12-25	WOS:000079751900060
J	Desterro, JMP; Rodriguez, MS; Kemp, GD; Hay, RT				Desterro, JMP; Rodriguez, MS; Kemp, GD; Hay, RT			Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; NUCLEAR-PORE COMPLEX; AFFINITY PURIFICATION; CONJUGATING ENZYME; SYSTEM; DEGRADATION; PML; TERMINUS; HOMOLOG; RANGAP1	The ubiquitin-like protein SUMO-1 is conjugated to a variety of proteins including Ran GTPase-activating protein 1 (RanGAP1), I kappa B alpha, and PML, SUMO-1-modified proteins display altered subcellular targeting and/or stability. We have purified the SUMO-1-activating enzyme from human cells and shown that it contains two subunits of 38 and 72 kDa, Isolation of cDNAs for each subunit indicates that they are homologous to ubiquitin-activating enzymes and to the Saccharomyces cerevisiae enzymes responsible for conjugation of Smt3p and Rub-1p, In vitro, recombinant SAE1/SAE2 (SUMO-1-activating enzyme) was capable of catalyzing the ATP-dependent formation of a thioester linkage between SUMO-1 and SAE2. The addition of the SUMO-1-conjugating enzyme Ubch9 resulted in efficient transfer of the thioester-linked SUMO-1 from SAE2 to Ubch9, In the presence of SAE1/SAE2, Ubch9, and ATP, SUMO-1 was efficiently conjugated to the protein substrate I kappa B alpha. As SAE1/SAE2, Ubch9, SUMO-1, and I kappa B alpha are all homogeneous, recombinant proteins, it appears that SUMO-1 conjugation of I kappa B alpha in vitro does not require the equivalent of an E3 ubiquitin protein ligase activity.	Univ St Andrews, Sch Biomed Sci, St Andrews KY16 9ST, Fife, Scotland	University of St Andrews	Hay, RT (corresponding author), Univ St Andrews, Sch Biomed Sci, BMS Bldg, St Andrews KY16 9ST, Fife, Scotland.		Hay, Ronald T/F-9338-2011	Hay, Ronald T/0000-0001-7113-9024; Desterro, Joana/0000-0002-6359-7233				Boddy MN, 1996, ONCOGENE, V13, P971; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kroll M, 1997, ONCOGENE, V15, P1841, DOI 10.1038/sj.onc.1201560; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543	34	278	292	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10618	10624		10.1074/jbc.274.15.10618	http://dx.doi.org/10.1074/jbc.274.15.10618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187858	hybrid			2022-12-25	WOS:000079663500097
J	Liou, ML; Liou, HC				Liou, ML; Liou, HC			The ubiquitin-homology protein, DAP-1, associates with tumor necrosis factor receptor (p60) death domain and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; TNF-RECEPTOR; SPHINGOMYELIN PATHWAY; SIGNAL-TRANSDUCTION; KINASE COMPLEX; DNA-REPAIR; ACTIVATION; INTERACTS; CYCLE	The tumor necrosis factor receptor, p60 (TNF-R1), transduces death signals via the association of its cytoplasmic domain with several intracellular proteins. By screening a mammalian cDNA library using the yeast two-hybrid cloning technique, we isolated a ubiquitin-homology protein, DAP-1, which specifically interacts with the cytoplasmic death domain of TNF-R1. Sequence analysis reveals that DAP-1 shares striking sequence homology with the yeast SMT3 protein that is essential for the maintenance of chromosome integrity during mitosis (Meluh, P. B., and Koshland, D. (1995) Mel. Biol. Cell 6, 793-807). DAP-1 is nearly identical to PIC1, a protein that interacts with the PML tumor suppressor implicated in acute promyelocytic leukemia (Boddy, M. N., Howe, K., Etkin, L. D., Solomon, E., and Freemont, P. S. (1996) Oncogene 13, 971-982), and the sentrin protein, which associates with the Fas death receptor (Okura, T., Gong, L., Kamitani, T., Wada, T., Okura, I., Wei, C. F., Chang, H. M., and Yeh, E. T. (1996) J. Immunol. 157, 4277-4281). The in vivo interaction between DAP-1 and TNF-R1 was further confirmed in mammalian cells. In transient transfection assays, overexpression of DAP-1 suppresses NF-kappa B/Rel activity in 293T cells, a human kidney embryonic carcinoma cell line. Overexpression of either DAP-1 or sentrin causes apoptosis of TNF-sensitive L929 fibroblast cell line, as well as TNF-resistant osteosarcoma cell line, U20S. Furthermore, the dominant negative Fas-associated death domain protein (FADD) protein blocks the cell death induced by either DAP-1 or FADD. Collectively, these observations highly suggest a role for DAP-1 in mediating TNF-induced cell death signaling pathways, presumably through the recruitment of FADD death effector.	Cornell Univ, Coll Med, Dept Med, Div Immunol, New York, NY 10021 USA; Cornell Univ, Coll Med, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University; Cornell University	Liou, HC (corresponding author), Cornell Univ, Coll Med, Dept Med, Div Immunol, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA068155] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA68155] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Andjelic S, 1998, EUR J IMMUNOL, V28, P570, DOI 10.1002/(SICI)1521-4141(199802)28:02<570::AID-IMMU570>3.0.CO;2-M; AUSUBEL FM, 1989, CURRENT PROTOCOS MOL; Boddy MN, 1996, ONCOGENE, V13, P971; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; Dunbar JD, 1997, J IMMUNOL, V158, P4252; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, J EXP MED, V185, P1275, DOI 10.1084/jem.185.7.1275; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Okura T, 1996, J IMMUNOL, V157, P4277; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	39	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10145	10153		10.1074/jbc.274.15.10145	http://dx.doi.org/10.1074/jbc.274.15.10145			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187798	hybrid			2022-12-25	WOS:000079663500037
J	Graca-Souza, AV; Silva-Neto, MAC; Oliveira, PL				Graca-Souza, AV; Silva-Neto, MAC; Oliveira, PL			Urate synthesis in the blood-sucking insect Rhodnius prolixus - Stimulation by hemin is mediated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIC-ACID; CELLULAR-REGULATION; OKADAIC ACID; ACTIVATION; CELLS; PHOSPHORYLATION; INHIBITION; PROTECTION; COMPOUND; POTENT	Hemin is a catalyst of the formation of reactive oxygen species. We proposed that hematophagous insects are exposed to intense oxidative stress because of hemoglobin hydrolysis in their midgut (Petretsky, NI. D., Ribeiro, J.M.C., Atella, G. C., Masuda, H., and Oliveira, P. L. (1995) J. Biol. Chem. 270, 10893-10896). We have shown that hemin stimulates urate synthesis in the blood-sucking insect Rhodnius prolixus (Graca-Souza, A. V., Petretsky, J. H., Demasi, M., Bechara, E. J. H,, and Oliveira, P. L. (1997) Free Radical Biol. Med. 22, 209-214). Once released by fat body cells, urate accumulates in the hemolymph, where this radical scavenger constitutes an important defense against blood-feeding derived oxidative stress. Incubation of Rhodnius fat bodies with okadaic acid raises the level of urate synthesis, suggesting that urate production can be controlled by protein phosphorylation/dephosphorylation. Urate synthesis is stimulated by dibutyryl cAMP and inhibited by N(2((p-bromocinnamil) amino)ethyl)-5-isoquinolinesulfonamide (H-89), an inhibitor of protein kinase A, as well as activated by the protein kinase C activator phorbol 12-myristate 13-acetate. In the presence of hemin, however, inhibition of urate synthesis by H-89 does not occur, suggesting that the hemin stimulatory effect is not mediated by protein kinase A Calphostin C completely inhibits the hemin-induced urate production, suggesting that the triggering of urate antioxidant response depends on protein kinase C activation. This conclusion is reinforced by the observation that in fat bodies exposed to hemin, both protein kinase C activity and phosphorylation of specific endogenous polypeptides are significantly increased.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, BR-21910590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Graca-Souza, AV (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Dept Bioquim Med, BR-21910590 Rio De Janeiro, Brazil.	avsouza@server.bioqmed.ufrj.br	Silva-Neto, Mario A C/C-1211-2013; L. Oliveira, Pedro/A-9438-2010	Silva-Neto, Mario A C/0000-0003-2273-194X; L. Oliveira, Pedro/0000-0003-0307-354X				AFT RL, 1983, J BIOL CHEM, V258, P2069; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAWN MK, 1995, FREE RADICAL RES, V22, P23, DOI 10.3109/10715769509147525; BURSELL E, 1965, ADV INSECT PHYSL, V9, P33; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cochran D. G., 1975, INSECT BIOCH FUNCTIO, P177; COCHRAN DG, 1985, ANNU REV ENTOMOL, V30, P29, DOI 10.1146/annurev.en.30.010185.000333; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAVIES KJA, 1986, BIOCHEM J, V235, P747, DOI 10.1042/bj2350747; de Meis L, 1974, Biochemistry, V13, P2057, DOI 10.1021/bi00707a009; DOMAGK GF, 1968, ANAL BIOCHEM, V22, P219, DOI 10.1016/0003-2697(68)90309-6; FEENER EP, 1994, BIOCHEM J, V303, P43, DOI 10.1042/bj3030043; GOPALAKRISHNA R, 1991, ARCH BIOCHEM BIOPHYS, V285, P382, DOI 10.1016/0003-9861(91)90377-U; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRACASOUZA AV, 1997, FREE RADICAL BIO MED, V22, P209; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HILLIKER AJ, 1992, P NATL ACAD SCI USA, V89, P4343, DOI 10.1073/pnas.89.10.4343; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KUO ML, 1995, BBA-MOL CELL RES, V1268, P229, DOI 10.1016/0167-4889(95)00076-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDRELL SH, 1969, J EXP BIOL, V51, P71; Maia J.C., 1983, GENES ANTIGENS PARAS, P144; MATSUSHITA S, 1963, ARCH BIOCHEM BIOPHYS, V102, P446, DOI 10.1016/0003-9861(63)90253-4; MEADOWS J, 1986, ARCH BIOCHEM BIOPHYS, V246, P838, DOI 10.1016/0003-9861(86)90340-1; NEMANI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P24, DOI 10.1006/abbi.1993.1004; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ODONNELL MJ, 1983, J EXP BIOL, V103, P169; OLIVEIRA PL, 1995, J BIOL CHEM, V270, P10897, DOI 10.1074/jbc.270.18.10897; PETRETSKI MD, 1995, J BIOL CHEM, V270, P10893; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TAPPEL AL, 1955, J BIOL CHEM, V217, P721; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WIGGLESWORTH VB, 1931, J EXP BIOL, V8, P448; YAMAGUCHI K, 1995, BIOCHEM BIOPH RES CO, V210, P639, DOI 10.1006/bbrc.1995.1708	50	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9673	9676		10.1074/jbc.274.14.9673	http://dx.doi.org/10.1074/jbc.274.14.9673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092654	hybrid			2022-12-25	WOS:000079451800073
J	Heck, S; Lezoualc'h, F; Engert, S; Behl, C				Heck, S; Lezoualc'h, F; Engert, S; Behl, C			Insulin-like growth factor-1-mediated neuroprotection against oxidative stress is associated with activation of nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; FACTOR-I; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; HIPPOCAMPAL-NEURONS; HYPOTHALAMIC CELLS; INDUCED APOPTOSIS; BINDING-PROTEINS; INHIBITION; ALPHA	The role of insulin-like growth factor 1 (IGF-I) for the treatment of neurodegenerative disorders, such as Alzheimer's disease, has recently gained attention. The present study demonstrates that IGF-1 promotes the survival of rat primary cerebellar neurons and of immortalized hypothalamic rat GT1-7 cells after challenge with oxidative stress induced by hydrogen peroxide (H2O2). Neuroprotective concentrations of IGF-1 specifically induce the transcriptional activity and the DNA binding activity of nuclear factor kappa B (NF-kappa B), a transcription factor that has been suggested to play a neuroprotective role. This induction is associated with increased nuclear translocation of the p65 subunit of NF-kappa B and with degradation of the NP-kappa B inhibitory protein I kappa B alpha. IGF-1-mediated protection of GT1-7 cells against oxidative challenges was mimicked by overexpression of the NF-kappa B subunit c-Rel. Partial inhibition of NF-kappa B baseline activity by overexpression of a dominant-negative I kappa B alpha mutant enhanced the toxicity of H2O2 in GT1-7 cells. The pathway by which IGF-1 promotes neuronal survival and activation of NF-kappa B involves the phosphoinositol (PI) 3-kinase, because both effects of IGF-1 are blocked by LY294002 and wortmannin, two specific PI 3-kinase inhibitors. Taken together, our results provide evidence for a novel molecular link between IGF-l-mediated neuroprotection and induction of NF-kappa B that is dependent on the PI 3-kinase pathway.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Behl, C (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.	chris@mpipsykl.mpg.de	Lezoualc'h, Frank/E-5031-2016	Behl, Christian/0000-0001-8453-2378				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Behl C, 1997, ENDOCRINOLOGY, V138, P101, DOI 10.1210/en.138.1.101; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Crowder RJ, 1998, J NEUROSCI, V18, P2933; DEPABLO F, 1995, TRENDS NEUROSCI, V18, P143, DOI 10.1016/0166-2236(95)93892-2; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dore S, 1997, TRENDS NEUROSCI, V20, P326; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Lezoualc'h F, 1998, MOL PSYCHIATR, V3, P15, DOI 10.1038/sj.mp.4000295; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Loddick SA, 1998, P NATL ACAD SCI USA, V95, P1894, DOI 10.1073/pnas.95.4.1894; MURPHY MF, 1995, ANN NEUROL, V38, P335; OLSON BR, 1995, NEUROENDOCRINOLOGY, V62, P155, DOI 10.1159/000127000; Parrizas M, 1997, J BIOL CHEM, V272, P154; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sagara Y, 1996, J NEUROSCI, V16, P497; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Sortino MA, 1996, ENDOCRINOLOGY, V137, P1418, DOI 10.1210/en.137.4.1418; Sparapani M, 1997, GLIA, V20, P203, DOI 10.1002/(SICI)1098-1136(199707)20:3<203::AID-GLIA4>3.0.CO;2-8; Taglialatela G, 1998, NEUROREPORT, V9, P489, DOI 10.1097/00001756-199802160-00024; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TORRESALEMAN I, 1990, NEUROSCIENCE, V35, P601, DOI 10.1016/0306-4522(90)90332-X; TORRESALEMAN I, 1994, J NEUROSCI RES, V39, P117, DOI 10.1002/jnr.490390202; TSAI PS, 1995, ENDOCRINOLOGY, V136, P3831, DOI 10.1210/en.136.9.3831; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yuen EC, 1996, ANN NEUROL, V40, P346, DOI 10.1002/ana.410400304	51	186	190	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9828	9835		10.1074/jbc.274.14.9828	http://dx.doi.org/10.1074/jbc.274.14.9828			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092673	hybrid			2022-12-25	WOS:000079451800092
J	Tsai, WY; Chow, YT; Chen, HR; Huang, KT; Hong, RI; Jan, SP; Kuo, NY; Tsao, TY; Chen, CH; Cheng, SC				Tsai, WY; Chow, YT; Chen, HR; Huang, KT; Hong, RI; Jan, SP; Kuo, NY; Tsao, TY; Chen, CH; Cheng, SC			Cef1p is a component of the Prp19p-associated complex and essential for pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RNAS; PRECURSOR MESSENGER-RNA; PREMESSENGER RNA; SITE REGION; IN-VITRO; C-MYB; SPLICEOSOME; YEAST; PROTEIN; RIBONUCLEOPROTEIN	The Prp19p protein of the budding yeast Saccharomyces cerevisiae is an essential splicing factor and is associated with the spliceosome during the splicing reaction. We have previously shown that Prp19p is not tightly associated with small nuclear ribonucleoprotein particles but is associated with a protein complex consisting of at least eight protein components. By sequencing components of the affinity-purified complex, we have identified Cef1p as a component of the Prp19p-associated complex, Ntc85p, Cef1p could directly interact with Prp19p and was required for pre-mRNA splicing both in vivo and in vitro. The c-Myb DNA binding motif at the amino terminus of Cef1p was required for cellular growth but not for interaction of Cef1p with Prp19p or Cef1p self-interaction. We have identified a small region of 30 amino acid residues near the carboxyl terminus required for both cell viability and protein-protein interactions. Cef1p was associated with the spliceosome in the same manner as Prp19p, i.e. concomitant with or immediately after dissociation of U4, The anti-Cef1p antibody inhibited binding to the spliceosome of Cef1p, Prp19p, and at least three other components of the Prp19p-associated complex, suggesting that the Prp19p-associated complex is likely associated with the spliceosome and functions as an integral complex.	Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan; Acad Sinica, Inst Mol Biol, Nankang, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Cheng, SC (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Shih Pai, Taiwan.		Chen, Chun-Hong/E-3990-2010	CHEN, CHUN-HONG/0000-0002-3028-5508				BEGGS JD, 1993, MOL BIOL REP, V18, P99, DOI 10.1007/BF00986763; Bernstein HS, 1997, J BIOL CHEM, V272, P5833, DOI 10.1074/jbc.272.9.5833; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; Chen HR, 1998, MOL CELL BIOL, V18, P2196, DOI 10.1128/MCB.18.4.2196; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; CHENG SC, 1990, METHOD ENZYMOL, V181, P89; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Guthrie C, 1991, METHODS ENZYMOL, V194; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Laggerbauer B, 1998, P NATL ACAD SCI USA, V95, P4188, DOI 10.1073/pnas.95.8.4188; LAMOND AI, 1988, P NATL ACAD SCI USA, V85, P411, DOI 10.1073/pnas.85.2.411; LIN RJ, 1987, GENE DEV, V1, P7, DOI 10.1101/gad.1.1.7; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; Moore M., 1993, RNA WORLD, P303; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PIKIELNY CW, 1986, CELL, V45, P869, DOI 10.1016/0092-8674(86)90561-1; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SAWA H, 1991, NUCLEIC ACIDS RES, V19, P3953, DOI 10.1093/nar/19.14.3953; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506	34	77	78	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9455	9462		10.1074/jbc.274.14.9455	http://dx.doi.org/10.1074/jbc.274.14.9455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092627	hybrid			2022-12-25	WOS:000079451800046
J	Ellerby, LM; Andrusiak, RL; Wellington, CL; Hackam, AS; Propp, SS; Wood, JD; Sharp, AH; Margolis, RL; Ross, CA; Salvesen, GS; Hayden, MR; Bredesen, DE				Ellerby, LM; Andrusiak, RL; Wellington, CL; Hackam, AS; Propp, SS; Wood, JD; Sharp, AH; Margolis, RL; Ross, CA; Salvesen, GS; Hayden, MR; Bredesen, DE			Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEAT NEURODEGENERATIVE DISEASES; NEURONAL INTRANUCLEAR INCLUSIONS; CAG REPEAT; POLYGLUTAMINE TRACT; GLUTAMINE REPEATS; DRPLA PROTEIN; GENE; HUNTINGTIN; EXPANSION; APOPTOSIS	Dentatorubropallidoluysian atrophy (DRPLA) is one of eight autosomal dominant neurodegenerative disorders characterized by an abnormal CAG repeat expansion which results in the expression of a protein with a polyglutamine stretch of excessive length. We have reported recently that four of the gene products (huntingtin, atrophin-1 (DRPLA), ataxin-3, and androgen receptor) associated with these open reading frame triplet repeat expansions are substrates for the cysteine protease cell death executioners, the caspases, This led us to hypothesize that caspase cleavage of these proteins may represent a common step in the pathogenesis of each of these four neurodegenerative diseases. Here we present evidence that caspase cleavage of atrophin-1 modulates cytotoxicity and aggregate formation. Cleavage of atrophin-1 at Asp(109) by caspases is critical for cytotoxicity because a mutant atrophin-1 that is resistant to caspase cleavage is associated with significantly decreased toxicity. Further, the altered cellular localization within the nucleus and aggregate formation associated with the expanded form of atrophin-1 are completely suppressed by mutation of the caspase cleavage site at Asp(109). These results provide support for the toxic fragment hypothesis whereby cleavage of atrophin-1 by caspases may be an important step in the pathogenesis of DRPLA. Therefore, inhibiting caspase cleavage of the polyglutamine-containing proteins may be a feasible therapeutic strategy to prevent cell death.	Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Burnham Inst, Program Apoptosis, La Jolla, CA 92037 USA; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V52 4H4, Canada; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of British Columbia; Johns Hopkins University; University of California System; University of California San Diego	Bredesen, DE (corresponding author), Burnham Inst, Program Aging, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dbredesen@ljcrf.edu	Wood, Jonathan D/A-5060-2009; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NCI NIH HHS [CA69381] Funding Source: Medline; NIA NIH HHS [AG12282] Funding Source: Medline; NINDS NIH HHS [NS34172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hackam AS, 1998, J CELL BIOL, V141, P1097, DOI 10.1083/jcb.141.5.1097; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Margolis RL, 1996, MOL BRAIN RES, V36, P219, DOI 10.1016/0169-328X(95)00241-J; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; Nance MA, 1997, BRAIN PATHOL, V7, P881, DOI 10.1111/j.1750-3639.1997.tb00892.x; Nishiyama K, 1997, ANN NEUROL, V41, P599, DOI 10.1002/ana.410410508; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Perutz MF, 1996, CURR OPIN STRUC BIOL, V6, P848, DOI 10.1016/S0959-440X(96)80016-9; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; SALVESEN G, 1990, BIOCHEMISTRY-US, V29, P5304, DOI 10.1021/bi00474a013; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Yazawa I, 1997, NEUROSCI LETT, V225, P53, DOI 10.1016/S0304-3940(97)00189-4; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	41	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8730	8736		10.1074/jbc.274.13.8730	http://dx.doi.org/10.1074/jbc.274.13.8730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085113	hybrid			2022-12-25	WOS:000079451600055
J	Pangalos, MN; Neefs, JM; Somers, M; Verhasselt, P; Bekkers, M; van der Helm, L; Fraiponts, E; Ashton, D; Gordon, RD				Pangalos, MN; Neefs, JM; Somers, M; Verhasselt, P; Bekkers, M; van der Helm, L; Fraiponts, E; Ashton, D; Gordon, RD			Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTYL-L-GLUTAMATE; AEROMONAS-PROTEOLYTICA AMINOPEPTIDASE; TUMOR-SUPPRESSOR GENE; MEMBRANE ANTIGEN; RAT-BRAIN; INSITU HYBRIDIZATION; MOLECULAR-CLONING; ACETYLASPARTYLGLUTAMATE; CELLS; LOCALIZATION	Hydrolysis of the neuropeptide N-acetyl-L-aspartyl-L-glutamate (NAAG) by N-acetylated alpha-linked acidic dipeptidase (NAALADase) to release glutamate may be important in a number of neurodegenerative disorders in which excitotoxic mechanisms are implicated. The gene coding for human prostate-specific membrane antigen, a marker of prostatic carcinomas, and its rat homologue glutamate carboxypeptidase II have recently been shown to possess such NAALADase activity. In contrast, a closely related member of this gene family, rat ileal 100-kDa protein, possesses a dipeptidyl peptidase IV activity. Here, we describe the cloning of human ileal 100-kDa protein, which we have called a NAALADase-"like" (NAALADase L) peptidase based on its sequence similarity to other members of this gene family, and its inability to hydrolyze NAAG in transient transfection experiments. Furthermore, we describe the cloning of a third novel member of this gene family, NAALADase II, which codes for a type II integral membrane protein and which we have localized to chromosome 11 by fluorescent in situ hybridization analysis, Transient transfection of NAALADase II cDNA confers both NAALADase and dipeptidyl peptidase IV activity to COS cells. Expression studies using reverse transcription-polymerase chain reaction and Northern blot hybridization show that NAALADase II is highly expressed in ovary and testis as well as within discrete brain areas.	Janssen Res Fdn, Dept Biotechnol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Biochem, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Neuropsychopharmacol, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson; Johnson & Johnson	Pangalos, MN (corresponding author), SmithKline Beecham Pharmaceut, Neuropharmacol Res, Harlow CM19 5AW, Essex, England.	menelas_n_pangalos@sbphrd.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Banerjee D, 1995, ACTA BIOCHIM POL, V42, P457; BLAKELY RD, 1988, J NEUROCHEM, V50, P1200, DOI 10.1111/j.1471-4159.1988.tb10593.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bzdega T, 1997, J NEUROCHEM, V69, P2270; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CHANDLER CJ, 1986, J BIOL CHEM, V261, P928; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; GOOSSENS F, 1995, EUR J BIOCHEM, V233, P432, DOI 10.1111/j.1432-1033.1995.432_2.x; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ISRAELI RS, 1993, CANCER RES, V53, P227; ISRAELI RS, 1994, CANCER RES, V54, P1807; JAARSMA D, 1994, J NEUROL SCI, V127, P230, DOI 10.1016/0022-510X(94)90077-9; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEEK J, 1995, BRIT J CANCER, V72, P583, DOI 10.1038/bjc.1995.377; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MEYERHOFF JL, 1992, EPILEPSY RES, P163; MEYERHOFF JL, 1985, BRAIN RES, V346, P392, DOI 10.1016/0006-8993(85)90877-7; MISRA BC, 1989, AM J HUM GENET, V45, P565; Passani LA, 1997, BRAIN RES, V772, P9, DOI 10.1016/S0006-8993(97)00784-1; Passani LA, 1997, MOL CHEM NEUROPATHOL, V31, P97, DOI 10.1007/BF02815236; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; PUTTFARCKEN PS, 1993, J PHARMACOL EXP THER, V266, P796; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; ROBINSON MB, 1986, EUR J PHARMACOL, V130, P345, DOI 10.1016/0014-2999(86)90291-8; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; SEKIGUCHI M, 1992, FEBS LETT, V311, P285, DOI 10.1016/0014-5793(92)81121-2; Shneider BL, 1997, J BIOL CHEM, V272, P31006, DOI 10.1074/jbc.272.49.31006; SLUSHER BS, 1990, J BIOL CHEM, V265, P21297; SLUSHER S, 1997, SOC NEUR ABSTR; SU SL, 1995, CANCER RES, V55, P1441; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; VALIVULLAH HM, 1994, J NEUROCHEM, V63, P1714; Wroblewska B, 1997, J NEUROCHEM, V69, P174; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x	45	83	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8470	8483		10.1074/jbc.274.13.8470	http://dx.doi.org/10.1074/jbc.274.13.8470			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085079	hybrid			2022-12-25	WOS:000079451600021
J	Qi, HY; Bernstein, HD				Qi, HY; Bernstein, HD			SecA is required for the insertion of inner membrane proteins targeted by the Escherichia coli signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE; PLASMA-MEMBRANE; ER MEMBRANE; 4.5S RNA; TRANSLOCATION; EXPORT; SECRETION; GENE; ATP; RIBONUCLEOPROTEIN	Recent work has demonstrated that the signal recognition particle (SRP) is required for the efficient insertion of many proteins into the Escherichia coli inner membrane (IM), Based on an analogy to eukaryotic SRP, it is likely that bacterial SRP binds to inner membrane proteins (IMPs) co-translationally and then targets them to protein transport channels ("translocons"), Here we present evidence that SecA, which has previously been shown to facilitate the export of proteins targeted in a post-translational fashion, is also required for the membrane insertion of proteins targeted by SRP. The introduction of SecA mutations into strains that have modest SRP deficiencies produced a synthetic lethal effect, suggesting that SecA and SRP might function in the same biochemical pathway. Consistent with this explanation, depletion of SecA by inactivating a temperature-sensitive amber suppressor in a secA(am) strain completely blocked the membrane insertion of AcrB, a protein that is targeted by SRP. In the absence of substantial SecA, pulse-labeled AcrB was retained in the cytoplasm even after a prolonged chase period and was eventually degraded. Although protein export was also severely impaired by SecA depletion, the observation that more than 20% of the OmpA molecules were translocated properly showed that translocons were still active. Taken together, these results imply that SecA plays a much broader role in the transport of proteins across the E. coli IM than has been previously recognized.	NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bernstein, HD (corresponding author), NIDDK, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D-20, Bethesda, MD 20892 USA.	harris_bernstein@nih.gov						Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FILIP C, 1973, J BACTERIOL, V115, P717, DOI 10.1128/JB.115.3.717-722.1973; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HUFFAKER TC, 1987, ANNU REV GENET, V21, P259; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LEE CA, 1986, J BACTERIOL, V166, P878, DOI 10.1128/jb.166.3.878-883.1986; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Newitt JA, 1998, J BIOL CHEM, V273, P12451, DOI 10.1074/jbc.273.20.12451; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Snyders S, 1997, J BIOL CHEM, V272, P11302; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; TRAXLER B, 1992, J BIOL CHEM, V267, P5339; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	38	72	72	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8993	8997		10.1074/jbc.274.13.8993	http://dx.doi.org/10.1074/jbc.274.13.8993			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085146	hybrid			2022-12-25	WOS:000079451600088
J	Rutberg, SE; Adams, TL; Olive, M; Alexander, N; Vinson, C; Yuspa, SH				Rutberg, SE; Adams, TL; Olive, M; Alexander, N; Vinson, C; Yuspa, SH			CRE DNA binding proteins bind to the AP-1 target sequence and suppress AP-1 transcriptional activity in mouse keratinocytes	ONCOGENE			English	Article						keratinocyte; differentiation; AP-1; transcription	DIFFERENTIATION-SPECIFIC EXPRESSION; HUMAN INVOLUCRIN GENE; C-JUN; EPIDERMAL DIFFERENTIATION; REPRESSES TRANSCRIPTION; SKIN CARCINOGENESIS; PROXIMAL PROMOTER; PROFILAGGRIN GENE; RESPONSE ELEMENT; CARCINOMA-CELLS	Previously, we have shown that nuclear extracts from cultured mouse keratinocytes induced to differentiate by increasing the levels of extra-cellular calcium contain Fra-1, Fra-2, Jun B, Jun D and c-Jun proteins that bind to the AP-1 DNA binding sequence. Despite this DNA binding activity, AP-1 reporter activity was suppressed in these cells. Here, we have detected the CREB family proteins CREB and CREM alpha as additional participants in the AP-1 DNA binding complex in differentiating keratinocytes, AP-1 and CRE DNA binding activity correlated with the induction of CREB, CREM alpha and ATF-1 and CREB phosphorylation at ser(133) (ser(133) phospho-CREB) in the transition from basal to differentiating keratinocytes, but the activity of a CRE reporter remained unchanged. In contrast, the CRE reporter was activated in the presence of the dominant-negative (DN) CREB mutants, KCREB and A-CREB, proteins that dimerize with CREB family members and block their ability to bind to DNA. The increase in CRE reporter activity in the presence of these mutants suggests that CRE-mediated transcriptional activity is suppressed in keratinocytes through protein-protein interactions involving a factor that dimerizes with the CREB leucine zipper. In experiments where the A-CREB mutant was co-transfected with an AP-1 reporter construct, transcriptional activity was also increased indicating that a CREB family member binds AP-1 sites and represses AP-1 transcriptional activity as well. Exogenous expression of the transcriptional repressor CREM alpha down-regulated both CRE and AP-1 reporters in keratinocytes suggesting that this factor may contribute to the suppression of AP-1 transcriptional activity observed in differentiating keratinocytes.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuspa, SH (corresponding author), Bldg 37,Room 3B25,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC005445, ZIABC005445] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bernerd Francoise, 1993, Gene Expression, V3, P187; BROWN AD, 1995, ONCOGENE, V10, P1749; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHATTON B, 1994, ONCOGENE, V9, P375; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; FISHER C, 1991, DEVELOPMENT, V111, P253; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUFF CA, 1993, J BIOL CHEM, V268, P377; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; LAFYATIS R, 1990, J BIOL CHEM, V265, P19128; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; OFIR R, 1991, GENE EXPRESSION, V1, P55; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; Rutberg SE, 1997, ONCOGENE, V15, P1337, DOI 10.1038/sj.onc.1201293; Rutberg SE, 1996, ONCOGENE, V13, P167; RYSECK RP, 1991, ONCOGENE, V6, P533; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WATT FM, 1993, DEVELOPMENT, P185; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG XK, 1994, CANCER RES, V54, P5663	56	42	42	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1569	1579		10.1038/sj.onc.1202463	http://dx.doi.org/10.1038/sj.onc.1202463			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102627				2022-12-25	WOS:000078770700007
J	Chaves-Olarte, E; Low, P; Freer, E; Norlin, T; Weidmann, M; von Eichel-Streiber, C; Thelestam, M				Chaves-Olarte, E; Low, P; Freer, E; Norlin, T; Weidmann, M; von Eichel-Streiber, C; Thelestam, M			A novel cytotoxin from Clostridium difficile serogroup F is a functional hybrid between two other large clostridial cytotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; R-RAS; RHO-PROTEINS; BINDING; GLUCOSYLATION; CELLS	The large clostridial cytotoxins (LCTs) constitute a group of high molecular weight clostridial cytotoxins that inactivate cellular small GTP-binding proteins. We demonstrate that a novel LCT (TcdB-1470) from Clostridium difficile strain 1470 is a functional hybrid between "reference" TcdB-10463 and Clostridium sordellii TcsL-1522. It bound to the same specific receptor as TcdB-10463 but glucosylated the same GTP-binding proteins as TcsL-1522. Ah three toxins had equal enzymatic potencies but were equally cytotoxic only when micro injected. When applied extracellularly TcdB-1470 and TcdB-10463 were considerably more potent cytotoxins than TcsL-1522. The small GTP-binding protein R-Ras was identified as a target for TcdB-1470 and also for Test-1522 but not for TcdB-10463. R-Ras is known to control integrin-extracellular matrix interactions from inside the cell. Its glucosylation may be a major determinant for the cell rounding and detachment induced by the two R-Ras-attacking toxins. In contrast, fibroblasts treated with TcdB-10463 were arborized and remained attached, with phosphotyrosine containing structures located at the cell-to-cell contacts and beta(3)-integrin remaining at the tips of cellular protrusions. These components were absent from cells treated with the R-Ras-inactivating toxins. The novel hybrid toxin will broaden the utility of the LCTs for clarifying the functions of several small GTPases, now including also R-Ras.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Costa Rica, Unidad Microscopia Elect, San Jose, Costa Rica; Karolinska Inst, Nobel Inst Neurophysiol, Dept Neurosci, S-17177 Stockholm, Sweden; Johannes Gutenberg Univ Mainz, Inst Med Mikrobiol & Hyg, Verfugungagebaude Forsch & Entwicklung, D-55101 Mainz, Germany	Karolinska Institutet; Universidad Costa Rica; Karolinska Institutet; Johannes Gutenberg University of Mainz	Thelestam, M (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Box 280, S-17177 Stockholm, Sweden.	monica.thelestam@mtc.ki.se	Weidmann, Manfred/G-1817-2015	Weidmann, Manfred/0000-0002-7063-7491				AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; ChavesOlarte E, 1996, J BIOL CHEM, V271, P6925, DOI 10.1074/jbc.271.12.6925; DEPITRE C, 1993, J MED MICROBIOL, V38, P434, DOI 10.1099/00222615-38-6-434; EICHELSTREIBER CV, 1995, MOL MICROBIOL, V17, P313; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; Hofmann F, 1996, BIOCHEM BIOPH RES CO, V227, P77, DOI 10.1006/bbrc.1996.1470; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; O'Farrell P H, 1977, Methods Cell Biol, V16, P407; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Sauerborn M, 1997, FEMS MICROBIOL LETT, V155, P45, DOI 10.1016/S0378-1097(97)00365-0; THELESTAM M, 1997, BACTERIAL TOXINS TOO, P141; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	21	92	98	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11046	11052		10.1074/jbc.274.16.11046	http://dx.doi.org/10.1074/jbc.274.16.11046			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196187	hybrid			2022-12-25	WOS:000079751900055
J	Druillennec, S; Caneparo, A; de Rocquigny, H; Roques, BP				Druillennec, S; Caneparo, A; de Rocquigny, H; Roques, BP			Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RNASE-H ACTIVITY; MURINE LEUKEMIA-VIRUS; TERMINAL ZINC-FINGER; PRIMER BINDING-SITE; DNA STRAND TRANSFER; IN-VITRO; RIBONUCLEASE-H; ANNEALING ACTIVITIES; DOMAIN	The human immunodeficiency virus (HIV-1) nucleocapsid protein NCp7 containing two CX2CX4HX4C-type zinc fingers was proposed to be involved in reverse transcriptase (RT)-catalyzed proviral DNA synthesis through promotion of tRNA(3)(LYS) annealing to the RNA primer binding site, improvement of DNA strand transfers, and enhancement of RT processivity. The NCp7 structural characteristics are crucial because mutations altering the finger domain conformation led to noninfectious viruses characterized by defects in provirus integration. These findings prompted us to study a putative RT/NCp7 protein-protein interaction. Binding as says using far Western analysis or RT immobilized on beads clearly showed the formation of a complex between NCp7 and RT. The affinity of NCp7 for p66/p51RT was 0.60 mu M with a 1:1 stoichiometry. This interaction was confirmed by chemical cross-linking and co-immunoprecipitation of the two proteins in a viral environment. Competition experiments using different NCp7 mutants showed that alteration of the finger structure disrupted RT recognition giving insights into the loss of infectivity of corresponding HIV-1 mutants. Together with structural data on RT, these results suggest that the role of NCp7 could be to enhance RT processivity through stabilization of a p51-induced active form of the p66 subunit and open the way for designing new antiviral agents.	UFR Sci Pharmaceut & Biol 4, Dept Pharmacochim Mol & Struct, CNRS, UMR 8600,INSERM,U266, F-75270 Paris 06, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Roques, BP (corresponding author), UFR Sci Pharmaceut & Biol 4, Dept Pharmacochim Mol & Struct, CNRS, UMR 8600,INSERM,U266, 4 Ave Observ, F-75270 Paris 06, France.		DRUILLENNEC, Sabine/B-2572-2019	DRUILLENNEC, Sabine/0000-0003-0237-1465				ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Coffin JM, 1990, VIROLOGY, V2, P1437; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DORFMAN T, 1993, J VIROL, V67, P6159, DOI 10.1128/JVI.67.10.6159-6169.1993; Drummond JE, 1997, AIDS RES HUM RETROV, V13, P533, DOI 10.1089/aid.1997.13.533; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; KANAYA S, 1991, J BIOL CHEM, V266, P11621; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; KHAN R, 1992, J BIOL CHEM, V267, P6689; Lee BM, 1998, J MOL BIOL, V279, P633, DOI 10.1006/jmbi.1998.1766; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; SCHWARTZ O, 1995, J VIROL, V69, P528, DOI 10.1128/JVI.69.1.528-533.1995; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; TANCHOU V, 1994, AIDS RES HUM RETROV, V10, P983, DOI 10.1089/aid.1994.10.983; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; Yu QA, 1996, J VIROL, V70, P5791, DOI 10.1128/JVI.70.9.5791-5798.1996	43	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11283	11288		10.1074/jbc.274.16.11283	http://dx.doi.org/10.1074/jbc.274.16.11283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196217	hybrid			2022-12-25	WOS:000079751900085
J	Heimann, K; Percival, JM; Weinberger, R; Gunning, P; Stow, JL				Heimann, K; Percival, JM; Weinberger, R; Gunning, P; Stow, JL			Specific isoforms of actin-binding proteins on distinct populations of Golgi-derived vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN-II; COATED VESICLES; TROPOMYOSIN ISOFORMS; TRANSPORT VESICLES; SUBCELLULAR-LOCALIZATION; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; VESICULAR TRANSPORT; ENDOCYTIC PATHWAY; EPITHELIAL-CELLS	Golgi membranes and Golgi-derived vesicles are associated with multiple cytoskeletal proteins and motors, the diversity and distribution of which have not yet been defined. Carrier vesicles were separated from Golgi membranes, using an in vitro budding assay, and different populations of vesicles were separated using sucrose density gradients. Three main populations of vesicles labeled with beta-COP, gamma-adaptin, or p200/myosin II were separated and analyzed for the presence of actin/actin-binding proteins, beta-Actin was bound to Golgi cisternae and to all populations of newly budded vesicles. Centractin was selectively associated with vesicles co-distributing with beta-COP-vesicles, while p200/myosin II (non-muscle myosin IIA) and non-muscle myosin IIB were found on different vesicle populations. Isoforms of the Tm5 tropomyosins were found on selected Golgi-derived vesicles, while other Tm isoforms did not colocalize with Tm5 indicating the association of specialized actin filaments with Golgi-derived vesicles. Golgi-derived vesicles were shown to bind to F-actin polymerized from cytosol with Jasplakinolide. Thus, newly budded, coated vesicles derived from Golgi membranes can bind to actin and are customized for differential interactions with microfilaments by the presence of selective arrays of actin-binding proteins.	Univ Queensland, Ctr Cellular & Mol Biol, Brisbane, Qld 4072, Australia; Univ Sydney, Dept Paediat & Child Hlth, Westmead, NSW 2145, Australia; New Childrens Hosp, Oncol Res Unit, Westmead, NSW, Australia	University of Queensland; University of Sydney; University of Sydney	Stow, JL (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, Brisbane, Qld 4072, Australia.	j.stow@cmcb.uq.edu.au	Stow, Jennifer L/I-4723-2013; Heimann, Kirsten/M-4814-2019; Heimann, Kirsten/C-4539-2012; Gunning, Peter W/E-9058-2010; Heimann, Kirsten/N-1512-2013	Stow, Jennifer L/0000-0002-5409-9101; Heimann, Kirsten/0000-0003-2691-9659; Heimann, Kirsten/0000-0003-2691-9659; Gunning, Peter/0000-0003-0833-3128				BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; Beck KA, 1997, J CELL SCI, V110, P1239; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Burkhardt JK, 1998, BBA-MOL CELL RES, V1404, P113, DOI 10.1016/S0167-4889(98)00052-4; CLARK SW, 1994, MOL BIOL CELL, V5, P1301, DOI 10.1091/mbc.5.12.1301; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; DEALMEIDA JB, 1993, J CELL SCI, V106, P1239; DeOca GM, 1997, ARCH MED RES, V28, P321; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Evans LL, 1997, J CELL SCI, V110, P439; FANNING AS, 1994, CELL MOTIL CYTOSKEL, V29, P29, DOI 10.1002/cm.970290104; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; Gleeson PA, 1996, J CELL SCI, V109, P2811; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; Gunning P, 1998, ANNU REV CELL DEV BI, V14, P339, DOI 10.1146/annurev.cellbio.14.1.339; Gunning P, 1997, ANAT EMBRYOL, V195, P311, DOI 10.1007/s004290050050; HEUSER J, 1989, CELL BIOL INT REP, V13, P1063, DOI 10.1016/0309-1651(89)90020-9; Hill KL, 1996, J CELL BIOL, V135, P1535, DOI 10.1083/jcb.135.6.1535; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Ikonen E, 1997, J CELL SCI, V110, P2155; Ikonen E, 1996, MOL BIOL CELL, V7, P961, DOI 10.1091/mbc.7.6.961; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LIU HP, 1992, J CELL BIOL, V118, P285, DOI 10.1083/jcb.118.2.285; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MAUPIN P, 1994, J CELL SCI, V107, P3077; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; NARULA N, 1995, P NATL ACAD SCI USA, V92, P2874, DOI 10.1073/pnas.92.7.2874; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; Nickel W, 1997, P NATL ACAD SCI USA, V94, P11393, DOI 10.1073/pnas.94.21.11393; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PoucellHatton S, 1997, GASTROENTEROLOGY, V113, P649, DOI 10.1053/gast.1997.v113.pm9247487; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; SCHEVZOV G, 1992, J CELL BIOL, V117, P775, DOI 10.1083/jcb.117.4.775; SERAFINI T, 1992, METHOD ENZYMOL, V219, P286; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; Simon JP, 1998, P NATL ACAD SCI USA, V95, P1073, DOI 10.1073/pnas.95.3.1073; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Stow JL, 1998, TRENDS CELL BIOL, V8, P138, DOI 10.1016/S0962-8924(98)01238-0; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; Weinberger R, 1996, J NEUROSCI, V16, P238; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	61	94	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10743	10750		10.1074/jbc.274.16.10743	http://dx.doi.org/10.1074/jbc.274.16.10743			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196146	hybrid			2022-12-25	WOS:000079751900014
J	Rittershaus, CW; Thomas, LJ; Miller, DP; Picard, MD; Geoghegan-Barek, KM; Scesney, SM; Henry, LD; Sen, AC; Bertino, AM; Hannig, G; Adari, H; Mealey, RA; Gosselin, ML; Couto, M; Hayman, EG; Levin, JL; Reinhold, VN; Marsh, HC				Rittershaus, CW; Thomas, LJ; Miller, DP; Picard, MD; Geoghegan-Barek, KM; Scesney, SM; Henry, LD; Sen, AC; Bertino, AM; Hannig, G; Adari, H; Mealey, RA; Gosselin, ML; Couto, M; Hayman, EG; Levin, JL; Reinhold, VN; Marsh, HC			Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SENSITIVE FLUORESCENCE DETECTION; IONIZATION MASS-SPECTROMETRY; REPERFUSION INJURY; QUANTITATIVE-DETERMINATION; CELL-SURFACE; LUNG INJURY; RECEPTOR-TYPE-1; PROTECTS; CR-1	Soluble human complement receptor type 1 (sCR1, TP10) has been expressed in Chinese hamster ovary (CHO) DUKX-B11 cells and shown to inhibit the classical and alternative complement pathways in vitro and in vivo, A truncated version of sCR1 lacking the long homologous repeat-A domain (LHR-A) containing the C4b binding site has similarly been expressed and designated sCR1[desLHR-A]. sCR1[desLHR-A] was shown to be a selective inhibitor of the alternative complement pathway in vitro and to function in vivo, In this study, sCR1 and sCR1[desLHR-A] were expressed in CHO LEC11 cells with an active alpha(1,3)-fucosyltransferase, which makes possible the biosynthesis of the sialyl-Lewis(x) (sLe(x)) tetrasaccharide (NeuNAc alpha 2-3Gal beta 1-4 (Fuc alpha 1-3)GlcNAc) during post-translational glycosylation, The resulting glycoproteins, designated sCRlsLe(x) and sCR1[desLHR-A]sLe(x), respectively, retained the complement regulatory activities of their DUKX B11 counterparts, which lack alpha(1-3)-fucose. Carbohydrate analysis of purified sCRlsLe(x) and sCR1[desLHR-A]sLe(x) indicated an average incorporation of 10 and 8 mol of sLe(x)/mol of glycoprotein, respectively. sLe(x) is a carbohydrate ligand for the selectin adhesion molecules, sCR1sLe(x) was shown to specifically bind CHO cells expressing cell surface E-selectin. sCR1[desLHR-A]sLe(x) inhibited the binding of the monocytic cell line U937 to human aortic endothelial cells, which had been activated with tumor necrosis factor-alpha to up-regulate the expression of E-selectin. sCR1sLe(x) inhibited the binding of U937 cells to surface-adsorbed P-selectin-IgG, sCR1sLe(x) and sCR1[desLHR-A]sLe(x) have thus demonstrated both complement regulatory activity and the capacity to bind selectins and to inhibit selectin-mediated cell adhesion in vitro.	Avant Immunotherapeut Inc, Needham, MA 02494 USA; Univ New Hampshire, Dept Chem, Durham, NH USA	University System Of New Hampshire; University of New Hampshire	Marsh, HC (corresponding author), Avant Immunotherapeut Inc, Needham, MA 02494 USA.			Marsh, Henry/0000-0001-5637-6013				ANUMULA KR, 1995, ANAL BIOCHEM, V230, P24, DOI 10.1006/abio.1995.1432; ANUMULA KR, 1994, ANAL BIOCHEM, V220, P275, DOI 10.1006/abio.1994.1338; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BUERKE M, 1994, J CLIN INVEST, V93, P1140, DOI 10.1172/JCI117066; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; CARSON GR, 1991, J BIOL CHEM, V266, P7883; CHAVEZCARTAYA RE, 1995, TRANSPLANTATION, V59, P1047, DOI 10.1097/00007890-199504150-00023; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Gralinski MR, 1996, IMMUNOPHARMACOLOGY, V34, P79, DOI 10.1016/0162-3109(96)00105-1; Lennon PF, 1996, AM J PHYSIOL-HEART C, V270, pH1924, DOI 10.1152/ajpheart.1996.270.6.H1924; LINSLEY KB, 1994, ANAL BIOCHEM, V219, P207, DOI 10.1006/abio.1994.1259; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; MULLIGAN MS, 1992, J IMMUNOL, V148, P1479; MULLIGAN MS, 1993, J EXP MED, V178, P623, DOI 10.1084/jem.178.2.623; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MUROHARA T, 1995, METHOD FIND EXP CLIN, V17, P499; Nickells M, 1998, CLIN EXP IMMUNOL, V112, P27; PICARD MD, 1996, GLYCOBIOLOGY, V6, P766; Piddlesden SJ, 1996, J NEUROIMMUNOL, V71, P173, DOI 10.1016/S0165-5728(96)00144-0; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; REINHOLD BB, 1992, J AM SOC MASS SPECTR, V3, P207, DOI 10.1016/1044-0305(92)87004-I; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; Reinhold VN, 1996, METHOD ENZYMOL, V271, P377; Scesney SM, 1996, EUR J IMMUNOL, V26, P1729, DOI 10.1002/eji.1830260810; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; WELPLY JK, 1994, GLYCOBIOLOGY, V4, P259, DOI 10.1093/glycob/4.3.259; Witte K, 1997, J AM CHEM SOC, V119, P2114, DOI 10.1021/ja961846z	33	44	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11237	11244		10.1074/jbc.274.16.11237	http://dx.doi.org/10.1074/jbc.274.16.11237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196211	hybrid			2022-12-25	WOS:000079751900079
J	Feltkamp, D; Wiebel, FF; Alberti, S; Gustafsson, JA				Feltkamp, D; Wiebel, FF; Alberti, S; Gustafsson, JA			Identification of a novel DNA binding site for nuclear orphan receptor OR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTOR; THYROID-HORMONE RECEPTORS; ACID RECEPTORS; DIRECT REPEATS; LIGAND-BINDING; S14 GENE; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENTS; ESTROGEN-RECEPTOR	The nuclear orphan receptor OR1 has been shown to bind as a heterodimer with retinoid X receptor (RXR) to direct repeat 4 (DR4) response elements. It remained unclear, however, whether this represents the only or the optimal binding site for this receptor, Therefore, we performed a DNA binding site selection assay that allows the identification of novel DNA binding sites for OR1 in an unbiased manner. While ORI alone was not able to select a specific sequence from the pool of oligonucleotides, the OR1/RXR heterodimer selected a highly conserved DR1 element, termed DR1s, with two AG-GTCA motifs spaced by one adenosine, The functional activity of the consensus binding site was verified in transient transfection assays and corroborated by in vitro studies. Based on the sequence of the consensus DR1s, we located putative natural binding sites in the 5'-promoter flanking regions of the rat S14 gene and the rat cholecystokinin type A receptor gene. Furthermore, we could show that although the OR1/RXR heterodimer has a distinct binding orientation on a DR4 element, it is able to bind in both orientations to the DR1s element. The OR1 paralog LXR alpha does not bind as a heterodimer with RXR to the DR1s element, indicating that these receptors, despite their homology, are involved in the regulation of different sets of genes.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Karolinska Inst, Dept Med Nutr, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Feltkamp, D (corresponding author), Karolinska Inst, Novum, Dept Biosci, Halsovogen 7, S-14157 Huddinge, Sweden.							ALEX R, 1992, NUCLEIC ACIDS RES, V20, P2257, DOI 10.1093/nar/20.9.2257; APFEL R, 1994, MOL CELL BIOL, V14, P7025, DOI 10.1128/MCB.14.10.7025; Castelein H, 1996, MOL CELL ENDOCRINOL, V119, P11, DOI 10.1016/0303-7207(96)03794-X; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FREAKE HC, 1987, P NATL ACAD SCI USA, V84, P3070, DOI 10.1073/pnas.84.9.3070; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GLASS CK, 1991, MOL ASPECTS CELLULAR; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JORPES JE, 1966, ACTA PHYSIOL SCAND, V66, P196; JUMP DB, 1990, J BIOL CHEM, V265, P3474; Kainu T, 1996, J MOL NEUROSCI, V7, P29, DOI 10.1007/BF02736846; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; LUETJOHANN D, 1996, P NATL ACAD SCI USA, V93, P9799; LUND E, 1995, ACCOUNTS CHEM RES, V28, P241, DOI 10.1021/ar00054a001; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; ONATE SA, 1995, SCIENCE, V270, P1354; Ota Y, 1997, MOL CELL ENDOCRINOL, V126, P75, DOI 10.1016/S0303-7207(96)03971-8; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GEN DEV, V9, P796; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SHINAR DM, 1994, GENE, V147, P273, DOI 10.1016/0378-1119(94)90080-9; SILVER AJ, 1991, PROG NEUROBIOL, V36, P23, DOI 10.1016/0301-0082(91)90035-Y; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; SPENCER TA, 1985, J BIOL CHEM, V260, P3391; TAKATA Y, 1995, BIOCHEM BIOPH RES CO, V213, P958, DOI 10.1006/bbrc.1995.2222; TEBOUL M, 1995, P NATL ACAD SCI USA, V92, P2096, DOI 10.1073/pnas.92.6.2096; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDERHAEGHEN JJ, 1975, NATURE, V221, P557; Wiebel FF, 1997, MOL CELL BIOL, V17, P3977, DOI 10.1128/MCB.17.7.3977; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Yan ZH, 1997, J BIOL CHEM, V272, P10565; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1991, NEW BIOL, V3, P169; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	63	14	14	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10421	10429		10.1074/jbc.274.15.10421	http://dx.doi.org/10.1074/jbc.274.15.10421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187832	hybrid			2022-12-25	WOS:000079663500071
J	Miranti, CK; Ohno, S; Brugge, JS				Miranti, CK; Ohno, S; Brugge, JS			Protein kinase C regulates integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR ACTIVATION; T-CELL ACTIVATION; NIH 3T3 CELLS; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; MAP KINASE; DIFFERENTIAL TRANSLOCATION; SERINE PHOSPHORYLATION; DEPENDENT MECHANISM	Adhesion of fibroblasts to extracellular matrices via integrin receptors is accompanied by extensive cytoskeletal rearrangements and intracellular signaling events. The protein kinase C (PKC) family of serine/threonine kinases has been implicated in several integrin-mediated events including focal adhesion formation, cell spreading, cell migration, and cytoskeletal rearrangements. However, the mechanism by which PKC regulates integrin function is not known. To characterize the role of PKC family kinases in mediating integrin-induced signaling, we monitored the effects of PKC inhibition on fibronectin-induced signaling events in Cos7 cells using pharmacological and genetic approaches. We found that inhibition of classical and novel isoforms of PKC by down-regulation with 12-O-tetradeconoyl-phorbol-13-acetate or overexpression of dominant-negative mutants of PKC significantly reduced extracellular regulated kinase 2 (Erk2) activation by fibronectin receptors in Cos7 cells. Furthermore, overexpression of constitutively active PKC alpha, PKC delta, or PKC epsilon was sufficient to rescue 12-O-tetradeconoyl-phorbol-13-acetate-mediated down-regulation of Erk2 activation, and all three of these PKC isoforms were activated following adhesion. PKC was required for maximal activation of mitogen-activated kinase kinase 1, Raf-1, and Ras, tyrosine phosphorylation of Shc, and Shc association with Grb2. PKC inhibition does not appear to have a generalized effect on integrin signaling, because it does not block integrin-induced focal adhesion kinase or paxillin tyrosine phosphorylation. These results indicate that PKC activity enhances Erk2 activation in response to fibronectin by stimulating the Erk/mitogen-activated protein kinase pathway at an early step upstream of Shc.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Yokohama City Univ, Sch Med, Dept Mol Biol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan	Harvard University; Harvard Medical School; Yokohama City University	Brugge, JS (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Miranti, Cindy/AAJ-3783-2020; Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269	NCI NIH HHS [CA72203, CA27951, CA 78773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078773, R01CA027951, F32CA072203, R37CA027951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Aplin AE, 1998, PHARMACOL REV, V50, P197; Asano T, 1998, EUR J BIOCHEM, V251, P314, DOI 10.1046/j.1432-1327.1998.2510314.x; Banno Y, 1996, J BIOL CHEM, V271, P14989, DOI 10.1074/jbc.271.25.14989; BARRY ST, 1994, J CELL SCI, V107, P2033; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BERTI L, 1994, J BIOL CHEM, V269, P3381; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Blobe GC, 1996, CANCER SURV, V27, P213; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Chen Y, 1998, J BIOL CHEM, V273, P19809, DOI 10.1074/jbc.273.31.19809; CHUN JS, 1993, MOL BIOL CELL, V4, P271; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; CYBULSKY AV, 1993, AM J PHYSIOL, V264, P323; Dabrowski A, 1996, J BIOL CHEM, V271, P27125, DOI 10.1074/jbc.271.43.27125; Daulhac L, 1997, BIOCHEM J, V325, P383, DOI 10.1042/bj3250383; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1996, CANCER SURV, V27, P87; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; HABIB T, 1994, J BIOL CHEM, V269, P25243; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; Haller H, 1998, CIRC RES, V82, P157; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Huang XZ, 1998, J CELL SCI, V111, P2189; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Ktistakis NT, 1998, BIOESSAYS, V20, P495; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1993, CELL GROWTH DIFFER, V4, P309; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Miki H, 1997, CELL GROWTH DIFFER, V8, P195; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Ohtsuka T, 1996, BBA-MOL CELL RES, V1310, P223, DOI 10.1016/0167-4889(95)00172-7; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Smithgall TE, 1998, PHARMACOL REV, V50, P1; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VUORI K, 1993, J BIOL CHEM, V268, P21459; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; WOODS A, 1992, J CELL SCI, V101, P277; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; Zhao H, 1997, J BIOL CHEM, V272, P21625, DOI 10.1074/jbc.272.34.21625; Zheng LM, 1996, P NATL ACAD SCI USA, V93, P8431, DOI 10.1073/pnas.93.16.8431	87	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10571	10581		10.1074/jbc.274.15.10571	http://dx.doi.org/10.1074/jbc.274.15.10571			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187852	hybrid			2022-12-25	WOS:000079663500091
J	James, EL; Whisstock, JC; Gore, MG; Bottomley, SP				James, EL; Whisstock, JC; Gore, MG; Bottomley, SP			Probing the unfolding pathway of alpha(1)-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR EXTRAPOLATION METHOD; FLUORESCENCE SPECTROSCOPY; ALPHA-1-PROTEINASE INHIBITOR; FOLDING PATHWAY; HINGE REGION; POLYMERIZATION; MECHANISM; LOOP; SERPINS; ALPHA-1-ANTITRYPSIN	Protein misfolding plays a role in the pathogenesis of many diseases, alpha(1)-Antitrypsin misfolding leads to the accumulation of long chain polymers within the hepatocyte, reducing its plasma concentration and predisposing the patient to emphysema and liver disease, In order to understand the misfolding process, it is necessary to examine the folding of alpha(1)-antitrypsin through the different structures involved in this process. In this study we have used a novel technique in which unique cysteine residues were introduced at various positions into ru,antitrypsin and fluorescently labeled with N,N'-dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine, The fluorescence properties of each protein were studied in the native state and as a function of guanidine hydrochloride-mediated unfolding. The studies found that alpha(1)-antitrypsin unfolded through a series of intermediate structures. From the position of the fluorescence probes, the fluorescence quenching data, and the molecular modeling, we show that unfolding of alpha(1)-antitrypsin occurs via disruption of the A and C beta-sheets followed by the B beta-sheet, The implications of these data on both alpha(1)-antitrypsin function and polymerization are discussed.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Univ Southampton, Sch Biol Sci, Dept Biochem, Southampton SO16 7PX, Hants, England	Monash University; University of Southampton	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia.			Whisstock, James/0000-0003-4200-5611				BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Bottomley SP, 1998, PROTEIN ENG, V11, P1243, DOI 10.1093/protein/11.12.1243; Bottomley SP, 1998, BIOCHEM BIOPH RES CO, V251, P1, DOI 10.1006/bbrc.1998.9254; BOTTOMLEY SP, 1994, PROTEIN ENG, V7, P1463, DOI 10.1093/protein/7.12.1463; Carrell RW, 1996, CHEST, V110, pS243, DOI 10.1378/chest.110.6_Supplement.243S; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Chang WSW, 1997, PROTEIN SCI, V6, P89; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Hopkins PCR, 1997, J BIOL CHEM, V272, P3905, DOI 10.1074/jbc.272.7.3905; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; James EL, 1998, ARCH BIOCHEM BIOPHYS, V356, P296, DOI 10.1006/abbi.1998.0751; Kang HA, 1997, J BIOL CHEM, V272, P510; Kim DY, 1996, BIOCHEM BIOPH RES CO, V226, P378, DOI 10.1006/bbrc.1996.1364; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; Koloczek H, 1996, J PROTEIN CHEM, V15, P447, DOI 10.1007/BF01886851; Koloczek H, 1996, PROTEIN SCI, V5, P2226, DOI 10.1002/pro.5560051109; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWON KS, 1994, J BIOL CHEM, V269, P9627; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LEBONNIEC BF, 1995, BIOCHEMISTRY-US, V34, P12241, DOI 10.1021/bi00038a019; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Lomas DA, 1996, QJM-INT J MED, V89, P807, DOI 10.1093/qjmed/89.11.807; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SMITH CJ, 1991, BIOCHEMISTRY-US, V30, P1028, DOI 10.1021/bi00218a021; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WHISSTOCK J, 1996, THESIS U CAMBRIDGE U; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	47	70	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9482	9488		10.1074/jbc.274.14.9482	http://dx.doi.org/10.1074/jbc.274.14.9482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092631	hybrid			2022-12-25	WOS:000079451800050
J	Matsuno-Yagi, A; Hatefi, Y				Matsuno-Yagi, A; Hatefi, Y			Ubiquinol : cytochrome c oxidoreductase - Effects of inhibitors on reverse electron transfer from the iron-sulfur protein to cytochrome b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BC1 COMPLEX; BOVINE HEART-MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; BC(1) COMPLEX; ETHOXYFORMIC ANHYDRIDE; REDOX REACTIONS; Q-CYCLE; MECHANISM; REDUCTASE; BINDING	The effects of inhibitors on the reduction of the bis-heme cytochrome b of ubiquinol: cytochrome c oxidoreductase (complex III, bc(1) complex) has been studied in bovine heart submitochondrial particles (SMP) when cytochrome b was reduced by NADH and succinate via the ubiquinone (Q) pool or by ascorbate plus N,N,N',N'-tetramethyl-p-phenylenediamine via cytochrome c(1) and the iron-sulfur protein of complex III (ISP). The inhibitors used were antimycin (an N-side inhibitor), beta-methoxyacrylate derivatives, stigmatellin (P-side inhibitors), and ethoxyformic anhydride, which modifies essential histidyl residues in ISP, In agreement with our previous findings, the following results were obtained: (i) When ISP/cytochrome c(1) were prereduced or SMP were treated with a P-side inhibitor, the high potential heme b(H) was fully and rapidly reduced by NADH or succinate, whereas the low potential heme b(L) was only partially reduced. (ii) Reverse electron transfer from ISP/c(1) to cytochrome b was inhibited more by antimycin than by the P-side inhibitors. This reverse electron transfer was unaffected when, instead of normal SMP, Q-extracted SMP containing 200-fold less Q (0.06 mol Q/mol cytochrome b or c(1)) were used. (iii) The cytochrome b reduced by reverse electron transfer through the leak of a P-side inhibitor was rapidly oxidized upon subsequent addition of antimycin. This antimycin-induced reoxidation did not happen when Q-extracted SMP were used. The implications of these results on the path of electrons in complex III, on oxidant-induced extra cytochrome b reduction, and on the inhibition of forward electron transfer to cytochrome b by a P-side plus an N-side inhibitor have been discussed.	Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Hatefi, Y (corresponding author), Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIDDK NIH HHS [DK-08126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK008126, R37DK008126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3351, DOI 10.1021/bi00128a007; ESPOSTI MD, 1986, EUR J BIOCHEM, V160, P547, DOI 10.1111/j.1432-1033.1986.tb10073.x; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HOWELL N, 1993, BIOCHEMISTRY-US, V32, P11162, DOI 10.1021/bi00092a028; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MatsunoYagi A, 1997, J BIOL CHEM, V272, P16928, DOI 10.1074/jbc.272.27.16928; MatsunoYagi A, 1996, J BIOL CHEM, V271, P6164, DOI 10.1074/jbc.271.11.6164; MATSUNOYAGI A, 1985, J BIOL CHEM, V260, P4424; MATSUNOYAGI A, 1987, J BIOL CHEM, V262, P14158; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; OHNISHI T, 1994, FEBS LETT, V353, P103, DOI 10.1016/0014-5793(94)01021-8; Rieske J. S., 1967, METHOD ENZYMOL, V10, P239; RIESKE JS, 1967, J BIOL CHEM, V242, P4854; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSAI AL, 1987, J BIOL CHEM, V262, P8677; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YAGI T, 1982, BIOCHEMISTRY-US, V21, P4777, DOI 10.1021/bi00262a039; YU CA, 1996, BIOCHIM BIOPHYS ACTA, V127, P47; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	26	17	17	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9283	9288		10.1074/jbc.274.14.9283	http://dx.doi.org/10.1074/jbc.274.14.9283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092604	hybrid			2022-12-25	WOS:000079451800023
J	Robertson, AP; Bjorn, HE; Martin, RJ				Robertson, AP; Bjorn, HE; Martin, RJ			Resistance to levamisole resolved at the single-channel level	FASEB JOURNAL			English	Article						Oesophagostomum dentatum; nAChR; patch; clamp; heterogeneity; subtypes	NICOTINIC ACETYLCHOLINE-RECEPTORS; PARASITE ASCARIS-SUUM; SUBUNIT GENE TAR-1; OESOPHAGOSTOMUM-DENTATUM; TRICHOSTRONGYLUS-COLUBRIFORMIS; MUSCLE; DIVERSITY; MEMBRANE; CURRENTS; SEQUENCE	Levamisole is commonly used to treat nematode parasite infections but therapy is limited by resistance. The purpose of this study was to determine the mechanism of resistance to this selective nicotinic drug. Levamisole receptor channel currents in muscle patches from levamisole-sensitive and levamisole-resistant isolates of the parasitic nematode Oesophagostomum dentatum were compared. The number of channels present in patches of sensitive and resistant isolates was similar at 10 mu M levamisole, but at 30 mu M and 100 mu M the resistant isolate contained fewer active patches, suggesting desensitization. Mean P-o and open times were reduced in resistant isolates, The distribution of conductances of channels in the sensitive isolate revealed a heterogeneous receptor population and the presence of G25, G35, G40, and G45 subtypes. A G35 subtype was missing in the resistant isolate. Resistance to levamisole was produced by changes in the averaged properties of the levamisole receptor population, with some receptors from sensitive and resistant isolates having indistinguishable characteristics.	Univ Edinburgh, Dept Preclin Vet Sci, RDSVS, Edinburgh EH9 1QH, Midlothian, Scotland; Royal Vet & Agr Univ, Danish Ctr Expt Parasitol, Dept Pharmacol & Toxicol, Frederiksberg C, Denmark	University of Edinburgh; University of Copenhagen	Robertson, AP (corresponding author), Univ Edinburgh, Dept Preclin Vet Sci, RDSVS, Edinburgh EH9 1QH, Midlothian, Scotland.	alanr@lab0.vet.ed.ac.uk	Martin, Richard John/A-1783-2011	Martin, Richard John/0000-0003-2422-1847	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACEVES J, 1970, BRIT J PHARMACOL, V38, P602, DOI 10.1111/j.1476-5381.1970.tb10601.x; ALBERT A, 1985, SELECTIVE TOXICITY, P206; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; BLOUIN MS, 1995, GENETICS, V141, P1007; BROWNING C, 1907, BRIT MED J, V2, P1405; CamposCaro A, 1997, BIOCHEMISTRY-US, V36, P2709, DOI 10.1021/bi9623486; CHANGEAU JP, 1996, SCIENCE, V225, P1335; Corringer PJ, 1998, J NEUROSCI, V18, P648; COVERNTON PJO, 1994, J PHYSIOL-LONDON, V481, P27, DOI 10.1113/jphysiol.1994.sp020416; DUNN AM, 1969, VET HELMINTHOLOY; Ehrlich P, 1909, BER DTSCH CHEM GES, V42, P17, DOI 10.1002/cber.19090420105; EHRLICH P, 1904, BERL KLIN WOCHENSCHR, V22, P329; Fleming JT, 1997, J NEUROSCI, V17, P5843; Hoekstra R, 1997, MOL BIOCHEM PARASIT, V84, P179, DOI 10.1016/S0166-6851(96)02793-4; HOLLAND CV, 1989, PARASITOLOGY, V99, P275, DOI 10.1017/S003118200005873X; KAN SC, 1979, J PROTOZOOL, V26, P660, DOI 10.1111/j.1550-7408.1979.tb04216.x; KAO CY, 1996, J BIOL CHEM, V261, P8085; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Martin RJ, 1996, PARASITOLOGY, V113, pS137, DOI 10.1017/S0031182000077945; Martin RJ, 1997, PARASITOLOGY, V114, pS111, DOI 10.1017/S0031182097001029; Martin RJ, 1997, EUR J PHARMACOL, V322, P249, DOI 10.1016/S0014-2999(96)00996-X; MARTIN RJ, 1980, BRIT J PHARMACOL, V71, P99, DOI 10.1111/j.1476-5381.1980.tb10914.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; ROBERTSON SJ, 1993, BRIT J PHARMACOL, V108, P170, DOI 10.1111/j.1476-5381.1993.tb13458.x; ROBERTSON SJ, 1993, PESTIC SCI, V37, P293, DOI 10.1002/ps.2780370310; SANGSTER N, 1996, PARASITOLOGY, V113, pS210; Slotved HC, 1996, VET PARASITOL, V63, P237, DOI 10.1016/0304-4017(95)00916-7; UNWIN N, 1988, J CELL BIOL, V107, P1123, DOI 10.1083/jcb.107.3.1123; Varady M, 1997, INT J PARASITOL, V27, P77, DOI 10.1016/S0020-7519(96)00159-2; Wiley LJ, 1996, GENE, V182, P97, DOI 10.1016/S0378-1119(96)00520-3; Wiley LJ, 1997, MOL BIOCHEM PARASIT, V90, P415, DOI 10.1016/S0166-6851(97)00179-5; YORKE WARRINGTON, 1931, Annals of Tropical Medicine and Parasitology, V25, P351	34	69	73	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					749	760		10.1096/fasebj.13.6.749	http://dx.doi.org/10.1096/fasebj.13.6.749			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094935				2022-12-25	WOS:000079527200016
J	Li, SL; Paulsson, KM; Sjogren, HO; Wang, P				Li, SL; Paulsson, KM; Sjogren, HO; Wang, P			Peptide-bound major histocompatibility complex class I molecules associate with tapasin before dissociation from transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; ENDOPLASMIC-RETICULUM; TAP TRANSPORTERS; BINDING; CHAPERONE; CALNEXIN; GLYCOPROTEIN; GENERATION; SELECTION; PROTEINS	Major histocompatibility complex (MHC) class I molecules present antigenic peptides to CD8 T cells. The peptides are generated in the cytosol, then translocated across the membrane of the endoplasmic reticulum by the transporter associated with antigen processing (TAP). TAP is a trimeric complex consisting of TAP1, TAP2, and tapasin (TAP-A) as indicated for human cells by reciprocal coprecipitation with anti TAP1/2 and anti-tapasin antibodies, respectively. TAP1 and TAP2 are required for the peptide transport. Tapasin is involved in the association of class I with TAP and in the assembly of class I with peptide. The mechanisms of tapasin function are still unknown. Moreover, there has been no evidence for a murine tapasin analogue, which has led to the suggestion that murine MHC class I binds directly to TAP1/2. In this study, we have cloned the mouse analogue of tapasin. The predicted amino acid sequence showed 78% identity to human tapasin with identical consensus sequences of signal peptide, N-linked glycosylation site, transmembrane domain and double lysine motif. However, there was less homology (47%) found at the predicted cytosolic domain, and in addition, mouse tapasin is 14 amino acids longer than the human analogue at the C terminus. This part of the molecule may determine the species specificity for interaction with MHC class I or TAP1/2. Like human tapasin, mouse tapasin binds both to TAP1/2 and MHC class I. In TAP2-mutated RMA-S cells, both TAP1 and MHC class I were coprecipitated by anti-tapasin antiserum indicative of association of tapasin with TAP1 but not TAP2. With crosslinker-modified peptides and purified microsomes, anti-tapasin coprecipitated both peptide-bound MHC class I and TAP1/2. In contrast, anti-calreticulin only coprecipitated peptide-free MHC class I molecules. This difference in association with peptide-loaded class I suggests that tapasin functions later than calreticulin during MHC class I assembly, and controls peptide loading onto MHC class I molecules in the endoplasmic reticulum.	Univ Lund, S-22007 Lund, Sweden	Lund University	Li, SL (corresponding author), Univ Lund, Box 7031, S-22007 Lund, Sweden.			Wang, Ping/0000-0001-8992-1233				ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHEN AP, 1998, IMMUNITY, V8, P531; DAVID V, 1993, J BIOL CHEM, V268, P9585; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOWARD JC, 1995, CURR OPIN IMMUNOL, V7, P69, DOI 10.1016/0952-7915(95)80031-X; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KALTOFT MB, 1992, HYBRIDOMA, V11, P507, DOI 10.1089/hyb.1992.11.507; Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; MOMBURG F, 1994, CURR OPIN IMMUNOL, V6, P32, DOI 10.1016/0952-7915(94)90030-2; Neisig A, 1996, J IMMUNOL, V156, P3196; Noessner Elfriede, 1995, Journal of Experimental Medicine, V181, P327; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SUCH WK, 1994, SCIENCE, V264, P1322; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANLEEUWEN JE, 1996, P NATL ACAD SCI USA, V24, P13997; Wang P, 1996, J IMMUNOL, V157, P213; Wang P, 1996, J BIOL CHEM, V271, P24830, DOI 10.1074/jbc.271.40.24830; YANG Y, 1992, J BIOL CHEM, V267, P11669	37	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8649	8654		10.1074/jbc.274.13.8649	http://dx.doi.org/10.1074/jbc.274.13.8649			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085102	hybrid			2022-12-25	WOS:000079451600044
J	Notbohm, H; Nokelainen, M; Myllyharju, J; Fietzek, PP; Muller, PK; Kivirikko, KI				Notbohm, H; Nokelainen, M; Myllyharju, J; Fietzek, PP; Muller, PK; Kivirikko, KI			Recombinant human type II collagens with low and high levels of hydroxylysine and its glycosylated forms show marked differences in fibrillogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; INSECT CELLS; PROCOLLAGEN; EXPRESSION; CLEAVAGE; PROTEIN; TENDON	Type II collagen is the main structural component of hyaline cartilages where it forms networks of thin fibrils that differ in morphology from the much thicker fibrils of type I collagen. We studied here in vitro the formation of fibrils of pepsin-treated recombinant human type II collagen produced in insect cells. Two kinds of type II collagen preparation were used: low hydroxylysine collagen having 2.0 hydroxylysine residues/1,000 amino acids, including 1.3 glycosylated hydroxylysines; and high hydroxylysine collagen having 19 hydroxylysines/1,000 amino acids, including 8.9 glycosylated hydroxylysines. A marked difference in fibril formation was found between these two kinds of collagen preparation, in that the maximal turbidity of the former was reached within 5 min under the standard assay conditions, whereas the absorbance of the latter increased until about 600 min. The critical concentration with the latter was about 10-fold, and the absorbance/microgram collagen incorporated into the fibrils was about one-sixth. The morphology of the fibrils was also different, in that the high hydroxylysine collagen formed thin fibrils with essentially no interfibril interaction or aggregation, whereas the low hydroxylysine collagen formed thick fibrils on a background of thin ones. The data thus indicate that regulation of the extents of lysine hydroxylation and hydroxylysine glycosylation may play a major role in the regulation of collagen fibril formation and the morphology of the fibrils.	Univ Oulu, Dept Med Biochem, FIN-90220 Oulu, Finland; Univ Lubeck, Inst Med Mol Biol, D-23538 Lubeck, Germany; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90220 Oulu, Finland	University of Oulu; University of Lubeck; University of Oulu	Kivirikko, KI (corresponding author), Univ Oulu, Dept Med Biochem, Kajaanintie 52 A, FIN-90220 Oulu, Finland.							Birk DE, 1997, EUR J CELL BIOL, V72, P352; Birk DE, 1996, MATRIX BIOL, V15, P111, DOI 10.1016/S0945-053X(96)90152-3; FERTALA A, 1994, J BIOL CHEM, V269, P11584; Kadler KE, 1996, BIOCHEM J, V316, P1; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1995, PR MED BIOL, V3, P233; Lamberg A, 1996, J BIOL CHEM, V271, P11988, DOI 10.1074/jbc.271.20.11988; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; Nokelainen M, 1998, MATRIX BIOL, V16, P329, DOI 10.1016/S0945-053X(98)90004-X; NOTBOHM H, 1993, INT J BIOL MACROMOL, V15, P299, DOI 10.1016/0141-8130(93)90030-P; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SCOTT JE, 1992, INT J BIOL MACROMOL, V14, P292, DOI 10.1016/S0141-8130(05)80043-1; TENNI R, 1984, ITAL J BIOCHEM, V33, P117; TORREBLANCO A, 1992, J BIOL CHEM, V267, P2650; WILLIAMS BR, 1978, J BIOL CHEM, V253, P6578; YANG CLL, 1993, EUR J BIOCHEM, V213, P1297, DOI 10.1111/j.1432-1033.1993.tb17881.x	20	77	81	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8988	8992		10.1074/jbc.274.13.8988	http://dx.doi.org/10.1074/jbc.274.13.8988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085145	hybrid			2022-12-25	WOS:000079451600087
J	Sano, Y; Harada, J; Tashiro, S; Gotoh-Mandeville, R; Maekawa, T; Ishii, S				Sano, Y; Harada, J; Tashiro, S; Gotoh-Mandeville, R; Maekawa, T; Ishii, S			ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; LEUCINE ZIPPER PROTEINS; DNA-BINDING DOMAINS; N-TERMINAL KINASE; CYCLIC-AMP; MAP KINASE; C-JUN; INDUCED TRANSCRIPTION; TRANSDUCTION PATHWAY; CDNA CLONES	Upon transforming growth factor-beta (TGF-beta) binding to its cognate receptor, Smad3 and Smad4 form heterodimers and transduce the TGF-beta signal to the nucleus. In addition to the Smad pathway, another pathway involving a member of the mitogen-activated protein kinase kinase kinase family of kinases, TGF-beta-activated kinase-1 (TAK1), is required for TGF-beta signaling. However, it is unknown how these pathways function together to synergistically amplify TGF-beta signaling. Here we report that the transcription factor ATF-2 (also called CRE-BP1) is bound by a hetero-oligomer of Smad3 and Smad4 upon TGF-beta stimulation. ATF-2 is one member of the ATF/CREB family that binds to the cAMP response element, and its activity is enhanced after phosphorylation by stress-activated protein kinases such as c-Jun N-terminal kinase and p38. The binding between ATF-2 and Smad3/4 is mediated via the MH1 region of the Smad proteins and the basic leucine zipper region of ATF-2. TGF-beta signaling also induces the phosphorylation of ATF-2 via TAK1 and p38. Both of these actions are shown to be responsible for the synergistic stimulation of ATF-2 trans-activating capacity. These results indicate that ATF-2 plays a central role in TGF-beta signaling by acting as a common nuclear target of both Smad and TAK1 pathways.	RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, Ibaraki, Osaka 3050074, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka, Japan	RIKEN; Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), RIKEN, Tsukuba Life Sci Ctr, Mol Genet Lab, 3-1-1 Koyadai, Ibaraki, Osaka 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MATSUDA S, 1991, J BIOL CHEM, V266, P18188; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NOMURA N, 1993, J BIOL CHEM, V268, P4259; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; TAKEDA J, 1991, ONCOGENE, V6, P1009; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; VANDAM H, 1997, EMBO J, V14, P31798; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	65	304	317	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8949	8957		10.1074/jbc.274.13.8949	http://dx.doi.org/10.1074/jbc.274.13.8949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085140	hybrid			2022-12-25	WOS:000079451600082
J	di Iasio, MG; Calin, G; Tibiletti, MG; Vorechovsky, I; Benediktsson, KP; Taramelli, R; Barbanti-Brodano, G; Negrini, M				di Iasio, MG; Calin, G; Tibiletti, MG; Vorechovsky, I; Benediktsson, KP; Taramelli, R; Barbanti-Brodano, G; Negrini, M			Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region	ONCOGENE			English	Article						LOH at 11q23; breast cancer	ATAXIA-TELANGIECTASIA; CERVICAL-CARCINOMA; OVARIAN-CANCER; MALIGNANT-MELANOMA; ATM MUTATIONS; CHROMOSOME-II; LONG ARM; HETEROZYGOSITY; GENE; TUMORS	Loss of constitutive heterozygosity at 11q23 has been detected in various human solid tumors. Here, we described the analysis of a series of normal and tumor pairs from 110 breast carcinomas for the presence of loss of heterozygosity at 11q23 loci. The overall frequency of LOH was 48%, confirming the importance of deletions at 11q23 in breast tumorigenesis. Previously, we have identified two independent regions of LOH at 11q23, the LOH region 1 at 11q23.1 and the LOH region 2 at 11q23.3. The most telomeric region was recently refined between loci D11S1345 and D11S1316, a region of about 1 Mb. However, the LOH region 1, most centromeric, was still not finely refined: the boundaries were defined by loci D11S2000 and D11S897, separated by about 8 Mb. Here, me refined its boundaries between loci D11S1347 and D11S927, a region of about 2 Mb. We have mapped 11 expressed sequence tags (ESTs) within this region and excluded another 20. This study represents a further step toward the identification of the putative tumor suppressor gene found within the LOH region 1 at 11q23.1.	Univ Ferrara, Dept Mol & Diagnost Med, I-44100 Ferrara, Italy; Univ Pavia, Dept Clin & Biol Sci, I-21100 Varese, Italy; Huddinge Hosp, Dept Surg, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ Varese, Dept Struct & Funct Biol, I-21110 Varese, Italy	University of Ferrara; University of Pavia; Karolinska Institutet; University of Insubria	Negrini, M (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Microbiol Sect, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Calin, George/E-9390-2011; Negrini, Massimo/J-2377-2016	Negrini, Massimo/0000-0002-0007-1920; Calin, George/0000-0001-6704-5615				Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; BETHWAITE PB, 1995, BRIT J CANCER, V71, P814, DOI 10.1038/bjc.1995.157; CARTER SL, 1994, CANCER RES, V54, P6270; Dahiya R, 1997, INT J CANCER, V72, P283, DOI 10.1002/(SICI)1097-0215(19970717)72:2<283::AID-IJC14>3.0.CO;2-H; Davis M, 1996, CANCER RES, V56, P741; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; FOULKES WD, 1993, BRIT J CANCER, V67, P268, DOI 10.1038/bjc.1993.51; Gabra H, 1996, CANCER RES, V56, P950; GUSTAFSON CE, 1994, BRIT J CANCER, V70, P395, DOI 10.1038/bjc.1994.315; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HERBST RA, 1995, CANCER RES, V55, P2494; Hui ABY, 1996, CANCER RES, V56, P3225; IIZUKA M, 1995, GENE CHROMOSOME CANC, V13, P40; KELDYSH PL, 1993, GENE CHROMOSOME CANC, V6, P45, DOI 10.1002/gcc.2870060109; Kerangueven F, 1997, ONCOGENE, V14, P339, DOI 10.1038/sj.onc.1200818; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; LOU WE, 1992, P NATL ACAD SCI USA, V89, P1755; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1995, CANCER RES, V55, P3003; RASIO D, 1995, CANCER RES, V55, P3988; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STILGENBAUER S, 1997, NAT MED, V3, P1115; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Tomlinson IPM, 1996, J PATHOL, V180, P38, DOI 10.1002/(SICI)1096-9896(199609)180:1<38::AID-PATH638>3.0.CO;2-C; TOMLINSON IPM, 1993, GENE CHROMOSOME CANC, V7, P169, DOI 10.1002/gcc.2870070310; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Vorechovsky I, 1996, CANCER RES, V56, P4130; Vorechovsky I, 1996, CANCER RES, V56, P2726; WINQVIST R, 1995, CANCER RES, V55, P2660	33	27	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1635	1638		10.1038/sj.onc.1202453	http://dx.doi.org/10.1038/sj.onc.1202453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102634				2022-12-25	WOS:000078770700014
J	Dougher, M; Terman, BI				Dougher, M; Terman, BI			Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization	ONCOGENE			English	Article						VEGF; KDR receptor; autophosphorylation; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TYROSINE KINASE; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CELLS; IDENTIFICATION; EXPRESSION; SITES; PHOSPHORYLATION	We have previously reported the identification of four autophosphorylation sites on the KDR VEGF receptor. Two of these sites (tyrosines 951 and 996) are located in the receptor's kinase insert domain, and two (tyrosines 1054 and 1059) are located in the catalytic domain. In order to clarify the functional significance of these sites, we made DNA constructs in which tyrosine codons were replaced with those for phenylalanine, and expressed the DNA constructs in 293 cells. VEGF binding to cells expressing the native receptor led to a rapid increase in receptor and PLC gamma phosphorylation, and a slower increase in the phosphorylation of p(125)FAK and paxillin. VEGF binding to KDR(Y951F) and KDR(Y996F) expressing cells resulted in phosphorylation of all cellular substrates tested, although the level of PLC gamma phosphorylation was decreased for KDR(Y996F). The decreased level of PLC gamma phosphorylation was not because PLC gamma-containing SH2 domains bind to the Y996 autophosphorylation site. We conclude that there exists receptor autophosphorylation sites not previously identified which allow for signaling via PLC gamma, as well as p(125)FAK and paxillin. VEGF binding to cells expressing KDR mutated at both tyrosine's 1054 and 1059 activated receptor autophosphorylation but at a level which was only 10% of that seen for cells expressing native receptor. Tyrosine phosphorylation of cell signaling proteins was not observed in KDR(Y1054,1059) expressing cells. Utilizing an in vitro assay which directly measures receptor catalytic activity allowed us to determine that the tyrosine kinase activity of the native receptor was significantly greater than that for the double mutant. We conclude from this result that VEGF-induced autophosphorylation at tyrosines 1054 and 1059 is a required step for allowing maximal KDR kinase activity. Maximal rates of receptor kinase activity is required for VEGF-induced receptor internalization, as internalization was delayed in the KDR(Y1054,1059F) expressing cells when compared to cells expressing native receptor.	Wyeth Ayerst Oncol Res, Pearl River, NY 10965 USA	Pfizer	Terman, BI (corresponding author), Wyeth Ayerst Oncol Res, Bldg 200-4623, Pearl River, NY 10965 USA.							Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROWN LF, 1993, AM J PATHOL, V143, P1255; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; CUNNINGHAM SA, 1997, BIOCHEM BIOPH RES CO, V240, P35; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1991, J NATL CANCER I, V82, P4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GARNER A, 1994, DYNAMIC APPROACH, P1625; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LONGATI P, 1994, ONCOGENE, V9, P3457; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; WILEY HS, 1991, J BIOL CHEM, V266, P11083	45	151	166	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1619	1627		10.1038/sj.onc.1202478	http://dx.doi.org/10.1038/sj.onc.1202478			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102632				2022-12-25	WOS:000078770700012
J	Wan, MH; Sun, T; Vyas, R; Zheng, JP; Granada, E; Dubeau, L				Wan, MH; Sun, T; Vyas, R; Zheng, JP; Granada, E; Dubeau, L			Suppression of tumorigenicity in human ovarian cancer cell lines is controlled by a 2 cM fragment in chromosomal region 6q24-q25	ONCOGENE			English	Article						tumor suppressor; chromosome 6; ovarian cancer; chromosome transfer	ACUTE LYMPHOBLASTIC-LEUKEMIA; COMMONLY DELETED REGION; KARYOTYPIC ANALYSIS; FREQUENT LOSS; HUMAN GENOME; LONG ARM; 6Q; HETEROZYGOSITY; CARCINOMAS; TUMORS	Multiple distinct regions of chromosome 6 are frequently affected by losses of heterozygosity in primary human ovarian carcinomas. We introduced a normal human chromosome 6 into HEY and SKOV-3 ovarian carcinoma cell lines using microcell-mediated chromosome transfer techniques to further investigate the role of this chromosome in ovarian tumorigenesis, The exogenous chromosome was stably propagated in the recipient cells based on fluorescence in situ hybridization (FISH) analyses with a chromosome 6 painting probe. The tumorigenicity of HEY and SKOV-3 cells was completely suppressed after transfer of chromosome 6, but not after transfer of a chromosome 11q13-qter fragment used as control. Using 46 polymorphic microsatellite markers, the region bounded by D6S1649 and D6S1564 was found to be commonly deleted in HEY: chromosome 6 tumorigenic revertant clones. The boundaries of the commonly deleted region could be further narrowed down to a 2 cM (based on the Whitehead genetic map) or 0.36 megabase (based on gdb mapping data) region between D6S1637 and D6S1564 after transferring the exogenous chromosome from revertants into mouse L cells and performing allelic deletion mapping studies against this mouse background. We conclude that this region contains a tumor suppressor gene important for the control of ovarian tumor development.	Univ So Calif, Sch Med, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Urol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Dubeau, L (corresponding author), Univ So Calif, Sch Med, Dept Pathol, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.				NATIONAL CANCER INSTITUTE [R01CA051167] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51167] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BUICK RN, 1985, CANCER RES, V45, P3668; CLIBY W, 1993, CANCER RES, V53, P2393; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; Deger RB, 1997, CANCER GENET CYTOGEN, V96, P166, DOI 10.1016/S0165-4608(96)00327-5; DEVILEE P, 1991, ONCOGENE, V6, P1705; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EHLEN T, 1990, ONCOGENE, V5, P219; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Gerard B, 1997, LEUKEMIA, V11, P228, DOI 10.1038/sj.leu.2400566; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; LEE JH, 1990, CANCER RES, V50, P2724; LUGO TG, 1987, MOL CELL BIOL, V7, P2814, DOI 10.1128/MCB.7.8.2814; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MERLO A, 1994, CANCER RES, V54, P2322; NEGRINI M, 1994, CANCER RES, V54, P1331; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1994, GENOMICS, V20, P301, DOI 10.1006/geno.1994.1172; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sandhu AK, 1996, ONCOGENE, V12, P247; SHEER D, 1987, CANCER GENET CYTOGEN, V26, P339, DOI 10.1016/0165-4608(87)90068-9; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1997, BRIT J CANCER, V75, P1831, DOI 10.1038/bjc.1997.312; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; TRENT JM, 1981, CANCER GENET CYTOGEN, V3, P279, DOI 10.1016/0165-4608(81)90037-6; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; VOLTZ A, 1994, GENOMICS, V21, P464; WAKE N, 1980, CANCER RES, V40, P4512; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; Wan M, 1996, BRIT J CANCER, V73, P1398, DOI 10.1038/bjc.1996.265; WAN MH, 1994, INT J ONCOL, V5, P1043; WELCH DR, 1994, ONCOGENE, V9, P255; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X	39	41	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1545	1551		10.1038/sj.onc.1202476	http://dx.doi.org/10.1038/sj.onc.1202476			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102624				2022-12-25	WOS:000078770700004
J	Easton, JB; Moody, NM; Zhu, XY; Middlemas, DS				Easton, JB; Moody, NM; Zhu, XY; Middlemas, DS			Brain-derived neurotrophic factor induces phosphorylation of fibroblast growth factor receptor substrate 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRK PROTOONCOGENE PRODUCT; TYROSINE KINASE-ACTIVITY; EAR SENSORY NEURONS; PROTEIN-KINASE; AUTOPHOSPHORYLATION SITES; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; SNT PROTEIN; HIPPOCAMPAL	Brain-derived neurotrophic factor (BDNF) promotes neuronal survival. Gaining an understanding of how BDNF, via the tropomyosin-related kinase B (TRKB) receptor, elicits specific cellular responses is of contemporary interest. Expression of mutant TrkB in fibroblasts, where tyrosine 484 was changed to phenylalanine, abrogated Shc association with TrkB, but only attenuated and did not block BDNF-induced phosphorylation of mitogen-activated protein kinase (MAPK), This suggests there is another BDNF-induced signaling mechanism for activating MAPK, which compelled a search for other TrkB substrates. BDNF induces phosphorylation of fibroblast growth factor receptor substrate 2 (FRS2) in both fibroblasts engineered to express TrkB and human neuroblastoma (NB) cells that naturally express TrkB, Additionally, BDNF induces phosphorylation of FRS2 in primary cultures of cortical neurons, thus showing that FRS2 is a physiologically relevant substrate of TrkB. Data are presented demonstrating that BDNF induces association of FRS2 with growth factor receptor-binding protein 2 (GRB2) in cortical neurons, fibroblasts, and NE cells, which in turn could activate the RAS/MAPK pathway. This is not dependent on Shc, since BDNF does not induce association of Shc and FRS2. Finally, the experiments suggest that FRS2 and sue-associated neurotrophic factor-induced tyrosine-phosphorylated target are the same protein.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Middlemas, DS (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale,POB 318, Memphis, TN 38101 USA.			Easton, John/0000-0003-4503-6608	NATIONAL CANCER INSTITUTE [R29CA071628, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765, 1 R29 CA 71628] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU T, 1994, ONCOGENE, V9, P3483; BUTLER WB, 1984, ANAL BIOCHEM, V141, P70, DOI 10.1016/0003-2697(84)90426-3; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FURSHPAN EJ, 1989, NEURON, V3, P199, DOI 10.1016/0896-6273(89)90033-0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Harlow E., 1988, ANTIBODIES LAB MANUA; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kwon YW, 1996, J NEUROBIOL, V29, P503; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIDDLEMAS DS, 1994, J BIOL CHEM, V269, P5458; MIDDLEMAS DS, 1993, METHODS NEUROSCI, V12, P139; Minichiello L, 1995, DEVELOPMENT, V121, P4067; Minichiello L, 1996, GENE DEV, V10, P2849, DOI 10.1101/gad.10.22.2849; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 1996, BIOCHEM BIOPH RES CO, V225, P1021, DOI 10.1006/bbrc.1996.1288; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Sawai H, 1996, J NEUROSCI, V16, P3887; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schimmang T, 1997, MECH DEVELOP, V64, P77, DOI 10.1016/S0925-4773(97)00047-6; Segal RA, 1996, J BIOL CHEM, V271, P20175, DOI 10.1074/jbc.271.33.20175; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	50	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11321	11327		10.1074/jbc.274.16.11321	http://dx.doi.org/10.1074/jbc.274.16.11321			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196222	hybrid			2022-12-25	WOS:000079751900090
J	Goldsmith, PK; Fan, GF; Ray, K; Shiloach, J; McPhie, P; Rogers, KV; Spiegel, AM				Goldsmith, PK; Fan, GF; Ray, K; Shiloach, J; McPhie, P; Rogers, KV; Spiegel, AM			Expression, purification, and biochemical characterization of the amino-terminal extracellular domain of the human calcium receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; HUMAN CA2+ RECEPTOR; SENSING RECEPTOR; CELL-SURFACE; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; GLUTAMATE RECEPTORS; CIRCULAR-DICHROISM; BINDING-PROTEINS; MULTIGENE FAMILY	We purified the extracellular domain (ECD) of the human calcium receptor (hCaR) from the medium of HEK-293 cells stably transfected with a hCaR cDNA containing an isoleucine 599 nonsense mutation. A combination of lectin, anion exchange, and gel permeation chromatography yielded milligram quantities of >95% pure protein from 15 liters of starting culture medium. The purified ECD ran as an similar to 78-kDa protein on SDS-polyacrylamide gel electrophoresis and was found to be a disulfide-linked dimer. Its NH2-terminal sequence, carbohydrate content, and CD spectrum were defined. Tryptic proteolysis studies showed two major sites accessible to cleavage. These studies provide new insights into the structure of the hCaR ECD. Availability of purified ECD protein should permit further structural studies to help define the mechanism of Ca2+ activation of this G protein-coupled receptor.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Biotechnol Unit, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA; NPS Pharmaceut, Salt Lake City, UT 84108 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Spiegel, AM (corresponding author), NIDDK, Metab Dis Branch, NIH, 10-9N-222, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043011] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; MCPHIE P, 1992, ARCH BIOCHEM BIOPHYS, V293, P46, DOI 10.1016/0003-9861(92)90363-2; MITHAL A, 1995, ENDOCRINOLOGY, V136, P3087, DOI 10.1210/en.136.7.3087; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476	25	56	56	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11303	11309		10.1074/jbc.274.16.11303	http://dx.doi.org/10.1074/jbc.274.16.11303			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196220	hybrid			2022-12-25	WOS:000079751900088
J	van den Berghe, N; Cool, RH; Wittinghofer, A				van den Berghe, N; Cool, RH; Wittinghofer, A			Discriminatory residues in Ras and Rap for guanine nucleotide exchange factor recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ACTIVATION; H-RAS; SACCHAROMYCES-CEREVISIAE; DISSOCIATION STIMULATOR; DEPENDENT ACTIVATION; MOLECULAR MECHANISM; CATALYTIC DOMAIN; STRUCTURAL BASIS; ONCOGENIC RAS; AMINO-ACIDS	The inability of the S17N mutant of Rap1A to sequester the catalytic domain of the Rap guanine nucleotide exchange factor C3G (van den Berghe, N., Cool, R, H., Horn, G., and Wittinghofer, A. (1997) Oncogene 15, 845-850) prompted us to study possible fundamental differences in the way Rap1 interacts with C3G compared with the interaction of Ras with the catalytic domain of the mouse Ras guanine nucleotide exchange factor Cdc25(Mm), A variety of mutants in both Ras and Rap1A were designed, and both the C3G and Cdc25(Mm) catalyzed release of guanine nucleotide from these mutants was studied. In addition, we could identify regions in Rap2A that are responsible for the lack of recognition by C3G and induce high C3G activity by replacement of these residues with the corresponding Rap1A residues. The different Ras and Rap mutants showed that many residues were equally important for both C3G and Cdc25(Mm), suggesting that they interact similarly with their substrates, However, several residues were also identified to be important for the exchange reaction with only C3G (Leu(70)) or only Cdc25(Mm) (Gln(61) and Tyr(40)). These results are discussed in the light of the structure of the Ras-Sos complex and suggest that some important differences in the interaction of Rap1 with C3G and Ras with Cdc25(Mm) indeed exist and that marker residues have been identified for the different structural requirements.	Max Planck Inst Mol Physiol, Abt Strukt Biol, D-44139 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukt Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.d		Cool, Robbert/0000-0002-9845-2202				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Carrera V, 1998, FEBS LETT, V440, P291, DOI 10.1016/S0014-5793(98)01481-1; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOWE LR, 1993, ONCOGENE, V8, P2583; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Leonardsen L, 1996, ONCOGENE, V13, P2177; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MOSTELLER RD, 1995, METHOD ENZYMOL, V255, P135; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHIROUZU M, 1992, ONCOGENE, V7, P475; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	57	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11078	11085		10.1074/jbc.274.16.11078	http://dx.doi.org/10.1074/jbc.274.16.11078			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196191	hybrid			2022-12-25	WOS:000079751900059
J	Ayyoub, M; Mazarguil, H; Monsarrat, B; Van den Eynde, B; Gairin, JE				Ayyoub, M; Mazarguil, H; Monsarrat, B; Van den Eynde, B; Gairin, JE			A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CYTOLYTIC LYMPHOCYTES-T; CLASS-I MOLECULES; HIGH-AFFINITY; SYNTHETIC PEPTIDES; DRUG DEVELOPMENT; GENE MAGE-3; MHC; BINDING; STABILITY	Tumor antigens presented by major histocompatibility complex (MHC) class I molecules and recognized by CD8(+) cytotoxic T lymphocytes (CTLs) may generate an efficient antitumor immune response after appropriate immunization. Antigenic peptides can be used in vivo to induce antitumor or antiviral immunity. The efficiency of naked peptides may be greatly limited by their degradation in the biological fluids. We present a rational, structure-based approach to design structurally modified, peptidase-resistant and biologically active analogues of human tumor antigen MAGE-1.A1. This approach is based on our understanding of the peptide interaction with the MHC and the T cell receptor and its precise degradation pathway. Knowledge of these mechanisms led to the design of a non-natural, minimally modified analogue of MAGE-1.A1, [Aib(2),MMe-Ser(8)]MAGE-1.A1, which was highly peptidase-resistant and bound to MHC and activated MAGE-1.A1-specific anti-melanoma CTLs. Thus, we showed that it is possible to structurally modify peptide epitopes to obtain analogues that are still specifically recognized by CTLs. Such analogues may represent interesting leads for antitumor synthetic vaccines.	Inst Pharmacol & Biol Struct, CNRS, UPR 9062, F-31400 Toulouse, France; Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Ludwig Institute for Cancer Research	Gairin, JE (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UPR 9062, 205 Route Narbonne, F-31400 Toulouse, France.	gairin@ipbs.fr	Ayyoub, Maha/G-2778-2013; Ayyoub, Maha/A-2074-2017	Ayyoub, Maha/0000-0003-2022-0898				AICHELE P, 1995, J EXP MED, V182, P261, DOI 10.1084/jem.182.1.261; BARINAGA M, 1992, SCIENCE, V257, P880, DOI 10.1126/science.1502554; BOON T, 1993, INT J CANCER, V54, P177, DOI 10.1002/ijc.2910540202; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Chen WS, 1996, J IMMUNOL, V157, P1000; DIBRINO M, 1994, J IMMUNOL, V152, P620; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; Fairchild PJ, 1996, IMMUNOL TODAY, V17, P80, DOI 10.1016/0167-5699(96)80584-6; FALO LD, 1992, P NATL ACAD SCI USA, V89, P8347, DOI 10.1073/pnas.89.17.8347; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; Herve M, 1997, MOL IMMUNOL, V34, P157, DOI 10.1016/S0161-5890(97)00004-7; Hu XY, 1996, CANCER RES, V56, P2479; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; HUDRISIER D, 1995, MOL IMMUNOL, V32, P895, DOI 10.1016/0161-5890(95)00043-E; Hudrisier D, 1996, J BIOL CHEM, V271, P17829, DOI 10.1074/jbc.271.30.17829; Hudrisier D, 1998, CURR TOP MICROBIOL, V232, P75; Jaeger E, 1996, INT J CANCER, V66, P162; JAMESON SC, 1992, EUR J IMMUNOL, V22, P2663, DOI 10.1002/eji.1830221028; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kondo A, 1997, IMMUNOGENETICS, V45, P249, DOI 10.1007/s002510050200; KOZLOWSKI S, 1992, J EXP MED, V175, P1417, DOI 10.1084/jem.175.6.1417; KOZLOWSKI S, 1993, J IMMUNOL, V151, P4033; LAMONT AG, 1990, J IMMUNOL, V144, P2493; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Maillere B, 1995, MOL IMMUNOL, V32, P1073, DOI 10.1016/0161-5890(95)00073-9; MALARKANNAN S, 1995, J IMMUNOL, V154, P585; MANDELBOIM O, 1995, NAT MED, V1, P1179, DOI 10.1038/nm1195-1179; Marchand M, 1995, INT J CANCER, V63, P883, DOI 10.1002/ijc.2910630622; Melief CJM, 1996, CURR OPIN IMMUNOL, V8, P651, DOI 10.1016/S0952-7915(96)80081-1; OJCIUS DM, 1994, J IMMUNOL, V152, P2798; POWELL MF, 1992, J PHARM SCI, V81, P731, DOI 10.1002/jps.2600810802; POWELL MF, 1993, PHARMACEUT RES, V10, P1268, DOI 10.1023/A:1018953309913; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; ROMERO P, 1995, J EXP MED, V182, P1019, DOI 10.1084/jem.182.4.1019; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; SCHULZ M, 1991, P NATL ACAD SCI USA, V88, P991, DOI 10.1073/pnas.88.3.991; Toes REM, 1996, P NATL ACAD SCI USA, V93, P7855, DOI 10.1073/pnas.93.15.7855; TRAVERSARI C, 1992, J EXP MED, V176, P1453, DOI 10.1084/jem.176.5.1453; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; Valmori D, 1998, J IMMUNOL, V160, P1750; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Verdoliva A, 1995, J BIOL CHEM, V270, P30422, DOI 10.1074/jbc.270.51.30422; WIDMANN C, 1991, J IMMUNOL, V147, P3745	48	13	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10227	10234		10.1074/jbc.274.15.10227	http://dx.doi.org/10.1074/jbc.274.15.10227			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187808	hybrid			2022-12-25	WOS:000079663500047
J	Higashi, S; Miyazaki, K				Higashi, S; Miyazaki, K			Reactive site-modified tissue inhibitor of metalloproteinases-2 inhibits the cell-mediated activation of progelatinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX METALLOPROTEINASE; IV COLLAGENASE; EXTRACELLULAR-MATRIX; CATALYTIC DOMAIN; TIMP-2; SURFACE; GELATINASE; PURIFICATION; FIBROBLASTS; EXPRESSION	Tissue inhibitor of metalloproteinases-a (TIMP-2) is supposed to play a regulatory role in the cell-mediated activation of progelatinase A To investigate the mechanism of the regulation, we prepared and characterized a chemically modified TIMP-2, and examined its effects on the activation of progelatinase A. We found that treatment of TIMP-2 with cyanate ion led to loss of inhibitory activity toward matrilysin or gelatinase A Structural and functional analyses of the modified TIMP-2 showed that carbamylation of the alpha-amino group of the NH2-terminal Cys(1) of TIMP-2 led to complete loss of the inhibitory activity. When the reactive-site modified TIMP-2 was added to culture medium of concanavalin A-stimulated HT1080 cells, the conversion of endogenous progelatinase A to the intermediate form was partially inhibited, whereas that of the intermediate form to the mature one was strongly inhibited. The reactive site-modified TIMP-2 also prevented an accumulation of active gelatinase A on the cell surface. We speculate that occupation of the hemopexin-like domain of gelatinase A by the reactive site-modified TIMP-2 makes it unable for gelatinase A to be retained on the cell surface, thus preventing the autocatalytic conversion of the intermediate fern of gelatinase A to its mature form.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 244, Japan	Yokohama City University	Higashi, S (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 244, Japan.	shigashi@cserv2.yokohama-cu.ac.jp						Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1992, CANCER RES, V52, P4540; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Kinoshita T, 1996, CANCER RES, V56, P2535; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1993, BIOCHIM BIOPHYS ACTA, V1203, P147, DOI 10.1016/0167-4838(93)90049-W	28	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10497	10504		10.1074/jbc.274.15.10497	http://dx.doi.org/10.1074/jbc.274.15.10497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187841	hybrid			2022-12-25	WOS:000079663500080
J	Messner, KR; Imlay, JA				Messner, KR; Imlay, JA			The identification of primary sites of superoxide and hydrogen peroxide formation in the aerobic respiratory chain and sulfite reductase complex of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-DINUCLEOTIDE; XANTHINE-OXIDASE; FLAVOPROTEIN COMPONENT; FLAVIN MONONUCLEOTIDE; PROSTHETIC GROUPS; DNA-DAMAGE; HEMOFLAVOPROTEIN; ENTEROBACTERIA; DISMUTASE; RADICALS	The fitness of organisms depends upon the rate at which they generate superoxide (O-2(radical anion)) and hydrogen peroxide (H2O2) as toxic by-products of aerobic metabolism. In Escherichia coli these oxidants arise primarily from the autoxidation of components of its respiratory chain. Inverted vesicles that were incubated with NADH generated O-2(radical anion) and H2O2 at accelerated rates either when treated with cyanide or when devoid of quinones, implicating an NADH dehydrogenase as their source. Null mutations in the gene encoding NADH dehydrogenase II averted autoxidation of vesicles, and its overproduction accelerated it. Thus NADH dehydrogenase II but not NADH dehydrogenase I, respiratory quinones, or cytochrome oxidases formed substantial O2(radical) (anion) and H2O2. NADH dehydrogenase II that was purified from both wild-type and quinone-deficient cells generated similar to 130 H2O2 and 15 O-2(radical anion) min(-1) by autoxidation of its reduced FAD cofactor, Sulfite reductase is a second autoxidizable electron transport chain of E, coli, containing FAD, FMN, [4Fe-4S], and siroheme moieties, Purified flavoprotein that contained only the FAD and FMN cofactors had about the same oxidation turnover number as did the holoenzyme, 7 min(-1) FAD(-1). Oxidase activity was largely lost upon FMN removal. Thus the autoxidation of sulfite reductase, like that of the respiratory chain, occurs primarily by autoxidation of an exposed flavin cofactor. Great variability in the oxidation turnover numbers of these and other flavoproteins suggests that endogenous oxidants will be predominantly formed by only a few oxidizable enzymes. Thus the degree of oxidative stress in a cell may depend upon the titer of such enzymes and accordingly may vary with growth conditions and among different cell types. Furthermore, the chemical nature of these reactions was manifested by their acceleration at high temperatures and oxygen concentrations. Thus these environmental parameters may also directly affect the O2(radical anion) and H2O2 loads that organisms must bear.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Imlay, JA (corresponding author), Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA.		Messner, Kevin/J-2242-2014; Messner, Kevin/ABC-8801-2020	Messner, Kevin/0000-0003-2516-0695; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049640, T32GM007283, R37GM049640] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07283-20, GM49640, R01 GM049640] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU DCT, 1984, J BACTERIOL, V157, P122, DOI 10.1128/JB.157.1.122-125.1984; BOEHME DE, 1976, NATURE, V262, P418, DOI 10.1038/262418a0; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BRANDT R, 1965, ANAL BIOCHEM, V11, P6, DOI 10.1016/0003-2697(65)90035-7; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Coves J, 1997, BIOCHEMISTRY-US, V36, P5921, DOI 10.1021/bi9623744; ESCHENBRENNER M, 1995, J BIOL CHEM, V270, P20550, DOI 10.1074/jbc.270.35.20550; FAEDER EJ, 1974, J BIOL CHEM, V249, P1599; FARR SB, 1986, P NATL ACAD SCI USA, V83, P8268, DOI 10.1073/pnas.83.21.8268; FLINT D H, 1990, P285; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Fridovich I., 1982, SUPEROXIDE DISMUTASE, V1, P69; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GAUDU P, 1994, J BIOL CHEM, V269, P8182; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1981, J BIOL CHEM, V256, P9090; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1987, J BACTERIOL, V169, P2967, DOI 10.1128/jb.169.7.2967-2976.1987; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; JAWOROWSKI A, 1981, BIOCHEMISTRY-US, V20, P3621, DOI 10.1021/bi00515a049; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KUO CF, 1987, J BIOL CHEM, V262, P4724; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOEWEN PC, 1984, J BACTERIOL, V157, P622, DOI 10.1128/JB.157.2.622-626.1984; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1971, P NATL ACAD SCI USA, V68, P1024, DOI 10.1073/pnas.68.5.1024; Miller J. H., 1972, EXPT MOL GENETICS, P432; MINGHETTI KC, 1988, BIOCHEM BIOPH RES CO, V155, P243; MISRA HP, 1977, ANAL BIOCHEM, V79, P553, DOI 10.1016/0003-2697(77)90429-8; MULLER F, 1987, FREE RADICAL BIO MED, V3, P215, DOI 10.1016/0891-5849(87)90009-8; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; SAMBROOK J, 1989, MOL CLONING LAB MANU, pA6; SHAW DJ, 1981, MOL GEN GENET, V181, P95, DOI 10.1007/BF00339011; SIEGEL LM, 1974, J BIOL CHEM, V249, P1587; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SIEGEL LM, 1974, J BIOL CHEM, V249, P1572; SPIRO S, 1989, MOL MICROBIOL, V3, P601, DOI 10.1111/j.1365-2958.1989.tb00207.x; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WU JY, 1991, J BACTERIOL, V173, P325, DOI 10.1128/jb.173.1.325-333.1991; YOUNG IG, 1976, BIOCHIM BIOPHYS ACTA, V449, P376, DOI 10.1016/0005-2728(76)90149-3; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	54	205	211	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10119	10128		10.1074/jbc.274.15.10119	http://dx.doi.org/10.1074/jbc.274.15.10119			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187794	hybrid			2022-12-25	WOS:000079663500033
J	Mizutani, K; Yamashita, H; Kurokawa, H; Mikami, B; Hirose, M				Mizutani, K; Yamashita, H; Kurokawa, H; Mikami, B; Hirose, M			Alternative structural state of transferrin - The crystallographic analysis of iron-loaded but domain-opened ovotransferrin N-lobe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CONFORMATIONAL CHANGE; TERMINAL HALF-MOLECULE; HUMAN LACTOFERRIN; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; X-RAY; DUCK OVOTRANSFERRIN; HEN OVOTRANSFERRIN; SERUM TRANSFERRIN; OPEN FORM	Transferrins bind Fe3+ very tightly in a closed interdomain cleft by the coordination of four protein ligands (Asp(60), Tyr(92) Tyr(191) and His(250) in ovotransferrin N-lobe) and of a synergistic anion, physiologically bidentate CO32-. Upon Fe3+ uptake, transferrins undergo a large scale conformational transition: the apo structure with an opening of the interdomain cleft is transformed into the closed hole structure, implying initial Fe3+ binding in the open form. To solve the Fe3+-loaded, domain-opened structure, an ovotransferrin N-lobe crystal that had been grown as the apo form was soaked with Fe3+ -nitrilotriacetate, and its structure was solved at 2.1 Angstrom resolution. The Fe3+-soaked form showed almost exactly the same overall open structure as the iron-free apo form. The electron density map unequivocally proved the presence of an iron atom with the coordination by the two protein ligands of Tyr(92)-OH and Tyr(191)-OH. Other Fe3+ coordination sites are occupied by a nitrilotriacetate anion, which is stabilized through the hydrogen bonds with the peptide NH groups of Ser(122), Ala(123), and Gly(124) and a side chain group of Thr(117). There is, however, no clear interaction between the nitrilotriacetate anion and the synergistic anion binding site, Arg(121).	Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan	Kyoto University	Hirose, M (corresponding author), Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan.		Kurokawa, Hirofumi/A-7231-2010	Hirose, Masaaki/0000-0003-2672-4384				AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; DAY CL, 1993, J MOL BIOL, V232, P1084, DOI 10.1006/jmbi.1993.1462; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; Faber HR, 1996, BIOCHEMISTRY-US, V35, P14473, DOI 10.1021/bi961729g; Faber HR, 1996, J MOL BIOL, V256, P352; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GROSSMANN JG, 1993, J MOL BIOL, V229, P585, DOI 10.1006/jmbi.1993.1063; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDLEY PF, 1993, ACTA CRYSTALLOGR D, V49, P292, DOI 10.1107/S0907444992012101; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Mecklenburg SL, 1997, J MOL BIOL, V270, P739, DOI 10.1006/jmbi.1997.1126; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Nicholson H, 1997, BIOCHEMISTRY-US, V36, P341, DOI 10.1021/bi961908y; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Rawas A, 1997, ACTA CRYSTALLOGR D, V53, P464, DOI 10.1107/S0907444997000838; SARRA R, 1990, ACTA CRYSTALLOGR B, V46, P763, DOI 10.1107/S0108768190006450; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182	29	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10190	10194		10.1074/jbc.274.15.10190	http://dx.doi.org/10.1074/jbc.274.15.10190			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187803	hybrid			2022-12-25	WOS:000079663500042
J	Muller, JMM; Meyer, HH; Ruhrberg, C; Stamp, GW; Warren, G; Shima, DT				Muller, JMM; Meyer, HH; Ruhrberg, C; Stamp, GW; Warren, G; Shima, DT			The mouse p97 (CDC48) gene - Genomic structure, definition of transcriptional regulatory sequences, gene expression, and characterization of a pseudogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; MEMBRANE-FUSION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; MAMMALIAN HOMOLOG; ATPASE; VCP; LOCALIZATION; HYBRIDIZATION	Here we present the first description of the genomic organization, transcriptional regulatory sequences, and adult and embryonic gene expression for the mouse p97(CDC48) AAA ATPase. Clones representing two distinct p97 genes were isolated in a genomic library screen, one of them likely representing a non-functional processed pseudogene. The coding region of the gene encoding the functional mRNA is interrupted by 16 introns and encompasses 20.4 kilobase pairs. Definition of the transcriptional initiation site and sequence analysis showed that the gene contains a TATA-less, CC-rich promoter region with an initiator element spanning the transcription start site. Cis-acting elements necessary for basal transcription activity reside within 410 base pairs of the flanking region as determined by transient transfection assays. In immunohistological analyses, p97 was widely expressed in embryos and adults, but protein levels were tightly controlled in a cell type- and cell differentiation-dependent manner. A remarkable heterogeneity in p97 immunostaining was found on a cellular level within a given tissue, and protein amounts in the cytoplasm and nucleus varied widely, suggesting a highly regulated and intermittent function for p97, This study provides the basis for a detailed analysis of the complex regulation of p97 and the reagents required for assessing its functional significance using targeted gene manipulation in the mouse.	Imperial Canc Res Fund, Cell Biol Lab 624, London WC2A 3PX, England; Natl Inst Med Res, London NW7 1AA, England; Hammersmith Hosp, Imperial Coll, Sch Med, Dept Histopathol, London W12 0HS, England	Cancer Research UK; MRC National Institute for Medical Research; Imperial College London	Shima, DT (corresponding author), Imperial Canc Res Fund, Cell Biol Lab 624, 44 Lincolns Inn Fields, London WC2A 3PX, England.	shima@icrf.icnet.uk	Ruhrberg, Christiana/C-6404-2009; Meyer, Hemmo/GNH-5784-2022	Ruhrberg, Christiana/0000-0002-3212-9381; Meyer, Hemmo/0000-0003-1883-1796				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERG K, 1983, GEOTEKTONISCHE FORSC, V66, P1; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hoyle J, 1997, MAMM GENOME, V8, P778, DOI 10.1007/s003359900566; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; MOIR D, 1982, GENETICS, V100, P547; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; Pinter M, 1998, INSECT BIOCHEM MOLEC, V28, P91, DOI 10.1016/S0965-1748(97)00095-7; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; Poulsom R, 1998, EUR J HISTOCHEM, V42, P121; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Richardson MP, 1998, GENE, V206, P145, DOI 10.1016/S0378-1119(97)00586-6; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHULTE RJ, 1994, J IMMUNOL, V153, P5465; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871	32	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10154	10162		10.1074/jbc.274.15.10154	http://dx.doi.org/10.1074/jbc.274.15.10154			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187799	hybrid			2022-12-25	WOS:000079663500038
J	Shearstone, JR; Baneyx, F				Shearstone, JR; Baneyx, F			Biochemical characterization of the small heat shock protein IbpB from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; MOLECULAR CHAPERONE ACTIVITY; QUATERNARY STRUCTURE; A-CRYSTALLIN; IN-VITRO; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; CELLULAR THERMORESISTANCE; GUANIDINE-HYDROCHLORIDE; H-1-NMR SPECTROSCOPY; HYDROPHOBIC SURFACES	Escherichia coli IbpB was overexpressed in a strain carrying a deletion in the chromosomal ibp operon and purified by refolding, Under our experimental conditions, IbpB exhibited pronounced size heterogeneity, Basic oligomers, roughly spherical and approximately 15 nn in diameter, interacted to form larger particles in the 100-200-nm range, which themselves associated to yield loose aggregates of micrometer size. IbpB suppressed the thermal aggregation of model proteins in a concentration-dependent manner, and its CD spectrum was consistent with a mostly P-pleated secondary structure. Incubation at high temperatures led to a partial loss of secondary structure, the progressive exposure of tryptophan residues to the solvent, the dissociation of high molecular mass aggregates into approximate to 600-kDa oligomers, and an increase in surface hydrophobicity, Structural changes were reversible between 37 and 55 degrees C, and, up to 55 degrees C, hydrophobic sites were reburied upon cooling. IbpB exhibited a biphasic unfolding trend upon guanidine hydrochloride (GdnHCl) treatment and underwent comparable conformational changes upon melting and during the first GdnHCl-induced transition. However, hydrophobicity decreased with increasing GdnHCl concentrations, suggesting that efficient exposure of structured hydrophobic sites involves denaturant-sensitive structural features. By contrast, IbpB hydrophobicity rose at high NaCl concentrations and increased further at high temperatures. Our results support a model in which temperature-driven conformational changes lead to the reversible exposure of normally shielded binding sites for nonnative proteins and suggest that both hydrophobicity and charge context may determine substrate binding to IbpB.	Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Baneyx, F (corresponding author), Univ Washington, Dept Chem Engn, Box 351750, Seattle, WA 98195 USA.			Shearstone, Jeffrey/0000-0002-6875-1826				ALLEN SP, 1992, J BACTERIOL, V174, P6938, DOI 10.1128/JB.174.21.6938-6947.1992; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Ayling A, 1996, PROTEIN SCI, V5, P478; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BOND U, 1987, ADV GENET, V24, P1, DOI 10.1016/S0065-2660(08)60005-X; Boston RS, 1996, PLANT MOL BIOL, V32, P191, DOI 10.1007/BF00039383; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; Chin WC, 1998, NATURE, V391, P568, DOI 10.1038/35345; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; GERNOLD M, 1993, DEV GENET, V14, P103, DOI 10.1002/dvg.1020140204; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Jones PG, 1996, MOL MICROBIOL, V21, P1207, DOI 10.1111/j.1365-2958.1996.tb02582.x; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KOENIG SH, 1992, BIOPHYS J, V61, P776, DOI 10.1016/S0006-3495(92)81882-9; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Laskowska E, 1996, BIOCHIMIE, V78, P117, DOI 10.1016/0300-9084(96)82643-5; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; Lee GJ, 1995, METHOD CELL BIOL, V50, P325, DOI 10.1016/S0091-679X(08)61040-7; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Leroux MR, 1997, J BIOL CHEM, V272, P12847, DOI 10.1074/jbc.272.19.12847; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Muchowski PJ, 1998, P NATL ACAD SCI USA, V95, P1004, DOI 10.1073/pnas.95.3.1004; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; RAMAN B, 1994, J BIOL CHEM, V269, P27264; ROSENBERG HF, 1993, J BIOL CHEM, V268, P4499; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; Seale JW, 1998, METHOD ENZYMOL, V290, P318, DOI 10.1016/S0076-6879(98)90028-3; SHAKOORI AR, 1992, J CELL BIOCHEM, V48, P277, DOI 10.1002/jcb.240480308; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; SIEZEN RJ, 1982, EXP EYE RES, V34, P969, DOI 10.1016/0014-4835(82)90077-X; SINGH M, 1970, J BIOL CHEM, V245, P4636; SPECTOR A, 1971, BIOCHEM J, V124, P337, DOI 10.1042/bj1240337; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; TARDIEU A, 1986, J MOL BIOL, V192, P711, DOI 10.1016/0022-2836(86)90023-9; TAURA T, 1989, BIOCHEM BIOPH RES CO, V163, P438, DOI 10.1016/0006-291X(89)92155-4; Thomas JG, 1996, J BIOL CHEM, V271, P11141, DOI 10.1074/jbc.271.19.11141; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; TIFFANY ML, 1973, BIOPOLYMERS, V12, P575, DOI 10.1002/bip.1973.360120310; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; ZHU X, 1996, NATURE, V272, P1606	64	88	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9937	9945		10.1074/jbc.274.15.9937	http://dx.doi.org/10.1074/jbc.274.15.9937			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187768	hybrid			2022-12-25	WOS:000079663500007
J	Sweeney, G; Somwar, R; Ramlal, T; Volchuk, A; Ueyama, A; Klip, A				Sweeney, G; Somwar, R; Ramlal, T; Volchuk, A; Ueyama, A; Klip, A			An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; RAT ADIPOSE-CELLS; SKELETAL-MUSCLE CELLS; N-TERMINAL KINASE; GROWTH-FACTOR-I; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC ACTIVITY; GLUT4-CONTAINING VESICLES; GLUT4 TRANSLOCATION	The precise mechanisms underlying insulin-stimulated glucose transport still require investigation. Here we assessed the effect of SB203580, an inhibitor of the p38 MAP kinase family, on insulin-stimulated glucose transport in 3T3-L1 adipocytes and L6 myotubes, We found that SB203580, but not its inactive analogue (SB202474), prevented insulin-stimulated glucose transport in both cell types with an IC50 similar to that for inhibition of p38 MAP kinase (0.6 mu M). Basal glucose uptake was not affected. Moreover, SB203580 added only during the transport assay did not inhibit basal or insulin-stimulated transport. SB203580 did not inhibit insulin-stimulated translocation of the glucose transporters GLUT1 or GLUT4 in 3T3-L1 adipocytes as assessed by immunoblotting of subcellular fractions or by immunofluorescence of membrane lawns. L6 muscle cells expressing GLUT4 tagged on an extracellular domain with a Myc epitope (GLUT4myc) were used to assess the functional insertion of GLUT4 into the plasma membrane. SB203580 did not affect the insulin-induced gain in GLUT4myc exposure at the cell surface but largely reduced the stimulation of glucose uptake. SB203580 had no effect on insulin-dependent insulin receptor substrate-1 phosphorylation, association of the p85 subunit of phosphatidylinositol 3-kinase with insulin receptor substrate-1, nor on pho sphatidylinositol 3-kinase, Akt1, Akt2, or Akt3 activities in 3T3-L1 adipocytes, In conclusion, in the presence of SB203580, insulin caused normal translocation and cell surface membrane insertion of glucose transporters without stimulating glucose transport. We propose that insulin stimulates two independent signals contributing to stimulation of glucose transport: phosphatidylinositol 3-kinase leads to glucose transporter translocation and a pathway involving p38 MAP kinase leads to activation of the recruited glucose transporter at the membrane.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ARMONI M, 1995, ENDOCRINOLOGY, V136, P3292, DOI 10.1210/en.136.8.3292; Baldwin SA, 1995, BIOSCIENCE REP, V15, P419, DOI 10.1007/BF01204346; Barros LF, 1997, J PHYSIOL-LONDON, V504, P517, DOI 10.1111/j.1469-7793.1997.517bd.x; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; BILAN PJ, 1992, FEBS LETT, V298, P285, DOI 10.1016/0014-5793(92)80078-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Carel K, 1996, DIABETES, V45, P666; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HARRISON SA, 1991, J BIOL CHEM, V266, P19438; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JOOST HG, 1987, MOL PHARMACOL, V31, P279; KARNIELI E, 1993, ENDOCRINOLOGY, V133, P2943, DOI 10.1210/en.133.6.2943; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KLIP A, 1988, BIOCHEM J, V255, P1023, DOI 10.1042/bj2551023; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lee-Kwon W, 1998, BIOCHEMISTRY-US, V37, P15747, DOI 10.1021/bi9805947; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; Moriguchi T, 1996, Adv Pharmacol, V36, P121, DOI 10.1016/S1054-3589(08)60579-7; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shimizu Y, 1998, BIOCHEM J, V330, P397, DOI 10.1042/bj3300397; Somwar R, 1998, AM J PHYSIOL-ENDOC M, V275, pE618, DOI 10.1152/ajpendo.1998.275.4.E618; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; Taha C, 1997, AM J PHYSIOL-ENDOC M, V273, pE68, DOI 10.1152/ajpendo.1997.273.1.E68; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; VANNUCCI SJ, 1992, BIOCHEM J, V288, P325, DOI 10.1042/bj2880325; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829; Zierler K, 1998, DIABETOLOGIA, V41, P724, DOI 10.1007/s001250050975	55	262	276	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10071	10078		10.1074/jbc.274.15.10071	http://dx.doi.org/10.1074/jbc.274.15.10071			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187787	hybrid			2022-12-25	WOS:000079663500026
J	Thome, M; Martinon, F; Hofmann, K; Rubio, V; Steiner, V; Schneider, P; Mattmann, C; Tschopp, J				Thome, M; Martinon, F; Hofmann, K; Rubio, V; Steiner, V; Schneider, P; Mattmann, C; Tschopp, J			Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappa B transcription factor and c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK/SAPK ACTIVATION; CYTOCHROME-C; APOPTOSIS; DEATH; PROTEINS; RECEPTOR; ADAPTER; MYD88; SEQUENCE; CASPASES	We have previously reported on the death effector domain containing E8 gene product from equine herpesvirus-a, designated FLICE inhibitory protein (v-FLIP), and on its cellular homologue, c-FLIP, which inhibit the activation of caspase-8 by death receptors, Here we report on the structure and function of the E10 gene product of equine herpesvirus-a, designated v-CARMEN, and on its cellular homologue, c-CARMEN, which contain a caspase-recruiting domain (CARD) motif, c-CARMEN is highly homologous to the viral protein in its N-terminal CARD motif but differs in its C-terminal extension. v-CARMEN and c-CARMEN interact directly in a CARD-dependent manner yet reveal different binding specificities toward members of the tumor necrosis factor receptor-associated factor (TRAF) family. v-CARMEN binds to TRAF6 and weakly to TRAF3 and, upon overexpression, potently induces the c-Jun N-terminal kinase (JNK), p38, and nuclear factor (NF)-kappa B transcriptional pathways. c-CARMEN or truncated versions thereof do not appear to induce JNK and NF-kappa B activation by themselves, nor do they affect the JNK and NF-kappa B activating potential of v-CARMEN, Thus, in contrast to the cellular homologue, v-CARMEN may have additional properties in its unique C terminus that allow for an autonomous activator effect on NF-B kappa and JNK, Through activation of NF-kappa B, V-CARMEN may regulate the expression of the cellular and viral genes important for viral replication.	Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Swiss Canc Res Inst, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland	University of Lausanne	Tschopp, J (corresponding author), Univ Lausanne, Inst Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.		Martinon, Fabio/A-5575-2009; Hofmann, Kay/D-6714-2011; Thome, Margot/F-8167-2011	Martinon, Fabio/0000-0002-6969-822X; Hofmann, Kay/0000-0002-2289-9083; Thome, Margot/0000-0002-5656-2139; Schneider, Pascal/0000-0003-0677-9409				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BLAKESLEE JR, 1975, CAN J MICROBIOL, V21, P1940, DOI 10.1139/m75-281; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McFadden G, 1998, SEMIN CELL DEV BIOL, V9, P359, DOI 10.1006/scdb.1998.0245; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	89	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9962	9968		10.1074/jbc.274.15.9962	http://dx.doi.org/10.1074/jbc.274.15.9962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187771	hybrid, Green Published			2022-12-25	WOS:000079663500010
J	Hussein, AS; Chacon, MR; Smith, AM; Tosado-Acevedo, R; Selkirk, ME				Hussein, AS; Chacon, MR; Smith, AM; Tosado-Acevedo, R; Selkirk, ME			Cloning, expression, and properties of a nonneuronal secreted acetylcholinesterase from the parasitic nematode Nippostrongylus brasiliensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM CHOLINESTERASE; CAENORHABDITIS-ELEGANS; TORPEDO-CALIFORNICA; PERIPHERAL SITE; MOLECULAR-FORMS; DISULFIDE BONDS; CDNA SEQUENCE; GENE; PROTEIN; IDENTIFICATION	We have isolated a full-length cDNA encoding an acetylcholinesterase secreted by the nematode parasite Nippostrongylus brasiliensis. The predicted protein is truncated in comparison with acetylcholinesterases from other organisms such that the carboxyl terminus aligns closely to the end of the catalytic domain of the vertebrate enzymes. The residues in the catalytic triad are conserved, as are the six cysteines which form the three intramolecular disulfide bonds. Three of the fourteen aromatic residues which line the active site gorge in the Torpedo enzyme are substituted by nonaromatic residues, corresponding to Tyr-70 (Thr), Trp-279 (Asn), and Phe-288 (Met), High level expression was obtained via secretion from Pichia pastoris. The purified enzyme behaved as a monomeric hydrophilic species. Although of invertebrate origin and possessing the above substitutions in the active site gorge residues, the enzyme efficiently hydrolyzed acetylthiocholine and showed minimal activity against butyrylthiocholine, It displayed excess substrate inhibition with acetylthiocholine at concentrations over 2.5 mM and was highly sensitive to both active site and "peripheral" site inhibitors, Northern blot analysis indicated a progressive increase in mRNA for AChE B in parasites isolated from 6 days postinfection.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England	Imperial College London	Selkirk, ME (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AY, England.	m.selkirk@ic.ac.uk	Chacón, Matilde R./E-5574-2019	Chacón, Matilde R./0000-0003-1531-2165; Selkirk, Murray/0000-0002-6274-6014	FIC NIH HHS [T37-TW00046] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [T37TW000046] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; AUSTIN L, 1953, BIOCHEM J, V54, P695, DOI 10.1042/bj0540695; BLACKBURN CC, 1992, MOL BIOCHEM PARASIT, V53, P79, DOI 10.1016/0166-6851(92)90009-9; BRADBURY JE, 1980, EUR J PHARMACOL, V68, P417, DOI 10.1016/0014-2999(80)90416-1; BURT JS, 1975, EXP PARASITOL, V38, P75, DOI 10.1016/0014-4894(75)90039-9; COOKE HJ, 1994, AM J PHYSIOL, V266, pG167, DOI 10.1152/ajpgi.1994.266.2.G167; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Cousin X, 1996, FEBS LETT, V387, P196, DOI 10.1016/0014-5793(96)00447-4; CULOTTI JG, 1981, GENETICS, V97, P281; EDWARDS AJ, 1971, PARASITOLOGY, V62, P339, DOI 10.1017/S0031182000071572; EICHLER J, 1994, MOL PHARMACOL, V45, P335; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GNAGEY AL, 1987, J BIOL CHEM, V262, P13290; Grauso M, 1998, FEBS LETT, V424, P279, DOI 10.1016/S0014-5793(98)00191-4; GRIFFITHS G, 1994, PARASITOLOGY, V108, P579, DOI 10.1017/S0031182000077441; Grigg ME, 1997, MOL BIOCHEM PARASIT, V90, P513, DOI 10.1016/S0166-6851(97)00202-8; HALL LMC, 1986, EMBO J, V5, P2949, DOI 10.1002/j.1460-2075.1986.tb04591.x; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; JOHNSON CD, 1981, GENETICS, V97, P261; JOHNSON CD, 1988, NEURON, V1, P165, DOI 10.1016/0896-6273(88)90201-2; JOHNSON CD, 1983, J NEUROCHEM, V41, P30, DOI 10.1111/j.1471-4159.1983.tb11811.x; JOHNSON CD, 1985, J NEUROSCI, V5, P1984; JONES VE, 1972, IMMUNOLOGY, V22, P119; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; LEE D L, 1970, Tissue and Cell, V2, P225, DOI 10.1016/S0040-8166(70)80017-9; Lee DL, 1996, INT J PARASITOL, V26, P499, DOI 10.1016/0020-7519(96)00040-9; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P12945; LOCKRIDGE O, 1987, J BIOL CHEM, V262, P549; MACPHEEQUIGLEY K, 1986, J BIOL CHEM, V261, P3565; MACPHEEQUIGLEY K, 1987, FASEB J, V46, P2150; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCLAREN D J, 1974, International Journal for Parasitology, V4, P39, DOI 10.1016/0020-7519(74)90007-1; Morel N, 1997, BIOCHEM J, V328, P121, DOI 10.1042/bj3280121; OGILVIE B M, 1973, International Journal for Parasitology, V3, P589, DOI 10.1016/0020-7519(73)90083-0; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; PRITCHARD DI, 1994, EUR J BIOCHEM, V219, P317, DOI 10.1111/j.1432-1033.1994.tb19943.x; PRITCHARD DI, 1991, PARASITE IMMUNOL, V13, P187, DOI 10.1111/j.1365-3024.1991.tb00274.x; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; RHOADS M L, 1984, Tropical Veterinarian, V2, P3; RHOADS ML, 1981, J BIOL CHEM, V256, P9316; RIMELE TJ, 1981, J PHARMACOL EXP THER, V218, P426; Sanderson B E, 1972, Int J Parasitol, V2, P227, DOI 10.1016/0020-7519(72)90010-0; SANDERSON BE, 1972, Z PARASITENK, V40, P1, DOI 10.1007/BF00329610; SANDERSON BE, 1971, PARASITOLOGY, V62, P367, DOI 10.1017/S0031182000077519; SATOH Y, 1992, CELL TISSUE RES, V269, P213, DOI 10.1007/BF00319611; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SEGERBERG MA, 1993, J GEN PHYSIOL, V101, P271, DOI 10.1085/jgp.101.2.271; SOREQ H, 1994, P NATL ACAD SCI USA, V91, P7907, DOI 10.1073/pnas.91.17.7907; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4670; TWEEDIE S, 1993, MOL BIOCHEM PARASIT, V61, P149, DOI 10.1016/0166-6851(93)90168-W; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	56	67	70	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9312	9319		10.1074/jbc.274.14.9312	http://dx.doi.org/10.1074/jbc.274.14.9312			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092608	hybrid			2022-12-25	WOS:000079451800027
J	Brown, NR; Noble, MEM; Lawrie, AM; Morris, MC; Tunnah, P; Divita, G; Johnson, LN; Endicott, JA				Brown, NR; Noble, MEM; Lawrie, AM; Morris, MC; Tunnah, P; Divita, G; Johnson, LN; Endicott, JA			Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; CRYSTAL-STRUCTURE; CATALYTIC SUBUNIT; CELL-CYCLE; DUAL PHOSPHORYLATION; PEPTIDE SUBSTRATE; BUDDING YEAST; S-PHASE	We have prepared phosphorylated cyclin-dependent protein kinase 2 (CDK2) for crystallization using the CDK-activating kinase 1 (CAK1) from Saccharomyces cerevisiae and have grown crystals using microseeding techniques. Phosphorylation of monomeric human CDK2 by CAK1 is more efficient than phosphorylation of the binary CDK2-cyclin A complex. Phosphorylated CDK2 exhibits histone H1 kinase activity corresponding to approximately 0.3% of that observed with the fully activated phosphorylated CDK2-cyclin A complex. Fluorescence measurements have shown that Thr(160) phosphorylation increases the affinity of CDK2 for both histone substrate and ATP and decreases its affinity for ADP, By contrast, phosphorylation of CDK2 has a negligible effect on the affinity for cyclin A. The crystal structures of the ATP-bound forms of phosphorylated CDK2 and unphosphorylated CDK2 have been solved at 2.1-Angstrom resolution. The structures are similar, with the major difference occurring in the activation segment, which is disordered in phosphorylated CDK2, The greater mobility of the activation segment in phosphorylated CDK2 and the absence of spontaneous crystallization suggest that phosphorylated CDK2 may adopt several different mobile states. The majority of these states are likely to correspond to inactive conformations, but a small fraction of phosphorylated CDK2 may be in an active conformation and hence explain the basal activity observed.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; CNRS, Ctr Rech Biochem Macromol, F-34293 Montpellier, France	University of Oxford; University of Oxford; Centre National de la Recherche Scientifique (CNRS)	Endicott, JA (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.		MORRIS, May C/J-5940-2016; MORRIS, May/ABB-2629-2021	MORRIS, May C/0000-0001-8106-9728; MORRIS, May/0000-0001-8106-9728; Noble, Martin/0000-0002-3595-9807; Endicott, Jane/0000-0003-4868-0116				BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Heitz F, 1997, BIOCHEMISTRY-US, V36, P4995, DOI 10.1021/bi962349y; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KREK W, 1992, NEW BIOL, V4, P323; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LORCA T, 1992, J CELL SCI, V102, P55; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	57	191	201	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8746	8756		10.1074/jbc.274.13.8746	http://dx.doi.org/10.1074/jbc.274.13.8746			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085115	Green Published, hybrid			2022-12-25	WOS:000079451600057
J	Crass, T; Ames, RS; Sarau, HM; Tornetta, MA; Foley, JJ; Kohl, J; Klos, A; Bautsch, W				Crass, T; Ames, RS; Sarau, HM; Tornetta, MA; Foley, JJ; Kohl, J; Klos, A; Bautsch, W			Chimeric receptors of the human C3a receptor and C5a receptor (CD88)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; EXPRESSION CLONING; ANAPHYLATOXIN; CELLS; ANALOGS; REGION; SITE; C3A-ANAPHYLATOXIN; ACTIVATION; DISTINCT	Chimeras were generated between the human anaphylatoxin C3a and C5a receptors (C3aR and C5aR, respectively) to define the structural requirements for ligand binding and discrimination. Chimeric receptors were generated by systematically exchanging between the two receptors four receptor modules (the N terminus, transmembrane regions 1 to 4, the second extracellular loop, and transmembrane region 5 to the C terminus). The mutants were transiently expressed in HEK293 cells (with or without G alpha-16) and analyzed for cell surface expression, binding of C3a and C5a, and functional responsiveness (calcium mobilization) toward C3a, C5a, and a C3a as well as a C5a analogue peptide. The data indicate that in both anaphylatoxin receptors the transmembrane regions and the second extracellular loop act as a functional unit that is disrupted by any reciprocal exchange. N-terminal substitution confirmed the two-binding site model for the human C5aR, in which the receptor N terminus is required for high affinity binding of the native ligand but not a C5a analogue peptide, In contrast, the human C3a receptor did not require the original N terminus for high affinity binding of and activation by C3a, a result that was confirmed by N-terminal deletion mutants. This indicates a completely different binding mode of the anaphylatoxins to their corresponding receptors. The C5a analogue peptide, but not C5a, was an agonist of the C5aR. Replacement of the C3aR N terminus by the C5aR sequence, however, lead to the generation of a true hybrid C3a/C5a receptor, which bound and functionally responded to both ligands, C3a and C5a.	Hannover Med Sch, Inst Med Microbiol, D-30623 Hannover, Germany; SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA	Hannover Medical School; GlaxoSmithKline; GlaxoSmithKline	Bautsch, W (corresponding author), Hannover Med Sch, Inst Med Microbiol, Carl Neuberg Str 1, D-30623 Hannover, Germany.		Koehl, Joerg/C-8531-2011	Koehl, Joerg/0000-0003-1121-3178				AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Ames RS, 1997, IMMUNOPHARMACOLOGY, V38, P87, DOI 10.1016/S0162-3109(97)00079-9; BOULAY F, 1991, BIOCHEMISTRY-US, V30, P2993, DOI 10.1021/bi00226a002; BUHL AM, 1993, FEBS LETT, V323, P132, DOI 10.1016/0014-5793(93)81464-B; CHAZIN WJ, 1988, BIOCHEMISTRY-US, V27, P9139, DOI 10.1021/bi00426a011; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; EMBER JA, 1992, J IMMUNOL, V148, P3165; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HUBER R, 1980, H-S Z PHYSIOL CHEM, V361, P1389, DOI 10.1515/bchm2.1980.361.2.1389; KOHL J, 1993, COMPLEMENT HLTH DIS, P299; Lienenklaus S, 1998, J IMMUNOL, V161, P2089; MERY L, 1994, J BIOL CHEM, V269, P3457; MONK PN, 1995, J BIOL CHEM, V270, P16625, DOI 10.1074/jbc.270.28.16625; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; PEREZ HD, 1993, J BIOL CHEM, V268, P2292; Raffetseder U, 1996, EUR J BIOCHEM, V235, P82, DOI 10.1111/j.1432-1033.1996.00082.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Werfel T, 1996, J IMMUNOL, V157, P1729; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P172, DOI 10.1021/bi00427a025	28	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8367	8370		10.1074/jbc.274.13.8367	http://dx.doi.org/10.1074/jbc.274.13.8367			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085065	hybrid			2022-12-25	WOS:000079451600007
J	Doornbos, RP; Theelen, M; van der Hoeven, PCJ; van Blitterswijk, WJ; Verkleij, AJ; Henegouwen, PMPVE				Doornbos, RP; Theelen, M; van der Hoeven, PCJ; van Blitterswijk, WJ; Verkleij, AJ; Henegouwen, PMPVE			Protein kinase C zeta is a negative regulator of protein kinase B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GLYCOGEN-SYNTHASE KINASE-3; BETA-GAMMA-SUBUNITS; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; AKT PROTOONCOGENE; INDUCED APOPTOSIS	Protein kinase B (PKB), also known as Akt or RAC-PK, is a serine/threonine kinase that can be activated by growth factors via phosphatidylinositol 3-kinase. In this article we show that PKC zeta but not PKC alpha and PKC delta can co-immunoprecipitate PKB from CHO cell lysates. Association of PKB with PKC zeta was also found in COS-1 cells transiently expressing PKB and PKC zeta, and moreover we found that this association is mediated by the AH domain of PKB. Stimulation of COS-1 cells with platelet-derived growth factor (PDGF) resulted in a decrease in the PKB-PKC zeta interaction. The use of kinase-inactive mutants of both kinases revealed that dissociation of the complex depends upon PKB activity. Analysis of the activities of the interacting kinases showed that PDGF-induced activation of PKC zeta was not affected by co expression of PKB. However, both PDGF- and p110-CAAX-induced activation of PKB were significantly abolished in cells co-expressing PKC zeta. In contrast, co-expression of a kinase-dead PKC zeta mutant showed an increased induction of PKB activity upon PDGF treatment. Downstream signaling of PKB, such as the inhibition of glycogen synthase kinase-3, was also reduced by coexpression of PKC zeta. A clear inhibitory effect of PKC zeta was found on the constitutively active double PKB mutant (T308D/S473D). In summary, our results demonstrate that PKB interacts with PKC zeta in vivo and that PKC zeta acts as a negative regulator of PKB.	Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Netherlands Canc Inst, Dept Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Utrecht University; Netherlands Cancer Institute	Henegouwen, PMPVE (corresponding author), Univ Utrecht, Biomembrane Inst, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands.	bergenp@bio.uu.nl	van Bergen en Henegouwen, Paul/B-8870-2011	van Bergen en Henegouwen, Paul/0000-0001-6050-9042				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P244; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHOU MM, 1998, CURR BIOL, V6, P1271; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; WAYS DK, 1992, J BIOL CHEM, V267, P4799; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	42	121	124	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8589	8596		10.1074/jbc.274.13.8589	http://dx.doi.org/10.1074/jbc.274.13.8589			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085094	hybrid			2022-12-25	WOS:000079451600036
J	Matkovic-Calogovic, D; Loregian, A; D'Acunto, MR; Battistutta, R; Tossi, A; Palu, G; Zanotti, G				Matkovic-Calogovic, D; Loregian, A; D'Acunto, MR; Battistutta, R; Tossi, A; Palu, G; Zanotti, G			Crystal structure of the B subunit of Escherichia coli heat-labile enterotoxin carrying peptides with anti-herpes simplex virus type 1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; CHOLERA-TOXIN; RIBONUCLEOTIDE REDUCTASE; CARBOXY-TERMINUS; FUSION PROTEINS; C-TERMINUS; A-SUBUNIT; INHIBITION; BINDING; VIBRIO	Two chimeric proteins, consisting of the B subunit of Escherichia coli heat-labile enterotoxin with different peptides fused to the COOH-terminal ends, have been crystallized and their three-dimensional structure determined. The two extensions correspond to la) a nonapeptide representing the COOH-terminal sequence of the small subunit of herpes simplex virus type 1 ribonucleotide reductase and (b) a 27-amino acid long peptide, corresponding to the COOH-terminal end of the catalytic subunit (POL) of DNA polymerase from the same virus. Both proteins crystallize in the P4(1)2(1)2 space group with one pentameric molecule per asymmetric unit, corresponding to a solvent content of about 75%. The overall conformation of the B subunit pentamer in the two chimeric proteins, which consists of five identical polypeptide chains, is very similar to that in the native AB complex and conforms strictly to 5-fold symmetry. On the contrary, the peptide extensions are essentially disordered: in the case of the nonapeptide, only 5 and 6 amino acids were, respectively, positioned in two monomers, while in the other three only 2 residues are ordered. The extension is fully confined to the surface of the pentamer opposite to the face that interacts with the membrane and consequently it does not interfere with the ability of the B subunit to interact with membrane receptors, Moreover, the conformational flexibility of the two peptide extensions could be correlated to their propensity for proteolytic processing and consequent release of a biologically active molecule into cultured cells.	Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Padua, Biopolymer Res Ctr, I-35131 Padua, Italy; Univ Padua, Inst Microbiol, I-35121 Padua, Italy; Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy	University of Padua; University of Padua; University of Padua; University of Trieste	Matkovic-Calogovic, D (corresponding author), Univ Padua, Dept Organ Chem, Via Marzolo 1, I-35131 Padua, Italy.		Tossi, Alessandro/U-2474-2017; Tossi, Alessandro/ABC-9061-2020	Tossi, Alessandro/0000-0001-9087-5764; LOREGIAN, ARIANNA/0000-0002-8900-861X; Zanotti, Giuseppe/0000-0002-0945-6501				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; FERGUSSON LF, 1990, BACTERIAL PROTEIN TO, P519; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HIRST TR, 1991, SOURCE BOOK BACTERIA, P75; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Loregian A, 1996, PROTEIN EXPRES PURIF, V8, P381, DOI 10.1006/prep.1996.0114; Loregian A, 1997, MINERVA BIOTECNOL, V9, P61; LOREGIAN A, 1995, BIOCHEM SOC T, V23, pS61, DOI 10.1042/bst023061s; MARCELLO A, 1994, P NATL ACAD SCI USA, V91, P8994, DOI 10.1073/pnas.91.19.8994; MARCELLO A, 1994, FEMS MICROBIOL LETT, V117, P47, DOI 10.1016/0378-1097(94)90169-4; MARSDEN HS, 1994, J GEN VIROL, V75, P3127, DOI 10.1099/0022-1317-75-11-3127; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1995, NAT STRUCT BIOL, V2, P269, DOI 10.1038/nsb0495-269; Merritt EA, 1997, STRUCTURE, V5, P1485, DOI 10.1016/S0969-2126(97)00298-0; MERRITT EA, 1994, FEBS LETT, V337, P88, DOI 10.1016/0014-5793(94)80635-7; MERRITT EA, 1994, MOL MICROBIOL, V13, P745, DOI 10.1111/j.1365-2958.1994.tb00467.x; NASHAR TO, 1993, VACCINE, V11, P235, DOI 10.1016/0264-410X(93)90023-Q; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLSVIK O, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P5; PARADIS H, 1988, J BIOL CHEM, V263, P16045; PIZZA M, 1994, J EXP MED, V180, P2147, DOI 10.1084/jem.180.6.2147; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; STOW ND, 1993, NUCLEIC ACIDS RES, V21, P87, DOI 10.1093/nar/21.1.87; TAKEDA Y, 1983, INFECT IMMUN, V41, P50, DOI 10.1128/IAI.41.1.50-53.1983; VandenAkker F, 1996, PROTEIN SCI, V5, P1184; VANDENAKKER F, 1995, BIOCHEMISTRY-US, V34, P10996, DOI 10.1021/bi00035a005; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	41	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8764	8769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085117				2022-12-25	WOS:000079451600059
J	Roy, CN; Penny, DM; Feder, JN; Enns, CA				Roy, CN; Penny, DM; Feder, JN; Enns, CA			The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN HEPATOMA-CELLS; HISTOCOMPATIBILITY ANTIGENS; INTERNALIZATION MOTIF; SURFACE EXPRESSION; INDEPENDENT UPTAKE; INSULIN-RECEPTORS; HLA-H; RELEASE; COMPLEX	HFE is the protein product of the gene mutated in the autosomal recessive disease hereditary hemochromatosis (Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R. J., Ellis, M. C., Fullan, A., Hinton, L. M., Jones, N. L., Kimmel, B. E., Kronmal, G. S., Lauer, P., Lee, V. K., Loeb, D. B., Mapa, F. A., McClelland, E., Meyer, N. C., Mintier, G. A., Moeller, N., Moore, T., Morikang, E., Prasss, C. E., Quintana, L., Starnes, S. M., Schatzman, R. C., Brunke, K. J., Drayna, D. T., Risch, N. J., Bacon, B. R., and Wolff, R. R, (1996) Nat. Genet. 13, 399-408). At the cell surface, HFE complexes with transferrin receptor (TfR), increasing the dissociation constant of transferrin (Tf) for its receptor 10-fold (Gross, C. N., Irrinki, A., Feder, J. N., and Enns, C. A. (1998) J. Biol. Chem. 273, 22068-22074; Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebron, J. A., Watson, N., Tsuchihashi, Z., Sigal, E., Bjorkman, P. J., and Schatzman, R. C. (1998) Proc. Natl. Acad. Sci. U S A 95, 1472-1477). HFE does not remain at the cell surface, but traffics with TfR to Tf-positive internal compartments (Gross ct at, 1998). Using a HeLa cell line in which the expression of HFE is controlled by tetracycline, we show that the expression of HFE reduces Fe-55 uptake from Tf by 33% but does not affect the endocytic or exocytic rates of TfR cycling. Therefore, HFE appears to reduce cellular acquisition of iron from Tf within endocytic compartments. HFE specifically reduces iron uptake from Tf, as non-Tf-mediated iron uptake from Fe-nitrilotriacetic acid is not altered. These results explain the decreased ferritin levels seen in our HeLa cell system and demonstrate the specific control of HFE over the Tf-mediated pathway of iron uptake. These results also have implications for the understanding of cellular iron homeostasis in organs such as the liver, pancreas, heart, and spleen that are iron loaded in hereditary hemochromatotic individuals lacking functional HFE.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Progenitor Inc, Menlo Park, CA 94025 USA	Oregon Health & Science University	Enns, CA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, L215,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL00781] Funding Source: Medline; NIDDK NIH HHS [DK 40608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALI PK, 1991, BIOCHEMISTRY-US, V30, P9947, DOI 10.1021/bi00105a019; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BALI PK, 1992, BIOCHEMISTRY-US, V31, P3963, DOI 10.1021/bi00131a011; DeSilva DM, 1996, PHYSIOL REV, V76, P31, DOI 10.1152/physrev.1996.76.1.31; DUE C, 1986, P NATL ACAD SCI USA, V83, P6007, DOI 10.1073/pnas.83.16.6007; EGAN TJ, 1993, BIOCHEMISTRY-US, V32, P8162, DOI 10.1021/bi00083a016; Enns C.A., 1996, BIOMEMBRANE, V4, P255, DOI [10.1016/S1874-5342(96)80012-2, DOI 10.1016/S1874-5342(96)80012-2]; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; FEHLMANN M, 1985, P NATL ACAD SCI USA, V82, P8634, DOI 10.1073/pnas.82.24.8634; Ferm M, 1996, IMMUNOL INVEST, V25, P37, DOI 10.3109/08820139609059289; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; INMAN RS, 1993, J BIOL CHEM, V268, P8521; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lok CN, 1998, BIOL SIGNAL RECEPT, V7, P157; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P2534, DOI 10.1073/pnas.94.6.2534; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PENHALLOW RC, 1986, J CELL PHYSIOL, V128, P251, DOI 10.1002/jcp.1041280217; PHILLIPS ML, 1986, P NATL ACAD SCI USA, V83, P3474, DOI 10.1073/pnas.83.10.3474; PLANASBOHNE F, 1988, INT J RADIAT BIOL, V53, P489, DOI 10.1080/09553008814552611; Ponka P, 1998, SEMIN HEMATOL, V35, P35; SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SHAH D, 1994, J DRUG TARGET, V2, P93, DOI 10.3109/10611869409015897; SIPE DM, 1991, J BIOL CHEM, V266, P8002; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; STURROCK A, 1990, J BIOL CHEM, V265, P3139; Su MA, 1998, BLOOD, V92, P2157, DOI 10.1182/blood.V92.6.2157.418k16_2157_2163; Trinder D, 1996, HEPATOLOGY, V23, P1512, DOI 10.1002/hep.510230631; VERLAND S, 1989, J IMMUNOL, V143, P945; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; YOUNG SP, 1984, BIOCHEM J, V219, P505, DOI 10.1042/bj2190505; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	43	184	188	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9022	9028		10.1074/jbc.274.13.9022	http://dx.doi.org/10.1074/jbc.274.13.9022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085150	hybrid			2022-12-25	WOS:000079451600092
J	Xin, XH; Yang, SY; Kowalski, J; Gerritsen, ME				Xin, XH; Yang, SY; Kowalski, J; Gerritsen, ME			Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; ENDOTHELIAL GROWTH-FACTOR; PPAR-GAMMA; CANCER; ALPHA; DIFFERENTIATION; CELLS; REGULATOR; BIOLOGY; J(2)	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that functions as a transcription factor to mediate ligand-dependent transcriptional regulation. Activation of PPAR gamma by the naturally occurring ligand, 15-deoxy-Delta 12,14-prostaglandin J(2) (15d-PGJ(2)), or members of a new class of oral antidiabetic agents, e.g. BRL49653 and ciglitizone, has been linked to adipocyte differentiation, regulation of glucose homeostasis, inhibition of macrophage and monocyte activation, and inhibition of tumor cell proliferation. Here we report that human umbilical vein endothelial cells (HUVEC) express PPAR gamma mRNA and protein. Activation of PPAR gamma by the specific ligands 15d-PGJ(2), BRL49653, or ciglitizone, dose dependently suppresses HUVEC differentiation into tube-like structures in three-dimensional collagen gels. In contrast, specific PPAR alpha and -beta ligands do not affect tube formation although mRNA for these receptors are expressed in HUVEC. PPAR gamma ligands also inhibit the proliferative response of HUVEC to exogenous growth factors. Treatment of HUVEC with 15d-PGJ(2) also reduced mRNA levels of vascular endothelial cell growth factor receptors 1 (Flt-1) and 2 (Flk/KDR) and urokinase plasminogen activator and increased plasminogen activator inhibitor-1 (PAI-1) mRNA. Finally, administration of 15d-PGJ(2) inhibited vascular endothelial cell growth factor-induced angiogenesis in the rat cornea. These observations demonstrate that PPAR gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo, and suggest that PPAR gamma may be an important molecular target for the development of small-molecule inhibitors of angiogenesis.	Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Gerritsen, ME (corresponding author), Genentech Inc, Dept Cardiovasc Res, 1 DNA Way, S San Francisco, CA 94080 USA.	meg@gene.com						Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; EISTNER E, 1998, P NATL ACAD SCI USA, V95, P8806; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713; FOLKMAN J, 1986, CANCER RES, V46, P467; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ilan N, 1998, J CELL SCI, V111, P3621; Inoue I, 1998, BIOCHEM BIOPH RES CO, V246, P370, DOI 10.1006/bbrc.1998.8622; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Johnson W, 1997, J MATER PROCESS TECH, V63, P1, DOI 10.1016/S0924-0136(96)02594-0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kubota T, 1998, CANCER RES, V58, P3344; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237	32	459	502	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9116	9121		10.1074/jbc.274.13.9116	http://dx.doi.org/10.1074/jbc.274.13.9116			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085162	hybrid			2022-12-25	WOS:000079451600104
J	Bi, L; Okabe, I; Bernard, DJ; Wynshaw-Boris, A; Nussbaum, RL				Bi, L; Okabe, I; Bernard, DJ; Wynshaw-Boris, A; Nussbaum, RL			Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110 alpha subunit of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; P85-ALPHA GENE; INHIBITION; GROWTH; 3,4,5-TRISPHOSPHATE; WORTMANNIN; PATHWAYS; KINASES; CROSS	Phosphatidylinositol 3,4,5-trisphosphate is a phospholipid signaling molecule involved in many cellular functions including growth factor receptor signaling, cytoskeletal organization, chemotaxis, apoptosis, and protein trafficking. Phosphorylation at the 3 position of the inositol ring is catalyzed by many different 3-kinases (classified as types I-A, I-B, II, and III), but the physiological roles played by each of the different 3-kinase isozymes during embryonic development and in homeostasis in animals is incompletely understood, Mammalian type I-A kinase isozymes are heterodimers that are active at 37 degrees C when the catalytic 110-kDa subunit interacts through an amino-terminal binding domain with a regulatory 85- or 55-kDa subunit, Using gene targeting in embryonic stem cells, we deleted this binding domain in the gene encoding the alpha isoform of the 110-kDa catalytic subunit (Pik3ca) of the alpha isozyme of the type I-A kinases, leading to loss of expression of the p110 catalytic subunit. We show that Pik3ca(del/del) embryos are developmentally delayed at embryonic day (E) 9.5 and die between E9.5 and E10.5. E9.5 Pik3ca(del/del) embryos have a profound proliferative defect but no increase in apoptosis, A proliferative defect is supported by the observation that fibroblasts from Pik3ca(del/del) embryos fail to replicate in Dulbecco's modified Eagle's medium and fetal calf serum, even with supplemental growth factors.	NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Nussbaum, RL (corresponding author), NHGRI, Genet Dis Res Branch, NIH, 49 Convent Dr MSC 4472, Bethesda, MD 20892 USA.							ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Batty IH, 1997, BIOCHEM SOC T, V25, P1132, DOI 10.1042/bst0251132; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1996, GENOMICS, V37, P113, DOI 10.1006/geno.1996.0527; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LACY ER, 1991, GASTROENTEROLOGY, V100, P259, DOI 10.1016/0016-5085(91)90610-W; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Nave BT, 1996, BIOCHEM J, V318, P203, DOI 10.1042/bj3180203; OAKEY RJ, 1995, GENETICS, V141, P667; Oikawa T, 1996, EUR J PHARMACOL, V318, P93, DOI 10.1016/S0014-2999(96)00864-3; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUGH R, 1993, MOUSE; Sambrook J., 2002, MOL CLONING LAB MANU; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; VANHAESEBROECK B, 1997, TRENDS BIOCHEM SCI, V22, P233; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	36	361	407	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10963	10968		10.1074/jbc.274.16.10963	http://dx.doi.org/10.1074/jbc.274.16.10963			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196176	hybrid			2022-12-25	WOS:000079751900044
J	Li, BL; Li, XL; Duan, ZJ; Lee, O; Lin, S; Ma, ZM; Chang, CCY; Yang, XY; Park, JP; Mohandas, TK; Noll, W; Chan, L; Chang, TY				Li, BL; Li, XL; Duan, ZJ; Lee, O; Lin, S; Ma, ZM; Chang, CCY; Yang, XY; Park, JP; Mohandas, TK; Noll, W; Chan, L; Chang, TY			Human acyl-CoA : cholesterol acyltransferase-1 (ACAT-1) gene organization and evidence that the 4.3-kilobase ACAT-1 mRNA is produced from two different chromosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MESSENGER-RNA LEVELS; C-MYB PROTOONCOGENE; COENZYME-A; MOLECULAR-CLONING; INTERMOLECULAR RECOMBINATION; CODING SEQUENCES; MAMMALIAN-CELLS; HUMAN MONOCYTES; POINT MUTATION	Acyl-CoA:cholesterol acyltransferase (ACAT) plays important roles in cellular cholesterol homeostasis. Four human ACAT-1 mRNAs (7.0, 4.3, 3.6, and 2.8 kilobases (kb)) share the same short 5'-untranslated region (exon 1) and coding sequence (exons 2-15). The 4.3-kb mRNA contains an additional 5'-untranslated region (1289 nucleotides in length; exons X-a and X-b) immediately upstream from the exon 1 sequence. One ACAT-1 genomic DNA insert covers exons 1-16 and a promoter (the P1 promoter). A separate insert covers exon X-a (1277 base pairs) and a different promoter (the P7 promoter). Gene mapping shows that exons 1-16 and the P1 promoter sequences are located in chromosome 1, while exon X-a and the P7 promoter sequence are located in chromosome 7. RNase protection assays demonstrate three different protected fragments, corresponding to the 4.3 kb mRNA and the two other mRNAs transcribed from the two promoters. These results are consistent with the interpretation that the 4.3-kb mRNA is produced from two different chromosomes, by a novel RNA recombination mechanism involving trans-splicing of two discontinuous precursor RNAs.	Shanghai Inst Biochem, Shanghai, Peoples R China; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03756 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Dartmouth College; Baylor College of Medicine; Baylor College of Medicine; Dartmouth College	Chang, TY (corresponding author), Shanghai Inst Biochem, Shanghai, Peoples R China.			Chang, Ta-Yuan/0000-0002-3249-0468	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036709, R01HL060306, R37HL036709, R37HL016512, R01HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36709, HL 60306, HL 16512] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BASU A, 1993, J BIOL CHEM, V268, P4188; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG CCY, 1994, SOMAT CELL MOLEC GEN, V20, P71, DOI 10.1007/BF02257489; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CHENG WL, 1995, AM J PHYSIOL-ENDOC M, V269, pE642, DOI 10.1152/ajpendo.1995.269.4.E642; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DEANDRADE M, 1995, AM J HUM GENET, V56, P1379; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DODGSON JB, 1983, J BIOL CHEM, V258, P4623; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HASAN MT, 1991, SOMAT CELL MOLEC GEN, V17, P513, DOI 10.1007/BF01233175; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUANG DH, 1988, J BIOL CHEM, V263, P12596; KING CR, 1983, CELL, V32, P707, DOI 10.1016/0092-8674(83)90056-9; KRAUSE BR, 1995, ACAT INHIBITORS PHYS, P173; Lee O, 1998, J LIPID RES, V39, P1722; Matsuda H, 1996, BBA-LIPID LIPID MET, V1301, P76, DOI 10.1016/0005-2760(96)00020-3; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Miyazaki A, 1998, ARTERIOSCL THROM VAS, V18, P1568, DOI 10.1161/01.ATV.18.10.1568; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; PAPE ME, 1995, J LIPID RES, V36, P823; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Sambrook J., 2002, MOL CLONING LAB MANU; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SUCHI M, 1995, GENOMICS, V29, P98, DOI 10.1006/geno.1995.1219; SUCKLING KE, 1985, J LIPID RES, V26, P647; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; SUREAU A, 1991, CR ACAD SCI III-VIE, V312, P323; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TROUTT AB, 1992, P NATL ACAD SCI USA, V89, P9823, DOI 10.1073/pnas.89.20.9823; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; VELLARD M, 1991, ONCOGENE, V6, P505; Wang HX, 1996, ARTERIOSCL THROM VAS, V16, P809, DOI 10.1161/01.ATV.16.6.809; WILSON MD, 1994, J LIPID RES, V35, P943; WOOD KV, 1991, BIOLUMINESCENCE CHEM; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	57	102	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11060	11071		10.1074/jbc.274.16.11060	http://dx.doi.org/10.1074/jbc.274.16.11060			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196189	hybrid			2022-12-25	WOS:000079751900057
J	Li, J; Lin, ML; Wiepz, GJ; Guadarrama, AG; Bertics, PJ				Li, J; Lin, ML; Wiepz, GJ; Guadarrama, AG; Bertics, PJ			Integrin-mediated migration of murine B82L fibroblasts is dependent on the expression of an intact epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; FOCAL ADHESION KINASE; UROKINASE PLASMINOGEN-ACTIVATOR; CARCINOMA-CELLS A-431; EGF RECEPTOR; SELF-PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CARBOXYL TERMINUS; PROTEIN-KINASE; FACTOR-ALPHA	To evaluate the mechanisms by which epidermal growth factor (EGF) regulates actin-based cellular processes such as cell migration, we first examined the effects of EGF on cell adhesion, which is essential for cell migration. In mouse B82L fibroblasts transfected with the full-length EGF receptor, EGF promotes cell Pounding and attenuates cell spreading on fibronectin, laminin, and vitronectin, and thus appears to reduce the strength of cell adhesion. Moreover, EGF synergizes with multiple extracellular matrix (ECM) components in the promotion of integrin-mediated cell migration of several different cell types, including fibroblasts and various carcinoma and osteosarcoma cell lilies. Interestingly, co-presentation (co-positioning) of EGF with laminin or fibronectin is essential for EGF-stimulated migration. When EGF is mixed with the cells instead of the ECM components, it has little effect on cell migration. These results suggest that co-presentation of EGF with ECM components can enhance the polarization events required for directional cell movement. To identify the EGF receptor elements critical for the EGF stimulation of cell migration, B82L fibroblasts were transfected with either mutated or wild-type EGF receptors, Surprisingly, we found that B82L-Parental cells that lack the EGF receptor are not able to migrate to fibronectin, even though they can adhere to fibronectin. However, the introduction of wild-type EGF receptors into these fibroblasts enables them to migrate toward fibronectin even in the absence of EGF, The requirement of the EGF receptor for cell migration does not appear to result from the secretion of EGF or TGF-alpha by the cells transfected with the EGF receptor. Furthermore, cells expressing EGF receptors that are kinase-inactive, or C-terminally truncated, exhibit little migration toward fibronectin, indicating that an intact EGF receptor kinase is required for fibronectin-induced cell migration. In addition, neutralizing anti-EGF receptor antibodies attenuate cell migration in the presence of EGF, and inhibit migration to fibronectin or laminin alone. These results further suggest that the EGF receptor is downstream of integrin activation in the signal transduction pathways leading to fibroblast migration.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Bertics, PJ (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07259] Funding Source: Medline; NIGMS NIH HHS [R01 GM53271] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BERTICS PJ, 1985, J CELL BIOCHEM, V29, P195, DOI 10.1002/jcb.240290304; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CHANG CP, 1991, J BIOL CHEM, V266, P23467; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHINKERS M, 1981, J CELL BIOL, V88, P422, DOI 10.1083/jcb.88.2.422; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEDHAR S, 1996, CURR OPIN CELL BIOL, V8, P667; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DUBAND JL, 1991, J CELL SCI, V98, P517; DUNLEVY JR, 1995, J CELL SCI, V108, P311; DUNLEVY JR, 1993, J CELL SCI, V105, P489; ENHENEGOUWEN PMPV, 1992, EXP CELL RES, V199, P90, DOI 10.1016/0014-4827(92)90465-K; EPPSTEIN DA, 1989, J CELL PHYSIOL, V141, P420, DOI 10.1002/jcp.1041410224; FUJII K, 1995, EXP CELL RES, V216, P261, DOI 10.1006/excr.1995.1032; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRONOWSKI AM, 1993, ENDOCRINOLOGY, V133, P2838, DOI 10.1210/en.133.6.2838; GRONOWSKI AM, 1995, ENDOCRINOLOGY, V136, P2198, DOI 10.1210/en.136.5.2198; HAAFUSA H, 1977, COMPREHENSIVE VIROL, V10, P401; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEELY PJ, 1995, J CELL SCI, V108, P595; KESSLER TL, 1991, SEMIN THROMB HEMOST, V17, P217, DOI 10.1055/s-2007-1002612; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KUIJPERS TW, 1993, J EXP MED, V178, P279, DOI 10.1084/jem.178.1.279; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LIN ML, 1995, J CELL PHYSIOL, V164, P593, DOI 10.1002/jcp.1041640318; MATTHAY MA, 1993, J CELL SCI, V106, P869; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; NIEDBALA MJ, 1990, CANCER COMMUN, V2, P317; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RIJKEN PJ, 1991, AVIAT SPACE ENVIR MD, V62, P32; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROY LM, 1989, J CELL PHYSIOL, V140, P295, DOI 10.1002/jcp.1041400215; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SIMONSEN CC, 1983, P NATL ACAD SCI USA, V80, P2485; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANBELZEN N, 1990, J CELL PHYSIOL, V145, P365, DOI 10.1002/jcp.1041450223; VUORI K, 1994, SCIENCE, V266, P1575; WALTON GM, 1990, J BIOL CHEM, V265, P1750; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WESTERMARK K, 1991, ENDOCRINOLOGY, V129, P2180, DOI 10.1210/endo-129-4-2180; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; Xie H, 1998, J CELL SCI, V111, P615; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YOSHIDA K, 1990, JPN J CANCER RES, V81, P793, DOI 10.1111/j.1349-7006.1990.tb02647.x	80	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11209	11219		10.1074/jbc.274.16.11209	http://dx.doi.org/10.1074/jbc.274.16.11209			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196208	hybrid			2022-12-25	WOS:000079751900076
J	Strausak, D; La Fontaine, S; Hill, J; Firth, SD; Lockhart, PJ; Mercer, JFB				Strausak, D; La Fontaine, S; Hill, J; Firth, SD; Lockhart, PJ; Mercer, JFB			The role of GMXCXXC metal binding sites in the copper-induced redistribution of the Menkes protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; TRANS-GOLGI NETWORK; LOW-COPY-NUMBER; DISEASE PROTEIN; FUNCTIONAL EXPRESSION; CANDIDATE GENE; INTRACELLULAR-LOCALIZATION; TRANSPORTING ATPASE; TRAFFICKING; ENCODES	The Menkes protein (MNK or ATP7A) is a transmembrane, copper-transporting CPX-type ATPase, a subgroup of the extensive family of P-type ATPases, A striking feature of the protein is the presence of six metal binding sites (MBSs) in the N-terminal region with the highly conserved consensus sequence GMXCXXC, MNK is normally located in the trans-Golgi network (TGN) but has been shown to relocalize to the plasma membrane when cells are cultured in media containing high concentrations of copper, The experiments described in this report test the hypothesis that the six MBSs are required for this copper-induced trafficking of MNR, Site-directed mutagenesis was used to convert both cysteine residues in the conserved MBS motifs to serines, Mutation of MBS 1, MBS 6, and MBSs 1-3 resulted in a molecule that appeared to relocalize normally with copper, but when MBSs 4-6 or MBSs 1-6 were mutated, MNK remained in the TGN, even when cells were exposed to 300 mu M copper, Furthermore, the ability of the MNK variants to relocalize corresponded well with their ability to confer copper resistance, To further define the critical motifs, MBS 5 and MBS 6 were mutated, and these changes abolished the response to copper. The region from amino acid 8 to amino acid 485 was deleted, resulting in mutant MNK that lacked 478 amino acids from the N-terminal region, including the first four MBSs. This truncated molecule responded normally to copper. Moreover, when either one of the remaining MBS 5 and MBS 6 was mutated to GMXSXXS, the resulting proteins were localized to the TGN in low copper and relocalized in response to elevated copper. These experiments demonstrated that the deleted N-terminal region from amino acid 8 to amino acid 485 was not essential for copper-induced trafficking and that one MBS close to the membrane channel of MNK was necessary and sufficient for the copper-induced redistribution.	Deakin Univ, Ctr Cellular & Mol Biol, Sch Biol & Chem Sci, Burwood, Vic 3125, Australia; Royal Childrens Hosp, Murdoch Inst Res Birth Defects, Parkville, Vic 3052, Australia	Deakin University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Mercer, JFB (corresponding author), Deakin Univ, Ctr Cellular & Mol Biol, Sch Biol & Chem Sci, Burwood Campus,221 Burwood Highway, Burwood, Vic 3125, Australia.		Lockhart, Paul J/E-7753-2011; Mercer, Julian/R-8583-2019; La Fontaine, Sharon/G-7113-2018	Lockhart, Paul J/0000-0003-2531-8413; La Fontaine, Sharon/0000-0002-9948-074X				BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CAMAKARIS J, 1995, HUM MOL GENET, V4, P2117, DOI 10.1093/hmg/4.11.2117; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; Francis MJ, 1998, HUM MOL GENET, V7, P1245, DOI 10.1093/hmg/7.8.1245; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; JOHNSTONE A, 1987, IMMUNOCYTOCHEMISTRY, P50; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; La Fontaine S, 1998, HUM MOL GENET, V7, P1293, DOI 10.1093/hmg/7.8.1293; La Fontaine S, 1998, PLASMID, V39, P245, DOI 10.1006/plas.1997.1334; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Lutsenko S, 1998, P NATL ACAD SCI USA, V95, P6004, DOI 10.1073/pnas.95.11.6004; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 1998, HUM MOL GENET, V7, P2063, DOI 10.1093/hmg/7.13.2063; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Tumer Z, 1997, AM J HUM GENET, V60, P63; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yang XL, 1997, BIOCHEM J, V326, P897, DOI 10.1042/bj3260897	32	138	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11170	11177		10.1074/jbc.274.16.11170	http://dx.doi.org/10.1074/jbc.274.16.11170			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196202	hybrid, Green Published			2022-12-25	WOS:000079751900070
J	Weisburg, JH; Roepe, PD; Dzekunov, S; Scheinberg, DA				Weisburg, JH; Roepe, PD; Dzekunov, S; Scheinberg, DA			Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; EXPRESSING DIFFERENT LEVELS; CYTOSOLIC PH; CHLORIDE CHANNELS; ALTERED PH(I); MDR PROTEIN; TUMOR-CELLS; GLYCOPROTEIN; TRANSPORTER; ATP	In previous work (Weisburg, J. H., Curcio, M., Caron, P. C., Raghi, G., Meehetner, E. B., Roepe, P. D., and Scheinberg, D, A. (1996) J. Exp. Med. 183, 2699-2704), we showed that multidrug resistance (MDR) cells created by continuous selection with the vinca alkaloid vincristine (HL60 RV+) or by retroviral infection (K562/human MDR 1 cells) exhibited significant resistance to complement-mediated cytotoxicity (CMC). This resistance was due to the presence of overexpressed P-glycoprotein (P-GP). In this paper, we probe the molecular mechanism of this phenomenon. We test whether the significant elevated intracellular pH (pH(i)) that accompanies P-GP overexpression is sufficient to confer resistance to CMC and whether this resistance is related to effects on complement function in the cell membrane. Control HL60 cells not expressing P-GP, but comparably elevated in cytosolic pH(i) by two independent methods (CO2 "conditioning" or isotonic Cl- substitution), are tested for CMC using two different antibody-antigen systems (human IgG and murine IgM; protein and carbohydrate) and two complement sources (rabbit and human). Elevation of pH, by either of these methods or by expression of P-GP confers resistance to CMC, Resistance is not observed when the alkalinization mediated by reverse Cl-/HCO3- exchange upon Cl- substitution is blocked by treatment with dihydro-4,4'-diisothiocyanostilbene-2,2'-disulfonate. Continuous photometric monitoring of 2',7'-bis(carboxyethyl)-5,6-carboxyfluorescein (BCECF), to assess changes in pH(i) or efflux of the probe through MAC pores, in single cells or cell populations, respectively, verifies changes in pH(i) upon CO2 conditioning and Cl- substitution and release of BCECF upon formation of MAC pores. Antibody binding and internalization kinetics are similar in both the parental and resistant cell lines as measured by radioimmunoassay, but flow cytometric data showed that net complement deposition in the cell membrane is both delayed and reduced in magnitude in the MDR cells and in the cells with increased pH(i). This interpretation is supported by comparison of BCECF release data for the different cells, Dual isotopic labeling of key complement components shows no significant change in molecular stoichiometry of the MACs formed at different pH(i). The results are relevant to understanding clinical implications of MDR, the physiology of P-GP, and the biochemistry of the complement cascade and further suggest that the "drug pump" model of P-GP action cannot account for all of its effects.	Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA; Georgetown Univ, Dept Chem, Washington, DC 20057 USA; Georgetown Univ, Lombardi Canc Ctr, Program Tumor Biol, Washington, DC 20057 USA	Memorial Sloan Kettering Cancer Center; Georgetown University; Georgetown University	Scheinberg, DA (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Therapeut, 1275 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA055349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054516] Funding Source: NIH RePORTER; NCI NIH HHS [CA55349] Funding Source: Medline; NIGMS NIH HHS [GM54516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; ANDREWS NW, 1990, CELL, V61, P1277, DOI 10.1016/0092-8674(90)90692-8; ASSHAR SS, 1984, PHARMACOL REV, V36, P223; CARON PC, 1992, CANCER RES, V52, P6761; ESSER AF, 1982, BIOL MEMBR, V4, P277; ESSER AF, 1979, P NATL ACAD SCI USA, V76, P1410, DOI 10.1073/pnas.76.3.1410; GILL DR, 1992, CELL, V71, P223; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; Hoffman MM, 1997, BIOCHEMISTRY-US, V36, P11153, DOI 10.1021/bi970530g; Hoffman MM, 1996, J GEN PHYSIOL, V108, P295, DOI 10.1085/jgp.108.4.295; HUANG NN, 1992, BIOCHEM BIOPH RES CO, V182, P836, DOI 10.1016/0006-291X(92)91808-4; JACKSON MB, 1981, P NATL ACAD SCI-BIOL, V78, P6421, DOI 10.1073/pnas.78.10.6421; KEIZER HG, 1989, J NATL CANCER I, V81, P706, DOI 10.1093/jnci/81.9.706; LAW SKA, 1988, COMPLEMENT, P1; LUZ JG, 1994, BIOCHEMISTRY-US, V33, P7239, DOI 10.1021/bi00189a028; MIYAZAWA K, 1990, J IMMUNOL, V145, P650; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; RAMM LE, 1982, J IMMUNOL, V129, P1143; RESTREPO D, 1988, J GEN PHYSIOL, V92, P489, DOI 10.1085/jgp.92.4.489; REUTZ S, 1994, J BIOL CHEM, V269, P12277; Robinson LJ, 1997, BIOCHEMISTRY-US, V36, P11169, DOI 10.1021/bi9627830; Roepe PD, 1996, J BIOENERG BIOMEMBR, V28, P541, DOI 10.1007/BF02110444; ROEPE PD, 1994, BIOCHEMISTRY-US, V33, P11008, DOI 10.1021/bi00202a021; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; ROEPE PD, 1992, BIOCHEMISTRY-US, V31, P12555, DOI 10.1021/bi00165a003; SCHEINBERG DA, 1989, LEUKEMIA, V3, P440; SIEGEL J, 1974, J EXP MED, V140, P631, DOI 10.1084/jem.140.3.631; TANIMOTO M, 1989, LEUKEMIA, V3, P339; THIEBAUT F, 1990, J HISTOCHEM CYTOCHEM, V38, P685, DOI 10.1177/38.5.1692055; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VOLANAKIS JE, 1981, J IMMUNOL, V126, P1820; Wadkins RM, 1997, INT REV CYTOL, V171, P121; WARE CF, 1981, MOL IMMUNOL, V18, P521, DOI 10.1016/0161-5890(81)90130-9; Wei LY, 1997, AM J PHYSIOL-CELL PH, V272, pC1642, DOI 10.1152/ajpcell.1997.272.5.C1642; Weisburg JH, 1996, J EXP MED, V183, P2699, DOI 10.1084/jem.183.6.2699	41	45	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10877	10888		10.1074/jbc.274.16.10877	http://dx.doi.org/10.1074/jbc.274.16.10877			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196165	hybrid			2022-12-25	WOS:000079751900033
J	Pan, ZK; Christiansen, SC; Ptasznik, A; Zuraw, BL				Pan, ZK; Christiansen, SC; Ptasznik, A; Zuraw, BL			Requirement of phosphatidylinositol 3-kinase activity for bradykinin stimulation of NF-kappa B activation in cultured human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; ADP-RIBOSYLATION; GENE-EXPRESSION; RHO; ZETA; RECEPTORS; 3,4,5-TRISPHOSPHATE	The signaling mechanisms utilized by bradykinin (BK) to activate the transcription factor nuclear factor kappa B (NF-kappa B) are poorly defined. We previously demonstrated that BK-stimulated NF-kappa B activation requires the small GTPase RhoA, We present evidence that BK-induced NF-kappa B activation both activates and requires phosphatidylinositol 3-kinase (PI 3-kinase) in A549 human epithelial cells. Pre-treatment with the PI 3-kinase-specific inhibitors, wortmannin, and LY294002 effectively blocked BK-induced PI 3-kinase activity. Wortmannin and LY294002 also abolished BK-induced NF-kappa B activation, as did transient transfection with a dominant negative mutant of the p85 subunit, BR-stimulated PI 3-kinase activity and NF-kappa B activation were sensitive to pertussis but not cholera toxin, suggesting that the B2 BK receptors transducing the response were coupled to G alpha i or G alpha o heterotrimeric G proteins. Tumor necrosis factor alpha (TNF alpha) also stimulated increased PI 3-kinase activity, however TNF alpha-stimulated NF-kappa B activation was not affected by the PI 3-kinase inhibitors or the p85 dominant negative mutant. These findings provide evidence that BK-induced NF-kappa B activation utilizes a signaling pathway that requires activity of both RhoA and PI 3-kinase and is distinct from the signaling pathway utilized by TNF alpha, Furthermore, we show that the p85 regulatory subunit is required for activation of PI 3-kinase activity by this G protein-coupled receptor.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92037 USA	Scripps Research Institute; University of California System; University of California San Diego	Zuraw, BL (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	zuraw@scripps.edu		Zuraw, Bruce/0000-0003-0640-6768	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036220, U19AI042244] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAID NIH HHS [AI42244, AI36220] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BURNETTE WN, 1994, STRUCTURE, V2, P151, DOI 10.1016/S0969-2126(00)00017-4; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Edmead CE, 1996, J IMMUNOL, V157, P3290; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Gomez J, 1997, J IMMUNOL, V158, P1516; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; Hu ZW, 1996, J BIOL CHEM, V271, P8977, DOI 10.1074/jbc.271.15.8977; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KowalskiChauvel A, 1996, J BIOL CHEM, V271, P26356, DOI 10.1074/jbc.271.42.26356; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; Pan ZK, 1996, J CLIN INVEST, V98, P2042, DOI 10.1172/JCI119009; Pan ZXK, 1998, J IMMUNOL, V160, P3038; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TOKER A, 1994, J BIOL CHEM, V269, P32358; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Yanagihara Y, 1997, CELL IMMUNOL, V176, P66, DOI 10.1006/cimm.1996.1071; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zuraw BL, 1998, LUNG BIOL HEALTH DIS, V117, P783	40	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9918	9922		10.1074/jbc.274.15.9918	http://dx.doi.org/10.1074/jbc.274.15.9918			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187765	hybrid			2022-12-25	WOS:000079663500004
J	Redding, K; Cournac, L; Vassiliev, IR; Golbeck, JH; Peltier, G; Rochaix, JD				Redding, K; Cournac, L; Vassiliev, IR; Golbeck, JH; Peltier, G; Rochaix, JD			Photosystem I is indispensable for photoautotrophic growth, CO2 fixation, and H-2 photoproduction in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM OSCILLATORIA-LIMNETICA; FACULTATIVE ANOXYGENIC PHOTOSYNTHESIS; REACTION CENTERS; ELECTRON-TRANSFER; CROSS-LINKING; AMINO-ACIDS; PSAC GENE; CHLOROPLAST; DEFICIENT; MUTANTS	Certain Chlamydomonas reinhardtii mutants deficient in photosystem I due to defects in psaA mRNA maturation have been reported to be capable of CO2 fixation, H-2 photoevolution, and photoautotrophic growth (Greenbaum, E,, Lee, J. W,, Tevault, C, V., Blankinship, S, L,, and Mets, L, J, (1995) Nature 376, 438-441 and Lee, J, W., Tevault, C, V., Owens, T, G.; Greenbaum, E. (1996) Science 273, 364-367), We have generated deletions of photosystem I core subunits in both wild type and these mutant strains and have analyzed their abilities to grow photoautotrophically, to fix CO2, and to photoevolve O-2 or H-2 (using mass spectrometry) as well as their photosystem I content (using immunological and spectroscopic analyses). We find no instance of a strain that can perform photosynthesis in the absence of photosystem I. The F8 strain harbored a small amount of photosystem I, and it could fix CO2 and grow slowly, but it lost these abilities after deletion of either psaA or psaC; these activities could be restored to the F8-psaA Delta mutant by reintroduction of psaA, We observed limited O-2 photoevolution in mutants lacking photosystem I; use of O-18(2) indicated that this O-2 evolution is coupled to O-2 uptake (i.e. respiration) rather than CO2 fixation or H-2 evolution. We conclude that the reported instances of CO2 fixation, H-2 photoevolution, and photoautotrophic growth of photosystem I-deficient mutants result from the presence of unrecognized photosystem I.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Plant Biol, CH-1211 Geneva 4, Switzerland; CEA, CEN Cadarache, Dept Ecophysiol Vegetale & Microbiol, Lab Ecophysiol Photosynth, F-13108 St Paul Les Durance, France; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Geneva; University of Geneva; CEA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Redding, K (corresponding author), Univ Alabama, Dept Chem, 120 Lloyd Hall,6th Ave, Tuscaloosa, AL 35487 USA.	Kevin.Redding@mail.ua.edu	Rochaix, Jean-David/ABC-5243-2020; PELTIER, Gilles/ABD-4484-2021; Cournac, Laurent/G-2564-2010	Cournac, Laurent/0000-0003-0371-938X; Peltier, Gilles/0000-0002-2226-3931; Redding, Kevin/0000-0003-2819-4022				ALBERTSSON PA, 1983, P NATL ACAD SCI-BIOL, V80, P3971, DOI 10.1073/pnas.80.13.3971; Arnon DI, 1995, PHOTOSYNTH RES, V46, P47, DOI 10.1007/BF00020416; ARNON DI, 1990, P NATL ACAD SCI USA, V87, P5930, DOI 10.1073/pnas.87.15.5930; BENNOUN P, 1977, MOL GEN GENET, V153, P343, DOI 10.1007/BF00431600; BENNOUN P, 1976, GENETICS BIOGENESIS, P33; Boichenko VA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P164; Boichenko VA, 1996, PHOTOSYNTH RES, V47, P291, DOI 10.1007/BF02184289; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; CHOQUET Y, 1988, CELL, V52, P903, DOI 10.1016/0092-8674(88)90432-1; COHEN Y, 1975, NATURE, V257, P489, DOI 10.1038/257489a0; COHEN Y, 1975, J BACTERIOL, V123, P855, DOI 10.1128/JB.123.3.855-861.1975; Cournac L, 1997, FEBS LETT, V416, P65, DOI 10.1016/S0014-5793(97)01170-8; DUYSENS LN, 1961, NATURE, V190, P510, DOI 10.1038/190510a0; EMERSON R, 1958, ANNU REV PLANT PHYS, V9, P1, DOI 10.1146/annurev.pp.09.060158.000245; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; FENTON JM, 1990, PHOTOSYNTH RES, V26, P59, DOI 10.1007/BF00048977; Fischer N, 1997, BIOCHEMISTRY-US, V36, P93, DOI 10.1021/bi962244v; Fischer N, 1996, MOL GEN GENET, V251, P373, DOI 10.1007/s004380050179; Gaffron Hans, 1942, JOUR GEN PHYSIOL, V26, P219, DOI 10.1085/jgp.26.2.219; GARLICK S, 1977, J BACTERIOL, V129, P623, DOI 10.1128/JB.129.2.623-629.1977; GIRARD J, 1980, CURR GENET, V2, P215, DOI 10.1007/BF00435689; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; GOLDSCHMIDTCLERMONT M, 1990, MOL GEN GENET, V223, P417, DOI 10.1007/BF00264448; GREENBAUM E, 1995, NATURE, V376, P438, DOI 10.1038/376438a0; GREENE EVARTS BOUTELL, 1898, P 1998 HYDR PROGR AN, P1; Hanley J, 1996, BIOCHEMISTRY-US, V35, P8563, DOI 10.1021/bi960399x; HARBINSON J, 1987, PLANT CELL ENVIRON, V10, P131, DOI 10.1111/j.1365-3040.1987.tb02089.x; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HILL R, 1960, NATURE, V186, P136, DOI 10.1038/186136a0; HOOBER JK, 1984, CHLOROPLASTS CELLULA; KLIMOV VV, 1982, BIOFIZIKA+, V27, P179; KLIMOV VV, 1977, FEBS LETT, V82, P183, DOI 10.1016/0014-5793(77)80580-2; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KUCK U, 1987, EMBO J, V6, P2185, DOI 10.1002/j.1460-2075.1987.tb02489.x; Lee JW, 1996, SCIENCE, V273, P364, DOI 10.1126/science.273.5273.364; LELONG C, 1994, J BIOL CHEM, V269, P10034; LEVINE RP, 1968, SCIENCE, V162, P768, DOI 10.1126/science.162.3855.768; MYERS J, 1971, ANN REV PLANT PHYSIO, V22, P289, DOI 10.1146/annurev.pp.22.060171.001445; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; PELTIER G, 1988, BIOCHIM BIOPHYS ACTA, V936, P319, DOI 10.1016/0005-2728(88)90007-2; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; SMART LB, 1991, EMBO J, V10, P3289, DOI 10.1002/j.1460-2075.1991.tb04893.x; STAEHELIN LA, 1984, J CELL BIOCHEM, V24, P261, DOI 10.1002/jcb.240240307; STIEHL HH, 1969, Z NATURFORSCH PT B, VB 24, P1588; STRYER L, 1995, BIOCHEMISTRY-US, P653; STUART TS, 1972, PLANTA, V106, P91, DOI 10.1007/BF00383989; STUART TS, 1972, PLANTA, V106, P101, DOI 10.1007/BF00383990; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TOELGE M, 1991, BIOCHIM BIOPHYS ACTA, V1060, P233, DOI 10.1016/S0005-2728(09)91011-8; TOGASAKI RK, 1986, PHOTOSYNTH RES, V10, P415, DOI 10.1007/BF00118307; TREBST A, 1974, ANNU REV PLANT PHYS, V25, P423, DOI 10.1146/annurev.pp.25.060174.002231; TRISSL HW, 1993, TRENDS BIOCHEM SCI, V18, P415, DOI 10.1016/0968-0004(93)90136-B	55	51	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10466	10473		10.1074/jbc.274.15.10466	http://dx.doi.org/10.1074/jbc.274.15.10466			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187837	hybrid, Green Published			2022-12-25	WOS:000079663500076
J	Sonoda, Y; Watanabe, S; Matsumoto, Y; Aizu-Yokota, E; Kasahara, T				Sonoda, Y; Watanabe, S; Matsumoto, Y; Aizu-Yokota, E; Kasahara, T			FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; GROWTH-FACTOR; BCL-2; HOMOLOG; DEATH; BAX; PHOSPHORYLATION; STIMULATION; FAMILY	Protein phosphorylation in a human glioblastoma cell line, T98G, was examined after exposure to oxidative stress in vitro. Hydrogen peroxide (1 mM) markedly induced tyrosine phosphorylation of focal adhesion kinase (FAK) and serine phosphorylation of Akt at 1 h after stimulation. Concommitantly, the association of FAK with phosphatidylinositide 3'-OH-kinase (PI 3-kinase) was also observed by the hydrogen peroxide stimulation. When T98G cells were incubated with wortmannin, a PI 3-kinase inhibitor, both PI 3-kinase activity and phosphorylation of Akt were inhibited, whereas apoptosis by oxidative stress was accelerated. Concomitant with apoptosis, elevated level of CPP32 protease activity (caspase-3) was observed, with decreases in Bcl-2 protein and increases in Pax protein. These results suggested that in the signal transduction pathway from FAR to PI 3-kinase, Akt promotes survival. Thus, it became apparent that FAK is the upstream signal protein of the PI 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis in T98G cells.	Kyoritsu Coll Pharm, Dept Biochem, Minato Ku, Tokyo 1058512, Japan	Keio University	Kasahara, T (corresponding author), Kyoritsu Coll Pharm, Dept Biochem, Minato Ku, Shibakoen 1-5-30, Tokyo 105, Japan.	kasahara-td@kyoritsu-ph.ac.jp	Aizu-Yokota, Eriko/AAH-1318-2020					Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Motyl T, 1998, EUR J CELL BIOL, V75, P367, DOI 10.1016/S0171-9335(98)80070-8; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Qin SF, 1996, EUR J BIOCHEM, V236, P443, DOI 10.1111/j.1432-1033.1996.00443.x; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V91, P9931; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; Suzuki Y, 1996, IMMUNOLOGY, V87, P396, DOI 10.1046/j.1365-2567.1996.431546.x; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; YANG E, 1995, CELL, V80, P585; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	23	219	223	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10566	10570		10.1074/jbc.274.15.10566	http://dx.doi.org/10.1074/jbc.274.15.10566			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187851	hybrid			2022-12-25	WOS:000079663500090
J	Xu, PA; Winston, JH; Datta, SK; Kellems, RE				Xu, PA; Winston, JH; Datta, SK; Kellems, RE			Regulation of forestomach-specific expression of the murine adenosine deaminase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INVOLUCRIN PROMOTER; DIFFERENTIATION-SPECIFIC EXPRESSION; KRUPPEL-LIKE FACTOR; ETS TRANSCRIPTION FACTORS; PROTEIN-KINASE-C; TRANSGENIC MICE; EPIDERMAL KERATINOCYTE; FLANKING SEQUENCES; SQUAMOUS EPITHELIA; PROXIMAL PROMOTER	The maturation of stratified squamous epithelium of the upper gastrointestinal tract is a highly ordered process of development and differentiation. Information on the molecular basis of this process is, however, limited. Here we report the identification of the first murine forestomach regulatory element using the murine adenosine deaminase (Ada) gene as a model. In the adult mouse, Ada is highly expressed in the terminally differentiated epithelial layer of upper gastrointestinal tract tissues. The data reported here represent the identification and detailed analysis of a 1.1-kilobase (kb) sequence located 3,4-kb upstream of the transcription initiation site of the murine Ada gene, which is sufficient to target caf reporter gene expression to the forestomach in transgenic mice. This 1.1-kb fragment is capable of directing caf reporter gene expression mainly to the forestomach of transgenic mice, with a level comparable to the endogenous Ada gene. This expression is localized to the appropriate cell types, confers copy number dependence, and shows the same developmental regulation. Mutational analysis revealed the functional importance of multiple transcription factor-binding sites.	Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine	Kellems, RE (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	rkellems@bmb.med.uth.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46207] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBECHT U, 1997, MOL CELLULAR METHODS, P23; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ARONOW BJ, 1995, MOL CELL BIOL, V15, P1123; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; Banks EB, 1998, BIOCHEM J, V331, P61, DOI 10.1042/bj3310061; Bernerd Francoise, 1993, Gene Expression, V3, P187; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHINSKY JM, 1990, DIFFERENTIATION, V42, P172, DOI 10.1111/j.1432-0436.1990.tb00759.x; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; Eckert RL, 1997, PHYSIOL REV, V77, P397, DOI 10.1152/physrev.1997.77.2.397; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FRANKFURT OS, 1967, EXP CELL RES, V46, P603, DOI 10.1016/0014-4827(67)90387-4; FREDERIK.S, 1966, ARCH BIOCHEM BIOPHYS, V113, P383, DOI 10.1016/0003-9861(66)90202-5; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FUCHS E, 1993, J CELL SCI, P197; GREEN H, 1981, COLD SPRING HARB SYM, V46, P293; HUFF CA, 1993, J BIOL CHEM, V268, P377; HUMMEL KP, 1966, BIOL LABORATORY MOUS, P263; Jenkins TD, 1997, J BIOL CHEM, V272, P24433, DOI 10.1074/jbc.272.39.24433; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; LaPres JJ, 1996, J BIOL CHEM, V271, P23154, DOI 10.1074/jbc.271.38.23154; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; Lee JH, 1996, J BIOL CHEM, V271, P4561; LopezBayghen E, 1996, J BIOL CHEM, V271, P512, DOI 10.1074/jbc.271.1.512; LU B, 1994, J BIOL CHEM, V269, P7443; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moser M, 1997, DEV DYNAM, V208, P115, DOI 10.1002/(SICI)1097-0177(199701)208:1<115::AID-AJA11>3.0.CO;2-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; Nakagawa H, 1997, J BIOL CHEM, V272, P16688, DOI 10.1074/jbc.272.26.16688; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; Pennisi E, 1997, SCIENCE, V275, P155, DOI 10.1126/science.275.5297.155; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; ROWDEN G, 1967, J INVEST DERMATOL, V48, P571, DOI 10.1038/jid.1967.90; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SCHWEIZER J, 1988, CELL TISSUE RES, V253, P221; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Welter JF, 1996, J BIOL CHEM, V271, P11034; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; Winston JH, 1996, SOMAT CELL MOLEC GEN, V22, P261, DOI 10.1007/BF02369566; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	64	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10316	10323		10.1074/jbc.274.15.10316	http://dx.doi.org/10.1074/jbc.274.15.10316			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187819	hybrid			2022-12-25	WOS:000079663500058
J	El Kouhen, R; Kouhen, OM; Law, PY; Loh, HH				El Kouhen, R; Kouhen, OM; Law, PY; Loh, HH			The absence of a direct correlation between the loss of [D-Ala(2),MePhe(4),Gly(5)-ol]enkephalin inhibition of adenylyl cyclase activity and agonist-induced mu-opioid receptor phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NG108-15 HYBRID-CELLS; INDUCED DESENSITIZATION; DIFFERENTIAL REGULATION; MOLECULAR MECHANISMS; CARBOXYL-TERMINUS; DOWN-REGULATION; KINASES; INTERNALIZATION; RESENSITIZATION	Chronic activation of the mu-opioid receptor (MOR1TAG) results in the loss of agonist response that has been attributed to desensitization and down-regulation of the receptor. It has been suggested that opioid receptor phosphorylation is the mechanism by which this desensitization and down-regulation occurs. When MOR1TAG; was stably expressed in both neuroblastoma neuro2A and human embryonic kidney HEK293 cells, the opioid agonist [D-Ala(2),MePhe(4),Gly(5)-ol]enkephalin (DAMGO) induced a time- and concentration-dependent phosphorylation of the receptor, in both cell lines, that could be reversed by the antagonist naloxone, Protein kinase C can phosphorylate the receptor, but is not involved in DAMGO-induced MOR1TAG phosphorylation. The rapid rate of receptor phosphorylation, occurring within minutes, did not correlate with the rate of the loss of agonist-mediated inhibition of adenylyl cyclase, which occurs in hours. This lack of correlation between receptor phosphorylation and the loss of response was further demonstrated when receptor phosphorylation was increased by either calyculin A or overexpression of the G-protein receptor kinases. Calyculin A increased the magnitude of MOR1TAG phosphorylation without altering the DAMGO-induced loss of the adenylyl cyclase response. Similarly, when mu- and delta-opioid (DOR1TAG) receptors were expressed in the same system, overexpression of beta-adrenergic receptor kinase 2 elevated agonist-induced phosphorylation for both receptors, However, in the same cell lines under the same conditions, overexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 accelerated the rate of DPDPE- but not DAMGO-induced receptor desensitization. Thus, these data show that phosphorylation of MOR1TAG is not an obligatory event for the DAMGO-induced loss in the adenylyl cyclase regulation by the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	El Kouhen, R (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	elkou001@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA-00546, DA-05695, DA-01583] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA001583, R37DA001583, P01DA005695] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bohm SK, 1997, BIOCHEM J, V322, P1; Bot G, 1997, MOL PHARMACOL, V52, P272, DOI 10.1124/mol.52.2.272; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Diviani D, 1996, J BIOL CHEM, V271, P5049; HAGA T, 1994, J NEUROCHEM, V63, P400; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; Kim JY, 1997, J BIOL CHEM, V272, P27313, DOI 10.1074/jbc.272.43.27313; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; LAW PY, 1991, J PHARMACOL EXP THER, V256, P710; LAW PY, 1983, MOL PHARMACOL, V24, P413; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; Tiberi M, 1996, J BIOL CHEM, V271, P3771; WHITE AA, 1978, ANAL BIOCHEM, V85, P451, DOI 10.1016/0003-2697(78)90242-7; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	42	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9207	9215		10.1074/jbc.274.14.9207	http://dx.doi.org/10.1074/jbc.274.14.9207			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092593	hybrid			2022-12-25	WOS:000079451800012
J	Guo, LN; Fatig, RO; Orr, GL; Schafer, BW; Strickland, JA; Sukhapinda, K; Woodsworth, AT; Petell, JK				Guo, LN; Fatig, RO; Orr, GL; Schafer, BW; Strickland, JA; Sukhapinda, K; Woodsworth, AT; Petell, JK			Photorhabdus luminescens W-14 insecticidal activity consists of at least two similar but distinct proteins - Purification and characterization of toxin A and toxin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENORHABDUS-NEMATOPHILUS; BACILLUS-THURINGIENSIS; GALLERIA-MELLONELLA; HETERORHABDITIS-BACTERIOPHORA; ENTOMOPATHOGENIC NEMATODES; SYMBIOTIC BACTERIA; LARVAL GROWTH; BUSH LUPINE; GEN-NOV; ENTEROBACTERIACEAE	Both the bacterium Photorhabdus luminescens alone and its symbiotic Photorhabdus-nematode complex are known to be highly pathogenic to insects, The nature of the insecticidal activity of Photorhabdus bacteria was investigated for its potential application as an insect control agent. It was found that in the fermentation broth of P. luminescens strain W-14, at least two proteins, toxin A and toxin B, independently contributed to the oral insecticidal activity against Southern corn rootworm, Purified toxin A and toxin B exhibited single bands on native polyacrylamide gel electrophoresis and two peptides of 208 and 63 kDa on SDS-polyacrylamide gel electrophoresis. The native molecular weight of both the toxin A and toxin B was determined to be approximately 860 kDa, suggesting that they are tetrameric, NH2-terminal amino acid sequencing and Western analysis using monospecific antibodies to each toxin demonstrated that the two toxins were distinct but homologous, The oral potency (LD,,) of toxin A and toxin B against Southern corn rootworm larvae was determined to be similar to that observed with highly potent Bt toxins against lepidopteran pests, In addition, it was found that the two peptides present in toxin B could be processed in vitro from a 281-kDa protoxin by endogenous P. luminescens proteases. Proteolytic processing was shown to enhance insecticidal activity.	Dow AgroSci LLC, Input Agr Gene Discovery, Biotechnol, Indianapolis, IN 46268 USA	Dow Chemical Company	Petell, JK (corresponding author), Dow AgroSci LLC, Input Agr Gene Discovery, Biotechnol, Indianapolis, IN 46268 USA.							AKHURST R, 1993, NEMATODES AND THE BIOLOGICAL CONTROL OF INSECT PESTS, P127; Akhurst R., 2012, PARASITES PATHOGENS, P1; Akhurst R. J., 1990, Entomopathogenic nematodes in biological control., P75; AKHURST RJ, 1988, J GEN MICROBIOL, V134, P1835; AKHURST RJ, 1993, ENTOMOPATHOGENIC NEM, V2, P75; BALCERZAK M, 1991, Acta Parasitologica Polonica, V36, P175; Bintrim SB, 1998, J BACTERIOL, V180, P1261, DOI 10.1128/JB.180.5.1261-1269.1998; Boemare N, 1996, BIOCONTROL SCI TECHN, V6, P333, DOI 10.1080/09583159631316; BOEMARE NE, 1993, INT J SYST BACTERIOL, V43, P249, DOI 10.1099/00207713-43-2-249; Bovien P., 1937, Videnskabelige Meddelelser fra Dansk Naturhistorisk Forening i Kjobenhavn, V101, P1; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; BOWEN D, 1995, THESIS U WISCONSIN M; BOWEN D, 1987, P M AM SOC MICROBIOL, V183, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlton BC., 1993, ADV ENG PESTICIDES, P43; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CLARKE DJ, 1995, J INVERTEBR PATHOL, V66, P149, DOI 10.1006/jipa.1995.1078; COUCHE GA, 1987, J BACTERIOL, V169, P5279, DOI 10.1128/jb.169.11.5279-5288.1987; DUNPHY GB, 1988, J GEN MICROBIOL, V134, P1017; DUNPHY GB, 1991, J INVERTEBR PATHOL, V58, P40, DOI 10.1016/0022-2011(91)90160-R; Estruch JJ, 1996, P NATL ACAD SCI USA, V93, P5389, DOI 10.1073/pnas.93.11.5389; FARMER JJ, 1989, J CLIN MICROBIOL, V27, P1594, DOI 10.1128/JCM.27.7.1594-1600.1989; Forst S, 1996, MICROBIOL REV, V60, P21, DOI 10.1128/MMBR.60.1.21-43.1996; Gaertner F.H., 1993, ADV ENG PESTICIDES, P73; GERRITSEN LJM, 1993, FUND APPL NEMATOL, V16, P367; GOTZ P, 1981, PROC R SOC SER B-BIO, V212, P333, DOI 10.1098/rspb.1981.0043; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; Hilder V.A., 1993, TRANSGENIC PLANTS, V1, P317; HOFTE H, 1989, MICROBIOL REV, V53, P242; JAROSZ J, 1991, ENTOMOPHAGA, V36, P361, DOI 10.1007/BF02377940; Klein M. G., 1990, Entomopathogenic nematodes in biological control., P195; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBO AL, 1994, METHOD ENZYMOL, V235, P667; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MILSTEAD JE, 1979, J INVERTEBR PATHOL, V33, P324, DOI 10.1016/0022-2011(79)90033-8; Nealson K. H., 1990, Entomopathogenic nematodes in biological control., P271; ORR GL, 1994, J INSECT PHYSIOL, V40, P893, DOI 10.1016/0022-1910(94)90023-X; POINAR GO, 1967, J INVERTEBR PATHOL, V9, P510, DOI 10.1016/0022-2011(67)90131-0; POINAR GO, 1966, NEMATOLOGICA, V12, P105, DOI 10.1163/187529266X00068; PURCELL JP, 1993, BIOCHEM BIOPH RES CO, V196, P1406, DOI 10.1006/bbrc.1993.2409; Qin X. X. (et al.), 1988, Forest Research, V1, P179; ROSE RI, 1973, J ECON ENTOMOL, V66, P398, DOI 10.1093/jee/66.2.398; RUPAR MJ, 1991, APPL ENVIRON MICROB, V57, P3337, DOI 10.1128/AEM.57.11.3337-3344.1991; SCHMIDT TM, 1988, APPL ENVIRON MICROB, V54, P2793, DOI 10.1128/AEM.54.11.2793-2797.1988; SHUKLE RH, 1983, ENVIRON ENTOMOL, V12, P787, DOI 10.1093/ee/12.3.787; Strong DR, 1996, OECOLOGIA, V108, P167, DOI 10.1007/BF00333228; STRONG DR, 1995, OECOLOGIA, V104, P85, DOI 10.1007/BF00365566; Szallas E, 1997, INT J SYST BACTERIOL, V47, P402, DOI 10.1099/00207713-47-2-402; THOMAS GM, 1979, INT J SYST BACTERIOL, V29, P352, DOI 10.1099/00207713-29-4-352; VONEICHELSTREIBER C, 1992, MOL GEN GENET, V233, P260, DOI 10.1007/BF00587587; WANG J X, 1987, Revue de Nematologie, V10, P483; Yamamoto T, 1993, ADV ENG PESTICIDES, P1; Yu CG, 1997, APPL ENVIRON MICROB, V63, P532, DOI 10.1128/AEM.63.2.532-536.1997	53	49	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9836	9842		10.1074/jbc.274.14.9836	http://dx.doi.org/10.1074/jbc.274.14.9836			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092674	hybrid			2022-12-25	WOS:000079451800093
J	Herr, FM; Li, E; Weinberg, RB; Cook, VR; Storch, J				Herr, FM; Li, E; Weinberg, RB; Cook, VR; Storch, J			Differential mechanisms of retinoid transfer from cellular retinol binding proteins types I and II to phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSFER; APOLIPOPROTEIN-A-I; AIR-WATER-INTERFACE; CYTOCHROME-C; UNILAMELLAR VESICLES; COLLISIONAL TRANSFER; SURFACE-ACTIVITIES; LIPID-COMPOSITION; LYSINE RESIDUES; HIGH-DENSITY	Cellular retinol-binding proteins types I and LI (CRBP-I and CRBP-II) are known to differentially facilitate retinoid metabolism by several membrane-associated enzymes. The mechanism of ligand transfer to phospholipid small unilamellar vesicles was compared in order to determine whether differences in ligand trafficking properties could underlie these functional differences. Unidirectional transfer of retinol from the CRBPs to membranes was monitored by following the increase in intrinsic protein fluorescence that occurs upon ligand dissociation, The results showed that ligand transfer of retinol from CRBP-I was >5-fold faster than transfer from CRBP-II, For both proteins, transfer of the other naturally occurring retinoid, retinaldehyde, was 4-5-fold faster than transfer of retinol, Rates of ligand transfer from CRBP-I to small unilamellar vesicles increased with increasing concentration of acceptor membrane and with the incorporation of the anionic lipids cardiolipin or phosphatidylserine into membranes. In contrast, transfer from CRBP-II was unaffected by either membrane concentration or composition. Preincubation of anionic vesicles with CRBP-I was able to prevent cytochrome c, a peripheral membrane protein, from binding, whereas CRBP-II was ineffective. In addition, monolayer exclusion experiments demonstrated differences in the rate and magnitude of the CRBP interactions with phospholipid membranes. These results suggest that the mechanisms of ligand transfer from CRBP-I and CRBP-II to membranes are markedly different as follows: transfer from CRBP-I may involve and require effective collisional interactions with membranes, whereas a diffusional process primarily mediates transfer from CRBP-II. These differences may help account for their distinct functional roles in the modulation of intracellular retinoid metabolism.	Rutgers State Univ, Cook Coll, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA	Rutgers State University New Brunswick; Washington University (WUSTL); Wake Forest University; Wake Forest Baptist Medical Center	Storch, J (corresponding author), Rutgers State Univ, Cook Coll, Dept Nutr Sci, New Brunswick, NJ 08901 USA.	storch@aesop.rutgers.edu		Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANATHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P110; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DEPIERRE JW, 1975, BIOCHIM BIOPHYS ACTA, V415, P411, DOI 10.1016/0304-4157(75)90006-4; FAUCON JF, 1976, BIOCHIM BIOPHYS ACTA, V435, P283; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; Gomori G, 1942, J LAB CLIN MED, V27, P955; HERR FM, 1993, J LIPID RES, V34, P1545; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; HERR FM, 1995, BIOCHEMISTRY-US, V34, P11840, DOI 10.1021/bi00037a023; HO MTP, 1989, J BIOL CHEM, V264, P17759; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P2278, DOI 10.1021/bi962018l; Hodsdon ME, 1997, BIOCHEMISTRY-US, V36, P1450, DOI 10.1021/bi961890r; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LEVIN MS, 1987, J BIOL CHEM, V262, P7118; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; LI E, 1991, J BIOL CHEM, V266, P3622; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; NOY N, 1990, BIOCHEMISTRY-US, V29, P3883, DOI 10.1021/bi00468a013; Ong David E., 1994, P283; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; ROISE D, 1993, AMPHIPATHIC HELIX, P258; Rong D, 1997, FEBS LETT, V402, P116, DOI 10.1016/S0014-5793(96)01509-8; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Storch J, 1996, COMP BIOCHEM PHYS B, V115, P333, DOI 10.1016/S0305-0491(96)00180-0; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, PROTEIN ENG, V10, P31, DOI 10.1093/protein/10.1.31; WEINBERG RB, 1994, J BIOL CHEM, V269, P29588; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; Yun CH, 1996, J BIOL CHEM, V271, P31312, DOI 10.1074/jbc.271.49.31312	50	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9556	9563		10.1074/jbc.274.14.9556	http://dx.doi.org/10.1074/jbc.274.14.9556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092641	hybrid			2022-12-25	WOS:000079451800060
J	Labrecque, J; Mc Nicoll, N; Marquis, M; De Lean, A				Labrecque, J; Mc Nicoll, N; Marquis, M; De Lean, A			A disulfide-bridged mutant of natriuretic peptide receptor-A displays constitutive activity - Role of receptor dimerization in signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; MUTATIONAL ANALYSIS; FACTOR-R1 RECEPTOR; ACTIVITY REQUIRES; ZONA GLOMERULOSA; BINDING ACTIVITY; ENZYME SUBUNITS; ACTIVATION	Natriuretic peptide receptor-A (NPR-A), a particulate guanylyl cyclase receptor, is composed of an extracellular domain (ECD) with a ligand binding site, a transmembrane spanning, a kinase homology domain (KHD), and a guanylyl cyclase domain. Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), the natural agonists, bind and activate the receptor leading to cyclic GMP production. This receptor has been reported to be spontaneously dimeric or oligomeric. In response to agonists, the KI-ID-mediated guanylate cyclase repression is removed, and it is assumed that. ATP binds to the KHD. Since NPR-A displays a pair of juxtamembrane cysteines separated by 8 residues, we hypothesized that the removal of one of those cysteines would leave the other unpaired and reactive, thus susceptible to form an interchain disulfide bridge and to favor the dimeric interactions. Here we show that NPR-A(C423S) mutant, expressed mainly as a covalent dimer, increases the affinity of pBNP for this receptor by enhancing a high affinity binding component, Dimerization primarily depends on ECD since a secreted NPB-A C423S soluble ectodomain (EGD(C423S)) also documents a covalent dimer, ANP binding to the unmutated ECD yields up to 80-fold affinity loss as compared with the membrane receptor. However, the ECD C423S mutation restores a high binding affinity. Furthermore, C423S mutation leads to cellular constitutive activation (20-40-fold) of basal catalytic production of cyclic GMP by the full-length mutant. In vitro particulate guanylyl cyclase assays demonstrate that NPR-A(C423S) displays an increased sensitivity to ATP treatment alone and that the effect of ANP + ATP joint treatment is cumulative instead of synergistic, Finally, the cellular and particulate guanylyl cyclase assays indicate that the receptor is desensitized to agonist stimulation. We conclude the following: I) dimers are functional units of NPR-A guanylyl cyclase activation; and 2) agonists are inducing dimeric contact of the juxtamembranous region leading to the removal of the KHD-mediated guanylyl cyclase repression, hence allowing catalytic activation.	Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	De Lean, A (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, CP 6128,Ctr Ville, Montreal, PQ H3C 3J7, Canada.							AnandSrivastava MB, 1996, J BIOL CHEM, V271, P19324, DOI 10.1074/jbc.271.32.19324; ASAI N, 1995, MOL CELL BIOL, V15, P1613; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Cohen D, 1996, J BIOL CHEM, V271, P9863, DOI 10.1074/jbc.271.16.9863; d'Avis PY, 1998, CELL GROWTH DIFFER, V9, P71; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; ESPINER EA, 1995, ENDOCRIN METAB CLIN, V24, P481, DOI 10.1016/S0889-8529(18)30028-8; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FETHIERE J, 1989, MOL PHARMACOL, V35, P584; HARDMAN JG, 1971, ANN NY ACAD SCI, V185, P27; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; ITAKURA M, 1994, J BIOL CHEM, V269, P8314; IWASHINA M, 1994, J BIOCHEM-TOKYO, V115, P563, DOI 10.1093/oxfordjournals.jbchem.a124376; IWATA T, 1991, J BIOCHEM-TOKYO, V110, P35, DOI 10.1093/oxfordjournals.jbchem.a123539; JEWETT JRS, 1993, EMBO J, V12, P769, DOI 10.1002/j.1460-2075.1993.tb05711.x; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; MANGASARIAN K, 1997, J CELL PHYSL, V172, P177; MARQUIS M, 1999, IN PRESS MOL CELL BI; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MIZUNO T, 1993, J BIOL CHEM, V268, P5162; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAKAO K, 1992, J HYPERTENS, V10, P907; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; RONDEAU JJ, 1995, BIOCHEMISTRY-US, V34, P2130, DOI 10.1021/bi00007a005; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SUGA SI, 1992, ENDOCRINOLOGY, V130, P229, DOI 10.1210/en.130.1.229; THOMPSON DK, 1995, J BIOL CHEM, V270, P425, DOI 10.1074/jbc.270.1.425; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; Wedel BJ, 1997, P NATL ACAD SCI USA, V94, P459, DOI 10.1073/pnas.94.2.459; WILSON EM, 1995, BIOCHEMISTRY-US, V34, P4696, DOI 10.1021/bi00014a025	41	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9752	9759		10.1074/jbc.274.14.9752	http://dx.doi.org/10.1074/jbc.274.14.9752			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092664	hybrid			2022-12-25	WOS:000079451800083
J	Neufeld, EB; Wastney, M; Patel, S; Suresh, S; Cooney, AM; Dwyer, NK; Roff, CF; Ohno, K; Morris, JA; Carstea, ED; Incardona, JP; Strauss, JF; Vanier, MT; Patterson, MC; Brady, RO; Pentchev, PG; Blanchette-Mackie, EJ				Neufeld, EB; Wastney, M; Patel, S; Suresh, S; Cooney, AM; Dwyer, NK; Roff, CF; Ohno, K; Morris, JA; Carstea, ED; Incardona, JP; Strauss, JF; Vanier, MT; Patterson, MC; Brady, RO; Pentchev, PG; Blanchette-Mackie, EJ			The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; DISEASE TYPE-C; METHYLAMINE ACCUMULATION; CHOLESTEROL HOMEOSTASIS; INTRACELLULAR-TRANSPORT; MEMBRANE GLYCOPROTEIN; KINETIC EVIDENCE; GM2 GANGLIOSIDE; PLASMA-MEMBRANE; CULTURED-CELLS	Niemann-Pick C disease (NP-C) is a neurovisceral lysosomal storage disorder. A variety of studies have highlighted defective sterol trafficking from lysosomes in NP-C cells. However, the heterogeneous nature of additional accumulating metabolites suggests that the cellular lesion may involve a more generalized block in retrograde lysosomal trafficking. Immunocytochemical studies in fibroblasts reveal that the NPC1 gene product resides in a novel set of lysosome-associated membrane protein-2 (LAMPS)(+)/ mannose g-phosphate receptor(-) vesicles that can be distinguished from cholesterol-enriched LAMP2(+) lysosomes, Drugs that block sterol transport out of lysosomes also redistribute NPC1 to cholesterol-laden lysosomes. Sterol relocation from lysosomes in cultured human fibroblasts can be blocked at 21 degrees C, consistent with vesicle-mediated transfer. These findings suggest that NPC1(+) vesicles may transiently interact with lysosomes to facilitate sterol relocation. Independent of defective sterol trafficking, NP-C fibroblasts are also deficient in vesicle-mediated clearance of endocytosed [C-14]sucrose. Compartmental modeling of the observed [C-14]sucrose clearance data targets the trafficking defect caused by mutations in NPC1 to an endocytic compartment proximal to lysosomes, Low density lipoprotein uptake by normal cells retards retrograde transport of [C-14]sucrose through this same kinetic compartment, further suggesting that it may contain the sterol-sensing NPC1 protein. We conclude that a distinctive organelle containing NPC1 mediates retrograde lysosomal transport of endocytosed cargo that is not restricted to sterol.	NIDDK, Lipid Cell Biol Sect, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Dept Pediat, Div Neonatol, Washington, DC 20007 USA; Vet Affairs Med Ctr, Neurobiol Res Lab, Newington, CT 06111 USA; Tottori Univ, Fac Med, Yanago 6838503, Japan; St Marys Hosp, Saccomanno Res Inst, Grand Junct, CO 81502 USA; Univ Washington, Dept Pediat & Biol Struct, Seattle, WA 98195 USA; Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA; Fac Med Lyon Sud, Dept Biochem, F-69921 Oullins, France; Fac Med Lyon Sud, INSERM U189, F-69921 Oullins, France; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Georgetown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Tottori University; University of Washington; University of Washington Seattle; University of Pennsylvania; Institut National de la Sante et de la Recherche Medicale (Inserm); Mayo Clinic	Blanchette-Mackie, EJ (corresponding author), NIDDK, Lipid Cell Biol Sect, Lab Cell Biochem & Biol, NIH, Bldg 8,Rm 427,8 Ctr Dr,MSC 0850, Bethesda, MD 20892 USA.	joanbm@bdg8.niddk.nih.gov	Neufeld, Edward/R-3819-2019; Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Patterson, Marc/0000-0002-1116-126X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060003, ZIADK060003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASAKI K, 1993, J BIOCHEM-TOKYO, V114, P598, DOI 10.1093/oxfordjournals.jbchem.a124223; BERG T, 1995, BIOCHEM J, V307, P313, DOI 10.1042/bj3070313; BERMAN M, 1978, DHEW PUBLICATION NIH; BERMAN M, 1983, CONSAM USERS GUIDE, P3279; BESTERMAN JM, 1981, J CELL BIOL, V91, P716, DOI 10.1083/jcb.91.3.716; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BLOMHOFF R, 1989, BIOCHEM J, V262, P605, DOI 10.1042/bj2620605; Bright NA, 1997, J CELL SCI, V110, P2027; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; COXEY RA, 1993, J LIPID RES, V34, P1165; DENG YP, 1991, J CELL SCI, V99, P571; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; DUNN WA, 1980, J BIOL CHEM, V255, P5971; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GHOSH RN, 1994, J CELL SCI, V107, P2177; Goodman LA, 1996, DEV BRAIN RES, V93, P162, DOI 10.1016/0165-3806(96)00029-6; Greif P, 1998, ADV EXP MED BIOL, V445, P3; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; JAHRAUS A, 1994, J CELL SCI, V107, P145; Kopitz J, 1996, AM J MED GENET, V63, P198; KOPITZ J, 1994, CLIN CHIM ACTA, V227, P121, DOI 10.1016/0009-8981(94)90141-4; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mukherjee Sushmita, 1996, Molecular Biology of the Cell, V7, p266A; Mullock BM, 1998, J CELL BIOL, V140, P591, DOI 10.1083/jcb.140.3.591; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; PATTERSON MC, 1999, IN PRESS METABOLIC M; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; Sandhoff K, 1996, TRENDS CELL BIOL, V6, P98, DOI 10.1016/0962-8924(96)80999-8; SIEGEL DA, 1994, J NEUROCHEM, V62, P1852; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOKOL J, 1988, J BIOL CHEM, V263, P3411; Storrie Brian, 1996, Bioessays, V18, P895, DOI 10.1002/bies.950181108; Suzuki K, 1999, NEUROCHEM RES, V24, P471, DOI 10.1023/A:1022571410445; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537; WILSON RB, 1993, J BIOL CHEM, V268, P25357; Yano T, 1996, P JPN ACAD B-PHYS, V72, P214, DOI 10.2183/pjab.72.214	52	315	321	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9627	9635		10.1074/jbc.274.14.9627	http://dx.doi.org/10.1074/jbc.274.14.9627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092649	hybrid			2022-12-25	WOS:000079451800068
J	Bolognese, F; Wasner, M; Lange-zu Dohna, C; Gurtner, A; Ronchi, A; Muller, H; Manni, I; Mossner, J; Piaggio, G; Mantovani, R; Engeland, K				Bolognese, F; Wasner, M; Lange-zu Dohna, C; Gurtner, A; Ronchi, A; Muller, H; Manni, I; Mossner, J; Piaggio, G; Mantovani, R; Engeland, K			The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated	ONCOGENE			English	Article						NF-Y; cell cycle; cyclin B2	II GENE-TRANSCRIPTION; S-PHASE; GROWTH-REGULATION; BREAST-CANCER; A GENE; EXPRESSION; REPRESSION; PROTEIN; DIFFERENTIATION; ACTIVATION	Cyclin B2 is a regulator of p34cdc2 kinase, involved in G2/M progression of the cell cycle, whose gene is strictly regulated at the transcriptional level in cycling cells, The mouse promoter was cloned and three conserved CCAAT boxes were found. In this study, we analysed the mechanisms leading to activation of the cyclin B2 CCAAT boxes: a combination of (i) genomic footprinting, (ii) transfections with single, double and triple mutants, (iii) EMSAs with nuclear extracts, antibodies and NF-Y recombinant proteins and (iv) transfections with an NF-YA dominant negative mutant established the positive role of the three CCAAT sequences and proved that NF-Y plays a crucial role in their activation. NF-Y, an ubiquitous trimer containing histone fold subunits, activates several other promoters regulated during the cell cycle. To analyse the levels of NF-Y subunits in the different phases of the cycle, we separated MEL cells by elutriation, obtaining fractions >80% pure. The mRNA and protein levels of the histone-fold containing IVF-YB and NF-YC were invariant, whereas the NF-YA protein, but not its mRNA, was maximal in mid-S and decreased in G2/M. EMSA confirmed that the CCAAT-binding activity followed the amount of NF-YA, indicating that this subunit is limiting within the NF-Y complex, and suggesting that post-transcriptional mechanisms regulate NF-YA levels. Our results support a model whereby fine tuning of this activator is important for phase-specific transcription of CCAAT-containing promoters.	Univ Milan, Dipartimento Genet & Biol Microrganismi, I-20133 Milan, Italy; Univ Leipzig, Zentrum Innere Med, D-04103 Leipzig, Germany; Ctr Ricerca Sperimentale, Ist Regina Elena, I-00158 Rome, Italy; Ist Europeo Oncol, I-20141 Milan, Italy	University of Milan; Leipzig University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS European Institute of Oncology (IEO)	Mantovani, R (corresponding author), Univ Milan, Dipartimento Genet & Biol Microrganismi, Via Celoria 26, I-20133 Milan, Italy.		Engeland, Kurt/AAW-9965-2020; Piaggio, Giulia/AAD-7336-2022; gurtner, aymone/AAB-8843-2020; Piaggio, Giulia/J-7214-2018; Gurtner, Aymone/J-7217-2018; Manni, Isabella/ABH-6460-2020	Engeland, Kurt/0000-0003-3525-0440; gurtner, aymone/0000-0002-7661-9059; Piaggio, Giulia/0000-0003-2114-1892; Gurtner, Aymone/0000-0002-7661-9059; Manni, Isabella/0000-0003-4823-0596; Muller, Heiko/0000-0001-9873-3146	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Baxevanis AD, 1998, NUCLEIC ACIDS RES, V26, P372, DOI 10.1093/nar/26.1.372; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEY A, 1992, MOL CELL BIOL, V12, P3590, DOI 10.1128/MCB.12.8.3590; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; FARINA A, INP RESS ONCOGENE; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; GONG JP, 1994, CANCER RES, V54, P4285; Good LF, 1996, BIOL SIGNAL, V5, P163; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huet X, 1996, MOL CELL BIOL, V16, P3789; INOSTROZA JA, 1992, CELL, V70, P477; Isaacs RJ, 1996, J BIOL CHEM, V271, P16741, DOI 10.1074/jbc.271.28.16741; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Kishimoto T, 1997, Prog Cell Cycle Res, V3, P241; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LI XY, 1992, J BIOL CHEM, V267, P8984; Liberati C, 1998, J BIOL CHEM, V273, P16880, DOI 10.1074/jbc.273.27.16880; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu QQ, 1998, CIRC RES, V82, P251; Lu CC, 1996, VIROLOGY, V225, P387, DOI 10.1006/viro.1996.0613; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MARZIALI G, IN PRESS; Mermelstein F, 1996, GENE DEV, V10, P1033, DOI 10.1101/gad.10.8.1033; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; VIVILLE S, 1991, J IMMUNOL, V146, P3211; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	106	109	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1845	1853		10.1038/sj.onc.1202494	http://dx.doi.org/10.1038/sj.onc.1202494			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086339				2022-12-25	WOS:000079090000008
J	Frutos, S; Moscat, J; Diaz-Meco, MT				Frutos, S; Moscat, J; Diaz-Meco, MT			Cleavage of zeta PKC but not lambda/iota PKC by caspase-3 during UV-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; HYDROLYZING PHOSPHOLIPASE-C; XENOPUS-LAEVIS OOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEOLYTIC ACTIVATION; SIGNAL-TRANSDUCTION; TNF-ALPHA; SUBSPECIES BLOCKS; CELL-DEATH	The stimulation of caspases is a critical event in apoptotic cell death. Several kinases critically involved in cell proliferation pathways have been shown to be cleaved by caspase-mediated mechanisms, Thus, the degradation of delta protein kinase C (PKC) and MEKK-1 by caspase-3 generates activated fragments corresponding to their catalytic domains, consistent with the observations that both enzymes are important for apoptosis. In contrast, other kinases reported to have anti-apoptotic properties, such as Raf-1 and Akt, are inactivated by proteolytic degradation by the caspase system. Since the atypical PKCs have been shown to play critical roles in cell survival, in the study reported here we have addressed the potential degradation of these PKCs by the caspase system in UV-irradiated HeLa cells. Herein we show that although zeta PKC and lambda/iota PKC are both inhibited in UV-treated cells, only zeta PKC but not lambda/iota PKC is cleaved by a caspase-mediated process. This cleavage generates a fragment that corresponds to its catalytic domain that is enzymatically inactive, The sequence where caspase-3 cleaves zeta PKC was mapped, and a mutant resistant to degradation was shown to protect cells from apoptosis more efficiently than the wild-type enzyme.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Lab Glaxo Wellcome, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); GlaxoSmithKline	Diaz-Meco, MT (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Lab Glaxo Wellcome, Canto Blanco, E-28049 Madrid, Spain.		Moscat, Jorge/A-7011-2009	Diaz-Meco, Maria/0000-0003-0147-0998				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1993, MOL CELL BIOL, V13, P1290, DOI 10.1128/MCB.13.2.1290; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Kampfer S, 1998, EMBO J, V17, P4046, DOI 10.1093/emboj/17.14.4046; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ORR JW, 1994, J BIOL CHEM, V269, P27715; Parrizas M, 1997, J BIOL CHEM, V272, P154; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wooten MW, 1996, J NEUROCHEM, V67, P1023; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	61	82	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10765	10770		10.1074/jbc.274.16.10765	http://dx.doi.org/10.1074/jbc.274.16.10765			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196149	hybrid			2022-12-25	WOS:000079751900017
J	Netzer, KO; Leinonen, A; Boutaud, A; Borza, DB; Todd, P; Gunwar, S; Langeveld, JPM; Hudson, BG				Netzer, KO; Leinonen, A; Boutaud, A; Borza, DB; Todd, P; Gunwar, S; Langeveld, JPM; Hudson, BG			The Goodpasture autoantigen - Mapping the major conformational epitope(s) of alpha 3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; IV COLLAGEN; SYNTHETIC PEPTIDES; GBM ANTIBODIES; ALPHA-CHAINS; AMINO-ACID; ANTIGEN; IDENTIFICATION; PROTEINS; AUTOANTIBODIES	The Goodpasture (GP) autoantigen has been identified as the alpha 3(IV) collagen chain, one of six homologous chains designated alpha 1-alpha 6 that comprise type IV collagen (Hudson, B. G., Reeders, S. T., and Tryggvason, K. (1993) J. Biol. Chem. 268, 26033-26036). In this study, chimeric proteins were used to map the location of the major conformational, disulfide bond-dependent GP autoepitope(s) that has been previously localized to the non-collagenous (NC1) domain of alpha 3(IV) chain. Fourteen alpha 1/alpha 3 NC1 chimeras were constructed by substituting one or more short sequences of alpha 3(IV)NC1 at the corresponding positions in the non-immunoreactive alpha 1(IV)NC1 domain and expressed in mammalian cells for proper folding. The interaction between the chimeras and eight GP sera was assessed by both direct and inhibition enzyme-linked immunosorbent assay. Two chimeras, C2 containing residues 17-31 of alpha 3(IV)NC1 and C6 containing residues 127-141 of alpha 3(IV)NC1, bound autoantibodies, as did combination chimeras containing these regions. The epitope(s) that encompasses these sequences is immunodominant, showing strong reactivity with all GP sera and accounting for 50-90% of the autoantibody reactivity toward alpha 3(IV)NC1. The conformational nature of the epitope(s) in the C2 and C6 chimeras was established by reduction of the disulfide bonds and by PEPSCAN analysis of overlapping 12-mer peptides derived from alpha 1- and alpha 3(IV)NC1 sequences. The amino acid sequences 17-31 and 127-141 in alpha 3(IV)NC1 have thus been shown to contain the critical residues of one or two disulfide bond-dependent conformational autoepitopes that bind GP autoantibodies.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; DLO, ID, Inst Anim Sci & Hlth, NL-8200 AB Lelystad, Netherlands	University of Kansas; University of Kansas Medical Center	Hudson, BG (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Hudson, Billy/0000-0002-5420-4100	NIDDK NIH HHS [DK 18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; Dehan P, 1996, NEPHROL DIAL TRANSPL, V11, P2215, DOI 10.1093/oxfordjournals.ndt.a027139; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; Gunwar S, 1998, J BIOL CHEM, V273, P8767, DOI 10.1074/jbc.273.15.8767; HELLMARK T, 1994, KIDNEY INT, V46, P823, DOI 10.1038/ki.1994.338; Hellmark T, 1996, CLIN EXP IMMUNOL, V105, P504, DOI 10.1046/j.1365-2249.1996.119808.x; Henriksson EW, 1997, J AUTOIMMUN, V10, P559, DOI 10.1006/jaut.1997.0163; Hsia RC, 1996, MOL MICROBIOL, V19, P53, DOI 10.1046/j.1365-2958.1996.351878.x; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; KEFALIDES NA, 1993, KIDNEY INT, V43, P94, DOI 10.1038/ki.1993.16; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Levy JB, 1996, CLIN EXP IMMUNOL, V106, P79, DOI 10.1046/j.1365-2249.1996.d01-815.x; Levy JB, 1997, J AM SOC NEPHROL, V8, P1698; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MAYER U, 1994, EUR J BIOCHEM, V225, P573, DOI 10.1111/j.1432-1033.1994.00573.x; Meyers KEC, 1998, KIDNEY INT, V53, P402, DOI 10.1046/j.1523-1755.1998.00827.x; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; Netzer KO, 1998, PROTEIN SCI, V7, P1340, DOI 10.1002/pro.5560070610; PENADES JR, 1995, EUR J BIOCHEM, V229, P754, DOI 10.1111/j.1432-1033.1995.tb20524.x; PUSEY CD, 1987, LAB INVEST, V56, P23; Ryan JJ, 1998, CLIN EXP IMMUNOL, V113, P17, DOI 10.1046/j.1365-2249.1998.00623.x; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHWAB C, 1993, PROTEIN SCI, V2, P175; TZARTOS SJ, 1991, MOL NEUROBIOL, V5, P1, DOI 10.1007/BF02935610; WIESLANDER J, 1984, P NATL ACAD SCI-BIOL, V81, P1544, DOI 10.1073/pnas.81.5.1544; WIESLANDER J, 1987, CLIN EXP IMMUNOL, V69, P332; WILSON CB, 1986, KIDNEY, P800; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189	38	123	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11267	11274		10.1074/jbc.274.16.11267	http://dx.doi.org/10.1074/jbc.274.16.11267			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196215	hybrid			2022-12-25	WOS:000079751900083
J	van den Brink, MRM; Kapeller, R; Pratt, JC; Chang, JH; Burakoff, SJ				van den Brink, MRM; Kapeller, R; Pratt, JC; Chang, JH; Burakoff, SJ			The extracellular signal-regulated kinase pathway is required for activation-induced cell death of T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-LIGAND EXPRESSION; NIH 3T3 CELLS; PROTEIN-KINASE; INDUCED APOPTOSIS; ANTIGEN RECEPTOR; TYROSINE KINASE; HYBRIDOMAS; LYMPHOCYTES; INHIBITOR; DIFFERENTIATION	T cells can undergo activation-induced cell death (AICD) upon stimulation of the T cell receptor-CD3 complex. We found that the extracellular signal-regulated kinase (ERK) pathway is activated during AICD, Transient transfection of a dominant interfering mutant of mitogen-activated/extracellular signal-regulated receptor protein kinase kinase (MEK1) demonstrated that down-regulation of the ERK pathway inhibited Fast expression during AICD, whereas activation of the ERK pathway with a constitutively active MEK1 resulted in increased expression of Fast. We also found that pretreatment with the specific MEK1 inhibitor PD98059 prevented the induction of Fast expression during AICD and inhibited AICD. However, PD98059 had no effect on other apoptotic stimuli. We found only very weak ERK activity during Fas-mediated apoptosis (induced by Fas cross-linking). Furthermore, preincubation with the MEK1 inhibitor did not inhibit Fas-mediated apoptosis, Finally, we also demonstrated that pretreatment with the MEK1 inhibitor could delay and decrease the expression of the orphan nuclear steroid receptor Nur77, which has been shown to be essential for AICD. In conclusion, this study demonstrates that the ERK pathway is required for AICD of T cells and appears to regulate the induction of Nur77 and Fast expression during AICD.	Dana Farber Canc Inst, Div Pediat Oncol, Dept Pediat Oncol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Beth Israel Deaconess Medical Center	van den Brink, MRM (corresponding author), Dana Farber Canc Inst, Div Pediat Oncol, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.		van den Brink, Marcel R. M./HGB-9434-2022	van den Brink, Marcel/0000-0003-0696-4401	NATIONAL CANCER INSTITUTE [T32CA009382, P30CA008748, P01CA039542] Funding Source: NIH RePORTER; NCI NIH HHS [CA09382, 5PO1 CA39542, P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; Alessandrini A, 1996, J BIOL CHEM, V271, P31612, DOI 10.1074/jbc.271.49.31612; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; ASHWELL JD, 1987, J EXP MED, V165, P173, DOI 10.1084/jem.165.1.173; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eischen CM, 1997, J IMMUNOL, V159, P1135; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; GonzalezGarcia A, 1997, J IMMUNOL, V158, P4104; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Latinis KM, 1997, J IMMUNOL, V158, P4602; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OYAIZU N, 1995, BIOCHEM BIOPH RES CO, V213, P994, DOI 10.1006/bbrc.1995.2227; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; Sahuquillo AG, 1998, J EXP MED, V187, P1179, DOI 10.1084/jem.187.8.1179; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sutherland CL, 1996, J IMMUNOL, V157, P3381; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	41	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11178	11185		10.1074/jbc.274.16.11178	http://dx.doi.org/10.1074/jbc.274.16.11178			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196203	hybrid			2022-12-25	WOS:000079751900071
J	Varnai, P; Rother, KI; Balla, T				Varnai, P; Rother, KI; Balla, T			Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PH DOMAIN; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; INOSITOL TRISPHOSPHATE; ACTIVATION; 3-KINASE; MUTATION; TRANSLOCATION; SPECIFICITY	Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) has been proposed to act as a second messenger to recruit regulatory proteins to the plasma membrane via their pleckstrin homology (PH) domains. The PH domain of Bruton's tyrosine kinase (Btk), which is mutated in the human disease X-linked agammaglobulinemia, has been shown to interact with PI(3,4,5)P-3 in vitro. In this study, a fusion protein containing the PH domain of Btk and the enhanced green fluorescent protein (BtkPH-GFP) was constructed and utilized to study the ability of this PH domain to interact with membrane inositol phospholipids inside living cells. The localization of expressed BtkPH-GFP in quiescent NIH 3T3 cells was indistinguishable from that of GFP alone, both being cytosolic as assessed by confocal microscopy. In NIH 3T3 cells coexpressing BtkPH-GFP and the epidermal growth factor receptor, activation of epidermal growth factor or endogenous platelet-derived growth factor receptors caused a rapid (<3 min) translocation of the cytosolic fluorescence to ruffle-like membrane structures. This response was not observed in cells expressing GFP only and was completely inhibited by treatment with the PI 3-kinase inhibitors wortmannin and LY 292004, Membrane-targeted PI 3-kinase also caused membrane localization of BtkPH-GFP that was slowly reversed by wortmannin. When the R28C mutation of the Btk PH domain, which causes X-linked agammaglobulinemia, was introduced into the fluorescent construct, no translocation was observed after stimulation. Tn contrast, the E41K mutation, which confers transforming activity to native Btk, caused significant membrane localization of BtkPH-GFP with characteristics indicating its possible binding to PI(4,5)P-2. This mutant, but not wild-type BtkPH-GFP, interfered with agonist-induced PI(4,5)P-2 hydrolysis in COS-7 cells. These results show in intact cells that the PH domain of Btk binds selectively to 3-phosphorylated lipids after activation of PI 3-kinase enzymes and that losing such binding ability or specificity results in gross abnormalities in the function of the enzyme. Therefore, the interaction with PI(3,4,5)P-3 is likely to be an important determinant of the physiological regulation of Btk and can be utilized to visualize the dynamics and spatiotemporal organization of changes in this phospholipid in living cells.	NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Balla, T (corresponding author), NICHD, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A35,49 Convent Dr, Bethesda, MD 20892 USA.	tambal@box-t.nih.gov		Balla, Tamas/0000-0002-9077-3335	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033	42	242	251	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10983	10989		10.1074/jbc.274.16.10983	http://dx.doi.org/10.1074/jbc.274.16.10983			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196179	hybrid			2022-12-25	WOS:000079751900047
J	Huang, YS; Chuang, DT				Huang, YS; Chuang, DT			Mechanisms for GroEL/GroES-mediated folding of a large 86-kDa fusion polypeptide in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETOACID DEHYDROGENASE COMPLEX; MALTOSE-BINDING-PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; CELLULAR PROTEIN; IN-VITRO; GROEL; RELEASE; ALPHA-2-BETA-2; RECONSTITUTION	Our understanding of mechanisms for GroEL/GroES-assisted protein folding to date has been derived mostly from studies with small proteins. Little is known concerning the interaction of these chaperonins with large multidomain polypeptides during folding. In the present study, we investigated chaperonin-dependent folding of a large 86-kDa fusion polypeptide, in which the mature maltose-binding protein (MBP) sequence was linked to the N terminus of the alpha subunit of the decarboxylase (E1) component of the human mitochondrial branched-chain alpha-ketoacid dehydrogenase complex. The fusion polypeptide, MBP-alpha, when co-expressed with the beta subunit of E1, produced a chimeric protein MBP-E1 with an (MBP-alpha)(2)beta(2) structure, similar to the alpha(2)beta(2) structure in native E1, Reactivation of MBP-E1 denatured in 8 M urea was absolutely dependent on GroEL/GroES and Mg2+-ATP, and exhibited strikingly slow kinetics with a rate constant of 376 M-1 s(-1), analogous to denatured untagged E1. Chaperonin-mediated refolding of the MBP-alpha fusion polypeptide showed that the folding of the MBP moiety was about 7-fold faster than that of the cu moiety on the same chain with rate constants of 1.9 x 10(-3) s(-1) and 2.95 x 10(-4) s(-1), respectively. This explained the occurrence of an MBP-alpha.GroEL binary complex that was isolated with amylose resin from the refolding mixture and transformed Escherichia coli lysates. The data support the thesis that distinct functional sequences in a large polypeptide exhibit different folding characteristics on the same GroEL scaffold. Moreover, we show that when the alpha.GroEL complex (molar ratio 1:1) was incubated with GroES, the latter was capable of capping either the very ring that harbored the 48-kDa (His)(6)-alpha polypeptide (in cis) or the opposite unoccupied cavity (in trans). In contrast, the MBP-alpha.GroEL (1:1) complex was capped by GroES exclusively in the trans configuration. These findings suggest that the productive folding of a large multidomain polypeptide can only occur in the GroEL cavity that is not sequestered by GroES.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Biochem & Mol Biol Grad Program, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Huang, Yi-Shuian/P-2824-2018	Huang, Yi-Shuian/0000-0001-9000-7748	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BLOND S, 1986, Proteins Structure Function and Genetics, V1, P247, DOI 10.1002/prot.340010307; BLONDELGUINDI S, 1990, BIOCHEMISTRY-US, V29, P2409, DOI 10.1021/bi00461a026; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; CHUN SY, 1993, J BIOL CHEM, V268, P20855; DAUTRYVARSAT A, 1981, BIOCHEMISTRY-US, V20, P1396, DOI 10.1021/bi00508a056; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; DEVILLEBONNE D, 1989, BIOCHEMISTRY-US, V28, P1917, DOI 10.1021/bi00430a073; ELLIS J, 1992, NATURE, V358, P191, DOI 10.1038/358191a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; GAREL JR, 1980, P NATL ACAD SCI-BIOL, V77, P3379, DOI 10.1073/pnas.77.6.3379; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORDON CL, 1994, J BIOL CHEM, V269, P27941; GRIMM R, 1993, J BIOL CHEM, V268, P5220; Hartl F U, 1991, Semin Immunol, V3, P5; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; JAENICKE R, 1979, BIOCHEMISTRY-US, V18, P1217, DOI 10.1021/bi00574a016; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; LEGNAME G, 1995, FEBS LETT, V361, P211, DOI 10.1016/0014-5793(95)00184-B; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; Richarme G, 1997, J BIOL CHEM, V272, P15607, DOI 10.1074/jbc.272.25.15607; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SINCLAIR JF, 1994, NAT STRUCT BIOL, V1, P320, DOI 10.1038/nsb0594-320; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; Voet D VJ, 1990, BIOCHEMISTRY; WALDINGER D, 1988, BIOL CHEM H-S, V369, P1185, DOI 10.1515/bchm3.1988.369.2.1185; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; WYNN RM, 1994, BIOCHEMISTRY-US, V33, P8962, DOI 10.1021/bi00196a014; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625	50	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10405	10412		10.1074/jbc.274.15.10405	http://dx.doi.org/10.1074/jbc.274.15.10405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187830	hybrid			2022-12-25	WOS:000079663500069
J	Lee, RCH; Walters, JA; Reyland, ME; Anderson, SM				Lee, RCH; Walters, JA; Reyland, ME; Anderson, SM			Constitutive activation of the prolactin receptor results in the induction of growth factor-independent proliferation and constitutive activation of signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; FMS PROTO-ONCOGENE; TYROSINE KINASE JAK2; BREAST-CANCER-CELLS; COMMON BETA-SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASE; POINT MUTATION; MAP KINASE; NB2 CELLS; INTERLEUKIN-3 DEPENDENCE	The ability to induce the oncogenic activation of the human prolactin receptor (PRLR) was examined by deleting 178 amino acids of the extracellular ligand-binding domain. Expression of this deletion mutant in the interleukin-3 (IL-3)-dependent murine myeloid cell line 32Dc13 resulted in the induction of growth factor-independent proliferation. Parental 32Dc13 cells proliferated only in the presence of exogenous murine IL-3 (mIL-3), while 32Dc13 cells transfected with the long form of the human PRLR were able to proliferate in response to mIL-3, ovine prolactin, or human PRL, Cells expressing the Delta 178 deletion mutant contained numerous phosphotyrosine-containing proteins in the absence of stimulation with either mIL-3 or ovine prolactin, Growth factor stimulation increased the number of proteins phosphorylated and the intensity of phosphorylation, These proteins included constitutively phosphorylated Janus kinase 2, signal transducer and activator of transcription 5, and SHC. Activated extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) were observed in unstimulated 32Dc13 cells expressing the Delta 178 mutant. Likewise, transfection of Nb2 cells with the Delta 178 deletion mutant induced growth factor-independent proliferation and constitutive activation of Janus kinase 2, ERK1, and ERK2, In addition to the induction of a growth factor-independent state, the expression of the Delta 178 deletion mutant also suppressed the apoptosis that occurs when 32Dc13 cells are cultured in the absence of growth factors such as IL-3, These data suggest that the constitutive activation of the PRLR can be achieved by deletion of the ligand binding domain and that this mutation leads to the oncogenic activation of the receptor as determined by the ability of the receptor to induce growth factor-independent proliferation of factor-dependent hematopoietic cells.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Dent, Dept Basic Sci & Oral Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Anderson, SM (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pathol, Box B-216,4200 E 9th Ave, Denver, CO 80262 USA.	steve.anderson@uchsc.edu			NCI NIH HHS [CA46934] Funding Source: Medline; NIDDK NIH HHS [DK48879] Funding Source: Medline; NIGMS NIH HHS [GM08497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlSakkaf KA, 1996, BIOCHEM BIOPH RES CO, V221, P779, DOI 10.1006/bbrc.1996.0673; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDERSON SM, 1990, ONCOGENE, V5, P317; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Berlanga JJ, 1997, J BIOL CHEM, V272, P2050; BISWAS R, 1987, CANCER RES, V47, P3509; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; CAREY GB, 1995, ARCH BIOCHEM BIOPHYS, V316, P179, DOI 10.1006/abbi.1995.1026; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DAndrea RJ, 1996, BLOOD, V87, P2641, DOI 10.1182/blood.V87.7.2641.bloodjournal8772641; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 1997, J MAMMARY GLAND BIOL, V2, P7, DOI 10.1023/A:1026313211704; Gonda TJ, 1997, BLOOD, V89, P355, DOI 10.1182/blood.V89.2.355; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Gourdou I, 1996, MOL ENDOCRINOL, V10, P45, DOI 10.1210/me.10.1.45; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; Jenkins BJ, 1996, J BIOL CHEM, V271, P29707, DOI 10.1074/jbc.271.47.29707; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; LAX I, 1985, EMBO J, V4, P3179, DOI 10.1002/j.1460-2075.1985.tb04062.x; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LINNEKIN D, 1990, BIOCHEM J, V27, P317; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; METCALF D, 1985, BLOOD, V65, P357; OKUDA K, 1992, BLOOD, V79, P2880; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PICCOLETTI R, 1994, BIOCHEM J, V303, P429, DOI 10.1042/bj3030429; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROVERA G, 1987, ONCOGENE, V1, P29; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOMMERS W, 1994, NATURE, V372, P478; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	66	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10024	10034		10.1074/jbc.274.15.10024	http://dx.doi.org/10.1074/jbc.274.15.10024			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187780	hybrid			2022-12-25	WOS:000079663500019
J	Sadhukhan, R; Santhamma, KR; Reddy, P; Peschon, JJ; Black, RA; Sen, I				Sadhukhan, R; Santhamma, KR; Reddy, P; Peschon, JJ; Black, RA; Sen, I			Unaltered cleavage and secretion of angiotensin-converting enzyme in tumor necrosis factor-alpha-converting enzyme-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE; PROTEIN; METALLOPROTEASE; ECTODOMAIN; PRECURSOR; DISINTEGRIN; EXPRESSION; FERTILITY; RELEASE	Mammalian angiotensin-converting enzyme (ACE) is one of several biologically important ectoproteins that exist in both membrane-bound and soluble forms as a result of a post-translational proteolytic cleavage. It has been suggested that a common proteolytic system is responsible for the cleavage of a diverse group of membrane ectoproteins, and tumor necrosis factor-alpha-converting enzyme (TACE), a recently purified disintegrin-metalloprotease, has been implicated in the proteolytic cleavage of several cell surface proteins. Mice devoid of TACE have been developed by gene targeting. Such mice could provide a useful system to determine if TACE is responsible for the cleavage of other ectoproteins, Cultured fibroblasts without TACE activity, when transfected with cDNA encoding for the testicular isozyme of ACE (ACE(T)), synthesized and secreted ACE(T) normally after a proteolytic cleavage near the C terminus. In addition, similar quantities of the soluble, C-terminally truncated somatic isozyme of ACE (ACE(P)) were present in the serum of wild-type and TACE-deficient mice. These results demonstrate that TACE is not essential in the generation of soluble ACE under physiological conditions. Finally, we also report solubilization of ACE-secretase, the enzyme that cleaves ACE, from mouse ACE89 cells and from rabbit lung. We demonstrate that soluble ACE-secretase from both sources failed to cleave its substrate in solution, suggesting a requirement for anchoring to the membrane.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA	Cleveland Clinic Foundation	Sen, I (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL54297] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054297] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KASTURI S, 1994, BIOCHEMISTRY-US, V33, P6228, DOI 10.1021/bi00186a024; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1995, J IMMUNOL, V155, P5198; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; Ramchandran R, 1996, AM J PHYSIOL-HEART C, V271, pH744, DOI 10.1152/ajpheart.1996.271.2.H744; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SEN I, 1991, J BIOL CHEM, V266, P21985; SEN I, 1993, J BIOL CHEM, V268, P25748; WEI L, 1991, J BIOL CHEM, V266, P5540	23	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10511	10516		10.1074/jbc.274.15.10511	http://dx.doi.org/10.1074/jbc.274.15.10511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187843	hybrid			2022-12-25	WOS:000079663500082
J	Xing, MZ; Post, S; Ostrom, RS; Samardzija, M; Insel, PA				Xing, MZ; Post, S; Ostrom, RS; Samardzija, M; Insel, PA			Inhibition of phospholipase A(2)-mediated arachidonic acid release by cyclic AMP defines a negative feedback loop for P-2Y receptor activation in Madin-Darby canine kidney D-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA(1)-ADRENERGIC RECEPTORS; EPITHELIAL-CELLS; CAMP PRODUCTION; PHORBOL ESTER; PATHWAY; PROSTAGLANDIN-E2; STIMULATION; HYDROLYSIS; ALPHA	In Madin-Darby canine kidney D-1 cells extracellular nucleotides activate P-2Y receptors that couple to several signal transduction pathways, including stimulation of multiple phospholipases and adenylyl cyclase, For one class of P-2Y receptors, P-2Y2 receptors, this stimulation of adenylyl cyclase and increase in cAMP occurs via the conversion of phospholipase A(2) (PLA(2))-generated arachidonic acid (AA) to prostaglandins (e.g. PGE(2)). These prostaglandins then stimulate adenylyl cyclase activity, presumably via activation of prostanoid receptors, In the current study we show that agents that increase cellular cAMP levels (including PGE(2), forskolin, and the beta-adrenergic agonist isoproterenol) can inhibit P-2Y receptor-promoted AA release. The protein kinase A (PKA) inhibitor H89 blocks this effect, suggesting that this feedback inhibition occurs via activation of PKA. Studies with PGE(2) indicate that inhibition of AA release is attributable to inhibition of mitogen-activated protein kinase activity and in turn of P-2Y receptor stimulated PLA(2) activity. Although cAMP/PKA-mediated inhibition occurs for P-2Y receptor-promoted AA release, we did not find such inhibition for epinephrine (alpha(1)-adrenergic) or bradykinin-mediated AA release. Taken together, these results indicate that negative feedback regulation via cAMP/PKA-mediated inhibition of mitogen-activated protein kinase occurs for some, but not all, classes of receptors that promote PLA(2) activation and AA release. We speculate that receptor-selective feedback inhibition occurs because PLA(2) activation by different receptors in Madin-Darby canine kidney D-1 cells involves the utilization of different signaling components that are differentially sensitive to increases in cAMP or, alternatively, because of compartmentation of signaling components.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Greater Baltimore Med Ctr, Dept Med, Baltimore, MD 21204 USA	University of California System; University of California San Diego; Greater Baltimore Medical Center	Insel, PA (corresponding author), Univ Calif San Diego, Dept Pharmacol, 0636, La Jolla, CA 92093 USA.			Ostrom, Rennolds/0000-0002-7204-0357	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35847] Funding Source: Medline; NIGMS NIH HHS [GM31987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balboa MA, 1998, MOL PHARMACOL, V53, P221, DOI 10.1124/mol.53.2.221; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; CHABOT MC, 1986, J CRAN GENET DEV BIO, V6, P223; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; KENNEDY CRJ, 1995, BBA-LIPID LIPID MET, V1258, P206, DOI 10.1016/0005-2760(95)00049-I; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Mallat A, 1996, J CLIN INVEST, V98, P2771, DOI 10.1172/JCI119103; NIELSON CP, 1992, J IMMUNOL, V149, P4036; Post SR, 1998, J BIOL CHEM, V273, P23093, DOI 10.1074/jbc.273.36.23093; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; SLIVKA SR, 1987, J BIOL CHEM, V262, P4200; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; TAKENAWA T, 1986, J BIOL CHEM, V261, P1092; WEISS BA, 1991, J BIOL CHEM, V266, P2126; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xing MB, 1996, J CLIN INVEST, V97, P1302, DOI 10.1172/JCI118546; Xing MZ, 1997, AM J PHYSIOL-CELL PH, V272, pC1380, DOI 10.1152/ajpcell.1997.272.4.C1380; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227	18	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10035	10038		10.1074/jbc.274.15.10035	http://dx.doi.org/10.1074/jbc.274.15.10035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187781	hybrid			2022-12-25	WOS:000079663500020
J	Fleming, JF; Spitsen, GM; Hui, TY; Olivier, L; Du, EZ; Raabe, M; Davis, RA				Fleming, JF; Spitsen, GM; Hui, TY; Olivier, L; Du, EZ; Raabe, M; Davis, RA			Chinese hamster ovary cells require the coexpression of microsomal triglyceride transfer protein and cholesterol 7 alpha-hydroxylase for the assembly and secretion of apolipoprotein B containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; HEPG2 CELLS; ABETALIPOPROTEINEMIA GENE; MCA-RH7777 CELLS; DEGRADATION; TRANSLOCATION; DISEASE; EXPRESSION	Due to the absence of microsomal triglyceride transfer protein (MTP), Chinese hamster ovary (CHO) cells lack the ability to translocate apoB into the lumen of the endoplasmic reticulum, causing apoB to be rapidly degraded by an N-acetyl-leucyl-leucyl-norleucinal-inhibitable process. The goal of this study was to examine if expression of MTP, whose genetic deletion is responsible for the human recessive disorder abetalipoproteinemia, would recapitulate the lipoprotein assembly pathway in CHO cells. Unexpectedly, expression of MTP mRNA and protein in CHO cells did not allow apoB-containing lipoproteins to be assembled and secreted by CHO cells expressing apoB53, Although expression of MTP in cells allowed apoB to completely enter the endoplasmic reticulum, it was degraded by a proteolytic process that was inhibited by dithiothreitol (1 mM) and chloroquine (100 mu M), but resistant to N-acetyl-leucylleucyl-norleucinal, In marked contrast, coexpression of the liver-specific gene product cholesterol 7 alpha-hydroxylase with MTP resulted in levels of MTP lipid transfer activity that were similar to those in mouse liver and allowed intact apoB53 to be secreted as a lipoprotein particle. These data suggest that, although MTP-facilitated lipid transport is not required for apoB translocation, it is required for the secretion of apoB-containing lipoproteins. We propose that, in CHO cells, MTP plays two roles in the assembly and secretion of apoB-containing-lipoproteins: 1) it acts as a chaperone that facilitates apoB53 translocation, and 2) its lipid transfer activity allows apoB-containing lipoproteins to be assembled and secreted. Our results suggest that the phenotype of the cell (e.g. expression of cholesterol 7 alpha-hydroxylase by the liver) may profoundly influence the metabolic relationships determining how apoB is processed into lipoproteins and/or degraded.	San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA	California State University System; San Diego State University; California State University System; San Diego State University; University of California System; University of California San Francisco; The J David Gladstone Institutes	Davis, RA (corresponding author), San Diego State Univ, Dept Biol, Mammalian Cell & Mol Biol Lab, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051648, P01HL047660, R01HL052005] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51648, HL-47660, HL-52005] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOUMA ME, 1986, J CLIN INVEST, V78, P398, DOI 10.1172/JCI112590; DAVIS RA, 1982, J BIOL CHEM, V257, P2634; DAVIS RA, 1996, N COMP BIOC, V31, P473; Du EZ, 1999, J BIOL CHEM, V274, P1856, DOI 10.1074/jbc.274.3.1856; DU EZ, 1994, J BIOL CHEM, V269, P24169; Du EZ, 1996, J LIPID RES, V37, P1309; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KANE JP, 1989, METABOLIC BASIS INHE; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; MARCEL YL, 1987, ARTERIOSCLEROSIS, V7, P166, DOI 10.1161/01.ATV.7.2.166; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; PATEL S, 1994, ATHEROSCLEROSIS, V108, P201, DOI 10.1016/0021-9150(94)90115-5; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; PESSAH M, 1991, J CLIN INVEST, V87, P367, DOI 10.1172/JCI114996; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; RADER DJ, 1993, JAMA-J AM MED ASSOC, V270, P865, DOI 10.1001/jama.270.7.865; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TRAWICK JD, 1996, J LIPID RES, V37, P24169; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang L, 1997, J BIOL CHEM, V272, P27644, DOI 10.1074/jbc.272.44.27644; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang SL, 1997, J BIOL CHEM, V272, P19351, DOI 10.1074/jbc.272.31.19351; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9509	9514		10.1074/jbc.274.14.9509	http://dx.doi.org/10.1074/jbc.274.14.9509			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092635	hybrid			2022-12-25	WOS:000079451800054
J	Fox, KM; Karplus, PA				Fox, KM; Karplus, PA			The flavin environment in old yellow enzyme - An evaluation of insights from spectroscopic and artificial flavin studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE PROBES; NUCLEAR MAGNETIC-RESONANCE; FLAVOPROTEINS; MONONUCLEOTIDES; 2-THIOFLAVINS; FAMILY	Spectroscopic and chemical modification studies of modified flavins bound to old yellow enzyme have led to predictions about the flavin environment of this enzyme. These studies analyzed solvent accessibility and hydrogen bonding patterns of particular flavin atoms, in addition to suggesting amino acid residues that are in close proximity to those atoms. Here, these studies are evaluated in the light of the crystal structure of old yellow enzyme to reveal that the spectroscopic and modified flavin results are generally consistent with the crystal structure. This highlights the fact that these are useful methods for studying flavin binding site structure. Although several of the inferred properties of the flavin environment are not consistent with the crystal structure, these discrepancies occurred in cases where an incorrect choice was made from among multiple plausible explanations for an experimental result. We conclude that modified flavin studies are powerful probes of flavin environment; however, it is risky to specify details of interactions, especially because of uncertainties due to induced charge delocalization in the flavin.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Union Coll, Dept Chem, Schenectady, NY 12308 USA	Oregon State University; Union College	Karplus, PA (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	karplusp@ucs.orst.edu		Karplus, Paul/0000-0001-8725-6292				BEINERT WD, 1985, EUR J BIOCHEM, V152, P573, DOI 10.1111/j.1432-1033.1985.tb09234.x; BEINERT WD, 1985, EUR J BIOCHEM, V152, P581, DOI 10.1111/j.1432-1033.1985.tb09235.x; BIEMANN M, 1983, J BIOL CHEM, V258, P5440; CLAIBORNE A, 1982, J BIOL CHEM, V257, P174; EBERLEIN G, 1983, J AM CHEM SOC, V105, P6679, DOI 10.1021/ja00360a023; FITZPATRICK PF, 1985, J BIOL CHEM, V260, P8483; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8095, DOI 10.1021/bi00372a045; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8103, DOI 10.1021/bi00372a046; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1984, J BIOL CHEM, V259, P9667; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4859, DOI 10.1021/bi00316a007; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAITO K, 1991, J BIOL CHEM, V266, P20720; Schopfer L. M., 1991, STUDY ENZYMES, P247; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; STOTT K, 1993, J BIOL CHEM, V268, P6097; THEORELL H, 1954, ACTA CHEM SCAND, V8, P877, DOI 10.3891/acta.chem.scand.08-0877; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M	23	23	24	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9357	9362		10.1074/jbc.274.14.9357	http://dx.doi.org/10.1074/jbc.274.14.9357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092614	hybrid			2022-12-25	WOS:000079451800033
J	Ma, ZM; Wang, XY; Nowatzke, W; Ramanadham, S; Turk, J				Ma, ZM; Wang, XY; Nowatzke, W; Ramanadham, S; Turk, J			Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A(2) (iPLA(2)) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA(2) gene on chromosome 22q13.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; ARACHIDONIC-ACID MOBILIZATION; P388D(1) MACROPHAGES; SUBCELLULAR MEMBRANES; INSITU HYBRIDIZATION; SUICIDE INHIBITION; MESSENGER-RNA; ALLELIC LOSS; BETA-CELLS; RAT	An 85-kDa Group VI phospholipase A, enzyme (iPLA(2)) that does not require Ca2+ for catalysis has recently been cloned from three rodent species. A homologous 88-kDa enzyme has been cloned from human B-lymphocyte lines that contains a 54-amino acid insert not present in the rodent enzymes, but human cells have not previously been observed to express catalytically active iPLA(2) isoforms other than the 88-kDa protein. We have cloned cDNA species that encode two distinct iPLA(2) isoforms from human pancreatic islet RNA and a human insulinoma cDNA library. One isoform is an 85-kDa protein (short isoform of human iPLA(2) (SH-iPLA(2))) and the other an 88-kDa protein (long isoform of human iPLA, (LH-iPLA(2))). Transcripts encoding both isoforms are also observed in human promonocytic U937 cells. Recombinant SH-iPLA(2) and LH-iPLA(2) are both catalytically active in the absence of Ca2+ and inhibited by a bromoenol lactone suicide substrate, but LH-iPLA(2) is activated by ATP, whereas SH-iPLA(2) is not. The human iPLA(2) gene has been found to reside on chromosome 22 in region q13.1 and to contain 16 exons represented in the LH-iPLA(2) transcript. Exon 8 is not represented in the SH-iPLA(2) transcript, indicating that it arises by an exon-skipping mechanism of alternative splicing. The amino acid sequence encoded by exon 8 of the human iPLA(2) gene is proline-rich and shares a consensus motif of PX(5)PX(8)HHPX(12)NX(4)Q with the proline-rich middle linker domains of the Smad proteins DAF-3 and Smad4, Expression of mRNA species encoding two active iPLA(2) isoforms with distinguishable catalytic properties in two different types of human cells demonstrated here may have regulatory or functional implications about the roles of products of the iPLA(2) gene in cell biologic processes.	Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Turk, J (corresponding author), Washington Univ, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, 660 S Euclid Ave,Box 8127, St Louis, MO 63110 USA.	jturk@imgate.wustl.edu			NCRR NIH HHS [P41 RR000954] Funding Source: Medline; NIDDK NIH HHS [R37 DK034388, R37-DK-34388, R01 DK069455] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388, R01DK069455] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; Balboa MA, 1998, J BIOL CHEM, V273, P7684, DOI 10.1074/jbc.273.13.7684; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BENNETT V, 1992, J BIOL CHEM, V267, P8703; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DAVIS LG, 1994, BASIC METHODS MOL BI, P335; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; Ferrer J, 1996, DIABETOLOGIA, V39, P891, DOI 10.1007/BF00403907; Forsell PKAL, 1998, FEBS LETT, V434, P295, DOI 10.1016/S0014-5793(98)00999-5; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Iida A, 1998, GENE CHROMOSOME CANC, V21, P108, DOI 10.1002/(SICI)1098-2264(199802)21:2<108::AID-GCC5>3.0.CO;2-4; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Loweth AC, 1998, DIABETES, V47, P727, DOI 10.2337/diabetes.47.5.727; Ma ZM, 1998, BBA-LIPID LIPID MET, V1391, P384, DOI 10.1016/S0005-2760(98)00027-7; Ma ZM, 1997, J BIOL CHEM, V272, P11118; Ma ZM, 1996, J BIOL CHEM, V271, P1029, DOI 10.1074/jbc.271.2.1029; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Miyakawa A, 1998, INT J ONCOL, V13, P705; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Patterson GI, 1997, GENE DEV, V11, P2679, DOI 10.1101/gad.11.20.2679; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; Ramanadham S, 1998, BIOCHEMISTRY-US, V37, P4553, DOI 10.1021/bi9722507; Ramanadham S, 1996, BIOCHEMISTRY-US, V35, P5464, DOI 10.1021/bi952652j; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wolf MJ, 1996, J BIOL CHEM, V271, P30879, DOI 10.1074/jbc.271.48.30879; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhou YP, 1998, J CLIN INVEST, V101, P1623, DOI 10.1172/JCI1245; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	64	88	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9607	9616		10.1074/jbc.274.14.9607	http://dx.doi.org/10.1074/jbc.274.14.9607			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092647	hybrid, Green Accepted			2022-12-25	WOS:000079451800066
J	Schurmann, A; Schmidt, M; Asmus, M; Bayer, S; Fliegert, F; Koling, S; Massmann, S; Schilf, C; Subauste, MC; Voss, M; Jakobs, KH; Joost, HG				Schurmann, A; Schmidt, M; Asmus, M; Bayer, S; Fliegert, F; Koling, S; Massmann, S; Schilf, C; Subauste, MC; Voss, M; Jakobs, KH; Joost, HG			The ADP-ribosylation factor (ARF)-related GTPase ARF-related protein binds to the ARF-specific guanine nucleotide exchange factor cytohesin and inhibits the ARF-dependent activation of phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-HYBRID SYSTEM; RAT-BRAIN; HOMOLOGY DOMAINS; SEC7 DOMAIN; FACTOR ARNO; FAMILY; CLONING; IDENTIFICATION; STIMULATION; PLECKSTRIN	ADP-ribosylation factor-related protein (ARP) is a membrane-associated GTPase with remote similarity to the family of ADP-ribosylation factors (ARF). In a yeast two-hybrid screen designed to identify proteins interacting with ARP, we isolated a partial cDNA of the ARF-specific guanine nucleotide exchange factor msec7-1/cytohesin encoding its N terminus and most of the See? domain (codons 1-200). ARP and ARP-Q79L (GTPase-negative ARP) exhibited a higher affinity to mSec7-1-(1-200) than ARP-T31N (nucleotide exchange-defective ARP) in the two-hybrid assay. Similarly, full-length [S-35]mSec7-1/cytohesin was specifically adsorbed to glutathione-Sepharose loaded with glutathione S-transferase (GST)-ARP-Q79L, GST-ARP, or GST-ARP-T31N, the latter exhibiting the lowest binding affinity. Overexpression of ARP-Q79L, but not of ARP-T31N, in COS-7 cells reduced the fluorescence from co-expressed green fluorescent protein fused with mSea7-1/cytohesin or mSec7-2/ARNO in plasma membranes as detected by deconvolution microscopy, Recombinant ARP and ARP-Q79L, but not ARP-T31N, inhibited the phospholipase D (PLD) activity stimulated by mSec7-2/ARNO and ARF in a system of isolated membranes. Furthermore, transfection of HEK-293 cells with ARP or ARP-Q79L, but not ARP-T31N, inhibited the muscarinic acetylcholine receptor-3 induced PLD stimulation and translocation of ARF from cytosol to membranes. These data suggest that the GTP-bound form of ARP specifically binds mSec7-1/cytohesin, and that ARP may be involved in a pathway inhibiting the ARF-controlled activity of PLD.	Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, D-52057 Aachen, Germany; Univ Essen Gesamthsch Klinikum, Inst Pharmakol, D-45122 Essen, Germany; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	RWTH Aachen University; University of Duisburg Essen; Scripps Research Institute	Joost, HG (corresponding author), Rhein Westfal TH Aachen, Fak Med, Inst Pharmakol & Toxikol, Wendlingweg 2, D-52057 Aachen, Germany.	joost@rwth-aachen.de	Joost, Hans-Georg/J-4462-2013	Joost, Hans-Georg/0000-0002-5860-606X; Schurmann, Annette/0000-0002-4113-4377				Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Breiner M, 1996, BBA-GENE STRUCT EXPR, V1308, P1, DOI 10.1016/0167-4781(96)00081-4; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Castleman K. R., 1996, DIGITAL IMAGE PROCES; CAVENAGH MM, 1994, J BIOL CHEM, V269, P18937; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COCKCROFT S, 1997, PROG LIPID RES, V35, P345; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KAHN RA, 1991, J BIOL CHEM, V266, P2606; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Provost JJ, 1996, BIOCHEM J, V319, P285, DOI 10.1042/bj3190285; Rose M, 1990, LAB COURSE MANUAL ME; Rumenapp U, 1997, EUR J BIOCHEM, V248, P407, DOI 10.1111/j.1432-1033.1997.00407.x; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; SCHURMANN A, 1994, J BIOL CHEM, V269, P15683; Schurmann A, 1995, J BIOL CHEM, V270, P30657, DOI 10.1074/jbc.270.51.30657; Telemenakis I, 1997, EUR J CELL BIOL, V74, P143; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	44	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9744	9751		10.1074/jbc.274.14.9744	http://dx.doi.org/10.1074/jbc.274.14.9744			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092663	hybrid			2022-12-25	WOS:000079451800082
J	Kang, HY; Yeh, SY; Fujimoto, N; Chang, CS				Kang, HY; Yeh, SY; Fujimoto, N; Chang, CS			Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING FINGER DOMAIN; CANCER DU145 CELLS; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; ZINC FINGER; GENE; SEQUENCE; HORMONE	Androgen receptor (AR) is a member of the steroid receptor superfamily that may require coactivators for proper or maximal transactivation. Using a yeast two-hybrid screening followed by mammalian cell analyses, we identified a novel ligand-dependent AR-associated protein, ARA54, which Consists of 474 amino acids with a molecular mass of 54 kDa. We demonstrated that ARA54 might function as a preferential coactivator for AR-mediated transactivation in human prostate cancer DU145 cells. Interestingly, our data also showed that ARA54 could significantly enhance the transcriptional activity of LNCaP mutant AR (ARt877a) but not wild type AR or another mutant AR (ARe708k) in the presence of 10 nM 17 beta-estradiol or 1 mu M hydroxyflutamide. These results imply that both ARA54 and the positions of the AR mutation (877 versus 708) might contribute to the specificity of AR-mediated transactivation. Our findings further demonstrated that the C-terminal domain of ARA54 can serve as a dominant negative inhibitor and exogenous full-length ARA54 can reverse this squelching effect on AR transcriptional activity. Co-expression of ARA54 with other AR coactivators, such as ARA70 or SRC-1, showed additive stimulation of AR-mediated transactivation, which indicates that these cofactors may function individually as AR coactivators to induce AR target gene expression. Through our findings, we have identified and characterized a novel AR coactivator, ARA54, which may play an important role in the AR signaling pathway in human prostate.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.	chang@pathology.rochester.edu	Kang, Hong-Yo/W-9031-2019	Kang, Hong-Yo/0000-0003-0626-5037	NATIONAL CANCER INSTITUTE [F32CA075732, R29CA055639, R01CA055639] Funding Source: NIH RePORTER; NCI NIH HHS [CA75732, CA55639, CA68568] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; ISHIDA A, 1993, GENE, V129, P249, DOI 10.1016/0378-1119(93)90275-8; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; MCLEOD DG, 1993, CANCER, V71, P1046, DOI 10.1002/1097-0142(19930201)71:3+<1046::AID-CNCR2820711424>3.0.CO;2-M; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; MIYAMOTO H, 1998, MOL BASIS HORMONE RE, P42; ONATE SA, 1995, SCIENCE, V270, P1354; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG C, 1997, THESIS U MADISON WIS; Yeh SY, 1997, LANCET, V349, P852, DOI 10.1016/S0140-6736(05)61756-4; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	40	175	183	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8570	8576		10.1074/jbc.274.13.8570	http://dx.doi.org/10.1074/jbc.274.13.8570			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085091	hybrid			2022-12-25	WOS:000079451600033
J	Peschel, A; Otto, M; Jack, RW; Kalbacher, H; Jung, G; Gotz, F				Peschel, A; Otto, M; Jack, RW; Kalbacher, H; Jung, G; Gotz, F			Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL TEICHOIC-ACID; LIPOTEICHOIC ACID; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; D-ALANINE; BIOSYNTHESIS; EPIDERMIN; BACTERIA; GENES	Positively charged antimicrobial peptides with membrane-damaging activity are produced by animals and humans as components of their innate immunity against bacterial infections and also by many bacteria to inhibit competing microorganisms. Staphylococcus aureus and Staphylococcus xylosus, which tolerate high concentrations of several antimicrobial peptides, were mutagenized to identify genes responsible for this insensitivity. Several mutants with increased sensitivity were obtained, which exhibited an altered structure of teichoic acids, major components of the Gram-positive cell wall. The mutant teichoic acids lacked D-alanine, as a result of which the cells carried an increased negative surface charge. The mutant cells bound fewer anionic, but more positively charged proteins, They were sensitive to human defensin HNP1-3, animal-derived protegrins, tachyplesins, and magainin II, and to the bacteria-derived peptides gallidermin and nisin, The mutated genes shared sequence similarity with the dlt genes involved in the transfer of D-alanine into teichoic acids from other Gram-positive bacteria. Wild-type strains bearing additional copies of the dlt operon produced teichoic acids with higher amounts of D-alanine esters, bound cationic proteins less effectively and were less sensitive to antimicrobial peptides. We propose a role of the D-alanine-esterified teichoic acids which occur in many pathogenic bacteria in the protection against human and animal defense systems.	Univ Tubingen, D-72076 Tubingen, Germany; ECHAZ Microcollect, D-72070 Tubingen, Germany	Eberhard Karls University of Tubingen	Peschel, A (corresponding author), Univ Tubingen, Waldhauser Str 70-8, D-72076 Tubingen, Germany.	mikrogen@uni-tuebingen.de		Otto, Michael/0000-0002-2222-4115				AUGUSTIN J, 1990, FEMS MICROBIOL LETT, V66, P203, DOI 10.1016/0378-1097(90)90283-V; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BERKOWITZ BA, 1990, BIOCHEM PHARMACOL, V39, P625, DOI 10.1016/0006-2952(90)90138-B; BIERBAUM G, 1987, J BACTERIOL, V169, P5452, DOI 10.1128/jb.169.12.5452-5458.1987; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRUCKNER R, 1992, GENE, V122, P187, DOI 10.1016/0378-1119(92)90048-T; Bruckner R, 1997, FEMS MICROBIOL LETT, V151, P1; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DEBABOV DV, 1996, J BACTERIOL, V178, P2869; FISCHER W, 1988, ADV MICROB PHYSIOL, V29, P233, DOI 10.1016/S0065-2911(08)60349-5; Franklin MJ, 1996, J BACTERIOL, V178, P2186, DOI 10.1128/jb.178.8.2186-2195.1996; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; GOTZ F, 1981, J BACTERIOL, V145, P74; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; HEATON MP, 1992, J BACTERIOL, V174, P4707, DOI 10.1128/JB.174.14.4707-4717.1992; HEPTINSTALL S, 1970, NATURE, V225, P519, DOI 10.1038/225519a0; IORDANESCU S, 1976, J GEN MICROBIOL, V96, P277, DOI 10.1099/00221287-96-2-277; IWANAGA S, 1994, CIBA F SYMP, V186, P160; Jack RW, 1996, APPL ENVIRON MICROB, V62, P2897, DOI 10.1128/AEM.62.8.2897-2903.1996; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KOCH HU, 1984, EUR J BIOCHEM, V138, P357, DOI 10.1111/j.1432-1033.1984.tb07923.x; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; MURPHY E, 1985, EMBO J, V4, P3357, DOI 10.1002/j.1460-2075.1985.tb04089.x; Nes IF, 1996, ANTON LEEUW INT J G, V70, P113, DOI 10.1007/BF00395929; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; Otto M, 1998, FEMS MICROBIOL LETT, V166, P203, DOI 10.1016/S0378-1097(98)00333-4; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Peschel A, 1996, FEMS MICROBIOL LETT, V137, P279; Peschel A, 1997, MOL GEN GENET, V254, P312, DOI 10.1007/s004380050421; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; POLLACK JH, 1994, J BACTERIOL, V176, P7252, DOI 10.1128/JB.176.23.7252-7259.1994; POOLEY HM, 1994, BACTERIAL CELL WALL; SAHL HG, 1995, EUR J BIOCHEM, V230, P827, DOI 10.1111/j.1432-1033.1995.tb20627.x; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WU T, 1994, ANTIMICROB AGENTS CH, V38, P729, DOI 10.1128/AAC.38.4.729; YOUNGMAN P, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P65	40	762	787	0	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8405	8410		10.1074/jbc.274.13.8405	http://dx.doi.org/10.1074/jbc.274.13.8405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085071	hybrid			2022-12-25	WOS:000079451600013
J	Prescott, SM				Prescott, SM			A thematic series on kinases and phosphatases that regulate lipid signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.								0	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8345	8345		10.1074/jbc.274.13.8345	http://dx.doi.org/10.1074/jbc.274.13.8345			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085059	hybrid			2022-12-25	WOS:000079451600001
J	Stempka, L; Schnolzer, M; Radke, S; Rincke, G; Marks, F; Gschwendt, M				Stempka, L; Schnolzer, M; Radke, S; Rincke, G; Marks, F; Gschwendt, M			Requirements of protein kinase C delta for catalytic function - Role of glutamic acid 500 and autophosphorylation on serine 643	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; TYROSINE PHOSPHORYLATION; PHORBOL ESTER; PKC-DELTA; ADDITIONAL MEMBERS; ENZYMATIC-ACTIVITY; MASS-SPECTROMETRY; IMMUNOGLOBULIN-E; IN-VIVO; ACTIVATION	Recently, we reported that, in contrast to protein kinase C (PKC) alpha and beta(II), PKC delta does not require phosphorylation of a specific threonine (Thr(505)) in the activation loop for catalytic competence (Stempka ct al, (1997) J, Biol, Chem, 272, 6805-6811). Here, we show that the acidic residue glutamic acid 500 (Glu(500)) in the activation loop is important for the catalytic function of PKC delta, A Glu(500) to valine mutant shows 76 and 73% reduced kinase activity toward autophosphorylation and substrate phosphorylation, respectively. With regard to thermal stability and inhibition by the inhibitors Go6976 and Go6983 the mutant does not differ from the wild type, indicating that the general conformation of the molecule is not altered by the site directed mutagenesis. Thus, Glu(500) in the activation loop of PKC delta might take over at least part of the role of the phosphate groups on Thr(497) and Thr(500) Of PKC alpha and beta(II), respectively. Accordingly, PKC delta exhibits kinase activity and is able to autophosphorylate probably without posttranslational modification. Autophosphorylation of PKC delta in vitro occurs on Ser(643), as demonstrated by matrix-assisted laser desorption ionization mass spectrometry of tryptic peptides of autophosphorylated PKC delta wild type and mutants. A peptide containing this site is phosphorylated also in vivo, i.e, in recombinant PKC delta purified from baculovirus-infected insect cells. A Ser(643) to alanine mutation indicates that autophosphorylation of Ser(643) is not essential for the kinase activity of PKC delta, Probably additional (auto)phosphorylation site(s) exist that have not yet been identified.	German Canc Res Ctr, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Gschwendt, M (corresponding author), German Canc Res Ctr, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	gschwendt@dbfi-heidelberg.de						Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Blobe GC, 1996, CANCER SURV, V27, P213; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GSCHWENDT M, 1986, BIOCHEM BIOPH RES CO, V137, P766, DOI 10.1016/0006-291X(86)91145-9; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hunn M, 1997, FEBS LETT, V400, P226, DOI 10.1016/S0014-5793(96)01395-6; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Li WQ, 1996, ONCOGENE, V13, P731; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; LIEBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MAIZELS ET, 1992, J BIOL CHEM, V267, P17061; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Marks Friedrich, 1996, P81, DOI 10.1002/9783527615032.ch3; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; ORR JW, 1994, J BIOL CHEM, V269, P27715; PARKER PJ, 1997, PROTEIN KINASE C; Schnolzer M, 1997, INT J MASS SPECTROM, V169, P263, DOI 10.1016/S0168-1176(97)00233-4; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang WJ, 1997, J BIOL CHEM, V272, P76; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZHANG J, 1994, J BIOL CHEM, V269, P19578	54	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8886	8892		10.1074/jbc.274.13.8886	http://dx.doi.org/10.1074/jbc.274.13.8886			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085132	hybrid			2022-12-25	WOS:000079451600074
J	Wong, L; Deb, TB; Thompson, SA; Wells, A; Johnson, GR				Wong, L; Deb, TB; Thompson, SA; Wells, A; Johnson, GR			A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC-CANCER; TYROSINE PHOSPHORYLATION; EPITHELIAL-CELLS; KINASE-ACTIVITY; AUTOPHOSPHORYLATION SITES; HEPARAN-SULFATE; HUMAN-PLACENTA; ERBB-2 KINASE; FACTOR FAMILY; FACTOR-ALPHA	The epidermal growth factor receptor (EGFR) mediates the actions of a family of bioactive peptides that include epidermal growth factor (EGF) and amphiregulin (AR). Here we have studied AR and EGF mitogenic signaling in EGFR devoid NR6 fibroblasts that ectopically express either wild type EGFR (WT) or a truncated EGFR that lacks the three major sites of autophosphorylation (c'1000). COOH-terminal truncation of the EGFR significantly impairs the ability of AR to (i) stimulate DNA synthesis, (ii) elicit Elk-1 transactivation, and (iii) generate sustained enzymatic activation of mitogen-activated protein kinase. EGFR truncation had no significant effect on AR binding to receptor but did result in defective GRB2 adaptor function. In contrast, EGFR truncation did not impair EGF mitogenic signaling, and in c'1000 cells EGF was able to stimulate the association of ErbB2 with GRB2 and SHC. Elk-1 transactivation was monitored when either ErbB2 or a truncated dominant-negative ErbB2 mutant (ErbB2-(1-813)) was overexpressed in cells. Overexpression of full-length ErbB2 resulted in a strong constitutive transactivation of Elk-1 in c'1000 but only slightly stimulated Elk-1 in WT or parental NR6 cells. Conversely, overexpression of ErbB2-(1-813) inhibited EGF-stimulated Elk-1 transactivation in c'1000 but not in WT cells. Thus, the cytoplasmic tail of the EGFR plays a critical role in AR mitogenic signaling but is dispensable for EGF, since EGF-activated truncated EGFRs can signal through ErbB2.	US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA; Berlex Biosci, Dept Prot Chem & Biophys, Richmond, CA 94804 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35294 USA	US Food & Drug Administration (FDA); University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Johnson, GR (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Cytokine Biol, Bldg 29A,Rm 3B-16,8800 Rockville Pike, Bethesda, MD 20892 USA.			Wells, Alan/0000-0002-1637-8150	PHS HHS [R01-54739] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1992, CANCER RES, V52, P3224; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; EBERT M, 1994, CANCER RES, V54, P3959; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANES PW, 1994, ONCOGENE, V9, P3601; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; JOHNSON GR, 1993, J BIOL CHEM, V268, P18835; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI NX, 1994, ONCOGENE, V9, P3457; LYSIAK JJ, 1995, PLACENTA, V16, P359, DOI 10.1016/0143-4004(95)90093-4; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PIPEKORN M, 1994, J CELL PHYSL, V159, P114; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Qian XL, 1996, ONCOGENE, V13, P2149; RICCI A, 1995, ONCOGENE, V11, P1519; Saeki T, 1995, JPN J CLIN ONCOL, V25, P240; SAEKI T, 1992, CANCER RES, V52, P3467; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEHGAL I, 1994, MOL BIOL CELL, V5, P339, DOI 10.1091/mbc.5.3.339; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SOLER C, 1994, ONCOGENE, V9, P2207; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Thompson SA, 1996, J BIOL CHEM, V271, P17927, DOI 10.1074/jbc.271.30.17927; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YOKOYAMA M, 1995, INT J ONCOL, V6, P625	69	17	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8900	8909		10.1074/jbc.274.13.8900	http://dx.doi.org/10.1074/jbc.274.13.8900			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085134	hybrid			2022-12-25	WOS:000079451600076
J	Fazio, S; Linton, MF; Hasty, AH; Swift, LL				Fazio, S; Linton, MF; Hasty, AH; Swift, LL			Recycling of apolipoprotein E in mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; HEPARAN-SULFATE PROTEOGLYCANS; BONE-MARROW TRANSPLANTATION; E-DEFICIENT MICE; LIPOPROTEIN RECEPTOR; PERITONEAL-MACROPHAGES; GOLGI-APPARATUS; HEPATIC GOLGI; APOPROTEIN-E; BETA-VLDL	Following the internalization of low density lipoprotein (LDL) by the LDL receptor within cells, both the lipid and the protein components of LDL are completely degraded within the lysosomes. Remnant lipoproteins are also internalized by cells via the LDL receptor as well as other receptors, but the events following the internalization of these complexes, which use apolipoprotein E (apoE) as their ligand for receptor capture, have not been defined. There is evidence that apoE-containing beta-very low density lipoproteins follow differential intracellular routing depending on their size and apoE content and that apoE internalized with lipoproteins can be resecreted by cultured hepatocytes and fibroblasts. In the present studies, we addressed the question of apoE sparing or recycling as a physiologic phenomenon. Remnant lipoproteins (d < 1.019 g/ml) from normal mouse plasma were iodinated and injected into normal C57BL/6 mice. Livers were collected at 10, 30, 60, and 120 min after injection, and hepatic Golgi fractions were prepared for gel electrophoresis analysis. Golgi preparations were analyzed for galactosyltransferase enrichment (>40-fold above cell homogenate) and by appearance of the Golgis stacks and vesicles on electron microscopy. Iodinated apoE was consistently found in the Golgi fractions peaking at 10 min and disappearing by 2 h after injection. Although traces of apoB48 were present in the Golgi fractions, the apoE/apoB ratio in the Golgi was 50-fold higher compared with serum. Quantitatively similar results were obtained when the very low density lipoprotein remnants were injected into mice deficient in either apoE or the LDL receptor, indicating that the phenomenon of apoE recycling is not influenced by the production of endogenous apoE and is not dependent on the presence of LDL receptors. In addition, radioactive apoE in the Golgi fractions was part of d = 1.019-1.21 g/ml complexes, indicating an association of recycled apoE with either newly formed lipoproteins or the internalized complexes. These studies show that apoE recycling is a physiologic phenomenon in vivo and establish the presence of a unique pathway of intracellular processing of apoE-containing remnant lipoproteins.	Vanderbilt Univ, Ctr Med, Div Endocrinol & Diabet,Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Fazio, S (corresponding author), Vanderbilt Univ, Ctr Med, Div Endocrinol & Diabet,Sch Med, Dept Med, 715 MRB 2, Nashville, TN 37232 USA.	sergio.fazio@mcmail.vanderbilt.edu	Hasty, Alyssa/AAA-2757-2020	Hasty, Alyssa/0000-0001-7302-8045	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057984, R01HL057986] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57986, HL57984, R01 HL057986] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1995, CIRCULATION S, V92, P691; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BROWN MS, 1978, MICROENVIRONMENTS ME, P87; BROWN MS, 1907, J SUPRAMOL STRUCT, V6, P85; CHEN CM, 1995, CIRCULATION S, V92, P691; DAUTRYVARSAT A, 1986, BIOCHIMIE, V68, P375, DOI 10.1016/S0300-9084(86)80004-9; DAVIS RA, 1989, J BIOL CHEM, V264, P8970; ECK MV, 1997, ARTERIOSCLER THROMB, V17, P3117; FAZIO S, 1992, J BIOL CHEM, V267, P6941; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; HAMILTON RL, 1991, J LIPID RES, V32, P529; HARRISON JC, 1988, J LIPID RES, V29, P1439; HASTY AH, 1997, CIRCULATION S, V96, P104; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HORNICK CA, 1985, J CELL BIOL, V100, P1558, DOI 10.1083/jcb.100.5.1558; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACKLE S, 1991, J BIOL CHEM, V266, P1396; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1989, METABOLIC BASIS INHE, V1, P1195; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MORRE DJ, 1969, BIOCHEM BIOPH RES CO, V37, P813; PALMITER RD, 1969, BIOCHIM BIOPHYS ACTA, V178, P35, DOI 10.1016/0005-2744(69)90129-6; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SHIMANO H, 1994, J CLIN INVEST, V93, P2215, DOI 10.1172/JCI117218; SWIFT LL, 1987, J LIPID RES, V28, P207; SWIFT LL, 1980, J CLIN INVEST, V66, P415, DOI 10.1172/JCI109871; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; WONG L, 1989, J CELL PHYSIOL, V141, P441, DOI 10.1002/jcp.1041410227; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	44	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8247	8253		10.1074/jbc.274.12.8247	http://dx.doi.org/10.1074/jbc.274.12.8247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075730	hybrid			2022-12-25	WOS:000079268100089
J	Blankenship, C; Naglich, JG; Whaley, JM; Seizinger, B; Kley, N				Blankenship, C; Naglich, JG; Whaley, JM; Seizinger, B; Kley, N			Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity	ONCOGENE			English	Article						pVHL; VEGF; elongins; Hs-CUL2	ENDOTHELIAL GROWTH-FACTOR; RENAL-CARCINOMA; MESSENGER-RNA; SOMATIC MUTATIONS; HUMAN TISSUES; PROTEIN; TRANSLATION; EXPRESSION; BINDING; HEMANGIOBLASTOMAS	The VHL tumor suppressor gene has previously been reported to encode a protein of 213 amino acid residues. Here we report the identification of a second major VHL gene product with an apparent molecular weight of 18 kD, pVHL18, which appears to arise from alternate translation initiation at a second AUG codon (codon 54) within the VHL open reading frame. In vitro and in vivo studies indicate that the internal codon in the VHL mRNA is necessary and sufficient for production of pVHL18. pVHL18 can bind to elongin B, elongin C, and Hs-CUL2, When reintroduced into renal carcinoma cells that lack a wild-type VHL allele, pVHL18 suppresses basal levels of VEGF expression, restores hypoxia-inducibility of VEGF expression, and inhibits tumor formation in nude mice. These data strongly support the existence of two distinct VHL gene products in VHL tumor suppression.	Genome Therapeut Corp, Dept Funct Genom, Waltham, MA 02154 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08540 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08540 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Kley, N (corresponding author), Genome Therapeut Corp, Dept Funct Genom, 100 Beaver St, Waltham, MA 02154 USA.							ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Corless CL, 1997, HUM PATHOL, V28, P459, DOI 10.1016/S0046-8177(97)90035-6; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GAO JZ, 1995, CANCER RES, V55, P743; GILLMAN EC, 1991, MOL CELL BIOL, V11, P2382, DOI 10.1128/MCB.11.5.2382; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Harlow E., 1988, ANTIBODIES LAB MANUA; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Knebelmann B, 1998, CANCER RES, V58, P226; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Los M, 1996, LAB INVEST, V75, P231; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SHUIN T, 1994, CANCER RES, V54, P2852; Siemeister G, 1996, CANCER RES, V56, P2299; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Zbar Berton, 1995, V25, P219	33	96	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1529	1535		10.1038/sj.onc.1202473	http://dx.doi.org/10.1038/sj.onc.1202473			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102622				2022-12-25	WOS:000078770700002
J	Zucker, SD; Goessling, W; Hoppin, AG				Zucker, SD; Goessling, W; Hoppin, AG			Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION UPTAKE; PERFUSED-RAT-LIVER; PLASMA-MEMBRANE; UDP-GLUCURONOSYLTRANSFERASE; BINDING-PROTEIN; HEPATIC-UPTAKE; SERUM-ALBUMIN; FATTY-ACIDS; PHOSPHOLIPID-BILAYERS; FLIP-FLOP	The liver is responsible for the clearance and metabolism of unconjugated bilirubin, the hydrophobic end-product of heme catabolism. Although several putative bilirubin transporters have been described, it has been alternatively proposed that bilirubin enters the hepatocyte by passive diffusion through the plasma membrane. In order to elucidate the mechanism of bilirubin uptake, we measured the rate of bilirubin transmembrane diffusion (flip-flop) using stopped-flow fluorescence techniques. Unconjugated bilirubin rapidly diffuses through model phosphatidylcholine vesicles, with a first-order rate constant of 5.3 s(-1) (t(1/2) = 130 ms). The flip-flop rate is independent of membrane cholesterol content, phospholipid acyl saturation, and lipid packing, consistent with thermodynamic analyses demonstrating minimal steric constraint to bilirubin transmembrane diffusion. The coincident decrease in pH of the entrapped vesicle volume supports a mechanism whereby the bilirubin molecule crosses the lipid bilayer as the uncharged diacid. Transport of bilirubin by native rat hepatocyte membranes exhibits kinetics comparable with that in model vesicles, suggesting that unconjugated bilirubin crosses cellular membranes by passive diffusion through the hydrophobic lipid core. In contrast, there is no demonstrable flip-flop of bilirubin diglucuronide or bilirubin ditaurate in phospholipid vesicles, yet these compounds rapidly traverse isolated rat hepatocyte membranes, confirming the presence of a facilitated uptake system(s) for hydrophilic bilirubin conjugates.	Univ Cincinnati, Med Ctr, Div Digest Dis, Cincinnati, OH 45267 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Div Pediat Gastroenterol, Boston, MA 02114 USA	University System of Ohio; University of Cincinnati; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Zucker, SD (corresponding author), Univ Cincinnati, Med Ctr, Div Digest Dis, 231 Bethesda Ave,ML 0595, Cincinnati, OH 45267 USA.		Zucker, Stephen/AAJ-3359-2020	Zucker, MD, Stephen/0000-0003-1451-905X; Goessling, Wolfram/0000-0001-9972-1569	NIDDK NIH HHS [DK-51679] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051679] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANCHORDOGUY TJ, 1992, BIOCHIM BIOPHYS ACTA, V1104, P117, DOI 10.1016/0005-2736(92)90139-D; BALDINI G, 1996, BIOCHIM BIOPHYS ACTA, V856, P1; Banhegyi G, 1996, BIOCHEM J, V315, P171, DOI 10.1042/bj3150171; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERK PD, 1994, SEMIN LIVER DIS, V14, P331; BERK PD, 1997, SEMIN LIVER DIS, V7, P165; BONNETT R, 1978, PROC R SOC SER B-BIO, V202, P249, DOI 10.1098/rspb.1978.0066; BRATLID D, 1990, CLIN PERINATOL, V17, P449, DOI 10.1016/S0095-5108(18)30578-5; BRODERSEN R, 1979, J BIOL CHEM, V254, P2364; DEAMER DW, 1983, P NATL ACAD SCI-BIOL, V80, P165, DOI 10.1073/pnas.80.1.165; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; GHERSIEGEA JF, 1988, LIFE SCI, V42, P2515, DOI 10.1016/0024-3205(88)90351-7; GOESSLING W, 1997, HEPATOLOGY, V26, P385; HAYWARD D, 1986, BIOCHIM BIOPHYS ACTA, V860, P149, DOI 10.1016/0005-2736(86)90509-2; IGA T, 1979, AM J PHYSIOL, V236, pC9, DOI 10.1152/ajpcell.1979.236.1.C9; JANSEN PLM, 1992, HEPATOLOGY, V15, P532, DOI 10.1002/hep.1840150328; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF319, DOI 10.1152/ajprenal.1996.270.2.F319; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; LEININGERMULLER B, 1994, NEUROSCI LETT, V175, P37, DOI 10.1016/0304-3940(94)91072-3; LEONARD M, 1989, J BIOL CHEM, V264, P5648; MEIER PJ, 1990, METHOD ENZYMOL, V192, P534; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; NOGALES D, 1995, J BIOL CHEM, V270, P73, DOI 10.1074/jbc.270.1.73; NOY N, 1992, BIOPHYS CHEM, V42, P177, DOI 10.1016/0301-4622(92)85007-Q; OSTROW JD, 1994, J LIPID RES, V35, P1715; Pascolo L, 1996, BIOCHEM J, V316, P999, DOI 10.1042/bj3160999; PAUMGARTNER G, 1976, CLIN SCI MOL MED, V51, P169, DOI 10.1042/cs0510169; REED RG, 1977, J BIOL CHEM, V252, P7483; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SCHMID R, 1972, NEW ENGL J MED, V287, P703, DOI 10.1056/NEJM197210052871407; Seppen J, 1996, BIOCHEM J, V314, P477, DOI 10.1042/bj3140477; SHEPHERD SRP, 1989, BIOCHEM J, V259, P617, DOI 10.1042/bj2590617; Sottocasa GL, 1996, J HEPATOL, V24, P36; SOTTOCASA GL, 1979, FUNCTION MOL ASPECTS, P451; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; STREMMEL W, 1986, J CLIN INVEST, V78, P822, DOI 10.1172/JCI112646; STREMMEL W, 1990, J HEPATOL, V10, P99, DOI 10.1016/0168-8278(90)90079-7; TIRIBELLI C, 1993, HEPATOLOGY, V17, P715, DOI 10.1002/hep.1840170428; TORRES AM, 1993, P NATL ACAD SCI USA, V90, P8136, DOI 10.1073/pnas.90.17.8136; WEISIGER RA, 1985, P NATL ACAD SCI USA, V82, P1563, DOI 10.1073/pnas.82.5.1563; WENNBERG RP, 1988, PEDIATR RES, V23, P443, DOI 10.1203/00006450-198804000-00021; WISHART GJ, 1978, BIOCHEM J, V174, P485, DOI 10.1042/bj1740485; Wolkoff AW, 1996, SEMIN LIVER DIS, V16, P121, DOI 10.1055/s-2007-1007225; YANG BJ, 1991, BIOCHEMISTRY-US, V30, P688, DOI 10.1021/bi00217a015; ZUCKER SD, 1994, J BIOL CHEM, V269, P19262; ZUCKER SD, 1995, J BIOL CHEM, V270, P1074, DOI 10.1074/jbc.270.3.1074; ZUCKER SD, 1992, BIOCHEMISTRY-US, V31, P3184, DOI 10.1021/bi00127a020; Zuckert C, 1996, POLIT THEORY, V24, P132, DOI 10.1177/0090591796024001009	54	103	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10852	10862		10.1074/jbc.274.16.10852	http://dx.doi.org/10.1074/jbc.274.16.10852			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196162	hybrid			2022-12-25	WOS:000079751900030
J	Etchegaray, JP; Inouye, M				Etchegaray, JP; Inouye, M			Translational enhancement by an element downstream of the initiation codon in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; BOX; EXPRESSION; PROTEIN; REGION; CSPA	The translation initiation of Escherichia coli mRNAs is known to be facilitated by a cis element upstream of the initiation codon, called the Shine-Dalgarno (SD) sequence. This sequence complementary to the 3' end of 16 S rRNA enhances the formation of the translation initiation complex of the 30 S ribosomal subunit with mRNAs, It has been debated that a cis element called the downstream box downstream of the initiation codon, in addition to the SD sequence, facilitates formation of the translation initiation complex; however, conclusive evidence remains elusive. Here, we show evidence that the downstream box plays a major role in the enhancement of translation initiation in concert with SD.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	inouye@rwja.umdnj.edu			NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAMMEL CS, 1995, GENE DEV, V9, P626, DOI 10.1101/gad.9.5.626; Etchegaray JP, 1998, MOL MICROBIOL, V27, P873, DOI 10.1046/j.1365-2958.1998.00730.x; ETCHEGARAY JP, 1999, IN PRESS; FAXEN M, 1991, NUCLEIC ACIDS RES, V19, P5247, DOI 10.1093/nar/19.19.5247; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; INOUYE M, 1983, EXPT MANIPULATION GE, P15; INOUYE S, 1991, DIRECTED MUTAGENESIS, P202; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; ITO K, 1993, P NATL ACAD SCI USA, V90, P302, DOI 10.1073/pnas.90.1.302; Jiang WN, 1996, J BACTERIOL, V178, P4919, DOI 10.1128/jb.178.16.4919-4925.1996; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; MCCARTHY JEG, 1994, TRENDS GENET, V10, P402, DOI 10.1016/0168-9525(94)90057-4; Miller JH., 1972, EXPT MOL GENETICS; Mitta M, 1997, MOL MICROBIOL, V26, P321, DOI 10.1046/j.1365-2958.1997.5771943.x; NAGAI H, 1991, P NATL ACAD SCI USA, V88, P10515, DOI 10.1073/pnas.88.23.10515; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; Resch A, 1996, EMBO J, V15, P4740, DOI 10.1002/j.1460-2075.1996.tb00851.x; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; RON EZ, 1966, SCIENCE, V153, P1119, DOI 10.1126/science.153.3740.1119; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SHEAN CS, 1992, CELL, V70, P513, DOI 10.1016/0092-8674(92)90175-C; Sprengart ML, 1997, MOL MICROBIOL, V24, P19, DOI 10.1046/j.1365-2958.1997.3161684.x; Sprengart ML, 1996, EMBO J, V15, P665, DOI 10.1002/j.1460-2075.1996.tb00399.x; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; VIND J, 1993, J MOL BIOL, V231, P678, DOI 10.1006/jmbi.1993.1319; Winzeler E, 1997, J BACTERIOL, V179, P3981, DOI 10.1128/jb.179.12.3981-3988.1997; Wu XQ, 1996, EMBO J, V15, P4734, DOI 10.1002/j.1460-2075.1996.tb00850.x; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	28	83	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10079	10085		10.1074/jbc.274.15.10079	http://dx.doi.org/10.1074/jbc.274.15.10079			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187788	hybrid			2022-12-25	WOS:000079663500027
J	Bogerd, HP; Benson, RE; Truant, R; Herold, A; Phingbodhipakkiya, M; Cullen, BR				Bogerd, HP; Benson, RE; Truant, R; Herold, A; Phingbodhipakkiya, M; Cullen, BR			Definition of a consensus transportin-specific nucleocytoplasmic transport signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN IMPORT; RNA-BINDING-PROTEIN; HNRNP A1; EXPORT SIGNAL; IDENTIFICATION; CYTOPLASM; RECEPTOR; PATHWAY; RANGTP	The low cytoplasmic and high nuclear concentration of the GTP-bound form of Ran provides directionality for both nuclear protein import and export. Both import and export factors bind RanGTP directly, yet this interaction produces opposite effects; in the former case, RanGTP binding induces nuclear cargo release, whereas in the latter, RanGTP binding induces nuclear cargo assembly. Therefore, nuclear import and export receptors and their protein recognition sites are predicted to be distinct. Nevertheless, the similar to 38-amino acid M9 sequence present in heterogeneous nuclear ribonucleoprotein Al has been reported to serve as both a nuclear localization signal and a nuclear export signal, even though only one protein, the nuclear import factor transportin, has been shown to bind M9 directly. We have used a combination of mutational randomization followed by selection for transportin binding to exhaustively define amino acids in M9 that are critical for transportin binding in vivo, As expected, the resultant similar to 12-amino acid transportin-binding consensus sequence is also predictive of nuclear localization signal activity. Surprisingly, however, this extensive mutational analysis failed to dissect M9 nuclear localization signal and nuclear export signal function. Nevertheless, transportin appears unlikely to be the M9 export receptor, as RanGTP can be shown to block M9 binding by transportin not only in vitro, but also in the nucleus in vivo, This analysis therefore predicts the existence of a nuclear export receptor distinct from transportin that nevertheless shares a common protein-binding site on heterogeneous nuclear ribonucleoprotein A1.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.							BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Blair WS, 1997, MOL CELL BIOL, V17, P2888, DOI 10.1128/MCB.17.5.2888; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fridell RA, 1997, J CELL SCI, V110, P1325; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HARPER JW, 1993, CELL, V75, P805; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Izaurralde E, 1998, RNA, V4, P351; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MICHAEL WM, 1995, CELL, V83, P415; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; WEIGHARDT F, 1995, J CELL SCI, V108, P545; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3	23	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9771	9777		10.1074/jbc.274.14.9771	http://dx.doi.org/10.1074/jbc.274.14.9771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092666	hybrid			2022-12-25	WOS:000079451800085
J	Mahajan, S; Ghosh, S; Sudbeck, EA; Zheng, YG; Downs, S; Hupke, M; Uckun, FM				Mahajan, S; Ghosh, S; Sudbeck, EA; Zheng, YG; Downs, S; Hupke, M; Uckun, FM			Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide]	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; SRC FAMILY; CRYSTAL-STRUCTURE; CELL-DEATH; APOPTOSIS; RECEPTOR; COMPLEX; INHIBITORS; REGULATOR; PROTEINS	In a systematic effort to design potent inhibitors of the anti-apoptotic tyrosine kinase BTK (Bruton's tyrosine kinase) as anti-leukemic agents with apoptosis-promoting and chemosensitizing properties, we have constructed a three-dimensional homology model of the BTK kinase domain. Our modeling studies revealed a distinct rectangular binding pocket near the hinge region of the BTK kinase domain with Leu(460), Tyr(476) Arg(525), and Asp(539) residues occupying the corners of the rectangle. The dimensions of this rectangle are approximately 18 x 8 x 9 x 17 Angstrom, and the thickness of the pocket is approximately 7 Angstrom. Advanced docking procedures were employed for the rational design of leflunomide metabolite (LFM) analogs with a high likelihood to bind favorably to the catalytic site within the kinase domain of BTK. The lead compound LFM-A13, for which we calculated a K-i value of 1.4 mu M, inhibited human BTK in vitro with an IC50 value of 17.2 +/- 0.8 mu M. Similarly, LFRIA13 inhibited recombinant BTK expressed in a baculovirus expression vector system with an IC50 value of 2.5 mu M, The energetically favorable position of LFM-A13 in the binding pocket is such that its aromatic ring is close to Tyr(476), and its substituent group is sandwiched between residues Arg(525) and Asp(539). In addition, LFM-A13 is capable of favorable hydrogen bonding interactions with BTK via Asp(539) and Arg(525) residues. Besides its remarkable potency in BTK kinase assays, LFM-A13 was also discovered to be a highly specific inhibitor of BTK, Even at concentrations as high as 100 mu g/ml (similar to 278 mu M), this novel inhibitor did not affect the enzymatic activity of other protein tyrosine kinases, including JAK1, JAK3, HCK, epidermal growth factor receptor kinase, and insulin receptor kinase, In accordance with the anti-apoptotic function of BTK, treatment of BTK+ B-lineage leukemic cells with LFM-A13 enhanced their sensitivity to ceramide- or vincristine-induced apoptosis, To our knowledge, LFM-A13 is the first BTK-specific tyrosine kinase inhibitor and the first anti-leukemic agent targeting BTK.	Huges Inst, Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Huges Inst, Dept Biol Struct, St Paul, MN 55113 USA; Huges Inst, Dept Chem, St Paul, MN 55113 USA; Huges Inst, Dept Biochem, St Paul, MN 55113 USA; Huges Inst, Dept Expt Oncol, St Paul, MN 55113 USA; Huges Inst, Drug Discovery Program, St Paul, MN 55113 USA		Uckun, FM (corresponding author), Huges Inst, Parker Hughes Canc Ctr, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.	Fatih_Uckun@mercury.ih.org		Uckun, Fatih M./0000-0001-9334-183X				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217; BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743; BRUNGER AT, 1992, X PLOR VERSION 3 1; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goodman PA, 1998, J BIOL CHEM, V273, P17742, DOI 10.1074/jbc.273.28.17742; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo EA, 1996, J MED CHEM, V39, P4608, DOI 10.1021/jm9604437; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; *MOL SIM INC, 1996, INS 2; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; SAOUAF SJ, 1995, J BIOL CHEM, V270, P27072, DOI 10.1074/jbc.270.45.27072; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SJOGREN EB, 1991, J MED CHEM, V34, P3295, DOI 10.1021/jm00115a020; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; Uckun FM, 1998, BIOCHEM PHARMACOL, V56, P683, DOI 10.1016/S0006-2952(98)00122-1; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; WHYLLIE AH, 1980, INT REV CYTOL, V68, P251; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; [No title captured]	40	185	245	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9587	9599		10.1074/jbc.274.14.9587	http://dx.doi.org/10.1074/jbc.274.14.9587			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092645	hybrid			2022-12-25	WOS:000079451800064
J	Snyders, S; Kohorn, BD				Snyders, S; Kohorn, BD			TAKs, thylakoid membrane protein kinases associated with energy transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; PHOSPHORYLATION; SPECIFICITY; ACTIVATION; RECEPTOR	The phosphorylation of proteins within the eukaryotic photosynthetic membrane is thought to regulate a number of photosynthetic processes in land plants and algae. Both light quality and intensity influence protein kinase activity via the levels of reductants produced by the thylakoid electron transport chain. We have isolated a family of proteins called TAKs, Arabidopsis thylakoid membrane threonine kinases that phosphorylate the light harvesting complex proteins. TAK activity is enhanced by reductant and is associated with the photosynthetic reaction center II and the cytochrome b(6)f complex. TAKs are encoded by a gene family that has striking similarity to transforming growth factor beta receptors of metazoans. Thus thylakoid protein phosphorylation may be regulated by a cascade of reductant-controlled membrane-bound protein kinases.	Duke Univ, Dev Cell & Mol Biol Grp, Dept Bot, Durham, NC 27708 USA	Duke University	Kohorn, BD (corresponding author), Duke Univ, Dev Cell & Mol Biol Grp, Dept Bot, Box 91000, Durham, NC 27708 USA.	kohorn@acpub.duke.edu						Allen J. F., 1981, NATURE, V291, P21; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; AUCHINCLOSS AH, 1992, J BIOL CHEM, V267, P10439; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GAL A, 1995, PHOTOSYNTHESIS LIGHT, V3, P341; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; He ZH, 1996, J BIOL CHEM, V271, P19789, DOI 10.1074/jbc.271.33.19789; HENRIK N, 1997, PROTEIN ENG, V10, P1; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; KEREN N, 1995, PHOTOSYNTHESIS LIGHT, V4, P299; KOHORN BD, 1992, P NATL ACAD SCI USA, V89, P10989, DOI 10.1073/pnas.89.22.10989; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Race HL, 1996, BIOCHEMISTRY-US, V35, P13006, DOI 10.1021/bi961809k; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SMITH TA, 1991, P NATL ACAD SCI USA, V88, P5159, DOI 10.1073/pnas.88.12.5159; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	22	87	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9137	9140		10.1074/jbc.274.14.9137	http://dx.doi.org/10.1074/jbc.274.14.9137			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092584	hybrid			2022-12-25	WOS:000079451800003
J	Tobiason, DM; Lenich, AG; Glasgow, AC				Tobiason, DM; Lenich, AG; Glasgow, AC			Multiple DNA binding activities of the novel site-specific recombinase, Piv, from Moraxella lacunata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MU-DNA; HIN RECOMBINASE; PILIN GENES; PROTEIN; TRANSPOSITION; INVERSION; COMPLEX; CLEAVAGE; PROMOTER	The recombinase, Piv, is essential for site-specific DNA inversion of the type IV pilin DNA segment in Moraxella lacunata and Moraxella bovis. Piv shows significant homology with the transposases of the IS110/IS492 family of insertion elements, but, surprisingly, Piv contains none of the conserved amino acid motifs of the lambda Int or Hin/Res families of site-specific recombinases. Therefore, Piv may mediate site-specific recombination by a novel mechanism, To begin to determine how Piv may assemble a synaptic nucleoprotein structure for DNA cleavage and strand exchange, we have characterized the interaction of Piv with the DNA inversion region of M. lacunata, Gel shift and nuclease/chemical protection assays, competition and dissociation rate analyses, and cooperativity studies indicate that Piv binds two distinct recognition sequences. Cine recognition sequence, found at multiple sites within and outside of the invertible segment, is bound by Piv protomers with high affinity. The second recognition sequence is located at the recombination cross-over sites at the ends of the invertible element; Piv interacts with this sequence as an oligomer with apparent low affinity. A model is proposed for the role of the different Piv binding sites of the M. lacunata inversion region in the formation of an active synaptosome.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA	Emory University	Glasgow, AC (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, 1510 Clifton Rd, Atlanta, GA 30322 USA.				NIGMS NIH HHS [GM49794-05, R01 GM049794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049794, R29GM049794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; Craig N., 1996, ESCHERICHIA COLI SAL, V2, P2339; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DIGUAN C, 1988, GENE, V67, P21, DOI 10.1016/0378-1119(88)90004-2; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FULKS KA, 1990, J BACTERIOL, V172, P310, DOI 10.1128/JB.172.1.310-316.1990; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; Hallet B, 1997, FEMS MICROBIOL REV, V21, P157, DOI 10.1016/S0168-6445(97)00055-7; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; KOO HS, 1990, BIOCHEMISTRY-US, V29, P4227, DOI 10.1021/bi00469a027; Kristensen HH, 1996, J MOL BIOL, V260, P113, DOI 10.1006/jmbi.1996.0385; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; LENICH AG, 1994, J BACTERIOL, V176, P4160, DOI 10.1128/JB.176.13.4160-4164.1994; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARRS CF, 1990, J BACTERIOL, V172, P4370, DOI 10.1128/jb.172.8.4370-4377.1990; Maxam A M, 1980, Methods Enzymol, V65, P499; Merickel SK, 1998, GENE DEV, V12, P2803, DOI 10.1101/gad.12.17.2803; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; RICHET E, 1988, CELL, V52, P9, DOI 10.1016/0092-8674(88)90526-0; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; ROZSA FW, 1991, J BACTERIOL, V173, P4000, DOI 10.1128/jb.173.13.4000-4006.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; THOMPSON JF, 1987, J MOL BIOL, V195, P481, DOI 10.1016/0022-2836(87)90177-X	28	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9698	9706		10.1074/jbc.274.14.9698	http://dx.doi.org/10.1074/jbc.274.14.9698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092658	hybrid			2022-12-25	WOS:000079451800077
J	Albini, A; Florio, T; Giunciuglio, D; Masiello, L; Carlone, S; Corsaro, A; Thellung, S; Cai, T; Noonan, DM; Schettini, G				Albini, A; Florio, T; Giunciuglio, D; Masiello, L; Carlone, S; Corsaro, A; Thellung, S; Cai, T; Noonan, DM; Schettini, G			Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis	FASEB JOURNAL			English	Article						endothelial cells; monocytes; macrophages; invasion; neovascularization; somatostatin receptors	PHOSPHOTYROSINE PHOSPHATASE-ACTIVITY; VASCULAR ENDOTHELIAL-CELLS; MONOCYTE CHEMOTAXIS; TAT PROTEIN; TYROSINE-PHOSPHATASE; PANCREATIC-CANCER; BASEMENT-MEMBRANE; IN-VITRO; PROLIFERATION; RECEPTOR	Somatostatin and its analogs are active in the inhibition of SST receptor-positive endocrine neoplasms, but their activity and mechanism in non endocrine tumors is not clear. Somatostatin potently inhibited growth of a Kaposi's sarcoma xenograft in nude mice, yet in vitro the tumor cells did not express any known somatostatin receptors and were not growth inhibited by somatostatin. Histological examination revealed limited vascularization in the somatostatin-treated tumors as compared with the controls. Somatostatin was a potent inhibitor of angiogenesis in an in vivo assay. In vitro, somatostatin inhibited endothelial cell growth and invasion. Migration of monocytes, important mediators of the angiogenic cascade, was also inhibited by somatostatin. Both cells types expressed somatostatin receptor mRNAs. These data demonstrate that somatostatin is a potent antitumor angiogenesis compound directly affecting both endothelial and monocytic cells. The debated function of somatostatin in tumor treatment and the design of therapeutic protocols should be reexamined considering these data.	Ist Nazl Ric Canc, Modulo Progress Neoplast, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Serv Farmacol & Neurosci, I-16132 Genoa, Italy; Univ Genoa, Dept Oncol, Sez Farmacol, I-16132 Genoa, Italy; Ctr Biotecnol Avanzate, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa	Albini, A (corresponding author), Ist Nazl Ric Canc, Adv Biotechnol Ctr, Tumor Progress Sect, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		FLORIO, TULLIO/ABG-3182-2020; Noonan, Douglas M/A-8620-2010; Thellung, Stefano/L-8802-2015; Florio, Tullio/A-2211-2012	Noonan, Douglas M/0000-0001-8058-0719; Thellung, Stefano/0000-0002-2010-331X; Florio, Tullio/0000-0002-2394-996X; Albini, Adriana/0000-0002-9624-5103; Corsaro, Alessandro/0000-0003-4565-7914				Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, ONCOGENE, V12, P289; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ALBINI A, 1992, INT J CANCER, V52, P234, DOI 10.1002/ijc.2910520214; Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895; BENELLI R, 1994, RES VIROLOGY, V145, P251, DOI 10.1016/S0923-2516(07)80030-6; Benelli R, 1998, AIDS, V12, P261, DOI 10.1097/00002030-199803000-00003; BENSAID M, 1992, INT J CANCER, V50, P796, DOI 10.1002/ijc.2910500522; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHEUNG NW, 1995, ENDOCRINOLOGY, V136, P4174, DOI 10.1210/en.136.10.4174; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Danesi R, 1997, CLIN CANCER RES, V3, P265; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Fisher WE, 1998, J NATL CANCER I, V90, P322, DOI 10.1093/jnci/90.4.322; Florio T, 1996, J BIOL CHEM, V271, P6129, DOI 10.1074/jbc.271.11.6129; FLORIO T, 1992, J BIOL CHEM, V267, P24169; Florio T, 1996, J MOL ENDOCRINOL, V17, P89, DOI 10.1677/jme.0.0170089; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Keri G, 1996, P NATL ACAD SCI USA, V93, P12513, DOI 10.1073/pnas.93.22.12513; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Lafrenie RM, 1996, J IMMUNOL, V157, P974; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MARTINET Y, 1994, J IMMUNOL METHODS, V174, P209, DOI 10.1016/0022-1759(94)90024-8; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; PASSANITI A, 1992, LAB INVEST, V67, P519; POLVERINI PJ, 1997, REGULATION ANGIOGENE, P11; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; Reardon DB, 1997, MOL ENDOCRINOL, V11, P1062, DOI 10.1210/me.11.8.1062; REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427; REUBI JC, 1994, INT J CANCER, V56, P681, DOI 10.1002/ijc.2910560513; REUBI JC, 1995, TRENDS PHARMACOL SCI, V16, P110, DOI 10.1016/S0165-6147(00)88992-0; Robbins RJ, 1996, METABOLISM, V45, P98, DOI 10.1016/S0026-0495(96)90096-7; SCHALLY AV, 1988, CANCER RES, V48, P6977; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THOMPSON EW, 1991, CANCER RES, V51, P2670; WIEDERMANN CJ, 1993, BLOOD, V82, P954; WOLTERING E, 1990, J SURG RES, V50, P245	45	107	114	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					647	655		10.1096/fasebj.13.6.647	http://dx.doi.org/10.1096/fasebj.13.6.647			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094925				2022-12-25	WOS:000079527200006
J	Shimura, M; Tanaka, Y; Nakamura, S; Minemoto, Y; Yamashita, K; Hatake, K; Takaku, F; Ishizaka, Y				Shimura, M; Tanaka, Y; Nakamura, S; Minemoto, Y; Yamashita, K; Hatake, K; Takaku, F; Ishizaka, Y			Micronuclei formation and aneuploidy induced by Vpr, an accessory gene of human immunodeficiency virus type 1	FASEB JOURNAL			English	Article						HIV-1/Vpr; multinucleation; genomic instability	CELL-CYCLE CONTROL; WILD-TYPE P53; VIRION-ASSOCIATED PROTEIN; PRODUCTIVE INFECTION; MAMMALIAN-CELLS; HIV-1 VPR; TRANSCRIPTIONAL ACTIVATION; CHECKPOINT CONTROL; HUMAN-LYMPHOCYTES; GROWTH ARREST	Vpr, an accessory gene of HIV-1, induces cell cycle abnormality with accumulation at G2/M phase and increased ploidy, Since abnormality of mitotic checkpoint control provides a molecular basis of genomic instability, we studied the effects of Vpr on genetic integrity using a stable clone, named MIT-23, in which Vpr expression is controlled by the tetracycline-responsive promoter. Treatment of MIT-23 cells with doxycycline (DOX) induced Vpr expression with a giant multinuclear cell formation. Increased micronuclei (MIN) formation was also detected in these cells. Abolishment of Vpr expression by DOX removal induced numerous asynchronous cytokinesis in the multinuclear cells with leaving MIN in cytoplasm, suggesting that the transient Vpr expression could cause genetic unbalance. Consistent with this expectation, MIT-23 cells, originally pseudodiploid cells, became aneuploid after repeated expression of Vpr, Experiments using deletion mutants of Vpr revealed that the domain inducing MIN formation as well as multinucleation was located in the carboxy-terminal region of Vpr protein. These results suggest that Vpr induces genomic instability, implicating the possible role in the development of AIDS-related malignancies.	Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; Tokyo Metropolitan Inst Med Sci, Dept Microbiol, Bunkyo Ku, Tokyo 1138613, Japan; Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol Biol & Cellular Biol, Kanazawa, Ishikawa 9200934, Japan; Jichi Med Sch, Minami Kawachi, Tochigi 3290498, Japan	National Center for Global Health & Medicine - Japan; Tokyo Metropolitan Institute of Medical Science; Kanazawa University; Jichi Medical University	Ishizaka, Y (corresponding author), Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.imcj.go.jp						ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Andreassen PR, 1996, MUTAT RES-FUND MOL M, V372, P181, DOI 10.1016/S0027-5107(96)00138-8; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; BENN PA, 1992, HUMAN CYTOGENETICS P, P91; BERAL V, 1991, LANCET, V337, P805, DOI 10.1016/0140-6736(91)92513-2; Biggar RJ, 1996, INT J CANCER, V68, P754; Bodeus M, 1997, RES VIROLOGY, V148, P207, DOI 10.1016/S0923-2516(97)83990-8; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cohen EA, 1996, CURR TOP MICROBIOL, V214, P219; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; EASTMOND DA, 1989, ENVIRON MOL MUTAGEN, V13, P34, DOI 10.1002/em.2850130104; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gu JR, 1997, MOL CELL BIOL, V17, P4033, DOI 10.1128/MCB.17.7.4033; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HATTORI N, 1990, P NATL ACAD SCI USA, V87, P8080, DOI 10.1073/pnas.87.20.8080; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEVY DN, 1995, J VIROL, V69, P1243, DOI 10.1128/JVI.69.2.1243-1252.1995; LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWENTHAL DA, 1988, CANCER, V61, P2325, DOI 10.1002/1097-0142(19880601)61:11<2325::AID-CNCR2820611130>3.0.CO;2-0; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; Macreadie IG, 1997, FEBS LETT, V410, P145, DOI 10.1016/S0014-5793(97)00542-5; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARZIO PD, 1995, J VIROL, V69, P7909; MAYER V, 1995, EUR J CANCER PREV, V4, P211, DOI 10.1097/00008469-199506000-00001; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; OHTA H, 1994, EMBO J, V13, P2044, DOI 10.1002/j.1460-2075.1994.tb06479.x; Ohtsuki T, 1997, BIOCHEM BIOPH RES CO, V230, P81, DOI 10.1006/bbrc.1996.5887; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; PENN I, 1978, SURGERY, V83, P492; PLANELLES V, 1995, J VIROL, V69, P5883, DOI 10.1128/JVI.69.9.5883-5889.1995; Planelles V, 1996, J VIROL, V70, P2516, DOI 10.1128/JVI.70.4.2516-2524.1996; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; SCHMID W, 1975, MUTAT RES, V31, P9, DOI 10.1016/0165-1161(75)90058-8; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Shimura M, 1997, FEBS LETT, V417, P379, DOI 10.1016/S0014-5793(97)01327-6; SPECTOR BD, 1978, CLIN IMMUNOL IMMUNOP, V11, P12, DOI 10.1016/0090-1229(78)90200-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Wang LL, 1996, GENE, V178, P7, DOI 10.1016/0378-1119(96)00312-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTERVELT P, 1992, J VIROL, V66, P3925, DOI 10.1128/JVI.66.6.3925-3931.1992; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YU XF, 1990, J VIROL, V64, P5688, DOI 10.1128/JVI.64.11.5688-5693.1990; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; Zhang CS, 1997, VIROLOGY, V230, P103, DOI 10.1006/viro.1997.8459; ZHAO LJ, 1994, J BIOL CHEM, V269, P15577	70	41	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					621	637		10.1096/fasebj.13.6.621	http://dx.doi.org/10.1096/fasebj.13.6.621			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094923				2022-12-25	WOS:000079527200004
J	Cascieri, MA; Koch, GE; Ber, E; Sadowski, SJ; Louizides, D; de Laszlo, SE; Hacker, C; Hagmann, WK; MacCoss, M; Chicchi, GG; Vicario, PP				Cascieri, MA; Koch, GE; Ber, E; Sadowski, SJ; Louizides, D; de Laszlo, SE; Hacker, C; Hagmann, WK; MacCoss, M; Chicchi, GG; Vicario, PP			Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; BINDING; HYPERGLYCEMIA; DELETION	We have identified a series of potent, orally bioavailable, non-peptidyl, triarylimidazole and triarylpyrrole glucagon receptor antagonists. 2-(4-Pyridyl)-5-(4-chlorophenyl)-3-(5-bromo-2-propyloxyphenyl)pyrrole (L-168,049), a prototypical member of this series, inhibits binding of labeled glucagon to the human glucagon receptor with an IC50 = 3.7 +/- 3.4 nM (n = 7) but does not inhibit binding of labeled glucagon-like peptide to the highly homologous human glucagon-like peptide receptor at concentrations up to 10 mu M. The binding affinity of L-168,049 for the human glucagon receptor is decreased 24-fold by the inclusion of divalent cations (5 mM), L-168,049 increases the apparent EC50 for glucagon stimulation of adenylyl cyclase in Chinese hamster ovary cells expressing the human glucagon receptor and decreases the maximal glucagon stimulation observed, with a K-b (concentration of antagonist that shifts the agonist dose-response 2-fold) of 25 nM. These data suggest that L-168,049 is a noncompetitive antagonist of glucagon action. Inclusion of L-168,049 increases the rate of dissociation of labeled glucagon from the receptor 4-fold, confirming that the compound is a noncompetitive glucagon antagonist, In addition, we have identified two putative transmembrane domain residues, phenylalanine 184 in transmembrane domain 2 and tyrosine 239 in transmembrane domain 3, for which substitution by alanine reduces the affinity of L-168,049 46- and 4.5-fold, respectively. These mutations do not alter the binding of labeled glucagon, suggesting that the binding sites for glucagon and L-168,049 are distinct.	Merck Res Labs, Dept Mol Pharmacol & Biochem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Cascieri, MA (corresponding author), Merck Res Labs, Dept Mol Pharmacol & Biochem, 80M-213,POB 2000, Rahway, NJ 07065 USA.							BRAND CL, 1994, DIABETOLOGIA, V37, P985, DOI 10.1007/BF00400461; Burcelin R, 1996, DIABETES METAB, V22, P373; Cascieri Margaret A., 1996, Drugs of the Future, V21, P521; Chicchi GG, 1997, J BIOL CHEM, V272, P7765, DOI 10.1074/jbc.272.12.7765; COLLINS JL, 1992, BIOORG MED CHEM LETT, V2, P915, DOI 10.1016/S0960-894X(00)80587-9; DELASZLO SE, 1999, IN PRESS BIOORG MED; Graziano MP, 1996, RECEPTOR CHANNEL, V4, P9; GYSIN B, 1987, J MED CHEM, V30, P1409, DOI 10.1021/jm00391a024; JELENEK LJ, 1993, SCIENCE, V259, P1614; JOHNSON DG, 1982, SCIENCE, V215, P1115, DOI 10.1126/science.6278587; MACNEIL DJ, 1994, BIOCHEM BIOPH RES CO, V198, P328, DOI 10.1006/bbrc.1994.1046; Roden M, 1996, J CLIN INVEST, V97, P642, DOI 10.1172/JCI118460; UNSON CG, 1987, P NATL ACAD SCI USA, V84, P4083, DOI 10.1073/pnas.84.12.4083; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; Unson CG, 1996, P NATL ACAD SCI USA, V93, P310, DOI 10.1073/pnas.93.1.310	15	85	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8694	8697		10.1074/jbc.274.13.8694	http://dx.doi.org/10.1074/jbc.274.13.8694			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085108	hybrid			2022-12-25	WOS:000079451600050
J	Franke, CM; Tiemersma, J; Venema, G; Kok, J				Franke, CM; Tiemersma, J; Venema, G; Kok, J			Membrane topology of the lactococcal bacteriocin ATP-binding cassette transporter protein LcnC - Involvement of LcnC in lactococcin A maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIS SUBSP LACTIS; ESCHERICHIA-COLI; STREPTOCOCCUS-LACTIS; ALKALINE-PHOSPHATASE; P-GLYCOPROTEIN; ABC TRANSPORTERS; IMMUNITY PROTEIN; CLONING VECTORS; PLASMID; FUSION	Many non-lantibiotic bacteriocins of lactic acid bacteria are produced as precursors with N-terminal leader peptides different from those present in preproteins exported by the general sec-dependent (type II) secretion pathway. These bacteriocins utilize a dedicated (type I) secretion system for externalization. The secretion apparatus for the lactococcins A, B, and M/N (LcnA, B, and M/N) from Lactococcus lactis is composed of the two membrane proteins LcnC and LcnD, LcnC belongs to the ATP-binding cassette transporters, whereas LcnD is a protein with similarities to other accessory proteins of type I secretion systems, This paper shows that the N-terminal part of LcnC is involved in the processing of the precursor of LcnA By making translational fusions of LcnC to the reporter proteins beta-galactosidase (LacZ) and alkaline phosphatase (PhoA*), it was shown that both the N- and C-terminal parts of LcnC are located in the cytoplasm, As the N terminus of LcnC is required for LcnA maturation and is localized in the cytoplasm, we conclude that the processing of the bacteriocin LcnA to its mature form takes place at the cytosolic side of the cytoplasmic membrane.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Kok, J (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	J.Kok@biol.rug.nl	Kok, Jan/C-9972-2012					AXELSSON L, 1995, J BACTERIOL, V177, P2125, DOI 10.1128/jb.177.8.2125-2137.1995; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHOPIN A, 1984, PLASMID, V11, P260, DOI 10.1016/0147-619X(84)90033-7; DANIELSEN S, 1995, MICROBIOL-SGM, V141, P2905, DOI 10.1099/13500872-141-11-2905; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DIAZGUERRA L, 1989, J BACTERIOL, V171, P2906, DOI 10.1128/jb.171.5.2906-2908.1989; DIEP DB, 1994, APPL ENVIRON MICROB, V60, P160, DOI 10.1128/AEM.60.1.160-166.1994; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DOVER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Franke CM, 1996, J BACTERIOL, V178, P1766, DOI 10.1128/jb.178.6.1766-1769.1996; GASSON MJ, 1983, J BACTERIOL, V154, P1; GILMORE MS, 1994, J BACTERIOL, V176, P7335, DOI 10.1128/JB.176.23.7335-7344.1994; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; Hwang JW, 1997, J BACTERIOL, V179, P6264, DOI 10.1128/jb.179.20.6264-6270.1997; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KOK J, 1993, BACTERIOCINS LACTIC, P121; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; NEWTON G, 1991, MOL MICROBIOL, V5, P2511, DOI 10.1111/j.1365-2958.1991.tb02097.x; PEARCE SR, 1992, MOL MICROBIOL, V6, P47, DOI 10.1111/j.1365-2958.1992.tb00836.x; PRINZ WA, 1994, J BACTERIOL, V176, P6410, DOI 10.1128/jb.176.20.6410-6413.1994; QUADRI LEN, 1994, J BIOL CHEM, V269, P12204; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RINCE A, 1994, APPL ENVIRON MICROB, V60, P1652, DOI 10.1128/AEM.60.5.1652-1657.1994; ROTTLANDER E, 1970, MOL GEN GENET, V108, P47, DOI 10.1007/BF00343184; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMON D, 1988, BIOCHIMIE, V70, P559, DOI 10.1016/0300-9084(88)90093-4; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VANBELKUM MJ, 1989, APPL ENVIRON MICROB, V55, P1187, DOI 10.1128/AEM.55.5.1187-1191.1989; VANDEGUCHTE M, 1989, APPL ENVIRON MICROB, V55, P224, DOI 10.1128/AEM.55.1.224-228.1989; VENEMA K, 1994, MOL MICROBIOL, V14, P521, DOI 10.1111/j.1365-2958.1994.tb02186.x; Venema K, 1996, APPL ENVIRON MICROB, V62, P1689, DOI 10.1128/AEM.62.5.1689-1692.1996; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; VENEMA K, 1995, THESIS U GRONINGEN G; VIEIRA J, 1991, GENE, V100, P189, DOI 10.1016/0378-1119(91)90365-I; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WU JH, 1992, J BIOL CHEM, V267, P12570; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhang M, 1996, BIOCHEMISTRY-US, V35, P9728, DOI 10.1021/bi960400s	58	39	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8484	8490		10.1074/jbc.274.13.8484	http://dx.doi.org/10.1074/jbc.274.13.8484			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085080	hybrid			2022-12-25	WOS:000079451600022
J	Martin, V; Ronde, P; Unett, D; Wong, A; Hoffman, TL; Edinger, AL; Doms, RW; Funk, CD				Martin, V; Ronde, P; Unett, D; Wong, A; Hoffman, TL; Edinger, AL; Doms, RW; Funk, CD			Leukotriene binding, signaling, and analysis of HIV coreceptor function in mouse and human leukotriene B-4 receptor-transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PLATELET-ACTIVATING-FACTOR; ACTIVE ULCERATIVE-COLITIS; PROTEIN-COUPLED RECEPTORS; CHEMOKINE RECEPTORS; POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR-CLONING; DIVERSE HUMAN; IN-VIVO; GENE	The mouse leukotriene B-4 receptor (m-BLTR) gene was cloned. Membrane fractions of human embryonic kidney 293 cells stably expressing m-BLTR demonstrated a high affinity and specific binding for leukotriene B-4 (LTB4, K-d = 0.24 +/- 0.03 nM). In competition binding experiments, LTB4 was the most potent competitor (K-i = 0.23 +/- 0.05 nM) followed by 20-hydroxy-LTB4 (K-i = 1.1 +/- 0.2 mu M) and by 6-trans-12-epi-LTB4 and LTD4 (K-i > 1 mu M). In stably transfected Chinese hamster ovary cells, LTB4 inhibited forskolin-activated cAMP production and induced an increase of intracellular calcium, suggesting that this receptor is coupled to G(i)- and G(o)-like proteins. In Xenopus laevis melanophores transiently expressing m-BLTR, LTB4 induced the aggregation of pigment granules, confirming the inhibition of cAMP production induced by LTB4. BLT receptors share significant sequence homology with chemokine receptors (CCR5 and CXCR4) that act as human immunodeficiency virus (HIV) coreceptors. However, among the 16 HIV/SIV strains tested, the human BLT receptor did not act as a coreceptor for virus entry into CD4-expressing cells based on infection and cell-cell fusion assays. In 5-lipoxygenase-deficient mice, the absence of leukotriene B-4 biosynthesis did not detectably alter m-BLT receptor binding in membranes obtained from glycogen-elicited neutrophils. Isolation of the m-BLTR gene will form the basis of future experiments to elucidate the selective role of LTB4, as opposed to cysteinyl-leukotrienes, in murine models of inflammation.	Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 806, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Allegheny Univ Hlth Sci, Dept Pharmacol, Philadelphia, PA 19129 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75235 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Drexel University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Stellar Chance Labs 806, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040880] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58464] Funding Source: Medline; NIAID NIH HHS [AI40880] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARONE FC, 1995, MOL CHEM NEUROPATHOL, V24, P13, DOI 10.1007/BF03160109; BOUCHELOUCHE PN, 1995, EUR J GASTROEN HEPAT, V7, P349; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; DRYDEN P, 1992, PROSTAGLANDINS, V44, P11, DOI 10.1016/0090-6980(92)90103-Z; Edinger AL, 1998, J VIROL, V72, P7934, DOI 10.1128/JVI.72.10.7934-7940.1998; Edinger AL, 1998, VIROLOGY, V249, P367, DOI 10.1006/viro.1998.9306; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; FISHER AR, 1997, THORAX, V52, P1074; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; GRAMINSKI GF, 1993, J BIOL CHEM, V268, P5957; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HILLINGSO J, 1995, CLIN PHARMACOL THER, V57, P335, DOI 10.1016/0009-9236(95)90159-0; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; KJELDSEN J, 1995, PHARMACOL TOXICOL, V77, P371, DOI 10.1111/j.1600-0773.1995.tb01044.x; LEDERER ED, 1993, CELL SIGNAL, V5, P735, DOI 10.1016/0898-6568(93)90034-J; LERNER MR, 1994, TRENDS NEUROSCI, V17, P142, DOI 10.1016/0166-2236(94)90087-6; MCCLINTOCK TS, 1993, ANAL BIOCHEM, V209, P298, DOI 10.1006/abio.1993.1123; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; MIKI I, 1990, BIOCHEM BIOPH RES CO, V166, P342, DOI 10.1016/0006-291X(90)91951-N; Nohgawa M, 1997, J LEUKOCYTE BIOL, V62, P203, DOI 10.1002/jlb.62.2.203; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Owman C, 1996, GENOMICS, V37, P187, DOI 10.1006/geno.1996.0541; Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530; Owman C, 1997, BIOCHEM BIOPH RES CO, V241, P390, DOI 10.1006/bbrc.1997.7822; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18, DOI 10.1002/jlb.59.1.18; Rucker J, 1997, METHOD ENZYMOL, V288, P118; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Shindo K, 1997, THORAX, V52, P1024, DOI 10.1136/thx.52.12.1024; Teixeira MM, 1997, BLOOD, V89, P4566, DOI 10.1182/blood.V89.12.4566; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOSHIKAWA D, 1992, CIRC SHOCK, V38, P29	48	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8597	8603		10.1074/jbc.274.13.8597	http://dx.doi.org/10.1074/jbc.274.13.8597			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085095	hybrid			2022-12-25	WOS:000079451600037
J	Montaner, S; Perona, R; Saniger, L; Lacal, JC				Montaner, S; Perona, R; Saniger, L; Lacal, JC			Activation of serum response factor by RhoA is mediated by the nuclear factor-kappa B and C/EBP transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TERNARY COMPLEX-FORMATION; TATA-BINDING PROTEIN; DNA-BINDING; SIGNALING PATHWAYS; RAS TRANSFORMATION; LEUCINE-ZIPPER; GROWTH-FACTOR; CELL-DEATH; ALPHA PROTEOLYSIS; INDUCED APOPTOSIS	The activity of the transcription factor NF-kappa B can be modulated by members of the Rho family of small GT-Pases (Perona, R,, Montaner, S,, Saniger, L., Sanchez-Perez, I., Brave, R,, and Lacal, J. C, (1997) Genes Dev, 11, 463-475), Ectopic expression of RhoA, Rac1, and Cdc42Hs proteins induces the translocation of NF-kappa B dimers to the nucleus, triggering the transactivation of the NF-kappa B-dependent promoter from the human immunodeficiency virus. Here, we demonstrate that activation of NF-kappa B by RhoA does not exclusively promote its nuclear translocation and binding to the specific kappa B sequences, NF-kappa B is also involved in the regulation of the transcriptional activity of the c-fos serum response factor (SRF), since the activation of a SRE-dependent promoter by RhoA can be efficiently interfered by the double mutant I kappa B alpha S32A/S36A, an inhibitor of the NF-kappa B activity. We also present evidence that RelA. and p50 NF-kappa B subunits cooperate with the transcription factor C/EBP beta in the transactivation of the 4 x SRE-CAT reporter. Furthermore, RhoA increases the levels of C/EBP beta protein, facilitating the functional cooperation between NF-kappa B, C/EBP beta, and SRF proteins. These results strengthen the pivotal importance of the Rho family of small GTPases in signal transduction pathways which modulate gene expression and reveal that NF-kappa B and C/EBP beta transcription factors are accessory proteins for the RhoA-linked regulation of the activity of the SRF.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; del Peso L, 1997, ONCOGENE, V15, P3047; delPeso L, 1997, BIOCHEM J, V322, P519; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; Esteve P, 1995, ONCOGENE, V11, P2657; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; JIMENEZ B, 1995, ONCOGENE, V10, P811; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim BC, 1997, FEBS LETT, V415, P325, DOI 10.1016/S0014-5793(97)01152-6; Kim BC, 1997, FEBS LETT, V407, P7, DOI 10.1016/S0014-5793(97)00289-5; Kim JH, 1997, FEBS LETT, V406, P93, DOI 10.1016/S0014-5793(97)00249-4; Kim JH, 1997, BIOCHEM BIOPH RES CO, V232, P223, DOI 10.1006/bbrc.1997.6261; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KUANG AA, 1993, MOL CELL BIOL, V13, P2536, DOI 10.1128/MCB.13.4.2536; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; METZ R, 1991, ONCOGENE, V6, P2165; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PERONA R, 1993, ONCOGENE, V8, P1285; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; Ruocco MR, 1996, J BIOL CHEM, V271, P22479, DOI 10.1074/jbc.271.37.22479; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P6339; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xia CL, 1997, INT J BIOCHEM CELL B, V29, P1525, DOI 10.1016/S1357-2725(97)00083-6; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	112	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8506	8515		10.1074/jbc.274.13.8506	http://dx.doi.org/10.1074/jbc.274.13.8506			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085083	hybrid			2022-12-25	WOS:000079451600025
J	Pryzdial, ELG; Lavigne, N; Dupuis, N; Kessler, GE				Pryzdial, ELG; Lavigne, N; Dupuis, N; Kessler, GE			Plasmin converts factor X from coagulation zymogen to fibrinolysis cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RECEPTOR; FACTOR-VA; ANNEXIN-II; HUMAN-PROTHROMBIN; ACTIVATION; BINDING; PROTEINS; PATHWAY; PURIFICATION; INACTIVATION	Known anticoagulant pathways have been shown to exclusively inhibit blood coagulation cofactors and enzymes. In the current work, we first investigated the possibility of a novel anticoagulant mechanism that functions at the level of zymogen inactivation. Utilizing both clotting and chromogenic assays, the fibrinolysis protease plasmin was found to irreversibly inhibit the pivotal function of factor X (FX) in coagulation, This was due to cleavage at several sites, the location of which were altered by association of FX with procoagulant phospholipid (proPL), The final products were similar to 28 and similar to 47 kDa for proPL-bound and unbound FX, respectively, which did not have analogues when activated FX (FXa) was cleaved instead. We next investigated whether the FX derivatives could interact with the plasmin precursor plasminogen, and we found that plasmin exposed a binding site only on proPL-bound FX, The highest apparent affinity was for the 28-kDa fragment, which was identified as the light subunit disulfide linked to a small fragment of the heavy subunit (Met-296 to similar to Lys-330). After cleavage by plasmin, proPL-bound FX furthermore was observed to accelerate plasmin generation by tissue plasminogen activator. Thus, a feedback mechanism localized by proPL is suggested in which plasmin simultaneously inhibits FX clotting function and converts proPL-bound FX into a fibrinolysis cofactor. These data also provide the first evidence for an anticoagulant mechanism aimed directly at the zymogen FX.	Canadian Blood Serv, Dept Res & Dev, Ottawa, ON K1G 4J5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1G 4J5, Canada	Canadian Blood Services; University of Ottawa	Pryzdial, ELG (corresponding author), Canadian Blood Serv, Dept Res & Dev, 1800 Alta Vista Dr, Ottawa, ON K1G 4J5, Canada.	ed.pryzdial@bloodservices.ca						BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; DUDANI AK, 1993, THROMB RES, V69, P185, DOI 10.1016/0049-3848(93)90044-O; DUDANI AK, 1994, BIOCHEM CELL BIOL, V72, P126, DOI 10.1139/o94-019; EBY CS, 1992, BLOOD S, V80, pA306; ESMON CT, 1995, SEMIN CELL BIOL, V6, P259, DOI 10.1006/scel.1995.0035; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HOJRUP P, 1987, BIOCHEM J, V245, P887, DOI 10.1042/bj2450887; JESTY J, 1974, J BIOL CHEM, V249, P5614; Jesty J, 1976, Methods Enzymol, V45, P95; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; KELM RJ, 1994, J BIOL CHEM, V269, P30147; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CD, 1989, BLOOD, V73, P185; LIJNEN HR, 1993, METHOD ENZYMOL, V223, P197; MANN KG, 1990, BLOOD, V76, P1; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OMAR MN, 1987, J BIOL CHEM, V262, P9750; PRYZDIAL ELG, 1987, J BIOL CHEM, V262, P1519; Pryzdial ELG, 1996, J BIOL CHEM, V271, P16614, DOI 10.1074/jbc.271.28.16614; PRYZDIAL ELG, 1995, J BIOL CHEM, V270, P17871, DOI 10.1074/jbc.270.30.17871; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; REINARTZ J, 1995, J IMMUNOL, V154, P844; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	38	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8500	8505		10.1074/jbc.274.13.8500	http://dx.doi.org/10.1074/jbc.274.13.8500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085082	hybrid			2022-12-25	WOS:000079451600024
J	Stennicke, HR; Deveraux, QL; Humke, EW; Reed, JC; Dixit, VM; Salvesen, GS				Stennicke, HR; Deveraux, QL; Humke, EW; Reed, JC; Dixit, VM; Salvesen, GS			Caspase-9 can be activated without proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; PLASMINOGEN-ACTIVATOR; CELL-DEATH; PROTEASE; APOPTOSIS; OLIGOMERIZATION; COMPLEX; CED-4; FADD; DATP	The recombinant form of the proapoptotic caspase-9 purified following expression in Escherichia coli is processed at Asp(315), but largely inactive; however, when added to cytosolic extracts of human 293 cells it is activated 2000-fold in the presence of cytochrome c and dATP. Thus, the characteristic activities of caspase-9 are context-dependent, and its activation may not recapitulate conventional caspase activation mechanisms. To explore this hypothesis we produced recombinant forms of procaspase-9 containing mutations that disabled one or both of the interdomain processing sites of the zymogen. These mutants were able to activate downstream caspases, but only in the presence of cytosolic factors. The mutant with both processing sites abolished had 10% of the activity of wild-type, and was able to support apoptosis, with equal vigor to wild-type, when transiently expressed in 293 cells. Thus caspase-9 has an unusually active zymogen that does not require proteolytic processing, but instead is dependent on cytosolic factors for expression of its activity.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Genentech Inc, San Francisco, CA 94080 USA; Univ Michigan, Sch Med, Dept Cellular & Mol Biol, Ann Arbor, MI 48109 USA	Sanford Burnham Prebys Medical Discovery Institute; Roche Holding; Genentech; University of Michigan System; University of Michigan	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gsalvesen@burnham-inst.org	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326	NCI NIH HHS [CA72994] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07863] Funding Source: Medline; NINDS NIH HHS [NS37878] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bode W, 1997, CURR OPIN STRUC BIOL, V7, P865, DOI 10.1016/S0959-440X(97)80159-5; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Krajewska M, 1997, CANCER RES, V57, P1605; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEURATH H, 1989, TRENDS BIOCHEM SCI, V14, P268, DOI 10.1016/0968-0004(89)90061-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WARE CF, 1998, CYTOKINE HDB; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	28	384	405	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8359	8362		10.1074/jbc.274.13.8359	http://dx.doi.org/10.1074/jbc.274.13.8359			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085063	hybrid			2022-12-25	WOS:000079451600005
J	Artrip, JH; Kwiatkowski, P; Michler, RE; Wang, SF; Tugulea, S; Ankersmit, J; Chisholm, L; McKenzie, IFC; Sandrin, MS; Itescu, S				Artrip, JH; Kwiatkowski, P; Michler, RE; Wang, SF; Tugulea, S; Ankersmit, J; Chisholm, L; McKenzie, IFC; Sandrin, MS; Itescu, S			Target cell susceptibility to lysis by human natural killer cells is augmented by alpha(1,3)-galactosyltransferase and reduced by alpha(1,2)-fucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-COMPLEMENT INHIBITOR; ANTI-PIG XENOANTIBODY; CARDIAC XENOTRANSPLANTATION; CARBOHYDRATE-RECOGNITION; INDEPENDENT ANTIGENS; XENOGRAFT REJECTION; MONONUCLEAR-CELLS; TRANSGENIC PIGS; HLA-C; ANTIBODIES	Susceptibility of porcine endothelial cells to human natural killer (NK) cell lysis was found to reflect surface expression of ligands containing Gal alpha(1,3)GlcNAc, the principal antigen on porcine endothelium recognized by xenoreactive human antibodies. Genetically modifying expression of this epitope on porcine endothelium by transfection with the alpha(1,2)-fucosyltransferase gene reduced susceptibility to human NK lysis, These results indicate that surface carbohydrate remodeling profoundly affects target cell susceptibility to NK lysis, and suggest that successful transgenic strategies to limit xenograft rejection by NK cells and xenoreactive antibodies will need to incorporate carbohydrate remodeling.	Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA; Austin Hosp, Heidelberg, Vic 3084, Australia	Columbia University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Itescu, S (corresponding author), Columbia Presbyterian Med Ctr, Dept Surg, 630 W 168th St, New York, NY 10032 USA.			Ankersmit, Hendrik Jan/0000-0002-8761-3517	NHLBI NIH HHS [HL09744] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barber LD, 1996, J IMMUNOL, V156, P3275; BECKER JC, 1990, SCAND J IMMUNOL, V32, P153, DOI 10.1111/j.1365-3083.1990.tb02905.x; BEZOUSKA K, 1994, J BIOL CHEM, V269, P16945; BEZOUSKA K, 1994, NATURE, V372, P151; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BRENNAN J, 1995, J BIOL CHEM, V270, P9691, DOI 10.1074/jbc.270.17.9691; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Cohney S, 1996, IMMUNOGENETICS, V44, P76, DOI 10.1007/BF02602660; Coligan JE., 1994, CURRENT PROTOCOLS IM; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; Diamond LE, 1996, TRANSPLANTATION, V61, P1241, DOI 10.1097/00007890-199604270-00021; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HAYES CE, 1974, J BIOL CHEM, V249, P1904; INVERARDI L, 1997, TRANSPLANTATION, V63, P318; Itescu S, 1996, TRANSPLANTATION, V62, P1927, DOI 10.1097/00007890-199612270-00043; Itescu S, 1998, HUM IMMUNOL, V59, P275, DOI 10.1016/S0198-8859(98)00026-3; KAPLON RJ, 1995, TRANSPLANTATION, V59, P1, DOI 10.1097/00007890-199501150-00001; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; Michler RE, 1996, TRANSPLANT P, V28, P651; Minanov OP, 1997, TRANSPLANTATION, V63, P182, DOI 10.1097/00007890-199701270-00002; Minanov OP, 1998, J THORAC CARDIOV SUR, V115, P998, DOI 10.1016/S0022-5223(98)70397-6; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MOND JJ, 1995, CURR OPIN IMMUNOL, V7, P349, DOI 10.1016/0952-7915(95)80109-X; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PARHAM P, 1977, J BIOL CHEM, V252, P7555; PARKER W, 1994, J IMMUNOL, V153, P3791; PLATT JL, 1990, TRANSPLANTATION, V50, P817, DOI 10.1097/00007890-199011000-00015; ROSENGARD AM, 1995, TRANSPLANTATION, V59, P1325, DOI 10.1097/00007890-199505150-00018; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1994, IMMUNOL REV, V141, P169, DOI 10.1111/j.1600-065X.1994.tb00877.x; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; Sepp A, 1997, J BIOL CHEM, V272, P23104, DOI 10.1074/jbc.272.37.23104; Shinkel TA, 1997, TRANSPLANTATION, V64, P197, DOI 10.1097/00007890-199707270-00003; Snapper CM, 1996, J IMMUNOL, V157, P2229; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNAPPER CM, 1993, J IMMUNOL, V151, P5251; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; VAUGHAN HA, 1994, TRANSPLANTATION, V58, P879, DOI 10.1097/00007890-199410270-00003; Watier H, 1996, TRANSPLANTATION, V62, P105, DOI 10.1097/00007890-199607150-00020; XU H, 1995, J THORAC CARDIOV SUR, V110, P1023, DOI 10.1016/S0022-5223(05)80170-9; XU H, 1995, TRANSPLANTATION, V59, P1189, DOI 10.1097/00007890-199504270-00019; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081	48	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10717	10722		10.1074/jbc.274.16.10717	http://dx.doi.org/10.1074/jbc.274.16.10717			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196142	hybrid			2022-12-25	WOS:000079751900010
J	He, YP; Gaal, T; Karls, R; Donohue, TJ; Gourse, RL; Roberts, GP				He, YP; Gaal, T; Karls, R; Donohue, TJ; Gourse, RL; Roberts, GP			Transcription activation by CooA, the CO-sensing factor from Rhodospirillum rubrum - The interaction between CooA and the C-terminal domain of the alpha subunit of RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAP-DEPENDENT PROMOTERS; CARBON-MONOXIDE DEHYDROGENASE; ESCHERICHIA-COLI; RECEPTOR PROTEIN; DNA-BINDING; OPEN COMPLEX; RRNB P1; RECOGNITION; ELEMENT; CRP	CooA, a member of the cAMP receptor protein (CRP) family, is a CO-sensing transcription activator from Rhodospirillum rubrum that binds specific DNA sequences in response to CO. The location of the CooA-binding sites relative to the start sites of transcription suggested that the CooA-dependent promoters are analogous to class II CRP-dependent promoters. In this study, we developed an in vivo CooA reporter system in Escherichia coli and an in vitro transcription assay using RNA polymerases (RNAP) from E. coli and from Rhodobacter sphaeroides to study the transcription properties of CooA and the protein-protein interaction between CooA and RNAP. The ability of CooA to activate CO-dependent transcription in vivo in heterologous backgrounds suggested that CooA is sufficient to direct RNAP to initiate transcription and that no other factors are required. This hypothesis was confirmed in vitro with purified CooA and purified RNAP. Use of a mutant form of E. coli RNAP with cu subunits lacking their C-terminal domain (alpha-CTD) dramatically decreased CooA-dependent transcription of the CooA-regulated R. rubrum promoter P-cooF in vitro, which indicates that alpha-CTD plays an important role in this activation. DNase I footprinting analysis showed that CooA facilitates binding of wild-type RNAP, but not alpha-CTD-truncated RNAP, to P-cooF. This facilitated binding provides evidence for a direct contact between CooA and alpha-CTD of RNAP during activation of transcription. Mapping the CooA-contact site in alpha-CTD suggests that CooA is similar but not identical to GRP in terms of its contact sites to the alpha-CTD at class II promoters.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, 106A EB Fred Hall,1550 Linden Dr, Madison, WI 53706 USA.		Donohue, Timothy/C-3273-2015	Donohue, Timothy/0000-0001-8738-2467; Karls, Russell/0000-0002-6474-6106	NIGMS NIH HHS [R01 GM037509, GM 37509, GM 37048, GM 53228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037048, R01GM037048, R01GM053228, R01GM037509] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; Bokal AJ, 1997, EMBO J, V16, P154, DOI 10.1093/emboj/16.1.154; BONAM D, 1989, J BACTERIOL, V171, P3102, DOI 10.1128/jb.171.6.3102-3107.1989; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; Dove SL, 1997, NATURE, V386, P627, DOI 10.1038/386627a0; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Eichenberger P, 1996, BIOCHEMISTRY-US, V35, P15302, DOI 10.1021/bi961377d; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JEON YH, 1995, SCIENCE, V270, P1495, DOI 10.1126/science.270.5241.1495; KARLS RK, 1993, J BACTERIOL, V175, P7629, DOI 10.1128/JB.175.23.7629-7638.1993; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LEIRMO S, 1991, J MOL BIOL, V220, P550; Miller JH., 1992, EXPT MOL GENETICS; Murakami K, 1996, EMBO J, V15, P4358, DOI 10.1002/j.1460-2075.1996.tb00809.x; Niu W, 1996, CELL, V87, P1123, DOI 10.1016/S0092-8674(00)81806-1; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; Savery NJ, 1998, EMBO J, V17, P3439, DOI 10.1093/emboj/17.12.3439; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; Tagami H, 1998, EMBO J, V17, P1759, DOI 10.1093/emboj/17.6.1759; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x	37	39	39	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10840	10845		10.1074/jbc.274.16.10840	http://dx.doi.org/10.1074/jbc.274.16.10840			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196160	hybrid			2022-12-25	WOS:000079751900028
J	Luo, Y; Denker, BM				Luo, Y; Denker, BM			Interaction of heterotrimeric G protein G alpha(o) with Purkinje cell protein-2 - Evidence for a novel nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; GOLGI MEMBRANES; ALPHA-SUBUNITS; CDNA CLONING; MICE LACKING; EXPRESSION; CEREBELLUM; RECEPTOR; REGIONS; GAP-43	The heterotrimeric G protein G alpha(o) is ubiquitously expressed throughout the central nervous system, but many of its functions remain to be defined. To search for novel proteins that interact with G alpha(o) a mouse brain library was screened using the yeast two-hybrid interaction system. Pcp2 (Purkinje cell protein-2) was identified as a partner for G alpha(o) in this system. Pcp2 is expressed in cerebellar Purkinje cells and retinal bipolar neurons, two locations where G alpha(o) is also expressed. Pcp2 was first identified as a candidate gene to explain Purkinje cell degeneration in pcd mice (Nordquist, D. T., Kozak, C, A., and Orr, H. T, (1988) J, Neurosci, 8, 4780-4789), but its function remains unknown as Pcp2 knockout mice are normal (Mohn, A. R,, Feddersen, R, M,, Nguyen, M, S., and Koller, B, H, (1997) Mol. Cell. Neurosci, 9, 63-76), G alpha(o) and Pcp2 binding was confirmed in vitro using glutathione S-transferase-Pcp2 fusion proteins and in vitro translated [S-35]methionine-labeled G alpha(o). In addition, when G alpha(o) and Pcp2 were cotransfected into COS cells, G alpha(o) was detected in immunoprecipitates of Pcp2. To determine whether Pcp2 could modulate G alpha(o) function, kinetic constants k(cat) and k(off) of bovine brain G alpha(o) were determined in the presence and absence of Pcp2, Pcp2 stimulates GDP release from G alpha(o) more than 5-fold without affecting k(cat). These findings define a novel nucleotide exchange function for Pcpa and suggest that the interaction between Pcp2 and G alpha(o) is important to Purkinje cell function.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Denker, BM (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	bdenker@rics.bwh.harvard.edu						Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Busconi L, 1997, BIOCHEM J, V328, P23, DOI 10.1042/bj3280023; DENKER BM, 1991, BIOCHEM J, V278, P341, DOI 10.1042/bj2780341; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; GILLARDON F, 1995, J NEUROSCI RES, V41, P708, DOI 10.1002/jnr.490410517; HUFF RM, 1985, J BIOL CHEM, V260, P864; HUNT TW, 1994, J BIOL CHEM, V269, P29565; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Mohn AR, 1997, MOL CELL NEUROSCI, V9, P63, DOI 10.1006/mcne.1997.0606; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; OBERDICK J, 1988, NEURON, V1, P367, DOI 10.1016/0896-6273(88)90186-9; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; Vassileva G, 1997, MOL BRAIN RES, V46, P333, DOI 10.1016/S0169-328X(97)00081-8; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349	29	76	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10685	10688		10.1074/jbc.274.16.10685	http://dx.doi.org/10.1074/jbc.274.16.10685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196137	hybrid			2022-12-25	WOS:000079751900005
J	Subbaramaiah, K; Altorki, N; Chung, WJ; Mestre, JR; Sampat, A; Dannenberg, AJ				Subbaramaiah, K; Altorki, N; Chung, WJ; Mestre, JR; Sampat, A; Dannenberg, AJ			Inhibition of cyclooxygenase-2 gene expression by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; WILD-TYPE P53; INTESTINAL EPITHELIAL-CELLS; PHORBOL ESTER; GROWTH; TRANSCRIPTION; APOPTOSIS; PROTEIN; CARCINOMA; MICE	Oncogenes enhance the expression of cyclooxygenase (Cox)-2, but interactions between tumor suppressor genes and Cox-a have not been studied. In the present work, we have compared the levels of Cox-2 and the production of prostaglandin E-2 in mouse embryo fibroblasts that do not express any p53 ((10)1) versus the same cell line ((10.1)Val5) engineered to overexpress wild-type (wt) p53 at 32 degrees C or mutant p53 at 39 degrees C. Cells expressing wt p53 showed about a 10-fold decrease in synthesis of prostaglandin E-2 compared with those expressing mutant p53. Levels of Cox-2 protein and mRNA were markedly suppressed by wt p53 but not by mutant p53. Nuclear run-offs revealed decreased rates of Cox-2 transcription in cells expressing wt p53. The activity of the Cox-2 promoter was reduced by 85% in cells expressing wt p53 but was reduced only by 30% in cells express ing mutant p53 compared with cells null for p53. The effect of p53 on the suppression of Cox-2 promoter activity was localized to the first 40 base pairs 5' from the transcription start site. Electrophoretic mobility shift assay revealed that p53 competed with TATA-binding protein for binding to mouse Cox-2 or human Cox-2 promoter extending from -50 to +52 base pairs. The results of this study suggest that interactions between p53 and Cox-2 could be important for understanding why levels of Cox-2 are undetectable in normal cells and increased in many tumors.	Cornell Univ, New York Presbyterian Hosp, Dept Med, Div Gastroenterol, New York, NY 10021 USA; Cornell Univ, New York Presbyterian Hosp, Dept Surg, New York, NY 10021 USA; Cornell Univ, New York Presbyterian Hosp, Dept Cardiothorac Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Head & Neck Serv, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center	Dannenberg, AJ (corresponding author), Cornell Univ, New York Presbyterian Hosp, Dept Med, Div Gastroenterol, Room F-231,1300 York Ave, New York, NY 10021 USA.	ajdannen@mail.med.cornell.edu			NCI NIH HHS [CA68136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bouvet M, 1998, CANCER RES, V58, P2288; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEB SP, 1994, ONCOGENE, V9, P1341; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Huang M, 1998, CANCER RES, V58, P1208; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawamori T, 1998, CANCER RES, V58, P409; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mestre JR, 1997, CANCER RES, V57, P2890; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Parrett ML, 1997, INT J ONCOL, V10, P503; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; Ristimaki A, 1997, CANCER RES, V57, P1276; SANO H, 1995, CANCER RES, V55, P3785; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	52	300	320	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10911	10915		10.1074/jbc.274.16.10911	http://dx.doi.org/10.1074/jbc.274.16.10911			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196169	hybrid			2022-12-25	WOS:000079751900037
J	Ning, Q; Liu, MF; Kongkham, P; Lai, MMC; Marsden, PA; Tseng, J; Pereira, B; Belyavskyi, M; Leibowitz, J; Phillips, MJ; Levy, G				Ning, Q; Liu, MF; Kongkham, P; Lai, MMC; Marsden, PA; Tseng, J; Pereira, B; Belyavskyi, M; Leibowitz, J; Phillips, MJ; Levy, G			The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA RECOMBINATION; STRAIN-3 INFECTION; LIVER; CORONAVIRUSES; EXPRESSION; INDUCTION; SEQUENCE; PROMOTER; ELEMENT; PATTERN	Using a set of parental and recombinant murine hepatitis virus strains, we demonstrate that the nucleocapsid protein induces transcription of the novel fg12 prothrombinase gene and elevated procoagulant activity in those strains that produce fulminant hepatitis. Chinese hamster ovary cells cotransfected with a construct expressing nucleocapsid protein from susceptible strains and with a luciferase reporter construct containing the fg12 promoter showed a B-fold increase in luciferase activity compared with nontransfected cells or cells cotransfected with a construct expressing nucleocapsid protein from resistant strains. Two deletions found at coding sites 111-123 and 1143-1145 of structural domains I and III, respectively, of the nucleocapsid gene may account for the differences between pathogenic and nonpathogenic strains. Preliminary mapping of the fg12 promoter has defined a region from -372 to -306 upstream from the ATG translation initiation site to be responsive to nucleocapsid protein. Hence, mapping of genetic determinants in parental and recombinant strains demonstrates that the nucleocapsid protein of strains that induce fulminant hepatitis is responsible for transcription of the fg12 prothrombinase gene. These studies provide new insights into the role of the nucleocapsid gene in the pathogenesis of viral hepatitis.	Toronto Hosp, Multiorgan Transplant Program, Toronto, ON M5G 2C4, Canada; Toronto Hosp, Dept Med, Toronto, ON M5G 2C4, Canada; Toronto Hosp, Dept Pathol, Toronto, ON M5G 2C4, Canada; St Michaels Hosp, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON M5G 2C4, Canada; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Texas A&M Univ, Dept Pathol, College Stn, TX 77843 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Howard Hughes Medical Institute; University of Southern California; University of Southern California; Texas A&M University System; Texas A&M University College Station	Levy, G (corresponding author), Toronto Hosp, Multiorgan Transplant Program, 621 Univ Ave,10th Floor,Rm 151, Toronto, ON M5G 2C4, Canada.	fgl2@msn.com	Lai, Michael M. C./I-7001-2012; Marsden, Philip A/B-1441-2012	Kongkham, Paul/0000-0002-1047-9305	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019244, R29AI030169] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19244, AI30169] Funding Source: Medline; NINDS NIH HHS [NS18146] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CATTRAL MC, 1995, NEW ENGL J MED, V331, P268; CHISARI FV, 1995, SPRINGER SEMIN IMMUN, V17, P261, DOI 10.1007/BF00196169; CITARELLA F, 1993, BIOCHIM BIOPHYS ACTA, V1172, P197, DOI 10.1016/0167-4781(93)90294-N; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; EVANS R, 1990, BIOTECHNIQUES, V8, P357; FICKENSCHER H, 1989, J GEN VIROL, V70, P107, DOI 10.1099/0022-1317-70-1-107; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; KECK HJG, 1997, VIROLOGY, V156, P331; KECK JG, 1988, J VIROL, V62, P1989, DOI 10.1128/JVI.62.6.1989-1998.1988; KOYAMA T, 1987, P NATL ACAD SCI USA, V84, P1609, DOI 10.1073/pnas.84.6.1609; LAI MMC, 1978, J VIROL, V26, P236, DOI 10.1128/JVI.26.2.236-242.1978; Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; LAVI E, 1990, LAB INVEST, V62, P570; LEVY GA, 1981, J EXP MED, V154, P1150, DOI 10.1084/jem.154.4.1150; LEVY GA, 1983, HEPATOLOGY, V3, P964; LI C, 1992, J EXP MED, V176, P689, DOI 10.1084/jem.176.3.689; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACPHEE PJ, 1985, HEPATOLOGY, V5, P649, DOI 10.1002/hep.1840050422; MAKINO S, 1986, J VIROL, V57, P729, DOI 10.1128/JVI.57.3.729-737.1986; MAKINO S, 1989, P NATL ACAD SCI USA, V84, P6569; MASTERS PS, 1990, ADV EXP MED BIOL, V276, P235; MIAO CH, 1992, J BIOL CHEM, V267, P7395; Ning Q, 1998, J IMMUNOL, V160, P3487; PARLER MM, 1990, VIROLOGY, V179, P463; PARR RL, 1995, J VIROL, V69, P5033, DOI 10.1128/JVI.69.8.5033-5038.1995; POPE M, 1995, J VIROL, V69, P5252, DOI 10.1128/JVI.69.9.5252-5260.1995; RUSSELL NH, 1992, BLOOD REV, V6, P149, DOI 10.1016/0268-960X(92)90026-M; SIDWELL RW, 1977, ANN NY ACAD SCI, V284, P239, DOI 10.1111/j.1749-6632.1977.tb21956.x	31	43	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9930	9936		10.1074/jbc.274.15.9930	http://dx.doi.org/10.1074/jbc.274.15.9930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187767	hybrid			2022-12-25	WOS:000079663500006
J	Qiao, LY; Goldberg, JL; Russell, JC; Sun, XJ				Qiao, LY; Goldberg, JL; Russell, JC; Sun, XJ			Identification of enhanced serine kinase activity in insulin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SUBSTRATE-1 TYROSINE PHOSPHORYLATION; LA/N CORPULENT RAT; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; OKADAIC ACID; PHOSPHOTYROSINE PROTEIN; GLUCOSE-METABOLISM	Insulin receptor substrate (IRS) proteins play a crucial role as signaling molecules in insulin action. Serine phosphorylation of IRS proteins has been hypothesized as a cause of attenuating insulin signaling. The current study investigated serine kinase activity toward IRS-1 in several models of insulin resistance. An in vitro kinase assay was developed that used partially purified cell lysates as a kinase and glutathione S-transferase fusion proteins that contained various of IRS-1 fragments as substrates. Elevated serine kinase activity was detected in Chinese hamster ovary/insulin receptor (IR)/IRS-1 cells and 3T3-L1 adipocytes chronically treated with insulin, and in liver and muscle of obese JCR:LA-cp rats. It phosphorylated the 526-859 amino acid region of IRS-1, whereas phosphorylation of the 2-516 and 900-1235 amino acid regions was not altered. Phosphopeptide mapping of the 526-859 region of IRS-1 showed three major phosphopeptides (P1, P2, and P3) with different patterns of phosphorylation depending on the source of serine kinase activity. P1 and P2 were strongly phosphorylated when the kinase activity was prepared from insulin-resistant Chinese hamster ovary/IR/IRS-1 cells, weakly phosphorylated by the kinase activity from insulin-resistant 3T3-L1 adipocytes, and barely phosphorylated when the extract was derived from insulin-resistant liver. In contrast, P3 was phosphorylated by the serine kinase activity prepared from all insulin-resistant cells and tissues of animals. P1 and P2 phosphorylation can be explained by mitogen-activated protein kinase activity based on the phosphopeptide map generated by recombinant ERK2. In contrast, mitogen-activated protein kinase failed to phosphorylate the P3 peptide, suggesting that another serine kinase regulates this modification of IRS-1 in insulin-resistant state.	Univ Vermont, Coll Med, Div Endocrinol, Burlington, VT 05405 USA; Univ Alberta, Dept Surg, Edmonton, AB T6G 2S2, Canada	University of Vermont; University of Alberta	Sun, XJ (corresponding author), Univ Vermont, Coll Med, Div Endocrinol, Given Bldg C-350, Burlington, VT 05405 USA.	xsun@zoo.uvm.edu			NIAID NIH HHS [AI41426-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041426] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHANG PY, 1995, J BIOL CHEM, V270, P29928; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; Craparo A, 1997, J BIOL CHEM, V272, P11663; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; delPeso L, 1997, SCIENCE, V278, P687; DELPRATO S, 1994, DIABETOLOGIA, V37, P1025, DOI 10.1007/BF00400466; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kolter T, 1997, AM J PHYSIOL-ENDOC M, V273, pE59, DOI 10.1152/ajpendo.1997.273.1.E59; Koopmans SJ, 1997, DIABETES, V46, P1572, DOI 10.2337/diabetes.46.10.1572; Kosaki A, 1998, J BIOL CHEM, V273, P940, DOI 10.1074/jbc.273.2.940; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAM K, 1994, J BIOL CHEM, V269, P20648; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LAWRENCE JC, 1990, J BIOL CHEM, V265, P19768; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; RICE KM, 1992, J BIOL CHEM, V267, P10163; Ricort JM, 1997, J BIOL CHEM, V272, P19814, DOI 10.1074/jbc.272.32.19814; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; RUSSELL JC, 1987, ARTERIOSCLEROSIS, V7, P620, DOI 10.1161/01.ATV.7.6.620; RUSSELL JC, 1986, CAN J PHYSIOL PHARM, V64, P750, DOI 10.1139/y86-127; RUSSELL JC, 1994, METABOLISM, V43, P538, DOI 10.1016/0026-0495(94)90192-9; Russell JC, 1998, DIABETES, V47, P770, DOI 10.2337/diabetes.47.5.770; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Sun XJ, 1996, J BIOL CHEM, V271, P10583, DOI 10.1074/jbc.271.18.10583; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; White MF, 1996, PHILOS T ROY SOC B, V351, P181, DOI 10.1098/rstb.1996.0015; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	60	88	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10625	10632		10.1074/jbc.274.15.10625	http://dx.doi.org/10.1074/jbc.274.15.10625			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187859	hybrid			2022-12-25	WOS:000079663500098
J	Fukumoto, S; Miyazaki, H; Goto, G; Urano, T; Furukawa, K; Furukawa, K				Fukumoto, S; Miyazaki, H; Goto, G; Urano, T; Furukawa, K; Furukawa, K			Expression cloning of mouse cDNA of CMP-NeuAc : lactosylceramide alpha 2,3-sialyltransferase, an enzyme that initiates the synthesis of gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MOLECULAR-CLONING; SYNTHASE GENE; GOLGI VESICLES; RAT-LIVER; MONOCLONAL-ANTIBODIES; MEDIATED MODULATION; CELL-ADHESION; G(M3); BRAIN	Expression cloning of a cDNA for the alpha 2,3-sialyltransferase (GM3 synthase) (EC 2.4.99.-) gene was performed using a GM3-lacking mouse fibroblast line L cell and anti-GM3 monoclonal antibody. Plasmids from a cDNA library generated with poly(A)(+) RNA of a mouse fibrosarcoma line CMS5j and pdl3027 (polyoma T antigen) were co-transfected into L cells. The isolated cDNA clone pM3T-7 predicted a type II membrane protein with 13 amino acids of cytoplasmic domain, 17 amino acids of transmembrane region, and a large catalytic domain with 329 amino acids. Introduction of the cDNA clone into L cells resulted in the neo-synthesis of GM3 and high activity of alpha 2,3-sialyltransferase. Among glycosphingolipids, only lactosylceramide showed significant activity as an acceptor, indicating that this gene product is a sialyltransferase specific for the synthesis of GM3. An amino acid sequence deduced from the cloned cDNA showed the typical sialyl motif with common features among alpha 2,3-sialyltransferases. Among various mouse tissues, brain, liver, and testis showed relatively high expression of a 2,3-kilobase mRNA, whereas all tissues, more or less, expressed this gene.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Dent, Dept Pediat Dent, Nagasaki 8528102, Japan	Nagoya University; Nagasaki University	Furukawa, K (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.			Urano, Takeshi/0000-0003-3383-3554; Fukumoto, Satoshi/0000-0002-5046-6891				BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; FURUKAWA K, 1985, BIOCHEMISTRY-US, V24, P7820, DOI 10.1021/bi00347a047; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; IBER H, 1991, EUR J BIOCHEM, V195, P115, DOI 10.1111/j.1432-1033.1991.tb15683.x; IBER H, 1989, FEBS LETT, V254, P124, DOI 10.1016/0014-5793(89)81022-1; IBER H, 1989, FEBS LETT, V248, P18, DOI 10.1016/0014-5793(89)80423-5; Ishii A, 1998, J BIOL CHEM, V273, P31652, DOI 10.1074/jbc.273.48.31652; KAUFMAN B, 1967, INBORN DISORDERS SPH, P193; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Kono M, 1997, GLYCOBIOLOGY, V7, P469, DOI 10.1093/glycob/7.4.469; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; Lloyd KO, 1998, GLYCOCONJUGATE J, V15, P627, DOI 10.1023/A:1006924128550; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PREUSS U, 1993, J BIOL CHEM, V268, P26273; RUAN S, 1992, CANCER RES, V52, P5725; Sasaki K, 1996, TRENDS GLYCOSCI GLYC, V8, P195, DOI 10.4052/tigg.8.195; SONG WX, 1993, BIOCHEMISTRY-US, V32, P8602, DOI 10.1021/bi00084a030; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; WAKABAYASHI S, 1984, J INVEST DERMATOL, V83, P128, DOI 10.1111/1523-1747.ep12263312; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Wiegandt H, 1985, GLYCOLIPIDS, V10, P199, DOI DOI 10.1016/S0167-7306(08)60022-8; Yamamoto A, 1996, J NEUROCHEM, V66, P26; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YAMASHIRO S, 1995, GLYCOCONJUGATE J, V12, P894, DOI 10.1007/BF00731251; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YAMASHIRO S, 1993, CANCER RES, V53, P5305; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; Yoshida Y, 1996, J BIOL CHEM, V271, P30167, DOI 10.1074/jbc.271.47.30167; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	48	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9271	9276		10.1074/jbc.274.14.9271	http://dx.doi.org/10.1074/jbc.274.14.9271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092602	hybrid			2022-12-25	WOS:000079451800021
J	Ghahremani, MH; Cheng, PH; Lembo, PMC; Albert, PR				Ghahremani, MH; Cheng, PH; Lembo, PMC; Albert, PR			Distinct roles for G alpha(i)2, G alpha(i)3, and G beta gamma in modulation of forskolin- or G(s)-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MAMMALIAN ADENYLYL CYCLASES; HETEROTRIMERIC G-PROTEINS; PITUITARY-CELLS; POTASSIUM CHANNELS; INHIBITION; EXPRESSION; ACTIVATION; FIBROBLASTS; STIMULATION	Previous studies have shown that a single G protein-coupled receptor can regulate different effector systems by signaling through multiple subtypes of heterotrimeric G proteins. In LD2S fibroblast cells, the dopamine D2S receptor couples to pertussis toxin (PTX)-sensitive G(i)/G(o) proteins to inhibit forskolin- or prostaglandin E-1-stimulated cAMP production and to stimulate calcium mobilization, To analyze the role of distinct G alpha(i/o) protein subtypes, LD2S cells were stably transfected with a series of PTX-insensitive G alpha(i/o) protein Cys --> Ser point mutants and assayed for D2S receptor signaling after PTX treatment, The level of expression of the transfected G alpha mutant subunits was similar to the endogenous level of the most abundant G alpha(i/o) proteins (G alpha(o), G alpha(i)3). D2S receptor-mediated inhibition of forskolin-stimulated cAMP production was retained only in clones expressing mutant G alpha(i)2. In contrast, the D2S receptor utilized G alpha(i)3 to inhibit PGE(i)-induced (G(s)-coupled) enhancement of cAMP production. Following stable or transient transfection, no single or pair set of mutant G alpha(i/o) subtypes rescued the D2S-mediated calcium response following PTX pretreatment. On the other hand, in LD2S cells stably transfected with GRK-CT, a receptor kinase fragment that specifically antagonizes G beta gamma subunit activity, D2S receptor-mediated calcium mobilization was blocked. The observed specificity of G alpha(i)2 and G alpha(i)3 for different states of adenylyl cyclase activation suggests a higher level of specificity for interaction of G alpha(i) subunits with forskolin- versus G(s)-activated states of adenylyl cyclase than has been previously appreciated.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	University of Ottawa; McGill University	Albert, PR (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd,Rm 2464, Ottawa, ON K1H 8M5, Canada.	palbert@uottawa.ca	Ghahremani, Mohammad H/F-1615-2013; Albert, Paul/E-4804-2010	Ghahremani, Mohammad H/0000-0001-5051-6214; Albert, Paul/0000-0002-1809-3554				ALBERT PR, 1994, VITAM HORM, V48, P59, DOI 10.1016/S0083-6729(08)60496-3; ALBERT PR, 1990, J BIOL CHEM, V265, P2098; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; CAMPS M, 1992, EUR J BIOCHEM, V206, P23066; CASTELLANO MA, 1993, MOL PHARMACOL, V44, P649; Chuprun JK, 1997, J BIOL CHEM, V272, P773, DOI 10.1074/jbc.272.2.773; CIVELLI O, 1993, ANNU REV PHARMACOL, V33, P281, DOI 10.1146/annurev.pa.33.040193.001433; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; EINHORN LC, 1991, J NEUROSCI, V11, P3727; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; GHAHREMANI MH, 1995, P SOC NEUROSCI, V21, P1863; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAYES G, 1992, MOL ENDOCRINOL, V6, P920, DOI 10.1210/me.6.6.920; HUFF RM, 1994, J CELL BIOCH B, V18, P220; HUNT TW, 1994, J BIOL CHEM, V269, P29565; IZENWASSER S, 1995, J NEUROCHEM, V64, P1614; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAJINESS ME, 1993, J PHARMACOL EXP THER, V267, P1573; Lembo PMC, 1999, MOL ENDOCRINOL, V13, P138, DOI 10.1210/me.13.1.138; LEW AM, 1995, J BIOL CHEM, V270, P7156, DOI 10.1074/jbc.270.13.7156; LIU YF, 1992, J NEUROCHEM, V59, P2311; LIU YF, 1991, J BIOL CHEM, V266, P23689; LIU YF, 1994, J BIOL CHEM, V269, P13880; LLEDO PM, 1992, NEURON, V8, P455, DOI 10.1016/0896-6273(92)90273-G; MALEK D, 1993, FEBS LETT, V325, P215; MEMO M, 1992, J NEUROCHEM, V59, P1829, DOI 10.1111/j.1471-4159.1992.tb11016.x; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MORRIS SJ, 1996, P SOC NEUR, V22; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Nevo I, 1998, MOL PHARMACOL, V54, P419, DOI 10.1124/mol.54.2.419; RAYMOND JR, 1995, AM J PHYSIOL, V28, pF141; Robinson SW, 1997, MOL PHARMACOL, V52, P508, DOI 10.1124/mol.52.3.508; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SENOGLES SE, 1994, ENDOCRINOLOGY, V134, P783, DOI 10.1210/en.134.2.783; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG L, 1994, J PHARMACOL EXP THER, V268, P495; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VALLAR L, 1990, J BIOL CHEM, V265, P10320; YAMANE HK, 1993, ANNU REV PHARMACOL, V33, P201, DOI 10.1146/annurev.pharmtox.33.1.201; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	48	72	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9238	9245		10.1074/jbc.274.14.9238	http://dx.doi.org/10.1074/jbc.274.14.9238			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092597	hybrid			2022-12-25	WOS:000079451800016
J	Henkel, JR; Popovich, JL; Gibson, GA; Watkins, SC; Weisz, OA				Henkel, JR; Popovich, JL; Gibson, GA; Watkins, SC; Weisz, OA			Selective perturbation of early endosome and/or trans-Golgi network pH but not lysosome pH by dose-dependent expression of influenza M2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL ACTIVITY; MANNOSE 6-PHOSPHATE RECEPTOR; PLAGUE VIRUS HEMAGGLUTININ; VACUOLAR PROTON PUMP; H+-ATPASES; M(2) PROTEIN; CATHEPSIN-D; A VIRUS; SECRETORY PATHWAY; RAT HEPATOCYTES	Many sorting stations along the biosynthetic and endocytic pathways are acidified, suggesting a role for pH regulation in protein traffic, However, the function of acidification in individual compartments has been difficult to examine because global pH perturbants affect all acidified organelles in the cell and also have numerous side effects, To circumvent this problem, we have developed a method to selectively perturb the pH of a subset of acidified compartments, We infected HeLa cells with a recombinant adenovirus encoding influenza virus M2 protein (an acid-activated ion channel that dissipates proton gradients across membranes) and measured the effects on various steps in protein transport, Al low multiplicity of infection (m.o.i.), delivery of influenza hemagglutinin from the trans-Golgi network to the cell surface was blocked, but there was almost no effect on the rate of recycling of internalized transferrin, At higher m.o.i., transferrin recycling was inhibited, suggesting increased accumulation of M2 in endosomes, Interestingly, even at the higher m.o.i., M2 expression had no effect on lysosome morphology or on EGF degradation, suggesting that lysosomal pH was not compromised by M2 expression. However, delivery of newly synthesized cathepsin D to lysosomes was slowed in cells expressing active M2, suggesting that acidification of the TGN and endosomes is important for efficient delivery of lysosomal hydrolases, Fluorescence labeling using a pH-sensitive dye confirmed the reversible effect of M2 on the pH of a subset of acidified compartments in the cell, The ability to dissect the role of acidification in individual steps of a complex pathway should be useful for numerous other studies on protein processing and transport.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, 978 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15213 USA.	weisz@med1.dept-med.pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	PHS HHS [R01DL54407] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CIAMPOR F, 1992, VIROLOGY, V188, P14, DOI 10.1016/0042-6822(92)90730-D; DIMENT S, 1988, J BIOL CHEM, V263, P6901; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; GRAMBAS S, 1992, VIROLOGY, V191, P541, DOI 10.1016/0042-6822(92)90229-I; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; Harada M, 1997, LIVER, V17, P244; Harada M, 1996, J HEPATOL, V24, P594, DOI 10.1016/S0168-8278(96)80146-2; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 1998, J BIOL CHEM, V273, P6518, DOI 10.1074/jbc.273.11.6518; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; IMORT M, 1983, BIOCHEM J, V214, P671, DOI 10.1042/bj2140671; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; Matsuoka K, 1997, PLANT CELL, V9, P533; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MUROI M, 1993, CELL STRUCT FUNCT, V18, P139, DOI 10.1247/csf.18.139; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V262, P159, DOI 10.1016/0003-9861(88)90178-6; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; OHUCHI M, 1994, J VIROL, V68, P920, DOI 10.1128/JVI.68.2.920-926.1994; PALOKANGAS H, 1994, J BIOL CHEM, V269, P17577; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RIJNBOUTT S, 1992, J BIOL CHEM, V267, P15665; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; Temesvari LA, 1996, J CELL SCI, V109, P1479; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; vanWeert AWM, 1997, EUR J CELL BIOL, V74, P417; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; XU HX, 1994, J BIOL CHEM, V269, P22875; YILLA M, 1993, J BIOL CHEM, V268, P19092; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	47	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9854	9860		10.1074/jbc.274.14.9854	http://dx.doi.org/10.1074/jbc.274.14.9854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092677	hybrid			2022-12-25	WOS:000079451800096
J	Viard, P; Exner, T; Maier, U; Mironneau, J; Nurnberg, B; Macrez, N				Viard, P; Exner, T; Maier, U; Mironneau, J; Nurnberg, B; Macrez, N			G beta gamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase	FASEB JOURNAL			English	Article						G-protein; PI3K; protein kinase C; smooth muscle	PROTEIN-KINASE-C; PORTAL-VEIN MYOCYTES; VOLTAGE-DEPENDENT POTENTIATION; CALCIUM CHANNELS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; COUPLED RECEPTORS; ALPHA(1) SUBUNIT; CELLS; ACTIVATION; MODULATION	We have previously reported that, in venous myocytes, G beta gamma scavengers inhibit angiotensin AT(1A) receptor-induced stimulation of L-type Ca2+ channels (1). Here, we demonstrate that intracellular infusion of purified G beta gamma complexes stimulates the L-type Ca2+ channel current in a concentration-dependent manner. Additional intracellular dialysis of GDP-bound inactive G alpha(o) or of a peptide corresponding to the G beta gamma binding region of the beta-adrenergic receptor kinase completely inhibited the G beta gamma-induced stimulation of Ca2+ channel currents. The gating properties of the channel were not affected by intracellular application of G beta gamma, suggesting that G beta gamma increased the whole-cell calcium conductance. In addition, both the angiotensin AT(1A) receptor- and the G beta gamma-induced stimulation of L-type Ca2+ channels were blocked by pretreatment of the cells with wortmannin, at nanomolar concentrations. Correspondingly, intracellular infusion of an enzymatically active purified recombinant G beta gamma-sensitive phosphoinositide 3-kinase, PI3K gamma, mimicked G beta gamma-induced stimulation of Ca2+ channels. Both G beta gamma- and PI3K gamma-induced stimulations of Ca2+ channel currents were reduced by protein kinase C inhibitors suggesting that the G beta gamma/PI3K gamma-activated transduction pathway involves a protein kinase C. These results indicate for the first time that G beta gamma dimers stimulate the vascular L-type Ca2+ channels through a G beta gamma-sensitive PI3K.	Univ Bordeaux 2, Lab Physiol Cellulaire & Pharmacol Mol, CNRS, F-33076 Bordeaux, France; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Free University of Berlin	Macrez, N (corresponding author), Univ Bordeaux 2, Lab Physiol Cellulaire & Pharmacol Mol, CNRS, ESA 5017,146 Rue Leo Saignat, F-33076 Bordeaux, France.			MACREZ, Nathalie/0000-0002-3844-4403; Nurnberg, Bernd/0000-0002-5995-6555				Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; BOURINET E, 1994, EMBO J, V13, P5032, DOI 10.1002/j.1460-2075.1994.tb06832.x; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; Dolphin AC, 1996, TRENDS NEUROSCI, V19, P35, DOI 10.1016/0166-2236(96)81865-0; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HELL JW, 1993, J BIOL CHEM, V268, P19451; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; KLEPPISCH T, 1994, EMBO J, V13, P2502, DOI 10.1002/j.1460-2075.1994.tb06538.x; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LEPRETRE N, 1994, J BIOL CHEM, V269, P29546; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MacrezLepretre N, 1996, J PHARMACOL EXP THER, V278, P468; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAIR LA, 1995, CIRC RES, V76, P832, DOI 10.1161/01.RES.76.5.832; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NURNBERG B, 1994, BIOCHEM J, V300, P387; Page KM, 1998, J NEUROSCI, V18, P4815; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; SCULPTOREANU A, 1993, P NATL ACAD SCI USA, V90, P10135, DOI 10.1073/pnas.90.21.10135; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; YANO H, 1993, J BIOL CHEM, V268, P25846; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; ZANG WJ, 1993, J PHYSIOL-LONDON, V464, P649, DOI 10.1113/jphysiol.1993.sp019656	47	102	103	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					685	694		10.1096/fasebj.13.6.685	http://dx.doi.org/10.1096/fasebj.13.6.685			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094929				2022-12-25	WOS:000079527200010
J	Oppermann, M; Mack, M; Proudfoot, AEI; Olbrich, H				Oppermann, M; Mack, M; Proudfoot, AEI; Olbrich, H			Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTERLEUKIN-8 RECEPTOR; C5A ANAPHYLATOXIN; EXPRESSION VECTOR; MOLECULAR-CLONING; AMINO-ACIDS; DESENSITIZATION; INTERNALIZATION; SPECIFICITY; PEPTIDE	The binding of CC chemokines to CC chemokine receptor 5 (CCR5) triggers cellular responses that, generally, are only transient in nature. To explore the potential role of G protein coupled receptor kinases (GRKs) in the regulation of CCR5, we performed phosphorylation experiments in a rat basophilic leukemia cell line stably expressing CCR5, The ability of various CCR5 ligands to stimulate calcium mobilization in these cells correlated with their ability to induce receptor phosphorylation, desensitization, internalization, and GRK association with the receptor. Aminooxypentane-RANTES, a potent inhibitor of human immunodeficiency virus infection, has been proposed to act through enhanced CCR5 internalization and inhibition of receptor recycling. Aminooxypentane-RANTES profoundly induced CCR5 phosphorylation, but had no effect on CCR1, In permeabilized rat basophilic leukemia CCR5 cells, monoclonal antibodies with specificity for GRK2/3 inhibited RANTES-induced receptor phosphorylation, Consistent with a role for these kinases in CCR5 regulation, 1-2 x 10(5) copies of GRK2 or GRK3 were found to be expressed in peripheral blood leukocytes. Phosphoamino acid analysis revealed that RANTES-induced CCR5 phosphorylation selectively occurs on serine residues. Our findings with receptor mutants indicate that serine residues at positions 336, 337, 342, and 349 represent GRK phosphorylation sites on CCR5, This study demonstrates that chemokines differ in their ability to induce CCR5 phosphorylation and desensitization and provides a molecular mechanism for the agonist-induced attenuation of CCR5 signaling.	Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany; Univ Munich, Med Policlin, D-80336 Munich, Germany; Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland	University of Gottingen; University of Munich	Oppermann, M (corresponding author), Univ Kliniken Gottingen, Dept Immunol, Kreuzbergring 57, D-37075 Gottingen, Germany.	mopperm@gwdg.de						AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; Franci C, 1996, J IMMUNOL, V157, P5606; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GUAN XM, 1992, J BIOL CHEM, V267, P21995; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Kuang YN, 1996, J BIOL CHEM, V271, P3975; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Solari R, 1997, J BIOL CHEM, V272, P9617; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4	41	165	172	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8875	8885		10.1074/jbc.274.13.8875	http://dx.doi.org/10.1074/jbc.274.13.8875			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085131	hybrid			2022-12-25	WOS:000079451600073
J	Pickard, RT; Strifler, BA; Kramer, RM; Sharp, JD				Pickard, RT; Strifler, BA; Kramer, RM; Sharp, JD			Molecular cloning of two new human paralogs of 85-kDa cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; LIPID-BINDING DOMAIN; PRECURSOR TRANSCRIPTS; GENE-EXPRESSION; THEMATIC SERIES; ACID; IDENTIFICATION; CONTAINS; CELLS; PHOSPHORYLATION	Two new cloned human cDNAs encode paralogs of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)). We propose to call these cPLA(2)beta (114 kDa) and cPLA(2)gamma (61 kDa), giving the name cPLA(2)alpha to the well known 85-kDa enzyme. cPLA(2)beta mRNA is expressed more highly in cerebellum and pancreas and cPLA(2)gamma more highly in cardiac and skeletal muscle, Sequence-tagged site mapping places cPLA(2)beta on chromosome 15 in a region near a phosphoinositol bisphosphate phosphatase. The mRNA for cPLA(2)beta is spliced only at a very low level, and Northern blots in 24 tissues show exclusively the unspliced form. cPLA(2)beta has much lower activity on 2-arachidonoyl-phosphatidylcholine liposomes than either of the other two enzymes. Its sequence contains a histidine motif characteristic of the catalytic center of caspase proteases of the apoptotic cascade but no region characteristic of the catalytic cysteine, Sequence-tagged site mapping places cPLA(2)gamma on chromosome 19 near calmodulin, cPLA(2)gamma lacks the C2 domain, which gives cPLA(2)alpha its Ca(2+) sensitivity, and accordingly cPLA(2)gamma has no dependence upon calcium, although cPLA(2)beta does, cPLA(2)gamma contains a prenyl group-binding site motif and appears to be largely membrane-bound. cPLA(2)alpha residues activated by phosphorylation do not appear to be well conserved in either new enzyme. In contrast, all three previously known catalytic residues, as well as one additional essential arginine, Arg-566 in cPLA(2)alpha, are conserved in both new enzyme sequences. Mutagenesis shows strong dependence on these residues for catalytic activity of all three enzymes.	Eli Lilly & Co, Lilly Res Lab, Indianapolis, IN 46285 USA	Eli Lilly	Sharp, JD (corresponding author), Millennium Biotherapeut, 620 Mem Dr, Cambridge, MA 02139 USA.	sharp@mpi.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; *GEN COMP GROUP, 1996, WISC PACK VERS 8 1 9; GEREZ L, 1995, J BIOL CHEM, V270, P19569, DOI 10.1074/jbc.270.33.19569; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; JARROUS N, 1994, J BIOL CHEM, V269, P23141; Jarrous N, 1996, MOL CELL BIOL, V16, P2814; KRAMER JM, 1996, BIOCHIM BIOPHYS ACTA, V959, P269; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Prescott SM, 1997, J BIOL CHEM, V272, P15043, DOI 10.1074/jbc.272.24.15043; QIU ZH, 1993, J BIOL CHEM, V268, P24506; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Srinivasan SR, 1996, ATHEROSCLEROSIS, V123, P33, DOI 10.1016/0021-9150(95)05762-5; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989	47	172	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8823	8831		10.1074/jbc.274.13.8823	http://dx.doi.org/10.1074/jbc.274.13.8823			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085124	hybrid			2022-12-25	WOS:000079451600066
J	Ritty, TM; Broekelmann, T; Tisdale, C; Milewicz, DM; Mecham, RP				Ritty, TM; Broekelmann, T; Tisdale, C; Milewicz, DM; Mecham, RP			Processing of the fibrillin-1 carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAIN; MARFAN-SYNDROME; ENDOPLASMIC-RETICULUM; CALCIUM-BINDING; FBN1 MUTATIONS; BREFELDIN-A; RETROGRADE TRANSPORT; PRECURSOR PROTEINS; GOLGI-APPARATUS; CELL-LINE	To investigate the processing and general properties of the fibrillin-1 carboxyl-terminal domain, three protein expression constructs have been developed as follows: one without the domain, one with the domain, and one with a mutation near the putative proteolytic processing site. The constructs have been expressed in two eukaryotic model systems, baculoviral and CHO-K1, Post-translational modifications that normally occur in fibrillin-1, including glycosylation, signal peptide cleavage, and carboxyl-terminal processing, occur in the three constructs in both cell systems. Amino-terminal sequencing of secreted protein revealed leader sequence processing at two sites, a primary site between Gly-24/Ala-25 and a secondary site of Ala-27/Asn-28. Processing of the carboxyl-terminal domain could be observed by migration differences in SDS-polyacrylamide gel electrophoresis and was evident in both mammalian and insect cells. Immunological identification by Western blotting confirmed the loss of the expected region. The failure of both cell systems to process the mutant construct shows that the multi-basic sequence is the site of proteolytic processing, Cleavage of the fibrillin-1 carboxyl-terminal domain occurred intracellularly in CHO-K1 cells in an early secretory pathway compartment as demonstrated by studies with secretion blocking agents, This finding, taken with the multi-basic nature of the cleavage site and observed calcium sensitivity of cleavage, suggests that the processing enzyme is a secretory pathway resident furin-like protease.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA	Washington University (WUSTL); University of Texas System	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041926, P01HL029594, R37HL053325, R01HL053325] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41926, HL29594, HL53325] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BECCARI T, 1992, BIOCHEM INT, V27, P783; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; Beers MF, 1996, J BIOL CHEM, V271, P14361, DOI 10.1074/jbc.271.24.14361; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; COUKELL MB, 1992, J CELL SCI, V103, P371; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; CROUCH E, 1994, J BIOL CHEM, V269, P15808; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HALBAN PA, 1994, BIOCHEM J, V299, P1; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HAYWARD C, 1994, HUM MUTAT, V3, P159, DOI 10.1002/humu.1380030212; HU SL, 1987, J VIROL, V61, P3617, DOI 10.1128/JVI.61.11.3617-3620.1987; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KIELTY CM, 1995, INT J BIOCHEM CELL B, V27, P747, DOI 10.1016/1357-2725(95)00028-N; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LISSITZKY JCS, 1988, BIOCHEM J, V250, P843, DOI 10.1042/bj2500843; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; Milewicz DM, 1996, CIRCULATION, V94, P2708, DOI 10.1161/01.CIR.94.11.2708; MILEWICZ DM, 1995, J CLIN INVEST, V95, P2373, DOI 10.1172/JCI117930; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NIJBROEK G, 1995, AM J HUM GENET, V57, P8; ODA K, 1992, J BIOL CHEM, V267, P17465; OREILLY DO, 1992, BACULOVIRUS EXPRESSI, P218; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PRESSMAN BC, 1982, ANNU REV PHARMACOL, V22, P465, DOI 10.1146/annurev.pa.22.040182.002341; RAGHUNATH M, 1995, J MOL BIOL, V248, P901, DOI 10.1006/jmbi.1995.0270; RAMABHADRAN TV, 1993, J BIOL CHEM, V268, P2009; REDICK SD, 1995, J CELL SCI, V108, P1761; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; Sood S, 1996, NAT GENET, V12, P209, DOI 10.1038/ng0296-209; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; ZHANG CY, 1995, BIOCHEM BIOPH RES CO, V207, P238, DOI 10.1006/bbrc.1995.1178	48	60	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8933	8940		10.1074/jbc.274.13.8933	http://dx.doi.org/10.1074/jbc.274.13.8933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085138	hybrid			2022-12-25	WOS:000079451600080
J	Strahl-Bolsinger, S; Scheinost, A				Strahl-Bolsinger, S; Scheinost, A			Transmembrane topology of Pmt1p, a member of an evolutionarily conserved family of protein O-mannosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-LINKED OLIGOSACCHARIDE; PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; INNER MEMBRANE-PROTEINS; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GENE FAMILY; GLCNAC-1-P TRANSFERASE; CANDIDA-ALBICANS; N-GLYCOSYLATION; PIG-B	The identification of the evolutionarily conserved family of dolichyl-phosphate-D-mannose:protein O-mannosyltransferases (Pmts) revealed that protein O-mannosylation plays an essential role in a number of physiologically important processes, Strikingly, all members of the Pmt protein family share almost identical hydropathy profiles; a central hydrophilic domain is flanked by amino- and carboxyl-terminal sequences containing several putative transmembrane helices, This pattern is of particular interest because it diverges from structural models of all glycosyltransferases characterized so far. Here, we examine the transmembrane topology of Pmt1p, an integral membrane protein of the endoplasmic reticulum, from Saccharomyces cerevisiae. Structural predictions were directly tested by site-directed mutagenesis of endogenous N-glycosylation sites, by fusing a topology-sensitive monitor protein domain to carboxyl-terminal truncated versions of the Pmt1 protein and, in addition, by N-glycosylation scanning. Based on our results we propose a seven-transmembrane helical model for the yeast Pmt1p mannosyltransferase. The Pmt1p amino terminus faces the cytoplasm, whereas the carboxyl terminus faces the lumen of the endoplasmic reticulum, A large hydrophilic segment that is oriented toward the lumen of the endoplasmic reticulum is flanked by five amino-terminal and two carboxyl-terminal membrane spanning domains. We could demonstrate that this central loop is essential for the function of Pmt1p.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Strahl-Bolsinger, S (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany.	sabine.strahl-bolsinger@biologie.uni-regensburg.de	Scheinost, Andreas C/D-2275-2010	Scheinost, Andreas C/0000-0002-6608-5428				Aebi M, 1996, GLYCOBIOLOGY, V6, P439, DOI 10.1093/glycob/6.4.439; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; Burda P, 1996, P NATL ACAD SCI USA, V93, P7160, DOI 10.1073/pnas.93.14.7160; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; Dan N, 1997, J BIOL CHEM, V272, P14214, DOI 10.1074/jbc.272.22.14214; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; Eckert V, 1998, GLYCOBIOLOGY, V8, P77, DOI 10.1093/glycob/8.1.77; GABRIEL O, 1969, ANAL BIOCHEM, V27, P545, DOI 10.1016/0003-2697(69)90068-2; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gentzsch M, 1997, GLYCOBIOLOGY, V7, P481, DOI 10.1093/glycob/7.4.481; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUEIRREIRO P, 1996, YEAST, V12, P273; Harlow E., 1988, ANTIBODIES LAB MANUA; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARRIBA G, 1976, FEBS LETT, V71, P316, DOI 10.1016/0014-5793(76)80960-X; Lehle L., 1995, GLYCOPROTEINS A, V29a, P475; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARRIOTT M, 1979, J BACTERIOL, V139, P565, DOI 10.1128/JB.139.2.566-572.1979; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; Menon AK, 1997, BIOCHEM SOC T, V25, P861, DOI 10.1042/bst0250861; NILSSON I, 1993, J BIOL CHEM, V268, P5798; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; Orlean P., 1997, MOL CELLULAR BIOL YE, V21, P229; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; Reiss G, 1996, GLYCOBIOLOGY, V6, P493, DOI 10.1093/glycob/6.5.493; Roemer T, 1996, GENE DEV, V10, P777, DOI 10.1101/gad.10.7.777; Rothe C, 1998, EUR J BIOCHEM, V252, P16, DOI 10.1046/j.1432-1327.1998.2520016.x; SAKAGUCHI M, 1997, MOL B INT U, P135; Sambrook J., 2002, MOL CLONING LAB MANU; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SENTANDREU R, 1969, CARBOHYD RES, V10, P584, DOI 10.1016/S0008-6215(00)80126-3; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; STRAHLBOLSINGER S, 1991, THESIS U REGENSBURG; Sutterlin C, 1998, BIOCHEM J, V332, P153; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Timpel C, 1998, J BIOL CHEM, V273, P20837, DOI 10.1074/jbc.273.33.20837; VONHEIJNE G, 1997, MOL B INT U, P55; WESTON A, 1993, EUR J BIOCHEM, V215, P845, DOI 10.1111/j.1432-1033.1993.tb18101.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZHU XY, 1990, J BIOL CHEM, V265, P14250; [No title captured]	60	87	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9068	9075		10.1074/jbc.274.13.9068	http://dx.doi.org/10.1074/jbc.274.13.9068			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085156	hybrid			2022-12-25	WOS:000079451600098
J	Yang, WN; Lin, Q; Guan, JL; Cerione, RA				Yang, WN; Lin, Q; Guan, JL; Cerione, RA			Activation of the Cdc42-associated tyrosine kinase-2 (ACK-2) by cell adhesion via integrin beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; BINDING PROTEINS RAC1; N-TERMINAL KINASE; FOCAL ADHESIONS; SIGNALING PATHWAY; CDC42HS BINDING; V-SRC; IDENTIFICATION	Activated Cdc42-associated kinase-2 (ACK-2) is a nonreceptor tyrosine kinase that appears to be a highly specific target for the Rho-related GTP-binding protein Cdc42. In order to understand better how ACK-2 activity is regulated in cells, we have expressed epitope-tagged forms of this tyrosine kinase in COS-7 and NIH3T3 cells. We find that ACK-2 can be activated by cell adhesion in a Cdc42-dependent manner. However, unlike the focal adhesion kinase, which also is activated by cell adhesion, the activation of ACK-2 is F-actin-independent and does not require cell spreading. In addition, overexpression of ACK-2 in COS-7 cells did not result in the stimulation of extracellular signal-regulated kinase activity but rather activated the c-Jun kinase. Both anti-integrin beta(1) antibody and RGD peptides inhibited the activation of ACR-S by cell adhesion. In addition, ACK-2 was coimmunoprecipitated with integrin beta(1). Overall, these findings suggest that AGK-2 interacts with integrin complexes and mediates cell adhesion signals in a Cdc42-dependent manner.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Nutr Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM40654, GM47458, GM52890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890, R01GM040654, R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Brill S, 1996, MOL CELL BIOL, V16, P4869; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8481; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rudel T, 1998, J IMMUNOL, V160, P7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAWIL N, 1993, J CELL BIOL, V120, P261, DOI 10.1083/jcb.120.1.261; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	55	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8524	8530		10.1074/jbc.274.13.8524	http://dx.doi.org/10.1074/jbc.274.13.8524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085085	hybrid			2022-12-25	WOS:000079451600027
J	Shiojima, I; Komuro, I; Oka, T; Hiroi, Y; Mizuno, T; Takimoto, E; Monzen, K; Aikawa, R; Akazawa, H; Yamazaki, T; Kudoh, S; Yazaki, Y				Shiojima, I; Komuro, I; Oka, T; Hiroi, Y; Mizuno, T; Takimoto, E; Monzen, K; Aikawa, R; Akazawa, H; Yamazaki, T; Kudoh, S; Yazaki, Y			Context-dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx-2.5 and GATA-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; DNA-BINDING SPECIFICITY; SERUM RESPONSE FACTOR; HEART TUBE FORMATION; VENTRAL MORPHOGENESIS; HOMEODOMAIN FACTOR; DROSOPHILA; TINMAN; PROTEINS; EXTRADENTICLE	Although the cardiac homeobox gene Csx/Nkx-2.5 is essential for normal heart development, little is known about its regulatory mechanisms. In a search for the downstream target genes of Csx/Nkx-2.5, we found that the atrial natriuretic peptide (ANP) gene promoter was strongly transactivated by Csx/Nkx-2.5. Deletion and mutational analyses of the ANP promoter revealed that the Csx/Nkx-2.5-binding element (NKE2) located at -240 was required for high level transactivation by Csx/Nkx-2.5. We also found that Csx/Nkx-2.5 and GATA-4 displayed synergistic transcriptional activation of the ANP promoter, and in contrast to previous reports (Durocher, D., Charron, F., Warren, R., Schwartz, R. J., and Namer, M. (1997) EMBO J. 16, 5687-5696; Lee, Y., Shioi, T., Kasahara, H., Jobe, S. M., Wiese, R. J., Markham, B., and Izumo, S (1998) Mel; Cell. Biol. 18, 3120-3129), this synergism was dependent on binding of Csx/Nkx-2.5 to NKE2, but not on GATA-4-DNA interactions. Although GATA-4 also potentiated the Csx/Nkx-2.5-induced transactivation of the artificial promoter that contains multimerized Csx/Nkx-2.5-binding sites, Csx/Nkx-2.5 reduced the GATA-4-induced transactivation of the GATA-4-dependent promoters. These findings indicate that the cooperative transcriptional regulation mediated by Csx/Nkx-2.5 and GATA-4 is promoter context-dependent and suggest that the complex cis-trans interactions may fine-tune gene expression in cardiac myocytes.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo	Komuro, I (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	komuro-tky@umin.ac.jp	Takimoto, Eiki/AAC-5100-2021	Akazawa, Hiroshi/0000-0002-3574-9607				AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BODMER R, 1990, DEVELOPMENT, V110, P661; BODMER R, 1993, DEVELOPMENT, V118, P719; BODMER R, 1995, TRENDS CARDIOVAS MED, V5, P21, DOI 10.1016/1050-1738(94)00032-Q; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen JN, 1996, DEVELOPMENT, V122, P3809; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LU QA, 1995, MOL CELL BIOL, V15, P3786; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TONISSEN KF, 1994, DEV BIOL, V162, P325, DOI 10.1006/dbio.1994.1089; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WU XS, 1995, DEV BIOL, V169, P619, DOI 10.1006/dbio.1995.1174; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zou YM, 1997, DEVELOPMENT, V124, P793	39	102	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8231	8239		10.1074/jbc.274.12.8231	http://dx.doi.org/10.1074/jbc.274.12.8231			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075728	hybrid			2022-12-25	WOS:000079268100087
J	Wang, TH; Popp, DM; Wang, HS; Saitoh, M; Mural, JG; Henley, DC; Ichijo, H; Wimalasena, J				Wang, TH; Popp, DM; Wang, HS; Saitoh, M; Mural, JG; Henley, DC; Ichijo, H; Wimalasena, J			Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ACTIVATION; PROTEIN-KINASES; BCL-2; PHOSPHORYLATION; TAXOL; STRESS; DEATH; PROGRESSION; CASPASES; GENE	The antineoplastic agent paclitaxel (Taxol(TM)), a microtubule stabilizing agent, is known to arrest cells at the G(2)/M phase of the cell cycle and induce apoptosis. We and others have recently demonstrated that paclitaxel also activates the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) signal transduction pathway in various human cell types, however, no clear role has been established for JNK/SAPK in paclitaxel-induced apoptosis. To further examine the role of JNK/SAPK signaling cascades in apoptosis resulting from microtubular dysfunction induced by paclitaxel, we have coexpressed dominant negative (dn) mutants of signaling proteins of the JNK/SAPK pathway (Ras, ASK1, Rac, JNKK, and JNK) in human ovarian cancer cells with a selectable marker to analyze the apoptotic characteristics of cells expressing dn vectors following exposure to paclitaxel, Expression of these dn signaling proteins had no effect on Bcl-2 phosphorylation, yet inhibited apoptotic changes induced by paclitaxel up to 16 h after treatment. Coexpression of these dn signaling proteins had no protective effect after 48 h of paclitaxel treatment. Our data indicate that: (i) activated JNK/SAPK acts upstream of membrane changes and caspase-3 activation in paclitaxel-initiated apoptotic pathways, independently of cell cycle stage, (ii) activated JNK/SAPK is not responsible for paclitaxel-induced phosphorylation of Bcl-2, and (iii) apoptosis resulting from microtubule damage may comprise multiple mechanisms, including a JNK/SAPK-dependent early phase and a JNK/SAPK-independent late phase.	Univ Tennessee, Dept Obstet & Gynecol, Ctr Med, Grad Sch Med, Knoxville, TN 37920 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Oak Ridge Natl Lab, Div Environm Sci, Oak Ridge, TN 37831 USA; Chang Gung Mem Hosp, Chang Gung Med Sch, Dept Obstet & Gynecol, Taipei 10591, Taiwan; Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Tokyo 1138549, Japan	University of Tennessee System; University of Tennessee Health Science Center; United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; Chang Gung Memorial Hospital; Tokyo Medical & Dental University (TMDU)	Wimalasena, J (corresponding author), Univ Tennessee, Dept Obstet & Gynecol, Ctr Med, Grad Sch Med, 1924 Alcoa Highway, Knoxville, TN 37920 USA.			Ichijo, Hidenori/0000-0002-5005-6438	NCI NIH HHS [CA-68538] Funding Source: Medline; NIAAA NIH HHS [AA-08328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Amato SF, 1998, CANCER RES, V58, P241; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Blagosklonny MV, 1997, CANCER RES, V57, P130; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COSA OA, 1995, CELL, V81, P1137; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; Green DR, 1997, P NATL ACAD SCI USA, V94, P5986, DOI 10.1073/pnas.94.12.5986; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1998, CANCER RES, V58, P1609; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Heimbrook DC, 1998, CURR OPIN CELL BIOL, V10, P284, DOI 10.1016/S0955-0674(98)80152-X; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Huang TS, 1997, CANCER RES, V57, P2974; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Lee YJ, 1998, J BIOL CHEM, V273, P29857, DOI 10.1074/jbc.273.45.29857; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LONG BH, 1994, CANCER RES, V54, P4355; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MILAS L, 1995, CANCER CHEMOTH PHARM, V35, P297, DOI 10.1007/BF00689448; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; PRESTON GA, 1994, CANCER RES, V54, P4214; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Roth W, 1998, BRIT J CANCER, V77, P404, DOI 10.1038/bjc.1998.64; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang TH, 1996, J FORMOS MED ASSOC, V95, P509; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WIMALASENA J, 1991, GYNECOL ONCOL, V41, P56, DOI 10.1016/0090-8258(91)90255-4; Wolfson M, 1997, INT J CANCER, V70, P248, DOI 10.1002/(SICI)1097-0215(19970117)70:2<248::AID-IJC17>3.0.CO;2-E; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Zanke BW, 1998, CANCER RES, V58, P2801	74	196	205	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8208	8216		10.1074/jbc.274.12.8208	http://dx.doi.org/10.1074/jbc.274.12.8208			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075725	hybrid			2022-12-25	WOS:000079268100084
J	Plattner, R; Gupta, S; Khosravi-Far, R; Sato, KY; Perucho, M; Der, CJ; Stanbridge, EJ				Plattner, R; Gupta, S; Khosravi-Far, R; Sato, KY; Perucho, M; Der, CJ; Stanbridge, EJ			Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells	ONCOGENE			English	Article						Ras; ERK; JNK	NUCLEOTIDE DISSOCIATION STIMULATOR; EPITHELIAL-CELLS; PLASMA-MEMBRANE; IN-VITRO; C-JUN; GROWTH; IDENTIFICATION; SUFFICIENT; EXPRESSION; ONCOGENES	Although an important contribution of ERK and JNK mitogen-activated protein kinase (MAPK) activation in Ras transformation of rodent fibroblasts has been determined, their role in mediating oncogenic Ras transformation of human tumor cells remains to be established. We have utilized the human HT1080 fibrosarcoma and DLD-1 colon carcinoma cell lines, which contain endogenous mutated and oncogenic N- and K-ras alleles, respectively, to address this role. Study of these cells is advantageous over Ras-transformed rodent model cell systems for two key reasons. First, the ras mutations occurred naturally in the progression of the tumors from which the cell lines were derived, rather than due to overexpression of an exogenously introduced gene, Second, although these tumor cells possess defects in multiple genetic loci, it has been established that mutated Ras contributes significantly to the transformed phenotype of these cells. Clonal variant lines of HT1080 and DLD-1 have been isolated which have lost the oncogenic was allele and exhibit a corresponding impairment in growth transformation in vitro and in vivo. We found that upregulation of Raf/MEK/ERK and JNK correlated with expression of oncogenic Ras in HT1080, but not DLD-1 cells. Furthermore, inhibition of ERK activation in parental HT1080 cells caused the same changes in cell morphology and actin stress fiber organization seen with loss of expression of activated N-Ras(61K). Thus, we suggest that constitutive activation of the Raf/MEK/ERK and JNK pathways is necessary for Ras-induced transformation of HT1080 but not DLD-1 cells. These results emphasize that cell type differences exist in the signaling pathways by which oncogenic pas causes transformation.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol,Dept Pharmacol, Chapel Hill, NC 27599 USA; Burnham Inst, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Sanford Burnham Prebys Medical Discovery Institute	Stanbridge, EJ (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Khosravi-Far, Roya/C-3789-2008	Der, Channing/0000-0002-7751-2747; Perucho, Manuel/0000-0002-2169-2662	NCI NIH HHS [CA69515, CA42978, CA19401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978, R01CA019401, R01CA069515, R37CA019401] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P266, DOI 10.1002/gcc.2870090407; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Graham SM, 1996, MOL CELL BIOL, V16, P6132; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hua VY, 1997, P NATL ACAD SCI USA, V94, P9614, DOI 10.1073/pnas.94.18.9614; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLDHAM SM, 1998, IN PRESS ONCOGENE; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peterson SN, 1996, J BIOL CHEM, V271, P29903, DOI 10.1074/jbc.271.47.29903; Plattner R, 1996, P NATL ACAD SCI USA, V93, P6665, DOI 10.1073/pnas.93.13.6665; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; Wolthuis RMF, 1996, ONCOGENE, V13, P353	48	50	50	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1807	1817		10.1038/sj.onc.1202482	http://dx.doi.org/10.1038/sj.onc.1202482			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086335				2022-12-25	WOS:000079090000004
J	Schmandt, R; Liu, SK; McGlade, CJ				Schmandt, R; Liu, SK; McGlade, CJ			Cloning and characterization of mPAL, a novel Shc SH2 domain-binding protein expressed in proliferating cells	ONCOGENE			English	Article						SHC; SH2 domain; phosphotyrosine-independent; cell proliferation	NUCLEOTIDE EXCHANGE FACTOR; PHOSPHOTYROSINE-INDEPENDENT LIGAND; TYROSINE-PHOSPHORYLATED PROTEIN; GROWTH-FACTOR RECEPTORS; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; CONSTITUTIVE PHOSPHORYLATION; NEURONAL DIFFERENTIATION; KINASE ACTIVATION; DEPENDENT MANNER	Shc adaptor proteins play a role in linking activated cell surface receptors to the Ras signaling pathway in response to receptor mediated tyrosine kinase activation. While the function of Shc in the activation of the Ras pathway, ia binding to Grb2 has been well characterized, it is becoming increasingly apparent that Shc participates in additional signaling pathways through interactions with other cytoplasmic proteins. Using the yeast two-hybrid system, we have identified a unique She binding protein designated PAL (Protein expressed in Activated Lymphocytes) with no similarity to other known proteins. mPAL binds specifically to the Shc SH2 domain and unlike previously described Shc SH2 domain-protein interactions, the association of mPAL and She is phosphotyrosine-independent. RNA and protein expression are restricted to tissues containing actively dividing cells and proliferating cells in culture, mPAL expression is induced upon growth factor stimulation and is down-regulated upon growth inhibition. This pattern, and timing of mPAL expression and its association with the She adaptor molecule suggests a role for this protein in signaling pathways governing cell cycle progression.	Univ Toronto, Dept Med Biophys, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	McGlade, CJ (corresponding author), Univ Toronto, Dept Med Biophys, Ontario Canc Inst, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.			Liu, Stanley/0000-0001-6851-0857				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bai C, 1996, METHOD ENZYMOL, V273, P331; BALDARI CT, 1995, ONCOGENE, V10, P1141; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CROWE AJ, 1994, ONCOGENE, V9, P537; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; Gotoh N, 1995, ONCOGENE, V11, P2525; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU SK, 1998, IN PRESS ONCOGENE; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MALEK SN, 1994, J BIOL CHEM, V269, P33009; Marengere LEM, 1997, J IMMUNOL, V159, P70; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDNICKI MA, 1990, J CELL PHYSIOL, V142, P89, DOI 10.1002/jcp.1041420112; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAXTON TM, 1994, J IMMUNOL, V153, P623; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	79	46	48	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1867	1879		10.1038/sj.onc.1202507	http://dx.doi.org/10.1038/sj.onc.1202507			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086341				2022-12-25	WOS:000079090000010
J	Kakuta, Y; Sueyoshi, T; Negishi, M; Pedersen, LC				Kakuta, Y; Sueyoshi, T; Negishi, M; Pedersen, LC			Crystal structure of the sulfotransferase domain of human heparan sulfate N-deacetylase/N-sulfotransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN SULFOTRANSFERASE; REFINEMENT	Heparan sulfate N-deacetylase/N-sulfotransferase (HSNST) catalyzes the first and obligatory step in the biosynthesis of heparan sulfates and heparin, The crystal structure of the sulfotransferase domain (NST1) of human HSNST-1 has been determined at 2.3-Angstrom resolution in a binary complex with 3'-phosphoadenosine 5'-phosphate (PAP), NST1 is approximately spherical with an open cleft, and consists of a single alpha/beta fold with a central five-stranded parallel beta-sheet and a three-stranded anti-parallel beta-sheet bearing an interstrand disulfide bond. The structural regions alpha 1, alpha 6, beta 1, beta 7, 5'-phosphosulfate binding loop (between beta 1 and alpha 1), and a random coil (between beta 8 and alpha 13) constitute the PAP binding site of NST1, The alpha 6 and random coil (between beta 2 and alpha 2), which form an open cleft near the 5'-phosphate of the PAP molecule, may provide interactions for substrate binding. The conserved residue Lys-614 is in position to form a hydrogen bond with the bridge oxygen of the 5'-phosphate.	NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Reprod & Dev Toxicol Lab, Pharmacogenet Sect, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berninsone P, 1998, J BIOL CHEM, V273, P25556, DOI 10.1074/jbc.273.40.25556; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hacker U, 1997, DEVELOPMENT, V124, P3565; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	23	111	117	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10673	10676		10.1074/jbc.274.16.10673	http://dx.doi.org/10.1074/jbc.274.16.10673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196134	hybrid			2022-12-25	WOS:000079751900002
J	Krylov, DM; Niemi, GA; Dizhoor, AM; Hurley, JB				Krylov, DM; Niemi, GA; Dizhoor, AM; Hurley, JB			Mapping sites in guanylyl cyclase activating protein-1 required for regulation of photoreceptor membrane guanylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONE DYSTROPHY; CALCIUM SENSOR; RECOVERIN; CLONING; EXPRESSION; MUTANT; VISION; RETGC	Guanylyl cyclase activating protein (GCAP)-1 regulates photoreceptor membrane guanylyl cyclase, RetGC, in a Ca2+-sensitive manner. It contains four Ca2+-binding motifs, EF-hands, three of which are capable of binding Ca2+. GCAP-1 activates RetGC in low Ca2+ and inhibits it in high Ca2+, In this study we used deletion and substitution analysis to identify regions of GCAP-1 sequence that are specifically required for inhibition and activation. A COOH-terminal sequence within Met(157) to Arg(182) is required for activation but not for inhibition of RetGC, We localized one essential stretch to 5 residues from Arg(178) to Arg(182). Another sequence essential for activation is within the N-terminal residues Trp(21) to Thr(27). The region between EF-hands 1 and 3 of GCAP-1 also contains elements needed for activation of RetGC, Finally, we found that inhibition of RetGC requires the first 9 amino-terminal residues of GCAP-1, but none of the residues from Gln(33) to the COOH-terminal Gly(205) are specifically required for inhibition. The ability of GCAP-1 mutants to regulate RetGC was tested on total guanylyl cyclase activity present in rod outer segments. In addition, the key mutants were also shown to produce similar effects on recombinant bovine outer segment cyclases GC1 and GC2.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Wayne State Univ, Kresge Eye Inst, Dept Ophthalmol, Sch Med, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Wayne State University; Wayne State University	Hurley, JB (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.			Dizhoor, Alexander/0000-0001-6770-9186	NEI NIH HHS [EY06614, EY11522, R01 EY006641] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006641, R01EY011522] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Dizhoor AM, 1998, J BIOL CHEM, V273, P17311, DOI 10.1074/jbc.273.28.17311; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; Dizhoor AM, 1996, J BIOL CHEM, V271, P19346, DOI 10.1074/jbc.271.32.19346; DURONIO RJ, 1991, J BIOL CHEM, V266, P10498; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; HORTON RM, 1991, DIRECTED MUTAGENESIS; HURLEY JB, 1993, SCIENCE, V260, P740, DOI 10.1126/science.8097896; KAWAMURA S, 1994, BIOCHEM BIOPH RES CO, V203, P121, DOI 10.1006/bbrc.1994.2157; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; OttoBruc A, 1997, BIOCHEMISTRY-US, V36, P4295, DOI 10.1021/bi963000d; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Payne AM, 1998, HUM MOL GENET, V7, P273, DOI 10.1093/hmg/7.2.273; POZDNYAKOV N, 1995, BIOCHEMISTRY-US, V34, P14279, DOI 10.1021/bi00044a002; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; Rudnicka-Nawrot M, 1998, BIOCHEMISTRY-US, V37, P248, DOI 10.1021/bi972306x; Sokal I, 1998, MOL CELL, V2, P129, DOI 10.1016/S1097-2765(00)80121-5; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	24	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10833	10839		10.1074/jbc.274.16.10833	http://dx.doi.org/10.1074/jbc.274.16.10833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196159	hybrid			2022-12-25	WOS:000079751900027
J	Burner, U; Obinger, C; Paumann, M; Furtmuller, PG; Kettle, AJ				Burner, U; Obinger, C; Paumann, M; Furtmuller, PG; Kettle, AJ			Transient and steady-state kinetics of the oxidation of substituted benzoic acid hydrazides by myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDASE COMPOUND-I; HYDROGEN-PEROXIDE; SALICYLHYDROXAMIC ACID; HYPOCHLOROUS ACID; ASCORBIC-ACID; SUPEROXIDE; INHIBITION; MECHANISM; NEUTROPHILS; CHLORIDE	Myeloperoxidase is the most abundant, protein in neutrophils and catalyzes the production of hypochlorous acid. This potent oxidant plays a central role in microbial killing and inflammatory tissue damage. 4-Aminobenzoic acid hydrazide (ABAH) is a mechanism-based inhibitor of myeloperoxidase that is oxidized to radical intermediates that cause enzyme inactivation. We have investigated the mechanism by which benzoic acid hydrazides (BAH) are oxidized by myeloperoxidase, and we have determined the features that enable them to inactivate the enzyme. BAHs readily reduced compound I of myeloperoxidase, The rate constants for these reactions ranged from 1 to 3 x 10(6) M-1 s(-1) (15 degrees C, pH 7.0) and were relatively insensitive to the substituents on the aromatic ring. Rate constants for reduction of compound II varied between 6.5 x 10(5) M-1 s(-1) for ABAH and 1,3 x 10(3) M-1 s(-1) for 4-nitrobenzoic acid hydrazide (15 degrees C, pH 7.0). Reduction of both compound I and compound II by BAHs adhered to the Hammett rule, and there were significant correlations with Brown-Okamoto substituent constants. This indicates that the rates of these reactions were simply determines by the ease of oxidation of the substrates and that the incipient free radical carried a positive charge. ABAH was oxidized by myeloperoxidase without added hydrogen peroxide because it underwent auto-oxidation, Although BAHs generally reacted rapidly with compound II, they should be poor peroxidase substrates because the free radicals formed during peroxidation converted myeloperoxidase to compound III. We found that the reduction of ferric myeloperoxidase by BAH radicals was strongly influenced by Hansch's hydrophobicity constants. BAHs containing more hydrophilic substituents were more effective at converting the enzyme to compound III, This implies that BAH radicals must hydrogen bond to residues in the distal heme pocket before they can reduce the ferric enzyme. Inactivation of myeloperoxidase by BAHs was related to how readily they were oxidized, but there was no correlation with their rate constants for reduction of compounds I or II. We propose that BAHs destroy the heme prosthetic groups of the enzyme by reducing a ferrous myeloperoxidase-hydrogen peroxide complex.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; Christchurch Sch Med, Dept Pathol, Free Rad Res Grp, Christchurch, New Zealand	University of Natural Resources & Life Sciences, Vienna; University of Otago	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.		Obinger, Christian/AAV-3173-2021; Furtmüller, Paul G./Y-5819-2018; Kettle, Anthony J/A-8520-2008	Furtmüller, Paul G./0000-0002-1199-2469; Kettle, Anthony J/0000-0002-8218-7766; Obinger, Christian/0000-0002-7133-3430				BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V788, P1, DOI 10.1016/0167-4838(84)90290-5; Candeias LP, 1996, BIOCHEMISTRY-US, V35, P102, DOI 10.1021/bi9514424; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; DAVIES B, 1989, BIOCHEM J, V258, P801, DOI 10.1042/bj2580801; DUNFORD HB, 1986, ARCH BIOCHEM BIOPHYS, V251, P536, DOI 10.1016/0003-9861(86)90361-9; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; Hansch C, 1979, SUBSTITUENT CONSTANT; HAZEN SL, 1996, J CLIN INVEST, V98, P1238; HOOGLAND H, 1987, BIOCHIM BIOPHYS ACTA, V916, P76, DOI 10.1016/0167-4838(87)90212-3; HURST JK, 1991, EUR J BIOCHEM, V202, P1275, DOI 10.1111/j.1432-1033.1991.tb16500.x; HURST JK, 1991, PEROXIDASES CHEM BIO, P37; IKEDASAITO M, 1991, J BIOL CHEM, V266, P3611; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; JOB D, 1976, EUR J BIOCHEM, V66, P607, DOI 10.1111/j.1432-1033.1976.tb10588.x; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503; KETTLE AJ, 1991, BIOCHEM PHARMACOL, V41, P1485, DOI 10.1016/0006-2952(91)90565-M; KETTLE AJ, 1994, J BIOL CHEM, V269, P17146; KETTLE AJ, 1988, BIOCHEM J, V252, P529, DOI 10.1042/bj2520529; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; MARCH J, 1977, ADV ORGANIC CHEM REA, P273; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; Marquez LA, 1997, BIOCHEMISTRY-US, V36, P9349, DOI 10.1021/bi970595j; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MARQUEZ LA, 1990, J BIOL CHEM, V265, P6074; MISRA HP, 1976, BIOCHEMISTRY-US, V15, P681, DOI 10.1021/bi00648a036; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; ODAJIMA T, 1970, BIOCHIM BIOPHYS ACTA, V206, P71, DOI 10.1016/0005-2744(70)90083-5; SVENSSON BE, 1988, BIOCHEM J, V249, P521, DOI 10.1042/bj2490521; UTRECHT JP, 1992, DRUG METAB REV, V24, P299; vanDalen CJ, 1997, BIOCHEM J, V327, P487; VANDERWALT BJ, 1994, BIOCHEM PHARMACOL, V47, P1039, DOI 10.1016/0006-2952(94)90415-4; VANZYL JM, 1989, BIOCHEM PHARMACOL, V38, P2363, DOI 10.1016/0006-2952(89)90477-2; WINTERBOURN CC, 1985, BIOCHEM J, V228, P583, DOI 10.1042/bj2280583	37	64	64	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9494	9502		10.1074/jbc.274.14.9494	http://dx.doi.org/10.1074/jbc.274.14.9494			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092633	hybrid			2022-12-25	WOS:000079451800052
J	Kieber-Emmons, T; Lin, CM; Foster, MH; Kleyman, TR				Kieber-Emmons, T; Lin, CM; Foster, MH; Kleyman, TR			Antiidiotypic antibody recognizes an amiloride binding domain within the alpha subunit of the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; CONFORMATIONAL SEARCH; NEUTRALIZING ANTIBODY; INDUCED HYPERKALEMIA; MEMBRANE TOPOLOGY; CELL-LINE; PEPTIDE; PROTEIN; ANTIGEN; IDENTIFICATION	We previously raised an antibody (RA6.3) by an antidiotypic approach which was designed to be directed against an amiloride binding domain on the epithelial Na+ channel (ENaC). This antibody mimicked amiloride in that it inhibited transepithelial Na+ transport across A6 cell monolayers. RA6.3 recognized a 72-kDa polypeptide in A6 epithelia treated with tunicamycin, consistent with the size of nonglycosylated Xenopus laevis alpha ENaC. RA6.3 specifically recognized an amiloride binding domain within the alpha-subunit of mouse and bovine ENaC. The deduced amino acid sequence of RA6.3 was used to generate a three-dimensional model structure of the antibody. The combining site of RA6.3 was epitope mapped using a novel computer-based strategy. Organic residues that potentially interact with the RA6.3 combining site were identified by data base screening using the program LUDI. Selected residues docked to the antibody in a manner corresponding to the ordered linear array of amino acid residues within an amiloride binding domain on the alpha-subunit of ENaC, A synthetic peptide spanning this domain inhibited the binding of RA6.3 to alpha ENaC. This analysis provided a novel approach to develop models of antibody-antigen interaction as well as a molecular perspective of RA6.3 binding to an amiloride binding domain within alpha ENaC.	Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Kleyman, TR (corresponding author), Vet Affairs Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	kleyman@mail.med.upenn.edu			NIDDK NIH HHS [DK50268] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050268] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALABAN RS, 1979, J MEMBRANE BIOL, V49, P363, DOI 10.1007/BF01868992; Berdiev BK, 1998, BIOPHYS J, V75, P2292, DOI 10.1016/S0006-3495(98)77673-8; BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/bf00124387; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFANT ML, 1993, AM J PHYSIOL, V264, pC1480, DOI 10.1152/ajpcell.1993.264.6.C1480; CHOI MJ, 1993, NEW ENGL J MED, V328, P703, DOI 10.1056/NEJM199303113281006; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; CoupayeGerard B, 1996, AM J PHYSIOL-CELL PH, V271, pC1639, DOI 10.1152/ajpcell.1996.271.5.C1639; CoupayeGerard B, 1997, AM J PHYSIOL-CELL PH, V272, pC1781, DOI 10.1152/ajpcell.1997.272.6.C1781; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FINE R M, 1986, Proteins Structure Function and Genetics, V1, P342, DOI 10.1002/prot.340010408; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOTTLIEB GP, 1978, BIOPHYS J, V22, P125, DOI 10.1016/S0006-3495(78)85477-0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILLAUME T, 1990, J IMMUNOL, V145, P1934; HAMILTON KL, 1985, AM J PHYSIOL, V249, pC200, DOI 10.1152/ajpcell.1985.249.3.C200; Ismailov II, 1997, J BIOL CHEM, V272, P21075, DOI 10.1074/jbc.272.34.21075; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KARP SL, 1993, J IMMUNOL, V150, P867; KIEBEREMMONS T, 1995, KIDNEY INT, V48, P956, DOI 10.1038/ki.1995.377; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1995, ANN INTERN MED, V122, P103, DOI 10.7326/0003-4819-122-2-199501150-00004; KLEYMAN TR, 1991, J BIOL CHEM, V266, P3907; KLEYMAN TR, 1990, METHOD ENZYMOL, V191, P739; KLEYMAN TR, 1992, J BIOL CHEM, V267, P9622; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; LEVY S, 1987, GENE, V54, P167, DOI 10.1016/0378-1119(87)90484-7; LI JHY, 1985, J MEMBRANE BIOL, V83, P45, DOI 10.1007/BF01868737; LI JHY, 1982, BASIC MECHANISMS ACT, P28; Li S, 1997, P NATL ACAD SCI USA, V94, P73, DOI 10.1073/pnas.94.1.73; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LIN CM, 1994, J BIOL CHEM, V269, P2805; Ling BN, 1997, J BIOL CHEM, V272, P594; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOHMAN KL, 1993, MOL IMMUNOL, V30, P1295, DOI 10.1016/0161-5890(93)90046-E; MARTIN ACR, 1991, METHOD ENZYMOL, V203, P121; MAS MT, 1992, PROTEINS, V14, P483, DOI 10.1002/prot.340140409; Murali R, 1997, J MOL RECOGNIT, V10, P269, DOI 10.1002/(SICI)1099-1352(199711/12)10:6<269::AID-JMR370>3.0.CO;2-9; NELL LJ, 1992, BIOPOLYMERS, V32, P11, DOI 10.1002/bip.360320104; NISONOFF A, 1991, J IMMUNOL, V147, P2429; NOVOTNY J, 1990, PROTEINS, V7, P93, DOI 10.1002/prot.340070109; PALMER LG, 1984, J MEMBRANE BIOL, V80, P153, DOI 10.1007/BF01868771; PEDEMONTE CH, 1995, J MEMBRANE BIOL, V147, P223; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; Sambrook J., 1989, MOL CLONING LAB MANU, V1; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SHENKIN PS, 1987, BIOPOLYMERS, V26, P2053, DOI 10.1002/bip.360261207; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TORMO J, 1994, EMBO J, V13, P2247, DOI 10.1002/j.1460-2075.1994.tb06506.x; VANDRIESSCHE W, 1983, PFLUG ARCH EUR J PHY, V398, P179, DOI 10.1007/BF00657149; Verdaguer N, 1996, J MOL BIOL, V256, P364, DOI 10.1006/jmbi.1996.0092; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WARNCKE J, 1985, J MEMBRANE BIOL, V86, P255, DOI 10.1007/BF01870605; WILSON IA, 1994, RES IMMUNOL, V145, P73, DOI 10.1016/S0923-2494(94)80049-9; WORRELL RT, 1995, FASEB J, V9, pA309; Young ACM, 1997, J MOL BIOL, V274, P622, DOI 10.1006/jmbi.1997.1407	68	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9648	9655		10.1074/jbc.274.14.9648	http://dx.doi.org/10.1074/jbc.274.14.9648			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092651	hybrid			2022-12-25	WOS:000079451800070
J	Medvedev, AE; Blanco, JCG; Qureshi, N; Vogel, SN				Medvedev, AE; Blanco, JCG; Qureshi, N; Vogel, SN			Limited role of ceramide in lipopolysaccharide-mediated mitogen-activated protein kinase activation, transcription factor induction, and cytokine release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; DIPHOSPHORYL LIPID-A; LPS BINDING-PROTEIN; MURINE MACROPHAGES; BACTERIAL LIPOPOLYSACCHARIDE; RHODOPSEUDOMONAS-SPHAEROIDES; ACID SPHINGOMYELINASE; INDUCED APOPTOSIS	The involvement of ceramide in lipopolysaccharide-mediated activation of mouse macrophages was studied. Lipopolysaccharide cell-permeable ceramide analogs, and bacterial sphingomyelinase led to phosphorylation of the extracellular signal-regulated kinases, c-Jun NH2-terminal kinases, and p38 kinase and induced AP-1 DNA binding in C3H/OuJ (Lps(n)) but not in C3H/HeJ (Lps(d)) macrophages. Lipopolysaccharide and ceramide mimetics showed distinct kinetics of mitogen-activated protein kinase phosphorylation and AP-1 induction and activated AP-1 complexes with different subunit compositions. Lipopolysaccharide-activated AP-1 consisted of c-Fos, Jun-E, Jun-D, and c-Jun, while C-2-ceramide induced Jun-D and c-Jun only. Lipopolysaccharide and, less potently, C-2-ceramide or sphingomyelinase, stimulated AP-1-dependent reporter gene transcription in RAW 264.7 cells. Unlike lipopolysaccharide, C-2-ceramide failed to activate NF-kappa B and did not induce production of tumor necrosis factor or interleukin-6. The lipopolysaccharide antagonist, Rhodobacter sphaeroides diphosphoryl lipid A, inhibited lipopolysaccharide activation of NF-kappa B and AP-1 but did not block C-2-ceramide-induced AP-1. Pretreatment of C3H/OuJ macrophages with C-2-ceramide greatly diminished AP-1 induction following subsequent C-2-ceramide stimulation. However, lipopolysaccharide-induced transcription factor activation and cytokine release were not influenced, In contrast, lipopolysaccharide pretreatment inhibited both lipopolysaccharide- and C-2-ceramide-mediated responses. Thus, ceramide partially mimics lipopolysaccharide in activating the mitogen-activated protein kinases and AP-1 but not in mediating NF-kappa B induction or cytokine production, suggesting a limited role in lipopolysaccharide signaling.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA	Uniformed Services University of the Health Sciences - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital	Vogel, SN (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vogel@bob.usuf2.usuhs.mil	Blanco, Jorge/AAW-3752-2020	Blanco, Jorge/0000-0002-6173-0213	NIAID NIH HHS [AI-18797] Funding Source: Medline; NIGMS NIH HHS [GM-50870] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018797, R37AI018797, R01AI018797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050870] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barber SA, 1996, INFECT IMMUN, V64, P3397, DOI 10.1128/IAI.64.8.3397-3400.1996; BARBER SA, 1995, J IMMUNOL, V155, P2303; BETTS JC, 1994, J BIOL CHEM, V269, P8455; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; BURAS JA, 1995, MOL IMMUNOL, V32, P541, DOI 10.1016/0161-5890(95)00018-A; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; FERRERO E, 1993, P NATL ACAD SCI USA, V90, P2380, DOI 10.1073/pnas.90.6.2380; GODAMBE SA, 1994, J IMMUNOL, V153, P143; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; HENRICSON BE, 1992, INFECT IMMUN, V60, P4285, DOI 10.1128/IAI.60.10.4285-4290.1992; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIRKLAND TN, 1991, INFECT IMMUN, V59, P131, DOI 10.1128/IAI.59.1.131-136.1991; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; KUNO K, 1994, INT IMMUNOL, V6, P1269, DOI 10.1093/intimm/6.8.1269; Lakics V, 1998, J IMMUNOL, V161, P2490; LEE JD, 1992, J EXP MED, V175, P1697, DOI 10.1084/jem.175.6.1697; LEE WY, 1994, J BIOL CHEM, V269, P17971; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MANTHEY CL, 1993, J EXP MED, V178, P695, DOI 10.1084/jem.178.2.695; Manthey CL, 1998, CYTOKINE, V10, P654, DOI 10.1006/cyto.1998.0344; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P18994; MCINTIRE FC, 1967, BIOCHEMISTRY-US, V6, P2363, DOI 10.1021/bi00860a011; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; OTTERLEI M, 1991, J IMMUNOTHER, V10, P286, DOI 10.1097/00002371-199108000-00007; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Perera PY, 1997, J IMMUNOL, V158, P4422; Pietzsch A, 1997, BIOCHEM BIOPH RES CO, V235, P4, DOI 10.1006/bbrc.1997.6715; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; QURESHI N, 1991, J BIOL CHEM, V266, P6532; RAINES MA, 1993, J BIOL CHEM, V268, P14572; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SERKKOLA E, 1993, EUR J BIOCHEM, V213, P243, DOI 10.1111/j.1432-1033.1993.tb17754.x; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Thieblemont N, 1997, J EXP MED, V185, P2095, DOI 10.1084/jem.185.12.2095; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VIRCA GD, 1989, J BIOL CHEM, V264, P21951; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WRIGHT SD, 1990, J IMMUNOL, V144, P2566; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5; WRIGHT SD, 1991, J EXP MED, V173, P1281, DOI 10.1084/jem.173.5.1281; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG ZH, 1993, J BIOL CHEM, V268, P20520; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	74	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9342	9350		10.1074/jbc.274.14.9342	http://dx.doi.org/10.1074/jbc.274.14.9342			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092612	hybrid			2022-12-25	WOS:000079451800031
J	Mohr, S; Hallak, H; de Boitte, A; Lapetina, EG; Brune, B				Mohr, S; Hallak, H; de Boitte, A; Lapetina, EG; Brune, B			Nitric oxide induced S-glutathionylation and inactivation of glyceraldehyde-3-phosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; NITROSYLATION; PROTEIN; THIOLATION; CELLS; BIOCHEMISTRY; INHIBITION; CYSTEINE; ENZYME	S-Nitrosylation of protein thiol groups by nitric oxide (NO) is a widely recognized protein modification. In this study we show that nitrosonium tetrafluoroborate (BF4NO), a NO+ donor, modified the thiol groups of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by S-nitrosylation and caused enzyme inhibition. The resultant protein-S-nitrosothiol was found to be unstable and to decompose spontaneously, thereby restoring enzyme activity. In contrast, the NO-releasing compound S-nitrosoglutathione (GSNO) promoted S-glutathionylation of a thiol group of GAPDH both in vitro and under cellular conditions. The GSH-mixed protein disulfide formed led to a permanent enzyme inhibition, but upon dithiothreitol addition a functional active GAPDH was recovered. This S-glutathionylation is specific for GSNO because GSH itself was unable to produce protein-mixed disulfides. During cellular nitrosative stress, the production of intracellular GSNO might channel signaling responses to form protein-mixed disulfide that can regulate intracellular function.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany; Case Western Reserve Univ, Sch Med, Mol Cardiovasc Res Ctr, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	University of Erlangen Nuremberg; Case Western Reserve University; University Hospitals of Cleveland; Cleveland Clinic Foundation	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestr 8, D-91054 Erlangen, Germany.	mfm423@rzmail.uni-erlangen.de						AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BUTLER J, 1976, ANAL BIOCHEM, V75, P674, DOI 10.1016/0003-2697(76)90129-9; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Figueiredo-Pereira ME, 1998, J BIOL CHEM, V273, P12703, DOI 10.1074/jbc.273.21.12703; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; Knight RJ, 1996, CARDIOVASC RES, V32, P1016, DOI 10.1016/S0008-6363(96)00137-X; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Mohr S, 1996, J BIOL CHEM, V271, P4209; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; WELSH N, 1991, ENDOCRINOLOGY, V129, P3167, DOI 10.1210/endo-129-6-3167	26	267	279	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9427	9430		10.1074/jbc.274.14.9427	http://dx.doi.org/10.1074/jbc.274.14.9427			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092623	hybrid			2022-12-25	WOS:000079451800042
J	Nett, JH; Trumpower, BL				Nett, JH; Trumpower, BL			Intermediate length Rieske iron-sulfur protein is present and functionally active in the cytochrome bc(1) complex of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; YEAST MITOCHONDRIA; PROCESSING PEPTIDASE; IMPORT; CLEAVAGE; SUBUNIT; PURIFICATION; PRESEQUENCE; PRECURSOR; INSERTION	To investigate the relationship between post-translational processing of the Rieske iron-sulfur protein of Saccharomyces cerevisiae and its assembly into the mitochondrial cytochrome bc(1) complex we used iron-sulfur proteins in which the presequences had been changed by site-directed mutagenesis of the cloned iron-sulfur protein gene, so that the recognition sites for the matrix processing peptidase or the mitochondrial intermediate peptidase (MIP) had been destroyed. When yeast strain JPJ1, in which the gene for the iron-sulfur protein is deleted, was transformed with these constructs on a single copy expression vector, mitochondrial membranes and bc(1) complexes isolated from these strains accumulated intermediate length iron-sulfur proteins in vivo. The cytochrome bc(1) complex activities of these membranes and bc(1) complexes indicate that intermediate iron-sulfur protein (i-ISP) has full activity when compared with that of mature sized iron-sulfur protein (m-ISP). Therefore the iron-sulfur cluster must have been inserted before processing of i-ISP to m-ISP by MIP, When iron-sulfur protein is imported into mitochondria in vitro, i-ISP interacts with components of the bc(1) complex before it is processed to m-ISP. These results establish that the iron-sulfur cluster is inserted into the apoprotein before MIP cleaves off the second part of the presequence and that this second processing step takes place after i-ISP has been assembled into the bc(1) complex.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Trumpower, BL (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail, Hanover, NH 03755 USA.				NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020379, R37GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOHNI PC, 1983, J BIOL CHEM, V258, P4937; Boumans H, 1997, EUR J BIOCHEM, V249, P762, DOI 10.1111/j.1432-1033.1997.t01-3-00762.x; Boumans H, 1997, J BIOL CHEM, V272, P16753, DOI 10.1074/jbc.272.27.16753; BRANDA SS, 1995, J BIOL CHEM, V270, P27366, DOI 10.1074/jbc.270.45.27366; BRANDT U, 1994, J BIOL CHEM, V269, P12947; BRANDT U, 1993, J BIOL CHEM, V268, P8387; Denke E, 1998, J BIOL CHEM, V273, P9085, DOI 10.1074/jbc.273.15.9085; FU W, 1991, J BIOL CHEM, V266, P16212; FU W, 1990, J BIOL CHEM, V265, P16541; GLICK B, 1994, ANNU REV GENET, V25, P21; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GRAHAM LA, 1994, BIOCHEM SOC T, V22, P188, DOI 10.1042/bst0220188; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P631; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; ISAYA G, 1994, MOL CELL BIOL, V14, P5603, DOI 10.1128/MCB.14.8.5603; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; Luciano P, 1996, EXPERIENTIA, V52, P1077, DOI 10.1007/BF01952105; MCADA PC, 1982, J BIOL CHEM, V257, P3177; Nett JH, 1997, J BIOL CHEM, V272, P2212; Nett JH, 1996, J BIOL CHEM, V271, P26713, DOI 10.1074/jbc.271.43.26713; Nett JH, 1998, J BIOL CHEM, V273, P8652, DOI 10.1074/jbc.273.15.8652; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; RAMABADRAN RS, 1992, ARCH BIOCHEM BIOPHYS, V296, P279, DOI 10.1016/0003-9861(92)90573-F; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YANG XH, 1986, METHOD ENZYMOL, V126, P316; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	31	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9253	9257		10.1074/jbc.274.14.9253	http://dx.doi.org/10.1074/jbc.274.14.9253			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092599	hybrid			2022-12-25	WOS:000079451800018
J	Bianco, C; Kannan, S; De Santis, M; Seno, M; Tang, CK; Martinez-Lacaci, I; Kim, N; Wallace-Jones, B; Lippman, ME; Ebert, AD; Wechselberger, C; Salomon, DS				Bianco, C; Kannan, S; De Santis, M; Seno, M; Tang, CK; Martinez-Lacaci, I; Kim, N; Wallace-Jones, B; Lippman, ME; Ebert, AD; Wechselberger, C; Salomon, DS			Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; SIGNALING NETWORK; PROTEIN; GENE; ACTIVATION; EXPRESSION; FAMILY	Cripto-1 (CR-1) is a recently discovered protein of the epidermal growth factor family that fails to directly bind to any of the four known erb B type 1 receptor tyrosine kinases. The present study demonstrates that CR-1 indirectly induces tyrosine phosphorylation of erb B-4 but not of the epidermal growth factor-related receptors erb B-2 and erb B-3 in different mouse and human mammary epithelial cell lines. In addition, downregulation of erb B-4 in NMuMG mouse mammary epithelial cells and in T47D human breast cancer cells, using an anti-erb B-4 blocking antibody or a hammerhead ribozyme vector targeted to erb B-4 mRNA, impairs the ability of CR-1 to fully activate mitogen-activated protein kinase. Finally, chemical cross-linking of I-125-CR-1 to mouse and human mammary epithelial cell membranes results in the labeling of two specific bands with a molecular weight of 130 and 60 kDa, suggesting that the CR-1 receptor represents a novel receptor structurally unrelated to any of the known type I receptor tyrosine kinases. In conclusion, these data demonstrate that CR-1, upon binding to an unknown receptor, can enhance the tyrosine kinase activity of erb B-4 and that a functional erb B-4 receptor is required for CR-1-induced MAPK activation.	NCI, Tumor Growth Factor Sect, Lab Tumor Immunol & Biol, NIH, Bethesda, MD 20892 USA; Macmaster Univ, Hamilton, ON L8S 4K1, Canada; Okayama Univ, Fac Engn, Dept Biosci & Biotechnol, Okayama 7008530, Japan; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Biochem, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); McMaster University; Okayama University; Georgetown University	Salomon, DS (corresponding author), NCI, Tumor Growth Factor Sect, Lab Tumor Immunol & Biol, NIH, Bldg 10,Room 5B39, Bethesda, MD 20892 USA.	davetgfa@helix.nih.gov		Wechselberger, Christian/0000-0002-2164-3019				BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DESANTIS LM, 1997, CELL GROWTH DIFFER, V8, P1257; DONO R, 1991, AM J HUM GENET, V49, P555; DONO R, 1993, DEVELOPMENT, V118, P1157; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8131; Habib AA, 1998, J BIOL CHEM, V273, P6885, DOI 10.1074/jbc.273.12.6885; HELDIN CH, 1996, GROWTH FACTOR REV, V7, P33; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; Shen MM, 1997, DEVELOPMENT, V124, P429; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Tang CK, 1998, CANCER RES, V58, P3415; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; XU C, 1999, IN PRESS P NATL ACAD; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yang DJ, 1998, CLIN CANCER RES, V4, P993; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	39	66	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8624	8629		10.1074/jbc.274.13.8624	http://dx.doi.org/10.1074/jbc.274.13.8624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085099	hybrid			2022-12-25	WOS:000079451600041
J	Ching, TT; Wang, DS; Hsu, AL; Lu, PJ; Chen, CS				Ching, TT; Wang, DS; Hsu, AL; Lu, PJ; Chen, CS			Identification of multiple phosphoinositide-specific phospholipases D as new regulatory enzymes for phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TUMOR-SUPPRESSOR; BIOCHEMICAL-CHARACTERIZATION; CELL-SURVIVAL; 4,5-BISPHOSPHATE; 3-KINASE; BRAIN; ACTIVATION; PHOSPHATES; PKB/AKT	In the course of delineating the regulatory mechanism underlying phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P-3) metabolism, we have discovered three distinct phosphoinositide-specific phospholipase D (PI-PLD) isozymes from rat brain, tentatively designated as PI-PLD, PI-PLDb, and PI-PLDc. These enzymes convert [H-3]PI(3,4,5)P-3 to generate a novel inositol phosphate, D-myo [H-3]inositol 3,4,5-trisphosphate ([H-3]Ins(3,4,5)P-3) and phosphatidic acid. These isozymes are predominantly associated with the cytosol, a notable difference from phosphatidylcholine PLDs. They are partially purified by a three-step procedure consisting of DEAE, heparin, and Sephacryl S-200 chromatography. PI-PLDa and PI-PLDb display a high degree of substrate specificity for PI(3,4,5)P-3, with a relative potency of PI(3,4,5)P-3 >> phosphatidylinositol 3-phosphate (PI(3)P) or phosphatidylinositol 4-phosphate (PI(4)P) > phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-3) > phosphatidylinositol 3,4-bisphosphate (PI(3,4)P-3). In contrast, PI-PLDc preferentially utilizes PI(3)P as substrate, followed by, in sequence, PI(3,4,5)P-3, PI(C)P, PI(3,4)P-2, and PI(4,5)P-2. Both PI(3,4)P-2 and PI(4,5)P-2 are poor substrates for all three isozymes, indicating that the regulatory mechanisms underlying these phosphoinositides are different from that of PI(3,4,5)P-3. None of these enzymes reacts with phosphatidylcholine, phosphatidylserine, or phosphatidylethanolamine. All three PI-PLDs are Ca2+-dependent. Among them, PI-PLDb and PI-PLDc show maximum activities within a sub-mu M range (0.3 and 0.9 mu M Ca2+ respectively), whereas PI-PLDa exhibits an optimal [Ca2+] at 20 mu M. In contrast to PC-PLD, Mg2+ has no significant effect on the enzyme activity. All three enzymes require sodium deoxycholate for optimal activities; other detergents examined including Triton X-100 and Nonidet P-40 are, however, inhibitory. In addition, PI(4,5)P-2 stimulates these isozymes in a dose-dependent manner. Enhancement in the enzyme activity is noted only when the molar ratio of PI(4,5)P-2 to PI(3,4,5)P-3 is between 1:1 and 2:1.	Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, ASTeCC Facil, Lexington, KY 40506 USA	University of Kentucky	Chen, CS (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, ASTeCC Facil, Rm 323B, Lexington, KY 40506 USA.	cchen1@pop.uky.edu	Hsu, Ao-Lin Allen/AAX-1856-2020	Ching, Tsui-Ting/0000-0001-7650-1766; Hsu, Ao-Lin/0000-0002-2864-3134	NIGMS NIH HHS [R01 GM53448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Drayer AL, 1996, BIOCHEM BIOPH RES CO, V225, P243, DOI 10.1006/bbrc.1996.1161; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hopkin K, 1998, SCIENCE, V282, P1027, DOI 10.1126/science.282.5391.1027; HUANG CF, 1992, J BIOL CHEM, V267, P16859; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LISCOVITCH M, 1991, BIOCHEM J, V279, P319, DOI 10.1042/bj2790319; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LU PJ, 1994, BIOCHEMISTRY-US, V33, P11586, DOI 10.1021/bi00204a021; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Pennisi E, 1997, SCIENCE, V275, P1876, DOI 10.1126/science.275.5308.1876; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEPHENS L, 1988, BIOCHEM J, V249, P271, DOI 10.1042/bj2490271; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WANG P, 1991, J BIOL CHEM, V266, P14877; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, J BIOL CHEM, V272, P9625	36	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8611	8617		10.1074/jbc.274.13.8611	http://dx.doi.org/10.1074/jbc.274.13.8611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085097	hybrid			2022-12-25	WOS:000079451600039
J	Lynch, CN; Wang, YC; Lund, JK; Chen, YW; Leal, JA; Wiley, SR				Lynch, CN; Wang, YC; Lund, JK; Chen, YW; Leal, JA; Wiley, SR			TWEAK induces angiogenesis and proliferation of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; HUMAN T-LYMPHOCYTES; DIABETIC-RETINOPATHY; GENE-EXPRESSION; EMERGING FAMILY; IN-VIVO; LIGAND; ACTIVATION	TWEAK is a recently described member of the Tumor Necrosis Factor (TNF) ligand family whose transcripts are present in a wide variety of human tissues (Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu Y. M., Scott, H., Hession, C., Garcia, I., and Browning, J. L. (1997) J. Biol. Chem. 272, 32401-32410). TWEAK is a weak inducer of apoptosis in transformed cells when administered with interferon-gamma or cycloheximide (Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu Y. M., Scott, H., Hession, C., Garcia, I,, and Browning, J. L. (1997) J. Biol. Chem. 272, 32401-32410; Masters, S. A., Sheridan, J. P., Pitti, R. M., Brush, A. G., and Ashkenazi, A. (1998) Curr. Biol. 8, 525-528) and also promotes IL-8 secretion in cultured cells. We report here that picomolar concentrations of recombinant soluble TWEAK induce proliferation in a variety of normal human endothelial cells and in aortic smooth muscle cells and reduce culture requirements for serum and growth factors. Blocking antibodies to Vascular Endothelial Growth Factor (VEGF) do not significantly inhibit TWEAK-induced proliferation, indicating that TWEAK does not function indirectly through up-regulation of VEGF. Pellets containing TWEAK induce a strong angiogenic response when implanted in rat corneas, suggesting a role for TWEAK in vasculature formation in vivo.	Abbott Labs, Abbott Pk, IL 60064 USA	Abbott Laboratories	Wiley, SR (corresponding author), 51 Univ St, Seattle, WA 98101 USA.							AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; BIKFALVI A, 1995, EUR J CANCER, V31A, P1101, DOI 10.1016/0959-8049(95)00169-J; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BROWN LF, 1995, J IMMUNOL, V154, P2801; Bussolino F, 1996, EUR J CANCER, V32A, P2401, DOI 10.1016/S0959-8049(96)00390-5; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P89; Carpenter G, 1993, CURR OPIN CELL BIOL, V5, P261, DOI 10.1016/0955-0674(93)90113-5; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HELDIN CH, 1991, J CELL BIOCHEM, V47, P208, DOI 10.1002/jcb.240470304; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; MASTERS SA, 1998, CURR BIOL, V8, P525; Montrucchio G, 1997, AM J PATHOL, V151, P557; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Paques M, 1997, DIABETES METAB, V23, P125; Pels K, 1997, JPN CIRC J, V61, P893, DOI 10.1253/jcj.61.893; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; ROBAYE B, 1991, AM J PATHOL, V138, P447; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P997, DOI 10.1016/0006-291X(87)90350-0; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; Van Belle E, 1998, CIRCULATION, V97, P381; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	42	216	247	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8455	8459		10.1074/jbc.274.13.8455	http://dx.doi.org/10.1074/jbc.274.13.8455			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085077	hybrid			2022-12-25	WOS:000079451600019
J	Thakur, S; Croce, CM				Thakur, S; Croce, CM			Positive regulation of the BRCA1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE BRCA1; SPORADIC BREAST-CANCER; CYCLIC-AMP; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; SOMATOSTATIN GENE; NUCLEAR FACTOR; CELL-CYCLE; EXPRESSION; REGION	Inherited mutations in the BRCA1 gene, presumably leading to loss of function, confer susceptibility to breast and ovarian neoplasms and are thought to be responsible for approximately 2.5-5% of all breast cancers. It has been suggested that alternative mechanisms, such as disruption of transcription, may also be involved in the suppression of BRCA1 gene expression/ function in breast cancers. Therefore, we initiated studies on the BRCA1 transcriptional promoter. Utilizing systematic promoter deletions and transient transfection assays, a 36-base pair region was determined to be important for the positive regulation of BRCA1 transcription. Deletion of this positive regulatory region resulted in a significant loss of promoter activity. Utilizing DNA binding assays, proteins with specific affinities for the positive regulatory region were detected. Disruption of the DNA-protein complexes could affect normal BRCA1 transcription and may contribute to breast cancer susceptibility.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Croce, CM (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NCI NIH HHS [5-T32-CA09678-05, CA76780-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009678, F32CA076780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Dobrovic A, 1997, CANCER RES, V57, P3347; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; SANTRA M, 1994, J BIOL CHEM, V269, P579; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; THAKUR S, 1994, ONCOGENE, V9, P2335; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994	31	44	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8837	8843		10.1074/jbc.274.13.8837	http://dx.doi.org/10.1074/jbc.274.13.8837			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085126	hybrid			2022-12-25	WOS:000079451600068
J	Saito, F; Masaki, T; Kamakura, K; Anderson, LVB; Fujita, S; Fukuta-Ohi, H; Sunada, Y; Shimizu, T; Matsumura, K				Saito, F; Masaki, T; Kamakura, K; Anderson, LVB; Fujita, S; Fukuta-Ohi, H; Sunada, Y; Shimizu, T; Matsumura, K			Characterization of the transmembrane molecular architecture of the dystroglycan complex in Schwann cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; PERIPHERAL-NERVE; GLYCOPROTEIN-COMPLEX; MEMBRANE ORGANIZATION; ALPHA-DYSTROGLYCAN; BETA-DYSTROGLYCAN; CHAIN GENE; LAMININ-M; MEROSIN; BINDING	We have demonstrated previously 1) that the dystroglycan complex, but not the sarcoglycan complex, is expressed in peripheral nerve, and 2) that alpha-dystroglycan is an extracellular laminin-a-binding protein anchored to beta-dystroglycan in the Schwann cell membrane. In the present study, we investigated the transmembrane molecular architecture of the dystroglycan complex in Schwann cells. The cytoplasmic domain of beta-dystroglycan was co-localized with Dp116, the Schwann cell-specific isoform of dystrophin, in the abaxonal Schwann cell cytoplasm adjacent to the outer membrane, beta-dystroglycan bound to Dp116 mainly via the 15 C-terminal amino acids of its cytoplasmic domain, but these amino acids were not solely responsible for the interaction of these two proteins. Interestingly, the beta-dystroglycan-precipitating antibody precipitated only a small fraction of alpha-dystroglycan and did not precipitate laminin and Dp116 from the peripheral nerve extracts. Our results indicate 1) that Dp116 is a component of the submembranous cytoskeletal system that anchors the dystroglycan complex in Schwann cells, and 2) that the dystroglycan complex in Schwann cells is fragile compared with that in striated muscle cells. We propose that this fragility may be attributable to the absence of the sarcoglycan complex in Schwann cells.	Teikyo Univ, Sch Med, Dept Neurol & Neurosci, Tokyo 1738605, Japan; Natl Def Med Coll, Dept Internal Med 3, Tokorozawa, Saitama 3598513, Japan; Newcastle Univ, Sch Neurosci & Muscular Dystrophy Grp Labs, Reg Neurosci Ctr, Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Teikyo University; National Defense Medical College - Japan; Newcastle General Hospital; Newcastle University - UK	Matsumura, K (corresponding author), Teikyo Univ, Sch Med, Dept Neurol, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	k-matsu@med.teikyo-u.ac.jp						ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BRADLEY WG, 1973, J NEUROL SCI, V18, P227, DOI 10.1016/0022-510X(73)90009-9; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Chiba A, 1997, J BIOL CHEM, V272, P2156; COMI GP, 1995, HUM MOL GENET, V4, P2171, DOI 10.1093/hmg/4.11.2171; CULLEN MJ, 1994, ACTA NEUROPATHOL, V87, P349; DEYST KA, 1995, J BIOL CHEM, V270, P25956, DOI 10.1074/jbc.270.43.25956; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; GEE SH, 1993, J BIOL CHEM, V268, P14972; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; MADRID RE, 1975, NATURE, V257, P319, DOI 10.1038/257319a0; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHORER Z, 1995, J CHILD NEUROL, V10, P472, DOI 10.1177/088307389501000610; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SUNADA Y, 1995, HUM MOL GENET, V4, P1055, DOI 10.1093/hmg/4.6.1055; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572; Yamada H, 1996, J NEUROCHEM, V66, P1518; YAMADA H, 1994, FEBS LETT, V352, P49, DOI 10.1016/0014-5793(94)00917-1; Yamada H, 1996, J BIOL CHEM, V271, P23418, DOI 10.1074/jbc.271.38.23418; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yuasa K, 1998, FEBS LETT, V425, P329, DOI 10.1016/S0014-5793(98)00251-8	40	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8240	8246		10.1074/jbc.274.12.8240	http://dx.doi.org/10.1074/jbc.274.12.8240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075729	hybrid			2022-12-25	WOS:000079268100088
J	Baskakov, IV; Kumar, R; Srinivasan, G; Ji, YS; Bolen, DW; Thompson, EB				Baskakov, IV; Kumar, R; Srinivasan, G; Ji, YS; Bolen, DW; Thompson, EB			Trimethylamine N-oxide-induced cooperative folding of an intrinsically unfolded transcription-activating fragment of human glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSACTIVATION DOMAIN; STRUCTURAL CHARACTERIZATION; SECONDARY STRUCTURE; GENE-REGULATION; BETA-SHEET; TRIFLUOROETHANOL; DNA; MECHANISM; PROTEINS; CELLS	A number of biologically important proteins or protein domains identified recently are fully or partially unstructured (unfolded), Methods that allow studies of the propensity of such proteins to fold naturally are valuable. The traditional biophysical approaches using alcohols to drive alpha-helix formation raise serious questions of the relevance of alcohol-induced structure to the biologically important conformations. Recently we illustrated the extraordinary capability of the naturally occurring solute, trimethylamine N-oxide (TMAO), to force two unfolded proteins to fold to native-like species with significant functional activity. In the present work we apply this technique to recombinant human glucocorticoid receptor fragments consisting of residues 1-500 and residues 77-262. CD and fluorescence spectroscopy showed that both were largely disordered in aqueous solution. TMAO induced a condensed structure in the large fragment, indicated by the substantial enhancement in intrinsic fluorescence and blue shift of fluorescent maxima, CD spectroscopy demonstrated that the TMAO-induced structure is different from the alpha-helix-rich conformation driven by trifluoroethanol (TFE), In contrast to TFE, the conformational transition of the 1-500 fragment induced by TMAO is cooperative, a condition characteristic of proteins with unique structures.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Thompson, EB (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd,605 Basic Sci Bldg, Galveston, TX 77555 USA.	bthompso@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA041407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049760] Funding Source: NIH RePORTER; NCI NIH HHS [CA41407] Funding Source: Medline; NIGMS NIH HHS [GM 49760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov I, 1998, BIOPHYS J, V74, P2666, DOI 10.1016/S0006-3495(98)77972-X; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUCK M, 1995, BIOCHEMISTRY-US, V34, P13219, DOI 10.1021/bi00040a038; CammersGoodwin A, 1996, J AM CHEM SOC, V118, P3082, DOI 10.1021/ja952900z; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; FAN P, 1993, BIOCHEMISTRY-US, V32, P1573, DOI 10.1021/bi00057a023; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOY MV, 1993, CELL, V72, P587; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; Luo YZ, 1998, J MOL BIOL, V279, P49, DOI 10.1006/jmbi.1998.1774; MASON SA, 1993, J BIOL CHEM, V268, P21501; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	30	141	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10693	10696		10.1074/jbc.274.16.10693	http://dx.doi.org/10.1074/jbc.274.16.10693			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196139	hybrid			2022-12-25	WOS:000079751900007
J	Nagai, Y; Aoki, J; Sato, T; Amano, R; Matsuda, Y; Arai, H; Inoue, K				Nagai, Y; Aoki, J; Sato, T; Amano, R; Matsuda, Y; Arai, H; Inoue, K			An alternative splicing form of phosphatidylserine-specific phospholipase A(1) that exhibits lysophosphatidylserine-specific lysophospholipase activity in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC LIPASE; ACTIVATED PLATELETS; LIPOPROTEIN-LIPASE; CYTOSOLIC PHOSPHOLIPASE-A(2); HEPATIC LIPASE; ANNEXIN-V; CELLS; MEMBRANE; BINDING; TRANSLOCATION	Phosphatidylserine-specific phospholipase A(1) (PS-PLA(1)), which acts specifically on phosphatidylserine (PS) and 1-acyl-2-lysophosphatidylserine (lyso-PS) to hydrolyze fatty acids at the sn-l position of these phospholipids, was first identified in rat platelets (Sato, T., Aoki, J., Nagai, Y., Dohmae, N., Takio, K., Doi, T., Arai, H., and Inoue, K. (1997) J. Biol. Chem. 272, 2192-2198). In this study we isolated and sequenced cDNA clones encoding human PS-PLA(1), which showed 80% homology with rat PS-PLA(1) at the amino acid level. In addition to an mRNA encoding a 456-amino acid product (PS-PLA(1)), an mRNA with four extra bases inserted at the boundary of the exon-intron junction was detected in human tissues and various human cell lines. This mRNA is most probably produced via an alternative use of the 5'-splicing site (two consensus sequences for RNA splicing occur at the boundary of the exon-intron junction) and encodes a 376-amino acid product (PS-PLA(1)Delta C) that lacks two-thirds of the C-terminal domain of PS PLA(1). Unlike PS-PLA(1), PS-PLA(1)Delta C hydrolyzed exclusively lyso-PS but not PS appreciably. Any other phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA), and their lyse derivatives were not hydrolyzed at all. These data demonstrated that PS-PLA(1)Delta C exhibits lyso-PS-specific lysophospholipase activity and that the C-terminal domain of PS-PLA(1) is responsible for recognizing diacylphospholipids. In addition, human PS-PLA(1) gene was mapped to chromosome 3q13.13-13.2 and was unexpectedly identical to the nmd gene, which is highly expressed in nonmetastatic melanoma cell lines but poorly expressed in metastatic cell lines (van Groningen, J. J., Bloemers, H. P., and Swart, G. W. (1995) Cancer Res. 55, 6237-6243).	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; Nagoya Univ, Sch Agr Sci, Lab Anim Genet, Chikusa Ku, Nagoya, Aichi 4640814, Japan	University of Tokyo; Nagoya University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	jaoki@mol.f.u-tokyo.ac.jp		Aoki, Junken/0000-0001-9435-1896				BASSE F, 1993, BIOCHEMISTRY-US, V32, P2337, DOI 10.1021/bi00060a027; BELLINI F, 1993, FEBS LETT, V316, P1, DOI 10.1016/0014-5793(93)81724-E; BITBOL M, 1988, P NATL ACAD SCI USA, V85, P6783, DOI 10.1073/pnas.85.18.6783; BOHN E, 1992, FEBS LETT, V296, P237, DOI 10.1016/0014-5793(92)80294-Q; BRUNI A, 1984, AGENTS ACTIONS, V14, P619, DOI 10.1007/BF01978896; Bruni A, 1988, Prog Clin Biol Res, V282, P165; CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; FADOK VA, 1993, J IMMUNOL, V151, P4274; FUJIMORI Y, 1993, EUR J BIOCHEM, V218, P629, DOI 10.1111/j.1432-1033.1993.tb18416.x; GASSAMADIAGNE A, 1991, METHOD ENZYMOL, V197, P316; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GILLETT MPT, 1993, INT J BIOCHEM, V25, P449, DOI 10.1016/0020-711X(93)90639-V; Grant KA, 1997, INFECT IMMUN, V65, P1172, DOI 10.1128/IAI.65.4.1172-1180.1997; HIDE WA, 1992, J LIPID RES, V33, P167; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; HORIGOME K, 1986, J BIOCHEM-TOKYO, V100, P571, DOI 10.1093/oxfordjournals.jbchem.a121748; JENNENS ML, 1994, J BIOL CHEM, V269, P25470; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; SAITO K, 1991, METHOD ENZYMOL, V197, P446; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SANTAMARINAFOJO S, 1994, INT J CLIN LAB RES, V24, P143, DOI 10.1007/BF02592444; Sato T, 1997, J BIOL CHEM, V272, P2192; SATTA N, 1994, J IMMUNOL, V153, P3245; STOCKERT M, 1992, ADV EXP MED BIOL, V318, P325; TAKAHASHI E, 1990, HUM GENET, V86, P14; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TUMA PL, 1993, J BIOL CHEM, V268, P17240; vanGroningen JJM, 1997, FEBS LETT, V404, P82, DOI 10.1016/S0014-5793(97)00098-7; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; YOKOYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1280, DOI 10.1093/oxfordjournals.jbchem.a124856; ZWAAL RFA, 1989, MOL CELL BIOCHEM, V91, P23, DOI 10.1007/BF00228075	41	51	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11053	11059		10.1074/jbc.274.16.11053	http://dx.doi.org/10.1074/jbc.274.16.11053			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196188	hybrid			2022-12-25	WOS:000079751900056
J	Yang, W; Wang, DZ; Richmond, A				Yang, W; Wang, DZ; Richmond, A			Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization, and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; HUMAN INTERLEUKIN-8 RECEPTOR; COATED VESICLE FORMATION; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; CHEMOTACTIC CYTOKINES; HUMAN NEUTROPHILS; DYNAMIN; CHEMOKINES; FAMILY	CXCR2 is a seven-transmembrane receptor that transduces intracellular signals in response to the chemokines interleukin-8, melanoma growth-stimulatory activity/growth-regulatory protein, and other ELR motif-containing CXC chemokines by coupling to heterotrimeric GTP-binding proteins. In this study, we explored the mechanism responsible for ligand-induced CXCR2 endocytosis. Here, we demonstrate that dynamin, a component of clathrin-mediated endocytosis, is essential for CXCR2 endocytosis and resensitization. In HEK293 cells, dynamin I K44A, a dominant-negative mutant of dynamin that inhibits the clathrin-mediated endocytosis, blocks the ligand-stimulated CXCR2 sequestration. Furthermore, co-expression of dynamin I K44A significantly delays dephosphorylation of CXCR2 after ligand stimulation, suggesting that clathrin-mediated endocytosis plays an important role in receptor dephosphorylation and resensitization. In addition, ligand-mediated receptor down-regulation is attenuated when receptor internalization is inhibited by dynamin I K44A. Interestingly, inhibition of receptor endocytosis by dynamin I K44A does not affect the CXCR2-mediated stimulation of mitogen-activated protein kinase. Most significantly, our data indicate that the ligand-stimulated receptor endocytosis is required for CXCR2-mediated chemotaxis in HEK293 cells. Taken together, our findings suggest that clathrin-mediated CXCR2 internalization is crucial for receptor endocytosis, resensitization, and chemotaxis.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NATIONAL CANCER INSTITUTE [R01CA034590, R23CA034590, P30CA068485] Funding Source: NIH RePORTER; NCI NIH HHS [CA34590, CA68485] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Krueger KM, 1997, J BIOL CHEM, V272, P5; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MUELLER SG, 1994, J BIOL CHEM, V269, P1973; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; OPPENHEIM JJ, 1993, ADV EXP MED BIOL, V351, P183; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Yang W, 1997, BIOCHEMISTRY-US, V36, P15193, DOI 10.1021/bi971594u; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	35	110	112	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11328	11333		10.1074/jbc.274.16.11328	http://dx.doi.org/10.1074/jbc.274.16.11328			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196223	hybrid			2022-12-25	WOS:000079751900091
J	Jerome, LJ; Frost, LS				Jerome, LJ; Frost, LS			In vitro analysis of the interaction between the FinO protein and FinP antisense RNA of F-like conjugative plasmids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REV-RESPONSE ELEMENT; COPY NUMBER CONTROL; MESSENGER-RNA; FERTILITY INHIBITION; STRUCTURAL-ANALYSIS; ROM PROTEIN; BINDING; RECOGNITION; EXPRESSION; SEQUENCES	The FinO protein regulates the transfer potential of F-like conjugative plasmids through its interaction with FinP antisense RNA and its target, traJ mRNk FinO binds to and protects FinP from degradation and promotes duplex formation between FinP and traJ mRNA in vitro. The FinP secondary structure consists of two stem-loop domains separated by a 4-base spacer and terminated by a B-base tail. Previous studies suggested FinO bound to the smooth 14-base pair helix of stem-loop II. In this investigation, RNA mobility shift analysis was used to study the interaction between a glutathione S-transferase (GST)-FinO fusion protein and a series of synthetic FinP and traJ mRNA variants. Mutations in 16 of the 28 bases in stem II of FinP that are predicted to disrupt base pairing did not significantly alter the GST-FinO binding affinity. Removal of the single-stranded regions on either side of stem-loop II led to a dramatic decrease in GST-FinO binding to FinP and to the complementary region of the traJ mRNA leader. While no evidence for sequence-specific contacts was found, the results suggest that FinO recognizes the overall shape of the RNA and is influenced by the length of the single-stranded regions flanking the stem-loop.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Frost, LS (corresponding author), Univ Alberta, Dept Biol Sci, CW405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.		Frost, Laura/A-2639-2014	Frost, Laura/0000-0002-8433-8230				Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHANDLER M, 1983, J MOL BIOL, V170, P61, DOI 10.1016/S0022-2836(83)80227-7; CHEAH KC, 1986, J GEN MICROBIOL, V132, P3269; DEMPSEY WB, 1987, MOL GEN GENET, V209, P533, DOI 10.1007/BF00331160; DRAPER DE, 1995, ANNU REV BIOCHEM, V64, P593, DOI 10.1146/annurev.bi.64.070195.003113; EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B; FINLAY BB, 1986, J BACTERIOL, V167, P754, DOI 10.1128/jb.167.2.754-757.1986; FINNEGAN D, 1973, MOL GEN GENET, V127, P307, DOI 10.1007/BF00267101; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; Jerome LJ, 1999, J MOL BIOL, V285, P1457, DOI 10.1006/jmbi.1998.2404; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; Koraimann G, 1996, MOL MICROBIOL, V21, P811, DOI 10.1046/j.1365-2958.1996.361401.x; KORAIMANN G, 1991, MOL MICROBIOL, V5, P77, DOI 10.1111/j.1365-2958.1991.tb01828.x; LEE SH, 1992, MOL GEN GENET, V235, P131, DOI 10.1007/BF00286190; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MULLINEAUX P, 1985, PLASMIDS BACTERIA, P605; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; Sandercock JR, 1998, MOL GEN GENET, V259, P622, DOI 10.1007/s004380050856; Sozhamannan S, 1997, J MOL BIOL, V268, P689, DOI 10.1006/jmbi.1997.1004; STEITZ TA, 1993, RNA WORLD, P219; TAMM J, 1983, NUCLEIC ACIDS RES, V11, P6381, DOI 10.1093/nar/11.18.6381; TOMIZAWA J, 1984, CELL, V38, P871, DOI 10.1016/0092-8674(84)90282-4; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; VANBIESEN T, 1993, MOL MICROBIOL, V10, P35; VANBIESEN T, 1992, MOL MICROBIOL, V6, P771, DOI 10.1111/j.1365-2958.1992.tb01527.x; VANBIESEN T, 1994, MOL MICROBIOL, V14, P427, DOI 10.1111/j.1365-2958.1994.tb02177.x; VARANI G, 1994, RNA PROTEIN INTERACT, P1; WILLETTS N, 1986, GENET RES, V47, P1, DOI 10.1017/S0016672300024447; WILLIAMS AS, 1995, NUCLEIC ACIDS RES, V23, P654, DOI 10.1093/nar/23.4.654; YOSHIOKA Y, 1987, J BACTERIOL, V169, P619, DOI 10.1128/jb.169.2.619-623.1987	36	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10356	10362		10.1074/jbc.274.15.10356	http://dx.doi.org/10.1074/jbc.274.15.10356			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187824	hybrid			2022-12-25	WOS:000079663500063
J	Shaw, AL; Hochkoeppler, A; Bonora, P; Zannoni, D; Hanson, GR; McEwan, AG				Shaw, AL; Hochkoeppler, A; Bonora, P; Zannoni, D; Hanson, GR; McEwan, AG			Characterization of DorC from Rhodobacter capsulatus, a c-type cytochrome involved in electron transfer to dimethyl sulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; DIMETHYLSULFOXIDE REDUCTASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DMSO REDUCTASE; IDENTIFICATION; MOLYBDOENZYME; RESOLUTION; PROTEIN; HEMES	The dorC gene of the dimethyl sulfoxide respiratory (dor) operon of Rhodobacter capsulatus encodes a pentaheme c-type cytochrome that is involved in electron transfer from ubiquinol to periplasmic dimethyl sulfoxide reductase, DorC was expressed as a C-terminal fusion to an 8-amino acid FLAG epitope and was purified from detergent-solubilized membranes by ion exchange chromatography and immunoaffinity chromatography, The DorC protein had a subunit M-r = 46,000, and pyridine hemochrome analysis indicated that it contained 5 mol heme c/mol DorC polypeptide, as predicted from the derived amino acid sequence of the dorC gene. The reduced form of DorC exhibited visible absorption maxima at 551.5 nm (alpha-band), 522 nm (beta-band), and 419 nm (Soret band). Redox potentiometry of the heme centers of DorC identified five components (n = 1) with midpoint potentials of -34, -128, -184, -185, and -276 mV, Despite the low redox potentials of the heme centers, DorC was reduced by duroquinol and was oxidized by dimethyl sulfoxide reductase.	Univ Queensland, Dept Microbiol, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Magnet Resonance, Brisbane, Qld 4072, Australia; Univ Bologna, Dipartimento Biol, I-40126 Bologna, Italy	University of Queensland; University of Queensland; University of Bologna	McEwan, AG (corresponding author), Univ Queensland, Dept Microbiol, Brisbane, Qld 4072, Australia.	mcewan@biosci.uq.edu.au	/C-3940-2008	/0000-0003-0306-4360; ZANNONI, DAVIDE/0000-0002-7291-4253; McEwan, Alastair/0000-0002-2419-1003				Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERTRAND P, 1994, BIOCHIMIE, V76, P524, DOI 10.1016/0300-9084(94)90176-7; Dutton P L, 1978, Methods Enzymol, V54, P411; GAYDA JP, 1988, EUR J BIOCHEM, V177, P199, DOI 10.1111/j.1432-1033.1988.tb14362.x; HATTON AD, 1994, ARCH MICROBIOL, V162, P148; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS CK, 1995, BIOCHEMISTRY-US, P524; McAlpine AS, 1997, J BIOL INORG CHEM, V2, P690, DOI 10.1007/s007750050185; MCEWAN AG, 1991, BIOCHEM J, V274, P305, DOI 10.1042/bj2740305; McEwan AG, 1998, BIOCHEM SOC T, V26, P390, DOI 10.1042/bst0260390; MCEWAN AG, 1989, BIOCHIM BIOPHYS ACTA, V973, P308, DOI 10.1016/S0005-2728(89)80437-2; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; MOORE GR, 1987, CYTOCHROMES C BIOL A; Mouncey NJ, 1997, J BACTERIOL, V179, P7617, DOI 10.1128/jb.179.24.7617-7624.1997; RICHARDSON DJ, 1988, ARCH MICROBIOL, V150, P130; SANTOS H, 1984, EUR J BIOCHEM, V141, P283, DOI 10.1111/j.1432-1033.1984.tb08190.x; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W	25	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9911	9914		10.1074/jbc.274.15.9911	http://dx.doi.org/10.1074/jbc.274.15.9911			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187763	hybrid			2022-12-25	WOS:000079663500002
J	Umayahara, Y; Billiard, J; Ji, CH; Centrella, M; McCarthy, TL; Rotwein, P				Umayahara, Y; Billiard, J; Ji, CH; Centrella, M; McCarthy, TL; Rotwein, P			CCAAT enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; CAMP RESPONSE ELEMENT; ENRICHED CULTURES; PROSTAGLANDIN E(2); C/EBP; IDENTIFICATION; PROMOTER; FAMILY; CELLS; LIVER	Insulin-like growth factor-I (IGF-I) plays a major role in promoting skeletal growth by stimulating bone cell replication and differentiation. Prostaglandin E-2 and other agents that induce cAMP production enhance IGF-I gene transcription in cultured rat osteoblasts through a DNA element termed HS3D, located in the proximal part of the major rat IGF-I promoter. We previously determined that CCAAT/enhancer-binding protein delta (C/EBP delta) is the key cAMP-stimulated regulator of IGF-I transcription in these cells and showed that it transactivates the rat IGF-I promoter through the HS3D site. We now have defined the physical-chemical properties and functional consequences of the interactions between C/EBP delta and HS3D. C/EBP delta, expressed in COS-7 cells or purified as a recombinant protein from Escherichia coli, bound to HS3D with an affinity at least equivalent to that of the albumin D-site, a known high affinity C/EBP binding sequence, and both DNA elements competed equally for C/EBP delta, C/EBP delta bound to HS3D as a dimer, with protein-DNA contact points located on guanine residues on both DNA strands within and just adjacent to the core C/EBP half-site, GCAAT, as determined by methylation interference footprinting, C/EBP delta also formed protein-protein dimers in the absence of interactions with its DNA binding site, as indicated by results of glutaraldehyde cross-linking studies, As established by competition gel-mobility shift experiments, the conserved HS3D sequence from rat, human, and chicken also bound C/EBP delta with similar affinity. We also found that prostaglandin E-2-induced expression of reporter genes containing human IGF-I promoter 1 or four tandem copies of the human HS3D element fused to a minimal promoter and show that these effects were enhanced by a co-transfected C/EBP delta expression plasmid, Taken together, our results provide evidence that C/EBP delta is a critical activator of IGF-I gene transcription in osteoblasts and potentially in other cell types and species.	Oregon Hlth Sci Univ, Dept Med, Div Mol Med, Portland, OR 97201 USA; Yale Univ, Sch Med, Sect Plast Surg, New Haven, CT 06520 USA	Oregon Health & Science University; Yale University	Rotwein, P (corresponding author), Oregon Hlth Sci Univ, Dept Med, Div Mol Med, 3181 SW Sam Jackson Pk Rd,NRC3, Portland, OR 97201 USA.	rotweinp@ohsu.edu	Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NICHD NIH HHS [5-PO1-HD20805] Funding Source: Medline; NIDDK NIH HHS [T32 DK007674, 5-RO1-DK37449] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037449, T32DK007674] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HAYDEN JM, 1995, BONE, V17, P93; Ishizuya T, 1997, J CLIN INVEST, V99, P2961, DOI 10.1172/JCI119491; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Jux C, 1998, ENDOCRINOLOGY, V139, P3296, DOI 10.1210/en.139.7.3296; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; KAVSAN VM, 1993, DNA CELL BIOL, V12, P729, DOI 10.1089/dna.1993.12.729; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lean JM, 1996, AM J PHYSIOL-ENDOC M, V270, pE937, DOI 10.1152/ajpendo.1996.270.6.E937; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1991, ENDOCRINOLOGY, V128, P2895, DOI 10.1210/endo-128-6-2895; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1993, ADV EXP MED BIOL, V343, P407; Osada S, 1996, J BIOL CHEM, V271, P3891; PASH JM, 1995, ENDOCRINOLOGY, V136, P33, DOI 10.1210/en.136.1.33; POLL V, 1990, CELL, V63, P643; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; THOMAS MJ, 1995, ENDOCRINOLOGY, V136, P562, DOI 10.1210/en.136.2.562; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3	39	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10609	10617		10.1074/jbc.274.15.10609	http://dx.doi.org/10.1074/jbc.274.15.10609			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187857	hybrid			2022-12-25	WOS:000079663500096
J	Vichi, P; Whelchel, A; Posada, J				Vichi, P; Whelchel, A; Posada, J			Transmembrane helix 7 of the endothelin B receptor regulates downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TERNARY COMPLEX MODEL; CONSTITUTIVE ACTIVATION; RHODOPSIN; KINASES; EXPRESSION; CLONING; CELLS; AP-1; PROLIFERATION	Endothelin is a al-amino acid peptide with a striking diversity of important biological responses, including, vasoconstriction, bronchoconstriction, and mitogenesis, Endothelin-l binding to the endothelin B receptor (ETB), a member of the superfamily of G-protein-coupled receptors, was associated with catalytic activation of the extracellular-regulated kinase 2 (ERK2) and stimulation of AP-1 transcriptional reporter activity. A panel of single point mutations in transmembrane helix 6 (TM6), intracellular loop 3, and transmembrane helix 7 (TM7) were developed to study the structural requirements for ETB activation. Point mutations within highly conserved regions of TM6 and intracellular loop 3 were without effect on agonist-stimulated ERK activation. However, mutations within TM7 of the ETB significantly impacted ligand-stimulated downstream signaling. For example, nine point mutations within TM7 of the ETB were identified that prevented endothelin-stimulated ERK activation. Interestingly, the TM7 mutants fell into two classes; several exhibited greatly decreased AP-1 activity, relative to wild type ETB, whereas others displayed augmented endothelin-stimulated AP-1 transcriptional activity relative to wild type ETB, Our results suggest that TM7 of the ETB is involved in its activation mechanism and regulates agonist-stimulated ERK activation.	Univ Vermont, Sch Allied Hlth, Dept Biomed Technol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Vichi, P (corresponding author), Univ Vermont, Sch Allied Hlth, Dept Biomed Technol, Burlington, VT 05405 USA.			Posada, James/0000-0003-3582-9612	NHLBI NIH HHS [HL55327, HL49570] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049570, R29HL055327] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1993, J CARDIOVASC PHAR S8, V22, P121; Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DRATZ EA, 1983, TRENDS BIOCHEM SCI, V8, P128, DOI 10.1016/0968-0004(83)90235-9; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HASHIDO K, 1993, CELL MOL BIOL RES, V39, P3; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; Rincon M, 1996, MOL CELL BIOL, V16, P1074; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	26	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10331	10338		10.1074/jbc.274.15.10331	http://dx.doi.org/10.1074/jbc.274.15.10331			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187821	hybrid			2022-12-25	WOS:000079663500060
J	Baxter, GT; Kuo, RC; Jupp, OJ; Vandenabeele, P; MacEwan, DJ				Baxter, GT; Kuo, RC; Jupp, OJ; Vandenabeele, P; MacEwan, DJ			Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF RECEPTOR; SIGNAL-TRANSDUCTION; VIRAL-PROTEINS; C-MYC; ACTIVATION; BCL-2; CYTOTOXICITY; MECHANISM; BINDING; DOMAIN	The TF-1 human erythroleukemic cell line exhibits opposing physiological responses toward tumor necrosis factor-alpha (TNF) treatment, dependent upon the mitotic state of the cells. Mitotically active cells in log growth respond to TNF by rapidly undergoing apoptosis whereas TNF exposure stimulates cellular proliferation in mitotically quiescent cells, The concentration-dependent TNF-induced apoptosis was monitored by cellular metabolic activity and confirmed by both DNA epifluorescence and DNA fragmentation. Moreover, these responses could be detected by measuring extracellular acidification activity, enabling rapid prediction (within similar to 1.5 h of TNF treatment) of the fate of the cell in response to TNF. Growth factor resupplementation of quiescent cells, resulting in reactivation of cell cycling, altered TNF action from a proliferative stimulus to an apoptotic signal. Expression levels of the type II TNF receptor subtype (p75TNFR) were found to correlate with sensitivity to TNF-induced apoptosis. Pretreatment of log growth TF-1 cells with a neutralizing anti-p75TNFR monoclonal antibody inhibited TNF-induced apoptosis by greater than 80%. Studies utilizing TNF receptor subtype-specific TNF mutants and neutralizing antisera implicated p75TNFR in TNF-dependent apoptotic signaling. These data show a bifunctional physiological role for TNF in TF-1 cells that is dependent on mitotic activity and controlled by the p75TNFR.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA; Cornell Univ, Cornell Nanofabricat Facil, Ithaca, NY 14853 USA; State Univ Ghent VIB, Dept Biol Mol, B-9000 Ghent, Belgium	University of Aberdeen; Stanford University; Cornell University; Flanders Institute for Biotechnology (VIB); Ghent University	MacEwan, DJ (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	david.macewan@abdn.ac.uk	MacEwan, David/F-7044-2011; Vandenabeele, Peter/AAD-5793-2022; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; MacEwan, David/0000-0002-2879-0935				ABDOLRASULNIA R, 1992, AM J RESP CELL MOL, V7, P42, DOI 10.1165/ajrcmb/7.1.42; ALAOUI SE, 1992, FEBS LETT, V311, P174; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRY MA, 1992, BIOCHEM BIOPH RES CO, V186, P782, DOI 10.1016/0006-291X(92)90814-2; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; Declercq W, 1998, J IMMUNOL, V161, P390; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fiers W, 1996, J INFLAMM, V47, P67; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HELLER RA, 1992, CELL, V70, P47; HIGUCHI M, 1993, FEBS LETT, V331, P252, DOI 10.1016/0014-5793(93)80347-W; KITAMURA T, 1991, INT IMMUNOL, V3, P571, DOI 10.1093/intimm/3.6.571; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORSMEYER SJ, 1992, BLOOD, V80, P879; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MacEwan DJ, 1996, FEBS LETT, V379, P77, DOI 10.1016/0014-5793(95)01495-0; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; Martelli AM, 1998, J CELL BIOCHEM, V71, P11, DOI 10.1002/(SICI)1097-4644(19981001)71:1<11::AID-JCB2>3.0.CO;2-4; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OWICKI JC, 1992, BIOSENS BIOELECTRON, V7, P255, DOI 10.1016/0956-5663(92)87004-9; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; PARCE JW, 1989, SCIENCE, V246, P243, DOI 10.1126/science.2799384; PERROS P, 1991, CELL PROLIFERAT, V24, P517, DOI 10.1111/j.1365-2184.1991.tb01179.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VOLLAND S, 1994, INT J CANCER, V56, P698, DOI 10.1002/ijc.2910560515; WALLENOHMAN M, 1993, CANCER LETT, V75, P103, DOI 10.1016/0304-3835(93)90194-E; WARREN DJ, 1990, EUR J HAEMATOL, V45, P158; Weiss T, 1997, J IMMUNOL, V158, P2398; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40	61	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9539	9547		10.1074/jbc.274.14.9539	http://dx.doi.org/10.1074/jbc.274.14.9539			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092639	hybrid			2022-12-25	WOS:000079451800058
J	Nikolaev, I; Lenouvel, F; Felenbok, B				Nikolaev, I; Lenouvel, F; Felenbok, B			Unique DNA binding specificity of the binuclear zinc AlcR activator of the ethanol utilization pathway in Aspergillus nidulans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ALCR; CRYSTAL-STRUCTURE; CLUSTER PROTEINS; RECOGNITION; SEQUENCE; COMPLEX; DOMAIN; REGION; FAMILY; MOTIF	AlcR is the transcriptional activator in Aspergillus nidulans, necessary for the induction of the ale gene cluster. It belongs to the Zn(2)Cys(6) zinc cluster protein family, but contains some striking differences compared with other proteins of this group. In this report, we show that no dimerization element is present in the entire AlcR protein which occurs in solution as a monomer and binds also to its cognate sites as a monomer. Another important feature of AlcR is its unique specificity for single sites occurring naturally as inverted or direct repeats and sharing a common motif, 5'-(T/A)GCGG-S', Like most other Zn(2)Cys(6) proteins, AlcR contacts directly with the CGG triplet and, in addition, the upstream adjacent guanine is required for high affinity binding. We also establish that the flanking regions outside the core play an essential role in tight binding. From our in vitro analysis, we propose an optimal AlcR-binding site which is 5'-PuNGCGG-AT rich 3'.	Univ Paris 11, CNRS, UMR 8621, Ctr Univ Orsay,Inst Genet & Microbiol, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Felenbok, B (corresponding author), Univ Paris 11, CNRS, UMR 8621, Ctr Univ Orsay,Inst Genet & Microbiol, Batiment 409, F-91405 Orsay, France.							Ascone I, 1997, BBA-PROTEIN STRUCT M, V1343, P211, DOI 10.1016/S0167-4838(97)00112-X; BATTAGLIA PA, 1994, BIOCHEM BIOPH RES CO, V201, P701, DOI 10.1006/bbrc.1994.1757; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; Cerdan R, 1997, FEBS LETT, V408, P235, DOI 10.1016/S0014-5793(97)00430-4; CERDAN R, 1997, THESIS U PARIS SUD F; Felenbok B, 1994, Prog Ind Microbiol, V29, P141; Fillinger S, 1996, MOL MICROBIOL, V20, P475, DOI 10.1046/j.1365-2958.1996.5301061.x; FILLINGER S, 1996, THESIS U PARIS SUD F; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; KULMBURG P, 1992, J BIOL CHEM, V267, P21146; KULMBURG P, 1991, FEBS LETT, V280, P11, DOI 10.1016/0014-5793(91)80193-7; KULMBURG P, 1992, MOL CELL BIOL, V12, P1932, DOI 10.1128/MCB.12.5.1932; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; LENOUVEL F, 1996, THESIS U PARIS SUD F; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MARCHETTI A, 1995, J MOL BIOL, V248, P541, DOI 10.1006/jmbi.1995.0241; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; MAXAM AM, 1980, METHOD ENZYMOL, V65, P497; Nikolaev I, 1999, MOL MICROBIOL, V31, P1115, DOI 10.1046/j.1365-2958.1999.01250.x; Panozzo C, 1997, J BIOL CHEM, V272, P22859, DOI 10.1074/jbc.272.36.22859; Poch O, 1997, GENE, V184, P229, DOI 10.1016/S0378-1119(96)00602-6; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; SCAZZOCCHIO C, 1994, ASPERGILLUS 50 YEARS, V29, P259; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SEQUEVAL D, 1994, MOL GEN GENET, V242, P33, DOI 10.1007/BF00277345; Strauss J, 1998, MOL CELL BIOL, V18, P1339, DOI 10.1128/MCB.18.3.1339; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; Walters KJ, 1997, NAT STRUCT BIOL, V4, P744, DOI 10.1038/nsb0997-744	33	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9795	9802		10.1074/jbc.274.14.9795	http://dx.doi.org/10.1074/jbc.274.14.9795			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092669	hybrid			2022-12-25	WOS:000079451800088
J	Wuytens, G; Verschueren, K; de Winter, JP; Gajendran, N; Beek, L; Devos, K; Bosman, F; de Waele, P; Andries, M; van den Eijnden-van Raaij, AJM; Smith, JC; Huylebroeck, D				Wuytens, G; Verschueren, K; de Winter, JP; Gajendran, N; Beek, L; Devos, K; Bosman, F; de Waele, P; Andries, M; van den Eijnden-van Raaij, AJM; Smith, JC; Huylebroeck, D			Identification of two amino acids in activin A that are important for biological activity and binding to the activin type II receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-2; OSTEOGENIC PROTEIN-1; FUNCTIONAL-ANALYSIS; MESODERM INDUCTION; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE; NEURAL INDUCTION; XENOPUS-LAEVIS; SUPERFAMILY	Activins are members of the transforming growth factor-beta family of growth and differentiation factors. In this paper, we report the results of a structure-function analysis of activin A. The primary targets for directed mutagenesis were charged, individual amino acids located in accessible domains of the protein, concentrating on those that differ from transforming growth factor-beta 2, the x-ray crystal structure of which is known. Based on the activities of the recombinant activin mutants in two bioassays, 4 out of 39 mutant proteins (D27K, K102A, K102E, and K102R) produced in a vaccinia virus system were selected for further investigation. After production in insect cells and purification of these four mutants to homogeneity, they were studied in bioassays and in cross-linking experiments involving transfected receptor combinations. Mutant D27K has a 2-fold higher specific bio-activity and binding affinity to an ActRIIA/ALK-4 activin receptor complex than wild type activin, whereas mutant K102E had no detectable biological activity and did not bind to any of the activin receptors. Mutant K102R and wild type activin bound to all the activin receptor combinations tested and were equipotent in bioassays. Our results with the Lys-102 mutants indicate that the positive charge of amino acid 102 is important for biological activity and type II receptor binding of activins.	Catholic Univ Louvain, Mol Biol Lab, CELGEN, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol VIB, Dept Cell Growth Differentiat & Dev VIB07, B-3000 Louvain, Belgium; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Innogenet SA, B-9052 Zwijnaarde, Belgium; Catholic Univ Louvain, Lab Cell Pharmacol, B-3000 Louvain, Belgium; Natl Inst Med Res, Div Dev Biol, London NW7 1AA, England	Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Innogenetics NV; Universite Catholique Louvain; MRC National Institute for Medical Research	Huylebroeck, D (corresponding author), Catholic Univ Louvain, Mol Biol Lab, CELGEN, Herestr 49, B-3000 Louvain, Belgium.	dhu@sgi.celgen.kuleuven.ac.be		Smith, Jim/0000-0003-2413-9392; , Nadesan/0000-0002-7463-4220; Huylebroeck, Danny/0000-0003-4862-1079				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DENEF C, 1989, METHOD ENZYMOL, V168, P47; ENGSTROM U, 1992, J BIOL CHEM, V267, P16581; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAWLEY SHB, 1995, GENE DEV, V9, P2923, DOI 10.1101/gad.9.23.2923; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUYLEBROECK D, 1990, MOL ENDOCRINOL, V4, P1153, DOI 10.1210/mend-4-8-1153; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JONES CM, 1995, DEVELOPMENT, V121, P3651; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; Mason AJ, 1996, MOL ENDOCRINOL, V10, P1055, DOI 10.1210/me.10.9.1055; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Nishitoh H, 1997, Kokubyo Gakkai Zasshi, V64, P24; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; ROEBROEK AJM, 1993, EMBO J, V12, P1853, DOI 10.1002/j.1460-2075.1993.tb05834.x; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SYMES K, 1987, DEVELOPMENT, V101, P339; Thomas JT, 1997, NAT GENET, V17, P58, DOI 10.1038/ng0997-58; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217	42	35	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9821	9827		10.1074/jbc.274.14.9821	http://dx.doi.org/10.1074/jbc.274.14.9821			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092672	hybrid			2022-12-25	WOS:000079451800091
J	Cho, MR; Thatte, HS; Silvia, MT; Golan, DE				Cho, MR; Thatte, HS; Silvia, MT; Golan, DE			Transmembrane calcium influx induced by ac electric fields	FASEB JOURNAL			English	Article						intracellular calcium; stretch-activated cation channels; signal transduction	ACTIVATED ION CHANNELS; EMBRYONIC MUSCLE-CELL; RAT-LIVER CELLS; INDUCED REDISTRIBUTION; INTRACELLULAR CALCIUM; CATION CHANNELS; SHAPE CHANGES; CA2+ INFLOW; MEMBRANE; RECEPTORS	Exogenous electric fields induce cellular responses including redistribution of integral membrane proteins, reorganization of microfilament structures, and changes in intracellular calcium ion concentration ([Ca2+](i)). Although increases in [Ca2+](i) caused by application of direct current electric fields have been documented, quantitative measurements of the effects of alternating current (ac) electric fields on [Ca2+](i) are lacking and the Ca2+ pathways that mediate such effects remain to be identified, Using epifluorescence microscopy, we have examined in a model cell type the [Ca2+](i) response to ac electric fields. Application of a 1 or 10 Hz electric field to human hepatoma (Hep3B) cells induces a fourfold increase in [Ca2+](i) (from 50 nM to 200 nM) within 30 min of continuous field exposure. Depletion of Ca2+ in the extracellular medium prevents the electric field-induced increase in [Ca2+](i), suggesting that Ca2+ influx across the plasma membrane is responsible for the [Ca2+](i) increase. Incubation of cells with the phospholipase C inhibitor U73122 does not inhibit ac electric field-induced increases in [Ca2+](i), suggesting that receptor-regulated release of intracellular Ca2+ is not important for this effect. Treatment of cells with either the stretch-activated cation channel inhibitor GdCl3 or the nonspecific calcium channel blocker CoCl2 partially inhibits the [Ca2+](i) increase induced by ac electric fields, and concomitant treatment with both GdCl3 and CoCl2 completely inhibits the field-induced [Ca2+](i) increase. Since neither Gd3+ nor Co2+ is efficiently transported across the plasma membrane, these data suggest that the increase in [Ca2+](i) induced by ac electric fields depends entirely on Ca2+ influx from the extracellular medium.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Golan, DE (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA.	dgolan@hms.harvard.edu		Cho, Myoung Rae/0000-0002-8191-8045	NHLBI NIH HHS [HL-15157, HL-32854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157, R01HL032854, R37HL032854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAR CE, 1991, AM J PHYSIOL, V261, pC1018, DOI 10.1152/ajpcell.1991.261.6.C1018; BEAR CE, 1990, AM J PHYSIOL, V258, pC421, DOI 10.1152/ajpcell.1990.258.3.C421; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERVEN LA, 1995, BIOCHEM PHARMACOL, V49, P1373, DOI 10.1016/0006-2952(95)00050-A; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; BROWN MJ, 1994, J CELL BIOL, V127, P117, DOI 10.1083/jcb.127.1.117; BYGRAVE FL, 1995, FASEB J, V9, P1297, DOI 10.1096/fasebj.9.13.7557019; CARSON JJL, 1990, AM J PHYSIOL, V259, pC687, DOI 10.1152/ajpcell.1990.259.4.C687; CHO MR, 1994, FASEB J, V8, P771, DOI 10.1096/fasebj.8.10.8050677; Cho MR, 1996, FASEB J, V10, P1552, DOI 10.1096/fasebj.10.13.8940302; DOCHERTY RJ, 1988, J PHYSIOL-LONDON, V398, P33, DOI 10.1113/jphysiol.1988.sp017027; FERNANDO KC, 1995, BBA-MOL CELL RES, V1268, P97, DOI 10.1016/0167-4889(95)00041-P; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GIUGNI TD, 1987, J CELL BIOL, V104, P1291, DOI 10.1083/jcb.104.5.1291; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; JAFFE LF, 1977, NATURE, V265, P600, DOI 10.1038/265600a0; KAO JPY, 1989, J BIOL CHEM, V264, P8179; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LAUB F, 1984, BIOCHIM BIOPHYS ACTA, V803, P308, DOI 10.1016/0167-4889(84)90122-8; Lee Raphael C., 1993, Journal of Burn Care and Rehabilitation, V14, P319, DOI 10.1097/00004630-199305000-00003; LEE RC, 1993, BIOPHYS J, V64, P44, DOI 10.1016/S0006-3495(93)81339-0; LUTHER PW, 1983, NATURE, V303, P61, DOI 10.1038/303061a0; MCLAUGHLIN S, 1981, BIOPHYS J, V34, P85, DOI 10.1016/S0006-3495(81)84838-2; ONUMA EK, 1985, CELL CALCIUM, V6, P281, DOI 10.1016/0143-4160(85)90012-0; ONUMA EK, 1988, J CELL BIOL, V106, P2067, DOI 10.1083/jcb.106.6.2067; Perelson A. S., 1984, CELL SURFACE DYNAMIC, P223; POO MM, 1977, NATURE, V265, P602, DOI 10.1038/265602a0; POO MM, 1978, J CELL BIOL, V76, P483, DOI 10.1083/jcb.76.2.483; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rink TJ, 1990, CURR OPIN CELL BIOL, V2, P198, DOI 10.1016/0955-0674(90)90007-2; RINK TJ, 1989, TRENDS NEUROSCI, V12, P43, DOI 10.1016/0166-2236(89)90133-1; ROBERTSON B, 1992, BIOCHEMISTRY-US, V31, P138, DOI 10.1021/bi00116a020; ROBERTSON B, 1990, BIOPHYS J, V58, P969, DOI 10.1016/S0006-3495(90)82441-3; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; RYAN TA, 1988, SCIENCE, V239, P61, DOI 10.1126/science.2962287; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SANCHEZBUENO A, 1993, BIOCHEM J, V291, P169, DOI 10.1042/bj2910169; SANCHEZBUENO A, 1990, ADV SEC MESS PHOSPH, V24, P115; SAWANOBORI T, 1989, J CELL PHYSIOL, V139, P580, DOI 10.1002/jcp.1041390318; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TANK DW, 1985, J CELL BIOL, V101, P148, DOI 10.1083/jcb.101.1.148; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; TSONG TY, 1988, METHOD ENZYMOL, V157, P240; WAGNER KA, 1993, BIOCHEM J, V292, P175, DOI 10.1042/bj2920175; WALLECZEK J, 1992, FASEB J, V6, P3177, DOI 10.1096/fasebj.6.13.1397839; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WESTERHOFF HV, 1986, P NATL ACAD SCI USA, V83, P4734, DOI 10.1073/pnas.83.13.4734; WOFSY C, 1992, MATH BIOSCI, V112, P115, DOI 10.1016/0025-5564(92)90090-J; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	53	115	121	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					677	683		10.1096/fasebj.13.6.677	http://dx.doi.org/10.1096/fasebj.13.6.677			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094928				2022-12-25	WOS:000079527200009
J	Witting, PK; Pettersson, K; Ostlund-Lindqvist, AM; Westerlund, C; Eriksson, AW; Stocker, R				Witting, PK; Pettersson, K; Ostlund-Lindqvist, AM; Westerlund, C; Eriksson, AW; Stocker, R			Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice	FASEB JOURNAL			English	Article						antioxidants; coantioxidation; LDL; alpha-tocopherol	TOCOPHEROL-MEDIATED PEROXIDATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; CHOLESTEROL-FED RABBITS; ALPHA-TOCOPHEROL; VITAMIN-E; OXIDIZED LIPOPROTEINS; DEFICIENT MICE; SCREENING-TEST; OXIDATION; LDL	Antioxidants can inhibit atherosclerosis in animals, though it is not clear whether this is due to the inhibition of aortic lipoprotein lipid (per)oxidation, Coantioxidants inhibit radical-induced, tocopherol-mediated peroxidation of lipids in lipoproteins through elimination of tocopheroxyl radical. Here we tested the effect of the bisphenolic probucol metabolite and coantioxidant H 212/43 on atherogenesis in apolipoprotein E and low density lipoprotein (LDL) receptor gene double knockout (apoE-/-;LDLr-/-) mice, and how this related to aortic lipid (per)oxidation measured by specific HPLC analyses. Dietary supplementation with H 212/43 resulted in circulating drug levels of similar to 200 mu M, increased plasma total cholesterol slightly and decreased plasma and aortic a-tocopherol significantly relative to age-matched control mice. Treatment with H 212/43 increased the antioxidant capacity of plasma, as indicated by prolonged inhibition of peroxyl radical-induced, ex vivo lipid peroxidation. Aortic tissue from control apoE-/-;LDLr-/- mice contained lipid hydro(pero)xides and substantial atherosclerotic lesions, both of which were decreased strongly by supplementation of the animals with H 212/43, The results show that a coantioxidant effectively inhibits in vivo lipid peroxidation and atherosclerosis in apoE-/-;LDLr-/- mice, consistent with though not proving a causal relationship between aortic lipoprotein lipid oxidation and atherosclerosis in this model of the disease.	Heart Res Inst, Biochem Grp, Camperdown, NSW 2050, Australia; AB Hassle, S-43183 Molndal, Sweden	University of Sydney; Heart Research Institute	Stocker, R (corresponding author), Heart Res Inst, Biochem Grp, 145 Missenden Rd, Camperdown, NSW 2050, Australia.	r.stocker@hri.org.au	Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020; Stocker, Roland/AAV-4489-2021	Witting, Paul/0000-0003-2237-7004; 				Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bird DA, 1998, J LIPID RES, V39, P1079; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P125; CARPENTER KLH, 1995, BBA-LIPID LIPID MET, V1256, P141, DOI 10.1016/0005-2760(94)00247-V; CHIN JH, 1992, J CLIN INVEST, V89, P10, DOI 10.1172/JCI115549; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; Cynshi O, 1998, P NATL ACAD SCI USA, V95, P10123, DOI 10.1073/pnas.95.17.10123; FRANK JS, 1989, J LIPID RES, V30, P967; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; FRUEBIS J, 1995, ATHEROSCLEROSIS, V117, P217, DOI 10.1016/0021-9150(95)05574-G; Fruebis J, 1997, J LIPID RES, V38, P2455; Hazell LJ, 1997, FEBS LETT, V414, P541, DOI 10.1016/S0014-5793(97)01066-1; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LINDQVIST AM, 1997, 97535465199749 WPI; LYNCH SM, 1994, NATURAL ANTIOXIDANTS, P353; Munday JS, 1998, ARTERIOSCL THROM VAS, V18, P114, DOI 10.1161/01.ATV.18.1.114; Neuzil J, 1998, J LIPID RES, V39, P354; Ohlsson BG, 1996, J CLIN INVEST, V98, P78, DOI 10.1172/JCI118780; OLeary VJ, 1996, ATHEROSCLEROSIS, V119, P169, DOI 10.1016/0021-9150(95)05644-0; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; PELTER A, 1988, TETRAHEDRON LETT, V29, P677, DOI 10.1016/S0040-4039(00)80182-3; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SHAISH A, 1995, J CLIN INVEST, V96, P2075, DOI 10.1172/JCI118256; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEIN Y, 1989, ATHEROSCLEROSIS, V75, P145, DOI 10.1016/0021-9150(89)90171-8; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUARNA C, 1993, BIOCHIM BIOPHYS ACTA, V1166, P163, DOI 10.1016/0005-2760(93)90092-N; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H; Witting PK, 1996, J LIPID RES, V37, P853; Witting PK, 1998, SUB CELL BIOCHEM, V30, P345; Witting PK, 1999, METHOD ENZYMOL, V299, P362; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WITZTUM JL, 1993, J CLIN INVEST, V92, P536, DOI 10.1172/JCI116619; XIU RJ, 1994, J CLIN INVEST, V93, P2732, DOI 10.1172/JCI117288; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; Zhang SH, 1997, J CLIN INVEST, V99, P2858, DOI 10.1172/JCI119479	47	82	83	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					667	675		10.1096/fasebj.13.6.667	http://dx.doi.org/10.1096/fasebj.13.6.667			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094927				2022-12-25	WOS:000079527200008
J	Ho, IHM; Murrell-Lagnado, RD				Ho, IHM; Murrell-Lagnado, RD			Molecular determinants for sodium-dependent activation of G protein-gated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; POTASSIUM CHANNELS; BINDING; G(BETA-GAMMA); EXPRESSION; CLONING; NEURONS; REGIONS; CELLS	G protein-gated inwardly rectifying K+ channels (GIRKs) are activated by a direct interaction with G beta gamma subunits and also by raised internal [Na+]. Both processes require the presence of phosphatidylinositol bisphosphate (PIP2). Here we show that the proximal C-terminal region of GIRK2 mediates the Na+-dependent activation of both the GIRK2 homomeric channels and the GIRK1/GIRK2 heteromeric channels. Within this region, GIRK2 has an aspartate at position 226, whereas GIRK1 has an asparagine at the equivalent position (217), A single point mutation, D226N, in GIRK2, abolished the Na+-dependent activation of both the homomeric and heteromeric channels, Neutralizing a nearby negative charge, E234S had no effect. The reverse mutation in GIRK1, N217D, was sufficient to restore Na+-dependent activation to the GIRK1N217D/GIRK2D226N heteromeric channels. The D226N mutation did not alter either the single channel properties or the ability of these channels to be activated via the m2-muscarinic receptor. PIP2 dramatically increased the open probability of GIRK1/GIRK2 channels in the absence of Na+ or G beta gamma but did not preclude further activation by Na+, suggesting that Na+ is not acting simply to promote PIP2 binding to GIRKs. We conclude that aspartate 226 in GIRK2 plays a crucial role in Na+ dependent gating of GIRK1/GIRK2 channels.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1QJ, England	University of Cambridge	Murrell-Lagnado, RD (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1QJ, England.	rdm1003@cus.cam.ac.uk		Murrell-Lagnado, Ruth/0000-0003-2743-7977				BOND CT, 1995, FEBS LETT, V367, P61, DOI 10.1016/0014-5793(95)00497-W; Callaway JC, 1997, J NEUROPHYSIOL, V77, P145, DOI 10.1152/jn.1997.77.1.145; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Kofuji P, 1996, NEURON, V16, P941, DOI 10.1016/S0896-6273(00)80117-8; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; NEVE KA, 1991, MOL PHARMACOL, V39, P733; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; Stevens EB, 1997, J PHYSIOL-LONDON, V503, P547, DOI 10.1111/j.1469-7793.1997.547bg.x; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAGLIALATELA M, 1995, EMBO J, V14, P5532, DOI 10.1002/j.1460-2075.1995.tb00240.x; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877	23	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8639	8648		10.1074/jbc.274.13.8639	http://dx.doi.org/10.1074/jbc.274.13.8639			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085101	hybrid			2022-12-25	WOS:000079451600043
J	Koticha, DK; Huddleston, SJ; Witkin, JW; Baldini, G				Koticha, DK; Huddleston, SJ; Witkin, JW; Baldini, G			Role of the cysteine-rich domain of the t-SNARE component, SYNDET, in membrane binding and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; PLASMA-MEMBRANE; DIRECTED MUTAGENESIS; CELL-SURFACE; CDNA CLONES; SNAP-25; PALMITOYLATION; TRANSPORT; FUSION; INSULIN	Wild-type syndet is efficiently recruited at the plasma membrane in transfected AtT-20 cells. A deletion at the cysteine-rich domain abolishes palmitoylation, membrane binding, and plasma membrane distribution of syndet. Syndet, SNAP-25A, and SNAP-25B share four cysteine residues, of which three, Cys(2), Cys(4), and Cys(5), are absolutely conserved in all three homologs, Mutations at any pair of cysteines within cysteines 2, 4, and 5 shift syndet from the cell surface into the cytoplasm, Thus, at least two cysteines within the conserved triplet are necessary for plasma membrane localization. Syndet C1S/C3S, with substitutions at the pair Cys(1) and Cys(3), distributes to the plasma membrane, a Gels-like compartment, and the cytosol, We conclude that Cys(1) and Cys(3) are not absolutely necessary for membrane binding or plasma membrane localization. Our results show that the cysteine-rich domain of syndet plays a major role in its subcellular distribution.	Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	Columbia University	Baldini, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, 630 W 168th St, New York, NY 10032 USA.			Huddleston, Stephen/0000-0002-9244-9854	NIDDK NIH HHS [R01-DK53293] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053293] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bijlmakers MJJE, 1997, J CELL BIOL, V137, P1029, DOI 10.1083/jcb.137.5.1029; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; DECAMILLI P, 1993, NATURE, V364, P387; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; HESS DT, 1992, J NEUROSCI, V12, P4634; Hidajat R, 1997, BIOTECHNIQUES, V22, P32, DOI 10.2144/97221bm04; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lane SR, 1997, J NEUROCHEM, V69, P1864; Low SH, 1998, J BIOL CHEM, V273, P3422, DOI 10.1074/jbc.273.6.3422; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MATSUUCHI L, 1988, J CELL BIOL, V106, P239, DOI 10.1083/jcb.106.2.239; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; RISINGER C, 1993, J BIOL CHEM, V268, P24408; SHAHINIAN S, 1995, BIOCHEMISTRY-US, V34, P3813, DOI 10.1021/bi00011a039; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884	37	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9053	9060		10.1074/jbc.274.13.9053	http://dx.doi.org/10.1074/jbc.274.13.9053			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085154	hybrid			2022-12-25	WOS:000079451600096
J	Stathakis, P; Lay, AJ; Fitzgerald, M; Schlieker, C; Matthias, LJ; Hogg, PJ				Stathakis, P; Lay, AJ; Fitzgerald, M; Schlieker, C; Matthias, LJ; Hogg, PJ			Angiostatin formation involves disulfide bond reduction and proteolysis in kringle 5 of plasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS INHIBITOR; ENDOTHELIAL-CELLS; BINDING; GLUTATHIONE; GROWTH; CANCER; PURIFICATION; MICROPLASMIN; SENSITIVITY; GENERATION	Plasmin is processed in the conditioned medium of HT1080 fibrosarcoma cells producing fragments with the domain structures of the angiogenesis inhibitor, angiostatin, and microplasmin, Angiostatin consists of kringle domains 1-4 and part of kringle 5, while microplasmin consists of the remainder of kringle 5 and the serine proteinase domain. Our findings indicate that formation of angiostatin/microplasmin involves reduction of plasmin by a plasmin reductase followed by proteolysis of the reduced enzyme. We present evidence that the Cys(461)-Cys(540) and Cys(511)-Cys(535) disulfide bonds in kringle 5 of plasmin were reduced by plasmin reductase, Plasmin reductase activity was secreted by HT1080 and Chinese hamster ovary cells and the human mammary carcinoma cell lines MCF-7, MDA231, and BT20 but not by the monocyte/macrophage cell line THP-1. Neither primary foreskin fibroblasts, blood monocyte/ macrophages, nor macrovascular or microvascular endothelial cells secreted detectable plasmin reductase. In contrast, cultured bovine and rat vascular smooth muscle cells secreted small but reproducible levels of plasmin reductase. Reduction of the kringle 5 disulfide bonds triggered cleavage at either Arg(529)-Lys(530) Or two other positions C-terminal of Cys(461) in kringle 5 by a serine proteinase. Plasmin autoproteolysis could account for the cleavage, although another proteinase was mostly responsible in HT1080 conditioned medium. Three serine proteinases with apparent M-r of 70, 50, and 39 were purified from HT1080 conditioned medium, one or more of which could contribute to proteolysis of reduced plasmin.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Hogg, PJ (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Fitzgerald, Melinda/C-4235-2011	Fitzgerald, Melinda/0000-0002-4823-8179; Hogg, Philip/0000-0001-6486-2863				BANNAI S, 1979, J BIOL CHEM, V254, P3444; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Dudman NPB, 1996, CLIN CHEM, V42, P2028; Field SL, 1996, J CELL PHYSIOL, V168, P322, DOI 10.1002/(SICI)1097-4652(199608)168:2<322::AID-JCP11>3.0.CO;2-5; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gately S, 1996, CANCER RES, V56, P4887; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; HASSAN NF, 1986, J IMMUNOL METHODS, V95, P273, DOI 10.1016/0022-1759(86)90415-1; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOGG PJ, 1992, BIOCHEMISTRY-US, V31, P265, DOI 10.1021/bi00116a036; HOGG PJ, 1992, J BIOL CHEM, V267, P703; JACKSON CJ, 1990, J CELL SCI, V96, P257; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lannutti BJ, 1997, CANCER RES, V57, P5277; Lijnen HR, 1998, BIOCHEMISTRY-US, V37, P4699, DOI 10.1021/bi9731798; LITTLE PJ, 1986, AM J PHYSIOL, V251, pC707, DOI 10.1152/ajpcell.1986.251.5.C707; MARTIN GM, 1973, TISSUE CULTURE METHO, P39; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Sim BKL, 1997, CANCER RES, V57, P1329; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; WU HL, 1992, BIOCHEM BIOPH RES CO, V188, P703, DOI 10.1016/0006-291X(92)91113-5; WU HL, 1987, P NATL ACAD SCI USA, V84, P8292, DOI 10.1073/pnas.84.23.8292; WU HL, 1987, P NATL ACAD SCI USA, V84, P8793, DOI 10.1073/pnas.84.24.8793	31	78	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8910	8916		10.1074/jbc.274.13.8910	http://dx.doi.org/10.1074/jbc.274.13.8910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085135				2022-12-25	WOS:000079451600077
J	Beggah, AT; Beguin, P; Bamberg, K; Sachs, G; Geering, K				Beggah, AT; Beguin, P; Bamberg, K; Sachs, G; Geering, K			beta-subunit assembly is essential for the correct packing and the stable membrane insertion of the H,K-ATPase alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSLATION; NA,K-ATPASE; TOPOLOGY; TRANSMEMBRANE; TRANSLOCATION; NA,K-PUMPS; SYSTEM	The alpha-subunits of H,K-ATPase (HKA alpha) and Na,K-ATPase require a beta-subunit for maturation. We investigated the role of the beta-subunit in the membrane insertion and stability of the HKA alpha expressed in Xenopus oocytes, Individual membrane segments M1, M2, M3, M4, and M9 linked to a glycosylation reporter act as signal anchor (SA) motifs, and M10 acts as a partial stop transfer motif. In combined HKA alpha constructs, M2 acts as an efficient stop transfer sequence, and M3 acts as a SA sequence. However, M5 and M9 have only partial SA function, and M7 has no SA function. Consistent with the membrane insertion properties of segments in combined a constructs, M1-3 alpha-proteins are resistant to cellular degradation, and M1-5 up to M1-10 alpha-proteins are not resistant to cellular degradation. However, co-expression with beta-subunits increases the membrane insertion of M9 in a M1-9 alpha-protein and completely protects M1-10 alpha-proteins against cellular degradation. Our results indicate that HKA alpha N-terminal (M1-M4) membrane insertion and stabilization are mediated by intrinsic molecular characteristics; however, the C-terminal (M5-M10) membrane insertion and thus the stabilization of the entire alpha-subunit depend on intramolecular and intermolecular beta-subunit interactions that are similar but not identical to data obtained for the Na,K-ATPase alpha-subunit.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Astra Hassle AB, S-43183 Molndal, Sweden; W Los Angeles Wadsworth Vet Adm Med Ctr, Los Angeles, CA 90073 USA	University of Lausanne; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Geering, K (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.							BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J RECEPT SIGNAL TR R, V17, P29, DOI 10.3109/10799899709036593; Beguin P, 1997, ANN NY ACAD SCI, V834, P540, DOI 10.1111/j.1749-6632.1997.tb52312.x; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; Beguin P, 1996, BIOCHEMISTRY-US, V35, P14098, DOI 10.1021/bi960516o; Chen PX, 1998, AM J PHYSIOL-CELL PH, V275, pC139, DOI 10.1152/ajpcell.1998.275.1.C139; Claeys D, 1997, GASTROENTEROLOGY, V113, P1136, DOI 10.1053/gast.1997.v113.pm9322508; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; DEBER CM, 1997, MOL B INT U, P25; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; High S, 1997, TRENDS CELL BIOL, V7, P206; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Karlish SJD, 1997, ANN NY ACAD SCI, V834, P30, DOI 10.1111/j.1749-6632.1997.tb52223.x; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; Wahle S, 1996, J CELL BIOL, V135, P1867, DOI 10.1083/jcb.135.6.1867; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	26	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8217	8223		10.1074/jbc.274.12.8217	http://dx.doi.org/10.1074/jbc.274.12.8217			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075726	hybrid			2022-12-25	WOS:000079268100085
J	Meade, EA; McIntyre, TM; Zimmerman, GA; Prescott, SM				Meade, EA; McIntyre, TM; Zimmerman, GA; Prescott, SM			Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN-H SYNTHASE-2; FATTY-ACIDS; COLON-CANCER; COLORECTAL ADENOMAS; TISSUE DISTRIBUTION; NUCLEAR RECEPTOR; GENE-EXPRESSION; ASPIRIN USE	The formation of prostaglandins requires the catalytic activity of cyclooxygenase (COX) which converts arachidonic acid to the prostaglandin endoperoxide PGH(2), from which all other prostaglandins are formed. COX-2 is the highly inducible isozyme of COX which is responsible for much of the prostaglandin production in inflammation and is a key factor in colon carcinogenesis. Because COX-2 activity can be rate-limiting in prostaglandin formation, COX-2 expression must be regulated tightly. Numerous factors, including mitogens, tumor promoters, and cytokines have been found to stimulate the transcription of COX-2. We show that fatty acids, prostaglandins, and non-steroidal anti-inflammatory drugs, compounds that are substrates, products, and inhibitors, respectively, of COX enzymatic activity, also increase its expression. These compounds are members of a heterogeneous group of compounds known as peroxisome proliferators, and the prototypical peroxisome proliferator, WY-14,643, also enhanced COX-2 expression. We demonstrate that these compounds increase COX-2 transcription, and we identify a region of the COX-2 promoter containing a peroxisome proliferator response element that is responsible for the enhancement of COX-2 expression seen with these compounds.	Univ Utah, Huntsman Canc Inst, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Nora Eccles Harrison Cardiovasc Training & Res In, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Huntsman Canc Inst, Eccles Program Human Mol Biol & Genet, 15 N 2030 E Rm 4220, Salt Lake City, UT 84112 USA.				NCI NIH HHS [CA 42014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANDYOPADHYAY GK, 1987, J BIOL CHEM, V262, P2750; CARTER CA, 1983, CANCER RES, V43, P3559; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HABIB A, 1993, J BIOL CHEM, V268, P23448; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; MEADE EA, 1992, HDB LIPID RES, V8, P285; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; POTTER JD, 1992, JAMA-J AM MED ASSOC, V268, P1573; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	40	263	274	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8328	8334		10.1074/jbc.274.12.8328	http://dx.doi.org/10.1074/jbc.274.12.8328			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075740	hybrid			2022-12-25	WOS:000079268100099
J	Jang, JS; Lee, SJ; Choi, YH; Nguyen, P; Lee, J; Hwang, SG; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB				Jang, JS; Lee, SJ; Choi, YH; Nguyen, P; Lee, J; Hwang, SG; Wu, ML; Takano, E; Maki, M; Henkart, PA; Trepel, JB			Posttranslational regulation of the retinoblastoma gene family member p107 by calpain protease	ONCOGENE			English	Article						proteolysis; p107; calpain; proteasome	LARGE T-ANTIGEN; ACTIVATED NEUTRAL PROTEASE; CELL-CYCLE; PROTEINS P130; KAPPA-B; IN-VIVO; C-JUN; UBIQUITIN; DEGRADATION; PATHWAY	The retinoblastoma protein plays a critical role in regulating the G1/S transition. Less is known about the function and regulation of the homologous pocket protein p107. Here we present evidence for the posttranslational regulation of p107 by the Ca2+-activated protease calpain. Three negative growth regulators, the HMG-CoA reductase inhibitor lovastatin, the antimetabolite 5-fluorouracil, and the cyclic nucleotide dibutyryl cAMP were found to induce cell type-specific loss of p107 protein which was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by the serine protease inhibitor phenylmethylsulfonylfluoride, caspase inhibitors, or lactacystin, a specific inhibitor of the 26S proteasome, Purified calpain induced Ca2+-dependent p107 degradation in cell lysates. Transient expression of the specific calpain inhibitor calpastatin blocked the loss of p107 protein in lovastatin-treated cells, and the half-life of p107 was markedly lengthened in lovastatian-treated cells stably transfected with a calpastatin expression vector versus cells transfected with vector alone. The data presented here demonstrate downregulation of p107 protein in response to various antiproliferative signals, and implicate calpain in p107 posttranslational regulation.	NCI, Med Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Natl Kyoto Hosp, Kyoto 612, Japan; Nagoya Univ, Nagoya, Aichi 46401, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Nagoya University	Trepel, JB (corresponding author), NCI, Med Branch, Div Clin Sci, NIH, Bldg 10,Room 12N226, Bethesda, MD 20892 USA.		Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491	DIVISION OF BASIC SCIENCES - NCI [Z01BC009263] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Bonvini P, 1998, ONCOGENE, V16, P1131, DOI 10.1038/sj.onc.1201625; Boyer SN, 1996, CANCER RES, V56, P4620; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KATO J, 1993, GENE DEV, V7, P331; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Lee MJ, 1996, FASEB J, V10, P16; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Maki CG, 1996, CANCER RES, V56, P2649; MAYOL X, 1993, ONCOGENE, V8, P2561; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOHAN PS, 1995, J NEUROCHEM, V64, P859; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SZEKELY L, 1991, CELL GROWTH DIFFER, V2, P287; TORTORA G, 1994, ONCOGENE, V9, P3233; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	68	23	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1789	1796		10.1038/sj.onc.1202497	http://dx.doi.org/10.1038/sj.onc.1202497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086333				2022-12-25	WOS:000079090000002
J	Gibson, S; Widmann, C; Johnson, GL				Gibson, S; Widmann, C; Johnson, GL			Differential involvement of MEK kinase 1 (MEKK1) in the induction of apoptosis in response to microtubule-targeted drugs versus DNA damaging agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PACLITAXEL-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; CARCINOMA-CELLS; CANCER CELLS; TAXOL; ACTIVATION; BCL-2; PHOSPHORYLATION; CISPLATIN; CASPASES	MEK kinase 1 (MEKK1) is a 196-kDa enzyme that is involved in the regulation of the c-Jun N-terminal kinase (JNK) pathway and apoptosis, In cells exposed to genotoxic agents including etoposide and cytosine arabinoside, MEKK1 is cleaved at Asp(874) by caspases. The cleaved kinase domain of MEKK1, itself, stimulates caspase activity leading to apoptosis. Kinase-inactive MEKK1 expressed in HEK293 cells effectively blocks genotoxin-induced apoptosis. Treatment of cells with taxol, a microtubule stabilizing agent, did not induce MEKK1 cleavage in cells, and kinase-inactive MEKK1 expression failed to block taxol-induced apoptosis, MEKK1 became activated in HEK293 cells exposed to taxol, but in contrast to etoposide-treatment, taxol failed to increase JNK activity. Taxol treatment of cells, therefore, dissociates MEKK1 activation from the regulation of the JNK pathway. Overexpression of anti-apoptotic Bcl2 blocked MEKK1 and taxol-induced apoptosis but did not block the caspase-dependent cleavage of MEKX1 in response to etoposide. This indicates Bcl2 inhibition of apoptosis is, therefore, downstream of caspase dependent MEKK1 cleavage. The results define the involvement of MEKK1 in the induction of apoptosis by genotoxins but not microtubule altering drugs.	Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gibson, S (corresponding author), Natl Jewish Med & Res Ctr, Program Mol Signal Transduct, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		Widmann, Christian/N-9851-2013	Widmann, Christian/0000-0002-6881-0363; Gibson, Spencer/0000-0003-0119-732X	NIDDK NIH HHS [DK 37871, DK 48845] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048845, R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; BHALLA K, 1993, LEUKEMIA, V7, P563; Capranico G, 1997, CANCER CHEMOTHER BIO, V17, P114; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Correa P, 1998, BRIT MED BULL, V54, P151; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; GONG M, 1994, VIROLOGY, V204, P38, DOI 10.1006/viro.1994.1508; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1997, CANCER RES, V57, P229; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; Jensen PB, 1997, BIOCHEM PHARMACOL, V54, P755; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jones NA, 1998, MOL PHARMACOL, V53, P819; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kroning R, 1998, LEUKEMIA RES, V22, P275, DOI 10.1016/S0145-2126(97)00170-7; Kuan NK, 1998, ARCH SURG-CHICAGO, V133, P773, DOI 10.1001/archsurg.133.7.773; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lokich J, 1998, EUR J CANCER, V34, P664, DOI 10.1016/S0959-8049(97)10108-3; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Reed JC, 1998, CANCER J, V4, pS8; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Staunton MJ, 1998, ARCH PATHOL LAB MED, V122, P310; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zaffaroni N, 1998, BRIT J CANCER, V77, P1378, DOI 10.1038/bjc.1998.230; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	38	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10916	10922		10.1074/jbc.274.16.10916	http://dx.doi.org/10.1074/jbc.274.16.10916			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196170	hybrid			2022-12-25	WOS:000079751900038
J	Krishnan, P; Hocking, AM; Scholtz, JM; Pace, CN; Holik, KK; McQuillan, DJ				Krishnan, P; Hocking, AM; Scholtz, JM; Pace, CN; Holik, KK; McQuillan, DJ			Distinct secondary structures of the leucine-rich repeat proteoglycans decorin and biglycan - Glycosylation-dependent conformational stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN ARTICULAR-CARTILAGE; CIRCULAR-DICHROISM; COLLAGEN FIBRILLOGENESIS; EXTRACELLULAR-MATRIX; FACTOR RECEPTOR; CORE PROTEIN; INHIBITOR; SULFATE; PROTEODERMATAN	Biglycan and decorin have been overexpressed in eukaryotic cells and two major glycoforms isolated under native conditions: a proteoglycan substituted with glycosaminoglycan chains; and a core protein form secreted devoid of glycosaminoglycans (Hocking, A. M,, Strugnell, R. A., Ramamurthy, P., and McQuillan, D. J. (1996) J. Biol. Chem. 271, 19571-19577; Ramamurthy, P., Hocking, A. M., and McQuillan, D, J, (1996) J. Biol. Chem. 271, 19578-19584). Far-UV CD spectroscopy of decorin and biglycan proteoglycans indicates that, although they are predominantly beta-sheet, biglycan has a significantly higher content of alpha-helical structure, Decorin proteoglycan and core protein are very similar, whereas the biglycan core protein exhibits closer similarity to the decorin glycoforms than to the biglycan proteoglycan form. However, enzymatic removal of the chondroitin sulfate chains from biglycan proteoglycan does not induce a shift to the core protein structure, suggesting that the final form is influenced by polysaccharide addition only during biosynthesis. Fluorescence emission spectroscopy demonstrated that the single tryptophan residue, which is at a conserved position at the C-terminal domain of both biglycan and decorin, is found in similar microenvironments. This indicates that in this specific domain the different glycoforms do exhibit apparent conservation of structure. Exposure of decorin and biglycan to 10 M urea resulted in an increase in fluorescent intensity, which indicates that the emission from tryptophan in the native state is quenched. Comparison of urea-induced protein unfolding curves provide further evidence that decorin and biglycan assume different structures in solution. Decorin proteoglycan and core protein unfold in a manner similar to a classic two-state model, in which there is a steep transition to an unfolded state between 1 and 2 an urea. The biglycan core protein also shows a similar steep transition. However, biglycan proteoglycan shows a broad unfolding transition between 1 and 6 M urea, probably indicating the presence of stable unfolding intermediates.	Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	McQuillan, DJ (corresponding author), Inst Biosci & Technol, Ctr Extracellular Matrix Biol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.			Hocking, Anne/0000-0003-2130-3732	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042826] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42826] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; Font B, 1998, EUR J BIOCHEM, V254, P580, DOI 10.1046/j.1432-1327.1998.2540580.x; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; HARPER JR, 1994, METHODS ENZYMOL, V245, P241; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; JOHNSON WC, 1988, ANNU REV BIOPHYS BIO, V17, P145, DOI 10.1146/annurev.bb.17.060188.001045; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; PACE CN, 1989, BIOCHEMISTRY-US, V28, P2520, DOI 10.1021/bi00432a026; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; RUOSLAHTI E, 1992, COLD SPRING HARB SYM, V57, P309, DOI 10.1101/SQB.1992.057.01.035; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; TOUMADJE A, 1992, ANAL BIOCHEM, V200, P321, DOI 10.1016/0003-2697(92)90473-K; VOGEL KG, 1987, BIOCHEM BIOPH RES CO, V148, P658, DOI 10.1016/0006-291X(87)90927-2; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767	34	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10945	10950		10.1074/jbc.274.16.10945	http://dx.doi.org/10.1074/jbc.274.16.10945			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196174	hybrid			2022-12-25	WOS:000079751900042
J	Trivedi, A; Young, LS; Ouyang, C; Johnson, DL; Sprague, KU				Trivedi, A; Young, LS; Ouyang, C; Johnson, DL; Sprague, KU			A TATA element is required for tRNA promoter activity and confers TATA-binding protein responsiveness in Drosophila Schneider-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENE; POLYMERASE-III PROMOTERS; IN-VIVO EXPRESSION; SEQUENCE ELEMENTS; TRANSCRIPTIONAL PROPERTIES; SACCHAROMYCES-CEREVISIAE; INVITRO TRANSCRIPTION; DNA INTERACTIONS; BOMBYX-MORI; BASE-PAIRS	In contrast to yeast and mammalian systems, which depend principally on internal promoter elements for tRNA gene transcription, insect systems require additional upstream sequences. To understand the function of the upstream sequences, we have asked whether the Bombyx mori tRNA(C)(Ala) and tRNA(SG)(Ala) genes, which are absolutely dependent on these sequences in vitro, also require them for transcription in vivo, We introduced wild-type and mutant versions of the Bombyx tRNA(Ala) genes into Drosophila Schneider-2 cells and found that the tRNA(C)(Ala) gene is efficiently transcribed and that its transcription depends strongly on the distal segment of its upstream promoter. In contrast, the tRNA(SG)(Ala) gene is inefficiently transcribed, and this inefficiency results from lack of a specific sequence within the distal tRNA(C)(Ala) upstream promoter. This sequence, 5'-TTTATAT-3', is sufficient to increase the activity of the tRNA(SG)(Ala) promoter to that of the tRNA(C)(Ala) promoter. Moreover, promoters containing the 5'-TTTATAT-3' element are stimulated by increased levels of cellular TATA-binding protein. Together these results indicate that, in insect cells, a TATA-like element is specifically required to form functional TATA-binding protein-containing complexes that promote efficient transcription of tRNA genes.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Phys, Eugene, OR 97403 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Pharmacol, Los Angeles, CA 90033 USA	University of Oregon; University of Oregon; University of Oregon; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Sprague, KU (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.		ouyang, chuying/K-9577-2017	ouyang, chuying/0000-0001-8891-1682	NATIONAL CANCER INSTITUTE [R01CA074138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025388] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA074138, CA74138] Funding Source: Medline; NIGMS NIH HHS [GM25388] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN DD, 1985, CELL, V42, P759, DOI 10.1016/0092-8674(85)90272-7; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; FOURNIER A, 1984, EMBO J, V3, P1547, DOI 10.1002/j.1460-2075.1984.tb02009.x; FRANCIS MA, 1990, MOL CELL BIOL, V10, P4486, DOI 10.1128/MCB.10.9.4486; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; KURJAN J, 1980, CELL, V20, P701, DOI 10.1016/0092-8674(80)90316-5; LOFQUIST AK, 1988, MOL CELL BIOL, V8, P4441, DOI 10.1128/MCB.8.10.4441; MORTON DG, 1984, P NATL ACAD SCI-BIOL, V81, P5519, DOI 10.1073/pnas.81.17.5519; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; PALIDA FA, 1993, NUCLEIC ACIDS RES, V21, P5875, DOI 10.1093/nar/21.25.5875; RAYMOND GJ, 1983, NUCLEIC ACIDS RES, V11, P5969, DOI 10.1093/nar/11.17.5969; SAJJADI FG, 1987, MOL GEN GENET, V206, P279, DOI 10.1007/BF00333585; Sambrook J., 1989, MOL CLONING LAB MANU, P412; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHAACK J, 1984, J BIOL CHEM, V259, P1461; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Sethy-Coraci I, 1998, NUCLEIC ACIDS RES, V26, P2344, DOI 10.1093/nar/26.10.2344; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SHAW KJ, 1984, MOL CELL BIOL, V4, P657, DOI 10.1128/MCB.4.4.657; SPRAGUE KU, 1994, TRANSCRIPTION EUKARY; STRABY KB, 1988, NUCLEIC ACIDS RES, V16, P2841, DOI 10.1093/nar/16.7.2841; TANEJA R, 1992, P NATL ACAD SCI USA, V89, P1070, DOI 10.1073/pnas.89.3.1070; TAPPING RI, 1993, NUCLEIC ACIDS RES, V21, P4476, DOI 10.1093/nar/21.19.4476; Trivedi A, 1996, MOL CELL BIOL, V16, P6909; ULMASOV B, 1995, PLANT CELL, V7, P1723, DOI 10.1105/tpc.7.10.1611; WHITE RJ, 1998, RNA POLYM 3 TRANSCRI; WILSON ET, 1988, MOL CELL BIOL, V8, P624, DOI 10.1128/MCB.8.2.624; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; Young LS, 1996, MOL CELL BIOL, V16, P1256; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	36	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11369	11375		10.1074/jbc.274.16.11369	http://dx.doi.org/10.1074/jbc.274.16.11369			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196229	hybrid			2022-12-25	WOS:000079751900097
J	Colasanti, M; Persichini, T; Cavalieri, E; Fabrizi, C; Mariotto, S; Menegazzi, M; Lauro, GM; Suzuki, H				Colasanti, M; Persichini, T; Cavalieri, E; Fabrizi, C; Mariotto, S; Menegazzi, M; Lauro, GM; Suzuki, H			Rapid inactivation of NOS-I by lipopolysaccharide plus interferon-gamma-induced tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; KINASE INHIBITORS; EXPRESSION; INDUCTION; CELLS; SUPPRESSION	Human astrocytoma T67 cells constitutively express a neuronal NO synthase (NOS-I) and, following administration of lipopolysaccharide (LPS) plus interferon-gamma (IFN gamma), an inducible NOS isoform (NOS-II). Previous results indicated that a treatment of T67 cells with the combination of LPS plus IFN gamma, by affecting NOS-I activity, also inhibited NO production in a very short time. Here, we report that under basal conditions, a NOS-I protein of about 150 kDa was weakly and partially tyrosine-phosphorylated, as verified by immunoprecipitation and Western blotting. Furthermore, LPS plus IFN gamma increased the tyrosine phosphorylation of NOS-I, with a concomitant inhibition of its enzyme activity. The same effect was observed in the presence of vanadate, an inhibitor of phosphotyrosine-specific phosphatases. On the contrary, genistein, an inhibitor of protein-tyrosine kinases, reduced tyrosine phosphorylation of NOS-I, enhancing its enzyme activity. Finally, using reverse transcriptase-polymerase chain reaction, we have observed that a suboptimal induction of NOS-II mRNA expression in T67 cells was enhanced by vanadate (or L-NAME) and inhibited by genistein. Because exogenous NO has been found to suppress NOS-II expression, the decrease of NO production that we have obtained from the inactivation of NOS-I by LPS/IFN gamma-induced tyrosine phosphorylation provides the best conditions for NOS-II expression in human astrocytoma T67 cells.	Univ Verona, Dipartimento Sci Neurol & Vis, Sez Chim Biol, Biol Chem Lab, I-37134 Verona, Italy; Univ Rome, Dept Biol, Roma TRE, I-00146 Rome, Italy	University of Verona	Suzuki, H (corresponding author), Univ Verona, Dipartimento Sci Neurol & Vis, Sez Chim Biol, Biol Chem Lab, Str Le Grazie 8, I-37134 Verona, Italy.		Menegazzi, Marta/AAE-7079-2019; fabrizi, cinzia/G-2379-2012; COLASANTI, MARCO/A-5616-2010; mariotto, sofia/AAH-5473-2019	Menegazzi, Marta/0000-0003-1310-9227; COLASANTI, MARCO/0000-0002-5752-4943; PERSICHINI, TIZIANA/0000-0001-8291-6706				AKARASEREENONT P, 1994, BRIT J PHARMACOL, V113, P1522, DOI 10.1111/j.1476-5381.1994.tb17169.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V246, P453, DOI 10.1006/bbrc.1998.8642; Colasanti M, 1997, J BIOL CHEM, V272, P7582, DOI 10.1074/jbc.272.12.7582; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; Faure V, 1998, AM J PHYSIOL-CELL PH, V275, pC208, DOI 10.1152/ajpcell.1998.275.1.C208; FEINSTEIN DL, 1994, ANN NY ACAD SCI, V738, P325; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; GENG Y, 1995, J CELL PHYSIOL, V163, P545, DOI 10.1002/jcp.1041630315; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; LAURO GM, 1986, ACTA NEUROPATHOL, V69, P278, DOI 10.1007/BF00688305; MARIOTTO S, 1995, BRIT J PHARMACOL, V114, P1105, DOI 10.1111/j.1476-5381.1995.tb13320.x; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Moncada S, 1997, PHARMACOL REV, V49, P137; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; PAUL A, 1995, BRIT J PHARMACOL, V114, P482, DOI 10.1111/j.1476-5381.1995.tb13252.x; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	24	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9915	9917		10.1074/jbc.274.15.9915	http://dx.doi.org/10.1074/jbc.274.15.9915			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187764	hybrid			2022-12-25	WOS:000079663500003
J	Hossain, MZ; Jagdale, AB; Ao, P; Kazlauskas, A; Boynton, AL				Hossain, MZ; Jagdale, AB; Ao, P; Kazlauskas, A; Boynton, AL			Disruption of gap junctional communication by the platelet-derived growth factor is mediated via multiple signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-C-GAMMA; RECEPTOR TYROSINE KINASE; TO-CELL COMMUNICATION; RAT-LIVER CELLS; INTERCELLULAR COMMUNICATION; BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PDGF RECEPTOR; PHORBOL-ESTER	The platelet-derived growth factor (PDGF) mediates its cellular functions via activation of its receptor tyrosine kinase followed by the recruitment and activation of several signaling molecules. These signaling molecules then initiate specific signaling cascades, finally resulting in distinct physiological effects. To delineate the PDGF signaling pathway responsible for the disruption of gap junctional communication (GJC), wild-type PDGF receptor beta (PDGFR beta) and a series of PDGFR beta mutants were expressed in T51B rat liver epithelial cells. In cells expressing wild-type PDGFR beta, PDGF induced disruption of GJC and phosphorylation of a gap junctional protein, connexin-43 (Cx43), which required activation of mitogen-activated protein kinase, although involvement of additional factors was also evident. In the F5 mutant lacking binding sites for phosphatidylinositol 3-kinase, GTPase-activating protein, SHP-2, and phospholipase C gamma 1 (PLC gamma 1), PDGF induced mitogen-activated protein kinase, but failed to affect GJC or Cx43, indicating involvement of additional signals presumably initiated by one or more of the mutated binding sites. Examination of the single-site mutants revealed that PDGF effects were not mediated via a single signaling component. This was confirmed by the "add-back" mutants, which showed that restoration of either SHP-2 or PLC gamma 1 binding was sufficient to propagate the GJC inhibitory actions of PDGF. Further analysis showed that activation of PLC gamma 1 is involved in Cx43 phosphorylation, which surprisingly failed to correlate with GJC blockade. The results of our study demonstrate that PDGF-induced disruption of GJC can be mediated by multiple signaling pathways and requires participation of multiple components.	Northwest Hosp, Seattle, WA 98125 USA; Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Hossain, MZ (corresponding author), Northwest Hosp, 120 Northgate Plaza,Suite 230, Seattle, WA 98125 USA.	mhossain@nwhsea.org			NCI NIH HHS [CA 57064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057064, R55CA057064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BERTHOUD VM, 1993, EUR J CELL BIOL, V62, P384; BOYNTON AL, 1984, CANCER LETT, V21, P293, DOI 10.1016/0304-3835(84)90008-9; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; Calero G, 1998, CIRC RES, V82, P929, DOI 10.1161/01.RES.82.9.929; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; Cruciani VR, 1997, INT J CANCER, V73, P240, DOI 10.1002/(SICI)1097-0215(19971009)73:2<240::AID-IJC14>3.3.CO;2-D; Delmar M, 1998, GAP JUNCTIONS, P8; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fanger GR, 1997, MOL CELL BIOL, V17, P89, DOI 10.1128/MCB.17.1.89; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hossain MZ, 1998, J CELL PHYSIOL, V176, P332, DOI 10.1002/(SICI)1097-4652(199808)176:2<332::AID-JCP11>3.3.CO;2-O; HOSSAIN MZ, 1989, CARCINOGENESIS, V10, P1743, DOI 10.1093/carcin/10.9.1743; Hossain MZ, 1998, J CELL PHYSIOL, V174, P66; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; Jansen LAM, 1996, CARCINOGENESIS, V17, P333, DOI 10.1093/carcin/17.2.333; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KURATA WE, 1994, ONCOGENE, V9, P329; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Loewenstein W R, 1992, Semin Cell Biol, V3, P59; MA YH, 1994, J BIOL CHEM, V269, P30734; MALDONADO PE, 1988, J MEMBRANE BIOL, V106, P203, DOI 10.1007/BF01872158; MATESIC DF, 1994, MOL CARCINOGEN, V10, P226, DOI 10.1002/mc.2940100407; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; MunariSilem Y, 1996, EUR J ENDOCRINOL, V135, P251, DOI 10.1530/eje.0.1350251; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELLETIER DB, 1994, J CELL PHYSIOL, V158, P427, DOI 10.1002/jcp.1041580306; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Proulx A, 1997, DEV GENET, V20, P133, DOI 10.1002/(SICI)1520-6408(1997)20:2<133::AID-DVG6>3.0.CO;2-8; Ridefelt P, 1998, ANTICANCER RES, V18, P1819; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Robinson CJM, 1996, BIOCHEM J, V320, P123, DOI 10.1042/bj3200123; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; ShiokawaSawada M, 1997, J BONE MINER RES, V12, P1165, DOI 10.1359/jbmr.1997.12.8.1165; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Swierenga S H, 1980, Ann N Y Acad Sci, V349, P294; TATRAI A, 1994, BBA-MOL CELL RES, V1224, P575, DOI 10.1016/0167-4889(94)90296-8; TenBroek E, 1998, GAP JUNCTIONS, P215; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; vanDijk MCM, 1997, BIOCHEM J, V325, P303, DOI 10.1042/bj3250303; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Warner A., 1992, Seminars in Cell Biology, V3, P81; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHANG LX, 1991, CARCINOGENESIS, V12, P2109, DOI 10.1093/carcin/12.11.2109	81	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10489	10496		10.1074/jbc.274.15.10489	http://dx.doi.org/10.1074/jbc.274.15.10489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187840	hybrid			2022-12-25	WOS:000079663500079
J	Araujo, FD; Knox, JD; Ramchandani, S; Pelletier, R; Bigey, P; Price, G; Szyf, M; Zannis-Hadjopoulos, M				Araujo, FD; Knox, JD; Ramchandani, S; Pelletier, R; Bigey, P; Price, G; Szyf, M; Zannis-Hadjopoulos, M			Identification of initiation sites for DNA replication in the human dnmt1 (DNA-methyltransferase) locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; C-MYC GENE; AUTONOMOUS REPLICATION; DELETION ANALYSIS; METHYLATED DNA; MONKEY DNA; ORIGIN; SEQUENCE; BINDING; CELLS	Vertebrates have developed multiple mechanisms to coordinate the replication of epigenetic and genetic information. Dnmt1 encodes the maintenance enzyme DNA-methyltransferase, which is responsible for propagating the DNA methylation pattern and the epigenetic information that it encodes during replication. Direct sequence analysis and bisulfite mapping of the 5' region of DNA-methyltransferase 1 (dnmt1) have indicated the presence of many sequence elements associated with previously characterized origins of DNA replication. This study tests the hypothesis that the dnmt1 region containing these elements is an origin of replication in human cells. First, we demonstrate that a vector containing this dnmt1 sequence is able to support autonomous replication when transfected into HeLa cells. Second, using a gel retardation assay, we show that it contains a site for binding of origin-rich sequences binding activity, a recently purified replication protein. Finally, using competitive polymerase chain reaction, we show that replication initiates in this region in vivo, Based on these lines of evidence, we propose that initiation sites for DNA replication are located between the first intron and exon 7 of the human dnmt1 locus.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.			bigey, pascal/0000-0002-6795-8569				Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; FRAPPIER L, 1987, P NATL ACAD SCI USA, V84, P6668, DOI 10.1073/pnas.84.19.6668; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HEINZEL SS, 1991, MOL CELL BIOL, V11, P2263, DOI 10.1128/MCB.11.4.2263; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KIPLING D, 1990, MOL CELL BIOL, V10, P265, DOI 10.1128/MCB.10.1.265; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; LANDRY S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P234, DOI 10.1016/0167-4781(91)90059-U; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; ORRWEAVER TL, 1991, BIOESSAYS, V13, P97, DOI 10.1002/bies.950130302; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; Pelizon C, 1996, MOL CELL BIOL, V16, P5358; Pelletier R, 1997, J CELL BIOCHEM, V66, P87; Ramchandani S, 1998, BIOL CHEM, V379, P535; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; RUIZ MT, 1995, J CELL BIOCHEM, V58, P221, DOI 10.1002/jcb.240580211; STILLMAN B, 1994, J BIOL CHEM, V269, P7047; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5636, DOI 10.1128/MCB.14.9.5636; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; Yisraeli J., 1984, DNA METHYLATION BIOC; Zannis-Hadjopoulos M, 1998, CRIT REV EUKAR GENE, V8, P81, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.40; ZANNISHADJOPOULOS M, 1994, GENE, V151, P273, DOI 10.1016/0378-1119(94)90670-X; ZANNISHADJOPOULOS M, 1981, CELL, V27, P155, DOI 10.1016/0092-8674(81)90369-X	41	37	37	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9335	9341		10.1074/jbc.274.14.9335	http://dx.doi.org/10.1074/jbc.274.14.9335			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092611	hybrid			2022-12-25	WOS:000079451800030
J	Forster, C; Santos, MA; Ruffert, S; Kramer, R; Revuelta, JL				Forster, C; Santos, MA; Ruffert, S; Kramer, R; Revuelta, JL			Physiological consequence of disruption of the VMA1 gene in the riboflavin overproducer Ashbya gossypii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; CATALYTIC SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MUTATIONAL ANALYSIS; SECRETORY PATHWAY; ENZYME COMPLEX; AMINO-ACIDS	The vacuolar ATPase subunit A structural gene VMA1 of the biotechnologically important riboflavin overproducer Ashbya gossypii was cloned and disrupted to prevent riboflavin retention in the vacuolar compartment and to redirect the riboflavin flux into the medium, Cloning was achieved by polymerase chain reaction using oligonucleotide primers derived form conserved sequences of the Vma1 proteins from yeast and filamentous fungi, The deduced polypeptide comprises 617 amino acids with a calculated molecular mass of 67.8 kDa. The deduced amino acid sequence is highly similar to that of the catalytic subunits of Saccharomyces cerevisiae (67 kDa), Candida tropicalis (67 kDa), and Neurospora crassa (67 kDa) with 89, 87, and 60% identity, respectively, and shows about 25% identity to the beta-subunit of the FoF1-ATPase of S. cerevisiae and Schizosaccharomyces pombe. In contrast to S. cerevisiae, however, where disruption of the VMA1 gene was conditionally lethal, and to N. crassa, where viable disruptants could not be isolated, disruption of the VMA1 gene in A. gossypii did not cause a lethal phenotype, Disruption of the AgVMA1 gene led to complete excretion of riboflavin into the medium instead of retention in the vacuolar compartment, as observed in the wild type.	Univ Cologne, Inst Biochem, D-0674 Cologne, Germany; Univ Salamanca, Dept Microbiol & Genet, Salamanca 37007, Spain	University of Cologne; University of Salamanca	Kramer, R (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-0674 Cologne, Germany.		Santos, Maria Angeles/H-2239-2015; Revuelta, Jose Luis/ABG-1502-2020; Revuelta, Jose L/C-2324-2012	Santos, Maria Angeles/0000-0002-1257-7611; Revuelta, Jose Luis/0000-0001-7838-5308; Revuelta, Jose L/0000-0001-7838-5308				Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1982, J BACTERIOL, V151, P1326, DOI 10.1128/JB.151.3.1326-1337.1982; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CARNICERO E, 1996, THESIS U SALAMANCA S; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; CONONICO PG, 1969, J CELL BIOL, V43, P367; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Ferea TL, 1996, GENETICS, V143, P147; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forster C, 1998, FEMS MICROBIOL LETT, V167, P209; GHISLAIN M, 1992, YEAST, V8, P791, DOI 10.1002/yea.320080913; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; GU HH, 1993, J BIOL CHEM, V268, P7372; GUILLIERMOND P, 1928, REV GEN BOT, V40, P328; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MESSENGUY F, 1980, EUR J BIOCHEM, V108, P439, DOI 10.1111/j.1432-1033.1980.tb04740.x; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; OHYA Y, 1991, J BIOL CHEM, V266, P13971; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; Roos W, 1997, J BIOL CHEM, V272, P15849, DOI 10.1074/jbc.272.25.15849; RUSSO P, 1995, YEAST, V11, P447, DOI 10.1002/yea.320110507; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmidt G, 1996, MICROBIOL-SGM, V142, P419, DOI 10.1099/13500872-142-2-419; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STEINER S, 1995, GENETICS, V140, P973; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; WEISS RL, 1976, J BACTERIOL, V126, P1173, DOI 10.1128/JB.126.3.1173-1179.1976	59	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9442	9448		10.1074/jbc.274.14.9442	http://dx.doi.org/10.1074/jbc.274.14.9442			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092625	hybrid			2022-12-25	WOS:000079451800044
J	Horton, ND; Biswal, SS; Corrigan, LL; Bratta, J; Kehrer, JP				Horton, ND; Biswal, SS; Corrigan, LL; Bratta, J; Kehrer, JP			Acrolein causes inhibitor kappa B-independent decreases in nuclear factor kappa B activation in human lung adenocarcinoma (A549) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; INTRACELLULAR GLUTATHIONE; DNA; TRANSCRIPTION; TOXICITY; BINDING; THIOLS; GROWTH; P50; CYCLOPHOSPHAMIDE	Acrolein is a highly electrophilic alpha,beta-unsaturated aldehyde to which humans are exposed in various situations. In the present study, the effects of sublethal doses of acrolein on nuclear factor kappa B (NF-kappa B) activation in A549 human lung adenocarcinoma cells were investigated. Immediately following a 30-min exposure to 45 fmol of acrolein/cell, glutathione (GSH) and DNA synthesis and NF-kappa B binding mere reduced by more than 80%. All parameters returned to normal or supranormal levels by 8 h post-treatment. Pretreatment with acrolein completely blocked 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced activation of NF-kappa B. Cells treated for 1 h with 1 mM diethyl maleate (DEM) showed a 34 and 53% decrease in GSH and DNA synthesis, respectively, DEM also reduced NF-kappa B activation by 64% at 2 h post-treatment, with recovery to within 22% of control at 8 h, Both acrolein and DEM decreased NF-kappa B function similar to 50% at 2 h after treatment with TPA, as shown by a secreted alkaline phosphatase reporter assay. GSH: returned to control levels by 8 h after DEM treatment, but proliferation remained significantly depressed for 24 h, Interestingly, DEM caused a profound decrease in NF-kappa B binding, even at doses as low as 0.125 mM that had little effect on GSH. Neither acrolein nor DEM had any effect on the levels of phosphorylated or nonphosphorylated inhibitor kappa B-alpha: (I kappa B-alpha), Furthermore, acrolein decreased NF-kappa B activation in cells depleted of I kappa B-alpha by TPA stimulation in the presence of cycloheximide:, demonstrating that the decrease in NF-kappa B activation was not the result of increased binding by the inhibitory protein. This conclusion was further supported by the finding that acrolein modified NF-kappa B in the cytosol prior to chemical dissociation from I kappa B with detergent, Together, these data support the conclusion that the inhibition of NF-kappa B activation by acrolein and DEM is I kappa B-independent. The mechanism appears to be related to direct modification of thiol groups in the NF-kappa B subunits.	Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Kehrer, JP (corresponding author), Univ Texas, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78712 USA.	kehrerjim@mail.utexas.edu			NHLBI NIH HHS [HL48035] Funding Source: Medline; NIEHS NIH HHS [1 F32 ES05825, ES07784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784, F32ES005825] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ATZORI L, 1994, EXP CELL RES, V211, P115, DOI 10.1006/excr.1994.1066; Ausbel FM, 1994, CURRENT PROTOCOLS MO; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BOWES RC, 1995, ARCH BIOCHEM BIOPHYS, V323, P243, DOI 10.1006/abbi.1995.9968; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; COOPER KO, 1992, FUND APPL TOXICOL, V19, P343, DOI 10.1016/0272-0590(92)90172-E; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; FRANCELEYNE M, 1982, TOXICOL LETT, V14, P143; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GinnPease ME, 1996, BIOCHEM BIOPH RES CO, V226, P695, DOI 10.1006/bbrc.1996.1416; GRAFSTROM RC, 1990, MUTAT RES, V238, P175, DOI 10.1016/0165-1110(90)90009-Z; GRAFSTROM RC, 1988, CANCER RES, V48, P1717; GRILLI M, 1993, INT REV CYTOL, V143, P1; KANG YJ, 1990, EXP CELL RES, V187, P177, DOI 10.1016/0014-4827(90)90134-V; KARSTEN U, 1977, ANAL BIOCHEM, V77, P464, DOI 10.1016/0003-2697(77)90259-7; KROKAN H, 1985, CARCINOGENESIS, V6, P1755, DOI 10.1093/carcin/6.12.1755; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARANO F, 1976, EXPERIENTIA, V32, P501, DOI 10.1007/BF01920821; MARINELLI ER, 1990, CHEM RES TOXICOL, V3, P49, DOI 10.1021/tx00013a009; MIHM S, 1995, FASEB J, V9, P246, DOI 10.1096/fasebj.9.2.7781927; MOULE Y, 1971, FEBS LETT, V16, P216, DOI 10.1016/0014-5793(71)80137-0; Nath RG, 1996, CANCER RES, V56, P452; NEUSCHWANDERTETRI BA, 1989, ANAL BIOCHEM, V179, P236, DOI 10.1016/0003-2697(89)90121-8; Norton ND, 1997, TOXICOLOGY, V122, P111, DOI 10.1016/S0300-483X(97)00086-3; OHNO Y, 1985, ARCH TOXICOL, V57, P99, DOI 10.1007/BF00343118; PATEL JM, 1993, TOXICOL APPL PHARM, V122, P46, DOI 10.1006/taap.1993.1170; PERRY CS, 1995, TOXICOL IN VITRO, V9, P21, DOI 10.1016/0887-2333(94)00187-Y; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Ramu K, 1996, TOXICOL APPL PHARM, V140, P487, DOI 10.1006/taap.1996.0245; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SLADEK NE, 1988, PHARMACOL THERAPEUT, V37, P301, DOI 10.1016/0163-7258(88)90004-6; SMITH RA, 1990, CANCER RES, V50, P3005; Snapper CM, 1996, J IMMUNOL, V156, P183; SONNENSHEIN GE, 1997, SEMIN CANCER BIOL, V8, P113; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; WU HY, 1994, J BIOL CHEM, V269, P20067	51	82	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9200	9206		10.1074/jbc.274.14.9200	http://dx.doi.org/10.1074/jbc.274.14.9200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092592	hybrid			2022-12-25	WOS:000079451800011
J	Liochev, SI; Benov, L; Touati, D; Fridovich, I				Liochev, SI; Benov, L; Touati, D; Fridovich, I			Induction of the soxRS regulon of Escherichia coli by superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS REGULON; IN-VIVO; DISMUTASE; GENE; TRANSCRIPTION; FORM	The soxRS regulon orchestrates a multifaceted defense against oxidative stress, by inducing the transcription of similar to 15 genes. The induction of this regulon by redox agents, known to mediate O radical anion production, led to the view that O2 radical anion is one signal to which it responds. However, redox cycling agents deplete cellular reductants while producing O2 radical anion, and one may question whether the regulon responds to the depletion of some cytoplasmic reductant or to O2 radical anion, or both. We demonstrate that raising [O2 radical anion] by mutational deletion of superoxide dismutases and/or by addition of paraquat, both under aerobic conditions, causes induction of a member of the soxRS regulon and that a mutational defect in soxRS eliminates that induction. This establishes that O2 radical anion, directly or indirectly, can cause induction of this defensive regulon.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Paris 06, Dept Microbiol, Inst Jacques Monod, CNRS, F-75252 Paris 05, France; Univ Paris 07, Dept Microbiol, Inst Jacques Monod, CNRS, F-75252 Paris 05, France	Duke University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Fridovich, I (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146				AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; FARRINGTON JA, 1973, BIOCHIM BIOPHYS ACTA, V314, P372, DOI 10.1016/0005-2728(73)90121-7; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, J BIOL CHEM, V268, P12958; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; Liochev SI, 1997, P NATL ACAD SCI USA, V94, P2891, DOI 10.1073/pnas.94.7.2891; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; PRIVALLE CT, 1989, J BIOL CHEM, V264, P2758; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992	25	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9479	9481		10.1074/jbc.274.14.9479	http://dx.doi.org/10.1074/jbc.274.14.9479			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092630	hybrid			2022-12-25	WOS:000079451800049
J	Tornquist, K; Malm, AM; Pasternack, M; Kronqvist, R; Bjorklund, S; Tuominen, R; Slotte, JP				Tornquist, K; Malm, AM; Pasternack, M; Kronqvist, R; Bjorklund, S; Tuominen, R; Slotte, JP			Tumor necrosis factor-alpha, sphingomyelinase, and ceramide inhibit store-operated calcium entry in thyroid FRTL-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR-KAPPA-B; IODIDE EFFLUX; FACTOR-BETA; EPITHELIAL-CELLS; INTERFERON-GAMMA; HL-60 CELLS; CA2+ ENTRY; THYROTROPIN; SPHINGOSINE	Tumor necrosis factor alpha (TNF-alpha) is a potent inhibitor of proliferation in several cell types, including thyroid FRTL-5 cells. As intracellular free calcium ([Ca2+](i)) is a major signal in activating proliferation, we investigated the effect of TNF-alpha on calcium fluxes in FRTL-5 cells, TNF-alpha per se did not modulate resting [Ca2+](i). However, preincubation (10 min) of the cells with 1-100 ng/ml TNF-alpha decreased the thapsigargin (Tg)-evoked store-operated calcium entry in a concentration-dependent manner. TNF-alpha did not inhibit the mobilization of sequestered calcium, To investigate whether the effect of TNF-alpha on calcium entry was mediated via the sphingomyelinase pathway, the cells were pretreated with sphingomyelinase (SMase) prior to stimulation with Tg. SMase inhibited the Tg-evoked calcium entry in a concentration-dependent manner. Furthermore, an inhibition of calcium entry was obtained after preincubation of the cells with the membrane-permeable C-2-ceramide and C-6-ceramide analogues, The inactive ceramides dihydro-C-2 and dihydro-C-6 showed only marginal effects, Neither SMase, C-2-ceramide, nor C-6-ceramide affected the release of sequestered calcium. C-2- and C-6-ceramide also decreased the ATP-evoked calcium entry, without affecting the release of sequestered calcium. The effect of TNF-alpha and SMase was inhibited by the kinase inhibitor staurosporin and by the protein kinase C (PKC) inhibitor calphostin C but not by down-regulation of PKC. However, Ive were unable to measure a significant activation of PKC using TNF-alpha or C-6-ceramide, The effect of TNF-alpha was not mediated via activation of either c-Sun N-terminal kinase or p38 kinase, We were unable to detect an increase in the ceramide (or sphingosine) content of the cells after stimulation with TNF-alpha for up to 30 min, Thus, one mechanism of action of TNF-alpha; SMase, and ceramide on thyroid FRTL-5 cells is to inhibit calcium entry.	Abo Akad Univ, Dept Biol, Turku 20520, Finland; Abo Akad Univ, Dept Biochem & Pharm, Turku 20520, Finland; Univ Helsinki, Dept Pharmacol & Toxicol, Inst Biomed, Helsinki 00250, Finland; Univ Helsinki, Dept Biosci, Div Anim Physiol, Helsinki 00250, Finland; Univ Helsinki, Inst Biotechnol, Helsinki 00250, Finland; Minerva Fdn, Inst Med Res, SF-00250 Helsinki, Finland	Abo Akademi University; Abo Akademi University; University of Helsinki; University of Helsinki; University of Helsinki	Tornquist, K (corresponding author), Abo Akad Univ, Dept Biol, BioCity,Artillerigatan 6, Turku 20520, Finland.	kid.tornqvist@abo.fi						AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; CHAKRAVARTHY BR, 1991, ANAL BIOCHEM, V196, P144, DOI 10.1016/0003-2697(91)90130-L; CHEN GE, 1992, ENDOCRINOLOGY, V131, P863, DOI 10.1210/en.131.2.863; CORDA D, 1985, J BIOL CHEM, V260, P9230; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Haverstick DM, 1997, J BIOL CHEM, V272, P15426, DOI 10.1074/jbc.272.24.15426; Hida H, 1998, J NEUROSCI, V18, P8712; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; Kimura T, 1997, AM J PHYSIOL-ENDOC M, V273, pE638, DOI 10.1152/ajpendo.1997.273.3.E638; KWAN CY, 1990, J BIOL CHEM, V265, P678; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARCOCCI C, 1987, ENDOCRINOLOGY, V120, P1127, DOI 10.1210/endo-120-3-1127; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; Mori K, 1996, ENDOCRINOLOGY, V137, P4994, DOI 10.1210/en.137.11.4994; Okajima F, 1997, ENDOCRINOLOGY, V138, P220, DOI 10.1210/en.138.1.220; ONGPHIPHADHANAKUL B, 1994, EUR J ENDOCRINOL, V130, P502, DOI 10.1530/eje.0.1300502; Orlati S, 1996, CELL CALCIUM, V20, P399, DOI 10.1016/S0143-4160(96)90002-0; OZAWA M, 1988, ENDOCRINOLOGY, V123, P1461, DOI 10.1210/endo-123-3-1461; PANG XP, 1993, THYROID, V3, P325, DOI 10.1089/thy.1993.3.325; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PANG XP, 1992, J BIOL CHEM, V267, P12826; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PATWARDHAN NA, 1991, SURGERY, V110, P972; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RASMUSSEN AK, 1994, J ENDOCRINOL, V143, P359, DOI 10.1677/joe.0.1430359; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAMBASIVARAO K, 1963, J LIPID RES, V4, P106; SATO K, 1990, J CLIN ENDOCR METAB, V70, P1735, DOI 10.1210/jcem-70-6-1735; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; TAKADA K, 1990, J CLIN INVEST, V86, P1548, DOI 10.1172/JCI114874; TAM VK, 1988, AM J PHYSIOL, V274, pC1686; TAN KT, 1995, ENDOCRINOLOGY, V136, P881; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TORNQUIST K, 1993, BIOCHEM J, V290, P443; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; Tornquist K, 1997, ENDOCRINOLOGY, V138, P4049, DOI 10.1210/en.138.10.4049; Tornquist K, 1996, J CELL PHYSIOL, V166, P241; TORNQUIST K, 1992, J CELL PHYSIOL, V150, P90, DOI 10.1002/jcp.1041500113; TUOMINEN RK, 1992, J NEUROCHEM, V58, P1652, DOI 10.1111/j.1471-4159.1992.tb10037.x; VALENTE WA, 1983, ENDOCRINOLOGY, V112, P71, DOI 10.1210/endo-112-1-71; VANDERPOLL T, 1990, J CLIN ENDOCR METAB, V71, P1567; WANG XD, 1995, THYROID, V5, P137, DOI 10.1089/thy.1995.5.137; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; XU YP, 1995, J BIOL CHEM, V270, P23887, DOI 10.1074/jbc.270.41.23887; YANAGA F, 1992, FEBS LETT, V314, P297, DOI 10.1016/0014-5793(92)81493-6; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZAKARIJA M, 1989, ENDOCRINOLOGY, V125, P1260, DOI 10.1210/endo-125-3-1260; ZHENG RQH, 1992, IMMUNOLOGY, V75, P456	62	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9370	9377		10.1074/jbc.274.14.9370	http://dx.doi.org/10.1074/jbc.274.14.9370			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092616	hybrid			2022-12-25	WOS:000079451800035
J	Yamauchi, K; Nakajima, J; Hayashi, H; Horiuchi, R; Tata, JR				Yamauchi, K; Nakajima, J; Hayashi, H; Horiuchi, R; Tata, JR			Xenopus cytosolic thyroid hormone-binding protein (xCTBP) is aldehyde dehydrogenase catalyzing the formation of retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RAT-LIVER; 3,5,3'-TRIIODO-L-THYRONINE-BINDING PROTEIN; RECEPTOR SUPERFAMILY; MESSENGER-RNAS; CLONING; PURIFICATION; EXPRESSION; RETINALDEHYDE; OXIDATION	Amino acid sequencing of an internal peptide fragment derived from purified Xenopus cytosolic thyroid hormone-binding protein (xCTBP) demonstrates high similarity to the corresponding sequence of mammalian aldehyde dehydrogenase 1 (ALDH1) (Yamauchi, K., and Tata, J. R. (1994) fur. J. Biochem. 225, 1105-1112). Here we show that xCTBP was co-purified with ALDH and 3,3',5-triiodo-L-thyronine (T-3) binding activities. By photoaffinity labeling with [I-125]T-3, a T-3-binding site in the xCTBP was estimated to reside in amino acid residues 93-114, which is distinct from the active site of the enzyme but present in the NAD(+) binding domain. The amino acid sequences deduced from the two isolated xALDH1 cDNAs (xALDH1-I and xALDH1-II) were 94.6% identical to each other and very similar to those of mammalian ALDH1 enzymes. The two recombinant xALDH1 proteins exhibit both T-3 binding activity and ALDH activity converting retinal to retinoic acid (BA), which are similar to those of xCTBP. The mRNAs were present abundantly in kidney and intestine of adult female Xenopus. Interestingly, their T-3 binding activities were inhibited by NAD(+) and NADH but not by NADP(+) and NADPH, whereas NAD(+) was required for their ALDH activities. Our results demonstrate that xCTBP is identical to ALDH1 and suggest that this protein might modulate RA synthesis and intracellular level of free T-3.	Shizuoka Univ, Fac Sci, Dept Biol, Shizuoka 4228529, Japan; Gunma Univ, Sch Med, Dept Pharm, Maebashi, Gumma 3718511, Japan; Natl Inst Med Res, Lab Dev Biochem, London NW7 1AA, England	Shizuoka University; Gunma University; MRC National Institute for Medical Research	Yamauchi, K (corresponding author), Shizuoka Univ, Fac Sci, Dept Biol, 836 Ohya, Shizuoka 4228529, Japan.	sbkyama@ipc.shizuoka.ac.jp						ABRIOLA DP, 1987, BIOCHEMISTRY-US, V26, P5679, DOI 10.1021/bi00392a015; AMBROZIAK W, 1991, J BIOL CHEM, V266, P13011; ASHIZAWA K, 1992, P NATL ACAD SCI USA, V89, P9277, DOI 10.1073/pnas.89.19.9277; BARTH LG, 1959, J EMBRYOL EXP MORPH, V7, P210; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P2298; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Bhat PV, 1996, BIOCHEM CELL BIOL, V74, P695, DOI 10.1139/o96-076; BRADFORD M, 1976, ANAL BIOCHEM, V72, P112; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; CHATTERJEE VKK, 1997, MOL ENDOCRINOLOGY GE, P73; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; ELDER TD, 1962, BIOCHIM BIOPHYS ACTA, V64, P430, DOI 10.1016/0006-3002(62)90300-1; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gorbman A., 1962, TXB COMP ENDOCRINOLO; Graham C, 1996, J BIOL CHEM, V271, P15623, DOI 10.1074/jbc.271.26.15623; HASHIZUME K, 1989, J BIOL CHEM, V264, P4857; HEMPEL J, 1982, BIOCHEMISTRY-US, V21, P6834, DOI 10.1021/bi00269a032; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; Hennemann, 1996, THYROID ITS DIS; HSU LC, 1985, P NATL ACAD SCI USA, V82, P3771, DOI 10.1073/pnas.82.11.3771; IWASE K, 1995, BBA-GENE STRUCT EXPR, V1260, P139, DOI 10.1016/0167-4781(94)00183-4; KATO H, 1989, P NATL ACAD SCI USA, V86, P7861, DOI 10.1073/pnas.86.20.7861; KOBAYASHI M, 1991, ENDOCRINOLOGY, V129, P1701, DOI 10.1210/endo-129-4-1701; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LENNON AM, 1992, EUR J BIOCHEM, V210, P79, DOI 10.1111/j.1432-1033.1992.tb17393.x; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; MUKERJEE N, 1992, ARCH BIOCHEM BIOPHYS, V299, P23, DOI 10.1016/0003-9861(92)90239-S; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1993, RETINOIDS PROGR RES, P29; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; PEREIRA F, 1991, BIOCHEM BIOPH RES CO, V175, P831, DOI 10.1016/0006-291X(91)91640-X; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pitt-Rivers R., 1959, THYROID HORMONES; POSCH KC, 1992, J BIOL CHEM, V267, P19676; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shambaugh G. E., 1986, WERNERS THYROID FUND, P201; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Vie MP, 1997, MOL ENDOCRINOL, V11, P1728, DOI 10.1210/me.11.11.1728; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5; Yamauchi K, 1997, COMP BIOCHEM PHYS C, V118, P27, DOI 10.1016/S0742-8413(97)00077-7; YAMAUCHI K, 1994, EUR J BIOCHEM, V225, P1105, DOI 10.1111/j.1432-1033.1994.1105b.x; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; YOSHIDA A, 1984, P NATL ACAD SCI-BIOL, V81, P258, DOI 10.1073/pnas.81.1.258; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; YOSHIZATO K, 1975, J BIOL CHEM, V250, P8337; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; Zhou JZ, 1997, EUR J BIOCHEM, V245, P123, DOI 10.1111/j.1432-1033.1997.00123.x	62	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8460	8469		10.1074/jbc.274.13.8460	http://dx.doi.org/10.1074/jbc.274.13.8460			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085078	hybrid			2022-12-25	WOS:000079451600020
J	Kon, A; Vindevoghel, L; Kouba, DJ; Fujimura, Y; Uitto, J; Mauviel, A				Kon, A; Vindevoghel, L; Kouba, DJ; Fujimura, Y; Uitto, J; Mauviel, A			Cooperation between SMAD and NF-kappa B in growth factor regulated type VII collagen gene expression	ONCOGENE			English	Article						SMAD; NF-kappa B; TGF-beta; TNF-alpha; transcription; promoter	HUMAN DERMAL FIBROBLASTS; NECROSIS-FACTOR-ALPHA; FACTOR-BETA; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; DNA-BINDING; C-REL; PROTEINS; KERATINOCYTES; ACTIVATION	We have previously demonstrated that transforming growth factor-beta (TGF-beta) and pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interteukin-1 beta, synergistically enhance the expression of type VII collagen gene (COL7A1) in human dermal fibroblasts in culture (Mauviel rt nl., 1994), Recently, we identified a SMAD-containing complex, rapidly induced by TGF-beta and binding the region [-496/-444] of the COL7A1 promoter, responsible for COL7A1 gene transactivation (Vindevoghel rt al., 1998a), In this report, we demonstrate that TGF-beta and TNF-alpha response elements are distinct entities within the COL7A1 promoter. In particular, we demonstrate that the TNF-alpha effect is mediated by NF-kappa B1/RelA (p50/p65) and RelA/RelA (p65/p65) NF-kappa B complexes binding the TNF-alpha response element (TaRE) located in the region [-252/-230], with RelA acting as the transcriptional activator, Finally, we provide definitive evidence for the role of both TGF-beta and TNF-alpha response elements as enhancer sequences, functioning in the contest of a heterologous promoter in an additive manner in response to TGF-beta and TNF-alpha, This study provides the first identification of a functional interaction between the two immediate-early transcription factors, SMAD and NF-kappa B, to activate the expression of an extracellular matrix-related gene, COL7Al.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Allegheny Univ Hlth Sci, Dept Human Genet, Philadelphia, PA 19102 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Drexel University	Mauviel, A (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.		MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [R29-AR43751, R01-AR41439, T32-AR07651] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439, R29AR043751] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1996, J BIOL CHEM, V271, P29672, DOI 10.1074/jbc.271.47.29672; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; Chen Y.Q., 1994, J GERIATR DERMATOL, V2, P163; CHEN YQ, 1994, J INVEST DERMATOL, V102, P205, DOI 10.1111/1523-1747.ep12371763; CHRISTIANO AM, 1996, CURR OPIN DERMATOL, V3, P225; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; IWASAKI T, 1993, BIOCHEM BIOPH RES CO, V193, P604, DOI 10.1006/bbrc.1993.1667; Kouba DJ, 1997, J INVEST DERMATOL, V108, P292; LANOIX J, 1994, ONCOGENE, V9, P841; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, WOUNDS, V5, P137; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sambrook J., 2002, MOL CLONING LAB MANU; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; Trebilcock GU, 1996, GERONTOLOGY, V42, P137, DOI 10.1159/000213785; UITTO J, 1998, PRINCIPLES MOL MED, P729; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; VINDEVOGHEL L, 1998, IN PRESS P NATL ACAD; WOODLEY DT, 1990, JAMA-J AM MED ASSOC, V263, P3057, DOI 10.1001/jama.263.22.3057	33	54	55	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1837	1844		10.1038/sj.onc.1202495	http://dx.doi.org/10.1038/sj.onc.1202495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086338				2022-12-25	WOS:000079090000007
J	Sakisaka, T; Nakanishi, H; Takahashi, K; Mandai, K; Miyahara, M; Satoh, A; Takaishi, K; Takai, Y				Sakisaka, T; Nakanishi, H; Takahashi, K; Mandai, K; Miyahara, M; Satoh, A; Takaishi, K; Takai, Y			Different behavior of l-afadin and Neurabin-II during the formation and destruction of cell-cell adherens junction	ONCOGENE			English	Article						1-afadin; Neurabin-II; ZO-1; E-cadherin; cell-cell adherens junction	FILAMENT-BINDING PROTEIN; EPITHELIAL-CELLS; TIGHT JUNCTIONS; CYTOPLASMIC DOMAIN; ADHESION COMPLEX; CDNA CLONING; E-CADHERIN; ACTIN; CATENIN; ZO-1	We have recently isolated two novel actin filament-binding proteins, l-afadin and neurabin-II and shown that they are localized at cell-cell adherens junction (AJ) in epithelial cells. We found here that l-afadin, neurabin-II, ZO-1, and E-cadherin showed similar and different behavior during the formation and destruction of cell-cell AJ in MDCK cells. In MDCK cells, the accumulation of both l-afadin and E-cadherin, but not that of ZO-1, changed in parallel depending on Rac small G protein activity. Dissociation of MDCK cells by culturing the cells at 2 mu M Ca2+ caused rapid endocytosis of E-cadherin, but not that of l-afadin or ZO-1, Addition of phorbol 12-myristate 13-acetate to these dissociated cells formed a tight junction-like structure where ZO-1 and l-afadin, but not neurabin-II or E-cadherin, accumulated. We furthermore found that, in nonepithelial EL cells, which expressed E-cadherin and attached to each other, l-afadin, neurabin-II, ZO-1 and E-cadherin were all localized at AJ. In cadherin-deficient L cells, l-afadin was mainly localized at cell-cell contact sites, but ZO-1 was mainly localized at the tip area of cell processes. Neurabin-II did not accumulate at the plasma membrane area. Neither l-afadin nor neurabin-II significantly interacted with alpha-, beta-catenin, E-cadherin, ZO-1 or occludin.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Takai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 1993, CURR OPIN CELL BIOL, V5, P653, DOI 10.1016/0955-0674(93)90136-E; CIMINO G, 1991, CANCER RES, V51, P6712; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PRASAD R, 1993, CANCER RES, V53, P5624; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	36	77	77	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1609	1617		10.1038/sj.onc.1202451	http://dx.doi.org/10.1038/sj.onc.1202451			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102631				2022-12-25	WOS:000078770700011
J	Edwards, DC; Gill, GN				Edwards, DC; Gill, GN			Structural features of LIM kinase that control effects on the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FILAMENT-BINDING PROTEIN; DEPOLYMERIZING FACTOR; DOMAIN PROTEINS; ZINC-FINGER; C-SRC; COFILIN; PHOSPHORYLATION; IDENTIFICATION; SEQUENCE	LIM kinase phosphorylates and inactivates the actin binding/depolymerizing factor cofilin and induces actin cytoskeletal changes. Several unique structural features within LIM kinase were investigated for their roles in regulation of LIM kinase activity. Disruption of the second LIM domain or the PDZ domain or deletion of the entire amino terminus increased activity in vivo measured as increasing aggregation of the actin cytoskeleton. A kinase deleted alternate splice product was identified and characterized. This alternate splice product and a kinase inactive mutant inhibited LIM kinase in vivo, indicating that the amino terminus suppresses activity of the kinase domain. Mutation of threonine 508 in the activation loop to valine abolished activity whereas replacement with 2 glutamic acid residues resulted in a fully active enzyme. Dephosphorylation of LIM kinase inhibited cofilin phosphorylation. Mutation of the basic insert in the activation loop inhibited activity in vivo, but not in vitro. These results indicate phosphorylation is an essential regulatory feature of LIM kinase and indicate that threonine 508 and the adjacent basic insert sequences of the activation loop are required for this process. A combination of structural features are thus involved in receiving upstream signals that regulate LIM kinase-induced actin cytoskeletal reorganization.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Gill, GN (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 9500 Gilman Dr 0650, La Jolla, CA 92093 USA.	ggill@ucsd.edu			NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013149, R01DK013149] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS ME, 1990, BIOCHEMISTRY-US, V29, P7414, DOI 10.1021/bi00484a009; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; Herberg FW, 1997, PROTEIN SCI, V6, P569; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1990, J IMMUNOL, V145, P1782; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Ikebe C, 1998, BIOCHEM BIOPH RES CO, V246, P307, DOI 10.1006/bbrc.1998.8609; Jiang Y, 1997, J BIOL CHEM, V272, P11096; Johnson LN, 1996, CURR OPIN STRUC BIOL, V6, P762, DOI 10.1016/S0959-440X(96)80005-4; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; KAGEN A, 1979, METHOD HORM RADIOIMM, P328; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; LIU XQ, 1993, ONCOGENE, V8, P1119; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MIZUNO K, 1994, ONCOGENE, V9, P1605; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ORR JW, 1994, J BIOL CHEM, V269, P27715; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; PROSCHEL C, 1995, ONCOGENE, V11, P1271; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Theriot JA, 1997, J CELL BIOL, V136, P1165, DOI 10.1083/jcb.136.6.1165; TURNER CE, 1994, J CELL SCI, V107, P1583; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	62	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11352	11361		10.1074/jbc.274.16.11352	http://dx.doi.org/10.1074/jbc.274.16.11352			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196227	hybrid			2022-12-25	WOS:000079751900095
J	Kirby, JR; Saulmon, MM; Kristich, CJ; Ordal, GW				Kirby, JR; Saulmon, MM; Kristich, CJ; Ordal, GW			CheY-dependent methylation of the asparagine receptor, McpB, during chemotaxis in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; SIGNAL-TRANSDUCTION; ESCHERICHIA-COLI; PROTEIN-PHOSPHORYLATION; FLAGELLAR SWITCH; SALMONELLA-TYPHIMURIUM; PROMOTES ADAPTATION; GROUP TURNOVER; GENES; METHYLESTERASE	For the Gram-positive organism Bacillus subtilis, chemotaxis to the attractant asparagine is mediated by the chemoreceptor McpB. In this study, we show that rapid net demethylation of B. subtilis McpB results in the immediate production of methanol, presumably due to the action of CheB. We also show that net demethylation of McpB occurs upon both addition and removal of asparagine. After each demethylation event, McpB is remethylated to nearly prestimulus levels. Both remethylation events are attributable to CheR using S-adenosylmethionine as a substrate. Therefore, no methyl transfer to an intermediate carrier need be postulated to occur during chemotaxis in B. subtilis as was previously suggested. Furthermore, we show that the remethylation of asparagine-bound McpB requires the response regulator, CheY-P, suggesting that CheY-P acts in a feedback mechanism to facilitate adaptation to positive stimuli during chemotaxis in B. subtilis, This hypothesis is supported by two observations: a cheRBCD mutant is capable of transient excitation and subsequent oscillations that bring the flagellar rotational bias below the prestimulus value in the tethered cell assay, and the cheRBCD mutant is capable of swarming in a Tryptone swarm plate.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Liberal Arts & Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GW (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 190 Med Sci Bldg,506 S Mathews, Urbana, IL 61801 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054365, R56GM054365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20336] Funding Source: Medline; NIGMS NIH HHS [GM54365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLGREN JA, 1983, BIOCHEM J, V213, P759, DOI 10.1042/bj2130759; Appleby JL, 1996, CELL, V86, P845, DOI 10.1016/S0092-8674(00)80158-0; BEDALE WA, 1988, J BACTERIOL, V170, P223, DOI 10.1128/jb.170.1.223-227.1988; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BISCHOFF DS, 1993, BIOCHEMISTRY-US, V32, P9256, DOI 10.1021/bi00086a035; BISCHOFF DS, 1991, J BIOL CHEM, V266, P12301; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; BLOCK SM, 1983, J BACTERIOL, V154, P312, DOI 10.1128/JB.154.1.312-323.1983; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; Bren A, 1996, P NATL ACAD SCI USA, V93, P10090, DOI 10.1073/pnas.93.19.10090; BURGESSCASSLER A, 1982, J BIOL CHEM, V257, P8412; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; FERRARI E, 1981, J BACTERIOL, V146, P430, DOI 10.1128/JB.146.1.430-432.1981; FREDRICK KL, 1994, J BACTERIOL, V176, P2727, DOI 10.1128/JB.176.9.2727-2735.1994; FUHRER DK, 1991, J BACTERIOL, V173, P7443, DOI 10.1128/jb.173.23.7443-7448.1991; Garrity LF, 1997, MICROBIOL-UK, V143, P2945, DOI 10.1099/00221287-143-9-2945; GOLDMAN DJ, 1984, BIOCHEMISTRY-US, V23, P675, DOI 10.1021/bi00299a014; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; HANLON DW, 1992, J BIOL CHEM, V267, P12055; HANLON DW, 1992, J BACTERIOL, V174, P4218, DOI 10.1128/JB.174.13.4218-4222.1992; HANLON DW, 1994, J BIOL CHEM, V269, P14038; HANLON DW, 1994, MICROBIOL-SGM, V140, P1847, DOI 10.1099/13500872-140-8-1847; HENNER DJ, 1990, METHOD ENZYMOL, V185, P223; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; KEHRY MR, 1984, J BIOL CHEM, V259, P1828; KIHARA M, 1989, J BACTERIOL, V171, P3247, DOI 10.1128/jb.171.6.3247-3257.1989; Kirby JR, 1997, MOL MICROBIOL, V24, P869, DOI 10.1046/j.1365-2958.1997.3941759.x; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; KIRSCH ML, 1993, J BIOL CHEM, V268, P25350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; Muller J, 1997, MICROBIOL-UK, V143, P3231, DOI 10.1099/00221287-143-10-3231; NINFA EG, 1991, J BIOL CHEM, V266, P9764; NORDMANN B, 1994, J BIOL CHEM, V269, P16449; ORDAL GW, 1983, J BACTERIOL, V154, P1088, DOI 10.1128/JB.154.3.1088-1097.1983; ORDAL GW, 1977, J BACTERIOL, V129, P156, DOI 10.1128/JB.129.1.156-165.1977; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; Rosario MML, 1996, MOL MICROBIOL, V21, P511, DOI 10.1111/j.1365-2958.1996.tb02560.x; ROSARIO MML, 1995, BIOCHEMISTRY-US, V34, P3823, DOI 10.1021/bi00011a040; ROSARIO MML, 1994, J BACTERIOL, V176, P2736, DOI 10.1128/JB.176.9.2736-2739.1994; Satir B.H., 1991, MODERN CELL BIOL, P137; SLACK FJ, 1995, MOL MICROBIOL, V15, P689, DOI 10.1111/j.1365-2958.1995.tb02378.x; SMIBERT RM, 1994, METHODS GEN MOL BACT, V1, P603; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1996, ESCHERICHIA COLI SAL, V2, P1103; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1988, BIOCHEMISTRY-US, V27, P8453, DOI 10.1021/bi00422a024; THOELKE MS, 1987, J BIOL CHEM, V262, P2811; THOELKE MS, 1990, J BACTERIOL, V172, P1148, DOI 10.1128/jb.172.2.1148-1150.1990; THOELKE MS, 1989, BIOCHEMISTRY-US, V28, P5585, DOI 10.1021/bi00439a037; TOEWS ML, 1979, P NATL ACAD SCI USA, V81, P5544; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; Wang H, 1996, MOL MICROBIOL, V19, P695, DOI 10.1046/j.1365-2958.1996.393934.x; WEINRAUCH Y, 1991, J BACTERIOL, V173, P5685, DOI 10.1128/jb.173.18.5685-5693.1991; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WONG LS, 1995, J BACTERIOL, V177, P4342, DOI 10.1128/jb.177.15.4342-4349.1995	66	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11092	11100		10.1074/jbc.274.16.11092	http://dx.doi.org/10.1074/jbc.274.16.11092			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196193	hybrid			2022-12-25	WOS:000079751900061
J	Nemes, Z; Marekov, LN; Steinert, PM				Nemes, Z; Marekov, LN; Steinert, PM			Involucrin cross-linking by transglutaminase 1 - Binding to membranes directs residue specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; PROLINE-RICH PROTEINS; LAMELLAR ICHTHYOSIS; KERATINOCYTE TRANSGLUTAMINASE; EPIDERMAL-KERATINOCYTES; TERMINAL DIFFERENTIATION; SUBSTRATE PROPERTIES; CALCIUM REGULATION; ENZYME; COMPONENTS	The transglutaminase 1 (TGase 1) enzyme is essential for the assembly of the cell envelope barrier in stratified squamous epithelia, It is usually bound to membranes, but to date most studies with it have involved solution assays. Here we describe an in vitro model system for characterizing the function of TGase 1 on the surface of synthetic lipid vesicles (SLV) of composition similar to eukaryote plasma membranes. Recombinant baculovirus-expressed human TGase 1 readily binds to SLV and becomes active in cross-linking above 10 mu M Ca2+, in comparison to above 100 mu M in solution assays, suggesting that the membrane surface is important for enzyme function. Involucrin also binds to SLV containing 12-18% phosphatidylserine and at Ca2+ concentrations above 1 mu M. In reactions of involucrin with TGase 1 enzyme in solution, 80 of its 150 glutamines serve as donor residues. However, on SLV carrying both involucrin and TGase 1, only five glutamines serve as donors, of which glutamine 496 was the most favored, As controls, there was no change in specificity toward the glutamines of other substrates used by free or SLV-bound TGase 1 enzyme. We propose a model in which involucrin and TGase 1 bind to membranes shortly after expression in differentiating keratinocytes, but cross-linking begins only later as intracellular Ca2+ levels increase. Furthermore, the data suggest that the membrane surface regulates the steric interaction of TGase 1 with substrates such as involucrin to permit specific cross linking for initiation of cell envelope barrier formation.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Steinert, PM (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldg 6,Rm 425, Bethesda, MD 20892 USA.	pemast@helix.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041086, Z01AR041087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aeschlimann D, 1998, J BIOL CHEM, V273, P3452, DOI 10.1074/jbc.273.6.3452; BERS DM, 1994, METHOD CELL BIOL, V40, P1; Candi E, 1998, J BIOL CHEM, V273, P13693, DOI 10.1074/jbc.273.22.13693; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; DEVIRAGH PA, 1994, J INVEST DERMATOL, V103, P815, DOI 10.1111/1523-1747.ep12413482; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ETOH Y, 1986, BIOCHEM BIOPH RES CO, V136, P51, DOI 10.1016/0006-291X(86)90875-2; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; FORSLIND B, 1984, SCAN ELECTRON MICROS, P755; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hauser H, 1991, STRUCTURE BIOL MEMBR, P3; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; Jarnik M, 1998, J CELL SCI, V111, P1051; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1994, J BIOL CHEM, V269, P27979; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; LEE MH, 1989, J BIOL CHEM, V264, P14797; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; MCLAUGHLIN S, 1988, J PHYSIOL-LONDON, V396, P189, DOI 10.1113/jphysiol.1988.sp016958; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; MOISOR M, 1994, J BOIL CHEM, V269, P13798; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; Parmentier L, 1996, HUM MOL GENET, V5, P555, DOI 10.1093/hmg/5.4.555; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; PILLAI S, 1990, J CELL PHYSIOL, V143, P294, DOI 10.1002/jcp.1041430213; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SIMON M, 1988, J BIOL CHEM, V263, P18093; SIMON M, 1984, CELL, V36, P827, DOI 10.1016/0092-8674(84)90032-1; SIMON M, 1994, KERATINOCYTE HDB, P275; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; Steinert PM, 1996, J BIOL CHEM, V271, P26242, DOI 10.1074/jbc.271.42.26242; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; SUN TT, 1976, CELL, V9, P511, DOI 10.1016/0092-8674(76)90033-7; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; THOMAS MV, 1991, CELLULAR CALCIUM, P115; THOMSON JM, 1985, BLOOD COAGULATION HA, P301; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; Vicanova J, 1998, J INVEST DERMATOL, V111, P97, DOI 10.1046/j.1523-1747.1998.00251.x; WATT FM, 1983, J INVEST DERMATOL, V81, pS100, DOI 10.1111/1523-1747.ep12540786; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAFFE MB, 1992, J BIOL CHEM, V267, P12233	59	45	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11013	11021		10.1074/jbc.274.16.11013	http://dx.doi.org/10.1074/jbc.274.16.11013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196183	hybrid			2022-12-25	WOS:000079751900051
J	Kimura, S; Tokishita, S; Ohta, T; Kobayashi, M; Yamagata, H				Kimura, S; Tokishita, S; Ohta, T; Kobayashi, M; Yamagata, H			Heterogeneity and differential expression under hypoxia of two-domain hemoglobin chains in the water flea, Daphnia magna	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; 2-DOMAIN HEMOGLOBIN; BARBATIA-LIMA; PROTEINS; GLOBIN; CDNA; CLONING	Hemoglobin (Hb) purified from the water flea, Daphnia magna, reared under hypoxia was analyzed by two dimensional gel electrophoresis. The Hb was shown to be composed of six major subunit chain species (designated as DHbA to DHbF). The NH2-terminal amino acid sequences of DHbA, DHbB, DHbC, and DHbF are different from one another, indicating that at least four Hb genes are present in D. magna. The NH2-terminal amino acid sequences of DHbD and DHbE are the same as those of DHbA and DHbB, respectively. The six Hb chains were also found in the animal reared under normoxia in small amounts and with altered composition; the extent of decrease under normoxia was higher in the amounts of DHbC, DHbD, and DHbF than those of others. These results indicate that the Hb genes are differentially regulated by the ambient oxygen concentration. Four Hb genes constituting a cluster in the order, dhb4, dhb3, dhb1, and dhb2, were found on the chromosome of D. magna, The complete nucleotide sequences of the dhb1, dhb2, and dhb3 genes and their cDNAs showed that the genes have a seven-exon, six-intron structure. The structure consists of an intron separating an exon encoding a secretory signal sequence, two large repeated regions of a three-exon, two-intron structure that encode each a domain containing a heme-binding site, and an intron bridging the two repeated regions. The deduced amino acid sequences of the gene products showed higher than 79% identity to one another and showed unique features conserved in D. magna Hb chains. The analysis also suggested that DHbB (or DHbE), DHbF, and DHbC are encoded by the dhb1, dhb2, and dhb3 genes, respectively.	Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Environm Sci, Lab Environm & Mol Biol, Tokyo 1920392, Japan; Niigata Univ, Fac Sci, Dept Biol, Niigata 9502181, Japan	Tokyo University of Pharmacy & Life Sciences; Niigata University	Yamagata, H (corresponding author), Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Environm Sci, Lab Environm & Mol Biol, Tokyo 1920392, Japan.							BAERE DE, 1992, P NATL ACAD SCI USA, V89, P4638; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P126; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAVINS JF, 1970, ANAL BIOCHEM, V35, P489, DOI 10.1016/0003-2697(70)90211-3; DIXON B, 1991, P NATL ACAD SCI USA, V88, P5655, DOI 10.1073/pnas.88.13.5655; EDMAN P, 1956, ACTA CHEM SCAND, V10, P761, DOI 10.3891/acta.chem.scand.10-0761; ILAN E, 1982, BIOCHEM J, V207, P297, DOI 10.1042/bj2070297; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KOBAYASHI M, 1984, ZOOL SCI, V1, P523; KOBAYASHI M, 1988, PHYSIOL ZOOL, V61, P415, DOI 10.1086/physzool.61.5.30161263; KOBAYASHI M, 1990, COMP BIOCHEM PHYS A, V97, P513; KOBAYASHI M, 1985, PHYSIOL ZOOL, V58, P190, DOI 10.1086/physzool.58.2.30158566; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1980, ANNU REV GENET, V14, P45; Mashiko K., 1951, Japanese Journal of Limnology, V15, P88; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MINNING DM, 1995, J BIOL CHEM, V270, P22248, DOI 10.1074/jbc.270.38.22248; MOENS L, 1990, J BIOL CHEM, V265, P14285; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Sambrook J., 2002, MOL CLONING LAB MANU; SUGANO H, 1971, BIOCHIM BIOPHYS ACTA, V229, P349, DOI 10.1016/0005-2795(71)90194-2; SUZUKI T, 1989, ZOOL SCI, V6, P269; SUZUKI T, 1995, J PROTEIN CHEM, V14, P499, DOI 10.1007/BF01886875; SWOFFORD DL, 1993, PAUP PHYLOGENETIC AN; Tokishita S, 1997, GENE, V189, P73, DOI 10.1016/S0378-1119(96)00836-0; URICH K, 1990, COMP ANIMAL BIOCH, P249; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M	31	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10649	10653		10.1074/jbc.274.15.10649	http://dx.doi.org/10.1074/jbc.274.15.10649			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187862	hybrid			2022-12-25	WOS:000079663500101
J	Minamisawa, S; Gu, YS; Ross, J; Chien, KR; Chen, J				Minamisawa, S; Gu, YS; Ross, J; Chien, KR; Chen, J			A post-transcriptional compensatory pathway in heterozygous ventricular myosin light chain 2-deficient mice results in lack of gene dosage effect during normal cardiac growth or hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; SKELETAL-MUSCLE; ALPHA-TROPOMYOSIN; HEART; ABLATION; PHOSPHORYLATION; MORPHOGENESIS; CONTRACTION; REQUIREMENT; DROSOPHILA	Our previous study of homozygous mutants of the ventricular specific isoform of myosin light chain 2 (mlc-2v) demonstrated that mlc-ev plays an essential role in murine heart development (Chen, J,, Kubalak, S, W,, Minamisawa, S,, Price, R, L,, Becker, K, D., Hickey, R,, Ross, J,, Jr,, and Chien, K, R, (1998) J. Biol. Chem. 273, 1252-1256), As gene dosage of some myofibrillar proteins can affect muscle function, we have analyzed heterozygous mutants in depth. Ventricles of heterozygous mutants displayed a 50% reduction in mlc-2v mRNA, yet expressed normal levels of protein both under basal conditions and following induction of cardiac hypertrophy by aortic constriction. Heterozygous mutants exhibited cardiac function comparable to that of wild-type littermate controls both prior to and following aortic constriction. There were no significant differences in contractility and responses to calcium between wild-type and heterozygous unloaded cardiomyocytes, We conclude that heterozygous mutants show neither a molecular nor a physiological cardiac phenotype either at base line or following hypertrophic stimuli, These results suggest that post-transcriptional compensatory mechanisms play a major role in maintaining the level of MLC-SV protein in murine hearts, In addition, as our mlc-2v knockout mutants were created by a knock-in of Cre recombinase into the endogenous mlc-ev locus, this study demonstrates that heterozygous mlc-ev cre knock-in mice are appropriate for ventricular specific gene targeting.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Chen, J (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Chen, Ju/E-5579-2011; gu, yu/GSD-4507-2022	Minamisawa, Susumu/0000-0003-4728-2116	NHLBI NIH HHS [HL-46345] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046345] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; Blanchard EM, 1997, CIRC RES, V81, P1005; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chen J, 1998, DEVELOPMENT, V125, P1943; DIFFEE GM, 1995, BIOPHYS J, V68, P1443, DOI 10.1016/S0006-3495(95)80317-6; HIROTA H, 1999, IN PRESS CELL; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Rethinasamy P, 1998, CIRC RES, V82, P116; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Sata M, 1996, CIRCULATION, V93, P310, DOI 10.1161/01.CIR.93.2.310; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Szczesna D, 1996, J BIOL CHEM, V271, P5246; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523	27	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10066	10070		10.1074/jbc.274.15.10066	http://dx.doi.org/10.1074/jbc.274.15.10066			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187786	hybrid			2022-12-25	WOS:000079663500025
J	Tirosh, A; Potashnik, R; Bashan, N; Rudich, A				Tirosh, A; Potashnik, R; Bashan, N; Rudich, A			Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes - A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RAT ADIPOSE-CELLS; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORT; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4-CONTAINING VESICLES; STIMULATED TRANSLOCATION; MOLECULAR-CLONING	In a recent study we have demonstrated that 3T3-L1 adipocytes exposed to low micromolar H2O2 concentrations display impaired insulin stimulated GLUT4 translocation from internal membrane pools to the plasma membrane (Rudich, A., Tirosh, A., Potashnik, R., Hemi, R., Kannety, H., and Bashan, N, (1998) Diabetes 47, 1562-1569), In this study we further characterize the cellular mechanisms responsible for this observation, Two-hour exposure to similar to 25 mu M H2O2 (generated by adding glucose oxidase to the medium) resulted in disruption of the normal insulin stimulated insulin receptor substrate (IRS)-1 and phosphatidylinositol (PI) 3-kinase cellular redistribution between the cytosol and an internal membrane pool (low density microsomal fraction (LDM)). This was associated with reduced insulin-stimulated IRS-1 and p85 associated PI 3-kinase activities in the LDM (84 and 96% inhibition, respectively). The effect of this finding on the downstream insulin signal was demonstrated by a 90% reduction in insulin stimulated protein kinase B (PKB) serine 473 phosphorylation and impaired activation of PKB alpha and PKB gamma. Both control and oxidized cells exposed to heat shock displayed a wortmannin insensitive PKB serine phosphorylation and activity. These data suggest that activation of PKB and GLUT4 translocation are insulin signaling events dependent upon a normal insulin induced cellular compartmentalization of PI 3-kinase and IRS-1, which is oxidative stress-sensitive. These findings represent a novel cellular mechanism for the induction of insulin resistance in response to changes in the extracellular environment.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84103 Beer Sheva, Israel; Soroka Med Ctr, IL-84101 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Soroka Medical Center	Bashan, N (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel.			Rudich, Assaf/0000-0002-1366-1444; Tirosh, Amir/0000-0003-2210-5906				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Caro Jose F., 1996, P519; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; HADARI YR, 1992, J BIOL CHEM, V267, P17483; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1988, BIOCHEM J, V256, P725, DOI 10.1042/bj2560725; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Matsuzaki H, 1996, FEBS LETT, V396, P305, DOI 10.1016/0014-5793(96)01120-9; MAY JM, 1979, J BIOL CHEM, V254, P9017; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NOUROOZZADEH J, 1995, DIABETES, V44, P1054, DOI 10.2337/diabetes.44.9.1054; NouroozZadeh J, 1997, DIABETOLOGIA, V40, P647, DOI 10.1007/s001250050729; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; PAOLISSO G, 1994, METABOLISM, V43, P1426, DOI 10.1016/0026-0495(94)90039-6; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; PAZ K, 1998, 7 INT S INS REC INS, P66; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; Rudich A, 1997, AM J PHYSIOL-ENDOC M, V272, pE935, DOI 10.1152/ajpendo.1997.272.5.E935; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; SALONEN JT, 1995, BRIT MED J, V311, P1124, DOI 10.1136/bmj.311.7013.1124; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Slein M.W., 1965, METHODS ENZYMATIC AN, P117, DOI 10.1016/B978-0-12-395630-9.50023-2; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILDEN PA, 1995, J CELL BIOCHEM, V58, P279, DOI 10.1002/jcb.240580303; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	67	243	256	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10595	10602		10.1074/jbc.274.15.10595	http://dx.doi.org/10.1074/jbc.274.15.10595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187855	hybrid			2022-12-25	WOS:000079663500094
J	Ueba, T; Kaspar, B; Zhao, XY; Gage, FH				Ueba, T; Kaspar, B; Zhao, XY; Gage, FH			Repression of human fibroblast growth factor 2 by a novel transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; DNA METHYLTRANSFERASE; CELLS; SEQUENCE; PROTEINS; PROMOTER; RECEPTOR; CLONING; DISEASE; VARIANT	Here we describe the cloning of the regulator of fibroblast growth factor 2 (FGF-2) transcription (RFT) using a yeast one-hybrid screening with a defined motif in FGF-S promoter as a target sequence. Overexpression of human RFT (RFT-A) reduces FGF-2 RNA and protein levels in both normal and tumor cell lines. Its splice variants, RFT-A' and RFT-B, have deletions in the putative DNA binding domain and fail to bind FGF-S promoter and repress FGF-2 gene expression. The ratios of RFT isoforms differ between normal and tumor cells, with the splice variants dominating in tumor cells. Overexpression of RFT-A induces glioma cell death. Our data suggest that regulation of FGF-2 by RFT is important for cellular functions and may be impaired in certain tumors.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Gage, FH (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fgage@salk.edu	Kaspar, Brian/E-6490-2010; Ueba, Tetsuya/AFL-6434-2022; Kaspar, Brian/E-3349-2011; Ueba, Tetsuya/AAG-6548-2022		NINDS NIH HHS [N01-NS-6-23438] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; Care A, 1996, MOL CELL BIOL, V16, P4842; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; COTMAN CW, 1991, ANN NY ACAD SCI, V638, P221, DOI 10.1111/j.1749-6632.1991.tb49033.x; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; GOSPODAROWICZ D, 1989, J INVEST DERMATOL, V93, P39; Grabowski PJ, 1998, CELL, V92, P709, DOI 10.1016/S0092-8674(00)81399-9; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; Murai N, 1996, J NEUROSURG, V85, P1072, DOI 10.3171/jns.1996.85.6.1072; PESCINI R, 1994, J BIOL CHEM, V269, P1159; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; TOOYAMA I, 1993, BRAIN RES, V610, P1, DOI 10.1016/0006-8993(93)91209-B; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZHOU SZ, 1994, J EXP MED, V179, P1867, DOI 10.1084/jem.179.6.1867	33	11	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10382	10387		10.1074/jbc.274.15.10382	http://dx.doi.org/10.1074/jbc.274.15.10382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187827	hybrid			2022-12-25	WOS:000079663500066
J	Baburina, I; Jackowski, S				Baburina, I; Jackowski, S			Cellular responses to excess phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CHOLINE KINASE-ACTIVITY; SIGNAL-TRANSDUCTION; RAS ONCOGENE; P388D(1) MACROPHAGES; PHOSPHATIDYLCHOLINE HYDROLYSIS; A(2) ENZYMES; CELLS; EXPRESSION; MECHANISM	Phosphatidylcholine (PtdCho) is the major membrane phospholipid in mammalian cells, and its synthesis is controlled by the activity of CDP:phosphocholine cytidylyl-transferase (CCT), Enforced CCT expression accelerated the rate of PtdCho synthesis. However, the amount, of cellular PtdCho did not increase as a result of the turnover of both the choline and glycerol components of PtdCho. Metabolic labeling experiments demonstrated that cells compensated for elevated CCT activity by the degradation of PtdCho to glycerophosphocholine (GPC). Phospholipase D-mediated PtdCho hydrolysis and phosphocholine formation were unaffected, Most of the GPC produced in response to excess phospholipid production was secreted into the medium. Cells also degraded the excess membrane PtdCho to GPC when phospholipid formation was increased by exposure to exogenous lysophosphatidylcholine or lysophosphatidylethanolamine. The replacement of the acyl moiety at the 1-position of PtdCho with a non-hydrolyzable alkyl moiety prevented degradation to GPC. Accumulation of alkylacyl-PtdCho was associated with the inhibition of cell proliferation, demonstrating that alternative pathways of degradation will not substitute. GPC formation was blocked by bromoenol lactone, implicating the calcium-independent phospholipase A(2) as a key participant in the response to excess phospholipid. Owing to the fact that PtdCho is biosynthetically converted to PtdEtn, excess PtdCho resulted in overproduction and exit of GPE as well as GPC. Thus, general membrane phospholipid homeostasis is achieved by a balance between the opposing activities of CCT and phospholipase A(2).	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	suzanne.jackowski@stjude.org	Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAUERNSCHMITT HG, 1993, BIOCHIM BIOPHYS ACTA, V1148, P331, DOI 10.1016/0005-2736(93)90147-R; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boggs K, 1998, BBA-LIPID LIPID MET, V1389, P1, DOI 10.1016/S0005-2760(97)00145-8; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHARLES J, 1980, ANAL BIOCHEM, V104, P10; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Cornell R.B., 1996, ADV LIPOBIOLOGY, P1; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Farooqui AA, 1995, BRAIN RES REV, V21, P152, DOI 10.1016/0165-0173(95)00008-9; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Geilen CC, 1996, BBA-LIPID LIPID MET, V1299, P299, DOI 10.1016/0005-2760(95)00221-9; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HOFFMAN DR, 1984, BLOOD, V63, P545; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Kim TS, 1997, J BIOL CHEM, V272, P2542; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PRICE BD, 1989, J BIOL CHEM, V264, P16638; PROTILLA D, 1998, J BIOL CHEM, V271, P15451; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; Sugimoto H, 1996, J BIOL CHEM, V271, P7705, DOI 10.1074/jbc.271.13.7705; Sugimoto H, 1998, J BIOL CHEM, V273, P12536, DOI 10.1074/jbc.273.20.12536; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; XU XX, 1994, J BIOL CHEM, V269, P31693; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; ZABLOCKI K, 1991, P NATL ACAD SCI USA, V88, P7820, DOI 10.1073/pnas.88.17.7820	57	165	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9400	9408		10.1074/jbc.274.14.9400	http://dx.doi.org/10.1074/jbc.274.14.9400			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092620	hybrid			2022-12-25	WOS:000079451800039
J	Day, ML; Zhao, X; Vallorosi, CJ; Putzi, M; Powell, CT; Lin, C; Day, KC				Day, ML; Zhao, X; Vallorosi, CJ; Putzi, M; Powell, CT; Lin, C; Day, KC			E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADHESION MOLECULE UVOMORULIN; CANCER-CELLS; BETA-CATENIN; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; ALLELIC LOSS; ACTIVATION; GENE; EXPRESSION	E-cadherin and the retinoblastoma tumor suppressor (Rb) are traditionally associated with diverse regulatory aspects of cell growth and differentiation, However, we have discovered new evidence, which suggests that these proteins are functionally linked in a physiologic pathway required for cell survival and programmed cell death. pharmacological activation of protein kinase C (PKC) or inducible overexpression and activation of the alpha isozyme of PRC (PHC alpha) resulted in approximately 60% apoptosis of mammary and prostate epithelial cells, Interestingly, the surviving cells had undergone dramatic aggregation concurrent with increased E-cadherin expression. When aggregation was inhibited by the addition of an E-cadherin-blocking antibody, apoptosis increased synergistically, We hypothesized that survival of the aggregated population was associated with contact-inhibited growth and that apoptosis might result from aberrant growth regulatory signals in non-aggregated, cycling cells. This hypothesis was confirmed by experiments that demonstrated that E-cadherin-dependent aggregation resulted in Rb-mediated GI arrest and survival, Immunoblot analysis and Bow cytometry revealed that hypophosphorylated Rb was present in non-aggregated, S phase cultures concurrent with synergistic cell death. We have also determined that the loss of membrane E-cadherin and subsequent hypophosphorylation of Rb in luminal epithelial cells preceded apoptosis induced by castration. These findings provide compelling evidence that suggests that E-cadherin-mediated aggregation results in Rb activation and G(1), arrest that is critical for survival of prostate and mammary epithelial cells, These data also indicate that Rb can initiate a fatal growth signal conflict in non-aggregated, cycling cells when the protein is hypophosphorylated as these epithelial cells enter S phase.	Univ Michigan, Dept Surg, Urol Sect, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center	Day, ML (corresponding author), Univ Michigan, Dept Surg, Urol Sect, Box 0944,Rm 6219 CGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NATIONAL CANCER INSTITUTE [P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047650] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA69568] Funding Source: Medline; NIDDK NIH HHS [DK/CA47650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cooney KA, 1996, CANCER RES, V56, P1142; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DAY ML, 1994, CELL GROWTH DIFFER, V5, P735; DAY ML, 1993, CANCER RES, V53, P5597; DELBINO G, 1991, EXP CELL RES, V193, P27, DOI 10.1016/0014-4827(91)90534-2; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; FABRE M, 1993, J CELL SCI, V106, P513; Fishman DD, 1998, INT J ONCOL, V12, P181; GAMALLO C, 1993, AM J PATHOL, V142, P987; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GUENETTE RS, 1994, J MOL ENDOCRINOL, V12, P47, DOI 10.1677/jme.0.0120047; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Ilyas M, 1997, J PATHOL, V182, P128; Ittmann MM, 1996, HUM PATHOL, V27, P28, DOI 10.1016/S0046-8177(96)90134-3; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEWIS JE, 1994, J CELL SCI, V107, P3615; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; Pollack A, 1990, Methods Cell Biol, V33, P19; Potter SW, 1996, J CELL PHYSIOL, V169, P1, DOI 10.1002/(SICI)1097-4652(199610)169:1<1::AID-JCP1>3.0.CO;2-S; Powell CT, 1996, CELL GROWTH DIFFER, V7, P419; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; SKOUDY A, 1995, FEBS LETT, V374, P415, DOI 10.1016/0014-5793(95)01167-D; Spinedi A, 1998, BIOCHEM BIOPH RES CO, V243, P852, DOI 10.1006/bbrc.1998.8184; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; UMBAS R, 1994, CANCER RES, V54, P3929; UMBAS R, 1992, CANCER RES, V52, P5104; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Wang H, 1996, ONCOGENE, V13, P373; WINKEL GK, 1990, DEV BIOL, V138, P1, DOI 10.1016/0012-1606(90)90171-E; Zhao X, 1997, J BIOL CHEM, V272, P22751, DOI 10.1074/jbc.272.36.22751	52	99	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9656	9664		10.1074/jbc.274.14.9656	http://dx.doi.org/10.1074/jbc.274.14.9656			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092652	hybrid			2022-12-25	WOS:000079451800071
J	Ernst, M; Novak, U; Nicholson, SE; Layton, JE; Dunn, AR				Ernst, M; Novak, U; Nicholson, SE; Layton, JE; Dunn, AR			The carboxyl-terminal domains of gp130-related cytokine receptors are necessary for suppressing embryonic stem cell differentiation - Involvement of STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; LEUKEMIA INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; SIGNAL TRANSDUCER GP130; TYROSINE PHOSPHORYLATION; TARGETED DISRUPTION; CYTOPLASMIC DOMAIN; DISTINCT REGIONS; CSF RECEPTOR; ONCOSTATIN-M	Cell type-specific responses to the leukemia inhibitory factor (LIF)/interleukin 6 cytokine family are mediated by dimerization of the LIF receptor alpha-chain (LIFR alpha) with the signal transducer gp130 or of two gp130 molecules followed by activation of the JAK/STAT and Ras/mitogen-activated protein kinase cascades. In order to dissect the contribution of gp130 and LIFR alpha individually, chimeric molecules consisting of the extracellular domain of the granulocyte colony stimulating factor receptor (GCSF-R) and various mutant forms of the cytoplasmic domains of gp130 or LIFR alpha were expressed in embryonic stem (ES) cells to test for suppression of differentiation, or in a factor-dependent plasma cytoma cell line to assess for induction of proliferation. Carboxyl-terminal domains downstream of the phosphatase (SHP2)-binding sites were dispensable for mitogen-activated protein kinase activation and the transduction of proliferative signals. Moreover, carboxyl-terminal truncation mutants which lacked intact Box 3 homology domains showed decreased STAT3 activation, failed to induce Hck kinase activity and suppress ES cell differentiation. Moreover, STAT3 antisense oligonucleotides impaired LIF-dependent inhibition of differentiation. Substitution of the tyrosine residue within the Box 3 region of the GSCF-R abolished receptor-mediated suppression of differentiation without affecting the transduction of proliferative signals. Thus, distinct cytoplasmic domains within the LIFR alpha, gp130, and GCSF-R transduce proliferative and differentiation suppressing signals.	Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Med, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; University of Melbourne	Ernst, M (corresponding author), Ludwig Inst Canc Res, Melbourne Tumour Biol Branch, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.	matthias.ernst@ludwig.edu.au	Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177; , Sandra/0000-0002-1314-2134				ALEXANDER WS, 1995, ONCOGENE, V10, P795; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Fujitani Y, 1997, ONCOGENE, V14, P751, DOI 10.1038/sj.onc.1200907; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Giordano V, 1997, J IMMUNOL, V158, P4097; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; Karras JG, 1997, J EXP MED, V185, P1035, DOI 10.1084/jem.185.6.1035; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LIU W, 1997, GENE DEV, V11, P179; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; SADOWSKI HB, 1993, SCIENCE, V26, P1749; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1701; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	47	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9729	9737		10.1074/jbc.274.14.9729	http://dx.doi.org/10.1074/jbc.274.14.9729			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092661	hybrid			2022-12-25	WOS:000079451800080
J	Joshi, L; St Leger, RJ				Joshi, L; St Leger, RJ			Cloning, expression, and substrate specificity of MeCPA, a zinc carboxypeptidase that is secreted into infected tissues by the fungal entomopathogen Metarhizium anisopliae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROCARBOXYPEPTIDASE A2; ULTRASTRUCTURAL-LOCALIZATION; SERINE CARBOXYPEPTIDASES; RAT CARBOXYPEPTIDASE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; GENE FAMILY; ACTIVATION; PROTEASE; CDNA	To date zinc carboxypeptidases have only been found in animals and actinomycete bacteria. A cDNA clone (MeCPA) for a novel fungal (Metarhizium anisopliae) carboxypeptidase (MeCPA) was obtained by using reverse transcription differential display polymerase chain reaction to identify pathogenicity genes. MeCPA resembles pancreatic carboxypeptidases in being synthesized as a precursor species (418 amino acids) containing a large amino-terminal fragment (99 amino acids). The mature (secreted) form of MeCPA shows closest amino acid identity to human carboxypeptidases Al (35%) and A2 (37%). MeCPA was expressed in an insect cell line yielding an enzyme with dual A1 + A2 specificity for branched aliphatic and aromatic COOH-terminal amino acids. However, in contrast to the very broad spectrum A + B-type bacterial enzymes, MeCPA lacks B-type activity against charged amino acids. This is predictable as key catalytic residues determining the specificity of MeCPA are conserved with those of mammalian A-type carboxypeptidases. Thus, in evolutionary terms the fungal enzyme is an intermediate between the divergence of A and B forms and the differentiation of the A form into A1 and A2 isoforms, Ultrastructural immunocytochemistry of infected host (Manduca sexta) cuticle demonstrated that MeCPA participates with the concurrently produced endoproteases in procuring nutrients; an equivalent function to digestive pancreatic enzymes.	Univ Maryland, Dept Entomol, College Pk, MD 20742 USA; Cornell Univ, Boyce Thompson Inst, Ithaca, NY 14853 USA	University System of Maryland; University of Maryland College Park; Cornell University; Boyce Thompson Institute for Plant Research	St Leger, RJ (corresponding author), Univ Maryland, Dept Entomol, 4112 Plant Sci Bldg, College Pk, MD 20742 USA.	rl106@umailsrv0.umd.edu	St. Leger, Raymond/N-3219-2013					AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; BREDDAM K, 1988, CARLSBERG RES COMMUN, V53, P309, DOI 10.1007/BF02904436; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; CATASUS L, 1995, J BIOL CHEM, V270, P6651, DOI 10.1074/jbc.270.12.6651; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; CUENI LB, 1980, ANAL BIOCHEM, V107, P341, DOI 10.1016/0003-2697(80)90394-2; DALDEGAN F, 1992, APPL ENVIRON MICROB, V58, P2144, DOI 10.1128/AEM.58.7.2144-2152.1992; DISANTO ME, 1992, J BACTERIOL, V174, P447, DOI 10.1128/jb.174.2.447-455.1992; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; GROEBE DR, 1990, NUCLEIC ACIDS RES, V18, P4033, DOI 10.1093/nar/18.13.4033; HAMBLIN M, 1990, APPL ENVIRON MICROB, V56, P3057, DOI 10.1128/AEM.56.10.3057-3062.1990; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; Joshi L, 1997, GENE, V197, P1, DOI 10.1016/S0378-1119(97)00132-7; LEHUEROU I, 1991, BIOCHEM BIOPH RES CO, V175, P110, DOI 10.1016/S0006-291X(05)81207-0; Luckow Verne A., 1995, P51; NEURATH H, 1986, J CELL BIOCHEM, V32, P35, DOI 10.1002/jcb.240320105; OPPEZZO O, 1994, EUR J BIOCHEM, V222, P55, DOI 10.1111/j.1432-1033.1994.tb18841.x; OSTERMAN AL, 1992, J PROTEIN CHEM, V11, P561, DOI 10.1007/BF01025034; Phillips MA, 1996, BIOCHEMISTRY-US, V35, P6771, DOI 10.1021/bi960113o; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Reverter D, 1998, J BIOL CHEM, V273, P3535, DOI 10.1074/jbc.273.6.3535; StLeger RJ, 1996, APPL ENVIRON MICROB, V62, P1257, DOI 10.1128/AEM.62.4.1257-1264.1996; StLeger RJ, 1996, P NATL ACAD SCI USA, V93, P6349, DOI 10.1073/pnas.93.13.6349; STLEGER RJ, 1992, EUR J BIOCHEM, V204, P991, DOI 10.1111/j.1432-1033.1992.tb16721.x; STLEGER RJ, 1987, ARCH BIOCHEM BIOPHYS, V253, P221, DOI 10.1016/0003-9861(87)90655-2; STLEGER RJ, 1995, CAN J BOT, V73, pS1119, DOI 10.1139/b95-367; STLEGER RJ, 1989, EXP MYCOL, V13, P274, DOI 10.1016/0147-5975(89)90049-2; StLeger RJ, 1996, APPL ENVIRON MICROB, V62, P907, DOI 10.1128/AEM.62.3.907-912.1996; WOOD HA, 1977, J INVERTEBR PATHOL, V29, P304, DOI 10.1016/S0022-2011(77)80035-9; ZHANG FM, 1991, J BIOL CHEM, V266, P24606	31	36	43	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9803	9811		10.1074/jbc.274.14.9803	http://dx.doi.org/10.1074/jbc.274.14.9803			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092670	hybrid			2022-12-25	WOS:000079451800089
J	Lamberty, M; Ades, S; Uttenweiler-Joseph, S; Brookhart, G; Bushey, D; Hoffmann, JA; Bulet, P				Lamberty, M; Ades, S; Uttenweiler-Joseph, S; Brookhart, G; Bushey, D; Hoffmann, JA; Bulet, P			Insect immunity - Isolation from the lepidopteran Heliothis virescens of a novel insect defensin with potent antifungal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ANTIBACTERIAL PEPTIDE; 3-DIMENSIONAL SOLUTION STRUCTURE; RICH ANTIMICROBIAL PEPTIDES; DIPTERAN PHORMIA-TERRANOVAE; ANTI-BACTERIAL PROTEINS; SEQUENCE HOMOLOGY; INNATE IMMUNITY; BOMBYX-MORI; LARVAE; FAMILY	Lepidoptera have been reported to produce several antibacterial peptides in response to septic injury, However, in marked contrast to other insect groups, no inducible antifungal molecules had been described so far in this insect order. Surprisingly, also cysteine-rich antimicrobial peptides, which predominate in the antimicrobial defense of other insects, had not been discovered in Lepidoptera, Here we report the isolation from the hemolymph of immune induced larvae of the lepidopteran Heliothis virescens of a cysteine-rich molecule with exclusive antifungal activity. We have fully characterized this antifungal molecule, which has significant homology with the insect defensins, a large family of antibacterial peptides directed against Gram-positive strains. Interestingly, the novel peptide shows also similarities with the antifungal peptide drosomycin from Drosophila. Thus, Lepidoptera appear to have built their humoral immune response against bacteria on cecropins and attacins. In addition, we report that Lepidoptera have conferred antifungal properties to the well conserves structure of antibacterial insect defensins through amino acid replacements.	CNRS, Unite Propre Rech 9022, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Rhone Poulenc Agro, Res Triangle Pk, NC 27709 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bulet, P (corresponding author), CNRS, Unite Propre Rech 9022, Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	bulet@ibmc.u-strasbg.fr	BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Axen A, 1997, EUR J BIOCHEM, V247, P614, DOI 10.1111/j.1432-1033.1997.00614.x; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; BULET P, 1992, EUR J BIOCHEM, V209, P977, DOI 10.1111/j.1432-1033.1992.tb17371.x; BULET P, 1995, BIOCHEMISTRY-US, V34, P7394, DOI 10.1021/bi00022a012; BULET P, 1993, J BIOL CHEM, V268, P14893; Charlet M, 1996, J BIOL CHEM, V271, P21808, DOI 10.1074/jbc.271.36.21808; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; DIMARCQ JL, 1988, EUR J BIOCHEM, V171, P17, DOI 10.1111/j.1432-1033.1988.tb13752.x; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; Fant F, 1998, J MOL BIOL, V279, P257, DOI 10.1006/jmbi.1998.1767; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; HARA S, 1995, J BIOL CHEM, V270, P29923, DOI 10.1074/jbc.270.50.29923; HARA S, 1995, BIOCHEM J, V310, P651, DOI 10.1042/bj3100651; Hetru Charles, 1998, P40; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; Landon C, 1997, PROTEIN SCI, V6, P1878, DOI 10.1002/pro.5560060908; Lockey TD, 1996, EUR J BIOCHEM, V236, P263, DOI 10.1111/j.1432-1033.1996.00263.x; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Michaut L, 1996, FEBS LETT, V395, P6, DOI 10.1016/0014-5793(96)00992-1; Oerke EC., 1994, CROP PRODUCTION CROP; OURTH DD, 1994, BIOCHEM BIOPH RES CO, V200, P35, DOI 10.1006/bbrc.1994.1410; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; TAMAOKI H, 1991, PROTEIN ENG, V4, P509, DOI 10.1093/protein/4.5.509; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; UttenweilerJoseph S, 1997, ANAL BIOCHEM, V247, P366, DOI 10.1006/abio.1997.2083	36	136	160	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9320	9326		10.1074/jbc.274.14.9320	http://dx.doi.org/10.1074/jbc.274.14.9320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092609	hybrid			2022-12-25	WOS:000079451800028
J	Ness, LS; Booth, IR				Ness, LS; Booth, IR			Different foci for the regulation of the activity of the KefB and KefC glutathione-gated K+ efflux systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; POTASSIUM CHANNELS; ACTIVATION; CLONING; TRANSPORT; GENE	KefB and KefC are glutathione-gated K+ efflux systems in Escherichia coti, and the proteins exhibit strong similarity at the level of both primary sequence and domain organization. The proteins are maintained closed by glutathione and are activated by binding of adducts formed between glutathione and electrophiles. By construction of equivalent mutations in each protein, this study has analyzed the control over inactive state of the proteins. A UV-induced mutation in KefB, L75S, causes rapid spontaneous K+ efflux but has only a minor effect on K+ efflux via KefC. Similarly amino acid substitutions that cause increased spontaneous activity in RefC have only small effects in RefB. Exchange of an eight amino acid region from KefC (HALESDIE) with the equivalent sequence from KefB (HELETAID) has identified a role for a group of acidic residues in controlling KefC activity. The mutations HELETALD and L74S in KefC act synergistically, and the activity of the resultant protein resembles that of KefB. We conclude that, despite the high degree of sequence similarity, KefB and KefC: exhibit different sensitivities to the same site-specific mutations.	Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Booth, IR (corresponding author), Univ Aberdeen, Dept Mol & Cell Biol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.							Booth I. R., 1996, HDB BIOL PHYS, V2, P693; BOOTH IR, 1985, BIOCHIMIE, V67, P83, DOI 10.1016/S0300-9084(85)80233-9; DOUGLAS RM, 1994, MOL MEMBR BIOL, V11, P55, DOI 10.3109/09687689409161030; ELMORE MJ, 1990, MOL MICROBIOL, V4, P405, DOI 10.1111/j.1365-2958.1990.tb00607.x; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FERGUSON GP, 1995, MOL MICROBIOL, V17, P1025, DOI 10.1111/j.1365-2958.1995.mmi_17061025.x; FERGUSON GP, 1993, MOL MICROBIOL, V9, P1297, DOI 10.1111/j.1365-2958.1993.tb01259.x; Ferguson GP, 1997, J BACTERIOL, V179, P1007, DOI 10.1128/jb.179.4.1007-1012.1997; Maniatis T., 1982, MOL CLONING LAB MANU; MEURY J, 1982, EMBO J, V1, P339, DOI 10.1002/j.1460-2075.1982.tb01171.x; Miller S, 1997, J BIOL CHEM, V272, P24942, DOI 10.1074/jbc.272.40.24942; MUNRO AW, 1991, MOL MICROBIOL, V5, P607, DOI 10.1111/j.1365-2958.1991.tb00731.x; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; WOOD CM, 1996, THESIS U ABERDEEN AB; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	15	27	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9524	9530		10.1074/jbc.274.14.9524	http://dx.doi.org/10.1074/jbc.274.14.9524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092637	hybrid			2022-12-25	WOS:000079451800056
J	Niswender, CM; Copeland, SC; Herrick-Davis, K; Emeson, RB; Sanders-Bush, E				Niswender, CM; Copeland, SC; Herrick-Davis, K; Emeson, RB; Sanders-Bush, E			RNA editing of the human serotonin 5-Hydroxytryptamine 2C receptor silences constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 2ND INTRACELLULAR LOOP; HORMONE RECEPTOR; 5-HT2C RECEPTOR; AMINO-ACID; ION FLOW; ACTIVATION; MUTATIONS; CHANNELS; INTERNALIZATION	RNA transcripts encoding the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor (5-HT2CR) undergo adenosine-to-inosine RNA editing events at up to five specific sites. Compared with rat brain, human brain samples expressed higher levels of RNA transcripts encoding the amino acids valine-serine-valine (5-HT2C-VSV) and valine-glycine-valine (5-HT2C-VGV) at positions 156, 158, and 160, respectively. Agonist stimulation of the nonedited human receptor (5-HT2C-INI) and the edited 5-HT2C-VSV and 5-HT2C-VGV receptor variants stably expressed in NIH-3T3 fibroblasts demonstrated that serotonergic agonists were less potent at the edited receptors, Competition binding experiments revealed a guanine nucleotide-sensitive serotonin high affinity state only for the 5-HT2C-INI receptor; the loss of high affinity agonist binding to the edited receptor demonstrates that RNA editing generates unique 5-HT(2C)Rs that couple less efficiently to G proteins. This reduced G protein coupling for the edited isoforms is primarily due to silencing of the constitutive activity of the nonedited 5-HT2CR. The distinctions in agonist potency and constitutive activity suggest that different edited 5-HT(2C)Rs exhibit distinct responses to serotonergic ligands and further imply that RNA editing represents a novel mechanism for controlling physiological signaling at serotonergic synapses.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Psychiat, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37232 USA; Albany Med Coll, Dept Pharmacol, Albany, NY 12208 USA; Albany Med Coll, Dept Neurosci, Albany, NY 12208 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Albany Medical College; Albany Medical College	Sanders-Bush, E (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.			Emeson, Ronald/0000-0002-4585-1648				Arora KK, 1997, MOL ENDOCRINOL, V11, P1203, DOI 10.1210/me.11.9.1203; ARORA KK, 1995, J BIOL CHEM, V270, P22820, DOI 10.1074/jbc.270.39.22820; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; BARKER EL, 1994, J BIOL CHEM, V269, P11687; BASS BL, 1993, RNA WORLD, P383; BLIN N, 1995, J BIOL CHEM, V270, P17741, DOI 10.1074/jbc.270.30.17741; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; FURCHGOTT RF, 1967, ANN NY ACAD SCI, V144, P882, DOI 10.1111/j.1749-6632.1967.tb53817.x; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HerrickDavis K, 1997, J NEUROCHEM, V69, P1138; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOYER D, 1994, PHARMACOL REV, V46, P157; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MORO O, 1993, J BIOL CHEM, V268, P22273; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Perez DM, 1996, MOL PHARMACOL, V49, P112; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sanders-Bush Elaine, 1995, P431; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WONG SKF, 1990, J BIOL CHEM, V265, P6219; Xie EZ, 1996, GENOMICS, V35, P551, DOI 10.1006/geno.1996.0397	30	295	312	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9472	9478		10.1074/jbc.274.14.9472	http://dx.doi.org/10.1074/jbc.274.14.9472			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092629	hybrid			2022-12-25	WOS:000079451800048
J	Stroschein, SL; Wang, W; Luo, KX				Stroschein, SL; Wang, W; Luo, KX			Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor beta-induced Smad-dependent transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR SMAD4; DPC4 GENE; SIGNAL-TRANSDUCTION; INDUCIBLE ELEMENTS; II RECEPTOR; CELLS; EXPRESSION; COMPLEX; MADR2; PHOSPHORYLATION	Transforming growth factor beta (TGF beta) activates transcription of the plasminogen activator inhibitor type-1 (PAI-1) gene through a major TGF beta-responsive region (-740 and -647) in the PAI-1 promoter. This process requires the Smad family of signaling molecules. Upon phosphorylation by the TGF beta receptors, Smad2 and Smad3 homoligomerize and heteroligomerize with Smad4, translocate to the nucleus and activate transcription of TGF beta responsive genes. Smad3 and Smad4 have been shown to bind to various sites in the PAI-1 promoter. To determine the number of Smad-binding sites within the 94-base pair major TGF beta-responsive region and the mechanism of Smad-mediated transactivation, we systematically mapped the Smad-binding sites and show that Smad4 and Smad3 bind cooperatively to two adjacent DNA elements in this region. Both elements were required for TGF beta-induced, Smad3- and Smad4-dependent activation of PAI-1 transcription. Contrary to previous reports, transactivation of the PAI-1 promoter was mediated by the amino- but not carboxyl-terminal domains of the Smads. Furthermore, oligomerization of Smad3 markedly enhanced its binding to the two binding sites, Finally, a Smad4 mutation identified in a human pancreatic carcinoma that inactivates Smad4 signaling abolished Smad4: DNA binding activity, hence preventing transactivation of TGF beta-responsive genes. These results underscore the importance of the Smad4 DNA binding activity in controlling cell growth and carcinogenesis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Sci & Technol China, Dept Biol, Hefei, Anhui, Peoples R China	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Luo, KX (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall,Mail Code 3206, Berkeley, CA 94720 USA.							Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Barrett MT, 1996, CANCER RES, V56, P4351; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BURATOWSKI S, 1997, CURRENT PROTOCOLS MO; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kim SK, 1996, CANCER RES, V56, P2519; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagatake M, 1996, CANCER RES, V56, P2718; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SMITH DB, 1997, CURRENT PROTOCOLS MO; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	49	108	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9431	9441		10.1074/jbc.274.14.9431	http://dx.doi.org/10.1074/jbc.274.14.9431			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092624	hybrid			2022-12-25	WOS:000079451800043
J	Deissler, H; Blass-Kampmann, S; Bruyneel, E; Mareel, M; Rajewsky, MF				Deissler, H; Blass-Kampmann, S; Bruyneel, E; Mareel, M; Rajewsky, MF			Neural cell surface differentiation antigen gp130(RB13-6) induces fibroblasts and glioma cells to express astroglial proteins and invasive properties	FASEB JOURNAL			English	Article						glial cells; astrocytes; GFAP; invasion; neurooncogenesis	FIBRILLARY ACIDIC PROTEIN; MEMBRANE GLYCOPROTEIN PC-1; PRENATAL RAT-BRAIN; LONG-TERM CULTURES; CDNA CLONING; PROGENITOR CELLS; INSULIN-RECEPTOR; GROWTH-FACTORS; THY-1 ANTIGEN; MESSENGER-RNA	Transient expression of the differentiation and tumor cell surface antigen gp130(RB13-6) characterizes a subset of rat glial progenitor cells susceptible to ethylnitrosourea-induced neurooncogenesis, gp130(RB13-6) is as a member of an emerging protein family of ecto-phosphodiesterases/nucleotide pyrophosphatases that includes PC-1 and the tumor cell motility factor autotaxin. We have investigated the potential role of gp130(RB13-6), glial differentiation by transfection of three cell lines of different origin that do not express endogenous gp130(RB13-6) (NIH-3T3 mouse fibroblasts; C6 and BT7Ca rat glioma cells) with the cDNA encoding gp130(RB13-6). The effect of gp130(RB13-6) expression was analyzed in terms of overall cell morphology, the expression of glial cell-specific marker proteins, and invasiveness. Transfectant sublines, consisting of 100% gp130(RB13-6)-positive cells, exhibited an altered, bipolar morphology. Fascicular aggregates of fibroblastoid cells subsequently developed into mesh-like patterns. Contrary to the parental NIH-3T3 and BT7Ca cells, the transfectant cells invaded into collagen type I. As shown by immunofluorescence staining of the transfectant sublines as well as of primary cultures composed of gp130(RB13-6)-positive and -negative cells, expression of gp130(RB13-6) induced coexpression of proteins typical for glial cells and their precursors, i.e., glial fibrillary acidic protein, the low affinity nerve growth factor receptor, and the neural proteins Thy-1, Ran-2, and S-100. In accordance with its expression in the immature rat nervous system, gp130(RB13-6) may thus have a significant role in the glial differentiation program and its subversion in neurooncogenesis.	Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium	University of Duisburg Essen; Ghent University; Ghent University Hospital	Rajewsky, MF (corresponding author), Univ Essen Gesamthsch, Sch Med, Inst Cell Biol Canc Res, Hufelandstr 55, D-45122 Essen, Germany.	rajewsky@uni-essen.de						BARTLETT PF, 1981, BRAIN RES, V204, P339, DOI 10.1016/0006-8993(81)90593-X; BELLI SI, 1993, EUR J BIOCHEM, V217, P421, DOI 10.1111/j.1432-1033.1993.tb18261.x; Blass-Kampmann S, 1998, NEUROPATH APPL NEURO, V24, P9; BlassKampmann S, 1997, J NEUROSCI RES, V48, P95, DOI 10.1002/(SICI)1097-4547(19970415)48:2<95::AID-JNR2>3.0.CO;2-7; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P55; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; BROWN RH, 1984, BRAIN RES, V296, P87, DOI 10.1016/0006-8993(84)90513-4; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CHIU FC, 1985, J NEUROIMMUNOL, V8, P283, DOI 10.1016/S0165-5728(85)80067-9; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; Deissler H, 1996, J NEUROSCI RES, V43, P664, DOI 10.1002/(SICI)1097-4547(19960315)43:6<664::AID-JNR3>3.3.CO;2-L; DIMANCHEBOITREL MT, 1994, CANCER LETT, V85, P171, DOI 10.1016/0304-3835(94)90271-2; DUX R, 1991, CYTOMETRY, V12, P422, DOI 10.1002/cyto.990120507; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; GOLDMAN JE, 1984, J NEUROCHEM, V42, P175, DOI 10.1111/j.1471-4159.1984.tb09714.x; GRUPE A, 1995, J BIOL CHEM, V270, P22085, DOI 10.1074/jbc.270.38.22085; INAGAKI M, 1994, BRAIN PATHOL, V4, P239, DOI 10.1111/j.1750-3639.1994.tb00839.x; JinHua P, 1997, GENOMICS, V45, P412, DOI 10.1006/geno.1997.4949; Kettenhofen R, 1998, J MOL BIOL, V279, P323, DOI 10.1006/jmbi.1998.1768; KILPATRICK TJ, 1995, MOL CELL NEUROSCI, V6, P2, DOI 10.1006/mcne.1995.1002; KINDLERROHRBORN A, 1985, DIFFERENTIATION, V30, P53, DOI 10.1111/j.1432-0436.1985.tb00513.x; KINDLERROHRBORN A, 1994, DIFFERENTIATION, V57, P215, DOI 10.1007/s002580050057; LAERUM OD, 1977, Z KREBSFORSCH KLIN O, V89, P273, DOI 10.1007/BF00283783; LAPING NJ, 1994, BRAIN PATHOL, V4, P259, DOI 10.1111/j.1750-3639.1994.tb00841.x; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MORRISON RS, 1983, DEV BRAIN RES, V9, P337, DOI 10.1016/0165-3806(83)90030-5; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; MURATA J, 1994, J BIOL CHEM, V269, P30479; ODA Y, 1991, J BIOL CHEM, V266, P16791; PRUSS RM, 1979, NATURE, V280, P688, DOI 10.1038/280688a0; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RUTKA JT, 1988, INT J CANCER, V42, P419, DOI 10.1002/ijc.2910420319; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Scott LJ, 1997, HEPATOLOGY, V25, P995, DOI 10.1002/hep.510250434; SHAFITZAGARDO B, 1988, GLIA, V1, P346, DOI 10.1002/glia.440010507; Stefan C, 1996, DIABETES, V45, P980, DOI 10.2337/diabetes.45.7.980; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; VAKAET L, 1991, INVAS METAST, V11, P249; VANDRIEL IR, 1987, J BIOL CHEM, V262, P4882	42	38	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1999	13	6					657	666		10.1096/fasebj.13.6.657	http://dx.doi.org/10.1096/fasebj.13.6.657			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094926				2022-12-25	WOS:000079527200007
J	Fluiter, K; Sattler, W; De Beer, MC; Connell, PM; van der Westhuyzen, DR; van Berkel, TJC				Fluiter, K; Sattler, W; De Beer, MC; Connell, PM; van der Westhuyzen, DR; van Berkel, TJC			Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; SR-BI; PARENCHYMAL-CELLS; OXIDATIVE MODIFICATION; LIPID HYDROPEROXIDES; PLASMA-LIPOPROTEINS; KUPFFER CELLS; ADRENAL-GLAND; VIVO	High density lipoprotein (HDL) can protect low density lipoprotein (LDL) against oxidation, Oxidized cholesterol esters from LDL can be transferred to HDL and efficiently and selectively removed from the blood circulation by the liver and adrenal in vivo. In the present study, we investigated whether scavenger receptor BI (SR-BI) is responsible for this process. At 30 min after injection, the selective uptake of oxidized cholesterol esters from HDL for liver and adrenal was 2.3- and 2.6-fold higher, respectively, than for native cholesterol esters, whereas other tissues showed no significant difference. The selective uptake of oxidized cholesterol esters from HDL by isolated liver parenchymal cells could be blocked for 75% by oxidized LDL and for 50% by phosphatidylserine liposomes, both of which are known substrates of SR-BI, In vivo uptake of oxidized cholesterol esters from HDL by parenchymal cells decreased by 64 and 81% when rats were treated with estradiol and a high cholesterol diet, respectively, whereas Kupffer cells showed 660 and 475% increases, respectively. These contrasting changes in oxidized cholesterol ester uptake were accompanied by similar contrasting changes in SR-BI expression of parenchymal and Kupffer cells. The rates of SR-BI-mediated selective uptake of oxidized and native cholesterol esters were analyzed in SR-BI-transfected Chinese hamster ovary cells. SR-BI-mediated selective uptake was 3.4-fold higher for oxidized than for native cholesterol esters (30 min of incubation). It is concluded that in addition to the selective uptake of native cholesterol esters, SR-BI is responsible for the highly efficient Selective uptake of oxidized cholesterol esters from HDL and thus forms an essential mediator in the HDL-associated protection system for atherogenic oxidized cholesterol esters.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Sylvius Labs, NL-2300 RA Leiden, Netherlands; Graz Univ, Inst Med Biochem, A-8010 Graz, Austria; Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA	Leiden University; Leiden University - Excl LUMC; University of Graz; University of Kentucky	van Berkel, TJC (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Sylvius Labs, POB 9503, NL-2300 RA Leiden, Netherlands.		Van Berkel, Theo/ABD-7677-2021; Eckhardt, Erik/G-1567-2010; Fluiter, Kees/H-2828-2015	Fluiter, Kees/0000-0003-0898-7260	NHLBI NIH HHS [HL59376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWRY VW, 1992, P NATL ACAD SCI USA, V89, P10316, DOI 10.1073/pnas.89.21.10316; CHRISTISON JK, 1995, J LIPID RES, V36, P2017; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; Fluiter K, 1996, BIOCHEM J, V319, P471, DOI 10.1042/bj3190471; Fluiter K, 1998, J BIOL CHEM, V273, P8434, DOI 10.1074/jbc.273.14.8434; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLOMSET JA, 1968, J LIPID RES, V9, P155; GRAF J, 1990, J HEPATOL, V10, P387, DOI 10.1016/0168-8278(90)90152-H; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KUNITAKE ST, 1992, P NATL ACAD SCI USA, V89, P6993, DOI 10.1073/pnas.89.15.6993; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKNESS MI, 1995, ATHEROSCLEROSIS, V115, P243, DOI 10.1016/0021-9150(94)05524-M; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sakai M, 1996, ATHEROSCLEROSIS, V119, P191, DOI 10.1016/0021-9150(95)05646-7; SATTLER W, 1993, BIOCHEM J, V294, P771, DOI 10.1042/bj2940771; SATTLER W, 1995, FREE RADICAL BIO MED, V18, P421, DOI 10.1016/0891-5849(94)00170-O; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Thuren TY, 1998, CIRCULATION, V98, P201; VANBERKEL TJC, 1985, J BIOL CHEM, V260, P2203; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1982, BIOCHEM J, V208, P493, DOI 10.1042/bj2080493; VANKUIJK FJGM, 1990, METHOD ENZYMOL, V186, P388; VanVelzen AG, 1997, BIOCHEM J, V322, P411; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; WEISGRABER KH, 1980, J LIPID RES, V21, P316; Xu SZ, 1997, J LIPID RES, V38, P1289	45	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8893	8899		10.1074/jbc.274.13.8893	http://dx.doi.org/10.1074/jbc.274.13.8893			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085133	Green Published, hybrid			2022-12-25	WOS:000079451600075
J	Skiba, NP; Yang, CS; Huang, T; Bae, H; Hamm, HE				Skiba, NP; Yang, CS; Huang, T; Bae, H; Hamm, HE			The alpha-helical domain of G alpha(t) determines specific interaction with regulator of G protein signaling 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; PHOTORECEPTOR G-PROTEIN; HETEROTRIMERIC G-PROTEIN; ROD OUTER SEGMENTS; CGMP PHOSPHODIESTERASE; CRYSTAL-STRUCTURE; RGS PROTEINS; GAMMA-SUBUNIT; ACCELERATING PROTEIN; INHIBITORY SUBUNIT	RGS proteins (regulators of G protein signaling) are potent accelerators of the intrinsic GTPase activity of G protein alpha subunits (GAPs), thus controlling the response kinetics of a variety of cell signaling processes. Most RGS domains that have been studied have relatively little GTPase activating specificity especially for G proteins within the G(i) subfamily. Retinal RGS9 is unique in its ability to act synergistically with a downstream effector cGMP phosphodiesterase to stimulate the GTPase activity of the alpha subunit of transducin, G alpha(t). Here we report another unique property of RGS9: high specificity for G alpha(t). The core (RGS) domain of RGS9 (RGS9) stimulates G alpha(t) GTPase activity by 10-fold and G alpha(i1) GTPase activity by only 2-fold at a concentration of 10 mu M. Using chimeric G alpha(t)/G alpha(i1) subunits we demonstrated that the alpha-helical domain of G alpha(t) imparts this specificity. The functional effects of RGS9 were well correlated with its affinity for activated G alpha subunits as measured by a change in fluorescence of a mutant G alpha(t) (Chi6b) selectively labeled at Cys-210, K-d values for RGS9 complexes with G alpha(t) and G alpha(i1) calculated from the direct binding and competition experiments were 185 nM and 2 mu M, respectively. The gamma subunit of phosphodiesterase increases the GAP activity of RGS9, We demonstrate that this is because of the ability of P gamma to increase the affinity of RGS9 for G alpha(t). A distinct, nonoverlapping pattern of RGS and P gamma interaction with G alpha(t) suggests a unique mechanism of effector-mediated GAP function of the RGS9.	Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Dept Ophthalmol, Chicago, IL 60611 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60612 USA	Northwestern University; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Hamm, HE (corresponding author), Northwestern Univ, Inst Neurosci, Dept Mol Pharmacol & Biol Chem, Searle Bldg,Rm 5-555,320 E Super St, Chicago, IL 60611 USA.	h-hamm@nwu.edu	Hamm, Heidi E/G-2374-2014; Bae, Hyunsu/ABH-6248-2020	Bae, Hyunsu/0000-0002-0299-3582; YANG, CHII-SHEN/0000-0002-2792-6247	NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER; NEI NIH HHS [EY10291, EY06062] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 1998, J BIOL CHEM, V273, P21808, DOI 10.1074/jbc.273.34.21808; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Natochin M, 1998, BIOCHEMISTRY-US, V37, P13776, DOI 10.1021/bi981155a; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OTTOBRUC A, 1994, BIOCHEMISTRY-US, V33, P15215, DOI 10.1021/bi00255a001; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Seno K, 1998, J BIOL CHEM, V273, P22169, DOI 10.1074/jbc.273.35.22169; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Wieland T, 1997, J BIOL CHEM, V272, P8853; Yang CS, 1999, J BIOL CHEM, V274, P2379, DOI 10.1074/jbc.274.4.2379	54	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8770	8778		10.1074/jbc.274.13.8770	http://dx.doi.org/10.1074/jbc.274.13.8770			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085118	hybrid			2022-12-25	WOS:000079451600060
J	Chen, SC; Costa, CHRM; Nakamura, K; Ribeiro, RCJ; Gardner, DG				Chen, SC; Costa, CHRM; Nakamura, K; Ribeiro, RCJ; Gardner, DG			Vitamin D-dependent suppression of human atrial natriuretic peptide gene promoter activity requires heterodimer assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; D-RESPONSIVE ELEMENT; THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; TRANSCRIPTIONAL REPRESSION; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATION; 5'-FLANKING REGION; OSTEOCALCIN GENE	Crystallographic structures of the ligand-binding domains for the retinoid X (RXR) and estrogen receptors have identified conserved surface residues that participate in dimer formation. Homologous regions have been identified in the human vitamin D receptor (hVDR). Mutating Lys-386 to Ala (K386A) in hVDR significantly reduced binding to glutathione S-transferase-RXR alpha in solution3 whereas binding of an I384R/Q385R VDR mutant was almost undetectable. The K386A mutant formed heterodimers with RXR alpha on DR-3 (a direct repeat of AG-GTCA spaced by three nucleotides), whereas the I384R/Q385R mutant completely eliminated heterodimer formation. Wild type hVDR effected a 3-fold induction of DR-3-dependent thymidine kinase-luciferase activity in cultured neonatal rat atrial myocytes, an effect that was increased to 8-9-fold by cotransfected hRXR alpha. Induction by K386A, in the presence or absence of RXRa, was only slightly lower than that seen with wild type VDR. On the other hand, I384R/Q385R alone displayed no stimulatory activity and less than 2-fold induction in the presence of hRXR alpha. Qualitatively similar findings were observed with the negative regulation of the human atrial natriuretic peptide gene promoter by these mutants. Collectively, these studies identify specific amino acids in hVDR that play a critical role in heterodimer formation and subsequent modulation of gene transcription.	Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia	Gardner, DG (corresponding author), Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35753] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BAUER RF, 1976, IN VITRO CELL DEV B, V12, P558; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAO X, 1993, J BIOL CHEM, V268, P27371; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Chen SC, 1998, HYPERTENSION, V31, P1338, DOI 10.1161/01.HYP.31.6.1338; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DEMAY MB, 1992, P NATL ACAD SCI USA, V89, P8097, DOI 10.1073/pnas.89.17.8097; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DOKOH S, 1981, ANAL BIOCHEM, V116, P211, DOI 10.1016/0003-2697(81)90346-8; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; LI Q, 1994, J BIOL CHEM, V269, P4934; Liu SM, 1996, MOL ENDOCRINOL, V10, P206, DOI 10.1210/me.10.2.206; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; OZONO K, 1990, J BIOL CHEM, V265, P21881; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; RIBEIRO RCJ, 1998, KEYST S NUCL REC GEN, P64; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WHITFIELD GK, 1995, MOL ENDOCRINOL, V9, P1166, DOI 10.1210/me.9.9.1166; WU J, 1995, AM J PHYSIOL-ENDOC M, V268, pE1108, DOI 10.1152/ajpendo.1995.268.6.E1108; Wu JM, 1996, J CLIN INVEST, V97, P1577, DOI 10.1172/JCI118582; WU JP, 1989, J BIOL CHEM, V264, P6472	39	20	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11260	11266		10.1074/jbc.274.16.11260	http://dx.doi.org/10.1074/jbc.274.16.11260			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196214	hybrid			2022-12-25	WOS:000079751900082
J	Chin, BY; Petrache, I; Choi, AMK; Choi, ME				Chin, BY; Petrache, I; Choi, AMK; Choi, ME			Transforming growth factor beta(1) rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TGF-BETA; EPITHELIAL-CELLS; IN-VITRO; FACTOR-BETA-1; INHIBITION; RECEPTORS; EXPRESSION; MECHANISMS; CASCADE	Cell death and cell survival are central components of normal development and pathologic states. Transforming growth factor beta(1) (TGF-beta(1)) is a pleiotropic cytokine that regulates both cell growth and cell death. To better understand the molecular mechanisms that control cell death or survival, we investigated the role of TGF-beta(1) in the apoptotic process by dominant-negative inhibition of both TGF-beta(1) and mitogen-activated protein kinase (MAPK) signaling pathways. Murine macrophages (RAW 264.7) undergo apoptosis following serum deprivation, as determined by DNA laddering assay. However, apoptosis is prevented in serum-deprived macrophages by the presence of exogenous TGF-beta(1). Using stably transfected RAW 264.7 cells with the kinase-deleted dominant-negative mutant of T beta R-II (T beta R-IIM) cDNA, we demonstrate that this protective effect by TGF-beta(1) is completely abrogated. To determine the downstream signaling pathways, we examined TGF-beta(1) effects on the MAPK pathway. We show that TGF-beta(1) induces the extracellular signal-regulated kinase (ERK) activity in a time-dependent manner up to 4 h after stimulation. Furthermore, TGF-beta(1) does not rescue serum deprivation-induced apoptosis in RAW 264.7 cells transfected with a dominant-negative mutant MAPK (ERK2) cDNA or in wild type RAW 264.7 cells in the presence of the MAPK kinase (MEK1) inhibitor. Taken together, our data demonstrate for the first time that TGF-beta(1) is an inhibitor of apoptosis in cultured macrophages and may serve as a cell survival factor via T beta R-II-mediated signaling and downstream intracellular MAPK signaling pathway.	Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA; Vet Affairs Connecticut Healthcare Syst, New Haven, CT 06520 USA; Johns Hopkins Med Inst, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Johns Hopkins University; Johns Hopkins Medicine; Yale University	Choi, ME (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, 333 Cedar St,2073 LMP, New Haven, CT 06520 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010028, R29HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL-55330, F32 HL010028] Funding Source: Medline; NIAID NIH HHS [R01 AI-42365] Funding Source: Medline; NIDDK NIH HHS [5-K12-DK0129809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andjelic S, 1997, J IMMUNOL, V158, P2527; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano Liliana, 1996, Cytokine and Growth Factor Reviews, V7, P327, DOI 10.1016/S1359-6101(96)00042-1; CHOI ME, 1995, J BIOL CHEM, V270, P21144, DOI 10.1074/jbc.270.36.21144; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Frey RS, 1997, CANCER RES, V57, P628; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LOTEM J, 1992, BLOOD, V80, P1750; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	33	92	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11362	11368		10.1074/jbc.274.16.11362	http://dx.doi.org/10.1074/jbc.274.16.11362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196228	hybrid			2022-12-25	WOS:000079751900096
J	Chuang, TL; Schleef, RR				Chuang, TL; Schleef, RR			Identification of a nuclear targeting domain in the insertion between helices C and D in protease inhibitor-10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-2; SERINE PROTEINASE-INHIBITOR; MOLECULAR CHARACTERIZATION; OVALBUMIN FAMILY; HUMAN SERPIN; CLONING; CELLS; DIFFERENTIATION; EXPRESSION; TRANSPORT	Protease inhibitor 10 (PI-10), an intracellular ovalbumin-serpin, contains a series of basic amino acids in the loop between helices C and D that exhibit homology to known nuclear targeting signals. Transfection of HeLa cells with plasmids encoding enhanced green fluorescent protein (EGFP) coupled to PI-10 revealed an intense fluorescence of the nucleus. Immunoblotting demonstrated a single M-r 80,000 EGFP . PI-10 complex in isolated nuclei. Mutation of four basic amino acids in the interhelical loop to alanines (i.e. K74A, K75A, R76A, K77A) resulted in the fluorescent complex being confined to the cytoplasm, Further evidence for a nuclear targeting signal in this region was provided by localization of the fluorescent label to the nucleus in cells transfected with a plasmid encoding EGFP fused to the 25 amino acids comprising the interhelical loop of PI-10 (i.e. Arg-63 to Glu-87), whereas a cytoplasmic distribution was noted for the construct encoding EGFP coupled to the mutated interhelical loop. These data raise the possibility that PI-10 may play a role in regulating protease activity within the nucleus, a property unique in the field of serpin biology.	Scripps Res Inst, Dept Vasc Biol VB1, La Jolla, CA 92037 USA	Scripps Research Institute	Schleef, RR (corresponding author), Scripps Res Inst, Dept Vasc Biol VB1, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049563, R01HL045954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45954, HL49563] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENZ WC, 1975, P NATL ACAD SCI USA, V72, P2413, DOI 10.1073/pnas.72.6.2413; CARTER DB, 1976, BIOCHEMISTRY-US, V15, P180, DOI 10.1021/bi00646a028; CHONG MT, 1974, BIOCHEMISTRY-US, V13, P5128, DOI 10.1021/bi00722a012; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; GOMBAU L, 1994, J BIOL CHEM, V269, P3875; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Jensen PH, 1996, J BIOL CHEM, V271, P26892, DOI 10.1074/jbc.271.43.26892; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; Riewald M, 1998, BLOOD, V91, P1256, DOI 10.1182/blood.V91.4.1256; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; Rivett AJ, 1998, CURR OPIN IMMUNOL, V10, P110, DOI 10.1016/S0952-7915(98)80040-X; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; SILVER P, 1989, CRIT REV BIOCHEM MOL, V24, P419, DOI 10.3109/10409238909082557; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; TOKES ZA, 1989, J BIOL CHEM, V264, P15059; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; YE RD, 1989, J BIOL CHEM, V264, P5495; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	30	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11194	11198		10.1074/jbc.274.16.11194	http://dx.doi.org/10.1074/jbc.274.16.11194			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196205	hybrid			2022-12-25	WOS:000079751900073
J	Fukao, M; Mason, HS; Britton, FC; Kenyon, JL; Horowitz, B; Keef, KD				Fukao, M; Mason, HS; Britton, FC; Kenyon, JL; Horowitz, B; Keef, KD			Cyclic GMP-dependent protein kinase activates cloned BKCa channels expressed in mammalian cells by direct phosphorylation at serine 1072	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CA2+-ACTIVATED K+ CHANNEL; PORCINE CORONARY-ARTERY; POTASSIUM CHANNELS; NITRIC-OXIDE; CA CHANNELS; VASORELAXATION; IDENTIFICATION; VASODILATION; STIMULATION	NO-induced activation of cGMP-dependent protein kinase (PKG) increases the open probability of large conductance Ca2+-activated K+ channels and results in smooth muscle relaxation, However, the molecular mechanism of channel regulation by the NO-PKG pathway has not been determined on cloned channels. The present study was designed to clarify PKG-mediated modulation of channels at the molecular level. The cDNA encoding the alpha-subunit of the large conductance Ca2+-activated K+ channel, cslo-alpha, was expressed in HER293 cells. Whole cell and single channel characteristics of cslo-alpha exhibited functional features of native large conductance Ca2+-activated K+ channels in smooth muscle cells. The NO-donor sodium nitroprusside increased outward current 2.3-fold in whole cell recordings. In cell-attached patches, sodium nitroprusside increased the channel open probability (NPo) of cslo-alpha channels 3.3-fold without affecting unitary conductance. The stimulatory effect of sodium nitroprusside was inhibited by the PKG-inhibitor KT5823. Direct application of PKG-I alpha to the cytosolic surface of inside-out patches increased NPo 3.2-fold only in the presence of ATP and cGMP without affecting unitary conductance. A point mutation of cslo-alpha in which Ser-1072 (the only optimal consensus sequence for PKG phosphorylation) was replaced by Ala abolished the PKG effect on NPo in inside-out patches and the effect of SNP in cell attached patches. These results indicate that PKG activates cslo-alpha by direct phosphorylation at serine 1072.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Keef, KD (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA.		Britton, Fiona/Q-5338-2016	Britton, Fiona/0000-0002-3834-9940; Kenyon, James/0000-0001-8699-4680	NHLBI NIH HHS [HL40399] Funding Source: Medline; NIDDK NIH HHS [DK41315] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040399, R01HL040399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BERS D, 1994, METHODS CELL BIOL PR, V40; BIALECKI RA, 1995, AM J PHYSIOL-LUNG C, V268, pL152, DOI 10.1152/ajplung.1995.268.1.L152; Bischof G, 1997, CELL CALCIUM, V21, P135, DOI 10.1016/S0143-4160(97)90037-3; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Bychkov R, 1998, J PHARMACOL EXP THER, V285, P293; CARL A, 1989, AM J PHYSIOL, V257, pC470, DOI 10.1152/ajpcell.1989.257.3.C470; DINERMAN JL, 1994, NEUROPHARMACOLOGY, V33, P1245, DOI 10.1016/0028-3908(94)90023-X; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; ESGUERRA M, 1994, NATURE, V369, P563, DOI 10.1038/369563a0; FUJINO K, 1991, J PHARMACOL EXP THER, V256, P371; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; Goyal RK, 1998, AM J PHYSIOL-GASTR L, V275, pG1185, DOI 10.1152/ajpgi.1998.275.5.G1185; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Jiang F, 1998, BRIT J PHARMACOL, V123, P106, DOI 10.1038/sj.bjp.0701552; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KHAN SA, 1993, J PHARMACOL EXP THER, V267, P1327; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LECHLEITER JD, 1988, NEURON, V1, P227, DOI 10.1016/0896-6273(88)90143-2; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; MINAMI K, 1993, BIOCHEM BIOPH RES CO, V190, P263, DOI 10.1006/bbrc.1993.1040; Mistry DK, 1998, BRIT J PHARMACOL, V124, P1131, DOI 10.1038/sj.bjp.0701940; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; PREVARSKAYA NB, 1995, J BIOL CHEM, V270, P24292, DOI 10.1074/jbc.270.41.24292; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Saito M, 1997, J BIOL CHEM, V272, P11710, DOI 10.1074/jbc.272.18.11710; Sansom SC, 1996, CLIN EXP PHARMACOL P, V23, P76; Tanaka Y, 1998, N-S ARCH PHARMACOL, V357, P705, DOI 10.1007/PL00005228; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vaali K, 1998, J PHARMACOL EXP THER, V286, P110; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WILLIAMS DL, 1988, P NATL ACAD SCI USA, V85, P9360, DOI 10.1073/pnas.85.23.9360; Yu SP, 1998, J NEUROSCI RES, V52, P612, DOI 10.1002/(SICI)1097-4547(19980601)52:5<612::AID-JNR13>3.0.CO;2-3; Zhou XB, 1998, PFLUG ARCH EUR J PHY, V436, P725, DOI 10.1007/s004240050695; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; Zhu GY, 1998, J NEUROSCI METH, V81, P73, DOI 10.1016/S0165-0270(98)00019-3	49	156	168	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10927	10935		10.1074/jbc.274.16.10927	http://dx.doi.org/10.1074/jbc.274.16.10927			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196172	hybrid			2022-12-25	WOS:000079751900040
J	Reimers, L; Borras, AM; Kurdistani, SK; Garreau, JR; Chung, M; Aaronson, SA; Lee, SW				Reimers, L; Borras, AM; Kurdistani, SK; Garreau, JR; Chung, M; Aaronson, SA; Lee, SW			Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; TUMOR-SUPPRESSOR PROTEIN; MESSENGER-RNA; GENE; GROWTH; OVEREXPRESSION; EXPRESSION; SITES; PCNA; PROLIFERATION	Cyclin G, a recent addition to the cyclin family, was initially identified in screens for new src kinase family members and soon thereafter by differential screening for transcriptional targets of the tumor suppressor gene, p53. We have identified cyclin G as being overexpressed in breast and prostate cancer cells using differential display polymerase chain reaction screening. We demonstrate here that cyclin G is overexpressed in human breast and prostate cancer cells and in cancer cells in sifu from tumor specimens. Cyclin G expression was tightly regulated throughout the cell cycle in normal breast cells, peaking at the S and G(2)/M phases of the cell cycle with lower levels in G(1). The cell cycle-dependent expression was absent in breast cancer cells. Following DNA damage in normal p53+/+ cells, cyclin G is triggered to cluster in discrete nuclear DNA replication foci that contain replication-associated proteins such as proliferating cell nuclear antigen (PCNA). While p53-/- cells displayed a faint cyclin G nuclear staining pattern, there was no increased expression and no change in distribution of the staining pattern after DNA damage. The specific subcellular localization of cyclin G at DNA replication foci provides an additional link between p53-mediated growth arrest and cell cycle regulation and suggests that cyclin G may act as an effector of p53-mediated events by functional association with replication foci protein(s).	Harvard Univ, Inst Med, Sch Med, Beth Israel Deaconess Med Ctr,Dept Med, Boston, MA 02115 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Lee, SW (corresponding author), Harvard Univ, Inst Med, Sch Med, Beth Israel Deaconess Med Ctr,Dept Med, Rm 921,77 Ave Louis Pasteur, Boston, MA 02115 USA.			Kurdistani, Siavash/0000-0003-3295-3511				BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Bates S, 1996, ONCOGENE, V13, P1103; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Chen DS, 1997, HUM GENE THER, V8, P1667, DOI 10.1089/hum.1997.8.14-1667; Chen JD, 1996, MOL CELL BIOL, V16, P2445; EMERMAN JT, 1990, IN VITRO CELL DEV B, V26, P1186; ETHIER SP, 1993, CANCER RES, V53, P627; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JIANG W, 1992, CANCER RES, V52, P2980; KEOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1998, EXP CELL RES, V242, P235, DOI 10.1006/excr.1998.4078; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; TAMURA K, 1993, ONCOGENE, V8, P2113; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395; WU LT, 1994, ONCOL REP, V1, P705; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	38	75	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11022	11029		10.1074/jbc.274.16.11022	http://dx.doi.org/10.1074/jbc.274.16.11022			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196184	hybrid			2022-12-25	WOS:000079751900052
J	Boensch, C; Huang, SS; Connolly, DT; Huang, JS				Boensch, C; Huang, SS; Connolly, DT; Huang, JS			Cell surface retention sequence binding protein-1 interacts with the v-sis gene product and platelet-derived growth factor beta-type receptor in simian sarcoma virus-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-A-CHAIN; ALTERNATIVELY SPLICED EXON; NIH 3T3 CELLS; AUTOCRINE TRANSFORMATION; EXTRACELLULAR-MATRIX; ONCOGENE PRODUCT; PDGF; IDENTIFICATION; MECHANISM; SURAMIN	The cell surface retention sequence (CRS) binding protein-1 (CRSBP-1) is a newly identified membrane glycoprotein which is hypothesized to be responsible for cell surface retention of the oncogene v-sis and c-sis gene products and other secretory proteins containing CRSs, In simian sarcoma virus-transformed NIH 3T3 cells (SSV-NIH 3T3 cells), a fraction of CRSBP-1 was demonstrated at the cell surface and underwent internalization/recycling as revealed by cell surface I-125 labeling and its resistance/sensitivity to trypsin digestion. However, the majority of CRSBP-1 was localized in intracellular compartments as evidenced by the resistance of most of the S-35-metabolically labeled CRSBP-1 to trypsin digestion, and by indirect immunofluorescent staining. CRSBP-1 appeared to form complexes with proteolytically processed forms (generated at and/or after the trans-Golgi network) of the v-sis gene product and with a similar to 140-kDa proteolytically cleaved form of the platelet-derived growth factor (PDGF) beta-type receptor, as demonstrated by metabolic labeling and co-immunoprecipitation. CRSBP-1, like the v-sis gene product and PDGF beta-type receptor, underwent rapid turnover which was blocked in the presence of 100 mu M suramin, In normal and other transformed NIH 3T3 cells, CRSBP-1 was relatively stable and did not undergo rapid turnover and internalization/recycling at the cell surface. These results suggest that in SSV-NIH 3T3 cells, CRSBP-1 interacts with and forms ternary and binary complexes with the newly synthesized v-sis gene product and PDGF P-type receptor at the trans-Golgi network and that the stable binary (CRSBP-1.v-sis gene product) complex is transported to the cell surface where it presents the v-sis gene product to unoccupied PDGF beta-type receptors during internalization/recycling.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Monsanto Co, Atherosclerosis Res, St Louis, MO 63167 USA	Saint Louis University; Monsanto	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.				NCI NIH HHS [CA38808] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baghdiguian S, 1996, EUR J CANCER, V32A, P525, DOI 10.1016/0959-8049(95)00588-9; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOENSCH C, 1995, J BIOL CHEM, V270, P1807, DOI 10.1074/jbc.270.4.1807; BOENSCH C, 1998, THESIS ST LOUIS U; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DEUEL TF, 1984, BLOOD, V64, P951; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANNINK M, 1988, J CELL BIOL, V107, P287, DOI 10.1083/jcb.107.1.287; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; Huang SS, 1997, FEBS LETT, V416, P297, DOI 10.1016/S0014-5793(97)01213-1; HUANG SS, 1988, J BIOL CHEM, V263, P12608; HUBBARD AL, 1972, J CELL BIOL, V55, P390, DOI 10.1083/jcb.55.2.390; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P7478; KHACHIGIAN LM, 1992, J BIOL CHEM, V267, P1660; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RORSMAN F, 1988, MOL CELL BIOL, V8, P571, DOI 10.1128/MCB.8.2.571; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	38	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10582	10589		10.1074/jbc.274.15.10582	http://dx.doi.org/10.1074/jbc.274.15.10582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187853	hybrid			2022-12-25	WOS:000079663500092
J	Kobayashi, M; Sugumaran, G; Liu, JA; Shworak, NW; Silbert, JE; Rosenberg, RD				Kobayashi, M; Sugumaran, G; Liu, JA; Shworak, NW; Silbert, JE; Rosenberg, RD			Molecular cloning and characterization of a human uronyl 2-sulfotransferase that sulfates iduronyl and glucuronyl residues in dermatan chondroitin sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; N-DEACETYLASE/N-SULFOTRANSFERASE; HAMSTER OVARY CELLS; HIGH-AFFINITY; CDNA CLONING; EXPRESSION; SEQUENCE; BINDING; BIOSYNTHESIS	A partial-length human cDNA with a predicted amino acid sequence homologous to a previously described heparan sulfate iduronyl 2-sulfotransferase (Kobayashi, M., Habuchi, H,, Yoneda, M,, Habuchi, O,, and Kimata, K, (1997) J, Biol, Chem. 272, 13980-13985) was obtained by searching the expressed sequence-tagged data bank. Northern blot analysis was performed using this homologous cDNA as a probe, which demonstrated ubiquitous expression of messages of 5.1 and 2.0 kilobases in a number of human tissues and in several human cancer cell lines. Since the human lymphoma Raji cell line had the highest level of expression, it was used to isolate a full-length cDNA clone, The full-length cDNA was found to contain an open reading frame that predicted a type IT transmembrane protein composed of 406 amino acid residues. The cDNA in a baculovirus expression vector was expressed in Sf9 insect cells, and cell extracts were then incubated together with 3'-phosphoadenosine 5'phospho[S-35]sulfate and potential glycosaminoglycan accepters. This demonstrated substantial sulfotransferase activity with dermatan sulfate, a small degree of activity with chondroitin sulfate, but no sulfotransferase activity with desulfated N-resulfated heparin, Analysis of [S-35]sulfate-labeled disaccharide products of chondroitin ABC, chondroitin AC, and chondroitin B lyase treatment demonstrated that the enzyme only transferred sulfate to the a-position of uronyl residues, which were preponderantly iduronyl residues in dermatan sulfate, but some lesser transfer to glucuronyl residues of chondroitin sulfate.	MIT, Dept Biol, Cambridge, MA 02139 USA; Edith Nourse Rogers Mem Vet Adm Hosp, Bedford, MA 01730 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02215 USA; Beth Israel Hosp, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Rosenberg, RD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave,68-480, Cambridge, MA 02139 USA.		Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66385] Funding Source: Medline; NIAMS NIH HHS [AR-41649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS MD, 1995, NATURE, V377, P3; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; CLARKE D, 1995, CYTOKINE, V7, P325, DOI 10.1006/cyto.1995.0041; DAVIDSON S, 1990, J BIOL CHEM, V265, P12324; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fransson L.-A., 1993, DERMATAN SULPHATE PR, P11; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Habuchi H, 1998, J BIOL CHEM, V273, P9208, DOI 10.1074/jbc.273.15.9208; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; MARK M P, 1990, International Journal of Developmental Biology, V34, P191; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; POWERS PA, 1991, GENETICS, V129, P133; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Silbert JE, 1996, GLYCOCONJUGATE J, V13, P907, DOI 10.1007/BF01053185; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; SILBERT JE, 1993, DERMATAN SULFATE PRO, P147; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGUMARAN G, 1989, METHOD ENZYMOL, V169, P428; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	49	119	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10474	10480		10.1074/jbc.274.15.10474	http://dx.doi.org/10.1074/jbc.274.15.10474			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187838	hybrid			2022-12-25	WOS:000079663500077
J	Pandey, P; Avraham, S; Kumar, S; Nakazawa, A; Place, A; Ghanem, L; Rana, A; Kumar, V; Majumder, PK; Avraham, H; Davis, RJ; Kharbanda, S				Pandey, P; Avraham, S; Kumar, S; Nakazawa, A; Place, A; Ghanem, L; Rana, A; Kumar, V; Majumder, PK; Avraham, H; Davis, RJ; Kharbanda, S			Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; C-JUN; MAP KINASE; IONIZING-RADIATION; STRESS-RESPONSE; GENE-EXPRESSION; ABL; PHOSPHORYLATION; CALCIUM	The stress-activated p38 mitogen-activated protein kinase (p38 MAPK), a member of the subgroup of mammalian kinases, appears to play an important role in regulating inflammatory responses, including cytokine secretion and apoptosis, The upstream mediators that link extracellular signals with the p38 MAPK signaling pathway are currently unknown. Here we demonstrate that pp125 focal adhesion kinase-related tyrosine kinase RAFTK (also known as PYK2, CADTK) is activated specifically by methylmethane sulfonate (MMS) and hyperosmolarity but not by ultraviolet radiation, ionizing radiation, or cis-platinum. Overexpression of RAFTK leads to the activation of p38 MAPK, Furthermore, overexpression of a dominant-negative mutant of RAFTK (RAFTK K-M) inhibits MMS-induced p38 MAPK activation. MKK3 and MKK6 are known potential constituents of p38 MAPK signaling pathway, whereas SEK1 and MEK1 are upstream activators of SAPK/JNK and ERK pathways, respectively. We observe that the dominant-negative mutant of MKK3 but not of MKK6, SEK1, or MEK1 inhibits RAFTK-induced p38 MAPK activity. Furthermore, the results demonstrate that treatment of cells with 1,2-bis(2-aminophenoxy)ethane-N,N,N'.N'-tetraacetic acid, tetra(acetoxymethyl)-ester, a membrane-permeable calcium chelator, inhibits MMS-induced activation of RAFTK and p38 MAPK. Taken together, these findings indicate that RAFTK represents a stress-sensitive mediator of the p38 MAPK signaling pathway in response to certain cytotoxic agents.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Inst Med, Deaconess Med Ctr, Div Expt Med & Hematol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Howard Hughes Med Inst,Program Mol Med, Worcester, MA 01605 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Kharbanda, S (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Ghanem, Louis/R-3733-2016; Rana, Ajay/ABE-3739-2020	Ghanem, Louis/0000-0002-7723-5241; Rana, Ajay/0000-0003-0951-2566; Avraham, Hava/0000-0002-7545-3640; Kumar, Vijay/0000-0001-6477-8274	NATIONAL CANCER INSTITUTE [R01CA075216, R01CA065861] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NCI NIH HHS [CA75216, CA65861] Funding Source: Medline; NHLBI NIH HHS [R01 HL55445] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; NARAHARA H, 1995, J CLIN ENDOCR METAB, V80, P3121, DOI 10.1210/jc.80.11.3121; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SMITH GJ, 1986, AM J PATHOL, V122, P488; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	37	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10140	10144		10.1074/jbc.274.15.10140	http://dx.doi.org/10.1074/jbc.274.15.10140			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187797	hybrid			2022-12-25	WOS:000079663500036
J	Thakker, GD; Hajjar, DP; Muller, WA; Rosengart, TK				Thakker, GD; Hajjar, DP; Muller, WA; Rosengart, TK			The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; FOCAL ADHESION KINASE; PERMEABILITY FACTOR; CATALYTIC SUBUNIT; RECEPTOR; ACTIVATION; PROTEIN; CELLS; KDR; PHOSPHORYLATION	Vascular endothelial growth factor (VEGF) receptor Flk-1/KDR in endothelial cells is activated during vasculogenesis and angiogenesis upon ligand-receptor interaction. Activated Flk-1/KDR has been shown to recruit Src homology 2 domain-containing signaling molecules that are known to serve as links to the activation of the mitogen-activated protein (MAP) kinase signaling pathway. To define the functional significance of phosphatidylinositol (PI) 3-kinase in VEGF signaling, we have examined its role in human umbilical vein endothelial cell (HUVEC) cycle progression. We show herein that p85, the regulatory subunit of PI 3-kinase, is constitutively associated with Flk-1/KDR. The treatment of HUVECs with VEGF promoted tyrosine autophosphorylation of Flk-1/KDR and also induced phosphorylation of p85, This was followed by an increase in the PI 3-kinase activity, which was sensitive to wortmannin, a potent PI 3-kinase inhibitor, VEGF also induced a striking activation of MAP kinase in a time-dependent manner. Inhibition studies with both a dominant-negative p85 mutant and the PI 3-kinase inhibitor, wortmannin, were employed to show for the first time that VEGF-stimulated PI 3-kinase modulates MAP kinase activation and nuclear events such as transcription from c-fos promoter and entry into the synthesis (S)-phase, Our data demonstrate the importance of PI 3-kinase as a necessary signaling component of VEGF-mediated cell cycle progression.	Cornell Univ, Weill Med Coll, Dept Cardiothorac Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Cornell University; Cornell University	Rosengart, TK (corresponding author), Cornell Univ, Weill Med Coll, Dept Cardiothorac Surg, Rm F2103,1300 York Ave, New York, NY 10021 USA.	tkrosen@mail.med.cornell.edu						Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Brown LF, 1997, LAB INVEST, V76, P245; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; Iwama A., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS318, DOI 10.1111/j.1440-1681.1995.tb02935.x; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Phillips G D, 1994, In Vivo, V8, P961; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; TAKHASHI T, 1997, ONCOGENE, V14, P2079; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TRIESMAN R, 1995, EMBO J, V14, P4905; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANDERGREER P, 1995, CURR BIOL, V5, P405; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YUSOFF P, 1994, GROWTH FACTORS, V10, P181, DOI 10.3109/08977199409000236	46	206	216	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10002	10007		10.1074/jbc.274.15.10002	http://dx.doi.org/10.1074/jbc.274.15.10002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187776	hybrid			2022-12-25	WOS:000079663500015
J	Ganesan, AK; Mende-Mueller, L; Selzer, J; Barbieri, JT				Ganesan, AK; Mende-Mueller, L; Selzer, J; Barbieri, JT			Pseudomonas aeruginosa exoenzyme S, a double ADP-ribosyltransferase, resembles vertebrate mono-ADP-ribosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; EUKARYOTIC CELLS; RAS; RIBOSYLATION; EXPRESSION; PROTEIN; SEQUENCE; CLONING; TARGET; ACTIN	Previous data indicated that Pseudomonas aeruginosa exoenzyme S (ExoS) ADP-ribosylated Ras at multiple sites. One site appeared to be Arg(41), but the second site could not be localized. In this study, the sites of ADP-ribosylation of c-Ha-Ras by ExoS were directly determined. Under saturating conditions, ExoS ADP-ribosylated Ras to a stoichiometry of 2 mol of ADP-ribose incorporated per mol of Ras, Nucleotide occupancy did not influence the stoichiometry or velocity of ADP-ribosylation of Ras by ExoS. Edman degradation and mass spectrometry of V8 protease generated peptides of ADP-ribosylated Ras identified the sites of ADP-ribosylation to be Arg(41) and Arg(128). ExoS ADP-ribosylated the double mutant, RasR41K,R128K, to a stoichiometry of 1 mol of ADP-ribose incorporated per mol of Pas, which indicated that Ras possessed an alternative site of ADP-ribosylation. The alternative site of ADP-ribosylation on Has was identified as Arg(135), which was on the same alpha-helix as Arg(128). Arg(41) and Arg(128) are located within two different secondary structure motifs, beta-sheet and alpha-helix, respectively, and are spatially separated within the three-dimensional structure of Has. The fact that ExoS could ADP-ribosylate a target protein at multiple sites, along with earlier observations that ExoS could ADP-ribosylate numerous target proteins, were properties that have been attributed to several vertebrate ADP-ribosyltransferases, This prompted a detailed alignment study which showed that the catalytic domain of ExoS possessed considerably more primary amino acid homology with the vertebrate mono-ADP-ribosyltransferases than the bacterial ADP-ribosyltransferases. These data are consistent with the hypothesis that ExoS may represent an evolutionary link between bacterial and vertebrate mono-ADP-ribosyltransferases.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Freiburg, Inst Pharmacol & Toxicol, D-79104 Freiburg, Germany	Medical College of Wisconsin; Medical College of Wisconsin; University of Freiburg	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	toxin@mcw.edu			NIAID NIH HHS [AI-30162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BODEY GP, 1983, REV INFECT DIS, V5, P279; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; FRITZ G, 1994, EUR J BIOCHEM, V223, P909, DOI 10.1111/j.1432-1033.1994.tb19068.x; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; JUST I, 1995, BIOCHEMISTRY-US, V34, P326, DOI 10.1021/bi00001a040; Klebl BM, 1997, ARCH BIOCHEM BIOPHYS, V347, P155, DOI 10.1006/abbi.1997.0330; Knight DA, 1997, INFECT IMMUN, V65, P3304, DOI 10.1128/IAI.65.8.3304-3309.1997; KRUEGER KM, 1995, CLIN MICROBIOL REV, V8, P34, DOI 10.1128/CMR.8.1.34; KULICH SM, 1993, INFECT IMMUN, V61, P307, DOI 10.1128/IAI.61.1.307-313.1993; McGuffie EM, 1998, INFECT IMMUN, V66, P2607, DOI 10.1128/IAI.66.6.2607-2613.1998; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OKAZAKI IJ, 1994, BIOCHEMISTRY-US, V33, P12828, DOI 10.1021/bi00209a014; Olson JC, 1997, INFECT IMMUN, V65, P248, DOI 10.1128/IAI.65.1.248-256.1997; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; TERASHIMA M, 1995, EUR J BIOCHEM, V231, P242, DOI 10.1111/j.1432-1033.1995.0242f.x; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; WANG J, 1994, J IMMUNOL, V153, P4048; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; Yu YJ, 1997, DNA CELL BIOL, V16, P235, DOI 10.1089/dna.1997.16.235; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	27	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9503	9508		10.1074/jbc.274.14.9503	http://dx.doi.org/10.1074/jbc.274.14.9503			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092634	hybrid			2022-12-25	WOS:000079451800053
J	Idriss, SD; Gudi, T; Casteel, DE; Kharitonov, VG; Pilz, RB; Boss, GR				Idriss, SD; Gudi, T; Casteel, DE; Kharitonov, VG; Pilz, RB; Boss, GR			Nitric oxide regulation of gene transcription via soluble guanylate cyclase and type I cGMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; C-FOS; EXPRESSION; CELLS; PHOSPHORYLATION; DIFFERENTIATION; STIMULATION; CLONING; SIGNAL; ALPHA	Nitric oxide (NO) regulates the expression of multiple genes but in most cases its precise mechanism of action is unclear. We used baby hamster kidney (BHK) cells, which have very low soluble guanylate cyclase and cGMP-dependent protein kinase (G-kinase) activity, and CS-54 arterial smooth muscle cells, which express these two enzymes, to study NO regulation of the human fos promoter. The NO-releasing agent Deta-NONOate (ethanamine-2,2'-(hydroxynitrosohydrazone)bis-) had no effect on a chloramphenicol acetyltransferase (CAT) reporter gene under control of the fos promoter in BHK cells transfected with an empty vector or in cells transfected with a G-kinase I beta expression vector. In BHK cells transfected with expression vectors for guanylate cyclase, Deta-NONOate markedly increased the intracellular cGMP concentration and caused a small (2-fold) increase in CAT activity; the increased CAT activity appeared to be from cGMP activation of cAMP-dependent protein kinase, In BHK cells co-transfected with guanylate cyclase and G-kinase expression vectors, CAT activity was increased 5-fold in the absence of Deta-NONOate and 7-fold in the presence of Deta-NONOate, Stimulation of CAT activity in the absence of Deta-NONOate appeared to be largely from endogenous NO since we found that: (i) BHK cells produced high amounts of NO; (ii) CAT activity was partially inhibited by a NO synthase inhibitor; and (iii) the inhibition by the NO synthase inhibitor was reversed by exogenous NO. In CS-54 cells, we found that NO increased fos promoter activity and that the increase was prevented by a guanylate cyclase inhibitor. In summary, we found that NO activates the fos promoter by a guanylate cyclase- and G-kinase-dependent mechanism.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Alliance Pharmaceut Co, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	gboss@UCSD.edu		Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM055586] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BOSCOFELLEY E, 1994, AM J RESP CELL MOL B, V11, P159; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CORNWELL TL, 1994, AM J PHYSIOL, pC1405; DE CR, 1995, J CLIN INVEST, V96, P60; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; EIGENTHALER M, 1998, REV PHYSL BIOCH PHAR, V135, P173; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HABY C, 1994, J NEUROCHEM, V62, P496; IDRISS SD, 1992, BIOCHEM BIOPH RES CO, V183, P312, DOI 10.1016/0006-291X(92)91645-7; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAKAZAWA K, 1993, NEUROREPORT, V4, P1275, DOI 10.1097/00001756-199309000-00017; OHKI K, 1995, BRAIN RES, V696, P140, DOI 10.1016/0006-8993(95)00914-C; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PILZ RB, 1994, J BIOL CHEM, V269, P32155; ROTHMAN A, 1992, CIRCULATION, V86, P1977, DOI 10.1161/01.CIR.86.6.1977; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Whorton AR, 1997, AM J PHYSIOL-LUNG C, V272, pL1161, DOI 10.1152/ajplung.1997.272.6.L1161; WOLFE L, 1989, J BIOL CHEM, V264, P7734	34	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9489	9493		10.1074/jbc.274.14.9489	http://dx.doi.org/10.1074/jbc.274.14.9489			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092632	hybrid			2022-12-25	WOS:000079451800051
J	Collins, SP; Uhler, MD				Collins, SP; Uhler, MD			Cyclic AMP- and cyclic GMP-dependent protein kinases differ in their regulation of cyclic AMP response element-dependent gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; HUMAN-PLATELETS; C-FOS; MOLECULAR-CLONING; MAMMALIAN-CELLS; FOCAL ADHESION; SMOOTH-MUSCLE; 2 ISOFORMS; IN-VITRO; CAMP	The ability of cGMP-dependent protein kinases (cGKs) to activate cAMP response element (CRE)-dependent gene transcription was compared with that of cAMP-dependent protein kinases (cAKs). Although both the type IP cGMP-dependent protein kinase (cGKI beta) and the type II cAMP-dependent protein kinase (cAKII) phosphorylated the cytoplasmic substrate VASP (vasodilator- and A kinase-stimulated phosphoprotein) to a similar extent, cyclic nucleotide regulation of CRE-dependent transcription was at least 10-fold higher in cAKII-transfected cells than in cGKI beta-transfected cells. Overexpression of each kinase in mammalian cells resulted in a cytoplasmic localization of the unactivated enzyme. As reported previously, the catalytic (C) subunit of cAKII translocated to the nucleus following activation by 8-bromo-cyclic AMP. However, cGKI beta did not translocate to the nucleus upon activation by 8-bromocyclic GMP. Replacement of an autophosphorylated serine (Ser(79)) of cGKI beta with an aspartic acid resulted in a mutant kinase with constitutive kinase activity in vitro and in vivo. The cGKI beta S79D mutant localized to the cytoplasm and was only a weak activator of CRE-dependent gene transcription. However, an amino-terminal deletion mutant of cGKI beta was found in the nucleus as well as the cytoplasm and was a strong activator of CRE-dependent gene transcription. These data suggest that the inability of cGKs to translocate to the nucleus is responsible for the differential ability of cAKs and cGKs to activate CRE-dependent gene transcription and that nuclear redistribution of cGKs is not required for NO/cGMP regulation of gene transcription.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48104 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Uhler, MD (corresponding author), Univ Michigan, Neurosci Labs, Bldg 1103 E Huron St, Ann Arbor, MI 48104 USA.				NIGMS NIH HHS [GM 38788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038788, R29GM038788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASWAD DW, 1981, J BIOL CHEM, V256, P3487; BOERTH NJ, 1994, FEBS LETT, V342, P255, DOI 10.1016/0014-5793(94)80512-1; BROWN NA, 1990, J BIOL CHEM, V265, P13181; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; Collins SP, 1997, J BIOL CHEM, V272, P18169, DOI 10.1074/jbc.272.29.18169; CORNWELL TL, 1991, MOL PHARMACOL, V40, P923; Coven E, 1998, J NEUROCHEM, V71, P1865; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; COX S, 1994, J BIOL CHEM, V269, P22614; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GEAHLEN RL, 1980, J BIOL CHEM, V255, P1164; Gibson RM, 1997, J BIOL CHEM, V272, P31998, DOI 10.1074/jbc.272.51.31998; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GLASS DB, 1982, J BIOL CHEM, V257, P1196; Gudi T, 1996, J BIOL CHEM, V271, P4597; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; HABY C, 1994, J NEUROCHEM, V62, P496; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KUO JF, 1975, P NATL ACAD SCI USA, V72, P2256, DOI 10.1073/pnas.72.6.2256; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINCOLN TM, 1993, ADV SEC MESS PHOSPH, V28, P121; LOHMANN SM, 1981, P NATL ACAD SCI-BIOL, V78, P653, DOI 10.1073/pnas.78.1.653; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; UHLER MD, 1993, J BIOL CHEM, V268, P13586; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; Vaandrager AB, 1996, J BIOL CHEM, V271, P7025, DOI 10.1074/jbc.271.12.7025; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; Walter U, 1989, REV PHYSL BIOCH PHAR, V113, P41; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zimmer M, 1996, GENOMICS, V36, P227, DOI 10.1006/geno.1996.0457	76	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8391	8404		10.1074/jbc.274.13.8391	http://dx.doi.org/10.1074/jbc.274.13.8391			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085070	hybrid			2022-12-25	WOS:000079451600012
J	Egan, BS; Lane, KB; Shepherd, VL				Egan, BS; Lane, KB; Shepherd, VL			PU.1 and USF are required for macrophage-specific mannose receptor promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; TRANSCRIPTION FACTOR PU.1; LOOP-HELIX PROTEIN; DNA-BINDING; COOPERATIVE INTERACTION; REGULATES EXPRESSION; GENE-EXPRESSION; CD11B PROMOTER; MYELOID CELLS; ETS ONCOGENE	In the current study we report the isolation of 854 base pairs of the rat mannose receptor promoter. Analysis of the sequence revealed one Sp1 site, three PU.1 sites, and a potential TATA box (TTTAAA) 33 base pairs 5' of the transcriptional start site. The tissue specificity of the promoter was determined using transient transfections, The promoter was most active in the mature macrophage cell line NR8383 although the promoter also showed activity in the monocytic cell line RAW. No activity was observed in pre-monocytic cell lines or epithelial cell lines, Mutation of the TTTAAA sequence to TTGGAA resulted in a 50% decrease in activity in transient transfection assays suggesting that the promoter contains a functional TATA box, Using electrophoretic mobility shift assays and mutagenesis we established that the transcription factors Sp1, PU.1, and USF bound to the mannose receptor promoter, but only PU.1 and USF contributed to activation. Transient transfections using a dominant negative construct of USF resulted in a 50% decrease in mannose receptor promoter activity, further establishing the role of USF in activating the rat mannose receptor promoter. Comparison of the rat, mouse, and human sequence demonstrated that some binding sites are not conserved. Gel shifts were performed to investigate differences in protein binding between species. USF bound to the rat and human promoter but not to the mouse promoter, suggesting that different mechanisms are involved in regulation of mannose receptor expression in these species. From these results we conclude that, similar to other myeloid promoters, transcription of the rat mannose receptor is regulated by binding of PU.1 and a ubiquitous factor at an adjacent site. However, unlike other myeloid promoters, we have identified USF as the ubiquitous factor, and demonstrated that the promoter contains a functional TATA box.	Dept Vet Affairs Med Ctr, Res Serv, Nashville, TN 37212 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37212 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37212 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37212 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University	Shepherd, VL (corresponding author), Dept Vet Affairs Med Ctr, Res Serv, 1310 24th Ave S, Nashville, TN 37212 USA.	virginia.l.shepherd@vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY002853] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055977] Funding Source: NIH RePORTER; NEI NIH HHS [EY02853] Funding Source: Medline; NHLBI NIH HHS [HL55977] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLUM JS, 1991, CARBOHYD RES, V213, P145, DOI 10.1016/S0008-6215(00)90605-0; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; Gao EW, 1997, J BIOL CHEM, V272, P23398, DOI 10.1074/jbc.272.37.23398; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HARRIS N, 1992, BLOOD, V80, P2363; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honda H, 1997, BIOCHEM BIOPH RES CO, V234, P376, DOI 10.1006/bbrc.1997.6650; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; HROMAS R, 1993, BLOOD, V82, P2998; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KONISH M, 1983, METHOD ENZYMOL, V98, P301; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lane KB, 1998, J LEUKOCYTE BIOL, V64, P345, DOI 10.1002/jlb.64.3.345; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Longoni D, 1998, INT J CLIN LAB RES, V28, P162, DOI 10.1007/s005990050037; MARODI L, 1991, J IMMUNOL, V146, P2783; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Prigozy TI, 1997, IMMUNITY, V6, P187, DOI 10.1016/S1074-7613(00)80425-2; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; ROULEUX F, 1994, EXP CELL RES, V214, P113, DOI 10.1006/excr.1994.1239; ROULEUXBONNIN F, 1995, BIOCHEM BIOPH RES CO, V217, P106, DOI 10.1006/bbrc.1995.2751; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779; SHEPHERD VL, 1990, AM J RESP CELL MOL, V2, P335, DOI 10.1165/ajrcmb/2.4.335; SHEPHERD VL, 1985, J BIOL CHEM, V260, P160; SHEPHERD VL, 1982, J RETICULOENDOTH SOC, V32, P423; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SPEERT DP, 1988, J CLIN INVEST, V82, P872, DOI 10.1172/JCI113692; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STEPHENSON JD, 1987, BIOCHEM BIOPH RES CO, V148, P883, DOI 10.1016/0006-291X(87)90958-2; Sturrock A, 1996, J BIOL CHEM, V271, P32392, DOI 10.1074/jbc.271.50.32392; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	63	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9098	9107		10.1074/jbc.274.13.9098	http://dx.doi.org/10.1074/jbc.274.13.9098			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085160	hybrid			2022-12-25	WOS:000079451600102
J	Haugh, JM; Schooler, K; Wells, A; Wiley, HS; Lauffenburger, DA				Haugh, JM; Schooler, K; Wells, A; Wiley, HS; Lauffenburger, DA			Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-gamma 1 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED CELL MOTILITY; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; C ACTIVITY; PROTEIN; KINASE; TRANSDUCTION; TRAFFICKING	The epidermal growth factor receptor (EGFR) ligands, epidermal growth factor (EGF), and transforming growth factor-alpha (TGF alpha) elicit differential postendocytic processing of ligand and receptor molecules, which impacts long-term cell signaling outcomes. These differences arise from the higher affinity of the EGF-EGFR interaction versus that of TGF alpha-EGFR in the acidic conditions of sorting endosomes, To determine whether EGFR occupancy in endosomes might also affect short-term signaling events, we examined activation of the phospholipase C-gamma 1 (PLC-gamma 1) pathway, an event shown to be essential for growth factor-induced cell motility, We found that EGF continues to stimulate maximal tyrosine phosphorylation of EGFR following internalization, while, as expected, TGF alpha stimulates markedly less. The resulting higher level of receptor activation by EGF, however, did not yield higher levels of phosphatidylinositol (4,5)-bisphosphate (PIP2) hydrolysis over those stimulated by TGF alpha. By altering the ratio of activated receptors between the cell surface and the internalized compartment, we found that only cell surface receptors effectively participate in PLC function. In contrast to PIP2 hydrolysis, PLC-gamma 1 tyrosine phosphorylation correlated linearly with the total level of Tyr(P)-EGFR stimulated by either ligand, indicating that the functional deficiency of internal EGFR cannot be attributed to an inability to interact with and phosphorylate signaling proteins. We conclude that EGFR signaling through the PLC pathway is spatially restricted at a point between PLC-gamma 1 phosphorylation and PIP2 hydrolysis, perhaps because of limited access of EGFR-bound PLC-gamma 1 to its substrate in endocytic trafficking organelles.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Alabama System; University of Alabama Birmingham; Utah System of Higher Education; University of Utah	Lauffenburger, DA (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lauffen@mit.edu		Wiley, Steven/0000-0003-0232-6867; Wells, Alan/0000-0002-1637-8150; Haugh, Jason/0000-0002-2476-4027				ASCOLI M, 1982, J BIOL CHEM, V257, P13306; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; Batty IH, 1998, BIOCHEM J, V330, P1069; BERTICS PJ, 1985, J CELL BIOCHEM, V29, P195, DOI 10.1002/jcb.240290304; Bevan AP, 1996, TRENDS ENDOCRIN MET, V7, P13, DOI 10.1016/1043-2760(95)00179-4; CARPENTIER JL, 1987, J CELL BIOL, V105, P2751, DOI 10.1083/jcb.105.6.2751; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CHANG CP, 1993, J BIOL CHEM, V268, P19312; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; Chen P, 1996, J CELL BIOL, V134, P689, DOI 10.1083/jcb.134.3.689; Cockcroft S, 1998, BIOESSAYS, V20, P423, DOI 10.1002/(SICI)1521-1878(199805)20:5<423::AID-BIES9>3.3.CO;2-U; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FRENCH AR, 1995, J BIOL CHEM, V270, P4334, DOI 10.1074/jbc.270.9.4334; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GILL GN, 1988, COLD SPRING HARB SYM, V53, P467, DOI 10.1101/SQB.1988.053.01.054; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; KAY DG, 1986, J BIOL CHEM, V261, P8473; KORC M, 1989, J BIOL CHEM, V264, P14990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LUND KA, 1994, REGULATION CELLULAR, P277; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; REDDY CC, 1994, BIOTECHNOL PROGR, V10, P377, DOI 10.1021/bp00028a006; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Ringerike T, 1998, J BIOL CHEM, V273, P16639, DOI 10.1074/jbc.273.27.16639; SORKIN A, 1991, J BIOL CHEM, V266, P23453; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xie H, 1998, J CELL SCI, V111, P615	50	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8958	8965		10.1074/jbc.274.13.8958	http://dx.doi.org/10.1074/jbc.274.13.8958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085141	hybrid			2022-12-25	WOS:000079451600083
J	Montessuit, C; Thorburn, A				Montessuit, C; Thorburn, A			Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MUSCLE CELL HYPERTROPHY; GENE-EXPRESSION; MAP KINASE; RAT-HEART; GROWTH-FACTOR; DEVELOPMENTAL REGULATION; TYROSINE-PHOSPHATASE; OXIDATIVE STRESS; ANGIOTENSIN-II	Myocardial hypertrophy is associated with increased basal glucose metabolism. Basal glucose transport into cardiac myocytes is mediated by the GLUT1 isoform of glucose transporters, whereas the GLUT4 isoform is responsible for regulatable glucose transport. Treatment of neonatal cardiac myocytes with the hypertrophic agonist 12-O-tetradecanoylphorbol-13-acetate or phenylephrine increased expression of Glut1 mRNA relative to Glut4 mRNA. To study the transcriptional regulation of GLUT1 expression, myocytes were transfected with luciferase reporter constructs under the control of the Glut1 promoter. Stimulation of the cells with 12-O-tetradecanoylphorbol-13-acetate or phenylephrine induced transcription from the Glut1 promoter, which was inhibited by cotransfection with the mitogen-activated protein kinase phosphatases CL100 and MKP-3. Cotransfection of the myocytes with constitutively active versions of has and MEK1 or an estrogen-inducible version of Raf1 also stimulated transcription from the Glut1 promoter. Hypertrophic induction of the Glut1 promoter was also partially sensitive to inhibition of the phosphatidylinositol 3-kinase pathway and was strongly inhibited by cotransfection with dominant-negative Ras. Thus, Ras activation and pathways downstream of Ras mediate induction of the Glut1 promoter during myocardial hypertrophy.	Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Program Human Mol Biol & Genet, Dept Internal Med, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Montessuit, C (corresponding author), Univ Utah, Eccles Inst Human Genet, 15N 2030E,Rm 4220, Salt Lake City, UT 84112 USA.	christophe.montessuit@hci.utah.edu	Montessuit, Christophe/B-5650-2011	Montessuit, Christophe/0000-0002-2580-7711	NHLBI NIH HHS [HL-50210] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; ALLARD MF, 1994, AM J PHYSIOL, V267, pH742, DOI 10.1152/ajpheart.1994.267.2.H742; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; CHEN SY, 1994, ONCOGENE, V9, P2691; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; ELALAOUITALIBI Z, 1992, AM J PHYSIOL, V262, pH1068, DOI 10.1152/ajpheart.1992.262.4.H1068; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Hines WA, 1998, J MOL CELL CARDIOL, V30, P485, DOI 10.1006/jmcc.1997.0613; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1996, J BIOL CHEM, V271, P4319; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NAGAO M, 1993, J BIOL CHEM, V268, P24114; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRASAD MR, 1992, BASIC RES CARDIOL, V87, P19, DOI 10.1007/BF00795386; Remondino-Mueller Andrea, 1997, Journal of Molecular and Cellular Cardiology, V29, pA85; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SANTALUCIA T, 1992, ENDOCRINOLOGY, V130, P837, DOI 10.1210/en.130.2.837; SCHONEKESS BO, 1995, CIRC RES, V77, P726, DOI 10.1161/01.RES.77.4.726; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; SIVITZ WI, 1991, ENDOCRINOLOGY, V128, P2387, DOI 10.1210/endo-128-5-2387; SPEAKE BK, 1993, BIOCHIM BIOPHYS ACTA, V1165, P263, DOI 10.1016/0005-2760(93)90135-V; STEWART AFR, 1994, CIRC RES, V75, P796, DOI 10.1161/01.RES.75.4.796; STUDELSKA DR, 1992, AM J PHYSIOL, V263, pE102, DOI 10.1152/ajpendo.1992.263.1.E102; TARDY I, 1996, J MOL CELL CARDIOL, V28, pA16; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THORBURN A, 1994, BIOCHEM BIOPH RES CO, V205, P1417, DOI 10.1006/bbrc.1994.2823; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG C, 1991, BIOCHEM BIOPH RES CO, V177, P1095, DOI 10.1016/0006-291X(91)90651-M; WEINBERG EO, 1995, CIRCULATION, V92, P385; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yoshida K, 1996, BBA-MOL BASIS DIS, V1317, P36, DOI 10.1016/0925-4439(96)00035-X	62	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9006	9012		10.1074/jbc.274.13.9006	http://dx.doi.org/10.1074/jbc.274.13.9006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085148	hybrid			2022-12-25	WOS:000079451600090
J	Sheehy, AM; Schlissel, MS				Sheehy, AM; Schlissel, MS			Overexpression of RelA causes G(1) arrest and apoptosis in a pro-B cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C-REL; GENE-TRANSCRIPTION; DNA-BINDING; SPLENIC MICROARCHITECTURE; TRANSACTIVATION DOMAIN; TARGETED DISRUPTION; IMMUNE-RESPONSES; MICE LACKING; B/REL FAMILY	NF-kappa B/Rel family proteins form a network of posttranslationally regulated transcription factors that respond to a variety of extracellular stimuli and mediate distinct cellular responses. These responses include cytokine gene expression, regulated cell cycle activation, and both the protection from and induction of the cell death program. To examine the function of individual Rel family proteins in B cell development and resolve their role in the signaling of apoptosis, we used a tetracycline-regulated gene expression system to overexpress either c-Rel or RelA in the transformed pro-B cell line 220-8. Elevated levels of RelA, but not c-Rel, induced a G(1) cell cycle arrest followed by apoptosis. Both the DNA binding and transactivation domains of RelA were required for this effect. When RelA was overexpressed in the immature B cell line WEHI 231 or the mature B cell line M12, neither cell cycle arrest nor apoptosis was evident. The differential effects of elevated RelA levels in these cell lines suggests that susceptibility to NF-kappa B-induced apoptosis may reflect a relevant selection event during B cell development.	Johns Hopkins Univ, Sch Med, Dept Med, Grad Program Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Schlissel, MS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Grad Program Immunol, 720 Rutland Ave, Baltimore, MD 21205 USA.	mss@welchlink.welch.jhu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL48702] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; ATCHISON ML, 1987, CELL, V48, P121, DOI 10.1016/0092-8674(87)90362-X; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fang W, 1996, IMMUNITY, V4, P291, DOI 10.1016/S1074-7613(00)80437-9; FISCHER G, 1994, J EXP MED, V179, P221, DOI 10.1084/jem.179.1.221; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GANCHI PA, 1992, MOL CELL BIOL, V13, P1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; HANNINK M, 1990, ONCOGENE, V5, P1843; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; KALLENBACH S, 1993, EUR J IMMUNOL, V23, P1917, DOI 10.1002/eji.1830230828; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Scherer DC, 1996, IMMUNITY, V5, P563, DOI 10.1016/S1074-7613(00)80271-X; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANNESS BG, 1981, CELL, V27, P593, DOI 10.1016/0092-8674(81)90401-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATERS C, 1991, ONCOGENE, V6, P101; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	70	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8708	8716		10.1074/jbc.274.13.8708	http://dx.doi.org/10.1074/jbc.274.13.8708			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085110	hybrid			2022-12-25	WOS:000079451600052
J	Wang, B; Feng, L; Hu, Y; Huang, SH; Reynolds, CP; Wu, LT; Jong, AY				Wang, B; Feng, L; Hu, Y; Huang, SH; Reynolds, CP; Wu, LT; Jong, AY			The essential role of Saccharomyces cerevisiae CDC6 nucleotide-binding site in cell growth, DNA synthesis, and Orc1 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; REPLICATION ORIGINS; BUDDING YEAST; S-PHASE; DIRECTED MUTAGENESIS; NUCLEAR DIVISION; FISSION YEAST; MCM PROTEINS; GENE-PRODUCT; CYCLE	Saccharomyces cerevisiae Cdc6 is a protein required for the initiation of DNA replication. The biochemical function of the protein is unknown, but the primary sequence contains motifs characteristic of nucleotide-binding sites. To study the requirement of the nucleotide-binding site for the essential function of Cdc6, we have changed the conserved Lys(114) at the nucleotide-binding site to five other amino acid residues. We have used these mutants to investigate in vivo roles of the conserved lysine in the growth rate of transformant cells and the complementation of cdc6 temperature-sensitive mutant cells. Our results suggest that replacement of Lys with Glu (K114E) and Pro (K114P) leads to loss-of-function in supporting cell growth, replacement of the Lys with Gln (K114Q) or Leu (K114L) yields partially functional proteins, and replacement with Arg yields a phenotype equivalent to wild-type, a silent mutation. To investigate what leads to the growth defects derived from the mutations at the nucleotide-binding site, we evaluated its gene functions in DNA replication by the assays of the plasmid stability and chromosomal DNA synthesis. Indeed, the K114P and K114E mutants showed the complete retraction of DNA synthesis. In order to test its effect on the G(1)/S transition of the cell cycle, we have carried out the temporal and spatial studies of yeast replication complex. To do this, yeast chromatin fractions from synchronized culture were prepared to detect the Mcm5 loading onto the chromatin in the presence of the wild-type CdcG or mutant cdc6(K114E) proteins, We found that cdc6(K114E) is defective in the association with chromatin and in the loading of Mcm5 onto chromatin origins. To further investigate the molecular mechanism of nucleotide-binding function, we have demonstrated that the Cdc6 protein associates with Orc1 in vitro and in vivo, Intriguingly, the interaction between Orc1 and Cdc6 is disrupted when the cdc6(K114E) protein is used. Our results suggest that a proper molecular interaction between Orc1 and Cdc6 depends on the functional ATP-binding of Cdc6, which may be a prerequisite step to assemble the operational replicative complex at the G(1)/S transition.	Univ So Calif, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Dept Microbiol, Los Angeles, CA 90027 USA; Univ So Calif, Dept Pathol, Los Angeles, CA 90027 USA	University of Southern California; University of Southern California; University of Southern California	Jong, AY (corresponding author), Childrens Hosp Los Angeles, 4650 Sunset Blvd,Mail Stop 57, Los Angeles, CA 90027 USA.			Reynolds, C. Patrick/0000-0002-2827-8536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048492] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48492] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357-2725(96)00178-1; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BOTSTEIN D, 1985, SCIENCE, V229, P1193, DOI 10.1126/science.2994214; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; Detweiler CS, 1997, J CELL SCI, V110, P753; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Feng L, 1998, J BIOL CHEM, V273, P1298, DOI 10.1074/jbc.273.3.1298; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GAVIN KA, 1995, SCIENCE, V270, P1585; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HARTWELL LH, 1985, GENETICS, V110, P381; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Jong A, 1996, DNA CELL BIOL, V15, P883, DOI 10.1089/dna.1996.15.883; JONG AY, 1995, ANAL BIOCHEM, V227, P32, DOI 10.1006/abio.1995.1249; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WHEALS AE, 1987, YEAST, P284; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; ZHOU C, 1993, DNA CELL BIOL, V12, P363, DOI 10.1089/dna.1993.12.363; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZHOU C, 1990, BIOTECHNIQUES, V8, P503; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	50	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8291	8298		10.1074/jbc.274.12.8291	http://dx.doi.org/10.1074/jbc.274.12.8291			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075735	hybrid			2022-12-25	WOS:000079268100094
J	Hurlstone, AFL; Reid, G; Reeves, JR; Fraser, J; Strathdee, G; Rahilly, M; Parkinson, EK; Black, DM				Hurlstone, AFL; Reid, G; Reeves, JR; Fraser, J; Strathdee, G; Rahilly, M; Parkinson, EK; Black, DM			Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines	ONCOGENE			English	Article						CAVEOLIN-1; CpG island; methylation; tumour suppressor gene	ONCOGENICALLY TRANSFORMED-CELLS; PRIMARY BREAST-CANCER; ROUS-SARCOMA VIRUS; SUPPRESSOR GENE; FREQUENT LOSS; LONG ARM; TYROSINE PHOSPHORYLATION; INDEFINITE DIVISION; PROTEIN-COMPONENT; MEMBRANE-PROTEIN	We identified CAVEOLIN-1 as a candidate for a tumour suppresser gent mapping to human chromosome 7q31.1. A number of studies suggest that caveolin could function as a tumour suppressor. Expression of caveolin, and in turn the number of caveolae within a cell, are inversely correlated with the transforming ability of numerous oncoproteins, including H-ras, v-abl, and bcr-abl, and caveolin is a major transformation-dependent substrate of v-src. Heterologous expression of caveolin has been shown to abrogate anchorage-independent growth and induce apoptosis in transformed fibroblasts and also to suppress anchorage-independent growth in human mammary carcinoma cells. We have analysed the status and expression of the human CA VEOLIN-1 gene in primary tumours and tumour-derived cell lines. We found no evidence for mutation of CAVEOLIN-1 in human cancers, Additionally, we found that while the first two exons of CAVEOLIN-1 are associated with a CpG island, this is not methylated in either primary tumours or in tumour-derived cell lines in which Caveolin-1 expression is low or undetectable. The level of expression of Caveolin-1 does not correlate,vith loss of heterozygosity at the CAVEOLIN-1 locus in these same cell lines. Contrary to other published studies, we have shown that CAVEOLIN-1 is not expressed in normal breast ductal epithelial cells in vivo. CAVEOLIN-1 is however highly expressed in breast myoepithelial cells and its expression is retained in tumours derived from breast myoepithelium. Together our data refute a role for CAVEOLIN-1 as a breast tumour suppressor gene in vivo.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Dept Med Oncol, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Stobhill Gen Hosp, Dept Pathol, Glasgow G21 3UW, Lanark, Scotland; Univ Glasgow, Royal Infirm, Dept Surg, Glasgow G31 2ER, Lanark, Scotland	Beatson Institute; Beatson Institute; University of Glasgow; Royal Infirmary of Edinburgh; University of Glasgow	Black, DM (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			Strathdee, Gordon/0000-0001-9681-8429; Reid, George/0000-0002-0298-693X; Hurlstone, Adam/0000-0001-5260-9457				Achille A, 1996, CANCER RES, V56, P3808; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HERMAN JG, 1995, CANCER RES, V55, P4525; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kerr J, 1996, ONCOGENE, V13, P1815; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Loughran O, 1996, ONCOGENE, V13, P561; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; REESE MG, 1996, LARGE SCALE SEQUENCI; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHULER GD, 1996, SCIENCE, V274, P50; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; TAKAHASHI S, 1995, CANCER RES, V55, P4114; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 1997, ONCOGENE, V14, P109, DOI 10.1038/sj.onc.1200806; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen JC, 1996, GENOME RES, V6, P1070, DOI 10.1101/gr.6.11.1070	50	118	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	1999	18	10					1881	1890		10.1038/sj.onc.1202491	http://dx.doi.org/10.1038/sj.onc.1202491			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086342				2022-12-25	WOS:000079090000011
J	Abraham, J; Spaner, D; Benchimol, S				Abraham, J; Spaner, D; Benchimol, S			Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells	ONCOGENE			English	Article						p53; phosphorylation; DNA-PK; scid; ionizing radiation	PHOSPHATIDYLINOSITOL 3-KINASE; MOUSE CELLS; KINASE; DAMAGE; MICE; APOPTOSIS; INDUCTION; MUTATION; TRANSACTIVATION; ACTIVATION	The tumour suppressor gene product, p53, is involved in mediating cellular responses to DNA damage including growth arrest and/or apoptosis, The mechanism by which p53 protein senses the presence of damaged DNA is not understood. The possibility that p53 may be posttranslationally modified by enzymes that are activated in response to DNA damage including DNA-dependent protein kinase (DNA-PK), poly(ADP-ribose) polymerase and stress activated protein kinase has received considerable attention. Recent studies have indicated that DNA-PK is not required for the transactivation or apoptosis-promoting activities of p53 protein. However, the possibility that other functions of p53 may be dependent on phosphorylation by DNA-PK has not been explored. Here we describe a series of experiments that compares the expression, function and phosphorylation status of p53 protein in normal and DNA-PK-deficient scid cells. While several novel p53 phosphoforms are generated in response to DNA damage in normal cells, the same phosphoforms are observed in scid cells.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Benchimol, S (corresponding author), Univ Toronto, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				ADAMS LD, 1995, CURRENT PROTOCOLS MO, V2; Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOVER R, 1994, J CELL SCI, V107, P1181; FISCELLA M, 1994, ONCOGENE, V9, P3249; FISCELLA M, 1993, ONCOGENE, V8, P1519; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; FUCHS B, 1995, ONCOGENE, V10, P789; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KHANNA KK, 1993, ONCOGENE, V8, P3307; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mayo LD, 1997, CANCER RES, V57, P5013; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Price BD, 1996, CANCER RES, V56, P246; Rathmell WK, 1997, CANCER RES, V57, P68; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SPANER D, 1994, RES IMMUNOL, V145, P337, DOI 10.1016/S0923-2494(94)80196-7; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU JM, 1993, BIOCHEM BIOPH RES CO, V193, P13, DOI 10.1006/bbrc.1993.1583; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	48	17	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1521	1527		10.1038/sj.onc.1202454	http://dx.doi.org/10.1038/sj.onc.1202454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102621				2022-12-25	WOS:000078770700001
J	Corbet, SW; Clarke, AR; Gledhill, S; Wyllie, AH				Corbet, SW; Clarke, AR; Gledhill, S; Wyllie, AH			P53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells	ONCOGENE			English	Article						p53; apoptosis; mutation; DNA-damage; tissue specificity	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; P53-DEFICIENT MICE; IONIZING-RADIATION; GAMMA-IRRADIATION; TUMOR-SUPPRESSOR; NUCLEAR ACCUMULATION; GENE AMPLIFICATION; TRANSGENIC MICE; GROWTH ARREST	The hypothesis that p53 deficiency enhances the survival of DNA-damage bearing cells was investigated in wildtype and p53 mutant embryonic stem (ES) cells. Following UV-C irradiation, p53 is rapidly induced in wild-type cells and p53-dependent apoptosis follows within 8 h, resulting in the death of the majority of cells within 36 h. Increasing doses of UV-irradiation resulted in enhanced clonogenic survival of null cells as compared to wild-type. Amongst surviving clones, the Hprt mutation frequency was found to be dependent upon UV dose and influenced by p53 status. Treatment with ionizing radiation led to enhanced expression of p53 but resulted in little induction of apoptosis irrespective of p53 status. However, clonogenic potential was considerably reduced, particularly in wild-type cells which showed a tenfold lower survival than null cells. In contrast to the effects of UV-irradiation, the incidence of Hprt mutation did not differ significantly between wild-type and p53 null survivors. The data confirm that p53 restricts the numbers of cells bearing mutations that survive DNA damage induced by either agent, albeit by different mechanisms.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh, Midlothian, Scotland	University of Edinburgh	Corbet, SW (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRAIN R, 1994, ONCOGENE, V9, P1775; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clutton SM, 1996, CELL DEATH DIFFER, V3, P141; CROLLA JA, 1990, GENET RES, V55, P107, DOI 10.1017/S0016672300025349; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANGLEY RE, 1994, INT J RADIAT BIOL, V65, P605, DOI 10.1080/09553009414550691; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Li G, 1996, AM J PATHOL, V148, P1113; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1997, CANCER RES, V57, P1171; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MAHMUD KKS, 1992, CELL, V69, P367; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1976, J CELL PHYSIOL, V89, P441, DOI 10.1002/jcp.1040890310; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NISHINO H, 1995, ONCOGENE, V11, P263; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; RENZING J, 1995, ONCOGENE, V10, P1865; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBERTSON EJ, 1986, EXPT APPROACHES MAMM, P475; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; TSUKADA T, 1993, ONCOGENE, V8, P3313; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	71	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1537	1544		10.1038/sj.onc.1202436	http://dx.doi.org/10.1038/sj.onc.1202436			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102623				2022-12-25	WOS:000078770700003
J	Muller, C; Yang, R; Beck-Von-Peccoz, L; Idos, G; Verbeek, W; Koeffler, HP				Muller, C; Yang, R; Beck-Von-Peccoz, L; Idos, G; Verbeek, W; Koeffler, HP			Cloning of the cyclin A1 genomic structure and characterization of the promoter region - GC boxes are essential for cell cycle-regulated transcription of the cyclin A1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; MYELOID CELLS; S-PHASE; C-MYB; SP1; EXPRESSION; ACTIVATION; REPRESSION; MOUSE; BINDING	Cyclin A1 is a recently cloned cyclin with high level expression in meiotic cells in the testis, However, it is also frequently expressed at high levels in acute myeloid leukemia. To elucidate the regulation of cyclin A1 gene expression, we cloned and analyzed the genomic structure of cyclin. A1. It consists of 9 exons within 13 kilobase pairs. The TATA-less promoter initiates transcription from several start sites with the majority of transcripts beginning within a 4-base pair stretch. A construct containing a fragment from -190 to +145 showed the highest transcriptional activity. Transfection of cyclin A1 promoter constructs into S2 Drosophila cells demonstrated that Sp1 is essential for the activity of the promoter. Sp1, as well as Sp3, bound to four GC boxes between nucleotides -130 and -80 as observed by gel shift analysis. Mutations in two or more of the four GC boxes decreased promoter activity by >80%. The promoter was found to be cell cycle-regulated with highest activities found in late S and G(2)/M phase. Further analyses suggested that cell cycle regulation was accomplished by periodic repression of the GC boxes in G(1) phase. Taken together, our data show that cyclin A1 promoter activity critically depends on four GC boxes, and members of the Sp1 family appear to be involved in directing expression of cyclin A1 in both a tissue- and cell cycle-specific manner.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Muller, C (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Div Hematol Oncol, Davis Bldg,RM5066, Los Angeles, CA 90048 USA.	muellerc@CSMC.edu	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018	Müller-Tidow, Carsten/0000-0002-7166-5232				Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; Chao Y, 1998, CANCER RES, V58, P985; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Huet X, 1996, MOL CELL BIOL, V16, P3789; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LAM EWF, 1992, ONCOGENE, V7, P1885; LANS MS, 1994, J BIOL CHEM, V269, P14170; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OHNISHI H, 1990, LEUKEMIA RES, V14, P423, DOI 10.1016/0145-2126(90)90028-8; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sitzmann J, 1995, ONCOGENE, V11, P2273; Strassburg C. P., 1992, Neoplasma (Bratislava), V39, P343; Suzuki M, 1998, MOL CELL BIOL, V18, P3010, DOI 10.1128/MCB.18.5.3010; Sweeney C, 1996, DEVELOPMENT, V122, P53; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Yang R, 1999, MOL CELL BIOL, V19, P2400; Yang R, 1997, CANCER RES, V57, P913; Yang R, 1999, BLOOD, V93, P2067; Zwicker J, 1997, NUCLEIC ACIDS RES, V25, P4926, DOI 10.1093/nar/25.24.4926; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	47	41	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11220	11228		10.1074/jbc.274.16.11220	http://dx.doi.org/10.1074/jbc.274.16.11220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196209	hybrid			2022-12-25	WOS:000079751900077
J	Rao, S; Matsumura, A; Yoon, J; Simon, MC				Rao, S; Matsumura, A; Yoon, J; Simon, MC			SPI-B activates transcription via a unique proline, serine, and threonine domain and exhibits DNA binding affinity differences from PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN GENE ENHANCER; STIMULATING FACTOR-RECEPTOR; ETS-DOMAIN; REGULATES EXPRESSION; FACTORS INTERACT; CD11B PROMOTER; FAMILY MEMBER; T-CELLS; MACROPHAGE; COMPLEX	SPI-B is a B lymphocyte-specific Ets transcription factor that shares a high degree of similarity with PU.1/SPI-1. In direct contrast to PU.1(-/-) mice that die in utero and lack monocytes, neutrophils, B cells, and T cells, Spi-B-/- mice are viable and exhibit a severe B cell proliferation defect. Since PU.1 is expressed at wild type levels in Spi-B-/- B cells, the mutant mice provide genetic evidence that SPI-B and PU.1 have at least some non-redundant roles in B lymphocytes, To begin to understand the molecular basis for these defects, we delineated functional domains of SPI-B for comparison to those of PU.1. By using a heterologous co-transfection system, we identified two independent transactivation domains in the N terminus of SPI-B, Interestingly, only one of these domains (amino acids 31-61), a proline/serine/threonine-rich region, unique among Ets proteins, is necessary for transactivation of the immunoglobulin lambda light chain enhancer. This transactivation motif is in marked contrast to PU.1, which contains acidic and glutamine-rich domains. In addition, we describe a functional PU.1 site within the c-FES promoter which SPI-B fails to bind efficiently and transactivate. Finally, we show that SPI-B interacts with the PU.1 cofactors Pip, TBP, c-Jun and with lower affinity to nuclear factor interleukin-6 beta and retinoblastoma. Takes together, these data suggest that SPI-B binds DNA with a different affinity for certain sites than PU.1 and harbors different transactivation domains. We conclude that SPI-B may activate unique target genes in B lymphocytes and interact with unique, although currently unidentified, cofactors.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Med & Mol Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago; University of Chicago	Simon, MC (corresponding author), Univ Chicago, Howard Hughes Med Inst, 5841 S Maryland Ave,MC 1028, Chicago, IL 60637 USA.	csimon@medicine.bsd.uchicago.edu	Simon, Celeste/AAG-3941-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL5-2094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Celada A, 1996, J EXP MED, V184, P61, DOI 10.1084/jem.184.1.61; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Dang W, 1998, MOL CELL BIOL, V18, P1477, DOI 10.1128/MCB.18.3.1477; Eichbaum Q, 1997, BLOOD, V90, P4135, DOI 10.1182/blood.V90.10.4135; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Erman B, 1996, EMBO J, V15, P4665, DOI 10.1002/j.1460-2075.1996.tb00843.x; Erman B, 1998, MOL CELL BIOL, V18, P1322, DOI 10.1128/MCB.18.3.1322; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Henkel GW, 1996, BLOOD, V88, P2917, DOI 10.1182/blood.V88.8.2917.bloodjournal8882917; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOHAUS S, 1995, MOL CELL BIOL, V15, P5830; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LEPRINCE D, 1992, ONCOGENE, V7, P9; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; Mao C, 1996, ONCOGENE, V12, P863; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Morrisey EE, 1997, J BIOL CHEM, V272, P8515, DOI 10.1074/jbc.272.13.8515; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Scott EW, 1997, IMMUNITY, V6, P437, DOI 10.1016/S1074-7613(00)80287-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; StraussSoukup JK, 1997, J BIOL CHEM, V272, P31570, DOI 10.1074/jbc.272.50.31570; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	57	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11115	11124		10.1074/jbc.274.16.11115	http://dx.doi.org/10.1074/jbc.274.16.11115			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196196	hybrid			2022-12-25	WOS:000079751900064
J	Valentine, AM; LeTadic-Biadatti, MH; Toy, PH; Newcomb, M; Lippard, SJ				Valentine, AM; LeTadic-Biadatti, MH; Toy, PH; Newcomb, M; Lippard, SJ			Oxidation of ultrafast radical clock substrate probes by the soluble methane monooxygenase from Methylococcus capsulatus (Bath)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONO-OXYGENASE; CYTOCHROME-P-450 ENZYMES; COMPONENT INTERACTIONS; CONCERTED MECHANISM; REGULATORY PROTEIN; CATALYTIC CYCLE; RING OPENINGS; DIIRON CENTER; HYDROXYLATION; ACTIVATION	Radical clock substrate probes were used to assess the viability of a discrete substrate radical species in the mechanism of hydrocarbon oxidation by the soluble methane monooxygenase (sMMO) from Methylococcus capsulatus (Bath). New substituted cyclopropane probes were used with very fast ring-opening rate constants and other desirable attributes, such as the ability to discriminate between radical and cationic intermediates. Oxidation of these substrates by a reconstituted sMMO system resulted in no rearranged products, allowing an upper limit of 150 fs to be placed on the lifetime of a putative radical species. This limit strongly suggests that there is no such substrate radical intermediate. The two enantiomers of trans-1-methyl-2-phenyl-cyclopropane were prepared, and the regioselectivity of their oxidation to the corresponding cyclopropylmethanol and cyclopropylphenol products was determined The results are consistent with selective orientation of the two enantiomeric substrates in the hydrophobic cavity at the active site of sMMO, specific models for which were examined by molecular modeling.	MIT, Dept Chem, Cambridge, MA 02139 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA	Massachusetts Institute of Technology (MIT); Wayne State University	Lippard, SJ (corresponding author), MIT, Dept Chem, Rm 18-590, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048722, R01GM032134, R37GM032134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32134, GM48722] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON JK, 1994, BIOCHEMISTRY-US, V33, P10630, DOI 10.1021/bi00201a009; CASTELLINO AJ, 1988, J AM CHEM SOC, V110, P7512, DOI 10.1021/ja00230a039; Choi SY, 1996, J AM CHEM SOC, V118, P6547, DOI 10.1021/ja952226l; COLBY J, 1978, BIOCHEM J, V171, P461, DOI 10.1042/bj1710461; COLBY J, 1979, BIOCHEM J, V177, P903, DOI 10.1042/bj1770903; COLBY J, 1977, BIOCHEM J, V165, P395, DOI 10.1042/bj1650395; Collman JP, 1998, J AM CHEM SOC, V120, P425, DOI 10.1021/ja973111f; DALTON H, 1980, ADV APPL MICROBIOL, V26, P71; Deeth RJ, 1998, J BIOL INORG CHEM, V3, P302, DOI 10.1007/s007750050236; DEIGHTON N, 1991, J CHEM SOC CHEM COMM, P1086, DOI 10.1039/c39910001086; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GREEN J, 1989, J BIOL CHEM, V264, P17698; GREEN J, 1985, J BIOL CHEM, V260, P5795; GRILLER D, 1980, ACCOUNTS CHEM RES, V13, P317, DOI 10.1021/ar50153a004; Lee DW, 1998, J AM CHEM SOC, V120, P12153, DOI 10.1021/ja9831094; LEE SK, 1993, J BIOL CHEM, V268, P21569; LEE SK, 1993, J AM CHEM SOC, V115, P6450, DOI 10.1021/ja00067a086; LeTadicBiadatti MH, 1996, J CHEM SOC PERK T 2, P1467, DOI 10.1039/p29960001467; Lipscomb JD, 1998, J BIOL INORG CHEM, V3, P331, DOI 10.1007/s007750050241; LIU KE, 1994, J AM CHEM SOC, V116, P7465, DOI 10.1021/ja00095a083; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU KE, 1993, J AM CHEM SOC, V115, P939, DOI 10.1021/ja00056a018; LIU KE, 1995, ADV INORG CHEM RAD, V42, P263; NEWCOMB M, 1993, TETRAHEDRON, V49, P1151, DOI 10.1016/S0040-4020(01)85808-7; NEWCOMB M, 1992, J AM CHEM SOC, V114, P10915, DOI 10.1021/ja00053a031; NEWCOMB M, 1995, J AM CHEM SOC, V117, P12085, DOI 10.1021/ja00154a008; NEWCOMB M, 1995, J AM CHEM SOC, V117, P3312, DOI 10.1021/ja00116a052; Nordlander E, 1998, J BIOL INORG CHEM, V3, P300; PRIESTLEY ND, 1992, J AM CHEM SOC, V114, P7561, DOI 10.1021/ja00045a037; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1994, ACCOUNTS CHEM RES, V27, P229, DOI 10.1021/ar00044a003; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; RUZICKA F, 1990, BIOCHEMISTRY-US, V29, P1696, DOI 10.1021/bi00459a005; Shteinman AA, 1998, J BIOL INORG CHEM, V3, P325, DOI 10.1007/s007750050240; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Siegbahn PEM, 1998, J BIOL INORG CHEM, V3, P314, DOI 10.1007/s007750050238; Siegbahn PEM, 1997, J AM CHEM SOC, V119, P3103, DOI 10.1021/ja963939m; Toy PH, 1997, J ORG CHEM, V62, P9114, DOI 10.1021/jo9712097; Valentine AM, 1997, J AM CHEM SOC, V119, P1818, DOI 10.1021/ja963971g; VALENTINE AM, 1997, J CHEM SOC DA, V21, P3925; VANNI R, 1995, TETRAHEDRON LETT, V36, P7999, DOI 10.1016/0040-4039(95)01666-6; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Whittington DA, 1998, J BIOL INORG CHEM, V3, P307, DOI 10.1007/s007750050237; WHITTINGTON DA, 1998, ACS SYM SER, V692, P334; Willems JP, 1998, J AM CHEM SOC, V120, P9410, DOI 10.1021/ja980795y; WOODLAND MP, 1984, J BIOL CHEM, V259, P53; Yoshizawa K, 1998, ORGANOMETALLICS, V17, P2825, DOI 10.1021/om980067j; Yoshizawa K, 1998, J BIOL INORG CHEM, V3, P318, DOI 10.1007/s007750050239; Yoshizawa K, 1997, CHEM-EUR J, V3, P1160, DOI 10.1002/chem.19970030722	52	62	62	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10771	10776		10.1074/jbc.274.16.10771	http://dx.doi.org/10.1074/jbc.274.16.10771			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196150	hybrid			2022-12-25	WOS:000079751900018
J	Li, YT; Li, SC; Hasegawa, A; Ishida, H; Kiso, M; Bernardi, A; Brocca, P; Raimondi, L; Sonnino, S				Li, YT; Li, SC; Hasegawa, A; Ishida, H; Kiso, M; Bernardi, A; Brocca, P; Raimondi, L; Sonnino, S			Structural basis for the resistance of Tay-Sachs ganglioside GM2 to enzymatic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXOSAMINIDASE-A; MOLECULAR MECHANICS; ACTIVATOR PROTEIN; CONFORMATIONAL PROPERTIES; OLIGOSACCHARIDE CHAIN; ENZYMIC-HYDROLYSIS; HUMAN-BRAIN; DYNAMICS; SPECTROSCOPY; PARAMETERS	To understand the reason why, in the absence of GM2 activator protein, the GaLNAc and the NeuAc in GM2 (GalNAc beta 1-->4(NeuAc alpha 2-->3)Gal beta 1-->4Glc beta 1-1'Cer) are refractory to beta-hexosaminidase A and sialidase, respectively, we have recently synthesized a linkage analogue of GM2 named 6'GM2 (GalNAc beta 1-->6(NeuAc alpha 2-->3)Gal beta 1-->4Glc beta 1-1'Cer). While GM2 has GalNAc beta 1-->4Gal linkage, 6'-GM2 has GalNAc beta 1-->6Gal linkage (Ishida, H., Ito, Y,, Tanahashi, E., Li, Y.-T., Kiso, M., and Hasegawa, A (1997) Carbohydr. Res. 302, 223-227). We have studied the enzymatic susceptibilities of GM2 and 6'GM2, as well as that of the oligosaccharides derived from GM2, asialo-GM2 (GalNAc beta 1-->4Gal beta 1-->4Glc beta 1-1'Cer) and 6'GM2. In addition, the conformational properties of both GM2 and 6'GM2 were analyzed using NMR spectroscopy and molecular mechanics computation. In sharp contrast to GM2, the GalNAc and the Neu5Ac of 6'GM2 were readily hydrolyzed by beta-hexosaminidase A and sialidase, respectively, without GM2 activator. Among the oligosaccharides derived from GM2, asialo-GM2, and 6'GM2, only the oligosaccharide from GM2 was resistant to p-hexosaminidase A. Conformational analyses revealed that while GM2 has a compact and rigid oligosaccharide head group, 6'GM2 has an open spatial arrangement of the sugar units, with the GalNAc and the Neu5Ac freely accessible to external interactions. These results strongly indicate that the resistance of GM2 to enzymatic hydrolysis is because of the specific rigid conformation of the GM2 oligosaccharide.	Tulane Univ, Sch Med, Dept Biochem, New Orleans, LA 70112 USA; Gifu Univ, Dept Bioorgan Chem, Gifu 50111, Japan; Univ Milan, Dept Organ & Ind Chem, I-20133 Milan, Italy; Univ Milan, Dept Med Chem & Biochem, I-20090 Segrate, Mi, Italy	Tulane University; Gifu University; University of Milan; University of Milan	Li, YT (corresponding author), Tulane Univ, Sch Med, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Sonnino, Sandro/R-4154-2017; Bernardi, Anna/A-1167-2012; Raimondi, Laura M/A-1327-2012; BROCCA, PAOLA/E-3778-2018	Sonnino, Sandro/0000-0001-8180-5908; Bernardi, Anna/0000-0002-1258-2007; Raimondi, Laura M/0000-0002-7314-1387; BROCCA, PAOLA/0000-0002-9852-6056	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 09626] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUOTTI D, 1994, EUR J BIOCHEM, V225, P271, DOI 10.1111/j.1432-1033.1994.00271.x; ACQUOTTI D, 1990, J AM CHEM SOC, V112, P7772, DOI 10.1021/ja00177a043; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERNARDI A, 1995, J ORG CHEM, V60, P3370, DOI 10.1021/jo00116a021; Brocca P, 1998, BIOPHYS J, V74, P309, DOI 10.1016/S0006-3495(98)77788-4; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; FARMER BT, 1987, J MAGN RESON, V72, P197, DOI 10.1016/0022-2364(87)90189-2; GOODMAN JM, 1991, J COMPUT CHEM, V12, P1110, DOI 10.1002/jcc.540120908; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HECTMAN P, 1977, BIOCHEM J, V167, P693; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; HOMANS SW, 1993, GLYCOBIOLOGY, V3, P551, DOI 10.1093/glycob/3.6.551; HULTBERG B, 1969, LANCET, V2, P1195; Ishida H, 1997, CARBOHYD RES, V302, P223, DOI 10.1016/S0008-6215(97)00120-1; LI SC, 1981, J BIOL CHEM, V256, P6234; LI YT, 1973, J BIOL CHEM, V248, P7512; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; OKADA S, 1969, SCIENCE, V165, P698, DOI 10.1126/science.165.3894.698; PONDER JW, 1987, J COMPUT CHEM, V8, P1016, DOI 10.1002/jcc.540080710; POPPE L, 1994, BIOPHYS J, V66, P1642, DOI 10.1016/S0006-3495(94)80956-7; RUTHERFORD TJ, 1994, GLYCOBIOLOGY, V4, P59, DOI 10.1093/glycob/4.1.59; SABESAN S, 1984, CAN J CHEM, V62, P1034, DOI 10.1139/v84-172; SANDHOFF K, 1969, FEBS LETT, V4, P351, DOI 10.1016/0014-5793(69)80274-7; Senderowitz H, 1997, J ORG CHEM, V62, P1427, DOI 10.1021/jo9612483; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; WU YY, 1994, J BIOL CHEM, V269, P16276; ZHOU B, 1989, J BIOL CHEM, V264, P12272	32	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10014	10018		10.1074/jbc.274.15.10014	http://dx.doi.org/10.1074/jbc.274.15.10014			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187778	hybrid			2022-12-25	WOS:000079663500017
J	Rui, LY; Herrington, J; Carter-Su, C				Rui, LY; Herrington, J; Carter-Su, C			SH2-B is required for nerve growth factor-induced neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-SITES; PC12 CELLS; SHC; ACTIVATION; DOMAIN; IDENTIFICATION; ASSOCIATION	Nerve growth factor (NGF) is essential for the development and survival of sympathetic and sensory neurons. NGF binds to TrkA, activates the intrinsic kinase activity of TrkA, and promotes the differentiation of pheochromocytoma (PC12) cells into sympathetic-like neurons. Several signaling molecules and pathways are known to be activated by NGF, including phospholipase C gamma, phosphatidylinositol-3 kinase, and the mitogen-activated protein kinase cascade. However, the mechanism of NGF-induced neuronal differentiation remains unclear. In this study, we examined whether SH2-B beta, a recently identified pleckstrin homology and SH2 domain-containing signaling protein, is a critical signaling protein for NGF, TrkA bound to glutathione S-transferase fusion proteins containing SH2-B beta, and NGF stimulation dramatically increased that binding. In contrast, NGF was unable to stimulate the association of TrkA with a glutathione S-transferase fusion protein containing a mutant SH2-B beta(R555E) with a defective SH2 domain. When overexpressed in PC12 cells, SH2-B beta coimmunoprecipitated with TrkA in response to NGF. NGF stimulated tyrosyl phosphorylation of endogenous SH2-B beta as well as exogenously expressed GFP-SH2-B beta but not GFP-SH2-B beta(R555E). Overexpression of SH2-B beta(R555E) blocked NGF-induced neurite outgrowth of PC12 cells, whereas overexpression of wild type SH2-B beta enhanced NGF-induced neurite outgrowth. Overexpression of either wild type or mutant SH2-B beta(R555E) did not alter tyrosyl phosphorylation of TrkA, Shc, or phospholipase C gamma in response to NGF or NGF-induced activation of ERK1/2, suggesting that SH2-B beta may initiate a previously unknown pathway(s) that is essential for NGF-induced neurite outgrowth. Taken together, these data indicate that SH2-B beta is a novel signaling molecule required for NGF-induced neuronal differentiation.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.	cartersu@umich.edu			NIDDK NIH HHS [R01 DK034171, F32 DK009756, P60-DK-20572, DK 34171, F32-DK-09756] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, P60DK020572, F32DK009756, R01DK034171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	24	73	82	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10590	10594		10.1074/jbc.274.15.10590	http://dx.doi.org/10.1074/jbc.274.15.10590			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187854	hybrid			2022-12-25	WOS:000079663500093
J	Driscoll, B; T'Ang, A; Hu, YH; Yan, CL; Fu, Y; Luo, Y; Wu, KJ; Wen, SM; Shi, XH; Barsky, L; Weinberg, K; Murphree, AL; Fung, YK				Driscoll, B; T'Ang, A; Hu, YH; Yan, CL; Fu, Y; Luo, Y; Wu, KJ; Wen, SM; Shi, XH; Barsky, L; Weinberg, K; Murphree, AL; Fung, YK			Discovery of a regulatory motif that controls the exposure of specific upstream cyclin-dependent kinase sites that determine both conformation and growth suppressing activity of pRb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; FACTOR-BETA; RB PROTEIN; TGF-BETA; NEGATIVE REGULATION; EPITHELIAL-CELLS; T-ANTIGEN; PHOSPHORYLATION; BINDING	The conformation and activity of pRb, the product of the retinoblastoma susceptibility gene, is dependent on the phosphorylation status of one or more of its 16 potential cyclin-dependent kinase (cdk) sites. However, it is not clear whether the phosphorylation status of one or more of these sites contributes to the determination of the various conformations and activity of pRb. Moreover, whether and how the conformation of pRb may regulate the phosphorylation of the cdk sites is also unclear. In the process of analyzing the function and regulation of pRb, we uncovered the existence of an unusual structural motif, m89 (amino acids 880-900), the mutation of which confers upon pRb a hypophosphorylated conformation. Mutation of this structural domain activates, rather than inactivates, the growth suppressor function of pRb. In order to understand the effect of the mutation of m89 on the phosphorylation of cdk sites, we identified all the cdk sites (Thr-356, Ser-807/Ser-811, and Thr821) the phosphorylation of which drastically modify the conformation of pRb. Mutation of each of these four sites alone or in combinations results in the different conformations of pRb, the migration pattern of which, on SDS-polyacrylamide gel electrophoresis, resembles various in vivo hypophosphorylated forms. Each of these hypophosphorylated forms of pRb has enhanced growth suppressing activity relative to the wild type. Our data revealed that the m89 structural motif controls the exposure of the cdk sites Ser-807/Ser-811 in vitro and in vivo. Moreover, the m89 mutant has enhanced growth suppressing activity, similar to a mutant with alanine substitutions at Ser-807/Ser-811, Our recent finding, that the m89 region is part of a structural domain, p5, conserved antigenically and functionally between pRb and p53, suggests that the evolutionarily conserved p5 domain may play a role in the coordinated regulation of the activity of these two tumor suppressors, under certain growth conditions.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Div Ophthalmol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Div Pathol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Div Res Immunol Bone Marrow Transplant, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Pathol, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Dept Immunol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; Children's Hospital Los Angeles; Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Children's Hospital Los Angeles	Fung, YK (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, MS94,4650 Sunset Blvd,Smith Res Tower, Los Angeles, CA 90027 USA.				NCI NIH HHS [R01-CA44754] Funding Source: Medline; NHLBI NIH HHS [R01-HL 54850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044754] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Driscoll Barbara, 1995, Molecular and Cellular Differentiation, V3, P361; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FUNG YKT, 1993, ONCOGENE, V8, P2659; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GHABRIAL SA, 1973, VIROLOGY, V51, P485, DOI 10.1016/0042-6822(73)90447-9; Giannini G, 1997, J BIOL CHEM, V272, P5313, DOI 10.1074/jbc.272.8.5313; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, ONCOGENE, V7, P693; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN MF, 1990, CANCER GENET CYTOGEN, V49, P15, DOI 10.1016/0165-4608(90)90159-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES JA, 1991, EMBO J, V10, P857; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; TANG A, 1995, CHALLENGES MODERN ME, V10, P73; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TUNG JS, 1971, BIOCHEM BIOPH RES CO, V42, P1117, DOI 10.1016/0006-291X(71)90020-9; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	47	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9463	9471		10.1074/jbc.274.14.9463	http://dx.doi.org/10.1074/jbc.274.14.9463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092628	hybrid			2022-12-25	WOS:000079451800047
J	Dwyer, MA; Huang, AJ; Pan, CQ; Lazarus, RA				Dwyer, MA; Huang, AJ; Pan, CQ; Lazarus, RA			Expression and characterization of a DNase I-Fc fusion enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN DEOXYRIBONUCLEASE; SYSTEMIC LUPUS-ERYTHEMATOSUS; CYSTIC-FIBROSIS; BINDING; VARIANTS; IMMUNOADHESINS; RECOGNITION; DEPENDENCE; MECHANISM; CLEAVAGE	Recombinant human deoxyribonuclease I (DNase I) is an important clinical agent that is inhaled into the airways where it degrades DNA to lower molecular weight fragments, thus reducing the viscoelasticity of sputum and improving the lung function of cystic fibrosis patients, To investigate DNases with potentially improved properties, we constructed a molecular fusion of human DNase I with the hinge and Fe region of human IgG1 heavy chain, creating a DNase I-Fc fusion protein. Infection of Sf9 insect cells with recombinant baculovirus resulted in the expression and secretion of the DNase I-Fc fusion protein, The fusion protein was purified from the culture medium using protein A affinity chromatography followed by desalting by gel filtration and was characterized by amino-terminal sequence, amino acid composition, and a variety of enzyme-linked immunosorbent assays (ELISA) and activity assays. The purified fusion contains DNase I, as determined by a DNase I ELISA and an actin-binding ELISA, and an intact antibody Fc region, which was quantified by an Fc ELISA, in a 2:1 stoichiometric ratio, respectively. The dimeric DNase I-Fc fusion was functionally active in enzymatic DNA digestion assays, albeit about 10-fold less than monomeric DNase I. Cleavage of the DNase I-Fc fusion by papain resulted in a specific activity comparable to the monomeric enzyme. Salt was inhibitory for wild type monomeric DNase I but actually enhanced the activity of the dimeric DNase I-Fc fusion, The DNase I-Fc fusion protein was also less Ca2+-dependent than DNase I itself. These results are consistent with a higher affinity of the dimeric: fusion protein to DNA than monomeric DNase I, The engineered DNase I-Fc fusion protein described herein has properties that may have clinical benefits.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Lazarus, RA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.	lazarus.bob@gene.com						Ashkenazi A, 1997, CURR OPIN IMMUNOL, V9, P195, DOI 10.1016/S0952-7915(97)80135-5; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; Chamow SM, 1996, TRENDS BIOTECHNOL, V14, P52, DOI 10.1016/0167-7799(96)80921-8; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; HOGAN ME, 1987, NATURE, V329, P263, DOI 10.1038/329263a0; Hsu TA, 1996, PROTEIN EXPRES PURIF, V7, P281, DOI 10.1006/prep.1996.0040; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO TH, 1988, BIOCHEM J, V255, P781, DOI 10.1042/bj2550781; Macanovic M, 1996, CLIN EXP IMMUNOL, V106, P243, DOI 10.1046/j.1365-2249.1996.d01-839.x; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOHLER M, 1993, DRUG METAB DISPOS, V21, P71; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Pan CQ, 1998, J BIOL CHEM, V273, P18374, DOI 10.1074/jbc.273.29.18374; Pan CQ, 1998, J BIOL CHEM, V273, P11701, DOI 10.1074/jbc.273.19.11701; Pan CQ, 1997, BIOCHEMISTRY-US, V36, P6624, DOI 10.1021/bi962960x; Pan CQ, 1998, PROTEIN SCI, V7, P628, DOI 10.1002/pro.5560070312; PRICE PA, 1969, J BIOL CHEM, V244, P929; RAMSEY BW, 1993, AM REV RESPIR DIS, V148, P145, DOI 10.1164/ajrccm/148.1.145; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; Sambrook J., 2002, MOL CLONING LAB MANU; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; Suck Dietrich, 1994, Journal of Molecular Recognition, V7, P65, DOI 10.1002/jmr.300070203; Tournay C, 1996, DNA CELL BIOL, V15, P617, DOI 10.1089/dna.1996.15.617; Ulmer JS, 1996, P NATL ACAD SCI USA, V93, P8225, DOI 10.1073/pnas.93.16.8225	31	10	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9738	9743		10.1074/jbc.274.14.9738	http://dx.doi.org/10.1074/jbc.274.14.9738			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092662	hybrid			2022-12-25	WOS:000079451800081
J	Manfred, G; Gupta, N; Vazquez-Memije, ME; Sadlock, JE; Spinazzola, A; De Vivo, DC; Schon, EA				Manfred, G; Gupta, N; Vazquez-Memije, ME; Sadlock, JE; Spinazzola, A; De Vivo, DC; Schon, EA			Oligomycin induces a decrease in the cellular content of a pathogenic mutation in the human mitochondrial ATPase 6 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEIGH-SYNDROME; WILD-TYPE; DNA; CELLS; MTDNA; FIBROBLASTS; SEGREGATION; RESPIRATION; SUBUNIT-6; NT-8993	AT --> G mutation at position 8993 in human mitochondrial DNA is associated with the syndrome neuropathy, ataxia, and retinitis pigmentosa and with a maternally inherited form of Leigh's syndrome. The mutation substitutes an arginine for a leucine at amino acid position 156 in ATPase 6, a component of the F-0 portion of the mitochondrial ATP synthase complex Fibroblasts harboring high levels of the T8993G mutation have decreased ATP synthesis activity, hut do not display any growth defect under standard culture conditions, Combining the notions that cells with respiratory chain defects grow poorly in medium containing galactose as the major carbon source, and that resistance to oligomycin, a mitochondrial inhibitor, is associated with mutations in the ATPase 6 gene in the same transmembrane domain where the T8993G amino acid substitution is located, we created selective culture conditions using galactose and oligomycin that elicited a pathological phenotype in T8993G: cells and that allowed for the rapid selection of wild-type over T8993G mutant cells. We then generated cytoplasmic hybrid clones containing heteroplasmic levels of the T8993G mutation, and showed that selection in galactose-oligomycin caused a significant increase in the fraction of wild-type molecules (from 16 to 28%) in these cells.	Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, H Houston Merritt Clin Res Ctr Muscular Dystrophy, New York, NY 10032 USA; Bronx High Sch Sci, Bronx, NY USA; IMSS, Ctr Med Nacl, Hosp Pediat, Unidad Invest Genet Humana, Mexico City 06725, DF, Mexico	Columbia University; Columbia University; Instituto Mexicano del Seguro Social	Manfred, G (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, Rm 4-431,630 W 168th St, New York, NY 10032 USA.		Spinazzola, Antonella/P-5298-2017; Spinazzola, Antonella/P-5791-2019	Spinazzola, Antonella/0000-0003-4242-8091; Spinazzola, Antonella/0000-0003-4242-8091	NINDS NIH HHS [NS32527, NS28828, NS11766] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032527, P50NS011766, P01NS011766, R01NS028828] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453; BREEN GAM, 1982, MOL CELL BIOL, V2, P772, DOI 10.1128/MCB.2.7.772; BREEN GAM, 1986, J BIOL CHEM, V261, P1680; HOLT IJ, 1990, AM J HUM GENET, V46, P428; JOHN UP, 1986, FEBS LETT, V207, P79, DOI 10.1016/0014-5793(86)80016-3; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; MILLIS AJT, 1973, BIOCHIM BIOPHYS ACTA, V292, P73, DOI 10.1016/0005-2728(73)90251-X; Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612; SANTORELLI FM, 1992, ANN NEUROL, V32, P467; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Spelbrink JN, 1997, CURR GENET, V32, P115, DOI 10.1007/s002940050255; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TONSGARD JH, 1990, BIOCHEM J, V270, P511, DOI 10.1042/bj2700511; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; TULINIUS MH, 1995, HUM GENET, V96, P290; VazquezMemije ME, 1996, J INHERIT METAB DIS, V19, P43, DOI 10.1007/BF01799347; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZEVIANI M, 1988, NEUROLOGY, V38, P1339	26	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9386	9391		10.1074/jbc.274.14.9386	http://dx.doi.org/10.1074/jbc.274.14.9386			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092618	hybrid			2022-12-25	WOS:000079451800037
J	Osaka, H; Malany, S; Kanter, JR; Sine, SM; Taylor, P				Osaka, H; Malany, S; Kanter, JR; Sine, SM; Taylor, P			Subunit interface selectivity of the alpha-neurotoxins for the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING SITES; TORPEDO-CALIFORNICA; DELTA-SUBUNIT; CHOLINERGIC RECEPTOR; MOLECULAR DISSECTION; CROSS-LINKING; SNAKE TOXINS; RESIDUES; IDENTIFICATION	Peptide toxins selective for particular subunit interfaces of the nicotinic acetylcholine receptor have proven invaluable in assigning candidate residues located in the two binding sites and for determining probable orientations of the bound peptide. We report here on a short alpha-neurotoxin from Naja mossambica mossambica (NmmI) that, similar to other alpha-neurotoxins, binds with high affinity to alpha gamma and alpha delta subunit interfaces (K-D similar to 100 pM) but binds with markedly reduced affinity to the alpha epsilon interface (K-D similar to 100 nM). By constructing chimeras composed of portions of the gamma and epsilon subunits and coexpressing them with wild type alpha, beta, and delta subunits in HEK 293 cells, we identify a region of the subunit sequence responsible for the difference in affinity. Within this region, gamma Pro-175 and gamma Glu-176 confer high affinity, whereas Thr and Ala, found at homologous positions in epsilon, confer low affinity. To identify an interaction between gamma Glu-176 and residues in NmmI, we have examined cationic residues in the central loop of the toxin and measured binding of mutant toxin-receptor combinations. The data show strong pairwise interactions or coupling between gamma Glu-176 and Lys-27 of NmmI and progressively weaker interactions with Arg-33 and Arg-36 in loop II of this three-loop toxin, Thus, loop II of NmmI, and in particular the face of this loop closest to loop III, appears to come into close apposition with Glu-176 of the gamma subunit surface of the binding site interface.	Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA; Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Receptor Biol Lab, Rochester, MN 55905 USA	University of California System; University of California San Diego; Mayo Clinic	Taylor, P (corresponding author), Univ Calif San Diego, Dept Pharmacol 0636, La Jolla, CA 92093 USA.				NIGMS NIH HHS [GM 18360] Funding Source: Medline; NINDS NIH HHS [NS 31744] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744, R37NS031744] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; Arias HR, 1997, BRAIN RES REV, V25, P133, DOI 10.1016/S0165-0173(97)00020-9; CHANG C. C., 1963, ARCH INTERNATL PHARMACODYN THER, V144, P241; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; CHATRENET B, 1990, P NATL ACAD SCI USA, V87, P3378, DOI 10.1073/pnas.87.9.3378; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; ENDO T, 1987, PHARMACOL THERAPEUT, V34, P403, DOI 10.1016/0163-7258(87)90002-7; Faiman GA, 1996, PROTEIN ENG, V9, P315, DOI 10.1093/protein/9.3.315; Galzi JL, 1996, EMBO J, V15, P5824, DOI 10.1002/j.1460-2075.1996.tb00969.x; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; HAMILTON SL, 1985, BIOCHEMISTRY-US, V24, P2210, DOI 10.1021/bi00330a015; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1992, BIOCHEMISTRY-US, V31, P8239, DOI 10.1021/bi00150a017; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MARCHOT P, 1988, EUR J BIOCHEM, V174, P537, DOI 10.1111/j.1432-1033.1988.tb14132.x; Martin MD, 1997, BIOCHEMISTRY-US, V36, P10742, DOI 10.1021/bi970896t; Molles B. E., 1998, Journal of Physiology Paris, V92, P470, DOI 10.1016/S0928-4257(99)80086-2; Osaka H, 1998, J BIOL CHEM, V273, P12758, DOI 10.1074/jbc.273.21.12758; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; PILLET L, 1993, J BIOL CHEM, V268, P909; Prince RJ, 1996, J BIOL CHEM, V271, P25770, DOI 10.1074/jbc.271.42.25770; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; SINE S, 1979, J BIOL CHEM, V254, P3315; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; SINE SM, 1981, J BIOL CHEM, V256, P6692; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; Utkin YN, 1998, EUR J BIOCHEM, V253, P229, DOI 10.1046/j.1432-1327.1998.2530229.x; WITZEMANN V, 1979, BIOCHEMISTRY-US, V18, P5511, DOI 10.1021/bi00591a039	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9581	9586		10.1074/jbc.274.14.9581	http://dx.doi.org/10.1074/jbc.274.14.9581			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092644	hybrid			2022-12-25	WOS:000079451800063
J	Sangha, N; Kaur, S; Sharma, V; Krishnasastry, MV				Sangha, N; Kaur, S; Sharma, V; Krishnasastry, MV			Importance of the carboxyl terminus in the folding and function of alpha-hemolysin of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CIRCULAR-DICHROISM; TRANSMEMBRANE PORE; ESCHERICHIA-COLI; KEY RESIDUES; PROTEIN; STATE; TRANSLOCATION; MUTAGENESIS; BINDING	The physical state of two model mutants of alpha-hemolysin (alpha HL), alpha HL(1-289), a carboxyl-terminal deletion mutant (CDM), and alpha HL(1-331), a carboxyl-terminal extension mutant (CEM), were examined in detail to identify the role of the carboxyl terminus in the folding and function of native alpha HL, Denatured alpha HL can be refolded efficiently with nearly total recovery of its activity upon restoration of nondenaturing conditions. Various biophysical and biochemical studies on the three proteins have revealed the importance of an intact carboxyl terminus in the folding of alpha HL. The CDM exhibits a marked increase in susceptibility to proteases as compared with alpha HL, alpha HL and CEM exhibit similar fluorescence emission maxima, and that of the CDM is red-shifted by 9 nm, which indicates a greater solvent exposure of the tryptophan residues of the CDM, In addition, the CDM binds 8-anilino-1-naphthalene sulfonic acid (ANS) and increases its fluorescence intensity significantly unlike alpha HL and GEM, which show marginal binding. The circular dichroism studies point that the CDM possesses significant secondary structure, but its tertiary structure is greatly diminished as compared with alpha HL, These data show that the CDM has several of the features that characterize a molten globule state. Experiments with freshly translated mutants, using coupled in vitro transcription and translation, have further supported our observations that deletion at the carboxyl terminus leads to major structural perturbations in the water-soluble form of alpha HL. The studies demonstrate a critical role of the carboxyl terminus of alpha HL in attaining the native folded state.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Krishnasastry, MV (corresponding author), Natl Ctr Cell Sci, Univ Pune Campus, Pune 411007, Maharashtra, India.	infonccs@giaspn01.vsnl.net.in						Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; Fink A L, 1995, Methods Mol Biol, V40, P343; Fontana A, 1997, FOLD DES, V2, pR17, DOI 10.1016/S1359-0278(97)00010-2; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND I, 1987, ANAL BIOCHEM, V164, P84, DOI 10.1016/0003-2697(87)90371-X; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SEMJEN BV, 1996, J BIOL CHEM, V271, P8655; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; Valeva A, 1997, BBA-BIOMEMBRANES, V1325, P281, DOI 10.1016/S0005-2736(96)00266-0; Vandana S, 1997, J BIOL CHEM, V272, P24858, DOI 10.1074/jbc.272.40.24858; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065; WALLACE BA, 1984, P NATL ACAD SCI-BIOL, V81, P1406, DOI 10.1073/pnas.81.5.1406	25	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9193	9199		10.1074/jbc.274.14.9193	http://dx.doi.org/10.1074/jbc.274.14.9193			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092591	hybrid			2022-12-25	WOS:000079451800010
J	Brown, JD; DiChiara, MR; Anderson, KR; Gimbrone, MA; Topper, JN				Brown, JD; DiChiara, MR; Anderson, KR; Gimbrone, MA; Topper, JN			MEKK-1, a component of the stress (stress-activated protein kinase c-Jun N-terminal kinase) pathway, can selectively activate Smad2-mediated transcriptional activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; FLUID MECHANICAL STIMULI; VASCULAR ENDOTHELIUM; SIGNAL-TRANSDUCTION; SHEAR-STRESS; KAPPA-B; SMAD2; PHOSPHORYLATION; RECEPTOR; IDENTIFICATION	Smad proteins are essential components of the intracellular signaling pathways utilized by members of the transforming growth factor-beta (TGF-beta) superfamily of growth factors. Certain Smad proteins (e.g. Smad1, -2, and -3) can act as regulated transcriptional activators, a process that involves phosphorylation of these proteins by activated TGF-beta superfamily receptors, We demonstrate that the intracellular kinase mitogen-activated protein kinase kinase kinase-1 (MEKK-1), an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase pathway, can participate in Smad2-dependent transcriptional events in cultured endothelial cells, A constitutively active form of MEKK-1 but not mitogen-activated protein kinase kinase-1 (MEK-1) or TGF-beta-activated kinase-1, two distinct intracellular kinases, can specifically activate a Gal4-Smad2 fusion protein, and this effect correlates with an increase in the phosphorylation state of the Smad2 protein. These effects do not require the presence of the C-terminal SSXS motif of Smad2 that is the site of TGF-beta type 1 receptor-mediated phosphorylation. Activation of Smad2 by active MEKK-1 results in enhanced Smad2-Smad4 interactions, nuclear localization of Smad2 and Smad4, and the stimulation of Smad protein-transcriptional coactivator interactions in endothelial cells, Overexpression of Smad7 can inhibit the MEKK-1-mediated stimulation of Smad2 transcriptional activity, A physiological level of fluid shear stress, a known activator of endogenous MEKK-1 activity in endothelial cells, can stimulate Smad2-mediated transcriptional activity. These data demonstrate a novel mechanism for activation of Smad protein-mediated signaling in endothelial cells and suggest that Smad2 may act as an integrator of diverse stimuli in these cells.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Dept Med,Div Cardiovasc, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Div Vasc Res, Boston, MA 02115 USA	Stanford University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Topper, JN (corresponding author), Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Dept Med,Div Cardiovasc, 300 Pasteur Dr, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL051150, P50HL056985] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL56985, R37-HL51150] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Frey RS, 1997, CANCER RES, V57, P628; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gimbrone MA, 1997, J CLIN INVEST, V99, P1809, DOI 10.1172/JCI119346; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li YS, 1996, MOL CELL BIOL, V16, P5947; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Topper JN, 1998, CIRCULATION, V98, P2396, DOI 10.1161/01.CIR.98.22.2396; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	34	138	143	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8797	8805		10.1074/jbc.274.13.8797	http://dx.doi.org/10.1074/jbc.274.13.8797			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085121	hybrid			2022-12-25	WOS:000079451600063
J	Gadal, O; Shpakovski, GV; Thuriaux, P				Gadal, O; Shpakovski, GV; Thuriaux, P			Mutants in ABC10 beta, a conserved subunit shared by all three yeast RNA polymerases, specifically affect RNA polymerase I assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; COMMON SUBUNITS; III MUTATIONS; ACTIVE-SITE; GENE; SUPPRESSOR; SEQUENCE; VECTORS; NOPP140; ENZYMES	ABC10 beta, a small polypeptide common to the three yeast RNA polymerases, has close homology to the N subunit of the archaeal enzyme and is remotely related to the smallest subunit of vaccinial RNA polymerase, The eucaryotic, archaeal, and viral polypeptides share an invariant motif CX,C.., CC that is strictly essential for yeast growth, as shown by site-directed mutagenesis, whereas the rest of the ABC10 beta sequence is fairly tolerant to amino acid replacements. ABC10 beta has Zn2+ binding properties in vitro, and the CX2C ... CC motif may therefore define an atypical metal-chelating site. Hybrid subunits that derive most of their amino acids from the archaeal subunit are functional in yeast, indicating that the archaeal and eucaryotic polypeptides have a largely equivalent role in the organization of their respective transcription complexes. However, all eucaryotic forms of ABC10 beta harbor a HVDLIEK motif that, when mutated or replaced by its archaeal counterpart, leads to a polymerase I-specific lethal defect in vivo. This is accompanied by a specific lack in the largest subunit of RNA polymerase I (A190) in cell-free extracts, showing that the mutant enzyme is not properly assembled in vivo.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia	CEA; UDICE-French Research Universities; Universite Paris Saclay; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Thuriaux, P (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.		Shpakovski, George V. Вячеславович/AAU-7443-2020; Gadal, Olivier/A-4731-2008	Shpakovski, George V. Вячеславович/0000-0003-2851-7020; Gadal, Olivier/0000-0001-9421-0831				AMEGADZIE BY, 1992, J VIROL, V66, P3003, DOI 10.1128/JVI.66.5.3003-3010.1992; ARCHAMBAULT J, 1990, MOL CELL BIOL, V10, P6123, DOI 10.1128/MCB.10.12.6123; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; CARLES C, 1991, J BIOL CHEM, V266, P24092; CHEDIN S, 1998, IN PRESS COLD SPRING; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Ikonomova R, 1997, DNA CELL BIOL, V16, P1161, DOI 10.1089/dna.1997.16.1161; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LANZENDORFER M, 1994, SYST APPL MICROBIOL, V16, P656; LANZENDORFER M, 1997, GENE DEV, V11, P1033; LEFEBVRE O, 1994, J BIOL CHEM, V269, P23374; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; MCKUNE K, 1994, J BACTERIOL, V176, P4754, DOI 10.1128/JB.176.15.4754-4756.1994; Meier UT, 1996, J BIOL CHEM, V271, P19376; MEIER UT, 1992, CELL, V70, P127; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Moss B, 1996, FIELDS VIROLOGY, V2, P2637; MUKERJEE K, 1997, EUR J BIOCHEM, V247, P884; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Nouraini S, 1996, MOL CELL BIOL, V16, P5985; RIVA M, 1990, J BIOL CHEM, V265, P16498; RIVA M, 1982, J BIOL CHEM, V257, P4570; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; Shpakovski GV, 1997, BIOORG KHIM+, V23, P110; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; STETTLER S, 1993, MOL GEN GENET, V239, P169, DOI 10.1007/BF00281615; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; THURIAUX P, 1995, METH MOL G, V6, P227; THURIAUX P, 1992, MOL CELLULAR BIOL YE, V2, P1; TREICH I, 1991, J BIOL CHEM, V266, P21971; Treich Isabelle, 1992, Gene Expression, V2, P31; WOYCHIK NA, 1990, J BIOL CHEM, V265, P17816; WOYCHIK NA, 1994, TRANSCRIPTION MECH R, P227; Woychik Nancy A., 1993, Gene Expression, V3, P77; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107	44	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8421	8427		10.1074/jbc.274.13.8421	http://dx.doi.org/10.1074/jbc.274.13.8421			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085073	hybrid			2022-12-25	WOS:000079451600015
J	Shenoy, SK; Yu, L; Yu, CA				Shenoy, SK; Yu, L; Yu, CA			Identification of quinone-binding and heme-ligating residues of the smallest membrane-anchoring subunit (QPs3) of bovine heart mitochondrial succinate : ubiquinone reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-REDUCTASE; ESCHERICHIA-COLI; COMPLEX-II; RECOMBINANT PROTEIN; OXIDOREDUCTASE; CLONING; RECONSTITUTION; EXPRESSION; LIGANDS; DOMAIN	The smallest membrane-anchoring subunit (QPs3) of bovine heart succinate:ubiquinone reductase was overexpressed in Escherichia coli JM109 as a glutathione S-transferase fusion protein using the expression vector pGEX2T/QPs3. The yield of soluble active recombinant glutathione S-transferase-QPs3 fusion protein was isopropyl-1-thio-beta-D-galactopyranoside concentration-, induction growth time-, temperature-, and medium-dependent. Maximum yield of soluble recombinant fusion protein was obtained from cells harvested 3.5 h post-isopropyl-1-thio-beta-D-galactopyranos (0.4 mM)-induction growth at 25 degrees C in 2.0% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mm KCl, 10 mM MgCl2, 20 mM glucose (SOC medium) containing 440 mM sorbitol and 2.5 mM betaine. QPs3 was released from the fusion protein by proteolytic cleavage with thrombin. Isolated recombinant QPs3 shows one protein band in sodium dodecyl sulfate-polyacrylamide gel electrophoresis that corresponds to subunit V of mitochondrial succinate: ubiquinone reductase. Although purified recombinant QPs3 is dispersed in 0.01% dodecylmaltoside, it is in a highly aggregated form, with an apparent molecular mass of more than 1 million. The recombinant QPs3 binds ubiquinone, causing a spectral blue shift. Upon titration of the recombinant protein with ubiquinone, a saturation behavior is observed, suggesting that the binding is specific and that recombinant QPs3 may be in the functionally active state. Two amino acid residues, serine 33 and tyrosine 37, in the putative ubiquinone binding domain of QPs3 are involved in ubiquinone binding because the S33A- or Y37A-substituted recombinant QPs3s do not cause the spectral blue shift of ubiquinone. Although recombinant QPs3 contains little cytochrome b(560) heme, the spectral characteristics of cytochrome b(560) are reconstituted upon addition of hemin chloride. Reconstituted cytochrome b(560) in recombinant QPs3 shows a EPR signal at g = 2.92. Histidine residues at positions 46 and 60 are responsible for heme ligation because the H46N- or H60N-substituted QPs3 fail to restore cytochrome b560 upon addition of hemin chloride.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	cayuq@okway.okstate.edu	Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKWELL JR, 1991, FEBS LETT, V295, P10, DOI 10.1016/0014-5793(91)81372-F; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMMACK R, 1986, IRON SULFUR PROTEIN, P40; Chen YR, 1996, J BIOL CHEM, V271, P2057, DOI 10.1074/jbc.271.4.2057; CROUSE BR, 1995, FEBS LETT, V367, P1, DOI 10.1016/0014-5793(95)00522-B; DEISENHOFER J, 1989, SCIENCE, V245, P1463, DOI 10.1126/science.245.4925.1463; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; Lee GY, 1998, BBA-BIOENERGETICS, V1363, P35, DOI 10.1016/S0005-2728(97)00089-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; Nakamura K, 1996, J BIOL CHEM, V271, P521, DOI 10.1074/jbc.271.1.521; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; ROSE CT, 1998, BIOCHEMISTRY-US, V37, P4148; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1980, BIOCHIM BIOPHYS ACTA, V593, P24, DOI 10.1016/0005-2728(80)90005-5; YU L, 1992, J BIOL CHEM, V267, P24508	26	21	22	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8717	8722		10.1074/jbc.274.13.8717	http://dx.doi.org/10.1074/jbc.274.13.8717			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085111	hybrid			2022-12-25	WOS:000079451600053
J	Zhao, Q; Lee, FS				Zhao, Q; Lee, FS			Mitogen-activated protein kinase ERK kinase kinases 2 and 3 activate nuclear factor-kappa B through I kappa B kinase-alpha and I kappa B kinase-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; SIGNAL-TRANSDUCTION; MEK KINASES; IKK-ALPHA; PATHWAYS; COMPLEX; INDUCTION; JNK; IDENTIFICATION; INTERACT	Recent evidence indicates that nuclear factor-kappa B (NF-kappa B), a transcription factor critically important for immune and inflammatory responses, is activated by a protein kinase cascade. The essential features of this cascade are that a mitogen-activated protein kinase kinase kinase (MAP3K) activates an I kappa B kinase (IKK) that site-specifically phosphorylates I kappa B. The I kappa B protein, which ordinarily sequesters NF-kappa B in the cytoplasm, is subsequently degraded by the ubiquitin-proteasome pathway, thereby allowing the nuclear translocation of NF-kappa B. Thus far, only two MAP3Ks, NIK and MEKK1, have been identified that can activate this pathway. We now show that MEKK2 and MEKK3 can in vivo activate IKK-alpha and IKK-beta, induce site-specific I kappa B alpha phosphorylation, and, relatively modestly, activate an NF-kappa B reporter gene. In addition, dominant negative versions of either IKK-alpha or IKK-beta abolish NF-kappa B activation induced by MEKK2 or MEKK3, thereby providing evidence that these IKKs mediate the NF-kappa B-inducing activities of these MEKKs, In contrast, other MAP3Ks, including MEKK4, ASK1, and MLK3, fail to show evidence of activation of the NF-kappa B pathway. We conclude that a distinct subset of MAP3Ks can activate NF-kappa B.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, FS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 218 John Morgan Bldg, Philadelphia, PA 19104 USA.			Lee, Frank/0000-0003-2511-1834				Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; EZOE K, 1994, ONCOGENE, V9, P935; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ING YL, 1994, ONCOGENE, V9, P1745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Sambrook J., 2002, MOL CLONING LAB MANU; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	36	240	258	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8355	8358		10.1074/jbc.274.13.8355	http://dx.doi.org/10.1074/jbc.274.13.8355			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085062	hybrid			2022-12-25	WOS:000079451600004
J	Prasad, MVVSV; Dhanasekaran, N				Prasad, MVVSV; Dhanasekaran, N			GTPase deficient mutant of G alpha(13) regulates the expression of Egr-1 through the small GTPase Rho	ONCOGENE			English	Article						G protein; G alpha(13); Rho; Egr-1; transcription factors; SRE; signal transduction; oncogene	TRANSCRIPTION FACTOR EGR-1; C-FOS; CELLS; DIFFERENTIATION; ACTIVATION; GROWTH; TRANSFORMATION; ELEMENTS; IDENTIFICATION; REPRESSION	The alpha-subunit of the heterotrimeric G protein G13 regulate cell growth, differentiation and apoptosis in different cell types. Expression of the constitutively activated mutant of G alpha(13) (G alpha(13)QL) increases the expression of Egr-1, an immediate-early response gene that is identified to be involved in cell growth, differentiation, and apoptosis. Here we report that G alpha(13)QL activates the promoter of Egr-1 through specific sequence which includes the characteristic CArG boxes. We also demonstrate that the G alpha(13)QL activation of Egr-1 promoter is mediated by the Ras-like small GTPase Rho.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG H, 1993, FEBS LETT, V3, P319; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; MICEL JB, 1994, J CLIN INVEST, V94, P277; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RIM M, 1992, ONCOGENE, V7, P2065; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; Wolf G, 1996, HYPERTENSION, V27, P897, DOI 10.1161/01.HYP.27.4.897; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	28	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1639	1642		10.1038/sj.onc.1202461	http://dx.doi.org/10.1038/sj.onc.1202461			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102635				2022-12-25	WOS:000078770700015
J	Li, S; Chen, PL; Subramanian, T; Chinnadurai, G; Tomlinson, G; Osborne, CK; Sharp, ZD; Lee, WH				Li, S; Chen, PL; Subramanian, T; Chinnadurai, G; Tomlinson, G; Osborne, CK; Sharp, ZD; Lee, WH			Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; C-TERMINAL REGION; INTERACT IN-VIVO; CELL-CYCLE; DROSOPHILA CTBP; GENE-PRODUCT; PROTEIN; BREAST; MUTATION; REPAIR	Mutations in BRCA1 are responsible for nearly all of the hereditary ovarian and breast cancers, and about half of those in breast cancer-only kindreds. The ability of BRCA1 to transactivate the p21 promoter can be inactivated by mutation of the conserved BRCA1 C-terminal (BRCT) repeats. To explore the mechanisms of this BRCA1 function, the BRCT repeats were used as bait in a yeast two-hybrid screen. A known protein, CtIP, a co-repressor with CtBP, was found. CtIP interacts specifically with the BRCT repeats of BRCA1, both in vitro and in vivo, and tumor-derived mutations in this region abolished these interactions. The association of BRCA1 with CtIP was also abrogated in cells treated with DNA-damaging agents including UV, gamma-irradiation, and adriamycin, a response correlated with BRCA1 phosphorylation. The transactivation of the p21 promoter by BRCA1 was diminished by expression of exogenous CtIP and CtBP. These results suggest that the binding of the BRCT repeats of BRCA1 to CtIP/CtBP is critical in mediating transcriptional regulation of p21 in response to DNA damage.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78245 USA; St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA; Univ Texas, SW Med Ctr, Dept Pediat, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Saint Louis University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.		Tomlinson, Gail/AAR-9776-2020; LI, SHANG/HII-4989-2022	LI, SHANG/0000-0002-6226-3362	NCI NIH HHS [CA58183, CA30195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, P01CA030195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EASTON DF, 1995, AM J HUM GENET, V56, P265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	37	162	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11334	11338		10.1074/jbc.274.16.11334	http://dx.doi.org/10.1074/jbc.274.16.11334			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196224	hybrid			2022-12-25	WOS:000079751900092
J	Martens, JS; Lougheed, M; Gomez-Munoz, A; Steinbrecher, UP				Martens, JS; Lougheed, M; Gomez-Munoz, A; Steinbrecher, UP			A modification of apolipoprotein B accounts for most of the induction of macrophage growth by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; COLONY-STIMULATING FACTOR; SMOOTH-MUSCLE CELLS; A TYPE I/II; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; HUMAN-PLASMA; IN-VITRO; OXIDATION	It has recently been shown that macrophage proliferation occurs during the progression of atherosclerotic lesions and that oxidized low density lipoprotein (LDL) stimulates macrophage growth. Possible mechanisms for this include the interaction of oxidized LDL with integral plasma membrane proteins coupled to signaling pathways, the release of growth factors and autocrine activation of growth factor receptors, or the potentiation of mitogenic signal transduction by a component of oxidized LDL after internalization. The present study was undertaken to further elucidate the mechanisms involved in the growth-stimulating effect of oxidized LDL in macrophages, Only extensively oxidized LDL caused significant growth stimulation, whereas mildly oxidized LDL, native LDL, and acetyl LDL were ineffective. LDL that had been methylated before oxidation (to block lysine derivatization by oxidation products and thereby prevent the formation of a scavenger receptor ligand) did not promote growth, even though extensive lipid peroxidation had occurred. The growth stimulation could not be attributed to lysophosphatidylcholine (lyso-PC) because incubation of oxidized LDL with fatty acid-free bovine serum albumin resulted in a 97% decrease in lyse-PC content but only a 20% decrease in mitogenic activity. Similarly, treatment of acetyl LDL with phospholipase A(2) converted more than 90% of the initial content of phosphatidylcholine (PC) to lyso-PC, but the phospholipase A(2)-treated acetyl LDL was nearly 10-fold less potent than oxidized LDL at stimulating growth. Platelet-activating factor receptor antagonists partly inhibited growth stimulation by oxidized LDL, but platelet-activating factor itself did not induce growth. Digestion of oxidized LDL with phospholipase A(2) resulted in the hydrolysis of PC and oxidized PC but did not attenuate growth induction. Native LDL, treated with autoxidized arachidonic acid under conditions that caused extensive modification of lysine residues by lipid peroxidation products but did not result in oxidation of LDL lipids, was equal to oxidized LDL in potency at stimulating macrophage growth. Albumin modified by arachidonic acid peroxidation products also stimulated growth, demonstrating that LDL lipids that oxidatively modified apolipoprotein B is the main growth-stimulating component of oxidized LDL, but that oxidized phospholipids may play a secondary role.	Univ British Columbia, Dept Med, Div Gastroenterol, Vancouver, BC V5Z 4E3, Canada	University of British Columbia	Steinbrecher, UP (corresponding author), Univ British Columbia, Dept Med, Div Gastroenterol, 3300-950 W 10th Ave, Vancouver, BC V5Z 4E3, Canada.			GOMEZ MUNOZ, ANTONIO/0000-0002-2539-016X				Antonov AS, 1997, J CLIN INVEST, V99, P2867, DOI 10.1172/JCI119480; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Dentan C, 1996, BBA-LIPID LIPID MET, V1299, P353, DOI 10.1016/0005-2760(95)00226-X; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P335; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; KATSUDA S, 1993, AM J PATHOL, V142, P1787; KIM JA, 1994, ARTERIOSCLER THROMB, V14, P427, DOI 10.1161/01.ATV.14.3.427; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LIAPIKOS TA, 1994, BBA-LIPID LIPID MET, V1212, P353, DOI 10.1016/0005-2760(94)90210-0; Ling WH, 1997, J CLIN INVEST, V100, P244, DOI 10.1172/JCI119528; Lougheed M, 1997, J BIOL CHEM, V272, P12938, DOI 10.1074/jbc.272.20.12938; Lougheed M, 1996, J BIOL CHEM, V271, P11798, DOI 10.1074/jbc.271.20.11798; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Martens JS, 1998, J BIOL CHEM, V273, P4915, DOI 10.1074/jbc.273.9.4915; Matsumura T, 1997, ARTERIOSCL THROM VAS, V17, P3013, DOI 10.1161/01.ATV.17.11.3013; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REKHTER MD, 1995, AM J PATHOL, V147, P668; ROSENFELD ME, 1992, AM J PATHOL, V140, P291; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SCHWARTZ D, 1994, J CLIN INVEST, V94, P1968, DOI 10.1172/JCI117548; SCUDIERO DA, 1988, CANCER RES, V48, P4827; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1992, ARTERIOSCLER THROMB, V12, P608, DOI 10.1161/01.ATV.12.5.608; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; YLAHERTTUALA S, 1990, EUR HEART J, V11, P88, DOI 10.1093/eurheartj/11.suppl_E.88; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331; ZHANG H, 1993, CLIN CHEM ENZYMOL CO, V2, P142	44	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10903	10910		10.1074/jbc.274.16.10903	http://dx.doi.org/10.1074/jbc.274.16.10903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196168	hybrid			2022-12-25	WOS:000079751900036
J	Moodie, SA; Alleman-Sposeto, J; Gustafson, TA				Moodie, SA; Alleman-Sposeto, J; Gustafson, TA			Identification of the APS protein as a novel insulin receptor substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; FACTOR-I RECEPTORS; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; KINASE-B; GLUT4 TRANSLOCATION; DNA-SYNTHESIS; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAYS	In order to identify novel substrates involved in insulin receptor signaling, a yeast two-hybrid 3T3-L1 adipocyte cDNA library was screened with the cytoplasmic domain of the human insulin receptor as bait. Here we describe the isolation and characterization of an interacting protein, APS, which contains pleckstrin homology and Src homology 2 domains and several potential tyrosine phosphorylation sites. APS mRNA and protein are expressed primarily in skeletal muscle, heart, and adipose tissue, and in differentiated 3T3-L1 adipocytes, We show that APS associates with phosphotyrosines situated within the activation loop of the insulin receptor via the APS Src homology 2 domain. Insulin stimulation of 3T3-L1 adipocytes resulted in rapid tyrosine phosphorylation of endogenous APS on tyrosine 618, whereas platelet-derived growth factor treatment resulted in no APS phosphorylation, In summary, we have identified a new insulin receptor substrate that is primarily expressed in insulin-responsive tissues and in 3T3-L1 adipocytes whose phosphorylation shows insulin receptor specificity. These findings suggest a potential role for APS in insulin-regulated metabolic signaling pathways.	Metabolex Inc, Hayward, CA 94545 USA		Moodie, SA (corresponding author), Metabolex Inc, 3876 Bay Ctr Pl, Hayward, CA 94545 USA.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; EVANS JL, 1995, CELL SIGNAL, V7, P365, DOI 10.1016/0898-6568(95)00007-C; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HERBST JJ, 1995, J BIOL CHEM, V270, P26000, DOI 10.1074/jbc.270.43.26000; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shepherd PR, 1997, BIOCHEM SOC T, V25, P978, DOI 10.1042/bst0250978; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	44	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11186	11193		10.1074/jbc.274.16.11186	http://dx.doi.org/10.1074/jbc.274.16.11186			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196204	hybrid			2022-12-25	WOS:000079751900072
J	Coscoy, S; de Weille, JR; Lingueglia, E; Lazdunski, M				Coscoy, S; de Weille, JR; Lingueglia, E; Lazdunski, M			The pre-transmembrane 1 domain of acid-sensing ion channels participates in the ion pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; SENSITIVE NA+ CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; CAENORHABDITIS-ELEGANS; PSEUDOHYPOALDOSTERONISM TYPE-1; MEMBRANE TOPOLOGY; MOLECULAR-CLONING; SUBUNIT; IDENTIFICATION; RESIDUES	The acid-sensing ion channel (ASIC) subunits ASIC1, ASIC2, and ASIC3 are members of the amiloride-sensitive Na+ channel/degenerin family of ion channels. They form proton-gated channels that are expressed in the central nervous system and in sensory neurons, where they are thought to play an important role in pain accompanying tissue acidosis, A splice variant of ASIC2, ASIC2b, is not active on its own but modifies the properties of ASIC3, In particular, whereas most members of the amiloride-sensitive Na+ channel/degenerin family are highly selective for Na+ over K+, ASIC3/ASIC2b heteromultimers show a nonselective component, Chimeras of the two splice variants allowed identification of a 9-amino acid region preceding the first transmembrane (TM) domain (pre-TM1) of ASIC2 that is involved in ion permeation and is critical for Na+ selectivity. Three amino acids in this region (Ile-19, Phe-20, and Thr-25) appear to be particularly important, because channels mutated at these residues discriminate poorly between Na+ and K+. In addition, the pH dependences of the activity of the F20S and T25K mutants are changed as compared with that of wild-type ASIC2, A corresponding ASIC3 mutant (T26K) also has modified Na+ selectivity. Our results suggest that the pre-TM1 region of ASICs participates in the ion pore.	Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, 660 Route Lucioles,Sophia Antipolis, F-06560 Valbonne, France.	ipmc@ipmc.cnrs.fr	LINGUEGLIA, Eric/F-5509-2013; de Weille, Jan R/F-8103-2014	LINGUEGLIA, Eric/0000-0003-3902-3405; de Weille, Jan R/0000-0002-0505-3166; Coscoy, Sylvie/0000-0003-3963-3609				BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Coscoy S, 1998, J BIOL CHEM, V273, P8317, DOI 10.1074/jbc.273.14.8317; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; RENARD S, 1994, J BIOL CHEM, V269, P12981; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	27	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10129	10132		10.1074/jbc.274.15.10129	http://dx.doi.org/10.1074/jbc.274.15.10129			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187795	hybrid			2022-12-25	WOS:000079663500034
J	Brodbeck, D; Cron, P; Hemmings, BA				Brodbeck, D; Cron, P; Hemmings, BA			A human protein kinase B gamma with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; PHOSPHOINOSITIDE-3-OH KINASE; AKT; INSULIN; PDK1; BETA; TRANSLOCATION; EXPRESSION	We have cloned human protein kinase B gamma (PKB gamma) and found that it contains two regulatory phosphorylation sites, Thr(305) and Ser(472), which correspond to Thr(308) and Ser(473) Of PKB alpha. Thus it differs significantly from the previously published rat PKB gamma. We have also isolated a similar clone from a mouse cDNA library. In human tissues, PKB gamma is widely expressed as two transcripts. A mutational analysis of the two regulatory sites of human PKB gamma showed that phosphorylation of both sites, occurring in a phosphoinositide 3-kinase-dependent manner, is required for full activity. Our results suggest that the two phosphorylation sites act in concert to produce full activation of PKB gamma, similar to PKB alpha. This contrasts with rat PKB gamma, which is thought to be regulated by 3-phosphoinositide-dependent protein kinase 1 alone.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BELLACOSA A, 1993, ONCOGENE, V8, P745; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299	29	154	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9133	9136		10.1074/jbc.274.14.9133	http://dx.doi.org/10.1074/jbc.274.14.9133			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092583	hybrid			2022-12-25	WOS:000079451800002
J	Gurezka, R; Laage, R; Brosig, B; Langosch, D				Gurezka, R; Laage, R; Brosig, B; Langosch, D			A heptad motif of leucine residues found in membrane proteins can drive self-assembly of artificial transmembrane segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLOMAVIRUS-E5 TRANSFORMING PROTEIN; FOCUS-FORMING VIRUS; GROWTH-FACTOR RECEPTOR; ERYTHROPOIETIN RECEPTOR; ALPHA-HELICES; COILED COILS; GP55 GLYCOPROTEIN; STOP-TRANSFER; AMINO-ACIDS; ACTIVATION	Specific interactions between cu-helical transmembrane segments are important for folding and/or oligomerization of membrane proteins. Previously, we have shown that most transmembrane helix-helix interfaces of a set of crystallized membrane proteins are structurally equivalent to soluble leucine zipper interaction domains. To establish a simplified model of these membrane-spanning leucine zippers, we studied the homophilic interactions of artificial transmembrane segments using different experimental approaches. Importantly, an oligoleucine, but not an oligoalanine, sequence efficiently self-assembled in membranes as well as in detergent solution. Self-assembly was maintained when a leucine zipper type of heptad motif consisting of leucine residues was grafted onto an alanine host sequence. Analysis of point mutants or of a random sequence confirmed that the heptad motif of leucines mediates self-recognition of our artificial transmembrane segments. Further, a data base search identified degenerate versions of this leucine motif within transmembrane segments of a variety of functionally different proteins. For several of these natural transmembrane segments, self-interaction was experimentally verified. These results support various lines of previously reported evidence where these transmembrane segments were implicated in the oligomeric assembly of the corresponding proteins.	Univ Heidelberg, Inst Neurobiol, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Langosch, D (corresponding author), Univ Heidelberg, Inst Neurobiol, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.							ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; Brosig B, 1998, PROTEIN SCI, V7, P1052; CHEN HF, 1995, J BIOL CHEM, V270, P14115, DOI 10.1074/jbc.270.23.14115; CHUNG SW, 1989, P NATL ACAD SCI USA, V86, P7957, DOI 10.1073/pnas.86.20.7957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P142; Dieckmann GR, 1997, CURR OPIN STRUC BIOL, V7, P486, DOI 10.1016/S0959-440X(97)80111-X; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; DRICKAMER K, 1995, CURR OPIN STRUC BIOL, V5, P612, DOI 10.1016/0959-440X(95)80052-2; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; HEIDIN CH, 1995, CELL, V80, P213; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOLMAR H, 1995, EMBO J, V14, P3895, DOI 10.1002/j.1460-2075.1995.tb00061.x; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; Laage R, 1997, EUR J BIOCHEM, V249, P540, DOI 10.1111/j.1432-1033.1997.00540.x; Langosch D, 1998, PROTEINS, V31, P150, DOI 10.1002/(SICI)1097-0134(19980501)31:2<150::AID-PROT5>3.0.CO;2-Q; Langosch D, 1996, J MOL BIOL, V263, P525, DOI 10.1006/jmbi.1996.0595; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LOEB JA, 1987, J BIOL CHEM, V262, P3022; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MCGINNES L, 1993, VIROLOGY, V196, P101, DOI 10.1006/viro.1993.1458; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; REES DC, 1989, ANNU REV BIOCHEM, V58, P607; SCHRAUBER H, 1993, J MOL BIOL, V230, P592, DOI 10.1006/jmbi.1993.1172; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Subczynski WK, 1998, BIOCHEMISTRY-US, V37, P3156, DOI 10.1021/bi972148+; Tarr K, 1997, J BIOL CHEM, V272, P9099; VERREY F, 1993, BIOCHEM J, V292, P149, DOI 10.1042/bj2920149; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITLEY P, 1994, NAT STRUCT BIOL, V1, P858, DOI 10.1038/nsb1294-858; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; WOLFF L, 1985, J VIROL, V53, P570, DOI 10.1128/JVI.53.2.570-578.1985; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; ZHANG YP, 1992, BIOCHEMISTRY-US, V31, P11579, DOI 10.1021/bi00161a042; ZON LI, 1992, MOL CELL BIOL, V12, P2949, DOI 10.1128/MCB.12.7.2949	57	161	163	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9265	9270		10.1074/jbc.274.14.9265	http://dx.doi.org/10.1074/jbc.274.14.9265			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092601	hybrid			2022-12-25	WOS:000079451800020
J	Li, HL; Davis, W; Pure, E				Li, HL; Davis, W; Pure, E			Suboptimal cross-linking of antigen receptor induces Syk-dependent activation of p70S6 kinase through protein kinase C and phosphoinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED SIGNAL-TRANSDUCTION; BRUTONS TYROSINE KINASE; B-CELL DEVELOPMENT; S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; RAPAMYCIN SENSITIVITY; INSULIN STIMULATION; INDEPENDENT PATHWAY; DOWN-REGULATION; LYMPHOCYTES-B	Ligation of the B cell antigen receptor (BCR) induces a cascade of signaling pathways that lead to clonal expansion, differentiation, or abortive activation-induced apoptosis of B lymphocytes, BCR-mediated cross-linking induces the sapid phosphorylation of protein tyrosine kinases. However, the pathways leading to the activation of downstream serine/threonine kinases such as mitogen-activated protein kinase, p90(Rsk), and p70S6 kinase (p70(S6k)) that mediate reorganization of the actin cytoskeleton, cell cycle progression, gene transcription, and protein synthesis have not been delineated. We recently demonstrated that cross-linking of BCR leads to activation of p70(S6k) in B lymphocytes, In this report, we demonstrate that multiple protein tyrosine kinase-dependent signal transduction pathways induced by BCR lead to the activation of p70(S6k). These distinct pathways exhibit different thresholds with respect Co the extent of receptor cross-linking required for their activation. Activation of p70S6k by suboptimal doses of anti-Ig is Syk-dependent and is mediated by protein kinase C and phosphoinositol 3-kinase. Moreover, the activation of p70(S6k) results in phosphorylation of S6. protein which is important for ribosomal protein synthesis and may be coupled to BCR-induced protein and DNA synthesis in primary murine B cells.	Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Pure, E (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.		Li, Hsiu-Ling/C-3567-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025185] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AAGAARDTILLERY KM, 1994, CELL IMMUNOL, V156, P493, DOI 10.1006/cimm.1994.1193; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; CHANG PY, 1995, J BIOL CHEM, V270, P29928; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dumont F J, 1996, Life Sci, V58, P373; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Fulcher D A, 1997, Int Rev Immunol, V15, P33, DOI 10.3109/08830189709068170; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GSCHWENDT M, 1991, TRENDS BIOCHEM SCI, V16, P167, DOI 10.1016/0968-0004(91)90064-3; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; IGARASHI H, 1994, J IMMUNOL, V153, P2381; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Jugloff LS, 1997, J IMMUNOL, V159, P1096; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Katsuta H, 1998, J IMMUNOL, V160, P1547; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Li HL, 1997, J BIOL CHEM, V272, P18200, DOI 10.1074/jbc.272.29.18200; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Lin JJ, 1997, J IMMUNOL, V159, P4823; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Mishell B.B., 1980, SELECTED METHODS CEL; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NOORCHASHM H, 1999, IN PRESS INT IMMUNOL; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SEGER R, 1995, J BIOL CHEM, V270, P28325; Seva C, 1997, BIOCHEM BIOPH RES CO, V238, P202, DOI 10.1006/bbrc.1997.7163; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1995, J IMMUNOL, V155, P3418; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tudan C, 1998, BIOCHEM J, V331, P531, DOI 10.1042/bj3310531; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; vonManteuffel SR, 1997, MOL CELL BIOL, V17, P5426, DOI 10.1128/MCB.17.9.5426; Watson KL, 1996, P NATL ACAD SCI USA, V93, P13694, DOI 10.1073/pnas.93.24.13694; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	77	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9812	9820		10.1074/jbc.274.14.9812	http://dx.doi.org/10.1074/jbc.274.14.9812			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092671	hybrid			2022-12-25	WOS:000079451800090
J	Cartwright, JL; McLennan, AG				Cartwright, JL; McLennan, AG			The Saccharomyces cerevisiae YOR163w gene encodes a diadenosine 5 ',5 '''-P-1,P-6-hexaphosphate (Ap(6)A) hydrolase member of the MutT motif (nudix hydrolase) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASES; P-1,P-4-BIS(5'-ADENOSYL) TETRAPHOSPHATE; BIS(5'-NUCLEOSIDYL) TETRAPHOSPHATES; ADENOSINE 5'-TETRAPHOSPHATE; ESCHERICHIA-COLI; AP4A; HYDROLYSIS; PYROPHOSPHOHYDROLASES; PHOSPHODIESTERASE; 5'-PENTAPHOSPHATE	The YOR163w open reading frame on chromosome XV of the Saccharomyces cerevisiae genome encodes a member of the MutT motif (nudix hydrolase) family of enzymes of M-r 21,443. By cloning and expressing this gene in Escherichia coli and S. cerevisiae, we have shown the product to be a (di)adenosine polyphosphate hydrolase with a previously undescribed substrate specificity. Diadenosine 5',5'''-P-1,P-6-hexaphosphate is the preferred substrate, and hydrolysis in (H2O)-O-18 shows that ADP and adenosine 5'-tetraphosphate are produced by attack at P beta and AMP and adenosine 5'-pentaphosphate are produced by attack at P-alpha with a K-m of 56 mu m and k(cat) of 0.4 s(-1). Diadenosine 5',5'''-P-1,P-5-pentaphosphate, adenosine 5'-pentaphosphate, and adenosine 5'-tetraphosphate are also substrates, but not diadenosine 5',5"-P-1,P-4-tetraphosphate or other dinucleotides, mononucleotides, nucleotide sugars, or nucleotide alcohols. The enzyme, which was shown to be expressed in log phase yeast cells by immunoblotting, displays optimal activity at pH 6.9, 50 degrees C, and 4-10 mM Mg2+ (or 200 mu M Mn2+). It has an absolute requirement for a reducing agent, such as dithiothreitol (1 mM), and is inhibited by Ca2+ with an IC50 of 3.3 mM and F- (noncompetitively) with a K-i of 80 mu M. Its function may be to eliminate potentially toxic dinucleoside polyphosphates during sporulation.	Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Liverpool	McLennan, AG (corresponding author), Univ Liverpool, Sch Biol Sci, Life Sci Bldg,POB 147, Liverpool L69 7ZB, Merseyside, England.	agmclen@liv.ac.uk						Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BLACKBURN GM, 1987, NUCLEIC ACIDS RES, V15, P6991, DOI 10.1093/nar/15.17.6991; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BREVET A, 1989, P NATL ACAD SCI USA, V86, P8275, DOI 10.1073/pnas.86.21.8275; Cartwright JL, 1997, BIOCHEM SOC T, V25, pS580, DOI 10.1042/bst025s580; DIXON RM, 1989, J BIOL CHEM, V264, P2069; GOERLICH O, 1982, EUR J BIOCHEM, V126, P135, DOI 10.1111/j.1432-1033.1982.tb06757.x; GURANOWSKI A, 1994, BIOCHEMISTRY-US, V33, P235, DOI 10.1021/bi00167a031; GURANOWSKI A, 1994, J BACTERIOL, V176, P2986, DOI 10.1128/JB.176.10.2986-2990.1994; GURANOWSKI A, 1985, J BIOL CHEM, V260, P3542; GURANOWSKI A, 1990, FEBS LETT, V262, P205, DOI 10.1016/0014-5793(90)80190-T; GURANOWSKI A, 1992, AP4A OTHER DINUCLEOS, P81; JAKUBOWSKI H, 1983, J BIOL CHEM, V258, P9982; JAKUBOWSKI H, 1986, P NATL ACAD SCI USA, V83, P2378, DOI 10.1073/pnas.83.8.2378; KAUSHAL V, 1990, GENE, V95, P79, DOI 10.1016/0378-1119(90)90416-O; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MCLENNAN AG, 1989, BIOCHEMISTRY-US, V28, P3868, DOI 10.1021/bi00435a036; MCLENNAN AG, 1989, BIOMED ENVIRON MASS, V18, P450, DOI 10.1002/bms.1200180615; MCLENNAN AG, 1994, BIOCHEM J, V300, P183, DOI 10.1042/bj3000183; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; NG KME, 1987, NUCLEIC ACIDS RES, V15, P3573, DOI 10.1093/nar/15.8.3573; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PLATEAN P, 1982, BIOCHEMISTRY-US, V20, P4654; PLATEAU P, 1990, J BACTERIOL, V172, P6892, DOI 10.1128/jb.172.12.6892-6899.1990; PRESCOTT M, 1992, INT J BIOCHEM, V24, P565, DOI 10.1016/0020-711X(92)90328-X; RAPAPORT E, 1976, P NATL ACAD SCI USA, V73, P3984, DOI 10.1073/pnas.73.11.3984; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sozzi G, 1998, ADV CANCER RES, V74, P141, DOI 10.1016/S0065-230X(08)60766-6; Theoclitou M. E., 1996, J CHEM SOC P1, V16; Vartanian A, 1997, FEBS LETT, V415, P160, DOI 10.1016/S0014-5793(97)01086-7; WEBER DJ, 1993, BIOCHEMISTRY-US, V32, P13081, DOI 10.1021/bi00211a018	36	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8604	8610		10.1074/jbc.274.13.8604	http://dx.doi.org/10.1074/jbc.274.13.8604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085096	hybrid			2022-12-25	WOS:000079451600038
J	Nielsen, MS; Jacobsen, C; Olivecrona, G; Gliemann, J; Petersen, CM				Nielsen, MS; Jacobsen, C; Olivecrona, G; Gliemann, J; Petersen, CM			Sortilin/neurotensin receptor-3 binds and mediates degradation of lipoprotein lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ALPHA(2)-MACROGLOBULIN RECEPTOR; TERMINAL DOMAIN; PROTEIN BINDS; IN-VITRO; DENSITY; FAMILY; CELLS; INTERNALIZATION; FORMS	Lipoprotein lipase and the receptor-associated protein (RAP) bind to overlapping sites on the low density Lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP), We have investigated if lipoprotein lipase interacts with the RAP binding but structurally distinct receptor sortilin/neurotensin receptor-3, We show, by chemical cross-linking and surface plasmon resonance analysis, that soluble sortilin binds lipoprotein lipase with an affinity similar to that of LRP. The binding was inhibited by heparin and RAP and by the newly discovered sortilin ligand neurotensin. In S-35-labeled 3T3-L1 adipocytes treated with the cross-linker dithiobis(succinimidyl propionate), lipoprotein lipase-containing complexes were isolated by anti-sortilin antibodies. To elucidate function in cells, sortilin-negative Chinese hamster ovary cells were transfected with full-length sortilin and shown to express about 8% of the receptors on the cell surface. These cells degraded I-125-labeled lipoprotein lipase much faster than the wildtype cells. The degradation was inhibited by unlabeled lipoprotein lipase, indicating a saturable pathway, and by RAP and heparin. Moreover, inhibition by the weak base chloroquine suggested that degradation occurs in an acidic vesicle compartment. The results demonstrate that sortilin is a multifunctional receptor that binds lipoprotein lipase and, when expressed on the cell. surface, mediates its endocytosis and degradation.	Aarhus Univ, Dept Med Biochem, DK-8000 Aarhus C, Denmark; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Aarhus University; Umea University	Nielsen, MS (corresponding author), Aarhus Univ, Dept Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.	mn@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694				BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BERRYMAN DE, 1995, J BIOL CHEM, V270, P24525, DOI 10.1074/jbc.270.41.24525; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; FernandezBorja M, 1996, J LIPID RES, V37, P464; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Gerdes C, 1997, CIRCULATION, V96, P733; Gliemann J, 1998, BIOL CHEM, V379, P951; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P14176; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; MASUNO H, 1992, J LIPID RES, V33, P1343; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; Morris NJ, 1998, J BIOL CHEM, V273, P3582, DOI 10.1074/jbc.273.6.3582; Nielsen MS, 1997, J BIOL CHEM, V272, P5821, DOI 10.1074/jbc.272.9.5821; NIELSEN MS, 1995, J BIOL CHEM, V270, P23713, DOI 10.1074/jbc.270.40.23713; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1987, J BIOL CHEM, V262, P10748; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; Tauris J, 1998, FEBS LETT, V429, P27, DOI 10.1016/S0014-5793(98)00559-6; VILELLA E, 1993, J LIPID RES, V34, P1555; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Weaver AM, 1997, J LIPID RES, V38, P1841; Willnow TE, 1998, BIOL CHEM, V379, P1025; Wittrup HH, 1997, J CLIN INVEST, V99, P1606, DOI 10.1172/JCI119323	37	164	178	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8832	8836		10.1074/jbc.274.13.8832	http://dx.doi.org/10.1074/jbc.274.13.8832			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085125	hybrid			2022-12-25	WOS:000079451600067
J	Sionov, RV; Moallem, E; Berger, M; Kazaz, A; Gerlitz, O; Ben-Neriah, Y; Oren, M; Haupt, Y				Sionov, RV; Moallem, E; Berger, M; Kazaz, A; Gerlitz, O; Ben-Neriah, Y; Oren, M; Haupt, Y			c-Abl neutralizes the inhibitory effect of Mdm2 on p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; TYROSINE KINASE; DNA-DAMAGE; APOPTOSIS; DEGRADATION; PATHWAY; GROWTH; SIGNALS; ARREST	Upon exposure to stress signals, the p53 tumor suppressor protein is stabilized and induces growth suppression. p53 activities are efficiently inhibited by the Mdm2 oncoprotein through an autoregulatory feedback loop. In addition, Mdm2 promotes p53 degradation, thereby terminating its growth inhibitory signal. Hence, p53 exerts its effects during the interval between p53 activation and the subsequent inhibition by Mdma. Modulation of this interval by regulatory proteins may determine the extent and duration of p53 activity, Recent studies have shown that the c-Abl protein-tyrosine kinase binds p53 and enhances its transcriptional activity. Here we provide an explanation for the cooperation between these proteins. We demonstrate that c-Abl increases the expression level of the p53 protein, The enhanced expression is achieved by inhibiting Mdm2-mediated degradation of p53, This provides a likely mechanistic explanation for the findings that c-Abl overcomes the inhibitory effects of Mdma on p53-mediated transcriptional activation and apoptosis. These results suggest that c-Abl modulates the time window within which p53 remains active. The ability of c-Abl to neutralize the inhibitory effects of Mdma on p53 may be important for its growth inhibitory function.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Haupt, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.	haupt@md.huji.ac.il	Ben-Neriah, Yinon/L-6285-2019	Haupt, Ygal/0000-0001-5925-0096; Oren, Moshe/0000-0003-4311-7172; Gerlitz, Offer/0000-0002-1574-2088				Chen JD, 1996, MOL CELL BIOL, V16, P2445; Dai ZH, 1998, GENE DEV, V12, P1415, DOI 10.1101/gad.12.10.1415; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOGA A, 1995, ONCOGENE, V11, P791; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Momand J, 1997, J CELL BIOCHEM, V64, P343; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	25	91	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8371	8374		10.1074/jbc.274.13.8371	http://dx.doi.org/10.1074/jbc.274.13.8371			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085066	hybrid			2022-12-25	WOS:000079451600008
J	Biscardi, JS; Maa, MC; Tice, DA; Cox, ME; Leu, TH; Parsons, SJ				Biscardi, JS; Maa, MC; Tice, DA; Cox, ME; Leu, TH; Parsons, SJ			c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr(845) and Tyr(1101) is associated with modulation of receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GAP-ASSOCIATED PROTEINS; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; MITOGENIC RESPONSIVENESS; INSULIN-RECEPTOR; EGF RECEPTOR	Accumulating evidence indicates that interactions between the epidermal growth factor receptor (EGFR) and the nonreceptor tyrosine kinase c-Src may contribute to an aggressive phenotype in multiple human tumors. Previous work from our laboratory demonstrated that murine fibroblasts which overexpress both these tyrosine kinases display synergistic increases in DNA synthesis, soft agar growth, and tumor formation in nude mice, and increased phosphorylation of the receptor substrates Shc and phospholipase gamma as compared with single overexpressors, These parameters correlated with the ability of c-Src and EGFR to form an EGF-dependent heterocomplex in vivo, Here we provide evidence that association between c-Src and EGFR can occur directly, as shown by receptor overlay experiments, and that it results in the appearance of two novel tyrosine phosphorylations on the receptor that are seen both in vitro and in vivo following EGF stimulation. Edman degradation analyses and co-migration of synthetic peptides with EGFR-derived tryptic phosphopeptides identify these sites as Tyr(845) and Tyr(1101). Tyr(1101) lies within the carboxyl-terminal region of the EGFR among sites of receptor autophosphorylation, while Tyr845 resides in the catalytic domain, in a position analogous to Tyr(416) Of c-Src, Phosphorylation of Tyr(416) and homologous residues in other tyrosine kinase receptors has been shown to be required for or to increase catalytic activity, suggesting that c-Src can influence EGFR activity by mediating phosphorylation of Tyr(845). Indeed, EGF-induced phosphorylation of Tyr(845) was increased in MDA468 human breast cancer cells engineered to overexpress c-Src as compared with parental MDA 468 cells. Furthermore, transient expression of a Y845F variant EGFR in murine fibroblasts resulted in an ablation of EGF-induced DNA synthesis to nonstimulated levels. Together, these data support the hypothesis that c-Src-mediated phosphorylation of EGFR Tyr(845) is involved in regulation of receptor function, as well as in tumor progression.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Box 441, Charlottesville, VA 22908 USA.	sap@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NCI NIH HHS [CA3948, CA71449] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; BISCARDI JS, 1998, IN PRESS ADV CANC RE; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHANG JH, 1993, ONCOGENE, V8, P959; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COULL JM, 1991, ANAL BIOCHEM, V194, P110, DOI 10.1016/0003-2697(91)90157-O; DOWNWARD J, 1984, NATURE, V311, P483, DOI 10.1038/311483a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HSUAN JJ, 1989, BIOCHEM J, V262, P659, DOI 10.1042/bj2620659; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; LONGATI P, 1994, ONCOGENE, V9, P49; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1992, ONCOGENE, V7, P2429; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEYER HE, 1991, METHOD ENZYMOL, V201, P206; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; Stewart JM, 1984, SOLID PHASE PEPTIDE; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TICE DA, 1999, IN PRESS P NATL ACAD; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	56	537	557	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8335	8343		10.1074/jbc.274.12.8335	http://dx.doi.org/10.1074/jbc.274.12.8335			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075741				2022-12-25	WOS:000079268100100
J	Deyrup, AT; Krishnan, S; Singh, B; Schwartz, NB				Deyrup, AT; Krishnan, S; Singh, B; Schwartz, NB			Activity and stability of recombinant bifunctional rearranged and monofunctional domains of ATP-sulfurylase and adenosine 5 '-phosphosulfate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE BIENZYME COMPLEX; RAT CHONDROSARCOMA; BRACHYMORPHIC MICE; KINETIC MECHANISM; PROTEIN; DEFECT; MUTAGENESIS; ENZYMES; GENE	Murine adenosine 3'-phosphate 5'-phosphosulfate (PAPS) synthetase consists of a COOH-terminal ATP-sulfurylase domain covalently linked through a nonhomologous intervening sequence to an NH2-terminal adenosine 5'-phosphosulfate (APS) kinase domain forming a bifunctional fused protein. Possible advantages of bifunctionality were probed by separating the domains on the cDNA level and expressing them as monofunctional proteins. Expressed protein generated from the ATP-sulfurylase domain alone was fully active in both the forward and reverse sulfurylase assays. APS kinase-only recombinants exhibited no kinase activity. However, extension of the kinase domain at the COOH terminus by inclusion of the 36 residue linker region restored kinase activity. An equimolar mixture of the two monofunctional enzymes catalyzed the overall reaction (synthesis of PAPS from ATP + SO42-) comparably to the fused bifunctional enzyme. The importance of the domain order and organization was demonstrated by generation of a series of rearranged recombinants in which the order of the two active domains was reversed or altered relative to the linker region, The critical role of the linker region was established by generation of recombinants that had the linker deleted or rearranged relative to the two active domains. The intrinsic stability of the various recombinants was also investigated by measuring enzyme deactivation as a function of time of incubation at 25 or 37 degrees C, The expressed monofunctional ATP-sulfurylase, which was initially fully active, was unstable compared with the fused bifunctional wild type enzyme, decaying with a t(1/2) of 10 min at 37 degrees C, Progressive extension by addition of kinase sequence at the NH2-terminal side of the sulfurylase recombinant eventually stabilized sulfurylase activity. Sulfurylase activity was significantly destabilized in a time-dependent manner in the rearranged proteins as well. In contrast, no significant deactivation of any truncated kinase-containing recombinants or misordered kinase recombinants was observed at either temperature. It would therefore appear that fusion of the two enzymes enhances the intrinsic stability of the sulfurylase only.	Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, MC5058,5841 S Maryland Ave, Chicago, IL 60637 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402, R01HD017332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-17332, HD-09402] Funding Source: Medline; NIGMS NIH HHS [GM 07281] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI SA, 1995, BIOTECHNIQUES, V18, P746; Beaucamp N, 1997, PROTEIN SCI, V6, P2159; BRZOVIC PS, 1992, BIOCHEMISTRY-US, V31, P3831, DOI 10.1021/bi00130a014; Deyrup AT, 1998, J BIOL CHEM, V273, P9450, DOI 10.1074/jbc.273.16.9450; DEYRUP AT, 1997, THESIS U CHICAGO CHI; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GELLER DH, 1987, J BIOL CHEM, V262, P7374; JULIEN D, 1997, MECH DEVELOP, V68, P179; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1994, BIOCHEM J, V301, P349, DOI 10.1042/bj3010349; LYLE S, 1994, BIOCHEMISTRY-US, V33, P6822, DOI 10.1021/bi00188a010; LYLE S, 1994, BIOCHEM J, V301, P355, DOI 10.1042/bj3010355; LYLE S, 1995, BIOCHEMISTRY-US, V34, P940, DOI 10.1021/bi00003a028; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; STOKES AM, 1973, BIOCHIM BIOPHYS ACTA, V302, P64, DOI 10.1016/0005-2744(73)90008-9; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P589, DOI 10.1016/0003-9861(82)90064-9; SUGAHARA K, 1979, P NATL ACAD SCI USA, V76, P6615, DOI 10.1073/pnas.76.12.6615; SUGAHARA K, 1982, ARCH BIOCHEM BIOPHYS, V214, P601; Yablonski MJ, 1996, J BIOL CHEM, V271, P10704, DOI 10.1074/jbc.271.18.10704	22	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10751	10757		10.1074/jbc.274.16.10751	http://dx.doi.org/10.1074/jbc.274.16.10751			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196147	hybrid			2022-12-25	WOS:000079751900015
J	Hashimoto, A; Hirose, K; Okada, H; Kurosaki, T; Iino, M				Hashimoto, A; Hirose, K; Okada, H; Kurosaki, T; Iino, M			Inhibitory modulation of B cell receptor-mediated Ca2+ mobilization by Src homology 2 domain-containing inositol 5 '-phosphatase (SHIP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; POLYPHOSPHATE 5-PHOSPHATASE SHIP; TYROSINE-PHOSPHORYLATED PROTEIN; PHOSPHOLIPASE C-GAMMA; AFFINITY IGE RECEPTOR; ANTIGEN RECEPTOR; CALCIUM CURRENT; CROSS-LINKING; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; SIGNAL-TRANSDUCTION	Src homology 2 domain-containing inositol 5'-phosphatase (SHIP) mediates inhibitory signals that attenuate intracellular Ca2+ mobilization in B cells upon B cell receptor (BCR) stimulation. To clarify the mechanisms affected by SHIP, we analyzed Ca2+ mobilization in the DT40 B cell line in which the SHIP gene was disrupted. In SHIP-deficient cells, Ca2+ transient elicited by BCR stimulation was more prolonged than that in control cells both in the presence and absence of extracellular Ca2+, Inositol 1,4,5-trisphosphate production following BCR stimulation was enhanced in SHIP-deficient cells. In SHIP-deficient cells in comparison with the control cells, BCR stimulation in the absence of extracellular Ca2+ induced a greater degree of Ca2+ store depletion and the Ca2+ influx upon re-addition of extracellular Ca2+ was also greater. However, store-operated Ca2+ influx (SOC) elicited by thapsigargin-induced store depletion was not affected by SHIP. These results indicate that the primary target pathway of SHIP is the Ca2+ release from the stores, and that Ca2+ influx by the SOC mechanism is secondarily controlled by the level of Ca2+ in the stores without direct inhibition of SOC. In this way, SHIP may play an important role in ensuring the robust tuning of Ca2+ signaling in B cells.	Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 113, Japan; Japan Sci & Technol Corp, Tokyo 113, Japan; Kansai Med Univ, Inst Liver Res, Dept Mol Genet, Moriguchi, Osaka 570, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Kansai Medical University	Iino, M (corresponding author), Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Kurosaki, Tomohiro/D-1306-2009; Okada, Hidetaka/AAP-7775-2020; okada, hidetaka/C-6990-2011	Kurosaki, Tomohiro/0000-0002-6352-304X; Hashimoto-Tane, Akiko/0000-0001-8519-266X				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P290; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIEGEL ML, 1994, J BIOL CHEM, V269, P11409; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nadler MJS, 1997, J BIOL CHEM, V272, P20038, DOI 10.1074/jbc.272.32.20038; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; RANSOM JT, 1988, J IMMUNOL, V140, P3150; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SAXTON TM, 1994, J IMMUNOL, V153, P623; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	42	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11203	11208		10.1074/jbc.274.16.11203	http://dx.doi.org/10.1074/jbc.274.16.11203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196207	hybrid			2022-12-25	WOS:000079751900075
J	Krab, IM; Parmeggiani, A				Krab, IM; Parmeggiani, A			Functional-structural analysis of threonine 25, a residue coordinating the nucleotide-bound magnesium in elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; EF-TS COMPLEX; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; KIRROMYCIN RESISTANCE; EXCHANGE FACTOR; BINDING DOMAIN; ACTIVE-SITE; P21 RAS; GTP	Elongation factor (EF) Tu Thr-25 is a key residue binding the essential magnesium complexed to nucleotide. We have characterized mutations at this position to the related Ser and to Ala, which abolishes the bond to Mg2+, and a double mutation, H22Y/T25S. Nucleotide interaction was moderately destabilized in EF-Tu(T25S) but strongly in EF-Tu(T25A) and EF-Tu(H22Y/T25S), Binding Phe-tRNA(Phe) to poly(U) ribosome needed a higher magnesium concentration for the latter two mutants but was comparable at 10 mM MgCl2. Whereas EF-Tu(T25S) synthesized poly(Phe), as effectively as wild type, the rate was reduced to 50% for EF-Tu(H22Y/T25S) and was, surprisingly, still 10% for EF-Tu(T25A), In contrast, protection of Phe-tRNA(Phe) against spontaneous hydrolysis by the latter two mutants was very low. The intrinsic GTPase in EF-Tu(H22Y/T25S) and (T25A) was reduced, and the different responses to ribosomes and kirromycin suggest that stimulation by these two agents follows different mechanisms. Of the mutants, only EF-Tu(T25A) forms a more stable complex with EF-Ts than wild type. This implies that stabilization of the EF-Tu EF-Ts complex is related to the inability to bind Mg2+, rather than to a decreased nucleotide affinity. These results are discussed in the light of the three-dimensional structure. They emphasize the importance of the Thr-25-Mg2+ bond, although its absence is compatible with protein synthesis and thus with an active overall conformation of EF-Tu.	Ecole Polytech, Grp Biophys Equipe 2, F-91128 Palaiseau, France	Institut Polytechnique de Paris	Parmeggiani, A (corresponding author), Ecole Polytech, Grp Biophys Equipe 2, F-91128 Palaiseau, France.	andrea@poly.polytechnique.fr						ABDULKARIM F, 1994, FEBS LETT, V352, P118, DOI 10.1016/0014-5793(94)00937-6; Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; ANBORGH PH, 1991, EMBO J, V10, P779, DOI 10.1002/j.1460-2075.1991.tb08009.x; ANBORGH PH, 1993, J BIOL CHEM, V268, P24622; ANBORGH PH, 1993, THESIS LEIDEN U THE; ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cetin R, 1996, EMBO J, V15, P2604, DOI 10.1002/j.1460-2075.1996.tb00618.x; CHINALI G, 1977, EUR J BIOCHEM, V75, P55, DOI 10.1111/j.1432-1033.1977.tb11503.x; COOL RH, 1991, BIOCHEMISTRY-US, V30, P362, DOI 10.1021/bi00216a008; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Farrar CT, 1997, STRUCTURE, V5, P1055, DOI 10.1016/S0969-2126(97)00257-8; FASANO O, 1982, ANAL BIOCHEM, V124, P53, DOI 10.1016/0003-2697(82)90218-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HALKIDES CJ, 1994, BIOCHEMISTRY-US, V33, P4019, DOI 10.1021/bi00179a031; HWANG YW, 1989, ARCH BIOCHEM BIOPHYS, V274, P394, DOI 10.1016/0003-9861(89)90452-9; IVELL R, 1981, BIOCHEMISTRY-US, V20, P6852, DOI 10.1021/bi00527a017; JENSEN M, 1989, EUR J BIOCHEM, V182, P247, DOI 10.1111/j.1432-1033.1989.tb14824.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Krab IM, 1998, BBA-GENE STRUCT EXPR, V1443, P1, DOI 10.1016/S0167-4781(98)00169-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESTERS JR, 1994, EMBO J, V13, P4877, DOI 10.1002/j.1460-2075.1994.tb06815.x; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; MISTOU MY, 1992, EUR J BIOCHEM, V204, P179, DOI 10.1111/j.1432-1033.1992.tb16621.x; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; PARLATO G, 1983, J BIOL CHEM, V258, P995; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PARMEGGIANI A, 1971, METHODS ENZYMOLOGY C, V20, P291; PICONE D, 1983, BIOCHEMISTRY-US, V22, P4400, DOI 10.1021/bi00288a009; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SWART GWM, 1987, BIOCHEMISTRY-US, V26, P2047, DOI 10.1021/bi00381a038; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650	45	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11132	11138		10.1074/jbc.274.16.11132	http://dx.doi.org/10.1074/jbc.274.16.11132			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196198	hybrid			2022-12-25	WOS:000079751900066
J	Mueckler, M; Makepeace, C				Mueckler, M; Makepeace, C			Transmembrane segment 5 of the Glut1 glucose transporter is an amphipathic helix that forms part of the sugar permeation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOFACIAL LIGAND-BINDING; XENOPUS-OOCYTES; AMINO-ACID; MEMBRANE; MUTAGENESIS; DOMAINS; FAMILY; HEPG2; SITE	Transmembrane segment 5 of the Glut1 glucose transporter has been proposed to form an amphipathic transmembrane helix that lines the substrate translocation pathway (Mueckler, M., Caruso, C., Baldwin, S. A. Panico, M., Blench, I., Morris, H. R., Allard, W. J., Lienhard, G. E., and Lodish, H. F. (1985) Science 229, 941-945). This hypothesis was tested using cysteine-scanning mutagenesis in conjunction with the membrane-impermeant, sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS), A series of 21 mutants was created from a fully functional, cysteine-less, parental Glut1 molecule by changing each residue within putative transmembrane segment 5 to cysteine, Each mutant was then expressed in Xenopus oocytes and its steady-state protein level, alpha-deoxyglucose uptake activity, and sensitivity to pCMBS were measured. All 21 mutants exhibited measurable transport activity, although several of the mutants exhibited reduced activity due to a corresponding reduction in steady-state protein. Six of the amino acid side chains within transmembrane segment 5 were clearly accessible to pCMBS in the external medium, as determined by inhibition of transport activity, and a 7th residue showed inhibition that lacked statistical significance because of the extremely low transport activity of the corresponding mutant. All 7 of these residues were clustered along one face of a putative alpha-helix, proximal to the exoplasmic surface of the plasma membrane. These results comprise the first experimental evidence for the existence of an amphipathic transmembrane alpha-helix in a glucose transporter molecule and strongly suggest that transmembrane segment 5 of Glut1 forms part of the sugar permeation pathway.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	17	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10923	10926		10.1074/jbc.274.16.10923	http://dx.doi.org/10.1074/jbc.274.16.10923			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196171	hybrid			2022-12-25	WOS:000079751900039
J	Stratmann, A; Mahmud, T; Lee, S; Distler, J; Floss, HG; Piepersberg, W				Stratmann, A; Mahmud, T; Lee, S; Distler, J; Floss, HG; Piepersberg, W			The AcbC protein from Actinoplanes species is a C-7-cyclitol synthase related to 3-dehydroquinate synthases and is involved in the biosynthesis of the alpha-glucosidase inhibitor acarbose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; DEHYDROQUINATE SYNTHASE; STREPTOMYCES-GRISEUS; 2-DEOXY-SCYLLO-INOSOSE SYNTHASE; SHIKIMATE PATHWAY; ESCHERICHIA-COLI; CLONING; GENES; UNIT; DNA	The putative biosynthetic gene cluster for the a-glucosidase inhibitor acarbose was identified in the producer Actinoplanes sp, 50/110 by cloning a DNA segment containing the conserved gene for dTDP-D-glucose 4,6-dehydratase, acbB. The two flanking genes were acbA (dTDP-D-glucose synthase) and acbC, encoding a protein with significant similarity to 3-dehydroquinate synthases (AroB proteins). The acbC gene was overexpressed heterologously in Streptomyces lividans 66, and the product was shown to be a C-7-cyclitol synthase using sedo-heptulose 7-phosphate, but not ido-heptulose 7-phosphate, as its substrate. The cyclization product, 2-epi-5-epi-valiolone ((2S,3S,4S,5R)-5-(hydroxymethyl)cyclohexanon-2,3,4,5-tetrol), is a precursor of the valienamine moiety of acarbose. A possible five-step reaction mechanism is proposed for the cyclization reaction catalyzed by AcbC based on the recent analysis of the three-dimensional structure of a eukaryotic 3-dehydroquinate synthase domain (Carpenter, E. P., Hawkins, A. R., Frost, J. W., and Brown, K. A. (1998) Nature 394, 299-302).	Berg Univ Gesamthsch Wuppertal, D-42097 Wuppertal, Germany; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Wuppertal; University of Washington; University of Washington Seattle	Piepersberg, W (corresponding author), Berg Univ Gesamthsch Wuppertal, Gauss Str 20, D-42097 Wuppertal, Germany.		Mahmud, Taifo/A-1492-2015	Mahmud, Taifo/0000-0001-9639-526X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABCOCK MJ, 1988, J BACTERIOL, V170, P2802, DOI 10.1128/jb.170.6.2802-2808.1988; BENDER SL, 1989, BIOCHEMISTRY-US, V28, P7555, DOI 10.1021/bi00445a009; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Carpenter EP, 1998, NATURE, V394, P299, DOI 10.1038/28431; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Decker H, 1996, FEMS MICROBIOL LETT, V141, P195, DOI 10.1016/0378-1097(96)00221-2; DEGWERT U, 1987, J ANTIBIOT, V40, P855, DOI 10.7164/antibiotics.40.855; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; DISTLER J, 1985, FEMS MICROBIOL LETT, V30, P145; Drepper A, 1996, FEBS LETT, V388, P177, DOI 10.1016/0014-5793(96)00554-6; Floss HG, 1997, NAT PROD REP, V14, P433, DOI 10.1039/np9971400433; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HEMKER M, 1995, THESIS U MUNSTER; Hopwood D. A., 1985, GENETIC MANIPULATION; KAMEDA Y, 1984, J ANTIBIOT, V37, P1301, DOI 10.7164/antibiotics.37.1301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee S, 1997, J ANTIBIOT, V50, P954, DOI 10.7164/antibiotics.50.954; LEE SS, 1999, IN PRESS J MOL CATAL; LIU HW, 1994, ANNU REV MICROBIOL, V48, P223, DOI 10.1146/annurev.micro.48.1.223; LOEWUS MW, 1980, J BIOL CHEM, V255, P1710; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MULLER L, 1989, NOVEL MICROBIAL PROD, P109; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIEPERSBERG W, 1994, CRIT REV BIOTECHNOL, V14, P251, DOI 10.3109/07388554409079835; Piepersberg W., 1997, BIOTECHNOLOGY ANTIBI, P81; PISSOWOTZKI K, 1991, MOL GEN GENET, V231, P113, DOI 10.1007/BF00293829; Rehm H. J., 1997, BIOTECHNOLOGY, P397; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sohng JK, 1996, J BIOCHEM MOL BIOL, V29, P183; STOCKMANN M, 1992, FEMS MICROBIOL LETT, V90, P185, DOI 10.1111/j.1574-6968.1992.tb05149.x; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; TOYOKUNI T, 1987, J AM CHEM SOC, V109, P3481, DOI 10.1021/ja00245a061; TRUSCHEIT E, 1981, ANGEW CHEM INT EDIT, V20, P744, DOI 10.1002/anie.198107441; WIDLANSKI T, 1989, J AM CHEM SOC, V111, P2299, DOI 10.1021/ja00188a052; YAMAUCHI N, 1995, J ORG CHEM, V60, P5614, DOI 10.1021/jo00122a049; YAMAUCHI N, 1993, J ANTIBIOT, V46, P1916, DOI 10.7164/antibiotics.46.1916; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	41	60	71	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10889	10896		10.1074/jbc.274.16.10889	http://dx.doi.org/10.1074/jbc.274.16.10889			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196166	hybrid			2022-12-25	WOS:000079751900034
J	Chow, CW; Woodside, M; Demaurex, N; Yu, FH; Plant, P; Rotin, D; Grinstein, S; Orlowski, J				Chow, CW; Woodside, M; Demaurex, N; Yu, FH; Plant, P; Rotin, D; Grinstein, S; Orlowski, J			Proline-rich motifs of the Na+/H+ exchanger 2 isoform - Binding of Src homology domain 3 and role in apical targeting in epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; COLLECTING DUCT CELLS; THICK ASCENDING LIMB; AIRWAY ION-TRANSPORT; RAT NA/H EXCHANGER; SH3 DOMAIN; FUNCTIONAL EXPRESSION; TYROSINE KINASE; MAMMALIAN-CELLS; ATP DEPENDENCE	The NHE2 isoform of the Na+/H+ exchanger (NHE) displays two proline-rich sequences in its C-terminal region that resemble SH3 (Src homology 3)-binding domains. We investigated whether these regions ((PPS)-P-743-VTPAP(750), termed Pro-1, and (VPPKPPP792)-V-786, termed Pro-2) can bind to SH3 domains and whether they are essential for NHE2 function and targeting. A fusion protein containing the Pro-1 region showed promiscuous binding to SH3 domains of several proteins in vitro, whereas a Pro-2 fusion bound preferentially to domains derived from kinases. In contrast, cytoplasmic regions of NHE1, NHE3, or NHE4 failed to interact. When expressed in antiporter-deficient cells, truncated NHE2 lacking both Pro-rich regions catalyzed Na+/H+ exchange, retained sensitivity to intracellular ATP, and was activated by hyperosmolarity, resembling full-length NHE2, The role of the Pro-rich regions in subcellular targeting was examined by transfection of epitope-tagged forms of NHE2 in porcine renal epithelial LLC-PK1 cells. Both full-length and Pro-2-truncated NHE2 localized almost exclusively to the apical membrane. By contrast, a mutant devoid of both Pro-1 and Pro-2 was preferentially sorted to the basolateral surface but also accumulated intracellularly. These observations indicate that the region encompassing Pro-1 is essential for appropriate subcellular targeting of NHE2.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med, Div Resp Med, Toronto, ON M5G 1X8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St,McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	orlowski@physio.mcgill.ca	Chow, Chung-Wai/AAP-5533-2020	Chow, Chung-Wai/0000-0001-9344-8522; Yu, Frank/0000-0001-9306-1731; Demaurex, Nicolas/0000-0002-9933-6772; Orlowski, John/0000-0001-7371-175X				AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chow CW, 1997, J GEN PHYSIOL, V110, P185, DOI 10.1085/jgp.110.2.185; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEMAUREX N, 1994, J EXP BIOL, V196, P389; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; GOSS GG, 1994, J BIOL CHEM, V269, P8741; Guerra L, 1998, KIDNEY INT, V53, P1269, DOI 10.1046/j.1523-1755.1998.00897.x; Holleran EA, 1998, TRENDS CELL BIOL, V8, P26, DOI 10.1016/S0962-8924(97)01195-1; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAPUS A, 1994, J BIOL CHEM, V269, P23544; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McMahon HT, 1997, FEBS LETT, V413, P319, DOI 10.1016/S0014-5793(97)00928-9; Nakamura R, 1998, EUR J BIOCHEM, V251, P583, DOI 10.1046/j.1432-1327.1998.2510583.x; Nath SK, 1996, AM J PHYSIOL-GASTR L, V270, pG431, DOI 10.1152/ajpgi.1996.270.3.G431; Noel J, 1996, J CELL SCI, V109, P929; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Singh G, 1996, J MEMBRANE BIOL, V151, P261, DOI 10.1007/s002329900076; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sun AM, 1997, J MEMBRANE BIOL, V160, P85, DOI 10.1007/s002329900297; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1993, J BIOL CHEM, V268, P11917; TSE M, 1993, J MEMBRANE BIOL, V135, P93; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Wormmeester L, 1998, AM J PHYSIOL-CELL PH, V274, pC1261, DOI 10.1152/ajpcell.1998.274.5.C1261; Yoshioka S, 1997, J BIOCHEM-TOKYO, V122, P641; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	51	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10481	10488		10.1074/jbc.274.15.10481	http://dx.doi.org/10.1074/jbc.274.15.10481			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187839	hybrid			2022-12-25	WOS:000079663500078
J	Kumahara, E; Ebihara, T; Saffen, D				Kumahara, E; Ebihara, T; Saffen, D			Protein kinase inhibitor H7 blocks the induction of immediate-early genes zif268 and c-fos by a mechanism unrelated to inhibition of protein kinase C but possibly related to inhibition of phosphorylation of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PC12 PHEOCHROMOCYTOMA CELLS; TRANSCRIPTION FACTOR TFIIH; RAS-DEPENDENT ACTIVATION; TUMOR-NECROSIS-FACTOR; MAP KINASE; CYCLIC-AMP; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CALCIUM INFLUX	1-(5-Isoquinolinesulfonyl)-2-methylpiperazine (H7) has often been used in combination with protein kinase inhibitor (N-(2-guanidinoethyl)-5-isoquinolinesulfonamide) (HA1004) to assess the contribution of protein kinase C (PKC) to cellular processes, including the induction of gene expression. This use of H7 and HA1004 is based upon the fact that H7 inhibits PRC more potently than HA1004 in in vitro assays. Thus, although both compounds are broad spectrum protein kinase inhibitors, inhibition by H7, but not by HA1004, has often been interpreted as evidence for the involvement of PKC in the cellular process under study. Here we describe experiments that show that this interpretation is not correct with regard to the induction of two immediate early genes, zif268 and c-fos, in PC1SD cells. In these studies we confirmed that H7, but not HA1004, potently blocks the induction of zif268 and c-fos mRNA by nerve growth factor, carbachol, phorbol ester, Ca2+ ionophore, or forskolin, Surprisingly, however, H7 has no effect on the ability of these agents to activate mitogen-activated protein kinase (MAPK), an upstream activator of zif268 and c-fos gene expression. H7 also does not inhibit preactivated MAPK in vitro. Taken together, these results suggest that H7 blocks gene expression by acting at a site downstream from MAPK. H7 has previously been shown to block transcription in vitro by blocking the phosphorylation of the carboxyl-terminal domain of RNA polymerase II (Yankulov, K,, Yamashita, K,, Roy, R,, Egly, J,-M,, and Bentley, D, L,(1995) J, Biol, Chem, 270, 23922-23925). In this study, we show that pretreating PC12D cells with H7, but not with HA1004, significantly reduces levels of phosphorylated RNA polymerase II in vivo. These results suggest that H7 blocks gene expression by inhibiting the phosphorylation of RNA polymerase II, a step required for progression from transcription initiation to mRNA chain elongation.	Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Kumahara, E (corresponding author), Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.	kumahara@m.u-tokyo.ac.jp	EBIHARA, TAKAE/M-9420-2019	EBIHARA, TAKAE/0000-0003-2325-7637				ABBOUD SL, 1995, J CELL PHYSIOL, V164, P434, DOI 10.1002/jcp.1041640224; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Angel P. E., 1994, FOS JUN FAMILIES TRA; ASANO T, 1984, J PHARMACOL EXP THER, V231, P141; BALBI D, 1994, MOL BRAIN RES, V23, P310, DOI 10.1016/0169-328X(94)90240-2; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BERG MM, 1992, J BIOL CHEM, V267, P13; BETHEA JR, 1992, J CELL PHYSIOL, V152, P264, DOI 10.1002/jcp.1041520207; Boado RJ, 1996, NEUROSCI LETT, V220, P53, DOI 10.1016/S0304-3940(96)13237-7; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CAO XM, 1992, J BIOL CHEM, V267, P1345; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHODOSH LA, 1989, J BIOL CHEM, V264, P2250; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ebihara T, 1997, J NEUROCHEM, V68, P1001; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HARBERS M, 1991, BIOCHEM J, V278, P305, DOI 10.1042/bj2780305; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMES RI, 1992, EUR J BIOCHEM, V209, P813, DOI 10.1111/j.1432-1033.1992.tb17352.x; Jenab S, 1998, ENDOCRINOLOGY, V139, P1883, DOI 10.1210/en.139.4.1883; Jenab S, 1997, ENDOCRINOLOGY, V138, P2740, DOI 10.1210/en.138.7.2740; Johnson CM, 1997, J NEUROSCI, V17, P6189; KAHLE P, 1994, J NEUROCHEM, V62, P479; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KUMAHARA E, 1999, IN PRESS J BIOCH TOK, V125; MANTOVANI L, 1991, FEBS LETT, V280, P97, DOI 10.1016/0014-5793(91)80213-M; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; QUICK J, 1992, BIOCHEM BIOPH RES CO, V187, P657, DOI 10.1016/0006-291X(92)91245-L; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Suh Harold H., 1992, Biological Signals, V1, P257; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSAO H, 1990, J BIOL CHEM, V265, P15471; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; Yankulov KY, 1996, MOL CELL BIOL, V16, P3291; YIN TG, 1994, J BIOL CHEM, V269, P3731; YIN TG, 1993, CELL GROWTH DIFFER, V4, P603; Yu CW, 1997, FEBS LETT, V420, P69, DOI 10.1016/S0014-5793(97)01489-0	81	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10430	10438		10.1074/jbc.274.15.10430	http://dx.doi.org/10.1074/jbc.274.15.10430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187833	hybrid			2022-12-25	WOS:000079663500072
J	Okamoto, K; Tanaka, H; Ogawa, H; Makino, Y; Eguchi, H; Hayashi, S; Yoshikawa, N; Poellinger, L; Umesono, K; Makino, I				Okamoto, K; Tanaka, H; Ogawa, H; Makino, Y; Eguchi, H; Hayashi, S; Yoshikawa, N; Poellinger, L; Umesono, K; Makino, I			Redox-dependent regulation of nuclear import of the glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; THYROID-HORMONE RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTOR; RETINOIC ACID RECEPTOR; NF-KAPPA-B; DNA-BINDING; PEROXISOME-PROLIFERATOR; TRANSCRIPTION FACTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION	A number of transcription factors including the glucocorticoid receptor (GR) are regulated in a redox-dependent fashion. We have previously reported that the functional activity of the GR is suppressed under oxidative conditions and restored in the presence of reducing reagents. In the present study, we have used a chimeric human GR fused to the Aequorea green fluorescent protein and demonstrated that both ligand-dependent and -independent nuclear translocation of the GR is impaired under oxidative conditions in living cells. Substitution of Cys-481 for Ser within NL1 of the human GR resulted in reduction of sensitivity to oxidative treatment, strongly indicating that Cys-481 is one of the target amino acids for redox regulation of the receptor. Taken together, we may conclude that redox-dependent regulation of nuclear translocation of the GR constitutes an important mechanism for modulation of glucocorticoid-dependent signal transduction.	Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 0788510, Japan; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Kyoto 6068507, Japan; Saitama Canc Ctr, Res Inst, Dept Biochem, Ina, Saitama 3620800, Japan; Karolinska Inst, Nobel Med Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Asahikawa Medical College; Kyoto University; Karolinska Institutet	Tanaka, H (corresponding author), Asahikawa Med Coll, Dept Internal Med 2, Asahikawa, Hokkaido 0788510, Japan.	hirotnk@asahikawa-med.ac.jp	Ogawa, Hidesato/M-3778-2019; Ogawa, Hidesato/A-2079-2016; Eguchi, Hiromi/GWC-5633-2022	Ogawa, Hidesato/0000-0001-9740-9010; 				ALKSNIS M, 1991, J BIOL CHEM, V266, P10078; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BODWELL JE, 1984, BIOCHEMISTRY-US, V23, P1392, DOI 10.1021/bi00302a009; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BRESNICK EH, 1988, BIOCHEMISTRY-US, V27, P2866, DOI 10.1021/bi00408a030; Calleja C, 1998, NAT MED, V4, P92, DOI 10.1038/nm0198-092; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Eudy JD, 1998, GENOMICS, V50, P382, DOI 10.1006/geno.1998.5345; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hayashi S, 1997, NUCLEIC ACIDS RES, V25, P4035, DOI 10.1093/nar/25.20.4035; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; JEWELL CM, 1995, J STEROID BIOCHEM, V55, P135, DOI 10.1016/0960-0760(95)00174-X; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kapelle M, 1997, BBA-GENE STRUCT EXPR, V1352, P13, DOI 10.1016/S0167-4781(97)00043-2; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; Makino Y, 1996, MOL PHARMACOL, V49, P612; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Oba K, 1996, BIOCHEM BIOPH RES CO, V226, P261, DOI 10.1006/bbrc.1996.1343; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ohkura N, 1996, BBA-GENE STRUCT EXPR, V1308, P205, DOI 10.1016/0167-4781(96)00101-7; OKABE T, 1995, J IMMUNOL, V154, P3871; Okamoto K, 1998, BIOCHEM PHARMACOL, V56, P79, DOI 10.1016/S0006-2952(98)00121-X; OPOKU J, 1994, J BIOL CHEM, V269, P503; Pariante CM, 1997, MOL PHARMACOL, V52, P571, DOI 10.1124/mol.52.4.571; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1987, NUCLEIC ACIDS RES, V15, P9613, DOI 10.1093/nar/15.22.9613; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Sen CK, 1998, BIOCHEM PHARMACOL, V55, P1747, DOI 10.1016/S0006-2952(97)00672-2; Shepherd V L, 1986, Semin Respir Infect, V1, P99; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tanaka H, 1999, VITAM HORM, V57, P153; TANAKA H, 1995, MOL PHARMACOL, V48, P938; Tanaka H, 1996, J IMMUNOL, V156, P1601; Tang YT, 1996, MOL CELL BIOL, V16, P1989; Tang YT, 1997, MOL BIOL CELL, V8, P795, DOI 10.1091/mbc.8.5.795; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; TSAN MF, 1977, BLOOD, V49, P437; TYRRELL JB, 1995, ENDOCRINOL METAB, P855; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523; Yang J, 1996, MOL ENDOCRINOL, V10, P3, DOI 10.1210/me.10.1.3; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZILLIACUS J, 1992, J STEROID BIOCHEM, V42, P131, DOI 10.1016/0960-0760(92)90021-A	89	144	149	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10363	10371		10.1074/jbc.274.15.10363	http://dx.doi.org/10.1074/jbc.274.15.10363			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187825	hybrid			2022-12-25	WOS:000079663500064
J	Viljoen, M; Volschenk, H; Young, RA; van Vuuren, HJJ				Viljoen, M; Volschenk, H; Young, RA; van Vuuren, HJJ			Transcriptional regulation of the Schizosaccharomyces pombe malic enzyme gene, mae2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; L-MALATE; CAMP; EXPRESSION; PROTEIN; DNA; DIFFERENTIATION; IDENTIFICATION; METABOLISM; TRANSPORT	The NAD-dependent malic enzyme from Schizosaccharomyces pombe catalyzes the oxidative decarboxylation of L-malate to pyruvate and CO2. Transcription of the S, pombe malic enzyme gene, mae2, was studied to elucidate the regulatory mechanisms involved in the expression of the gene. No evidence for substrate-induced expression of mae2 was observed in the presence of 0.2% L-malate, However, transcription of mae2 was induced when cells were grown in high concentrations of glucose or under anaerobic conditions. The increased levels of malic enzyme may provide additional pyruvate or assist in maintaining the redox potential under fermentative conditions. Deletion and mutation analyses of the 5'-flanking region of the mae2 gene revealed the presence of three novel negative cis-acting elements, URS1, URS2, and URS3, that seem to function cooperatively to repress transcription of the mae2 gene. URS1 and URS2 are also present in the promoter region of the S, pombe malate transporter gene, suggesting co-regulation of their expression. Furthermore, two positive cis-acting elements in the mae2 promoter, UAS1 and UAS2, show homology with the DNA recognition sites of the cAMP-dependent transcription factors ADR1, AP-2, and ATF (activating transcription factor)/CREB (cAMP response element binding).	Univ Stellenbosch, Dept Microbiol, ZA-7600 Stellenbosch, South Africa; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Cambridge, MA 02142 USA; Brock Univ, Cool Climate Oenol & Viticulture Inst, St Catharines, ON L2S 3A1, Canada	Stellenbosch University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Brock University	Viljoen, M (corresponding author), Univ Stellenbosch, Dept Microbiol, Private Bag X1, ZA-7602 Matieland, South Africa.	mv4@maties.sun.ac.za	Volschenk, Heinrich/L-8400-2015; Young, Richard A/F-6495-2012	Volschenk, Heinrich/0000-0001-9287-0975; Young, Richard A/0000-0001-8855-8647; Viljoen-Bloom, Marinda/0000-0002-4825-2392				ARTUS NN, 1985, FEBS LETT, V182, P225, DOI 10.1016/0014-5793(85)80305-7; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAGCHI S, 1987, J BIOL CHEM, V262, P1558; BARANOWSKI K, 1984, A VAN LEEUW J MICROB, V50, P329, DOI 10.1007/BF00394646; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BYRNE SM, 1993, J CELL SCI, V105, P1095; CHEN TH, 1985, IEEE T COMPUT AID D, V4, P3, DOI 10.1109/TCAD.1985.1270093; CHENG C, 1994, MOL CELL BIOL, V14, P3842, DOI 10.1128/MCB.14.6.3842; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grobler J, 1995, YEAST, V11, P1485, DOI 10.1002/yea.320111503; GUILFOILE PG, 1992, J BACTERIOL, V174, P3651, DOI 10.1128/JB.174.11.3651-3658.1992; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HAYLES J, 1992, ANNU REV GENET, V26, P373, DOI 10.1146/annurev.ge.26.120192.002105; HOFFMAN CS, 1991, GENE DEV, V5, P561, DOI 10.1101/gad.5.4.561; HSU RY, 1992, BIOCHEM J, V284, P869, DOI 10.1042/bj2840869; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; KULKARNI G, 1993, ARCH BIOCHEM BIOPHYS, V300, P231, DOI 10.1006/abbi.1993.1032; MAGYAR I, 1989, AM J ENOL VITICULT, V40, P233; MAYER K, 1963, ARCH MIKROBIOL, V46, P321, DOI 10.1007/BF00422193; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OSOTHSILP C, 1986, CAN J MICROBIOL, V32, P481, DOI 10.1139/m86-088; OSOTHSILP C, 1986, J BACTERIOL, V168, P1439, DOI 10.1128/jb.168.3.1439-1443.1986; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P3383, DOI 10.1093/nar/20.13.3383; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; RODRIGUEZ SB, 1990, FEMS MICROBIOL LETT, V72, P17, DOI 10.1016/0378-1097(90)90337-P; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SIKORSKI RS, 1989, GENETICS, V122, P19; Singh MV, 1998, BBA-GENE STRUCT EXPR, V1398, P148, DOI 10.1016/S0167-4781(98)00037-2; TAILLANDIER P, 1991, APPL MICROBIOL BIOT, V35, P541; TEMPERLI A, 1965, BIOCHIM BIOPHYS ACTA, V110, P630, DOI 10.1016/S0926-6593(65)80080-7; VILJOEN M, 1994, YEAST, V10, P613, DOI 10.1002/yea.320100506; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	40	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9969	9975		10.1074/jbc.274.15.9969	http://dx.doi.org/10.1074/jbc.274.15.9969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187772	hybrid			2022-12-25	WOS:000079663500011
J	Wong, SC; Zhang, L; Witt, TL; Proefke, SA; Bhushan, A; Matherly, LH				Wong, SC; Zhang, L; Witt, TL; Proefke, SA; Bhushan, A; Matherly, LH			Impaired membrane transport in methotrexate-resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; L1210 LEUKEMIA-CELLS; TUMOR-CELLS; FOLIC-ACID; CELLULAR PHARMACOLOGY; ANTIFOLATE RESISTANCE; PROTEIN-DEGRADATION; GENE; EXPRESSION; MECHANISM	The basis for impaired reduced folate carrier (RFC) activity in methotrexate-resistant CCRF-CEM (CEM/Mtx-1) cells was examined. Parental and CEM/Mtx-1 cells expressed identical levels of the 3.1-kilobase RFC transcript. A similar to 85-kDa RFC protein was detected in parental cells by photoaffinity labeling and on Western blots with RFC-specific antiserum. In CEM/Mtx-1 cells, RFC protein was undetectable. By reverse transcriptase-polymerase chain reaction and sequence analysis, G to A point mutations were identified in CEM/Mtx-1 transcripts at positions 130 (P-1; changes glycine 44 --> arginine) and 380 (P-2; changes serine 127 --> asparagine), A 4-base pair (CATG) insertion detected at position 191 (in 19-30% of cDNA clones) resulted in a frameshift and early translation termination. Wild-type RFC was also detected (0-9% of clones). Wild-type RFC and double-mutated RFC (RFCP1+P2) cDNAs mere transfected into transport-impaired K562 and Chinese hamster ovary cells. Although RFC transcripts paralleled wild-type protein, for the RFCP1+P2 transfectants, disproportionately low RFCP1+P2 protein was detected, This reflected an increased turnover of RFCP1+P2 over wild type RFC, RFCP1+P2 did not restore methotrexate transport; however, uptake was partially restored by constructs with single mutations at the P-1 or P-2 loci. Cumulatively, our results show that loss of transport function in CEM/Mtx-1 cells results from complete loss of RFC protein due to early translation termination and increased turnover of a mutant RFC protein.	Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Idaho State Univ, Dept Pharmaceut Sci, Pocatello, ID 83209 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Idaho; Idaho State University	Matherly, LH (corresponding author), Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA.	matherly@kci.wayne.edu			NCI NIH HHS [CA 53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODANSKY O, 1963, J BIOL CHEM, V238, P3420; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DUCH DS, 1993, CANCER RES, V53, P810; FLINTOFF WF, 1983, ARCH BIOCHEM BIOPHYS, V223, P433, DOI 10.1016/0003-9861(83)90607-0; FRY DW, 1982, J BIOL CHEM, V257, P1890; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Goldberg AL, 1997, BIOL CHEM, V378, P131; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; GREEN DE, 1955, J BIOL CHEM, V217, P551; HARLOWE E, 1988, ANTIBODIES LAB MANUA; HENDERSON GB, 1990, CANCER RES, V50, P1709; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOO TW, 1994, J BIOL CHEM, V269, P28683; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1989, MOL CLONING LAB MANU; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MATHERLY LH, 1992, J BIOL CHEM, V267, P23253; MATHERLY LH, 1991, CANCER RES, V51, P3420; MOSCOW JA, 1995, CANCER RES, V55, P3790; Murray RC, 1996, J BIOL CHEM, V271, P19174, DOI 10.1074/jbc.271.32.19174; ROSOWSKY A, 1980, BIOCHEM PHARMACOL, V29, P648, DOI 10.1016/0006-2952(80)90391-3; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; SIROTNAK FM, 1981, CANCER RES, V41, P4442; Tolner B, 1998, GENE, V211, P331, DOI 10.1016/S0378-1119(98)00123-1; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Wong SC, 1998, BIOCHEM PHARMACOL, V55, P1135, DOI 10.1016/S0006-2952(97)00639-4; Zhang L, 1998, BBA-GENE STRUCT EXPR, V1442, P389, DOI 10.1016/S0167-4781(98)00168-7; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	42	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10388	10394		10.1074/jbc.274.15.10388	http://dx.doi.org/10.1074/jbc.274.15.10388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187828	hybrid			2022-12-25	WOS:000079663500067
J	Hausser, A; Storz, P; Link, G; Stoll, H; Liu, YC; Altman, A; Pfizenmaier, K; Johannes, FJ				Hausser, A; Storz, P; Link, G; Stoll, H; Liu, YC; Altman, A; Pfizenmaier, K; Johannes, FJ			Protein kinase C mu is negatively regulated by 14-3-3 signal transduction proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PHOSPHORYLATION; PHORBOL ESTER; T-CELLS; DOWN-REGULATION; NUCLEAR-FACTOR; IN-VITRO; ACTIVATION; ASSOCIATION; BINDING; DOMAIN	Recent studies have documented direct interaction between 14-3-3 proteins and hey molecules in signal transduction pathways like Ras, Cbl, and protein kinases, In T cells, the 14-3-3 tau isoform has been shown to associate with protein kinase C theta and to negatively regulate interleukin-2 secretion, Here we present data that 14-3-3 tau interacts with protein kinase C mu (PKC mu), a subtype that differs from other PKC members in structure and activation mechanisms. Specific interaction of PKC mu and 14-3-3 tau can be shown in the T cell line Jurkat by immunocoprecipitiation and by pulldown assays of either endogenous or overexpressed proteins using PKC mu-specific antibodies and GST-14-3-3 fusion proteins, respectively. Using PKC mu, deletion mutants, the 14-3-3 tau binding region is mapped within the regulatory C1 domain. Binding of 14-3-3 tau to PKC mu is significantly enhanced upon phorbol ester stimulation of PKC mu kinase activity in Jurkat cells and occurs via a Cbl-like serine containing consensus motif, However, 14-3-3 tau is not a substrate of PKC mu, In contrast 14-3-3 tau strongly down-regulates PKC mu kinase activity in vitro. Moreover, overexpression of 14-3-3 tau significantly reduced phorbol ester induced activation of PKC mu kinase activity in intact cells. We therefore conclude that 14-3-3 tau is a negative regulator of PKC mu in T cells.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; La Jolla Inst Allergy & Immunol, Div Cell Biol & Immunol, San Diego, CA 92121 USA	University of Stuttgart; La Jolla Institute for Immunology	Johannes, FJ (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.	Franz-Josef.Johannes@po.uni-stuttgart.de	Hausser, Angelika/AAC-4531-2021	LIU, YUN-CAI/0000-0002-0996-7109				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; delPeso L, 1997, SCIENCE, V278, P687; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; Meller N, 1996, MOL CELL BIOL, V16, P5782; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; TARN WY, 1994, EMBO J, V13, P2421, DOI 10.1002/j.1460-2075.1994.tb06527.x; WheelerJones CPD, 1996, BIOCHEM J, V315, P41, DOI 10.1042/bj3150041; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; Zhang SH, 1997, J BIOL CHEM, V272, P27281, DOI 10.1074/jbc.272.43.27281; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	43	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9258	9264		10.1074/jbc.274.14.9258	http://dx.doi.org/10.1074/jbc.274.14.9258			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092600	hybrid			2022-12-25	WOS:000079451800019
J	Narishige, T; Blade, KL; Ishibashi, Y; Nagai, T; Hamawaki, M; Menick, DR; Kuppuswamy, D; Cooper, G				Narishige, T; Blade, KL; Ishibashi, Y; Nagai, T; Hamawaki, M; Menick, DR; Kuppuswamy, D; Cooper, G			Cardiac hypertrophic and developmental regulation of the beta-tubulin multigene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE DYSFUNCTION; MICROTUBULES; MYOCARDIUM; CARDIOCYTES; ISOTYPES; CELLS; MAP4	Increased microtubule density, through viscous loading of active myofilaments, causes contractile dysfunction of hypertrophied and failing pressure-overloaded myocardium, which is normalized by microtubule depolymerization. We have found this to be based on augmented tubulin synthesis and microtubule stability. We show here that increased tubulin synthesis is accounted for by marked transcriptional up-regulation of the beta 1- and beta 2-tubulin isoforms, that hypertrophic regulation of these genes recapitulates their developmental regulation, and that the greater proportion of beta 1-tubulin protein may have a causative role in the microtubule stabilization found in cardiac hypertrophy.	Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, Charleston, SC 29403 USA; Vet Affairs Med Ctr, Charleston, SC 29403 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Cooper, G (corresponding author), Med Univ S Carolina, Gazes Cardiac Res Inst, Div Cardiol, Dept Med, POB 250773, Charleston, SC 29403 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48788] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooper G, 1997, ANNU REV MED, V48, P13, DOI 10.1146/annurev.med.48.1.13; COOPER G, 1986, CIRC RES, V58, P692, DOI 10.1161/01.RES.58.5.692; COOPER G, 1973, CIRC RES, V33, P213, DOI 10.1161/01.RES.33.2.213; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; LEE MG, 1983, CELL, V33, P477; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Mangan ME, 1996, DEVELOPMENT, V122, P771; MANN DL, 1991, CIRC RES, V68, P402, DOI 10.1161/01.RES.68.2.402; OBLINGER MM, 1994, DEV BRAIN RES, V77, P45, DOI 10.1016/0165-3806(94)90212-7; OSTLUND RE, 1979, ANAL BIOCHEM, V96, P155, DOI 10.1016/0003-2697(79)90568-2; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Raff EC, 1997, SCIENCE, V275, P70, DOI 10.1126/science.275.5296.70; RENTHAL R, 1993, CELL MOTIL CYTOSKEL, V25, P19, DOI 10.1002/cm.970250104; Sato H, 1997, J CELL BIOL, V139, P963, DOI 10.1083/jcb.139.4.963; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; Tagawa H, 1996, CIRCULATION, V93, P1230, DOI 10.1161/01.CIR.93.6.1230; Tagawa H, 1997, CIRC RES, V80, P281, DOI 10.1161/01.RES.80.2.281; TSUTSUI H, 1993, SCIENCE, V260, P682, DOI 10.1126/science.8097594; Wang XM, 1996, J CELL BIOL, V132, P345, DOI 10.1083/jcb.132.3.345; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	23	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9692	9697		10.1074/jbc.274.14.9692	http://dx.doi.org/10.1074/jbc.274.14.9692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092657	hybrid			2022-12-25	WOS:000079451800076
J	Nishiya, N; Iwabuchi, Y; Shibanuma, M; Cote, JF; Tremblay, ML; Nose, K				Nishiya, N; Iwabuchi, Y; Shibanuma, M; Cote, JF; Tremblay, ML; Nose, K			Hic-5, a paxillin homologue, binds to the protein-tyrosine phosphatase PEST (PTP-PEST) through its LIM3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELL-ADHESION; MOTIF; EXPRESSION; SENESCENCE; INTEGRINS; VINCULIN; CLONING; GENES; PHOSPHORYLATION	The Hic-5 protein is encoded by a transforming growth factor-beta 1- and hydrogen peroxide-inducible gene, hic-5, and has striking similarity to paxillin, especially in their C-terminal LIM domains. Like paxillin, Hic-5 is localized in focal adhesion plaques in association with focal adhesion kinase in cultured fibroblasts. We carried out yeast two-hybrid screening to identify cellular factors that form a complex with Hic-5 using its LIM domains as a bait, and we identified a cytoplasmic tyrosine phosphatase (PTP-PEST) as one of the partners of Hic-5. These two proteins are associated in mammalian cells. From in vitro binding experiments using deletion and point mutations, it was demonstrated that the essential domain in Hic-5 for the binding was LIM 3, As for PTP-PEST, one of the five proline-rich sequences found on PTP-PEST, Pro-2, was identified as the binding site for Hic-5 in in vitro binding assays. Paxillin also binds to the Pro-a domain of PTP-PEST. In conclusion, Hic-5 may participate in the regulation of signaling cascade through its interaction with distinct tyrosine kinases and phosphatases.	Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 142, Japan; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	Showa University; McGill University	Nose, K (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Hatanodai 1-5-8, Tokyo 142, Japan.	knose@pharm.showa-u.ac.jp		Nishiya, Naoyuki/0000-0003-1575-9944				BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1986, Cancer Reviews, V4, P18; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; Charest A, 1997, ONCOGENE, V14, P1643, DOI 10.1038/sj.onc.1201008; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HENIKOFF S, 1987, GENETICS, V117, P711; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; NAMBA M, 1985, INT J CANCER, V35, P275, DOI 10.1002/ijc.2910350221; Nishiya N, 1998, NUCLEIC ACIDS RES, V26, P4267, DOI 10.1093/nar/26.18.4267; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Shibanuma M, 1998, INT J BIOCHEM CELL B, V30, P39, DOI 10.1016/S1357-2725(97)00155-6; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; YANG Q, 1993, J BIOL CHEM, V268, P6622	42	76	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9847	9853		10.1074/jbc.274.14.9847	http://dx.doi.org/10.1074/jbc.274.14.9847			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092676	hybrid			2022-12-25	WOS:000079451800095
J	Lombardi, MS; Kavelaars, A; Schedlowski, M; Bijlsma, JWJ; Okihara, KL; Van de Pol, M; Ochsmann, S; Pawlak, C; Schmidt, RE; Heijnen, CJ				Lombardi, MS; Kavelaars, A; Schedlowski, M; Bijlsma, JWJ; Okihara, KL; Van de Pol, M; Ochsmann, S; Pawlak, C; Schmidt, RE; Heijnen, CJ			Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis	FASEB JOURNAL			English	Article						immune system; lymphocytes; cytokines; autoimmunity	MONOCYTE CHEMOATTRACTANT PROTEIN-1; BETA-ADRENERGIC RECEPTORS; FAILING HUMAN HEART; NERVOUS-SYSTEM; SUBSTANCE-P; DESENSITIZATION; GRK6; INTERNALIZATION; PHOSPHORYLATION; IDENTIFICATION	beta(2)-Adrenergic and chemokine receptor antagonists delay the onset and reduce the severity of joint injury in rheumatoid arthritis. beta(2)-adrenergic and chemokine receptors belong to the G-protein-coupled receptor family whose responsiveness is turned off by the G-protein-coupled receptor kinase family (GRK-1 to 6). GRKs phosphorylate receptors in an agonist-dependent manner resulting in receptor/G-protein uncoupling via subsequent binding of arrestin proteins. We assessed the activity of GRKs in lymphocytes of rheumatoid arthritis (RA) patients by rhodopsin phosphorylation. We found a significant decrease in GRK activity in RA subjects that is mirrored by a decrease in GRK-2 protein expression. Moreover, GRK-6 protein expression is reduced in RA patients whereas GRK-5 protein levels were unchanged. In search of an underlying mechanism, we demonstrated that proinflammatory cytokines induce a decrease in GRK-2 protein levels in leukocytes from healthy donors. Since proinflammatory cytokines are abundantly expressed in RA, it may provide an explanation for the decrease in GRK-2 expression and activity in patients. No changes in beta(2)-adrenergic receptor number and K-d were detected. However, RA patients showed a sig nificantly increased cAMP production and inhibition of TNF-alpha production by beta(2)-adrenergic stimulation, suggesting that reduced GRK activity is associated with increased sensitivity to beta(2)-adrenergic activation.	Univ Hosp Children & Youth, Het Wilhemina Kinderziekenhuis, Dept Immunol, NL-3584 CA Utrecht, Netherlands; Univ Essen Gesamthsch, Inst Med Psychol, D-45122 Essen, Germany; Univ Utrecht Hosp, Dept Rheumatol & Clin Immunol, NL-3584 CX Utrecht, Netherlands; Hannover Med Sch, Dept Clin Immunol, D-36025 Hannover, Germany; Hannover Med Sch, Dept Psychol Med, D-36025 Hannover, Germany	Wilhelmina Kinderziekenhuis; University of Duisburg Essen; Utrecht University; Utrecht University Medical Center; Hannover Medical School; Hannover Medical School	Lombardi, MS (corresponding author), Univ Hosp Children & Youth, Het Wilhemina Kinderziekenhuis, Dept Immunol, Lundlaan 6, NL-3584 CA Utrecht, Netherlands.	s.lombardi@wkz.azu.nl						Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BAKER GHB, 1982, PSYCHOTHER PSYCHOSOM, V38, P173, DOI 10.1159/000287625; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; DEBLASI A, 1985, J CLIN ENDOCR METAB, V61, P1081, DOI 10.1210/jcem-61-6-1081; DEBLASI A, 1995, J CLIN INVEST, V95, P203, DOI 10.1172/JCI117641; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Felten S Y, 1998, Adv Pharmacol, V42, P583; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIRSOV D, 1997, AM J PHYSIOL, V273, P953; Franci C, 1996, J IMMUNOL, V157, P5606; Gagnon AW, 1997, GENE, V184, P13, DOI 10.1016/S0378-1119(96)00567-7; GARCIAHIGUERA I, 1994, J CLIN INVEST, V93, P937, DOI 10.1172/JCI117099; GARCIAHIGUERA I, 1992, FEBS LETT, V302, P61, DOI 10.1016/0014-5793(92)80285-O; Geenen R, 1996, J RHEUMATOL, V23, P258; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; HARIGAI M, 1993, CLIN IMMUNOL IMMUNOP, V69, P83, DOI 10.1006/clin.1993.1153; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE JD, 1988, P NATL ACAD SCI USA, V85, P4553, DOI 10.1073/pnas.85.12.4553; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; Loudon RP, 1996, BLOOD, V88, P4547, DOI 10.1182/blood.V88.12.4547.bloodjournal88124547; MARSHALL KW, 1990, ARTHRITIS RHEUM, V33, P87; MITCHELL DM, 1982, ARTHRITIS RHEUM, V25, P481, DOI 10.1002/art.1780250501; Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222; PARRUTI G, 1993, J RECEPTOR RES, V13, P95, DOI 10.3109/10799899309073648; PENN RB, 1994, J BIOL CHEM, V269, P14924; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; Rockman HA, 1996, P NATL ACAD SCI USA, V93, P9954, DOI 10.1073/pnas.93.18.9954; SCHULZEKOOPS H, 1995, J IMMUNOL, V155, P5029; THOMPSON M, 1962, ANN RHEUM DIS, V21, P370, DOI 10.1136/ard.21.4.370; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	49	183	188	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					715	725		10.1096/fasebj.13.6.715	http://dx.doi.org/10.1096/fasebj.13.6.715			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094932				2022-12-25	WOS:000079527200013
J	Arabshahi, A; Frey, PA				Arabshahi, A; Frey, PA			Standard free energy for the hydrolysis of adenylylated T4 DNA ligase and the apparent pK(a) of lysine 159	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYNUCLEOTIDES; ATP	Equilibrium constants for the adenylylation of T4 DNA Ligase have been measured at 10 pH values. The values, when plotted against pH, fit a titration curve corresponding to a pK(a) of 8.4 +/- 0.1. The simplest interpretation is that the apparent pK(a) is that of the B-amino group of the AMP-aceepting residue Lys(159). Based on the pH dependence of the equilibrium constants, the value at pH 7.0 is 0.0213 at 25 degrees C, corresponding to Delta G'(o) = +2.3 kcal mol(-1). From this value and the standard free energy change of -10.9 kcal mol(-1) for the hydrolysis of ATP to AMP and PPi, we calculate that Delta G'(o) for the hydrolysis of the adenylyl-DNA ligase is -13.2 kcal mol(-1). The presence of conserved basic amino acid residues in the catalytic domain, which are proximal to the active site in the homologous catalytic domain of T7 DNA ligase, suggests that the pK(a) of Lys159 is perturbed downward by the electrostatic effects of nearby positively charged amino acid side chains. The lower than normal pK(a) 8.4 compared with 10.5 for the 6-amino group of lysine and the high energy of the alpha,beta-phosphoanhydride linkage in ATP significantly facilitate adenylylation of the enzyme.	Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53705 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Frey, PA (corresponding author), Univ Wisconsin, Grad Sch, Inst Enzyme Res, Madison, WI 53705 USA.				NIGMS NIH HHS [GM 30480] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTY RA, 1994, PURE APPL CHEM, V66, P1641, DOI 10.1351/pac199466081641; Arabshahi A, 1996, BIOCHEMISTRY-US, V35, P3426, DOI 10.1021/bi952983w; BECKER A, 1967, P NATL ACAD SCI USA, V58, P1996, DOI 10.1073/pnas.58.5.1996; COZZARELLI NR, 1967, BIOCHEM BIOPH RES CO, V28, P578, DOI 10.1016/0006-291X(67)90353-1; DAVIS RW, 1980, ADV BACTERIAL GENET, P196; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FREY PA, 1995, BIOCHEMISTRY-US, V34, P11307, DOI 10.1021/bi00036a001; GEFTER ML, 1976, P NATL ACAD SCI USA, V58, P240; GELLERT M, 1967, P NATL ACAD SCI USA, V57, P148, DOI 10.1073/pnas.57.1.148; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; LEHMAN IR, 1974, ENZYMES, V10, P237; LIDE DR, 1997, CRC HDB CHEM PHYSICS; MODRICH P, 1973, J BIOL CHEM, V248, P7502; OLIVERA BM, 1967, P NATL ACAD SCI USA, V57, P1426, DOI 10.1073/pnas.57.5.1426; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; Rossi R, 1997, NUCLEIC ACIDS RES, V25, P2106, DOI 10.1093/nar/25.11.2106; Sarasin A, 1997, CANCER DETECT PREV, V21, P406; Shuman S, 1996, STRUCTURE, V4, P653, DOI 10.1016/S0969-2126(96)00070-6; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; WEISS B, 1967, P NATL ACAD SCI USA, V57, P1021, DOI 10.1073/pnas.57.4.1021; YU GL, 1990, MOL CELL BIOL, V10, P2070, DOI 10.1128/MCB.10.5.2070	22	11	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8586	8588		10.1074/jbc.274.13.8586	http://dx.doi.org/10.1074/jbc.274.13.8586			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085093	hybrid			2022-12-25	WOS:000079451600035
J	Holtz, KM; Stec, B; Kantrowitz, ER				Holtz, KM; Stec, B; Kantrowitz, ER			A model of the transition state in the alkaline phosphatase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION-MECHANISM; CRYSTAL-STRUCTURES; VANADATE	A high resolution crystal structure of Escherichia coli alkaline phosphatase in the presence of vanadate has been refined to 1.9 Angstrom resolution. The vanadate ion takes on a trigonal bipyramidal geometry and is covalently bound by the active site serine nucleophile. A coordinated water molecule occupies the axial position opposite the serine nucleophile, whereas the equatorial oxygen atoms of the vanadate ion are stabilized by interactions with both Arg-166 and the zinc metal ions of the active site. This structural complex supports the in-line displacement mechanism of phosphomonoester hydrolysis by alkaline phosphatase and provides a model for the proposed transition state in the enzyme-catalyzed reaction.	Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02167 USA	Boston College	Kantrowitz, ER (corresponding author), Boston Coll, Dept Chem, Merkert Chem Ctr, Chestnut Hill, MA 02167 USA.			Stec, Boguslaw/0000-0002-8696-0349	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORAH B, 1985, BIOCHEMISTRY-US, V24, P2058, DOI 10.1021/bi00329a038; BRUNGER AT, 1992, X PLOR VERSION 3 1; CHAIDAROGLOU A, 1988, BIOCHEMISTRY-US, V27, P8338, DOI 10.1021/bi00422a008; Crans DC, 1996, PHOSPHORUS SULFUR, V109, P245, DOI 10.1080/10426509608545136; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; LINDQVIST Y, 1994, EUR J BIOCHEM, V221, P139, DOI 10.1111/j.1432-1033.1994.tb18722.x; LOPEZ V, 1976, ARCH BIOCHEM BIOPHYS, V175, P31, DOI 10.1016/0003-9861(76)90482-3; Murphy JE, 1997, NAT STRUCT BIOL, V4, P618, DOI 10.1038/nsb0897-618; MURPHY JE, 1995, J MOL BIOL, V253, P604, DOI 10.1006/jmbi.1995.0576; PAULING L, 1960, NATURE CHEM BOND STR, P251; Reid T.W., 1971, ENZYMES, V4, P373	13	146	151	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8351	8354		10.1074/jbc.274.13.8351	http://dx.doi.org/10.1074/jbc.274.13.8351			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085061	hybrid			2022-12-25	WOS:000079451600003
J	Butler, GS; Apte, SS; Willenbrock, F; Murphy, G				Butler, GS; Apte, SS; Willenbrock, F; Murphy, G			Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B - Regulation by polyanions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOPEXIN-LIKE DOMAIN; TIMP GENE FAMILY; PROGELATINASE-A; MATRIX METALLOPROTEINASES; 72-KDA GELATINASE; COMPLEX-FORMATION; IV COLLAGENASE; ACTIVATION; BINDING; CLONING	We compared the association constants of tissue inhibitor of metalloproteinases (TIMP)-3 with various matrix metalloproteinases with those for TIMP-1 and TIMP-2 using a continuous assay. TIMP-3 behaved more like TIMP-3 than TIMP-1, showing rapid association with gelatinases A and B. Experiments with the N-terminal domain of gelatinase A the isolated C-terminal domain, or an inactive progelatinase A mutant showed that the hemopexin domain of gelatinase A makes an important contribution to the interaction with TIMP-3. The exchange of portions of the gelatinase A hemopexin domain with that of stromelysin revealed that residues 568-631 of gelatinase A were required for rapid association with TIMP-3. The N-terminal domain of gelatinase B alone also showed slower association with TIMP-3, again implying significant C-domain interactions. The isolation of complexes between TIMP-3 and progelatinases A and B on gelatin-agarose demonstrated that TIMP-3 binds to both proenzymes. We analyzed the effect of various polyanions on the inhibitory activity of TIMP-3 in our soluble assay. The association rate was increased by dextran sulfate, heparin, and heparan sulfate, but not by dermatan sulfate or hyaluronic acid. Because TIMP-3 is sequestered in the extracellular matrix, the presence of certain heparan sulfate proteoglycans could enhance its inhibitory capacity.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Queen Mary Univ London, Dept Biochem, Lab Struct & Mech Enzymol, London E1 4NS, England	University of East Anglia; Cleveland Clinic Foundation; University of London; Queen Mary University London	Murphy, G (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	g.murphy@uea.ac.uk	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578; Apte, Suneel/0000-0001-8441-1226				ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DECLERCK YA, 1993, BIOCHEM J, V289, P65, DOI 10.1042/bj2890065; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EVANS DL, 1992, BIOCHEMISTRY-US, V31, P12629, DOI 10.1021/bi00165a013; GALLAGHER JT, 1995, ADV EXP MED BIOL, V376, P125; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; KISHNANI NS, 1995, MATRIX BIOL, V14, P479, DOI 10.1016/0945-053X(95)90005-5; KLEINER DE, 1992, BIOCHEMISTRY-US, V31, P1665, DOI 10.1021/bi00121a013; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LELIEVRE Y, 1990, MATRIX, V10, P292, DOI 10.1016/S0934-8832(11)80184-8; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OKADA Y, 1986, J BIOL CHEM, V261, P14245; SILBIGER SM, 1994, GENE, V141, P293, DOI 10.1016/0378-1119(94)90588-6; URIA JA, 1994, CANCER RES, V54, P2091; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WICK M, 1994, J BIOL CHEM, V269, P18953; WILDE CG, 1994, DNA CELL BIOL, V13, P711, DOI 10.1089/dna.1994.13.711; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267	51	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10846	10851		10.1074/jbc.274.16.10846	http://dx.doi.org/10.1074/jbc.274.16.10846			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196161	hybrid			2022-12-25	WOS:000079751900029
J	Penta, K; Varner, JA; Liaw, L; Hidai, C; Schatzman, R; Quertermous, T				Penta, K; Varner, JA; Liaw, L; Hidai, C; Schatzman, R; Quertermous, T			Del1 induces integrin signaling and angiogenesis by ligation of alpha V beta 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; IN-VITRO; BLOOD-VESSELS; ENDOTHELIAL-CELLS; FOCAL ADHESIONS; PROTEIN SHC; INTEGRIN-ALPHA-V-BETA-3; VITRONECTIN; OSTEOPONTIN; SPECIFICITY	Del1 is a novel extracellular matrix protein encoding three Notch-like epidermal growth factor repeats, an RGD motif, and two discoidin domains. Del1 is expressed in an endothelial cell-restricted pattern during early development, In studies reported here, recombinant baculovirus Del1 protein was shown to promote alpha v beta 3-dependent endothelial cell attachment and migration, Attachment of endothelial cells to Del1 was associated with clustering of alpha v beta 3, the formation of focal complexes, and recruitment of talin and vinculin into these complexes. These events were shown to be associated with phosphorylation of proteins in the focal complexes, including the time-dependent phosphorylation of p125(FAK), MAPK, and Shc. When recombinant Del1 was evaluated in an in ovo chick chorioallantoic membrane assay, it was found to have potent angiogenic activity. This angiogenic activity was inhibited by a monoclonal antibody directed against alpha v beta 3, and an RAD mutant Del1 protein was inactive. Thus Del1 provides a unique autocrine angiogenic pathway for the embryonic endothelium, and this function is mediated in part by productive ligation of integrin alpha v beta 3.	Stanford Univ, Sch Med, Div Cardiol, Falk CVRC, Stanford, CA 94305 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Maine Med Ctr, Res Inst, Ctr Mol Med, Portland, ME USA; Tokyo Womens Med Coll, Tokyo 162, Japan; Progenitor Inc, Menlo Pk, CA 94025 USA	Stanford University; University of California System; University of California San Diego; Maine Medical Center; Tokyo Women's Medical University	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiol, Falk CVRC, Falk Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	tomq1@leland.stanford.edu		Varner, Judith/0000-0002-9251-0600; Quertermous, Thomas/0000-0002-7645-9067	NATIONAL CANCER INSTITUTE [R01CA071619] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052168] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71619] Funding Source: Medline; NHLBI NIH HHS [R01 HL52168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; CAIXIA S, 1991, CELL IMMUNOL, V138, P216, DOI 10.1016/0008-8749(91)90146-3; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Harlow E., 1988, ANTIBODIES LAB MANUA; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIAW L, 1995, CIRC RES, V77, P665, DOI 10.1161/01.RES.77.4.665; LIAW L, 1994, CIRC RES, V74, P214, DOI 10.1161/01.RES.74.2.214; MACARAK EJ, 1983, J CELL PHYSIOL, V116, P76, DOI 10.1002/jcp.1041160112; MAHER PA, 1985, P NATL ACAD SCI USA, V82, P6576, DOI 10.1073/pnas.82.19.6576; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NODEN DM, 1989, AM REV RESPIR DIS, V140, P1097, DOI 10.1164/ajrccm/140.4.1097; OTEY C, 1990, HYBRIDOMA, V9, P57, DOI 10.1089/hyb.1990.9.57; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Weiner Michael P., 1995, P613; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	39	132	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11101	11109		10.1074/jbc.274.16.11101	http://dx.doi.org/10.1074/jbc.274.16.11101			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196194	hybrid			2022-12-25	WOS:000079751900062
J	Pikkarainen, T; Brannstrom, A; Tryggvason, K				Pikkarainen, T; Brannstrom, A; Tryggvason, K			Expression of macrophage MARCO receptor induces formation of dendritic plasma membrane processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR; FOCAL ADHESIONS; IN-VIVO; BACTERIA; BINDING; LIPOPROTEIN; GTPASES; CELLS; HOST	MARCO is a novel macrophage-specific receptor structurally related to macrophage class A scavenger receptors. It is constitutively expressed in macrophages of the marginal zone of the spleen and in lymph nodes and is up-regulated in other tissues during systemic bacterial infections. In this study, we show that ectopic expression of MARCO in cell lines such as Chinese hamster ovary, HeLa, NIH3T3, and 293 induces dramatic cell shape changes, Typically these changes include formation of large lamellipodia-like structures and of long dendritic processes. The morphological changes are accompanied by disassembly of actin stress fibers and often also by complete loss of focal adhesions. The MARCO induced changes are dependent on cell adhesion and are inhibited, but not completely abolished, when the cells are plated on fibronectin-coated surfaces. Similarly, a dominant-negative mutant of the Rho family GTPase Rac1 partially inhibited the morphogenic effects of MARCO in Chinese hamster ovary cells, whereas a dominant-negative form of a related protein, Cdc42, did not. Expression studies with a variety of truncated MARCO forms indicated that the proximal segment of the cysteine-rich domain V is important for the morphoregulatory activity. The results indicate that expression of MARCO has a direct effect in generating the phenotype of activated macrophages necessary for the trapping and removal of pathogens and other foreign substances.	Karolinska Inst, Dept Med Biochem & Biophys, Div Matrix Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Tryggvason, K (corresponding author), Karolinska Inst, Dept Biochem Med, Div Matrix Biol, S-17177 Stockholm, Sweden.							Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Domanico SZ, 1997, MOL BIOL CELL, V8, P2253, DOI 10.1091/mbc.8.11.2253; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; FAWCETT DW, 1994, TXB HIST, P150; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Haworth R, 1997, J EXP MED, V186, P1431, DOI 10.1084/jem.186.9.1431; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRAAL G, 1992, INT REV CYTOL, V132, P31, DOI 10.1016/S0074-7696(08)62453-5; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KUBY J, 1997, IMMUNOLOGY, P64; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHNEIDER G, 1994, EXP CELL RES, V214, P264, DOI 10.1006/excr.1994.1257; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; van der Laan LJW, 1999, J IMMUNOL, V162, P939; vanderLaan LJW, 1997, IMMUNOL LETT, V57, P203, DOI 10.1016/S0165-2478(97)00077-1	22	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10975	10982		10.1074/jbc.274.16.10975	http://dx.doi.org/10.1074/jbc.274.16.10975			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196178	hybrid			2022-12-25	WOS:000079751900046
J	Lux, A; Attisano, L; Marchuk, DA				Lux, A; Attisano, L; Marchuk, DA			Assignment of transforming growth factor beta 1 and beta 3 and a third new ligand to the type I receptor ALK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; SERINE/THREONINE KINASE RECEPTOR; BINDING PROTEIN ENDOGLIN; OSTEOGENIC PROTEIN-1; HETEROMERIC COMPLEX; ENDOTHELIAL-CELLS; ACTIVIN RECEPTORS; MOLECULAR-CLONING; III RECEPTOR; GENE	Germ line mutations in one of two distinct genes, endoglin or ALK-1, cause hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disorder of localized angiodysplasia, Both genes encode endothelial cell receptors for the transforming growth factor beta (TGF-beta) ligand superfamily, Endoglin has homology to the type III receptor, betaglycan, although its exact role in TGF-beta signaling is unclear. Activin receptor-like kinase 1 (ALK-1) has homology to the type I receptor family, but its ligand and corresponding type II receptor are unknown, In order to identify the ligand and type II receptor for ALK-1 and to investigate the role of endoglin in ALK-1 signaling, we devised a chimeric receptor signaling assay by exchanging the kinase domain of ALK-1 with either the TCF-beta type I receptor or the activin type IB receptor, both of which can activate an inducible PAI-1 promoter. we show that TGF-beta 1 and TGF-beta 3, as well as a third unknown ligand present in serum, can activate chimeric ALK-1, HHT-associated missense mutations in the ALK-1 extracellular domain abrogate signaling. The ALK-l/ligand interaction is mediated by the type II TGF-beta receptor for TGF-beta and most likely through the activin type II or type IIB receptors for the serum ligand, Endoglin is a bifunctional receptor partner since it can bind to ALK-1 as well as to type I TGF-beta receptor. These data suggest that HHT pathogenesis involves disruption of a complex network of positive and negative angiogenic factors, involving TGF-beta, a new unknown ligand, and their corresponding receptors.	Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA; Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada	Duke University; University of Toronto	Marchuk, DA (corresponding author), Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA.			Marchuk, Douglas/0000-0002-3110-6671	NHLBI NIH HHS [HL 49171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anders RA, 1996, J BIOL CHEM, V271, P21758, DOI 10.1074/jbc.271.36.21758; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Berg JN, 1997, AM J HUM GENET, V61, P60, DOI 10.1086/513903; Caniggia I, 1997, ENDOCRINOLOGY, V138, P4977, DOI 10.1210/en.138.11.4977; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; deWinter JP, 1996, EXP CELL RES, V224, P323, DOI 10.1006/excr.1996.0142; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Gallione CJ, 1998, HUM MUTAT, V11, P286, DOI 10.1002/(SICI)1098-1004(1998)11:4<286::AID-HUMU6>3.0.CO;2-B; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLAUS DJ, 1998, HUM MUTAT; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Martens JWM, 1997, ENDOCRINOLOGY, V138, P2928, DOI 10.1210/en.138.7.2928; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; MOREN A, 1992, BIOCHEM BIOPH RES CO, V189, P356, DOI 10.1016/0006-291X(92)91566-9; Muramatsu M, 1997, MOL BIOL CELL, V8, P469, DOI 10.1091/mbc.8.3.469; MUSSAGUE J, 1990, ANN REV CELL BIOL, V6, P597; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Panchenko MP, 1996, AM J PHYSIOL-LUNG C, V270, pL547, DOI 10.1152/ajplung.1996.270.4.L547; Pece N, 1997, J CLIN INVEST, V100, P2568, DOI 10.1172/JCI119800; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Persson U, 1997, J BIOL CHEM, V272, P21187, DOI 10.1074/jbc.272.34.21187; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; ROBERTSON DM, 1995, J ENDOCRINOL, V144, P261, DOI 10.1677/joe.0.1440261; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Shovlin CL, 1997, AM J HUM GENET, V61, P68, DOI 10.1086/513906; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yamaguchi H, 1997, THROMB HAEMOSTASIS, V77, P243; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Zhang HW, 1996, J IMMUNOL, V156, P565	65	120	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					9984	9992		10.1074/jbc.274.15.9984	http://dx.doi.org/10.1074/jbc.274.15.9984			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187774	hybrid			2022-12-25	WOS:000079663500013
J	Blaise, R; Grober, J; Rouet, P; Tavernier, G; Daegelen, D; Langin, D				Blaise, R; Grober, J; Rouet, P; Tavernier, G; Daegelen, D; Langin, D			Testis expression of hormone-sensitive lipase is conferred by a specific promoter that contains four regions binding testicular nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR-4 ENHANCER; CONVERTING ENZYME ACE; DNA-BINDING; GENE; SRY; SEQUENCE; SPERMATOGENESIS; CREM; MOUSE; CELLS	The testicular isoform of hormone-sensitive lipase (HSLtes) is encoded by a testis-specific exon and 9 exons common to the testis and adipocyte isoforms. In mouse, HSLtes mRNA appeared during spermiogenesis in round spermatids. Two constructs containing 1.4 and 0.5 kilobase pairs (kb) of the human HSLtes gene 5'-flanking region cloned upstream of the chloramphenicol acetyltransferase gene were microinjected into mouse oocytes. Analyses of enzyme activity in male and female transgenic mice showed that 0.5 kb of the HSLtes promoter was sufficient to direct expression only in testis, Cell transfection experiments showed that CREM tau, a testis-specific transcriptional activator, does not transactivate the HSLtes promoter. Using gel retardation assays, four testis-specific binding regions (TSBR) were identified using testis and liver nuclear extracts. The testis-specific protein binding on TSBR4 was selectively competed by a probe containing a SRY/Sox protein DNA recognition site. Sox5 and Sox6 which are expressed in post-meiotic germ cells bound TSBR4. Mutation of the AACAAAG motif in TSBR4 abolished the binding. Moreover, binding of the high mobility group domain of Sox5 induced a bend within TSBR4. Together, our results showed that 0.5 kb of the human HSLtes promoter bind Sox proteins and contain cis-acting elements essential for the testis specificity of HSL.	Univ Toulouse 3, Hop Rangueil, Inst Louis Bugnard, INSERM U317, F-31403 Toulouse 4, France; Fac Med, Inst Cochin Genet Mol, INSERM U129, F-75014 Paris, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Langin, D (corresponding author), CHU Rangueil, INSERM U317, Inst Louis Bugnard, Batiment L3, F-31403 Toulouse 4, France.			Tavernier, Genevieve/0000-0002-0214-0344; Blaise, Regis/0000-0001-7759-3244; Langin, Dominique/0000-0002-2669-7825; Rouet, Philippe/0000-0001-6204-2079				Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DAILEY L, 1994, MOL CELL BIOL, V14, P7758, DOI 10.1128/MCB.14.12.7758; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GAUTRON S, 1991, NUCLEIC ACIDS RES, V19, P767, DOI 10.1093/nar/19.4.767; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; Grober J, 1997, BIOCHEM J, V328, P453, DOI 10.1042/bj3280453; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HOGAN B, 1994, MANIPULATING MOUSE E, P226; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HOLST LS, 1994, FEBS LETT, V355, P125, DOI 10.1016/0014-5793(94)01185-0; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KILPATRICK DL, 1986, P NATL ACAD SCI USA, V83, P5015, DOI 10.1073/pnas.83.14.5015; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; KLEENE KC, 1983, DEV BIOL, V98, P455, DOI 10.1016/0012-1606(83)90375-5; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; LAURELL H, 1995, INT J OBESITY, V19, P590; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEHTA ND, 1994, ENDOCRINOLOGY, V135, P1543, DOI 10.1210/en.135.4.1543; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561; TAKAMATSU N, 1995, MOL CELL BIOL, V15, P3759; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	51	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9327	9334		10.1074/jbc.274.14.9327	http://dx.doi.org/10.1074/jbc.274.14.9327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092610	hybrid			2022-12-25	WOS:000079451800029
J	Larocca, D; Kassner, PD; Witte, A; Ladner, RC; Pierce, GF; Baird, A				Larocca, D; Kassner, PD; Witte, A; Ladner, RC; Pierce, GF; Baird, A			Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage	FASEB JOURNAL			English	Article						phage display; transfection; receptor-mediated; ligand	FIBROBLAST GROWTH-FACTOR; PHAGE DISPLAY; BINDING; DELIVERY; SURFACE; INTERLEUKIN-2; SELECTION; RECEPTOR; PEPTIDE; LAMBDA	We have genetically modified filamentous bacteriophage to deliver genes to mammalian cells. In previous studies we showed that noncovalently attached fibroblast growth factor (FGF2) can target bacteriophage to COS-1 cells, resulting in receptor-mediated transduction with a reporter gene, Thus, bacteriophage, which normally lack tropism for mammalian cells, can be adapted for mammalian cell gene transfer. To determine the potential of using phage-mediated gene transfer as a novel display phage screening strategy, we transfected COS-1 cells with phage that were engineered to display FGF2 on their surface coat as a fusion to the minor coat protein, pIII, Immunoblot and ELISA analysis confirmed the presence of FGF2 on the phage coat. Significant transduction was obtained in COS-1 cells with the targeted FGF2-phage compared with the nontargeted parent phage, Specificity was demonstrated by successful inhibition of transduction in the presence of excess free FGF2, Having demonstrated mammalian cell transduction by phage displaying a known gene targeting ligand, it is now feasible to apply phage-mediated transduction as a screen for discovering novel ligands.	Select Genet Inc, San Diego, CA 92121 USA; Dyax Corp, Boston, MA 02115 USA		Larocca, D (corresponding author), Select Genet Inc, 11035 Roselle St, San Diego, CA 92121 USA.			Kassner, Paul/0000-0002-1471-1191; Baird, Andrew/0000-0003-0027-9905; Larocca, Dana/0000-0001-5863-9833				Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; Buchli PJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P79, DOI 10.1006/abbi.1996.9853; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dunn IS, 1996, BIOCHIMIE, V78, P856, DOI 10.1016/S0300-9084(97)84338-6; FOX GM, 1988, J BIOL CHEM, V263, P18452; Goldman CK, 1997, CANCER RES, V57, P1447; GRAM H, 1993, J IMMUNOL METHODS, V161, P169, DOI 10.1016/0022-1759(93)90292-F; HART SL, 1994, J BIOL CHEM, V269, P12468; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HODGSON CP, 1995, BIO-TECHNOL, V13, P222, DOI 10.1038/nbt0395-222; HORST J, 1975, P NATL ACAD SCI USA, V72, P3531, DOI 10.1073/pnas.72.9.3531; ISHIURA M, 1982, MOL CELL BIOL, V2, P607, DOI 10.1128/MCB.2.6.607; KAY BK, 1998, PHAGE DISPLAY PEPTID, P55; LAPPI DA, 1993, ANAL BIOCHEM, V212, P446, DOI 10.1006/abio.1993.1353; Larocca D, 1998, HUM GENE THER, V9, P2393, DOI 10.1089/hum.1998.9.16-2393; Merlin S, 1997, APPL BIOCHEM BIOTECH, V67, P199, DOI 10.1007/BF02788798; MICHAEL SI, 1994, GENE THER, V1, P223; OKAYAMA H, 1985, MOL CELL BIOL, V5, P1136, DOI 10.1128/MCB.5.5.1136; PASQUALINI R, 1995, NAT BIOTECHNOL, V13, P222; ROGERS BE, 1998, TUMOR TARGET, V3, P25; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647; Souriau C, 1997, NUCLEIC ACIDS RES, V25, P1585, DOI 10.1093/nar/25.8.1585; Vallejo Abbe N., 1995, P603; Vispo NS, 1997, IMMUNOTECHNOLOGY, V3, P185, DOI 10.1016/S1380-2933(97)00012-2; YOKOYAMAKOBAYASHI M, 1993, BIOCHEM BIOPH RES CO, V192, P935, DOI 10.1006/bbrc.1993.1505; YOKOYAMAKOBAYASHI M, 1994, ANAL BIOCHEM, V223, P130, DOI 10.1006/abio.1994.1557	28	110	134	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	1999	13	6					727	734		10.1096/fasebj.13.6.727	http://dx.doi.org/10.1096/fasebj.13.6.727			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182ZC	10094933				2022-12-25	WOS:000079527200014
J	Cervoni, N; Bhattacharya, S; Szyf, M				Cervoni, N; Bhattacharya, S; Szyf, M			DNA demethylase is a processive enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE EMBRYO; METHYLATION PATTERNS; 5-METHYLCYTOSINE; GENE; DIFFERENTIATION	DNA methylation patterns are generated during development by a sequence of methylation and demethylation events. We have recently demonstrated that mammals bear a bona fide demethylase enzyme that removes methyl groups from methylated cytosines. A general genome wide demethylation occurs early in development and in differentiating cell lines. This manuscript tests the hypothesis that the demethylase enzyme is a processive enzyme. Using bisulfite mapping, this report demonstrates that demethylase is a processive enzyme and that the rate limiting step in demethylation is the initiation of demethylation. Initiation of demethylation is determined by the properties of the sequence. Once initiated, demethylation progresses processively. We suggest that these data provide a molecular explanation for global hypomethylation.	McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; BENVENISTY N, 1985, P NATL ACAD SCI USA, V82, P267, DOI 10.1073/pnas.82.2.267; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; FEINBERG AP, 1988, CANCER RES, V48, P1159; KAFRI T, 1993, P NATL ACAD SCI USA, V90, P10558, DOI 10.1073/pnas.90.22.10558; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; MONK M, 1987, DEVELOPMENT, V99, P371; NUR I, 1985, J BACTERIOL, V164, P19, DOI 10.1128/JB.164.1.19-24.1985; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; SALUZ HP, 1986, P NATL ACAD SCI USA, V83, P7167, DOI 10.1073/pnas.83.19.7167; SZYF M, 1985, P NATL ACAD SCI USA, V82, P8090, DOI 10.1073/pnas.82.23.8090; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; SZYF M, 1995, J BIOL CHEM, V270, P12690, DOI 10.1074/jbc.270.21.12690; SZYF M, 1994, TRENDS PHARMACOL SCI, V7, P233; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4	20	41	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8363	8366		10.1074/jbc.274.13.8363	http://dx.doi.org/10.1074/jbc.274.13.8363			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085064	hybrid			2022-12-25	WOS:000079451600006
J	Dell, H; Hadzopoulou-Cladaras, M				Dell, H; Hadzopoulou-Cladaras, M			CREB-binding protein is a transcriptional coactivator for hepatocyte nuclear factor-4 and enhances apolipoprotein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; RETINOID-X-RECEPTOR; HUMAN APOCIII GENE; RNA-POLYMERASE-II; DNA-BINDING; TRANSACTIVATION DOMAIN; HORMONE RECEPTORS; HISTONE ACETYLTRANSFERASES; PROXIMAL PROMOTER; RESPONSE ELEMENT	Hepatocyte nuclear factor-4 (HNF-4) is a liver-enriched transcription factor that is crucial in the regulation of a large number of genes involved in glucose, cholesterol, and fatty acid metabolism and in determining the hepatic phenotype. We have previously shown that HNF-4 contains transcription activation functions at the N terminus (AF-1) and the C terminus (AF-2) which work synergistically to confer full HNF-4 activity. Here, we show that HNF-4 recruits the CREB-binding protein (CBP) coactivator on promoters of genes that contain functional HNF-4 sites. HNF-4 interacts with the N-terminal region of CBP (amino acids 1-771) and the C-terminal region of CBP (amino acids 1812-2441). The two activating functions of HNF-4, AF-1 and AF-2, interact with the N terminus and the N and C terminus of CBP, respectively. In addition, we show that in contrast to the other nuclear hormone receptors the interaction between HNF-4 and CBP is ligand-independent. Recruitment of CBP by HNF-4 results in an enhancement of the transcriptional activity of the latter. CBP does not activate gene expression in the absence of HNF-4, and dominant negative forms of HNF-4 prevent transcriptional activation by CBP, suggesting that the mere recruitment of CBP by HNF-4 is not sufficient for enhancement of gene expression. These findings demonstrate that CBP acts as a transcriptional coactivator for HNF-4 and provide new insights into the regulatory function of HNF-4.	Boston Univ, Sch Med, Dept Med, Ctr Adv Biomed Res,Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA	Boston University	Hadzopoulou-Cladaras, M (corresponding author), Boston Univ, Sch Med, Dept Med, Ctr Adv Biomed Res,Cardiovasc Inst,Sect Mol Genet, 715 Albany St, Boston, MA 02118 USA.	cladaras@bu.edu			NHLBI NIH HHS [HL56104] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056104] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Drewes T, 1996, MOL CELL BIOL, V16, P925; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Fraser JD, 1998, NUCLEIC ACIDS RES, V26, P2702, DOI 10.1093/nar/26.11.2702; Furuta H, 1997, DIABETES, V46, P1652, DOI 10.2337/diabetes.46.10.1652; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hadzopoulou-Cladaras M, 1998, BIOCHEMISTRY-US, V37, P14078, DOI 10.1021/bi9804176; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HATA S, 1995, BBA-GENE STRUCT EXPR, V1260, P55, DOI 10.1016/0167-4781(94)00177-5; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Holewa B, 1997, MOL CELL BIOL, V17, P687, DOI 10.1128/MCB.17.2.687; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jiang GQ, 1997, J BIOL CHEM, V272, P1218, DOI 10.1074/jbc.272.2.1218; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kardassis D, 1998, J BIOL CHEM, V273, P17810, DOI 10.1074/jbc.273.28.17810; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LAVRENTIADOU SN, 1998, IN PRESS BIOCHEMISTR; Lee SK, 1998, MOL ENDOCRINOL, V12, P325, DOI 10.1210/me.12.3.325; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; METZGER S, 1993, J BIOL CHEM, V268, P16831; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakhei H, 1998, NUCLEIC ACIDS RES, V26, P497, DOI 10.1093/nar/26.2.497; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yoshida E, 1998, GENE, V208, P307, DOI 10.1016/S0378-1119(98)00008-0; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	63	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9013	9021		10.1074/jbc.274.13.9013	http://dx.doi.org/10.1074/jbc.274.13.9013			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085149	hybrid			2022-12-25	WOS:000079451600091
J	Frazier, WA; Gao, AG; Dimitry, J; Chung, J; Brown, EJ; Lindberg, FP; Linder, ME				Frazier, WA; Gao, AG; Dimitry, J; Chung, J; Brown, EJ; Lindberg, FP; Linder, ME			The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric G(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; LIGAND-BINDING; ALPHA(V)BETA(3); SPECIFICITY; EXPRESSION; MIGRATION; DOMAIN; ALPHA	Integrin-associated protein (IAP; CD47) is a thrombospondin receptor that forms a signaling complex with beta(3) integrins resulting in enhanced alpha(v)beta(3)-dependent cell spreading and chemotaxis and, in platelets, alpha(IIb)beta(3)-dependent spreading and aggregation. These actions of CD47 are all specifically abrogated by pertussis toxin treatment of cells. Here we report that CD47, its beta(3) integrin partner, and G(i) proteins form a stable, detergent-soluble complex that can be recovered by immunoprecipitation and affinity chromatography, G(i alpha) is released from this complex by treatment with GTP or AlF4. GTP and AlF4 also reduce the binding of CD47 to its agonist peptide (4N1K) derived from thrombospondin, indicating a direct association of CD47 with G(i). 4N1K peptide causes a rapid decrease in intraplatelet cyclic AMP levels, a G(i)-dependent event necessary for aggregation. Finally, 4N1K stimulates the binding of GTP gamma(35)S to membranes from cells expressing IAP and alpha(v)beta(3). This functional coupling of CD47 to heterotrimeric G proteins provides a mechanistic explanation for the biological effects of CD47 in a wide variety of systems.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Infect Dis, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Frazier, WA (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	frazier@biochem.wustl.edu	Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL CANCER INSTITUTE [R01CA065872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054390, R01GM051466] Funding Source: NIH RePORTER; NCI NIH HHS [CA65872] Funding Source: Medline; NIGMS NIH HHS [GM54390, GM51466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J. C., 1995, THROMBOSPONDIN GENE; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KRAUSE JE, 1994, TACHYKININ RECEPTORS, P165; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MCLEISH KR, 1993, GTPASE BIOL, V2, P363; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; PEROUTKA SJ, 1994, HDB RECEPTORS CHANNE; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Suchard SJ, 1996, J CELL PHYSIOL, V168, P217, DOI 10.1002/(SICI)1097-4652(199607)168:1<217::AID-JCP26>3.0.CO;2-2; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VANSTRIJP JAG, 1993, J IMMUNOL, V151, P3324; Wang XQ, 1998, MOL BIOL CELL, V9, P865, DOI 10.1091/mbc.9.4.865	29	136	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8554	8560		10.1074/jbc.274.13.8554	http://dx.doi.org/10.1074/jbc.274.13.8554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085089	hybrid			2022-12-25	WOS:000079451600031
J	Her, S; Bell, RA; Bloom, AK; Siddall, BJ; Wong, DL				Her, S; Bell, RA; Bloom, AK; Siddall, BJ; Wong, DL			Phenylethanolamine N-methyltransferase gene expression - SP1 and MAZ potential for tissue-specific expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REGULATION; C-MYC; PROMOTER; ACTIVATION; EGR-1; MOUSE; ELEMENTS; KINASE	Phenylethanolamine N-methyltransferase (PNMT) promoter-luciferase reporter gene constructs (pGL3RP863, pGL3RP444, and pGL3RP392) transfected into COS1, RS1, PC12, NIH/3T3, or Neuro2A cells showed the highest basal luciferase activity in the Neuro2A cells. DNase I footprinting with Neuro2A cell nuclear extract identified protected PNMT promoter regions spanning the -168/-165 and -48/-45 base pair Sp1/Egr-1 binding sites. Gel mobility shift assays and transient transfection assays using site-directed mutant PNMT promoter-luciferase reporter gene constructs indicated that the elevated basal luciferase activity in the Neuro2A cells was mediated by Sp-1. Furthermore, activation of the PNMT promoter by Sp1 depends on both its binding affinity for its cognate target sequences and its intracellular concentrations. When Sp1 levels were increased through an expression plasmid, luciferase reporter gene expression rose well beyond basal wild-type levels, even with either Sp1 binding element mutated. Finally, another transcription factor expressed in the Neuro2A cells competes with Sp1 by interacting with DNA sequences 3' to the -48 base pair Sp1 site to prevent Sp1 binding and induction of the PNMT promoter. The DNA consensus sequence, Southwestern analysis, and gel mobility shift assays with antibodies identify MAZ as the competitive factor. These findings suggest that Sp1 may potentially contribute to the tissue-specific expression of the PNMT gene, with the competition between Sp1 and MAZ conferring additional tissue-specific control.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Stanford University	Wong, DL (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, MSLS Bldg,Rm P106, Stanford, CA 94305 USA.	ms.dlw@forsythe.stanford.edu						ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BAETGE EE, 1986, P NATL ACAD SCI USA, V83, P5454, DOI 10.1073/pnas.83.15.5454; BATTER DK, 1988, J NEUROSCI RES, V19, P367, DOI 10.1002/jnr.490190313; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATIGNANIKENNED.G, 1992, P NATL ACAD SCI USA, V89, P11498; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EBERT SN, 1994, J BIOL CHEM, V269, P20885; Ebert SN, 1998, J NEUROCHEM, V70, P2286; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; EBERT SN, 1990, J VIROL, V64, P4059, DOI 10.1128/JVI.64.9.4059-4066.1990; EVINGER MJ, 1998, CATECHOLAMINES BRIDG, V42, P73; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANEDA N, 1988, J BIOL CHEM, V263, P7672; LI Y, 1993, J BIOL CHEM, V268, P3563; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; PYRE JJ, 1992, BIOCHEMISTRY-US, V31, P4102; ROSS ME, 1990, J NEUROSCI, V10, P520; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 1989, MOL CLONING LAB MANU, V2	31	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8698	8707		10.1074/jbc.274.13.8698	http://dx.doi.org/10.1074/jbc.274.13.8698			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085109	hybrid			2022-12-25	WOS:000079451600051
J	Leahy, P; Crawford, DR; Grossman, G; Gronostajski, RM; Hanson, RW				Leahy, P; Crawford, DR; Grossman, G; Gronostajski, RM; Hanson, RW			CREB binding protein coordinates the function of multiple transcription factors including nuclear factor I to regulate phosphoenolpyruvate carboxykinase (GTP) gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE UNIT; MAMMARY-TUMOR VIRUS; DNA-BINDING; TRANSGENIC MICE; PROMOTER; ELEMENTS; IDENTIFICATION; EXPRESSION; RECEPTOR; REGION	Nuclear factor I (NFI) binds to a region of the phosphoenolpyruvate carboxykinase (GTP) (PEPCK) gene promoter adjacent to the cAMP regulatory element (CRE) and inhibits the induction of transcription from the gene promoter caused by the catalytic subunit of protein kinase A. In vivo footprinting studies demonstrated that both the CRE and the NFI-binding site are occupied by transcription factors, regardless of the presence of factors that stimulate (dibutyryl cAMP or dexamethasone) or inhibit (insulin) transcription from the PEPCK gene promoter. The NFI effects on transcription from the PEPCK gene promoter were observed even in the absence of the NFI binding site, suggesting the possibility of other weaker binding sites on the promoter or an interaction of NFI with a transcriptional co-activator. A mammalian two-hybrid system was used to demonstrate direct interaction between the transactivation domain of NFI-C and the CREB binding domain of the CREB-binding protein (CBP), Overexpression of a gene fragment encoding the CREB binding domain of CBP stimulates transcription from the PEPCK gene promoter. The inhibitory effect of NFI on transcription of the PEPCK gene induced by the catalytic subunit of protein kinase A appears to be the result of an interaction between NFI and the CREB-binding protein in which NFI competes with CREB for binding to the CREB-binding site on CBP, In contrast, glucocorticoids and thyroid hormone use the steroid hormone receptor binding domain of CBP to stimulate transcription from the PEPCK gene promoter. NFI-A combines with dexamethasone or thyroid hormone in an additive manner to stimulate PEPCK gene transcription. We conclude that CBP coordinates the action of the multiple factors known to control transcription of the PEPCK gene.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA	Case Western Reserve University; Cleveland Clinic Foundation	Leahy, P (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.			Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025541] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34908] Funding Source: Medline; NIDDK NIH HHS [DK-25541, DK-07319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; AUSUBEL FM, 1987, CURRENT PROTOCOLS MO, V1, P101; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Becker MM, 1993, FOOTPRINTING NUCL AC, P129; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHEN H, 1997, CELL, V90, P669; CHRIST B, 1991, BIOCHEM BIOPH RES CO, V181, P367, DOI 10.1016/S0006-291X(05)81428-7; Crawford DR, 1998, J BIOL CHEM, V273, P13387, DOI 10.1074/jbc.273.22.13387; Croniger C, 1997, J BIOL CHEM, V272, P26306, DOI 10.1074/jbc.272.42.26306; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; CUIF MH, 1993, J BIOL CHEM, V268, P13769; FABER S, 1993, J BIOL CHEM, V268, P24976; Garlatti M, 1996, J BIOL CHEM, V271, P32629, DOI 10.1074/jbc.271.51.32629; GIRALT M, 1991, J BIOL CHEM, V266, P21991; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENNIGHAUSEN L, 1986, EMBO J, V5, P1367, DOI 10.1002/j.1460-2075.1986.tb04368.x; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Klemm DJ, 1996, J BIOL CHEM, V271, P8082, DOI 10.1074/jbc.271.14.8082; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; LEAHY P, 1995, BIOTECHNIQUES, V19, P894; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIU JS, 1991, J BIOL CHEM, V266, P19095; LIU JS, 1990, BIOTECHNIQUES, V9, P738; MANDEL HG, 1995, ANAL BIOCHEM, V230, P191, DOI 10.1006/abio.1995.1460; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHORT JM, 1986, J BIOL CHEM, V261, P9721; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; ZAR JH, 1974, BIOSTAT ANAL, P101	59	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8813	8822		10.1074/jbc.274.13.8813	http://dx.doi.org/10.1074/jbc.274.13.8813			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085123	hybrid			2022-12-25	WOS:000079451600065
J	Sekiguchi, T; Nishimoto, T; Hunter, T				Sekiguchi, T; Nishimoto, T; Hunter, T			Overexpression of D-type cyclins, E2F-1, SV40 large T antigen and HPV16 E7 rescue cell cycle arrest of tsBN462 cells caused by the CCG1/TAF(II)250 mutation	ONCOGENE			English	Article						CCG1/TAF(II)250; ELF-1; SV40; large T antigen; HPV16 E7; cyclin D; TFIID	BASAL TRANSCRIPTION FACTOR; BOX-BINDING PROTEIN; RETINOBLASTOMA PROTEIN; PROMOTER SELECTIVITY; TAF(II)250 SUBUNIT; BHK CELLS; EXPRESSION; GENE; ACTIVATION; TEMPERATURE	tsBN462 cells which have a point mutation in CCG1/TAF(11)250, a component of TFIID complex, arrest in G1 at the nonpermissive temperature of 39.5 degrees C. Overexpression of D-type cyclins rescued the cell cycle arrest of tsBN462 cells, suggesting that the cell cycle arrest was through Rb, Consistent,vith this, overexpression of E2F-1, whose function is repressed by the hypophosphorylated form of Rb, also rescued the cell cycle arrest, Moreover, expression of the viral oncoproteins SV40 large T antigen and HPV16 E7, which both bind Rb and inactivate its function, rescued the cell cycle arrest, whereas HPV16 E6 did not. Mutation of the Rb-binding motif in E7 abrogated its ability to rescue the cell cycle arrest, Expression of exogenous cyclin D1, SV40 large T antigen or CCG1/TAF(11)250 increased cyclin A expression at 39.5 degrees C. Coexpression of HPV16 E7 and adenovirus E1b19K, which blocks apoptosis, rescued the proliferation of tsBN462 cells at 38.5 degrees C. To investigate the mechanism underlying the lack of cyclin D1 expression, deletion analysis of cyclin D1 promoter was performed. The 0.15 kbp cyclin D1 core promoter region, which lacks any transcription factor binding motifs, still exhibited a temperature-sensitive phenotype in tsBN462 cells suggesting that CCG1/TAF(11)250 is critical for the function of the cyclin D1 core promoter.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 812, Japan	Salk Institute; Kyushu University	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; Berezutskaya E, 1997, J BIOL CHEM, V272, P30135, DOI 10.1074/jbc.272.48.30135; Boyer SN, 1996, CANCER RES, V56, P4620; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAYASHIDA T, 1994, GENE, V141, P267; HERBER B, 1994, ONCOGENE, V9, P1295; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Massimi P, 1996, ONCOGENE, V12, P2325; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NISHIMOTO T, 1982, SOMAT CELL GENET, V8, P811, DOI 10.1007/BF01543021; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; Rushton JJ, 1997, CELL GROWTH DIFFER, V8, P1099; Sekiguchi T, 1998, ONCOGENE, V16, P369, DOI 10.1038/sj.onc.1201539; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; Sekiguchi T, 1996, GENES CELLS, V1, P687, DOI 10.1046/j.1365-2443.1996.00259.x; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Shao ZH, 1997, ONCOGENE, V15, P385, DOI 10.1038/sj.onc.1201204; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; Tooze J., 1980, MOL BIOL TUMOR VIR 2; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014	42	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 11	1999	18	10					1797	1806		10.1038/sj.onc.1202508	http://dx.doi.org/10.1038/sj.onc.1202508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175JM	10086334				2022-12-25	WOS:000079090000003
J	Chow, JC; Young, DW; Golenbock, DT; Christ, WJ; Gusovsky, F				Chow, JC; Young, DW; Golenbock, DT; Christ, WJ; Gusovsky, F			Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TOLL; KAPPA-B; BACTERIAL-ENDOTOXIN; GENE; ACTIVATION; PATHWAY; PROTEIN; FAMILY; RESPONSIVENESS; EXPRESSION	TLR4 is a member of the recently identified Toll-like receptor family of proteins and has been putatively identified as Lps, the gene necessary for potent responses to lipopolysaccharide in mammals. In order to determine whether TLR4 is involved in lipopolysaccharide-induced activation of the nuclear factor-kappa B (NF-kappa B) pathway, HEK 293 cells were transiently transfected with human TLR4 cDNA and an NF-kappa B-dependent luciferase reporter plasmid followed by stimulation with lipopolysaccharide/CD14 complexes. The results demonstrate that lipopolysaccharide stimulates NF-kappa B-mediated gene expression in cells transfected with the TLR4 gene in a dose- and time-dependent fashion. Furthermore, E5531, a lipopolysaccharide antagonist, blocked TLR4-mediated transgene activation in a dose-dependent manner (IC50 similar to 30 nM). These data demonstrate that TLR4 is involved in lipopolysaccharide signaling and serves as a cell-surface co-receptor for CD14, leading to lipopolysaccharide-mediated NF-kappa B activation and subsequent cellular events.	Eisai Res Inst, Div Inflammatory Dis, Andover, MA 01810 USA; Eisai Res Inst, Div Synthet Chem, Andover, MA 01810 USA; Boston Univ, Boston Med Ctr, Sch Med, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA	Eisai Co Ltd; Eisai Co Ltd; Boston Medical Center; Boston University	Chow, JC (corresponding author), Eisai Res Inst, 100 Res Dr, Wilmington, MA 01887 USA.							Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KUWATA T, 1995, BACTERIAL ENDOTOXINS, V392, P499; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Rossignol DP, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P699; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	23	1556	1632	0	95	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10689	10692		10.1074/jbc.274.16.10689	http://dx.doi.org/10.1074/jbc.274.16.10689			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196138	hybrid			2022-12-25	WOS:000079751900006
J	Furge, KA; Cheng, QC; Jwa, M; Shin, SJ; Song, KW; Albright, CF				Furge, KA; Cheng, QC; Jwa, M; Shin, SJ; Song, KW; Albright, CF			Regions of Byr4, a regulator of septation in fission yeast, that bind Spg1 or Cdc16 and form a two-component GTPase-activating protein with Cdc16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSAGE-DEPENDENT REGULATOR; SCHIZOSACCHAROMYCES-POMBE; SEPTUM FORMATION; SACCHAROMYCES-CEREVISIAE; S-POMBE; CYTOKINESIS; KINASE; DOMAIN; CDC42; GENE	In the fission yeast Schizosaccharomyces pombe, septation and constriction of the actomyosin ring for cell division are positively regulated by the Spg1. GTPase, a member of the Ras superfamily. Spg1 is negatively regulated by Byr4 and Cdc16, which together form a two-component GTPase-activating protein for the Spg1 GTPase. To better understand how Byr4 regulates septation, Byr4 mutants were tested for in vitro functions. This analysis revealed that Byr4 contained one Cdc16-binding site and four Spg1-binding sites (SBS), designated SBS1-SBS4. Although mutants with a single SBS bound Spg1 and inhibited GTP dissociation, the equilibrium binding affinity of these mutants was 28-280-fold weaker than Byr4. Because some Byr4 mutants with multiple SBSs bound Spg1 tighter than the corresponding mutants with a single SBS, multiple SBSs probably interact to cause the high affinity binding of Byr4 to Spg1. A region of Byr4 that bound Spg1, SBS4, and the region that bound Cdc16, Cdc16-binding site, was necessary and sufficient to form Cdc16-dependent Spg1GAP activity that was similar to that of wild-type Byr4 with Cdc16.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea	Vanderbilt University; Yonsei University	Albright, CF (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 655 Light Hall, Nashville, TN 37232 USA.				NCI NIH HHS [T32-CA09582] Funding Source: Medline; NIGMS NIH HHS [GM-51952] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balasubramanian MK, 1998, GENETICS, V149, P1265; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chang F, 1997, J CELL BIOL, V137, P169, DOI 10.1083/jcb.137.1.169; FANKHAUSER C, 1993, EMBO J, V12, P2697, DOI 10.1002/j.1460-2075.1993.tb05931.x; FANKHAUSER C, 1994, EMBO J, V13, P3011, DOI 10.1002/j.1460-2075.1994.tb06600.x; Furge KA, 1998, CURR BIOL, V8, P947, DOI 10.1016/S0960-9822(98)70394-X; Gould KL, 1997, GENE DEV, V11, P2939, DOI 10.1101/gad.11.22.2939; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; JOCHOVA J, 1991, CELL BIOL INT REP, V15, P607, DOI 10.1016/0309-1651(91)90007-6; JOHNSON BF, 1973, J BACTERIOL, V115, P358, DOI 10.1128/JB.115.1.358-366.1973; Jwa M, 1998, MOL CELLS, V8, P240; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MCCOLLUM D, 1995, J CELL BIOL, V130, P1; MINET M, 1979, J BACTERIOL, V137, P440, DOI 10.1128/JB.137.1.440-446.1979; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P243, DOI 10.1016/S0968-0004(97)01073-6; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Song KW, 1996, J CELL BIOL, V133, P1307, DOI 10.1083/jcb.133.6.1307; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	27	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11339	11343		10.1074/jbc.274.16.11339	http://dx.doi.org/10.1074/jbc.274.16.11339			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196225	hybrid			2022-12-25	WOS:000079751900093
J	Lohmann, V; Overton, H; Bartenschlager, R				Lohmann, V; Overton, H; Bartenschlager, R			Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLIOVIRUS PROTEIN 3AB; RIBOSOME ENTRY SITE; NUCLEOTIDE-BINDING; NONSTRUCTURAL PROTEIN-3; HELICASE ACTIVITY; ESCHERICHIA-COLI; GENOME RNA; IDENTIFICATION; INITIATION; 3'-TERMINUS	NS5B of the hepatitis C virus is an RNA template-dependent RNA polymerase and therefore the key player of the viral replicase complex. Using a highly purified enzyme expressed with recombinant baculoviruses in insect cells, we demonstrate a stimulation of RNA synthesis up to 2 orders of magnitude by high concentrations of GTP but not with ATP, CTP, UTP, GDP, or C;Mg, Enhancement of RNA synthesis was found with various heteropolymeric RNA templates, with poly(C)-oligo(G)(12) but not with poly(A)-oligo(U)(12). Several amino acid substitutions in polymerase motifs B, C, and D previously shown to be crucial for RdRp activity were tested for GTP stimulation of RNA synthesis. Most of these mutations, in particular those affecting the GDD motif (motif C) strongly reduced or completely abolished activation by GTP, suggesting that the same NTP-binding site is used for stimulation and RNA synthesis. Since GTP did not affect the overall RNA binding properties or the elongation rate, high concentrations of GTP appear to accelerate a rate-limiting step at the level of initiation of RNA synthesis, Finally, enhancement of RNA synthesis by high GTP concentrations was also found with NS5B of the pestivirus classical swine fever virus, but not with the 3D polymerase of poliovirus, Thus, stimulation of RdRp activity by GTP is evolutionarily conserved between the closely related hepaciviruses and pestiviruses but not between these and the more distantly related picornaviruses.	Univ Mainz, Inst Virol, D-55131 Mainz, Germany; Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England	Johannes Gutenberg University of Mainz; Roche Holding	Bartenschlager, R (corresponding author), Univ Mainz, Inst Virol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.		Lohmann, Volker/H-4211-2019; Bartenschlager, Ralf/L-2582-2015	Lohmann, Volker/0000-0001-8719-7608; Bartenschlager, Ralf/0000-0001-5601-9307				Al RH, 1998, VIRUS RES, V53, P141, DOI 10.1016/S0168-1702(97)00147-0; BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 1997, J VIROL, V71, P7345, DOI 10.1128/JVI.71.10.7345-7352.1997; Booth JCL, 1998, J VIRAL HEPATITIS, V5, P213, DOI 10.1046/j.1365-2893.1998.00115.x; CHO MW, 1993, J VIROL, V67, P3010, DOI 10.1128/JVI.67.6.3010-3018.1993; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hong Z, 1996, J VIROL, V70, P4261, DOI 10.1128/JVI.70.7.4261-4268.1996; HOUGHTON M, 1996, VIROLOGY, P1035; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; Kao CC, 1996, J VIROL, V70, P6826, DOI 10.1128/JVI.70.10.6826-6830.1996; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; LAMA J, 1994, J BIOL CHEM, V269, P66; LAMA J, 1995, J BIOL CHEM, V270, P14430, DOI 10.1074/jbc.270.24.14430; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; MOLLA A, 1994, J BIOL CHEM, V269, P27015; MURPHY FA, 1995, CLASSIFICATION NOMEN, P424; PATA JD, 1995, RNA, V1, P466; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, J BIOL CHEM, V269, P29173; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; REDDY PS, 1994, EUR J BIOCHEM, V225, P737, DOI 10.1111/j.1432-1033.1994.00737.x; RICE CM, 1996, VIROLOGY, P931; Richards OC, 1996, J VIROL, V70, P8564, DOI 10.1128/JVI.70.12.8564-8570.1996; RICHARDS OC, 1992, J BIOL CHEM, V267, P17141; RICHARDS OC, 1995, BIOCHEMISTRY-US, V34, P6288, DOI 10.1021/bi00019a005; Richards OC, 1997, J BIOL CHEM, V272, P23261, DOI 10.1074/jbc.272.37.23261; Ruggli N, 1996, J VIROL, V70, P3478, DOI 10.1128/JVI.70.6.3478-3487.1996; SELBY MJ, 1993, J GEN VIROL, V74, P1103, DOI 10.1099/0022-1317-74-6-1103; Sun JH, 1997, VIROLOGY, V236, P348, DOI 10.1006/viro.1997.8742; Sun JH, 1997, VIROLOGY, V233, P63, DOI 10.1006/viro.1997.8583; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; Wang C, 1995, CURR TOP MICROBIOL, V203, P99; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249	52	83	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10807	10815		10.1074/jbc.274.16.10807	http://dx.doi.org/10.1074/jbc.274.16.10807			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196156	hybrid			2022-12-25	WOS:000079751900024
J	Sakuragi, S; Liu, QL; Craig, E				Sakuragi, S; Liu, QL; Craig, E			Interaction between the nucleotide exchange factor Mge1 and the mitochondrial Hsp70 Ssc1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GRPE; MOLECULAR CHAPERONE DNAK; SACCHAROMYCES-CEREVISIAE; PROTEIN IMPORT; ATPASE DOMAIN; TRANSLOCATION; GENE; MEMBRANE; BINDING; PURIFICATION	Function of Hsp70s such as DnaK of the Escherichia coli cytoplasm and Ssc1 of the mitochondrial matrix of Saccharomyces cerevisiae requires the nucleotide release factors, GrpE and Mge1, respectively. A loop, which protrudes from domain IA of the DnaK ATPase domain, is one of six sites of interaction revealed in the GrpE:DnaK co-crystal structure and has been implicated as a functionally important site in both DnaK and Ssc1, Alanine substitutions for the amino acids (Lys-108 and Arg-213 of Mge1) predicted to interact with the Hsp70 loop were analyzed. Mge1 having both substitutions was able to support growth in the absence of the essential wild-type protein. K108A/R213A Mge1 was able to stimulate nucleotide release from Ssc1 and function in refolding of denatured luciferase, albeit higher concentrations of mutant protein than wild-type protein were required. In vitro and in vivo assays using K108A/R213A Mge1 and Ssc1 indicated that the disruption of contact at this site destabilized the interaction between the two proteins. We propose that the direct interaction between the loop of Ssc1 and Mge1 is not required to effect nucleotide release but plays a role in stabilization of the Mge1-Ssc1 interaction. The robust growth of the K108A/R213A MGE1 mutant suggests that the interaction between Mge1 and Ssc1 is tighter than required for function in vivo.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Craig, E (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.	ecraig@facstaff.wisc.edu			NIGMS NIH HHS [GM27870] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG D, 1986, J BACTERIOL, V167, P25, DOI 10.1128/jb.167.1.25-29.1986; ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CORMACK B, 1994, CURRENT PROTOCOLS MO, V1; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; Deloche O, 1997, J BACTERIOL, V179, P6066, DOI 10.1128/jb.179.19.6066-6075.1997; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horst M, 1996, PROTEIN SCI, V5, P759; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAMATHLOEB AS, 1995, J BIOL CHEM, V270, P30051; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCKAY DB, 1994, BIOL HEAT SHOCK PROT, P153; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Rose MD., 1990, METHODS YEAST GENETI; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WU B, 1994, J BACTERIOL, V176, P6965, DOI 10.1128/JB.176.22.6965-6973.1994; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	33	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11275	11282		10.1074/jbc.274.16.11275	http://dx.doi.org/10.1074/jbc.274.16.11275			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196216	hybrid			2022-12-25	WOS:000079751900084
J	Seyama, K; Osborne, WRA; Ochs, HD				Seyama, K; Osborne, WRA; Ochs, HD			CD40 ligand mutants responsible for X-linked hyper-IgM syndrome associate with wild type CD40 ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; HUMAN FAS LIGAND; CELL-SURFACE; DEFECTIVE EXPRESSION; HETEROMERIC COMPLEX; CRYSTAL-STRUCTURE; SOLUBLE CD40; GENE; RECEPTOR; TNF	CD40 ligand (CD40L) is a 33-kDa type II membrane glycoprotein mainly expressed on activated CD4(+) T cells in trimeric form. When it is mutated, the clinical consequences are X-linked hyper-IgM syndrome (XHIM), a primary immunodeficiency disorder characterized by low levels of IgG, IgA, and elevated or normal levels of IgM. Mutated CD40L can no longer bind CD40 nor provide signals for B cells to proliferate and to switch from IgM to other immunoglobulin isotypes. When considering gene therapy for XHIM, it is important to address the possibility that the mutated CD40L associates with transduced wild type CD40L, and as a consequence, immune reconstitution is not attained. In this study, we demonstrate that the various mutated CD40L species we have identified in patients with XHIM, including both full-length and truncated mutants, associate with wild type CD40L on the cell surface of co-transfected COS cells. The association between wild type and mutated CD40L was also observed in CD4(+) T cell lines established from XHIM patients with leaky splice site mutations. The clinical phenotype of these patients suggests that this association between wild type and mutated CD40L species may result in less efficient cross-linking of CD40.	Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Juntendo Univ, Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo 1130033, Japan	University of Washington; University of Washington Seattle; Juntendo University	Ochs, HD (corresponding author), Univ Washington, Sch Med, Dept Pediat, Box 356320, Seattle, WA 98195 USA.				NIAID NIH HHS [AI40102] Funding Source: Medline; NICHD NIH HHS [HD17427] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017427, R37HD017427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040102] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P9884, DOI 10.1021/bi00031a009; BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P1833, DOI 10.1021/bi00006a003; Bajorath J, 1996, PROTEIN SCI, V5, P531; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BJORCK P, 1994, IMMUNOLOGY, V83, P430; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; Grewal IS, 1996, IMMUNOL TODAY, V17, P410, DOI 10.1016/0167-5699(96)10030-X; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; Schwabe RF, 1997, HYBRIDOMA, V16, P217, DOI 10.1089/hyb.1997.16.217; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Seyama K, 1996, HUM GENET, V97, P180, DOI 10.1007/BF02265262; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; Stout RD, 1996, IMMUNOL TODAY, V17, P487, DOI 10.1016/0167-5699(96)10060-I; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; VILLA A, 1994, P NATL ACAD SCI USA, V91, P2110, DOI 10.1073/pnas.91.6.2110; WAGNER DH, 1994, EUR J IMMUNOL, V24, P3148, DOI 10.1002/eji.1830241235	37	20	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11310	11320		10.1074/jbc.274.16.11310	http://dx.doi.org/10.1074/jbc.274.16.11310			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196221	hybrid			2022-12-25	WOS:000079751900089
J	Bemark, M; Martensson, A; Liberg, D; Leanderson, T				Bemark, M; Martensson, A; Liberg, D; Leanderson, T			Spi-C, a novel Ets protein that is temporally regulated during B lymphocyte development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; CONSERVED SEQUENCE ELEMENTS; TISSUE-SPECIFIC EXPRESSION; T-CELLS; INSITU HYBRIDIZATION; KAPPA-PROMOTERS; CHAIN GENE; BINDING; DOMAIN; DNA	A novel Ets protein was isolated by yeast one-hybrid screening of a cDNA library made from lipopolysaccharide-stimulated mouse splenic B cells, using the SP6 kappa promoter kappa Y element as a bait. The novel Ets protein was most closely related to PU.1 and Spi-B within the DNA binding Ets domain and was therefore named Spi-C. However, Spi-C may represent a novel subgroup within the Ets protein family, as it differed significantly from Spi-B and PU.1 within helix 1 of the Ets domain. Spi-C was encoded by a single-copy gene that was mapped to chromosome 10, region C. Spi-C interacted with DNA similarly to PU.1 as judged by methylation interference, band-shift and site selection analysis, and activated transcription of a kappa Y element reporter gene upon co-transfection of HeLa cells. Spi-C RNA was expressed in mature B lymphocytes and at lower levels in macrophages, Furthermore, pre-B cell and plasma cell lines were Spi-C-negative, suggesting that Spi-C might be a regulatory molecule during a specific phase of B lymphoid development.	Univ Lund, Dept Cell & Mol Biol, Immunol Unit, S-22007 Lund, Sweden	Lund University	Leanderson, T (corresponding author), Univ Lund, Dept Cell & Mol Biol, Immunol Unit, POB 7031, S-22007 Lund, Sweden.		Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819				ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bemark M, 1998, IMMUNOGENETICS, V47, P183, DOI 10.1007/s002510050347; Bemark M, 1997, EUR J IMMUNOL, V27, P1308, DOI 10.1002/eji.1830270603; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Martensson IL, 1997, J EXP MED, V185, P653, DOI 10.1084/jem.185.4.653; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SIGVARDSSON M, 1995, MOL CELL BIOL, V15, P1343; Sigvardsson M, 1996, J IMMUNOL, V156, P3788; SIGVARDSSON M, 1995, EUR J IMMUNOL, V25, P298, DOI 10.1002/eji.1830250150; Singh H, 1996, CURR OPIN IMMUNOL, V8, P160, DOI 10.1016/S0952-7915(96)80053-7; Su GH, 1996, J EXP MED, V184, P203, DOI 10.1084/jem.184.1.203; Su GH, 1997, EMBO J, V16, P7118, DOI 10.1093/emboj/16.23.7118; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	44	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10259	10267		10.1074/jbc.274.15.10259	http://dx.doi.org/10.1074/jbc.274.15.10259			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187812	hybrid			2022-12-25	WOS:000079663500051
J	Craddock, BL; Orchiston, EA; Hinton, HJ; Welham, MJ				Craddock, BL; Orchiston, EA; Hinton, HJ; Welham, MJ			Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; COLORIMETRIC ASSAY; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; GENE-EXPRESSION; SURVIVAL FACTOR	Interleukin-3 (IL-3) acts as both a growth and survival factor for many hemopoietic cells. IL-3 treatment of responsive cells leads to the rapid and transient activation of Class I-A phosphoinositide-3-kinases (PI3Ks) and the serine/threonine kinase Akt/protein kinase B (PKB) and phosphorylation of BAD. Each of these molecules has been implicated in anti-apoptotic signaling in a wide range of cells. Using regulated expression of dominant-negative p85 (Delta p85) in stably transfected IL-3-dependent BaF/3 cells, we have specifically investigated the role of class I-A PI3K in IL-3 signaling. The major functional consequence of Delta p85 expression in these cells is a highly reproducible, dramatic reduction in IL-3-induced proliferation. Expression of Delta p85 reduces IL-3-induced PKB phosphorylation and activation and phosphorylation of BAD dramatically, to levels seen in unstimulated cells. Despite these reductions, the levels of apoptosis observed in the same cells are very low and do not account for the reduction in IL-3-dependent proliferation we observe. These results show that Delta p85 inhibits both PKB activity and BAD phosphorylation without significantly affecting levels of apoptosis, suggesting that there are targets other than PKB and BAD that can transmit survival signals in these cells. Our data indicate that the prime target for PI3K action in IL-3 signaling is at the level of regulation of proliferation.	Univ Bath, Dept Pharmacol, Bath BA2 7AY, Avon, England	University of Bath	Welham, MJ (corresponding author), Univ Bath, Dept Pharmacol, Bath BA2 7AY, Avon, England.	M.J.Welham@bath.ac.uk						Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; delPeso L, 1997, SCIENCE, V278, P687; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1994, TRENDS BIOTECHNOL, V12, P58, DOI 10.1016/0167-7799(94)90101-5; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAM K, 1994, J BIOL CHEM, V269, P20648; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Minshall C, 1996, J IMMUNOL, V156, P939; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; ROCHE H, 1994, ANN ONCOL S8, V5, P91; ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	61	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10633	10640		10.1074/jbc.274.15.10633	http://dx.doi.org/10.1074/jbc.274.15.10633			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187860	hybrid			2022-12-25	WOS:000079663500099
J	Farrar, SJ; Whiting, PJ; Bonnert, TP; McKernan, RM				Farrar, SJ; Whiting, PJ; Bonnert, TP; McKernan, RM			Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT GABA(A) RECEPTOR; A RECEPTOR; ACETYLCHOLINE-RECEPTOR; GAMMA-SUBUNIT; RAT-BRAIN; ACID; EXPRESSION; POPULATIONS; MODULATION; ANTIBODIES	We have developed a method to determine the stoichiometry of subunits within an oligomeric cell surface receptor using fluorescently tagged antibodies to the individual subunits and measuring energy transfer between them. Anti-c-Myc monoclonal antibody (mAb 9-E10) derivatized with a fluorophore (europium cryptate, EuK) was used to individually label c-Myc-tagged alpha(1)-, beta(2)-, or gamma(2)-subunits of the hetero-oligomeric gamma-aminobutyric acid (GABA(A)) receptor in intact cells. The maximal fluorescent signal derived from the alpha(1)(c-Myc)beta(2)gamma(2) and the alpha(1)beta(2)(c-Myc)gamma(2) receptors was twice that obtained with alpha(1)beta(2)gamma(2)(c-Myc), suggesting that there are 2x alpha-, 2x beta-, and 1x gamma-subunits in a receptor monomer, This observation was extended using fluorescence energy transfer. Receptors were half-maximally saturated with EuK-anti-c-Myc mAb, and the remaining alpha(1)(c-Myc) subunits were labeled with excess anti-c-Myc mAb derivatized with the fluorescence energy acceptor, XL665. On exposure to laser light, energy transfer from EuK to XL665 occurred with alpha(1)(c-Myc)beta(2)gamma(2) and alpha(1)beta(2)(c-Myc)gamma(2), but no significant energy transfer was observed with alpha(1)beta(2)gamma(2)(c-Myc) receptors, indicating the absence of a second gamma-subunit in a receptor monomer, We confirm that the GABA, receptor subtype, alpha(1)beta(2)gamma(2), is composed of two copies each of the alpha- and beta-subunits and one copy of the gamma-subunit (i,e, (alpha(1)),(beta(2))(2)(gamma(2))(1)) and conclude that this method would have general applicability to other multisubunit cell surface proteins.	Merck Sharp & Dohme Res Labs, Dept Biochem & Mol Biol, Harlow CM20 2QR, Essex, England	Merck & Company	McKernan, RM (corresponding author), Merck Sharp & Dohme Res Labs, Dept Biochem & Mol Biol, Terlings Pk,Eastwick Rd, Harlow CM20 2QR, Essex, England.			Whiting, Paul/0000-0002-4121-1379				ANGELOTTI TP, 1993, J NEUROSCI, V13, P1429; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; Chang YC, 1996, J NEUROSCI, V16, P5415; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Damjanovich S, 1997, P NATL ACAD SCI USA, V94, P13134, DOI 10.1073/pnas.94.24.13134; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HADINGHAM KL, 1992, P NATL ACAD SCI USA, V89, P6378, DOI 10.1073/pnas.89.14.6378; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; KHAN ZU, 1994, J NEUROCHEM, V63, P1466; LUDDENS H, 1991, J RECEPTOR RES, V11, P523; MAMALAKI C, 1989, J NEUROCHEM, V52, P124, DOI 10.1111/j.1471-4159.1989.tb10906.x; MATHIS G, 1995, CLIN CHEM, V41, P1391; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MERTENS S, 1993, J BIOL CHEM, V268, P5965; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; THOMAS DD, 1978, P NATL ACAD SCI USA, V75, P5746, DOI 10.1073/pnas.75.12.5746; Tretter V, 1997, J NEUROSCI, V17, P2728; WINGROVE PB, 1994, P NATL ACAD SCI USA, V91, P4569, DOI 10.1073/pnas.91.10.4569; Wingrove PB, 1997, MOL PHARMACOL, V52, P874, DOI 10.1124/mol.52.5.874; ZEZULA J, 1991, FEBS LETT, V284, P15, DOI 10.1016/0014-5793(91)80750-W	26	214	221	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10100	10104		10.1074/jbc.274.15.10100	http://dx.doi.org/10.1074/jbc.274.15.10100			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187791	hybrid			2022-12-25	WOS:000079663500030
J	Green, J; Marshall, FA				Green, J; Marshall, FA			Identification of a surface of FNR overlapping activating region 1 that is required for repression of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI FNR; TRANSCRIPTION ACTIVATION; CLASS-I; DEPENDENT PROMOTERS; PROTEIN; CONTACT; SITE	A library of Escherichia coli fnr mutants has been screened to identify FNR (regulator of fumarate and nitrate reduction) variants that are defective repressors, but competent activators. All but one of seventeen variants had substitutions close to or within the face of FNR that contains activating region 1 (AR1). Activating region 1 is known to contact the alpha subunit of RNA polymerase to facilitate transcription activation. It is now evident that this face also has a role in FNR-mediated repression. Single amino acid substitutions at Lys(54), Gly(74), Ala(95), Met(147), Leu(193), Arg(197), or Leu(239), and double substitutions at Ser(13) and Ser(145), Cys(16) and Ile(45), Tyr(69) and Ser(133), or Lys(164) and Phe(191), impaired FNR-mediated repression of ndh without greatly affecting activation from model Class I (FNR site at -71.5) and Class II (FNR site at -41.5) FNR-activated promoters. Although repression was impaired in a second group of FNR variants with substitutions at Leu(34), Arg(7) and Leul(193), Phe(92), or Ser(178), transcription activation from the simple FNR-dependent promoters was severely reduced. However, expression from pyfiD (FNR sites at -40.5 and -93.5) and a derivative lacking the site at -93.5, pyfiD-/+, remained relatively high indicating that this second group have a context-dependent activation defect as well as a repression defect. The prediction that the substitutions affecting repression were likely to be in solvent exposed regions of FNR was supported by analysis of peptides produced by partial proteolysis of FNR. Thus, FNR-mediated repression at promoters with multiple FNR sites requires regions of FNR that are different from, but overlap, AR1.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Green, J (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.							BELL A, 1994, MOL MICROBIOL, V11, P383, DOI 10.1111/j.1365-2958.1994.tb00318.x; CHOY H, 1996, ESCHERICHIA COLI SAL; COLE ST, 1980, MOL GEN GENET, V178, P409, DOI 10.1007/BF00270492; Green J, 1998, MOL MICROBIOL, V29, P1113, DOI 10.1046/j.1365-2958.1998.01002.x; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; GREEN J, 1994, MOL MICROBIOL, V12, P433, DOI 10.1111/j.1365-2958.1994.tb01032.x; Green J, 1996, MOL MICROBIOL, V19, P125, DOI 10.1046/j.1365-2958.1996.353884.x; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; Guest John R., 1996, P317; Meng WM, 1997, MICROBIOL-SGM, V143, P1521, DOI 10.1099/00221287-143-5-1521; Miller JH., 1972, EXPT MOL GENETICS; Ralph ET, 1998, P NATL ACAD SCI USA, V95, P10449, DOI 10.1073/pnas.95.18.10449; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; Savery N, 1996, PHILOS T ROY SOC B, V351, P543, DOI 10.1098/rstb.1996.0053; SHARROCKS AD, 1991, P ROY SOC B-BIOL SCI, V245, P219, DOI 10.1098/rspb.1991.0113; SPIRO S, 1987, J GEN MICROBIOL, V133, P3279; TAKAHASHI K, 1994, FEBS LETT, V340, P59, DOI 10.1016/0014-5793(94)80173-8; Tran QH, 1997, EUR J BIOCHEM, V244, P155, DOI 10.1111/j.1432-1033.1997.00155.x; Williams SM, 1997, NUCLEIC ACIDS RES, V25, P4028, DOI 10.1093/nar/25.20.4028; Williams SM, 1998, FEMS MICROBIOL LETT, V163, P203, DOI 10.1111/j.1574-6968.1998.tb13046.x; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995; ZHOU YH, 1994, J MOL BIOL, V243, P603, DOI 10.1016/0022-2836(94)90035-3	22	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10244	10248		10.1074/jbc.274.15.10244	http://dx.doi.org/10.1074/jbc.274.15.10244			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187810	hybrid			2022-12-25	WOS:000079663500049
J	Kim, CY; Takahashi, K; Nguyen, TB; Roberts, JKM; Webster, C				Kim, CY; Takahashi, K; Nguyen, TB; Roberts, JKM; Webster, C			Identification of a nucleic acid binding domain in eukaryotic initiation factor eIFiso4G from wheat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; FACTOR 4G EIF4G; MESSENGER-RNA; ISOZYME FORM; 7-METHYLGUANOSINE 5'-TRIPHOSPHATE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL DOMAINS; ELONGATION-FACTORS; FACTOR EIF-4-GAMMA; FACTOR EIF-4E	Higher plants have two complexes that bind the m (7)G-cap structure of mRNA and mediate interactions between mRNA and ribosomal subunits, designated eIF4F and eIFiso4F. Both complexes contain a small subunit that binds the 5'-cap structure of mRNA, and a large subunit, eIF4G or eIFiso4G, that binds other translation factors and RNA. Sequence-specific proteases were used to cleave native cap-binding complexes into structural domains, which were purified by affinity chromatography. We show here that eIFiso4G contains a central protease-resistant domain that binds specifically to nucleic acids. This domain spans Gln(170) to Glu(443) and includes four of the six homology blocks shared by eIFiso4G and eIF4G. A slightly shorter overlapping sequence, from Gly(202) to Lys(445), had no nucleic acid binding activity, indicating that the N-terminal end of the nucleic acid binding site lies within Gln(170) to Arg(201). The binding of the central domain and native eIFiso4F to RNA homopolymers and double- and single-stranded DNAs was studied. Both molecules had highest affinity for poly(G) and recognized single- and double-stranded sequences.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Webster, C (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.			Kim, Chang-Yub/0000-0001-9353-5909				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOKROS CL, 1995, P NATL ACAD SCI USA, V92, P7120, DOI 10.1073/pnas.92.15.7120; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; Browning KS, 1996, PLANT MOL BIOL, V32, P107, DOI 10.1007/BF00039380; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHAVAN AJ, 1990, BIOCHEMISTRY-US, V29, P5521, DOI 10.1021/bi00475a016; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GEISLER N, 1977, BIOCHEMISTRY-US, V16, P938, DOI 10.1021/bi00624a020; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; HERSHEY JWB, 1994, BIOCHIMIE, V76, P845; HUDGAHL JD, 1995, PLANT CELL, V7, P2129; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LANG V, 1994, J BIOL CHEM, V269, P6117; LAX S, 1985, P NATL ACAD SCI USA, V82, P330, DOI 10.1073/pnas.82.2.330; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; LOOMIS W.D., 1969, METHOD ENZYMOL, V13, P555; MADER S, 1995, MOL CELL BIOL, V15, P4990; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Metz AM, 1996, J BIOL CHEM, V271, P31033, DOI 10.1074/jbc.271.49.31033; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; SHA M, 1995, J BIOL CHEM, V270, P29904; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; YAN RQ, 1992, J BIOL CHEM, V267, P23226	38	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10603	10608		10.1074/jbc.274.15.10603	http://dx.doi.org/10.1074/jbc.274.15.10603			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187856	hybrid			2022-12-25	WOS:000079663500095
J	Mirochnitchenko, O; Weisbrot-Lefkowitz, M; Reuhl, K; Chen, LS; Yang, C; Inouye, M				Mirochnitchenko, O; Weisbrot-Lefkowitz, M; Reuhl, K; Chen, LS; Yang, C; Inouye, M			Acetaminophen toxicity - Opposite effects of two forms of glutathione peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; INDUCED HEPATOTOXICITY; LIPID-PEROXIDATION; BENZOQUINONE IMINE; TRANSGENIC MICE; RAT-LIVER; PARACETAMOL; MECHANISM; CATALASE	Acetaminophen is one of the most extensively used analgesics/antipyretics worldwide, and overdose or idiopathic reaction causes major morbidity and mortality in its victims. Research into the mechanisms of toxicity and possible therapeutic intervention is therefore essential. In this study, the response of transgenic mice overexpressing human antioxidant enzymes to acute acetaminophen overdose was investigated. Animals overexpressing superoxide dismutase or plasma glutathione peroxidase demonstrated dramatic resistance to acetaminophen toxicity. Intravenous injection of glutathione peroxidase provided normal mice with nearly complete protection against a lethal dose of acetaminophen. Surprisingly, animals overexpressing intracellular glutathione peroxidase in the liver were significantly more sensitive to acetaminophen toxicity compared with nontransgenic littermates. This sensitivity appears to be due to the inability of these animals to efficiently recover glutathione depleted as a result of acetaminophen metabolism. Finally, the results suggest that glutathione peroxidase overexpression modulates the synthesis of several acetaminophen metabolites. Our results demonstrate the ability of glutathione peroxidase levels to influence the outcome of acetaminophen toxicity.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Coll Pharm, Neurotoxicol Labs, Piscataway, NJ 08854 USA; Rutgers State Univ, Coll Pharm, Canc Res Lab, Dept Biol Chem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouye@rwja.umdnj.edu						AMIMOTO T, 1995, FREE RADICAL BIO MED, V19, P169, DOI 10.1016/0891-5849(94)00233-A; ARNAIZ SL, 1995, FREE RADICAL BIO MED, V19, P303, DOI 10.1016/0891-5849(95)00023-Q; BARANOWITZ SA, 1994, INT J VITAM NUTR RES, V65, P1175; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Gibson JD, 1996, CHEM RES TOXICOL, V9, P580, DOI 10.1021/tx950153d; Goldin RD, 1996, J PATHOL, V179, P432; JOLLOW DJ, 1974, PHARMACOLOGY, V12, P251, DOI 10.1159/000136547; KELLER RJ, 1991, DRUG METAB DISPOS, V19, P184; KYLE ME, 1987, BIOCHEM BIOPH RES CO, V149, P889, DOI 10.1016/0006-291X(87)90491-8; Lin M C, 1996, J Biochem Toxicol, V11, P11, DOI 10.1002/(SICI)1522-7146(1996)11:1<11::AID-JBT2>3.0.CO;2-Y; MASON RP, 1986, FED PROC, V45, P2493; MASUGI F, 1976, INT J VITAM NUTR RES, V46, P187; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Mirochnitchenko O, 1996, J IMMUNOL, V156, P1578; MIROCHNITCHENKO O, 1995, P NATL ACAD SCI USA, V92, P8120, DOI 10.1073/pnas.92.18.8120; MOHANDAS J, 1981, TOXICOL APPL PHARM, V61, P252, DOI 10.1016/0041-008X(81)90415-4; NAKAE D, 1990, AM J PATHOL, V136, P787; NAKAMURA M, 1989, J BIOL CHEM, V264, P12909; Nakatani T, 1997, EXP CELL RES, V236, P137, DOI 10.1006/excr.1997.3715; OZDEMIRLER G, 1994, J APPL TOXICOL, V14, P297, DOI 10.1002/jat.2550140410; Pirmohamed M, 1996, CLIN PHARMACOKINET, V31, P215, DOI 10.2165/00003088-199631030-00005; POTTER DW, 1987, J BIOL CHEM, V262, P966; RAVINDRANATH V, 1994, METHOD ENZYMOL, V233, P610; ROSEN GM, 1984, MOL PHARMACOL, V25, P151; SCHMITT K, 1990, PHOTOCHEM PHOTOBIOL, V51, P719, DOI 10.1111/php.1990.51.6.719; Smith CV, 1996, TOXICOL APPL PHARM, V140, P1, DOI 10.1006/taap.1996.0191; THOMAS SHL, 1993, PHARMACOL THERAPEUT, V60, P91, DOI 10.1016/0163-7258(93)90023-7; TOUSSAINT O, 1993, TOXICOLOGY, V81, P89, DOI 10.1016/0300-483X(93)90001-9; VENDEMIALE G, 1995, HEPATOLOGY, V21, P1450, DOI 10.1002/hep.1840210532; VERMEULEN NPE, 1992, DRUG METAB REV, V24, P367, DOI 10.3109/03602539208996298; Yagi K, 1996, BIOCHEM BIOPH RES CO, V219, P486, DOI 10.1006/bbrc.1996.0260	31	92	100	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10349	10355		10.1074/jbc.274.15.10349	http://dx.doi.org/10.1074/jbc.274.15.10349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187823	hybrid			2022-12-25	WOS:000079663500062
J	Lambert, H; Charette, SJ; Bernier, AF; Guimond, A; Landry, J				Lambert, H; Charette, SJ; Bernier, AF; Guimond, A; Landry, J			HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-A-CRYSTALLIN; P38 MAP KINASE; B-CRYSTALLIN; CELL-DEATH; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; ACTIN POLYMERIZATION; H-1-NMR SPECTROSCOPY; QUATERNARY STRUCTURE	Distinct biochemical activities have been reported for small and large molecular complexes of heat shock protein 27 (HSP27), respectively. Using glycerol gradient ultracentrifugation and chemical cross-linking, we show here that Chinese hamster HSP27 is expressed in cells as homotypic multimers ranging from dimers up to 700-kDa oligomers. Treatments with arsenite, which induces phosphorylation on Ser(15) and Ser(90) provoked a major change in the size distribution of the complexes that shifted from oligomers to dimers, Ser(90) phosphorylation was sufficient and necessary for causing this change in structure. Dimer formation was severely inhibited by replacing Ser(90) with Ala(90) but not by replacing Ser(15) with Ala(15). Using the yeast two-hybrid system, two domains were identified that were responsible for HSP27 intermolecular interactions. One domain was insensitive to phosphorylation and corresponded to the C-terminal alpha-crystallin domain. The other domain was sensitive to serine 90 phosphorylation and was located in the N-terminal region of the protein. Fusion of this N-terminal domain to firefly luciferase conferred luciferase with the capacity to form multimers that dissociated into monomers upon phosphorylation. A deletion within this domain of residues Arg(5)-Tyr(23), which contains a WDPF motif found in most proteins of the small heat shock protein family, yielded a protein that forms only phosphorylation-insensitive dimers. We propose that HSP27 forms stable dimers through the alpha-crystallin domain. These dimers further multimerize through intermolecular interactions mediated by the phosphorylation-sensitive N-terminal domain.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Landry, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 11 Cote du Palais, Quebec City, PQ G1R 2J6, Canada.		Charette, Steve/GYJ-3058-2022					ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Beresford PJ, 1998, J IMMUNOL, V161, P161; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; CARVER JA, 1992, FEBS LETT, V311, P143, DOI 10.1016/0014-5793(92)81386-Z; CARVER JA, 1995, FEBS LETT, V369, P305, DOI 10.1016/0014-5793(95)00770-A; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; Chaufour S, 1996, CELL STRESS CHAPERON, V1, P225, DOI 10.1379/1466-1268(1996)001<0225:TAPACI>2.3.CO;2; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUDICH IV, 1995, BBA-PROTEIN STRUCT M, V1253, P163, DOI 10.1016/0167-4838(95)00135-X; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; EHRNSPERGER M, 1998, MOL CHAPERONES LIFE, P533; Farnsworth PN, 1998, INT J BIOL MACROMOL, V22, P175, DOI 10.1016/S0141-8130(98)00015-4; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Garrido C, 1997, CANCER RES, V57, P2661; Guay J, 1997, J CELL SCI, V110, P357; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Harrison CJ, 1997, STRUCTURE, V5, P1261, DOI 10.1016/S0969-2126(97)00277-3; HICKEY E, 1986, GENE, V43, P147, DOI 10.1016/0378-1119(86)90018-1; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Horovitz A, 1998, CURR OPIN STRUC BIOL, V8, P93, DOI 10.1016/S0959-440X(98)80015-8; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; LANDRY J, 1992, J BIOL CHEM, V267, P794; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, MOL BIOL REP, V18, P209, DOI 10.1007/BF01674432; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; Piotrowicz RS, 1997, J BIOL CHEM, V272, P25920, DOI 10.1074/jbc.272.41.25920; PIOTROWICZ RS, 1995, FASEB J, V9, P1079, DOI 10.1096/fasebj.9.11.7649407; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Suzuki A, 1998, J CELL BIOL, V140, P1113, DOI 10.1083/jcb.140.5.1113; vandenIjssel PRLA, 1996, OPHTHALMIC RES, V28, P39, DOI 10.1159/000267941; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; ZANTEMA A, 1992, J BIOL CHEM, V267, P12936; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	68	275	285	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9378	9385		10.1074/jbc.274.14.9378	http://dx.doi.org/10.1074/jbc.274.14.9378			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092617	hybrid			2022-12-25	WOS:000079451800036
J	Motoike, HK; Bodi, I; Nakayama, H; Schwartz, A; Varadi, G				Motoike, HK; Bodi, I; Nakayama, H; Schwartz, A; Varadi, G			A region in IVS5 of the human cardiac L-type calcium channel is required for the use-dependent block by phenylalkylamines and benzothiazepines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MOLECULAR DETERMINANTS; CA2+ CHANNEL; ALPHA(1) SUBUNIT; 1,4-DIHYDROPYRIDINE SENSITIVITY; SODIUM-CHANNELS; DIHYDROPYRIDINE BINDING; RECEPTOR-SITE; INACTIVATION; SEGMENT	Mutations in motif IVS5 and IVS6 of the human cardiac calcium channel were made using homologous residues from the rat brain sodium channel 2a, [H-3]PN200-110 and allosteric binding assays revealed that the dihydropyridine and benzothiazepine receptor sites maintained normal coupling in the chimeric mutant channels. Whole cell voltage clamp recording from Xenopus oocytes showed a dramatically slowed inactivation and a complete loss of use-dependent block for mutations in the cytoplasmic connecting link to IVS5 (HHT-5371) and in IVS5 transmembrane segment (HHT-5411) with both diltiazem and verapamil, However, the use-dependent block by isradipine was retained by these two mutants. For mutants HHT-5411 and HHT-5371, the residual current appeared associated with a loss of voltage dependence in the rate of inactivation indicating a destabilization of the inactivated state. Furthermore, both HHT-5371 and -5411 recovered from inactivation significantly faster after drug block than that of the wild type channel. Our data demonstrate that accelerated recovery of HHT-5371 and HHT-5411 decreased accumulation of these channels in inactivation during pulse trains and suggest a close link between inactivation gating of the channel and use-dependent block by phenylalkylamines and benzothiazepines and provide evidence of a role for the transmembrane and cytoplasmic regions of IVS5 in the use-dependent block by diltiazem and verapamil.	Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA; Kumamoto Univ, Fac Pharmaceut Sci, Kumamoto 862, Japan	University of Cincinnati; Kumamoto University	Varadi, G (corresponding author), Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, 231 Bethesda Ave,POB 670828, Cincinnati, OH 45267 USA.	varadig@email.uc.edu			NHLBI NIH HHS [5R37-HL43231, P01-HL22619, T32-HL07382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, T32HL007382, R37HL043231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cai DM, 1997, MOL PHARMACOL, V51, P872, DOI 10.1124/mol.51.5.872; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; Doring F, 1996, J BIOL CHEM, V271, P11745, DOI 10.1074/jbc.271.20.11745; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Grabner M, 1996, NEURON, V16, P207, DOI 10.1016/S0896-6273(00)80037-9; He M, 1997, J BIOL CHEM, V272, P2629, DOI 10.1074/jbc.272.5.2629; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Hockerman GH, 1997, P NATL ACAD SCI USA, V94, P14906, DOI 10.1073/pnas.94.26.14906; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Johnson BD, 1996, MOL PHARMACOL, V50, P1388; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Kraus R, 1996, J BIOL CHEM, V271, P20113, DOI 10.1074/jbc.271.33.20113; Kraus RL, 1998, J BIOL CHEM, V273, P27205, DOI 10.1074/jbc.273.42.27205; Mikala G, 1998, MOL CELL BIOCHEM, V185, P95, DOI 10.1023/A:1006878106672; Mitterdorfer J, 1996, J BIOL CHEM, V271, P30330, DOI 10.1074/jbc.271.48.30330; Mitterdorfer J, 1998, J BIOENERG BIOMEMBR, V30, P319, DOI 10.1023/A:1021933504909; MIYAZAKI J, 1989, GENE, V79, P269; Mori Y, 1996, JPN J PHARMACOL, V72, P83, DOI 10.1254/jjp.72.83; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; Peterson BZ, 1997, J BIOL CHEM, V272, P18752, DOI 10.1074/jbc.272.30.18752; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; SANGUINETTI MC, 1984, CIRC RES, V55, P336, DOI 10.1161/01.RES.55.3.336; Schuster A, 1996, EMBO J, V15, P2365, DOI 10.1002/j.1460-2075.1996.tb00592.x; Sinnegger MJ, 1997, J BIOL CHEM, V272, P27686, DOI 10.1074/jbc.272.44.27686; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; STARMER CF, 1984, BIOPHYS J, V46, P15, DOI 10.1016/S0006-3495(84)83994-6; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1994, J BIOL CHEM, V269, P1635; YATANI A, 1988, AM J PHYSIOL, V254, pH140, DOI 10.1152/ajpheart.1988.254.1.H140; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	40	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9409	9420		10.1074/jbc.274.14.9409	http://dx.doi.org/10.1074/jbc.274.14.9409			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092621	hybrid			2022-12-25	WOS:000079451800040
J	Steinert, PM; Chou, YH; Prahlad, V; Parry, DAD; Marekov, LN; Wu, KC; Jang, SI; Goldman, RD				Steinert, PM; Chou, YH; Prahlad, V; Parry, DAD; Marekov, LN; Wu, KC; Jang, SI; Goldman, RD			A high molecular weight intermediate filament-associated protein in BHK-21 cells is nestin, a type VI intermediate filament protein - Limited co-assembly in vitro to form heteropolymers with type III vimentin and type IV alpha-internexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL; NF-L; END DOMAINS; ROD DOMAIN; IN-VIVO; INVITRO; EXPRESSION; MOUSE; RAT; GENE	BHK-21 fibroblasts contain type III vimentin/desmin intermediate filament (IF) proteins that typically coisolate and co-cycle in in vitro experiments with certain high molecular weight proteins. Here, we report purification of one of these and demonstrate that it is in fact the type VI IF protein nestin, Nestin is expressed in several fibroblastic but not epithelioid cell lines. We show that nestin forms homodimers and homotetramers but does not form IF by itself in vitro, In mixtures, nestin preferentially co-assembles with purified vimentin or the type IV IF protein alpha-internexin to form heterodimer coiled-coil molecules. These molecules may co-assemble into 10 nm IF provided that the total amount of nestin does not exceed about 25%. However, nestin does not dimerize with types I/II keratin IF chains. The bulk of the nestin protein consists of a long carboxyl-terminal tail composed of various highly charged peptide repeats. By analogy with the larger neurofilament chains, we postulate that these sequences serve as cross-bridgers or spacers between IF and/or other cytoskeletal constituents. In this way, we propose that direct incorporation of modest amounts of nestin into the backbone of cytoplasmic types III and IV Ifs affords a simple yet flexible method for the regulation of their dynamic supramolecular organization and function in cells.	NIAMSD, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Northwestern University; Massey University	Steinert, PM (corresponding author), NIAMSD, Skin Biol Lab, NIH, Bldg 6,Rm 425,9000 Rockville Pike, Bethesda, MD 20892 USA.	pemast@helix.nih.gov		Prahlad, Veena/0000-0002-0413-6074	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036806, R01GM036806] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36806-4] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], [No title captured]; Athlan ES, 1997, J NEUROSCI RES, V47, P300; Athlan ES, 1997, J BIOL CHEM, V272, P31073, DOI 10.1074/jbc.272.49.31073; Ausubel FM, 1991, CURRENT PROTOCOLS MO; AYNARDI MW, 1984, J CELL BIOL, V98, P1407, DOI 10.1083/jcb.98.4.1407; BECKER B, 1995, BIOCHEM BIOPH RES CO, V213, P796, DOI 10.1006/bbrc.1995.2200; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; Carpenter DA, 1996, J CELL SCI, V109, P2493; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUI FC, 1989, NEURON, V2, P1435; COHLBERG JA, 1995, J BIOL CHEM, V270, P9334, DOI 10.1074/jbc.270.16.9334; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; FLIEGNER KH, 1994, J COMP NEUROL, V342, P161, DOI 10.1002/cne.903420202; Frojdman K, 1997, DIFFERENTIATION, V61, P243, DOI 10.1046/j.1432-0436.1997.6140243.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDMAN RD, 1971, J CELL BIOL, V51, P752, DOI 10.1083/jcb.51.3.752; Goldman RD, 1996, J CELL BIOL, V134, P971, DOI 10.1083/jcb.134.4.971; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; Hemken PM, 1997, J BIOL CHEM, V272, P32489, DOI 10.1074/jbc.272.51.32489; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1988, J MOL BIOL, V202, P297, DOI 10.1016/0022-2836(88)90459-7; HOULE J, 1983, DEV BRAIN RES, V9, P189, DOI 10.1016/0165-3806(83)90051-2; IP W, 1985, J MOL BIOL, V183, P365, DOI 10.1016/0022-2836(85)90007-5; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JH, 1996, J BIOL CHEM, V271, P4561; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LIESKA N, 1985, J CELL BIOL, V101, P802, DOI 10.1083/jcb.101.3.802; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; MACK JW, 1993, J MOL BIOL, V232, P50, DOI 10.1006/jmbi.1993.1369; Meng JJ, 1997, J BIOL CHEM, V272, P21495, DOI 10.1074/jbc.272.34.21495; PACHTER JS, 1985, J CELL BIOL, V101, P1316, DOI 10.1083/jcb.101.4.1316; PARRY DAD, 1975, J MOL BIOL, V98, P519, DOI 10.1016/S0022-2836(75)80084-2; PARRY DAD, 1995, INTERMEDIATE FILAMEN; PARYSEK LM, 1987, J NEUROSCI, V7, P781; PARYSEK LM, 1991, J NEUROSCI RES, V30, P80, DOI 10.1002/jnr.490300110; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; STEINERT PM, 1978, J MOL BIOL, V123, P49, DOI 10.1016/0022-2836(78)90376-5; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1980, P NATL ACAD SCI-BIOL, V77, P4534, DOI 10.1073/pnas.77.8.4534; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; Steinert PM, 1999, J BIOL CHEM, V274, P1657, DOI 10.1074/jbc.274.3.1657; STEINERT PM, 1978, P NATL ACAD SCI USA, V75, P6098, DOI 10.1073/pnas.75.12.6098; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; TANAKA T, 1991, J BIOL CHEM, V266, P12555; TAPSCOTT SJ, 1981, DEV BIOL, V86, P40, DOI 10.1016/0012-1606(81)90313-4; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; Terling C, 1995, INT J DEV BIOL, V39, P947; VANDENHEUVEL RMM, 1987, J CELL SCI, V88, P475; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; Wroblewski J, 1997, DIFFERENTIATION, V61, P151, DOI 10.1046/j.1432-0436.1997.6130151.x; YANG HY, 1992, CELL MOTIL CYTOSKEL, V22, P185, DOI 10.1002/cm.970220306; YANG HY, 1985, J CELL BIOL, V100, P620, DOI 10.1083/jcb.100.2.620; YUSPA SH, 1974, EXP CELL RES, V86, P95, DOI 10.1016/0014-4827(74)90653-3	70	150	160	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9881	9890		10.1074/jbc.274.14.9881	http://dx.doi.org/10.1074/jbc.274.14.9881			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092680	hybrid			2022-12-25	WOS:000079451800099
J	Hoenderop, JGJ; van der Kemp, AWCM; Hartog, A; van de Graaf, SFJ; van Os, CH; Willems, PHGM; Bindels, RJM				Hoenderop, JGJ; van der Kemp, AWCM; Hartog, A; van de Graaf, SFJ; van Os, CH; Willems, PHGM; Bindels, RJM			Molecular identification of the apical Ca2+ channel in 1,25-dihydroxyvitamin D-3-responsive epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR CALCIUM-TRANSPORT; RECEPTOR; GENE; MUTATIONS; PROTEINS; RICKETS; KIDNEY; SODIUM; CELLS	In mammals, the extracellular calcium concentration is maintained within a narrow range despite large variations in daily dietary input and body demand. The small intestine and kidney constitute the influx pathways into the extracellular Ca2+ pool and, therefore, play a primary role in Ca2+ homeostasis, We identified an apical Ca2+ influx channel, which is expressed in proximal small intestine, the distal part of the nephron and placenta. This novel epithelial Ca2+ channel (ECaC) of 730 amino acids contains six putative membrane-spanning domains with an additional hydrophobic stretch predicted to be the pore region. ECaC resembles the recently cloned capsaicin receptor and the transient receptor potential-related ion channels with respect to its predicted topology but shares less than 30% sequence homology with these channels. In kidney, ECaC is abundantly present in the apical membrane of Ca2+ transporting cells and colocalizes with 1,25-dihydroxyvitamin D-3-dependent calbindin-D-28K. ECaC expression in Xenopus oocytes confers Ca2+ influx with properties identical to those observed in distal renal cells. Thus, ECaC has the expected properties for being the gatekeeper of 1,25-dihydroxyvitamin D-3-dependent active transepithelial Ca2+ transport.	Catholic Univ Nijmegen, Dept Cell Physiol, Inst Cellular Signaling, NL-6500 HB Nijmegen, Netherlands; Catholic Univ Nijmegen, Dept Biochem, Inst Cellular Signaling, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Bindels, RJM (corresponding author), Catholic Univ Nijmegen, Dept Cell Physiol, Inst Cellular Signaling, POB 9101, NL-6500 HB Nijmegen, Netherlands.	reneb@sci.kun.nl	Willems, P.H.G.M./L-4759-2015; Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Willems, P.H.G.M./0000-0002-0915-1599; Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544; van de Graaf, Stan/0000-0003-4238-4359				BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; BINDELS RJM, 1991, J AM SOC NEPHROL, V2, P1122; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Colbert HA, 1997, J NEUROSCI, V17, P8259; Favus MJ, 1996, KIDNEY, V2, P1893; FRIEDMAN PA, 1995, PHYSIOL REV, V75, P429, DOI 10.1152/physrev.1995.75.3.429; GROSS M, 1990, AM J PHYSIOL, V259, pF195, DOI 10.1152/ajprenal.1990.259.2.F195; HAGIWARA S, 1982, J PHYSIOL-LONDON, V331, P231, DOI 10.1113/jphysiol.1982.sp014371; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Kitanaka S, 1998, NEW ENGL J MED, V338, P653, DOI 10.1056/NEJM199803053381004; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; POLLAK MR, 1993, CELL, V75, P1237; Raber G, 1997, CELL CALCIUM, V22, P157, DOI 10.1016/S0143-4160(97)90009-9; SUKI WN, 1996, KIDNEY, V1, P472; SUTTON RAL, 1979, KIDNEY INT, V15, P520, DOI 10.1038/ki.1979.67; VANOS CH, 1987, BIOCHIM BIOPHYS ACTA, V906, P195, DOI 10.1016/0304-4157(87)90012-8; WASSERMAN RH, 1982, CALCIUM CELL FUNCTIO, V2, P175; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	22	445	477	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8375	8378		10.1074/jbc.274.13.8375	http://dx.doi.org/10.1074/jbc.274.13.8375			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085067	hybrid, Green Published			2022-12-25	WOS:000079451600009
J	Otto, JC; Kim, E; Young, SG; Casey, PJ				Otto, JC; Kim, E; Young, SG; Casey, PJ			Cloning and characterization of a mammalian prenyl protein-specific protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-FACTOR; PARTIAL-PURIFICATION; IN-VITRO; SACCHAROMYCES-CEREVISIAE; ISOPRENYLATED PEPTIDES; BOVINE BRAIN; RAS; ENDOPROTEASE; PROTEOLYSIS; METHYLATION	Proteins containing C-terminal "CAAX" sequence motifs undergo three sequential post-translational processing steps: modification of the cysteine with either a 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenyl lipid, proteolysis of the C-terminal. -AAX tripeptide, and methylation of the carboxyl group of the now C-terminal prenylcysteine. A putative prenyl protein protease in yeast, designated Rce1p, was recently identified. In this study, a portion of a putative human homologue of RCE1 (hRCE1) was identified in a human expressed sequence tag data base, and the corresponding cDNA was cloned, Expression of hRCE1 was detected in all tissues examined. Both yeast and human RCE1 proteins were produced in Sf9 insect cells by infection with a recombinant baculovirus; membrane preparations derived from the infected Sf9 cells exhibited a high level of prenyl protease activity. Recombinant hRCE1 so produced recognized both farnesylated and geranylgeranylated proteins as substrates, including farnesyl-Ki-Ras, farnesyl-N-Ras, farnesyl-Ha-Ras, and the farnesylated heterotrimeric G protein G(gamma 1) subunit, as well, as geranylgeranyl Ki-Ras and geranylgeranyl-Rap1b. The protease activity of hRCE1 activity was specific for prenylated proteins, because unprenylated peptides did not compete for enzyme activity. hRCE1 activity was also exquisitely sensitive to a prenyl peptide analogue that had been previously described as a potent inhibitor of the prenyl protease activity in mammalian tissues. These data indicate that both the yeast and the human RCE1 gene products are bona fide prenyl protein proteases and suggest that they play a major role in the processing of CAAX-type prenylated proteins.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	Duke University; Duke University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	casey006@mc.duke.edu		Casey, Patrick/0000-0002-7366-9309; Young, Stephen/0000-0001-7270-3176	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOPYAN TN, 1994, BIOCHEM BIOPH RES CO, V198, P787, DOI 10.1006/bbrc.1994.1113; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; ASHBY MN, 1992, P NATL ACAD SCI USA, V89, P4613, DOI 10.1073/pnas.89.10.4613; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; Hitz AM, 1996, FEBS LETT, V391, P310, DOI 10.1016/0014-5793(96)00766-1; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jang GF, 1998, BIOCHEMISTRY-US, V37, P4473, DOI 10.1021/bi972289b; JANG GF, 1993, BIOCHEMISTRY-US, V32, P9500, DOI 10.1021/bi00087a031; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; MA YT, 1993, BIOCHEMISTRY-US, V32, P2386, DOI 10.1021/bi00060a033; MA YT, 1992, P NATL ACAD SCI USA, V89, P6275, DOI 10.1073/pnas.89.14.6275; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; Nishii W, 1997, J BIOCHEM-TOKYO, V122, P402; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Thissen JA, 1996, ANAL BIOCHEM, V243, P80, DOI 10.1006/abio.1996.0484; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	36	139	146	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8379	8382		10.1074/jbc.274.13.8379	http://dx.doi.org/10.1074/jbc.274.13.8379			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085068	hybrid			2022-12-25	WOS:000079451600010
J	Yarwood, SJ; Sale, EM; Sale, GJ; Houslay, MD; Kilgour, E; Anderson, NG				Yarwood, SJ; Sale, EM; Sale, GJ; Houslay, MD; Kilgour, E; Anderson, NG			Growth hormone-dependent differentiation of 3T3-F442A preadipocytes requires Janus kinase signal transducer and activator of transcription but not mitogen-activated protein kinase or p70 S6 kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ADIPOCYTE DIFFERENTIATION; ADIPOSE CONVERSION; GENE-EXPRESSION; 3T3-L1 CELLS; MAP KINASE; FACTOR-I; INSULIN; RECEPTOR; JAK2	The signals mediating growth hormone (GH)-dependent differentiation of 3T3-F442A preadipocytes under serum-free conditions have been studied. GH priming of cells was required before the induction of terminal differentiation by a combination of epidermal growth factor, tri-iodothyronine, and insulin. Cellular depletion of Janus kinase-2 (JAK-2) using antisense oligodeoxynucleotides (ODNs) prevented GH-stimulated JAK-2 and signal transducer and activator of transcription (STAT)-5 tyrosine phosphorylation and severely attenuated the ability of GH to promote differentiation. Although p42(MAPK)/p44(MAPK) mitogen-activated protein kinases were activated during GH priming, treatment of cells with PD 098059, which prevented activation of these kinases, did not block GH priming. However, antisense ODN-mediated depletion of mitogen-activated protein kinases from the cells showed that their expression was necessary for terminal differentiation. Similarly, although p70(s6k) was activated during GH priming, pretreatment of cells with rapamycin, which prevented the activation of p70(s6k), had no effect on GH priming. However, rapamycin did partially block epidermal growth factor, tri-iodothyronine, and insulin-stimulated terminal differentiation. By contrast, cellular depletion of STAT-B with antisense ODNs completely abolished the ability of GH to promote differentiation. These results indicate that JAK-2, acting specifically via STAT-5, is necessary for GH-dependent differentiation of 3T3-F442A preadipocytes. Activation of p42(MAPK)/p44(MAPK) and p70(s6k) is not essential for the promotion of differentiation by GH, although these signals are required for GH-independent terminal differentiation.	Univ Manchester, Sch Biol Sci, Dept Surg, Manchester M13 9PT, Lancs, England; Univ Glasgow, Inst Biol & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Southampton, Dept Biochem, Southampton SO16 7PX, Hants, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	University of Manchester; University of Glasgow; University of Southampton	Anderson, NG (corresponding author), Univ Manchester, Sch Biol Sci, Dept Surg, Rm G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Yarwood, Stephen/0000-0001-9489-9253; Houslay, Miles/0000-0002-3826-8091				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; FLINT DJ, 1993, J ENDOCRINOL, V137, P203, DOI 10.1677/joe.0.1370203; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; KILGOUR E, 1994, FEBS LETT, V343, P205, DOI 10.1016/0014-5793(94)80556-3; KILGOUR E, 1993, FEBS LETT, V328, P271, DOI 10.1016/0014-5793(93)80942-N; LAI E, 1981, J BIOL CHEM, V256, P2866; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MADON RJ, 1986, J ENDOCRINOL, V111, P117, DOI 10.1677/joe.0.1110117; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MORIKAWA M, 1986, J CELL PHYSIOL, V128, P293, DOI 10.1002/jcp.1041280222; Saad MJA, 1996, J BIOL CHEM, V271, P22100, DOI 10.1074/jbc.271.36.22100; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WABITSCH M, 1995, METABOLISM, V44, P45, DOI 10.1016/0026-0495(95)90220-1; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WISE LS, 1979, J BIOL CHEM, V254, P273; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; ZEZULAK KM, 1986, SCIENCE, V233, P551, DOI 10.1126/science.3726546	34	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8662	8668		10.1074/jbc.274.13.8662	http://dx.doi.org/10.1074/jbc.274.13.8662			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085104	hybrid			2022-12-25	WOS:000079451600046
J	Dalle, S; Smith, P; Blache, P; Le-Nguyen, D; Le Brigand, L; Bergeron, F; Ashcroft, FM; Bataille, D				Dalle, S; Smith, P; Blache, P; Le-Nguyen, D; Le Brigand, L; Bergeron, F; Ashcroft, FM; Bataille, D			Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PLASMA-MEMBRANE; PANCREATIC B-CELLS; BETA-CELLS; CA-2+ PUMP; CHANNELS; CALCIUM; DIHYDROPYRIDINES; ENDOPEPTIDASE; SOMATOSTATIN; ACTIVATION	Using the MIN6 B-cell line, we investigated the hypothesis that miniglucagon, the C-terminal (19-29) fragment processed from glucagon and present in pancreatic A cells, modulates insulin release, and we analyzed its cellular mode of action. We show that, at concentrations ranging from 0.01 to 1000 phr, miniglucagon dose-dependently (ID50 = 1 pM) inhibited by 80-100% the insulin release triggered by glucose, glucagon, glucagonlike peptide-1-(7-36) amide (tGLP-1), or glibenclamide, but not that induced by carbachol, Miniglucagon had no significant effects on cellular cAMP levels. The increase in Ca-45(2+) uptake induced by depolarizing agents (glucose or extracellular K+), by glucagon, or by the Ca2+ channel agonist Bay K-8644 was blocked by miniglucagon at the doses active on insulin release. Electrophysiological experiments indicated that miniglucagon induces membrane hyperpolarization, probably by opening potassium channels, which terminated glucose-induced electrical activity. Pretreatment with pertussis toxin abolished the effects of miniglucagon on insulin release. It is concluded that miniglucagon is a highly potent and efficient inhibitor of insulin release by dosing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein.	CHU Arnaud de Villeneuve, INSERM, U376, F-34295 Montpellier, France; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University of Oxford	Bataille, D (corresponding author), CHU Arnaud de Villeneuve, INSERM, U376, F-34295 Montpellier, France.		blache, philippe/C-2009-2008	Smith, Paul/0000-0002-8710-6830				ASHCROFT FM, 1994, J CELL BIOCHEM, V56, P1; BATAILLE D, 1992, BIOMED RES-TOKYO, V13, P137; BATAILLE D, 1996, GLUACON, V3, P31; BATAILLE D, 1992, INT GLUCAGON MONITOR, V2, P1; BECHEM M, 1988, TRENDS PHARMACOL SCI, V9, P257, DOI 10.1016/0165-6147(88)90156-3; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLACHE P, 1989, CR ACAD SCI III-VIE, V308, P467; BLACHE P, 1990, J BIOL CHEM, V265, P21514; BLACHE P, 1993, J BIOL CHEM, V268, P21748; BLACHE P, 1988, BIOMED RES S3, V9, P19; BROWN AM, 1984, NATURE, V311, P570, DOI 10.1038/311570a0; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; COOK DL, 1982, DIABETES, V31, P985, DOI 10.2337/diabetes.31.11.985; DELAAGE MA, 1978, MOL BIOL PHARM CYCLI, P151; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DREWS G, 1990, ENDOCRINOLOGY, V126, P1646, DOI 10.1210/endo-126-3-1646; Gilon P, 1997, J PHYSIOL-LONDON, V499, P65, DOI 10.1113/jphysiol.1997.sp021911; Hughes SJ, 1998, DIABETES, V47, P73, DOI 10.2337/diabetes.47.1.73; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; KERVRAN A, 1976, DIABETES METAB, V2, P67; KOFOD H, 1988, AM J PHYSIOL, V254, pE454, DOI 10.1152/ajpendo.1988.254.4.E454; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; LENGUYEN D, 1988, PEPTIDE CHEM 1987, P391; LOTERSZTAJN S, 1990, J BIOL CHEM, V265, P9876; MALAISSELAGAE F, 1984, BIOCHEM BIOPH RES CO, V123, P1062, DOI 10.1016/S0006-291X(84)80241-7; MALLAT A, 1987, NATURE, V325, P620, DOI 10.1038/325620a0; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; PACE CS, 1977, AM J PHYSIOL, V233, pC164, DOI 10.1152/ajpcell.1977.233.5.C164; PACE CS, 1981, DIABETES, V30, P836, DOI 10.2337/diabetes.30.10.836; PAVOINE C, 1991, AM J PHYSIOL, V260, pC993, DOI 10.1152/ajpcell.1991.260.5.C993; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; Renstrom E, 1996, NEURON, V17, P513, DOI 10.1016/S0896-6273(00)80183-X; RODBELL M, 1983, GLUCAGON, V1, P263; RORSMAN P, 1991, NATURE, V349, P77, DOI 10.1038/349077a0; SMITH PA, 1993, J GEN PHYSIOL, V101, P767, DOI 10.1085/jgp.101.5.767; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914	37	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10869	10876		10.1074/jbc.274.16.10869	http://dx.doi.org/10.1074/jbc.274.16.10869			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196164	hybrid			2022-12-25	WOS:000079751900032
J	Gengrinovitch, S; Berman, B; David, G; Witte, L; Neufeld, G; Ron, D				Gengrinovitch, S; Berman, B; David, G; Witte, L; Neufeld, G; Ron, D			Glypican-1 is a VEGF(165) binding proteoglycan that acts as an extracellular chaperone for VEGF(165)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; PLATELET FACTOR-IV; VASCULAR ENDOTHELIAL-CELLS; FACTOR VEGF; MOLECULAR-CLONING; SOLUBLE RECEPTOR; NERVOUS-SYSTEM; CORE PROTEIN; MEMBRANE	Glypican-1 is a member of a family of glycosylphosphatidylinositol anchored cell surface heparan sulfate proteoglycans implicated in the control of cellular growth and differentiation. The 165-amino acid form of vascular endothelial growth factor (VEGF(165)) is a mitogen for endothelial cells and a potent angiogenic factor in vivo. Heparin binds to VEGF(165) and enhances its binding to VEGF receptors. However, native HSPGs that bind VEGF(165) and modulate its receptor binding have not been identified. Among the glypicans, glypican-1 is the only member that is expressed in the vascular system. We have therefore examined whether glypican-1 can interact with VEGF(165). Glypican-1 from rat myoblasts binds specifically to VEGF(165) but not to VEGF(121). The binding has an apparent dissociation constant of 3 x 10(-10) M. The binding of glypican-1 to VEGF(165) is mediated by the heparan sulfate chains of glypican-1, because heparinase treatment abolishes this interaction. Only an excess of heparin or heparan sulfates but not other types of glycosaminoglycans inhibited this interaction. VEGF(165) interacts specifically not only with rat myoblast glypican-1 but also with human endothelial cell-derived glypican-1. The binding of I-125-VEGF(165) to heparinase-treated human vascular endothelial cells is reduced following heparinase treatment, and addition of glypican-1 restores the binding. Glypican-1 also potentiates the binding of I-125-VEGF(165) to a soluble extracellular domain of the VEGF receptor KDR/flk-1. Furthermore, we show that glypican-1 acts as an extracellular chaperone that can restore the receptor binding ability of VEGF(165), which has been damaged by oxidation. Taken together, these results suggest that glypican-1 may play an important role in the control of angiogenesis by regulating the activity of VEGF(165), a regulation that may be critical under conditions such as wound repair, in which oxidizing agents that can impair the activity of VEGF are produced, and in situations were the concentrations of active VEGF are limiting.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv, Inst Biotechnol, B-3000 Louvain, Belgium; ImClone Syst Inc, New York, NY 10014 USA	Technion Israel Institute of Technology; KU Leuven; Eli Lilly	Ron, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	dinar@techninix.tecnion.ac.il	Neufeld, Gera/F-1524-2019					AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; AZIZKHAN RG, 1980, J EXP MED, V152, P931, DOI 10.1084/jem.152.4.931; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; CAREY DJ, 1989, J CELL BIOL, V108, P1891, DOI 10.1083/jcb.108.5.1891; CHIANG MK, 1995, GROWTH FACTORS, V12, P1, DOI 10.3109/08977199509003208; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DEBOECK H, 1987, BIOCHEM J, V247, P765, DOI 10.1042/bj2470765; Dougher AM, 1997, GROWTH FACTORS, V14, P257, DOI 10.3109/08977199709021524; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HECK DE, 1992, J BIOL CHEM, V267, P21277; KARTHIKEYAN L, 1992, BIOCHEM BIOPH RES CO, V188, P395, DOI 10.1016/0006-291X(92)92398-H; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; LAMMI M, 1988, ANAL BIOCHEM, V168, P352, DOI 10.1016/0003-2697(88)90329-6; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVINE SP, 1990, BLOOD, V75, P902; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; MERTENS G, 1992, J BIOL CHEM, V267, P20435; MOSCATELLI D, 1992, J BIOL CHEM, V267, P25803; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; RAPRAEGER AC, 1994, EXTRACELLULAR MATRIX, V245, P240; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RON D, 1993, J BIOL CHEM, V268, P2984; RON D, 1993, J BIOL CHEM, V268, P5388; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Ruef J, 1997, CIRC RES, V81, P24, DOI 10.1161/01.RES.81.1.24; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SCHRAUFSTATTER IU, 1988, METHOD ENZYMOL, V163, P328; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225	54	153	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10816	10822		10.1074/jbc.274.16.10816	http://dx.doi.org/10.1074/jbc.274.16.10816			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196157	hybrid			2022-12-25	WOS:000079751900025
J	Gotte, M; Maier, G; Onori, AM; Cellai, L; Wainberg, MA; Heumann, H				Gotte, M; Maier, G; Onori, AM; Cellai, L; Wainberg, MA; Heumann, H			Temporal coordination between initiation of HIV (+)-strand DNA synthesis and primer removal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE RESULT; RNASE-H; POLYPURINE TRACT; RETROTRANSPOSON TY1; RIBONUCLEASE H; BINDING; TRNA(3)(LYS); SEQUENCE; SITE	In this study, we have analyzed the interdependence between the polymerase and RNase H active sites of human immunodeficiency virus-1 reverse transcriptase (RT) using an in vitro system that closely mimics the initiation of (+)-strand DNA synthesis, Time course experiments show that RT pauses after addition of the 12th DNA residue, and at this stage the RNase H activity starts to cleave the RNA primer from newly synthesized DNA. Comparison of cleavage profiles obtained with 3'- and 5'-end-labeled primer strands indicates that RT now translocates in the opposite direction, i.e. in the 5' direction of the RNA strand. DNA synthesis resumes again in the 3' direction, after the RNA-DNA junction was efficiently cleaved. Moreover, we further characterized complexes generated before, during, and after position +12, by treating these with Fe2+ to localize the RNase H active site on the DNA template. Initially, when RT binds the RNA/DNA substrate, oxidative strand breaks were seen at a distance of 18 base pairs upstream from the primer terminus, whereas 17 base pairs were observed at later stages when the enzyme binds more and more DNA/DNA These data show that the initiation of (+)-strand synthesis is accompanied by a conformational change of the polymerase-competent complex.	McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; CNR, Ist Strutturistica Chim, I-00016 Monterotondo, Rome, Italy; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lady Davis Institute; McGill University; Consiglio Nazionale delle Ricerche (CNR); Max Planck Society	Gotte, M (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, McGill AIDS Ctr, 3755 Chem Cote-Ste-Catherine, Montreal, PQ H3T 1E2, Canada.							DAS AT, 1995, J VIROL, V69, P3090, DOI 10.1128/JVI.69.5.3090-3097.1995; DESTEFANO JJ, 1995, NUCLEIC ACIDS RES, V23, P3901, DOI 10.1093/nar/23.19.3901; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FEDOROFF OY, 1993, J MOL BIOL, V233, P509, DOI 10.1006/jmbi.1993.1528; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GOSH M, 1997, BIOCHEMISTRY-US, V36, P5758; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Gotte M, 1996, FEBS LETT, V390, P226, DOI 10.1016/0014-5793(96)00662-X; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; HOSTOMSKY Z, 1994, J VIROL, V68, P1970, DOI 10.1128/JVI.68.3.1970-1971.1994; HUBER HE, 1990, J BIOL CHEM, V265, P10565; Hughes SH, 1996, J VIROL, V70, P2679, DOI 10.1128/JVI.70.5.2679-2683.1996; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; LAUERMANN V, 1995, J VIROL, V69, P7845, DOI 10.1128/JVI.69.12.7845-7850.1995; Lauermann V, 1997, EMBO J, V16, P6603, DOI 10.1093/emboj/16.21.6603; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LI XG, 1994, J VIROL, V68, P6198, DOI 10.1128/JVI.68.10.6198-6206.1994; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; METZGER W, 1993, P NATL ACAD SCI USA, V90, P5909, DOI 10.1073/pnas.90.13.5909; Palaniappan C, 1997, J BIOL CHEM, V272, P11157, DOI 10.1074/jbc.272.17.11157; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; Saenger W, 1983, PRINCIPLES NUCL ACID; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; Telesnitsky A., 1997, P121; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; WAKEFIELD JK, 1995, J VIROL, V69, P6021, DOI 10.1128/JVI.69.10.6021-6029.1995; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; WOHRL BM, 1995, BIOCHEMISTRY-US, V34, P5343	37	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					11159	11169		10.1074/jbc.274.16.11159	http://dx.doi.org/10.1074/jbc.274.16.11159			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196201	hybrid			2022-12-25	WOS:000079751900069
J	McDonald, PH; Cote, NL; Lin, FT; Premont, RT; Pitcher, JA; Lefkowitz, RJ				McDonald, PH; Cote, NL; Lin, FT; Premont, RT; Pitcher, JA; Lefkowitz, RJ			Identification of NSF as a beta-arrestin1-binding protein - Implications for beta(2)-adrenergic receptor regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; BETA-ADRENERGIC-RECEPTOR; MEDIATED ENDOCYTOSIS; COUPLED RECEPTORS; AMPA RECEPTORS; ARRESTIN; SEQUESTRATION; KINASES; INTERNALIZATION; DESENSITIZATION	Previous studies have demonstrated that beta-arrestin1 serves to target G protein-coupled receptors for internalization via clathrin-coated pits and that its endocytic function is regulated by dephosphorylation at the plasma membrane. Using the yeast two-hybrid system, we have identified a novel beta-arrestin1-binding protein, NSF N-ethylmaleimide-sensitive fusion protein), an ATPase essential for many intracellular transport reactions. We demonstrate that purified recombinant beta-arrestin1 and NSF interact in vitro and that these proteins can be coimmunoprecipitated from cells. beta-Arrestin1-NSF complex formation exhibits a conformational dependence with beta-arrestin1 preferentially interacting with the ATP bound form of NSF, In contrast to the beta-arrestin1-clathrin interaction, however, the phosphorylation state of beta-arrestin1 does not affect NSF binding, Functionally, overexpression of NSF in HEK 293 cells significantly enhances agonist-mediated beta(2)-adrenergic receptor (beta(2)-AR) internalization. Furthermore, when coexpressed with a beta-arrestin1 mutant (beta arr1S412D) that mimics a constitutively phosphorylated form of beta-arrestin1 and that acts as a dominant negative with regards to beta(2)-AR internalization, NSF rescues the beta arr1S412D-mediated inhibition of beta(2)-AR internalization. The demonstration of beta-arrestin1-NSF complex formation and the functional consequences of NSF overexpression suggest a hitherto unappreciated role for NSF in facilitating clathrin coat-mediated G protein-coupled receptor internalization.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021	Premont, Richard/0000-0002-8053-5026	NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BLOCK MR, 1992, METHOD ENZYMOL, V219, P300; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Ferguson SSG, 1996, BIOCHEM SOC T, V24, P953, DOI 10.1042/bst0240953; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin JW, 1998, NEURON, V21, P267, DOI 10.1016/S0896-6273(00)80534-6; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	27	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10677	10680		10.1074/jbc.274.16.10677	http://dx.doi.org/10.1074/jbc.274.16.10677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196135	hybrid			2022-12-25	WOS:000079751900003
J	Bandyopadhyay, P; Ma, XM; Linehan-Stieers, C; Kren, BT; Steer, CJ				Bandyopadhyay, P; Ma, XM; Linehan-Stieers, C; Kren, BT; Steer, CJ			Nucleotide exchange in genomic DNA of rat hepatocytes using RNA/DNA oligonucleotides - Targeted delivery of liposomes and polyethyleneimine to the asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; FACTOR-IX GENE; IN-VIVO; MAMMALIAN-CELLS; ANTISENSE OLIGONUCLEOTIDES; SUSTAINED EXPRESSION; NONVIRAL VECTOR; HEPATOMA-CELLS; CONDENSED DNA; HUH-7 CELLS	Chimeric RNA/DNA oligonucleotides have been shown to promote single nucleotide exchange in genomic DNA. A chimeric molecule was designed to introduce an A to C nucleotide conversion at the Ser(365) position of the rat factor IX gene. The oligonucleotides were encapsulated in positive, neutral, and negatively charged liposomes containing galactocerebroside or complexed with lactosylated polyethyleneimine. The formulations were evaluated for stability and efficiency in targeting hepatocytes via the asialoglycoprotein receptor. Physical characterization and electron microscopy revealed that the oligonucleotides were efficiently encapsulated within the liposomes, with the positive and negative formulations remaining stable for at least 1 month. Transfection efficiencies in isolated rat hepatocytes approached 100% with each of the formulations. However, the negative liposomes and 25-kDa lactosylated polyethyleneimine provided the most intense nuclear fluorescence with the fluorescein-labeled oligonucleotides. The lactosylated polyethyleneimine and the three different liposomal formulations resulted in A to C conversion efficiencies of 19-24%. In addition, lactosylated polyethyleneimine was also highly effective in transfecting plasmid DNA into isolated hepatocytes. The results suggest that both the liposomal and polyethyleneimine formulations are simple to prepare and stable and give reliable, reproducible results. They provide efficient delivery systems to hepatocytes for the introduction or repair of genetic mutations by the chimeric RNA/DNA oligonucleotides.	Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Cell Biol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Steer, CJ (corresponding author), Univ Minnesota, Sch Med, Dept Med, Box 36 UMHC,420 Delaware St SE, Minneapolis, MN 55455 USA.	steer001@maroon.tc.umn.edu						Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Alexeev V, 1998, NAT BIOTECHNOL, V16, P1343, DOI 10.1038/4322; Bandyopadhyay P, 1998, BIOTECHNIQUES, V25, P282, DOI 10.2144/98252gt03; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Boletta A, 1997, HUM GENE THER, V8, P1243, DOI 10.1089/hum.1997.8.10-1243; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CHIN D J, 1990, New Biologist, V2, P1091; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; ColeStrauss A, 1997, ANTISENSE NUCLEIC A, V7, P211, DOI 10.1089/oli.1.1997.7.211; Connelly S, 1996, BLOOD, V87, P4671, DOI 10.1182/blood.V87.11.4671.bloodjournal87114671; Daemen T, 1997, HEPATOLOGY, V26, P416, DOI 10.1002/hep.510260223; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Fabrega AJ, 1996, TRANSPLANTATION, V62, P1866, DOI 10.1097/00007890-199612270-00032; Fasbender A, 1997, GENE THER, V4, P716, DOI 10.1038/sj.gt.3300459; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FINDEIS MA, 1994, METHODS ENZYMOL, V247, P341; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; FRALEY R, 1981, BIOCHEMISTRY-US, V20, P6978, DOI 10.1021/bi00527a031; GABIZON A, 1992, BIOCHIM BIOPHYS ACTA, V1103, P94, DOI 10.1016/0005-2736(92)90061-P; Gao X, 1996, BIOCHEMISTRY-US, V35, P1027, DOI 10.1021/bi952436a; Gao X, 1995, GENE THER, V2, P710; Ghoumari AM, 1996, GENE THER, V3, P483; GRAY GR, 1974, ARCH BIOCHEM BIOPHYS, V163, P426, DOI 10.1016/0003-9861(74)90495-0; HAMILTONATTWELL VL, 1987, J MICROSC-OXFORD, V145, P347; Hara T, 1997, P NATL ACAD SCI USA, V94, P14547, DOI 10.1073/pnas.94.26.14547; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOLMEN SL, 1995, IN VITRO CELL DEV-AN, V31, P347; Ilan Y, 1997, J CLIN INVEST, V99, P1098, DOI 10.1172/JCI119238; Kaufman SL, 1996, ANAL CHEM, V68, P1895, DOI 10.1021/ac951128f; Kmiec EB, 1995, ADV DRUG DELIVER REV, V17, P333, DOI 10.1016/0169-409X(95)00068-I; Kren BT, 1997, HEPATOLOGY, V25, P1462, DOI 10.1002/hep.510250626; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; Kren BT, 1998, HEPATOLOGY, V28, p498A; LAPPALAINEN K, 1994, PHARMACEUT RES, V11, P1127, DOI 10.1023/A:1018932714745; Lee RJ, 1996, J BIOL CHEM, V271, P8481, DOI 10.1074/jbc.271.14.8481; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MARTINEZFONG D, 1994, HEPATOLOGY, V20, P1602, DOI 10.1002/hep.1840200633; MELCHIOR WB, 1973, P NATL ACAD SCI USA, V70, P298, DOI 10.1073/pnas.70.2.298; Mouradian S, 1997, ANAL CHEM, V69, P919, DOI 10.1021/ac960785k; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; Perales JC, 1997, J BIOL CHEM, V272, P7398, DOI 10.1074/jbc.272.11.7398; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; SMITH JG, 1993, BIOCHIM BIOPHYS ACTA, V1154, P327, DOI 10.1016/0304-4157(93)90004-8; SPANJER HH, 1983, BIOCHIM BIOPHYS ACTA, V734, P40, DOI 10.1016/0005-2736(83)90072-X; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; WU GY, 1988, BIOCHEMISTRY-US, V27, P887, DOI 10.1021/bi00403a008; Yoon K, 1996, P NATL ACAD SCI USA, V93, P2071, DOI 10.1073/pnas.93.5.2071; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	59	110	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10163	10172		10.1074/jbc.274.15.10163	http://dx.doi.org/10.1074/jbc.274.15.10163			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187800	hybrid			2022-12-25	WOS:000079663500039
J	Freyssenet, D; Di Carlo, M; Hood, DA				Freyssenet, D; Di Carlo, M; Hood, DA			Calcium-dependent regulation of cytochrome c gene expression in skeletal muscle cells - Identification of a protein kinase C-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTRACTILE ACTIVITY; MITOCHONDRIAL BIOGENESIS; SIGNAL-TRANSDUCTION; CHRONIC STIMULATION; ENERGY-METABOLISM; MESSENGER-RNAS; CYCLIC-AMP; NUCLEAR; RAT; CA2+	Mitochondrial biogenesis can occur rapidly in mammalian skeletal muscle subjected to a variety of physiological conditions. However, the intracellular signal(s) involved in regulating this process remain unknown. Using nuclearly encoded cytochrome c, we show that its expression in muscle cells is increased by changes in cytosolic Ca2+ using the ionophore A23187. Treatment of myotubes with A23187 increased cytochrome c mRNA expression up to 1.7-fold. Transfection experiments using promoter-chloramphenicol acetyltransferase constructs revealed that this increase could be transcriptionally mediated since A23187 increased chloramphenicol acetyltransferase activity by 2.5-fold. This increase was not changed by KN62, an inhibitor of Ca2+/calmodulin-dependent kinases II and IV, and it was not modified by overexpression of protein kinase A and cAMP response element-binding protein, demonstrating that the A23187 effect was not mediated through Ca2+/calmodulin-dependent kinase- or protein kinase A-dependent pathways. However, treatment of myotubes with staurosporine or 12-O-tetradecanoylphorbol-13-acetate reduced the effect of A23187 on cytochrome c transactivation by 40-50%. Coexpression of the Ca2+-sensitive protein kinase C isoforms alpha and beta(II), but not the Ca2+-insensitive delta isoform, exaggerated the A23187-mediated response. The short-term effect of A23187 was mediated in part by mitogen-activated protein kinase (extracellular signal-regulated kinases 1 and 2) since its activation peaked 2 h after A23187 treatment, and cytochrome c transactivation was reduced by PD98089, a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor. These results demonstrate the existence of a Ca2+-sensitive, protein kinase C-dependent pathway involved in cytochrome c expression and implicate Ca2+ as a signal in the up-regulation of nuclear genes encoding mitochondrial proteins.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; York Univ, Dept Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada	York University - Canada; York University - Canada	Hood, DA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	dhood@yorku.ca						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLELAND PJF, 1989, J BIOL CHEM, V264, P17704; Connor MK, 1996, ARCH BIOCHEM BIOPHYS, V333, P103, DOI 10.1006/abbi.1996.0369; DONG YH, 1993, NUCLEIC ACIDS RES, V21, P771, DOI 10.1093/nar/21.3.771; Essig D A, 1996, Exerc Sport Sci Rev, V24, P289; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; Freyssenet D, 1996, ARCH PHYSIOL BIOCHEM, V104, P129, DOI 10.1076/apab.104.2.129.12878; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; HOOD DA, 1989, AM J PHYSIOL, V256, pC1092, DOI 10.1152/ajpcell.1989.256.5.C1092; HOOD DA, 1994, CAN J APPL PHYSIOL, V19, P12, DOI 10.1139/h94-002; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAWRENCE JC, 1983, AM J PHYSIOL, V244, pC348, DOI 10.1152/ajpcell.1983.244.5.C348; LI WWF, 1993, J BIOL CHEM, V268, P12003; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MCCORMACK JG, 1994, NEWS PHYSIOL SCI, V9, P71; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MUCHARDT C, 1990, J VIROL, V64, P4296, DOI 10.1128/JVI.64.9.4296-4305.1990; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; Orrenius S, 1996, ADV NEUROL, V71, P137; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Robey RB, 1996, BIOTECHNIQUES, V20, P40; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SCHUDT C, 1975, EUR J BIOCHEM, V60, P579, DOI 10.1111/j.1432-1033.1975.tb21036.x; SEEDORF U, 1986, BIOCHEM J, V239, P115, DOI 10.1042/bj2390115; STEVENS RJ, 1995, MOL CELL BIOCHEM, V143, P119, DOI 10.1007/BF01816945; STRETER FA, 1987, AM J PHYSIOL, V253, pC296; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Takahashi M, 1998, AM J PHYSIOL-CELL PH, V274, pC1380, DOI 10.1152/ajpcell.1998.274.5.C1380; Thompson MG, 1997, J BIOL CHEM, V272, P10910; UHLER MD, 1987, J BIOL CHEM, V262, P15202; WALKE W, 1994, J BIOL CHEM, V269, P19447; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593	49	87	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9305	9311		10.1074/jbc.274.14.9305	http://dx.doi.org/10.1074/jbc.274.14.9305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092607	hybrid			2022-12-25	WOS:000079451800026
J	Pou, S; Keaton, L; Surichamorn, W; Rosen, GM				Pou, S; Keaton, L; Surichamorn, W; Rosen, GM			Mechanism of superoxide generation by neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO-CENTER-DOT; L-ARGININE; AROMATIC HYDROXYLATION; GUANYLATE-CYCLASE; REDUCTASE DOMAIN; RELAXING FACTOR; IN-VIVO; PEROXYNITRITE; CELLS; TETRAHYDROBIOPTERIN	Neuronal nitric-oxide synthase (NOS I) in the absence of L-arginine has previously been shown to generate superoxide (O-2(radicalanion)) (Pou, S., Pou, W. S., Bredt, D. S., Snyder, S. H., and Rosen, G. M. (1992) J. Biol. Chem. 267, 24173-24176). In the presence of L-arginine, NOS I produces nitric oxide (NO.). Yet the competition between O-2 and L-arginine for electrons, and by implication formation of O-2(radicalanion), has until recently remained undefined. Herein, we investigated this relationship, observing O-2(radicalanion) generation even at saturating levels of L-arginine. Of interest was the finding that the frequently used NOS inhibitor N-G-monomethyl L-arginine enhanced O-2(radicalanion) production in the presence of L-arginine because this antagonist attenuated NO. formation. Whereas diphenyliodonium chloride inhibited O-2(radicalanion), blockers of heme such as NaCN, 1-phenylimidazole, and imidazole likewise prevented the formation of O-2(radicalanion) at concentrations that inhibited NO. formation from L-arginine, Taken together these data demonstrate that NOS I generates O-2(radicalanion) and the formation of this free radical occurs at the heme domain.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Rosen, GM (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 725 W Lombard St, Baltimore, MD 21201 USA.	grosen@umaryland.edu			NCI NIH HHS [CA-69538] Funding Source: Medline; NIA NIH HHS [AG-14829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG014829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; BANCI L, 1994, J AM CHEM SOC, V116, P4866, DOI 10.1021/ja00090a035; BONNETT R, 1959, J CHEM SOC, P2094, DOI 10.1039/jr9590002094; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DEGUCHI T, 1982, J BIOL CHEM, V257, P147; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; Fukuto JM, 1997, ACCOUNTS CHEM RES, V30, P149, DOI 10.1021/ar960010y; FURCHGOTT R F, 1988, P401; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GOLDSTEIN S, 1995, FREE RADICAL BIO MED, V19, P505, DOI 10.1016/0891-5849(95)00034-U; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Grisham MB, 1998, FREE RADICAL BIO MED, V25, P404, DOI 10.1016/S0891-5849(98)00094-X; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HANNA PM, 1992, ARCH BIOCHEM BIOPHYS, V296, P640, DOI 10.1016/0003-9861(92)90620-C; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Kaur H, 1997, FREE RADICAL RES, V26, P71, DOI 10.3109/10715769709097786; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; MAKINO K, 1992, CAN J CHEM, V70, P2818, DOI 10.1139/v92-358; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MIKI N, 1977, BIOCHEM BIOPH RES CO, V75, P851, DOI 10.1016/0006-291X(77)91460-7; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POU S, 1995, BBA-GEN SUBJECTS, V1244, P62, DOI 10.1016/0304-4165(94)00197-6; POU S, 1992, J BIOL CHEM, V267, P24173; POU S, 1989, J BIOL CHEM, V264, P12299; Richeson CE, 1998, J AM CHEM SOC, V120, P7211, DOI 10.1021/ja980871x; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; Tierney DL, 1998, J AM CHEM SOC, V120, P2983, DOI 10.1021/ja973648t; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; WHITE RE, 1994, CYTOCHROME P450, P333; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; YANG G, 1992, FREE RADICAL BIO MED, V12, P327, DOI 10.1016/0891-5849(92)90120-6	54	166	167	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9573	9580		10.1074/jbc.274.14.9573	http://dx.doi.org/10.1074/jbc.274.14.9573			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092643	hybrid			2022-12-25	WOS:000079451800062
J	Bachand, F; Yao, XJ; Hrimech, M; Rougeau, N; Cohen, EA				Bachand, F; Yao, XJ; Hrimech, M; Rougeau, N; Cohen, EA			Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 Gag precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID PROTEIN NCP7; CELL-CYCLE ARREST; VIRION INCORPORATION; NUCLEAR-LOCALIZATION; MUTATIONAL ANALYSIS; REGULATORY PROTEIN; HELICAL STRUCTURE; VIRAL EXPRESSION; T-CELLS; GENE	The 96-amino acid Vpr protein is the major virion-associated accessory protein of the human immunodeficiency virus type 1 (HIV-1), As Vpr is not part of the p55 Gag polyprotein precursor (Pr55(gag)), its incorporation requires an anchor to associate with the assembling viral particles. Although the molecular mechanism is presently unclear, the C-terminal region of the Pr55(gag) corresponding to the p6 domain appears to constitute such an anchor essential for the incorporation of the Vpr protein. In order to clarify the mechanism by which the Vpr accessory protein is trans-incorporated into progeny virion particles, we tested whether HIV-1 Vpr interacted with the Pr55(gag) using the yeast two-hybrid system and the maltose-binding protein pull-down assay. The present study provides genetic and biochemical evidence indicating that the Pr55(gag) can physically interact with the Vpr protein. Furthermore, point mutations affecting the integrity of the conserved L-X-S-L-F-G motif of P6(gag) completely abolish the interaction between Vpr and the Pr55(gag) and, as a consequence, prevent Vpr virion incorporation. In contrast to other studies, mutations affecting the integrity of the NCp7 zinc fingers impaired neither Vpr virion incorporation nor the binding between Vpr and the Pr55(gag). Conversely, amino acid substitutions in Vpr demonstrate that an intact N-terminal alpha-helical structure is essential for the Vpr-Pr55(gag) interaction. Vpr and the Pr55(gag) demonstrate a strong interaction in vitro as salt concentrations as high as 900 mM could not disrupt the interaction. Finally, the interaction is efficiently competed using anti-Vpr sera. Together, these results strongly suggest that Vpr trans-incorporation into HIV-1 particles requires a direct interaction between its N-terminal region and the C-terminal region of p6(gag). The development of Pr55(gag)-Vpr interaction assays may allow the screening of molecules that can prevent the incorporation of the Vpr accessory protein into HIV-1 virions, and thus inhibit its early functions.	Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Cohen, EA (corresponding author), Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Retrovirol Humaine, Montreal, PQ H3C 3J7, Canada.			Yao, Xiaojian/0000-0002-5022-1309				Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; DIMARZIO P, 1995, J VIROL, V69, P7909, DOI 10.1128/JVI.69.12.7909-7916.1995; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Huang Y, 1997, J VIROL, V71, P4378, DOI 10.1128/JVI.71.6.4378-4384.1997; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kewalramani VN, 1996, VIROLOGY, V218, P159, DOI 10.1006/viro.1996.0176; Kobinger GP, 1998, J VIROL, V72, P5441, DOI 10.1128/JVI.72.7.5441-5448.1998; Kondo E, 1996, J VIROL, V70, P159, DOI 10.1128/JVI.70.1.159-164.1996; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; LAVALLEE C, 1993, J ACQ IMMUN DEF SYND, V6, P529, DOI 10.1097/00126334-199305000-00014; LAVALLEE C, 1994, J VIROL, V68, P1926; Li MS, 1996, BIOCHEM BIOPH RES CO, V218, P352, DOI 10.1006/bbrc.1996.0061; Li XQ, 1997, J VIROL, V71, P5624, DOI 10.1128/JVI.71.7.5624-5630.1997; LU YL, 1995, J VIROL, V69, P6873, DOI 10.1128/JVI.69.11.6873-6879.1995; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Mahalingam S, 1997, J VIROL, V71, P6339, DOI 10.1128/JVI.71.9.6339-6347.1997; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; MAHALINGAM S, 1995, VIROLOGY, V207, P297, DOI 10.1006/viro.1995.1081; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SATO A, 1995, MICROBIOL IMMUNOL, V39, P1015, DOI 10.1111/j.1348-0421.1995.tb03293.x; Sato A, 1996, VIROLOGY, V220, P208, DOI 10.1006/viro.1996.0302; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Subbramanian RA, 1998, J EXP MED, V187, P1103, DOI 10.1084/jem.187.7.1103; Subbramanian RA, 1998, J MOL BIOL, V278, P13, DOI 10.1006/jmbi.1998.1685; TRISTEM M, 1992, EMBO J, V11, P3405, DOI 10.1002/j.1460-2075.1992.tb05419.x; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WANG JJ, 1994, J GEN VIROL, V75, P2607, DOI 10.1099/0022-1317-75-10-2607; WU XY, 1994, J VIROL, V68, P6161, DOI 10.1128/JVI.68.10.6161-6169.1994; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; YAO XJ, 1992, J VIROL, V66, P5119, DOI 10.1128/JVI.66.8.5119-5126.1992; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0	52	90	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9083	9091		10.1074/jbc.274.13.9083	http://dx.doi.org/10.1074/jbc.274.13.9083			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085158	hybrid			2022-12-25	WOS:000079451600100
J	Huang, LE; Willmore, WG; Gu, J; Goldberg, MA; Bunn, HF				Huang, LE; Willmore, WG; Gu, J; Goldberg, MA; Bunn, HF			Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide - Implications for oxygen sensing and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; ARNT TRANSCRIPTION FACTOR; LACTATE-DEHYDROGENASE-A; DNA-BINDING ACTIVITY; FACTOR-I; ERYTHROPOIETIN GENE; PHOSPHOGLYCERATE KINASE-1; RESPONSIVE ELEMENT; SYNTHASE PROMOTER	It has been proposed that cells sense hypoxia by a heme protein, which transmits a signal that activates the heterodimeric transcription factor hypoxia-inducible factor 1 (HIF-1), thereby inducing a number of physiologically relevant genes such as erythropoietin (Epo), We have investigated the mechanism by which two heme-binding ligands, carbon monoxide and nitric oxide, affect oxygen sensing and signaling, Two concentrations of CO (10 and 80%) suppressed the activation of HIF-1 and induction of Epo mRNA by hypoxia in a dose-dependent manner. In contrast, CO had no effect on the induction of HIF-1 activity and Epo expression by either cobalt chloride or the iron chelator desferrioxamine, The affinity of CO for the putative sensor was much lower than that of oxygen (Haldane coefficient, similar to 0.5). Parallel experiments were done with 100 mu M sodium nitroprusside, a nitric oxide donor. Both NO and CO inhibited HIF-1 DNA binding by abrogating hypoxia-induced accumulation of HIF-1 alpha protein. Moreover, both NO and CO specifically targeted the internal oxygen-dependent degradation domain of HIF-1 alpha, and also repressed the C-terminal transactivation domain of HIF-1 alpha. Thus, NO and CO act proximally, presumably as heme ligands binding to the oxygen sensor, whereas desferrioxamine and perhaps cobalt appear to act at a site downstream.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bunn, HF (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol Oncol, LMRC-2,221 Longwood Ave, Boston, MA 02115 USA.	bunn@calvin.bwh.harvard.edu		Huang, Eric/0000-0002-6444-1708	NIDDK NIH HHS [F32-DK09365, R01-DK45098, R01-DK41234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009365, R01DK045098, R01DK041234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKER H, 1994, ANN NY ACAD SCI, V718, P3; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BICKAR D, 1984, J BIOL CHEM, V259, P777; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; FANDREY J, 1993, BLOOD, V81, P617; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; GARBERS DL, 1992, CELL, V71, P1; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GOPFERT T, 1995, AM J PHYSIOL-REG I, V269, pR995, DOI 10.1152/ajpregu.1995.269.5.R995; GORLACH A, 1994, FEBS LETT, V348, P216, DOI 10.1016/0014-5793(94)00607-5; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Negelein E, 1931, BIOCHEM Z, V243, P386; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, HEMATOL ONCOL CLIN N, V8, P863, DOI 10.1016/S0889-8588(18)30134-5; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Srinivas V, 1998, J BIOL CHEM, V273, P18019, DOI 10.1074/jbc.273.29.18019; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WARBURG O, 1949, HEAVY METAL PROSTHET, P1; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; YONETANI T, 1972, J BIOL CHEM, V247, P2447	51	263	283	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9038	9044		10.1074/jbc.274.13.9038	http://dx.doi.org/10.1074/jbc.274.13.9038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085152	hybrid			2022-12-25	WOS:000079451600094
J	Lareyre, JJ; Thomas, TZ; Zheng, WL; Kasper, S; Ong, DE; Orgebin-Crist, MC; Matusik, RJ				Lareyre, JJ; Thomas, TZ; Zheng, WL; Kasper, S; Ong, DE; Orgebin-Crist, MC; Matusik, RJ			A 5-kilobase pair promoter fragment of the murine epididymal retinoic acid-binding protein gene drives the tissue-specific, cell-specific, and androgen-regulated expression of a foreign gene in the epididymis of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT EPIDIDYMIS; MOUSE EPIDIDYMIS; MOLECULAR-CLONING; PROBASIN GENE; VAS-DEFERENS; IN-VIVO; DNA; PROSTATE; ADULT; NITROCELLULOSE	The murine epididymis synthesizes and secretes a retinoic acid-binding protein (mE-RABP) that belongs to the lipocalin superfamily, The gene encoding mE-RABP is specifically expressed in the mouse mid/distal caput epididymidis under androgen control. In transgenic mice, a 5-kilobase pair (kb) promoter fragment, but not a 0.6-kb fragment, of the mE-RABP gene driving the chloramphenicol acetyltransferase (CAT) reporter gene restricted high level of transgene expression to the caput epididymidis, No transgene expression was detected in any other male or female tissues. Immunolocalization of the CAT protein and in situ hybridization of the corresponding CAT mRNA indicated that transgene expression occurred in the principal cells of the mid/distal caput epididymidis, thereby mimicking the spatial endogenous mE-RABP gene expression. Transgene and mE-RABP gene expression was detected from 30 days and progressively increased until 60 days of age. Castration, efferent duct ligation, and hormone replacement studies demonstrated that transgene expression was specifically regulated by androgen but not by any other testicular factors. Altogether, our results demonstrate that the 5-kb promoter fragment of the mE-RABP gene contains all of the information required for the hormonal regulation and the spatial and temporal expression of the mE-RABP gene in the epididymis.	Vanderbilt Univ, Ctr Reprod Biol Res, Sch Med, Med Ctr N, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Obstet & Gynecol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Orgebin-Crist, MC (corresponding author), Vanderbilt Univ, Ctr Reprod Biol Res, Sch Med, Med Ctr N, Room D2303, Nashville, TN 37232 USA.	m-c.orgebin-crist@mcmail.vanderbilt.edu		Matusik, Robert/0000-0003-2057-9892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD003820, R01HD036900, P30HD005797, R01HD003820] Funding Source: NIH RePORTER; NICHD NIH HHS [HD03820, HD05797, HD36900] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUHAILA A, 1984, ANAT REC, V209, P197, DOI 10.1002/ar.1092090207; ASTRAUDO C, 1995, ARCH ANDROLOGY, V35, P247, DOI 10.3109/01485019508987877; BEDFORD JM, 1967, J EXP ZOOL, V166, P271, DOI 10.1002/jez.1401660210; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BROOKS DE, 1986, J BIOL CHEM, V261, P4956; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; DOUGLASS J, 1991, ANN NY ACAD SCI, V637, P384, DOI 10.1111/j.1749-6632.1991.tb27324.x; DYSON ALMB, 1973, ENDOCRINOLOGY, V93, P391, DOI 10.1210/endo-93-2-391; FAURE J, 1991, BIOL REPROD, V44, P13, DOI 10.1095/biolreprod44.1.13; GALLON C, 1989, J ANDROL, V10, P188; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; JEANFAUCHER C, 1985, INT J ANDROL, V8, P44, DOI 10.1111/j.1365-2605.1985.tb00817.x; Lan ZJ, 1998, BIOL REPROD, V58, P197, DOI 10.1095/biolreprod58.1.197; Lareyre JJ, 1998, MOL REPROD DEV, V50, P387, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;387::AID-MRD2&gt;3.0.CO;2-E; Lareyre JJ, 1998, ENDOCRINOLOGY, V139, P2971, DOI 10.1210/en.139.6.2971; LAREYRE JJ, 1998, 10 EUR WORKSH MOL CE; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Miyamoto Y, 1997, J BIOL CHEM, V272, P26375, DOI 10.1074/jbc.272.42.26375; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NEWCOMER ME, 1990, J BIOL CHEM, V265, P12876; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; ONG DE, 1988, ARCH BIOCHEM BIOPHYS, V267, P474, DOI 10.1016/0003-9861(88)90053-7; ORGEBINCRIST MC, 1967, NATURE, V216, P816, DOI 10.1038/216816a0; OrgebinCrist MC, 1996, PHARMACOLOGY, BIOLOGY, AND CLINICAL APPLICATIONS OF ANDROGENS, P27; PALMITER RD, 1985, CELL, V41, P343, DOI 10.1016/S0092-8674(85)80004-0; PERRY ACF, 1993, BIOCHEM J, V293, P21, DOI 10.1042/bj2930021; RANKIN TL, 1992, BIOL REPROD, V46, P767, DOI 10.1095/biolreprod46.5.767; RANKIN TL, 1992, BIOL REPROD, V46, P747, DOI 10.1095/biolreprod46.5.747; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SKUDLAREK MD, 1986, BIOL REPROD, V35, P167, DOI 10.1095/biolreprod35.1.167; SKUDLAREK MD, 1992, BIOCHEM J, V286, P907, DOI 10.1042/bj2860907; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TONEY TW, 1989, ENDOCRINOLOGY, V125, P243, DOI 10.1210/endo-125-1-243; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428	43	37	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8282	8290		10.1074/jbc.274.12.8282	http://dx.doi.org/10.1074/jbc.274.12.8282			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075734	hybrid, Green Published			2022-12-25	WOS:000079268100093
J	Li, J; Wang, CC				Li, J; Wang, CC			"Half of the sites" binding of D-glyceraldehyde-3-phosphate dehydrogenase folding intermediate with GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CHAPERONE-LIKE ACTIVITY; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; THERMOTOGA-MARITIMA; LOW-TEMPERATURE; ATP; REACTIVATION; DISSOCIATION; CONSEQUENCES; DENATURATION	Two D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) folding intermediate subunits bind with chaperonin 60 (GroEL) to form a stable complex, which can no longer bind with additional GAPDH intermediate subunits, but does bind with one more lysozyme folding intermediate or one chaperonin 10 (GroES) molecule, suggesting that the two GAPDH subunits bind at one end of the GroEL molecule displaying a "half of the sites" binding profile. For lysozyme, GroEL binds with either one or two folding intermediates to form a stable 1:1 or 1:2 complex with one substrate on each end of the GroEL double ring for the latter, The 1:1 complex of GroEL.GroES binds with one lysozyme or one dimeric GAPDH folding intermediate to form a stable ternary complex. Both complexes of GroEL lysozyme, and GroEL GAPDH, bind with one GroES molecule only at the other end of the GroEL molecule forming a trans ternary complex. According to the stoichiometry of GroEL binding with the GAPDH folding intermediate and the formation of ternary complexes containing GroEL GAPDH,, it is suggested that the folding intermediate of GAPDH binds, very likely in the dimeric form, with GroEL at one end only.	Acad Sinica, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS	Wang, CC (corresponding author), Acad Sinica, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.							AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BARTHOLMES P, 1978, EUR J BIOCHEM, V87, P563, DOI 10.1111/j.1432-1033.1978.tb12407.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CAI H, 1994, J BIOL CHEM, V269, P24550; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Churchich JE, 1997, J BIOL CHEM, V272, P19645, DOI 10.1074/jbc.272.32.19645; Clark AC, 1997, J MOL BIOL, V268, P512, DOI 10.1006/jmbi.1997.0969; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HayerHartl MK, 1996, EMBO J, V15, P6111, DOI 10.1002/j.1460-2075.1996.tb00999.x; HE RQ, 1993, BIOCHIM BIOPHYS ACTA, V1163, P315, DOI 10.1016/0167-4838(93)90168-Q; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; KREBS H, 1979, EUR J BIOCHEM, V100, P359, DOI 10.1111/j.1432-1033.1979.tb04178.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Li XL, 1998, BIOCHEM J, V331, P505, DOI 10.1042/bj3310505; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MARANGOS PJ, 1974, BIOCHEMISTRY-US, V13, P904, DOI 10.1021/bi00702a012; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; REHABER V, 1992, J BIOL CHEM, V267, P10999; REHABER V, 1993, FEBS LETT, V317, P163, DOI 10.1016/0014-5793(93)81514-Z; RUDOLPH R, 1977, EUR J BIOCHEM, V81, P563, DOI 10.1111/j.1432-1033.1977.tb11983.x; SCHEEK RM, 1982, METHOD ENZYMOL, V89, P305; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SCHULTES V, 1991, FEBS LETT, V290, P235, DOI 10.1016/0014-5793(91)81268-D; Song SY, 1998, ACTA CRYSTALLOGR D, V54, P558, DOI 10.1107/S090744499701620X; Sparrer H, 1997, J BIOL CHEM, V272, P14080, DOI 10.1074/jbc.272.22.14080; Thiyagarajan P, 1996, STRUCTURE, V4, P79, DOI 10.1016/S0969-2126(96)00011-1; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; Torella C, 1998, J BIOL CHEM, V273, P3915, DOI 10.1074/jbc.273.7.3915; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zheng WD, 1997, ARCH BIOCHEM BIOPHYS, V337, P326, DOI 10.1006/abbi.1996.9783; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	38	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 16	1999	274	16					10790	10794		10.1074/jbc.274.16.10790	http://dx.doi.org/10.1074/jbc.274.16.10790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	186VV	10196153	hybrid			2022-12-25	WOS:000079751900021
J	Guan, L; Ehrmann, M; Yoneyama, H; Nakae, T				Guan, L; Ehrmann, M; Yoneyama, H; Nakae, T			Membrane topology of the xenobiotic-exporting subunit, MexB, of the MexA,B-OprM extrusion pump in Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE FUSIONS; MULTIDRUG EFFLUX SYSTEM; GRAM-NEGATIVE BACTERIA; PHOA-GENE FUSIONS; ESCHERICHIA-COLI; INNER MEMBRANE; RESISTANCE GENE; DRUG EXTRUSION; ACTIVE EFFLUX; PROTEIN	The MexA,B-OprM efflux pump assembly of Pseudomonas aeruginosa consists of two inner membrane proteins and one outer membrane protein. The cytoplasmic membrane protein, MexB, appears to function as the xenobiotic-exporting subunit, whereas the MexA and OprM proteins are supposed to function as the membrane fusion protein and the outer membrane channel protein, respectively. Computer-aided hydropathy analyses of MexB predicted the presence of up to 17 potential transmembrane segments. To verify the prediction, we analyzed the membrane topology of MexB using the alkaline phosphatase gene fusion method. We obtained the following unique characteristics. MexB bears 12 membrane spanning segments leaving both the amino and carboxyl termini in the cytoplasmic side of the inner membrane. Both the first and fourth periplasmic loops had very long hydrophilic domains containing 311 and 314 amino acid residues, respectively. This fact suggests that these loops may interact with other pump subunits, such as the membrane fusion protein MexA and the outer membrane protein OprM, Alignment of the amino- and the carboxyl-terminal halves of MexB showed a 30% homology and transmembrane segments 1, 2, 3, 4, 5, and 6 could be overlaid with the segments 7, 8, 9, 10, 11, and 12, respectively. This result suggested that the MexB has a a-fold repeat that strengthen the experimentally determined topology model. This paper reports the structure of the pump subunit, MexB, of the MexA,B-OprM efflux pump assembly. This is the first time to verify the topology of the resistant-nodulation-division efflux pump protein.	Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Tokai University; University of Konstanz	Nakae, T (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci, Isehara, Kanagawa 2591193, Japan.	nakae@is.icc.u-tokai.ac.jp	Ehrmann, Michael/A-7307-2012; Guan, Lan/B-5288-2010	Ehrmann, Michael/0000-0002-1927-260X; 				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; BROWN MRW, 1975, RESISTANCE PSEUDOMON, P71; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; DONG QH, 1994, MOL MICROBIOL, V14, P185, DOI 10.1111/j.1365-2958.1994.tb01278.x; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; Ehrmann M, 1997, P NATL ACAD SCI USA, V94, P13111, DOI 10.1073/pnas.94.24.13111; Enomoto H, 1998, BBA-BIOMEMBRANES, V1370, P77, DOI 10.1016/S0005-2736(97)00245-9; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; FUKUDA H, 1990, ANTIMICROB AGENTS CH, V34, P1757, DOI 10.1128/AAC.34.9.1757; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Gotoh N, 1998, FEMS MICROBIOL LETT, V165, P21, DOI 10.1016/S0378-1097(98)00250-X; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HIRAI K, 1987, ANTIMICROB AGENTS CH, V31, P582, DOI 10.1128/AAC.31.4.582; Kohler T, 1997, MOL MICROBIOL, V23, P345, DOI 10.1046/j.1365-2958.1997.2281594.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI Y, 1991, BIOCHEM BIOPH RES CO, V178, P1043, DOI 10.1016/0006-291X(91)90997-L; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MORSHED SRM, 1995, BIOCHEM BIOPH RES CO, V210, P356, DOI 10.1006/bbrc.1995.1669; Nakae Taiji, 1997, J Infect Chemother, V3, P173, DOI 10.1007/BF02490031; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ocaktan A, 1997, J BIOL CHEM, V272, P21964, DOI 10.1074/jbc.272.35.21964; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; POOLE K, 1993, J BACTERIOL, V175, P7363, DOI 10.1128/JB.175.22.7363-7372.1993; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; RELLA M, 1982, ANTIMICROB AGENTS CH, V22, P242, DOI 10.1128/AAC.22.2.242; SAIER MH, 1994, MOL MICROBIOL, V11, P841, DOI 10.1111/j.1365-2958.1994.tb00362.x; Srikumar R, 1997, J BACTERIOL, V179, P7875, DOI 10.1128/jb.179.24.7875-7881.1997; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Yoneyama H, 1997, BIOCHEM BIOPH RES CO, V233, P611, DOI 10.1006/bbrc.1997.6506; Yoneyama H, 1998, BIOCHEM BIOPH RES CO, V244, P898, DOI 10.1006/bbrc.1998.8351	38	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10517	10522		10.1074/jbc.274.15.10517	http://dx.doi.org/10.1074/jbc.274.15.10517			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187844	hybrid			2022-12-25	WOS:000079663500083
J	Roux, S; Terouanne, B; Couette, B; Rafestin-Oblin, ME; Nicolas, JC				Roux, S; Terouanne, B; Couette, B; Rafestin-Oblin, ME; Nicolas, JC			Conformational change in the human glucocorticoid receptor induced by ligand binding is altered by mutation of isoleucine 747 by a threonine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; HEAT-SHOCK PROTEIN; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; ANDROGEN RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; PROGESTERONE-RECEPTOR	Limited proteolysis experiments were performed to study conformation changes induced by ligand binding on in vitro produced wild-type and 1747T mutant glucocorticoid receptors, Dexamethasone-induced conformational changes were characterized by two resistant proteolysis fragments of 30 and 27 kDa. Although dexamethasone binding affinity was only slightly altered by the 1747T substitution (Roux, S., Terouanne, B., Balaguer, P., Loffreda-Jausons, N., Pons, M., Chambon, P., Gronemeyer, H., and Nicolas, J,-C, (1996) Mot. Endocrinol, 10, 1214-1226), higher dexamethasone concentrations were required to obtain the same proteolysis pattern. This difference was less marked when proteolysis experiments were conducted at 0 degrees C, indicating that a step of the conformational change after ligand binding was affected by the mutation. In contrast, RU486 binding to the wild-type receptor induced a different conformational change that was not affected by the mutation. Analysis of proteolysis fragments obtained in the presence of dexamethasone or RU486 indicated that the RU486-induced conformational change affected the C-terminal part of the ligand binding domain differently. These data suggest that the ligand-induced conformational change occurs via a multistep process. In the first step, characterized by compaction of the ligand binding domain, the mutation has no effect, The second step, which stabilizes the activated conformation and does not occur at 4 degrees C, seems to be a key element in the activation process that can be altered by the mutation. This step could involve modification of the helix H12 position, explaining why the conformation induced by RU486 is not affected by the mutation.	INSERM, U439, F-34090 Montpellier, France; Fac Med Xavier Bichat, INSERM, U478, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Nicolas, JC (corresponding author), INSERM, U439, 70 Rue Navacelles, F-34090 Montpellier, France.		Roux, Stephane/X-1326-2019; Couette, Brigitte/N-5579-2018	Roux, Stephane/0000-0003-4885-6732; 				ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; CHEN DG, 1994, MOL ENDOCRINOL, V8, P422, DOI 10.1210/me.8.4.422; Couette B, 1996, BIOCHEM J, V315, P421, DOI 10.1042/bj3150421; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Danielson M, 1991, NUCLEAR HORMONE RECE, P39; DEBELLIS A, 1994, J CLIN ENDOCR METAB, V78, P513, DOI 10.1210/jc.78.3.513; DENIS M, 1988, J BIOL CHEM, V263, P18520; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENIS M, 1989, J BIOL CHEM, V264, P6005; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KEIGHTLEY MC, 1994, MOL ENDOCRINOL, V8, P431, DOI 10.1210/me.8.4.431; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; KUIL CW, 1994, MOL CELL ENDOCRINOL, V102, pR1, DOI 10.1016/0303-7207(94)90112-0; LEE SY, 1995, MOL ENDOCRINOL, V9, P826, DOI 10.1210/me.9.7.826; LEID M, 1994, J BIOL CHEM, V269, P14175; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; MALCHOFF DM, 1993, J CLIN INVEST, V91, P1918, DOI 10.1172/JCI116410; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; ONATE SA, 1995, SCIENCE, V270, P1354; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PELEG S, 1995, J BIOL CHEM, V270, P10551, DOI 10.1074/jbc.270.18.10551; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Roux S, 1996, MOL ENDOCRINOL, V10, P1214, DOI 10.1210/me.10.10.1214; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SEIELSTAD DA, 1995, BIOCHEMISTRY-US, V34, P12605, DOI 10.1021/bi00039a016; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SIMONS SS, 1994, VITAM HORM, P49; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TATE BF, 1994, MOL CELL BIOL, V14, P2323, DOI 10.1128/MCB.14.4.2323; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TRAPP T, 1995, BIOCHEM BIOPH RES CO, V215, P286, DOI 10.1006/bbrc.1995.2464; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEISS K, 1996, MOL ENDOCRINOL, V10, P1338; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHENG Z, 1994, ENDOCRINOLOGY, V135, P248; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	63	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10059	10065		10.1074/jbc.274.15.10059	http://dx.doi.org/10.1074/jbc.274.15.10059			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187785	hybrid			2022-12-25	WOS:000079663500024
J	Sakurai, H; Miyoshi, H; Toriumi, W; Sugita, T				Sakurai, H; Miyoshi, H; Toriumi, W; Sugita, T			Functional interactions of transforming growth factor beta-activated kinase 1 with I kappa B kinases to stimulate NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; IKK-ALPHA; TERMINAL KINASE; PROTEIN; COMPLEX; DEGRADATION; UBIQUITINATION; FAMILY	Several mitogen-activated protein kinase kinase kinases play critical roles in nuclear factor-kappa B (NF-kappa B) activation. We recently reported that the overexpression of transforming growth factor-beta-activated kinase 1 (TAK1), a member of the mitogen-activated protein kinase kinase kinase family, together with its activator TAK1-binding protein 1 (TAB1) stimulates NF-kappa B activation. Here we investigated the molecular mechanism of TAK1-induced NF-kappa B activation. Dominant negative mutants of I kappa B kinase (IKK) alpha and IKK beta inhibited TAK1-induced NF-kappa B activation, TAK1 activated IKK alpha and IKK beta in the presence of TAB1, IKK alpha and IKK beta were coimmunoprecipitated with TAK1 in the absence of TAB1. TAB1-induced TAK1 activation promoted the dissociation of active forms of IKK alpha and IKK beta from active TAK1, whereas the IKK mutants remained to interact with active TAK1, Furthermore, tumor necrosis factor-alpha activated endogenous TAK1, and the kinase-negative TAK1 acted as a dominant negative inhibitor against tumor necrosis factor-alpha induced NF-kappa B activation. These results demonstrated a novel signaling pathway to NF-kappa B activation through TAK1 in which TAK1 may act as a regulatory kinase of IKKs.	Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, Osaka 5328505, Japan	Mitsubishi Tanabe Pharma Corporation	Sugita, T (corresponding author), Tanabe Seiyaku Co Ltd, Discovery Res Lab, Yodogawa Ku, 16-89 Kashima 3 Chome, Osaka 5328505, Japan.		Sakurai, Hiroaki/AAE-4294-2019	Sakurai, Hiroaki/0000-0003-0657-9570				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; HU MC, 1996, GENE DEV, V10, P2551; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Li Z, 1997, MOL CELL BIOL, V17, P6184, DOI 10.1128/MCB.17.10.6184; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SAKURAI H, 1992, J NEUROCHEM, V59, P2067; Sakurai H, 1998, BIOCHEM BIOPH RES CO, V243, P545, DOI 10.1006/bbrc.1998.8124; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Weil R, 1997, J BIOL CHEM, V272, P9942; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	51	197	205	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10641	10648		10.1074/jbc.274.15.10641	http://dx.doi.org/10.1074/jbc.274.15.10641			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187861	hybrid			2022-12-25	WOS:000079663500100
J	Walters, RW; Grunst, T; Bergelson, JM; Finberg, RW; Welsh, MJ; Zabner, J				Walters, RW; Grunst, T; Bergelson, JM; Finberg, RW; Welsh, MJ; Zabner, J			Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; CYSTIC-FIBROSIS; TRACHEAL EPITHELIUM; NASAL EPITHELIUM; HELA-CELLS; COOPERATIVE BINDING; IN-VITRO; VIRUS; ENTRY; VECTOR	Recent identification of two receptors for the adenovirus fiber protein, coxsackie B and adenovirus type 2 and 5 receptor (CAR), and the major histocompatibility complex (MHC) Class I alpha-2 domain allows the molecular basis of adenoviral infection to be investigated. Earlier work has shown that human airway epithelia are resistant to infection by adenovirus, Therefore, we examined the expression and localization of CAR and MHC Class I in an in vitro model of well differentiated, ciliated human airway epithelia. We found that airway epithelia express CAR and MHC Class I. However, neither receptor was present in the apical membrane; instead, both were polarized to the basolateral membrane. These findings explain the relative resistance to adenovirus infection from the apical surface. In contrast, when the virus was applied to the basolateral surface, gene transfer was much more efficient because of an interaction of adenovirus fiber with its receptors, In addition, when the integrity of the tight junctions was transiently disrupted, apically applied adenovirus gained access to the basolateral surface and enhanced gene transfer. These data suggest that the receptors required for efficient infection are not available on the apical surface, and interventions that allow access to the basolateral space where fiber receptors are located increase gene transfer efficiency.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Childrens Hosp Philadelphia, Div Immunol & Infect Dis, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Dana-Farber Cancer Institute	Zabner, J (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Internal Med, 500 EMRB, Iowa City, IA 52242 USA.	Joseph-Zabner@uiowa.edu	Finberg, Robert W/E-3323-2010	Welsh, Michael/0000-0002-1646-6206; Zabner, Joseph/0000-0002-9606-1339				Arcasoy SM, 1997, AM J RESP CELL MOL, V17, P422, DOI 10.1165/ajrcmb.17.4.2714; Azizi F, 1997, EXP LUNG RES, V23, P257, DOI 10.3109/01902149709087371; BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; BASAK S, 1989, J VIROL, V63, P3164, DOI 10.1128/JVI.63.7.3164-3167.1989; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BHAT M, 1993, PHARMACEUT RES, V10, P991, DOI 10.1023/A:1018906504944; BLAU DM, 1995, VIROLOGY, V210, P91, DOI 10.1006/viro.1995.1320; CLAYSON ET, 1988, MOL CELL BIOL, V8, P3391, DOI 10.1128/MCB.8.8.3391; DEFER C, 1990, J VIROL, V64, P3661, DOI 10.1128/JVI.64.8.3661-3673.1990; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; Flotte TR, 1998, GENE THER, V5, P166, DOI 10.1038/sj.gt.3300579; Gall J, 1996, J VIROL, V70, P2116, DOI 10.1128/JVI.70.4.2116-2123.1996; Ginsberg HS, 1984, ADENOVIRUSES; Goldman M, 1996, GENE THER, V3, P811; GOLDMAN MJ, 1995, J VIROL, V69, P5951, DOI 10.1128/JVI.69.10.5951-5958.1995; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Greber Urs F., 1994, Trends in Microbiology, V2, P52, DOI 10.1016/0966-842X(94)90126-0; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; HAY JG, 1995, HUM GENE THER, V6, P1487, DOI 10.1089/hum.1995.6.11-1487; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KONDO M, 1991, AM J PHYSIOL, V261, pL106, DOI 10.1152/ajplung.1991.261.2.L106; Krasnykh VN, 1996, J VIROL, V70, P6839, DOI 10.1128/JVI.70.10.6839-6846.1996; Leopold PL, 1998, HUM GENE THER, V9, P367, DOI 10.1089/hum.1998.9.3-367; Lin XQ, 1997, AM J VET RES, V58, P1120; MARTINEZPALOMO A, 1980, J CELL BIOL, V87, P736, DOI 10.1083/jcb.87.3.736; MATHIAS P, 1994, J VIROL, V68, P6811, DOI 10.1128/JVI.68.10.6811-6814.1994; Mayr GA, 1997, J VIROL, V71, P412, DOI 10.1128/JVI.71.1.412-418.1997; MCCRAY PB, 1997, CELL VISION, V4, P42; PERSSON R, 1985, J VIROL, V54, P92, DOI 10.1128/JVI.54.1.92-97.1985; PERSSON R, 1983, J VIROL, V46, P956, DOI 10.1128/JVI.46.3.956-963.1983; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Pickles RJ, 1996, HUM GENE THER, V7, P921, DOI 10.1089/hum.1996.7.8-921; PRINCE GA, 1993, J VIROL, V67, P101, DOI 10.1128/JVI.67.1.101-111.1993; RICH DP, 1993, HUM GENE THER, V4, P461, DOI 10.1089/hum.1993.4.4-461; Roelvink PW, 1996, J VIROL, V70, P7614, DOI 10.1128/JVI.70.11.7614-7621.1996; ROSSEN JWA, 1995, VIROLOGY, V210, P54, DOI 10.1006/viro.1995.1316; ROSSEN JWA, 1994, J VIROL, V68, P7966, DOI 10.1128/JVI.68.12.7966-7973.1994; Schultze B, 1996, J GEN VIROL, V77, P2507, DOI 10.1099/0022-1317-77-10-2507; Schultze B, 1995, Adv Exp Med Biol, V380, P375; SETH P, 1984, J BIOL CHEM, V259, P4350; SETH P, 1994, J VIROL, V68, P933, DOI 10.1128/JVI.68.2.933-940.1994; Stevenson SC, 1997, J VIROL, V71, P4782, DOI 10.1128/JVI.71.6.4782-4790.1997; SVENSSON L, 1991, J VIROL, V65, P4190, DOI 10.1128/JVI.65.8.4190-4197.1991; SVENSSON U, 1985, J VIROL, V55, P442, DOI 10.1128/JVI.55.2.442-449.1985; Topp KS, 1997, EXP EYE RES, V64, P343, DOI 10.1006/exer.1996.0209; WELSH MJ, 1995, HUM GENE THER, V6, P205, DOI 10.1089/hum.1995.6.2-205; WICKHAM TJ, 1994, J CELL BIOL, V127, P257, DOI 10.1083/jcb.127.1.257; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; Zabner J, 1996, GENE THER, V3, P458; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	57	286	308	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 9	1999	274	15					10219	10226		10.1074/jbc.274.15.10219	http://dx.doi.org/10.1074/jbc.274.15.10219			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	185HT	10187807	hybrid			2022-12-25	WOS:000079663500046
J	Jones, JM; Nau, K; Geraghty, MT; Erdmann, R; Gould, SJ				Jones, JM; Nau, K; Geraghty, MT; Erdmann, R; Gould, SJ			Identification of peroxisomal acyl-CoA thioesterases in yeast and humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAT-LIVER; LONG-CHAIN; BIOGENESIS DISORDERS; BETA-OXIDATION; GENE; PURIFICATION; MEMBRANE; PROLIFERATORS; BINDING	A computer-based screen of the Saccharomyces cerevisiae genome identified YJR019C as a candidate oleate-induced gene. YJR019C mRNA levels were increased significantly during growth on fatty acids, suggesting that; it may play a role in fatty acid metabolism, The YJR019C product is highly similar to tesB, a bacterial acyl-CoA thioesterase, and carries a tripeptide sequence, alanine-lysine-phenylalanine(COOH), that closely resembles the consensus sequence for type-1 peroxisomal targeting signals. YJR019C directed green fluorescence protein to peroxisomes, and biochemical studies revealed that YJR019C is an abundant component of purified yeast peroxisomes, Disruption of the YJR019C gene caused a significant decrease in total cellular thioesterase activity, and recombinant YJR019C was found to exhibit intrinsic acyl-CoA thioesterase activity of 6 units/mg, YJR019C also shared significant sequence similarity with hTE, a human thioesterase that was previously identified because of its interaction with human immunodeficiency virus-Nef in the yeast two-hybrid assay. We report here that hTE is also a peroxisomal protein, demonstrating that thioesterase activity is a conserved feature of peroxisomes, We propose that YJR019C and hTE be renamed as yeast, and human PTE1 to reflect the fact that they encode peroxisomal thioesterases. The physical segregation of yeast and human PTE1 from the cytosolic fatty acid synthase suggests that these enzymes are unlikely to play a role in formation of fatty acids. Instead, the observation that PTE1 contributes to growth on fatty acids implicates this thioesterase in fatty acid oxidation.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Ruhr Univ Bochum, Dept Physiol Chem, D-44780 Bochum, Germany	Johns Hopkins University; Johns Hopkins University; Ruhr University Bochum	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	Stephen.Gould@qmail.bs.jhu.edu			NIDDK NIH HHS [DK45787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKERBRACHMANN C, 1998, YEAST, V14, P115; CRANE DI, 1994, J BIOL CHEM, V269, P21835; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; FARRELL SO, 1984, J BIOL CHEM, V259, P3089; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P569; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; KUNAU WH, 1992, PROG CLIN BIOL RES, V375, P9; Lazarow P. B., 1995, METABOLIC MOL BASES, P2287; LEE KY, 1979, J BIOL CHEM, V254, P4516; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; Lindquist PJG, 1998, EUR J BIOCHEM, V251, P631, DOI 10.1046/j.1432-1327.1998.2510631.x; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Mannaerts GP, 1996, ANN NY ACAD SCI, V804, P99, DOI 10.1111/j.1749-6632.1996.tb18611.x; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; Sambrook J., 2002, MOL CLONING LAB MANU; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; Watanabe W, 1997, BIOCHEM BIOPH RES CO, V238, P234, DOI 10.1006/bbrc.1997.7217; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	30	68	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9216	9223		10.1074/jbc.274.14.9216	http://dx.doi.org/10.1074/jbc.274.14.9216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092594	hybrid			2022-12-25	WOS:000079451800013
J	Khoo, KH; Jarboe, E; Barker, A; Torrelles, J; Kuo, CW; Chatterjee, D				Khoo, KH; Jarboe, E; Barker, A; Torrelles, J; Kuo, CW; Chatterjee, D			Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH VARIANTS; CELL-WALL; ARABINAN BIOSYNTHESIS; INTRACELLULARE; ETHAMBUTOL; ANTIGENS; AIDS; LIPOARABINOMANNAN; GLYCOLIPIDS; LIPIDS	Members of the Mycobacterium avium complex are the most frequently encountered opportunistic bacterial pathogens among patients in the advanced stage of AIDS. Two clinical isolates of the same strain, numbers 397 and 417, were obtained from an AIDS patient with disseminated M. avium complex infection before and after treatment with a regimen of clarithromycin and ethambutol, To identify the biochemical consequence of drug treatment, the expression and chemical composition of their major cell wall constituents, the arabinogalactan, lipoarabinomannan, and the surface glycopeptidolipids (GPL), were critically examined. Through thin layer chromatography, mass spectrometry, and chemical analysis, it was found that the GPL expression profiles differ significantly in that several apolar GPLs were overexpressed in the clinically resistant 417 isolate at the expense of the serotype 1 polar GPL, which was the single predominant band in the ethambutol-susceptible 397 isolate. Thus, instead of additional rhamnosylation on the 6-deoxytalose (6-dTal) appendage to give the serotype 1-specific disaccharide hapten, the accumulation of this nonextended apolar GPL probably provided more precursor substrate available for further nonsaccharide substitutions including a higher degree of O-methylation to give 3-O-Me-6-dTal and the unusual 4-O-sulfation on 6-dTal. Further data showed that this alteration effectively neutralized ethambutol, which is known to inhibit arabinan synthesis. Thus, in contrast with derived Emb-resistant mutants of Mycobacterium smegmatis or Mycobacterium tuberculosis, which are devoid of a surface GPL layer, the lipoarabinomannan from resistant 417 isolate grown in the presence of this drug was not apparently truncated.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Colorado State University; Academia Sinica - Taiwan	Chatterjee, D (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.	delphi@lamar.colostate.edu	Torrelles, Jordi/E-4204-2011; Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	FOGARTY INTERNATIONAL CENTER [R03TW000943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041925, R21AI037139, R01AI037139] Funding Source: NIH RePORTER; FIC NIH HHS [TW 00943] Funding Source: Medline; NIAID NIH HHS [AI-37139, AI 41925] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aspinall GO, 1995, ADV CARBOHYD CHEM BI, V51, P169, DOI 10.1016/S0065-2318(08)60194-8; BARROW WW, 1993, INFECT IMMUN, V61, P5286, DOI 10.1128/IAI.61.12.5286-5293.1993; BARROW WW, 1982, J BACTERIOL, V150, P381, DOI 10.1128/JB.150.1.381-384.1982; BARROW WW, 1995, INFECT IMMUN, V63, P126, DOI 10.1128/IAI.63.1.126-133.1995; Belanger AE, 1996, P NATL ACAD SCI USA, V93, P11919, DOI 10.1073/pnas.93.21.11919; BELISLE JT, 1994, RES MICROBIOL, V145, P237, DOI 10.1016/0923-2508(94)90024-8; BELISLE JT, 1991, J BACTERIOL, V173, P6991, DOI 10.1128/jb.173.21.6991-6997.1991; BRENNAN PJ, 1979, J BIOL CHEM, V254, P4205; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; BROWNBACK PE, 1988, INFECT IMMUN, V56, P1044, DOI 10.1128/IAI.56.5.1044-1050.1988; CHAISSON RE, 1994, ANN INTERN MED, V121, P905, DOI 10.7326/0003-4819-121-12-199412150-00001; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Chatterjee D, 1997, CURR OPIN CHEM BIOL, V1, P579, DOI 10.1016/S1367-5931(97)80055-5; CHIU J, 1990, ANN INTERN MED, V113, P358, DOI 10.7326/0003-4819-113-5-358; Chopra I, 1998, TUBERCLE LUNG DIS, V78, P89, DOI 10.1016/S0962-8479(98)80001-4; Eckstein TM, 1998, J BACTERIOL, V180, P5567, DOI 10.1128/JB.180.21.5567-5573.1998; Frehel C, 1989, Acta Leprol, V7 Suppl 1, P160; FREHEL C, 1986, ANN INST PASTEUR MIC, V137B, P239, DOI 10.1016/S0769-2609(86)80115-6; Jarboe E, 1998, DIAGN MICR INFEC DIS, V30, P197, DOI 10.1016/S0732-8893(97)00241-1; KAJIOKA R, 1978, SCAND J RESPIR DIS, V59, P91; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; Khoo KH, 1996, J BIOL CHEM, V271, P12333, DOI 10.1074/jbc.271.21.12333; KORVICK JA, 1996, MYCOBACTERIUM AVIUM, P241; MARIN LML, 1992, BIOCHEMISTRY-US, V31, P11106, DOI 10.1021/bi00160a021; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; MOEHRING JM, 1965, AM REV RESPIR DIS, V92, P704; RASTOGI N, 1989, ZBL BAKT-INT J MED M, V270, P345; RASTOGI N, 1981, ANTIMICROB AGENTS CH, V20, P666, DOI 10.1128/AAC.20.5.666; SCHAEFER WB, 1970, AM REV RESPIR DIS, V102, P499; SLUTSKY AM, 1994, J CLIN MICROBIOL, V32, P1773, DOI 10.1128/JCM.32.7.1773-1778.1994	31	42	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9778	9785		10.1074/jbc.274.14.9778	http://dx.doi.org/10.1074/jbc.274.14.9778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092667	hybrid			2022-12-25	WOS:000079451800086
J	Shi, JY; Zhu, HF; Arvidson, DN; Woldegiorgis, G				Shi, JY; Zhu, HF; Arvidson, DN; Woldegiorgis, G			A single amino acid change (substitution of glutamate 3 with alanine) in the N-terminal region of rat liver carnitine palmitoyltransferase I abolishes malonyl-CoA inhibition and high affinity binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART; YEAST; SENSITIVITY; EXPRESSION; ENZYME; SITES; CDNA; POLYPEPTIDE; ISOFORM; PROTEIN	We have recently shown by deletion mutation analysis that the conserved first 18 N-terminal amino acid residues of rat liver carnitine palmitoyltransferase I (L-CPTI) are essential for malonyl-CoA inhibition and binding (Shi, J., Zhu, H,, Arvidson, D, N,, Cregg, J, M,, and Woldegiorgis, G, (1998) Biochemistry 37, 11033-11038), To identify specific residue(s) involved in malonyl-CoA binding and inhibition of L-CPTI, we constructed two more deletion mutants, Delta 12 and Delta 6, and three substitution mutations within the conserved first six amino acid residues. Mutant L-CPTI, lacking either the first six N-terminal amino acid residues or with a change of glutamic acid 3 to alanine, was expressed at steady-state levels similar to wild type and had near wild type catalytic activity, However, malonyl-CoA inhibition of these mutant enzymes was reduced 100-fold, and high affinity malonyl-CoA binding was lost, A mutant L-CPTI with a change of histidine 5 to alanine caused only partial loss of malonyl-CoA inhibition, whereas a mutant L-CPTI with a change of glutamine 6 to alanine had wild type properties. These results demonstrate that glutamic acid 3 and histidine 5 are necessary for malonyl-CoA binding and inhibition of L-CPTI by malonyl-CoA but are not required for catalysis.	Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, Portland, OR 97291 USA		Woldegiorgis, G (corresponding author), Oregon Grad Inst Sci & Technol, Dept Biochem & Mol Biol, POB 91000, Portland, OR 97291 USA.	gwoldeg@bmb.ogi.edu			NHLBI NIH HHS [HL52571] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BIEBER LL, 1988, ANNU REV BIOCHEM, V57, P261, DOI 10.1146/annurev.bi.57.070188.001401; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; BREMER J, 1985, BIOCHIM BIOPHYS ACTA, V833, P9, DOI 10.1016/0005-2760(85)90247-4; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P26438; COOK GA, 1994, J BIOL CHEM, V269, P8803; COOK GA, 1987, J BIOL CHEM, V262, P2050; CORR PB, 1995, HERZ, V20, P156; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Hamel FG, 1997, BIOCHEM BIOPH RES CO, V234, P671, DOI 10.1006/bbrc.1997.6693; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; KASHFI K, 1995, LIPIDS, V30, P383, DOI 10.1007/BF02536295; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND H, 1987, BIOCHIM BIOPHYS ACTA, V878, P243; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; PAULY DF, 1988, J BIOL CHEM, V263, P18160; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; STEPHENS TW, 1983, BIOCHEM J, V212, P521, DOI 10.1042/bj2120521; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yamazaki N, 1996, BBA-GENE STRUCT EXPR, V1307, P157, DOI 10.1016/0167-4781(96)00069-3; Zhu HF, 1997, BIOCHEM BIOPH RES CO, V239, P498, DOI 10.1006/bbrc.1997.7494; Zhu HF, 1997, ARCH BIOCHEM BIOPHYS, V347, P53, DOI 10.1006/abbi.1997.0314	35	59	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9421	9426		10.1074/jbc.274.14.9421	http://dx.doi.org/10.1074/jbc.274.14.9421			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092622	hybrid			2022-12-25	WOS:000079451800041
J	Svensson, L; Aszodi, A; Reinholt, FP; Fassler, R; Heinegard, D; Oldberg, A				Svensson, L; Aszodi, A; Reinholt, FP; Fassler, R; Heinegard, D; Oldberg, A			Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN CORE PROTEIN; LEUCINE-RICH REPEATS; TARGETED DISRUPTION; ARTICULAR-CARTILAGE; MATRIX PROTEINS; SKIN FRAGILITY; BIGLYCAN GENE; STEM-CELLS; DECORIN; FIBRILLOGENESIS	Fibromodulin is a member of a family of connective tissue glycoproteins/proteoglycans containing leucine-rich repeat motifs. Several members of this gene family bind to fibrillar collagens and are believed to function in the assembly of the collagen network in connective tissues. Here we show that mice lacking a functional fibromodulin gene exhibit an altered morphological phenotype in tail tendon with fewer and abnormal collagen fiber bundles. In fibromodulin-null animals virtually all collagen fiber bundles are disorganized and have an abnormal morphology. Also 10-20% of the bundles in heterozygous mice are similar to the abnormal bundles in fibromodulin-null tail tendon. Ultrastructural analysis of Achilles tendon from fibromodulin-null mice show collagen fibrils with irregular and rough outlines in cross-section. Morphometric analysis show that fibromodulin-null mice have on the average thinner fibrils than wild type animals as a result of a larger preponderance of very thin fibrils in an overall similar range of fibril diameters. Protein and RNA analyses show an approximately 4-fold increase in the content of lumican in fibromodulin-null as compared with wild type tail tendon, despite a decrease in lumican mRNA These results demonstrate a role for fibromodulin in collagen fibrillogenesis and suggest that the orchestrated action of several leucine-rich repeat glycoproteins/proteoglycans influence the architecture of collagen matrices.	Univ Lund, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Univ Lund Hosp, Dept Expt Pathol, S-22185 Lund, Sweden; Natl Hosp Norway, Dept Pathol, Lab Electron Microscopy, N-0027 Oslo, Norway	Lund University; Lund University; Skane University Hospital; University of Oslo; National Hospital Norway	Oldberg, A (corresponding author), Univ Lund, Dept Cell & Mol Biol, POB 94, S-22100 Lund, Sweden.	ake.oldberg@medkem.lu.se						ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; ANTONSSON P, 1993, BIOCHIM BIOPHYS ACTA, V1174, P204, DOI 10.1016/0167-4781(93)90117-V; Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; ASZODI A, 1994, MATRIX BIOL, V14, P181, DOI 10.1016/0945-053X(94)90007-8; BENGTSSON E, 1995, J BIOL CHEM, V270, P25639, DOI 10.1074/jbc.270.43.25639; BIRK DE, 1989, P NATL ACAD SCI USA, V86, P4549, DOI 10.1073/pnas.86.12.4549; BJORCK L, 1977, SCAND J IMMUNOL, V6, P1063; Blevins FT, 1997, ORTHOP CLIN N AM, V28, P1, DOI 10.1016/S0030-5898(05)70260-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FUNDERBURGH JL, 1993, J BIOL CHEM, V268, P11874; GLOSSL J, 1983, BIOCHEM J, V215, P295; GROVER J, 1995, J BIOL CHEM, V270, P21942, DOI 10.1074/jbc.270.37.21942; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kadler KE, 1996, BIOCHEM J, V316, P1; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LARSSON T, 1991, J BIOL CHEM, V266, P20428; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NEAME PJ, 1989, J BIOL CHEM, V264, P8653; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; NEUFELD EF, 1973, LYSOSOMES STORAGE DI, P261; Nurminskaya MV, 1998, ARCH BIOCHEM BIOPHYS, V350, P1, DOI 10.1006/abbi.1997.0498; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; REINHOLT FP, 1982, J ULTRA MOL STRUCT R, V80, P270, DOI 10.1016/S0022-5320(82)80040-3; ROUGHLEY PJ, 1996, OSTEOARTHR CARTILAGE, V4, P229; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; VOGEL KG, 1987, COLLAGEN REL RES, V7, P105; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; Xu TS, 1998, NAT GENET, V20, P78, DOI 10.1038/1746	54	348	361	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9636	9647		10.1074/jbc.274.14.9636	http://dx.doi.org/10.1074/jbc.274.14.9636			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092650	hybrid			2022-12-25	WOS:000079451800069
J	Waldron, RT; Iglesias, T; Rozengurt, E				Waldron, RT; Iglesias, T; Rozengurt, E			The pleckstrin homology domain of protein kinase D interacts preferentially with the eta isoform of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MOLECULAR-CLONING; PHORBOL ESTERS; GROWTH-FACTORS; INTACT-CELLS; PH DOMAINS; ACTIVATION; DIACYLGLYCEROL; TARGET; ASSOCIATION	The results presented here demonstrate that protein kinase D (PKD) and PKC eta transiently coexpressed in COS-7 cells form complexes that can be immunoprecipitated from cell lysates using specific antisera to PKD or PKC eta. The presence of PKC eta in PKD immune complexes was initially detected by in vitro kinase assays which reveal the presence of an 80-kDa phosphorylated band in addition to the 110-kDa band corresponding to autophosphorylated PHD. The association between PKD and PKC eta was further verified by Western blot analysis and peptide phosphorylation assays that exploited the distinct substrate specificity between PKCs and PKD. By the same criteria, PKD formed complexes only very weakly with PKC epsilon, and did not bind PKC zeta. When PKC eta was coexpressed with PHD mutants containing either complete or partial deletions of the PH domain, both PKC eta immunoreactivity and PKC activity in PHD immunoprecipitates were sharply reduced. In contrast, deletion of an amino-terminal portion of the molecule, either cysteine-rich region, or the entire cysteine-rich domain did not interfere with the association of PBD with PKC eta. Furthermore, a glutathione S-transferase-PKDPH fusion protein bound preferentially to PKC eta, These results indicate that the PHD PH domain can discriminate between closely related structures of a single enzyme family, e.g. novel PKCs epsilon and eta, thereby revealing a previously undetected degree of specificity among protein-protein interactions mediated by PH domains.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, London WC2A 3PX, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Warren Hall,Room 11-124, Los Angeles, CA 90095 USA.		Vacas, Teresa Iglesias/ABF-8663-2020; Waldron, Richard Taliesin/ABF-2773-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005; Waldron, Richard Taliesin/0000-0003-3151-6002				Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hurley JH, 1997, PROTEIN SCI, V6, P477; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1995, CANCER SURV, V24, P81; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	31	104	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9224	9230		10.1074/jbc.274.14.9224	http://dx.doi.org/10.1074/jbc.274.14.9224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092595	hybrid			2022-12-25	WOS:000079451800014
J	Loihl, AK; Whalen, S; Campbell, IL; Mudgett, JS; Murphy, S				Loihl, AK; Whalen, S; Campbell, IL; Mudgett, JS; Murphy, S			Transcriptional activation following cerebral ischemia in mice of a promoter-deleted nitric oxide synthase-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACKING; LIPOPOLYSACCHARIDE; SUPEROXIDE; OXYGENASE; RESPONSES; DOMAINS; CELLS	Nitric oxide synthase (NOS)-2 is transcriptionally activated in a wide variety of injurious conditions, including cerebral ischemia, and the resulting nitric oxide is implicated both in tissue damage and recovery. Studies in vitro suggest that the proximal region of the NOS-2 promoter is obligatory for gene activation by proinflammatory cytokines, However, following cerebral ischemia in a NOS-2 gene-deficient mouse in which this region and exons 1-4 have been deleted, we find temporal and spatial expression, identical to wild-type, from a previously unidentified promoter region. The resulting protein is predicted to lack the first 113 amino acids and is NOS-S-incompetent, Fortuitously, this gene-deficient mouse presents a unique opportunity to determine more about the mechanisms of NOS-2 gene regulation in vivo.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Neurosci Program, Iowa City, IA 52242 USA; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Merck Res Labs, Dept Mol Pharmacol Immunol & Rheumatol, Rahway, NJ 07065 USA	University of Iowa; University of Iowa; Scripps Research Institute; Merck & Company	Murphy, S (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, 2-530 Bowen Sci Bldg, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029226] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-29226] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRONSON SK, 1994, J BIOL CHEM, V269, P27155; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; KIM HH, 1994, J BIOL CHEM, V269, P24747; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Loihl AK, 1998, PROG BRAIN RES, V118, P253; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; MURPHY S, 1990, P33; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; POU S, 1992, J BIOL CHEM, V267, P24173; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	29	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8844	8849		10.1074/jbc.274.13.8844	http://dx.doi.org/10.1074/jbc.274.13.8844			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085127	hybrid			2022-12-25	WOS:000079451600069
J	Sanchez, M; Calzada, A; Bueno, A				Sanchez, M; Calzada, A; Bueno, A			The Cdc6 protein is ubiquitinated in vivo for proteolysis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST-CELL CYCLE; DNA-REPLICATION; BUDDING YEAST; FISSION YEAST; S-PHASE; CDK INHIBITOR; SCHIZOSACCHAROMYCES-POMBE; DEPENDENT PROTEOLYSIS; INITIATION; DEGRADATION	The Saccharomyces cerevisiae Cdc6 protein is necessary for the formation of pre-replicative complexes that are required for firing DNA replication at origins at the beginning of S phase. Cdc6p protein levels oscillate during the cell cycle. In a normal cell cycle the presence of this protein is restricted to G(1), partly because the CDC6 gene is transcribed only during G(1) and partly because the Cdc6p protein is rapidly degraded at late G(1)/early S phase, We report here that the Cdc6p protein is degraded in a Cdc4-dependent manner, suggesting that phosphorylated Cdc6 is specifically recognized by the ubiquitin-mediated proteolysis machinery. Indeed, we have found that Cdc6 is ubiquitinated in vivo and degraded by a Cdc4-dependent mechanism. Our data, together with previous observations regarding Cdc6 stability, suggest that under physiological conditions budding yeast cells degrade ubiquitinated Cdc6 every cell cycle at the beginning of S phase.	Univ Salamanca, CSIC, Inst Microbiol Bioquim,Edificio Dept, Ctr Invest Canc,Dept Microbiol & Genet, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Bueno, A (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim,Edificio Dept, Ctr Invest Canc,Dept Microbiol & Genet, Campus Miguel de Unamuno, Salamanca 37007, Spain.	abn@gugu.usal.es	SANCHEZ, MAR/L-1898-2017; Calzada, Arturo/M-1168-2014; Bueno, Avelino/A-9505-2016	Calzada, Arturo/0000-0002-3190-688X; Bueno, Avelino/0000-0002-0362-4391; Sanchez, Maria del Mar/0000-0003-4438-0722				[Anonymous], 1991, Methods Enzymol, V194, P1; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUTTER KJ, 1979, J GEN MICROBIOL, V113, P369, DOI 10.1099/00221287-113-2-369; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; WHITBREAD LA, 1995, GENE, V155, P113, DOI 10.1016/0378-1119(94)00925-I; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	40	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					9092	9097		10.1074/jbc.274.13.9092	http://dx.doi.org/10.1074/jbc.274.13.9092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085159	hybrid			2022-12-25	WOS:000079451600101
J	Schaubach, OL; Dombroski, AJ				Schaubach, OL; Dombroski, AJ			Transcription initiation at the flagellin promoter by RNA polymerase carrying sigma(28) from Salmonella typhimurium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; LAC UV5 PROMOTER; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; AMINO-ACIDS; START-SITE; NONTEMPLATE STRAND; SIGMA-70 SUBUNIT; TETR PROMOTER; BINDING	The sigma subunit of RNA polymerase is a critical factor in positive control of transcription initiation. Primary a factors are essential proteins required for vegetative growth, whereas alternative sigma factors mediate transcription in response to various stimuli. Late gene expression during flagellum biosynthesis in Salmonella typhimurium is dependent upon an alternative a factor, sigma(28), the product of the fliA gene. We have characterized the intermediate complexes formed by sigma(28) holoenzyme on the pathway to open complex formation. Interactions with the promoter for the flagellin gene fliC were analyzed using DNase I and KMnO4 footprinting over a range of temperatures. We propose a model in which closed complexes are established in the upstream region of the promoter, including the -35 element, but with little significant contact in the -10 element or downstream regions of the promoter. An isomerization event extends the DNA contacts into the -10 element and the start site, with loss of the most distal upstream contacts accompanied by DNA melting to form open complexes, Melting occurs efficiently even at 16 degrees C. Once open complexes have formed, they are unstable to heparin challenge even in the presence of nucleoside triphosphates, which have been observed to stabilize open complexes at rRNA promoters.	Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Dombroski, AJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.	dombros@utmmg.med.uth.tmc.edu			NIGMS NIH HHS [GM56453-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIYAR SE, 1994, BIOCHEMISTRY-US, V33, P11501, DOI 10.1021/bi00204a012; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Chen YF, 1997, J MOL BIOL, V267, P47, DOI 10.1006/jmbi.1996.0853; CHEN YF, 1992, P NATL ACAD SCI USA, V89, P5123, DOI 10.1073/pnas.89.11.5123; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DUVALVALENTIN G, 1987, NUCLEIC ACIDS RES, V15, P575, DOI 10.1093/nar/15.2.575; DUVALVALENTIN G, 1986, NUCLEIC ACIDS RES, V14, P1967, DOI 10.1093/nar/14.5.1967; Estrem ST, 1998, P NATL ACAD SCI USA, V95, P9761, DOI 10.1073/pnas.95.17.9761; Fredrick K, 1997, P NATL ACAD SCI USA, V94, P4982, DOI 10.1073/pnas.94.10.4982; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GILLEN KL, 1991, J BACTERIOL, V173, P6453, DOI 10.1128/jb.173.20.6453-6459.1991; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GRALLA JD, 1993, FOOTPRINTING TECHNIQ, P107; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOFER B, 1985, NUCLEIC ACIDS RES, V13, P5995, DOI 10.1093/nar/13.16.5995; Huang XJ, 1997, NUCLEIC ACIDS RES, V25, P2603, DOI 10.1093/nar/25.13.2603; Johnson BD, 1997, J BIOL CHEM, V272, P31029, DOI 10.1074/jbc.272.49.31029; JONES CH, 1992, J BACTERIOL, V174, P6815, DOI 10.1128/JB.174.21.6815-6821.1992; JONES CH, 1992, P NATL ACAD SCI USA, V89, P1958, DOI 10.1073/pnas.89.5.1958; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; MELANCON P, 1982, BIOCHEMISTRY-US, V21, P4318, DOI 10.1021/bi00261a022; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OHNISHI K, 1990, MOL GEN GENET, V221, P139, DOI 10.1007/BF00261713; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Roberts CW, 1996, CELL, V86, P495; ROE JH, 1984, J MOL BIOL, V176, P495, DOI 10.1016/0022-2836(84)90174-8; RONG JC, 1994, J BACTERIOL, V176, P5218, DOI 10.1128/JB.176.17.5218-5224.1994; SHORENSTEIN RG, 1973, J BIOL CHEM, V248, P6170; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P2723, DOI 10.1021/bi00332a019; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TAYLOR WE, 1979, GENE, V6, P331, DOI 10.1016/0378-1119(79)90073-8; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Wilson C, 1997, J MOL BIOL, V267, P60, DOI 10.1006/jmbi.1997.0875; Zaychikov E, 1997, J BIOL CHEM, V272, P2259; ZHOU YN, 1992, J BACTERIOL, V174, P5005, DOI 10.1128/JB.174.15.5005-5012.1992; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	57	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8757	8763		10.1074/jbc.274.13.8757	http://dx.doi.org/10.1074/jbc.274.13.8757			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085116	hybrid			2022-12-25	WOS:000079451600058
J	Worthylake, R; Opresko, LK; Wiley, HS				Worthylake, R; Opresko, LK; Wiley, HS			ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; MAMMARY EPITHELIAL-CELLS; BREAST-CANCER; POSTENDOCYTIC TRAFFICKING; ENDOCYTIC SYSTEM; EGF RECEPTORS; NEU; INTERNALIZATION; FAMILY; HETERODIMERIZATION	ErbB-2/HER2 is an important signaling partner for the epidermal growth factor receptor (EGFR), Overexpression of erbB-2 is also associated with poor prognosis in breast cancer. To investigate how erbB-2 amplification affects its interactions with the EGFR, we used a human mammary epithelial cell system in which erbB-2 expression was increased 7-20-fold by gene transfection. We found that amplification of erbB-2 caused constitutive activation of erbB-2 as well as ligand-independent activation of the EGFR. Overexpression of erbB-2 strongly inhibited erbB-2 down-regulation following transactivation by EGFR. Significantly, down-regulation of activated EGFR was also inhibited by erbB-2 amplification, resulting in enhanced ligand-dependent activation of the EGFR. The rate of EGFR endocytosis was not affected by erbB-2 overexpression, but the rate of lysosomal targeting was significantly reduced. In addition, erbB-2 overexpression promoted rapid recycling of activated EGFR back to the cell surface and decreased ligand dissociation from the EGFR. Our data suggest that overexpression of erbB-2 inhibits both its downregulation and that of the EGFR. The net effect is increased signaling through the EGFR system.	Univ Utah, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Wiley, HS (corresponding author), Univ Utah, Dept Pathol, Div Cell Biol & Immunol, Salt Lake City, UT 84132 USA.	Wiley@path.med.utah.edu		Wiley, Steven/0000-0003-0232-6867				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Baulida J, 1996, J BIOL CHEM, V271, P5251; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; DSOUZA B, 1993, ONCOGENE, V8, P1797; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GILL GN, 1984, J BIOL CHEM, V259, P7755; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAIGLER HT, 1985, J CELL PHYSIOL, V124, P322, DOI 10.1002/jcp.1041240223; Harlow E., 1988, ANTIBODIES LAB MANUA; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KORNILOVA ES, 1992, ONCOGENE, V7, P511; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; LUND KA, 1990, J BIOL CHEM, V265, P15713; LUND KA, 1993, REGULATION CELLULAR, V3, P277; MAIER LA, 1991, CANCER RES, V51, P5361; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Sasaoka T, 1996, J BIOL CHEM, V271, P8338, DOI 10.1074/jbc.271.14.8338; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tan M, 1997, CANCER RES, V57, P1199; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; WILEY HS, 1985, J BIOL CHEM, V260, P5290; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	56	258	268	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	1999	274	13					8865	8874		10.1074/jbc.274.13.8865	http://dx.doi.org/10.1074/jbc.274.13.8865			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PV	10085130	hybrid			2022-12-25	WOS:000079451600072
J	Rallapalli, R; Strachan, G; Cho, B; Mercer, WE; Hall, DJ				Rallapalli, R; Strachan, G; Cho, B; Mercer, WE; Hall, DJ			A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MEDIATED TRANSCRIPTION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; ONCOPROTEIN MDM2; BINDING DOMAIN; ACTIVATION; MUTATIONS; APOPTOSIS; DELETION	The MDMX gene product is related to the MDM2 oncoprotein, both of which interact with the p53 tumor suppressor. We have identified a novel transcript of the MDMX gene that is expressed in a variety of cell lines, and in particular, in growing and transformed cells. This transcript is identical to the published sequence yet it has a short internal deletion of 68 base pairs. This deletion produces a shift in the reading frame after codon 114, resulting in the inclusion of a stop codon at amino acid residue 127 (full-length MDMX is 489 residues). This truncated MDMX protein is termed MDMX-S ("short form"), represents only the p53-binding domain, and appears to bind p53 better than full-length MDMX The MDMX-S protein can be detected in cell extracts and when overexpressed is much more effective than MDMX at inhibiting p53-mediated transcriptional activation and induction of apoptosis, Since MDMX-S lacks the central and carboxyl-terminal regions contained within full length MDMX, it is likely to play a key role in the regulation of cell proliferation and apoptosis ina way distinct from MDMX.	Thomas Jefferson Univ, Jefferson Canc Inst, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Hall, DJ (corresponding author), Thomas Jefferson Univ, Dept Orthopaed Surg, 501 Curtis Bldg, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA67032] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD M, 1997, CANCER RES, V57, P614; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FREBOURG T, 1992, CANCER RES, V52, P6976; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Harlow E., 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOGAN TJ, 1995, CANCER RES, V55, P2883; LOGAN TJ, 1994, MOL BIOL CELL, V5, P667, DOI 10.1091/mbc.5.6.667; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOBERG KH, 1992, ONCOGENE, V7, P411; Momand J, 1997, J CELL BIOCHEM, V64, P343; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Schlott T, 1997, J PATHOL, V182, P54; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	38	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 19	1999	274	12					8299	8308		10.1074/jbc.274.12.8299	http://dx.doi.org/10.1074/jbc.274.12.8299			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	178LU	10075736	hybrid			2022-12-25	WOS:000079268100095
J	Lawson, TG; Gronros, DL; Evans, PE; Bastien, MC; Michalewich, KM; Clark, JK; Edmonds, JH; Graber, KH; Werner, JA; Lurvey, BA; Cate, JM				Lawson, TG; Gronros, DL; Evans, PE; Bastien, MC; Michalewich, KM; Clark, JK; Edmonds, JH; Graber, KH; Werner, JA; Lurvey, BA; Cate, JM			Identification and characterization of a protein destruction signal in the encephalomyocarditis virus 3C protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							END RULE PATHWAY; HEPATITIS-A VIRUS; UBIQUITIN-CONJUGATING ENZYME; MEDIATED PROTEOLYTIC SYSTEM; AMINO-ACID-SEQUENCES; SACCHAROMYCES-CEREVISIAE; RECOGNITION COMPONENT; NUCLEOTIDE-SEQUENCE; CYCLIN DEGRADATION; RNA-POLYMERASE	The amino acid sequence LLVRGRTLW, which is probably located in a strand-turn-strand structure, has been identified as a protein destruction signal in the rapidly degraded encephalomyocarditis virus 3C protease. Mutations within this sequence reduced the susceptibility of the 3C protease toward ubiquitination and degradation in rabbit reticulocyte lysate. This signal is transferable, since poliovirus 3C protease, which is a poor ubiquitin-mediated proteolytic system substrate, was found to be ubiquitinated and degraded when the signal sequence was either generated at an internal location in the protein or fused to the N terminus. An evaluation of the behavior of 3C protease proteins containing mutations in the signal region indicates that considerable variability in the primary structure is tolerated, although the conservation of certain features appears to be required for signal function. Two E3 ubiquitin-protein ligases that recognize the encephalomyocarditis virus 3C protease as a substrate were also partially purified. One of these was identified as the previously described E3 alpha, and this was shown to require the destruction signal sequence to catalyze efficiently the ubiquitination of the 3C protease. The other is a UbcB-dependent E3 that appears to recognize a different, unidentified feature of the 3C protease.	Bates Coll, Dept Chem, Lewiston, ME 04240 USA		Lawson, TG (corresponding author), Bates Coll, Dept Chem, Lewiston, ME 04240 USA.							ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Funabiki H, 1997, EMBO J, V16, P5977, DOI 10.1093/emboj/16.19.5977; GAUSSMULLER V, 1991, VIROLOGY, V182, P861, DOI 10.1016/0042-6822(91)90630-T; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Gladding RL, 1997, BIOCHEM BIOPH RES CO, V238, P119, DOI 10.1006/bbrc.1997.7251; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HATEBORER G, 1996, GENE DEV, V10, P2969; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; KRAUSSLICH HG, 1988, BIOCHIMIE, V70, P119, DOI 10.1016/0300-9084(88)90166-6; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; LAWSON TG, 1994, J BIOL CHEM, V269, P28429; LAWSON TG, 1989, J VIROL, V63, P5013, DOI 10.1128/JVI.63.12.5013-5022.1989; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Mosimann SC, 1997, J MOL BIOL, V273, P1032, DOI 10.1006/jmbi.1997.1306; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OBERST MD, 1993, VIROLOGY, V193, P28, DOI 10.1006/viro.1993.1100; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PALMENBERG AC, 1984, NUCLEIC ACIDS RES, V12, P2969, DOI 10.1093/nar/12.6.2969; PAUL AV, 1987, VIRUS RES, V8, P153, DOI 10.1016/0168-1702(87)90026-8; RACANIELLO VR, 1981, P NATL ACAD SCI-BIOL, V78, P4887, DOI 10.1073/pnas.78.8.4887; REISS Y, 1989, J BIOL CHEM, V264, P10378; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Ryan MD, 1997, J GEN VIROL, V78, P699, DOI 10.1099/0022-1317-78-4-699; SADIS S, 1995, MOL CELL BIOL, V15, P4086; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; Schauber C, 1998, GENES CELLS, V3, P307, DOI 10.1046/j.1365-2443.1998.00192.x; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Scheffner M., 1998, UBIQUITIN BIOL CELL, P65; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TESER M, 1994, VIROLOGY, V198, P524; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YPMAWONG MF, 1987, J VIROL, V61, P3181, DOI 10.1128/JVI.61.10.3181-3189.1987	61	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 2	1999	274	14					9871	9880		10.1074/jbc.274.14.9871	http://dx.doi.org/10.1074/jbc.274.14.9871			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181PX	10092683	hybrid			2022-12-25	WOS:000079451800098
